PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
2692851-2	1989	The wild type was least sensitive while the excision-deficient mutants rad1, rad2 and snm1 exhibited higher sensitivities to either platinum compound.	Platinum	132-140	ssDNA endodeoxyribonuclease RAD1	Saccharomyces cerevisiae S288C	71-75
2692851-2	1989	The wild type was least sensitive while the excision-deficient mutants rad1, rad2 and snm1 exhibited higher sensitivities to either platinum compound.	Platinum	132-140	ssDNA endodeoxyribonuclease RAD2	Saccharomyces cerevisiae S288C	77-81
2692851-2	1989	The wild type was least sensitive while the excision-deficient mutants rad1, rad2 and snm1 exhibited higher sensitivities to either platinum compound.	Platinum	132-140	Snm1p	Saccharomyces cerevisiae S288C	86-90
2525665-11	1989	The LH-to-FSH ratio after LHRH stimulation was significantly higher in the PP than in the PT group (p less than 0.001).	Platinum	90-92	gonadotropin releasing hormone 1	Homo sapiens	26-30
2588264-1	1989	Tetraplatin (tetrachloro[d,l-trans]1,2-diaminocyclohexane platinum IV (TTP)) is a new platinum analogue active against L1210 murine leukemia that is resistant to cisplatin (diamminedichloroplatinum II (DDP)).	Platinum	58-66	zinc finger protein 36	Mus musculus	71-74
2588264-10	1989	Thus, our results indicate that the distribution of platinum in the kidneys differs between rats treated with TTP and those treated with DDP.	Platinum	52-60	zinc finger protein 36	Mus musculus	110-113
2804422-3	1989	A polyamine oxidase immobilized column worked effectively as a post-column reactor to convert polyamines to hydrogen peroxide which was eventually detected by electrochemical oxidation on platinum electrode.	Platinum	188-196	polyamine oxidase	Homo sapiens	2-19
2556835-0	1989	[The effects of complex platinum compounds on the neuraminidase activity of the Sendai virus].	Platinum	24-32	neuraminidase 1	Homo sapiens	50-63
2556835-2	1989	The partial inhibition of neuraminidase activity was greater in the case of the divalent platinum complex derivative.	Platinum	89-97	neuraminidase 1	Homo sapiens	26-39
2637543-1	1989	The actin cytoskeleton of 8 transformed epithelial cell lines was studied using electron microscopy of platinum replicas.	Platinum	103-111	actin epsilon 1	Bos taurus	4-9
9947760-0	1989	Spin-dependent photoemission intensities from platinum (111).	Platinum	46-54	spindlin 1	Homo sapiens	0-4
2702983-0	1989	Carrier mediated action of platinum complexes on estrogen receptor positive tumors.	Platinum	27-35	estrogen receptor 1	Homo sapiens	49-66
3070345-9	1988	INAP responses are obtained by placing platinum-iridium bipolar stimulating electrodes proximal to the injury.	Platinum	39-47	NFKB inhibitor zeta	Homo sapiens	0-4
3194831-12	1988	Gastrin levels in mice bearing PT have ranged from 216 to 12,000 pg/ml.	Platinum	31-33	gastrin	Mus musculus	0-7
2521201-6	1989	In experiments with lower concentrations of cis-DDP, the amount of incorporated platinum directly correlated with the amount of inactivated alpha 2AP (1:1 stoichiometry).	Platinum	80-88	serpin family F member 2	Homo sapiens	140-149
9948363-0	1989	Spin-resolved photoemission from the (111) face of a platinum.	Platinum	53-61	spindlin 1	Homo sapiens	0-4
3214736-7	1988	Nevertheless, in cells pretreated with PT and then also with OXO, MOR and OXO inhibited the VIP-induced AC response.	Platinum	39-41	vasoactive intestinal peptide	Homo sapiens	92-95
2452164-0	1988	Evidence that the platinum-reactive methionyl residue of the alpha 2-macroglobulin receptor recognition site is not in the carboxyl-terminal receptor binding domain.	Platinum	18-26	LDL receptor related protein 1	Homo sapiens	61-91
3411596-0	1988	Platinum complexes with binding affinity for the estrogen receptor.	Platinum	0-8	estrogen receptor 1	Bos taurus	49-66
3257210-7	1988	alpha 1AT bound twice as much platinum when reacted with trans-DDP.	Platinum	30-38	serpin family A member 1	Homo sapiens	0-9
3289611-2	1988	We find two binding sites for dT(pT)34 per single strand binding (SSB) protein tetramer, with each site possessing widely different affinities depending on the salt concentration.	Platinum	33-35	single-stranded DNA-binding protein	Escherichia coli	66-69
3162402-14	1988	The t1/2 beta for total platinum in plasma was 29.10 h (7.47 h for unbound platinum) after the administration of tetraplatin and 23.70 h (13.09 h for unbound platinum) after cisplatin.	Platinum	24-32	brachyury, T-box transcription factor T	Mus musculus	4-13
3162402-14	1988	The t1/2 beta for total platinum in plasma was 29.10 h (7.47 h for unbound platinum) after the administration of tetraplatin and 23.70 h (13.09 h for unbound platinum) after cisplatin.	Platinum	75-83	brachyury, T-box transcription factor T	Mus musculus	4-13
3162402-14	1988	The t1/2 beta for total platinum in plasma was 29.10 h (7.47 h for unbound platinum) after the administration of tetraplatin and 23.70 h (13.09 h for unbound platinum) after cisplatin.	Platinum	75-83	brachyury, T-box transcription factor T	Mus musculus	4-13
3355185-0	1988	[Effect of a newly developed platinum compound cis-1, 1-cyclobutane dicarboxylato-(2R)-2-methyl-1,4-butane diamine platinum (II), on human ovarian tumors transplanted into nude mice].	Platinum	29-37	suppressor of cytokine signaling 1	Homo sapiens	47-52
2450578-7	1988	Incubation of trypsin-treated cis-DDP-alpha 2M with diethyldithiocarbamate (DDC), a potent chelator of platinum compounds, results in the removal of the intersubunit cross-links and completion of the alpha 2M conformational change as determined by nondenaturing PAGE.	Platinum	103-111	alpha-2-macroglobulin	Homo sapiens	38-46
2450578-7	1988	Incubation of trypsin-treated cis-DDP-alpha 2M with diethyldithiocarbamate (DDC), a potent chelator of platinum compounds, results in the removal of the intersubunit cross-links and completion of the alpha 2M conformational change as determined by nondenaturing PAGE.	Platinum	103-111	alpha-2-macroglobulin	Homo sapiens	200-208
2452164-7	1988	For this reason, experiments were performed to determine if the platinum-reactive methionyl residue is located in the COOH-terminal receptor binding fragment of alpha 2M.	Platinum	64-72	alpha-2-macroglobulin	Homo sapiens	161-169
2452164-9	1988	In addition, the COOH-terminal fragment did not bind to monoclonal antibody 7H11D6, a monoclonal antibody which binds to the platinum-reactive epitope of the alpha 2M-CH3NH2 receptor recognition site.	Platinum	125-133	alpha-2-macroglobulin	Homo sapiens	158-166
2452164-10	1988	In contrast, the 55-kDa fragment of alpha 2M bound approximately 1 mol platinum/mol of 55-kDa fragment and also bound to monoclonal antibody 7H11D6.	Platinum	71-79	alpha-2-macroglobulin	Homo sapiens	36-44
2452164-11	1988	Since the COOH-terminal fragment retains some receptor binding ability, the results of this investigation demonstrate that this fragment is not the complete receptor recognition site and suggest that a platinum-reactive methionyl residue located in the 55-kDa fragment of alpha 2M is another component of this site.	Platinum	202-210	alpha-2-macroglobulin	Homo sapiens	272-280
2839099-3	1988	After treatment with cis-DDP, significant platinum binding to plasma components with MW greater than 25 kD was observed; the ratio free-sulfhydryls/protein content decreased during the first two hours, returning to normal values at 24 hours after injection.	Platinum	42-50	translocase of inner mitochondrial membrane 8A	Homo sapiens	25-28
3335000-3	1988	DDP-resistant cells that were only 3.3-fold resistant had approximately 50% less accumulated platinum at all concentrations examined.	Platinum	93-101	translocase of inner mitochondrial membrane 8A	Homo sapiens	0-3
3342469-4	1988	Statistical analysis of individual values revealed a high correlation between the area under the plasma concentration-time curve (AUC) of free platinum (unbound to proteins) and the concentration of platinum bound to plasma proteins 24 h after drug administration (Cp24).	Platinum	143-151	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	265-269
3342469-4	1988	Statistical analysis of individual values revealed a high correlation between the area under the plasma concentration-time curve (AUC) of free platinum (unbound to proteins) and the concentration of platinum bound to plasma proteins 24 h after drug administration (Cp24).	Platinum	199-207	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	265-269
3342469-5	1988	A similar correlation was found between the peak plasma values of ultrafiltrable platinum (Cp0) and Cp24.	Platinum	81-89	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	100-104
3342469-6	1988	When studied in the same patient, increases in free platinum AUC and Cp0 were also found to result in increased Cp24.	Platinum	52-60	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	112-116
3180141-5	1988	We have developed a physiologically active platinum transferrin complex that has been tested on several cell lines in culture, a tumor model in the Fischer rat, and five human patients with advanced breast carcinoma.	Platinum	43-51	transferrin	Rattus norvegicus	52-63
3383986-3	1988	Plasma platinum elimination was biphasic with a short initial phase (t1/2 alpha 10-31 min) and a long beta-phase (t1/2 beta 65-91 h).	Platinum	7-15	interleukin 1 receptor like 1	Homo sapiens	69-85
3383986-3	1988	Plasma platinum elimination was biphasic with a short initial phase (t1/2 alpha 10-31 min) and a long beta-phase (t1/2 beta 65-91 h).	Platinum	7-15	interleukin 1 receptor like 1	Homo sapiens	114-129
2464185-5	1988	Therapeutic trials of CHOP-BLEO merit further assessment and the results should be compared to the baseline treatment using platinum and prednisolone.	Platinum	124-132	DNA damage inducible transcript 3	Homo sapiens	22-26
3278818-0	1988	Relationship between urine beta-2-microglobulin and platinum levels during cisplatin treatment.	Platinum	52-60	beta-2-microglobulin	Homo sapiens	27-47
3278818-1	1988	We evaluated whether urine beta 2-microglobulin (beta 2M) excretion as a function of nephrotoxicity correlated with plasma and urine platinum levels in patients receiving cisplatin.	Platinum	133-141	beta-2-microglobulin	Homo sapiens	27-47
3278818-1	1988	We evaluated whether urine beta 2-microglobulin (beta 2M) excretion as a function of nephrotoxicity correlated with plasma and urine platinum levels in patients receiving cisplatin.	Platinum	133-141	beta-2-microglobulin	Homo sapiens	49-56
3278818-4	1988	A significant correlation was obtained between urine platinum and beta 2M in the 6- to 24-h samples (r = 0.61, p less than 0.02).	Platinum	53-61	beta-2-microglobulin	Homo sapiens	66-73
3278818-5	1988	The mean plasma platinum levels were higher (12.6 +/- 6.1 mumol/L) in the patients with an increase in urine beta 2M compared to those patients with no change in beta 2M (6.8 +/- 4.1 mumol/L) (p less than 0.02).	Platinum	16-24	beta-2-microglobulin	Homo sapiens	109-116
3278818-5	1988	The mean plasma platinum levels were higher (12.6 +/- 6.1 mumol/L) in the patients with an increase in urine beta 2M compared to those patients with no change in beta 2M (6.8 +/- 4.1 mumol/L) (p less than 0.02).	Platinum	16-24	beta-2-microglobulin	Homo sapiens	162-169
2824223-8	1987	The ultrastructural organization of actin-depleted stress fibers was studied by transmission electron microscopy of platinum replicas.	Platinum	116-124	actin epsilon 1	Bos taurus	36-41
3127325-6	1987	On the other hand, CY was more effective than PT on the production of interleukin-3 (IL-3).	Platinum	46-48	interleukin 3	Mus musculus	70-83
3504440-4	1987	In TEM, the granular structure of platinum coats is resolved, and platinum decoration artifacts are observed on the surface of structures.	Platinum	34-42	MFT2	Homo sapiens	3-6
3504440-4	1987	In TEM, the granular structure of platinum coats is resolved, and platinum decoration artifacts are observed on the surface of structures.	Platinum	66-74	MFT2	Homo sapiens	3-6
3624223-1	1987	Electrochemical reduction of methemoglobin on a platinum electrode is studied by means of thin layer spectroelectrochemistry.	Platinum	48-56	hemoglobin subunit gamma 2	Homo sapiens	29-42
3607749-5	1987	In contrast, other cytotoxic anticancer drugs like mitomycin C, bleomycin, and ARK 73-21 (a platinum analogue) retain cytotoxic potency at low temperatures.	Platinum	92-100	AXL receptor tyrosine kinase	Homo sapiens	79-82
3504440-2	1987	Sputtered coats of 1-2 nm of platinum or tungsten provide both an adequate secondary electron signal for SEM and good contrast for STEM and TEM.	Platinum	29-37	MFT2	Homo sapiens	132-135
3039920-5	1987	Maximum total platinum levels in plasma were attained at the end of infusion, and thereafter decayed in a biphasic fashion, with an initial phase half-life (t1/2 alpha) of 10.2 to 14.6 min and a secondary phase half-life (t1/2 beta) of 41.7 to 81.3 h. The half-life was prolonged as the dosage was increased.	Platinum	14-22	interleukin 1 receptor like 1	Homo sapiens	157-167
3039920-5	1987	Maximum total platinum levels in plasma were attained at the end of infusion, and thereafter decayed in a biphasic fashion, with an initial phase half-life (t1/2 alpha) of 10.2 to 14.6 min and a secondary phase half-life (t1/2 beta) of 41.7 to 81.3 h. The half-life was prolonged as the dosage was increased.	Platinum	14-22	interleukin 1 receptor like 1	Homo sapiens	222-231
3039920-6	1987	Non-protein-bound platinum was rapidly cleared to below the measurable level within 4 hours at 80 mg/m2 and 120 mg/m2 of cisplatin, but declined in a biphasic manner, with t1/2 alpha of 31.2 min and t1/2 beta of 20.1 h at 150 mg/m2 of cisplatin.	Platinum	18-26	interleukin 1 receptor like 1	Homo sapiens	172-182
3039920-6	1987	Non-protein-bound platinum was rapidly cleared to below the measurable level within 4 hours at 80 mg/m2 and 120 mg/m2 of cisplatin, but declined in a biphasic manner, with t1/2 alpha of 31.2 min and t1/2 beta of 20.1 h at 150 mg/m2 of cisplatin.	Platinum	18-26	interleukin 1 receptor like 1	Homo sapiens	199-208
3127325-6	1987	On the other hand, CY was more effective than PT on the production of interleukin-3 (IL-3).	Platinum	46-48	interleukin 3	Mus musculus	85-89
3556580-0	1987	Electrochemical characteristics of platinum electrodes coated with cytochrome b5-phospholipid monolayers.	Platinum	35-43	cytochrome b5 type A	Homo sapiens	67-80
3308479-0	1987	The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapy.	Platinum	78-86	mucin 16, cell surface associated	Homo sapiens	28-33
3308479-4	1987	infusions of platinum therapy suggest that an elevated serum CA125 concentration after chemotherapy may identify the presence of residual tumour but a serum antigen level falling into the normal range does not always indicate the complete eradication of tumour.	Platinum	13-21	mucin 16, cell surface associated	Homo sapiens	61-66
2954556-15	1987	Chloride ion was found to reduce platinum-mediated enzyme inhibition in an unpredictable manner, the greatest effect being observed with LAP and GGTP and the least with the ATPases.	Platinum	33-41	leucine aminopeptidase 3	Rattus norvegicus	137-140
2954556-15	1987	Chloride ion was found to reduce platinum-mediated enzyme inhibition in an unpredictable manner, the greatest effect being observed with LAP and GGTP and the least with the ATPases.	Platinum	33-41	gamma-glutamyltransferase 1	Rattus norvegicus	145-149
3566301-6	1987	The CLp had a great influence on the peak plasma concentration and on the AUC of free Pt in serum.	Platinum	86-88	calmodulin like 3	Homo sapiens	4-7
3556580-1	1987	Platinum electrodes can be coated with cytochrome b5-phospholipid monolayers by the Langmuir-Blodgett technique.	Platinum	0-8	cytochrome b5 type A	Homo sapiens	39-52
3327431-8	1987	Acute treatment of rats with nickel, platinum, tin, antimony, bismuth, and cobalt results in induction of heme oxygenase, followed by decreased microsomal heme content and ALAS stimulation in the kidney.	Platinum	37-45	5'-aminolevulinate synthase 1	Rattus norvegicus	172-176
3652926-2	1987	The aim of the present work was to study the disposition of platinum (Pt) after a higher dose of cis-DDP, to verify the rate of free drug penetration into the tissue and to observe changes in protein binding relative to the dose.	Platinum	60-68	translocase of inner mitochondrial membrane 8A	Homo sapiens	101-104
3652926-2	1987	The aim of the present work was to study the disposition of platinum (Pt) after a higher dose of cis-DDP, to verify the rate of free drug penetration into the tissue and to observe changes in protein binding relative to the dose.	Platinum	70-72	translocase of inner mitochondrial membrane 8A	Homo sapiens	101-104
3766956-0	1986	High-performance liquid chromatographic separation of platinum complexes containing the cis-1,2-diaminocyclohexane carrier ligand.	Platinum	54-62	suppressor of cytokine signaling 1	Homo sapiens	88-93
3095337-4	1986	This protein is identified as myosin by its cross-reactivity with two monoclonal antibodies against human platelet myosin, the molecular weight of its heavy chain, its two light chains, its behavior on gel filtration, its ATP-dependent affinity for actin, its characteristic ATPase activity, its molecular morphology as demonstrated by platinum shadowing, and its ability to form bipolar filaments.	Platinum	336-344	myosin heavy chain 14	Homo sapiens	30-36
3026342-0	1986	Further characterization of the platinum-reactive component of the alpha 2-macroglobulin-receptor recognition site.	Platinum	32-40	LDL receptor related protein 1	Homo sapiens	67-97
3791256-3	1986	Ultrafiltrate serum platinum levels correlated with the CSF platinum levels, whereas total plasma platinum did not.	Platinum	20-28	colony stimulating factor 2	Homo sapiens	56-59
3791256-3	1986	Ultrafiltrate serum platinum levels correlated with the CSF platinum levels, whereas total plasma platinum did not.	Platinum	60-68	colony stimulating factor 2	Homo sapiens	56-59
3791256-3	1986	Ultrafiltrate serum platinum levels correlated with the CSF platinum levels, whereas total plasma platinum did not.	Platinum	60-68	colony stimulating factor 2	Homo sapiens	56-59
3001886-0	1985	In vitro binding of platinum compounds to human transferrin.	Platinum	20-28	transferrin	Homo sapiens	48-59
2876605-1	1986	Acute change in urinary gamma-glutamyl transpeptidase (GTP) activity following cis-diamminedichloride platinum (CDDP) administration was studied in 12 patients who had malignant tumors.	Platinum	102-110	inactive glutathione hydrolase 2	Homo sapiens	24-53
2876605-1	1986	Acute change in urinary gamma-glutamyl transpeptidase (GTP) activity following cis-diamminedichloride platinum (CDDP) administration was studied in 12 patients who had malignant tumors.	Platinum	102-110	inactive glutathione hydrolase 2	Homo sapiens	55-58
3791557-3	1986	The MPS-1 system equipped with YMT membranes showed less adsorption of the platinum compounds than CF50A cones and allowed more rapid processing of smaller plasma volumes.	Platinum	75-83	macrophage expressed 1	Homo sapiens	4-9
3941800-3	1986	The decrease in serum albumin from the time of the first dose of cisplatin to death correlated with liver platinum levels at autopsy (r = 0.46, p less than 0.05).	Platinum	106-114	albumin	Homo sapiens	16-29
3941800-4	1986	The decrease in serum albumin concentration associated with liver platinum concentration of less than or equal to 1.5 micrograms/g was 0.16 +/- 0.23 g/dl (range 0-0.6).	Platinum	66-74	albumin	Homo sapiens	16-29
3951788-1	1986	Cis-dichloro-trans-dihydroxy-bis(isopropylamine)platinum IV (CHIP) is a second-generation cis-platinum (DDP) derivative with an octahedral conformation of the platinum complex, far more water-soluble than DDP.	Platinum	48-56	translocase of inner mitochondrial membrane 8A	Homo sapiens	104-107
3951788-1	1986	Cis-dichloro-trans-dihydroxy-bis(isopropylamine)platinum IV (CHIP) is a second-generation cis-platinum (DDP) derivative with an octahedral conformation of the platinum complex, far more water-soluble than DDP.	Platinum	48-56	translocase of inner mitochondrial membrane 8A	Homo sapiens	205-208
3542271-0	1986	A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma.	Platinum	24-32	calcium voltage-gated channel subunit alpha1 F	Homo sapiens	43-46
3542271-1	1986	The platinum analogues JM8 and JM9 were assigned randomly to 16 patients with pleural mesothelioma.	Platinum	4-12	calcium voltage-gated channel subunit alpha1 F	Homo sapiens	23-26
4055896-3	1985	The enhanced stability of the 40-kD peptide when associated with microtubules suggests that this domain of the protein is closely associated with, or partially buried in, the microtubule surface; (d) MAP-2 is a slender, elongate molecule as determined by unidirectional platinum shadowing (90 +/- 30 nm), which is in approximate agreement with previous observations.	Platinum	270-278	microtubule associated protein 2	Homo sapiens	200-205
18963969-0	1985	Extraction chromatography of palladium and platinum complexes with nitroso-R-salt.	Platinum	43-51	sphingolipid transporter 1 (putative)	Homo sapiens	67-81
18963969-1	1985	The retention of palladium and platinum complexes with nitroso-R-salt on silica gel treated with Aliquat 336 has been investigated.	Platinum	31-39	sphingolipid transporter 1 (putative)	Homo sapiens	55-69
18963969-2	1985	The complexation of platinum with nitroso-R-salt (NRS) requires heating of H(2)PtCl(6) with an excess of NRS at 100 degrees .	Platinum	20-28	sphingolipid transporter 1 (putative)	Homo sapiens	34-48
18963969-2	1985	The complexation of platinum with nitroso-R-salt (NRS) requires heating of H(2)PtCl(6) with an excess of NRS at 100 degrees .	Platinum	20-28	sphingolipid transporter 1 (putative)	Homo sapiens	50-53
18963969-2	1985	The complexation of platinum with nitroso-R-salt (NRS) requires heating of H(2)PtCl(6) with an excess of NRS at 100 degrees .	Platinum	20-28	sphingolipid transporter 1 (putative)	Homo sapiens	105-108
2997500-4	1985	The MST for 52 non-surgical patient received VEMT regimen was 8 M, but MST for the recent 15 patients received CAV or COMP regimens is prolonged by 17 M. On the treatment for non-small cell lung cancer, our recent study shows a significant improvement in response rates for patients on platinum-containing combination chemotherapy.	Platinum	286-294	caveolin 2	Homo sapiens	111-114
4040806-9	1985	The cis-bisascorbato (mixed-isomer DACH):platinum (DAP-1) was administered i.p.	Platinum	41-49	death-associated protein	Mus musculus	51-56
6206074-2	1984	The binding sites of seven of 23 different monoclonal antibodies were localized by platinum shadowing of myosin monomer-antibody complexes.	Platinum	83-91	myosin heavy chain 14	Homo sapiens	105-111
6508249-4	1984	By the character of the action on the CD spectrum of the linear and condensed DNA [Pt (tetrameen)Cl2] which had no selective antimitotic effect might be referred to the above platinum compounds.	Platinum	175-183	endogenous retrovirus group W member 5	Homo sapiens	97-100
4039304-0	1985	Radiosensitization of EMT6 cells by four platinum complexes.	Platinum	41-49	IL2 inducible T cell kinase	Mus musculus	22-25
4039071-3	1985	Reduction of all the compounds, except cis-Flap, produces species of a lower oxidation state of platinum which subsequently have both chloride ligands replaced.	Platinum	96-104	arachidonate 5-lipoxygenase activating protein	Homo sapiens	43-47
4039530-5	1985	In patients receiving DDP 100-120 mg/m2, 5/20 with 5-minute plasma platinum concentrations greater than 6 micrograms/ml developed nephrotoxicity; 0/26 with concentrations less than 6 micrograms/ml became nephrotoxic (p less than 0.05).	Platinum	67-75	translocase of inner mitochondrial membrane 8A	Homo sapiens	22-25
2413603-3	1985	Pronounced decoration was observed on the catalase crystals at temperatures between 130 and 180 K. Disregarding the difficulties in interpretation, the averages of 0.1-0.2 nm thick Au and Pt films reveal more structural detail than the relief reconstruction.	Platinum	188-190	catalase	Homo sapiens	42-50
6209003-9	1984	This group of compounds also demonstrated a low level of reactivity with the purified alpha 2-macroglobulin-platinum(II) complex.	Platinum	108-116	alpha-2-macroglobulin	Homo sapiens	86-107
6207191-1	1984	The reaction of three platinum compounds, Pt(NH3)2Cl2, Pt(en)Cl2 and Pt(pn)Cl2 with nucleic acid fragments (Ade, Gua; GpG, GpA and ApA), both reactants (1:1, 1 X 10(-2) M; 1 X 10(-3) M) being dissolved in water, has been studied.	Platinum	22-30	DExD-box helicase 21	Homo sapiens	113-116
6315233-0	1983	Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.	Platinum	29-37	calcium voltage-gated channel subunit alpha1 F	Homo sapiens	18-21
6683993-1	1983	A newly synthesized platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate (TNO-6), was compared with cis-diamminedichloroplatinum(II) (cis-DDP) for antitumor activity and nephrotoxicity.	Platinum	20-28	cytokine inducible SH2-containing protein	Rattus norvegicus	39-44
6340821-6	1983	It is suggested that under the influence of chemotherapy with platinum the production of creatinine and beta-2-microglobulin is decreased rendering their serum levels unsuitable as parameters of renal function.	Platinum	62-70	beta-2-microglobulin	Homo sapiens	104-124
7201475-3	1982	Platinum complexes are retained on solvent generated anion exchangers, prepared by coating reversed-phase (C-18) supports with a monolayer of hexadecyltrimethylammonium bromide.	Platinum	0-8	Bardet-Biedl syndrome 9	Homo sapiens	107-111
6891601-7	1982	The only other products detected were obtained at high levels of cis-DDP and probably represented polymeric forms in which platinum chelates to itself.	Platinum	123-131	translocase of inner mitochondrial membrane 8A	Homo sapiens	69-72
7127319-6	1982	Pharmacokinetics performed at three dosage levels indicates that 4"-carboxyphthalato-(1,2-diaminocyclohexane)platinum(II) has a long t1/2 of 20 to 30 hr (total platinum) and is only partially excreted in the urine and that a high proportion of the drug is nonfilterable within 30 to 60 min of administration.	Platinum	109-117	interleukin 1 receptor like 1	Homo sapiens	133-143
6268741-1	1981	The ribonucleoprotein (RNP) of avian infectious bronchitis virus (IBV) was examined by electron microscopy after shadowing with carbon/platinum.	Platinum	135-143	RNA binding region (RNP1, RRM) containing 3	Homo sapiens	23-26
7272330-3	1981	Serum albumin, which itself has a surface tension of congruent to 70.3 erg/cm2, when dissolved in water lowers the surface tension of water from 72.5 to congruent to 50 erg/cm2, as measured by a variety of means, including the pendant drop, the Wilhelmy plate and the platinum ring methods.	Platinum	268-276	albumin	Homo sapiens	0-13
7194166-4	1981	Both total filterable platinum and cisplatin levels declined in a monophasic manner and exhibited t1/2 of 0.3 to 0.5 hr.	Platinum	22-30	interleukin 1 receptor like 1	Homo sapiens	98-107
7196807-6	1981	The mean (+/- SE) serum T 1/2 alpha of total platinum was 0.42 (+/- 0.10) h and the mean (+/- SE) T 1/2 beta was 44.43 (+/- 8.24) h. The intercompartment distribution rate constants of a two-compartment kinetic model indicate extensive tissue accumulation of total platinum, with a rate of transport into tissue compartments (K12) that is about six times the rate of transport out of tissues (K21).	Platinum	45-53	interleukin 1 receptor like 1	Homo sapiens	24-35
428003-3	1979	Two strains of L5178Y murine lymphoma, inversely cross-sensitive to X-rays and UV light, were shown previously to respond to treatment with an antitumour platinum complex, cis-dichlorobis(cyclopentylamine)-platinum(II) (cis-PAD), in a similar manner as to UV.	Platinum	154-162	paddle	Mus musculus	224-227
116685-4	1979	Glyceraldehyde-3-phosphate dehydrogenase was the only enzyme inhibited by all three Pt compounds tested, with K2PtCl4 being the most effective and cis-Pt(NH3)2Cl2 the least effective inhibitor.	Platinum	84-86	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	0-40
121143-2	1979	Platinum coordination complexes represent a new class of antineoplastic agents among which only cis-diamminedichloroplatinum(II) (cis-DDP) has undergone extensive clinical trials.	Platinum	0-8	translocase of inner mitochondrial membrane 8A	Homo sapiens	134-137
7470563-8	1980	Therefore, dissolution "rates" can be conveniently expressed in terms of nanograms of Pt per coulomb injected, e.g., 100 ng C-1.	Platinum	86-88	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	124-127
226172-3	1979	Platinum compound (K2PtCl4) changes the spectrum of ESR 1 due to the displacement of the label from the enzyme SH-groups and disintegration of the sarcoplasmic reticulum structure.	Platinum	0-8	estrogen receptor 1	Homo sapiens	52-57
466729-4	1979	Enzymic degradation observations on the DNA-cis-Pt(NH3)2Cl2 complexes indicated an important inhibition of the degradation and the absence of release of free drug.	Platinum	48-50	endogenous retrovirus group W member 5	Homo sapiens	56-59
370885-0	1978	[Technical advances in baking a pontic on to a platinum pin].	Platinum	47-55	dynein light chain LC8-type 1	Homo sapiens	56-59
212121-0	1978	Binding of platinum to human transferrin.	Platinum	11-19	transferrin	Homo sapiens	29-40
212121-1	1978	A complex of platinum and human transferrin has been formed by appropriately combining apotransferrin (metal free protein) and potassiumchloroplatinate (K2PtCl4).	Platinum	13-21	transferrin	Homo sapiens	32-43
60173-0	1976	Template primer inactivation by cis- and trans-dichlorodiammine platinum for human DNA polymerase alpha, beta, and Rauscher murine leukemia virus reverse transcriptase, as a mechanism of cytotoxicity.	Platinum	64-72	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	83-103
18962213-4	1978	The platinum-crucible technique yields fluorine and chlorine results for the standard rocks G-2 and GSP-1 that are comparable in value and precision to those obtained by other analytical methods.	Platinum	4-12	RAN, member RAS oncogene family	Homo sapiens	100-105
745586-3	1978	The plasma t1/2beta of platinum was approximately 240 hours after the last DDP dose.	Platinum	23-31	interleukin 1 receptor like 1	Homo sapiens	11-19
142520-4	1977	The acidoligands studied according to their inhibition effect can be arranged in the following line: NO2, Cl, Br, SCN, I, which is true both for platinum and palladium compounds.	Platinum	145-153	sorcin	Homo sapiens	114-117
925603-2	1977	Ni(2+) and Pt(4+), metals which do not enzymatically form metalloporphyrins, were found to regulate ALAS in kidney as they do in liver.	Platinum	11-13	5'-aminolevulinate synthase 1	Homo sapiens	100-104
1277140-9	1976	The apparent in vitro binding of platinum to dog plasma and to bovine serum albumin was studied by ultrafiltration and increased progressively during 48 hr of incubation at 37 degrees.	Platinum	33-41	albumin	Canis lupus familiaris	70-83
953006-5	1976	In addition, it has been possible in the case of the trans-Pt (NH3)CCl1 complex to follow the fixation of platinum to DNA by atomic absorption spectrophotometry.	Platinum	106-114	C-C motif chemokine ligand 1	Homo sapiens	67-71
240368-4	1975	Cortical pO2 was recorded with a multiwire platinum electrode.	Platinum	43-51	PO2	Sus scrofa	9-12
1070517-0	1976	The effects of single administration of an antitumor platinum compound on ornithine decarboxylase activity in certain tissues of mice bearing L1210 leukemia.	Platinum	53-61	ornithine decarboxylase, structural 1	Mus musculus	74-97
1070517-2	1976	The inhibition of ODC, the rate-limiting enzyme in polyamine synthesis, appeared to correlate with the prolonged chemotherapeutic efficacy of a single dose of the platinum complex.	Platinum	163-171	ornithine decarboxylase, structural 1	Mus musculus	18-21
1236953-0	1975	Studies of platinum complex inhibition of leucine aminopeptidase.	Platinum	11-19	leucine aminopeptidase	Sus scrofa	42-64
4371878-0	1974	[Effect of platinum and palladium complexes on the activity of and conformational transitions in transport ATPase].	Platinum	11-19	dynein axonemal heavy chain 8	Homo sapiens	107-114
4355308-0	1973	Chemical and structural relationships of NAD+ and platinum binding to malate dehydrogenase.	Platinum	50-58	malic enzyme 1	Homo sapiens	70-90
4367976-0	1974	The inhibition of malate dehydrogenase by chlorammine-platinum complexes.	Platinum	54-62	malic enzyme 1	Homo sapiens	18-38
5945249-2	1966	Flash illumination of a suspension of frog rod outer segments or rhodopsin solution in contact with a platinum electrode produces a rapidly developing negative displacement of potential of the electrode (with respect to a reversible electrode).2.	Platinum	102-110	rhodopsin	Homo sapiens	65-74
5727770-0	1968	Uncovered platinum electrodes for the measurement of delta PO2 as an aid in diagnostic cardiac catheterization.	Platinum	10-18	activation induced cytidine deaminase	Homo sapiens	69-72
31824059-1	1967	CaF2 crystals doped with 0.1 percent GdF3 were observed to develop surface layers when annealed above 700  C in air, during application of Pt paste electrodes.	Platinum	139-141	CCR4-NOT transcription complex subunit 8	Homo sapiens	0-4
31824059-1	1967	CaF2 crystals doped with 0.1 percent GdF3 were observed to develop surface layers when annealed above 700  C in air, during application of Pt paste electrodes.	Platinum	139-141	growth differentiation factor 3	Homo sapiens	37-41
5799414-0	1969	[Determination of cholinesterase activity by polarography with rotating platinum electrode].	Platinum	72-80	butyrylcholinesterase	Homo sapiens	18-32
5945249-4	1966	It is inferred that the response is due to an uptake of H(+) by the rod outer segments or rhodopsin, with the platinum surface acting as a pH electrode.3.	Platinum	110-118	rhodopsin	Homo sapiens	90-99
33744539-2	2021	Here, ultrafine bimetallic Ga-Pt nanocatalysts encapsulated into silicalite-1 (S-1) zeolites (GaPt@S-1) were synthesized by a facile ligand-protected direct H2-reduction method.	Platinum	30-32	GRB2 binding adaptor protein, transmembrane	Homo sapiens	94-98
17769917-1	1965	The activation energies of ice with varying amounts of impurities added were investigated with sintered platinum electrodes.	Platinum	104-112	carboxylesterase 2	Homo sapiens	27-30
33933489-3	2021	The Pt-Au/R-TNTs with 0.33 wt% of SA metals, exhibited a maximum of 149 times higher photocatalytic performance than unmodified R-TNT and a total apparent quantum yield (AQY) of 17.9%, in which the yield of CH4 and C2H6 reached to 360.0 and 28.8 mumol g-1 h-1, respectively.	Platinum	4-6	chromosome 16 open reading frame 82	Homo sapiens	12-15
33744543-6	2021	For MOR, the mass activity of Pt-Co3O4@NPC/CuO-400 (5 wt%) (1947 mA mgPt-1) is much higher than that of Pt/C (751 mA mgPt-1), mainly attributing to that the Pt active sites are uniformly dispersed on Co3O4@NPC/CuO support.	Platinum	30-32	opioid receptor mu 1	Homo sapiens	4-7
33899284-5	2021	Here, by studying spin transport in a magnetic-metal/magnetic-insulator/platinum multilayer, it is demonstrated that coherent magnons can transfer spins efficiently above the magnon bandgap of magnetic insulators.	Platinum	72-80	spindlin 1	Homo sapiens	18-22
33539540-1	2021	Preclinical studies have shown synergistic effects when combining PARP1/2-inhibitors and platinum drugs in BRCA1/2 mutated cancer cell models.	Platinum	89-97	BRCA1 DNA repair associated	Homo sapiens	107-114
33389085-10	2021	Risks factors linked to these DRP were a low Charlson Comorbidity Index, polypharmacy, the kind of hospital, and some chemotherapies (platinum preparations).	Platinum	134-142	utrophin	Homo sapiens	30-33
33388995-8	2021	IL-1beta and TNFalpha significantly correlated among them before and after platinum-based chemotherapy.	Platinum	75-83	interleukin 1 alpha	Homo sapiens	0-8
33675937-6	2021	For patients with recurrent high grade ovarian cancer, which responds to platinum-based treatment maintenance therapy with a poly(ADP-ribose) polymerase (PARP) inhibitor can be offered, regardless of BRCA mutation status.	Platinum	73-81	poly(ADP-ribose) polymerase 1	Homo sapiens	125-152
33675937-6	2021	For patients with recurrent high grade ovarian cancer, which responds to platinum-based treatment maintenance therapy with a poly(ADP-ribose) polymerase (PARP) inhibitor can be offered, regardless of BRCA mutation status.	Platinum	73-81	poly(ADP-ribose) polymerase 1	Homo sapiens	154-158
33932471-3	2021	Therefore, we aimed to test the hypothesis that 1) platinum-based chemotherapy and BEV equally damage isolated mitochondria from human ovarian cancers, and ovarian cancer cells through inducing mitochondrial dynamics dysregulation, mitochondrial dysfunction, increased mitophagy and apoptosis, as well as altered inflammation and VEGF; and 2) combined therapies exert greater damage than monotherapy.	Platinum	51-59	vascular endothelial growth factor A	Homo sapiens	330-334
33932471-6	2021	Platinum-based chemotherapy caused ovarian cancer mitochondria and cell damage through mitochondrial dysfunction, increased cell death with impairment of membrane integrity, and enhanced VEGF reduction, while BEV did not.	Platinum	0-8	vascular endothelial growth factor A	Homo sapiens	187-191
33741331-2	2021	A platinum(IV) conjugate ketoplatin deriving from FDA-approved drugs cisplatin and ketoprofen was designed and prepared to enhance antitumor activity and suppress EMT in TNBC via positive impact on inflammatory microenvironment by modulating COX-2 signal.	Platinum	2-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	242-247
33744756-6	2021	Pt/MgO nanoparticles downregulated Bcl-2 and upregulated Bax and p53 tumor suppressor proteins in the cancer cells.	Platinum	0-2	BCL2 apoptosis regulator	Homo sapiens	35-40
33744756-6	2021	Pt/MgO nanoparticles downregulated Bcl-2 and upregulated Bax and p53 tumor suppressor proteins in the cancer cells.	Platinum	0-2	BCL2 associated X, apoptosis regulator	Homo sapiens	57-60
33744756-6	2021	Pt/MgO nanoparticles downregulated Bcl-2 and upregulated Bax and p53 tumor suppressor proteins in the cancer cells.	Platinum	0-2	tumor protein p53	Homo sapiens	65-68
33388995-8	2021	IL-1beta and TNFalpha significantly correlated among them before and after platinum-based chemotherapy.	Platinum	75-83	tumor necrosis factor	Homo sapiens	13-21
33153817-18	2021	CONCLUSIONS: The hitherto unappreciated attenuation of the CXCR2/BCL-2 axis in taxane-treated mCRPC patients is an acquired vulnerability with potential predictive activity for platinum-based treatments.	Platinum	177-185	C-X-C motif chemokine receptor 2	Homo sapiens	59-64
33153817-0	2021	Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.	Platinum	81-89	C-X-C motif chemokine receptor 2	Homo sapiens	34-39
33153817-18	2021	CONCLUSIONS: The hitherto unappreciated attenuation of the CXCR2/BCL-2 axis in taxane-treated mCRPC patients is an acquired vulnerability with potential predictive activity for platinum-based treatments.	Platinum	177-185	BCL2 apoptosis regulator	Homo sapiens	65-70
33153817-0	2021	Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.	Platinum	81-89	BCL2 apoptosis regulator	Homo sapiens	40-45
33887703-3	2021	The assembled carbon nitride/positive carbon black anchoring PtNPs (Pt/CN2-CB+1) catalyst exhibits significantly improved specific surface area, high graphitization, and uniformly dispersed ultra-small platinum nanoparticles.	Platinum	202-210	carnosine dipeptidase 2	Homo sapiens	71-74
34031523-3	2021	The two parts with low and high tCo ranges are close to and away from the top interface (Co/Pt), respectively.	Platinum	92-94	TCO	Homo sapiens	32-35
34050247-0	2021	Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy.	Platinum	77-85	cell division cycle associated 3	Homo sapiens	10-15
34050247-4	2021	We demonstrate that in patients and in vitro analyses, CDCA3 levels correlate with measures of genome instability and platinum sensitivity, whereby CDCA3high tumours are sensitive to cisplatin and carboplatin.	Platinum	118-126	cell division cycle associated 3	Homo sapiens	55-60
34050247-8	2021	We propose that combining CK2 inhibitors with platinum-based chemotherapy could enhance platinum efficacy in CDCA3low NSCLC tumours and benefit patients.	Platinum	46-54	cell division cycle associated 3	Homo sapiens	109-114
34050247-8	2021	We propose that combining CK2 inhibitors with platinum-based chemotherapy could enhance platinum efficacy in CDCA3low NSCLC tumours and benefit patients.	Platinum	88-96	cell division cycle associated 3	Homo sapiens	109-114
33929183-5	2021	The levels of glutathione reductase (GR) and xeroderma pigmentosum group A (XPA) were down-regulated by ONOO-, thus synergistically decreasing detoxification and blocking DNA damage repair of Pt-based chemotherapy.	Platinum	192-194	glutathione-disulfide reductase	Homo sapiens	14-35
33929183-5	2021	The levels of glutathione reductase (GR) and xeroderma pigmentosum group A (XPA) were down-regulated by ONOO-, thus synergistically decreasing detoxification and blocking DNA damage repair of Pt-based chemotherapy.	Platinum	192-194	glutathione-disulfide reductase	Homo sapiens	37-39
33929183-5	2021	The levels of glutathione reductase (GR) and xeroderma pigmentosum group A (XPA) were down-regulated by ONOO-, thus synergistically decreasing detoxification and blocking DNA damage repair of Pt-based chemotherapy.	Platinum	192-194	XPA, DNA damage recognition and repair factor	Homo sapiens	45-74
33929183-5	2021	The levels of glutathione reductase (GR) and xeroderma pigmentosum group A (XPA) were down-regulated by ONOO-, thus synergistically decreasing detoxification and blocking DNA damage repair of Pt-based chemotherapy.	Platinum	192-194	XPA, DNA damage recognition and repair factor	Homo sapiens	76-79
33960368-8	2021	Mapping these pS/pT sites on the hTDO surface revealed their propinquity to acidic Asp/Glu (D/E) residues engendering negatively charged DEpSpT clusters vicinal to the ubiquitination K sites over the entire protein surface.	Platinum	17-19	tryptophan 2,3-dioxygenase	Homo sapiens	33-37
34045295-3	2021	ORRs within the approved patient populations ranged from 57% (95% CI: 46, 68) in patients with RET fusion-positive NSCLC previously treated with platinum chemotherapy to 89% (95% CI: 52, 100) in patients with RET fusion-positive thyroid cancer, with response duration of at least 6 months in most responders.	Platinum	145-153	ret proto-oncogene	Homo sapiens	95-98
33988965-2	2021	In the present work, the hydrogen storage mechanism and structural transformations of core (Pd)-shell (Pt) (CS) and solid-solution (SS) NPs during hydrogen absorption and desorption (PHAD) processes are investigated.	Platinum	103-105	citrate synthase	Homo sapiens	108-110
34039986-4	2021	The conversion of  99% is significantly superior to the corresponding values of mpg-C3N4-supported single Pt atoms and ultra-small Pt nanoparticles (~2 nm).	Platinum	106-108	N-methylpurine DNA glycosylase	Homo sapiens	80-83
34036692-1	2021	Pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) with manageable safety versus placebo plus pemetrexed-platinum in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations in the global, randomized, double-blind, phase 3 KEYNOTE-189 study.	Platinum	30-38	epidermal growth factor receptor	Homo sapiens	287-291
34036692-1	2021	Pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) with manageable safety versus placebo plus pemetrexed-platinum in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations in the global, randomized, double-blind, phase 3 KEYNOTE-189 study.	Platinum	30-38	ALK receptor tyrosine kinase	Homo sapiens	292-295
34029511-0	2021	Rs3802278 in 3"-UTR of SULF1 associated with platinum resistance and survival in Chinese epithelial ovarian cancer patients.	Platinum	45-53	sulfatase 1	Homo sapiens	23-28
34029511-2	2021	This study aims to examine the role of polymorphisms in sulfatase 1 (SULF1) in platinum resistance and survival in advanced epithelial ovarian cancer (EOC) patients.	Platinum	79-87	sulfatase 1	Homo sapiens	56-67
34029511-2	2021	This study aims to examine the role of polymorphisms in sulfatase 1 (SULF1) in platinum resistance and survival in advanced epithelial ovarian cancer (EOC) patients.	Platinum	79-87	sulfatase 1	Homo sapiens	69-74
34029511-3	2021	We genotyped 12 SNPs of SULF1 in 195 EOC patients treated with platinum using MassARRAY method and evaluated the association between the SNPs and platinum response.	Platinum	63-71	sulfatase 1	Homo sapiens	24-29
34029511-4	2021	SULF1 rs3802278 was marginal significantly associated with platinum resistance in recessive model with p value of 0.055.	Platinum	59-67	sulfatase 1	Homo sapiens	0-5
34029511-5	2021	The patients with SULF1 rs3802278 AA were more resistant to platinum-based chemotherapy comparing to those with AG/GG genotype (OR: 2.317, 95%CI: 0.982 ~ 5.465).	Platinum	60-68	sulfatase 1	Homo sapiens	18-23
34029511-8	2021	SULF1 rs3802278 may serve as a potential candidate biomarker for the prediction of platinum resistance and prognosis in Chinese EOC patients.	Platinum	83-91	sulfatase 1	Homo sapiens	0-5
33839227-0	2021	Fabricating nanoparticles co-loaded with survivin siRNA and Pt(IV) prodrug for the treatment of platinum-resistant lung cancer.	Platinum	96-104	baculoviral IAP repeat-containing 5	Mus musculus	41-49
34021944-4	2021	Patients with BRCA1/BRCA2 PVs display worse clinical outcomes but respond better to platinum-based chemotherapies and PARP inhibitors, a trait termed as "BRCAness".	Platinum	84-92	BRCA1 DNA repair associated	Homo sapiens	14-19
34021944-4	2021	Patients with BRCA1/BRCA2 PVs display worse clinical outcomes but respond better to platinum-based chemotherapies and PARP inhibitors, a trait termed as "BRCAness".	Platinum	84-92	BRCA2 DNA repair associated	Homo sapiens	20-25
33957043-6	2021	Electrochemical results indicate that the as-prepared Co-SAs-HCS catalyst shows a low potential difference (0.809 V) between the oxygen evolution reaction potential at 10 mA cm-2 and the oxygen reduction reaction half-wave potential, outperforming the commercial Pt/C catalysts (0.996 V).	Platinum	263-265	holocarboxylase synthetase	Homo sapiens	61-64
33685865-7	2021	Compared to a 2:1 cohort of patients with metastatic NSCLC without targetable alterations (n=192), EGFR ex20ins patients had longer overall survival (median 20 vs. 12 mo, HR 0.56, p=0.007) and longer time to treatment discontinuation (TTD) for platinum chemotherapy (median 7 vs. 4 mo, HR 0.6, p=0.02) and no improvement in TTD for immune checkpoint inhibitors (ICI) (HR 1.75, p=0.05).	Platinum	244-252	epidermal growth factor receptor	Homo sapiens	99-103
33685865-8	2021	CONCLUSIONS: With better outcomes on platinum chemotherapy, patients with EGFR ex20ins NSCLC have improved prognosis, lower PD-L1 expression and TMB, and derive less benefit from ICI compared to NSCLC patients without targetable oncogenes.	Platinum	37-45	epidermal growth factor receptor	Homo sapiens	74-78
34023505-8	2021	In clinical specimens from NSCLC patients SDF-1 levels were found to be higher in platinum-treated samples and related to a worse clinical outcome.	Platinum	82-90	C-X-C motif chemokine ligand 12	Homo sapiens	42-47
33839227-2	2021	To overcome the resistance of cells, the survivin protein is supposed to be decreased, since it has previously been found to be overexpressed in drug-resistant cancer cells in anti-apoptosis pathways, while the intracellular effective platinum accumulation should be increased.	Platinum	235-243	baculoviral IAP repeat-containing 5	Mus musculus	41-49
34025781-5	2021	Tumors that are deficient in DNA damage repair mechanisms such as BRCA mutants respond better to platinum-based chemotherapies.	Platinum	97-105	BRCA1 DNA repair associated	Homo sapiens	66-70
33990090-14	2021	Patients with a BRCA2 defect showed marked response to both PARP inhibitors and platinum-based chemotherapy.	Platinum	80-88	BRCA2 DNA repair associated	Homo sapiens	16-21
33980883-1	2021	The paper reports for the first time an innovative polyaniline (PANI)/platinum (Pt)-coated fiber optic-surface plasmon resonance (FO-SPR) sensor used for highly-sensitive 4-nitrophenol (4-NP) pollutant detection.	Platinum	70-78	sepiapterin reductase	Homo sapiens	133-136
33980883-1	2021	The paper reports for the first time an innovative polyaniline (PANI)/platinum (Pt)-coated fiber optic-surface plasmon resonance (FO-SPR) sensor used for highly-sensitive 4-nitrophenol (4-NP) pollutant detection.	Platinum	80-82	sepiapterin reductase	Homo sapiens	133-136
33952262-11	2021	High RAD51 expression indicated unfavorable survival outcomes and resistance to platinum, taxane, and PARP inhibitors in ovarian cancer.	Platinum	80-88	RAD51 recombinase	Homo sapiens	5-10
33709473-0	2021	Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer.	Platinum	56-64	RAD51 recombinase	Homo sapiens	24-29
33709473-3	2021	The DNA repair pathway homologous recombination (HR) repairs platinum-induced damage, and the HR recombinase RAD51 is overexpressed in cancer.	Platinum	61-69	RAD51 recombinase	Homo sapiens	109-114
33709473-8	2021	Our findings highlight RAD51 expression as a determinant of platinum resistance and suggest possible roles for therapy to overcome immune exclusion in RAD51-High EOC.	Platinum	60-68	RAD51 recombinase	Homo sapiens	23-28
34007132-4	2021	In patients with germline BRCA mutations, platinum-based chemotherapies and poly (ADP-ribose) polymerase inhibitors are effective treatment options which may offer survival benefits.	Platinum	42-50	BRCA1 DNA repair associated	Homo sapiens	26-30
33733573-0	2021	Toll-like receptor 4 is activated by platinum and contributes to cisplatin-induced ototoxicity.	Platinum	37-45	toll like receptor 4	Homo sapiens	0-20
33733573-2	2021	In this work, we test whether TLR4 can be activated by the Group 10 metal platinum and the platinum-based chemotherapeutic cisplatin.	Platinum	74-82	toll like receptor 4	Homo sapiens	30-34
33952262-12	2021	In the validation cohort (126 patients), high RAD51 expression indicated platinum resistance, and platinum-resistant patients expressed more RAD51.	Platinum	73-81	RAD51 recombinase	Homo sapiens	46-51
33733573-4	2021	We demonstrate that platinum and cisplatin activate pathways downstream of TLR4 to a similar extent as the known TLR4 agonists LPS and nickel.	Platinum	20-28	toll like receptor 4	Homo sapiens	75-79
33733573-4	2021	We demonstrate that platinum and cisplatin activate pathways downstream of TLR4 to a similar extent as the known TLR4 agonists LPS and nickel.	Platinum	20-28	toll like receptor 4	Homo sapiens	113-117
34029775-4	2021	Detailed mechanisms in SGC-7901/CDDP cells assays revealed that complex 14 efficiently induced apoptosis via down-regulating expression of P-gp for enhanced intracellular uptake of platinum, arrested cells at G2/M phase, induced DNA damage and initiated mitochondrial apoptosis pathway.	Platinum	181-189	ATP binding cassette subfamily B member 1	Homo sapiens	139-143
33952262-12	2021	In the validation cohort (126 patients), high RAD51 expression indicated platinum resistance, and platinum-resistant patients expressed more RAD51.	Platinum	98-106	RAD51 recombinase	Homo sapiens	141-146
33950302-7	2021	The DFT/CAM-B3LYP/Def2-SVP/SMD level can be recommended for theoretical estimations of absorption spectra of complexes of palladium or platinum and sulfur-containing ligands.	Platinum	135-143	small nuclear ribonucleoprotein polypeptide N	Homo sapiens	27-30
33855690-1	2021	INTRODUCTION: The phase III KEYNOTE-048 trial showed that the programmed death receptor 1 (PD-1) inhibitor pembrolizumab, in the combined positive score (CPS) >= 1 population and combined with platinum + 5-fluorouracil in the total population, improves survival over cetuximab + platinum + 5-fluorouracil in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).	Platinum	279-287	programmed cell death 1	Homo sapiens	62-89
33951465-3	2021	Here, we report that KIM-1 mediates PT uptake of palmitic acid (PA)-bound albumin, leading to enhanced tubule injury with DNA damage, PT cell-cycle arrest, interstitial inflammation and fibrosis, and secondary glomerulosclerosis.	Platinum	36-38	hepatitis A virus cellular receptor 1	Homo sapiens	21-26
33951465-3	2021	Here, we report that KIM-1 mediates PT uptake of palmitic acid (PA)-bound albumin, leading to enhanced tubule injury with DNA damage, PT cell-cycle arrest, interstitial inflammation and fibrosis, and secondary glomerulosclerosis.	Platinum	36-38	albumin	Homo sapiens	74-81
33617126-2	2021	The sandwich-shaped multinuclear Ag complexes showed two different types of fluxional behavior in solution: rapid slippage of Pt complex units on the Ag3 core and a reversible demetalation-metalation reaction by the treatment with Cl anion and Ag ion, respectively.	Platinum	126-128	anterior gradient 3, protein disulphide isomerase family member	Homo sapiens	150-153
33792090-2	2021	In this work, the tailoring of electronic structure of Pt single atoms supported on N-doped mesoporous hollow carbon spheres (Pt1 /NMHCS) via strong EMSI engineering is reported.	Platinum	55-57	zinc finger protein 77	Homo sapiens	126-129
33855690-1	2021	INTRODUCTION: The phase III KEYNOTE-048 trial showed that the programmed death receptor 1 (PD-1) inhibitor pembrolizumab, in the combined positive score (CPS) >= 1 population and combined with platinum + 5-fluorouracil in the total population, improves survival over cetuximab + platinum + 5-fluorouracil in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).	Platinum	279-287	programmed cell death 1	Homo sapiens	91-95
33382454-0	2021	Efficacy and safety of PD1/PDL1 blockade with platinum-based chemotherapy for extensive small cell lung cancer: a pooled analysis of randomized trials.	Platinum	46-54	programmed cell death 1	Homo sapiens	23-26
33952496-7	2021	CONCLUSION: Patients with tumors showing low ERCC1 expression had a better disease control rate on platinum-containing chemotherapy.	Platinum	99-107	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	45-50
33515422-3	2021	However, there is no doubt that the incorporation of PARP inhibitors as maintenance after the response to platinum-based chemotherapy, first in recurrent disease and recently also in first line, will change the natural history of the disease.The objective of this guide is to summarize the current evidence for the diagnosis, treatment, and follow-up of ovarian cancer, and to provide evidence-based recommendations for clinical practice.	Platinum	106-114	poly(ADP-ribose) polymerase 1	Homo sapiens	53-57
33580280-2	2021	A calcineurin inhibitor is initiated after cyclophosphamide administration in the commonly used PT/CY regimens.	Platinum	96-98	calcineurin binding protein 1	Homo sapiens	2-23
33382454-0	2021	Efficacy and safety of PD1/PDL1 blockade with platinum-based chemotherapy for extensive small cell lung cancer: a pooled analysis of randomized trials.	Platinum	46-54	CD274 molecule	Homo sapiens	27-31
33579575-0	2021	Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma" [Eur Urol 2020;78:907-15].	Platinum	117-125	fibroblast growth factor receptor 3	Homo sapiens	16-51
33662100-1	2021	Importance: The subtype of pancreatic ductal adenocarcinoma cancer (PDAC) with DNA damage repair (DDR) deficiency from BRCA1/2 variants has a favorable prognosis and is sensitive to platinum analogues and poly-(adenosine diphosphate-ripose) polymerase (PARP) inhibition with olaparib.	Platinum	182-190	BRCA1 DNA repair associated	Homo sapiens	119-126
33524400-13	2021	In four patients, BRCA2 reversion mutations associated with platinum resistance.	Platinum	60-68	BRCA2 DNA repair associated	Homo sapiens	18-23
33793071-4	2021	This study aimed to determine the prognostic significance of GAL3 expression in NSCLC patients receiving platinum-based AC.	Platinum	105-113	galectin 3	Homo sapiens	61-65
33743851-1	2021	BACKGROUND: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously been shown to extend progression-free survival versus placebo when given to patients with relapsed high-grade serous or endometrioid ovarian cancer who were platinum sensitive and who had a BRCA1 or BRCA2 (BRCA1/2) mutation, as part of the SOLO2/ENGOT-Ov21 trial.	Platinum	243-251	poly(ADP-ribose) polymerase 1	Homo sapiens	54-58
33724861-0	2021	Cytidine deaminase 435C>T polymorphism relates to gemcitabine-platinum efficacy and hematological toxicity in Chinese non-small-cell lung cancer patients.	Platinum	62-70	cytidine deaminase	Homo sapiens	0-18
33738956-7	2021	A collaborative hydrogen production mechanism via Volmer-Heyrovsky pathway is suggested: Te2 2- adsorbs protons and assists the mass transfer to adjacent Pt atoms where the protons are reduced and released as hydrogen.	Platinum	154-156	N-alpha-acetyltransferase 10, NatA catalytic subunit	Homo sapiens	89-92
32533488-5	2021	Increasing the doping amount of platinum on SAB (400) catalyst from 0.1 to 1 wt% increased particle size of platinum and lowered the temperature of TPR (TTP) for SAB (400) catalyst.	Platinum	32-40	translocated promoter region, nuclear basket protein	Homo sapiens	148-151
33687763-3	2021	Both trials demonstrated an improvement in overall survival (OS) with anti-PD-L1 antibodies when added to platinum-based chemotherapy as compared to chemotherapy alone.	Platinum	106-114	CD274 molecule	Homo sapiens	75-80
33793071-0	2021	Prognostic significance of galectin-3 expression in patients with resected NSCLC treated with platinum-based adjuvant chemotherapy.	Platinum	94-102	galectin 3	Homo sapiens	27-37
33793071-10	2021	CONCLUSIONS: GAL3 expression is a reliable biomarker to predict the prognosis of completely resected NSCLC patients receiving platinum-based AC.	Platinum	126-134	galectin 3	Homo sapiens	13-17
33931646-6	2021	Surprisingly, Pt-doping in gold increases the diatropic response of the superatomic electrons to an external magnetic field and enhances the aromaticity of [PtHAu8(PPh3)8]+.	Platinum	14-16	caveolin 1	Homo sapiens	164-168
33930176-21	2021	Single-agent ICI In the PD-L1 expression >= 50% group single-agent ICI probably improved OS compared to platinum-based chemotherapy (hazard ratio (HR) 0.68, 95% confidence interval (CI) 0.60 to 0.76, 6 RCTs, 2111 participants, moderate-certainty evidence).	Platinum	104-112	CD274 molecule	Homo sapiens	24-29
33930176-26	2021	More information about efficacy of single-agent ICI compared to platinum-based chemotherapy according to the level of PD-L1 expression and to TMB status or specific clinical characteristics is available in the full text.	Platinum	64-72	CD274 molecule	Homo sapiens	118-123
33876808-2	2021	To explore the tunability, we chose a [Ni/Co]/Pt-based spin Hall nano-oscillator with a moderate uniaxial anisotropy to systematically study the corresponding magnetodynamics excited by locally injecting a dc current into a nanoscale region of the extended multilayers [Ni/Co]/Pt under certain conditions.	Platinum	46-48	spindlin 1	Homo sapiens	55-59
33876808-0	2021	Controllable excitation of multiple spin wave bullet modes in a spin Hall nano-oscillator based on [Ni/Co]/Pt multilayers.	Platinum	107-109	spindlin 1	Homo sapiens	36-40
33876808-0	2021	Controllable excitation of multiple spin wave bullet modes in a spin Hall nano-oscillator based on [Ni/Co]/Pt multilayers.	Platinum	107-109	spindlin 1	Homo sapiens	64-68
33995018-11	2021	In addition, we defined six DNA DMPs consisting of four gene members (mesothelin, protein kinase cAMP-dependent type II regulatory subunit beta, msh homeobox 1, and par-6 family cell polarity regulator alpha) that may have favorable prognostic and predictive values for platinum chemotherapy.	Platinum	270-278	msh homeobox 1	Homo sapiens	97-159
33926263-0	2022	Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis.	Platinum	87-95	poly(ADP-ribose) polymerase 1	Homo sapiens	10-14
33926263-1	2022	BACKGROUND: Earlier trials on the efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors in platinum-sensitive relapsed ovarian cancer used the hazard ratio (HR) as an efficacy parameter.	Platinum	96-104	poly(ADP-ribose) polymerase 1	Homo sapiens	46-74
33926263-1	2022	BACKGROUND: Earlier trials on the efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors in platinum-sensitive relapsed ovarian cancer used the hazard ratio (HR) as an efficacy parameter.	Platinum	96-104	poly(ADP-ribose) polymerase 1	Homo sapiens	76-80
33995018-11	2021	In addition, we defined six DNA DMPs consisting of four gene members (mesothelin, protein kinase cAMP-dependent type II regulatory subunit beta, msh homeobox 1, and par-6 family cell polarity regulator alpha) that may have favorable prognostic and predictive values for platinum chemotherapy.	Platinum	270-278	par-6 family cell polarity regulator alpha	Homo sapiens	165-170
33996960-6	2021	In HepG2 cells, we identified 62 significantly differentially expressed genes (DEGs) (6,564 transcripts) and 319 lncRNAs (124 known lncRNAs and 195 novel lncRNAs) that were affected by ORF3, which were involved in systemic lupus erythematosus, Staphylococcus aureus infection, signaling pathways pluripotency regulation of stem cells, the peroxisome proliferator-activated receptor (PPAR) signaling pathway, and platinum drug resistance pathways.	Platinum	412-420	ankyrin repeat, SAM and basic leucine zipper domain containing 1	Homo sapiens	185-189
33754689-3	2021	Herein, by employing amorphous palladium phosphide (a-Pd-P) as substrates, we develop a class of leaching-free, ultrastable core-shell Pt catalysts with well-controlled shell thicknesses and surface structures for fuel cell electrocatalysis.	Platinum	135-137	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	54-58
33932503-3	2021	PATIENTS AND METHODS: KATHERINE enrolled HER2-positive EBC patients with residual invasive disease in the breast/axilla at surgery after NACT containing a taxane (+-anthracycline, +-platinum) and trastuzumab (+-pertuzumab).	Platinum	182-190	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
33925044-12	2021	Collectively, APOBEC3B expression was an independent prognostic factor in patients with metastatic urothelial carcinoma treated with platinum-based chemotherapy.	Platinum	133-141	apolipoprotein B mRNA editing enzyme catalytic subunit 3B	Homo sapiens	14-22
33754689-4	2021	When a submonolayer of Pt is deposited on the 6 nm nanocubes, the resulting Pd@a-Pd-P@PtSML core-shell catalyst can deliver a mass activity as high as 4.08 A/mgPt and 1.37 A/mgPd+Pt toward the oxygen reduction reaction at 0.9 V vs the reversible hydrogen electrode and undergoes 50 000 potential cycles with only ~9% activity loss and negligible structural deformation.	Platinum	23-25	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	81-85
33754689-5	2021	As elucidated by the DFT calculations, the superior durability of the catalysts originates from the high corrosion resistance of the disordered a-Pd-P substrates and the strong interfacial Pt-P interactions between the Pt shell and amorphous Pd-P layer.	Platinum	219-221	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	242-246
33894335-6	2021	RESULTS: After median follow-up of 31.0 months, pembrolizumab plus pemetrexed-platinum continued to improve OS (hazard ratio [HR], 0.56; 95% CI, 0.46-0.69), and PFS (HR, 0.49; 95% CI, 0.41-0.59) over placebo plus pemetrexed-platinum regardless of PD-L1 expression.	Platinum	78-86	CD274 molecule	Homo sapiens	247-252
33904759-11	2021	Patients with mCRPC harboring genomic defects in crucial HR genes either in the germline or somatic, especially BRCA2 and ATM, might experience superior outcomes to platinum-based chemotherapy, compared with those harboring CDK12 defect.	Platinum	165-173	BRCA2 DNA repair associated	Homo sapiens	112-117
33904759-11	2021	Patients with mCRPC harboring genomic defects in crucial HR genes either in the germline or somatic, especially BRCA2 and ATM, might experience superior outcomes to platinum-based chemotherapy, compared with those harboring CDK12 defect.	Platinum	165-173	ATM serine/threonine kinase	Homo sapiens	122-125
33896588-12	2021	[9% vs 18%, p = 0.019] and the time-to-HSRs curves show that the risk increases with the duration of platinum exposure, in BRCA mutated pts.	Platinum	101-109	BRCA1 DNA repair associated	Homo sapiens	123-127
33967938-0	2021	Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient"s Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing-Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study).	Platinum	254-262	proprotein convertase subtilisin/kexin type 1 inhibitor	Homo sapiens	133-136
33888137-4	2021	Here, we hypothesized that treating high grade, platinum resistant endometrioid cancer cells with an LCK inhibitor (LCKi) followed by co-treatment with cisplatin would lead to increased cisplatin efficacy.	Platinum	48-56	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	101-104
33882241-5	2021	Several PARP inhibitors, which target defective DNA repair have been approved as maintenance therapy for advanced ovarian cancer in both the first line and platinum sensitive relapsed settings.	Platinum	156-164	poly(ADP-ribose) polymerase 1	Homo sapiens	8-12
33881798-5	2021	For oxidation processes that require the activation of rather inert molecules at high T, like alkanes, catalytic combustion is attributed to stable single Pt atoms when the support is CHA, generated in situ in the O2 stream.	Platinum	155-157	transcription factor like 5	Homo sapiens	184-187
33871703-10	2021	Most recent PFI, response to the last platinum-based chemotherapy, and the number of previous chemotherapy lines were associated with PFS in patients with BRCA-mutated recurrent ovarian cancer.	Platinum	38-46	BRCA1 DNA repair associated	Homo sapiens	155-159
33574092-0	2021	The miR-181a-SFRP4 axis regulates Wnt activation to drive stemness and platinum resistance in ovarian cancer.	Platinum	71-79	secreted frizzled related protein 4	Homo sapiens	13-18
33896825-1	2021	BACKGROUND: To investigate the prognostic role of lung immune prognostic index LIPI in extensive-stage small-cell lung cancer (ES-SCLC) patients treated with platinum plus etoposide chemotherapy.	Platinum	158-166	lipase I	Homo sapiens	79-83
33896825-10	2021	CONCLUSION: Prognosis of patients with pretreatment LIPI score of 2 is poorer than those with LIPI score of 0-1 among ES-SCLC who received first-line platinum plus etoposide chemotherapy; Further studies are still recommended to confirm our findings in prospective studies.	Platinum	150-158	lipase I	Homo sapiens	52-56
33675811-12	2021	Overall, this study showed that sorcin can be used as a new target to prevent the ototoxicity of platinum drugs.	Platinum	97-105	sorcin	Mus musculus	32-38
33574092-5	2021	miR-181ahigh primary HGSOC cells exhibited increased Wnt/beta-catenin signaling, which was associated with increased stem-cell frequency and platinum resistance.	Platinum	141-149	catenin beta 1	Homo sapiens	57-69
33854036-7	2021	Co-treatment with carboplatin and chloroxine (but not either drug alone) caused an increase in gammaH2AX expression, followed by a reduction in platinum-induced RAD51 foci.	Platinum	144-152	RAD51 recombinase	Homo sapiens	161-166
33239432-3	2021	ORRs within the approved patient populations ranged from 64% (95% CI: 54, 73) in prior platinum treated RET fusion-positive NSCLC to 100% (95% CI: 63, 100) in systemic therapy naive RET fusion-positive thyroid cancer, with the majority of responders across indications demonstrating responses of at least 6 months.	Platinum	87-95	ret proto-oncogene	Homo sapiens	104-107
33994851-12	2021	In animal models, the depletion of CHD4 affected CRC tumor growth, and the combination of a histone deacetylase 1 (HDAC1) inhibitor and platinum drugs inhibited CHD4 expression and increased the cytotoxicity of platinum drugs.	Platinum	136-144	chromodomain helicase DNA binding protein 4	Homo sapiens	161-165
33928022-12	2021	Conclusions: Compared with EGFR-TKI monotherapy, the combination of first-generation EGFR-TKI and CT, especially when applying concurrent delivery of platinum-based doublet chemotherapeutic drugs, significantly improve ORR and prolong PFS and OS in first-line treatment for advanced EGFR-mutated NSCLC.	Platinum	150-158	epidermal growth factor receptor	Homo sapiens	85-89
33928022-12	2021	Conclusions: Compared with EGFR-TKI monotherapy, the combination of first-generation EGFR-TKI and CT, especially when applying concurrent delivery of platinum-based doublet chemotherapeutic drugs, significantly improve ORR and prolong PFS and OS in first-line treatment for advanced EGFR-mutated NSCLC.	Platinum	150-158	epidermal growth factor receptor	Homo sapiens	85-89
33845755-6	2021	RESULTS: Among 2,578 mature human miRNAs, high expression of miR-483-5p correlated with poor responses to platinum-based chemotherapy in EOC patients.	Platinum	106-114	microRNA 483	Homo sapiens	61-68
33919707-0	2021	FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers.	Platinum	18-26	flap structure-specific endonuclease 1	Homo sapiens	0-4
33919707-2	2021	In a clinical cohort, FEN1 overexpression is associated with aggressive phenotype and poor progression-free survival after platinum chemotherapy.	Platinum	123-131	flap structure-specific endonuclease 1	Homo sapiens	22-26
33919797-4	2021	Using the stepwise selection method, based on the area under the receiver operating characteristic curve (AUC) values, six variables associated with platinum sensitivity were selected: age, initial serum CA-125 levels, neoadjuvant chemotherapy, pelvic lymph node status, involvement of pelvic tissue other than the uterus and tubes, and involvement of the small bowel and mesentery.	Platinum	149-157	mucin 16, cell surface associated	Homo sapiens	204-210
33994851-12	2021	In animal models, the depletion of CHD4 affected CRC tumor growth, and the combination of a histone deacetylase 1 (HDAC1) inhibitor and platinum drugs inhibited CHD4 expression and increased the cytotoxicity of platinum drugs.	Platinum	211-219	histone deacetylase 1	Homo sapiens	92-113
33920140-1	2021	Poly (ADP-ribose) polymerase 1 inhibitors (PARPi) are used to treat recurrent ovarian cancer (OC) patients due to greater survival benefits and minimal side effects, especially in those patients with complete or partial response to platinum-based chemotherapy.	Platinum	232-240	poly(ADP-ribose) polymerase 1	Homo sapiens	0-30
33994851-12	2021	In animal models, the depletion of CHD4 affected CRC tumor growth, and the combination of a histone deacetylase 1 (HDAC1) inhibitor and platinum drugs inhibited CHD4 expression and increased the cytotoxicity of platinum drugs.	Platinum	211-219	histone deacetylase 1	Homo sapiens	115-120
33920283-7	2021	NF had significant negative correlations with BL, BUL, CL, PT, GL, and OC, which suggest that human activities had seriously interfered with NF.	Platinum	59-61	neurofascin	Homo sapiens	0-2
33920140-4	2021	In this study, we show how Twist knockdown cisplatin-resistant (CisR) OC cells blocked DNA damage response (DDR) to sensitize these cells to a concurrent treatment of cisplatin as a platinum-based chemotherapy agent and niraparib as a PARPi on in vitro two-dimensional (2D) and three-dimensional (3D) cell culture.	Platinum	182-190	twist family bHLH transcription factor 1	Homo sapiens	27-32
33920140-12	2021	Hence, lethality of PARPi with the combination of Cis on Twist knockdown CisR OC cells may provide an effective way to expand the therapeutic potential to overcome platinum-based chemotherapy resistance and PARPi cross resistance in OC.	Platinum	164-172	twist family bHLH transcription factor 1	Homo sapiens	57-62
33839362-2	2021	However, when used in combination with platinum-based chemotherapy, these PD-L1 inhibitors only improve overall survival by 2-3 months.	Platinum	39-47	CD274 molecule	Homo sapiens	74-79
33784109-4	2021	In vitro biological studies indicated that HY1-Pt can target CK2, suppress DNA damage repair, reinforce cellular accumulation of platinum, and reverse resistance apart from effectively inhibiting CSCs through Wnt/beta-catenin signal pathway in A549/cDDP cells.	Platinum	129-137	RNA, Ro60-associated Y1	Homo sapiens	43-46
33916671-7	2021	Studies carried out on the SKOV-3 cell line with the use of a synthesized targeting bioconjugate (Au@Pt-PEG-trastuzumab) revealed a high affinity of this preparation to HER2+ cells, its internalization, its placement in the perinuclear area and partial intranuclear location.	Platinum	101-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	169-173
33827148-0	2021	Role of FOXO protein"s abnormal activation through PI3K/AKT pathway in platinum resistance of ovarian cancer.	Platinum	71-79	AKT serine/threonine kinase 1	Homo sapiens	56-59
33827148-7	2021	DNA damage response and apoptosis including the relationship between FOXOs and ATM-Chk2-p53 are essential for platinum resistance of ovarian cancer.	Platinum	110-118	ATM serine/threonine kinase	Homo sapiens	79-82
33827148-7	2021	DNA damage response and apoptosis including the relationship between FOXOs and ATM-Chk2-p53 are essential for platinum resistance of ovarian cancer.	Platinum	110-118	checkpoint kinase 2	Homo sapiens	83-87
33827148-7	2021	DNA damage response and apoptosis including the relationship between FOXOs and ATM-Chk2-p53 are essential for platinum resistance of ovarian cancer.	Platinum	110-118	tumor protein p53	Homo sapiens	88-91
33827148-8	2021	Through gene expression analysis in platinum-resistant ovarian cancer cell model, it was found that FoxO-1 is decreased in platinum-resistant ovarian cancer, so studying the role of FOXO in the pathway on platinum-induced apoptosis may further guide the treatment of platinum-resistant ovarian cancer.	Platinum	36-44	forkhead box O1	Homo sapiens	100-106
32613829-8	2021	The photonucleoapzymes catalyze the photoinduced generation of NADPH, in the presence of ferredoxin-NADP+-reductase (FNR), or the photoinduced H2 evolution catalyzed by Pt nanoparticles.	Platinum	169-171	2,4-dienoyl-CoA reductase 1	Homo sapiens	63-68
32613829-8	2021	The photonucleoapzymes catalyze the photoinduced generation of NADPH, in the presence of ferredoxin-NADP+-reductase (FNR), or the photoinduced H2 evolution catalyzed by Pt nanoparticles.	Platinum	169-171	ferredoxin reductase	Homo sapiens	89-115
32613829-8	2021	The photonucleoapzymes catalyze the photoinduced generation of NADPH, in the presence of ferredoxin-NADP+-reductase (FNR), or the photoinduced H2 evolution catalyzed by Pt nanoparticles.	Platinum	169-171	ferredoxin reductase	Homo sapiens	117-120
33833901-5	2021	For Pt/Y catalysts prepared with CPA, a loading of 0.3 wt % Pt (n Pt/n A = 0.08 mol/mol) sufficed for n-heptane hydroisomerization, whereas a detrimental effect on n-hexadecane hydroisomerization was observed, in particular undesired secondary cracking occurred to a significant extent.	Platinum	4-6	carboxypeptidase A1	Homo sapiens	33-36
33833901-6	2021	The differences between PTA and CPA are explained by differences in Pt loading per zeolite Y crystal (size ~ 500 nm), shown from extensive transmission electron microscopy energy-dispersive X-ray spectroscopy experiments, whereby crystal-based n Pt/n A ratios could be determined.	Platinum	68-70	carboxypeptidase A1	Homo sapiens	32-35
33617901-4	2021	The FDA and EMA has recently approved olaparib, a Poly (ADP-ribose) polymerase (PARP) inhibitor, as a maintenance strategy for platinum-sensitive advanced PDAC patients with BRCA mutations.	Platinum	127-135	poly(ADP-ribose) polymerase 1	Homo sapiens	80-84
33894731-0	2021	Use of dexamethasone and a 5-HT3 receptor antagonist with or without aprepitant to prevent chemotherapy-induced nausea and vomiting among patients with lung cancer who are treated with platinum-based chemotherapy: a systematic review and meta-analysis of randomized controlled trials.	Platinum	185-193	5-hydroxytryptamine receptor 3A	Rattus norvegicus	27-41
33749954-3	2021	Benefiting from the Rh1 -tailored Pt (110) surface with tensile strain, the PtBi@PtRh1 nanoplates exhibit record-high and all-round superior electrocatalytic performance including activity, selectivity, stability, and anti-poisoning ability toward ethanol oxidation in alkaline electrolytes.	Platinum	34-36	peptidyl-tRNA hydrolase 1 homolog	Homo sapiens	81-86
33461346-0	2021	Erythropoietin promoter polymorphism is associated with treatment efficacy and severe hematologic toxicity for platinum-based chemotherapy.	Platinum	111-119	erythropoietin	Homo sapiens	0-14
33795649-0	2021	SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance.	Platinum	71-79	SUMO specific peptidase 1	Homo sapiens	0-5
33795649-0	2021	SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance.	Platinum	71-79	Janus kinase 2	Homo sapiens	32-36
33795649-5	2021	Significantly, this novel SENP1/JAK2 axis is activated in platinum-resistant ovarian cancer in a manner dependent on a transcription factor RUNX2 and activated RUNX2/SENP1/JAK2 is critical for platinum-resistance in ovarian cancer.	Platinum	58-66	SUMO specific peptidase 1	Homo sapiens	26-31
33795649-5	2021	Significantly, this novel SENP1/JAK2 axis is activated in platinum-resistant ovarian cancer in a manner dependent on a transcription factor RUNX2 and activated RUNX2/SENP1/JAK2 is critical for platinum-resistance in ovarian cancer.	Platinum	58-66	Janus kinase 2	Homo sapiens	32-36
33795649-5	2021	Significantly, this novel SENP1/JAK2 axis is activated in platinum-resistant ovarian cancer in a manner dependent on a transcription factor RUNX2 and activated RUNX2/SENP1/JAK2 is critical for platinum-resistance in ovarian cancer.	Platinum	58-66	RUNX family transcription factor 2	Homo sapiens	140-145
33795649-5	2021	Significantly, this novel SENP1/JAK2 axis is activated in platinum-resistant ovarian cancer in a manner dependent on a transcription factor RUNX2 and activated RUNX2/SENP1/JAK2 is critical for platinum-resistance in ovarian cancer.	Platinum	58-66	RUNX family transcription factor 2	Homo sapiens	160-165
33795649-5	2021	Significantly, this novel SENP1/JAK2 axis is activated in platinum-resistant ovarian cancer in a manner dependent on a transcription factor RUNX2 and activated RUNX2/SENP1/JAK2 is critical for platinum-resistance in ovarian cancer.	Platinum	58-66	SUMO specific peptidase 1	Homo sapiens	166-171
33795649-5	2021	Significantly, this novel SENP1/JAK2 axis is activated in platinum-resistant ovarian cancer in a manner dependent on a transcription factor RUNX2 and activated RUNX2/SENP1/JAK2 is critical for platinum-resistance in ovarian cancer.	Platinum	58-66	Janus kinase 2	Homo sapiens	172-176
33795649-6	2021	To explore the application of anti-SENP1/JAK2 for treatment of platinum-resistant ovarian cancer, we found SENP1 deficiency or treatment by SENP1 inhibitor Momordin Ic significantly overcomes platinum-resistance of ovarian cancer.	Platinum	63-71	SUMO specific peptidase 1	Homo sapiens	35-40
33795649-6	2021	To explore the application of anti-SENP1/JAK2 for treatment of platinum-resistant ovarian cancer, we found SENP1 deficiency or treatment by SENP1 inhibitor Momordin Ic significantly overcomes platinum-resistance of ovarian cancer.	Platinum	63-71	Janus kinase 2	Homo sapiens	41-45
33792569-0	2021	ATP11B mediates platinum resistance in ovarian cancer.	Platinum	16-24	ATPase phospholipid transporting 11B (putative)	Homo sapiens	0-6
33845459-10	2021	Treatment implications for germline BRCA carriers with PDAC include the use of platinum-based therapy and the validation of PARPi administration as a maintenance strategy in platinum-sensitive patients.	Platinum	79-87	BRCA1 DNA repair associated	Homo sapiens	36-40
33845459-10	2021	Treatment implications for germline BRCA carriers with PDAC include the use of platinum-based therapy and the validation of PARPi administration as a maintenance strategy in platinum-sensitive patients.	Platinum	174-182	BRCA1 DNA repair associated	Homo sapiens	36-40
33303972-10	2021	We found that reduced SMAD4 expression was more frequent in the patients with poor disease-free survival and resistance to platinum-based chemotherapy.	Platinum	123-131	SMAD family member 4	Homo sapiens	22-27
33303972-14	2021	In conclusion, these data suggest that SMAD4 mutation or loss as well as reduced expression can be used to identify the NSCLC patients with poor survival and resistance to platinum-based chemotherapy.	Platinum	172-180	SMAD family member 4	Homo sapiens	39-44
33667719-15	2021	Patients with MET exon 14 skipping alteration demonstrate disease control with crizotinib, platinum-based chemotherapy and immunotherapy.	Platinum	91-99	SAFB like transcription modulator	Homo sapiens	14-17
33547427-0	2021	WEE1 inhibition after platinum resistance.	Platinum	22-30	WEE1 G2 checkpoint kinase	Homo sapiens	0-4
33674744-0	2021	Molecular disruption of DNA polymerase beta for platinum sensitisation and synthetic lethality in epithelial ovarian cancers.	Platinum	48-56	DNA polymerase beta	Homo sapiens	24-43
33674744-6	2021	Polbeta depletion not only increased platinum sensitivity but also reduced invasion, migration and impaired EMT (epithelial to mesenchymal transition) of ovarian cancer cells.	Platinum	37-45	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	0-7
33538108-7	2021	First principle calculations results indicate that the interaction between the dyz and s orbitals of H and sp3 hybrid orbital of N should be the origin of the superior HER performance of these Pt single atom catalysts (SACs).	Platinum	193-195	Sp3 transcription factor	Homo sapiens	107-110
33253979-8	2021	Furthermore, miR-21, miR-25, miR-27b, miR-19b, miR-125b, miR-146a and miR-210 predicted response to platinum based treatments.	Platinum	100-108	microRNA 21	Homo sapiens	13-19
33253979-8	2021	Furthermore, miR-21, miR-25, miR-27b, miR-19b, miR-125b, miR-146a and miR-210 predicted response to platinum based treatments.	Platinum	100-108	microRNA 25	Homo sapiens	21-27
33253979-8	2021	Furthermore, miR-21, miR-25, miR-27b, miR-19b, miR-125b, miR-146a and miR-210 predicted response to platinum based treatments.	Platinum	100-108	microRNA 27b	Homo sapiens	29-36
33253979-8	2021	Furthermore, miR-21, miR-25, miR-27b, miR-19b, miR-125b, miR-146a and miR-210 predicted response to platinum based treatments.	Platinum	100-108	microRNA 19b-1	Homo sapiens	38-45
33253979-8	2021	Furthermore, miR-21, miR-25, miR-27b, miR-19b, miR-125b, miR-146a and miR-210 predicted response to platinum based treatments.	Platinum	100-108	microRNA 146a	Homo sapiens	57-65
33253979-8	2021	Furthermore, miR-21, miR-25, miR-27b, miR-19b, miR-125b, miR-146a and miR-210 predicted response to platinum based treatments.	Platinum	100-108	microRNA 210	Homo sapiens	70-77
33785877-0	2021	Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers.	Platinum	33-41	schlafen family member 11	Homo sapiens	0-11
33785877-4	2021	The impact of SLFN11 expression on the response to platinum and transition of SLFN11 expression upon long-term treatment with platinum were examined using GC cell lines and organoids.	Platinum	126-134	schlafen family member 11	Homo sapiens	78-84
33785877-5	2021	RESULTS: GC patients with high-SLFN11 expression exhibited significantly better survival than those with low-SLFN11 expression, and the significance increased when we selected patients treated with platinum-based chemotherapy.	Platinum	198-206	schlafen family member 11	Homo sapiens	31-37
33785877-5	2021	RESULTS: GC patients with high-SLFN11 expression exhibited significantly better survival than those with low-SLFN11 expression, and the significance increased when we selected patients treated with platinum-based chemotherapy.	Platinum	198-206	schlafen family member 11	Homo sapiens	109-115
33785877-6	2021	Knockout of SLFN11 and reactivation of SLFN11 in GC cells conferred resistance and sensitivity to platinum, respectively.	Platinum	98-106	schlafen family member 11	Homo sapiens	12-18
33785877-6	2021	Knockout of SLFN11 and reactivation of SLFN11 in GC cells conferred resistance and sensitivity to platinum, respectively.	Platinum	98-106	schlafen family member 11	Homo sapiens	39-45
33876083-6	2021	The results show that the PtnCun clusters with (n = 5-7) have similar vIP and vEA parameters compared to the unary Pt clusters, but the d-band center is slightly higher suggesting an enhanced reactivity for the bimetallic clusters.	Platinum	26-28	vasoactive intestinal peptide	Homo sapiens	70-73
33728696-0	2021	UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.	Platinum	90-98	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	0-6
33728696-19	2021	In this prospective cohort study of patients with small cell lung cancer receiving first-line irinotecan-platinum chemotherapy, the prevalence of UGT1A1*6 polymorphisms was found to be 10.8% UGT1A1*6 and 58.8% UGT1A1*28 homo/heterozygous mutant, respectively.	Platinum	105-113	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	146-152
33728696-19	2021	In this prospective cohort study of patients with small cell lung cancer receiving first-line irinotecan-platinum chemotherapy, the prevalence of UGT1A1*6 polymorphisms was found to be 10.8% UGT1A1*6 and 58.8% UGT1A1*28 homo/heterozygous mutant, respectively.	Platinum	105-113	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	191-197
33728696-19	2021	In this prospective cohort study of patients with small cell lung cancer receiving first-line irinotecan-platinum chemotherapy, the prevalence of UGT1A1*6 polymorphisms was found to be 10.8% UGT1A1*6 and 58.8% UGT1A1*28 homo/heterozygous mutant, respectively.	Platinum	105-113	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	191-197
33131943-5	2021	The experimental results indicate that MOR-2-QAS becomes rapidly attached and efficiently removes Pt(CN)42-, Pd(CN)42-, Co(CN)63-, and Fe(CN)63-.	Platinum	98-100	FRY like transcription coactivator	Homo sapiens	39-44
33417474-1	2021	PURPOSE: To prospectively evaluate the effectiveness of risk-adapted preemptive tocilizumab (PT) administration in preventing severe cytokine release syndrome (CRS) after CTL019, a CD19 chimeric antigen receptor T-cell therapy.	Platinum	93-95	CD19 molecule	Homo sapiens	181-185
33747898-6	2020	Results: A high prevalence of alterations in DNA damage repair (DDR) pathway, including BRCA1/2, was identified both in the platinum-sensitive and resistant HGSOC patients.	Platinum	124-132	BRCA1 DNA repair associated	Homo sapiens	88-95
33751064-4	2021	METHOD: A copper-based metal organic framework (Cu-MOF)/gold-platinum alloy nanoparticle(Au@Pt)-modified glassy carbon electrode (GCE) was developed via a simple wet chemical synthesis followed by electrochemical deposition of gold-platinum alloy nanoparticles onto the surface of a GCE.	Platinum	232-240	lysine acetyltransferase 8	Homo sapiens	51-54
33751064-9	2021	CONCLUSIONS: The Cu-MOF/Au@Pt/GCE exhibited good repeatability, reproducibility, stability, and selectivity to provide a capable analysis method for food samples.	Platinum	27-29	lysine acetyltransferase 8	Homo sapiens	20-23
33626338-8	2021	The key roles of ACTL9 in the PT structure and TFF after ICSI were further confirmed in an Actl9-mutated mouse model.	Platinum	30-32	actin-like 9	Mus musculus	17-22
33626338-10	2021	These findings identified the role of ACTL9 in the PT structure and the correct localization of PLCzeta.	Platinum	51-53	actin-like 9	Mus musculus	38-43
33663405-8	2021	The predictive value of UBE2Q1 as a potential biomarker was analysed by correlating its expression with 12-months relapse free survival of patients in response to platin/taxane, the standard first-line chemotherapy for ovarian cancer, and analysing area under the ROC curve.	Platinum	163-169	ubiquitin conjugating enzyme E2 Q1	Homo sapiens	24-30
33663405-9	2021	RESULTS: An integrated gene expression analysis and WGCNA, identified UBE2Q1 as a potential prognostic marker associated with poor relapse-free survival and response outcome to platin/taxane treatment of patients with high grade serous ovarian cancer.	Platinum	177-183	ubiquitin conjugating enzyme E2 Q1	Homo sapiens	70-76
33869015-3	2021	Our objective was to compare the clinical efficacy and safety of anti-PD-1/PD-L1 therapies in platinum-resistant UC patients.	Platinum	94-102	programmed cell death 1	Homo sapiens	70-74
33869015-3	2021	Our objective was to compare the clinical efficacy and safety of anti-PD-1/PD-L1 therapies in platinum-resistant UC patients.	Platinum	94-102	CD274 molecule	Homo sapiens	75-80
33360887-5	2021	Furthermore, the FeCoNiSx/NF acted as the anode towards overall water electrolysis with acceptable results, where commercial Pt/C dropped on the NF worked as the cathode.	Platinum	125-127	neurofascin	Homo sapiens	26-28
33360887-5	2021	Furthermore, the FeCoNiSx/NF acted as the anode towards overall water electrolysis with acceptable results, where commercial Pt/C dropped on the NF worked as the cathode.	Platinum	125-127	neurofascin	Homo sapiens	145-147
33073679-4	2021	The purpose of this study was to investigate the effect of therapeutic inhibition of mTOR (mechanistic target of rapamycin) on resistance of CSCs to cisplatin, a prototypic platinum-based chemotherapeutic agent.	Platinum	173-181	mechanistic target of rapamycin kinase	Homo sapiens	85-89
33073679-4	2021	The purpose of this study was to investigate the effect of therapeutic inhibition of mTOR (mechanistic target of rapamycin) on resistance of CSCs to cisplatin, a prototypic platinum-based chemotherapeutic agent.	Platinum	173-181	mechanistic target of rapamycin kinase	Homo sapiens	91-122
33073679-12	2021	Collectively, these results demonstrate that therapeutic inhibition of mTOR ablates cytotoxic-resistant CSCs, and they suggest that a combination of an mTOR inhibitor and platinum-based chemotherapy might be beneficial to patients with salivary gland mucoepidermoid carcinoma.	Platinum	171-179	mechanistic target of rapamycin kinase	Homo sapiens	71-75
33331136-0	2021	HSP90 identified by a proteomic approach as druggable target to reverse platinum-resistance in ovarian cancer.	Platinum	72-80	heat shock protein 90 alpha family class A member 1	Homo sapiens	0-5
33331136-3	2021	Using this approach, we identified several differentially expressed proteins in platinum-resistant compared to parental-cells, and the chaperone HSP90 as a central hub of these protein networks.	Platinum	80-88	heat shock protein 90 alpha family class A member 1	Homo sapiens	145-150
33331136-4	2021	Accordingly, up-regulation of HSP90 was observed in all platinum-resistant cells and HSP90alpha knockout re-sensitizes platinum-resistant cells to cisplatin treatment.	Platinum	56-64	heat shock protein 90 alpha family class A member 1	Homo sapiens	30-35
33331136-4	2021	Accordingly, up-regulation of HSP90 was observed in all platinum-resistant cells and HSP90alpha knockout re-sensitizes platinum-resistant cells to cisplatin treatment.	Platinum	119-127	heat shock protein 90 alpha family class A member 1	Homo sapiens	30-35
33331136-4	2021	Accordingly, up-regulation of HSP90 was observed in all platinum-resistant cells and HSP90alpha knockout re-sensitizes platinum-resistant cells to cisplatin treatment.	Platinum	119-127	heat shock protein 90 alpha family class A member 1	Homo sapiens	85-95
33331136-5	2021	Moreover, pharmacological HSP90 inhibition using two different inhibitors (17AAG and ganetespib) synergizes with cisplatin in killing platinum resistant cells in all tested models.	Platinum	134-142	heat shock protein 90 alpha family class A member 1	Homo sapiens	26-31
33331136-6	2021	Mechanistically, genetic or pharmacological HSP90 inhibition plus cisplatin induced apoptosis and increased DNA-damage, particularly in platinum-resistant cells.	Platinum	136-144	heat shock protein 90 alpha family class A member 1	Homo sapiens	44-49
33331136-7	2021	Importantly, the antitumor activities of HSP90 inhibitors were confirmed both ex vivo in primary cultures derived from platinum-resistant EOC patients ascites and in vivo in a xenograft model.	Platinum	119-127	heat shock protein 90 alpha family class A member 1	Homo sapiens	41-46
33331136-8	2021	Collectively, our data suggest an innovative antitumor strategy, based on platinum-compounds plus HSP90 inhibitors, to re-challenge platinum-resistant EOC patients that might warrant further clinical evaluation.	Platinum	132-140	heat shock protein 90 alpha family class A member 1	Homo sapiens	98-103
32885350-7	2021	An unresectable PDAC patient with BRCA2-mutant disease was successfully treated by conversion surgery using platinum-based neoadjuvant chemotherapy.	Platinum	108-116	BRCA2 DNA repair associated	Homo sapiens	34-39
33724122-7	2021	In this way, PARP inhibitors can obtain an important role in making a personalized therapeutic program in case of first-line, neoadjuvant, platinum-sensitive and resistant high-grade serous OC treatment.	Platinum	139-147	poly(ADP-ribose) polymerase 1	Homo sapiens	13-17
33620212-3	2021	By means of Pt doping, a type-II Dirac semimetal Ir1-xPtxTe2 with protected crystal structure and tunable Fermi level has been achieved in this work.	Platinum	12-14	nischarin	Homo sapiens	49-52
33689300-4	2021	The polymer encapsulated a platinum intercalator (56MESS, (5,6-dimethyl-1,10-phenanthroline) (1S,2S-diaminocyclohexane) platinum(II)) and was conjugated with both a cell-targeting RGD peptide and a caspase-3 cleavable peptide probe to form nanoparticles for simultaneous NIR-II and apoptosis imaging.	Platinum	27-35	caspase 3	Homo sapiens	198-207
33754211-6	2021	BRCA1/2 mutations predicted benefit from platinums in advanced, but not early stage breast cancer.	Platinum	41-50	BRCA1 DNA repair associated	Homo sapiens	0-7
33740262-0	2021	Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.	Platinum	132-140	poly(ADP-ribose) polymerase 1	Homo sapiens	95-99
33747934-1	2021	Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade.	Platinum	137-145	nectin cell adhesion molecule 4	Homo sapiens	24-32
33387446-4	2021	While the number of active sites of PdAu SAA is lower than that of Pt(111), the aforementioned desirable properties could bring the overall catalytic performance thereof close to that of Pt/C, indicating that the PdAu SAA could be a viable material for electrocatalytic ORR in PEM fuel-cells.	Platinum	67-69	mucin 1, cell surface associated	Homo sapiens	277-280
33461346-3	2021	This study investigated the association of EPO rs1617640 with treatment efficacy and severe toxicity in non-small cell lung cancer (NSCLC) patients undergoing platinum-based regimens.	Platinum	159-167	erythropoietin	Homo sapiens	43-46
33461346-6	2021	Results: The TT genotype of EPO rs1617640 was significantly correlated with higher response rate to platinum-based treatment than the other genotypes (OR, 0.507; 95% CI: 0.305-0.842; P = 0.009), particularly in elderly patients (>55 years), male gender, smokers, IV stage, cisplatin-based chemotherapies and platinum-gemcitabine regimen subgroups.	Platinum	100-108	erythropoietin	Homo sapiens	28-31
33461346-6	2021	Results: The TT genotype of EPO rs1617640 was significantly correlated with higher response rate to platinum-based treatment than the other genotypes (OR, 0.507; 95% CI: 0.305-0.842; P = 0.009), particularly in elderly patients (>55 years), male gender, smokers, IV stage, cisplatin-based chemotherapies and platinum-gemcitabine regimen subgroups.	Platinum	308-316	erythropoietin	Homo sapiens	28-31
33461346-8	2021	Conclusion: Our results demonstrated the role of EPO rs1617640 as a possible predictive marker of treatment efficacy and severe toxicity for platinum-based chemotherapy.	Platinum	141-149	erythropoietin	Homo sapiens	49-52
33199228-9	2021	CONCLUSIONS: This is the first study to explore the efficacy and safety of osimertinib combined with platinum-based chemotherapy in previously untreated NSCLC patients with EGFR-sensitizing mutations.	Platinum	101-109	epidermal growth factor receptor	Homo sapiens	173-177
33324989-10	2021	High NKD2 was correlated with lower recurrence rate (P = 0.002) and higher percentage of platinum-sensitive recurrence (P = 0.006).	Platinum	89-97	NKD inhibitor of WNT signaling pathway 2	Homo sapiens	5-9
33654182-7	2021	Robust re-sensitization of resistant ovarian cancer cells to platinum-based therapy was achieved using human monoclonal biologics inhibiting CLPTM1L in both orthotopic isografts and patient-derived cisplatin resistant xenograft models.	Platinum	61-69	CLPTM1 like	Homo sapiens	141-148
33604960-3	2021	To circumvent this shortcoming, the common practice has been to utilize the large SOC of nonmagnetic layers of 5d heavy metals (HMs), such as Pt, to generate spin currents and, in turn, exert spin torques on the magnetic layers.	Platinum	142-144	spindlin 1	Homo sapiens	158-162
33604960-3	2021	To circumvent this shortcoming, the common practice has been to utilize the large SOC of nonmagnetic layers of 5d heavy metals (HMs), such as Pt, to generate spin currents and, in turn, exert spin torques on the magnetic layers.	Platinum	142-144	spindlin 1	Homo sapiens	192-196
33791146-7	2021	Nine related DEGs were found in the classic platinum resistance pathway, three of which (ATM, IAP-1, and IAP-2) also appeared in the top five differentially expressed pathways, with elevated IAP-1 showing the highest fold change.	Platinum	44-52	ATM serine/threonine kinase	Homo sapiens	89-92
33791146-7	2021	Nine related DEGs were found in the classic platinum resistance pathway, three of which (ATM, IAP-1, and IAP-2) also appeared in the top five differentially expressed pathways, with elevated IAP-1 showing the highest fold change.	Platinum	44-52	baculoviral IAP repeat containing 3	Homo sapiens	94-99
33791146-7	2021	Nine related DEGs were found in the classic platinum resistance pathway, three of which (ATM, IAP-1, and IAP-2) also appeared in the top five differentially expressed pathways, with elevated IAP-1 showing the highest fold change.	Platinum	44-52	baculoviral IAP repeat containing 2	Homo sapiens	105-110
33791146-7	2021	Nine related DEGs were found in the classic platinum resistance pathway, three of which (ATM, IAP-1, and IAP-2) also appeared in the top five differentially expressed pathways, with elevated IAP-1 showing the highest fold change.	Platinum	44-52	baculoviral IAP repeat containing 3	Homo sapiens	191-196
33929876-2	2021	Testing for deleterious germline mutations in BRCA1/2 impacts patient selection for platinum-based chemotherapy regimens and selection of patients who are candidates to receive maintenance therapy with olaparib.	Platinum	84-92	BRCA1 DNA repair associated	Homo sapiens	46-53
33080152-1	2021	PURPOSE: Five programmed cell death protein 1 (PD-1) or its ligand (L1) inhibitors are approved for treatment of platinum-refractory locally advanced/unresectable or metastatic urothelial carcinoma.	Platinum	113-121	programmed cell death 1	Homo sapiens	14-45
33375991-7	2021	Multivariate logistic regression was used to analyze the effects of TP53 mutation type on platinum resistance.	Platinum	90-98	tumor protein p53	Homo sapiens	68-72
33375991-11	2021	TP53 mutations were associated with platinum sensitivity, even after adjusting for BRCA mutation status (OR 0.41, p = 0.048).	Platinum	36-44	tumor protein p53	Homo sapiens	0-4
33375991-14	2021	After adjusting for BRCA mutations, TP53 mutations are associated with platinum sensitivity, and this effect is not dependent on TP53 mutation type.	Platinum	71-79	BRCA2 DNA repair associated	Homo sapiens	20-24
33375991-14	2021	After adjusting for BRCA mutations, TP53 mutations are associated with platinum sensitivity, and this effect is not dependent on TP53 mutation type.	Platinum	71-79	tumor protein p53	Homo sapiens	36-40
33279692-3	2021	The optimal photocatalyst 25% Ru-CoP-1:8/GCN NSs exhibits an excellent hydrogen evolution rate of 1172.5 micromol g-1 h-1 under visible light with a high apparent quantum efficiency (AQE) of 3.49% at 420 nm, which is close to Pt/g-C3N4 photocatalytic system and higher than most reported transition metal phosphides (TMP)/g-C3N4 photocatalytic system.	Platinum	226-228	caspase recruitment domain family member 16	Homo sapiens	33-38
32970266-2	2021	METHODS: The study includes patients with HER2(-) AGC treated with platin and fluoropyrimidine (PF) or with DPF in first line.	Platinum	67-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-46
33559413-1	2021	BACKGROUND: The optimal treatment of BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer remains unknown.	Platinum	66-74	BRCA1 DNA repair associated	Homo sapiens	37-41
33559413-4	2021	METHODS: BRCA wild-type patients who received two previous courses of platinum-containing therapy, achieved complete or partial response to last treatment, and the treatment-free interval is >6 months after the penultimate platinum-based chemotherapy offered olaparib maintenance with pembrolizumab and bevacizumab.	Platinum	70-78	BRCA1 DNA repair associated	Homo sapiens	9-13
33559413-4	2021	METHODS: BRCA wild-type patients who received two previous courses of platinum-containing therapy, achieved complete or partial response to last treatment, and the treatment-free interval is >6 months after the penultimate platinum-based chemotherapy offered olaparib maintenance with pembrolizumab and bevacizumab.	Platinum	223-231	BRCA1 DNA repair associated	Homo sapiens	9-13
33080152-12	2021	CONCLUSIONS: In this large real-world cohort, effectiveness in terms of TTTTD and OS with PD-1/L1 inhibitors in patients with platinum-refractory locally advanced/unresectable or metastatic urothelial carcinoma was similar.	Platinum	126-134	programmed cell death 1	Homo sapiens	90-94
33080152-1	2021	PURPOSE: Five programmed cell death protein 1 (PD-1) or its ligand (L1) inhibitors are approved for treatment of platinum-refractory locally advanced/unresectable or metastatic urothelial carcinoma.	Platinum	113-121	programmed cell death 1	Homo sapiens	47-51
32361873-5	2021	More recently, several anti-PD-L1 and anti-PD-1 antibodies have shown promising activity in the first-line and post-platinum setting; however, immunotherapy remains ineffective in most patients.	Platinum	116-124	CD274 molecule	Homo sapiens	28-33
33172976-9	2021	Notably, NSCLC cell lines with low levels of SLFN11, a known predictive biomarker for platinum and PARP inhibitor sensitivity, were more sensitive to AXL/ATR co-targeting.	Platinum	86-94	schlafen family member 11	Homo sapiens	45-51
33172976-9	2021	Notably, NSCLC cell lines with low levels of SLFN11, a known predictive biomarker for platinum and PARP inhibitor sensitivity, were more sensitive to AXL/ATR co-targeting.	Platinum	86-94	AXL receptor tyrosine kinase	Homo sapiens	150-153
33172976-9	2021	Notably, NSCLC cell lines with low levels of SLFN11, a known predictive biomarker for platinum and PARP inhibitor sensitivity, were more sensitive to AXL/ATR co-targeting.	Platinum	86-94	ATR serine/threonine kinase	Homo sapiens	154-157
33272936-7	2021	p21-deficient sg12 clones demonstrated less repair of DNA-platinum adducts and increased -H2AX foci after cisplatin exposure, suggesting there was persistent DNA damage after p21 loss.	Platinum	58-66	cyclin dependent kinase inhibitor 1A	Homo sapiens	0-3
33408043-1	2021	INTRODUCTION: AGXT gene codes for the enzyme alanine glyoxylate aminotransferase, which is involved in hepatic peroxisomal metabolism of platinum-based chemotherapeutic agents.	Platinum	137-145	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	14-18
33408043-1	2021	INTRODUCTION: AGXT gene codes for the enzyme alanine glyoxylate aminotransferase, which is involved in hepatic peroxisomal metabolism of platinum-based chemotherapeutic agents.	Platinum	137-145	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	45-80
33605070-3	2021	In this work, high loading Pt single atoms on graphitic carbon nitride (g-C3 N4 )-derived N-doped carbon nanosheets (Pt1 /NCNS) is achieved through atomic layer deposition.	Platinum	27-29	zinc finger protein 77	Homo sapiens	117-120
32361873-5	2021	More recently, several anti-PD-L1 and anti-PD-1 antibodies have shown promising activity in the first-line and post-platinum setting; however, immunotherapy remains ineffective in most patients.	Platinum	116-124	programmed cell death 1	Homo sapiens	43-47
33631884-10	2021	At the same time, the combined detection of GAS5 and HOTAIR has a certain diagnostic efficiency for patients with platinum-resistant EOC.	Platinum	114-122	growth arrest specific 5	Homo sapiens	44-48
33709738-2	2021	To this end, we use NbN-Ni_{80}Fe_{20}(Py) heterostructures with a Pt spin sink layer and excite ferromagnetic resonance in the Permalloy layer by placing the samples onto a coplanar waveguide.	Platinum	67-69	nibrin	Homo sapiens	20-23
33709738-4	2021	Below the superconducting transition temperature T_{c}, we observe a suppression of the dampinglike torque generated in the Pt layer by the inverse spin Hall effect, which can be understood by the changes in spin current transport in the superconducting NbN layer.	Platinum	124-126	spindlin 1	Homo sapiens	148-152
33709738-4	2021	Below the superconducting transition temperature T_{c}, we observe a suppression of the dampinglike torque generated in the Pt layer by the inverse spin Hall effect, which can be understood by the changes in spin current transport in the superconducting NbN layer.	Platinum	124-126	spindlin 1	Homo sapiens	208-212
33709738-4	2021	Below the superconducting transition temperature T_{c}, we observe a suppression of the dampinglike torque generated in the Pt layer by the inverse spin Hall effect, which can be understood by the changes in spin current transport in the superconducting NbN layer.	Platinum	124-126	nibrin	Homo sapiens	254-257
33631884-10	2021	At the same time, the combined detection of GAS5 and HOTAIR has a certain diagnostic efficiency for patients with platinum-resistant EOC.	Platinum	114-122	HOX transcript antisense RNA	Homo sapiens	53-59
33692936-0	2020	Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.	Platinum	77-85	poly(ADP-ribose) polymerase 1	Homo sapiens	35-39
33544604-6	2021	As a proof of concept, prostate-specific antigen is chosen as the target analyte to demonstrate the superiority of the Pt SAs-CdS-based PEC sensing system.	Platinum	119-121	kallikrein related peptidase 3	Homo sapiens	23-48
33619265-5	2021	Two unique BRCA2 somatic alterations (p.N255fs and p.D252fs) were identified upon resistance to PARP inhibitor and platinum treatment, respectively.	Platinum	115-123	BRCA2 DNA repair associated	Homo sapiens	11-16
33608381-0	2021	Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance.	Platinum	147-155	BRCA2 DNA repair associated	Homo sapiens	66-71
33669671-5	2021	However, and in contrast with the findings of others, we detected no synergistic effect between olaparib and oxaliplatin, and we found that the Akt pathway inhibitor augmented the cytostatic properties of the platinum compound and/or prevented the cytoprotective effects of PARP inhibition.	Platinum	209-217	AKT serine/threonine kinase 1	Homo sapiens	144-147
33669671-5	2021	However, and in contrast with the findings of others, we detected no synergistic effect between olaparib and oxaliplatin, and we found that the Akt pathway inhibitor augmented the cytostatic properties of the platinum compound and/or prevented the cytoprotective effects of PARP inhibition.	Platinum	209-217	poly(ADP-ribose) polymerase 1	Homo sapiens	274-278
33596034-0	2021	Spectroscopic characterization of the interactions of bovine serum albumin with medicinally important metal ions: platinum (IV), iridium (III) and iron (II).	Platinum	114-122	albumin	Homo sapiens	61-74
33670664-0	2021	BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis.	Platinum	56-64	beclin 1	Homo sapiens	0-5
33539102-2	2021	Superoxide anion species (O2-) are detected on the Pt(111) surface in an O2-saturated solution with a NaF/HClO4 mixture with pH 5.5 by the observation of a O-O vibration band at ca.	Platinum	51-53	C-X-C motif chemokine ligand 8	Homo sapiens	102-105
33643602-6	2021	Moreover, the average of 2.5 muM of H2O2 and 34 mug/L of dissolved Pt were measured from the electrically stimulated media (ES media), which also corresponded with the increases in SPP1 mRNA expression and cell metabolic activities.	Platinum	67-69	secreted phosphoprotein 1	Homo sapiens	181-185
33596916-0	2021	Targeting SNHG3/miR-186-5p reverses the increased m6A level caused by platinum treatment through regulating METTL3 in esophageal cancer.	Platinum	70-78	small nucleolar RNA host gene 3	Homo sapiens	10-15
33596916-0	2021	Targeting SNHG3/miR-186-5p reverses the increased m6A level caused by platinum treatment through regulating METTL3 in esophageal cancer.	Platinum	70-78	microRNA 186	Homo sapiens	16-23
33596916-0	2021	Targeting SNHG3/miR-186-5p reverses the increased m6A level caused by platinum treatment through regulating METTL3 in esophageal cancer.	Platinum	70-78	methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit	Homo sapiens	108-114
33596916-8	2021	Besides, SNHG3 expression was induced and miR-186-5p expression was suppressed by platinum.	Platinum	82-90	microRNA 186	Homo sapiens	42-49
33596916-12	2021	SNHG3/miR-186-5p, induced by platinum, was involved in regulating m6A level by targeting METTL3.	Platinum	29-37	small nucleolar RNA host gene 3	Homo sapiens	0-5
33596916-12	2021	SNHG3/miR-186-5p, induced by platinum, was involved in regulating m6A level by targeting METTL3.	Platinum	29-37	microRNA 186	Homo sapiens	6-13
33596916-12	2021	SNHG3/miR-186-5p, induced by platinum, was involved in regulating m6A level by targeting METTL3.	Platinum	29-37	methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit	Homo sapiens	89-95
33745863-1	2021	BACKGROUND: The ErbB family blocker, afatinib, is approved for patients with squamous cell carcinoma (SqCC) of the lung following platinum-doublet chemotherapy but has not been explored following immunochemotherapy.	Platinum	130-138	epidermal growth factor receptor	Homo sapiens	16-20
33461716-0	2021	A reusable colorimetric assay based on mixed valence state Ce-MOF@Pt nanoparticles for highly sensitive detection of visfatin.	Platinum	66-68	nicotinamide phosphoribosyltransferase	Homo sapiens	117-125
33569679-0	2021	Sensitive sandwich-type voltammetric immunosensor for breast cancer biomarker HER2 detection based on gold nanoparticles decorated Cu-MOF and Cu2ZnSnS4 NPs/Pt/g-C3N4 composite.	Platinum	156-158	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82
33492928-2	2021	Initially, a sandwich-type immunoreaction for target carcinoembryonic antigen (CEA, as a model analyte) was carried out using the capture antibody (cAb) and platinum nanoparticles-labeled detection antibody (PtNPs-dAb) in a reaction cell.	Platinum	157-165	CEA cell adhesion molecule 3	Homo sapiens	79-82
33558461-7	2021	Noninvasive imaging of autophagic flux using a novel autophagy sensor (mtFL-p62 fusion reporter) showed that combinatorial treatment of platinum-taxol along with Trametinib/chloroquine blocked autophagic flux in live cells and tumor xenografts.	Platinum	136-144	nucleoporin 62	Mus musculus	76-79
33245078-0	2021	Sensitive SERS assay for glyphosate based on the prevention of L-cysteine inhibition of a Au-Pt nanozyme.	Platinum	93-95	seryl-tRNA synthetase 1	Homo sapiens	10-14
33549120-14	2021	The hypothesis that HNF-1beta is a portent of platinum-resistance and an important predictive biomarker in OCCC needs further confirmation.	Platinum	46-54	HNF1 homeobox A	Homo sapiens	20-29
33592864-0	2021	Meta-analysis of P53 expression and sensitivity to platinum-based chemotherapy in patients with non-small cell lung cancer.	Platinum	51-59	tumor protein p53	Homo sapiens	17-20
33592864-2	2021	This study aims to explore the correlation between p53 expression and sensitivity to platinum-based chemotherapy in patients with NSCLC.	Platinum	85-93	tumor protein p53	Homo sapiens	51-54
33592864-3	2021	METHODS: Pubmed, Web of Science, EMBASE, CNKI, China Wanfang databases were searched for studies on the relationship between the p53 expression and the chemosensitivity to platinum drugs in patients with NSCLC.	Platinum	172-180	tumor protein p53	Homo sapiens	129-132
33592864-10	2021	CONCLUSION: Patients with p53 negative expression is more sensitive to platinum-based chemotherapy than those with p53 positive expression in NSCLC, especially in advanced NSCLC.	Platinum	71-79	tumor protein p53	Homo sapiens	26-29
33613670-0	2021	DOCK4 Is a Platinum-Chemosensitive and Prognostic-Related Biomarker in Ovarian Cancer.	Platinum	11-19	dedicator of cytokinesis 4	Homo sapiens	0-5
33613670-9	2021	A total of 4 genes (AP2A2, DOCK4, HSDL2, and PDK4) were the candidate differentially expressed genes (DEGs) of PPAR-TRGs with platinum chemosensitivity.	Platinum	126-134	adaptor related protein complex 2 subunit alpha 2	Homo sapiens	20-25
33613670-9	2021	A total of 4 genes (AP2A2, DOCK4, HSDL2, and PDK4) were the candidate differentially expressed genes (DEGs) of PPAR-TRGs with platinum chemosensitivity.	Platinum	126-134	dedicator of cytokinesis 4	Homo sapiens	27-32
33613670-9	2021	A total of 4 genes (AP2A2, DOCK4, HSDL2, and PDK4) were the candidate differentially expressed genes (DEGs) of PPAR-TRGs with platinum chemosensitivity.	Platinum	126-134	hydroxysteroid dehydrogenase like 2	Homo sapiens	34-39
33613670-9	2021	A total of 4 genes (AP2A2, DOCK4, HSDL2, and PDK4) were the candidate differentially expressed genes (DEGs) of PPAR-TRGs with platinum chemosensitivity.	Platinum	126-134	pyruvate dehydrogenase kinase 4	Homo sapiens	45-49
33613670-9	2021	A total of 4 genes (AP2A2, DOCK4, HSDL2, and PDK4) were the candidate differentially expressed genes (DEGs) of PPAR-TRGs with platinum chemosensitivity.	Platinum	126-134	peroxisome proliferator activated receptor alpha	Homo sapiens	111-115
33613670-13	2021	In addition, we verified the expression level of DOCK4 in OV cell lines treated with platinum drugs and found that DOCK4 is potentially responsive to platinum drugs.	Platinum	85-93	dedicator of cytokinesis 4	Homo sapiens	49-54
33613670-13	2021	In addition, we verified the expression level of DOCK4 in OV cell lines treated with platinum drugs and found that DOCK4 is potentially responsive to platinum drugs.	Platinum	85-93	dedicator of cytokinesis 4	Homo sapiens	115-120
33613670-13	2021	In addition, we verified the expression level of DOCK4 in OV cell lines treated with platinum drugs and found that DOCK4 is potentially responsive to platinum drugs.	Platinum	150-158	dedicator of cytokinesis 4	Homo sapiens	49-54
33613670-13	2021	In addition, we verified the expression level of DOCK4 in OV cell lines treated with platinum drugs and found that DOCK4 is potentially responsive to platinum drugs.	Platinum	150-158	dedicator of cytokinesis 4	Homo sapiens	115-120
33399940-0	2021	Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair.	Platinum	26-34	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	73-78
33399940-0	2021	Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair.	Platinum	26-34	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	79-82
32458023-3	2021	Following treatment with a platinum-based chemotherapeutic, there is a reduction in global levels of H2Bub1 accompanied by an increase in levels of the tumor suppressor p53.	Platinum	27-35	tumor protein p53	Homo sapiens	169-172
32458023-6	2021	H2Bub1-enriched genes encompassed fifteen p53 target genes including PPM1D, BTG2, PLK2, MDM2, CDKN1A and BBC3, genes related to ERK/MAPK signalling, those participating in nucleotide excision repair including XPC, and genes involved in the immune response and platinum drug resistance including POLH.	Platinum	260-268	tumor protein p53	Homo sapiens	42-45
33422766-0	2021	Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy.	Platinum	141-149	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	77-82
33603473-3	2021	Patients and Methods: We recruited a total of 341 consecutive patients who underwent platinum-based NACT followed by radical surgery (RS) at the Hubei Cancer Hospital between January 1, 2010 and April 1, 2020.	Platinum	85-93	solute carrier family 13 member 5	Homo sapiens	100-104
33422766-0	2021	Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy.	Platinum	141-149	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	83-86
33422766-3	2021	Excision repair cross-complementation group 1 (ERCC1) has been considered a potential biomarker to predict the outcome of platinum-based chemotherapy in NSCLC.	Platinum	122-130	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-45
33422766-3	2021	Excision repair cross-complementation group 1 (ERCC1) has been considered a potential biomarker to predict the outcome of platinum-based chemotherapy in NSCLC.	Platinum	122-130	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
33638052-11	2021	Theracal PT and MTA promoted the upregulation of DSPP and RUNX2 gene expression (p < 0.05).	Platinum	9-11	dentin sialophosphoprotein	Homo sapiens	49-53
33638052-11	2021	Theracal PT and MTA promoted the upregulation of DSPP and RUNX2 gene expression (p < 0.05).	Platinum	9-11	RUNX family transcription factor 2	Homo sapiens	58-63
33422766-5	2021	Here, we prospectively investigated if the active form of ERCC1, as assessed by the ERCC1/XPF complex (ERCC1/XPF), could predict the sensitivity to platinum compounds.	Platinum	148-156	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	58-63
33422766-5	2021	Here, we prospectively investigated if the active form of ERCC1, as assessed by the ERCC1/XPF complex (ERCC1/XPF), could predict the sensitivity to platinum compounds.	Platinum	148-156	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	84-89
33422766-5	2021	Here, we prospectively investigated if the active form of ERCC1, as assessed by the ERCC1/XPF complex (ERCC1/XPF), could predict the sensitivity to platinum compounds.	Platinum	148-156	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	90-93
33422766-5	2021	Here, we prospectively investigated if the active form of ERCC1, as assessed by the ERCC1/XPF complex (ERCC1/XPF), could predict the sensitivity to platinum compounds.	Platinum	148-156	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	84-89
33422766-5	2021	Here, we prospectively investigated if the active form of ERCC1, as assessed by the ERCC1/XPF complex (ERCC1/XPF), could predict the sensitivity to platinum compounds.	Platinum	148-156	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	109-112
33422766-10	2021	CONCLUSION: The lack of ERCC1/XPF complex in NSCLC tumor cells might delineate a group of patients with poor outcomes when treated with platinum compounds.	Platinum	136-144	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	24-29
33422766-10	2021	CONCLUSION: The lack of ERCC1/XPF complex in NSCLC tumor cells might delineate a group of patients with poor outcomes when treated with platinum compounds.	Platinum	136-144	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	30-33
33423551-2	2021	Despite novel compound classes like vascular endothelial growth factor (VEGF) inhibitors or poly-ADP ribose polymerase (PARP) inhibitors are available, which improve significantly efficacy of platinum-based chemotherapy, OC prognosis remains poor and innovative strategies are needed.	Platinum	192-200	vascular endothelial growth factor A	Homo sapiens	36-70
33423551-2	2021	Despite novel compound classes like vascular endothelial growth factor (VEGF) inhibitors or poly-ADP ribose polymerase (PARP) inhibitors are available, which improve significantly efficacy of platinum-based chemotherapy, OC prognosis remains poor and innovative strategies are needed.	Platinum	192-200	vascular endothelial growth factor A	Homo sapiens	72-76
33423551-2	2021	Despite novel compound classes like vascular endothelial growth factor (VEGF) inhibitors or poly-ADP ribose polymerase (PARP) inhibitors are available, which improve significantly efficacy of platinum-based chemotherapy, OC prognosis remains poor and innovative strategies are needed.	Platinum	192-200	poly(ADP-ribose) polymerase 1	Homo sapiens	92-118
33423551-2	2021	Despite novel compound classes like vascular endothelial growth factor (VEGF) inhibitors or poly-ADP ribose polymerase (PARP) inhibitors are available, which improve significantly efficacy of platinum-based chemotherapy, OC prognosis remains poor and innovative strategies are needed.	Platinum	192-200	poly(ADP-ribose) polymerase 1	Homo sapiens	120-124
33476136-4	2021	In the reaction of [PtMe(C N)(PPh3)] with CF3CO2H, the Pt-C N bond is cleaved rather than the Pt-Me bond.	Platinum	20-22	caveolin 1	Homo sapiens	30-34
33523504-1	2021	Organic cation transporter (OCT) 3 (SLC22A3) is a widely-expressed drug transporter, handling notably metformin and platinum derivatives, as well as endogenous compounds like monoamine neurotransmitters.	Platinum	116-124	solute carrier family 22 member 3	Homo sapiens	0-34
33523504-1	2021	Organic cation transporter (OCT) 3 (SLC22A3) is a widely-expressed drug transporter, handling notably metformin and platinum derivatives, as well as endogenous compounds like monoamine neurotransmitters.	Platinum	116-124	solute carrier family 22 member 3	Homo sapiens	36-43
33326837-3	2021	In this study, we fabricated two kind of poly(amino acid)-based PS delivery systems by using poly (L-glutamic acid) (PLG) as the backbone material to physically encapsulate (P(T)) and chemically conjugate PS (PT), respectively.	Platinum	174-178	plasminogen	Homo sapiens	117-120
33326837-3	2021	In this study, we fabricated two kind of poly(amino acid)-based PS delivery systems by using poly (L-glutamic acid) (PLG) as the backbone material to physically encapsulate (P(T)) and chemically conjugate PS (PT), respectively.	Platinum	209-211	plasminogen	Homo sapiens	117-120
33326837-5	2021	In vitro experiments verified that the delivery system of PT exhibited more effective treatment effect than that of P(T) because PS was chemically conjugated with PLG in PT which could obviously avoid the pi-pi stacking effect of PS and induced the aggregation.	Platinum	58-60	plasminogen	Homo sapiens	163-166
33326837-5	2021	In vitro experiments verified that the delivery system of PT exhibited more effective treatment effect than that of P(T) because PS was chemically conjugated with PLG in PT which could obviously avoid the pi-pi stacking effect of PS and induced the aggregation.	Platinum	116-120	plasminogen	Homo sapiens	163-166
33326837-5	2021	In vitro experiments verified that the delivery system of PT exhibited more effective treatment effect than that of P(T) because PS was chemically conjugated with PLG in PT which could obviously avoid the pi-pi stacking effect of PS and induced the aggregation.	Platinum	170-172	plasminogen	Homo sapiens	163-166
33476136-4	2021	In the reaction of [PtMe(C N)(PPh3)] with CF3CO2H, the Pt-C N bond is cleaved rather than the Pt-Me bond.	Platinum	55-57	caveolin 1	Homo sapiens	30-34
33476136-7	2021	The reasons for this difference in selectivity for complexes 1 are computationally discussed based on the energy barrier needed for the protonolysis of the Pt-Csp3 bond versus the Pt-Csp2 bond.	Platinum	156-158	regulator of calcineurin 2	Homo sapiens	183-187
33476136-7	2021	The reasons for this difference in selectivity for complexes 1 are computationally discussed based on the energy barrier needed for the protonolysis of the Pt-Csp3 bond versus the Pt-Csp2 bond.	Platinum	180-182	regulator of calcineurin 2	Homo sapiens	183-187
33476136-8	2021	Two pathways including the direct one-step acid attack at the Pt-C bond (SE2) and stepwise oxidative-addition on the Pt(II) center followed by reductive elimination [SE(ox)] are proposed.	Platinum	62-64	fucosyltransferase 2	Homo sapiens	73-76
33476136-8	2021	Two pathways including the direct one-step acid attack at the Pt-C bond (SE2) and stepwise oxidative-addition on the Pt(II) center followed by reductive elimination [SE(ox)] are proposed.	Platinum	117-119	fucosyltransferase 2	Homo sapiens	73-76
33476136-9	2021	A detailed density functional theory (DFT) study of these protonations along with experimental UV-vis kinetics suggests that a one-step electrophilic attack (SE2) at the Pt-C bond is the most likely mechanism for complexes 1, and changing the nature of the ancillary ligand can influence the selectivity in the Pt-C bond cleavage.	Platinum	170-172	fucosyltransferase 2	Homo sapiens	158-161
33476136-9	2021	A detailed density functional theory (DFT) study of these protonations along with experimental UV-vis kinetics suggests that a one-step electrophilic attack (SE2) at the Pt-C bond is the most likely mechanism for complexes 1, and changing the nature of the ancillary ligand can influence the selectivity in the Pt-C bond cleavage.	Platinum	311-313	fucosyltransferase 2	Homo sapiens	158-161
33183422-0	2021	Effect of Nano-Platinum on Proliferation and Apoptosis of Non-Small Cell Lung Cancer Cells via P53 Pathway.	Platinum	15-23	tumor protein p53	Homo sapiens	95-98
33355035-1	2021	BACKGROUND: Several immuno-oncology (IO) agents targeting programmed death-1 or programmed death-ligand 1 (PD-1/L1) are approved second-line therapy options for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) previously treated with platinum-based chemotherapy or first-line options in patients ineligible for cisplatin whose tumors express PD-L1 or for any platinum-based chemotherapy regardless of PD-L1 expression levels.	Platinum	260-268	programmed cell death 1	Homo sapiens	107-111
33355035-1	2021	BACKGROUND: Several immuno-oncology (IO) agents targeting programmed death-1 or programmed death-ligand 1 (PD-1/L1) are approved second-line therapy options for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) previously treated with platinum-based chemotherapy or first-line options in patients ineligible for cisplatin whose tumors express PD-L1 or for any platinum-based chemotherapy regardless of PD-L1 expression levels.	Platinum	385-393	programmed cell death 1	Homo sapiens	107-111
32954856-6	2021	On the one hand, the positive effects of platinum-based chemotherapy on immunomodulation can be harnessed to increase the sensitivity of tumor cells to PD-1/PD-L1 inhibitors.	Platinum	41-49	programmed cell death 1	Homo sapiens	152-156
32954856-6	2021	On the one hand, the positive effects of platinum-based chemotherapy on immunomodulation can be harnessed to increase the sensitivity of tumor cells to PD-1/PD-L1 inhibitors.	Platinum	41-49	CD274 molecule	Homo sapiens	157-162
32954856-7	2021	On the other hand, platinum-based chemotherapy may upregulate PD-L1 expression in tumor tissue and exert a negative immunomodulatory effect, which can be counteracted by PD-1/PD-L1 inhibitors through their action pathway.	Platinum	19-27	CD274 molecule	Homo sapiens	62-67
32954856-7	2021	On the other hand, platinum-based chemotherapy may upregulate PD-L1 expression in tumor tissue and exert a negative immunomodulatory effect, which can be counteracted by PD-1/PD-L1 inhibitors through their action pathway.	Platinum	19-27	programmed cell death 1	Homo sapiens	170-174
32954856-7	2021	On the other hand, platinum-based chemotherapy may upregulate PD-L1 expression in tumor tissue and exert a negative immunomodulatory effect, which can be counteracted by PD-1/PD-L1 inhibitors through their action pathway.	Platinum	19-27	CD274 molecule	Homo sapiens	175-180
33523301-0	2021	Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.	Platinum	46-54	programmed cell death 1	Homo sapiens	28-31
33523301-2	2021	METHODS: We investigated 1181 Korean patients with programmed death-1 ligand 1 (PD-L1)-positive [tumor proportion score (TPS) >= 10% by the SP263 assay or >= 50% by the 22C3 assay] R/M-NSCLC treated with pembrolizumab or nivolumab after failure of platinum-based chemotherapy.	Platinum	248-256	CD274 molecule	Homo sapiens	80-85
33313950-12	2021	To conclude, Gli and NANOG may be effective indicators of platinum resistance and prognosis in EOC.	Platinum	58-66	GLI family zinc finger 1	Homo sapiens	13-16
33313950-12	2021	To conclude, Gli and NANOG may be effective indicators of platinum resistance and prognosis in EOC.	Platinum	58-66	Nanog homeobox	Homo sapiens	21-26
33585454-0	2020	PRSS1 Upregulation Predicts Platinum Resistance in Ovarian Cancer Patients.	Platinum	28-36	serine protease 1	Homo sapiens	0-5
33552280-0	2021	PRMT1 expression predicts sensitivity to platinum-based chemotherapy in patients with ovarian serous carcinoma.	Platinum	41-49	protein arginine methyltransferase 1	Homo sapiens	0-5
33552280-5	2021	The present study investigated the association between PRMT1 expression and sensitivity to platinum-based chemotherapy in 51 patients with ovarian serous carcinoma (International Federation of Gynecology and Obstetrics stages III and IV), and the effect of RNA interference-mediated downregulation of PRMT1 on the sensitivity of ovarian cancer cells to cisplatin and carboplatin in vitro.	Platinum	91-99	protein arginine methyltransferase 1	Homo sapiens	55-60
33552280-8	2021	PRMT1 expression was significantly lower in the platinum-sensitive group than in the platinum-resistant group (P=0.019).	Platinum	48-56	protein arginine methyltransferase 1	Homo sapiens	0-5
33552280-8	2021	PRMT1 expression was significantly lower in the platinum-sensitive group than in the platinum-resistant group (P=0.019).	Platinum	85-93	protein arginine methyltransferase 1	Homo sapiens	0-5
33552280-9	2021	When patients were categorized according to PRMT1 expression, those in the low PRMT1 expression group were more sensitive to platinum-based chemotherapy than those in the high PRMT1 expression group (P=0.01).	Platinum	125-133	protein arginine methyltransferase 1	Homo sapiens	44-49
33552280-9	2021	When patients were categorized according to PRMT1 expression, those in the low PRMT1 expression group were more sensitive to platinum-based chemotherapy than those in the high PRMT1 expression group (P=0.01).	Platinum	125-133	protein arginine methyltransferase 1	Homo sapiens	79-84
33552280-9	2021	When patients were categorized according to PRMT1 expression, those in the low PRMT1 expression group were more sensitive to platinum-based chemotherapy than those in the high PRMT1 expression group (P=0.01).	Platinum	125-133	protein arginine methyltransferase 1	Homo sapiens	79-84
33552280-11	2021	In conclusion, PRMT1 expression could predict sensitivity to platinum-based chemotherapy in patients with ovarian serous carcinoma.	Platinum	61-69	protein arginine methyltransferase 1	Homo sapiens	15-20
33617491-6	2021	The electrocatalytic degradation mechanism of E-Co(II)-PO43- system on MB was the combination of indirect oxidation of the intermediate oxidants like Co(III), P2O84- and the hydroxyl radical with direct electrocatalysis on the platinum titanium electrode, where the electrocatalytic oxidation of Co(III) was dominant.	Platinum	227-235	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	296-303
33585454-8	2020	Hereafter, we conducted in-depth explorations on PRSS1"s platinum response to ovarian cancer through tissue and cytological experiments.	Platinum	57-65	serine protease 1	Homo sapiens	49-54
33585454-9	2020	Quantitative real-time polymerase chain reaction and Western blot assay results indicated that PRSS1 expression levels in platinum-resistant samples (tissue/cell) were significantly higher than in samples sensitive to platinum.	Platinum	122-130	serine protease 1	Homo sapiens	95-100
33585454-9	2020	Quantitative real-time polymerase chain reaction and Western blot assay results indicated that PRSS1 expression levels in platinum-resistant samples (tissue/cell) were significantly higher than in samples sensitive to platinum.	Platinum	218-226	serine protease 1	Homo sapiens	95-100
33585454-12	2020	In conclusion, we identified a novel risk gene PRSS1 related to ovarian cancer platinum response and confirmed its key roles using multiple levels of low-throughput experiments, revealing a new treatment strategy based on a novel target factor for overcoming cisplatin resistance in ovarian cancer.	Platinum	79-87	serine protease 1	Homo sapiens	47-52
33495506-8	2021	Furthermore, to test the exact role of both the cognate receptors of C5a (C5aR1 and C5aR2), experimental PT + HS was induced in C5aR1 knockout (C5aR1 KO) and C5aR2 KO mice.	Platinum	105-107	complement component 5a receptor 1	Mus musculus	128-133
33530588-0	2021	RUNX3 Transcript Variants Have Distinct Roles in Ovarian Carcinoma and Differently Influence Platinum Sensitivity and Angiogenesis.	Platinum	93-101	runt related transcription factor 3	Gallus gallus	0-5
33530588-12	2021	Altogether, the presented data support the hypothesis of different functions of RUNX3 transcript variants related to the clinically relevant processes-platinum resistance and angiogenesis.	Platinum	151-159	runt related transcription factor 3	Gallus gallus	80-85
33495506-8	2021	Furthermore, to test the exact role of both the cognate receptors of C5a (C5aR1 and C5aR2), experimental PT + HS was induced in C5aR1 knockout (C5aR1 KO) and C5aR2 KO mice.	Platinum	105-107	complement component 5a receptor 1	Mus musculus	128-133
33482905-0	2021	CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.	Platinum	110-118	calcium/calmodulin dependent protein kinase II inhibitor 1	Homo sapiens	0-7
33482905-0	2021	CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.	Platinum	110-118	RUNX family transcription factor 3	Homo sapiens	8-13
33482905-3	2021	RESULTS: The marker combination CAMK2N1/RUNX3 exhibited a significant prognostic value for progression-free (PFS) and overall survival (OS) of sporadic platinum-sensitive EOC (n = 188) both in univariate Kaplan-Meier (LogRank p < 0.05) and multivariate Cox regression analysis (p < 0.05; hazard ratio HR = 1.587).	Platinum	152-160	calcium/calmodulin dependent protein kinase II inhibitor 1	Homo sapiens	32-39
33482905-3	2021	RESULTS: The marker combination CAMK2N1/RUNX3 exhibited a significant prognostic value for progression-free (PFS) and overall survival (OS) of sporadic platinum-sensitive EOC (n = 188) both in univariate Kaplan-Meier (LogRank p < 0.05) and multivariate Cox regression analysis (p < 0.05; hazard ratio HR = 1.587).	Platinum	152-160	RUNX family transcription factor 3	Homo sapiens	40-45
33482905-8	2021	CONCLUSION: The retrospective analysis of 188 sporadic platinum-sensitive EOC proved an independent prognostic value of the methylation marker combination CAMK2N1/RUNX3 for PFS and OS.	Platinum	55-63	calcium/calmodulin dependent protein kinase II inhibitor 1	Homo sapiens	155-162
33482905-8	2021	CONCLUSION: The retrospective analysis of 188 sporadic platinum-sensitive EOC proved an independent prognostic value of the methylation marker combination CAMK2N1/RUNX3 for PFS and OS.	Platinum	55-63	RUNX family transcription factor 3	Homo sapiens	163-168
33404211-3	2021	Here, we demonstrate that through the molecular adsorption of melamine onto the Pt(111) surface [Pt(111)-Mad], the activity can be improved by a factor of 20 compared to bare Pt(111) for the ORR in a strongly adsorbing sulfuric acid solution.	Platinum	80-82	MAX dimerization protein 1	Homo sapiens	105-108
33494783-12	2021	Western blot showed that application of Pt-MWNTS can significantly upregulate the expression level of Bax, Bim, Bid, Caspase-3 and Caspase-9 while downregulate the expression level of Bcl-2, compared with free cisplatin.	Platinum	40-42	BCL2-associated X protein	Mus musculus	102-105
33494783-12	2021	Western blot showed that application of Pt-MWNTS can significantly upregulate the expression level of Bax, Bim, Bid, Caspase-3 and Caspase-9 while downregulate the expression level of Bcl-2, compared with free cisplatin.	Platinum	40-42	BCL2-like 11 (apoptosis facilitator)	Mus musculus	107-110
33494783-12	2021	Western blot showed that application of Pt-MWNTS can significantly upregulate the expression level of Bax, Bim, Bid, Caspase-3 and Caspase-9 while downregulate the expression level of Bcl-2, compared with free cisplatin.	Platinum	40-42	BH3 interacting domain death agonist	Mus musculus	112-115
33494783-12	2021	Western blot showed that application of Pt-MWNTS can significantly upregulate the expression level of Bax, Bim, Bid, Caspase-3 and Caspase-9 while downregulate the expression level of Bcl-2, compared with free cisplatin.	Platinum	40-42	caspase 3	Mus musculus	117-126
33494783-12	2021	Western blot showed that application of Pt-MWNTS can significantly upregulate the expression level of Bax, Bim, Bid, Caspase-3 and Caspase-9 while downregulate the expression level of Bcl-2, compared with free cisplatin.	Platinum	40-42	caspase 9	Mus musculus	131-140
33494783-12	2021	Western blot showed that application of Pt-MWNTS can significantly upregulate the expression level of Bax, Bim, Bid, Caspase-3 and Caspase-9 while downregulate the expression level of Bcl-2, compared with free cisplatin.	Platinum	40-42	B cell leukemia/lymphoma 2	Mus musculus	184-189
33494783-13	2021	Moreover, the expression level of mesenchymal markers like Vimentin and N-cadherin was more efficiently reduced by Pt-MWNTS treatment in A549/DDP cells than free cisplatin.	Platinum	115-117	vimentin	Mus musculus	59-67
33494783-13	2021	Moreover, the expression level of mesenchymal markers like Vimentin and N-cadherin was more efficiently reduced by Pt-MWNTS treatment in A549/DDP cells than free cisplatin.	Platinum	115-117	cadherin 2	Mus musculus	72-82
33404211-3	2021	Here, we demonstrate that through the molecular adsorption of melamine onto the Pt(111) surface [Pt(111)-Mad], the activity can be improved by a factor of 20 compared to bare Pt(111) for the ORR in a strongly adsorbing sulfuric acid solution.	Platinum	97-99	MAX dimerization protein 1	Homo sapiens	105-108
33404211-3	2021	Here, we demonstrate that through the molecular adsorption of melamine onto the Pt(111) surface [Pt(111)-Mad], the activity can be improved by a factor of 20 compared to bare Pt(111) for the ORR in a strongly adsorbing sulfuric acid solution.	Platinum	97-99	MAX dimerization protein 1	Homo sapiens	105-108
33613698-2	2021	On the contrary, based on subset analysis with the immune checkpoint inhibitor (ICI) plus platinum-doublet chemotherapy in advanced NSCLC with EGFR mutation, we hypothesized that this combination was worth testing as adjuvant therapy in patients with EGFR-mutated NSCLC.	Platinum	90-98	epidermal growth factor receptor	Homo sapiens	143-147
33404211-4	2021	The Mad moieties act as "surface-blocking bodies," selectively hindering the adsorption of (bi)sulfate anions (well-known poisoning spectator of the Pt(111) active sites) while the ORR is unhindered.	Platinum	149-151	MAX dimerization protein 1	Homo sapiens	4-7
33404211-6	2021	We suggest that the higher stability of the Pt(111)-Mad interface stems from melamine"s ability to form intermolecular hydrogen bonds, which effectively turns the melamine molecules into larger macromolecular entities with multiple anchoring sites and thus more difficult to remove.	Platinum	44-46	MAX dimerization protein 1	Homo sapiens	52-55
33408251-0	2021	ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer.	Platinum	75-83	actin like 6A	Homo sapiens	0-6
33478135-2	2021	The objective of our study was to evaluate the expression of an important DNA repair enzyme, the Poly (ADP-Ribose) Polymerase (PARP) expression in epithelial ovarian cancer (EOC) tissues depending on BRCA status and to assess its relationship with platinum resistance.	Platinum	248-256	poly(ADP-ribose) polymerase 1	Homo sapiens	97-125
33408251-5	2021	Here we identify ACTL6A overexpression as a novel cause for platinum resistance.	Platinum	60-68	actin like 6A	Homo sapiens	17-23
33478135-2	2021	The objective of our study was to evaluate the expression of an important DNA repair enzyme, the Poly (ADP-Ribose) Polymerase (PARP) expression in epithelial ovarian cancer (EOC) tissues depending on BRCA status and to assess its relationship with platinum resistance.	Platinum	248-256	poly(ADP-ribose) polymerase 1	Homo sapiens	127-131
33408251-11	2021	Taken together, our study uncovers a novel role for ACTL6A in platinum resistance, and provides evidence supporting the feasibility of using HDAC inhibitors for platinum resistant tumors.	Platinum	62-70	actin-like 6A	Mus musculus	52-58
33172933-0	2021	Frizzled-7 Identifies Platinum Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis.	Platinum	22-30	frizzled class receptor 7	Homo sapiens	0-10
33461544-2	2021	Tie1 is upregulated in hypoxia and is believed to counteract the effectiveness of platinum agents by promoting the stemness properties in cells.	Platinum	82-90	tyrosine kinase with immunoglobulin like and EGF like domains 1	Homo sapiens	0-4
33172933-4	2021	Additionally, platinum-tolerant cells and tumors exhibited expression of the Wnt receptor Frizzled 7 (FZD7).	Platinum	14-22	frizzled class receptor 7	Homo sapiens	90-100
33172933-10	2021	These results support the existence of a platinum-tolerant cell population with partial stem cell features, characterized by FZD7 expression and dependent on FZD7-beta-catenin-Tp63-GPX4 pathway for survival.	Platinum	41-49	frizzled class receptor 7	Homo sapiens	125-129
33172933-4	2021	Additionally, platinum-tolerant cells and tumors exhibited expression of the Wnt receptor Frizzled 7 (FZD7).	Platinum	14-22	frizzled class receptor 7	Homo sapiens	102-106
33172933-10	2021	These results support the existence of a platinum-tolerant cell population with partial stem cell features, characterized by FZD7 expression and dependent on FZD7-beta-catenin-Tp63-GPX4 pathway for survival.	Platinum	41-49	frizzled class receptor 7	Homo sapiens	158-162
33172933-5	2021	Knockdown of FZD7 improved sensitivity to platinum, decreased spheroid formation, and delayed tumor initiation.	Platinum	42-50	frizzled class receptor 7	Homo sapiens	13-17
33172933-8	2021	FZD7(+) platinum-tolerant OC cells were more sensitive and underwent ferroptosis after treatment with GPX4 inhibitors.	Platinum	8-16	frizzled class receptor 7	Homo sapiens	0-4
33172933-10	2021	These results support the existence of a platinum-tolerant cell population with partial stem cell features, characterized by FZD7 expression and dependent on FZD7-beta-catenin-Tp63-GPX4 pathway for survival.	Platinum	41-49	catenin beta 1	Homo sapiens	163-175
33172933-8	2021	FZD7(+) platinum-tolerant OC cells were more sensitive and underwent ferroptosis after treatment with GPX4 inhibitors.	Platinum	8-16	glutathione peroxidase 4	Homo sapiens	102-106
33201175-3	2021	Here, we showed that T cells including CD4+ T cells and CD8+ T cells of the patients with advanced gastric cancer after platinum and fluorouracil chemotherapy exhibited enhanced ex vivo proliferation ability as compared to that before chemotherapy.	Platinum	120-128	CD4 molecule	Homo sapiens	39-42
33172933-10	2021	These results support the existence of a platinum-tolerant cell population with partial stem cell features, characterized by FZD7 expression and dependent on FZD7-beta-catenin-Tp63-GPX4 pathway for survival.	Platinum	41-49	tumor protein p63	Homo sapiens	176-180
33172933-10	2021	These results support the existence of a platinum-tolerant cell population with partial stem cell features, characterized by FZD7 expression and dependent on FZD7-beta-catenin-Tp63-GPX4 pathway for survival.	Platinum	41-49	glutathione peroxidase 4	Homo sapiens	181-185
33254785-3	2021	3D LEPG with porous network structure can selective decorated with Pt nanoparticles (Pt NPs) by in situ electrochemical depositions (Pt-LEPG) as sensitively H2O2 sensors with a wide range of linear (0.01-29 nM) and high sensitivity (575.75 muA mM-1 cm-2).	Platinum	67-69	Mix1 homeobox-like 1 (Xenopus laevis)	Mus musculus	244-253
33254785-3	2021	3D LEPG with porous network structure can selective decorated with Pt nanoparticles (Pt NPs) by in situ electrochemical depositions (Pt-LEPG) as sensitively H2O2 sensors with a wide range of linear (0.01-29 nM) and high sensitivity (575.75 muA mM-1 cm-2).	Platinum	85-87	Mix1 homeobox-like 1 (Xenopus laevis)	Mus musculus	244-253
33167224-1	2021	An analytical methodology based on asymmetric flow field flow fractionation hyphenated to inductively coupled plasma mass spectrometry (AF4-ICP-MS) has been developed for monitoring citrate coated platinum nanoparticles (PtNPs) of different sizes (5, 30, and 50 nm) in water samples.	Platinum	197-205	AF4/FMR2 family member 1	Homo sapiens	136-139
32965028-11	2021	In the scope of the registration of PARP inhibitors (PARPi) for mCRPC, we provide initial insights on cross-resistance between PARPi and platinum compounds.	Platinum	137-145	collagen type XI alpha 2 chain	Homo sapiens	36-40
32965028-13	2021	In this cohort, only BRCA2mut patients treated with platinum first (n = 4), responded to both agents.	Platinum	52-60	BRCA2 DNA repair associated	Homo sapiens	21-26
32965028-14	2021	We confirm that BRCA2 inactivation is associated with meaningful responses to carboplatin, suggesting a role for both PARPi and platinum-based chemotherapy in pre-selected mCRPC patients.	Platinum	128-136	BRCA2 DNA repair associated	Homo sapiens	16-21
33201175-3	2021	Here, we showed that T cells including CD4+ T cells and CD8+ T cells of the patients with advanced gastric cancer after platinum and fluorouracil chemotherapy exhibited enhanced ex vivo proliferation ability as compared to that before chemotherapy.	Platinum	120-128	CD8a molecule	Homo sapiens	56-59
33423683-9	2021	The previous response status to platinum-based chemotherapy and baseline CA125 levels were significantly correlated with the ORR.	Platinum	32-40	mucin 16, cell surface associated	Homo sapiens	73-78
33045314-6	2021	In this study, we developed a novel ultrasmall Pt(II) dot (uPtD) from miriplatin and encapsulated it into our recently-reported integrin alpha5(ITGA5) active targeting nanoparticles (uPtDs NPs) and tested their therapeutic efficacy against TNBC metastasis.	Platinum	47-49	integrin subunit alpha 5	Homo sapiens	128-143
33432021-6	2021	Molecular characteristics of three patients responding to olapanib supported that BRCA mutation and HRD related mutations is the target of olaparib in platinum sensitive patients.	Platinum	151-159	BRCA1 DNA repair associated	Homo sapiens	82-86
33045314-6	2021	In this study, we developed a novel ultrasmall Pt(II) dot (uPtD) from miriplatin and encapsulated it into our recently-reported integrin alpha5(ITGA5) active targeting nanoparticles (uPtDs NPs) and tested their therapeutic efficacy against TNBC metastasis.	Platinum	47-49	integrin subunit alpha 5	Homo sapiens	144-149
33435590-2	2021	Human Epididymis protein 4 (HE4) is one of the most promising markers in predicting platinum therapy response.	Platinum	84-92	WAP four-disulfide core domain 2	Homo sapiens	28-31
33506032-0	2021	RBBP4 Enhances Platinum Chemo Resistance in Lung Adenocarcinoma.	Platinum	15-23	RB binding protein 4, chromatin remodeling factor	Homo sapiens	0-5
33435590-10	2021	In the BRCA WT group, 23 patients out of 53 (43%) were platinum-sensitive, while 30 patients out of 53 (57%) were platinum-resistant.	Platinum	55-63	BRCA1 DNA repair associated	Homo sapiens	7-11
33435590-12	2021	In the BRCA mutated group, 13 patients out of 16 (82%) were platinum-sensitive, while 3 patients (18%) were platinum-resistant.	Platinum	60-68	BRCA1 DNA repair associated	Homo sapiens	7-11
33435622-0	2021	Clinicopathological and Functional Evaluation Reveal NBS1 as a Predictor of Platinum Resistance in Epithelial Ovarian Cancers.	Platinum	76-84	nibrin	Homo sapiens	53-57
33435622-6	2021	Pre-clinically, sub-cellular localization of NBS1 at baseline and following cisplatin therapy was tested in platinum resistant (A2780cis, PEO4) and sensitive (A2780, PEO1) ovarian cancer cells.	Platinum	108-116	nibrin	Homo sapiens	45-49
33435622-8	2021	Nuclear NBS1 overexpression was associated with platinum resistance (p = 0.0001).	Platinum	48-56	nibrin	Homo sapiens	8-12
33435622-13	2021	NBS1 is a predictor of platinum sensitivity and could aid stratification of ovarian cancer therapy.	Platinum	23-31	nibrin	Homo sapiens	0-4
33411033-0	2021	Effects of SLC31A1 and ATP7B polymorphisms on platinum resistance in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy.	Platinum	46-54	solute carrier family 31 member 1	Homo sapiens	11-18
33140814-3	2021	It was found that the presence of -NH2 groups in Ce-MOFs played a crucial role in anchoring Pt species with high dispersion on the MOF framework.	Platinum	92-94	lysine acetyltransferase 8	Homo sapiens	52-55
33411033-0	2021	Effects of SLC31A1 and ATP7B polymorphisms on platinum resistance in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy.	Platinum	46-54	ATPase copper transporting beta	Homo sapiens	23-28
33411033-10	2021	Therefore, in neoadjuvant CRT for ESCC patients, the effect of platinum was affected by the SLC31A1 rs10981694 A > C polymorphism.	Platinum	63-71	solute carrier family 31 member 1	Homo sapiens	92-99
33442288-0	2021	MicroRNA-223 is Associated with Resistance Towards Platinum-based Chemotherapy and Worse Prognosis in Indonesian Triple-negative Breast Cancer Patients.	Platinum	51-59	microRNA 223	Homo sapiens	0-12
33442288-9	2021	Worse survival is observed in miR-223 overexpressed group receiving platinum-based chemotherapy compared to miR-223 underexpressed group (mean OS (95%CI) months: 24.7 (20.3-29.1) vs 34.3 (31.2-37.4); p<0.01), while no significant difference observed in non-platinum containing regimen.	Platinum	68-76	microRNA 223	Homo sapiens	30-37
33442288-9	2021	Worse survival is observed in miR-223 overexpressed group receiving platinum-based chemotherapy compared to miR-223 underexpressed group (mean OS (95%CI) months: 24.7 (20.3-29.1) vs 34.3 (31.2-37.4); p<0.01), while no significant difference observed in non-platinum containing regimen.	Platinum	257-265	microRNA 223	Homo sapiens	30-37
33442288-11	2021	Conclusion: Overexpression of miR-223 is associated with increased expression of EGFR, worse prognosis, and resistance toward platinum-based chemotherapy in Indonesian TNBC patients.	Platinum	126-134	microRNA 223	Homo sapiens	30-37
33397458-0	2021	Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer.	Platinum	53-61	WAP four-disulfide core domain 2	Homo sapiens	25-28
33397458-0	2021	Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer.	Platinum	53-61	mucin 16, cell surface associated	Homo sapiens	33-38
33397458-1	2021	OBJECTIVES: To assess the clinical value of early clearance of HE4 and CA125 for platinum sensitivity and prognosis in patients with ovarian cancer.	Platinum	81-89	WAP four-disulfide core domain 2	Homo sapiens	63-66
33397458-1	2021	OBJECTIVES: To assess the clinical value of early clearance of HE4 and CA125 for platinum sensitivity and prognosis in patients with ovarian cancer.	Platinum	81-89	mucin 16, cell surface associated	Homo sapiens	71-76
33397458-5	2021	When HE4 clearance after 3rd cycle chemotherapy or CA125 clearance after 1st cycle chemotherapy, it gave the highest AUC of 0.788, with 100% of sensitivity and 57.5% of specificity respectively between platinum resistant and platinum sensitive group.	Platinum	202-210	WAP four-disulfide core domain 2	Homo sapiens	5-8
33389237-0	2021	Handheld pH meter-assisted immunoassay for C-reactive protein using glucose oxidase-conjugated dendrimer loaded with platinum nanozymes.	Platinum	117-125	C-reactive protein	Homo sapiens	43-61
33397458-5	2021	When HE4 clearance after 3rd cycle chemotherapy or CA125 clearance after 1st cycle chemotherapy, it gave the highest AUC of 0.788, with 100% of sensitivity and 57.5% of specificity respectively between platinum resistant and platinum sensitive group.	Platinum	202-210	mucin 16, cell surface associated	Homo sapiens	51-56
33389237-1	2021	A simple and feasible pH meter-based immunoassay is reported for detection of C-reactive protein (CRP) using glucose oxidase (GOD)-conjugated dendrimer loaded with platinum nanozyme.	Platinum	164-172	C-reactive protein	Homo sapiens	78-96
33389237-1	2021	A simple and feasible pH meter-based immunoassay is reported for detection of C-reactive protein (CRP) using glucose oxidase (GOD)-conjugated dendrimer loaded with platinum nanozyme.	Platinum	164-172	C-reactive protein	Homo sapiens	98-101
33397458-5	2021	When HE4 clearance after 3rd cycle chemotherapy or CA125 clearance after 1st cycle chemotherapy, it gave the highest AUC of 0.788, with 100% of sensitivity and 57.5% of specificity respectively between platinum resistant and platinum sensitive group.	Platinum	225-233	WAP four-disulfide core domain 2	Homo sapiens	5-8
33397458-5	2021	When HE4 clearance after 3rd cycle chemotherapy or CA125 clearance after 1st cycle chemotherapy, it gave the highest AUC of 0.788, with 100% of sensitivity and 57.5% of specificity respectively between platinum resistant and platinum sensitive group.	Platinum	225-233	mucin 16, cell surface associated	Homo sapiens	51-56
33397458-9	2021	CONCLUSIONS: Our data suggested that the early clearance of HE4 and CA125 could predict platinum response and prognosis in patients with ovarian cancer.	Platinum	88-96	WAP four-disulfide core domain 2	Homo sapiens	60-63
33397458-9	2021	CONCLUSIONS: Our data suggested that the early clearance of HE4 and CA125 could predict platinum response and prognosis in patients with ovarian cancer.	Platinum	88-96	mucin 16, cell surface associated	Homo sapiens	68-73
33397458-10	2021	Monitoring the HE4 and CA125 during first-line chemotherapy might be helpful in predicting platinum sensitivity and risk to progress and relapse.	Platinum	91-99	WAP four-disulfide core domain 2	Homo sapiens	15-18
33397458-10	2021	Monitoring the HE4 and CA125 during first-line chemotherapy might be helpful in predicting platinum sensitivity and risk to progress and relapse.	Platinum	91-99	mucin 16, cell surface associated	Homo sapiens	23-28
33545805-0	2021	Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.	Platinum	74-82	CD274 molecule	Homo sapiens	5-10
33091561-2	2021	Tumours from these patients tend to lose both copies of the wild type BRCA gene, which makes them exquisitely sensitive to platinum drugs and PARP inhibitors (PARPi), treatments of choice in these disease settings.	Platinum	123-131	BRCA2 DNA repair associated	Homo sapiens	70-74
33078505-1	2021	Although nivolumab, a programmed cell death 1 (PD-1) inhibitor, is a standard therapy for platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), no definitive biomarkers have been reported thus far.	Platinum	90-98	programmed cell death 1	Homo sapiens	47-51
33227705-0	2021	Incorporating SULF1 polymorphisms in a pretreatment CT-based radiomic model for predicting platinum resistance in ovarian cancer treatment.	Platinum	91-99	sulfatase 1	Homo sapiens	14-19
33227705-2	2021	This study aims to develop a machine learning model incorporating genomic data such as Single-Nucleotide Polymorphisms (SNPs) of Human Sulfatase 1 (SULF1) with a CT radiomic model based on pre-treatment CT images, to predict platinum resistance for ovarian cancer (OC) treatment.	Platinum	225-233	sulfatase 1	Homo sapiens	135-146
33227705-2	2021	This study aims to develop a machine learning model incorporating genomic data such as Single-Nucleotide Polymorphisms (SNPs) of Human Sulfatase 1 (SULF1) with a CT radiomic model based on pre-treatment CT images, to predict platinum resistance for ovarian cancer (OC) treatment.	Platinum	225-233	sulfatase 1	Homo sapiens	148-153
33227705-13	2021	CONCLUSIONS: A predictive model combining pretreatment CT radiomics with genomic data such as SNPs of SULF1 could potentially help to predict platinum resistance in ovarian cancer treatment.	Platinum	142-150	sulfatase 1	Homo sapiens	102-107
33250205-1	2021	PURPOSE: Maintenance therapy with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib provided a substantial progression-free survival (PFS) benefit compared with placebo in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (BRCAm) who were in clinical complete or partial response following platinum-based chemotherapy in the Phase III SOLO1 global study.	Platinum	322-330	poly(ADP-ribose) polymerase 1	Homo sapiens	67-71
33338859-8	2021	At progression, platinum-based CT combined with cetuximab (a monoclonal anti-epidermal growth factor receptor antibody) is the only validated option available as the first-line therapy.	Platinum	16-24	epidermal growth factor receptor	Homo sapiens	77-109
33487630-8	2021	For example, somatic BRCA1/2 reversion mutations are often identified in patients with BRCA1/2-mutated cancers after treatment with platinum-based therapy, causing restoration of HR capacity and thus conferring PARPi resistance.	Platinum	132-140	BRCA1 DNA repair associated	Homo sapiens	21-28
33487630-8	2021	For example, somatic BRCA1/2 reversion mutations are often identified in patients with BRCA1/2-mutated cancers after treatment with platinum-based therapy, causing restoration of HR capacity and thus conferring PARPi resistance.	Platinum	132-140	BRCA1 DNA repair associated	Homo sapiens	87-94
32997802-11	2021	The majority although not all PALB2-driven BCs have somatic inactivation of the remaining PALB2 allele and therefore potential sensitivity to platinum compounds and PARP inhibitors.	Platinum	142-150	partner and localizer of BRCA2	Homo sapiens	30-35
33402502-0	2021	ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy.	Platinum	125-133	ATM serine/threonine kinase	Homo sapiens	0-3
33402502-8	2021	In a subgroup analysis, EH-CCC patients with ATM loss tended to have improved PFS after platinum-based chemotherapy compared to those with intact ATM (7.9 vs. 6.2 months, respectively; p=0.050).	Platinum	88-96	ATM serine/threonine kinase	Homo sapiens	45-48
33531973-0	2021	A pharmacogenetics study of platinum-based chemotherapy in lung cancer: ABCG2 polymorphism and its genetic interaction with SLC31A1 are associated with response and survival.	Platinum	28-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	72-77
33402502-9	2021	CONCLUSION: We demonstrated that ATM loss could be a prognostic marker after platinum-based chemotherapy in patients with advanced EH-CCC.	Platinum	77-85	ATM serine/threonine kinase	Homo sapiens	33-36
33531973-0	2021	A pharmacogenetics study of platinum-based chemotherapy in lung cancer: ABCG2 polymorphism and its genetic interaction with SLC31A1 are associated with response and survival.	Platinum	28-36	solute carrier family 31 member 1	Homo sapiens	124-131
33531973-2	2021	We had previously characterized functional variant of platinum intake transporter SLC31A1 gene.	Platinum	54-62	solute carrier family 31 member 1	Homo sapiens	82-89
33531973-3	2021	We aimed to investigate the association of platinum efflux transporter gene ABCG2 polymorphism and combined ABCG2 and SLC31A1 polymorphisms with clinical outcomes of NSCLC patients receiving platinum-based chemotherapy.	Platinum	43-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	76-81
33531973-9	2021	Conclusion: This study reveals divergent association of ABCG2 polymorphism with response and survival of NSCLC patients receiving platinum-based chemotherapy, demonstrates the combined effects of functional variants of ABCG2 and SLC31A1 on clinical outcomes, and highlights pharmacogenetic relevance of platinum transporter genes interaction.	Platinum	130-138	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	56-61
33531973-9	2021	Conclusion: This study reveals divergent association of ABCG2 polymorphism with response and survival of NSCLC patients receiving platinum-based chemotherapy, demonstrates the combined effects of functional variants of ABCG2 and SLC31A1 on clinical outcomes, and highlights pharmacogenetic relevance of platinum transporter genes interaction.	Platinum	130-138	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	219-224
33531973-9	2021	Conclusion: This study reveals divergent association of ABCG2 polymorphism with response and survival of NSCLC patients receiving platinum-based chemotherapy, demonstrates the combined effects of functional variants of ABCG2 and SLC31A1 on clinical outcomes, and highlights pharmacogenetic relevance of platinum transporter genes interaction.	Platinum	130-138	solute carrier family 31 member 1	Homo sapiens	229-236
33219317-4	2021	Here, we discovered that high UFBP1 expression increases the progression-free survival of advanced gastric cancer patients treated with platinum-based chemotherapy.	Platinum	136-144	DDRGK domain containing 1	Homo sapiens	30-35
33616009-0	2021	Spectroscopic and docking molecular study of new anticancer Pt complex binding with human serum albumin.	Platinum	60-62	albumin	Homo sapiens	90-103
33616009-1	2021	After synthesizing and identifying the nature of the new complex based on platinum metal, [Pt(NH3)2(butylgly)]NO3, the interaction of this complex with human serum albumin (HSA) was performed by spectroscopy and molecular docking methods at two temperatures of 27 and 37  C and under physiological conditions of the body.	Platinum	74-88	albumin	Homo sapiens	158-171
33473229-3	2021	Here we demonstrate that the structure (Pt1-Ptn)/alpha-MoC, where isolated platinum atoms (Pt1) and subnanometre platinum clusters (Ptn) are stabilized on alpha-molybdenum carbide (alpha-MoC), catalyses the WGS reaction even at 313 kelvin, with a hydrogen-production pathway involving direct carbon monoxide dissociation identified.	Platinum	75-83	zinc finger protein 77	Homo sapiens	40-43
33473229-3	2021	Here we demonstrate that the structure (Pt1-Ptn)/alpha-MoC, where isolated platinum atoms (Pt1) and subnanometre platinum clusters (Ptn) are stabilized on alpha-molybdenum carbide (alpha-MoC), catalyses the WGS reaction even at 313 kelvin, with a hydrogen-production pathway involving direct carbon monoxide dissociation identified.	Platinum	75-83	zinc finger protein 77	Homo sapiens	91-94
33473229-3	2021	Here we demonstrate that the structure (Pt1-Ptn)/alpha-MoC, where isolated platinum atoms (Pt1) and subnanometre platinum clusters (Ptn) are stabilized on alpha-molybdenum carbide (alpha-MoC), catalyses the WGS reaction even at 313 kelvin, with a hydrogen-production pathway involving direct carbon monoxide dissociation identified.	Platinum	113-121	zinc finger protein 77	Homo sapiens	40-43
33408782-14	2021	Finally, in clinical samples, ovarian cancer patients with high levels of EZH2 and CHK1 not only were more resistant to platinum but also had a poorer prognosis.	Platinum	120-128	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	74-78
33408782-14	2021	Finally, in clinical samples, ovarian cancer patients with high levels of EZH2 and CHK1 not only were more resistant to platinum but also had a poorer prognosis.	Platinum	120-128	checkpoint kinase 1	Homo sapiens	83-87
33396213-8	2020	MMP-7 was overexpressed in RT-112 and T-24 cells by stable transfection, to assess its functional involvement in platinum sensitivity.	Platinum	113-121	matrix metallopeptidase 7	Homo sapiens	0-5
33091827-3	2021	Therefore, we identified the expression of eight genes closely associated with platinum and fluorouracil metabolism (RRM1, RRM2, RRM2B, POLH, DUT, TYMS, TYMP, MKI67) in the discovery cohort (N=291).	Platinum	79-87	ribonucleotide reductase catalytic subunit M1	Homo sapiens	117-121
33396213-0	2020	MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients.	Platinum	67-75	matrix metallopeptidase 7	Homo sapiens	0-5
33569311-9	2021	The logistic model analyzing the association between decreased PD-L1 expression on CTCs after RRx-001 and response to reintroduced platinum doublet had an approximate 92.8% accuracy in its prediction of clinical benefit.	Platinum	131-139	CD274 molecule	Homo sapiens	63-68
33569311-11	2021	Conclusions: These results suggest that PD-L1 expression on CTCs decreased after RRx-001 was significantly correlated with response to reintroduced platinum-based doublet therapy.	Platinum	148-156	CD274 molecule	Homo sapiens	40-45
33307694-1	2020	Mass spectrometric analysis of the anionic products of interaction among Pt-, methane, and carbon dioxide shows that the methane activation complex, H3C-Pt-H-, reacts with CO2 to form [H3C-Pt-H(CO2)]-.	Platinum	73-75	parathyroid hormone	Homo sapiens	153-157
33375302-4	2020	By in situ polymerization of the Cur, platinum (IV) complex-based prodrug monomer (DHP), L-lysine diisocyanate (LDI), and then conjugation with a hydrophilic poly (ethylene glycol) monomethyl ether (mPEG) derivative, a backbone-type platinum (IV) and Cur linkage containing mPEG-poly(platinum-co-Cur)-mPEG (PCPt) copolymer was synthesized.	Platinum	38-46	dihydropyrimidinase	Homo sapiens	83-86
33307694-1	2020	Mass spectrometric analysis of the anionic products of interaction among Pt-, methane, and carbon dioxide shows that the methane activation complex, H3C-Pt-H-, reacts with CO2 to form [H3C-Pt-H(CO2)]-.	Platinum	73-75	parathyroid hormone	Homo sapiens	189-193
33307694-3	2020	Mechanistic study reveals that both CH4 and CO2 are activated by the anionic Pt atom and that the successive depletion of the negative charge on Pt drives the CO2 insertion into the Pt-H and Pt-C bonds of H3C-Pt-H-.	Platinum	145-147	parathyroid hormone	Homo sapiens	182-186
33362915-10	2020	Given the excellent response to platinum-based chemotherapy, BRCA testing was performed, and a BRCA1 germline mutation was detected.	Platinum	32-40	BRCA1 DNA repair associated	Homo sapiens	95-100
33307694-3	2020	Mechanistic study reveals that both CH4 and CO2 are activated by the anionic Pt atom and that the successive depletion of the negative charge on Pt drives the CO2 insertion into the Pt-H and Pt-C bonds of H3C-Pt-H-.	Platinum	145-147	coiled-coil domain containing 6	Homo sapiens	191-195
33307694-3	2020	Mechanistic study reveals that both CH4 and CO2 are activated by the anionic Pt atom and that the successive depletion of the negative charge on Pt drives the CO2 insertion into the Pt-H and Pt-C bonds of H3C-Pt-H-.	Platinum	145-147	parathyroid hormone	Homo sapiens	209-213
33245314-1	2020	Metallocorroles and metalloporphyrins (M-N-C) are some of the best alternative molecular catalysts for the replacement of the expensive platinum-group metals (PGM) in oxygen reduction reaction (ORR) catalysis in polymer electrolyte membrane (PEM) fuel cells.	Platinum	136-144	mucin 1, cell surface associated	Homo sapiens	242-245
32897000-0	2020	Multispecific Platinum(IV) Complex Deters Breast Cancer via Interposing Inflammation and Immunosuppression as an Inhibitor of COX-2 and PD-L1.	Platinum	14-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	126-131
33317551-10	2020	Expression of PAWR could predict platinum responsiveness in ovarian cancer and there was a positive correlation between PAWR gene effect and paclitaxel sensitivity.	Platinum	33-41	pro-apoptotic WT1 regulator	Homo sapiens	14-18
32897000-0	2020	Multispecific Platinum(IV) Complex Deters Breast Cancer via Interposing Inflammation and Immunosuppression as an Inhibitor of COX-2 and PD-L1.	Platinum	14-22	CD274 molecule	Homo sapiens	136-141
33316104-22	2020	Single-agent ICI In the PD-L1 expression >= 50% group single-agent ICI probably improved OS compared to platinum-based chemotherapy (hazard ratio (HR) 0.68, 95% confidence interval (CI) 0.60 to 0.76, 6 RCTs, 2111 participants, moderate-certainty evidence).	Platinum	104-112	CD274 molecule	Homo sapiens	24-29
33363149-4	2020	In the present study, we found that the poor outcome of ESCC patients receiving platinum-based regimens was associated with co-expression of Shh and Sox2.	Platinum	80-88	sonic hedgehog signaling molecule	Homo sapiens	141-144
33316104-27	2020	More information about efficacy of single-agent ICI compared to platinum-based chemotherapy according to the level of PD-L1 expression and to TMB status or specific clinical characteristics is available in the full text.	Platinum	64-72	CD274 molecule	Homo sapiens	118-123
32413141-1	2020	BACKGROUND: BRCA1 methylation has been associated with homologous recombination deficiency, a biomarker of platinum sensitivity.	Platinum	107-115	BRCA1 DNA repair associated	Homo sapiens	12-17
33363149-4	2020	In the present study, we found that the poor outcome of ESCC patients receiving platinum-based regimens was associated with co-expression of Shh and Sox2.	Platinum	80-88	SRY-box transcription factor 2	Homo sapiens	149-153
33363149-6	2020	Manipulating of Shh expression markedly changed the sensitivity of ESCC cells to platinum.	Platinum	81-89	sonic hedgehog signaling molecule	Homo sapiens	16-19
33490217-9	2020	Despite being in an early phase, both of these compounds, navicixizumab or demcizumab, two monoclonal antibodies targeting Dll4, showed promising efficacy data in platinum-resistant OC patients in recent studies.	Platinum	163-171	delta like canonical Notch ligand 4	Homo sapiens	123-127
33425535-5	2020	As TCHP is widely used for the treatment of HER2/neu overexpressed breast cancer, these cases highlight the need to further evaluate the link between taxane and platinum-based chemotherapeutics for breast cancer and the development of t-AML/t-MDS.	Platinum	161-169	trichoplein keratin filament binding	Homo sapiens	3-7
33276659-2	2020	In the integrated cathode, Pt nanoparticles were deposited uniformly with a small particle size on the SnO2@C/CP support.	Platinum	27-29	strawberry notch homolog 1	Homo sapiens	103-106
33376937-5	2020	Although solid tumors with defective DNA damage repair defect (DDR) genes such as BRCA show heightened sensitivity to platinum agents, tumors can exploit the PARP pathway as salvage pathways.	Platinum	118-126	BRCA1 DNA repair associated	Homo sapiens	82-86
33490218-5	2020	Furthermore, BRCA wild-type patients with other defects in the HR repair pathway, or those with platinum-resistant tumors may obtain benefit from this treatment.	Platinum	96-104	BRCA1 DNA repair associated	Homo sapiens	13-17
33068886-1	2020	Poly ADP -Ribose Polymerase (PARP) inhibitors (PARPi) were firstly licensed for maintenance treatment in recurrent, platinum-sensitive, platinum responsive epithelial ovarian cancer patients, harboring or not a BRCA mutation.	Platinum	116-124	poly(ADP-ribose) polymerase 1	Homo sapiens	0-27
32736329-4	2020	A specific "constant-current region" at 1-30 microm distances between the UME and the hBLM surface was observed in the approach curves, which were registered while a Pt-based ultramicroelectrode (UME) was approaching the glass/FTO/hBLM surface.	Platinum	166-168	BLM RecQ like helicase	Homo sapiens	86-90
32736329-4	2020	A specific "constant-current region" at 1-30 microm distances between the UME and the hBLM surface was observed in the approach curves, which were registered while a Pt-based ultramicroelectrode (UME) was approaching the glass/FTO/hBLM surface.	Platinum	166-168	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	227-230
32736329-4	2020	A specific "constant-current region" at 1-30 microm distances between the UME and the hBLM surface was observed in the approach curves, which were registered while a Pt-based ultramicroelectrode (UME) was approaching the glass/FTO/hBLM surface.	Platinum	166-168	BLM RecQ like helicase	Homo sapiens	231-235
33068886-1	2020	Poly ADP -Ribose Polymerase (PARP) inhibitors (PARPi) were firstly licensed for maintenance treatment in recurrent, platinum-sensitive, platinum responsive epithelial ovarian cancer patients, harboring or not a BRCA mutation.	Platinum	116-124	poly(ADP-ribose) polymerase 1	Homo sapiens	29-33
33068886-1	2020	Poly ADP -Ribose Polymerase (PARP) inhibitors (PARPi) were firstly licensed for maintenance treatment in recurrent, platinum-sensitive, platinum responsive epithelial ovarian cancer patients, harboring or not a BRCA mutation.	Platinum	136-144	poly(ADP-ribose) polymerase 1	Homo sapiens	0-27
33068886-1	2020	Poly ADP -Ribose Polymerase (PARP) inhibitors (PARPi) were firstly licensed for maintenance treatment in recurrent, platinum-sensitive, platinum responsive epithelial ovarian cancer patients, harboring or not a BRCA mutation.	Platinum	136-144	poly(ADP-ribose) polymerase 1	Homo sapiens	29-33
33468816-5	2020	We predicted from the patient"s background that the patient may be associated with BRCA1 gene mutation and was sensitive to the platinum salts.	Platinum	128-136	BRCA1 DNA repair associated	Homo sapiens	83-88
32753285-0	2020	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.	Platinum	101-109	fibroblast growth factor receptor 3	Homo sapiens	0-35
32753285-2	2020	OBJECTIVE: To determine the association between FGFR3 status and response to platinum-based chemotherapy in patients with MIBC or mUC.	Platinum	77-85	fibroblast growth factor receptor 3	Homo sapiens	48-53
32753285-12	2020	CONCLUSIONS: FGFR3 status is associated with lower responses to platinum-based chemotherapy, which may prompt exploration of nonchemotherapeutic approaches for perioperative management of FGFR3alt urothelial cancers.	Platinum	64-72	fibroblast growth factor receptor 3	Homo sapiens	13-18
32753285-12	2020	CONCLUSIONS: FGFR3 status is associated with lower responses to platinum-based chemotherapy, which may prompt exploration of nonchemotherapeutic approaches for perioperative management of FGFR3alt urothelial cancers.	Platinum	64-72	fibroblast growth factor receptor 3	Homo sapiens	188-193
32753285-14	2020	Our findings suggest that FGFR3 mutations might be associated with lower responses and shorter time to recurrence among patients with muscle-invasive bladder cancer who received perioperative platinum-based chemotherapy.	Platinum	192-200	fibroblast growth factor receptor 3	Homo sapiens	26-31
33207247-0	2020	GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates.	Platinum	33-41	growth differentiation factor 15	Mus musculus	0-6
33207247-1	2020	Platinum-based cancer therapy is restricted by dose-limiting side effects and is associated with elevation of growth differentiation factor 15 (GDF-15).	Platinum	0-8	growth differentiation factor 15	Mus musculus	110-142
33207247-1	2020	Platinum-based cancer therapy is restricted by dose-limiting side effects and is associated with elevation of growth differentiation factor 15 (GDF-15).	Platinum	0-8	growth differentiation factor 15	Mus musculus	144-150
33207247-3	2020	Here, we explored the effects of GDF-15 blockade on platinum-based chemotherapy-induced emesis, anorexia, and weight loss in mice and/or nonhuman primate models.	Platinum	52-60	growth differentiation factor 15	Mus musculus	33-39
33207247-4	2020	We found that circulating GDF-15 is higher in subjects with cancer receiving platinum-based chemotherapy and is positively associated with weight loss in colorectal cancer (NCT00609622).	Platinum	77-85	growth differentiation factor 15	Mus musculus	26-32
33207247-6	2020	Platinum-based treatment-induced anorexia and weight loss are attenuated in GDF-15 knockout mice, while GDF-15 neutralization with the monoclonal antibody mAB1 improves survival.	Platinum	0-8	growth differentiation factor 15	Mus musculus	76-82
33147530-0	2020	A functional polymorphism in the poly(ADP-ribose) polymerase-1 gene is associated with platinum-based chemotherapeutic response and prognosis in epithelial ovarian cancer patients.	Platinum	87-95	poly(ADP-ribose) polymerase 1	Homo sapiens	33-62
33147530-1	2020	OBJECTIVE: To explore the effects of two functional genetic variants of poly(ADP-ribose) polymerase-1 (PARP-1) on the susceptibility to epithelial ovarian cancer (EOC), the platinum-based chemotherapeutic response, and the prognosis of northern Chinese patients.	Platinum	173-181	poly(ADP-ribose) polymerase 1	Homo sapiens	72-101
33147530-1	2020	OBJECTIVE: To explore the effects of two functional genetic variants of poly(ADP-ribose) polymerase-1 (PARP-1) on the susceptibility to epithelial ovarian cancer (EOC), the platinum-based chemotherapeutic response, and the prognosis of northern Chinese patients.	Platinum	173-181	poly(ADP-ribose) polymerase 1	Homo sapiens	103-109
33058284-8	2020	Overexpression of LOX, LOXL3, and LOXL4 mRNA indicated worse OS and PFS among OC patients who received platinum, taxol, and taxol + platinum chemotherapy.	Platinum	103-111	lysyl oxidase	Homo sapiens	18-21
33693445-3	2020	Objectives  This study aimed to investigate the association between Excision repair cross-complementation groups 2 (ERCC2) single nucleotide polymorphisms (SNPs rs1799793 and rs13181) and the response to platinum-based chemotherapy among patients with oral squamous cell carcinoma (OSCC).	Platinum	204-212	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	116-121
33058284-8	2020	Overexpression of LOX, LOXL3, and LOXL4 mRNA indicated worse OS and PFS among OC patients who received platinum, taxol, and taxol + platinum chemotherapy.	Platinum	103-111	lysyl oxidase like 4	Homo sapiens	34-39
33058284-8	2020	Overexpression of LOX, LOXL3, and LOXL4 mRNA indicated worse OS and PFS among OC patients who received platinum, taxol, and taxol + platinum chemotherapy.	Platinum	132-140	lysyl oxidase	Homo sapiens	18-21
33058284-8	2020	Overexpression of LOX, LOXL3, and LOXL4 mRNA indicated worse OS and PFS among OC patients who received platinum, taxol, and taxol + platinum chemotherapy.	Platinum	132-140	lysyl oxidase like 4	Homo sapiens	34-39
33058284-9	2020	Overexpression of LOXL1 and LOXL2 mRNA was related to lower OS and PFS in OC patients who received platinum chemotherapy.	Platinum	99-107	lysyl oxidase like 1	Homo sapiens	18-23
33058284-9	2020	Overexpression of LOXL1 and LOXL2 mRNA was related to lower OS and PFS in OC patients who received platinum chemotherapy.	Platinum	99-107	lysyl oxidase like 2	Homo sapiens	28-33
33058284-11	2020	Moreover, the LOX family can serve as new molecular predictors for the efficiency of platinum-based chemotherapy in OC patients.	Platinum	85-93	lysyl oxidase	Homo sapiens	14-17
32552295-12	2020	CONCLUSIONS: A validated 5-factor model has satisfactory prognostic performance for survival across 3 PD-L1 inhibitors to treat mUC post-platinum and may assist in stratification, interpreting and designing trials incorporating PD-1/PD-L1 inhibitors in the post-platinum setting.	Platinum	137-145	CD274 molecule	Homo sapiens	102-107
32552295-12	2020	CONCLUSIONS: A validated 5-factor model has satisfactory prognostic performance for survival across 3 PD-L1 inhibitors to treat mUC post-platinum and may assist in stratification, interpreting and designing trials incorporating PD-1/PD-L1 inhibitors in the post-platinum setting.	Platinum	262-270	CD274 molecule	Homo sapiens	102-107
32060984-6	2020	Recent interest in targeting copper transport has been directed towards antioxidant protein 1 (Atox1) and copper chaperone for superoxide dismutase 1 (CCS), with Atox1 demonstrating the ability to aggregate platinum agents, preventing them from forming DNA adducts.	Platinum	207-215	peroxiredoxin 3	Homo sapiens	72-93
32928400-3	2020	Based on this, the nanozyme of bovine serum albumin-Pt nanoparticles@mesoporous MnCo2O4 (BSA-PtNP@MnCo2O4) was successfully synthesized and used to construct enzyme cascade bio-platform.	Platinum	52-54	albumin	Homo sapiens	38-51
33067780-2	2020	Here, we established a mouse model of partial transection of the infraorbital nerve (pT-ION) and found that the Connexin 36 (Cx36) inhibitor mefloquine caused greater alleviation of pT-ION-induced cold allodynia compared to the reduction of mechanical allodynia.	Platinum	85-87	gap junction protein, delta 2	Mus musculus	112-123
33067780-2	2020	Here, we established a mouse model of partial transection of the infraorbital nerve (pT-ION) and found that the Connexin 36 (Cx36) inhibitor mefloquine caused greater alleviation of pT-ION-induced cold allodynia compared to the reduction of mechanical allodynia.	Platinum	85-87	gap junction protein, delta 2	Mus musculus	125-129
33067780-2	2020	Here, we established a mouse model of partial transection of the infraorbital nerve (pT-ION) and found that the Connexin 36 (Cx36) inhibitor mefloquine caused greater alleviation of pT-ION-induced cold allodynia compared to the reduction of mechanical allodynia.	Platinum	182-184	gap junction protein, delta 2	Mus musculus	112-123
33067780-2	2020	Here, we established a mouse model of partial transection of the infraorbital nerve (pT-ION) and found that the Connexin 36 (Cx36) inhibitor mefloquine caused greater alleviation of pT-ION-induced cold allodynia compared to the reduction of mechanical allodynia.	Platinum	182-184	gap junction protein, delta 2	Mus musculus	125-129
33067780-3	2020	Mefloquine reversed the pT-ION-induced upregulation of Cx36, glutamate receptor ionotropic kainate 2 (GluK2), transient receptor potential ankyrin 1 (TRPA1), and phosphorylated extracellular signal regulated kinase (p-ERK) in the trigeminal ganglion.	Platinum	24-26	gap junction protein, delta 2	Mus musculus	55-59
33067780-3	2020	Mefloquine reversed the pT-ION-induced upregulation of Cx36, glutamate receptor ionotropic kainate 2 (GluK2), transient receptor potential ankyrin 1 (TRPA1), and phosphorylated extracellular signal regulated kinase (p-ERK) in the trigeminal ganglion.	Platinum	24-26	glutamate receptor, ionotropic, kainate 2 (beta 2)	Mus musculus	61-100
33067780-3	2020	Mefloquine reversed the pT-ION-induced upregulation of Cx36, glutamate receptor ionotropic kainate 2 (GluK2), transient receptor potential ankyrin 1 (TRPA1), and phosphorylated extracellular signal regulated kinase (p-ERK) in the trigeminal ganglion.	Platinum	24-26	glutamate receptor, ionotropic, kainate 2 (beta 2)	Mus musculus	102-107
33067780-3	2020	Mefloquine reversed the pT-ION-induced upregulation of Cx36, glutamate receptor ionotropic kainate 2 (GluK2), transient receptor potential ankyrin 1 (TRPA1), and phosphorylated extracellular signal regulated kinase (p-ERK) in the trigeminal ganglion.	Platinum	24-26	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	110-148
33067780-3	2020	Mefloquine reversed the pT-ION-induced upregulation of Cx36, glutamate receptor ionotropic kainate 2 (GluK2), transient receptor potential ankyrin 1 (TRPA1), and phosphorylated extracellular signal regulated kinase (p-ERK) in the trigeminal ganglion.	Platinum	24-26	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	150-155
33067780-3	2020	Mefloquine reversed the pT-ION-induced upregulation of Cx36, glutamate receptor ionotropic kainate 2 (GluK2), transient receptor potential ankyrin 1 (TRPA1), and phosphorylated extracellular signal regulated kinase (p-ERK) in the trigeminal ganglion.	Platinum	24-26	mitogen-activated protein kinase 1	Mus musculus	218-221
33073546-1	2020	INTRODUCTION: Platinum-based chemotherapy is currently the most frequently applied first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) without targetable mutations or high PD-L1 expression.	Platinum	14-22	CD274 molecule	Homo sapiens	203-208
32060984-6	2020	Recent interest in targeting copper transport has been directed towards antioxidant protein 1 (Atox1) and copper chaperone for superoxide dismutase 1 (CCS), with Atox1 demonstrating the ability to aggregate platinum agents, preventing them from forming DNA adducts.	Platinum	207-215	peroxiredoxin 3	Homo sapiens	95-100
32060984-6	2020	Recent interest in targeting copper transport has been directed towards antioxidant protein 1 (Atox1) and copper chaperone for superoxide dismutase 1 (CCS), with Atox1 demonstrating the ability to aggregate platinum agents, preventing them from forming DNA adducts.	Platinum	207-215	superoxide dismutase 1	Homo sapiens	127-149
32060984-6	2020	Recent interest in targeting copper transport has been directed towards antioxidant protein 1 (Atox1) and copper chaperone for superoxide dismutase 1 (CCS), with Atox1 demonstrating the ability to aggregate platinum agents, preventing them from forming DNA adducts.	Platinum	207-215	copper chaperone for superoxide dismutase	Homo sapiens	151-154
32060984-6	2020	Recent interest in targeting copper transport has been directed towards antioxidant protein 1 (Atox1) and copper chaperone for superoxide dismutase 1 (CCS), with Atox1 demonstrating the ability to aggregate platinum agents, preventing them from forming DNA adducts.	Platinum	207-215	peroxiredoxin 3	Homo sapiens	162-167
33261142-0	2020	Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.	Platinum	97-105	checkpoint kinase 1	Homo sapiens	0-19
31599277-4	2020	Based on these exciting results, we endeavored to thoroughly examine the effect of Pt(ii)-acetylide conjugation on the properties of BF2 formazanate dyes, which offer improved redox properties and red-shifted absorption and emission bands compared to many structurally related BODIPYs.	Platinum	83-99	forkhead box G1	Homo sapiens	133-136
32632984-5	2020	Consequently, the Pt/Co3O4 microflowers exhibit superior HER activity with a relatively low overpotential of 34 mV to deliver a current density of 10 mA cm-2, small Tafel slope (34 mV dec-1) and outstanding electrochemical stability, representing an attractive electrocatalyst for practical water splitting.	Platinum	18-20	deleted in esophageal cancer 1	Homo sapiens	184-189
33169980-8	2020	By combining X-ray photoelectron spectroscopy and electrochemical characterization, we reveal the electron transfer between Pt, Pb, and Bi; this would lead to weakened CO adsorption and enhanced OH adsorption, thereby promoting the removal of toxic intermediates and ensuring that PtPbBi HNP samples have high activity and excellent stability.	Platinum	124-126	kallikrein related peptidase 8	Homo sapiens	288-291
33256165-3	2020	By understanding tumor immunology in UC, immune checkpoint inhibitors, targeting on programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) pathways, had been proven as first-line treatment for cisplatin-ineligible metastatic UC and as second-line treatment for patients with platinum-refractory metastatic UC by the U.S Food and Drug Administration (FDA).	Platinum	303-311	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	114-157
33256165-3	2020	By understanding tumor immunology in UC, immune checkpoint inhibitors, targeting on programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) pathways, had been proven as first-line treatment for cisplatin-ineligible metastatic UC and as second-line treatment for patients with platinum-refractory metastatic UC by the U.S Food and Drug Administration (FDA).	Platinum	303-311	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	159-165
31599277-5	2020	The results showed that phosphine-supported Pt(ii)-acetylide incorporation enhanced electronic conjugation, rendering the electrochemical reduction of the BF2 formazanate dyes more difficult, while also red-shifting their absorption and emission maxima.	Platinum	44-60	forkhead box G1	Homo sapiens	155-158
33230143-9	2020	This small OC subgroup could be characterized by REV7-abrogated platinum hypersensitivity but concomitant PARP-inhibitor resistance.	Platinum	64-72	mitotic arrest deficient 2 like 2	Homo sapiens	49-53
33266377-2	2020	Overexpression of ERCC1 has been linked to increased DNA repair capacity and platinum resistance in solid tumors.	Platinum	77-85	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	18-23
33238536-2	2020	Here, a simple and inexpensive method has been developed to prepare a Pt-Ag3PO4/CdS/chitosan composite, which was characterized and used for the visible light-induced photocatalytic and antibacterial studies.	Platinum	70-72	CDP-diacylglycerol synthase 1	Homo sapiens	80-83
33238536-6	2020	In addition, the results indicated that the photodegradation rate for Pt-Ag3PO4/CdS/chitosan is 3.53 times higher than that of CdS and 1.73 times higher than that of the CdS/Ag3PO4 composite.	Platinum	70-72	CDP-diacylglycerol synthase 1	Homo sapiens	80-83
33238536-6	2020	In addition, the results indicated that the photodegradation rate for Pt-Ag3PO4/CdS/chitosan is 3.53 times higher than that of CdS and 1.73 times higher than that of the CdS/Ag3PO4 composite.	Platinum	70-72	CDP-diacylglycerol synthase 1	Homo sapiens	127-130
33238536-6	2020	In addition, the results indicated that the photodegradation rate for Pt-Ag3PO4/CdS/chitosan is 3.53 times higher than that of CdS and 1.73 times higher than that of the CdS/Ag3PO4 composite.	Platinum	70-72	CDP-diacylglycerol synthase 1	Homo sapiens	127-130
33238536-7	2020	Moreover, Pt-Ag3PO4/CdS/chitosan with an optimal amount of CdS killed large areas of different bacteria and different cells separately in a shorter time period under visible-light irradiation, which shows significantly higher efficiency than pure CdS and other CdS/Ag3PO4 composites.	Platinum	10-12	CDP-diacylglycerol synthase 1	Homo sapiens	20-23
33238536-7	2020	Moreover, Pt-Ag3PO4/CdS/chitosan with an optimal amount of CdS killed large areas of different bacteria and different cells separately in a shorter time period under visible-light irradiation, which shows significantly higher efficiency than pure CdS and other CdS/Ag3PO4 composites.	Platinum	10-12	CDP-diacylglycerol synthase 1	Homo sapiens	59-62
33238536-7	2020	Moreover, Pt-Ag3PO4/CdS/chitosan with an optimal amount of CdS killed large areas of different bacteria and different cells separately in a shorter time period under visible-light irradiation, which shows significantly higher efficiency than pure CdS and other CdS/Ag3PO4 composites.	Platinum	10-12	CDP-diacylglycerol synthase 1	Homo sapiens	59-62
33238536-7	2020	Moreover, Pt-Ag3PO4/CdS/chitosan with an optimal amount of CdS killed large areas of different bacteria and different cells separately in a shorter time period under visible-light irradiation, which shows significantly higher efficiency than pure CdS and other CdS/Ag3PO4 composites.	Platinum	10-12	CDP-diacylglycerol synthase 1	Homo sapiens	59-62
33238536-8	2020	The superb performances of this composite are attributed to its privileged properties, such as retarded recombination of photoinduced electron/hole pairs and a large specific surface area, making Pt-Ag3PO4/CdS/chitosan a valuable composite that can be deployed for a range of important applications, such as visible light-induced photocatalysis and antibacterial activity.	Platinum	196-198	CDP-diacylglycerol synthase 1	Homo sapiens	206-209
32846032-3	2020	The interaction with 5"-GMP with trinuclear complexes 3 and 6 shows that platinum centres appended with cyclometalated ligand in 3 facilitates the binding of two 5"-GMP unit/Pt(II) centre in preference to single unit/Pt(II) centre in 6.	Platinum	73-81	5'-nucleotidase, cytosolic II	Homo sapiens	24-27
32846032-3	2020	The interaction with 5"-GMP with trinuclear complexes 3 and 6 shows that platinum centres appended with cyclometalated ligand in 3 facilitates the binding of two 5"-GMP unit/Pt(II) centre in preference to single unit/Pt(II) centre in 6.	Platinum	73-81	5'-nucleotidase, cytosolic II	Homo sapiens	165-168
33207824-8	2020	Our study proposes that targeting SIRT2 may provide new strategies to potentiate platinum-based chemotherapy in ovarian cancer patients.	Platinum	81-89	sirtuin 2	Homo sapiens	34-39
33218331-1	2020	BACKGROUND: Schlafen 11 (SLFN11) was recently identified as a dominant determinant of sensitivity to DNA-targeting agents including platinum-based drugs.	Platinum	132-140	schlafen family member 11	Homo sapiens	12-23
33218331-1	2020	BACKGROUND: Schlafen 11 (SLFN11) was recently identified as a dominant determinant of sensitivity to DNA-targeting agents including platinum-based drugs.	Platinum	132-140	schlafen family member 11	Homo sapiens	25-31
33218331-11	2020	In in vitro study, SLFN11-proficient cells were highly sensitive to platinum derivatives compared to SLFN11-deficient cells.	Platinum	68-76	schlafen family member 11	Homo sapiens	19-25
32750194-6	2020	To the best of our knowledge, this is the first platinum-based complex inhibiting HER2 expression containing no protein or peptide.	Platinum	48-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
32914866-1	2020	BACKGROUND: Pembrolizumab plus platinum-based chemotherapy has demonstrated improved clinical outcomes over chemotherapy alone in patients with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC), regardless of tumor programmed death ligand 1 (PD-L1) expression.	Platinum	31-39	CD274 molecule	Homo sapiens	241-266
32914866-1	2020	BACKGROUND: Pembrolizumab plus platinum-based chemotherapy has demonstrated improved clinical outcomes over chemotherapy alone in patients with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC), regardless of tumor programmed death ligand 1 (PD-L1) expression.	Platinum	31-39	CD274 molecule	Homo sapiens	268-273
33184273-0	2020	Induction of NEDD8-conjugating enzyme E2 UBE2F by platinum protects lung cancer cells from apoptosis and confers to platinum-insensitivity.	Platinum	50-58	NEDD8 ubiquitin like modifier	Homo sapiens	13-18
33186371-8	2020	High NRF2 expression was associated with low treatment response rate in platinum-based chemotherapy (HR = 0.11, 95% CI 0.02-0.51; P = 0.005).	Platinum	72-80	NFE2 like bZIP transcription factor 2	Homo sapiens	5-9
33184273-0	2020	Induction of NEDD8-conjugating enzyme E2 UBE2F by platinum protects lung cancer cells from apoptosis and confers to platinum-insensitivity.	Platinum	50-58	ubiquitin conjugating enzyme E2 F (putative)	Homo sapiens	41-46
33184273-7	2020	Our observations uncover a previously unknown regulatory mechanism of UBE2F stability upon platinum chemotherapy and suggest that UBE2F might be a novel therapy target for sensitizing lung cancer cells to platinum-based chemotherapy.	Platinum	205-213	ubiquitin conjugating enzyme E2 F (putative)	Homo sapiens	70-75
33184273-7	2020	Our observations uncover a previously unknown regulatory mechanism of UBE2F stability upon platinum chemotherapy and suggest that UBE2F might be a novel therapy target for sensitizing lung cancer cells to platinum-based chemotherapy.	Platinum	205-213	ubiquitin conjugating enzyme E2 F (putative)	Homo sapiens	130-135
33184273-0	2020	Induction of NEDD8-conjugating enzyme E2 UBE2F by platinum protects lung cancer cells from apoptosis and confers to platinum-insensitivity.	Platinum	116-124	NEDD8 ubiquitin like modifier	Homo sapiens	13-18
33184273-0	2020	Induction of NEDD8-conjugating enzyme E2 UBE2F by platinum protects lung cancer cells from apoptosis and confers to platinum-insensitivity.	Platinum	116-124	ubiquitin conjugating enzyme E2 F (putative)	Homo sapiens	41-46
33184273-3	2020	Here, we report that the upregulation of the NEDD8-conjugating enzyme UBE2F is an important way for lung cancer cells to escape platinum-induced cell apoptosis, which confers to insensitivity to platinum-based chemotherapy.	Platinum	128-136	NEDD8 ubiquitin like modifier	Homo sapiens	45-50
33184273-3	2020	Here, we report that the upregulation of the NEDD8-conjugating enzyme UBE2F is an important way for lung cancer cells to escape platinum-induced cell apoptosis, which confers to insensitivity to platinum-based chemotherapy.	Platinum	128-136	ubiquitin conjugating enzyme E2 F (putative)	Homo sapiens	70-75
33184273-3	2020	Here, we report that the upregulation of the NEDD8-conjugating enzyme UBE2F is an important way for lung cancer cells to escape platinum-induced cell apoptosis, which confers to insensitivity to platinum-based chemotherapy.	Platinum	195-203	ubiquitin conjugating enzyme E2 F (putative)	Homo sapiens	70-75
33184273-4	2020	Mechanistically, platinum treatment impairs the complex formation for proteasome-mediated UBE2F degradation, evidenced by the weaker association between UBE2F and Ring-box protein 1 (RBX1), an essential component of Cullin-Ring E3 ligases (CRLs), thus leading to the accumulation of UBE2F.	Platinum	17-25	ubiquitin conjugating enzyme E2 F (putative)	Homo sapiens	90-95
33184273-4	2020	Mechanistically, platinum treatment impairs the complex formation for proteasome-mediated UBE2F degradation, evidenced by the weaker association between UBE2F and Ring-box protein 1 (RBX1), an essential component of Cullin-Ring E3 ligases (CRLs), thus leading to the accumulation of UBE2F.	Platinum	17-25	ubiquitin conjugating enzyme E2 F (putative)	Homo sapiens	153-158
33184273-4	2020	Mechanistically, platinum treatment impairs the complex formation for proteasome-mediated UBE2F degradation, evidenced by the weaker association between UBE2F and Ring-box protein 1 (RBX1), an essential component of Cullin-Ring E3 ligases (CRLs), thus leading to the accumulation of UBE2F.	Platinum	17-25	ring-box 1	Homo sapiens	163-181
33184273-4	2020	Mechanistically, platinum treatment impairs the complex formation for proteasome-mediated UBE2F degradation, evidenced by the weaker association between UBE2F and Ring-box protein 1 (RBX1), an essential component of Cullin-Ring E3 ligases (CRLs), thus leading to the accumulation of UBE2F.	Platinum	17-25	ring-box 1	Homo sapiens	183-187
33184273-4	2020	Mechanistically, platinum treatment impairs the complex formation for proteasome-mediated UBE2F degradation, evidenced by the weaker association between UBE2F and Ring-box protein 1 (RBX1), an essential component of Cullin-Ring E3 ligases (CRLs), thus leading to the accumulation of UBE2F.	Platinum	17-25	ubiquitin conjugating enzyme E2 F (putative)	Homo sapiens	153-158
33184273-6	2020	Additionally, knockout of UBE2F significantly sensitizes lung cancer cells to platinum treatment by enhancing the protein levels of NOXA and subsequently promoting cell apoptosis.	Platinum	78-86	ubiquitin conjugating enzyme E2 F (putative)	Homo sapiens	26-31
33184273-6	2020	Additionally, knockout of UBE2F significantly sensitizes lung cancer cells to platinum treatment by enhancing the protein levels of NOXA and subsequently promoting cell apoptosis.	Platinum	78-86	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	132-136
33184273-7	2020	Our observations uncover a previously unknown regulatory mechanism of UBE2F stability upon platinum chemotherapy and suggest that UBE2F might be a novel therapy target for sensitizing lung cancer cells to platinum-based chemotherapy.	Platinum	91-99	ubiquitin conjugating enzyme E2 F (putative)	Homo sapiens	70-75
33184273-7	2020	Our observations uncover a previously unknown regulatory mechanism of UBE2F stability upon platinum chemotherapy and suggest that UBE2F might be a novel therapy target for sensitizing lung cancer cells to platinum-based chemotherapy.	Platinum	91-99	ubiquitin conjugating enzyme E2 F (putative)	Homo sapiens	130-135
33058681-4	2020	BuChE could "light up" the PT signal through in situ generation of Prussian blue (PB) by MIL-53 (Fe), which allowed us to translate biological signals into temperature signals.	Platinum	27-29	butyrylcholinesterase	Homo sapiens	0-5
33000769-0	2020	Electrochemical aptasensor for analyzing alpha-fetoprotein using RGO-CS-Fc nanocomposites integrated with gold-platinum nanoparticles.	Platinum	111-119	alpha fetoprotein	Homo sapiens	41-58
33000769-2	2020	The AFP aptamer (AFP-Apt), as the recognition molecule, was immobilized on the surface of a screen-printed carbon electrode, which was modified by gold-platinum metallic nanoparticles and reduced graphene oxide-chitosan-ferrocene nanohybrids (Au-Pt NPs/RGO-CS-Fc), to build the AFP electrochemical aptasensor.	Platinum	152-160	alpha fetoprotein	Homo sapiens	4-7
33000769-2	2020	The AFP aptamer (AFP-Apt), as the recognition molecule, was immobilized on the surface of a screen-printed carbon electrode, which was modified by gold-platinum metallic nanoparticles and reduced graphene oxide-chitosan-ferrocene nanohybrids (Au-Pt NPs/RGO-CS-Fc), to build the AFP electrochemical aptasensor.	Platinum	152-160	alpha fetoprotein	Homo sapiens	17-20
33000769-2	2020	The AFP aptamer (AFP-Apt), as the recognition molecule, was immobilized on the surface of a screen-printed carbon electrode, which was modified by gold-platinum metallic nanoparticles and reduced graphene oxide-chitosan-ferrocene nanohybrids (Au-Pt NPs/RGO-CS-Fc), to build the AFP electrochemical aptasensor.	Platinum	152-160	alpha fetoprotein	Homo sapiens	17-20
33090798-0	2020	The Structure of Molecular and Surface Platinum Sites Determined by DNP-SENS and Fast MAS 195Pt Solid-State NMR Spectroscopy.	Platinum	39-47	potassium channel tetramerization domain containing 1	Homo sapiens	72-76
32833070-5	2020	RESULTS: Most notably, patients with BRCA1/2 mutant ovarian cancer benefit from maintenance treatment with PARP inhibitors after (complete or partial) response to platinum-based chemotherapy.	Platinum	163-171	BRCA1 DNA repair associated	Homo sapiens	37-44
33292230-0	2020	miR-206 as a prognostic and sensitivity biomarker for platinum chemotherapy in epithelial ovarian cancer.	Platinum	54-62	microRNA 206	Homo sapiens	0-7
33292230-2	2020	We found a subset of miRNAs associated with the response to first-line platinum-based chemotherapy in EOC by microarray, and miR-206 was one of the most significant miRNAs.	Platinum	71-79	microRNA 206	Homo sapiens	125-132
33292230-3	2020	The purposes of this study were to evaluate the prognostic and platinum-resistance predictive value of miR-206 in EOC patients and to investigate the functional roles of miR-206 in regulating the platinum resistance of EOC and the underlying mechanism.	Platinum	196-204	microRNA 206	Homo sapiens	170-177
33292230-9	2020	Murine xenograft models were used to determine the effects of miR-206 on platinum resistance in vivo.	Platinum	73-81	microRNA 206	Mus musculus	62-69
33292230-10	2020	RESULTS: miR-206 expression was increased in primary platinum-resistant EOC.	Platinum	53-61	microRNA 206	Mus musculus	9-16
33292230-11	2020	High miR-206 expression was related to poor prognosis in EOC patients who received platinum-based chemotherapy and predicted chemoresistance to platinum treatment.	Platinum	83-91	microRNA 206	Homo sapiens	5-12
33292230-11	2020	High miR-206 expression was related to poor prognosis in EOC patients who received platinum-based chemotherapy and predicted chemoresistance to platinum treatment.	Platinum	144-152	microRNA 206	Homo sapiens	5-12
33292230-13	2020	Cx43, a target gene of miR-206, was negatively regulated by miR-206 in EOC cell lines and significantly related to better prognosis in patients who received platinum-based chemotherapy (KmPlot).	Platinum	157-165	gap junction protein alpha 1	Homo sapiens	0-4
33292230-13	2020	Cx43, a target gene of miR-206, was negatively regulated by miR-206 in EOC cell lines and significantly related to better prognosis in patients who received platinum-based chemotherapy (KmPlot).	Platinum	157-165	microRNA 206	Homo sapiens	23-30
33292230-13	2020	Cx43, a target gene of miR-206, was negatively regulated by miR-206 in EOC cell lines and significantly related to better prognosis in patients who received platinum-based chemotherapy (KmPlot).	Platinum	157-165	microRNA 206	Homo sapiens	60-67
33292230-14	2020	miR-206 had high expression and Cx43 had low expression in platinum-sensitive EOC cell lines compared with resistant ones.	Platinum	59-67	microRNA 206	Homo sapiens	0-7
33292230-14	2020	miR-206 had high expression and Cx43 had low expression in platinum-sensitive EOC cell lines compared with resistant ones.	Platinum	59-67	gap junction protein alpha 1	Homo sapiens	32-36
33292230-16	2020	CONCLUSION: miR-206 was highly expressed in primary platinum-resistant EOCs and functionally promoted platinum resistance in part by downregulating Cx43 expression, thereby providing a useful biomarker for prognostic and platinum-resistance prediction.	Platinum	52-60	microRNA 206	Mus musculus	12-19
33292230-16	2020	CONCLUSION: miR-206 was highly expressed in primary platinum-resistant EOCs and functionally promoted platinum resistance in part by downregulating Cx43 expression, thereby providing a useful biomarker for prognostic and platinum-resistance prediction.	Platinum	52-60	gap junction protein, alpha 3	Mus musculus	148-152
33292230-16	2020	CONCLUSION: miR-206 was highly expressed in primary platinum-resistant EOCs and functionally promoted platinum resistance in part by downregulating Cx43 expression, thereby providing a useful biomarker for prognostic and platinum-resistance prediction.	Platinum	102-110	microRNA 206	Mus musculus	12-19
33292230-16	2020	CONCLUSION: miR-206 was highly expressed in primary platinum-resistant EOCs and functionally promoted platinum resistance in part by downregulating Cx43 expression, thereby providing a useful biomarker for prognostic and platinum-resistance prediction.	Platinum	102-110	gap junction protein, alpha 3	Mus musculus	148-152
33292230-16	2020	CONCLUSION: miR-206 was highly expressed in primary platinum-resistant EOCs and functionally promoted platinum resistance in part by downregulating Cx43 expression, thereby providing a useful biomarker for prognostic and platinum-resistance prediction.	Platinum	102-110	microRNA 206	Mus musculus	12-19
33292230-16	2020	CONCLUSION: miR-206 was highly expressed in primary platinum-resistant EOCs and functionally promoted platinum resistance in part by downregulating Cx43 expression, thereby providing a useful biomarker for prognostic and platinum-resistance prediction.	Platinum	102-110	gap junction protein, alpha 3	Mus musculus	148-152
32277714-0	2020	Rapid drug desensitization for platinum-based chemotherapy drugs significantly increases peripheral blood IL-10 levels.	Platinum	31-39	interleukin 10	Homo sapiens	106-111
33302660-5	2020	Univariate analysis showed that CD177+ was associated with VM formation, tumor differentiation degree, tumor diameter, tumor stages, and platinum sensitivity (P<0.05), and was not associated with age, tumor types, or lymph node metastasis (P>0.05).	Platinum	137-145	CD177 molecule	Homo sapiens	32-37
33302660-6	2020	Correlation analysis showed that CD177+ was positively correlated with VM formation, tumor differentiation degree, tumor diameter, and tumor stages (P<0.05), and was negatively correlated with platinum sensitivity (P<0.05).	Platinum	193-201	CD177 molecule	Homo sapiens	33-38
33144577-5	2020	Here, we provide a novel mechanism for protein-level regulation of p73 transcriptional activity by MCL1, while also framing a foundation for studying MCL1 inhibitors in combination with platinum-based chemotherapeutics.	Platinum	186-194	tumor protein p73	Homo sapiens	67-70
32833070-5	2020	RESULTS: Most notably, patients with BRCA1/2 mutant ovarian cancer benefit from maintenance treatment with PARP inhibitors after (complete or partial) response to platinum-based chemotherapy.	Platinum	163-171	collagen type XI alpha 2 chain	Homo sapiens	107-111
32747362-1	2020	Cancers that arise from BRCA1 germline mutations are deficient for homologous recombination (HR) DNA repair and are sensitive to DNA damaging agents such as platinum and PARP inhibitors (PARPi).	Platinum	157-165	BRCA1 DNA repair associated	Homo sapiens	24-29
32976830-10	2020	Inhibition of ETP by thrombomodulin was significantly lower (protein C resistance) in aPS/PT positive vs aPS/PT negative group (22.8%+-11.5 vs 34.9%+-20.4, p=0.01).	Platinum	90-92	thrombomodulin	Homo sapiens	21-35
32860850-4	2020	In platinum-resistant OC cells we document that the endothelin-1 (ET-1)/endothelin A receptor axis intercepts the YAP pathway.	Platinum	3-11	endothelin 1	Homo sapiens	52-64
32860850-4	2020	In platinum-resistant OC cells we document that the endothelin-1 (ET-1)/endothelin A receptor axis intercepts the YAP pathway.	Platinum	3-11	endothelin 1	Homo sapiens	66-70
32860850-4	2020	In platinum-resistant OC cells we document that the endothelin-1 (ET-1)/endothelin A receptor axis intercepts the YAP pathway.	Platinum	3-11	Yes1 associated transcriptional regulator	Homo sapiens	114-117
32860850-6	2020	Mechanistically, beta-arrestin1 (beta-arr1) and YAP form a complex shaping TEAD-dependent transcriptional activity on the promoters of YAP target genes, including EDN1, which fuels a feed-forward signaling circuit that sustains a platinum-tolerant state.	Platinum	230-238	arrestin beta 1	Homo sapiens	17-31
32860850-6	2020	Mechanistically, beta-arrestin1 (beta-arr1) and YAP form a complex shaping TEAD-dependent transcriptional activity on the promoters of YAP target genes, including EDN1, which fuels a feed-forward signaling circuit that sustains a platinum-tolerant state.	Platinum	230-238	Yes1 associated transcriptional regulator	Homo sapiens	48-51
32860850-6	2020	Mechanistically, beta-arrestin1 (beta-arr1) and YAP form a complex shaping TEAD-dependent transcriptional activity on the promoters of YAP target genes, including EDN1, which fuels a feed-forward signaling circuit that sustains a platinum-tolerant state.	Platinum	230-238	Yes1 associated transcriptional regulator	Homo sapiens	135-138
32860850-6	2020	Mechanistically, beta-arrestin1 (beta-arr1) and YAP form a complex shaping TEAD-dependent transcriptional activity on the promoters of YAP target genes, including EDN1, which fuels a feed-forward signaling circuit that sustains a platinum-tolerant state.	Platinum	230-238	endothelin 1	Homo sapiens	163-167
32860850-8	2020	Furthermore, high ETAR/YAP gene expression signature is associated with a poor platinum-response in OC patients.	Platinum	79-87	endothelin receptor type A	Homo sapiens	18-22
32860850-8	2020	Furthermore, high ETAR/YAP gene expression signature is associated with a poor platinum-response in OC patients.	Platinum	79-87	Yes1 associated transcriptional regulator	Homo sapiens	23-26
32976830-10	2020	Inhibition of ETP by thrombomodulin was significantly lower (protein C resistance) in aPS/PT positive vs aPS/PT negative group (22.8%+-11.5 vs 34.9%+-20.4, p=0.01).	Platinum	109-111	thrombomodulin	Homo sapiens	21-35
32977221-0	2020	Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.	Platinum	89-97	BRCA1 DNA repair associated	Homo sapiens	76-80
32030795-5	2020	In the sub-groups of the TCGA cohort, NCALD was suppressed in 90 platinum-resistant tissues vs in 197 sensitive tissues.	Platinum	65-73	neurocalcin delta	Homo sapiens	38-43
32804554-6	2020	Multivariate regression analysis shows that CXCL12 expression in the stromal cells and cytoreduction satisfaction are independent prognostic markers of platinum-containing chemotherapy sensitivity in 296 EOC patients.	Platinum	152-160	C-X-C motif chemokine ligand 12	Homo sapiens	44-50
32981695-1	2020	OBJECTIVE: Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved for use in heavily pretreated patients and as maintenance treatment in patients with newly-diagnosed or recurrent ovarian cancer following a response to platinum-based chemotherapy.	Platinum	233-241	poly(ADP-ribose) polymerase 1	Homo sapiens	55-59
32878963-1	2020	BACKGROUND: With the success of poly(ADP-ribose) polymerase (PARP) inhibitor therapy in the first-line and second-line treatment settings, a new patient population is emerging with platinum-sensitive relapsed ovarian cancer, who have previously received a PARP inhibitor in the maintenance setting and for whom no second maintenance standard of care exists.	Platinum	181-189	poly(ADP-ribose) polymerase 1	Homo sapiens	32-59
32878963-1	2020	BACKGROUND: With the success of poly(ADP-ribose) polymerase (PARP) inhibitor therapy in the first-line and second-line treatment settings, a new patient population is emerging with platinum-sensitive relapsed ovarian cancer, who have previously received a PARP inhibitor in the maintenance setting and for whom no second maintenance standard of care exists.	Platinum	181-189	poly(ADP-ribose) polymerase 1	Homo sapiens	61-65
32878963-1	2020	BACKGROUND: With the success of poly(ADP-ribose) polymerase (PARP) inhibitor therapy in the first-line and second-line treatment settings, a new patient population is emerging with platinum-sensitive relapsed ovarian cancer, who have previously received a PARP inhibitor in the maintenance setting and for whom no second maintenance standard of care exists.	Platinum	181-189	poly(ADP-ribose) polymerase 1	Homo sapiens	256-260
33037105-3	2020	METHODS: Patients with measurable recurrent or persistent cancer after treatment with a platinum containing regimen with positive epidermal growth factor receptor expression, as determined by immunohistochemistry, were eligible for the study.	Platinum	88-96	epidermal growth factor receptor	Homo sapiens	130-162
32514162-6	2020	When analyses were restricted to patients treated by taxane-platinum-based chemotherapy, low JAM-A protein expression was associated with poorer responses in the COEUR (p < 0.001) and OV16 cohorts (p = 0.006) by Kaplan-Meier.	Platinum	60-68	F11 receptor	Homo sapiens	93-98
33250641-7	2020	Amlodipine inhibited GGT enzyme, which participates in the metabolism of extracellular glutathione (GSH) and platinum-GSH-conjugates to a reactive toxic thiol.	Platinum	109-117	gamma-glutamyltransferase 1	Rattus norvegicus	21-24
33151228-8	2020	In particular, platinum drug treatment in colon and liver cancer cell lines down-regulated S484 phosphorylation of UBF1, which is an essential transcription factor responsible for ribosomal DNA transcription activation, implying that inhibition of ribosome biogenesis might be involved in the cytotoxic mechanism of platinum drugs.	Platinum	15-23	upstream binding transcription factor	Homo sapiens	115-119
33151228-8	2020	In particular, platinum drug treatment in colon and liver cancer cell lines down-regulated S484 phosphorylation of UBF1, which is an essential transcription factor responsible for ribosomal DNA transcription activation, implying that inhibition of ribosome biogenesis might be involved in the cytotoxic mechanism of platinum drugs.	Platinum	316-324	upstream binding transcription factor	Homo sapiens	115-119
32901857-7	2020	Furthermore, decreased plasma exosomal miR-1273a and increased plasma SDCBP levels were found to be associated with worse therapeutic outcomes of patients with advanced NSCLC receiving platinum-based chemotherapy.	Platinum	185-193	microRNA 1273a	Homo sapiens	39-48
32901857-7	2020	Furthermore, decreased plasma exosomal miR-1273a and increased plasma SDCBP levels were found to be associated with worse therapeutic outcomes of patients with advanced NSCLC receiving platinum-based chemotherapy.	Platinum	185-193	syndecan binding protein	Homo sapiens	70-75
32801161-0	2020	Platinum-Induced Ubiquitination of Phosphorylated H2AX by RING1A is Mediated by Replication Protein A in Ovarian Cancer.	Platinum	0-8	H2A.X variant histone	Homo sapiens	50-54
32801161-0	2020	Platinum-Induced Ubiquitination of Phosphorylated H2AX by RING1A is Mediated by Replication Protein A in Ovarian Cancer.	Platinum	0-8	ring finger protein 1	Homo sapiens	58-64
32801161-0	2020	Platinum-Induced Ubiquitination of Phosphorylated H2AX by RING1A is Mediated by Replication Protein A in Ovarian Cancer.	Platinum	0-8	replication protein A1	Homo sapiens	80-101
32801161-6	2020	We demonstrate that the PRC1 complex member RING1A mediates monoubiquitination of lysine 119 of phosphorylated H2AX (gammaH2AXub1) at sites of platinum DNA damage in OC cells.	Platinum	143-151	ring finger protein 1	Homo sapiens	44-50
32801161-6	2020	We demonstrate that the PRC1 complex member RING1A mediates monoubiquitination of lysine 119 of phosphorylated H2AX (gammaH2AXub1) at sites of platinum DNA damage in OC cells.	Platinum	143-151	H2A.X variant histone	Homo sapiens	111-115
32801161-7	2020	After platinum treatment, our results reveal that NER and HRR both contribute to RING1A localization and gammaH2AX monoubiquitination.	Platinum	6-14	ring finger protein 1	Homo sapiens	81-87
32801161-9	2020	Furthermore, RING1A deficiency impairs the activation of the G2/M DNA damage checkpoint, reduces the ability of OC cells to repair platinum DNA damage and increases sensitivity to platinum.	Platinum	131-139	ring finger protein 1	Homo sapiens	13-19
32801161-9	2020	Furthermore, RING1A deficiency impairs the activation of the G2/M DNA damage checkpoint, reduces the ability of OC cells to repair platinum DNA damage and increases sensitivity to platinum.	Platinum	180-188	ring finger protein 1	Homo sapiens	13-19
32801161-10	2020	Implications: Elucidating the role of RING1A in the DDR to platinum agents will allow for the identification of therapeutic targets to improve the response of OC to standard chemotherapy regimens.	Platinum	59-67	ring finger protein 1	Homo sapiens	38-44
32963615-3	2020	It has been demonstrated that upregulation of excision repair cross-complementary 1 (ERCC1) in lung cancer cells is closely associated with cell resistance to platinum-based chemotherapy.	Platinum	159-167	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	85-90
33194641-8	2020	In addition, the metastatic ovarian cancer in the proband"s half-sister harboring the same BRCA2 germline mutation also responded well to platinum chemotherapy.	Platinum	138-146	BRCA2 DNA repair associated	Homo sapiens	91-96
33195914-2	2020	The reaction of 1a with PhCH2Br gave the Pt(IV) product complex [PtBr(CH2Ph)Me2(pbt)].	Platinum	41-43	translocator protein	Homo sapiens	65-69
33112306-7	2020	Finally, our calculations show that CO adsorption at the single Pt atom is stabilized at the interface site, preventing its further agglomeration with Ptn clusters between the two Zr6 metal nodes.	Platinum	64-66	pleiotrophin	Homo sapiens	151-154
33114033-0	2020	Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients.	Platinum	58-66	syndecan 1	Homo sapiens	8-18
33104707-0	2020	The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy.	Platinum	107-115	delta like canonical Notch ligand 3	Homo sapiens	56-60
33114033-10	2020	Our results demonstrate an independent association between high baseline serum SDC1 concentration and poor survival in platinum-treated patients.	Platinum	119-127	syndecan 1	Homo sapiens	79-83
33114033-11	2020	Analyzing baseline serum SDC1 levels may help to predict platinum-containing chemotherapy and could help to optimize therapeutic decision-making.	Platinum	57-65	syndecan 1	Homo sapiens	25-29
33150172-0	2020	Pharmacogenetic Association between XRCC1 Polymorphisms and Response to Platinum-Based Chemotherapy in Asian Patients with NSCLC: A Meta-Analysis.	Platinum	72-80	X-ray repair cross complementing 1	Homo sapiens	36-41
33097745-7	2020	After having adjusted for ECOG performance status, histology, ascites, bevacizumab treatment at second line and BRCA status, NLR >= 3 and SII >= 730 are significantly associated with worse OS in platinum-sensitive (HR = 2.69, 95% CI 1.60-4.53, p = 0.002; HR = 2.11, 95% CI 1.29-3.43, p = 0.003, respectively), not in platinum-resistant EOC patients.	Platinum	195-203	BRCA1 DNA repair associated	Homo sapiens	112-116
33099543-13	2021	In this pilot study including few patients by subgroups, patients with KRAS (HR=3.60, 95%CI [1.06-12.04]) and BRAF (HR=4.25, 95%CI [1.11-16.40]) mutations had shorter progression-free survival (PFS) under platinum-etoposide, while the two patients with RB1 mutations had shorter PFS under FOLFIRI-based chemotherapy.	Platinum	205-213	KRAS proto-oncogene, GTPase	Homo sapiens	71-75
33099543-13	2021	In this pilot study including few patients by subgroups, patients with KRAS (HR=3.60, 95%CI [1.06-12.04]) and BRAF (HR=4.25, 95%CI [1.11-16.40]) mutations had shorter progression-free survival (PFS) under platinum-etoposide, while the two patients with RB1 mutations had shorter PFS under FOLFIRI-based chemotherapy.	Platinum	205-213	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	110-114
33156648-5	2020	Considering the weak spin-orbit coupling (SOC) of CuO_{x}, these surprising findings likely result from an orbital current generated at the interface between CuO_{x} and Pt, which is injected into the Pt layer and converted into a spin current by strong SOC.	Platinum	201-203	spindlin 1	Homo sapiens	21-25
33156648-5	2020	Considering the weak spin-orbit coupling (SOC) of CuO_{x}, these surprising findings likely result from an orbital current generated at the interface between CuO_{x} and Pt, which is injected into the Pt layer and converted into a spin current by strong SOC.	Platinum	201-203	spindlin 1	Homo sapiens	231-235
33156648-6	2020	The converted spin current decays across the Pt layer and exerts a "nonlocal" torque on TmIG.	Platinum	45-47	spindlin 1	Homo sapiens	14-18
33150172-2	2020	X-ray repair crosscomplementing protein 1 (XRCC1) participates in DNA repair and thus affects the sensitivity to platinum drugs.	Platinum	113-121	X-ray repair cross complementing 1	Homo sapiens	0-41
33150172-2	2020	X-ray repair crosscomplementing protein 1 (XRCC1) participates in DNA repair and thus affects the sensitivity to platinum drugs.	Platinum	113-121	X-ray repair cross complementing 1	Homo sapiens	43-48
33150172-3	2020	Two polymorphisms of XRCC1, rs25487 (Arg399Gln) and rs1799782 (Arg194Trp), have been widely studied for the association with clinical outcomes of platinum-based chemotherapy in Asian patients with non-small-cell lung cancer (NSCLC), but the results remain inconclusive.	Platinum	146-154	X-ray repair cross complementing 1	Homo sapiens	21-26
33150172-14	2020	Conclusion: Our results showed that rs25487 and rs1799782 of XRCC1 are potential markers to predict clinical outcomes of platinum-based chemotherapy in Asian patients with NSCLC.	Platinum	121-129	X-ray repair cross complementing 1	Homo sapiens	61-66
33156648-5	2020	Considering the weak spin-orbit coupling (SOC) of CuO_{x}, these surprising findings likely result from an orbital current generated at the interface between CuO_{x} and Pt, which is injected into the Pt layer and converted into a spin current by strong SOC.	Platinum	170-172	spindlin 1	Homo sapiens	21-25
33156648-5	2020	Considering the weak spin-orbit coupling (SOC) of CuO_{x}, these surprising findings likely result from an orbital current generated at the interface between CuO_{x} and Pt, which is injected into the Pt layer and converted into a spin current by strong SOC.	Platinum	170-172	spindlin 1	Homo sapiens	231-235
33059856-0	2020	Platinum nanozyme-encapsulated poly(amidoamine) dendrimer for voltammetric immunoassay of pro-gastrin-releasing peptide.	Platinum	0-8	gastrin releasing peptide	Homo sapiens	94-119
33194722-7	2020	LRH1 overexpression was extremely related with elevated International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.001), lymph node metastasis (P = 0.011), peritoneal metastasis (P = 0.001), and platinum resistance (P = 0.037).	Platinum	210-218	nuclear receptor subfamily 5 group A member 2	Homo sapiens	0-4
33080967-3	2020	Compared with the flat NiS/FTO electrode, this kind of nanoporous NiS film with inverse opal structure has higher catalytic activity and can be used as a cheap and efficient Pt-free electrode to replace the traditional Pt/FTO electrode.	Platinum	174-176	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	222-225
33059856-1	2020	An innovative electrochemical immunosensing platform was designed for the sensitive monitoring of lung cancer biomarker (pro-gastrin-releasing peptide; ProGRP) by using platinum nanoparticles encapsulated inside dendrimers (PtDEN) as enzymatic mimics for the signal amplification.	Platinum	169-177	gastrin releasing peptide	Homo sapiens	152-158
32859605-3	2020	Here we report that ovarian cancer cells overexpressing glutaminase (GLS), a MYC target and a key enzyme in glutaminolysis, are intrinsically resistant to platinum chemotherapy and are enriched in the intracellular antioxidant glutathione.	Platinum	155-163	glutaminase	Mus musculus	56-67
32816909-8	2020	Co-administration of EZH2 inhibitor GSK126 and RAC1 inhibitor NSC23766 suppressed OCSC survival in vitro and inhibited tumor growth and increased platinum sensitivity in vivo.	Platinum	146-154	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	21-25
32749686-17	2020	The results of the current study have highlighted the clinical value of EGFR and TP53 as predictive biomarkers of platinum-resistant recurrent and/or metastatic ESCC for afatinib sensitivity.	Platinum	114-122	epidermal growth factor receptor	Homo sapiens	72-76
32859605-3	2020	Here we report that ovarian cancer cells overexpressing glutaminase (GLS), a MYC target and a key enzyme in glutaminolysis, are intrinsically resistant to platinum chemotherapy and are enriched in the intracellular antioxidant glutathione.	Platinum	155-163	glutaminase	Mus musculus	69-72
32749686-17	2020	The results of the current study have highlighted the clinical value of EGFR and TP53 as predictive biomarkers of platinum-resistant recurrent and/or metastatic ESCC for afatinib sensitivity.	Platinum	114-122	tumor protein p53	Homo sapiens	81-85
32816909-8	2020	Co-administration of EZH2 inhibitor GSK126 and RAC1 inhibitor NSC23766 suppressed OCSC survival in vitro and inhibited tumor growth and increased platinum sensitivity in vivo.	Platinum	146-154	Rac family small GTPase 1	Homo sapiens	47-51
32816949-1	2020	PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) arising in patients with a germline BRCA1 or BRCA2 (gBRCA) mutation may be sensitive to platinums and poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi).	Platinum	137-146	BRCA1 DNA repair associated	Homo sapiens	85-90
32738410-1	2020	The structure-specific ERCC1-XPF endonuclease is essential for repairing bulky DNA lesions and helix distortions induced by UV radiation, which forms cyclobutane pyrimidine dimers (CPDs), or chemicals that crosslink DNA strands such as cyclophosphamide and platinum-based chemotherapeutic agents.	Platinum	257-265	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	23-28
32816949-1	2020	PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) arising in patients with a germline BRCA1 or BRCA2 (gBRCA) mutation may be sensitive to platinums and poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi).	Platinum	137-146	BRCA2 DNA repair associated	Homo sapiens	94-99
32738410-1	2020	The structure-specific ERCC1-XPF endonuclease is essential for repairing bulky DNA lesions and helix distortions induced by UV radiation, which forms cyclobutane pyrimidine dimers (CPDs), or chemicals that crosslink DNA strands such as cyclophosphamide and platinum-based chemotherapeutic agents.	Platinum	257-265	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	29-32
33065998-14	2020	Conclusions: In the Ramucirumab Mesothelioma clinical trial (RAMES), mutation of the gene BAP1 is related to a prolonged PFS for patients treated with platinum/pemetrexed regimens (p = 0.04).	Platinum	151-159	BRCA1 associated protein 1	Homo sapiens	90-94
32960060-2	2020	In this work, in situ ATR-SEIRAS technique incorporating a micro-machined Si wafer window, p-polarized infrared radiation and isotope labelling is extended to revisit acetaldehyde oxidation reaction (AOR) on Pt electrode in acidic media.	Platinum	208-210	ATR serine/threonine kinase	Homo sapiens	22-25
33026009-1	2020	In this work, uniform ultra-small core-shell Au-Pt nanoparticles (denoted as USCS Au-Pt NPs) with Au-decorated Pt surfaces are successfully prepared by Fe(ii)-assisted one-pot co-reduction of Au(iii) ions and Pt(ii) ions in a citrate solution.	Platinum	48-50	general transcription factor IIE subunit 1	Homo sapiens	152-158
33026009-1	2020	In this work, uniform ultra-small core-shell Au-Pt nanoparticles (denoted as USCS Au-Pt NPs) with Au-decorated Pt surfaces are successfully prepared by Fe(ii)-assisted one-pot co-reduction of Au(iii) ions and Pt(ii) ions in a citrate solution.	Platinum	48-50	general transcription factor IIE subunit 1	Homo sapiens	155-157
33026009-1	2020	In this work, uniform ultra-small core-shell Au-Pt nanoparticles (denoted as USCS Au-Pt NPs) with Au-decorated Pt surfaces are successfully prepared by Fe(ii)-assisted one-pot co-reduction of Au(iii) ions and Pt(ii) ions in a citrate solution.	Platinum	85-87	general transcription factor IIE subunit 1	Homo sapiens	152-158
33026009-1	2020	In this work, uniform ultra-small core-shell Au-Pt nanoparticles (denoted as USCS Au-Pt NPs) with Au-decorated Pt surfaces are successfully prepared by Fe(ii)-assisted one-pot co-reduction of Au(iii) ions and Pt(ii) ions in a citrate solution.	Platinum	85-87	general transcription factor IIE subunit 1	Homo sapiens	155-157
33026009-3	2020	It is found that the morphology, composition and size of Au-Pt NPs are highly dependent on the reaction conditions including the addition sequence of the precursors, and the concentrations of Fe(ii) ions, Au(iii) ions and Pt(ii) ions.	Platinum	60-62	general transcription factor IIE subunit 1	Homo sapiens	192-198
33026009-3	2020	It is found that the morphology, composition and size of Au-Pt NPs are highly dependent on the reaction conditions including the addition sequence of the precursors, and the concentrations of Fe(ii) ions, Au(iii) ions and Pt(ii) ions.	Platinum	60-62	general transcription factor IIE subunit 1	Homo sapiens	195-197
32955896-4	2020	This scheme is enabled by well-separated resonant fields of Pt/YIG and bare YIG due to substantial change of anisotropy in YIG films induced by a Pt overlayer, allowing for clearly distinguishable local and nonlocal spin pumping.	Platinum	60-62	spindlin 1	Homo sapiens	216-220
32955896-4	2020	This scheme is enabled by well-separated resonant fields of Pt/YIG and bare YIG due to substantial change of anisotropy in YIG films induced by a Pt overlayer, allowing for clearly distinguishable local and nonlocal spin pumping.	Platinum	146-148	spindlin 1	Homo sapiens	216-220
32554895-5	2020	After being uniformly loaded with 4 wt.% of the Pt nanoparticles, the TiO2 nanosheets displayed a photocatalytic hydrogen production rate of 2.239 mmol g-1 h-1 under simulated solar light, which was much higher than the pristine TiO2 nanosheets (0.045 mmol g-1 h-1) as well as most of the reported TiO2-based photocatalysts.	Platinum	48-50	H1.5 linker histone, cluster member	Homo sapiens	156-159
32557982-3	2020	Herein, two carbonic anhydrase IX (CAIX)-targeted platinum(IV) prodrugs have been developed, named as CAIXplatins .	Platinum	50-58	carbonic anhydrase 9	Homo sapiens	12-33
32557982-3	2020	Herein, two carbonic anhydrase IX (CAIX)-targeted platinum(IV) prodrugs have been developed, named as CAIXplatins .	Platinum	50-58	carbonic anhydrase 9	Homo sapiens	35-39
33163410-10	2020	Patients in the EGFR/ALK-negative/unknown cohort treated with first-line pemetrexed with platinum (PP) (15.8 months, 14.0-17.6, p<0.001) had longer mOS than those received non-PP regimens (13.1 months, 11.6-14.6).	Platinum	89-97	epidermal growth factor receptor	Homo sapiens	16-20
33163410-10	2020	Patients in the EGFR/ALK-negative/unknown cohort treated with first-line pemetrexed with platinum (PP) (15.8 months, 14.0-17.6, p<0.001) had longer mOS than those received non-PP regimens (13.1 months, 11.6-14.6).	Platinum	89-97	Moloney sarcoma oncogene	Mus musculus	148-151
33012286-11	2020	CONCLUSIONS: High areas of VAT, SAT, and IMAT were significantly associated with better outcomes in patients with platinum-resistant or platinum-refractory ovarian cancer who received VEGFR inhibitors.	Platinum	114-122	kinase insert domain receptor	Homo sapiens	184-189
32554895-5	2020	After being uniformly loaded with 4 wt.% of the Pt nanoparticles, the TiO2 nanosheets displayed a photocatalytic hydrogen production rate of 2.239 mmol g-1 h-1 under simulated solar light, which was much higher than the pristine TiO2 nanosheets (0.045 mmol g-1 h-1) as well as most of the reported TiO2-based photocatalysts.	Platinum	48-50	H1.5 linker histone, cluster member	Homo sapiens	261-264
32819112-2	2020	Interestingly, patients who are carriers of BRCA1/2 mutations have a higher risk for developing cancer, but respond better to DNA-damaging cytotoxic therapy, such as platinum-based chemotherapy.	Platinum	166-174	BRCA1 DNA repair associated	Homo sapiens	44-51
32172572-8	2020	CONCLUSIONS: PARP inhibitors can be used as a single agent for maintenance therapy for platinum-sensitive recurrent disease in patients with partial or complete response following 2 or more rounds of platinum-based therapy.	Platinum	87-95	poly(ADP-ribose) polymerase 1	Homo sapiens	13-17
32172572-8	2020	CONCLUSIONS: PARP inhibitors can be used as a single agent for maintenance therapy for platinum-sensitive recurrent disease in patients with partial or complete response following 2 or more rounds of platinum-based therapy.	Platinum	200-208	poly(ADP-ribose) polymerase 1	Homo sapiens	13-17
32562941-2	2020	Herein, porous platinum nanoparticles (pPt NPs) are developed to enable the combined electrodynamic therapy (EDT) with chemotherapy.	Platinum	15-23	tachykinin precursor 1	Homo sapiens	39-42
32699032-1	2020	Reversion mutations in BRCA1 or BRCA2 are associated with resistance to PARP inhibitors and platinum.	Platinum	92-100	BRCA1 DNA repair associated	Homo sapiens	23-28
32699032-1	2020	Reversion mutations in BRCA1 or BRCA2 are associated with resistance to PARP inhibitors and platinum.	Platinum	92-100	BRCA2 DNA repair associated	Homo sapiens	32-37
32844503-3	2020	The excitation, detection, and utilization of coherent and non-coherent spin waves on various modes in V(TCNE)x is demonstrated and show that the angular momentum carried by microwave-excited coherent spin waves in a V(TCNE)x film can be transferred into an adjacent Pt layer via spin pumping and detected using the inverse spin Hall effect.	Platinum	267-269	spindlin 1	Homo sapiens	72-76
32844503-3	2020	The excitation, detection, and utilization of coherent and non-coherent spin waves on various modes in V(TCNE)x is demonstrated and show that the angular momentum carried by microwave-excited coherent spin waves in a V(TCNE)x film can be transferred into an adjacent Pt layer via spin pumping and detected using the inverse spin Hall effect.	Platinum	267-269	spindlin 1	Homo sapiens	201-205
32844503-3	2020	The excitation, detection, and utilization of coherent and non-coherent spin waves on various modes in V(TCNE)x is demonstrated and show that the angular momentum carried by microwave-excited coherent spin waves in a V(TCNE)x film can be transferred into an adjacent Pt layer via spin pumping and detected using the inverse spin Hall effect.	Platinum	267-269	spindlin 1	Homo sapiens	201-205
32844503-3	2020	The excitation, detection, and utilization of coherent and non-coherent spin waves on various modes in V(TCNE)x is demonstrated and show that the angular momentum carried by microwave-excited coherent spin waves in a V(TCNE)x film can be transferred into an adjacent Pt layer via spin pumping and detected using the inverse spin Hall effect.	Platinum	267-269	spindlin 1	Homo sapiens	201-205
32888910-7	2020	Leukocyte infiltration and pro-inflammatory cytokines was determined by immunostaining and quantitative real-time PCR (qRT-PCR) respectively.The protein level of Numb was dramatically decreased in kidneys of PT-Nb-KO mice compared with PT-Nb-WT mice.	Platinum	208-210	NUMB endocytic adaptor protein	Mus musculus	162-166
33154302-1	2020	Background and Objectives: Cisplatin is one of the major drugs that used in the treatment of oral cancer.Excision repair cross-complementation group 1 (ERCC1) is a key DNA repair gene in the nucleotide excision repair pathway which is activated in the repair of intra- and interstrand DNA crosslink caused by platinum-based treatment.	Platinum	309-317	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	105-150
32888910-7	2020	Leukocyte infiltration and pro-inflammatory cytokines was determined by immunostaining and quantitative real-time PCR (qRT-PCR) respectively.The protein level of Numb was dramatically decreased in kidneys of PT-Nb-KO mice compared with PT-Nb-WT mice.	Platinum	236-238	NUMB endocytic adaptor protein	Mus musculus	162-166
32935605-5	2020	This treatment, recently approved in the U.S., is available for adult patients harboring FGFR2/FGFR3 genetic alterations who progressed within 12 months of an adjuvant or neoadjuvant chemotherapy regimen including platinum or progressed during or after prior a chemotherapy regimen including platinum.	Platinum	292-300	fibroblast growth factor receptor 2	Homo sapiens	89-94
32698955-9	2020	CONCLUSION: Dual inhibition of GSK3B and HDACs via APCS-540 showed potent anti-tumor activity in vitro and in vivo, suggesting that APCS-540 may provide a novel treatment option for ovarian cancer, including the platinum-resistant disease.	Platinum	212-220	glycogen synthase kinase 3 beta	Mus musculus	31-36
33154302-1	2020	Background and Objectives: Cisplatin is one of the major drugs that used in the treatment of oral cancer.Excision repair cross-complementation group 1 (ERCC1) is a key DNA repair gene in the nucleotide excision repair pathway which is activated in the repair of intra- and interstrand DNA crosslink caused by platinum-based treatment.	Platinum	309-317	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	152-157
32817083-1	2020	INTRODUCTION: We aimed to evaluate poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) regimens in BRCA-mutated ovarian cancer for patients responsive to front-line platinum (bevacizumab and olaparib, veliparib and chemotherapy, olaparib) or platinum-sensitive relapsed (olaparib, rucaprib, niraparib) patients in phase III randomized controlled trials.	Platinum	167-175	poly(ADP-ribose) polymerase 1	Homo sapiens	35-63
32666389-0	2020	Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study.	Platinum	115-123	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	30-36
32817083-1	2020	INTRODUCTION: We aimed to evaluate poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) regimens in BRCA-mutated ovarian cancer for patients responsive to front-line platinum (bevacizumab and olaparib, veliparib and chemotherapy, olaparib) or platinum-sensitive relapsed (olaparib, rucaprib, niraparib) patients in phase III randomized controlled trials.	Platinum	167-175	poly(ADP-ribose) polymerase 1	Homo sapiens	65-69
32817083-1	2020	INTRODUCTION: We aimed to evaluate poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) regimens in BRCA-mutated ovarian cancer for patients responsive to front-line platinum (bevacizumab and olaparib, veliparib and chemotherapy, olaparib) or platinum-sensitive relapsed (olaparib, rucaprib, niraparib) patients in phase III randomized controlled trials.	Platinum	244-252	poly(ADP-ribose) polymerase 1	Homo sapiens	35-63
32817083-1	2020	INTRODUCTION: We aimed to evaluate poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) regimens in BRCA-mutated ovarian cancer for patients responsive to front-line platinum (bevacizumab and olaparib, veliparib and chemotherapy, olaparib) or platinum-sensitive relapsed (olaparib, rucaprib, niraparib) patients in phase III randomized controlled trials.	Platinum	244-252	poly(ADP-ribose) polymerase 1	Homo sapiens	65-69
32861273-1	2020	BACKGROUND: BRCA1 or BRCA2-mutated breast cancers are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors and platinum agents owing to deficiency in homologous recombination repair of DNA damage.	Platinum	117-125	BRCA1 DNA repair associated	Homo sapiens	12-17
32945394-2	2020	Platinum-based chemotherapy is the main treatment for advanced non-small-cell lung cancer (NSCLC), and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have greatly improved the survival of patients with EGFR-sensitive mutations.	Platinum	0-8	epidermal growth factor receptor	Homo sapiens	164-168
32945394-2	2020	Platinum-based chemotherapy is the main treatment for advanced non-small-cell lung cancer (NSCLC), and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have greatly improved the survival of patients with EGFR-sensitive mutations.	Platinum	0-8	epidermal growth factor receptor	Homo sapiens	227-231
31981071-2	2020	Extensive preclinical evidence has demonstrated synergy of CDK4/6 inhibitors with platinum chemotherapy suggesting a potential role for clinical synthetic lethality.	Platinum	82-90	cyclin dependent kinase 4	Homo sapiens	59-65
33037118-1	2020	BACKGROUND: Anti-programmed cell death ligand 1 (PD-L1)/programmed cell death 1 antibodies have shown clinical activity in platinum-treated metastatic urothelial carcinoma, resulting in regulatory approval of several agents, including avelumab (anti-PD-L1).	Platinum	123-131	CD274 molecule	Homo sapiens	12-47
33037118-1	2020	BACKGROUND: Anti-programmed cell death ligand 1 (PD-L1)/programmed cell death 1 antibodies have shown clinical activity in platinum-treated metastatic urothelial carcinoma, resulting in regulatory approval of several agents, including avelumab (anti-PD-L1).	Platinum	123-131	CD274 molecule	Homo sapiens	49-54
33037118-1	2020	BACKGROUND: Anti-programmed cell death ligand 1 (PD-L1)/programmed cell death 1 antibodies have shown clinical activity in platinum-treated metastatic urothelial carcinoma, resulting in regulatory approval of several agents, including avelumab (anti-PD-L1).	Platinum	123-131	CD274 molecule	Homo sapiens	250-255
32861273-1	2020	BACKGROUND: BRCA1 or BRCA2-mutated breast cancers are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors and platinum agents owing to deficiency in homologous recombination repair of DNA damage.	Platinum	117-125	BRCA2 DNA repair associated	Homo sapiens	21-26
32594311-13	2020	The lack of PARP expression assessed by immunohistochemistry may predict improved PFS in ovarian cancer patients after adjuvant platinum-based chemotherapy.	Platinum	128-136	poly(ADP-ribose) polymerase 1	Homo sapiens	12-16
33112397-1	2020	Importance: DNA repair gene aberrations occur in 20% to 30% of patients with castration-resistant prostate cancer (CRPC), and some of these aberrations have been associated with sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition platinum-based treatments.	Platinum	239-247	poly(ADP-ribose) polymerase 1	Homo sapiens	193-220
33112397-1	2020	Importance: DNA repair gene aberrations occur in 20% to 30% of patients with castration-resistant prostate cancer (CRPC), and some of these aberrations have been associated with sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition platinum-based treatments.	Platinum	239-247	poly(ADP-ribose) polymerase 1	Homo sapiens	222-226
32848212-0	2020	Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells.	Platinum	98-106	serum/glucocorticoid regulated kinase 2	Homo sapiens	47-51
32848212-6	2020	We show here that EOC cells relay on the induction of autophagy to escape PT-induced death and that SGK2 inhibition increases PT sensitivity inducing a block in the autophagy cascade due to the impairment of lysosomal acidification.	Platinum	126-128	serum/glucocorticoid regulated kinase 2	Homo sapiens	100-104
32848212-8	2020	Accordingly, SGK2 phosphorylates the subunit V1H (ATP6V1H) of V-ATPase and silencing or chemical inhibition of SGK2, affects the normal autophagic flux and sensitizes EOC cells to platinum.	Platinum	180-188	serum/glucocorticoid regulated kinase 2	Homo sapiens	13-17
32848212-8	2020	Accordingly, SGK2 phosphorylates the subunit V1H (ATP6V1H) of V-ATPase and silencing or chemical inhibition of SGK2, affects the normal autophagic flux and sensitizes EOC cells to platinum.	Platinum	180-188	ATPase H+ transporting V1 subunit H	Homo sapiens	50-57
32848212-8	2020	Accordingly, SGK2 phosphorylates the subunit V1H (ATP6V1H) of V-ATPase and silencing or chemical inhibition of SGK2, affects the normal autophagic flux and sensitizes EOC cells to platinum.	Platinum	180-188	serum/glucocorticoid regulated kinase 2	Homo sapiens	111-115
32848212-9	2020	Hence, we identified a new pathway that links autophagy to the survival of cancer cells under platinum treatment in which the druggable kinase SGK2 plays a central role.	Platinum	94-102	serum/glucocorticoid regulated kinase 2	Homo sapiens	143-147
33112397-9	2020	Main Outcomes and Measures: The primary end points were as follows: (1) antitumor activity of platinum-based therapy, defined as a decrease in prostate-specific antigen (PSA) level of at least 50% and/or radiological soft tissue response in patients with measurable disease and (2) the association of response with the presence or absence of DNA repair gene aberrations.	Platinum	94-102	kallikrein related peptidase 3	Homo sapiens	143-168
33112397-9	2020	Main Outcomes and Measures: The primary end points were as follows: (1) antitumor activity of platinum-based therapy, defined as a decrease in prostate-specific antigen (PSA) level of at least 50% and/or radiological soft tissue response in patients with measurable disease and (2) the association of response with the presence or absence of DNA repair gene aberrations.	Platinum	94-102	kallikrein related peptidase 3	Homo sapiens	170-173
32848212-10	2020	Our data suggest that blocking autophagy via SGK2 inhibition could represent a novel therapeutic strategy to improve patients" response to platinum.	Platinum	139-147	serum/glucocorticoid regulated kinase 2	Homo sapiens	45-49
33305724-0	2020	Non-classical platinum-based compound 56MESS, with preferential cytotoxic effect on oral cancer cells by downregulating FACL4 expression.	Platinum	14-22	acyl-CoA synthetase long chain family member 4	Homo sapiens	120-125
32891532-4	2020	METHODS: We performed a subgroup analysis of the Japanese PanNEN-G3 study (multicenter, retrospective study), which revealed that Rb loss and KRAS mutation were predictors of the response to platinum-based regimen in PanNEN-G3.	Platinum	191-199	KRAS proto-oncogene, GTPase	Homo sapiens	142-146
32891532-7	2020	Patients with Rb loss and/or KRAS mutation showed a higher response rate to first-line platinum-based regimen than those without Rb loss or KRAS mutation (object response rate 70.0% vs 33.3%, odds ratio 9.22; 95% CI 1.26-67.3, P = 0.029), but tended to have shorter overall survival rates than those without Rb loss or KRAS mutation (median 239 vs 473 days, hazard ratio 2.11; 95% CI 0.92-4.86, P = 0.077).	Platinum	87-95	KRAS proto-oncogene, GTPase	Homo sapiens	29-33
32891532-9	2020	When grouped based on Rb loss and KRAS mutation, there seemed to be two groups with distinct prognoses and responses to the platinum-based regimen.	Platinum	124-132	KRAS proto-oncogene, GTPase	Homo sapiens	34-38
33123276-0	2020	Functional genetic variants of CTNNBIP1 predict platinum treatment response of Chinese epithelial ovarian cancer patients.	Platinum	48-56	catenin beta interacting protein 1	Homo sapiens	31-39
32912765-3	2020	In cases of triple negative BC with BRCA mutation, there is some evidence that adding platinum-agents in the neoadjuvant setting improves the pathologic complete response.	Platinum	86-94	BRCA1 DNA repair associated	Homo sapiens	36-40
32885649-5	2020	The synthesized folate (FA)/Pt-si-GPX4@IONPs exerted substantial effects on glioblastoma in U87MG and P3#GBM cells, but limited effects on normal human astrocytes (NHAs).	Platinum	28-30	glutathione peroxidase 4	Homo sapiens	34-38
32869633-2	2020	Herein, we present the successful fab-rication of a family of new rotaxane-branched dendrimers containing up to twenty-one platinum atoms and forty-two photosensitizer moieties through an efficient and controllable divergent approach.	Platinum	123-131	FA complementation group B	Homo sapiens	34-37
33123276-3	2020	In the present study, we investigated associations between single nucleotide polymorphisms (SNPs) of CTNNBIP1 and platinum treatment response of Han Chinese EOC patients and subsequently performed functional prediction and validation of the resultant SNPs.	Platinum	114-122	catenin beta interacting protein 1	Homo sapiens	101-109
33123276-4	2020	We found that CTNNBIP1 rs935072 AT/TT variant genotypes were associated with platinum treatment response in the multivariate logistic regression analysis of EOC patients.	Platinum	77-85	catenin beta interacting protein 1	Homo sapiens	14-22
33123276-7	2020	We further found that overexpression of CTNNBIP1 sensitized ovarian cancer cells to platinum treatment.	Platinum	84-92	catenin beta interacting protein 1	Homo sapiens	40-48
33123276-8	2020	Thus, the present study provides evidence that functional variants of CTNNBIP1 may regulate the expression of CTNNBIP1, a possible mechanism affecting platinum treatment response of EOC patients.	Platinum	151-159	catenin beta interacting protein 1	Homo sapiens	70-78
33123276-8	2020	Thus, the present study provides evidence that functional variants of CTNNBIP1 may regulate the expression of CTNNBIP1, a possible mechanism affecting platinum treatment response of EOC patients.	Platinum	151-159	catenin beta interacting protein 1	Homo sapiens	110-118
32989221-3	2020	Here, we show that dexamethasone induces upregulation of ROR1 expression in ovarian cancer (OC), including platinum-resistant OC.	Platinum	107-115	receptor tyrosine kinase like orphan receptor 1	Homo sapiens	57-61
32663249-6	2020	These results indicated that MNAT1 rs2284704 T>C and HUS1B rs61748571 A>G may serve as potential biomarkers for predicting platinum-treatment response of Chinese EOC patients, once validated by further functional studies.	Platinum	123-131	MNAT1 component of CDK activating kinase	Homo sapiens	29-34
32663249-6	2020	These results indicated that MNAT1 rs2284704 T>C and HUS1B rs61748571 A>G may serve as potential biomarkers for predicting platinum-treatment response of Chinese EOC patients, once validated by further functional studies.	Platinum	123-131	HUS1 checkpoint clamp component B	Homo sapiens	53-58
32611648-0	2020	A biomarker-enriched, randomized Phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer.	Platinum	120-128	tumor protein p53	Homo sapiens	139-143
32966352-2	2020	In the advanced stage of non-small cell non-squamous lung cancer, without actionable mutation, the immune monotherapy or combination treatment with platinum based chemotherapy is a new standard of care depending on PD-L1 status.	Platinum	148-156	CD274 molecule	Homo sapiens	215-220
32966352-9	2020	In extensive stage small cell lung cancer the platinum-etoposide treatment with PD-L1 inhibitor is a new standard, but we do not have any effective biomarkers yet.	Platinum	46-54	CD274 molecule	Homo sapiens	80-85
32957736-4	2020	For epidermal growth factor receptor (EGFR) mutations, patient survival following first-line pemetrexed-platinum was longer than for WTD.	Platinum	104-112	epidermal growth factor receptor	Homo sapiens	4-36
32957736-4	2020	For epidermal growth factor receptor (EGFR) mutations, patient survival following first-line pemetrexed-platinum was longer than for WTD.	Platinum	104-112	epidermal growth factor receptor	Homo sapiens	38-42
32938499-9	2020	As for PT level analyses, DPP-4is are associated with higher reporting of the gastrointestinal tract, pancreas, malignancies, infection, musculoskeletal disorders, general disorders, hypersensitivity, and skin AEs.	Platinum	7-9	dipeptidyl peptidase 4	Homo sapiens	26-31
32947924-2	2020	The combination of PD-1/PD-L1 immune checkpoint inhibitors (ICIs) with first-line platinum-etoposide chemotherapy has been recently evaluated in randomized clinical trials.	Platinum	82-90	programmed cell death 1	Homo sapiens	19-23
32948057-2	2020	Only recently, maintenance therapy with the PARP inhibitor olaparib showed improved progression-free survival in germline BRCA1/2-mutated PDAC patients after platinum-based induction for the first time.	Platinum	158-166	collagen type XI alpha 2 chain	Homo sapiens	44-48
32921017-0	2020	[Influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer who received platinum-based adjuvant chemotherapy].	Platinum	143-151	CD274 molecule	Homo sapiens	35-60
32921017-0	2020	[Influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer who received platinum-based adjuvant chemotherapy].	Platinum	143-151	CD274 molecule	Homo sapiens	62-67
32921017-1	2020	Objective: The aim of present study was to investigate the influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer (NSCLC) who received platinum-based adjuvant chemotherapy.	Platinum	209-217	CD274 molecule	Homo sapiens	93-118
32921017-1	2020	Objective: The aim of present study was to investigate the influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer (NSCLC) who received platinum-based adjuvant chemotherapy.	Platinum	209-217	CD274 molecule	Homo sapiens	120-125
32921017-16	2020	Conclusion: The prognosis of patients with postoperative non-small cell lung cancer who received platinum-based adjuvant chemotherapy is influenced by -1813G>C polymorphism of PD-L1 gene.	Platinum	97-105	CD274 molecule	Homo sapiens	176-181
32900227-9	2021	In addition, overexpression of pro-apoptotic (Bax) protein, caspase-3 activity and histone release were increased after treatment of both cell lines with different PT concentrations.	Platinum	164-166	BCL2 associated X, apoptosis regulator	Homo sapiens	46-49
32982420-5	2020	Results: Nuclear NF-kappaB p65 over-expression was closely associated with ovarian cancer with advanced FIGO stage, residual disease >=1 cm, low histologic grade, platinum resistance and refractory, chemotherapy resistance (P< 0.05).	Platinum	163-171	RELA proto-oncogene, NF-kB subunit	Homo sapiens	17-30
32982420-14	2020	The NF-kappaB inhibitor PDTC can enhance cisplatin sensitivity of platinum-resistant C13* and A2780cp ovarian cancer cells.	Platinum	66-74	nuclear factor kappa B subunit 1	Homo sapiens	4-13
32984690-4	2020	In this study, we designed and synthesized platinum (Pt) nanocluster bionanoprobes with red emission (Ex/Em = 535/630 nm) for fluorescence imaging of HER2.	Platinum	43-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	150-154
32984690-4	2020	In this study, we designed and synthesized platinum (Pt) nanocluster bionanoprobes with red emission (Ex/Em = 535/630 nm) for fluorescence imaging of HER2.	Platinum	53-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	150-154
32350496-9	2020	The rates of H2 evolution obtained in the photochemical cell (12.1 mmol g-1 h-1 on Pt/TiO2 and 1.01 mmol g-1 h-1 on Pt/g-C3N4-ns) were comparable to that obtained in a standard top-irradiated photoreactor (16.6 mmol g-1 h-1 on Pt/TiO2 and 1.76 mmol g-1 h-1 on Pt/g-C3N4-ns).	Platinum	83-85	H1.5 linker histone, cluster member	Homo sapiens	76-79
32900227-9	2021	In addition, overexpression of pro-apoptotic (Bax) protein, caspase-3 activity and histone release were increased after treatment of both cell lines with different PT concentrations.	Platinum	164-166	caspase 3	Homo sapiens	60-69
32350496-9	2020	The rates of H2 evolution obtained in the photochemical cell (12.1 mmol g-1 h-1 on Pt/TiO2 and 1.01 mmol g-1 h-1 on Pt/g-C3N4-ns) were comparable to that obtained in a standard top-irradiated photoreactor (16.6 mmol g-1 h-1 on Pt/TiO2 and 1.76 mmol g-1 h-1 on Pt/g-C3N4-ns).	Platinum	116-118	H1.5 linker histone, cluster member	Homo sapiens	109-112
32906729-12	2020	Exposure of OC cells to cobimetinib-a MEK1 inhibitor that also inhibits extracellular signal-regulated kinase (ERK) phosphorylation-which resulted in reduced sensitivity to the platinum compound.	Platinum	177-185	mitogen-activated protein kinase kinase 1	Homo sapiens	38-42
32350496-9	2020	The rates of H2 evolution obtained in the photochemical cell (12.1 mmol g-1 h-1 on Pt/TiO2 and 1.01 mmol g-1 h-1 on Pt/g-C3N4-ns) were comparable to that obtained in a standard top-irradiated photoreactor (16.6 mmol g-1 h-1 on Pt/TiO2 and 1.76 mmol g-1 h-1 on Pt/g-C3N4-ns).	Platinum	116-118	H1.5 linker histone, cluster member	Homo sapiens	109-112
32350496-9	2020	The rates of H2 evolution obtained in the photochemical cell (12.1 mmol g-1 h-1 on Pt/TiO2 and 1.01 mmol g-1 h-1 on Pt/g-C3N4-ns) were comparable to that obtained in a standard top-irradiated photoreactor (16.6 mmol g-1 h-1 on Pt/TiO2 and 1.76 mmol g-1 h-1 on Pt/g-C3N4-ns).	Platinum	116-118	H1.5 linker histone, cluster member	Homo sapiens	109-112
32350496-9	2020	The rates of H2 evolution obtained in the photochemical cell (12.1 mmol g-1 h-1 on Pt/TiO2 and 1.01 mmol g-1 h-1 on Pt/g-C3N4-ns) were comparable to that obtained in a standard top-irradiated photoreactor (16.6 mmol g-1 h-1 on Pt/TiO2 and 1.76 mmol g-1 h-1 on Pt/g-C3N4-ns).	Platinum	116-118	H1.5 linker histone, cluster member	Homo sapiens	109-112
32350496-9	2020	The rates of H2 evolution obtained in the photochemical cell (12.1 mmol g-1 h-1 on Pt/TiO2 and 1.01 mmol g-1 h-1 on Pt/g-C3N4-ns) were comparable to that obtained in a standard top-irradiated photoreactor (16.6 mmol g-1 h-1 on Pt/TiO2 and 1.76 mmol g-1 h-1 on Pt/g-C3N4-ns).	Platinum	116-118	H1.5 linker histone, cluster member	Homo sapiens	109-112
32350496-9	2020	The rates of H2 evolution obtained in the photochemical cell (12.1 mmol g-1 h-1 on Pt/TiO2 and 1.01 mmol g-1 h-1 on Pt/g-C3N4-ns) were comparable to that obtained in a standard top-irradiated photoreactor (16.6 mmol g-1 h-1 on Pt/TiO2 and 1.76 mmol g-1 h-1 on Pt/g-C3N4-ns).	Platinum	116-118	H1.5 linker histone, cluster member	Homo sapiens	109-112
32906729-12	2020	Exposure of OC cells to cobimetinib-a MEK1 inhibitor that also inhibits extracellular signal-regulated kinase (ERK) phosphorylation-which resulted in reduced sensitivity to the platinum compound.	Platinum	177-185	mitogen-activated protein kinase 1	Homo sapiens	72-109
32906729-12	2020	Exposure of OC cells to cobimetinib-a MEK1 inhibitor that also inhibits extracellular signal-regulated kinase (ERK) phosphorylation-which resulted in reduced sensitivity to the platinum compound.	Platinum	177-185	mitogen-activated protein kinase 1	Homo sapiens	111-114
32906729-13	2020	This suggests that ERK activity is involved in mediating the function of flavonoids in restoring platinum sensitivity to OC co-cultured with cellular components of the TME.	Platinum	97-105	mitogen-activated protein kinase 1	Homo sapiens	19-22
32890710-6	2021	PDS, such as ginsenoside Rb1, and PTS, such as ginsenoside Rg1 are the main anticancer compositions.	Platinum	34-37	protein phosphatase 1 regulatory subunit 3A	Homo sapiens	59-62
32785404-0	2020	Free electron laser infrared action spectroscopy of nitrous oxide binding to platinum clusters, Ptn(N2O).	Platinum	77-85	pleiotrophin	Homo sapiens	96-99
32785404-1	2020	Infrared multiple-photon dissociation spectroscopy has been applied to study Ptn(N2O)+ (n = 1-8) clusters which represent entrance-channel complexes on the reactive potential energy surface for nitrous oxide decomposition on platinum.	Platinum	225-233	pleiotrophin	Homo sapiens	77-80
32608165-6	2020	In particular, comparison of calculations at DFT, MP2 and CCSD levels with experimental results demonstrates that the localization of the radical is about equally shared between the d xz orbital of platinum and the p z  of nitrogen on the amino group, the latter acting as a non-innocent ligand.	Platinum	198-206	tryptase pseudogene 1	Homo sapiens	50-53
32878625-11	2020	Notably, the expression of HDAC1 and HtrA1 can be considered as biomarkers for the efficacy of platinum-based drugs and prognosis in NSCLC patients.	Platinum	95-103	histone deacetylase 1	Homo sapiens	27-32
32878625-11	2020	Notably, the expression of HDAC1 and HtrA1 can be considered as biomarkers for the efficacy of platinum-based drugs and prognosis in NSCLC patients.	Platinum	95-103	HtrA serine peptidase 1	Homo sapiens	37-42
33042614-9	2020	Twist has been shown to have roles in acquired resistance for both cetuximab and cisplatin, a platinum-based therapy that targets dividing cells, which suggests that it also has an integral role in resistance.	Platinum	94-102	twist family bHLH transcription factor 1	Homo sapiens	0-5
32384200-1	2020	BACKGROUND: Testicular Germ Cell Tumors (TGCTs) are highly sensitive to platinum-based chemotherapy, and wild-type p53 seems to play a pivotal role in this susceptibility.	Platinum	72-80	tumor protein p53	Homo sapiens	115-118
32648106-3	2020	Then, an ECL assay for miRNA-21 was fabricated, which was based on the use of probe 2 DNA-functionalized Pt/PAMAM nanocomposites (NCs) assembled on the surface of Au/TiO2 NT conjugate via DNA hybridization between probe 1 DNA and capture DNA.	Platinum	105-107	microRNA 21	Homo sapiens	23-31
32449598-2	2020	While this divinyldiborene coordinates to copper(I) and platinum(0) in a eta2-B2 and eta4-C2B2 fashion, respectively, it undergoes a complex rearrangement to a eta4-1,3-diborete upon complexation with nickel(0).	Platinum	56-64	DNA polymerase iota	Homo sapiens	73-80
32570116-4	2020	Recent studies suggest that the copper efflux transporters ATP7A and ATP7B play an important role in platinum resistance.	Platinum	101-109	ATPase copper transporting alpha	Homo sapiens	59-64
32569725-1	2020	BACKGROUND: In recurrent ovarian cancer, poly(ADP-ribose) polymerase (PARP)-inhibiting agents have transformed the treatment of platinum-sensitive disease.	Platinum	128-136	poly(ADP-ribose) polymerase 1	Homo sapiens	41-68
32569725-1	2020	BACKGROUND: In recurrent ovarian cancer, poly(ADP-ribose) polymerase (PARP)-inhibiting agents have transformed the treatment of platinum-sensitive disease.	Platinum	128-136	poly(ADP-ribose) polymerase 1	Homo sapiens	70-74
32512040-5	2020	Recently, functional evidence from patient-derived xenografts and organoids have suggested that maintenance with PARP-inhibitors might represent a therapeutic opportunity in CRC patients previously responsive to platinum-based treatment.	Platinum	212-220	poly(ADP-ribose) polymerase 1	Homo sapiens	113-117
32570116-4	2020	Recent studies suggest that the copper efflux transporters ATP7A and ATP7B play an important role in platinum resistance.	Platinum	101-109	ATPase copper transporting beta	Homo sapiens	69-74
32570116-8	2020	Based on the results of in vitro assays, disease-relevant animal models, and clinical studies to date, it may be concluded that APT7A and ATP7B deserve further development as predictive markers of platinum resistance in ovarian cancer.	Platinum	197-205	ATPase copper transporting beta	Homo sapiens	138-143
32569853-7	2020	PFS was prolonged for anti-EGFR agents against methotrexate when used in a second line setting (HR = 0 74, 95 %CI 0 62-0 87, p=0 001), and when cetuximab (HR = 0 60, 95%CI 0 49-0 72, p<0 0001) and panitumumab (HR = 0 76, 95%CI 0 65-0 89, p=0 001) were introduced to platinum-based regimens for first-line treatment.	Platinum	266-274	epidermal growth factor receptor	Homo sapiens	27-31
32376116-3	2020	PATIENTS AND METHODS: This retrospective observational study used a nationally representative database to identify adult patients with histologically confirmed aNSCLC and PD-L1 tumor proportion score (TPS) >= 1% previously treated with platinum-containing chemotherapy (and appropriate tyrosine kinase inhibitor if nonsquamous aNSCLC with EGFR/ALK genomic tumor aberration).	Platinum	236-244	epidermal growth factor receptor	Homo sapiens	339-343
32376116-3	2020	PATIENTS AND METHODS: This retrospective observational study used a nationally representative database to identify adult patients with histologically confirmed aNSCLC and PD-L1 tumor proportion score (TPS) >= 1% previously treated with platinum-containing chemotherapy (and appropriate tyrosine kinase inhibitor if nonsquamous aNSCLC with EGFR/ALK genomic tumor aberration).	Platinum	236-244	ALK receptor tyrosine kinase	Homo sapiens	344-347
33006584-3	2020	PARP inhibitors are also approved as maintenance treatment following a response to platinum-based therapy in the recurrent setting, irrespective of biomarker status.	Platinum	83-91	poly(ADP-ribose) polymerase 1	Homo sapiens	0-4
33006584-4	2020	Additionally, PARP inhibitors are approved as third-line treatment and beyond in lieu of chemotherapy for patients with BRCA-associated cancers, and as fourth-line treatment and beyond for patients with platinum-sensitive homologous recombination-deficient tumors.	Platinum	203-211	poly(ADP-ribose) polymerase 1	Homo sapiens	14-18
32964970-0	2020	Correlation between microRNA-766 expression in patients with advanced gastric cancer and the efficacy of platinum-containing chemotherapy.	Platinum	105-113	microRNA 766	Homo sapiens	20-32
32309901-0	2020	Platinum nanoparticles induced genotoxicity and apoptotic activity in human normal and cancer hepatic cells via oxidative stress-mediated Bax/Bcl-2 and caspase-3 expression.	Platinum	0-8	BCL2 associated X, apoptosis regulator	Homo sapiens	138-141
32309901-0	2020	Platinum nanoparticles induced genotoxicity and apoptotic activity in human normal and cancer hepatic cells via oxidative stress-mediated Bax/Bcl-2 and caspase-3 expression.	Platinum	0-8	BCL2 apoptosis regulator	Homo sapiens	142-147
32309901-0	2020	Platinum nanoparticles induced genotoxicity and apoptotic activity in human normal and cancer hepatic cells via oxidative stress-mediated Bax/Bcl-2 and caspase-3 expression.	Platinum	0-8	caspase 3	Homo sapiens	152-161
32964970-1	2020	OBJECTIVE: We aimed at observing the correlation between microRNA-766 expression and the efficacy of platinum-containing chemotherapy in patients with stage IV gastric cancer (GCa).	Platinum	101-109	microRNA 766	Homo sapiens	57-69
32964970-8	2020	CONCLUSIONS: Our study shows for the first time that the highly expressed microRNA-766 in tumor tissues of patients with stage IV GCa predicts better platinum-containing chemotherapy efficacy and prognosis.	Platinum	150-158	microRNA 766	Homo sapiens	74-86
32592623-0	2020	Long term disease control using taxane/platinum-based chemotherapy in CDK12-mutated advanced prostate cancer.	Platinum	39-47	cyclin dependent kinase 12	Homo sapiens	70-75
32789480-1	2020	Importance: The value of platinum-based adjuvant chemotherapy in patients with triple-negative breast cancer (TNBC) remains controversial, as does whether BRCA1 and BRCA2 (BRCA1/2) germline variants are associated with platinum treatment sensitivity.	Platinum	219-227	BRCA1 DNA repair associated	Homo sapiens	155-160
32789480-1	2020	Importance: The value of platinum-based adjuvant chemotherapy in patients with triple-negative breast cancer (TNBC) remains controversial, as does whether BRCA1 and BRCA2 (BRCA1/2) germline variants are associated with platinum treatment sensitivity.	Platinum	219-227	BRCA2 DNA repair associated	Homo sapiens	165-170
32789480-1	2020	Importance: The value of platinum-based adjuvant chemotherapy in patients with triple-negative breast cancer (TNBC) remains controversial, as does whether BRCA1 and BRCA2 (BRCA1/2) germline variants are associated with platinum treatment sensitivity.	Platinum	219-227	BRCA2 DNA repair associated	Homo sapiens	172-179
32567934-0	2020	miR-15a-5p targets PHLPP2 in gastric cancer cells to modulate platinum resistance and is a suitable serum biomarker for oxaliplatin resistance.	Platinum	62-70	PH domain and leucine rich repeat protein phosphatase 2	Homo sapiens	19-25
32880833-0	2020	Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh.	Platinum	88-96	glutathione S-transferase pi 1	Homo sapiens	25-30
32880833-0	2020	Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh.	Platinum	88-96	X-ray repair cross complementing 1	Homo sapiens	32-37
32880833-0	2020	Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh.	Platinum	88-96	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	39-42
32880833-0	2020	Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh.	Platinum	88-96	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
32880833-5	2020	XRCC1 (rs25487) polymorphism was found to act as a predictive factor for not only grade 3 and 4 anemia (p = 0.008), neutropenia (p = 0.010), thrombocytopenia (p = 0.025) and gastrointestinal toxicity (p = 0.002) but also for therapeutic response (p = 0.012) in platinum-based chemotherapy.	Platinum	261-269	X-ray repair cross complementing 1	Homo sapiens	0-5
32880833-6	2020	Although GSTP1 (rs1695) polymorphism might serve as prognostic factor regarding grade 3 or 4 neutropenia, a significant (p = 0.044) improvement in response to platinum-based chemotherapy was observed.	Platinum	159-167	glutathione S-transferase pi 1	Homo sapiens	9-14
32880833-8	2020	XRCC1 (rs2228001) and GSTP1 (rs1695) polymorphisms might explain platinum-induced clinical outcomes in terms of both toxicity and therapeutic response variations among Bangladeshi advanced NSCLC patients.	Platinum	65-73	X-ray repair cross complementing 1	Homo sapiens	0-5
32880833-8	2020	XRCC1 (rs2228001) and GSTP1 (rs1695) polymorphisms might explain platinum-induced clinical outcomes in terms of both toxicity and therapeutic response variations among Bangladeshi advanced NSCLC patients.	Platinum	65-73	glutathione S-transferase pi 1	Homo sapiens	22-27
32934772-6	2020	To target the interaction of 14-3-3epsilon with CDC25A for cancer therapy, we developed two novel phospho-peptides, pS and pT, corresponding to each of the 14-3-3 binding sites of CDC25A, to specifically interfere with 14-3-3epsilon binding to CDC25A.	Platinum	123-125	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon	Homo sapiens	29-42
32705213-11	2020	Four potential genes associated with NACT and platinum-based chemoresistance were screened, including nuclear factor of activated T-cells, cytoplasmic 1 (NAFTc1), Kruppel-like factor 4 (KLF4), nuclear receptor subfamily 4 group A member 3 (NR4A3) and hepatocyte growth factor (HGF).	Platinum	46-54	nuclear factor of activated T cells 1	Homo sapiens	102-152
32934772-6	2020	To target the interaction of 14-3-3epsilon with CDC25A for cancer therapy, we developed two novel phospho-peptides, pS and pT, corresponding to each of the 14-3-3 binding sites of CDC25A, to specifically interfere with 14-3-3epsilon binding to CDC25A.	Platinum	123-125	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta	Homo sapiens	29-35
32934772-6	2020	To target the interaction of 14-3-3epsilon with CDC25A for cancer therapy, we developed two novel phospho-peptides, pS and pT, corresponding to each of the 14-3-3 binding sites of CDC25A, to specifically interfere with 14-3-3epsilon binding to CDC25A.	Platinum	123-125	cell division cycle 25A	Homo sapiens	180-186
32782591-7	2020	Additionally, MBD2 expression was significantly higher in platinum-resistant cases compared with that in platinum-sensitive cases (P<0.05).	Platinum	58-66	methyl-CpG binding domain protein 2	Homo sapiens	14-18
32705213-11	2020	Four potential genes associated with NACT and platinum-based chemoresistance were screened, including nuclear factor of activated T-cells, cytoplasmic 1 (NAFTc1), Kruppel-like factor 4 (KLF4), nuclear receptor subfamily 4 group A member 3 (NR4A3) and hepatocyte growth factor (HGF).	Platinum	46-54	nuclear factor of activated T cells 1	Homo sapiens	154-160
32934772-6	2020	To target the interaction of 14-3-3epsilon with CDC25A for cancer therapy, we developed two novel phospho-peptides, pS and pT, corresponding to each of the 14-3-3 binding sites of CDC25A, to specifically interfere with 14-3-3epsilon binding to CDC25A.	Platinum	123-125	cell division cycle 25A	Homo sapiens	180-186
32705213-11	2020	Four potential genes associated with NACT and platinum-based chemoresistance were screened, including nuclear factor of activated T-cells, cytoplasmic 1 (NAFTc1), Kruppel-like factor 4 (KLF4), nuclear receptor subfamily 4 group A member 3 (NR4A3) and hepatocyte growth factor (HGF).	Platinum	46-54	Kruppel like factor 4	Homo sapiens	186-190
32934772-7	2020	Peptides pT (IC50 = 22.1 muM), and pS (IC50 = 29 muM) induced SCC cell death and blocked 14-3-3epsilon binding to CDC25A.	Platinum	9-11	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon	Homo sapiens	89-102
32934772-7	2020	Peptides pT (IC50 = 22.1 muM), and pS (IC50 = 29 muM) induced SCC cell death and blocked 14-3-3epsilon binding to CDC25A.	Platinum	9-11	cell division cycle 25A	Homo sapiens	114-120
32705213-11	2020	Four potential genes associated with NACT and platinum-based chemoresistance were screened, including nuclear factor of activated T-cells, cytoplasmic 1 (NAFTc1), Kruppel-like factor 4 (KLF4), nuclear receptor subfamily 4 group A member 3 (NR4A3) and hepatocyte growth factor (HGF).	Platinum	46-54	nuclear receptor subfamily 4 group A member 3	Homo sapiens	193-238
32934772-8	2020	pS or pT treatment of SCC xenografts increased apoptotic cell death and decreased pro-survival P-Akt (S473) and Survivin, demonstrating the effectiveness of the peptides in vivo.	Platinum	6-8	AKT serine/threonine kinase 1	Homo sapiens	97-100
32705213-11	2020	Four potential genes associated with NACT and platinum-based chemoresistance were screened, including nuclear factor of activated T-cells, cytoplasmic 1 (NAFTc1), Kruppel-like factor 4 (KLF4), nuclear receptor subfamily 4 group A member 3 (NR4A3) and hepatocyte growth factor (HGF).	Platinum	46-54	nuclear receptor subfamily 4 group A member 3	Homo sapiens	240-245
32705213-11	2020	Four potential genes associated with NACT and platinum-based chemoresistance were screened, including nuclear factor of activated T-cells, cytoplasmic 1 (NAFTc1), Kruppel-like factor 4 (KLF4), nuclear receptor subfamily 4 group A member 3 (NR4A3) and hepatocyte growth factor (HGF).	Platinum	46-54	hepatocyte growth factor	Homo sapiens	251-275
32705213-11	2020	Four potential genes associated with NACT and platinum-based chemoresistance were screened, including nuclear factor of activated T-cells, cytoplasmic 1 (NAFTc1), Kruppel-like factor 4 (KLF4), nuclear receptor subfamily 4 group A member 3 (NR4A3) and hepatocyte growth factor (HGF).	Platinum	46-54	hepatocyte growth factor	Homo sapiens	277-280
32705213-13	2020	The NAFTc1, KLF4, NR4A3 and HGF genes may be potential therapeutic targets for NACT and platinum-based chemoresistance factors as well as candidate biomarkers in AEOC.	Platinum	88-96	nuclear factor of activated T cells 1	Homo sapiens	4-10
32705213-13	2020	The NAFTc1, KLF4, NR4A3 and HGF genes may be potential therapeutic targets for NACT and platinum-based chemoresistance factors as well as candidate biomarkers in AEOC.	Platinum	88-96	Kruppel like factor 4	Homo sapiens	12-16
32705213-13	2020	The NAFTc1, KLF4, NR4A3 and HGF genes may be potential therapeutic targets for NACT and platinum-based chemoresistance factors as well as candidate biomarkers in AEOC.	Platinum	88-96	nuclear receptor subfamily 4 group A member 3	Homo sapiens	18-23
32705213-13	2020	The NAFTc1, KLF4, NR4A3 and HGF genes may be potential therapeutic targets for NACT and platinum-based chemoresistance factors as well as candidate biomarkers in AEOC.	Platinum	88-96	hepatocyte growth factor	Homo sapiens	28-31
33102389-9	2020	In cases of metastatic castration-resistant PCa, BRCA1/2 and DNA mismatch repair genes may be useful biomarkers for predicting the response to androgen receptor-targeting agents, poly (ADP-ribose) polymerase inhibitors, platinum chemotherapy, prostate-specific membrane antigen-targeted therapy, immunotherapy, and radium-223.	Platinum	220-228	BRCA1 DNA repair associated	Homo sapiens	49-56
32691982-10	2020	CONCLUSIONS: Our results revealed that DLL3 is a predictive marker of sensitivity to platinum-based adjuvant chemotherapy for LCNEC.	Platinum	85-93	delta like canonical Notch ligand 3	Homo sapiens	39-43
32691982-11	2020	KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: DLL3 was a predictive marker of sensitivity to platinum-based adjuvant chemotherapy for LCNEC.	Platinum	94-102	delta like canonical Notch ligand 3	Homo sapiens	47-51
32691982-12	2020	Among patients with DLL3 expression-negative LCNEC, platinum-based adjuvant chemotherapy significantly improved the OS and RFS, although it did not do so among patients with DLL3 expression-positive LCNEC.	Platinum	52-60	delta like canonical Notch ligand 3	Homo sapiens	20-24
32706170-5	2020	Conversely, an anti-PD-L1 antibody synergistic effect on platinum compounds was assessed in a preclinical study, which was reinforced by clinical data.	Platinum	57-65	CD274 molecule	Homo sapiens	20-25
32854746-0	2020	KIAA1522 potentiates TNFalpha-NFkappaB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma.	Platinum	63-71	expressed sequence C77080	Mus musculus	0-8
32846060-6	2020	RESULTS: In the first 105 consecutively enrolled patients with RET fusion-positive NSCLC who had previously received at least platinum-based chemotherapy, the percentage with an objective response was 64% (95% confidence interval [CI], 54 to 73).	Platinum	126-134	ret proto-oncogene	Homo sapiens	63-66
32854746-0	2020	KIAA1522 potentiates TNFalpha-NFkappaB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma.	Platinum	63-71	tumor necrosis factor	Mus musculus	21-29
32854746-5	2020	Here, we aimed to identify the role of KIAA1522 in lung adenocarcinomas, and the molecular events that underlie KIAA1522-mediated chemoresistance to the platinum.	Platinum	153-161	KIAA1522	Homo sapiens	112-120
32854746-11	2020	RESULTS: The clinical evidences reveal that KIAA1522 independently predicts both the overall survival and the outcome of platinum-based chemotherapy in lung adenocarcinomas.	Platinum	121-129	expressed sequence C77080	Mus musculus	44-52
32854746-16	2020	CONCLUSION: High expression of KIAA1522 is turned out to be an indicator of dismal effectiveness of platinum-based therapy in lung adenocarcinomas.	Platinum	100-108	expressed sequence C77080	Mus musculus	31-39
32854746-17	2020	KIAA1522 hyperactivates TNFalpha-NFkappaB signaling to facilitate resistance to platinum reagents.	Platinum	80-88	expressed sequence C77080	Mus musculus	0-8
32854746-17	2020	KIAA1522 hyperactivates TNFalpha-NFkappaB signaling to facilitate resistance to platinum reagents.	Platinum	80-88	tumor necrosis factor	Mus musculus	24-32
32854746-18	2020	Targeting NFkappaB signaling through small molecule inhibitors may be a rational strategy to conquer chemoresistance and synergize platinum-based chemotherapy in KIAA1522 overexpressed lung adenocarcinomas.	Platinum	131-139	expressed sequence C77080	Mus musculus	162-170
32984035-0	2020	Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder Cancer.	Platinum	80-88	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	29-34
32648568-5	2020	Compared with control polymers CP1 and CP2, after the introduction of Pt into CP3, the triplet state, which benefits the generation of reactive oxygen species for photodynamic therapy, was identified clearly in both CP3 and the prepared CP3 nanoparticles (CP3-NPs) by ultrafast femtosecond transient absorption (fs-TA) spectroscopy.	Platinum	70-72	ceruloplasmin	Homo sapiens	39-42
32799447-4	2020	Because of such double-layer structures of NNGF, stable Pt-N4 construction, and binder-free advantages, the Pt1/NNGF electrode exhibits a low overpotential of 0.023 V at 10 mA cm-2 and a small Tafel slope of 29.1 mV dec-1 as well as an excellent long-term durability.	Platinum	56-58	zinc finger protein 77	Homo sapiens	108-111
32984035-11	2020	Among this cohort, a patient harbored an ERCC2 helicase domain mutation and would be expected to respond to platinum-based therapy.	Platinum	108-116	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	41-46
32843536-7	2020	In addition to copper, CTR1 plays a central role in the trafficking of platinum.	Platinum	71-79	solute carrier family 31 member 1	Homo sapiens	23-27
32806073-3	2020	We demonstrate a long-lived hot electron state in a Pt nanocluster adsorbed on the MoS2 substrate.	Platinum	52-54	alcohol dehydrogenase iron containing 1	Homo sapiens	28-31
32843536-8	2020	The efficacy of platinum-based cancer drugs has been correlated with CTR1 expression.	Platinum	16-24	solute carrier family 31 member 1	Homo sapiens	69-73
32847049-0	2020	Impact of ERCC1, XPF and DNA Polymerase beta Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts.	Platinum	59-67	DNA polymerase beta	Homo sapiens	25-44
32847049-6	2020	We then correlated the proteins, gene expression and ERCC1/XPF complexes with OC-PDXs" response to platinum.	Platinum	99-107	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	53-58
32847049-6	2020	We then correlated the proteins, gene expression and ERCC1/XPF complexes with OC-PDXs" response to platinum.	Platinum	99-107	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	59-62
32847049-9	2020	These results were partially explained by the experimental evidence that the ERCC1/XPF complex increases after DDP treatment and this possibly better associates with the cancer cells" abilities to activate the NER pathway to repair platinum-induced damage than its basal level.	Platinum	232-240	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	77-82
32847049-9	2020	These results were partially explained by the experimental evidence that the ERCC1/XPF complex increases after DDP treatment and this possibly better associates with the cancer cells" abilities to activate the NER pathway to repair platinum-induced damage than its basal level.	Platinum	232-240	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	83-86
32825798-8	2020	Finally, p22phox might have binding specificity for the platinum drugs, including CDDP, carboplatin and oxaliplatin.	Platinum	56-64	cytochrome b-245 alpha chain	Homo sapiens	9-16
32857543-0	2020	Efficient Spin Torques in Antiferromagnetic CoO/Pt Quantified by Comparing Field- and Current-Induced Switching.	Platinum	48-50	spindlin 1	Homo sapiens	10-14
32827632-5	2021	Here, we reviewed the literature on the responsiveness of BRCA1/2-associated HGSOC to platinum-based chemotherapy and PARPis, and propose mechanisms underlying the frequent development of resistance to these therapeutic agents.	Platinum	86-94	BRCA1 DNA repair associated	Homo sapiens	58-65
32817372-3	2020	In urothelial carcinoma of the bladder (UCB), silencing of GULP1 facilitated the nuclear accumulation of NRF2, led to constitutive activation of NRF2 signaling, and conferred resistance to the platinum drug cisplatin.	Platinum	193-201	GULP PTB domain containing engulfment adaptor 1	Homo sapiens	59-64
32643724-4	2020	In addition, the ultrathin Pt7RuNi2-O NS catalyst also shows the highest performance among reported Pt-based catalysts for the MOR in acidic medium.	Platinum	27-29	opioid receptor mu 1	Homo sapiens	127-130
32778717-3	2020	In this study, we demonstrated that MRP4 was responsible for the extrusion of oxaliplatin (L-OHP), a platinum (Pt)-based chemotherapeutic drug, from BMCs of mice, and that the efflux transporter expression exhibited significant diurnal variation.	Platinum	101-109	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	36-40
32851091-8	2020	This study provided a possibility to use AURKA as a biomarker to predict the chemosensitivity of colon cancer to platinum in the clinic.	Platinum	113-121	aurora kinase A	Homo sapiens	41-46
32791996-2	2020	This study aimed to use CA-125 and computed tomography (CT) scanning to generate a simple and clinically applicable model of predicting complete cytoreduction by interval debulking surgery (IDS) and the overall survival in patients who receive taxane/platinum-based chemotherapy as neoadjuvant chemotherapy (NACT).	Platinum	251-259	mucin 16, cell surface associated	Homo sapiens	24-30
32793315-1	2020	Background: Patients with DNA-damage response genes (DDR)-related pancreas cancer (BRCA1/2 or other DNA-damage related genes) may have improved outcomes secondary to increased sensitivity to DNA-damaging drugs (platinum chemotherapy/ poly ADP ribose polymerase (PARP)-inhibitors).	Platinum	211-219	BRCA1 DNA repair associated	Homo sapiens	83-90
32793315-1	2020	Background: Patients with DNA-damage response genes (DDR)-related pancreas cancer (BRCA1/2 or other DNA-damage related genes) may have improved outcomes secondary to increased sensitivity to DNA-damaging drugs (platinum chemotherapy/ poly ADP ribose polymerase (PARP)-inhibitors).	Platinum	211-219	poly(ADP-ribose) polymerase 1	Homo sapiens	262-266
32778717-3	2020	In this study, we demonstrated that MRP4 was responsible for the extrusion of oxaliplatin (L-OHP), a platinum (Pt)-based chemotherapeutic drug, from BMCs of mice, and that the efflux transporter expression exhibited significant diurnal variation.	Platinum	111-113	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	36-40
32778717-6	2020	Lower Pt accumulation in BMCs was detected in mice after injection of L-OHP at the mid-dark phase, during which the expression levels of MRP4 increased.	Platinum	6-8	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	137-141
32999831-4	2020	The Co3Fe7@Co5.47N/NCF outperforms commercial platinum/carbon (Pt/C) toward ORR with an onset potential of 1.02 V and a positive half-wave potential of 0.92 V in an alkaline electrolyte (0.59 V in sodium chloride solution), which is ascribed to the unique interfacial structure between Co3Fe7 and Co5.47N supported by 3D N-doped carbon foam to facilitate fast electron and mass transfer.	Platinum	46-54	neutrophil cytosolic factor 4	Homo sapiens	19-22
32771026-6	2020	Preoperative CA125, albumin, and D-dimer levels; neutrophil to lymphocyte ratios (NLR); and monocyte to lymphocyte ratios were significantly correlated with FIGO stage, residual tumor, and platinum response.	Platinum	189-197	mucin 16, cell surface associated	Homo sapiens	13-18
32771026-13	2020	Elevated D-dimer and reduced albumin might be potential biomarkers for worse response to first-line platinum-based chemotherapy and poor clinical outcomes.	Platinum	100-108	albumin	Homo sapiens	29-36
32922531-10	2020	The levels of HSP90 were inversely associated with short-term efficacy in GC patients who had received fluorouracil/platinum-based advanced first-line treatment.	Platinum	116-124	heat shock protein 90 alpha family class A member 1	Homo sapiens	14-19
32801904-1	2020	Purpose: This study was done to investigate the influence of PDL1-gene polymorphism on the prognosis and safety of postoperative patients with non-small cell lung cancer (NSCLC) who had received platinum-based adjuvant chemotherapy.	Platinum	195-203	CD274 molecule	Homo sapiens	61-65
32801904-14	2020	Conclusion: The prognosis of postoperative patients with NSCLC who have received platinum-based adjuvant chemotherapy may be influenced by the rs822336 polymorphism through mediation of the mRNA expression of PDL1.	Platinum	81-89	CD274 molecule	Homo sapiens	209-213
32701304-4	2020	Our studies showed that the PtSn/reduced-graphene oxide (RGO) thin film gave better catalytic results for MOR in comparison to bare PtSn or Pt thin films.	Platinum	28-30	opioid receptor mu 1	Homo sapiens	106-109
32856869-1	2020	BACKGROUND AND OBJECTIVE: Ovarian, fallopian tube, or primary peritoneal cancer patients with BRCA gene mutation have enhanced sensitivity to platinum-based regimens and PARP inhibitors.	Platinum	142-150	BRCA1 DNA repair associated	Homo sapiens	94-98
32727751-0	2020	Variants of SLC22A16 Predict the Efficacy of Platinum Combination Chemotherapy in Advanced Non-small-cell Lung Cancer.	Platinum	45-53	solute carrier family 22 member 16	Homo sapiens	12-20
32179453-0	2020	Indirect photo-electrochemical detection of carbohydrates with Pt@g-C3N4 immobilised into a polymer of intrinsic microporosity (PIM-1) and attached to a palladium hydrogen capture membrane.	Platinum	63-65	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	128-133
32727751-1	2020	BACKGROUND: Organic cation transporter 6 (OCT6) encoded by solute carrier family 22 member 16 (SLC22A16) is involved in regulating cellular sensitivity and resistance to platinum derivatives.	Platinum	170-178	solute carrier family 22 member 16	Homo sapiens	12-40
32727751-1	2020	BACKGROUND: Organic cation transporter 6 (OCT6) encoded by solute carrier family 22 member 16 (SLC22A16) is involved in regulating cellular sensitivity and resistance to platinum derivatives.	Platinum	170-178	solute carrier family 22 member 16	Homo sapiens	42-46
32727751-1	2020	BACKGROUND: Organic cation transporter 6 (OCT6) encoded by solute carrier family 22 member 16 (SLC22A16) is involved in regulating cellular sensitivity and resistance to platinum derivatives.	Platinum	170-178	solute carrier family 22 member 16	Homo sapiens	59-93
32727751-1	2020	BACKGROUND: Organic cation transporter 6 (OCT6) encoded by solute carrier family 22 member 16 (SLC22A16) is involved in regulating cellular sensitivity and resistance to platinum derivatives.	Platinum	170-178	solute carrier family 22 member 16	Homo sapiens	95-103
32727751-8	2020	CONCLUSION: A genetic variant of SLC22A16 is a potential predictive biomarker for response to platinum-based chemotherapy for non-small cell lung cancer.	Platinum	94-102	solute carrier family 22 member 16	Homo sapiens	33-41
32910383-0	2020	Association of Molecular Genetic Markers of TP53, MDM2, and CDKN1A Genes with Progression-Free Survival of Patients with Ovarian Cancer after Platinum-Based Chemotherapy.	Platinum	142-150	tumor protein p53	Homo sapiens	44-48
32910383-0	2020	Association of Molecular Genetic Markers of TP53, MDM2, and CDKN1A Genes with Progression-Free Survival of Patients with Ovarian Cancer after Platinum-Based Chemotherapy.	Platinum	142-150	cyclin dependent kinase inhibitor 1A	Homo sapiens	60-66
32530527-10	2020	We further performed immunohistochemical analysis using clinical MPM samples obtained from patients who were treated with the combination of platinum plus pemetrexed, and found that the overexpression of IL-1R tended to correlate with poor overall survival.	Platinum	141-149	interleukin 1 receptor type 1	Homo sapiens	204-209
32633033-5	2020	Research has demonstrated improved response rates to platinum salts in BRCA-mutated compared with non-BRCA-mutated breast cancer, particularly in the metastatic setting.	Platinum	53-61	BRCA1 DNA repair associated	Homo sapiens	71-75
32587398-6	2020	We further evaluated HOXC10 expression in ESCC patients receiving adjuvant radiotherapy or platinum-based chemotherapy.	Platinum	91-99	homeobox C10	Homo sapiens	21-27
32558176-5	2020	Platinum-based therapy resulted in a reduced PFS (P = 0.02) and an induction of PIK3CA expression in CTCs AT.	Platinum	0-8	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Equus caballus	80-86
32953627-9	2020	More recently, the approach to secondary, tertiary, and later recurrence has been changed by the introduction of PARP inhibitors, which resulted effective as maintenance monotherapy in both platinum-sensitive and platinum-resistant recurrence when the genetic background of the tumor allows their application with a significant improvement of oncological outcomes.	Platinum	190-198	poly(ADP-ribose) polymerase 1	Homo sapiens	113-117
32953627-9	2020	More recently, the approach to secondary, tertiary, and later recurrence has been changed by the introduction of PARP inhibitors, which resulted effective as maintenance monotherapy in both platinum-sensitive and platinum-resistant recurrence when the genetic background of the tumor allows their application with a significant improvement of oncological outcomes.	Platinum	213-221	poly(ADP-ribose) polymerase 1	Homo sapiens	113-117
32922610-9	2020	PD-L1 rs2890658 C>A and rs822336 G>C are related to the prognoses of patients receiving platinum-based chemotherapy.	Platinum	88-96	CD274 molecule	Homo sapiens	0-5
32592097-8	2020	Pharmacological inhibition of ILK in KRAS mutant lung cancer cells suppresses cell growth, migration, EMT and increases sensitivity to platinum-based chemotherapy.	Platinum	135-143	integrin linked kinase	Mus musculus	30-33
32592097-8	2020	Pharmacological inhibition of ILK in KRAS mutant lung cancer cells suppresses cell growth, migration, EMT and increases sensitivity to platinum-based chemotherapy.	Platinum	135-143	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	37-41
32401088-6	2020	Taken together, we reported new ternary copper-based chalcogenide nanomaterials CuS-NiS2, which could be successfully applied for MRI-guided PT/PD therapy of gastric carcinoma through mitochondria-mediated apoptosis and MLKL/CAPG-mediated necroptosis.	Platinum	141-143	mixed lineage kinase domain like pseudokinase	Homo sapiens	220-224
32401088-6	2020	Taken together, we reported new ternary copper-based chalcogenide nanomaterials CuS-NiS2, which could be successfully applied for MRI-guided PT/PD therapy of gastric carcinoma through mitochondria-mediated apoptosis and MLKL/CAPG-mediated necroptosis.	Platinum	141-143	capping actin protein, gelsolin like	Homo sapiens	225-229
32419602-7	2020	This represents a relative increase of RE, FT and PT by 43.6%, 116.6% and 88.5%, respectively, in patients who received MT using STA.	Platinum	50-52	GCY	Homo sapiens	129-132
31828489-8	2020	The presence of metastatic disease and the use of platinum-based chemotherapy were strongly associated with CAT occurrence.	Platinum	50-58	catalase	Homo sapiens	108-111
32275806-9	2020	In 152 patients treated with platinum pooled from the three cohorts, the prognostic value of alterations in ATM as compared to other predefined DDR genes was substantially different (ATM: adjHR = 2.03, 95% CI 1.03-4, p = .04; other DDR: adjusted HR = 0.49, 95% CI 0.31-0.8, p = .003).	Platinum	29-37	ATM serine/threonine kinase	Homo sapiens	108-111
32275806-9	2020	In 152 patients treated with platinum pooled from the three cohorts, the prognostic value of alterations in ATM as compared to other predefined DDR genes was substantially different (ATM: adjHR = 2.03, 95% CI 1.03-4, p = .04; other DDR: adjusted HR = 0.49, 95% CI 0.31-0.8, p = .003).	Platinum	29-37	ATM serine/threonine kinase	Homo sapiens	183-186
32391581-9	2020	EXO70A2 also localized to the PT tip plasma membrane, consistent with a role in exocyst-mediated secretion.	Platinum	30-32	exocyst subunit exo70 family protein A2	Arabidopsis thaliana	0-7
32735623-8	2020	PFS-2/PPS medians gradually increased in monoCT, 2.6/5.1 months; polyCT 3.4/6.3 months; ramucirumab+CT, 4.1/6.5 months; platinum-reintroduction, 4.2/6.7 months, and for the HER2+ subgroup in particular, trastuzumab+CT, 5.2/11.7 months.	Platinum	120-128	GINS complex subunit 2	Homo sapiens	0-5
32735623-8	2020	PFS-2/PPS medians gradually increased in monoCT, 2.6/5.1 months; polyCT 3.4/6.3 months; ramucirumab+CT, 4.1/6.5 months; platinum-reintroduction, 4.2/6.7 months, and for the HER2+ subgroup in particular, trastuzumab+CT, 5.2/11.7 months.	Platinum	120-128	erb-b2 receptor tyrosine kinase 2	Homo sapiens	173-177
32751518-0	2020	Predicting the Role of DNA Polymerase beta Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy.	Platinum	109-117	DNA polymerase beta	Homo sapiens	23-42
32751518-2	2020	We prospectively investigate whether KRAS status and DNA polymerase beta expression could help identify patients responding to platinum compounds.	Platinum	127-135	KRAS proto-oncogene, GTPase	Homo sapiens	37-41
32751518-2	2020	We prospectively investigate whether KRAS status and DNA polymerase beta expression could help identify patients responding to platinum compounds.	Platinum	127-135	DNA polymerase beta	Homo sapiens	53-72
32751518-9	2020	KRAS may have a negative role in platinum-based therapy responses in NSCLC, but its impact is limited.	Platinum	33-41	KRAS proto-oncogene, GTPase	Homo sapiens	0-4
32751164-4	2020	The best morphology and, as a result, the highest sensitivity (~9960 microA/mM cm2) with respect to non-enzymatic determination of D-glucose were demonstrated by iridium-gold-platinum microstructures also showing low limit of detection (~0.12 microM), a wide linear range (0.5 microM-1 mM) along with good selectivity, reproducibility and stability.	Platinum	175-183	minichromosome maintenance complex component 2	Mus musculus	76-82
32884538-4	2020	Germline mutations in the BRCA1 and BRCA2 genes promote the incapacity of tumor cells to recover from DNA-accumulated damage caused by cytotoxic drugs, like platinum agents, and, most recently, through a diverse process by poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi).	Platinum	157-165	BRCA1 DNA repair associated	Homo sapiens	26-31
32884538-4	2020	Germline mutations in the BRCA1 and BRCA2 genes promote the incapacity of tumor cells to recover from DNA-accumulated damage caused by cytotoxic drugs, like platinum agents, and, most recently, through a diverse process by poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi).	Platinum	157-165	BRCA2 DNA repair associated	Homo sapiens	36-41
32724113-5	2020	The organoid that harboured the BRCA1 pathogenic variant (p.L63*) showed a higher sensitivity to PARP inhibitor, olaparib, as well as to platinum drugs compared to the other organoids, whereas an organoid derived from clear cell ovarian cancer was resistant to conventional drugs for ovarian cancer, namely platinum drugs, paclitaxel, and olaparib.	Platinum	137-145	BRCA1 DNA repair associated	Homo sapiens	32-37
32731632-4	2020	Low E-cadherin expression and high vimentin expression in all patient groups (as well as for E-cadherin in the platinum-resistant arm) were significantly associated with longer overall survival (OS).	Platinum	111-119	cadherin 1	Homo sapiens	93-103
32731632-5	2020	Low cytoplasmic OPN expression (and cytoplasmic and membrane OPN in the platinum-resistant arm) were significantly associated with longer OS.	Platinum	72-80	secreted phosphoprotein 1	Homo sapiens	61-64
32731632-10	2020	Nuclear OPN-c and cytoplasm OPN expression are putative predictive markers in platinum-resistant (PLD treated) ovarian cancer patients.	Platinum	78-86	secreted phosphoprotein 1	Homo sapiens	8-11
32724113-5	2020	The organoid that harboured the BRCA1 pathogenic variant (p.L63*) showed a higher sensitivity to PARP inhibitor, olaparib, as well as to platinum drugs compared to the other organoids, whereas an organoid derived from clear cell ovarian cancer was resistant to conventional drugs for ovarian cancer, namely platinum drugs, paclitaxel, and olaparib.	Platinum	307-315	BRCA1 DNA repair associated	Homo sapiens	32-37
32703189-14	2020	Exposure to PT resulted in the downregulation of anti-apoptotic proteins (Bcl2, BclxL, XIAP) and alteration in Cyclins expression.	Platinum	12-14	BCL2 apoptosis regulator	Homo sapiens	74-78
32720019-3	2020	This mono-immunotherapy approach for high PD-L1 metastatic NSCLC is associated with improved overall survival (OS) and radiological responses (RR) with lesser toxicity as compared with conventional platinum doublet chemotherapy for both non-squamous and squamous histological types.However, majority of NSCLC patients either have no or low expression of PD-L1 (< 50%) and such patients derive greater benefit from a combination of PD-1/PD-L1 ICIs with platinum doublet chemotherapy as compared with chemotherapy alone.	Platinum	452-460	CD274 molecule	Homo sapiens	42-47
32711554-10	2020	CONCLUSIONS: The digitalMLPA is a reliable method to detect a BRCA1- and BRCA2-like pattern on clinical samples and predicts platinum-based chemotherapy benefit in both triple-negative and luminal-type BC.	Platinum	125-133	BRCA1 DNA repair associated	Homo sapiens	62-67
32711554-10	2020	CONCLUSIONS: The digitalMLPA is a reliable method to detect a BRCA1- and BRCA2-like pattern on clinical samples and predicts platinum-based chemotherapy benefit in both triple-negative and luminal-type BC.	Platinum	125-133	BRCA2 DNA repair associated	Homo sapiens	73-78
32703189-14	2020	Exposure to PT resulted in the downregulation of anti-apoptotic proteins (Bcl2, BclxL, XIAP) and alteration in Cyclins expression.	Platinum	12-14	BCL2 like 1	Homo sapiens	80-85
32709856-0	2020	Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.	Platinum	64-72	collagen type XI alpha 2 chain	Homo sapiens	10-14
32703189-14	2020	Exposure to PT resulted in the downregulation of anti-apoptotic proteins (Bcl2, BclxL, XIAP) and alteration in Cyclins expression.	Platinum	12-14	X-linked inhibitor of apoptosis	Homo sapiens	87-91
32709856-0	2020	Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.	Platinum	64-72	ATR serine/threonine kinase	Homo sapiens	20-23
32703189-17	2020	Additionally, we show that PT-induced apoptosis was mediated by activating p38 MAPK and inhibiting AKT pathways.	Platinum	27-29	AKT serine/threonine kinase 1	Homo sapiens	99-102
32709856-4	2020	Sensitivity to PARPi-ATRi in diverse PARPi and platinum-resistant models, including BRCA1/2 reversion and CCNE1-amplified models, correlate with synergistic increases in replication fork stalling, double-strand breaks, and apoptosis.	Platinum	47-55	BRCA1 DNA repair associated	Homo sapiens	84-91
32656553-6	2020	Pt-TiN NTAs exhibited 15-fold higher mass activity towards HER than the benchmark 20 wt% Pt/C in acidic media, with an overpotential of 71 mV vs. RHE at a current density of 10 mA cm-2, a Tafel slope value of 46.4 mV dec-1 and excellent stability.	Platinum	0-2	deleted in esophageal cancer 1	Homo sapiens	217-222
32709856-4	2020	Sensitivity to PARPi-ATRi in diverse PARPi and platinum-resistant models, including BRCA1/2 reversion and CCNE1-amplified models, correlate with synergistic increases in replication fork stalling, double-strand breaks, and apoptosis.	Platinum	47-55	cyclin E1	Homo sapiens	106-111
32124602-6	2020	While CID of mass-selected [Au,Pt,(PPh3)4]+ results exclusively in the loss of PPh3, the resulting cation [Au,Pt,(PPh3)3]+ selectively eliminates C6H6.	Platinum	31-33	protein phosphatase 4 catalytic subunit	Homo sapiens	79-83
32124602-6	2020	While CID of mass-selected [Au,Pt,(PPh3)4]+ results exclusively in the loss of PPh3, the resulting cation [Au,Pt,(PPh3)3]+ selectively eliminates C6H6.	Platinum	110-112	protein phosphatase 4 catalytic subunit	Homo sapiens	79-83
32124602-6	2020	While CID of mass-selected [Au,Pt,(PPh3)4]+ results exclusively in the loss of PPh3, the resulting cation [Au,Pt,(PPh3)3]+ selectively eliminates C6H6.	Platinum	31-33	protein phosphatase 4 catalytic subunit	Homo sapiens	79-83
32124602-7	2020	Thus, the dissociation of a PPh3 ligand from [Au,Pt,(PPh3)3]+ is energetically not able to compete with processes which result in C-H- and C-P-bond cleavage.	Platinum	49-51	protein phosphatase 4 catalytic subunit	Homo sapiens	28-32
32124602-6	2020	While CID of mass-selected [Au,Pt,(PPh3)4]+ results exclusively in the loss of PPh3, the resulting cation [Au,Pt,(PPh3)3]+ selectively eliminates C6H6.	Platinum	110-112	protein phosphatase 4 catalytic subunit	Homo sapiens	79-83
32695401-1	2020	Advanced granulocyte colony-stimulating factor (G-CSF)-producing lung tumours are generally refractory to platinum-based chemotherapy and are associated with poor prognosis.	Platinum	106-114	colony stimulating factor 3	Homo sapiens	9-46
32832640-3	2020	The second mimicked functionality is that of catalase by incorporation of Pt nanoparticles, which catalyze hydrogen peroxide disproportionation to water and oxygen.	Platinum	74-76	catalase	Homo sapiens	45-53
32695401-1	2020	Advanced granulocyte colony-stimulating factor (G-CSF)-producing lung tumours are generally refractory to platinum-based chemotherapy and are associated with poor prognosis.	Platinum	106-114	colony stimulating factor 3	Homo sapiens	48-53
32341033-0	2020	DGKA provides platinum resistance in ovarian cancer through activation of cJUN-WEE1 signaling.	Platinum	14-22	diacylglycerol kinase alpha	Homo sapiens	0-4
32341033-0	2020	DGKA provides platinum resistance in ovarian cancer through activation of cJUN-WEE1 signaling.	Platinum	14-22	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	74-78
32341033-0	2020	DGKA provides platinum resistance in ovarian cancer through activation of cJUN-WEE1 signaling.	Platinum	14-22	WEE1 G2 checkpoint kinase	Homo sapiens	79-83
32341033-3	2020	The goal of our study is to decipher the mechanism by which a metabolic kinase, diacylglycerol kinase alpha (DGKA), confers platinum resistance in ovarian cancer.	Platinum	124-132	diacylglycerol kinase alpha	Homo sapiens	80-107
32341033-3	2020	The goal of our study is to decipher the mechanism by which a metabolic kinase, diacylglycerol kinase alpha (DGKA), confers platinum resistance in ovarian cancer.	Platinum	124-132	diacylglycerol kinase alpha	Homo sapiens	109-113
32341033-7	2020	Therapeutic efficacy of targeting DGKA was confirmed and clinical relevance of DGKA signaling was validated using ovarian cancer patient-derived tumors that had different responses to platinum-based therapy.	Platinum	184-192	diacylglycerol kinase alpha	Homo sapiens	79-83
32341033-8	2020	RESULTS: We found that platinum resistance was mediated by DGKA and its product, phosphatidic acid (PA), in ovarian cancer.	Platinum	23-31	diacylglycerol kinase alpha	Homo sapiens	59-63
32341033-11	2020	Pharmacological inhibition of DGKA sensitized ovarian cancer cells to cisplatin treatment and DGKA-c-JUN-WEE1 signaling positively correlated with platinum resistance in tumors derived from ovarian cancer patients.	Platinum	147-155	diacylglycerol kinase alpha	Homo sapiens	30-34
32341033-11	2020	Pharmacological inhibition of DGKA sensitized ovarian cancer cells to cisplatin treatment and DGKA-c-JUN-WEE1 signaling positively correlated with platinum resistance in tumors derived from ovarian cancer patients.	Platinum	147-155	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	99-104
32341033-11	2020	Pharmacological inhibition of DGKA sensitized ovarian cancer cells to cisplatin treatment and DGKA-c-JUN-WEE1 signaling positively correlated with platinum resistance in tumors derived from ovarian cancer patients.	Platinum	147-155	WEE1 G2 checkpoint kinase	Homo sapiens	105-109
32646443-4	2020	In inoperable Stage III NSCLC, consolidation immune checkpoint inhibition with the PD-L1 inhibitor durvalumab after completion of concurrent platinum-based chemoradiotherapy resulted in remarkable improvement of progression-free and overall survival.	Platinum	141-149	CD274 molecule	Homo sapiens	83-88
32679669-8	2020	Tumors with BRCA mutations are unable to repair double-strand DNA breaks, making them more sensitive to platinum-based chemotherapy and to PolyAdenosine Diphosphate-Ribose Polymerase (PARP) inhibitors.	Platinum	104-112	BRCA1 DNA repair associated	Homo sapiens	12-16
32428406-5	2020	Through benchmark studies of AuCl4-, Pt(CN)42-, and Mo(CN)83-, we discuss how relativistic effects are manifested in MCD for both closed-shell and open-shell molecular complexes and how the interplay between spin-orbit coupling and magnetic field modulates the MCD selection rules.	Platinum	37-39	malonyl-CoA decarboxylase	Homo sapiens	117-120
32668597-9	2020	Taken together, these results suggest that smoking-mediated upregulation of miR-216b increases NSCLC cell growth by downregulating Smad3 and inhibiting TGF-beta-induced tumor suppressor function, and induces resistance to platinum-based therapy.	Platinum	222-230	microRNA 216b	Homo sapiens	76-84
32742474-7	2020	Conclusion: Our findings suggest that the MSH2 rs4608577 and SAPCD1 rs707937 may be potential clinical biomarkers for predicting platinum-based chemotherapy prognosis in lung cancer patients.	Platinum	129-137	mutS homolog 2	Homo sapiens	42-46
32742474-7	2020	Conclusion: Our findings suggest that the MSH2 rs4608577 and SAPCD1 rs707937 may be potential clinical biomarkers for predicting platinum-based chemotherapy prognosis in lung cancer patients.	Platinum	129-137	suppressor APC domain containing 1	Homo sapiens	61-67
32995127-0	2020	Porous Pt Nanospheres Incorporated with GOx to Enable Synergistic Oxygen-Inductive Starvation/Electrodynamic Tumor Therapy.	Platinum	7-9	hydroxyacid oxidase 1	Homo sapiens	40-43
32555914-4	2020	Pt-1 showed an enhanced spin-orbit coupling (SOC), caused by the additional metal component through direct orbital hybridization at higher states, where the fixed molecular skeleton induced by the additional metal-ligand bonding also helped to suppress molecular distortion in the excited state, ensuring a high quantum yield (Phi, 0.89 in toluene), which is among the best results in bimetallic complexes.	Platinum	0-2	spindlin 1	Homo sapiens	24-28
32459232-2	2020	Here, as a conceptionally novel simplified option, pure gelatin thin films with covalently attached GOx were used to convert platinum (Pt) disk electrodes into rapidly responding amperometric glucose probes with a sub-micromolar limit of detection.	Platinum	125-133	hydroxyacid oxidase 1	Homo sapiens	100-103
32670420-0	2020	Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy.	Platinum	136-144	programmed cell death 1	Homo sapiens	23-27
32670420-10	2020	Conclusion: PD-1/PD-L1 inhibitor plus nab-paclitaxel resulted in significantly longer OS and higher response versus ICI single agent in metastatic NSCLC patients who have progressed after platinum-based chemotherapy.	Platinum	188-196	programmed cell death 1	Homo sapiens	12-16
32670420-10	2020	Conclusion: PD-1/PD-L1 inhibitor plus nab-paclitaxel resulted in significantly longer OS and higher response versus ICI single agent in metastatic NSCLC patients who have progressed after platinum-based chemotherapy.	Platinum	188-196	CD274 molecule	Homo sapiens	17-22
32459232-2	2020	Here, as a conceptionally novel simplified option, pure gelatin thin films with covalently attached GOx were used to convert platinum (Pt) disk electrodes into rapidly responding amperometric glucose probes with a sub-micromolar limit of detection.	Platinum	135-137	hydroxyacid oxidase 1	Homo sapiens	100-103
32558573-3	2020	In this letter, we report a new approach to controlling the efficiency of spin current injection into a Pt layer across a Pt/Y3Fe5O12 (YIG) interface by surface coverage of the intermediate layer.	Platinum	104-106	spindlin 1	Homo sapiens	74-78
32753889-6	2020	Nonsynonymous variants in EGFR, TTN, TP53 and KRAS, and copy number variations (SCNVs) in chromosome 8q24.3 and 22q11.21 were identified to be associated with platinum response.	Platinum	159-167	epidermal growth factor receptor	Homo sapiens	26-30
32753889-6	2020	Nonsynonymous variants in EGFR, TTN, TP53 and KRAS, and copy number variations (SCNVs) in chromosome 8q24.3 and 22q11.21 were identified to be associated with platinum response.	Platinum	159-167	titin	Homo sapiens	32-35
32753889-6	2020	Nonsynonymous variants in EGFR, TTN, TP53 and KRAS, and copy number variations (SCNVs) in chromosome 8q24.3 and 22q11.21 were identified to be associated with platinum response.	Platinum	159-167	tumor protein p53	Homo sapiens	37-41
32753889-6	2020	Nonsynonymous variants in EGFR, TTN, TP53 and KRAS, and copy number variations (SCNVs) in chromosome 8q24.3 and 22q11.21 were identified to be associated with platinum response.	Platinum	159-167	KRAS proto-oncogene, GTPase	Homo sapiens	46-50
32635291-9	2020	In conclusion, PD-(L)1 blockade added to standard platinum-based chemotherapy significantly improved PFS, OS, and ORR in the up-front treatment of advanced NSCLC.	Platinum	50-58	CD274 molecule	Homo sapiens	15-22
32558573-3	2020	In this letter, we report a new approach to controlling the efficiency of spin current injection into a Pt layer across a Pt/Y3Fe5O12 (YIG) interface by surface coverage of the intermediate layer.	Platinum	122-124	spindlin 1	Homo sapiens	74-78
32037007-3	2020	Here, we developed a cyclic Arg-Gly-Asp-Phe-Lys peptide (cRGD) modified and near-infrared (NIR) light triggered disintegratable liposomal nanoplatform (PAM/Pt@IcLipo), where photosensitizer indocyanine green (ICG) was loaded in the out layer and polyamindoamine (PAMAM) dendrimers grafting cisplatin prodrug (PAM/Pt) were encapsulated inside.	Platinum	313-315	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	152-155
32711417-0	2020	ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.	Platinum	121-129	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
32711417-0	2020	ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.	Platinum	121-129	glutathione S-transferase pi 1	Homo sapiens	18-23
32711417-3	2020	Methods: We conducted the study to investigate the association between polymorphisms of ERCC1, XRCC1 and GSTP1, which responsible for platinum"s metabolisms in Thai epithelial ovarian cancer patients.	Platinum	134-142	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	88-93
32037007-6	2020	When irradiated by NIR light locally at tumor site, ICG heating detonated the thermosensitive liposomes to release the small sized PAM/Pt nanoparticles (~8.6 nm), which were capable of penetrating into the deep tumor tissue.	Platinum	135-137	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	131-134
32711417-3	2020	Methods: We conducted the study to investigate the association between polymorphisms of ERCC1, XRCC1 and GSTP1, which responsible for platinum"s metabolisms in Thai epithelial ovarian cancer patients.	Platinum	134-142	X-ray repair cross complementing 1	Homo sapiens	95-100
32711417-3	2020	Methods: We conducted the study to investigate the association between polymorphisms of ERCC1, XRCC1 and GSTP1, which responsible for platinum"s metabolisms in Thai epithelial ovarian cancer patients.	Platinum	134-142	glutathione S-transferase pi 1	Homo sapiens	105-110
32711417-6	2020	Patients with homozygous variant type (A/A) of ERCC1 C8092A had higher rate of platinum-resistance (75% vs 16.7%, p =0.046).	Platinum	79-87	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
32711417-9	2020	CONCLUSIONS: Genetic polymorphisms of ERCC1, and GSTP1 might be useful biomarkers for prediction of clinical benefit and toxicities of platinum-based chemotherapy in Thai epithelial ovarian cancer patients.<br />.	Platinum	135-143	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	38-43
32037007-7	2020	The in vivo results also showed that the PAM/Pt@IcLipo could significantly improve the penetration of cisplatin drug in deep tumor tissues under NIR light irradiation, resulting in an excellent antitumor activity.	Platinum	45-47	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	41-44
32711417-9	2020	CONCLUSIONS: Genetic polymorphisms of ERCC1, and GSTP1 might be useful biomarkers for prediction of clinical benefit and toxicities of platinum-based chemotherapy in Thai epithelial ovarian cancer patients.<br />.	Platinum	135-143	glutathione S-transferase pi 1	Homo sapiens	49-54
32060098-0	2020	The DNA cytosine deaminase APOBEC3B is a molecular determinant of platinum responsiveness in clear cell ovarian cancer.	Platinum	66-74	apolipoprotein B mRNA editing enzyme catalytic subunit 3B	Homo sapiens	27-35
32415892-2	2020	Conventional anticancer drugs, such as alkylating agents and platinum compounds, have been used for the treatment of high-risk patients with MYCN-amplified neuroblastoma, whereas molecule-targeting drugs have not yet been approved.	Platinum	61-69	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	141-145
32060098-13	2020	Thus, APOBEC3B is a molecular determinant and a candidate predictive biomarker of the therapeutic response to platinum-based chemotherapy.	Platinum	110-118	apolipoprotein B mRNA editing enzyme catalytic subunit 3B	Homo sapiens	6-14
32321768-0	2020	Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.	Platinum	23-31	poly(ADP-ribose) polymerase 1	Homo sapiens	165-191
31970720-0	2020	Overexpression of YES1 is associated with favorable prognosis and increased platinum-sensitivity in patients with epithelial ovarian cancer.	Platinum	76-84	YES proto-oncogene 1, Src family tyrosine kinase	Homo sapiens	18-22
31970720-10	2020	Notably, within the high YES1 expression group, 40 cases (74.1%) were of the platinum-sensitive group while 14 (25.9%) overlapped were of the platinum-resistant group.	Platinum	77-85	YES proto-oncogene 1, Src family tyrosine kinase	Homo sapiens	25-29
31970720-10	2020	Notably, within the high YES1 expression group, 40 cases (74.1%) were of the platinum-sensitive group while 14 (25.9%) overlapped were of the platinum-resistant group.	Platinum	142-150	YES proto-oncogene 1, Src family tyrosine kinase	Homo sapiens	25-29
31970720-11	2020	Conversely, in the low YES1 expression group, 11 cases (47.8%) were platinum-sensitive, and 12 (52.2%) platinum-resistant.	Platinum	68-76	YES proto-oncogene 1, Src family tyrosine kinase	Homo sapiens	23-27
31970720-12	2020	Overall, patients within the high YES1 expression group were deemed significantly more sensitive to platinum-based chemotherapy than the low YES1 expression group (P=0.03), and YES1 levels were consistently and significantly higher in the platinum-sensitive group.	Platinum	100-108	YES proto-oncogene 1, Src family tyrosine kinase	Homo sapiens	34-38
31970720-12	2020	Overall, patients within the high YES1 expression group were deemed significantly more sensitive to platinum-based chemotherapy than the low YES1 expression group (P=0.03), and YES1 levels were consistently and significantly higher in the platinum-sensitive group.	Platinum	239-247	YES proto-oncogene 1, Src family tyrosine kinase	Homo sapiens	34-38
31970720-12	2020	Overall, patients within the high YES1 expression group were deemed significantly more sensitive to platinum-based chemotherapy than the low YES1 expression group (P=0.03), and YES1 levels were consistently and significantly higher in the platinum-sensitive group.	Platinum	239-247	YES proto-oncogene 1, Src family tyrosine kinase	Homo sapiens	141-145
31970720-12	2020	Overall, patients within the high YES1 expression group were deemed significantly more sensitive to platinum-based chemotherapy than the low YES1 expression group (P=0.03), and YES1 levels were consistently and significantly higher in the platinum-sensitive group.	Platinum	239-247	YES proto-oncogene 1, Src family tyrosine kinase	Homo sapiens	141-145
31970720-14	2020	Patients with high YES1 expression tend to be sensitive to platinum-based chemotherapy.	Platinum	59-67	YES proto-oncogene 1, Src family tyrosine kinase	Homo sapiens	19-23
32552213-1	2020	Introduction: In December 2019, the US Food and Drug Administration granted accelerated approval to the novel nectin-4-targeting antibody-drug conjugate, enfortumab vedotin, for the treatment of platinum-refractory and immune checkpoint blockade-refractory locally advanced or metastatic urothelial carcinoma.	Platinum	195-203	nectin cell adhesion molecule 4	Homo sapiens	110-118
32321768-1	2020	INTRODUCTION: The introduction of poly-ADP ribose polymerase inhibitors in ovarian cancer has demonstrated significantly improved progression free survival in four randomized controlled clinical trials in patients with platinum sensitive relapsed ovarian cancer.	Platinum	219-227	poly(ADP-ribose) polymerase 1	Homo sapiens	34-60
32527769-7	2020	PD-L1-positive expression was observed in 50.5% of patients and associated with more advanced stage (p=0.047), more aggressive histologic subtype (p=0.001), and platinum sensitivity defined by increasing treatment-free interval from first platinum-based chemotherapy to next systemic treatment (p=0.027).	Platinum	161-169	CD274 molecule	Homo sapiens	0-5
32527769-7	2020	PD-L1-positive expression was observed in 50.5% of patients and associated with more advanced stage (p=0.047), more aggressive histologic subtype (p=0.001), and platinum sensitivity defined by increasing treatment-free interval from first platinum-based chemotherapy to next systemic treatment (p=0.027).	Platinum	239-247	CD274 molecule	Homo sapiens	0-5
32601814-7	2020	How to move forward the preclinical promise of these newer DDR-targeting therapies into rational clinical trial combinations and sequence PARP inhibitors in relation to platinum chemotherapy remain areas of tremendous clinical research interest.	Platinum	169-177	poly(ADP-ribose) polymerase 1	Homo sapiens	138-142
32336530-6	2020	Median progression-free survival (PFS) was significantly longer in patients who received first-line platinum-based chemotherapy (6.4 m; 95 % CI: 5.7-7.1) than all-generation EGFR TKIs (2.9 m; 95 %CI: 1.5-4.3; P < 0.001) or 1st-generation EGFR TKIs (2.0 m; 95 %CI: 0.2-3.8; P < 0.001).	Platinum	100-108	epidermal growth factor receptor	Homo sapiens	238-242
32543783-1	2020	This study aims to explore lipidic mechanism towards low-density lipoprotein receptor (LDLR)-mediated platinum chemotherapy resistance.	Platinum	102-110	low density lipoprotein receptor	Homo sapiens	53-85
32543783-1	2020	This study aims to explore lipidic mechanism towards low-density lipoprotein receptor (LDLR)-mediated platinum chemotherapy resistance.	Platinum	102-110	low density lipoprotein receptor	Homo sapiens	87-91
32543783-6	2020	Moreover, LDLR knockdown increased the number of platinum-DNA adducts and reduced the LD platinum amount.	Platinum	49-57	low density lipoprotein receptor	Homo sapiens	10-14
32543783-6	2020	Moreover, LDLR knockdown increased the number of platinum-DNA adducts and reduced the LD platinum amount.	Platinum	89-97	low density lipoprotein receptor	Homo sapiens	10-14
32543783-13	2020	Thus, LDLR-platinum insensitivity can be due to a defective Lands cycle that hinders LPC production in LDs.	Platinum	11-19	low density lipoprotein receptor	Homo sapiens	6-10
32594094-0	2020	Down-Regulation of the Mammalian Target of Rapamycin (mTOR) Pathway Mediates the Effects of the Paeonol-Platinum(II) Complex in Human Thyroid Carcinoma Cells and Mouse SW1736 Tumor Xenografts.	Platinum	104-112	mechanistic target of rapamycin kinase	Homo sapiens	23-52
32594094-0	2020	Down-Regulation of the Mammalian Target of Rapamycin (mTOR) Pathway Mediates the Effects of the Paeonol-Platinum(II) Complex in Human Thyroid Carcinoma Cells and Mouse SW1736 Tumor Xenografts.	Platinum	104-112	mechanistic target of rapamycin kinase	Homo sapiens	54-58
32484216-2	2020	14-3-3 proteins are gold-standard scaffold modules that recognize phosphoSer/Thr (pS/pT) containing conserved motifs, and confer conformational changes leading to modulation of functional parameters of their target proteins.	Platinum	85-87	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta	Homo sapiens	0-6
32383328-0	2020	Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.	Platinum	123-131	CEA cell adhesion molecule 3	Homo sapiens	37-40
32383328-2	2020	The objective of this study was to investigate carcinoembryonic antigen (CEA) and lactate dehydrogenase (LDH) as biomarkers for early assessment of response in patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy.	Platinum	231-239	CEA cell adhesion molecule 3	Homo sapiens	47-71
32383328-8	2020	CONCLUSIONS: Our results support determination of CEA and LDH levels for earlier assessment of response to platinum-based chemotherapy in patients with advanced NSCLC.	Platinum	107-115	CEA cell adhesion molecule 3	Homo sapiens	50-53
32500904-0	2020	Heterobimetallic mu2-carbido complexes of platinum and tungsten.	Platinum	42-50	adaptor related protein complex 1 subunit mu 2	Homo sapiens	17-20
32585842-11	2020	Overall, the results suggest that the association of standard drugs, such as cDDP and/or 5-FU and/or RTX, with the novel peptidic TS inhibitor encapsulated into PEGylated pH-sensitive liposomes can represent a promising strategy for fighting resistance to cDDP and anti-hTS drugs.	Platinum	77-81	APC down-regulated 1	Homo sapiens	130-132
32655639-9	2020	Our study confirmed efficacy and safety of olaparib as the maintenance therapy of BRCA 1-2 mutated, platinum-sensitive, recurrent ovarian carcinoma.	Platinum	100-108	BRCA1 DNA repair associated	Homo sapiens	82-90
32585842-11	2020	Overall, the results suggest that the association of standard drugs, such as cDDP and/or 5-FU and/or RTX, with the novel peptidic TS inhibitor encapsulated into PEGylated pH-sensitive liposomes can represent a promising strategy for fighting resistance to cDDP and anti-hTS drugs.	Platinum	256-260	APC down-regulated 1	Homo sapiens	130-132
32575908-2	2020	In terms of maintenance therapies after platinum-based chemotherapy, PARP inhibitors significantly improve the overall survival of patients with BRCA mutations but is of little benefit to patients without homologous recombination deficiency (HRD).	Platinum	40-48	poly(ADP-ribose) polymerase 1	Homo sapiens	69-73
32704405-15	2020	In addition, the 64CuCl2 uptake is based on the expression of Ctr1 transporters seeking to differentiate between those patients who may benefit from platinum-based therapy.	Platinum	149-157	solute carrier family 31 member 1	Homo sapiens	62-66
32612955-15	2020	BRCA mutation, HRD-positive status, and sensitivity to platinum are effective prognostic factors for the efficacy of PARP inhibitors.	Platinum	55-63	poly(ADP-ribose) polymerase 1	Homo sapiens	117-121
32596455-0	2020	High-loading single Pt atom sites [Pt-O(OH) x ] catalyze the CO PROX reaction with high activity and selectivity at mild conditions.	Platinum	20-22	pyruvate dehydrogenase complex component X	Homo sapiens	64-68
32596455-0	2020	High-loading single Pt atom sites [Pt-O(OH) x ] catalyze the CO PROX reaction with high activity and selectivity at mild conditions.	Platinum	35-37	pyruvate dehydrogenase complex component X	Homo sapiens	64-68
32541668-8	2020	Mechanistically, BAP1 regulates genomic stability, in a catalytic independent manner, and its loss confers sensitivity to irradiation and platinum-based chemotherapy in pancreatic cancer.	Platinum	138-146	Brca1 associated protein 1	Mus musculus	17-21
32596618-2	2020	Herein, we used insulin amyloid fibrils as templates and their own one-dimensional spiral structure to synthesize Pt-Rh-Pd ternary alloy nanochains under mild conditions.	Platinum	114-116	insulin	Homo sapiens	16-23
32459494-3	2020	Here, we report the detection of the spin-Hall topological Hall effect (SH-THE) in Pt/Tm3Fe5O12 and Pt/Y3Fe5O12 bilayers grown on various orientations of Gd3Ga5O12 substrates as well as on epitaxial buffer layers of Y3Sc2Al3O12, which separates the FMI from the substrate without sacrificing the crystal quality.	Platinum	83-85	spindlin 1	Homo sapiens	37-41
32484164-0	2020	Ginkgolide-Platinum(II) Complex GPt(II) Exhibits Therapeutic Effect on Depression in Mice via Upregulation of DA and 5-HT Neurotransmitters.	Platinum	11-19	glutamic pyruvic transaminase, soluble	Mus musculus	32-35
32142859-2	2020	We recently reported a pulsatile nature of IGF1R during acquirement of platinum-taxol resistance in Epithelial Ovarian Cancer (EOC) cells and a therapy induced upregulation in IGF1R expression in tumors of a small cohort of high grade serous EOC patients.	Platinum	71-79	insulin like growth factor 1 receptor	Homo sapiens	43-48
32642416-6	2020	In addition, Pt-CUR@PSPPN blocked PI3K/AKT signal transduction pathway and inhibited MMP2 and VEGFR2, resulting in enhanced anti-metastatic activity.	Platinum	13-15	kinase insert domain receptor	Homo sapiens	94-100
32071115-1	2020	PURPOSE: Prostate cancers with mutations in genes involved in homologous recombination (HR), most commonly BRCA2, respond favorably to PARP inhibition and platinum-based chemotherapy.	Platinum	155-163	BRCA2 DNA repair associated	Homo sapiens	107-112
32642416-6	2020	In addition, Pt-CUR@PSPPN blocked PI3K/AKT signal transduction pathway and inhibited MMP2 and VEGFR2, resulting in enhanced anti-metastatic activity.	Platinum	13-15	AKT serine/threonine kinase 1	Homo sapiens	39-42
32642416-6	2020	In addition, Pt-CUR@PSPPN blocked PI3K/AKT signal transduction pathway and inhibited MMP2 and VEGFR2, resulting in enhanced anti-metastatic activity.	Platinum	13-15	matrix metallopeptidase 2	Homo sapiens	85-89
32774215-12	2020	Dose-dense schedules as well as platinum should be considered in the NACT setting.	Platinum	32-40	solute carrier family 13 member 5	Homo sapiens	69-73
32034076-2	2020	Acquired reversions can restore BRCA1/2 function, causing resistance to PARPi and/or platinum-based chemotherapy.	Platinum	85-93	BRCA1 DNA repair associated	Homo sapiens	32-39
32034076-9	2020	Serial cfDNA demonstrated emergence of reversion BRCA mutations under therapeutic pressure from initial PARPi exposure which contributed to subsequent resistance to PARPi and platinum therapy.	Platinum	175-183	BRCA1 DNA repair associated	Homo sapiens	49-53
32142859-3	2020	Here, we report Runt-related transcription factor 1 (RUNX1) as a novel transcriptional regulator which along with another known regulator Forkhead Box O3 (FOXO3a), drives the dynamic modulation of IGF1R expression during platinum-taxol resistance development in EOC cells.	Platinum	221-229	RUNX family transcription factor 1	Homo sapiens	16-51
32142859-3	2020	Here, we report Runt-related transcription factor 1 (RUNX1) as a novel transcriptional regulator which along with another known regulator Forkhead Box O3 (FOXO3a), drives the dynamic modulation of IGF1R expression during platinum-taxol resistance development in EOC cells.	Platinum	221-229	RUNX family transcription factor 1	Homo sapiens	53-58
32142859-3	2020	Here, we report Runt-related transcription factor 1 (RUNX1) as a novel transcriptional regulator which along with another known regulator Forkhead Box O3 (FOXO3a), drives the dynamic modulation of IGF1R expression during platinum-taxol resistance development in EOC cells.	Platinum	221-229	forkhead box O3	Homo sapiens	138-153
32142859-3	2020	Here, we report Runt-related transcription factor 1 (RUNX1) as a novel transcriptional regulator which along with another known regulator Forkhead Box O3 (FOXO3a), drives the dynamic modulation of IGF1R expression during platinum-taxol resistance development in EOC cells.	Platinum	221-229	forkhead box O3	Homo sapiens	155-161
32142859-3	2020	Here, we report Runt-related transcription factor 1 (RUNX1) as a novel transcriptional regulator which along with another known regulator Forkhead Box O3 (FOXO3a), drives the dynamic modulation of IGF1R expression during platinum-taxol resistance development in EOC cells.	Platinum	221-229	insulin like growth factor 1 receptor	Homo sapiens	197-202
32468256-1	2020	Resistance can be the result of secondary tissue variants (STVs), which restore the open reading frame of the germline BRCA allele, producing functional BRCA protein in germline BRCA1/2 (BRCA) pathogenic variant (PV) carriers, treated with platinum-based chemotherapy or poly-(ADP-ribose) polymerase inhibitors (PARP-1).	Platinum	240-248	BRCA1 DNA repair associated	Homo sapiens	119-123
32468256-1	2020	Resistance can be the result of secondary tissue variants (STVs), which restore the open reading frame of the germline BRCA allele, producing functional BRCA protein in germline BRCA1/2 (BRCA) pathogenic variant (PV) carriers, treated with platinum-based chemotherapy or poly-(ADP-ribose) polymerase inhibitors (PARP-1).	Platinum	240-248	BRCA1 DNA repair associated	Homo sapiens	153-157
32468256-1	2020	Resistance can be the result of secondary tissue variants (STVs), which restore the open reading frame of the germline BRCA allele, producing functional BRCA protein in germline BRCA1/2 (BRCA) pathogenic variant (PV) carriers, treated with platinum-based chemotherapy or poly-(ADP-ribose) polymerase inhibitors (PARP-1).	Platinum	240-248	BRCA1 DNA repair associated	Homo sapiens	153-157
32289483-3	2020	Herein, we designed the protein-drug conjugate HSAP-DC-CAT (human serum albumin/Pt (IV)-dibenzocyclooctyne/chlorin e6-catalase) by modification of CAT and cisplatin pro-drug loaded HSA with pH-sensitive azide linker 3-(azidomethyl)-4-methyl-2,5-furandione (AzMMMan) followed by click chemistry assembly with DC.	Platinum	80-82	mutS homolog 6	Homo sapiens	47-51
32289483-3	2020	Herein, we designed the protein-drug conjugate HSAP-DC-CAT (human serum albumin/Pt (IV)-dibenzocyclooctyne/chlorin e6-catalase) by modification of CAT and cisplatin pro-drug loaded HSA with pH-sensitive azide linker 3-(azidomethyl)-4-methyl-2,5-furandione (AzMMMan) followed by click chemistry assembly with DC.	Platinum	80-82	catalase	Homo sapiens	55-58
32289483-3	2020	Herein, we designed the protein-drug conjugate HSAP-DC-CAT (human serum albumin/Pt (IV)-dibenzocyclooctyne/chlorin e6-catalase) by modification of CAT and cisplatin pro-drug loaded HSA with pH-sensitive azide linker 3-(azidomethyl)-4-methyl-2,5-furandione (AzMMMan) followed by click chemistry assembly with DC.	Platinum	80-82	albumin	Homo sapiens	66-79
32289483-3	2020	Herein, we designed the protein-drug conjugate HSAP-DC-CAT (human serum albumin/Pt (IV)-dibenzocyclooctyne/chlorin e6-catalase) by modification of CAT and cisplatin pro-drug loaded HSA with pH-sensitive azide linker 3-(azidomethyl)-4-methyl-2,5-furandione (AzMMMan) followed by click chemistry assembly with DC.	Platinum	80-82	catalase	Homo sapiens	147-150
32471249-2	2020	In this setting, PARP inhibitors, either as single agent or in combination with platinum-based chemotherapy, significantly increased progression-free survival, as compared to conventional chemotherapy.	Platinum	80-88	poly(ADP-ribose) polymerase 1	Homo sapiens	17-21
32471250-0	2020	Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.	Platinum	55-63	poly(ADP-ribose) polymerase 1	Homo sapiens	15-19
32455721-1	2020	Porous Pt electrocatalysts have been developed as an example of carbon-free porous metal catalysts in anticipation of polymer electrolyte membrane (PEM) fuel cells and PEM water electrolyzers through the assembly of the metal precursor and surfactant.	Platinum	7-9	mucin 1, cell surface associated	Homo sapiens	148-151
32374154-2	2020	However, the prevalent industrial PDH catalyst, Pt-Sn, suffers from not only the high costs of Pt, but also fast deactivation triggered by sintering of Pt species.	Platinum	48-50	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	34-37
32528530-14	2020	Thus our findings suggest that inter individual variability in platinum based therapy may be anticipated by MDR1 genotypes.	Platinum	63-71	ATP binding cassette subfamily B member 1	Homo sapiens	108-112
32455721-1	2020	Porous Pt electrocatalysts have been developed as an example of carbon-free porous metal catalysts in anticipation of polymer electrolyte membrane (PEM) fuel cells and PEM water electrolyzers through the assembly of the metal precursor and surfactant.	Platinum	7-9	mucin 1, cell surface associated	Homo sapiens	168-171
32477008-10	2020	KEGG analysis showed that the 28 differently expressed autophagy-related genes were related to platinum drug resistance, apoptosis and p53 signaling pathway.	Platinum	95-103	tumor protein p53	Homo sapiens	135-138
32309921-5	2020	The mass peak current density for EOR and MOR of Pd43Ag21Pt36 is 7.08 / 3.50 times of Pt/C catalyst.	Platinum	57-59	opioid receptor mu 1	Homo sapiens	42-45
32438598-1	2020	The expression of microRNA (miR)-21, miR-128, miR-155, and miR-181a involved in DNA damage response (DDR) and tumor responsiveness to platinum was assessed by RT-qPCR in the plasma of patients with non-small cell lung cancer (NSCLC; n = 128) obtained prior to initiation of first-line platinum chemotherapy.	Platinum	134-142	microRNA 21	Homo sapiens	18-35
32438598-11	2020	Our study shows for the first time that plasma miR-128 and miR-155 hold independent prognostic implications in NSCLC patients treated with platinum-based chemotherapy possibly related to their involvement in tumor response to hypoxia.	Platinum	139-147	microRNA 155	Homo sapiens	59-66
32547317-4	2020	The current study is to investigate the possible mechanisms of platinum-resistance in epithelial ovarian cancer mediated by Notch1.	Platinum	63-71	notch receptor 1	Homo sapiens	124-130
32547356-13	2020	beta-Arrestin-2 was required for the protective action of AP9 in PT-induced brain ischemia.	Platinum	65-67	arrestin, beta 2	Mus musculus	0-15
32310665-6	2020	The influence of the SiO2 and Pt substrates was observed not only at the BAF-QAF/substrate interface, but also on the entire thin film.	Platinum	30-32	BAF nuclear assembly factor 1	Homo sapiens	73-76
32310665-8	2020	The BAF-QAF/SiO2 interface was rather hydrophilic, while the BAF-QAF/Pt interface was very hydrophobic.	Platinum	69-71	BAF nuclear assembly factor 1	Homo sapiens	61-64
32509491-6	2020	The same Ni/CTF-1-600 material shows a half-wave potential of 0.775 V for ORR, which is slightly lower than that of commercial Pt/C (0.890 V).	Platinum	127-129	cardiotrophin 1	Homo sapiens	12-17
32150489-1	2020	PURPOSE: In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) expression.	Platinum	66-74	CD274 molecule	Homo sapiens	301-326
32097092-1	2020	PURPOSE: Platinum compounds have activity in triple-negative breast cancer (TNBC) in germline BRCA mutation carriers (BRCA carriers).	Platinum	9-17	BRCA1 DNA repair associated	Homo sapiens	94-98
32097092-1	2020	PURPOSE: Platinum compounds have activity in triple-negative breast cancer (TNBC) in germline BRCA mutation carriers (BRCA carriers).	Platinum	9-17	BRCA1 DNA repair associated	Homo sapiens	118-122
32150489-1	2020	PURPOSE: In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) expression.	Platinum	66-74	CD274 molecule	Homo sapiens	328-333
32279102-0	2020	Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine.	Platinum	92-100	vascular endothelial growth factor A	Homo sapiens	24-30
32382008-9	2020	Moreover, we have shown that high levels of USP10 mRNA correlate with poor overall survival in a cohort of advanced NSCLC patients who received platinum-based chemotherapy.	Platinum	144-152	ubiquitin specific peptidase 10	Homo sapiens	44-49
32382008-10	2020	Overall, our studies suggest that USP10 could be a potential biomarker for predicting patient response to platinum, and that targeting USP10 could sensitize lung cancer patients lacking wild-type p53 to platinum-based therapy.	Platinum	106-114	ubiquitin specific peptidase 10	Homo sapiens	34-39
32382008-10	2020	Overall, our studies suggest that USP10 could be a potential biomarker for predicting patient response to platinum, and that targeting USP10 could sensitize lung cancer patients lacking wild-type p53 to platinum-based therapy.	Platinum	203-211	ubiquitin specific peptidase 10	Homo sapiens	135-140
32382008-10	2020	Overall, our studies suggest that USP10 could be a potential biomarker for predicting patient response to platinum, and that targeting USP10 could sensitize lung cancer patients lacking wild-type p53 to platinum-based therapy.	Platinum	203-211	tumor protein p53	Homo sapiens	196-199
32233427-6	2020	For the optimal gel probe based on 25 mum diameter Pt disk electrode of Rg   2, the lateral physical resolution of SGECM at contact position is ca.	Platinum	51-53	latexin	Homo sapiens	38-41
32092292-0	2020	Inhibition of thioredoxin reductase 1 correlates with platinum-based chemotherapeutic induced tissue injury.	Platinum	54-62	thioredoxin reductase 1	Homo sapiens	14-37
32504383-1	2020	The effect of inhibition of the tumor suppressor p53 on the antioxidant system genes expression under the influence of cytotoxic compounds of the platinum group was studied.	Platinum	146-154	tumor protein p53	Homo sapiens	49-52
32088115-0	2020	Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation.	Platinum	48-56	epidermal growth factor receptor	Homo sapiens	129-133
32504383-2	2020	It was found that the action of platinum(II) and platinum(IV) complexes induced accumulation of p53 protein with a maximum in 12 h, which was confirmed by an increase in the expression of the P21 gene, the target gene of the p53 protein.	Platinum	32-40	tumor protein p53	Homo sapiens	96-99
32504383-2	2020	It was found that the action of platinum(II) and platinum(IV) complexes induced accumulation of p53 protein with a maximum in 12 h, which was confirmed by an increase in the expression of the P21 gene, the target gene of the p53 protein.	Platinum	32-40	H3 histone pseudogene 16	Homo sapiens	192-195
32504383-2	2020	It was found that the action of platinum(II) and platinum(IV) complexes induced accumulation of p53 protein with a maximum in 12 h, which was confirmed by an increase in the expression of the P21 gene, the target gene of the p53 protein.	Platinum	32-40	tumor protein p53	Homo sapiens	225-228
32504383-2	2020	It was found that the action of platinum(II) and platinum(IV) complexes induced accumulation of p53 protein with a maximum in 12 h, which was confirmed by an increase in the expression of the P21 gene, the target gene of the p53 protein.	Platinum	49-57	tumor protein p53	Homo sapiens	96-99
32504383-2	2020	It was found that the action of platinum(II) and platinum(IV) complexes induced accumulation of p53 protein with a maximum in 12 h, which was confirmed by an increase in the expression of the P21 gene, the target gene of the p53 protein.	Platinum	49-57	H3 histone pseudogene 16	Homo sapiens	192-195
32504383-2	2020	It was found that the action of platinum(II) and platinum(IV) complexes induced accumulation of p53 protein with a maximum in 12 h, which was confirmed by an increase in the expression of the P21 gene, the target gene of the p53 protein.	Platinum	49-57	tumor protein p53	Homo sapiens	225-228
32504383-3	2020	It was shown that the action of platinum complexes activated the expression of catalase and superoxide dismutase 2 genes.	Platinum	32-40	catalase	Homo sapiens	79-87
32504383-4	2020	Suppression of p53 protein functions with specific inhibitor alpha-piphitrin under the action of platinum complexes reduced the expression of catalase and superoxide dismutase 2 genes and the target gene P21, which attested to the p53-dependent regulation of these genes.	Platinum	97-105	tumor protein p53	Homo sapiens	15-18
32504383-4	2020	Suppression of p53 protein functions with specific inhibitor alpha-piphitrin under the action of platinum complexes reduced the expression of catalase and superoxide dismutase 2 genes and the target gene P21, which attested to the p53-dependent regulation of these genes.	Platinum	97-105	catalase	Homo sapiens	142-150
32504383-4	2020	Suppression of p53 protein functions with specific inhibitor alpha-piphitrin under the action of platinum complexes reduced the expression of catalase and superoxide dismutase 2 genes and the target gene P21, which attested to the p53-dependent regulation of these genes.	Platinum	97-105	H3 histone pseudogene 16	Homo sapiens	204-207
32504383-4	2020	Suppression of p53 protein functions with specific inhibitor alpha-piphitrin under the action of platinum complexes reduced the expression of catalase and superoxide dismutase 2 genes and the target gene P21, which attested to the p53-dependent regulation of these genes.	Platinum	97-105	tumor protein p53	Homo sapiens	231-234
32168429-11	2020	CONCLUSIONS: First-line therapy with crizotinib is more beneficial than platinum-based chemotherapy in patients with advanced NSCLC with different ROS1 fusion variants.	Platinum	72-80	ROS proto-oncogene 1, receptor tyrosine kinase	Homo sapiens	147-151
31332704-7	2020	After adjusting for performance status, age and the presence of brain metastasis at baseline, treatment with pemetrexed-based platinum doublet was associated with an increased risk of death [HR 2.27 (95% CI 1.12-4.63), P = 0.02] among KRAS-mutant patients in multivariate analysis.	Platinum	126-134	KRAS proto-oncogene, GTPase	Homo sapiens	235-239
32167697-0	2020	Evaluation of nuclear NF-kappaB, transglutaminase2, and ERCC1 as predictors of platinum resistance in testicular tumors.	Platinum	79-87	nuclear factor kappa B subunit 1	Homo sapiens	22-31
32283495-12	2020	HPLC-ESI+-MS/MS sequencing of tryptic peptides originating from dG-Pt-AGT complexes revealed that the cross-linking occurred at six sites within this protein including Glu110, Lys125, Cys145, His146, Arg147, and Cys150.	Platinum	67-69	DEAH-box helicase 40	Homo sapiens	200-206
31818526-4	2020	Key inclusion criteria were prospective clinical trials examining platinum-based NACT for stage II-IV epithelial ovarian cancer.	Platinum	66-74	solute carrier family 13 member 5	Homo sapiens	81-85
32313790-9	2020	A larger Cobb angle of the PT curve was associated with a greater incidence of unacceptable SAPS at these levels.	Platinum	27-29	src kinase associated phosphoprotein 2	Homo sapiens	92-96
31509615-0	2020	Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer.	Platinum	49-57	calbindin 2	Homo sapiens	6-16
32509095-5	2020	Expression of Gal-3, p65 and IkappaB were found associated with EOC platinum resistance (P<0.05), and expression of Gal-3 and p65 correlated with pathologic grading (P<0.05).	Platinum	68-76	galectin 3	Homo sapiens	14-19
32167697-0	2020	Evaluation of nuclear NF-kappaB, transglutaminase2, and ERCC1 as predictors of platinum resistance in testicular tumors.	Platinum	79-87	transglutaminase 2	Homo sapiens	33-50
32167697-0	2020	Evaluation of nuclear NF-kappaB, transglutaminase2, and ERCC1 as predictors of platinum resistance in testicular tumors.	Platinum	79-87	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	56-61
32167697-3	2020	The aim of this study was to evaluate the risk of recurrence and overall survival related to the expression of nuclear factor kappa-B (NF-kappaB), transglutaminase 2 (TG2) and excision repair cross-complementation group 1 (ERCC1) in patients with TGCT treated with platinum combinations.	Platinum	265-273	nuclear factor kappa B subunit 1	Homo sapiens	111-133
32167697-11	2020	CONCLUSIONS: The expression of ERCC1 and NF-kappaB give a worse prognosis for relapse, and only ERCC1 had an influence on the overall survival of TGCT patients treated with platinum-based chemotherapy.	Platinum	173-181	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	31-36
32509095-5	2020	Expression of Gal-3, p65 and IkappaB were found associated with EOC platinum resistance (P<0.05), and expression of Gal-3 and p65 correlated with pathologic grading (P<0.05).	Platinum	68-76	RELA proto-oncogene, NF-kB subunit	Homo sapiens	21-24
32167697-11	2020	CONCLUSIONS: The expression of ERCC1 and NF-kappaB give a worse prognosis for relapse, and only ERCC1 had an influence on the overall survival of TGCT patients treated with platinum-based chemotherapy.	Platinum	173-181	nuclear factor kappa B subunit 1	Homo sapiens	41-50
32509095-8	2020	Multivariate analysis results showed that abnormal expression of Gal-3 may be an independent prognostic risk factors for the drug resistance to platinum-based chemotherapy (95% CI=5.336~34.112, P<0.05).	Platinum	144-152	galectin 3	Homo sapiens	65-70
32319573-5	2020	Moreover, a strong association was observed between FOXF1 upregulation and the presence of platinum-based chemotherapy resistance in patients with NSCLC.	Platinum	91-99	forkhead box F1	Homo sapiens	52-57
32167697-11	2020	CONCLUSIONS: The expression of ERCC1 and NF-kappaB give a worse prognosis for relapse, and only ERCC1 had an influence on the overall survival of TGCT patients treated with platinum-based chemotherapy.	Platinum	173-181	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	96-101
31486677-8	2020	Using the Platinum program, we found that hydrophilic amino acids were predominant on the surface of the four-subunit VirE2 complex.	Platinum	10-18	type IV secretion system single-stranded DNA binding protein VirE2	Agrobacterium tumefaciens	118-123
32319573-6	2020	On the whole, the findings of this study indicate the regulatory mechanisms of cisplatin resistance by FOXF1 in NSCLC, and suggest that FOXF1 may be used as a prognostic biomarker of platinum-based chemotherapy resistance in NSCLC.	Platinum	183-191	forkhead box F1	Homo sapiens	136-141
32448798-13	2020	CONCLUSION: The gene expression signature of CD3Z, CD8A and CXCL9 can assess the immune status of MIBC and stratify the survival of MIBC patients undergoing surgery and adjuvant platinum-based chemotherapy.	Platinum	178-186	CD247 molecule	Homo sapiens	45-49
32448798-13	2020	CONCLUSION: The gene expression signature of CD3Z, CD8A and CXCL9 can assess the immune status of MIBC and stratify the survival of MIBC patients undergoing surgery and adjuvant platinum-based chemotherapy.	Platinum	178-186	CD8a molecule	Homo sapiens	51-55
32448798-13	2020	CONCLUSION: The gene expression signature of CD3Z, CD8A and CXCL9 can assess the immune status of MIBC and stratify the survival of MIBC patients undergoing surgery and adjuvant platinum-based chemotherapy.	Platinum	178-186	C-X-C motif chemokine ligand 9	Homo sapiens	60-65
32068166-7	2020	STING activation in patient tumors and in platinum-treated preclinical NSCLC models was correlated with biomarkers of immunotherapy response.	Platinum	42-50	stimulator of interferon response cGAMP interactor 1	Homo sapiens	0-5
31635638-4	2020	The 100 nm of platinum-coated FTO substrate and polysulfide-based electrolyte are used to assemble the Gratzel Solar cell (GSC).	Platinum	14-22	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	30-33
32197264-3	2020	Especially, the TOF of Pt/@-La2O3/SBA-15 reached 2324h-1, 2.3-fold higher than the atomically dispersed catalyst(Pd1/TiO2, 1002 h-1) in the literature.	Platinum	23-25	programmed cell death 1	Homo sapiens	113-116
32163106-13	2020	Conclusions and Relevance: Effective chemotherapy for BRCA1/2-mutated TNBC is commonly suggested to be platinum based.	Platinum	103-111	BRCA1 DNA repair associated	Homo sapiens	54-61
32127465-0	2020	SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy.	Platinum	62-70	schlafen family member 11	Homo sapiens	0-6
32127465-2	2020	We assessed the impact of SLFN11 expression on response to platinum chemotherapy and outcomes in patients with metastatic castration-resistant prostate cancer (CRPC).	Platinum	59-67	schlafen family member 11	Homo sapiens	26-32
32127465-3	2020	Tumor expression of SLFN11 was assessed in 41 CRPC patients treated with platinum chemotherapy by RNAseq of metastatic biopsy tissue (n=27) and/or immunofluorescence in circulating tumor cells (CTCs) (n=20).	Platinum	73-81	schlafen family member 11	Homo sapiens	20-26
32127465-13	2020	On multivariable analysis, SLFN11 was an independent factor associated with rPFS on platinum therapy.	Platinum	84-92	schlafen family member 11	Homo sapiens	27-33
32127465-14	2020	Platinum response of organoids-expressing-SLFN11 was reduced after SLFN11 knockout.	Platinum	0-8	schlafen family member 11	Homo sapiens	42-48
32127465-14	2020	Platinum response of organoids-expressing-SLFN11 was reduced after SLFN11 knockout.	Platinum	0-8	schlafen family member 11	Homo sapiens	67-73
32127465-15	2020	Our data suggest that SLFN11 expression might identify CRPC patients with a better response to platinum-chemotherapy independent of histology or other genomic alterations.	Platinum	95-103	schlafen family member 11	Homo sapiens	22-28
32332923-0	2020	Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity.	Platinum	69-77	splicing factor proline and glutamine rich	Homo sapiens	0-43
32332923-0	2020	Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity.	Platinum	69-77	splicing factor proline and glutamine rich	Homo sapiens	45-49
32332923-0	2020	Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity.	Platinum	69-77	serine and arginine rich splicing factor 2	Homo sapiens	116-121
32332923-5	2020	At mechanistic level, we show that, under PT treatment, SFPQ, in complex with p54nrb, binds and regulates the activity of the splicing factor SRSF2.	Platinum	42-44	splicing factor proline and glutamine rich	Homo sapiens	56-60
32332923-5	2020	At mechanistic level, we show that, under PT treatment, SFPQ, in complex with p54nrb, binds and regulates the activity of the splicing factor SRSF2.	Platinum	42-44	non-POU domain containing octamer binding	Homo sapiens	78-84
32332923-5	2020	At mechanistic level, we show that, under PT treatment, SFPQ, in complex with p54nrb, binds and regulates the activity of the splicing factor SRSF2.	Platinum	42-44	serine and arginine rich splicing factor 2	Homo sapiens	142-147
32332923-8	2020	Overall, our work unveils a previously unreported SFPQ/p54nrb/SRSF2 pathway that in EOC cells plays a central role in regulating alternative splicing and PT-induced apoptosis and that could result in the design of new possible ways of intervention to overcome PT resistance.	Platinum	154-156	splicing factor proline and glutamine rich	Homo sapiens	50-54
32332923-8	2020	Overall, our work unveils a previously unreported SFPQ/p54nrb/SRSF2 pathway that in EOC cells plays a central role in regulating alternative splicing and PT-induced apoptosis and that could result in the design of new possible ways of intervention to overcome PT resistance.	Platinum	154-156	non-POU domain containing octamer binding	Homo sapiens	55-61
32332923-8	2020	Overall, our work unveils a previously unreported SFPQ/p54nrb/SRSF2 pathway that in EOC cells plays a central role in regulating alternative splicing and PT-induced apoptosis and that could result in the design of new possible ways of intervention to overcome PT resistance.	Platinum	154-156	serine and arginine rich splicing factor 2	Homo sapiens	62-67
32070915-0	2020	Anionic versus neutral Pt(II) complexes: The relevance of the charge for human serum albumin binding.	Platinum	23-29	albumin	Homo sapiens	79-92
32070915-1	2020	The focus of this work is pointing out the different behavior of two structurally related Pt(II) complexes, the anionic cyclometalated NBu4[(Bzq)Pt(Thio)], 1 and the neutral [(Phen)Pt(Thio)], 2, (Bzq = benzo[h]quinoline, Phen = 1,10-phenantroline, Thio = 1,2-benzenedithiolate), on the interaction with human serum albumin (HSA), a key drug-delivery protein in the bloodstream.	Platinum	90-96	albumin	Homo sapiens	309-322
32114315-3	2020	The marker is deposited prior to the deposition of a protective platinum strap (also by EBID) with the centre of the cross indicating the location of the feature of interest, while the arms of the square cross make an acute angle of 45  with the strap"s long axis.	Platinum	64-72	serine/threonine kinase receptor associated protein	Homo sapiens	73-78
32419821-1	2020	Objective: To carry out the meta-analysis on the relationship between the expression of nucleotide excision repair cross-complementary enzyme 1 (ERCC1) protein and platinum chemosensitivity in patients with advanced non-small-cell lung cancer (NSCLC).	Platinum	164-172	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	145-150
32419821-7	2020	Conclusion: The sensitivity to platinum chemotherapy in patients with ERCC1 protein negative expression in the middle and late stages of NSCLC is better than that in patients with positive expression, especially in Asian population.	Platinum	31-39	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	70-75
32365472-5	2020	The diameter and pitch of the Pt-coated electrodes were 150 mum and 350 mum, respectively, and the height of the protruded electrodes was around 20 mum.	Platinum	30-32	latexin	Homo sapiens	60-63
31859331-0	2020	Platinum ions mediate the interactions between DNA and carbon quantum dots: diagnosis of MRSA infections.	Platinum	0-8	solute carrier family 9 member A6	Homo sapiens	89-93
31859331-1	2020	In this study, we have developed a rapid and cost-effective method employing platinum ion (Pt4+)-capped fluorescent carbon quantum dots (CQDs) coupled with loop-mediated isothermal amplification (LAMP) to detect dual MRSA genes.	Platinum	77-85	solute carrier family 9 member A6	Homo sapiens	217-221
32365472-5	2020	The diameter and pitch of the Pt-coated electrodes were 150 mum and 350 mum, respectively, and the height of the protruded electrodes was around 20 mum.	Platinum	30-32	latexin	Homo sapiens	72-75
31859331-1	2020	In this study, we have developed a rapid and cost-effective method employing platinum ion (Pt4+)-capped fluorescent carbon quantum dots (CQDs) coupled with loop-mediated isothermal amplification (LAMP) to detect dual MRSA genes.	Platinum	91-95	solute carrier family 9 member A6	Homo sapiens	217-221
31859331-3	2020	The CQDSPDs capped with Pt4+ ions through the cooperative coordination of the amine and chlorine groups on the surface of CQDs facilitated the double-stranded DNA (dsDNA)-induced fluorescence quenching of CQDs, and enabled the construction of the CQDSPDs/Pt4+ probe for the detection of as few as 10 copies of the MRSA gene (mecA and femA).	Platinum	24-28	solute carrier family 9 member A6	Homo sapiens	314-318
32365472-5	2020	The diameter and pitch of the Pt-coated electrodes were 150 mum and 350 mum, respectively, and the height of the protruded electrodes was around 20 mum.	Platinum	30-32	latexin	Homo sapiens	72-75
31859331-3	2020	The CQDSPDs capped with Pt4+ ions through the cooperative coordination of the amine and chlorine groups on the surface of CQDs facilitated the double-stranded DNA (dsDNA)-induced fluorescence quenching of CQDs, and enabled the construction of the CQDSPDs/Pt4+ probe for the detection of as few as 10 copies of the MRSA gene (mecA and femA).	Platinum	255-259	solute carrier family 9 member A6	Homo sapiens	314-318
31859331-4	2020	The sensitivity and specificity of the CQDSPDs/Pt4+ probe for MRSA detection in clinical specimens (n = 24) were 94% and 86%, respectively.	Platinum	47-51	solute carrier family 9 member A6	Homo sapiens	62-66
31574532-15	2020	In addition, overexpression of PtHMGR increased expression of the stress-related genes KIN1, COR15, and AAO3, and decreased that of ABI, MYB, MYC2, and RD22, enhancing the stress resistance of poplar.	Platinum	31-37	MYB proto-oncogene, transcription factor	Homo sapiens	137-140
32236281-5	2020	The naproxen platinum(iv) complex could easily undergo reduction and liberate the platinum(ii) complex and naproxen as well as exert a multifunctional antitumor mechanism: (i) the liberated platinum(ii) fragment would cause serious DNA injury; (ii) naproxen would inhibit COX-2 and decrease tumor-associated inflammation; and (iii) the naproxen platinum(iv) complex exhibited remarkable MMP-9 inhibition in tumor tissues.	Platinum	13-21	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	272-277
32236281-5	2020	The naproxen platinum(iv) complex could easily undergo reduction and liberate the platinum(ii) complex and naproxen as well as exert a multifunctional antitumor mechanism: (i) the liberated platinum(ii) fragment would cause serious DNA injury; (ii) naproxen would inhibit COX-2 and decrease tumor-associated inflammation; and (iii) the naproxen platinum(iv) complex exhibited remarkable MMP-9 inhibition in tumor tissues.	Platinum	13-21	matrix metallopeptidase 9	Homo sapiens	387-392
32236281-5	2020	The naproxen platinum(iv) complex could easily undergo reduction and liberate the platinum(ii) complex and naproxen as well as exert a multifunctional antitumor mechanism: (i) the liberated platinum(ii) fragment would cause serious DNA injury; (ii) naproxen would inhibit COX-2 and decrease tumor-associated inflammation; and (iii) the naproxen platinum(iv) complex exhibited remarkable MMP-9 inhibition in tumor tissues.	Platinum	82-90	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	272-277
32236281-5	2020	The naproxen platinum(iv) complex could easily undergo reduction and liberate the platinum(ii) complex and naproxen as well as exert a multifunctional antitumor mechanism: (i) the liberated platinum(ii) fragment would cause serious DNA injury; (ii) naproxen would inhibit COX-2 and decrease tumor-associated inflammation; and (iii) the naproxen platinum(iv) complex exhibited remarkable MMP-9 inhibition in tumor tissues.	Platinum	82-90	matrix metallopeptidase 9	Homo sapiens	387-392
32411590-9	2020	Higher non-synonymous TMB correlates with inferior PFS for first-generation EGFR-TKIs in EGFR-driven patients and worse response to pemetrexed/platinum regimen in EGFR/ALK wild-type patients, which has potential clinical implications for cancer treatment but needs corroboration in larger studies.	Platinum	143-151	ALK receptor tyrosine kinase	Homo sapiens	168-171
32489453-1	2020	Purpose: We aimed to investigate the association of single-nucleotide polymorphisms (SNPs) in HMGB1, REV3L, and NFE2L2 with prognosis in lung cancer patients with platinum-based chemotherapy.	Platinum	163-171	high mobility group box 1	Homo sapiens	94-99
32489453-1	2020	Purpose: We aimed to investigate the association of single-nucleotide polymorphisms (SNPs) in HMGB1, REV3L, and NFE2L2 with prognosis in lung cancer patients with platinum-based chemotherapy.	Platinum	163-171	NFE2 like bZIP transcription factor 2	Homo sapiens	112-118
32489453-9	2020	The REV3L rs462779 and HMGB1 rs1045411 may serve as prognosis markers in lung cancer patients with platinum-based chemotherapy.	Platinum	99-107	REV3 like, DNA directed polymerase zeta catalytic subunit	Homo sapiens	4-9
32489453-9	2020	The REV3L rs462779 and HMGB1 rs1045411 may serve as prognosis markers in lung cancer patients with platinum-based chemotherapy.	Platinum	99-107	high mobility group box 1	Homo sapiens	23-28
32326107-0	2020	Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study.	Platinum	71-79	CD44 molecule (Indian blood group)	Homo sapiens	24-28
32344513-2	2020	A key cellular factor that contributes to sensitivity to platinums is the 5"-3" structure-specific endonuclease excision repair cross-complementation group 1 (ERCC1)/ xeroderma pigmentosum group F (XPF).	Platinum	57-66	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	159-164
32344513-2	2020	A key cellular factor that contributes to sensitivity to platinums is the 5"-3" structure-specific endonuclease excision repair cross-complementation group 1 (ERCC1)/ xeroderma pigmentosum group F (XPF).	Platinum	57-66	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	167-196
32344513-2	2020	A key cellular factor that contributes to sensitivity to platinums is the 5"-3" structure-specific endonuclease excision repair cross-complementation group 1 (ERCC1)/ xeroderma pigmentosum group F (XPF).	Platinum	57-66	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	198-201
32344513-3	2020	ERCC1/XPF is critical for the repair of platinum-induced DNA damage and has been the subject of intense research efforts to identify small molecule inhibitors of its nuclease activity for the purpose of enhancing patient response to platinum-based chemotherapy.	Platinum	40-48	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
32344513-3	2020	ERCC1/XPF is critical for the repair of platinum-induced DNA damage and has been the subject of intense research efforts to identify small molecule inhibitors of its nuclease activity for the purpose of enhancing patient response to platinum-based chemotherapy.	Platinum	40-48	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	6-9
32344513-3	2020	ERCC1/XPF is critical for the repair of platinum-induced DNA damage and has been the subject of intense research efforts to identify small molecule inhibitors of its nuclease activity for the purpose of enhancing patient response to platinum-based chemotherapy.	Platinum	233-241	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
32344513-3	2020	ERCC1/XPF is critical for the repair of platinum-induced DNA damage and has been the subject of intense research efforts to identify small molecule inhibitors of its nuclease activity for the purpose of enhancing patient response to platinum-based chemotherapy.	Platinum	233-241	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	6-9
32344513-7	2020	Second, we show that our siRNA-carrying nanoparticles enhanced platinum sensitivity in a p53 wildtype model of non-small cell lung cancer in vitro.	Platinum	63-71	tumor protein p53	Homo sapiens	89-92
32248213-0	2020	Spin crossover in Fe(triazole)-Pt nanoparticle self-assembly structured at the sub-5 nm scale.	Platinum	31-33	spindlin 1	Homo sapiens	0-4
32248213-5	2020	Here, we show that the association of ultra-small 1.2 nm platinum nanoparticles with FeII triazole-based spin crossover coordination polymers leads to self-assemblies, extremely well organized at the sub-3 nm scale.	Platinum	57-65	spindlin 1	Homo sapiens	105-109
32326107-0	2020	Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study.	Platinum	71-79	pyruvate kinase M1/2	Homo sapiens	15-19
32326107-2	2020	To clarify the clinical importance of this "cross-talk" as a mechanism of drug resistance, we assessed the expression both of PKM2 and of CD44 in cancer cells of patients with epithelial ovarian cancer (EOC) treated with platinum-based treatment.	Platinum	221-229	pyruvate kinase M1/2	Homo sapiens	126-130
32326107-2	2020	To clarify the clinical importance of this "cross-talk" as a mechanism of drug resistance, we assessed the expression both of PKM2 and of CD44 in cancer cells of patients with epithelial ovarian cancer (EOC) treated with platinum-based treatment.	Platinum	221-229	CD44 molecule (Indian blood group)	Homo sapiens	138-142
32326107-11	2020	In conclusion, PKM2 expression is a negative prognostic factor in EOC patients, but the interaction between CD44 and PKM2 that may be implicated in EOC platinum-resistance needs further investigation.	Platinum	152-160	CD44 molecule (Indian blood group)	Homo sapiens	108-112
32326107-11	2020	In conclusion, PKM2 expression is a negative prognostic factor in EOC patients, but the interaction between CD44 and PKM2 that may be implicated in EOC platinum-resistance needs further investigation.	Platinum	152-160	pyruvate kinase M1/2	Homo sapiens	117-121
31904865-0	2020	Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.	Platinum	60-68	fibronectin 1	Mus musculus	113-116
31904865-0	2020	Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.	Platinum	60-68	thymoma viral proto-oncogene 1	Mus musculus	117-120
31904865-8	2020	Mechanistically, OCAMs can induce decreased platinum-sensitivity in OvCa cells via induction of the FN1/Akt signaling pathway via cell-to-cell interactions.	Platinum	44-52	fibronectin 1	Mus musculus	100-103
31904865-8	2020	Mechanistically, OCAMs can induce decreased platinum-sensitivity in OvCa cells via induction of the FN1/Akt signaling pathway via cell-to-cell interactions.	Platinum	44-52	thymoma viral proto-oncogene 1	Mus musculus	104-107
32273462-3	2020	We report subterahertz spin pumping at the interface of the uniaxial insulating antiferromagnet manganese difluoride and platinum.	Platinum	121-129	spindlin 1	Homo sapiens	23-27
32073956-2	2020	We conducted a phase III trial (SOLO3) of olaparib tablets versus nonplatinum chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer who had received at least 2 prior lines of platinum-based chemotherapy.	Platinum	130-138	BRCA1 DNA repair associated	Homo sapiens	117-121
32073956-11	2020	CONCLUSION: Olaparib resulted in statistically significant and clinically relevant improvements in ORR and PFS compared with nonplatinum chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer who had received at least 2 prior lines of platinum-based chemotherapy.	Platinum	189-197	BRCA1 DNA repair associated	Homo sapiens	176-180
32351985-8	2020	TGF-beta2 was associated with poor OS and PFS from treatment with chemotherapy with platins, Taxol, or a platin+Taxol.	Platinum	84-90	transforming growth factor beta 2	Homo sapiens	0-9
32351985-9	2020	However, overexpression of TGF-beta3 was associated with poor OS from the use of platins and poor PFS of Taxol or a platin+Taxol in women with ovarian carcinoma.	Platinum	81-87	transforming growth factor beta 3	Homo sapiens	27-36
32351985-11	2020	Conclusion: Higher expression of TGF-beta2 functioned as a significant predictor of poor prognosis in women with ovarian cancer, especially those with TP53 mutations or who were undergoing chemotherapy with platins, Taxol, or a platin+Taxol.	Platinum	207-213	transforming growth factor beta 2	Homo sapiens	33-42
32273462-4	2020	The measured ISHE voltage arising from spin-charge conversion in the platinum layer depends on the chirality of the dynamical modes of the antiferromagnet, which is selectively excited and modulated by the handedness of the circularly polarized subterahertz irradiation.	Platinum	69-77	spindlin 1	Homo sapiens	39-43
32115889-5	2020	In combination with platinum, RSK inhibitors effectively sensitized even the most platinum-resistant EphA2high , GPRC5Ahigh cells to the therapy-induced apoptosis.	Platinum	20-28	EPH receptor A2	Homo sapiens	101-106
32115889-5	2020	In combination with platinum, RSK inhibitors effectively sensitized even the most platinum-resistant EphA2high , GPRC5Ahigh cells to the therapy-induced apoptosis.	Platinum	82-90	ribosomal protein S6 kinase A1	Homo sapiens	30-33
31713566-5	2020	In addition, compared to 0.5Pt/Ni1Mg2Al1Ox, 0.5Pt/Mn1Mg2Al1Ox exhibited a relatively higher SN2 and lower SN2O and SNH3.	Platinum	28-30	solute carrier family 38 member 5	Homo sapiens	92-95
31713566-5	2020	In addition, compared to 0.5Pt/Ni1Mg2Al1Ox, 0.5Pt/Mn1Mg2Al1Ox exhibited a relatively higher SN2 and lower SN2O and SNH3.	Platinum	47-49	solute carrier family 38 member 5	Homo sapiens	92-95
32115889-5	2020	In combination with platinum, RSK inhibitors effectively sensitized even the most platinum-resistant EphA2high , GPRC5Ahigh cells to the therapy-induced apoptosis.	Platinum	82-90	EPH receptor A2	Homo sapiens	101-106
31713566-7	2020	Both Pt-containing catalysts presented a quite stable XNO in ten cycles in the presence of 100 ppm SO2, and their SN2 can be remarkably enhanced to more than 80%, which could be attributed to the reactions of NH3-SCR and SO2 + NH3.	Platinum	5-7	solute carrier family 38 member 5	Homo sapiens	114-117
31800094-8	2020	RIG-I levels were also elevated in cancers that recurred after remission or were platinum-refractory.	Platinum	81-89	DExD/H-box helicase 58	Homo sapiens	0-5
32395516-6	2020	Results: Combined therapy by RAPA plus Zadaxin and PS-T obviously alleviated hepatic pathological changes and significantly decreased the levels of FoxP3+Tregs in peripheral blood, the spleen, and the liver (P<0.05) and expression of mTOR protein (P<0.01) in the liver, obviously improved survival time (P=0.02).	Platinum	51-55	forkhead box P3	Rattus norvegicus	148-153
32395516-6	2020	Results: Combined therapy by RAPA plus Zadaxin and PS-T obviously alleviated hepatic pathological changes and significantly decreased the levels of FoxP3+Tregs in peripheral blood, the spleen, and the liver (P<0.05) and expression of mTOR protein (P<0.01) in the liver, obviously improved survival time (P=0.02).	Platinum	51-55	mechanistic target of rapamycin kinase	Rattus norvegicus	234-238
31891209-2	2020	In cancer cells, ERCC1-XPF plays a central role in repairing DNA damage induced by chemotherapeutics including platinum-based and crosslinking agents, thus its inhibition is a promising strategy to enhance the effect of these therapies.	Platinum	111-119	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	17-22
31891209-2	2020	In cancer cells, ERCC1-XPF plays a central role in repairing DNA damage induced by chemotherapeutics including platinum-based and crosslinking agents, thus its inhibition is a promising strategy to enhance the effect of these therapies.	Platinum	111-119	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	23-26
32410793-0	2020	Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing.	Platinum	12-20	BRCA1 DNA repair associated	Homo sapiens	77-81
32410793-12	2020	Conclusions: Platinum-based regimens are more effective in patients with deleterious gBRCA mutations, but no difference in patients without BRCA gene mutations, so non-platinum is an option in patients without BRCA gene mutations considering the toxicity and side effect.	Platinum	13-21	BRCA1 DNA repair associated	Homo sapiens	86-90
32154703-4	2020	Anti-CRP functionalized micromotors (anti-CRP-rGO(reduced graphene oxide)/Ni/PtNPs (platinum nanoparticles))-based immunoassay coupled to thin layer Au-based electrochemical microfluidics operating at -0.20 V under controlled fluidic detection operations (30 muL min-1) allowed the sensitive (LOD = 0.54 mug/mL) and accurate CRP determination using very low volume preterm neonatal clinical samples (<10 muL) in just 8 min of total assay time.	Platinum	84-92	C-reactive protein	Homo sapiens	5-8
32264959-8	2020	Rescuing the downregulation of Tacr3 by AAV-mediated Tacr3 overexpression in the unilateral LHb significantly reversed pT-ION-induced anxiety-like behaviors but not allodynia.	Platinum	119-121	tachykinin receptor 3	Homo sapiens	31-36
32264959-8	2020	Rescuing the downregulation of Tacr3 by AAV-mediated Tacr3 overexpression in the unilateral LHb significantly reversed pT-ION-induced anxiety-like behaviors but not allodynia.	Platinum	119-121	tachykinin receptor 3	Homo sapiens	53-58
32264959-9	2020	Whole-cell patch clamp recording showed that Tacr3 overexpression suppressed nerve injury-induced hyperexcitation of LHb neurons, and western blotting showed that the pT-ION-induced upregulation of p-CaMKII was reversed by AAV-mediated Tacr3 overexpression or chemicogenetic inhibition of glutamatergic neurons in the LHb.	Platinum	167-169	tachykinin receptor 3	Homo sapiens	45-50
32264959-9	2020	Whole-cell patch clamp recording showed that Tacr3 overexpression suppressed nerve injury-induced hyperexcitation of LHb neurons, and western blotting showed that the pT-ION-induced upregulation of p-CaMKII was reversed by AAV-mediated Tacr3 overexpression or chemicogenetic inhibition of glutamatergic neurons in the LHb.	Platinum	167-169	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	200-206
32264959-9	2020	Whole-cell patch clamp recording showed that Tacr3 overexpression suppressed nerve injury-induced hyperexcitation of LHb neurons, and western blotting showed that the pT-ION-induced upregulation of p-CaMKII was reversed by AAV-mediated Tacr3 overexpression or chemicogenetic inhibition of glutamatergic neurons in the LHb.	Platinum	167-169	tachykinin receptor 3	Homo sapiens	236-241
32264959-10	2020	Moreover, not only anxiety-like behaviors, but also allodynia after pT-ION were significantly alleviated by chemicogenetic inhibition of bilateral LHb neurons or by bilateral Tacr3 overexpression in the LHb.	Platinum	68-70	tachykinin receptor 3	Homo sapiens	175-180
31989937-3	2020	The Pt-Nafion  sensor was characterized morphological and electrochemically showing a higher sensitivity of -2.496 nA/mmHg (-1.495 nA/muM) when comparing with its bare counterpart.	Platinum	4-13	latexin	Homo sapiens	134-137
32078962-1	2020	PURPOSE: The combination of an anti-programmed death 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) monoclonal antibody with platinum-based chemotherapy can improve outcomes for patients with advanced non-small-cell lung cancer (NSCLC) or small-cell lung cancer (SCLC) compared with chemotherapy alone.	Platinum	129-137	CD274 molecule	Homo sapiens	97-102
32078962-7	2020	Immune-mediated AEs and infusion reactions occurred more commonly in patients who received anti-PD-(L)1 immunotherapy with platinum-based chemotherapy compared with chemotherapy alone; however, there was no evidence of unexpected or unanticipated toxicity with these combinations.	Platinum	123-131	CD274 molecule	Homo sapiens	96-103
30421591-8	2020	In univariable analyses, pathological stage and platinum-based chemotherapy regimen were associated with OS (pT3-pT4 versus pT1-pT2, HR=3.228, P=0.005; other chemotherapies versus platinum-based, HR=6.249, P=0.035).	Platinum	48-56	zinc finger protein 135	Homo sapiens	109-112
32102735-3	2020	This phase II study evaluates the antitumor activity of a combination of IM and GEM in platinum-pemetrexed-pretreated MPM patients expressing PDGFR-beta and/or cKIT by immunohistochemistry (IHC).	Platinum	87-95	platelet derived growth factor receptor alpha	Homo sapiens	142-152
30421591-8	2020	In univariable analyses, pathological stage and platinum-based chemotherapy regimen were associated with OS (pT3-pT4 versus pT1-pT2, HR=3.228, P=0.005; other chemotherapies versus platinum-based, HR=6.249, P=0.035).	Platinum	48-56	zinc finger protein 77	Homo sapiens	124-127
30421591-8	2020	In univariable analyses, pathological stage and platinum-based chemotherapy regimen were associated with OS (pT3-pT4 versus pT1-pT2, HR=3.228, P=0.005; other chemotherapies versus platinum-based, HR=6.249, P=0.035).	Platinum	180-188	zinc finger protein 135	Homo sapiens	109-112
30421591-10	2020	In univariable analyses, pathological stage and platinum-based chemotherapy regimen were associated with CCS (pT3-pT4 versus pT1-pT2, HR=3.332, P=0.004; non-platinum based versus platinum-based, HR=7.784, P=0.025).	Platinum	48-56	zinc finger protein 135	Homo sapiens	110-113
30421591-10	2020	In univariable analyses, pathological stage and platinum-based chemotherapy regimen were associated with CCS (pT3-pT4 versus pT1-pT2, HR=3.332, P=0.004; non-platinum based versus platinum-based, HR=7.784, P=0.025).	Platinum	48-56	zinc finger protein 77	Homo sapiens	125-128
32235305-1	2020	Trastuzumab in combination with a platinum and fluorouracil is the treatment of choice for patients with advanced human epidermal growth factor receptor 2 (HER2) positive gastric cancer and gastroesophageal junction (GEJ) cancer.	Platinum	34-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-154
32179677-1	2020	Described here is the development of gadolinium(III) texaphyrin-platinum(IV) conjugates capable of overcoming platinum resistance by 1) localizing to solid tumors, 2) promoting enhanced cancer cell uptake, and 3) reactivating p53 in platinum-resistant models.	Platinum	64-72	transformation related protein 53, pseudogene	Mus musculus	226-229
32179677-1	2020	Described here is the development of gadolinium(III) texaphyrin-platinum(IV) conjugates capable of overcoming platinum resistance by 1) localizing to solid tumors, 2) promoting enhanced cancer cell uptake, and 3) reactivating p53 in platinum-resistant models.	Platinum	110-118	transformation related protein 53, pseudogene	Mus musculus	226-229
32230752-4	2020	Furthermore, the Pt/CdS/CdTe/FTO structure was prepared to improve its PEC stability and the photocurrent of 240 muAcm-2 had been achieved.	Platinum	17-19	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	29-32
32280916-3	2020	The platinum-cluster-modified molybdenum diselenide (Pt3-MoSe2) monolayer has been proposed as a gas sensing material.	Platinum	4-12	zinc finger protein 135	Homo sapiens	53-56
32224864-5	2020	Long-term cell exposure to platinum induces the frequent deletion of ITF2 gene.	Platinum	27-35	transcription factor 4	Homo sapiens	69-73
32235701-3	2020	Nevertheless, recent clinical studies have suggested Xeroderma Pigmentosum group A (XPA) protein, a key regulator of the NER pathway that is essential for the repair of DNA damage induced by platinum-based chemotherapeutics, as a potential prognostic and predictive biomarker for response to treatment.	Platinum	191-199	XPA, DNA damage recognition and repair factor	Homo sapiens	53-82
32235701-3	2020	Nevertheless, recent clinical studies have suggested Xeroderma Pigmentosum group A (XPA) protein, a key regulator of the NER pathway that is essential for the repair of DNA damage induced by platinum-based chemotherapeutics, as a potential prognostic and predictive biomarker for response to treatment.	Platinum	191-199	XPA, DNA damage recognition and repair factor	Homo sapiens	84-87
32069396-2	2020	Herein we present a trichromatic white-light-emitting MOF composite (Z3) by simultaneously incorporating red/green-emitting platinum/ruthenium complex cations into porous blue-emitting bio-MOF-1 through post-synthetic modification.	Platinum	124-132	lysine acetyltransferase 8	Homo sapiens	54-57
32213241-0	2020	Disruption of SSBs repair to combat platinum resistance via the JWA-targeted Pt(IV) prodrug conjugated with a wogonin derivative.	Platinum	36-44	ADP ribosylation factor like GTPase 6 interacting protein 5	Homo sapiens	64-67
32006874-6	2020	METHODS: We studied the expression of copper transporters CTR1, ATP7A and ATP7B which are presumably involved in the uptake, cellular transport and efflux of platinum compounds by immunofluorescence microscopy and flow-cytometry.	Platinum	158-166	solute carrier family 31 member 1	Homo sapiens	58-62
32006874-6	2020	METHODS: We studied the expression of copper transporters CTR1, ATP7A and ATP7B which are presumably involved in the uptake, cellular transport and efflux of platinum compounds by immunofluorescence microscopy and flow-cytometry.	Platinum	158-166	ATPase copper transporting alpha	Homo sapiens	64-69
32006874-6	2020	METHODS: We studied the expression of copper transporters CTR1, ATP7A and ATP7B which are presumably involved in the uptake, cellular transport and efflux of platinum compounds by immunofluorescence microscopy and flow-cytometry.	Platinum	158-166	ATPase copper transporting beta	Homo sapiens	74-79
32169110-0	2020	Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer.	Platinum	59-67	serpin family A member 4	Homo sapiens	15-26
32057234-5	2020	As an example, the resultant IrP2-rGO displays better HER electrocatalytic performance and longer durability than the benchmark materials of commercial Pt/C under acidic, neutral and basic electrolytes.	Platinum	152-154	iron responsive element binding protein 2	Homo sapiens	29-33
32245058-4	2020	The temperature coefficient of resistance values reached 2.29 x 10-2  C-1, which was almost six times higher than the traditional platinum-based sensors.	Platinum	130-138	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	70-73
32257953-8	2019	MTHFR rs1801131 and MDM2 rs1690924 were significantly correlated with platinum-induced GI toxicity (P = 0.04 and P = 0.02, respectively).	Platinum	70-78	methylenetetrahydrofolate reductase	Homo sapiens	0-5
32257953-8	2019	MTHFR rs1801131 and MDM2 rs1690924 were significantly correlated with platinum-induced GI toxicity (P = 0.04 and P = 0.02, respectively).	Platinum	70-78	MDM2 proto-oncogene	Homo sapiens	20-24
32171277-2	2020	Reversion mutations that restore BRCA1/2 function have been shown to be responsible for resistance to platinum-based chemotherapy and PARP inhibitors, however there is no information on the sequential use of these agents in prostate cancer.	Platinum	102-110	BRCA1 DNA repair associated	Homo sapiens	33-40
32171277-8	2020	CONCLUSIONS: Here we report a case of a patient with prostate cancer who received a platinum agent and PARP inhibitor sequentially and in whom polyclonal BRCA2 reversion mutations were identified as the likely mechanism of acquired resistance to carboplatin and primary resistance to PARP inhibition.	Platinum	84-92	BRCA2 DNA repair associated	Homo sapiens	154-159
32171277-8	2020	CONCLUSIONS: Here we report a case of a patient with prostate cancer who received a platinum agent and PARP inhibitor sequentially and in whom polyclonal BRCA2 reversion mutations were identified as the likely mechanism of acquired resistance to carboplatin and primary resistance to PARP inhibition.	Platinum	84-92	poly(ADP-ribose) polymerase 1	Homo sapiens	284-288
32355733-9	2020	Analysis of dynamic N-glycomic changes during the development of platinum resistance in cisplatin-resistant variants was performed with MALDI-time-of-flight (TOF)-MS combined with ethyl esterification derivatization, which were used to discriminate between alpha2,3- and alpha2,6-linkage N-acetylneuraminic acid.	Platinum	65-73	immunoglobulin kappa variable 2-24	Homo sapiens	257-265
32355733-9	2020	Analysis of dynamic N-glycomic changes during the development of platinum resistance in cisplatin-resistant variants was performed with MALDI-time-of-flight (TOF)-MS combined with ethyl esterification derivatization, which were used to discriminate between alpha2,3- and alpha2,6-linkage N-acetylneuraminic acid.	Platinum	65-73	immunoglobulin kappa variable 6-21 (non-functional)	Homo sapiens	271-279
32355733-13	2020	Conclusions: Analysis of N-glycans and glycogene expression showed that alpha2,3-linked sialic structures might serve as biomarkers to monitor the development of platinum resistance and to guide individualized treatment of ovarian cancer patients.	Platinum	162-170	immunoglobulin kappa variable 2-24	Homo sapiens	72-80
31853007-0	2020	PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.	Platinum	25-33	CD274 molecule	Homo sapiens	0-5
31832811-0	2020	Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients.	Platinum	80-88	REV3 like, DNA directed polymerase zeta catalytic subunit	Homo sapiens	25-30
32060649-2	2020	Here, we discuss the interactions of an organometallic complex consisting of an acetylsalicylic acid (ASA) moiety attached to a PtII center via an alkenol linker in a Zeise"s salt-type coordination (ASA-buten-PtCl3) with model peptides angiotensin 1 (AT), substance P (Sub P), and ubiquitin (UQ).	Platinum	128-132	tachykinin precursor 1	Homo sapiens	256-267
31930546-3	2020	Here, we report that the cytoplasmic distribution of APE1 plays a key role in the sensitivity of combination platinum chemotherapy in osteosarcoma.	Platinum	109-117	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	53-57
31930546-8	2020	This role is a supplement to the extranuclear function of APE1, and cytoplasmic APE1 expression level could be a promising predictor of platinum treatment prognosis for osteosarcoma patients.	Platinum	136-144	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	80-84
32609666-6	2020	On the basis of the principle of synthetic lethality, and to avert resistance to PARP inhibitors, clinical trials of combination therapy with PARP inhibitors and platinum-based chemotherapy have been conducted with an early signal.	Platinum	162-170	poly(ADP-ribose) polymerase 1	Homo sapiens	81-85
32352724-1	2020	INTRODUCTION: Somatic mutations in BRCA1/2 and other homologous recombination repair (HRR) genes have been associated with sensitivity to PARP inhibitors and/or platinum agents in several cancers, whereas hypermutant tumors caused by alterations in POLE or mismatch repair genes have demonstrated robust responses to immunotherapy.	Platinum	161-169	BRCA1 DNA repair associated	Homo sapiens	35-42
32186787-6	2020	Recently, phase 3 studies have shown that ovarian cancer patients with recurrent, platinum sensitive disease who were treated with PARP inhibitors have shown statistically significant improvement in progression free survival.	Platinum	82-90	poly(ADP-ribose) polymerase 1	Homo sapiens	131-135
32186787-9	2020	Following these studies, the FDA and the European authorities granted an accelerated approval for the use of PARP inhibitors as maintenance treatment after first line treatment, for BRCA carriers, and at the recurrence for platinum sensitive patients.	Platinum	223-231	poly(ADP-ribose) polymerase 1	Homo sapiens	109-113
32186787-10	2020	Subsequently, it was added to the benchmark medications for recurrent platinum sensitive BRCA carriers (germ line or somatic) by the Ministry of Health in Israel.	Platinum	70-78	BRCA1 DNA repair associated	Homo sapiens	89-93
32060649-2	2020	Here, we discuss the interactions of an organometallic complex consisting of an acetylsalicylic acid (ASA) moiety attached to a PtII center via an alkenol linker in a Zeise"s salt-type coordination (ASA-buten-PtCl3) with model peptides angiotensin 1 (AT), substance P (Sub P), and ubiquitin (UQ).	Platinum	128-132	tachykinin precursor 1	Homo sapiens	269-274
32194682-8	2020	In xenograft mice, GL-CDDP-Cy5.5 and CD24-GL-CDDP-Cy5.5 treatment had significantly higher platinum concentration in disseminated tumor cells than cisplatin (P<0.05).	Platinum	91-99	CD24a antigen	Mus musculus	37-41
31735414-3	2020	Benefiting from the structural advantages and multimetallic compositions, the as-prepared PtCoRu NAs displayed remarkably enhanced electrocatalytic performance for the HER in 1.0 M KOH, with a low overpotential (eta, 22 mV) to drive 10 mA cm-2, small Tafel slope (46 mV dec-1), and high exchange current density (j0, 3.30 mA cm-2) during the long-term electrolysis.	Platinum	90-96	endothelin receptor type A	Homo sapiens	52-55
31735414-3	2020	Benefiting from the structural advantages and multimetallic compositions, the as-prepared PtCoRu NAs displayed remarkably enhanced electrocatalytic performance for the HER in 1.0 M KOH, with a low overpotential (eta, 22 mV) to drive 10 mA cm-2, small Tafel slope (46 mV dec-1), and high exchange current density (j0, 3.30 mA cm-2) during the long-term electrolysis.	Platinum	90-96	deleted in esophageal cancer 1	Homo sapiens	270-275
31970886-9	2020	IHC analysis showed that platinum-resistant cancer tissues more frequently had high HOXB9 expression than platinum-sensitive cancer tissues.	Platinum	25-33	homeobox B9	Homo sapiens	84-89
31970886-10	2020	HOXB9, which is overexpressed in RMUG-S but not in SKOV-3 cells, appeared to be associated with cell line-specific platinum resistance in RMUG-S. Inhibiting HOXB9 overexpression in RMUG-S cells may effectively eliminate platinum-resistant ovarian cancer cells by facilitating apoptosis and inhibiting EMT.	Platinum	115-123	homeobox B9	Homo sapiens	0-5
31970886-10	2020	HOXB9, which is overexpressed in RMUG-S but not in SKOV-3 cells, appeared to be associated with cell line-specific platinum resistance in RMUG-S. Inhibiting HOXB9 overexpression in RMUG-S cells may effectively eliminate platinum-resistant ovarian cancer cells by facilitating apoptosis and inhibiting EMT.	Platinum	115-123	homeobox B9	Homo sapiens	157-162
31970886-10	2020	HOXB9, which is overexpressed in RMUG-S but not in SKOV-3 cells, appeared to be associated with cell line-specific platinum resistance in RMUG-S. Inhibiting HOXB9 overexpression in RMUG-S cells may effectively eliminate platinum-resistant ovarian cancer cells by facilitating apoptosis and inhibiting EMT.	Platinum	220-228	homeobox B9	Homo sapiens	0-5
31970886-10	2020	HOXB9, which is overexpressed in RMUG-S but not in SKOV-3 cells, appeared to be associated with cell line-specific platinum resistance in RMUG-S. Inhibiting HOXB9 overexpression in RMUG-S cells may effectively eliminate platinum-resistant ovarian cancer cells by facilitating apoptosis and inhibiting EMT.	Platinum	220-228	homeobox B9	Homo sapiens	157-162
32027803-6	2020	Strikingly, the mass activity and specific activity of H-PtNiCu-AAT NPs (0.977 A mg-1Pt and 1.458 mA cm-2) is 7.1 and 6.9 times higher than that of commercial Pt/C (0.138 A mg-1Pt and 0.212 mA cm-2), respectively.	Platinum	57-59	serpin family A member 1	Homo sapiens	64-67
32008866-2	2020	ERCC1 is a potential predictive biomarker for platinum-based chemotherapy.	Platinum	46-54	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
32027803-6	2020	Strikingly, the mass activity and specific activity of H-PtNiCu-AAT NPs (0.977 A mg-1Pt and 1.458 mA cm-2) is 7.1 and 6.9 times higher than that of commercial Pt/C (0.138 A mg-1Pt and 0.212 mA cm-2), respectively.	Platinum	85-87	serpin family A member 1	Homo sapiens	64-67
32027803-6	2020	Strikingly, the mass activity and specific activity of H-PtNiCu-AAT NPs (0.977 A mg-1Pt and 1.458 mA cm-2) is 7.1 and 6.9 times higher than that of commercial Pt/C (0.138 A mg-1Pt and 0.212 mA cm-2), respectively.	Platinum	85-87	serpin family A member 1	Homo sapiens	64-67
32080166-7	2020	Moreover, we found a significant correlation between the expression of ID1 and ATF6 in 1104 high grade serous ovarian cancer tissues, and that patients with the high expression of ID1 or ATF6 were resistant to platinum treatment and had the poor overall survival and progression-free survival.	Platinum	210-218	inhibitor of DNA binding 1, HLH protein	Homo sapiens	71-74
31999292-6	2020	The reaction commences by oxidation of the Pt(ii) complex to give the platinum(iv) species [Pt(bhq)(SMe2)(OAc)2](OAc) followed by C-H activation of benzene to afford the intermediate [PtPh(bhq)(SMe2)(OAc)](OAc) concurrently with the release of HOAc.	Platinum	43-49	hypoacusis 2 (autosomal recessive)	Homo sapiens	244-248
31999292-6	2020	The reaction commences by oxidation of the Pt(ii) complex to give the platinum(iv) species [Pt(bhq)(SMe2)(OAc)2](OAc) followed by C-H activation of benzene to afford the intermediate [PtPh(bhq)(SMe2)(OAc)](OAc) concurrently with the release of HOAc.	Platinum	70-78	hypoacusis 2 (autosomal recessive)	Homo sapiens	244-248
32121031-1	2020	A novel electrochemical method to assay phospholipase D (PLD) activity is proposed based on the employment of a choline biosensor realized by immobilizing choline oxidase through co-crosslinking on an overoxidized polypyrrole film previously deposited on a platinum electrode.	Platinum	257-265	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	40-55
32121031-1	2020	A novel electrochemical method to assay phospholipase D (PLD) activity is proposed based on the employment of a choline biosensor realized by immobilizing choline oxidase through co-crosslinking on an overoxidized polypyrrole film previously deposited on a platinum electrode.	Platinum	257-265	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	57-60
32080166-7	2020	Moreover, we found a significant correlation between the expression of ID1 and ATF6 in 1104 high grade serous ovarian cancer tissues, and that patients with the high expression of ID1 or ATF6 were resistant to platinum treatment and had the poor overall survival and progression-free survival.	Platinum	210-218	activating transcription factor 6	Homo sapiens	79-83
32080166-7	2020	Moreover, we found a significant correlation between the expression of ID1 and ATF6 in 1104 high grade serous ovarian cancer tissues, and that patients with the high expression of ID1 or ATF6 were resistant to platinum treatment and had the poor overall survival and progression-free survival.	Platinum	210-218	inhibitor of DNA binding 1, HLH protein	Homo sapiens	180-183
32080166-7	2020	Moreover, we found a significant correlation between the expression of ID1 and ATF6 in 1104 high grade serous ovarian cancer tissues, and that patients with the high expression of ID1 or ATF6 were resistant to platinum treatment and had the poor overall survival and progression-free survival.	Platinum	210-218	activating transcription factor 6	Homo sapiens	187-191
31830435-4	2020	The aim of this study was to adapt the alanine aminotransferase (ALT) enzyme to the platinum (Pt) thin film electrode system and quantitatively determine the enzyme levels via enzymatically generated H2O2 with differential pulse voltammetry (DPV).	Platinum	84-92	glutamic--pyruvic transaminase	Homo sapiens	39-63
31857293-6	2020	Here, we show that NAMPT inhibition suppresses senescence-associated CSCs induced by platinum-based chemotherapy in EOC.	Platinum	85-93	nicotinamide phosphoribosyltransferase	Mus musculus	19-24
31830435-4	2020	The aim of this study was to adapt the alanine aminotransferase (ALT) enzyme to the platinum (Pt) thin film electrode system and quantitatively determine the enzyme levels via enzymatically generated H2O2 with differential pulse voltammetry (DPV).	Platinum	94-96	glutamic--pyruvic transaminase	Homo sapiens	39-63
32053991-5	2020	CST shows prominent features of BRCA1-mutated triple-negative breast cancers including increased motility, high proliferation rate, genome instability and sensitivity to platinum chemotherapy and PARP inhibitors (olaparib, veliparib, rucaparib and talazoparib).	Platinum	170-178	cortistatin	Mus musculus	0-3
31703998-0	2020	Paper based colorimetric detection of miRNA-21 using Ag/Pt nanoclusters.	Platinum	56-58	microRNA 21	Homo sapiens	38-46
31703998-2	2020	In this work, a novel paper based biosensor was fabricated to detect sub-micro molar concentrations of miRNA-21 based on peroxidase mimetic activity of DNA-templated Ag/Pt nanoclusters (DNA-Ag/Pt NCs), which could catalyze the reaction of hydrogen peroxide and 3,3",5,5" tetramethylbenzidine (TMB), to produce a blue color.	Platinum	169-171	microRNA 21	Homo sapiens	103-111
31703998-2	2020	In this work, a novel paper based biosensor was fabricated to detect sub-micro molar concentrations of miRNA-21 based on peroxidase mimetic activity of DNA-templated Ag/Pt nanoclusters (DNA-Ag/Pt NCs), which could catalyze the reaction of hydrogen peroxide and 3,3",5,5" tetramethylbenzidine (TMB), to produce a blue color.	Platinum	193-195	microRNA 21	Homo sapiens	103-111
31815582-1	2020	PURPOSE: Platinum-based therapy is the standard of care in patients who have HER2-negative, advanced esophagogastric cancer (AEGC).	Platinum	9-17	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-81
31815582-2	2020	Retrospective data suggest that intratumoral ERCC1 levels may determine platinum sensitivity.	Platinum	72-80	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	45-50
31940170-3	2020	The obtained Ni3N/NF displays a high HER activity with a small overpotential of 44 mV and a low Tafel slope of 46 mV dec-1, which is competitive to Pt/C catalyst.	Platinum	148-150	deleted in esophageal cancer 1	Homo sapiens	117-122
31910959-1	2020	A simple electrochemical strategy has been designed for the analysis of MUC1 using electrodeposited gold platinum bimetallic nanoparticles (Au-PtBNPs) on the surface of carboxylated graphene oxide (CGO)/FTO electrode as a signal amplification platform.	Platinum	105-113	mucin 1, cell surface associated	Homo sapiens	72-76
31944103-5	2020	When Co9-xNixS8/NC is applied as a cathode catalyst in zinc-air batteries, considerably higher power density about 75 mW cm-2 and discharge voltage are achieved compared to those of batteries with commercial Pt/C and other ZIF-derived catalysts.	Platinum	208-210	phosphoserine phosphatase pseudogene 1	Homo sapiens	5-8
32083163-5	2020	Here we report the results of an abbreviated trial of AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian, fallopian tube, and primary peritoneal cancer with PTEN loss.	Platinum	79-87	AKT serine/threonine kinase 1	Homo sapiens	54-57
31942804-2	2020	The approach has been successful in the case of previously known O2BF4, O2MF6 (M = As, Sb, Au; Pt), O2GeF5, and (O2)2(Ti7F30).	Platinum	95-97	immunoglobulin kappa variable 1D-39	Homo sapiens	65-67
31651523-13	2020	CRS in the omentum had no significant association with platinum resistance; however, the adnexal CRS 1/2 were 3 times as likely to develop platinum resistance compared with CRS 3 (relative risk=3.94, 95% CI: 1.03-15.09, P=0.046).	Platinum	139-147	twist family bHLH transcription factor 1	Homo sapiens	97-102
31879997-3	2020	Here, a new strategy is demonstrated to synthesize active and stable Pt-based electrocatalysts for hydrogen evolution by confining Pt clusters in hollow mesoporous carbon spheres (Pt5 /HMCS).	Platinum	69-71	MKKS centrosomal shuttling protein	Homo sapiens	185-189
31879997-3	2020	Here, a new strategy is demonstrated to synthesize active and stable Pt-based electrocatalysts for hydrogen evolution by confining Pt clusters in hollow mesoporous carbon spheres (Pt5 /HMCS).	Platinum	131-133	MKKS centrosomal shuttling protein	Homo sapiens	185-189
31879997-5	2020	Particularly, the optimal Pt5 /HMCS electrocatalyst exhibits 12 times the mass activity of Pt in commercial Pt/C catalyst with similar Pt loading.	Platinum	26-29	MKKS centrosomal shuttling protein	Homo sapiens	31-35
31879997-5	2020	Particularly, the optimal Pt5 /HMCS electrocatalyst exhibits 12 times the mass activity of Pt in commercial Pt/C catalyst with similar Pt loading.	Platinum	26-28	MKKS centrosomal shuttling protein	Homo sapiens	31-35
31879997-5	2020	Particularly, the optimal Pt5 /HMCS electrocatalyst exhibits 12 times the mass activity of Pt in commercial Pt/C catalyst with similar Pt loading.	Platinum	91-93	MKKS centrosomal shuttling protein	Homo sapiens	31-35
31879997-5	2020	Particularly, the optimal Pt5 /HMCS electrocatalyst exhibits 12 times the mass activity of Pt in commercial Pt/C catalyst with similar Pt loading.	Platinum	91-93	MKKS centrosomal shuttling protein	Homo sapiens	31-35
32015953-4	2020	PtBXL8 and PtBXL9 were closely related to AtBXL1, an important enzyme in the normal development of the Arabidopsis cell wall structure.	Platinum	0-6	beta-xylosidase 1	Arabidopsis thaliana	42-48
32195021-10	2020	Moreover, increased expression of T cell-attracting chemokines (CXCL9, CXCL10 and CCL5) was detected in MC38 cells after platinum treatment.	Platinum	121-129	chemokine (C-X-C motif) ligand 9	Mus musculus	64-69
32195021-10	2020	Moreover, increased expression of T cell-attracting chemokines (CXCL9, CXCL10 and CCL5) was detected in MC38 cells after platinum treatment.	Platinum	121-129	chemokine (C-X-C motif) ligand 10	Mus musculus	71-77
32195021-10	2020	Moreover, increased expression of T cell-attracting chemokines (CXCL9, CXCL10 and CCL5) was detected in MC38 cells after platinum treatment.	Platinum	121-129	chemokine (C-C motif) ligand 5	Mus musculus	82-86
31651523-15	2020	Adnexal CRS 1/2 are more likely to develop platinum-resistant disease.	Platinum	43-51	twist family bHLH transcription factor 1	Homo sapiens	8-13
31787750-1	2020	Pancreatic cancers occurring in carriers of a pathogenic germline alteration in BRCA1/2 (gBRCA1/2) are assumed to demonstrate homologous recombination repair deficiency (HRD), associated with sensitivity to platinum-based chemotherapy and synthetic lethality with PARP inhibitors (PARPi).	Platinum	207-215	BRCA1 DNA repair associated	Homo sapiens	80-87
31388926-0	2020	Kinetic and Thermodynamic Investigation of Human Serum Albumin Interaction with Anticancer Glycine Derivative of Platinum Complex by Using Spectroscopic Methods and Molecular Docking.	Platinum	113-121	albumin	Homo sapiens	55-62
31388926-3	2020	The interaction of human serum albumin (HSA) with Pt complex was studied by using UV-Vis, fluorescence spectroscopy methods, and molecular docking at 27 and 37  C in the physiological situation (I = 10 mM, pH = 7.4).	Platinum	50-52	albumin	Homo sapiens	25-38
31396885-2	2020	This article discusses electrochemical methods to synthesize platinum-graphene hybrid nanosheets (Pt-GR), and how these methods can be utilized to create a new modified electrode, the platinum-graphene nanohybrid glass carbon electrode (Pt-GR/GCE).	Platinum	184-192	glycine decarboxylase	Homo sapiens	237-246
31919610-4	2020	For the ECL assay, activated CdS/TiO2 NTs were assembled with complementary DNA, PSA aptamer and probe DNA-functionalized SiO2@Pt nanoparticles (NPs) via DNA hybridization to form the detection platform.	Platinum	127-129	CDP-diacylglycerol synthase 1	Homo sapiens	29-32
31919610-5	2020	The SiO2@Pt NPs acted as ECL quencher of CdS/TiO2 NTs.	Platinum	9-11	CDP-diacylglycerol synthase 1	Homo sapiens	41-44
31919610-6	2020	In the presence of PSA, ECL increased after the release of pDNA-SiO2@Pt NPs because of the binding of PSA to the aptamer.	Platinum	69-71	kallikrein related peptidase 3	Homo sapiens	19-22
31919610-6	2020	In the presence of PSA, ECL increased after the release of pDNA-SiO2@Pt NPs because of the binding of PSA to the aptamer.	Platinum	69-71	kallikrein related peptidase 3	Homo sapiens	102-105
31726273-0	2020	Mulberry-like Au@PtPd porous nanorods composites as signal amplifiers for sensitive detection of CEA.	Platinum	17-21	CEA cell adhesion molecule 3	Homo sapiens	97-100
31761899-4	2020	METHODS: An international database of 439 patients who received post-platinum PD-1/L1 monotherapies was collected for validation.	Platinum	69-77	programmed cell death 1	Homo sapiens	78-82
31787750-1	2020	Pancreatic cancers occurring in carriers of a pathogenic germline alteration in BRCA1/2 (gBRCA1/2) are assumed to demonstrate homologous recombination repair deficiency (HRD), associated with sensitivity to platinum-based chemotherapy and synthetic lethality with PARP inhibitors (PARPi).	Platinum	207-215	collagen type XI alpha 2 chain	Homo sapiens	264-268
31787751-0	2020	Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.	Platinum	0-8	BRCA1 DNA repair associated	Homo sapiens	99-104
31739109-4	2020	Upon the addition cell extract, the telomerase primer could extend and then hybridize with assistant DNA2 in the triple-helix, leading to the structure of triple-helix changes and release the hairpin DNA to hybridize with the capture DNA on the surface of Pt@P-MOF(Fe), resulting in the electrochemical signal readout of H2O2 reduction.	Platinum	256-258	DNA replication helicase/nuclease 2	Homo sapiens	101-105
31787751-0	2020	Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.	Platinum	0-8	BRCA2 DNA repair associated	Homo sapiens	106-111
31813938-1	2020	BACKGROUND: Tumour cells with BRCA1/2 gene mutations demonstrate increased sensitivity to platinum and poly (ADP-ribose) polymerase (PARP) inhibitors.	Platinum	90-98	BRCA1 DNA repair associated	Homo sapiens	30-37
31787751-0	2020	Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.	Platinum	0-8	partner and localizer of BRCA2	Homo sapiens	115-120
31787751-1	2020	BACKGROUND: Retrospective studies suggest a survival benefit when platinum-based chemotherapy is administered to patients with pancreatic cancer harbouring a germline mutation in BRCA1, BRCA2 or PALB2 (mut-positive PDAC).	Platinum	66-74	BRCA1 DNA repair associated	Homo sapiens	179-184
31787751-1	2020	BACKGROUND: Retrospective studies suggest a survival benefit when platinum-based chemotherapy is administered to patients with pancreatic cancer harbouring a germline mutation in BRCA1, BRCA2 or PALB2 (mut-positive PDAC).	Platinum	66-74	BRCA2 DNA repair associated	Homo sapiens	186-191
31787751-1	2020	BACKGROUND: Retrospective studies suggest a survival benefit when platinum-based chemotherapy is administered to patients with pancreatic cancer harbouring a germline mutation in BRCA1, BRCA2 or PALB2 (mut-positive PDAC).	Platinum	66-74	partner and localizer of BRCA2	Homo sapiens	195-200
31863638-4	2020	Olaparib is a PARP inhibitor approved for maintenance therapy following platinum-based chemotherapy.	Platinum	72-80	poly(ADP-ribose) polymerase 1	Homo sapiens	14-18
31730712-9	2020	In a multivariable analysis, patients treated with platinum-containing chemotherapy had a 2.5-fold increased hazard ratio (HR; 95% CI, 1.8-3.5) for SMN mortality in comparison with patients without platinum-containing chemotherapy.	Platinum	51-59	survival of motor neuron 1, telomeric	Homo sapiens	148-151
31730712-9	2020	In a multivariable analysis, patients treated with platinum-containing chemotherapy had a 2.5-fold increased hazard ratio (HR; 95% CI, 1.8-3.5) for SMN mortality in comparison with patients without platinum-containing chemotherapy.	Platinum	198-206	survival of motor neuron 1, telomeric	Homo sapiens	148-151
31730712-10	2020	The HR for SMN mortality increased 0.29 (95% CI, 0.19-0.39) per 100 mg/m2 platinum dose administered (Ptrend  < .001).	Platinum	74-82	survival of motor neuron 1, telomeric	Homo sapiens	11-14
31730712-12	2020	CONCLUSIONS: Platinum-containing chemotherapy is associated with a dose-dependent increase in the risk of SMN mortality.	Platinum	13-21	survival of motor neuron 1, telomeric	Homo sapiens	106-109
31845438-6	2020	UCHL1 was found to be expressed in HGNECs, particularly in cell lines and patient samples of SCLC, and the combined use of platinum-doublets with selective UCHL1 inhibitors improved its therapeutic response in vitro.	Platinum	123-131	ubiquitin C-terminal hydrolase L1	Homo sapiens	0-5
32040573-3	2020	METHODS: Serum miR-622 expression was assessed in serum prior to first-line platinum-based chemotherapy in a prospective multicenter study (miRNA Serum Analysis, miRSA, NCT01391351) and a retrospective cohort (Biological Resource Center, BRC), and was also studied at relapse.	Platinum	76-84	microRNA 622	Homo sapiens	15-22
32040573-8	2020	Serum miR-622 expression is a predictive independent biomarker of response to platinum-based chemotherapy for newly diagnosed and recurrent HGSOC.	Platinum	78-86	microRNA 622	Homo sapiens	6-13
31815680-5	2020	Using public cDNA microarray database and single cohort study, LDLR expressions were positively associated with epithelial ovarian carcinomas (EOCs) platinum-based chemotherapy patients" disease prognosis.	Platinum	149-157	low density lipoprotein receptor	Homo sapiens	63-67
31815680-12	2020	Significance: this study describes the role of LDLR in the development of insensitivity to platinum-based chemotherapy in epithelial ovarian cancer.	Platinum	91-99	low density lipoprotein receptor	Homo sapiens	47-51
31650446-7	2020	This "PARP trapping" potentiates synergism between PARP inhibition and both alkylating agents and platinum-based chemotherapy.	Platinum	98-106	poly(ADP-ribose) polymerase 1	Homo sapiens	6-10
31669591-10	2020	CONCLUSIONS: Platinum/pemetrexed-based chemotherapy shows modest efficacy in ALK-positive NSCLC after failure of second-generation ALK TKIs.	Platinum	13-21	ALK receptor tyrosine kinase	Homo sapiens	77-80
31629274-2	2020	Herein, trimetallic PtRhCo petal-assembled alloyed nanoflowers (PtRhCo PAANFs) were fabricated via a one-pot solvothermal method, which showed remarkable enlargement in specific activity and mass activity over PtRh0.25Co nanodentrites (NDs), PtRh1.5Co NDs, PtCo NDs and commercial Pt/C catalysts for ethylene glycol oxidation in 0.5 M KOH solution.	Platinum	20-22	peptidyl-tRNA hydrolase 1 homolog	Homo sapiens	242-247
31669591-0	2020	Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors.	Platinum	12-20	ALK receptor tyrosine kinase	Homo sapiens	60-63
31669591-0	2020	Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors.	Platinum	12-20	ALK receptor tyrosine kinase	Homo sapiens	111-114
31669591-10	2020	CONCLUSIONS: Platinum/pemetrexed-based chemotherapy shows modest efficacy in ALK-positive NSCLC after failure of second-generation ALK TKIs.	Platinum	13-21	ALK receptor tyrosine kinase	Homo sapiens	131-134
31966052-6	2020	A total of 26 patients exhibited highly methylated PD-L1; in this group, the median progression-free survival time of patients receiving platinum/fluorouracil chemotherapy was 4.2 months longer than those receiving paclitaxel/fluorouracil chemotherapy, and the risk of disease progression in patients receiving paclitaxel/fluorouracil chemotherapy was 5.009 times higher compared with patients who received platinum/fluorouracil chemotherapy.	Platinum	137-145	CD274 molecule	Homo sapiens	51-56
31837576-4	2020	Adding the epidermal growth factor receptor (EGFR) inhibitor cetuximab to a platinum/5-fluorouracil doublet (the so-called EXTREME regimen) produced a statistically but also clinically significant improvement of survival and became thus the standard first-line palliative treatment in adequately fit patients.	Platinum	76-84	epidermal growth factor receptor	Homo sapiens	11-43
31837576-4	2020	Adding the epidermal growth factor receptor (EGFR) inhibitor cetuximab to a platinum/5-fluorouracil doublet (the so-called EXTREME regimen) produced a statistically but also clinically significant improvement of survival and became thus the standard first-line palliative treatment in adequately fit patients.	Platinum	76-84	epidermal growth factor receptor	Homo sapiens	45-49
31966052-6	2020	A total of 26 patients exhibited highly methylated PD-L1; in this group, the median progression-free survival time of patients receiving platinum/fluorouracil chemotherapy was 4.2 months longer than those receiving paclitaxel/fluorouracil chemotherapy, and the risk of disease progression in patients receiving paclitaxel/fluorouracil chemotherapy was 5.009 times higher compared with patients who received platinum/fluorouracil chemotherapy.	Platinum	407-415	CD274 molecule	Homo sapiens	51-56
33747282-4	2021	We undertook this retrospective study to determine the influence of SNPs in TOP2A (rs34300454; rs13695; rs11540720) and ERCC1 (rs11615; rs3212986) genes on the efficiency and toxicity of chemotherapy with platinum and etoposide in SCLC Caucasian patients.	Platinum	205-213	DNA topoisomerase II alpha	Homo sapiens	76-81
31902551-1	2020	OBJECTIVE: To evaluate the correlation between expression of p53, Livin, Excision repair cross-complementation group 1 (ERCC1), BRCA1 and Poly (ADP-ribose) polymerase 1 (PARP 1) in epithelial ovarian cancer (EOC) tissues with platinum-based chemotherapy and prognosis in patients who received either comprehensive surgical staging or cytoreductive surgery.	Platinum	226-234	poly(ADP-ribose) polymerase 1	Homo sapiens	170-176
32005272-7	2020	RESULTS: High miR-509-3 expression indicated better response to platinum and longer progression-free and overall survival in two independent ovarian cancer patient cohorts (high vs. low miR-509-3 expression; PFS: TCGA P &lt; 0.05, Qilu P &lt; 0.05; OS: TCGA P &lt; 0.05, Qilu P &lt; 0.01).	Platinum	64-72	microRNA 5093	Homo sapiens	14-23
31898905-5	2020	Interestingly, it displays a 0.88 V (vs reversible hydrogen electrode, RHE) half-wave potential (E1/2) with a four-electron-transfer pathway and excellent stability outperforming platinum/carbon (Pt/C) in an alkaline medium.	Platinum	196-198	factor interacting with PAPOLA and CPSF1	Homo sapiens	71-74
31797087-1	2020	Germline/somatic BRCA-mutated ovarian carcinomas (OC) are associated to have better response with platinum-based chemotherapy and long-term prognosis than non-BRCA-associated OCs.	Platinum	98-106	BRCA1 DNA repair associated	Homo sapiens	17-21
31913599-6	2020	The onset potential of nonprecious BCNT/Co-800 catalyst was 1.12 V. The half-wave potential was 0.881 V. The result was superior to that of commercial Pt/C (0.827 V vs RHE).	Platinum	151-153	craniofacial development protein 1	Homo sapiens	35-39
31669203-1	2020	PARP1 inhibitor (Niraparib, Olaparib, Rucaparib) maintenance therapy improves progression-free survival in platinum sensitive sporadic epithelial ovarian cancers.	Platinum	107-115	poly(ADP-ribose) polymerase 1	Homo sapiens	0-5
31979221-7	2020	Conversely, treatment of carboplatin-resistant cells expressing high levels of endogenous IL-6 with the monoclonal anti-IL-6R antibody tocilizumab changed their status to "platinum-sensitive", exhibiting a decreased IC50 value for carboplatin, decreased growth, and significantly higher estrogen metabolism.	Platinum	172-180	interleukin 6	Homo sapiens	90-94
31979221-7	2020	Conversely, treatment of carboplatin-resistant cells expressing high levels of endogenous IL-6 with the monoclonal anti-IL-6R antibody tocilizumab changed their status to "platinum-sensitive", exhibiting a decreased IC50 value for carboplatin, decreased growth, and significantly higher estrogen metabolism.	Platinum	172-180	interleukin 6 receptor	Homo sapiens	120-125
32004048-3	2020	When the magnetization has a component oriented perpendicular to the plane,  T_{OP} drives a spin current into Pt with out-of-plane polarization due to the spin Seebeck effect.	Platinum	111-113	spindlin 1	Homo sapiens	93-97
32004048-3	2020	When the magnetization has a component oriented perpendicular to the plane,  T_{OP} drives a spin current into Pt with out-of-plane polarization due to the spin Seebeck effect.	Platinum	111-113	spindlin 1	Homo sapiens	156-160
32004048-4	2020	T_{IP} then drags the resulting spin-polarized electrons in Pt parallel to the plane against the gradient direction.	Platinum	60-62	spindlin 1	Homo sapiens	32-36
32004048-5	2020	This finally produces an inverse spin Hall effect voltage in Pt, transverse to  T_{IP} and proportional to the out-of-plane component of the magnetization.	Platinum	61-63	spindlin 1	Homo sapiens	33-37
31894693-2	2020	In this paper, we report systematic studies on spin transport properties of a semiconducting polymer PBDTTT-C-T in the permalloy/polymer/Pt trilayer using the spin pumping method.	Platinum	137-139	spindlin 1	Homo sapiens	47-51
31965001-0	2020	MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab.	Platinum	131-139	methylthioadenosine phosphorylase	Homo sapiens	0-4
32645199-1	2020	The FDA approved enfortumab vedotinejfv (Padcev)-the first drug to treat adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a programmed cell death protein 1 (PD-1)/ programmed cell death ligand 1(PD-L1) inhibitor and platinum-containing chemotherapy.	Platinum	275-283	patr class I histocompatibility antigen, A-126 alpha chain-like	Sus scrofa	216-220
31654544-2	2020	Here, we report a highly efficient photocatalyst by assembling single Pt atoms on defective TiO 2 support (Pt 1 /def-TiO 2 ).	Platinum	70-72	zinc finger protein 77	Homo sapiens	107-111
31654544-2	2020	Here, we report a highly efficient photocatalyst by assembling single Pt atoms on defective TiO 2 support (Pt 1 /def-TiO 2 ).	Platinum	70-72	UTP25 small subunit processome component	Homo sapiens	82-85
31850427-5	2020	The Pt2+-exchanged ZIF-8 phase plays a dual role as a metal ion source for L10-PtZn nanoparticles and as a carbonaceous matrix that restrains the aggregation of nanoparticles during thermal treatment.	Platinum	4-8	immunoglobulin kappa variable 3-7 (non-functional)	Homo sapiens	75-78
31654544-5	2020	This unique structure makes Pt 1 /def-TiO 2 exhibit a recorded-level photocatalytic hydrogen production performance with an unexpectedly high turnover frequency of 51423 h -1 , exceeding the Pt nanoparticles supported TiO 2 catalyst by a factor of 591.	Platinum	28-30	UTP25 small subunit processome component	Homo sapiens	34-37
31850427-6	2020	The L10-PtZn nanoparticles embedded in a hollow carbon nanocage obtained from one-step annealing of Pt2+-exchanged ZIF-8 showed better electrocatalytic activity and durability toward methanol oxidation under acidic electrolyte conditions than those obtained from commercial Pt/C catalysts.	Platinum	100-104	immunoglobulin kappa variable 3-7 (non-functional)	Homo sapiens	4-7
31850427-6	2020	The L10-PtZn nanoparticles embedded in a hollow carbon nanocage obtained from one-step annealing of Pt2+-exchanged ZIF-8 showed better electrocatalytic activity and durability toward methanol oxidation under acidic electrolyte conditions than those obtained from commercial Pt/C catalysts.	Platinum	8-10	immunoglobulin kappa variable 3-7 (non-functional)	Homo sapiens	4-7
31478407-0	2020	ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.	Platinum	127-135	ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1	Homo sapiens	0-5
31834795-4	2020	(2) B undergoes 1,2-acyl migration from the platinum to the cyclometalated carbon through a three-membered platinacycle transition state to give Pt-arene eta2-complex E with an energy barrier of 14.0 kcal/mol.	Platinum	44-52	DNA polymerase iota	Homo sapiens	154-158
31926547-5	2020	RESULTS: We show that MYPT1 (PPP1R12A), encoding myosin phosphatase target subunit 1, is downregulated in ovarian tumors, leading to reduced survival and increased tumorigenesis, as well as resistance to platinum-based therapy.	Platinum	204-212	protein phosphatase 1 regulatory subunit 12A	Homo sapiens	22-27
31926547-5	2020	RESULTS: We show that MYPT1 (PPP1R12A), encoding myosin phosphatase target subunit 1, is downregulated in ovarian tumors, leading to reduced survival and increased tumorigenesis, as well as resistance to platinum-based therapy.	Platinum	204-212	protein phosphatase 1 regulatory subunit 12A	Homo sapiens	29-37
31926547-5	2020	RESULTS: We show that MYPT1 (PPP1R12A), encoding myosin phosphatase target subunit 1, is downregulated in ovarian tumors, leading to reduced survival and increased tumorigenesis, as well as resistance to platinum-based therapy.	Platinum	204-212	protein phosphatase 1 regulatory subunit 12A	Homo sapiens	49-84
31926547-7	2020	Inhibition of the Hippo pathway transcriptional co-activator YAP suppresses the resistance to platinum-based therapy induced by either low MYPT1 expression or miR-30b overexpression, both in vitro and in vivo.	Platinum	94-102	Yes1 associated transcriptional regulator	Homo sapiens	61-64
31926547-7	2020	Inhibition of the Hippo pathway transcriptional co-activator YAP suppresses the resistance to platinum-based therapy induced by either low MYPT1 expression or miR-30b overexpression, both in vitro and in vivo.	Platinum	94-102	protein phosphatase 1 regulatory subunit 12A	Homo sapiens	139-144
31926547-7	2020	Inhibition of the Hippo pathway transcriptional co-activator YAP suppresses the resistance to platinum-based therapy induced by either low MYPT1 expression or miR-30b overexpression, both in vitro and in vivo.	Platinum	94-102	microRNA 30b	Homo sapiens	159-166
31926547-9	2020	Combination therapy with cisplatin and YAP inhibitors suppresses MYPT1-induced resistance, demonstrating the possibility of using this treatment in patients with low MYPT1 expression, who are likely to be resistant to platinum-based therapy.	Platinum	218-226	Yes1 associated transcriptional regulator	Homo sapiens	39-42
31926547-9	2020	Combination therapy with cisplatin and YAP inhibitors suppresses MYPT1-induced resistance, demonstrating the possibility of using this treatment in patients with low MYPT1 expression, who are likely to be resistant to platinum-based therapy.	Platinum	218-226	protein phosphatase 1 regulatory subunit 12A	Homo sapiens	65-70
31926547-9	2020	Combination therapy with cisplatin and YAP inhibitors suppresses MYPT1-induced resistance, demonstrating the possibility of using this treatment in patients with low MYPT1 expression, who are likely to be resistant to platinum-based therapy.	Platinum	218-226	protein phosphatase 1 regulatory subunit 12A	Homo sapiens	166-171
31820986-0	2020	Platinum-Based Modification of Styrylbenzylsulfones as Multifunctional Antitumor Agents: Targeting RAS-RAF Pathway, Enhancing Antitumor Activity and Overcoming Multidrug Resistance.	Platinum	0-8	zinc fingers and homeoboxes 2	Homo sapiens	103-106
31820649-5	2020	These results reveal the spin-angular momentum transfer from metallic Pt to a magnetic moment in FePc molecules, which can be used as a spin torque in a molecular system.	Platinum	70-72	spindlin 1	Homo sapiens	25-29
31820649-5	2020	These results reveal the spin-angular momentum transfer from metallic Pt to a magnetic moment in FePc molecules, which can be used as a spin torque in a molecular system.	Platinum	70-72	spindlin 1	Homo sapiens	136-140
31478407-10	2020	Conclusions: This hypothesis generating study suggests that low expression of ARAP1 is an independent prognostic biomarker of shorter RFS in older patients with HGSC receiving first-line platinum-based antineoplastic therapy, which could be used to identify patients who should receive more intensive treatment and closer surveillance.	Platinum	187-195	ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1	Homo sapiens	78-83
31639439-2	2020	Although platinum-based drugs have shown initial activity in BRCA1-mutated TNBCs, chemoresistance remains a challenge.	Platinum	9-17	BRCA1 DNA repair associated	Homo sapiens	61-66
31721706-6	2020	Pt(II)-Bpy induced DNA damage, which was demonstrated through a marked increase in the expression of cleaved-poly (ADP ribose) polymerase (PARP) and gamma-H2A histone family member X and a decrease in PARP expression.	Platinum	0-10	poly(ADP-ribose) polymerase 1	Homo sapiens	109-137
31721706-6	2020	Pt(II)-Bpy induced DNA damage, which was demonstrated through a marked increase in the expression of cleaved-poly (ADP ribose) polymerase (PARP) and gamma-H2A histone family member X and a decrease in PARP expression.	Platinum	0-10	poly(ADP-ribose) polymerase 1	Homo sapiens	139-143
31721706-6	2020	Pt(II)-Bpy induced DNA damage, which was demonstrated through a marked increase in the expression of cleaved-poly (ADP ribose) polymerase (PARP) and gamma-H2A histone family member X and a decrease in PARP expression.	Platinum	0-10	poly(ADP-ribose) polymerase 1	Homo sapiens	201-205
31553293-13	2020	Understanding the mechanism of resistance to PARP inhibitors and their relationship with platinum resistance may help with the development of antiresistance therapies and optimization of the sequence of drug application in the future clinical treatment of ovarian cancer.	Platinum	89-97	poly(ADP-ribose) polymerase 1	Homo sapiens	45-49
32092740-0	2020	TRAP1 is a predictive biomarker of platinum-based adjuvant chemotherapy benefits in patients with resected lung adenocarcinoma.	Platinum	35-43	TNF receptor associated protein 1	Homo sapiens	0-5
32092740-3	2020	Among the 42 proteins identified here using a proteomics analysis that were recognized by autoantibodies in pretreated sera from patients with lung adenocarcinoma who received platinum-based adjuvant chemotherapy, the tumor necrosis factor-receptor-associated protein 1 (TRAP1) was detected in patients with a short disease-free survival.	Platinum	176-184	TNF receptor associated protein 1	Homo sapiens	218-269
32092740-3	2020	Among the 42 proteins identified here using a proteomics analysis that were recognized by autoantibodies in pretreated sera from patients with lung adenocarcinoma who received platinum-based adjuvant chemotherapy, the tumor necrosis factor-receptor-associated protein 1 (TRAP1) was detected in patients with a short disease-free survival.	Platinum	176-184	TNF receptor associated protein 1	Homo sapiens	271-276
32092740-4	2020	TRAP1 expression was immunohistochemically analyzed in 64 patients with completely resected stage II and IIIA lung adenocarcinoma treated with platinum-based adjuvant chemotherapy.	Platinum	143-151	TNF receptor associated protein 1	Homo sapiens	0-5
32092740-8	2020	These results suggest that TRAP1 expression is a valuable biomarker for predicting the poor survival of platinum-based adjuvant chemotherapy in patients with resected lung adenocarcinoma.	Platinum	104-112	TNF receptor associated protein 1	Homo sapiens	27-32
31548347-11	2020	Patients with metastatic NSCLC with mutations in KEAP1, NFE2L2, or CUL3 have shorter TTF and OS after first-line platinum doublet chemotherapy compared with matched controls.	Platinum	113-121	kelch like ECH associated protein 1	Homo sapiens	49-54
31548347-11	2020	Patients with metastatic NSCLC with mutations in KEAP1, NFE2L2, or CUL3 have shorter TTF and OS after first-line platinum doublet chemotherapy compared with matched controls.	Platinum	113-121	NFE2 like bZIP transcription factor 2	Homo sapiens	56-62
31548347-11	2020	Patients with metastatic NSCLC with mutations in KEAP1, NFE2L2, or CUL3 have shorter TTF and OS after first-line platinum doublet chemotherapy compared with matched controls.	Platinum	113-121	cullin 3	Homo sapiens	67-71
32013831-0	2020	BRCA Mutational Status is a Promising Predictive Biomarker for Platinum-based Chemotherapy in Triple-Negative Breast Cancer.	Platinum	63-71	BRCA1 DNA repair associated	Homo sapiens	0-4
32013831-8	2020	Through this paper, we review a number of recent studies on this topic to better understand the mechanisms and discuss the potential of BRCA mutational status as a predictive biomarker of platinum-based chemotherapy in TNBC.	Platinum	188-196	BRCA1 DNA repair associated	Homo sapiens	136-140
33166854-14	2020	CONCLUSION: Our study has identified that TP53 confers worse survival and response to platinum chemotherapy compared to BAP1.	Platinum	86-94	tumor protein p53	Homo sapiens	42-46
31865042-2	2020	We therefore investigated whether homeobox A9 (HOXA9) promoter methylation in circulating tumour DNA (meth-ctDNA) can serve as a biomarker in patients with platinum-resistant BRCA-mutated OC, undergoing treatment with a PARP inhibitor.	Platinum	156-164	homeobox A9	Homo sapiens	47-52
31865042-2	2020	We therefore investigated whether homeobox A9 (HOXA9) promoter methylation in circulating tumour DNA (meth-ctDNA) can serve as a biomarker in patients with platinum-resistant BRCA-mutated OC, undergoing treatment with a PARP inhibitor.	Platinum	156-164	BRCA1 DNA repair associated	Homo sapiens	175-179
31865042-11	2020	CONCLUSIONS: Longitudinal monitoring of HOXA9 meth-ctDNA is clinically feasible and is strongly correlated to clinical outcomes (PFS, OS), suggesting that it may serve as a valuable predictive biomarker to inform clinical decision-making in the setting of platinum-resistant BRCA-mutated OC treated with a PARP inhibitor.	Platinum	256-264	homeobox A9	Homo sapiens	40-45
31699415-1	2020	OBJECTIVES: Olaparib is approved as maintenance therapy in patients with BRCA mutated platinum sensitive (PS) recurrent ovarian cancer (OC) after response to last platinum based therapy.	Platinum	86-94	BRCA1 DNA repair associated	Homo sapiens	73-77
31776040-10	2020	Furthermore, CDK7 may be a potential therapeutic target for patients with EOC, whether platinum sensitive or resistant.	Platinum	87-95	cyclin dependent kinase 7	Homo sapiens	13-17
31506751-2	2020	Recently, anti-PD-1 antibody therapy became a key treatment for stage IV NSCLC as the combination of immune checkpoint inhibitors (ICIs) and platinum doublet chemotherapy.	Platinum	141-149	programmed cell death 1	Homo sapiens	15-19
33148925-3	2020	Excision repair cross-complementation group 1 enzyme (ERCC1) has been proposed as a molecular predictor of clinical resistance to platinum-based chemotherapy.	Platinum	130-138	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-45
33565499-1	2020	Immune checkpoint blockade with programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors has been standard care for metastatic nonsmall cell lung cancer (NSCLC) and after progression using first-line platinum-containing chemotherapy.	Platinum	232-240	programmed cell death 1	Sus scrofa	32-63
33565499-1	2020	Immune checkpoint blockade with programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors has been standard care for metastatic nonsmall cell lung cancer (NSCLC) and after progression using first-line platinum-containing chemotherapy.	Platinum	232-240	CD274 molecule	Sus scrofa	103-108
31856355-0	2020	Platinum-based combination chemotherapy triggers cancer cell death through induction of BNIP3 and ROS, but not autophagy.	Platinum	0-8	BCL2 interacting protein 3	Homo sapiens	88-93
33148925-3	2020	Excision repair cross-complementation group 1 enzyme (ERCC1) has been proposed as a molecular predictor of clinical resistance to platinum-based chemotherapy.	Platinum	130-138	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	54-59
33148925-11	2020	Platinum resistance was found in eight of the tumors with positive ERCC1 protein expression compared with two among the patients with negative tumor staining for ERCC1 (P = 0.643).	Platinum	0-8	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	67-72
33148925-11	2020	Platinum resistance was found in eight of the tumors with positive ERCC1 protein expression compared with two among the patients with negative tumor staining for ERCC1 (P = 0.643).	Platinum	0-8	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	162-167
31494272-4	2020	pT-ION caused primary (V2 skin) and secondary (V3 skin) hyperalgesia, which was reversed by the Cavalpha2delta1 antagonist gabapentin and by the expression of Cavalpha2delta1-targeting interfering RNA in trigeminal ganglion (TG)-V3 neurons.	Platinum	0-2	calcium channel, voltage-dependent, alpha2/delta subunit 1	Mus musculus	96-111
31494272-4	2020	pT-ION caused primary (V2 skin) and secondary (V3 skin) hyperalgesia, which was reversed by the Cavalpha2delta1 antagonist gabapentin and by the expression of Cavalpha2delta1-targeting interfering RNA in trigeminal ganglion (TG)-V3 neurons.	Platinum	0-2	calcium channel, voltage-dependent, alpha2/delta subunit 1	Mus musculus	159-174
31577852-1	2020	Development of resistance to platinum and PARP inhibitors via secondary BRCA gene mutations that restore functional homologous recombination has been observed in a number of cancer types.	Platinum	29-37	BRCA1 DNA repair associated	Homo sapiens	72-76
31788895-1	2020	A Pd/Pt-Bu3 catalyst having bulky, electron-rich ligands significantly outperforms conventional "step-growth catalysts" Pd(PPh3 )4 and Pd(Po-Tol3 )3 in the Suzuki polycondensation of the AB-type arylene-based monomers, such as some of the substituted fluorenes, carbazoles, and phenylenes.	Platinum	5-11	caveolin 1	Homo sapiens	123-127
31753727-1	2020	BACKGROUND: Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonist-plus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma.	Platinum	168-176	kinase insert domain receptor	Homo sapiens	32-77
31534014-1	2020	Poly (ADP-ribose) Polymerase (PARP) inhibitors (PARPi) are approved to treat recurrent ovarian cancer with BRCA1 or BRCA2 mutations, and as maintenance therapy for recurrent platinum sensitive ovarian cancer (BRCA wild-type or mutated) after treatment with platinum.	Platinum	174-182	poly(ADP-ribose) polymerase 1	Homo sapiens	0-28
31872332-3	2020	Since CD44 is a CSC marker as well as a transmembrane receptor for hyaluronic acid (HA) and many other extracellular matrix (ECM) components, in this protocol, a biocompatible platform was synthesized by conjugation of HA onto luminescent platinum nanoclusters (Pt NCs) in human hemoglobin (Hb) (Hb/Pt NCs).	Platinum	239-247	CD44 molecule (Indian blood group)	Homo sapiens	6-10
31872332-3	2020	Since CD44 is a CSC marker as well as a transmembrane receptor for hyaluronic acid (HA) and many other extracellular matrix (ECM) components, in this protocol, a biocompatible platform was synthesized by conjugation of HA onto luminescent platinum nanoclusters (Pt NCs) in human hemoglobin (Hb) (Hb/Pt NCs).	Platinum	262-264	CD44 molecule (Indian blood group)	Homo sapiens	6-10
31872332-3	2020	Since CD44 is a CSC marker as well as a transmembrane receptor for hyaluronic acid (HA) and many other extracellular matrix (ECM) components, in this protocol, a biocompatible platform was synthesized by conjugation of HA onto luminescent platinum nanoclusters (Pt NCs) in human hemoglobin (Hb) (Hb/Pt NCs).	Platinum	299-301	CD44 molecule (Indian blood group)	Homo sapiens	6-10
31534014-1	2020	Poly (ADP-ribose) Polymerase (PARP) inhibitors (PARPi) are approved to treat recurrent ovarian cancer with BRCA1 or BRCA2 mutations, and as maintenance therapy for recurrent platinum sensitive ovarian cancer (BRCA wild-type or mutated) after treatment with platinum.	Platinum	174-182	poly(ADP-ribose) polymerase 1	Homo sapiens	30-34
31534014-1	2020	Poly (ADP-ribose) Polymerase (PARP) inhibitors (PARPi) are approved to treat recurrent ovarian cancer with BRCA1 or BRCA2 mutations, and as maintenance therapy for recurrent platinum sensitive ovarian cancer (BRCA wild-type or mutated) after treatment with platinum.	Platinum	257-265	poly(ADP-ribose) polymerase 1	Homo sapiens	0-28
31534014-1	2020	Poly (ADP-ribose) Polymerase (PARP) inhibitors (PARPi) are approved to treat recurrent ovarian cancer with BRCA1 or BRCA2 mutations, and as maintenance therapy for recurrent platinum sensitive ovarian cancer (BRCA wild-type or mutated) after treatment with platinum.	Platinum	257-265	poly(ADP-ribose) polymerase 1	Homo sapiens	30-34
31958797-0	2020	Predictive Value of Excision Repair Cross-Complementation Group 1 in the Response to Platinum-Based Chemotherapy in Esophageal Cancer: A Meta-Analysis.	Platinum	85-93	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	20-65
33339576-1	2020	Severe gastrointestinal (GI) toxicity is a common side effect after platinum-based chemotherapy.	Platinum	68-76	G protein subunit alpha i1	Homo sapiens	7-28
33339576-3	2020	Genetic factors involved in platinum transport, metabolism, detoxification, DNA repair, cell cycle control, and apoptosis pathways may account for the interindividual difference in GI toxicity.	Platinum	28-36	G protein subunit alpha i1	Homo sapiens	181-183
33339576-4	2020	The influence of gene polymorphisms in the platinum pathway on GI toxicity has been extensively analyzed.	Platinum	43-51	G protein subunit alpha i1	Homo sapiens	63-65
31594824-7	2020	In addition, the levels and patterns of ADPRylation, PARP-1 protein, and gene expression correlated with clinical outcomes in response to platinum-based chemotherapy, with cancers exhibiting the highest levels of ADPRylation having the best outcomes independent of BRCA1/2 status.	Platinum	138-146	poly(ADP-ribose) polymerase 1	Homo sapiens	53-59
31594824-7	2020	In addition, the levels and patterns of ADPRylation, PARP-1 protein, and gene expression correlated with clinical outcomes in response to platinum-based chemotherapy, with cancers exhibiting the highest levels of ADPRylation having the best outcomes independent of BRCA1/2 status.	Platinum	138-146	BRCA1 DNA repair associated	Homo sapiens	265-270
31970128-7	2020	Univariate analysis indicated that NLR >3.38, PLR >210, CA125 >365, advanced stage, suboptimal disease, serous type, and ascites were significant predictive factors for platinum resistance.	Platinum	169-177	mucin 16, cell surface associated	Homo sapiens	56-61
31958797-3	2020	Excision repair cross-complementation group 1 (ERCC1) is thought to be the key in the resistance to platinum.	Platinum	100-108	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-45
31958797-3	2020	Excision repair cross-complementation group 1 (ERCC1) is thought to be the key in the resistance to platinum.	Platinum	100-108	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
31958797-5	2020	We conducted this meta-analysis to explore the association between ERCC1 polymorphisms, its expression levels and platinum-based chemotherapy response, and identify the most sensitive genotypes.	Platinum	114-122	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	67-72
31958797-12	2020	CONCLUSIONS: ERCC1 is a valuable biomarker for platinum-based chemotherapy in esophageal cancer.	Platinum	47-55	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	13-18
31856090-2	2020	Increasingly, the recommended treatment for those with a germline mutation in a gene involved in homologous recombination repair is with a platinum drug followed by a poly (ADP-ribose) polymerase (poly adenosine phosphate-ribose polymerase [PARP]) inhibitor.	Platinum	139-147	poly(ADP-ribose) polymerase 1	Homo sapiens	241-245
32063972-1	2020	Objective: To assess clinicopathological characteristics of primary gastro-entero-pancreatic poorly differentiated neuroendocrine carcinomas (GEP-PDNECAs) and evaluate overall survival in patients treated with systemic platinum and etoposide therapy.	Platinum	219-227	granulin precursor	Homo sapiens	142-145
31958797-13	2020	Patients with ERCC1 mutations or low-level ERCC1 expression are more sensitive to platinum-based chemotherapy.	Platinum	82-90	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-19
31958797-13	2020	Patients with ERCC1 mutations or low-level ERCC1 expression are more sensitive to platinum-based chemotherapy.	Platinum	82-90	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	43-48
33302812-0	2020	Periostin Secreted by Carcinoma-Associated Fibroblasts Promotes Ovarian Cancer Cell Platinum Resistance Through the PI3K/Akt Signaling Pathway.	Platinum	84-92	periostin	Homo sapiens	0-9
32063972-16	2020	Overall prognosis of GEP-PDNECA patients following platinum and etoposide therapy in our series was relatively favorable but remained poor in the presence of distant metastases.	Platinum	51-59	granulin precursor	Homo sapiens	21-24
33357097-0	2020	The BRCA2 p.N372 H i.a.1342A>C Could Regulate the Sensitivity of Ovarian Cancer Cells to Platinum-Based Drugs.	Platinum	89-97	BRCA2 DNA repair associated	Homo sapiens	4-9
31956823-0	2020	Oxaliplatin-Based Platinum(IV) Prodrug Bearing Toll-like Receptor 7 Agonist for Enhanced Immunochemotherapy.	Platinum	18-26	toll-like receptor 7	Mus musculus	47-67
33357097-1	2020	BACKGROUND AND OBJECTIVE: We have previously reported that BRCA2 N372 H i.a.1342A>C heterozygous variation presented in platinum-resistant patients.	Platinum	120-128	BRCA2 DNA repair associated	Homo sapiens	59-64
33357097-2	2020	This study aimed to further investigate the mechanism of BRCA2 N372 H mutation in the development of platinum resistance in ovarian cancer.	Platinum	101-109	BRCA2 DNA repair associated	Homo sapiens	57-62
33357097-13	2020	CONCLUSION: Over expression of mRNA and protein of BRCA2 was detected in the cells with BRCA2 N372 H i.a.1342A>C mutation but not in the lentivirus negative control (lenti-EGFP) or the cells without transfection (empty cells), which may lead to resistance to platinum-based drugs in ovarian cancer cells through homologous recombination repair pathway.	Platinum	259-267	BRCA2 DNA repair associated	Homo sapiens	51-56
33268682-10	2020	The results revealed that Mg regulates the expression of organic cation transporter 2, multidrug and toxin extrusion protein 1, and copper transporter 1, leading to reduced renal platinum accumulation, which results in CIN attenuation.	Platinum	179-187	solute carrier family 22 member 2	Homo sapiens	57-126
31956823-2	2020	Herein, a new type of immunochemotherapeutic was designed by tethering the toll-like receptor 7 (TLR7) agonist on the axial position of oxaliplatin-based platinum(IV) prodrug.	Platinum	154-162	toll-like receptor 7	Mus musculus	75-95
31956823-2	2020	Herein, a new type of immunochemotherapeutic was designed by tethering the toll-like receptor 7 (TLR7) agonist on the axial position of oxaliplatin-based platinum(IV) prodrug.	Platinum	154-162	toll-like receptor 7	Mus musculus	97-101
31956823-7	2020	These results highlight the potential of the conjugation of TLR7 agonist with oxaliplatin-based Pt(IV) prodrug as an effective anticancer agent to overcome the toxic side effects and drug resistance of traditional platinum chemotherapy.	Platinum	96-102	toll-like receptor 7	Mus musculus	60-64
31956823-7	2020	These results highlight the potential of the conjugation of TLR7 agonist with oxaliplatin-based Pt(IV) prodrug as an effective anticancer agent to overcome the toxic side effects and drug resistance of traditional platinum chemotherapy.	Platinum	214-222	toll-like receptor 7	Mus musculus	60-64
31892156-10	2019	Moreover, NCAPH promoted the migration and adhesion of endothelial cells to OSCC cells and promoted the resistance to platinum anticancer drugs.	Platinum	118-126	non-SMC condensin I complex subunit H	Homo sapiens	10-15
31884974-0	2019	Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer.	Platinum	44-52	serpin family A member 4	Homo sapiens	0-11
31884974-8	2019	Low expression of kallistatin was associated with unfavourable prognosis and platinum resistance in HGSOC.	Platinum	77-85	serpin family A member 4	Homo sapiens	18-29
31884974-9	2019	Overexpression of kallistatin significantly inhibited proliferation and metastasis, and enhanced platinum sensitivity and apoptosis in ovarian cancer cells.	Platinum	97-105	serpin family A member 4	Homo sapiens	18-29
31907140-1	2019	Bladder urothelial carcinoma(BUC)is a common malignant tumor in the urinary system.Pt-based chemotherapy has long been a standard therapeutic method for resectable or metastatic BUC,but with poor outcomes.Immune checkpoint inhibitors specific to programmed death 1(PD-1)/programmed death-ligand 1(PD-L1)and cytotoxic T lymphocyte-associated protein 4(CTLA-4)pathways have shown significant antitumor activities,safety,and enduring reactivity in clinical trials,thus creating a new epoch for the treatment of advanced-stage BUC.This article reviews the relationships of BUC with PD-1/PD-L1 and CTLA-4 pathways,as demonstrated in clinical trials.In particular,the authors elucidate the clinical studies on the application of immune checkpoint inhibitors in different BUC stages and their optimal combining strategies,with an attempt to improve the clinical use of immune inhibitors for BUC treatment.	Platinum	83-85	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	307-350
31907140-1	2019	Bladder urothelial carcinoma(BUC)is a common malignant tumor in the urinary system.Pt-based chemotherapy has long been a standard therapeutic method for resectable or metastatic BUC,but with poor outcomes.Immune checkpoint inhibitors specific to programmed death 1(PD-1)/programmed death-ligand 1(PD-L1)and cytotoxic T lymphocyte-associated protein 4(CTLA-4)pathways have shown significant antitumor activities,safety,and enduring reactivity in clinical trials,thus creating a new epoch for the treatment of advanced-stage BUC.This article reviews the relationships of BUC with PD-1/PD-L1 and CTLA-4 pathways,as demonstrated in clinical trials.In particular,the authors elucidate the clinical studies on the application of immune checkpoint inhibitors in different BUC stages and their optimal combining strategies,with an attempt to improve the clinical use of immune inhibitors for BUC treatment.	Platinum	83-85	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	351-357
31907140-1	2019	Bladder urothelial carcinoma(BUC)is a common malignant tumor in the urinary system.Pt-based chemotherapy has long been a standard therapeutic method for resectable or metastatic BUC,but with poor outcomes.Immune checkpoint inhibitors specific to programmed death 1(PD-1)/programmed death-ligand 1(PD-L1)and cytotoxic T lymphocyte-associated protein 4(CTLA-4)pathways have shown significant antitumor activities,safety,and enduring reactivity in clinical trials,thus creating a new epoch for the treatment of advanced-stage BUC.This article reviews the relationships of BUC with PD-1/PD-L1 and CTLA-4 pathways,as demonstrated in clinical trials.In particular,the authors elucidate the clinical studies on the application of immune checkpoint inhibitors in different BUC stages and their optimal combining strategies,with an attempt to improve the clinical use of immune inhibitors for BUC treatment.	Platinum	83-85	CD274 molecule	Homo sapiens	297-302
31907140-1	2019	Bladder urothelial carcinoma(BUC)is a common malignant tumor in the urinary system.Pt-based chemotherapy has long been a standard therapeutic method for resectable or metastatic BUC,but with poor outcomes.Immune checkpoint inhibitors specific to programmed death 1(PD-1)/programmed death-ligand 1(PD-L1)and cytotoxic T lymphocyte-associated protein 4(CTLA-4)pathways have shown significant antitumor activities,safety,and enduring reactivity in clinical trials,thus creating a new epoch for the treatment of advanced-stage BUC.This article reviews the relationships of BUC with PD-1/PD-L1 and CTLA-4 pathways,as demonstrated in clinical trials.In particular,the authors elucidate the clinical studies on the application of immune checkpoint inhibitors in different BUC stages and their optimal combining strategies,with an attempt to improve the clinical use of immune inhibitors for BUC treatment.	Platinum	83-85	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	593-599
31804817-4	2019	The AL-Pt/Pd3Pb exhibit an outstanding HER activity with only 13.8 mV overpotential to reach a current density of 10 mA/cm2 and a high mass activity 7834 A/gPd+Pt at - 0.05 V, both largely surpassing the commercial Pt/C (30 mV, 1486 A/gPt).	Platinum	7-9	glutamic--pyruvic transaminase	Homo sapiens	235-238
31861708-7	2019	In addition, targeting SRPK1 has enhanced sensitivity to platinum-based chemotherapy in some cancers.	Platinum	57-65	SRSF protein kinase 1	Homo sapiens	23-28
31877751-0	2019	Identification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer Cells.	Platinum	45-53	tumor protein p53	Homo sapiens	62-66
31877751-7	2019	Interestingly, we found that PT-resistant MDAH cells acquired in the TP53 gene a novel secondary mutation (i.e., S185G) that accompanied the R273H typical of MDAH cells.	Platinum	29-31	tumor protein p53	Homo sapiens	69-73
31877751-8	2019	The double p53S185G/R273H mutant increases the resistance to PT in a TP53 null EOC cellular model.	Platinum	61-63	tumor protein p53	Homo sapiens	11-14
31877751-8	2019	The double p53S185G/R273H mutant increases the resistance to PT in a TP53 null EOC cellular model.	Platinum	61-63	tumor protein p53	Homo sapiens	69-73
31877751-9	2019	Overall, we show how the selective pressure of PT is able to induce additional mutation in an already mutant TP53 gene in EOC and how this event could contribute to the acquisition of novel cellular phenotypes.	Platinum	47-49	tumor protein p53	Homo sapiens	109-113
31790150-0	2019	Copper-dependent ATP7B up-regulation drives the resistance of TMEM16A-overexpressing head-and-neck cancer models to platinum toxicity.	Platinum	116-124	ATPase copper transporting beta	Homo sapiens	17-22
31790150-0	2019	Copper-dependent ATP7B up-regulation drives the resistance of TMEM16A-overexpressing head-and-neck cancer models to platinum toxicity.	Platinum	116-124	anoctamin 1	Homo sapiens	62-69
31790150-3	2019	The resistance to platinum has been linked to the activity of divalent transporter ATP7B, which pumps platinum from the cytoplasm into lysosomes, decreasing its concentration in the cytoplasm.	Platinum	18-26	ATPase copper transporting beta	Homo sapiens	83-88
31790150-3	2019	The resistance to platinum has been linked to the activity of divalent transporter ATP7B, which pumps platinum from the cytoplasm into lysosomes, decreasing its concentration in the cytoplasm.	Platinum	102-110	ATPase copper transporting beta	Homo sapiens	83-88
31893221-6	2019	Based on this combination of electrochemical scanning tunneling microscopy (EC-STM) and CV data, we derive a detailed atomistic picture of the nanoisland evolution during potential cycling, delivering new insights into the initial stages of platinum electrode degradation.	Platinum	241-249	sulfotransferase family 1A member 3	Homo sapiens	79-82
31612916-2	2019	Several reports have demonstrated the utility of platinum-based chemotherapy for treating cancer patients who harbour a BRCA mutation.	Platinum	49-57	BRCA1 DNA repair associated	Homo sapiens	120-124
31562799-1	2019	BACKGROUND: Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), has been associated with significantly increased progression-free survival among patients with recurrent ovarian cancer after platinum-based chemotherapy, regardless of the presence or absence of BRCA mutations.	Platinum	225-233	poly(ADP-ribose) polymerase 1	Homo sapiens	92-96
31861382-0	2019	TIMP-1 is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells.	Platinum	40-48	TIMP metallopeptidase inhibitor 1	Homo sapiens	0-6
31861382-5	2019	We report that TIMP-1 acts as a double-edged sword in the EOC microenvironment, directly affecting the response to PT treatment on tumor cells and indirectly altering migration and proliferation of endothelial cells.	Platinum	115-117	TIMP metallopeptidase inhibitor 1	Homo sapiens	15-21
31722522-1	2019	We report a chemo/starvation/chemdynamic trimodal combination therapy to combat Multi-Drug-Resistant (MDR) tumors by developing a ferrocene-containing nano-vesicle (FcNV) which encapsulates glucose oxidase (GOx) in the hydrophilic core and coordinates cisplatin (Pt) in the hydrophobic layer (GOx&amp;Pt@FcNV).	Platinum	263-265	hydroxyacid oxidase 1, liver	Mus musculus	190-205
31793564-1	2019	Showing anti-proliferation activity against MCF7 cells better than cisplatin, a platinum(ii) complex, [PtL(DMSO)Cl], was found to potently and selectively inhibit protein tyrosine phosphatase 1B (PTP1B), a putative target for anticancer agents, suggesting a new possible anticancer strategy based on platinum drugs.	Platinum	80-88	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	163-194
31793564-1	2019	Showing anti-proliferation activity against MCF7 cells better than cisplatin, a platinum(ii) complex, [PtL(DMSO)Cl], was found to potently and selectively inhibit protein tyrosine phosphatase 1B (PTP1B), a putative target for anticancer agents, suggesting a new possible anticancer strategy based on platinum drugs.	Platinum	80-88	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	196-201
31837657-3	2019	Even at the collision energy of 1 eV per Pt atom, sufficiently strong Pt-Si interaction between PtN (N = 30 and 45) and the Si substrate allows them to be supported as close-packed monatomic-layered Pt disks, while at N = 60, multilayered shapes exist besides the monatomic-layered shape, the fraction of which increases at N = 71.	Platinum	70-72	pleiotrophin	Homo sapiens	96-99
31837657-3	2019	Even at the collision energy of 1 eV per Pt atom, sufficiently strong Pt-Si interaction between PtN (N = 30 and 45) and the Si substrate allows them to be supported as close-packed monatomic-layered Pt disks, while at N = 60, multilayered shapes exist besides the monatomic-layered shape, the fraction of which increases at N = 71.	Platinum	70-72	pleiotrophin	Homo sapiens	96-99
31890820-6	2020	The modification of Ag3PO4 by defect and platinum complexes dopant had changed the curve profile of Ag4d, P2p and O1s.	Platinum	41-49	pyrimidinergic receptor P2Y4	Homo sapiens	106-109
31890820-8	2020	The ratios of O-2/O-1 with the value of 0.25, 0.32, 0.49 and 0.51 were found in the sample of AP, DAP, AP/Pt, and DAP/Pt, respectively.	Platinum	106-108	immunoglobulin kappa variable 1D-39	Homo sapiens	14-21
31890820-8	2020	The ratios of O-2/O-1 with the value of 0.25, 0.32, 0.49 and 0.51 were found in the sample of AP, DAP, AP/Pt, and DAP/Pt, respectively.	Platinum	118-120	immunoglobulin kappa variable 1D-39	Homo sapiens	14-21
31890820-8	2020	The ratios of O-2/O-1 with the value of 0.25, 0.32, 0.49 and 0.51 were found in the sample of AP, DAP, AP/Pt, and DAP/Pt, respectively.	Platinum	118-120	death associated protein	Homo sapiens	114-117
31722522-1	2019	We report a chemo/starvation/chemdynamic trimodal combination therapy to combat Multi-Drug-Resistant (MDR) tumors by developing a ferrocene-containing nano-vesicle (FcNV) which encapsulates glucose oxidase (GOx) in the hydrophilic core and coordinates cisplatin (Pt) in the hydrophobic layer (GOx&amp;Pt@FcNV).	Platinum	301-303	hydroxyacid oxidase 1, liver	Mus musculus	190-205
31722522-4	2019	The in vitro studies reveal that GOx&amp;Pt@FcNV exhibits a highly efficient killing effect against various MDR tumor cells.	Platinum	41-43	hydroxyacid oxidase 1, liver	Mus musculus	33-36
31722522-5	2019	The in vivo studies of double-tumor-bearing nude mice demonstrate that the tumor inhibitory rates (TIR) of GOx&amp;Pt@FcNV against cisplatin-resistant A549/DDP are 8.1 times and 3.3 times higher than those of Pt and Pt@FcNV, respectively; they are also 8.6 times and 4.3 times higher than Pt and Pt@FcNV against adriamycin-resistant MCF-7/ADR, respectively.	Platinum	115-117	hydroxyacid oxidase 1, liver	Mus musculus	107-110
31722522-5	2019	The in vivo studies of double-tumor-bearing nude mice demonstrate that the tumor inhibitory rates (TIR) of GOx&amp;Pt@FcNV against cisplatin-resistant A549/DDP are 8.1 times and 3.3 times higher than those of Pt and Pt@FcNV, respectively; they are also 8.6 times and 4.3 times higher than Pt and Pt@FcNV against adriamycin-resistant MCF-7/ADR, respectively.	Platinum	209-211	hydroxyacid oxidase 1, liver	Mus musculus	107-110
31722522-5	2019	The in vivo studies of double-tumor-bearing nude mice demonstrate that the tumor inhibitory rates (TIR) of GOx&amp;Pt@FcNV against cisplatin-resistant A549/DDP are 8.1 times and 3.3 times higher than those of Pt and Pt@FcNV, respectively; they are also 8.6 times and 4.3 times higher than Pt and Pt@FcNV against adriamycin-resistant MCF-7/ADR, respectively.	Platinum	209-211	hydroxyacid oxidase 1, liver	Mus musculus	107-110
31722522-5	2019	The in vivo studies of double-tumor-bearing nude mice demonstrate that the tumor inhibitory rates (TIR) of GOx&amp;Pt@FcNV against cisplatin-resistant A549/DDP are 8.1 times and 3.3 times higher than those of Pt and Pt@FcNV, respectively; they are also 8.6 times and 4.3 times higher than Pt and Pt@FcNV against adriamycin-resistant MCF-7/ADR, respectively.	Platinum	209-211	hydroxyacid oxidase 1, liver	Mus musculus	107-110
31722522-5	2019	The in vivo studies of double-tumor-bearing nude mice demonstrate that the tumor inhibitory rates (TIR) of GOx&amp;Pt@FcNV against cisplatin-resistant A549/DDP are 8.1 times and 3.3 times higher than those of Pt and Pt@FcNV, respectively; they are also 8.6 times and 4.3 times higher than Pt and Pt@FcNV against adriamycin-resistant MCF-7/ADR, respectively.	Platinum	209-211	hydroxyacid oxidase 1, liver	Mus musculus	107-110
31722522-2	2019	Contrasting with other reported multimodal combination therapies, the new nanodrug (GOx&amp;Pt@FcNV) relies on cascade reactions to drastically increase the overall effectiveness against MDR tumors.	Platinum	92-94	hydroxyacid oxidase 1, liver	Mus musculus	84-87
31693378-4	2019	The incorporation of highly dispersed noble metal nanoparticles (e.g., Pt and Pd) with modulated electronic structure is enabled on a surfactant-free MOF surface.	Platinum	71-73	lysine acetyltransferase 8	Homo sapiens	150-153
31742378-1	2019	The electrodeposition of AuBr4- and PtBr42- onto an adlayer of circobiphenyl-a structurally defined nanographene with low symmetry-on a Au(111) electrode was investigated via electrochemical scanning tunneling microscopy (EC-STM) to control and understand the formation of characteristic nanoclusters.	Platinum	36-42	sulfotransferase family 1A member 3	Homo sapiens	225-228
31742378-5	2019	EC-STM revealed the formation of characteristic dimers of Pt clusters ranging from 2-4 nm in diameter on the circobiphenyl adlayer.	Platinum	58-60	sulfotransferase family 1A member 3	Homo sapiens	3-6
31693378-5	2019	As a proof-of-concept demonstration, the 2D Ni-MOF@Pt hybrid with well-defined interfaces is applied to boost the electrochemical hydrogen evolution reaction (HER) and delivers decent electrocatalytic activity under both acidic and alkaline conditions.	Platinum	51-53	lysine acetyltransferase 8	Homo sapiens	47-50
31729224-13	2019	The photogenerated MV+  by the two hybrid photosystems is used to catalyze H2-evolution in the presence of Pt nanoparticle catalysts, and to mediate the reduction of NADP+ to NADPH in the presence of ferredoxin-NADP+ reductase, FNR.	Platinum	107-109	ferredoxin reductase	Homo sapiens	200-226
31591753-5	2019	More importantly, the Pt II -PW 11 greatly reduced Abeta deposition and rescued memory loss in APP/PS1 transgenic AD model mice without noticeable cytotoxicity, demonstrating its potential as drugs for AD treatment.	Platinum	22-27	presenilin 1	Mus musculus	99-102
31857852-3	2019	The FDA has approved the PARP inhibitor olaparib (Lynparza ) as maintenance treatment after first-line platinum-containing chemotherapy and olaparib, niraparib (Zejula ) and rucaparib (Rubraca ) are approved as maintenance therapies in the recurrent, platinum-sensitive setting; nevertheless, development of resistance limits their efficacy.	Platinum	251-259	collagen type XI alpha 2 chain	Homo sapiens	25-29
31837696-3	2019	CPt2 - is identified as a C2v symmetric Pt-C-Pt bent structure, and CPt2 has a D h symmetric Pt-C-Pt linear structure.	Platinum	40-47	carnitine palmitoyltransferase 2	Homo sapiens	0-4
31837696-3	2019	CPt2 - is identified as a C2v symmetric Pt-C-Pt bent structure, and CPt2 has a D h symmetric Pt-C-Pt linear structure.	Platinum	93-100	carnitine palmitoyltransferase 2	Homo sapiens	0-4
31837696-3	2019	CPt2 - is identified as a C2v symmetric Pt-C-Pt bent structure, and CPt2 has a D h symmetric Pt-C-Pt linear structure.	Platinum	93-100	carnitine palmitoyltransferase 2	Homo sapiens	68-72
31837696-5	2019	The Pt-C bonds in CPt2 -/0 and CPt2H-/0 exhibit covalent double bonding characters.	Platinum	4-8	carnitine palmitoyltransferase 2	Homo sapiens	18-22
31295632-4	2019	Oxidations of dl-ethionine by Pt(IV) anticancer model complexes trans-[PtX2(CN4)]2- (X = Cl or Br) were thus analyzed by time-resolved and stopped-flow spectral techniques.	Platinum	30-32	paired like homeodomain 2	Homo sapiens	71-75
31642194-3	2019	The achieved composite exhibits superior electrocatalytic performance towards HER, more outstanding than the commercial Pt/C catalyst in the light of nearly zero onset overpotential, an extremely low overpotential of 25 mV to obtain a current density of -10 mA cm -2 , a Tafel slope of 58 mV dec -1 and a good durability for 24 h in 1.0 M KOH.	Platinum	120-122	deleted in esophageal cancer 1	Homo sapiens	292-298
31295632-7	2019	In the proposed reaction mechanism which is similar to that for the oxidation of Met by the same Pt(IV) compounds, the rate-determining steps are rationalized in terms of a bridge formation between one of the coordinated halides in [PtX2(CN4)]2- and the sulfur atom in ethionine, followed by an X+ transfer.	Platinum	97-99	paired like homeodomain 2	Homo sapiens	233-237
31798724-5	2019	CisPt decreased p53 protein phosphorylation in FaDu cells, but increased it in PE/CA-PJ49 cells.	Platinum	0-5	tumor protein p53	Homo sapiens	16-19
31721562-12	2019	The average binding distance (r) between Pt(II) complexes and HSA is obtained by Forster"s resonance energy-transfer theory.	Platinum	41-43	albumin	Homo sapiens	62-65
31657627-10	2019	This model was also compatible with patients with or without BRCA1/2 mutations and had the potential to predict the response to platinum-based adjuvant chemotherapy.	Platinum	128-136	BRCA1 DNA repair associated	Homo sapiens	61-66
31200951-1	2019	CONTEXT: Several anti-programmed death-1 (anti-PD-1) and anti-programmed death ligand-1 (anti-PD-L1) antibodies have been approved by regulatory authorities for treatment of platinum-resistant metastatic urothelial cancer (mUC).	Platinum	174-182	programmed cell death 1	Homo sapiens	47-51
31200951-1	2019	CONTEXT: Several anti-programmed death-1 (anti-PD-1) and anti-programmed death ligand-1 (anti-PD-L1) antibodies have been approved by regulatory authorities for treatment of platinum-resistant metastatic urothelial cancer (mUC).	Platinum	174-182	CD274 molecule	Homo sapiens	94-99
31200951-3	2019	OBJECTIVE: To determine the restricted mean survival time (RMST) of patients with platinum-resistant mUC treated with PD-1/PD-L1 inhibitors and to compare RMSTs in patients treated with PD-1 versus PD-L1 inhibitors.	Platinum	82-90	programmed cell death 1	Homo sapiens	118-122
31200951-3	2019	OBJECTIVE: To determine the restricted mean survival time (RMST) of patients with platinum-resistant mUC treated with PD-1/PD-L1 inhibitors and to compare RMSTs in patients treated with PD-1 versus PD-L1 inhibitors.	Platinum	82-90	CD274 molecule	Homo sapiens	123-128
31200951-4	2019	EVIDENCE ACQUISITION: We searched for phase 1, 2, and 3 clinical trials that assessed PD-1 or PD-L1 inhibition for patients with platinum-resistant mUC.	Platinum	129-137	programmed cell death 1	Homo sapiens	86-90
31200951-4	2019	EVIDENCE ACQUISITION: We searched for phase 1, 2, and 3 clinical trials that assessed PD-1 or PD-L1 inhibition for patients with platinum-resistant mUC.	Platinum	129-137	CD274 molecule	Homo sapiens	94-99
31738050-3	2019	Both the synthesized PARPi ligands and PARPi-Pt conjugates [PARPi-Pt(IV)] show inhibitory effects against PARP-1"s catalytic activity.	Platinum	45-47	poly(ADP-ribose) polymerase 1	Homo sapiens	106-112
31738050-3	2019	Both the synthesized PARPi ligands and PARPi-Pt conjugates [PARPi-Pt(IV)] show inhibitory effects against PARP-1"s catalytic activity.	Platinum	66-72	poly(ADP-ribose) polymerase 1	Homo sapiens	106-112
31738050-6	2019	Our study provides a strategy to improve the cytotoxicity of platinum(IV)-based anticancer complexes and overcome cisplatin resistance by using a small-molecule anticancer complex that simultaneously damages DNA and inhibits PARP.	Platinum	61-69	poly(ADP-ribose) polymerase 1	Homo sapiens	225-229
31798724-7	2019	ERK1/2 activation status was essential for both cell processes, proliferation and apoptosis induced by CisPt and/or CRM treatment on squamous cell carcinoma cells.	Platinum	103-108	mitogen-activated protein kinase 3	Homo sapiens	0-6
31798724-9	2019	In this regard the CisPt treatment suggested that p53 phosphorylation is ERK1/2 independent in FaDu cells having a p53 gene deletion and ERK1/2 dependent in PE/CA-PJ49 cells having a p53 gene amplification.	Platinum	19-24	tumor protein p53	Homo sapiens	50-53
31798724-9	2019	In this regard the CisPt treatment suggested that p53 phosphorylation is ERK1/2 independent in FaDu cells having a p53 gene deletion and ERK1/2 dependent in PE/CA-PJ49 cells having a p53 gene amplification.	Platinum	19-24	mitogen-activated protein kinase 3	Homo sapiens	73-79
31798724-9	2019	In this regard the CisPt treatment suggested that p53 phosphorylation is ERK1/2 independent in FaDu cells having a p53 gene deletion and ERK1/2 dependent in PE/CA-PJ49 cells having a p53 gene amplification.	Platinum	19-24	tumor protein p53	Homo sapiens	115-118
31798724-9	2019	In this regard the CisPt treatment suggested that p53 phosphorylation is ERK1/2 independent in FaDu cells having a p53 gene deletion and ERK1/2 dependent in PE/CA-PJ49 cells having a p53 gene amplification.	Platinum	19-24	mitogen-activated protein kinase 3	Homo sapiens	137-143
31798724-9	2019	In this regard the CisPt treatment suggested that p53 phosphorylation is ERK1/2 independent in FaDu cells having a p53 gene deletion and ERK1/2 dependent in PE/CA-PJ49 cells having a p53 gene amplification.	Platinum	19-24	tumor protein p53	Homo sapiens	115-118
31798724-10	2019	Moreover, in both tumor cell lines our results support the involvement of p53 phosphorylation-ERK1/2 activation-dependent in the apoptosis induced by combined treatments (CisPt and CRM).	Platinum	171-176	tumor protein p53	Homo sapiens	74-77
31798724-10	2019	Moreover, in both tumor cell lines our results support the involvement of p53 phosphorylation-ERK1/2 activation-dependent in the apoptosis induced by combined treatments (CisPt and CRM).	Platinum	171-176	mitogen-activated protein kinase 3	Homo sapiens	94-100
31807168-1	2019	The aim of the present study was to investigate epidermal growth factor receptor (EGFR) mutations as a prognostic factor for postoperative patients with positive EGFR mutations treated with postoperative platinum-based adjuvant chemotherapy (PBAC), and whether two common EGFR mutations exhibit different responses to PBAC.	Platinum	204-212	epidermal growth factor receptor	Homo sapiens	48-80
31612261-4	2019	RESULTS: The Keynote-048 study showed an improvement in overall survival with pembrolizumab monotherapy for patients with measurable programmed cell death ligand 1 (PD-L1) expression according to the combined positive score (CPS), and for the whole cohort with the combination of pembrolizumab and platin/5-fluorouracil (FU).	Platinum	298-304	CD274 molecule	Homo sapiens	165-170
31949929-16	2019	The established primary gastric culture could serve as a valuable tool for chemotherapy screening, while the repeated usage of platinum drugs may result in drug resistance via upregulation of IL-8 levels.	Platinum	127-135	C-X-C motif chemokine ligand 8	Homo sapiens	192-196
31852114-6	2019	The incidence rate of all-grade of hypothyroidism was lower in PD-1/PD-L1 inhibitor subgroup compared to chemotherapy (OR = 22.62, 95%CI:9.79-52.25), while the similar result was seen in another treatment regimen (PD-1 + platinum-based chemotherapy vs platinum-based chemotherapy) (OR = 2.93, 95%CI: [2.08, 4.11).	Platinum	221-229	CD274 molecule	Homo sapiens	68-73
31852114-6	2019	The incidence rate of all-grade of hypothyroidism was lower in PD-1/PD-L1 inhibitor subgroup compared to chemotherapy (OR = 22.62, 95%CI:9.79-52.25), while the similar result was seen in another treatment regimen (PD-1 + platinum-based chemotherapy vs platinum-based chemotherapy) (OR = 2.93, 95%CI: [2.08, 4.11).	Platinum	252-260	CD274 molecule	Homo sapiens	68-73
31807168-1	2019	The aim of the present study was to investigate epidermal growth factor receptor (EGFR) mutations as a prognostic factor for postoperative patients with positive EGFR mutations treated with postoperative platinum-based adjuvant chemotherapy (PBAC), and whether two common EGFR mutations exhibit different responses to PBAC.	Platinum	204-212	epidermal growth factor receptor	Homo sapiens	82-86
31346131-0	2019	Chemotherapy Toxicity in BRCA Mutation Carriers Undergoing First-Line Platinum-Based Chemotherapy.	Platinum	70-78	BRCA1 DNA repair associated	Homo sapiens	25-29
31807168-1	2019	The aim of the present study was to investigate epidermal growth factor receptor (EGFR) mutations as a prognostic factor for postoperative patients with positive EGFR mutations treated with postoperative platinum-based adjuvant chemotherapy (PBAC), and whether two common EGFR mutations exhibit different responses to PBAC.	Platinum	204-212	epidermal growth factor receptor	Homo sapiens	162-166
31346131-11	2019	CONCLUSION: BRCA mutation carriers and noncarriers receiving first-line platinum-based chemotherapy for EOC have similar hematologic toxicity profiles.	Platinum	72-80	BRCA1 DNA repair associated	Homo sapiens	12-16
31807168-1	2019	The aim of the present study was to investigate epidermal growth factor receptor (EGFR) mutations as a prognostic factor for postoperative patients with positive EGFR mutations treated with postoperative platinum-based adjuvant chemotherapy (PBAC), and whether two common EGFR mutations exhibit different responses to PBAC.	Platinum	204-212	epidermal growth factor receptor	Homo sapiens	162-166
31769895-5	2020	It exhibits MOR and EOR mass activities of 2.25 A mg -1 Pt and 1.62 A mg -1 Pt , around 1.26, 3.21 and 1.46, 2.96 times higher than those of PtNiCo NWs and commercial Pt/C, respectively.	Platinum	76-78	opioid receptor mu 1	Homo sapiens	12-15
31450416-0	2019	A C-reactive protein immunosensor based on platinum nanowire / titania nanotube composite sensitized electrochemiluminescence.	Platinum	43-51	C-reactive protein	Homo sapiens	2-20
31578585-3	2019	Previous studies have shown that serum apurinic/apyrimidinic endonuclease 1 (APE1) levels in patients with NSCLC are inversely associated with progression-free survival after platinum-containing doublet chemotherapy, and can serve as a biomarker for predicting disease prognosis and treatment efficacy.	Platinum	175-183	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	39-75
31578585-3	2019	Previous studies have shown that serum apurinic/apyrimidinic endonuclease 1 (APE1) levels in patients with NSCLC are inversely associated with progression-free survival after platinum-containing doublet chemotherapy, and can serve as a biomarker for predicting disease prognosis and treatment efficacy.	Platinum	175-183	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	77-81
31907114-4	2019	Vera, which can reverse chemotherapy resistance of tumor cells, showed no simple correlations with oxaliplatin drug resistance or P-gP expression and could enhance the anti-tumor effect of platinum chemotherapeutic agents by influencing the PARP pathway.	Platinum	189-197	poly(ADP-ribose) polymerase 1	Homo sapiens	241-245
31670945-4	2019	Results show that compared with combinational treatment of CDDP and SFN, the nanoparticles were more effectively internalized and could significantly reduce GSH content in breast cancer cells, leading to a notable increase in DNA-bound Pt and DNA damage-induced apoptosis.	Platinum	236-238	RNA exonuclease 2	Homo sapiens	68-71
31720619-8	2019	Moreover, the origin of the SAC"s reactivity enhancement is the electronic "acceptance-donation" interaction caused by orbital hybridization between Pd/Pt and preadsorbed O2/CO.	Platinum	152-154	immunoglobulin kappa variable 1D-39	Homo sapiens	171-176
31769895-5	2020	It exhibits MOR and EOR mass activities of 2.25 A mg -1 Pt and 1.62 A mg -1 Pt , around 1.26, 3.21 and 1.46, 2.96 times higher than those of PtNiCo NWs and commercial Pt/C, respectively.	Platinum	76-78	opioid receptor mu 1	Homo sapiens	12-15
31779206-2	2019	These phosphines were then allowed to react with (Pt(mu-Cl)(C6F5)(tht))2 (tht = tetrahydrothiophene) affording the water soluble Pt(II) complexes trans-(PtCl(C6F5)(PTA)2) (2a) and its bis-cationic congeners trans-(PtCl(C6F5)(APTA)2)(BF4)2 (2b) and trans-(PtCl(C6F5)(BzPTA)2)(BF4)2 (2c).	Platinum	129-135	pre T cell antigen receptor alpha	Homo sapiens	164-167
31768654-8	2019	Graphical abstractSchematic diagram of the apoptosis assay on the basis of microplate well-coated mitochondrial cytochrome c releasing by using Aptamer@Ag/Pt NCs.	Platinum	155-157	cytochrome c, somatic	Homo sapiens	112-124
31867425-0	2019	PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis.	Platinum	73-81	CD274 molecule	Homo sapiens	0-5
31539189-4	2019	It was found that the HER activity of Ni42 alloy drastically increased (eta = 140 mV at j=10 mA/cm2; pH1) when a platinum counter electrode was used during polarization experiments in acid.	Platinum	113-121	endothelin receptor type A	Homo sapiens	72-75
31644259-5	2019	In this study, an elastin-like polypeptide (ELP) is designed to modulate the morphology of Nafion ionomer on platinum surfaces.	Platinum	109-117	nuclear receptor subfamily 5 group A member 1	Homo sapiens	18-42
31644259-5	2019	In this study, an elastin-like polypeptide (ELP) is designed to modulate the morphology of Nafion ionomer on platinum surfaces.	Platinum	109-117	nuclear receptor subfamily 5 group A member 1	Homo sapiens	44-47
31644259-6	2019	The ELP shows an ability to assemble into a monolayer on platinum and change the ionomer interaction with platinum, thereby modifying its thin-film structure and improving the Nafion ionomer coverage.	Platinum	57-65	nuclear receptor subfamily 5 group A member 1	Homo sapiens	4-7
31644259-6	2019	The ELP shows an ability to assemble into a monolayer on platinum and change the ionomer interaction with platinum, thereby modifying its thin-film structure and improving the Nafion ionomer coverage.	Platinum	106-114	nuclear receptor subfamily 5 group A member 1	Homo sapiens	4-7
31701355-8	2019	Graphical abstractSchematic representation of a novel platinum particles/polyaniline/MXene nanocomposite (Pt/PANI/MXene) for screen-printed carbon electrode (SPCE) modification to enhance the specific surface area for immobilization of lactate oxidase (LOx) and use as enzymatic biosensor for lactate determination in milk sample.	Platinum	54-62	lysyl oxidase	Homo sapiens	236-251
31751381-1	2019	OBJECTIVES: Inhibition of pregnancy-associated plasma protein-A (PAPP-A), an upstream activator of the insulin-like growth factor (IGF) pathway, is known to augment sensitivity to platinum-based chemotherapy.	Platinum	180-188	pappalysin 1	Homo sapiens	65-71
31751381-2	2019	This study further tests the efficacy of PAPP-A inhibition with a monoclonal antibody inhibitor (mAb-PA) in ovarian cancer (OC) platinum-resistant patient-derived xenograft (PDX) models.	Platinum	128-136	pappalysin 1	Homo sapiens	41-47
31751381-3	2019	METHODS: PAPP-A expression was quantitated in platinum-resistant PDX models by ELISA.	Platinum	46-54	pappalysin 1	Homo sapiens	9-15
31751381-12	2019	Decreased phosphorylation of ERK1/2 correlated with conversion to platinum-sensitive.	Platinum	66-74	mitogen-activated protein kinase 3	Homo sapiens	29-35
31515456-9	2019	Low AR-active tumors were predicted to be more sensitive to poly (ADP-ribose) polymerase inhibition, platinum chemotherapy, and radiotherapy, and less sensitive to docetaxel and androgen-deprivation therapy.	Platinum	101-109	androgen receptor	Homo sapiens	4-6
31552976-4	2019	1 and 2 reacted with stoichiometric amounts of tristriphenylphosphine platinum(0) [Pt(PPh3)3] under toluene refluxing conditions leading to formation of Pt(ii) distorted square-planar complexes [Ph2P(o-C6H4CH2)Pt(SnR3)(PPh3)], (R = Ph, 4; R = Me, 5), each bearing a five-membered carbometallated ring resulting from Pt coordination to P and the benzylic C sp3 atom of the ligand architecture rather than from activation of the terminal Sn-C carbon bonds of the phenyl or methyl substituents which would have rendered six-membered rings.	Platinum	47-81	protein phosphatase 4 catalytic subunit	Homo sapiens	86-90
31552976-4	2019	1 and 2 reacted with stoichiometric amounts of tristriphenylphosphine platinum(0) [Pt(PPh3)3] under toluene refluxing conditions leading to formation of Pt(ii) distorted square-planar complexes [Ph2P(o-C6H4CH2)Pt(SnR3)(PPh3)], (R = Ph, 4; R = Me, 5), each bearing a five-membered carbometallated ring resulting from Pt coordination to P and the benzylic C sp3 atom of the ligand architecture rather than from activation of the terminal Sn-C carbon bonds of the phenyl or methyl substituents which would have rendered six-membered rings.	Platinum	153-159	protein phosphatase 4 catalytic subunit	Homo sapiens	86-90
31552976-4	2019	1 and 2 reacted with stoichiometric amounts of tristriphenylphosphine platinum(0) [Pt(PPh3)3] under toluene refluxing conditions leading to formation of Pt(ii) distorted square-planar complexes [Ph2P(o-C6H4CH2)Pt(SnR3)(PPh3)], (R = Ph, 4; R = Me, 5), each bearing a five-membered carbometallated ring resulting from Pt coordination to P and the benzylic C sp3 atom of the ligand architecture rather than from activation of the terminal Sn-C carbon bonds of the phenyl or methyl substituents which would have rendered six-membered rings.	Platinum	153-159	protein phosphatase 4 catalytic subunit	Homo sapiens	219-223
31552976-4	2019	1 and 2 reacted with stoichiometric amounts of tristriphenylphosphine platinum(0) [Pt(PPh3)3] under toluene refluxing conditions leading to formation of Pt(ii) distorted square-planar complexes [Ph2P(o-C6H4CH2)Pt(SnR3)(PPh3)], (R = Ph, 4; R = Me, 5), each bearing a five-membered carbometallated ring resulting from Pt coordination to P and the benzylic C sp3 atom of the ligand architecture rather than from activation of the terminal Sn-C carbon bonds of the phenyl or methyl substituents which would have rendered six-membered rings.	Platinum	83-85	protein phosphatase 4 catalytic subunit	Homo sapiens	86-90
31552976-4	2019	1 and 2 reacted with stoichiometric amounts of tristriphenylphosphine platinum(0) [Pt(PPh3)3] under toluene refluxing conditions leading to formation of Pt(ii) distorted square-planar complexes [Ph2P(o-C6H4CH2)Pt(SnR3)(PPh3)], (R = Ph, 4; R = Me, 5), each bearing a five-membered carbometallated ring resulting from Pt coordination to P and the benzylic C sp3 atom of the ligand architecture rather than from activation of the terminal Sn-C carbon bonds of the phenyl or methyl substituents which would have rendered six-membered rings.	Platinum	83-85	protein phosphatase 4 catalytic subunit	Homo sapiens	219-223
31713081-11	2019	Thus, PGRN could be considered as a candidate for explaining the high resistance to platinum-based treatment and a potential biomarker for therapy response to cell signaling inhibitors in patients with OCCC.	Platinum	84-92	granulin precursor	Homo sapiens	6-10
31719664-8	2019	The Ag/Pt bi-layers and Ag/Au/Pt tri-layers are systematically dewetted and transformed into various AgPt and AgAuPt nanostructures such as networked, elongated and semispherical configurations by means of enhanced surface diffusion, intermixing and energy minimization along with the temperature control.	Platinum	7-9	angiopoietin 1	Homo sapiens	101-105
31719664-8	2019	The Ag/Pt bi-layers and Ag/Au/Pt tri-layers are systematically dewetted and transformed into various AgPt and AgAuPt nanostructures such as networked, elongated and semispherical configurations by means of enhanced surface diffusion, intermixing and energy minimization along with the temperature control.	Platinum	30-32	angiopoietin 1	Homo sapiens	101-105
31751381-0	2019	Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.	Platinum	11-19	pappalysin 1	Homo sapiens	62-99
31751381-1	2019	OBJECTIVES: Inhibition of pregnancy-associated plasma protein-A (PAPP-A), an upstream activator of the insulin-like growth factor (IGF) pathway, is known to augment sensitivity to platinum-based chemotherapy.	Platinum	180-188	pappalysin 1	Homo sapiens	26-63
31670961-3	2019	In this study, influential properties of Pt(II) compounds were investigated using redistribution of nucleophosmin (NPM1) as a marker of nucleolar stress.	Platinum	41-47	nucleophosmin 1	Homo sapiens	100-113
31670961-3	2019	In this study, influential properties of Pt(II) compounds were investigated using redistribution of nucleophosmin (NPM1) as a marker of nucleolar stress.	Platinum	41-47	nucleophosmin 1	Homo sapiens	115-119
31621315-2	2019	To assess this, we prepare Pd@Pt and PdH@Pt core-shell octahedra enclosed by Pt(111) facets as model catalysts for controlling the DeltaGH affected by the ligand, the strain, and their ensemble effects.	Platinum	41-43	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	37-40
31621315-2	2019	To assess this, we prepare Pd@Pt and PdH@Pt core-shell octahedra enclosed by Pt(111) facets as model catalysts for controlling the DeltaGH affected by the ligand, the strain, and their ensemble effects.	Platinum	77-84	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	37-40
31621315-6	2019	However, enhanced HER activities of Pd@Pt and PdH@Pt core-shell nanocrystals over the Pt catalyst are inconsistent with the thermodynamic DeltaGH scaling relationship only but can be explained by the work function and apparent DeltaGH models that predict the interfacial electric field for the HER.	Platinum	50-52	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	46-49
31621315-6	2019	However, enhanced HER activities of Pd@Pt and PdH@Pt core-shell nanocrystals over the Pt catalyst are inconsistent with the thermodynamic DeltaGH scaling relationship only but can be explained by the work function and apparent DeltaGH models that predict the interfacial electric field for the HER.	Platinum	50-52	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	46-49
31701355-8	2019	Graphical abstractSchematic representation of a novel platinum particles/polyaniline/MXene nanocomposite (Pt/PANI/MXene) for screen-printed carbon electrode (SPCE) modification to enhance the specific surface area for immobilization of lactate oxidase (LOx) and use as enzymatic biosensor for lactate determination in milk sample.	Platinum	54-62	lysyl oxidase	Homo sapiens	253-256
31701355-8	2019	Graphical abstractSchematic representation of a novel platinum particles/polyaniline/MXene nanocomposite (Pt/PANI/MXene) for screen-printed carbon electrode (SPCE) modification to enhance the specific surface area for immobilization of lactate oxidase (LOx) and use as enzymatic biosensor for lactate determination in milk sample.	Platinum	106-108	lysyl oxidase	Homo sapiens	236-251
31701355-8	2019	Graphical abstractSchematic representation of a novel platinum particles/polyaniline/MXene nanocomposite (Pt/PANI/MXene) for screen-printed carbon electrode (SPCE) modification to enhance the specific surface area for immobilization of lactate oxidase (LOx) and use as enzymatic biosensor for lactate determination in milk sample.	Platinum	106-108	lysyl oxidase	Homo sapiens	253-256
31930091-2	2019	Due to restrictions by the FDA and EMA first-line treatment with Atezolizumab and Pembrolizumab in platinum-ineligible patients requires immunohistochemical PD-L1 testing.	Platinum	99-107	CD274 molecule	Homo sapiens	157-162
31603662-4	2019	When further used as the electrocatalyst for overall water splitting, H-CoP@NC delivers excellent activity (cell voltage of 1.72 V at a current density of 10 mA cm-2), close to that of the noble-metal-based benchmark catalyst couple of Pt/C  RuO2.	Platinum	236-238	caspase recruitment domain family member 16	Homo sapiens	72-75
31593831-1	2019	BACKGROUND: Nivolumab and pembrolizumab targeting programmed cell death protein 1 (PD-1) have recently been approved among patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) who failed platinum therapy.	Platinum	222-230	programmed cell death 1	Homo sapiens	50-81
31494328-1	2019	Here we report that three platinum(IV) prodrugs containing a tubulin inhibitor CA-4, as dual-targeting platinum(IV) prodrug, were synthesized and evaluated for antitumor activity using MTT assay.	Platinum	26-34	carbonic anhydrase 4	Homo sapiens	79-83
31494328-1	2019	Here we report that three platinum(IV) prodrugs containing a tubulin inhibitor CA-4, as dual-targeting platinum(IV) prodrug, were synthesized and evaluated for antitumor activity using MTT assay.	Platinum	103-111	carbonic anhydrase 4	Homo sapiens	79-83
31629204-0	2019	Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.	Platinum	44-52	poly(ADP-ribose) polymerase 1	Homo sapiens	0-4
31629204-5	2019	RESULTS: The analysis confirmed the positive effect of PARPis in patients with platinum sensitive ROC in case of germinal or somatic BRCA mutations.	Platinum	79-87	BRCA1 DNA repair associated	Homo sapiens	133-137
31593831-1	2019	BACKGROUND: Nivolumab and pembrolizumab targeting programmed cell death protein 1 (PD-1) have recently been approved among patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) who failed platinum therapy.	Platinum	222-230	programmed cell death 1	Homo sapiens	83-87
31604666-12	2019	CONCLUSIONS: Platinum-free interval >= 12 months, complete response and normalized CA-125 levels after ultimate platinum-based chemotherapy are associated with prolonged PFS and OS in relapsing BRCA1/BRCA2 mutated ovarian cancer patients who received olaparib as maintenance therapy.	Platinum	13-21	BRCA1 DNA repair associated	Homo sapiens	194-199
31604666-12	2019	CONCLUSIONS: Platinum-free interval >= 12 months, complete response and normalized CA-125 levels after ultimate platinum-based chemotherapy are associated with prolonged PFS and OS in relapsing BRCA1/BRCA2 mutated ovarian cancer patients who received olaparib as maintenance therapy.	Platinum	13-21	BRCA2 DNA repair associated	Homo sapiens	200-205
31477281-0	2019	MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy.	Platinum	127-135	metadherin	Homo sapiens	0-4
31477281-0	2019	MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy.	Platinum	127-135	metadherin	Homo sapiens	5-10
31477281-7	2019	RESULTS: MTDH, through its recently discovered role as an RNA binding protein, regulates expression of FANCD2 and FANCI, two components of the Fanconi anemia complementation group (FA) that play critical roles in interstrand crosslink damage induced by platinum compounds.	Platinum	253-261	metadherin	Homo sapiens	9-13
31477281-7	2019	RESULTS: MTDH, through its recently discovered role as an RNA binding protein, regulates expression of FANCD2 and FANCI, two components of the Fanconi anemia complementation group (FA) that play critical roles in interstrand crosslink damage induced by platinum compounds.	Platinum	253-261	FA complementation group D2	Homo sapiens	103-109
31604666-12	2019	CONCLUSIONS: Platinum-free interval >= 12 months, complete response and normalized CA-125 levels after ultimate platinum-based chemotherapy are associated with prolonged PFS and OS in relapsing BRCA1/BRCA2 mutated ovarian cancer patients who received olaparib as maintenance therapy.	Platinum	112-120	BRCA1 DNA repair associated	Homo sapiens	194-199
31477281-7	2019	RESULTS: MTDH, through its recently discovered role as an RNA binding protein, regulates expression of FANCD2 and FANCI, two components of the Fanconi anemia complementation group (FA) that play critical roles in interstrand crosslink damage induced by platinum compounds.	Platinum	253-261	FA complementation group I	Homo sapiens	114-119
31604666-12	2019	CONCLUSIONS: Platinum-free interval >= 12 months, complete response and normalized CA-125 levels after ultimate platinum-based chemotherapy are associated with prolonged PFS and OS in relapsing BRCA1/BRCA2 mutated ovarian cancer patients who received olaparib as maintenance therapy.	Platinum	112-120	BRCA2 DNA repair associated	Homo sapiens	200-205
31477281-11	2019	Pristimerin can increase sensitivity to platinum-based agents in tumors with MTDH overexpression by inhibiting the FA pathway.	Platinum	40-48	metadherin	Homo sapiens	77-81
31689861-3	2019	Given that the black module was validated to be the most related one, hub genes of this module, alcohol dehydrogenase 1B, cadherin 11, and vestigial like family member 3were revealed to be expressional related with platinum resistance, and could serve as prognostic markers for ovarian cancer.Our analysis might provide insight for molecular mechanisms of platinum-based chemotherapy resistance and treatment response in ovarian cancer.	Platinum	215-223	alcohol dehydrogenase 1B (class I), beta polypeptide	Homo sapiens	96-120
31522837-11	2019	Median PFS2 for platinum chemotherapy was longer than non-platinum (7.1 vs 3 months, p = 0.0114).	Platinum	16-24	GINS complex subunit 2	Homo sapiens	7-11
31522837-12	2019	Median PFS2 was significantly longer for platinum vs. targeted therapy (7.1 vs. 3 months p = 0.0431).	Platinum	41-49	GINS complex subunit 2	Homo sapiens	7-11
31685558-1	2019	OBJECTIVE: To report results from an integrated efficacy and safety analysis supporting the European Commission"s approval of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy treatment for relapsed, platinum-sensitive, BRCA-mutated ovarian cancer.	Platinum	217-225	poly(ADP-ribose) polymerase 1	Homo sapiens	130-157
31263157-0	2019	TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells.	Platinum	76-84	TNF alpha induced protein 2	Homo sapiens	0-7
31263157-4	2019	Following an investigation of urothelial carcinoma (UC) before and after the acquisition of platinum resistance, we offer the new target TNFAIP2, which led to EMT and tumor invasion in platinum-treated UC cells.	Platinum	92-100	TNF alpha induced protein 2	Homo sapiens	137-144
31263157-4	2019	Following an investigation of urothelial carcinoma (UC) before and after the acquisition of platinum resistance, we offer the new target TNFAIP2, which led to EMT and tumor invasion in platinum-treated UC cells.	Platinum	185-193	TNF alpha induced protein 2	Homo sapiens	137-144
31263157-9	2019	TNFAIP2 overexpression led to downregulation of E-cadherin expression and upregulation of TWIST1 expression in platinum-naive UC cells.	Platinum	111-119	TNF alpha induced protein 2	Homo sapiens	0-7
31263157-9	2019	TNFAIP2 overexpression led to downregulation of E-cadherin expression and upregulation of TWIST1 expression in platinum-naive UC cells.	Platinum	111-119	twist family bHLH transcription factor 1	Homo sapiens	90-96
31411802-8	2019	BRCA1/2 mutations were significantly associated with age; personal and family history; FIGO stage; secondary recurrence interval; sensitivity to platinum in 1st, 2nd and 3rd line treatment; and response to doxorubicin liposomes.	Platinum	145-153	BRCA1 DNA repair associated	Homo sapiens	0-7
31553341-5	2019	The Pt(ii) complexes could bind to and cleave DNA, while also inducing arrest of the cell cycle in S phase, leading to down-regulation of the levels of cyclin-dependent kinases and cyclin and up-regulation of the expression of p21.	Platinum	4-10	proliferating cell nuclear antigen	Homo sapiens	152-158
31553341-5	2019	The Pt(ii) complexes could bind to and cleave DNA, while also inducing arrest of the cell cycle in S phase, leading to down-regulation of the levels of cyclin-dependent kinases and cyclin and up-regulation of the expression of p21.	Platinum	4-10	proliferating cell nuclear antigen	Homo sapiens	181-187
31553341-5	2019	The Pt(ii) complexes could bind to and cleave DNA, while also inducing arrest of the cell cycle in S phase, leading to down-regulation of the levels of cyclin-dependent kinases and cyclin and up-regulation of the expression of p21.	Platinum	4-10	H3 histone pseudogene 16	Homo sapiens	227-230
31689861-3	2019	Given that the black module was validated to be the most related one, hub genes of this module, alcohol dehydrogenase 1B, cadherin 11, and vestigial like family member 3were revealed to be expressional related with platinum resistance, and could serve as prognostic markers for ovarian cancer.Our analysis might provide insight for molecular mechanisms of platinum-based chemotherapy resistance and treatment response in ovarian cancer.	Platinum	215-223	cadherin 11	Homo sapiens	122-133
31689861-3	2019	Given that the black module was validated to be the most related one, hub genes of this module, alcohol dehydrogenase 1B, cadherin 11, and vestigial like family member 3were revealed to be expressional related with platinum resistance, and could serve as prognostic markers for ovarian cancer.Our analysis might provide insight for molecular mechanisms of platinum-based chemotherapy resistance and treatment response in ovarian cancer.	Platinum	215-223	vestigial like family member 3	Homo sapiens	139-169
31689861-3	2019	Given that the black module was validated to be the most related one, hub genes of this module, alcohol dehydrogenase 1B, cadherin 11, and vestigial like family member 3were revealed to be expressional related with platinum resistance, and could serve as prognostic markers for ovarian cancer.Our analysis might provide insight for molecular mechanisms of platinum-based chemotherapy resistance and treatment response in ovarian cancer.	Platinum	356-364	alcohol dehydrogenase 1B (class I), beta polypeptide	Homo sapiens	96-120
31689861-3	2019	Given that the black module was validated to be the most related one, hub genes of this module, alcohol dehydrogenase 1B, cadherin 11, and vestigial like family member 3were revealed to be expressional related with platinum resistance, and could serve as prognostic markers for ovarian cancer.Our analysis might provide insight for molecular mechanisms of platinum-based chemotherapy resistance and treatment response in ovarian cancer.	Platinum	356-364	cadherin 11	Homo sapiens	122-133
31689861-3	2019	Given that the black module was validated to be the most related one, hub genes of this module, alcohol dehydrogenase 1B, cadherin 11, and vestigial like family member 3were revealed to be expressional related with platinum resistance, and could serve as prognostic markers for ovarian cancer.Our analysis might provide insight for molecular mechanisms of platinum-based chemotherapy resistance and treatment response in ovarian cancer.	Platinum	356-364	vestigial like family member 3	Homo sapiens	139-169
31591549-2	2019	The detection of DNA repair aberrations, such as mutation of BRCA2, could help select patients for poly(ADP-ribose) polymerase (PARP) inhibitor or platinum chemotherapy, and mismatch repair gene defects and microsatellite instability have been associated with responses to checkpoint inhibitor immunotherapy.	Platinum	147-155	BRCA2 DNA repair associated	Homo sapiens	61-66
31611995-13	2019	Additionally, transketolase family genes served a role in predicting PFS in patients with ovarian cancer treated with platinum and/or taxol.	Platinum	118-126	transketolase	Homo sapiens	14-27
31676812-3	2019	Here we show that quasi atomic-dispersion of Pd within the outermost layer of Ni nanoparticles to form a Pd1Ni single-atom surface alloy structure maximizes the Pd utilization and breaks the strong metal-selectivity relations in benzonitrile hydrogenation, by prompting the yield of dibenzylamine drastically from ~5 to 97% under mild conditions (80  C; 0.6 MPa), and boosting an activity to about eight and four times higher than Pd and Pt standard catalysts, respectively.	Platinum	438-440	programmed cell death 1	Homo sapiens	105-108
31871873-5	2019	Structure characterizations show that Pd3Pb/Pt2.37Pb and Pd3Pb/Pt2.07Pb are dominated by hexagonal-structured PtPb intermetallic phase on the surface, while the surface of Pd3Pb/Pt3.50Pb is mainly composed of face-centered cubic (fcc)-structured Pt x Pb phase.	Platinum	44-46	protein tyrosine phosphatase receptor type B	Homo sapiens	110-114
31666131-4	2019	METHODS: By initially screening of 16 platinum-sensitive/resistant samples from EOC patients with reduced representation bisulfite sequencing (RRBS), the upstream region of the hMSH2 gene was discovered hypermethylated in the platinum-resistant group.	Platinum	38-46	mutS homolog 2	Homo sapiens	177-182
31666131-4	2019	METHODS: By initially screening of 16 platinum-sensitive/resistant samples from EOC patients with reduced representation bisulfite sequencing (RRBS), the upstream region of the hMSH2 gene was discovered hypermethylated in the platinum-resistant group.	Platinum	226-234	mutS homolog 2	Homo sapiens	177-182
31666131-11	2019	MALDI-TOF mass spectrometry assay validated the strong association of hypermethylation of hMSH2 upstream region with platinum resistance.	Platinum	117-125	mutS homolog 2	Homo sapiens	90-95
31666131-15	2019	CONCLUSION: The hypermethylation of hMSH2 upstream region is associated with platinum resistant in EOC, and low expression of hMSH2 may be an index for the poor prognosis.	Platinum	77-85	mutS homolog 2	Homo sapiens	36-41
31671550-2	2019	Nearly 10 years after the approval of cetuximab, anti-PD1/PD-L1 checkpoint inhibitors are the first drugs that have shown any survival benefit for the treatment on platinum-refractory recurrent/metastatic (R/M) HNSCC.	Platinum	164-172	programmed cell death 1	Homo sapiens	54-57
31671550-2	2019	Nearly 10 years after the approval of cetuximab, anti-PD1/PD-L1 checkpoint inhibitors are the first drugs that have shown any survival benefit for the treatment on platinum-refractory recurrent/metastatic (R/M) HNSCC.	Platinum	164-172	CD274 molecule	Homo sapiens	58-63
31676542-1	2019	Despite the recent approval of immune-modulatory agents, EGFR inhibition continues to be a cornerstone in the management of squamous cell carcinoma of the head and neck (SCCHN) namely in combination with radiotherapy in the treatment of locoregionally advanced disease as well as in platinum-sensitive recurrent or metastatic disease in the first-line setting.	Platinum	283-291	epidermal growth factor receptor	Homo sapiens	57-61
31871873-5	2019	Structure characterizations show that Pd3Pb/Pt2.37Pb and Pd3Pb/Pt2.07Pb are dominated by hexagonal-structured PtPb intermetallic phase on the surface, while the surface of Pd3Pb/Pt3.50Pb is mainly composed of face-centered cubic (fcc)-structured Pt x Pb phase.	Platinum	63-65	protein tyrosine phosphatase receptor type B	Homo sapiens	110-114
31664600-4	2019	Four miRNA biomarkers (miR-454-3p, miR-98-5p, miR-183-5p and miR-22-3p) were identified with potential in stratifying platinum-sensitive and platinum-resistant HGSC patients and predicting prognostic outcome.	Platinum	118-126	microRNA 223	Homo sapiens	61-70
31871873-5	2019	Structure characterizations show that Pd3Pb/Pt2.37Pb and Pd3Pb/Pt2.07Pb are dominated by hexagonal-structured PtPb intermetallic phase on the surface, while the surface of Pd3Pb/Pt3.50Pb is mainly composed of face-centered cubic (fcc)-structured Pt x Pb phase.	Platinum	63-65	protein tyrosine phosphatase receptor type B	Homo sapiens	110-114
31664600-4	2019	Four miRNA biomarkers (miR-454-3p, miR-98-5p, miR-183-5p and miR-22-3p) were identified with potential in stratifying platinum-sensitive and platinum-resistant HGSC patients and predicting prognostic outcome.	Platinum	141-149	microRNA 223	Homo sapiens	61-70
31659785-6	2020	Interestingly the HER activity increases with increasing concentration of Pt4+ species in the nanoparticles, and the optimized catalyst even outperforms commercial Pt/C, exhibiting an overpotential of only -7.7 mV to reach the current density of 10 mA cm-2 and a Tafel slope of -26.3 mV dec-1.	Platinum	74-78	deleted in esophageal cancer 1	Homo sapiens	287-292
31664600-8	2019	CONCLUSIONS: With bioinformatics modeling and analysis, we identified and confirmed four novel putative miRNA biomarkers, miR-454-3p, miR-98-5p, miR-183-5p and miR-22-3p that could serve as indicators of resistance to platinum-based chemotherapy, thereby contributing to the improvement of chemotherapeutic efficiency and optimization of personalized treatments in HGSC.	Platinum	218-226	microRNA 223	Homo sapiens	160-169
31671878-1	2019	Herein we report the first example of a facile biomineralization process to produce ultra-small-sized highly fluorescent aqueous dispersions of platinum noble metal quantum clusters (Pt-NMQCs) using a multi-stimulus responsive, biomimetic intrinsically disordered protein (IDP), Rec1-resilin.	Platinum	144-152	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	273-276
31671878-1	2019	Herein we report the first example of a facile biomineralization process to produce ultra-small-sized highly fluorescent aqueous dispersions of platinum noble metal quantum clusters (Pt-NMQCs) using a multi-stimulus responsive, biomimetic intrinsically disordered protein (IDP), Rec1-resilin.	Platinum	144-152	RAD1 checkpoint DNA exonuclease	Homo sapiens	279-283
31671878-2	2019	We demonstrate that Rec1-resilin acts concurrently as the host, reducing agent, and stabilizer of the blue-green fluorescent Pt-NMQCs once they are being formed.	Platinum	125-127	RAD1 checkpoint DNA exonuclease	Homo sapiens	20-24
31659785-6	2020	Interestingly the HER activity increases with increasing concentration of Pt4+ species in the nanoparticles, and the optimized catalyst even outperforms commercial Pt/C, exhibiting an overpotential of only -7.7 mV to reach the current density of 10 mA cm-2 and a Tafel slope of -26.3 mV dec-1.	Platinum	74-76	deleted in esophageal cancer 1	Homo sapiens	287-292
31653094-1	2019	The PARP inhibitor olaparib has been approved in the maintenance setting of platinum-sensitive epithelial ovarian cancer patients with germline or somatic BRCA1/2 mutation.	Platinum	76-84	collagen type XI alpha 2 chain	Homo sapiens	4-8
31596295-2	2019	In the present work, Au@AgPt NPs with a {431}-faceted hexoctahedral Au core and an AgPt alloy shell exhibiting enhanced catalysis and good SERS activity were prepared by a facile silver-mediated temperature-controlled selective deposition of Pt.	Platinum	26-28	seryl-tRNA synthetase 2, mitochondrial	Homo sapiens	139-143
31596295-6	2019	By systematically investigating the effects of temperature, precursor consumption and synthesis time on the morphology, composition, optical properties, catalysis and SERS properties of the Au@AgPt NPs, the kinetic and thermodynamic mechanisms of the deposition of Pt on hexoctahedral Au nanoparticles were explored.	Platinum	195-197	seryl-tRNA synthetase 2, mitochondrial	Homo sapiens	167-171
31596295-8	2019	Besides, it is easy to regulate and control their SERS and catalytic performances through the selective deposition of Pt, according to the demand of the catalytic reaction and SERS monitoring.	Platinum	118-120	seryl-tRNA synthetase 2, mitochondrial	Homo sapiens	50-54
31596295-8	2019	Besides, it is easy to regulate and control their SERS and catalytic performances through the selective deposition of Pt, according to the demand of the catalytic reaction and SERS monitoring.	Platinum	118-120	seryl-tRNA synthetase 2, mitochondrial	Homo sapiens	176-180
31596295-9	2019	This work not only presents a new Au@AgPt nanostructure with good catalytic and SERS properties, but also develops a facile, universal and controllable method for selective deposition of Pt on Au nano-templates with a variety of morphologies.	Platinum	39-41	seryl-tRNA synthetase 2, mitochondrial	Homo sapiens	80-84
31596285-3	2019	Wavelength-dependent electric current over the Pt-edged Au NDs for the MOR in the visible-NIR light region demonstrates that the light-induced enhancement of the electric current is due to surface plasmon resonance (SPR) of the Au NDs.	Platinum	47-49	opioid receptor mu 1	Homo sapiens	71-74
31653006-8	2019	Moreover, chromatography data showed that PS and PTS possessed 17 identical anthocyanins as a negative regulator of ERK.	Platinum	49-52	mitogen-activated protein kinase 1	Mus musculus	116-119
31653006-9	2019	These findings suggested that anthocyanins from PS and PTS inhibited melanogenesis in vitro and in vivo by activating the ERK signaling pathway.	Platinum	55-58	mitogen-activated protein kinase 1	Mus musculus	122-125
31556584-2	2019	Herein, DNA repair blocker BRCA1 small interfering RNA (siRNA) was introduced with cisplatin (Pt) into the elaborately designed pH-sensitive shell-core platform to enhance the chemotherapeutic treatment effect by silencing the DNA repair related gene.	Platinum	94-96	BRCA1 DNA repair associated	Homo sapiens	27-32
31653094-1	2019	The PARP inhibitor olaparib has been approved in the maintenance setting of platinum-sensitive epithelial ovarian cancer patients with germline or somatic BRCA1/2 mutation.	Platinum	76-84	BRCA1 DNA repair associated	Homo sapiens	155-160
31635307-0	2019	ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85alpha Deficient Cancer Cells and Influence Platinum Sensitivity.	Platinum	117-125	ATM serine/threonine kinase	Homo sapiens	0-3
31648503-4	2019	Results: The objective response rates of patients with uncommon EGFR mutations receiving EGFR-TKIs or platinum-based chemotherapy were 33.0% and 27.1%, respectively.	Platinum	102-110	epidermal growth factor receptor	Homo sapiens	64-68
31464077-4	2019	Compared to commercial Pt/C catalyst, the L10 -W-PtCo/C catalyst shows significant improvement in both initial activity and high-temperature stability.	Platinum	23-25	immunoglobulin kappa variable 3-7 (non-functional)	Homo sapiens	42-45
31630258-0	2019	Bimodal determination of immunoglobulin E by fluorometry and ICP-MS by using platinum nanoclusters as a label in an immunoassay.	Platinum	77-85	immunoglobulin heavy constant epsilon	Homo sapiens	25-41
31630258-1	2019	The authors describe the use of platinum nanoclusters (PtNCs) as bimodal labels in a competitive immunoassay for immunoglobulin E (IgE).	Platinum	32-40	immunoglobulin heavy constant epsilon	Homo sapiens	113-129
31630258-1	2019	The authors describe the use of platinum nanoclusters (PtNCs) as bimodal labels in a competitive immunoassay for immunoglobulin E (IgE).	Platinum	32-40	immunoglobulin heavy constant epsilon	Homo sapiens	131-134
31630258-15	2019	Graphical abstract Schematic representation of the bimodal quantification (fluorescence and ICP-MS) of immunoglobulin E (Ig E) in human serum using antibody against human Ig E, labelled with several platinum nanoclusters (NCs) as immunoprobe.	Platinum	199-207	immunoglobulin heavy constant epsilon	Homo sapiens	103-119
31630258-15	2019	Graphical abstract Schematic representation of the bimodal quantification (fluorescence and ICP-MS) of immunoglobulin E (Ig E) in human serum using antibody against human Ig E, labelled with several platinum nanoclusters (NCs) as immunoprobe.	Platinum	199-207	immunoglobulin heavy constant epsilon	Homo sapiens	121-125
31649341-6	2019	The calculated electroactive surface area for the Pt-Ni/C-R2 nanoboxes was 190.8 m2.g-1, which is significantly higher compared to that of the Pt-Ni nanocatalyst (96.4 m2.g-1) synthesized by a conventional reduction method.	Platinum	50-52	complement C3d receptor 2	Homo sapiens	56-60
31649341-6	2019	The calculated electroactive surface area for the Pt-Ni/C-R2 nanoboxes was 190.8 m2.g-1, which is significantly higher compared to that of the Pt-Ni nanocatalyst (96.4 m2.g-1) synthesized by a conventional reduction method.	Platinum	143-145	complement C3d receptor 2	Homo sapiens	56-60
31573797-7	2019	This Janus configuration was then transformed into a core-shell Cu2-xS@Ag2S structure via surface Pt doping.	Platinum	98-100	angiotensin II receptor type 1	Homo sapiens	71-75
31635307-0	2019	ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85alpha Deficient Cancer Cells and Influence Platinum Sensitivity.	Platinum	117-125	phosphatase and tensin homolog	Homo sapiens	14-18
31635307-0	2019	ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85alpha Deficient Cancer Cells and Influence Platinum Sensitivity.	Platinum	117-125	X-linked inhibitor of apoptosis	Homo sapiens	34-38
31635307-15	2019	In ovarian cancer patients, ATM, PTEN, p85alpha, and XIAP protein levels predicted better progression free survival after platinum therapy.	Platinum	122-130	ATM serine/threonine kinase	Homo sapiens	28-31
31635307-15	2019	In ovarian cancer patients, ATM, PTEN, p85alpha, and XIAP protein levels predicted better progression free survival after platinum therapy.	Platinum	122-130	phosphatase and tensin homolog	Homo sapiens	33-37
31635307-15	2019	In ovarian cancer patients, ATM, PTEN, p85alpha, and XIAP protein levels predicted better progression free survival after platinum therapy.	Platinum	122-130	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	39-47
31635307-15	2019	In ovarian cancer patients, ATM, PTEN, p85alpha, and XIAP protein levels predicted better progression free survival after platinum therapy.	Platinum	122-130	X-linked inhibitor of apoptosis	Homo sapiens	53-57
31597567-5	2019	Moreover, neoplastic cells carrying a specific set of somatic mutations, such as EGFR(L858R), KRAS (p.G12C) were obviously correlated with platinum treatment.	Platinum	139-147	epidermal growth factor receptor	Homo sapiens	81-85
31615563-0	2019	CSB affected on the sensitivity of lung cancer cells to platinum-based drugs through the global decrease of let-7 and miR-29.	Platinum	56-64	ERCC excision repair 6, chromatin remodeling factor	Homo sapiens	0-3
31615563-2	2019	Cockayne syndrome protein B (CSB), the master sensor of TCR, is also involved in the platinum resistant.	Platinum	85-93	ERCC excision repair 6, chromatin remodeling factor	Homo sapiens	0-27
31615563-2	2019	Cockayne syndrome protein B (CSB), the master sensor of TCR, is also involved in the platinum resistant.	Platinum	85-93	ERCC excision repair 6, chromatin remodeling factor	Homo sapiens	29-32
31615563-12	2019	CONCLUSIONS: In conclusion, the platinum-based drug resistant of lung cancer cells may involve in the regulation of let-7 and miR-29 to CSB.	Platinum	32-40	ERCC excision repair 6, chromatin remodeling factor	Homo sapiens	136-139
31681568-8	2019	Strikingly, sPD-L1 levels >6.4 pg/ml were indicative of a reduced OS (p = 0.035) and PFS (p = 0.083) in platinum-sensitive patients, while OS and PFS in platinum-resistant patients did not differ when patients were stratified to this cut-off.	Platinum	104-112	spindle apparatus coiled-coil protein 1	Homo sapiens	12-18
31681568-8	2019	Strikingly, sPD-L1 levels >6.4 pg/ml were indicative of a reduced OS (p = 0.035) and PFS (p = 0.083) in platinum-sensitive patients, while OS and PFS in platinum-resistant patients did not differ when patients were stratified to this cut-off.	Platinum	153-161	spindle apparatus coiled-coil protein 1	Homo sapiens	12-18
31428774-7	2019	Mass spectrometry identifies NCOR as the main PT-S264-dependent interactor of PPARbeta/delta.	Platinum	46-48	nuclear receptor corepressor 1	Homo sapiens	29-33
31428774-7	2019	Mass spectrometry identifies NCOR as the main PT-S264-dependent interactor of PPARbeta/delta.	Platinum	46-48	peroxisome proliferator activated receptor alpha	Homo sapiens	78-92
31597567-5	2019	Moreover, neoplastic cells carrying a specific set of somatic mutations, such as EGFR(L858R), KRAS (p.G12C) were obviously correlated with platinum treatment.	Platinum	139-147	KRAS proto-oncogene, GTPase	Homo sapiens	94-98
31600989-0	2019	KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy.	Platinum	122-130	KRAS proto-oncogene, GTPase	Homo sapiens	0-4
31525916-1	2019	An efficient and selective method was developed for the synthesis of ubiquitous clusters, MAu24L18 (M = Pd or Pt; L = thiolates or al-kynyls), by the reaction of Au(I)L oligomers with quasi-spherical superatoms [HMAu8(PPh3)8]+ activated by hydride doping.	Platinum	110-112	caveolin 1	Homo sapiens	218-222
31632022-2	2019	Previously, we characterized circulating exosomal miR-425-3p as a non-invasive prognostic marker for predicting clinical response to platinum-based chemotherapy in patients with non-small cell lung cancer (NSCLC).	Platinum	133-141	microRNA 4253	Homo sapiens	50-60
31632022-3	2019	Methods: Circulating exosomal miR-425-3p was validated by qRT-PCR in paired serum samples from NSCLC patients during the course of platinum-based chemotherapy.	Platinum	131-139	microRNA 4253	Homo sapiens	30-40
31728434-0	2019	Excellent platinum dependent response to chemotherapy after relapse under TKI treatment in NSCLC with sensitizing EGFR mutations and no detectable resistance mutations: three case studies.	Platinum	10-18	epidermal growth factor receptor	Homo sapiens	114-118
31602282-5	2019	We found that the reactivity of CHD3 on Pd(111) is intermediate between and similar to either Pt(111) or Ni(111), depending on the incidence energy and the initial vibrational state distribution.	Platinum	94-101	chromodomain helicase DNA binding protein 3	Homo sapiens	32-36
31570444-0	2019	MLH1 Is a Prognostic Biomarker for Serous Ovarian Cancer Treated With Platinum- and Taxane-based Chemotherapy.	Platinum	70-78	mutL homolog 1	Homo sapiens	0-4
31435660-1	2019	BACKGROUND: In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on >=50% of tumor cells, first-line treatment with the PD-1 inhibitor pembrolizumab improves survival compared with platinum-doublet chemotherapy.	Platinum	209-217	CD274 molecule	Homo sapiens	48-73
31435660-1	2019	BACKGROUND: In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on >=50% of tumor cells, first-line treatment with the PD-1 inhibitor pembrolizumab improves survival compared with platinum-doublet chemotherapy.	Platinum	209-217	CD274 molecule	Homo sapiens	75-80
31570444-3	2019	PATIENTS AND METHODS: MLH1 expression was evaluated by immunohistochemistry in patients with advanced serous ovarian cancer treated with platinum- and taxane-based chemotherapy.	Platinum	137-145	mutL homolog 1	Homo sapiens	22-26
31285371-10	2019	Inhibition of TGFbeta1 by SB431542, ERK by selumetinib, or HIF1alpha by YC-1 efficiently overcame platinum resistance both in vitro and in vivo The results from clinical samples confirm activation of the ERK/PHD2/HIF1alpha axis in patients with PROC, correlating highly with poor prognoses for patients.Conclusions: HIF1alpha stabilization is regulated by TGFbeta1/ERK/PHD2 axis in PROC.	Platinum	98-106	hypoxia inducible factor 1 subunit alpha	Homo sapiens	213-222
31434988-0	2019	FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.	Platinum	70-78	FXYD domain containing ion transport regulator 5	Homo sapiens	0-5
31434988-0	2019	FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.	Platinum	70-78	FXYD domain containing ion transport regulator 5	Homo sapiens	7-17
31581548-7	2019	This study showed that (i) the splice mutation in TP53 was present as an early driver mutation at diagnosis; (ii) the mutational profile was shared in pre- and post-NACT tumor samples; (iii) the complete expansion of a single dominant mutant clone through loss of heterozygosity (LOH) had occurred, suggesting a possible mechanism of platinum-resistance in HGSOC under the pressure of NACT.	Platinum	334-342	tumor protein p53	Homo sapiens	50-54
31218944-0	2019	Polymorphisms in GSTM1 and GSTT1 influence the response and treatment outcome in lung cancer patients treated with platinum-based chemotherapy.	Platinum	115-123	glutathione S-transferase mu 1	Homo sapiens	17-22
31218944-0	2019	Polymorphisms in GSTM1 and GSTT1 influence the response and treatment outcome in lung cancer patients treated with platinum-based chemotherapy.	Platinum	115-123	glutathione S-transferase theta 1	Homo sapiens	27-32
31285371-0	2019	ERK Regulates HIF1alpha-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer.	Platinum	33-41	mitogen-activated protein kinase 1	Homo sapiens	0-3
31285371-10	2019	Inhibition of TGFbeta1 by SB431542, ERK by selumetinib, or HIF1alpha by YC-1 efficiently overcame platinum resistance both in vitro and in vivo The results from clinical samples confirm activation of the ERK/PHD2/HIF1alpha axis in patients with PROC, correlating highly with poor prognoses for patients.Conclusions: HIF1alpha stabilization is regulated by TGFbeta1/ERK/PHD2 axis in PROC.	Platinum	98-106	hypoxia inducible factor 1 subunit alpha	Homo sapiens	213-222
31285371-0	2019	ERK Regulates HIF1alpha-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer.	Platinum	33-41	hypoxia inducible factor 1 subunit alpha	Homo sapiens	14-23
31285371-0	2019	ERK Regulates HIF1alpha-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer.	Platinum	33-41	egl-9 family hypoxia inducible factor 1	Homo sapiens	75-79
31285371-10	2019	Inhibition of TGFbeta1 by SB431542, ERK by selumetinib, or HIF1alpha by YC-1 efficiently overcame platinum resistance both in vitro and in vivo The results from clinical samples confirm activation of the ERK/PHD2/HIF1alpha axis in patients with PROC, correlating highly with poor prognoses for patients.Conclusions: HIF1alpha stabilization is regulated by TGFbeta1/ERK/PHD2 axis in PROC.	Platinum	98-106	latent transforming growth factor beta binding protein 1	Homo sapiens	356-364
31285371-2	2019	Increased HIF1alpha level is an important mechanism governing platinum resistance in platinum-resistant ovarian cancer (PROC).	Platinum	62-70	hypoxia inducible factor 1 subunit alpha	Homo sapiens	10-19
31285371-2	2019	Increased HIF1alpha level is an important mechanism governing platinum resistance in platinum-resistant ovarian cancer (PROC).	Platinum	85-93	hypoxia inducible factor 1 subunit alpha	Homo sapiens	10-19
31285371-9	2019	Significantly, ERK/PHD2 signaling in PROC cells is dependent on TGFbeta1, promoting platinum resistance by stabilizing HIF1alpha.	Platinum	84-92	mitogen-activated protein kinase 1	Homo sapiens	15-18
31285371-9	2019	Significantly, ERK/PHD2 signaling in PROC cells is dependent on TGFbeta1, promoting platinum resistance by stabilizing HIF1alpha.	Platinum	84-92	egl-9 family hypoxia inducible factor 1	Homo sapiens	19-23
31285371-9	2019	Significantly, ERK/PHD2 signaling in PROC cells is dependent on TGFbeta1, promoting platinum resistance by stabilizing HIF1alpha.	Platinum	84-92	latent transforming growth factor beta binding protein 1	Homo sapiens	64-72
31285371-9	2019	Significantly, ERK/PHD2 signaling in PROC cells is dependent on TGFbeta1, promoting platinum resistance by stabilizing HIF1alpha.	Platinum	84-92	hypoxia inducible factor 1 subunit alpha	Homo sapiens	119-128
31285371-10	2019	Inhibition of TGFbeta1 by SB431542, ERK by selumetinib, or HIF1alpha by YC-1 efficiently overcame platinum resistance both in vitro and in vivo The results from clinical samples confirm activation of the ERK/PHD2/HIF1alpha axis in patients with PROC, correlating highly with poor prognoses for patients.Conclusions: HIF1alpha stabilization is regulated by TGFbeta1/ERK/PHD2 axis in PROC.	Platinum	98-106	mitogen-activated protein kinase 1	Homo sapiens	204-207
31285371-10	2019	Inhibition of TGFbeta1 by SB431542, ERK by selumetinib, or HIF1alpha by YC-1 efficiently overcame platinum resistance both in vitro and in vivo The results from clinical samples confirm activation of the ERK/PHD2/HIF1alpha axis in patients with PROC, correlating highly with poor prognoses for patients.Conclusions: HIF1alpha stabilization is regulated by TGFbeta1/ERK/PHD2 axis in PROC.	Platinum	98-106	latent transforming growth factor beta binding protein 1	Homo sapiens	14-22
31285371-10	2019	Inhibition of TGFbeta1 by SB431542, ERK by selumetinib, or HIF1alpha by YC-1 efficiently overcame platinum resistance both in vitro and in vivo The results from clinical samples confirm activation of the ERK/PHD2/HIF1alpha axis in patients with PROC, correlating highly with poor prognoses for patients.Conclusions: HIF1alpha stabilization is regulated by TGFbeta1/ERK/PHD2 axis in PROC.	Platinum	98-106	mitogen-activated protein kinase 1	Homo sapiens	36-39
31285371-10	2019	Inhibition of TGFbeta1 by SB431542, ERK by selumetinib, or HIF1alpha by YC-1 efficiently overcame platinum resistance both in vitro and in vivo The results from clinical samples confirm activation of the ERK/PHD2/HIF1alpha axis in patients with PROC, correlating highly with poor prognoses for patients.Conclusions: HIF1alpha stabilization is regulated by TGFbeta1/ERK/PHD2 axis in PROC.	Platinum	98-106	egl-9 family hypoxia inducible factor 1	Homo sapiens	369-373
31285371-10	2019	Inhibition of TGFbeta1 by SB431542, ERK by selumetinib, or HIF1alpha by YC-1 efficiently overcame platinum resistance both in vitro and in vivo The results from clinical samples confirm activation of the ERK/PHD2/HIF1alpha axis in patients with PROC, correlating highly with poor prognoses for patients.Conclusions: HIF1alpha stabilization is regulated by TGFbeta1/ERK/PHD2 axis in PROC.	Platinum	98-106	hypoxia inducible factor 1 subunit alpha	Homo sapiens	59-68
31285371-10	2019	Inhibition of TGFbeta1 by SB431542, ERK by selumetinib, or HIF1alpha by YC-1 efficiently overcame platinum resistance both in vitro and in vivo The results from clinical samples confirm activation of the ERK/PHD2/HIF1alpha axis in patients with PROC, correlating highly with poor prognoses for patients.Conclusions: HIF1alpha stabilization is regulated by TGFbeta1/ERK/PHD2 axis in PROC.	Platinum	98-106	mitogen-activated protein kinase 1	Homo sapiens	204-207
31499327-1	2019	Homologous recombination deficiency conferred by alterations in BRCA1 or BRCA2 are common in breast tumors and can drive sensitivity to platinum chemotherapy and PARP inhibitors.	Platinum	136-144	BRCA1 DNA repair associated	Homo sapiens	64-69
31285371-10	2019	Inhibition of TGFbeta1 by SB431542, ERK by selumetinib, or HIF1alpha by YC-1 efficiently overcame platinum resistance both in vitro and in vivo The results from clinical samples confirm activation of the ERK/PHD2/HIF1alpha axis in patients with PROC, correlating highly with poor prognoses for patients.Conclusions: HIF1alpha stabilization is regulated by TGFbeta1/ERK/PHD2 axis in PROC.	Platinum	98-106	egl-9 family hypoxia inducible factor 1	Homo sapiens	208-212
31499327-1	2019	Homologous recombination deficiency conferred by alterations in BRCA1 or BRCA2 are common in breast tumors and can drive sensitivity to platinum chemotherapy and PARP inhibitors.	Platinum	136-144	BRCA2 DNA repair associated	Homo sapiens	73-78
31656318-7	2019	In particular the "use" of a BRCA1/2 mutation or the biological characteristic HRD as a potential motive for therapy plays a role here in specifying the significance of platinum therapy and therapy with PARP inhibitors.	Platinum	169-177	BRCA1 DNA repair associated	Homo sapiens	29-36
31279298-10	2019	On the same cell lines, CDDP displayed IC50 of 2.1 muM, 0.5 muM and 1.0 muM, respectively.	Platinum	24-28	latexin	Homo sapiens	51-54
31279298-10	2019	On the same cell lines, CDDP displayed IC50 of 2.1 muM, 0.5 muM and 1.0 muM, respectively.	Platinum	24-28	latexin	Homo sapiens	60-63
31279298-10	2019	On the same cell lines, CDDP displayed IC50 of 2.1 muM, 0.5 muM and 1.0 muM, respectively.	Platinum	24-28	latexin	Homo sapiens	60-63
31279298-12	2019	This is not the case for CDDP showing IC50 of 1.3 muM and 5.1 muM on HT-29 and HaCat cells, respectively.	Platinum	25-29	latexin	Homo sapiens	50-53
31279298-12	2019	This is not the case for CDDP showing IC50 of 1.3 muM and 5.1 muM on HT-29 and HaCat cells, respectively.	Platinum	25-29	latexin	Homo sapiens	62-65
31478762-1	2019	The poly ADP ribose polymerase olaparib is currently approved in front line BRCA-associated epithelial ovarian cancer (EOC), platinum-sensitive recurrence agnostic to BRCA status and for gBRCA as treatment in the fourth line and beyond.	Platinum	125-133	poly(ADP-ribose) polymerase 1	Homo sapiens	4-30
31478762-1	2019	The poly ADP ribose polymerase olaparib is currently approved in front line BRCA-associated epithelial ovarian cancer (EOC), platinum-sensitive recurrence agnostic to BRCA status and for gBRCA as treatment in the fourth line and beyond.	Platinum	125-133	BRCA1 DNA repair associated	Homo sapiens	167-171
32184881-0	2019	Study of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers.	Platinum	70-78	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	34-39
31573752-7	2019	For platinum-sensitive or first-line patients, pembrolizumab monotherapy (patients with PD-L1 Combined Positive Score >= 20) or pembrolizumab-platinum-fluorouracil improved overall survival vs the EXTREME (cetuximab-platinum-fluorouracil).	Platinum	4-12	CD274 molecule	Homo sapiens	88-93
29209987-0	2019	Genetic Investigation of Polymorphic OGG1 and MUTYH Genes Towards Increased Susceptibility in Lung Adenocarcinoma and its Impact on Overall Survival of Lung Cancer Patients Treated with Platinum Based Chemotherapy.	Platinum	186-194	8-oxoguanine DNA glycosylase	Homo sapiens	37-41
31206244-2	2019	The aim of our study was to determine the prognostic and predictive relevance of these subgroups in the context of platinum/5-fluorouracil (5-FU) based preoperative chemotherapy (CTx).	Platinum	115-123	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	179-182
31626089-0	2019	Plasma miR-32 levels in non-small cell lung cancer patients receiving platinum-based chemotherapy can predict the effectiveness and prognosis of chemotherapy.	Platinum	70-78	microRNA 32	Homo sapiens	7-13
31626089-2	2019	In this study, our goal was to assess the expression of plasma microRNA-32 and its potential as a biomarker to predict the tumor response and survival of patients with NSCLC undergoing platinum-based chemotherapy.	Platinum	185-193	microRNA 32	Homo sapiens	63-74
31626089-9	2019	CONCLUSIONS: The plasma levels of microRNA-32 correlated with the efficacy of platinum-based chemotherapy and survival, indicating that microRNA-32 may be useful for predicting the effectiveness of platinum-based chemotherapy and prognosis in NSCLC.	Platinum	78-86	microRNA 32	Homo sapiens	34-45
31626089-9	2019	CONCLUSIONS: The plasma levels of microRNA-32 correlated with the efficacy of platinum-based chemotherapy and survival, indicating that microRNA-32 may be useful for predicting the effectiveness of platinum-based chemotherapy and prognosis in NSCLC.	Platinum	78-86	microRNA 32	Homo sapiens	136-147
31626089-9	2019	CONCLUSIONS: The plasma levels of microRNA-32 correlated with the efficacy of platinum-based chemotherapy and survival, indicating that microRNA-32 may be useful for predicting the effectiveness of platinum-based chemotherapy and prognosis in NSCLC.	Platinum	198-206	microRNA 32	Homo sapiens	34-45
31626089-9	2019	CONCLUSIONS: The plasma levels of microRNA-32 correlated with the efficacy of platinum-based chemotherapy and survival, indicating that microRNA-32 may be useful for predicting the effectiveness of platinum-based chemotherapy and prognosis in NSCLC.	Platinum	198-206	microRNA 32	Homo sapiens	136-147
31127646-9	2019	This finding suggests that the dysregulation between hsa-let-7a-5p/CDKN1A and hsa-miR-92b-3p/GSTM3 pairs is associated with platinum-based chemoresistance of metastatic cancer cells.	Platinum	124-132	cyclin dependent kinase inhibitor 1A	Homo sapiens	67-73
31127646-9	2019	This finding suggests that the dysregulation between hsa-let-7a-5p/CDKN1A and hsa-miR-92b-3p/GSTM3 pairs is associated with platinum-based chemoresistance of metastatic cancer cells.	Platinum	124-132	glutathione S-transferase mu 3	Homo sapiens	93-98
31347029-0	2019	Efficacy of Platinum-Based Adjuvant Chemotherapy on Prognosis of Pathological Stage II/III Lung Adenocarcinoma based on EGFR Mutation Status: A Propensity Score Matching Analysis.	Platinum	12-20	epidermal growth factor receptor	Homo sapiens	120-124
31347029-1	2019	OBJECTIVE: This study aimed to retrospectively evaluate the efficacy of platinum-based adjuvant chemotherapy (PBAC) for patients with pathological II/III pulmonary adenocarcinoma after curative resection based on epidermal growth factor receptor (EGFR) mutation status using propensity score matching (PSM) analysis.	Platinum	72-80	epidermal growth factor receptor	Homo sapiens	213-245
31347029-1	2019	OBJECTIVE: This study aimed to retrospectively evaluate the efficacy of platinum-based adjuvant chemotherapy (PBAC) for patients with pathological II/III pulmonary adenocarcinoma after curative resection based on epidermal growth factor receptor (EGFR) mutation status using propensity score matching (PSM) analysis.	Platinum	72-80	epidermal growth factor receptor	Homo sapiens	247-251
31391294-2	2019	A patient with platinum-refractory recurrent oral cavity HNSCC underwent comprehensive genomic profiling (CGP) that identified an activating MET mutation (R1004).	Platinum	15-23	SAFB like transcription modulator	Homo sapiens	141-144
29209987-0	2019	Genetic Investigation of Polymorphic OGG1 and MUTYH Genes Towards Increased Susceptibility in Lung Adenocarcinoma and its Impact on Overall Survival of Lung Cancer Patients Treated with Platinum Based Chemotherapy.	Platinum	186-194	mutY DNA glycosylase	Homo sapiens	46-51
31565185-1	2019	Background: ERCC1, a component of nucleotide excision repair pathway, is known to repair DNA breaks induced by platinum drugs.	Platinum	111-119	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	12-17
31561530-3	2019	In the effort to identify anti-TS drugs with new modes of action and able to overcome platinum drug resistance in ovarian cancer, octapeptides with a new allosteric inhibition mechanism were identified as cancer cell growth inhibitors that do not cause TS overexpression.	Platinum	86-94	thymidylate synthetase	Homo sapiens	31-33
31490657-3	2019	In the case of a Pt catalyst supported on the semiconducting oxide Nb-doped SnO2 with a fused-aggregate network structure (Pt/Nb-SnO2) for polymer electrolyte fuel cells, the electronic conductivity increased abruptly with increasing Pt loading, going from 10-4 to 10-2 S cm-1.	Platinum	17-19	strawberry notch homolog 2	Homo sapiens	76-79
31532756-3	2019	Low expression of TUG1 was found in NSCLC tissues obtained from non-responders to platinum-based chemotherapy and reflected poor overall survival.	Platinum	82-90	taurine up-regulated 1	Homo sapiens	18-22
31532756-6	2019	High expression of miR-221 and low expression of PTEN were determined in cancer tissues obtained from non-responders to platinum-based chemotherapy and reflected poor overall survival.	Platinum	120-128	microRNA 221	Homo sapiens	19-26
31532756-6	2019	High expression of miR-221 and low expression of PTEN were determined in cancer tissues obtained from non-responders to platinum-based chemotherapy and reflected poor overall survival.	Platinum	120-128	phosphatase and tensin homolog	Homo sapiens	49-53
31521181-2	2019	The aim of this study was to present our institutional observations regarding to the association of ERCC1 and overall survival (OS) of the lung adenocarcinoma patients who received chemotherapy based on platinum.	Platinum	203-211	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	100-105
31483609-4	2019	Three different Zr atoms, occupying three different sites, aid in the close-packing of the Pt and Sb atoms.	Platinum	91-93	activation induced cytidine deaminase	Homo sapiens	59-62
31279178-4	2019	Addition of target miR21 resulted in opening the hairpin moiety and subsequent hybridization with DNA-modified gold nanoflower/platinum electrode (GNF@Pt) to form the MB-3 sensor.	Platinum	127-135	microRNA 21	Homo sapiens	19-24
31228268-0	2019	Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma.	Platinum	45-53	signal transducer and activator of transcription 1	Homo sapiens	19-24
31228268-3	2019	In the present study, we investigated the regulatory role of STAT1 toward platinum-cytotoxicity in USC.	Platinum	74-82	signal transducer and activator of transcription 1	Homo sapiens	61-66
31226604-0	2019	An ultrasensitive luminol cathodic electrochemiluminescence probe with highly porous Pt on ionic liquid functionalized graphene film as platform for carcinoembryonic antigen sensing.	Platinum	85-87	CEA cell adhesion molecule 3	Homo sapiens	149-173
31226604-2	2019	In this work, highly porous platinum (Pt) nanostructures on ionic liquid functionalized graphene film (GR-IL/pPt) were prepared as platform to construct a label-free ECL sensor for the detection of carcinoembryonic antigen (CEA).	Platinum	28-36	CEA cell adhesion molecule 3	Homo sapiens	198-222
31226604-2	2019	In this work, highly porous platinum (Pt) nanostructures on ionic liquid functionalized graphene film (GR-IL/pPt) were prepared as platform to construct a label-free ECL sensor for the detection of carcinoembryonic antigen (CEA).	Platinum	28-36	CEA cell adhesion molecule 3	Homo sapiens	224-227
31226604-2	2019	In this work, highly porous platinum (Pt) nanostructures on ionic liquid functionalized graphene film (GR-IL/pPt) were prepared as platform to construct a label-free ECL sensor for the detection of carcinoembryonic antigen (CEA).	Platinum	38-40	CEA cell adhesion molecule 3	Homo sapiens	198-222
31226604-2	2019	In this work, highly porous platinum (Pt) nanostructures on ionic liquid functionalized graphene film (GR-IL/pPt) were prepared as platform to construct a label-free ECL sensor for the detection of carcinoembryonic antigen (CEA).	Platinum	38-40	CEA cell adhesion molecule 3	Homo sapiens	224-227
31521181-0	2019	Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study.	Platinum	113-121	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	4-9
31521181-1	2019	BACKGROUND: High ERCC1 expression is thought to be related with resistance to chemotherapy based on platinum.	Platinum	100-108	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	17-22
31521181-10	2019	Longer OS was strongly associated with a low ERCC1 expression, not only in the group of patients in TNM stage I-III, who were treated with combination of chemotherapy with surgery or radiotherapy (p = 0.002), but also in the group of patients in TNM stage IV who received only chemotherapy based on platinum (p < 0.001), compared with the patients in the same TNM stage and high ERCC1 expression.	Platinum	299-307	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	45-50
31521181-11	2019	CONCLUSIONS: ERCC1 expression in lung adenocarcinoma is a useful prognostic marker and moreover, a useful predictive marker in patients receiving chemotherapy based on platinum in all stages of the disease.	Platinum	168-176	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	13-18
31547268-8	2019	Importantly, MDM4 nuclear localization and intra-tumor estrogen availability correlate with decreased platinum-sensitivity and apoptosis and predicts poor disease-free survival in high-grade serous ovarian carcinoma.	Platinum	102-110	transformed mouse 3T3 cell double minute 4	Mus musculus	13-17
31547268-0	2019	Estrogens Counteract Platinum-Chemosensitivity by Modifying the Subcellular Localization of MDM4.	Platinum	21-29	transformed mouse 3T3 cell double minute 4	Mus musculus	92-96
31540259-6	2019	Furthermore, ATP7A/B activity and trafficking allow tumor cells to detoxify platinum (Pt)-based drugs (like cisplatin), which are used for the chemotherapy of different solid tumors.	Platinum	76-84	ATPase copper transporting alpha	Homo sapiens	13-18
31540259-6	2019	Furthermore, ATP7A/B activity and trafficking allow tumor cells to detoxify platinum (Pt)-based drugs (like cisplatin), which are used for the chemotherapy of different solid tumors.	Platinum	86-88	ATPase copper transporting alpha	Homo sapiens	13-18
31369707-3	2019	Inhibition of ERCC1-XPF has been shown to potentiate cytotoxicity of platinum-based drugs and cyclophosphamide in cancer cells.	Platinum	69-77	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-19
31369707-3	2019	Inhibition of ERCC1-XPF has been shown to potentiate cytotoxicity of platinum-based drugs and cyclophosphamide in cancer cells.	Platinum	69-77	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	20-23
31411235-3	2019	The PT-CCT treatment can greatly downregulate the P-gp expression level and achieve utmost MDR-reversal and antitumor efficacy by both a cocktail effect of CCT and a synergistic effect of CCT with PT; meanwhile, PT can inhibit the expression of heat shock protein 90 and enhance the thermosensitivity of cancer cells.	Platinum	4-6	phosphoglycolate phosphatase	Homo sapiens	50-54
31411235-3	2019	The PT-CCT treatment can greatly downregulate the P-gp expression level and achieve utmost MDR-reversal and antitumor efficacy by both a cocktail effect of CCT and a synergistic effect of CCT with PT; meanwhile, PT can inhibit the expression of heat shock protein 90 and enhance the thermosensitivity of cancer cells.	Platinum	197-199	phosphoglycolate phosphatase	Homo sapiens	50-54
31552170-0	2019	Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium.	Platinum	152-160	heat shock protein 90 alpha family class A member 1	Homo sapiens	67-72
31500118-4	2019	Atox1 has also been implicated in the resistance to platinum chemotherapy.	Platinum	52-60	antioxidant 1 copper chaperone	Homo sapiens	0-5
31519575-4	2019	This study determined whether PXR antagonists ketoconazole and phenethyl isothiocyanate (PEITC) enhance the antitumor activity of platinum compounds and by which mechanism(s) of action.	Platinum	130-138	nuclear receptor subfamily 1 group I member 2	Homo sapiens	30-33
31564904-2	2019	Expression of APE1 is commonly increased in OS, and this is negatively correlated with a sensitivity to platinum and a favorable prognosis.	Platinum	104-112	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	14-18
31274516-6	2019	Taken together, our research demonstrated that DN604 with the functional dicarboxylato ligand as the leaving group could effectively enhance chemo-sensitivity of SiHa cells to platinum-based agents via suppressing Beclin1 and CK2-mediated MRN-DSBs repair.	Platinum	176-184	beclin 1	Homo sapiens	214-221
31478830-2	2019	Stem phenotypes involving Wnt-beta-catenin, aldehyde dehydrogenase activities, intrinsic platinum resistance, and tumorsphere formation are here associated with spontaneous gains in Kras, Myc and FAK (KMF) genes in a new aggressive murine model of ovarian cancer.	Platinum	89-97	PTK2 protein tyrosine kinase 2	Mus musculus	196-199
31478830-4	2019	Platinum-resistant tumorspheres can acquire a dependence on FAK for growth.	Platinum	0-8	protein tyrosine kinase 2	Homo sapiens	60-63
31262689-2	2019	In this study, we investigated whether PD-L1 expression is affected by platinum-based chemotherapy.	Platinum	71-79	CD274 molecule	Homo sapiens	39-44
31387179-4	2019	WEE1 kinase, a G2/M checkpoint regulator, was recently considered as a putative biomarker for the platinum-based chemo-response.	Platinum	98-106	WEE1 G2 checkpoint kinase	Homo sapiens	0-4
31260134-2	2019	We previously reported that platinum (nPt) and palladium (nPd) nanoparticle-containing mixture (PAPLAL) has both superoxide dismutase and catalase activities and that the topical application of PAPLAL improved skin atrophy induced by chronic oxidative damage in an ageing mouse model.	Platinum	28-36	catalase	Mus musculus	138-146
31353799-2	2019	In the present work, uniform and well-distributed Pt nanoparticles (NPs) grown on an atomic carbon layer, that is in situ formed by means of dry-etching of silicon carbide nanoparticles (SiC NPs) with CCl4 gas, are explored as potential catalysts for MOR.	Platinum	50-52	C-C motif chemokine ligand 4	Homo sapiens	201-205
31273068-2	2019	In this study, we investigated the effects of two genetic polymorphisms in the hMSH2 and hMLH1 genes on the risk of epithelial ovarian cancer and the clinical outcome of patients treated with platinum-based chemotherapy.	Platinum	192-200	mutS homolog 2	Homo sapiens	79-84
31273068-2	2019	In this study, we investigated the effects of two genetic polymorphisms in the hMSH2 and hMLH1 genes on the risk of epithelial ovarian cancer and the clinical outcome of patients treated with platinum-based chemotherapy.	Platinum	192-200	mutL homolog 1	Homo sapiens	89-94
31273068-12	2019	CONCLUSION: Our research suggests that genetic polymorphisms in hMSH2 and hMLH1 may indicate the clinical progression of epithelial ovarian cancer patients treated with platinum-based chemotherapy.	Platinum	169-177	mutS homolog 2	Homo sapiens	64-69
31273068-12	2019	CONCLUSION: Our research suggests that genetic polymorphisms in hMSH2 and hMLH1 may indicate the clinical progression of epithelial ovarian cancer patients treated with platinum-based chemotherapy.	Platinum	169-177	mutL homolog 1	Homo sapiens	74-79
31934199-10	2019	The expression level of ATP7A was an important factor affecting tumor tissue"s histologic grade, the response to platinum-based chemotherapy and the prognosis of advanced ESCC patients.	Platinum	113-121	ATPase copper transporting alpha	Homo sapiens	24-29
31934199-11	2019	This indicates that ATP7A might be involved in the genesis and development of ESCC, and could be a resistance marker for platinum-based chemotherapy, and a prognostic factor for survival in patients with ESCC treated by Pt-based chemotherapy.	Platinum	121-129	ATPase copper transporting alpha	Homo sapiens	20-25
31934199-11	2019	This indicates that ATP7A might be involved in the genesis and development of ESCC, and could be a resistance marker for platinum-based chemotherapy, and a prognostic factor for survival in patients with ESCC treated by Pt-based chemotherapy.	Platinum	220-222	ATPase copper transporting alpha	Homo sapiens	20-25
31455033-8	2019	In contrast, higher counts of stromal PD-1+ cells in the peritoneal lesions have been associated with reduced platinum-sensitivity (p=0.045).	Platinum	110-118	programmed cell death 1	Sus scrofa	38-42
30374610-4	2019	The PD-1 and PD-L1 inhibitors provide a new and effective treatment option for patients with UC, particularly for patients with recurrence after platinum-based therapy and those who are ineligible for cisplatin.	Platinum	145-153	CD274 molecule	Homo sapiens	13-18
31252039-4	2019	Here, we report the construction and application of Au@Pt-based nanosystem with rationally designed peptide (LyP-1-PLGVRG-DPPA-1, LMDP) conjugation for cancer photothermal-immunotherapy.	Platinum	55-57	protein tyrosine phosphatase non-receptor type 22	Homo sapiens	109-114
31209956-6	2019	To the best of our knowledge, Pt-3 is the first multinuclear platinum complex to selectively kill breast CSCs over other breast cell types.	Platinum	61-69	zinc finger protein 135	Homo sapiens	30-34
31602266-4	2019	24%, 46%, 40%, 5%, and 44% GC had a potentially platinum sensitive phenotype by SNP analyses of GSTP1, ERCC1 rs11615, ERCC1 rs3212986, ERCC2, and XRCC1, respectively.	Platinum	48-56	glutathione S-transferase pi 1	Homo sapiens	96-101
31602266-4	2019	24%, 46%, 40%, 5%, and 44% GC had a potentially platinum sensitive phenotype by SNP analyses of GSTP1, ERCC1 rs11615, ERCC1 rs3212986, ERCC2, and XRCC1, respectively.	Platinum	48-56	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	103-108
31602266-4	2019	24%, 46%, 40%, 5%, and 44% GC had a potentially platinum sensitive phenotype by SNP analyses of GSTP1, ERCC1 rs11615, ERCC1 rs3212986, ERCC2, and XRCC1, respectively.	Platinum	48-56	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	118-123
31602266-4	2019	24%, 46%, 40%, 5%, and 44% GC had a potentially platinum sensitive phenotype by SNP analyses of GSTP1, ERCC1 rs11615, ERCC1 rs3212986, ERCC2, and XRCC1, respectively.	Platinum	48-56	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	135-140
31602266-4	2019	24%, 46%, 40%, 5%, and 44% GC had a potentially platinum sensitive phenotype by SNP analyses of GSTP1, ERCC1 rs11615, ERCC1 rs3212986, ERCC2, and XRCC1, respectively.	Platinum	48-56	X-ray repair cross complementing 1	Homo sapiens	146-151
31454018-10	2019	In patients with overexpression of ALK protein, the response rate was significantly better with crizotinib (a tyrosine kinase inhibitor) than with the combination of pemetrexed and either cisplatin or carboplatin (platinum-based chemotherapy) (74% vs 45%, respectively; P &lt; .001) and progression-free survival (median, 10.9 months vs 7.0 months; P &lt; .001).	Platinum	214-222	ALK receptor tyrosine kinase	Homo sapiens	35-38
31206996-4	2019	The L10 -CoPtAu catalyst is also stable, with negligible degradation in mass activities and no obvious Co/Pt/Au composition changes after 10 000 potential cycles.	Platinum	11-13	immunoglobulin kappa variable 3-7 (non-functional)	Homo sapiens	4-7
31444350-3	2019	The Pt atom in the ensemble is 100-1000 times more active than their single-atom Pt1/CeO2 parent in catalyzing the low-temperature CO oxidation under oxygen-rich conditions.	Platinum	4-6	zinc finger protein 77	Homo sapiens	81-84
31686841-0	2019	MAP3K1 rs889312 genotypes influence survival outcomes of Chinese gastric cancer patients who received adjuvant chemotherapy based on platinum and fluorouracil regimes.	Platinum	133-141	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	0-6
31154673-0	2019	High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.	Platinum	137-145	EMSY transcriptional repressor, BRCA2 interacting	Homo sapiens	5-9
31154673-0	2019	High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.	Platinum	137-145	BRCA1 DNA repair associated	Homo sapiens	31-35
31154673-5	2019	METHODS: Here we investigate the impact of EMSY expression on clinical outcome and sensitivity to platinum-based chemotherapy using available data from transcriptomically characterized HGSOC cohorts.	Platinum	98-106	EMSY transcriptional repressor, BRCA2 interacting	Homo sapiens	43-47
31154673-8	2019	Patients within the Edinburgh cohort who had high EMSY expression were found to demonstrate greater rates of complete response to multiple platinum-containing chemotherapy regimens (radiological complete response rate of 44.4% vs 12.5% at second exposure; P = .035) and corresponding prolonged time to disease progression (median, 151.5 days vs 60.5 days after third platinum exposure; P = .004).	Platinum	139-147	EMSY transcriptional repressor, BRCA2 interacting	Homo sapiens	50-54
31154673-8	2019	Patients within the Edinburgh cohort who had high EMSY expression were found to demonstrate greater rates of complete response to multiple platinum-containing chemotherapy regimens (radiological complete response rate of 44.4% vs 12.5% at second exposure; P = .035) and corresponding prolonged time to disease progression (median, 151.5 days vs 60.5 days after third platinum exposure; P = .004).	Platinum	367-375	EMSY transcriptional repressor, BRCA2 interacting	Homo sapiens	50-54
31154673-9	2019	CONCLUSIONS: Patients with HGSOCs demonstrating high EMSY expression appear to experience prolonged survival and greater platinum sensitivity, reminiscent of BRCA-mutant cases.	Platinum	121-129	EMSY transcriptional repressor, BRCA2 interacting	Homo sapiens	53-57
31287958-2	2019	The methanol/ethanol oxidation reaction (MOR/EOR) often requires high-performance yet expensive Pt-based catalysts that may be easily poisoned.	Platinum	96-98	opioid receptor mu 1	Homo sapiens	41-44
31206996-2	2019	Herein, a ternary CoPtAu nanoparticle catalyst system is reported in which Co and Pt form an intermetallic L10 -structure and Au segregates on the surface to alloy with Pt.	Platinum	20-22	immunoglobulin kappa variable 3-7 (non-functional)	Homo sapiens	107-110
31206996-2	2019	Herein, a ternary CoPtAu nanoparticle catalyst system is reported in which Co and Pt form an intermetallic L10 -structure and Au segregates on the surface to alloy with Pt.	Platinum	82-84	immunoglobulin kappa variable 3-7 (non-functional)	Homo sapiens	107-110
31507426-10	2019	In all the patients, including patients who received both pemetrexed and platinum, SNP rs1801133 on the MTHFR gene (665C &gt; T) was found to be significantly associated with hematological ADRs in 1 to 2 cycles (P = 0.0079, OR = 3.566).	Platinum	73-81	methylenetetrahydrofolate reductase	Homo sapiens	104-109
31393117-0	2019	Synthesis and Cytotoxic Study of a Platinum(IV) Anticancer Prodrug with Selectivity toward Luteinizing Hormone-Releasing Hormone (LHRH) Receptor-Positive Cancer Cells.	Platinum	35-43	gonadotropin releasing hormone 1	Homo sapiens	91-128
31393117-0	2019	Synthesis and Cytotoxic Study of a Platinum(IV) Anticancer Prodrug with Selectivity toward Luteinizing Hormone-Releasing Hormone (LHRH) Receptor-Positive Cancer Cells.	Platinum	35-43	gonadotropin releasing hormone 1	Homo sapiens	130-134
31393117-4	2019	In this study, we report the synthesis and cytotoxic study of a novel platinum(IV) anticancer prodrug functionalized with LHRH peptide.	Platinum	70-78	gonadotropin releasing hormone 1	Homo sapiens	122-126
31343162-2	2019	A careful first-principle investigation is herein presented on the above-mentioned conjugates (Pt-1 and Pt-2) and on the two metal-free precursors (1 and 2), aimed at revealing the influence of the platinum moiety on the physicochemical behavior of the photosensitizer (PS) and to inspect, in turn, the possible modulation of the hydrolysis rate of the PtII ligand induced by the PS.	Platinum	198-206	zinc finger protein 77	Homo sapiens	95-108
31355382-2	2019	In particular, the cubic rocksalt to hexagonal wurtzite PT in the CdO thin film annealed at 900  C was confirmed by X-ray diffraction (XRD), which was consistent with the high-resolution transmission electron microscopy (TEM) results.	Platinum	56-58	cell adhesion associated, oncogene regulated	Homo sapiens	66-69
31355382-8	2019	Finally, molecular dynamics simulation together with density functional theory calculation suggested that the symmetry modification at the Brillouin zone boundary provides a succinct signature for the PT in the CdO thin film.	Platinum	201-203	cell adhesion associated, oncogene regulated	Homo sapiens	211-214
31165553-7	2019	A bis-NHC-ligated Pt species generated from the hydrolysis of 1 a forms adducts with thiols and appears to target an active-site cysteine of ASNS.	Platinum	18-20	asparagine synthetase	Mus musculus	141-145
31382533-8	2019	Thus, this study highlights HLA-GEV as a potential novel biomarker for risk assessment of EOC patients with a rather beneficial prognosis defined by platinum-sensitivity or lack of residual tumor burden.	Platinum	149-157	major histocompatibility complex, class I, G	Homo sapiens	28-35
31382681-7	2019	Hereditary pancreatic cancer, especially associated with BRCA mutations, is responsive to platinum-containing regimens and/or poly (ADP-ribose) polymerase (PARP) inhibitors.	Platinum	90-98	BRCA1 DNA repair associated	Homo sapiens	57-61
31087045-7	2019	ICSI showed that inhibition of PT-anchored GSTO2 caused a delay in sperm nuclear decondensation, and further resulted in untimely embryo cleavage, and an increase in fragmentation beginning at the morula stage.	Platinum	31-33	glutathione S-transferase omega 2	Mus musculus	43-48
31376022-0	2019	An electrochemiluminescence immunosensor for myoglobin using an indium tin oxide glass electrode modified with gold nanoparticles and platinum nanowires.	Platinum	134-142	myoglobin	Homo sapiens	45-54
31376022-8	2019	Graphical abstract Schematic of an electrochemiluminescent immunosensor for myoglobin using gold nanoparticles and platinum nanowires as supporting matrix on indium tin oxide coated glass.	Platinum	115-123	myoglobin	Homo sapiens	76-85
30977010-9	2019	CONCLUSION: Our findings reinforce the potential clinical value of germline variants in VEGFA and VEGFR2 and show for the first time variants in ITGAV and MAPK11 as promising prognostic markers in metastatic NSCLC patients receiving platinum-based chemotherapy.	Platinum	233-241	integrin subunit alpha V	Homo sapiens	145-150
31423186-5	2019	Increased expression of SphK1 was significantly associated with shorter overall and disease free survival in patients treated with adjuvant platinum-based chemotherapy.	Platinum	140-148	sphingosine kinase 1	Homo sapiens	24-29
30958607-0	2019	Coordination of Platinum to alpha-Synuclein Inhibits Filamentous Aggregation in Solution.	Platinum	16-24	synuclein alpha	Homo sapiens	28-43
31219025-0	2019	Albumin-Encapsulated Platinum Nanoparticles for Targeted Photothermal Treatment of Glioma.	Platinum	21-29	albumin	Homo sapiens	0-7
31219025-2	2019	In this study, we utilized the human serum albumin (HSA) as a template to synthesize ultrasmall platinum nanoparticle for targeted photothermal treatment of glioma.	Platinum	96-104	albumin	Homo sapiens	37-50
31194214-0	2019	Immune Checkpoint and Poly(ADP-Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers.	Platinum	75-83	poly(ADP-ribose) polymerase 1	Homo sapiens	22-49
31523174-7	2019	Moreover, the decrease of filaggrin and loricrin induced by DNCB treatment was recovered by PT administration.	Platinum	92-94	filaggrin	Homo sapiens	26-35
31523174-7	2019	Moreover, the decrease of filaggrin and loricrin induced by DNCB treatment was recovered by PT administration.	Platinum	92-94	loricrin cornified envelope precursor protein	Homo sapiens	40-48
30973677-0	2019	Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment.	Platinum	100-108	glutathione S-transferase pi 1	Homo sapiens	15-20
30973677-0	2019	Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment.	Platinum	100-108	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	25-30
31173242-0	2019	Effect of platinum-based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death-1 ligand 1 and HLA class I in non-small cell lung cancer.	Platinum	10-18	killer cell lectin like receptor K1	Homo sapiens	59-90
31173242-0	2019	Effect of platinum-based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death-1 ligand 1 and HLA class I in non-small cell lung cancer.	Platinum	10-18	CD274 molecule	Homo sapiens	100-132
31423186-7	2019	Collectively, the results suggest that the immunohistochemical detection of SphK1 may be a promising predictive marker in NSCLC patients treated with adjuvant platinum-based chemotherapy.	Platinum	159-167	sphingosine kinase 1	Homo sapiens	76-81
31036541-0	2019	EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.	Platinum	94-102	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	0-4
31315599-21	2019	First- or second-generation EGFR-TKI demonstrated greater OS benefit than platinum-doublet chemotherapy among patients harboring uncommon EGFR-mutant NSCLC.	Platinum	74-82	epidermal growth factor receptor	Homo sapiens	138-142
31565603-4	2019	Molecular features commonly found in prostate adenocarcinomas are now well-recognized, including defects in homologous recombination (HR) genes, like breast cancer type 2 susceptibility protein (BRCA2), leading to increased sensitivity to deoxyribonucleic acid (DNA)-damaging agents (e.g., platinum chemotherapy or poly adenosine diphosphate-ribose polymerase (PARP) inhibitors).	Platinum	290-298	BRCA2 DNA repair associated	Homo sapiens	150-193
31565603-4	2019	Molecular features commonly found in prostate adenocarcinomas are now well-recognized, including defects in homologous recombination (HR) genes, like breast cancer type 2 susceptibility protein (BRCA2), leading to increased sensitivity to deoxyribonucleic acid (DNA)-damaging agents (e.g., platinum chemotherapy or poly adenosine diphosphate-ribose polymerase (PARP) inhibitors).	Platinum	290-298	BRCA2 DNA repair associated	Homo sapiens	195-200
31346466-1	2019	Background: The epidermal growth factor receptor (EGFR) monoclonal IgG1 antibody cetuximab is approved for first-line treatment of recurrent and metastatic (R/M) HNSCC as a part of the standard of care EXTREME regimen (platinum/5-fluorouracil/cetuximab).	Platinum	219-227	epidermal growth factor receptor	Homo sapiens	16-48
31346466-1	2019	Background: The epidermal growth factor receptor (EGFR) monoclonal IgG1 antibody cetuximab is approved for first-line treatment of recurrent and metastatic (R/M) HNSCC as a part of the standard of care EXTREME regimen (platinum/5-fluorouracil/cetuximab).	Platinum	219-227	epidermal growth factor receptor	Homo sapiens	50-54
31036541-8	2019	We observed a greater benefit from high-dose platinum-based chemotherapy in BRCA1-like and non-BRCA1-like patients with high EZH2 expression.	Platinum	45-53	BRCA1 DNA repair associated	Homo sapiens	76-81
31036541-8	2019	We observed a greater benefit from high-dose platinum-based chemotherapy in BRCA1-like and non-BRCA1-like patients with high EZH2 expression.	Platinum	45-53	BRCA1 DNA repair associated	Homo sapiens	95-100
31036541-8	2019	We observed a greater benefit from high-dose platinum-based chemotherapy in BRCA1-like and non-BRCA1-like patients with high EZH2 expression.	Platinum	45-53	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	125-129
31036541-12	2019	EZH2 inhibition improves the antitumor effect of platinum drugs in Brca1-deficient breast tumors in vivo.	Platinum	49-57	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	0-4
31321084-4	2019	We also begin to examine if NSD1 regulates response to platinum-based drugs and other DNA-damaging agents.	Platinum	55-63	nuclear receptor binding SET domain protein 1	Homo sapiens	28-32
30978440-2	2019	We identified the high pretherapeutical serum IL-8 level in gastric cancer patients was associated with poor response to platinum-based therapy, and it increased gradually during neoadjuvant chemotherapy and it decreased after radical surgery.	Platinum	121-129	C-X-C motif chemokine ligand 8	Homo sapiens	46-50
31295913-6	2019	The association between BRCA1/2 gene mutations and platinum sensitivity has been largely described.	Platinum	51-59	BRCA1 DNA repair associated	Homo sapiens	24-31
31295913-9	2019	Moreover, p53 and its family members (p63 and p73) might also be used as predictors of platinum response.	Platinum	87-95	tumor protein p53	Homo sapiens	10-13
31295913-9	2019	Moreover, p53 and its family members (p63 and p73) might also be used as predictors of platinum response.	Platinum	87-95	tumor protein p63	Homo sapiens	38-41
31295913-9	2019	Moreover, p53 and its family members (p63 and p73) might also be used as predictors of platinum response.	Platinum	87-95	tumor protein p73	Homo sapiens	46-49
31321084-21	2019	Increased sensitivity to platinum-based chemotherapy agents associated with NSD1 depletion may contribute to improved survival in HPV(-) HNSCCs.	Platinum	25-33	nuclear receptor binding SET domain protein 1	Homo sapiens	76-80
31321084-22	2019	Further studies are needed to determine mechanisms through which NSD1 protects HPV(-) HNSCC cells from platinum-based therapy, as well as confirmation of NSD1 effect in HPV(+) HNSCC.	Platinum	103-111	nuclear receptor binding SET domain protein 1	Homo sapiens	65-69
31179684-6	2019	While obscure even an overlapped interface was observed over Pt/CeZrO2, resulting in the formation of PtO because of the oxygen migration from CeZrO2 to Pt species (confirmed by CO-FTIR, the cycled H2-TPR and transmission electron microscopy results).	Platinum	61-63	translocated promoter region, nuclear basket protein	Homo sapiens	201-204
31252478-3	2019	In this article, we have reported a strategy to prepare sub-2 nm bimetallic Pt-Sn nanoclusters confined in the pores of a Zr-based metal-organic framework (MOF).	Platinum	76-78	lysine acetyltransferase 8	Homo sapiens	131-160
31307523-0	2019	APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC.	Platinum	40-48	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	0-4
31307523-0	2019	APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC.	Platinum	40-48	nucleophosmin 1	Homo sapiens	9-13
31307523-11	2019	HCC1937 cells, having higher levels of APE1/NPM1 proteins, are more resistant to Pt-salts treatment compared to the HCC70 cells.	Platinum	81-83	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	39-43
31307523-11	2019	HCC1937 cells, having higher levels of APE1/NPM1 proteins, are more resistant to Pt-salts treatment compared to the HCC70 cells.	Platinum	81-83	nucleophosmin 1	Homo sapiens	44-48
31309292-7	2019	Laminates made from expanded graphite and treated with platinum, detected H2O2 at a working potential of 0.3 V (vs. Ag/AgCl [0.1 M KCl]) with a 1.91 muM detection limit and sensitivity of 64 nA muM-1 cm-2.	Platinum	55-63	PWWP domain containing 3A, DNA repair factor	Homo sapiens	194-204
31309292-8	2019	Electrodes made from platinum treated nanoplatelet graphene had a H2O2 detection limit of 1.98 muM (at 0.3 V), and a sensitivity of 16.5 nA muM-1 cm-2.	Platinum	21-29	PWWP domain containing 3A, DNA repair factor	Homo sapiens	140-145
31179684-6	2019	While obscure even an overlapped interface was observed over Pt/CeZrO2, resulting in the formation of PtO because of the oxygen migration from CeZrO2 to Pt species (confirmed by CO-FTIR, the cycled H2-TPR and transmission electron microscopy results).	Platinum	102-104	translocated promoter region, nuclear basket protein	Homo sapiens	201-204
31262923-0	2019	S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma.	Platinum	33-41	proteasome 26S subunit, non-ATPase 1	Homo sapiens	0-3
30896089-8	2019	Alterations within the TP53-MDM2 signal transduction pathway appear to be enriched among patients with platinum-resistant disease.	Platinum	103-111	tumor protein p53	Homo sapiens	23-27
30896089-8	2019	Alterations within the TP53-MDM2 signal transduction pathway appear to be enriched among patients with platinum-resistant disease.	Platinum	103-111	MDM2 proto-oncogene	Homo sapiens	28-32
31262883-5	2019	Log10IC50 and EGFR protein level were significantly positively correlated under all investigated DNA topoisomerase (TOPO) II inhibitors, followed by 81% of alkylating agents and platinum-based compounds, 71% of anti-hormones, 66% of TOPO I inhibitors and 50% of antibiotics.	Platinum	178-186	epidermal growth factor receptor	Homo sapiens	14-18
31008727-4	2019	The aim was to determine the impact, in clinical practice, of trabectedin with pegylated liposomal doxorubicin (trabectedin/PLD) on the subsequent platinum-based therapy in these patients, and to explore the prognosis for breast cancer gene status and the expression of diverse genes.	Platinum	147-155	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	124-127
31074244-0	2019	Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer.	Platinum	51-59	programmed cell death 1	Homo sapiens	23-27
31219617-1	2019	The protein binding rates (PBR) of platinum-containing agents cisplatin (CDDP), carboplatin (CBDCA) and oxaliplatin (L-OHP) have been reported as 98%, 25-50% and 98%, respectively.	Platinum	35-43	translocator protein	Rattus norvegicus	27-30
30428640-0	2019	Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer.	Platinum	10-18	CD274 molecule	Homo sapiens	41-46
30428640-2	2019	We assessed the effect of platinum-based chemotherapy on tumor PD-L1 expression and its clinical implications.	Platinum	26-34	CD274 molecule	Homo sapiens	63-68
30428640-10	2019	CONCLUSION: Tumor PD-L1 expression increased after platinum-based NACT in a significant proportion of patients with NSCLC.	Platinum	51-59	CD274 molecule	Homo sapiens	18-23
30506132-0	2019	Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC).	Platinum	86-94	vacuole membrane protein 1	Homo sapiens	184-189
31169219-1	2019	Objective: To determine the prognostic value of excision repairs cross-complementation group1 (ERCC1) gene in cases with nasopharyngeal carcinoma (NPC) treated with platinum-containing chemotherapy (PCT).	Platinum	165-173	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	48-93
31169219-1	2019	Objective: To determine the prognostic value of excision repairs cross-complementation group1 (ERCC1) gene in cases with nasopharyngeal carcinoma (NPC) treated with platinum-containing chemotherapy (PCT).	Platinum	165-173	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	95-100
31079832-1	2019	OBJECTIVE: To evaluate hematologic adverse effect profiles associated with frontline platinum-based chemotherapy in ovarian cancer patients according to BRCA 1/2 mutational status.	Platinum	85-93	BRCA1 DNA repair associated	Homo sapiens	153-159
31079832-8	2019	CONCLUSIONS: Germline BRCA 1/2 mutations are associated with a higher hematologic toxicity in patients with ovarian cancer who underwent platinum-based chemotherapy.	Platinum	137-145	BRCA1 DNA repair associated	Homo sapiens	22-28
31646805-3	2019	Advances into the molecular underpinnings of DNA damage repair highlighted BRCA 1/2 and other related genes as key regulators of platinum sensitivity.	Platinum	129-137	BRCA1 DNA repair associated	Homo sapiens	75-83
31646805-8	2019	BRCA mutant cases represented 44% and were associated with a significantly higher frequency for complete pathologic response, first and second platinum sensitive relapse and a significantly longer overall survival for advanced stage cases treated with neoadjuvant chemotherapy.	Platinum	143-151	BRCA1 DNA repair associated	Homo sapiens	0-4
31140732-7	2019	More importantly, the Co/Cox My +Pt/C achieves higher voltaic efficiency and several times longer cycle life than conventional RuO2 +Pt/C catalysts in rechargeable Zn-air batteries.	Platinum	33-35	cytochrome c oxidase subunit 8A	Homo sapiens	25-28
31200831-10	2019	This benefit seems to be strongly correlated to adjuvant chemotherapy, therefore rendering c-MET H-score &gt;=20 a possible predictive biomarker for platinum-based adjuvant chemotherapy in early stage NSCLC.	Platinum	149-157	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	91-96
31292550-3	2019	Moreover, BRCA1/2-mutant tumours are often deficient in the repair of double-stranded DNA breaks by homologous recombination8-13, and consequently exhibit increased therapeutic sensitivity to platinum-containing therapy and inhibitors of poly-(ADP-ribose)-polymerase (PARP)14,15.	Platinum	192-200	BRCA1 DNA repair associated	Homo sapiens	10-17
31292550-3	2019	Moreover, BRCA1/2-mutant tumours are often deficient in the repair of double-stranded DNA breaks by homologous recombination8-13, and consequently exhibit increased therapeutic sensitivity to platinum-containing therapy and inhibitors of poly-(ADP-ribose)-polymerase (PARP)14,15.	Platinum	192-200	poly(ADP-ribose) polymerase family member 14	Homo sapiens	268-275
31289528-4	2019	In the present study, survival database analysis demonstrated that leptin expression was associated with poor prognoses in patients treated with platinum and paclitaxel/docetaxel.	Platinum	145-153	leptin	Homo sapiens	67-73
31289528-8	2019	Together, these results suggest that leptin serves an important role in chemoresistance and may serve as a novel therapeutic target for ovarian cancer in patients treated with platinum and paclitaxel chemotherapy.	Platinum	176-184	leptin	Homo sapiens	37-43
30929196-8	2019	In summary, our data suggested that platelet aggregation and activation were significantly higher in patients with PT than in those without PT, which might be associated with reduced beta2-GPI levels.	Platinum	115-117	apolipoprotein H	Homo sapiens	183-192
31210236-0	2019	Low-cost high-performance hydrogen evolution electrocatalysts based on Pt-CoP polyhedra with low Pt loading in both alkaline and neutral media.	Platinum	71-73	caspase recruitment domain family member 16	Homo sapiens	74-77
31320873-0	2019	Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC.	Platinum	182-190	BRCA2 DNA repair associated	Homo sapiens	8-13
31235732-3	2019	In this study, by assessing miRNAs simultaneously targeting a set of DDR genes that exhibited response to platinum, we found that miR-211 inhibited most of those genes, and proposed that miR-211 might affect the sensitivity of ovarian cancer cells to platinum by targeting multiple DDR genes and thereby determine the prognosis of ovarian cancer.	Platinum	106-114	microRNA 211	Homo sapiens	130-137
31235732-3	2019	In this study, by assessing miRNAs simultaneously targeting a set of DDR genes that exhibited response to platinum, we found that miR-211 inhibited most of those genes, and proposed that miR-211 might affect the sensitivity of ovarian cancer cells to platinum by targeting multiple DDR genes and thereby determine the prognosis of ovarian cancer.	Platinum	106-114	microRNA 211	Homo sapiens	187-194
31235732-3	2019	In this study, by assessing miRNAs simultaneously targeting a set of DDR genes that exhibited response to platinum, we found that miR-211 inhibited most of those genes, and proposed that miR-211 might affect the sensitivity of ovarian cancer cells to platinum by targeting multiple DDR genes and thereby determine the prognosis of ovarian cancer.	Platinum	251-259	microRNA 211	Homo sapiens	130-137
31235732-3	2019	In this study, by assessing miRNAs simultaneously targeting a set of DDR genes that exhibited response to platinum, we found that miR-211 inhibited most of those genes, and proposed that miR-211 might affect the sensitivity of ovarian cancer cells to platinum by targeting multiple DDR genes and thereby determine the prognosis of ovarian cancer.	Platinum	251-259	microRNA 211	Homo sapiens	187-194
31235732-7	2019	In contrast, TDP1 suppressed DNA damage and platinum chemosensitivity.	Platinum	44-52	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	13-17
31235732-9	2019	Conclusively, we demonstrated that miR-211 improves the prognosis of ovarian cancer patients by enhancing the chemosensitivity of cancer cells to platinum via inhibiting DDR gene expression, which provides an essential basis to identify novel treatment targets to block DDR effectively and improve chemosensitivity in ovarian cancer.	Platinum	146-154	microRNA 211	Homo sapiens	35-42
31409078-5	2019	A TNT trial showed that platinum derivatives have marked effects against metastatic breast cancer.	Platinum	24-32	chromosome 16 open reading frame 82	Homo sapiens	2-5
31409079-0	2019	Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno.	Platinum	42-50	BRCA1 DNA repair associated	Homo sapiens	82-87
31409079-0	2019	Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno.	Platinum	42-50	BRCA2 DNA repair associated	Homo sapiens	92-97
31409079-3	2019	The role of platinum-based drugs in systemic neoadjuvant BRCA1/2 breast cancer therapy, and its efficacy in increasing the probability of pathological complete remission (pCR) are discussed repeatedly; however, there are no clear recommendations.	Platinum	12-20	BRCA1 DNA repair associated	Homo sapiens	57-62
31409079-4	2019	PATIENTS AND METHODS: We retrospectively evaluated the contribution of a platinum-based antineoplastic drug to the achievement of pCR in a set of patients with BRCA1/2 mutant breast cancer treated with neoadjuvant chemotherapy from 2010 to 2017.	Platinum	73-81	BRCA1 DNA repair associated	Homo sapiens	160-167
31409079-9	2019	Patients treated in a neoadjuvant setting with platinum-based antineoplastic drugs had a 4.4x greater chance of achieving pCR than those not treated with platinum, assuming the same tumor phenotype (TNBC or SR+/HER2).	Platinum	47-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	211-215
31409079-10	2019	CONCLUSION: Neoadjuvant platinum-based chemotherapy for patients with a BRCA1/2 mutation is associated with a higher probability of achieving pCR, which is important for subsequent prognosis.	Platinum	24-32	BRCA1 DNA repair associated	Homo sapiens	72-79
31240480-9	2019	Anti-PD-1 nivolumab and pembrolizumab are now approved for platinum refractory patients, providing prolonged survival in the case of response, and improvement in quality of life.	Platinum	59-67	programmed cell death 1	Homo sapiens	5-9
31089613-9	2019	Interestingly, two types of novel inhibitors of MDM2, including cyclohexyl-triphenylamine derivatives and platinum complexes, were identified and their binding affinities were obtained.	Platinum	106-114	MDM2 proto-oncogene	Homo sapiens	48-52
31249881-0	2019	Layer-by-layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum-based drug resistance therapy in ovarian cancer.	Platinum	85-93	poly (ADP-ribose) polymerase family, member 1	Mus musculus	65-69
31117440-3	2019	Then, the cisplatin (CDDP)-crosslinked CPT-prodrug micelles (CPTP/CDDP) with a hybrid complex as a stable structure were successfully established via the CDDP (Pt)-carboxyl (COOH) chelate interaction.	Platinum	160-162	ceramide-1-phosphate transfer protein	Homo sapiens	61-65
31312656-8	2019	From TCGA and GEO data, SOC patients with ICAM1 mRNA overexpression treated with chemotherapeutic drugs that contained taxol or taxol and platin together had significantly reduced progression-free survival.	Platinum	138-144	intercellular adhesion molecule 1	Homo sapiens	42-47
30780146-0	2019	Tuning spin-orbit torques at magnetic domain walls in epitaxial Pt/Co/Pt1-x Au x trilayers.	Platinum	64-66	zinc finger protein 77	Homo sapiens	70-73
31333777-10	2019	Therefore, as a preliminary exploration of the lncRNA originated from ERCC1, the present study suggested AC138128.1 is of potential value in predicting platinum analogue benefit in lung cancer.	Platinum	152-160	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	70-75
31309123-12	2019	Platinum drugs cisplatin and oxaliplatin significantly inhibited phosphorylation of STAT6 during differentiation and maturation.	Platinum	0-8	signal transducer and activator of transcription 6	Homo sapiens	84-89
31309123-14	2019	As STAT6 is an important regulator of DC function, these findings suggest a role for platinum-based chemotherapeutics to enhance DC function via inhibition of STAT signaling, thereby potentially enhancing efficacy of DC-based immunotherapies.	Platinum	85-93	signal transducer and activator of transcription 6	Homo sapiens	3-8
31159852-11	2019	Furthermore, our in vitro results showed that the inhibition of the CSC-related targets lying at the intersection of the DNA damage, Notch and C-KIT/MAPK/MEK pathways sensitize CSC-enriched tumorspheres to platinum therapies, suggesting a new option for the treatment of patients with platinum-resistant ovarian cancer.	Platinum	206-214	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	143-148
30968506-1	2019	Mass spectrometric analysis of the anionic products of interaction between platinum atomic anions, Pt- , and methane, CH4 and CD4 , in a collision cell shows the preferred generation of [PtCH4 ]- and [PtCD4 ]- complexes and a low tendency toward dehydrogenation.	Platinum	75-83	CD4 molecule	Homo sapiens	126-129
30968506-1	2019	Mass spectrometric analysis of the anionic products of interaction between platinum atomic anions, Pt- , and methane, CH4 and CD4 , in a collision cell shows the preferred generation of [PtCH4 ]- and [PtCD4 ]- complexes and a low tendency toward dehydrogenation.	Platinum	99-101	CD4 molecule	Homo sapiens	126-129
31117626-3	2019	In contrast, three types of columnar structures with different Pt   Pt interactions were found for the R-1 crystal, probably because of the different packing of the chiral ester chains between the columns.	Platinum	63-65	CD1b molecule	Homo sapiens	103-106
31117626-3	2019	In contrast, three types of columnar structures with different Pt   Pt interactions were found for the R-1 crystal, probably because of the different packing of the chiral ester chains between the columns.	Platinum	68-70	CD1b molecule	Homo sapiens	103-106
31159852-11	2019	Furthermore, our in vitro results showed that the inhibition of the CSC-related targets lying at the intersection of the DNA damage, Notch and C-KIT/MAPK/MEK pathways sensitize CSC-enriched tumorspheres to platinum therapies, suggesting a new option for the treatment of patients with platinum-resistant ovarian cancer.	Platinum	206-214	mitogen-activated protein kinase kinase 7	Homo sapiens	154-157
30895466-3	2019	Early clinical data demonstrated the effectiveness of PARP inhibition in women with recurrent EOC harbouring BRCA1/2 mutations and those with platinum-sensitive recurrences.	Platinum	142-150	poly(ADP-ribose) polymerase 1	Homo sapiens	54-58
30895466-5	2019	Based upon randomised controlled trials, PARP inhibitors are in use as "maintenance" therapy for those with platinum-sensitive and platinum-responsive recurrences (irrespective of BRCA1/2 mutation status).	Platinum	108-116	poly(ADP-ribose) polymerase 1	Homo sapiens	41-45
30895466-5	2019	Based upon randomised controlled trials, PARP inhibitors are in use as "maintenance" therapy for those with platinum-sensitive and platinum-responsive recurrences (irrespective of BRCA1/2 mutation status).	Platinum	131-139	poly(ADP-ribose) polymerase 1	Homo sapiens	41-45
30851984-1	2019	Analysis of the IMvigor 210 trials involving patients with platinum-refractory or cisplatin-ineligible urothelial carcinoma who were treated with the PD-L1 inhibitor atezolizumab identified a resistance signature as an immune biomarker.	Platinum	59-67	CD274 molecule	Homo sapiens	150-155
31074636-2	2019	Three different poly ADP ribose polymerase inhibitors (olaparib, niraparib and rucaparib) have been already approved as maintenance after response to platinum-based chemotherapy; two of them (olaparib and rucaparib) also as single agents.	Platinum	150-158	poly(ADP-ribose) polymerase 1	Homo sapiens	16-42
30940721-1	2019	In an interim analysis, the targeted PARP inhibitor rucaparib showed encouraging signs of disease control when used as a maintenance therapy for patients with platinum-sensitive advanced pancreatic cancer and a pathogenic mutation in BRCA1, BRCA2, or PALB2.	Platinum	159-167	collagen type XI alpha 2 chain	Homo sapiens	37-41
31101688-5	2019	TRIAL DESIGN: Pre-menopausal women diagnosed with stage International Federation of Gynecology and Obstetrics (FIGO) IB2, 2-4 cm cervical cancer who wish to preserve fertility will receive three cycles of platinum/paclitaxel chemotherapy.	Platinum	205-213	mitogen-activated protein kinase 8 interacting protein 2	Homo sapiens	117-120
31186713-0	2019	The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents.	Platinum	83-91	BRCA1 DNA repair associated	Homo sapiens	15-20
30993885-3	2019	The purpose of the present study was to investigate the roles of Jagged1 in the platinum resistance of ovarian cancer and its possible mechanisms.	Platinum	80-88	jagged 1	Mus musculus	65-72
30993885-4	2019	Compared with a platinum responsive group of ovarian epithelial cell carcinomas, we found the positive staining intensity of Notch1, Notch2, Jagged1, STAT3 and Epithelial-mesenchymal transition (EMT) proteins were lower in a platinum-resistant group.	Platinum	16-24	notch 1	Mus musculus	125-131
30993885-4	2019	Compared with a platinum responsive group of ovarian epithelial cell carcinomas, we found the positive staining intensity of Notch1, Notch2, Jagged1, STAT3 and Epithelial-mesenchymal transition (EMT) proteins were lower in a platinum-resistant group.	Platinum	16-24	notch 2	Mus musculus	133-139
30993885-4	2019	Compared with a platinum responsive group of ovarian epithelial cell carcinomas, we found the positive staining intensity of Notch1, Notch2, Jagged1, STAT3 and Epithelial-mesenchymal transition (EMT) proteins were lower in a platinum-resistant group.	Platinum	16-24	jagged 1	Mus musculus	141-148
30993885-4	2019	Compared with a platinum responsive group of ovarian epithelial cell carcinomas, we found the positive staining intensity of Notch1, Notch2, Jagged1, STAT3 and Epithelial-mesenchymal transition (EMT) proteins were lower in a platinum-resistant group.	Platinum	225-233	notch 1	Mus musculus	125-131
30790354-9	2019	These data identify GFAT-mediated HBP as a target for improving platinum-based chemotherapy for NSCLC.	Platinum	64-72	glutamine--fructose-6-phosphate transaminase 1	Homo sapiens	20-24
31186713-7	2019	The present results revealed that the BRCA1 expression level in gastric cancer is variable and associated with the treatment response to platinum-based chemotherapy.	Platinum	137-145	BRCA1 DNA repair associated	Homo sapiens	38-43
31186713-8	2019	This suggests that BRCA1 may serve as a therapeutic marker for platinum-based chemotherapy in gastric cancer.	Platinum	63-71	BRCA1 DNA repair associated	Homo sapiens	19-24
30952082-3	2019	Herein, a strategy to introduce a TDO inhibitor into Pt(IV) complexes for reversing tumor immune suppression was adopted.	Platinum	53-55	tryptophan 2,3-dioxygenase	Homo sapiens	34-37
30940743-12	2019	IMPLICATIONS FOR PRACTICE: Despite standard laboratory tests and intravenous magnesium replacement prior to each cycle of chemotherapy, hypomagnesemia remains a common side effect of platinum-based chemotherapy.	Platinum	183-191	PRAC1 small nuclear protein	Homo sapiens	17-25
31127087-10	2019	Moreover, we observed that positive expression of HDAC1 was associated with the downregulation of OAZ1 in NSCLC patients with platinum-based treatment, and predicted drug resistance and poor prognosis.	Platinum	126-134	histone deacetylase 1	Homo sapiens	50-55
31089617-1	2019	Single atomic Pt supported on TiC was prepared from chloride Pt precursors, then the chloride ligands were intentionally removed by increasing the reduction temperature.	Platinum	14-16	pleckstrin and Sec7 domain containing 4	Homo sapiens	30-33
31130676-2	2019	Previously it was reported that platinum-based chemotherapy may change PD-L1 expression in solid cancers.	Platinum	32-40	CD274 molecule	Homo sapiens	71-76
31127087-10	2019	Moreover, we observed that positive expression of HDAC1 was associated with the downregulation of OAZ1 in NSCLC patients with platinum-based treatment, and predicted drug resistance and poor prognosis.	Platinum	126-134	ornithine decarboxylase antizyme 1	Homo sapiens	98-102
30913325-4	2019	Remarkably PtNi bimetallic catalyst with low metal loading (PtNi2 @CNS-600, 0.074 wt % Pt) exhibited outstanding HER activity with an overpotential as low as 68 mV at a current density of 10 mA cm-2 with a platinum loading of only 0.612 mugPt  cm-2 and Tafel slope of 35.27 mV dec-1 in a 0.5 m aqueous solution of H2 SO4 , which is comparable to that of the 20 % Pt/C catalyst (31 mV dec-1 ).	Platinum	11-13	deleted in esophageal cancer 1	Homo sapiens	277-282
31179244-2	2019	Preclinical studies found that copper-lowering agents could re-sensitize platinum-resistant cancer cells by enhancing the human copper transporter 1 (hCtr1)-mediated uptake of platinum.	Platinum	73-81	solute carrier family 31 member 1	Homo sapiens	128-148
31179244-2	2019	Preclinical studies found that copper-lowering agents could re-sensitize platinum-resistant cancer cells by enhancing the human copper transporter 1 (hCtr1)-mediated uptake of platinum.	Platinum	73-81	solute carrier family 31 member 1	Homo sapiens	150-155
31179244-2	2019	Preclinical studies found that copper-lowering agents could re-sensitize platinum-resistant cancer cells by enhancing the human copper transporter 1 (hCtr1)-mediated uptake of platinum.	Platinum	176-184	solute carrier family 31 member 1	Homo sapiens	128-148
31179244-2	2019	Preclinical studies found that copper-lowering agents could re-sensitize platinum-resistant cancer cells by enhancing the human copper transporter 1 (hCtr1)-mediated uptake of platinum.	Platinum	176-184	solute carrier family 31 member 1	Homo sapiens	150-155
30913325-4	2019	Remarkably PtNi bimetallic catalyst with low metal loading (PtNi2 @CNS-600, 0.074 wt % Pt) exhibited outstanding HER activity with an overpotential as low as 68 mV at a current density of 10 mA cm-2 with a platinum loading of only 0.612 mugPt  cm-2 and Tafel slope of 35.27 mV dec-1 in a 0.5 m aqueous solution of H2 SO4 , which is comparable to that of the 20 % Pt/C catalyst (31 mV dec-1 ).	Platinum	11-13	deleted in esophageal cancer 1	Homo sapiens	384-389
30844566-7	2019	X-ray photoelectron spectroscopy result indicates the loading of Pt is roughly 0.11 at%, thus, the improved performance is basically due to the synergistic effect between Pt and Fe/N-HCS.	Platinum	65-67	holocarboxylase synthetase	Homo sapiens	183-186
30913325-4	2019	Remarkably PtNi bimetallic catalyst with low metal loading (PtNi2 @CNS-600, 0.074 wt % Pt) exhibited outstanding HER activity with an overpotential as low as 68 mV at a current density of 10 mA cm-2 with a platinum loading of only 0.612 mugPt  cm-2 and Tafel slope of 35.27 mV dec-1 in a 0.5 m aqueous solution of H2 SO4 , which is comparable to that of the 20 % Pt/C catalyst (31 mV dec-1 ).	Platinum	60-62	deleted in esophageal cancer 1	Homo sapiens	277-282
30913325-4	2019	Remarkably PtNi bimetallic catalyst with low metal loading (PtNi2 @CNS-600, 0.074 wt % Pt) exhibited outstanding HER activity with an overpotential as low as 68 mV at a current density of 10 mA cm-2 with a platinum loading of only 0.612 mugPt  cm-2 and Tafel slope of 35.27 mV dec-1 in a 0.5 m aqueous solution of H2 SO4 , which is comparable to that of the 20 % Pt/C catalyst (31 mV dec-1 ).	Platinum	60-62	deleted in esophageal cancer 1	Homo sapiens	384-389
31190883-0	2019	Effect of XPC polymorphisms on the response to platinum-based chemotherapy: a meta-analysis.	Platinum	47-55	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	10-13
31190883-2	2019	To quantitatively elucidate the genetic impact of the XPC rs2228000 and rs2228001 polymorphisms on the response to platinum-based chemotherapy, the present meta-analysis was conducted.	Platinum	115-123	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	54-57
31190883-3	2019	Materials and methods: A systematic literature search was performed in seven cyber databases until February 20, 2019, for all relevant studies that assessed the relationship between XPC polymorphisms and the response to platinum-based chemotherapy.	Platinum	220-228	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	182-185
31086816-0	2019	USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability.	Platinum	11-19	ubiquitin specific peptidase 1	Homo sapiens	0-4
30965009-7	2019	During in vivo application, the bioinspired Rex coating endowed docking NPs with prolonged blood circulation, smart organ tropism, and enhanced biocompatibility, as well as robust platinum (Pt) chemotherapy for breast cancer cells in orthotopic tumors of fat pads and metastatic nodules of lungs.	Platinum	180-188	rex	Mus musculus	44-47
31091037-6	2019	For tubo-ovarian cancers, the concept of &lt;&lt; platinum-sensitive &gt;&gt; has been tempered since the arrival of antiangiogenic treatment and PARP inhibitors that prolong the disease control not only in patients with BRCA1/2 mutation, but also in others.	Platinum	50-58	poly(ADP-ribose) polymerase 1	Homo sapiens	146-150
31091037-6	2019	For tubo-ovarian cancers, the concept of &lt;&lt; platinum-sensitive &gt;&gt; has been tempered since the arrival of antiangiogenic treatment and PARP inhibitors that prolong the disease control not only in patients with BRCA1/2 mutation, but also in others.	Platinum	50-58	BRCA1 DNA repair associated	Homo sapiens	221-226
31293743-2	2019	The porous platinum with numerous grain boundaries (GBP-Pt) consisting of 3 nm crystals exhibits 7 times higher ORR activity than commercial Pt.	Platinum	11-19	transmembrane protein 132A	Homo sapiens	52-55
31086816-0	2019	USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability.	Platinum	11-19	snail family transcriptional repressor 1	Homo sapiens	74-79
31086816-3	2019	Here, we report that the ubiquitin-specific protease 1 (USP1) mediates ovarian cancer cell resistance to platinum, by regulating the stability of Snail, which, in turn, promotes tumor dissemination.	Platinum	105-113	ubiquitin specific peptidase 1	Homo sapiens	25-54
31086816-3	2019	Here, we report that the ubiquitin-specific protease 1 (USP1) mediates ovarian cancer cell resistance to platinum, by regulating the stability of Snail, which, in turn, promotes tumor dissemination.	Platinum	105-113	ubiquitin specific peptidase 1	Homo sapiens	56-60
31086816-3	2019	Here, we report that the ubiquitin-specific protease 1 (USP1) mediates ovarian cancer cell resistance to platinum, by regulating the stability of Snail, which, in turn, promotes tumor dissemination.	Platinum	105-113	snail family transcriptional repressor 1	Homo sapiens	146-151
31086816-4	2019	At the molecular level, we observed that upon platinum treatment, USP1 is phosphorylated by ATM and ATR and binds to Snail.	Platinum	46-54	ubiquitin specific peptidase 1	Homo sapiens	66-70
31086816-4	2019	At the molecular level, we observed that upon platinum treatment, USP1 is phosphorylated by ATM and ATR and binds to Snail.	Platinum	46-54	ATM serine/threonine kinase	Homo sapiens	92-95
31086816-4	2019	At the molecular level, we observed that upon platinum treatment, USP1 is phosphorylated by ATM and ATR and binds to Snail.	Platinum	46-54	ATR serine/threonine kinase	Homo sapiens	100-103
31086816-4	2019	At the molecular level, we observed that upon platinum treatment, USP1 is phosphorylated by ATM and ATR and binds to Snail.	Platinum	46-54	snail family transcriptional repressor 1	Homo sapiens	117-122
31086816-5	2019	Then, USP1 de-ubiquitinates and stabilizes Snail expression, conferring resistance to platinum, increased stem cell-like features, and metastatic ability.	Platinum	86-94	ubiquitin specific peptidase 1	Homo sapiens	6-10
31086816-6	2019	Consistently, knockout or pharmacological inhibition of USP1 increased platinum sensitivity and decreased metastatic dissemination in a Snail-dependent manner.	Platinum	71-79	ubiquitin specific peptidase 1	Homo sapiens	56-60
30843348-5	2019	Both platinum prodrug and XPF-targeted siRNA are efficiently carried into cells and released; the former damages DNA and the latter specifically downregulates both mRNA and protein levels of XPF to potentiate the platinum drug, leading to enhanced expression levels of apoptosis markers and improved cytotoxicity in both cisplatin-sensitive and -resistant human lung cancer cells.	Platinum	5-13	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	191-194
31060523-0	2019	Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.	Platinum	51-59	cyclin E1	Homo sapiens	155-160
31060523-0	2019	Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.	Platinum	51-59	RB transcriptional corepressor 1	Homo sapiens	165-168
31060523-9	2019	Response rate to platinum retreatment was 22% in patients with CCNE1 gains and 83.5% in patients with no CCNE1 gains (p = 0.041).	Platinum	17-25	cyclin E1	Homo sapiens	63-68
31060523-15	2019	Despite the small number of patients tested, CCNE1 gain and RB1 loss discriminate patients with tumors extremely sensitive to platinum retreatment.	Platinum	126-134	cyclin E1	Homo sapiens	45-50
31060523-15	2019	Despite the small number of patients tested, CCNE1 gain and RB1 loss discriminate patients with tumors extremely sensitive to platinum retreatment.	Platinum	126-134	RB transcriptional corepressor 1	Homo sapiens	60-63
30843348-5	2019	Both platinum prodrug and XPF-targeted siRNA are efficiently carried into cells and released; the former damages DNA and the latter specifically downregulates both mRNA and protein levels of XPF to potentiate the platinum drug, leading to enhanced expression levels of apoptosis markers and improved cytotoxicity in both cisplatin-sensitive and -resistant human lung cancer cells.	Platinum	213-221	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	26-29
30926680-10	2019	In addition, high SFN expression is associated with significantly worse overall survival in patients who received chemotherapy contains gemcitabine, taxol, taxol+platin, paclitaxel and avastin.	Platinum	162-168	stratifin	Homo sapiens	18-21
30843348-5	2019	Both platinum prodrug and XPF-targeted siRNA are efficiently carried into cells and released; the former damages DNA and the latter specifically downregulates both mRNA and protein levels of XPF to potentiate the platinum drug, leading to enhanced expression levels of apoptosis markers and improved cytotoxicity in both cisplatin-sensitive and -resistant human lung cancer cells.	Platinum	213-221	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	191-194
30797591-1	2019	PURPOSE: PARP inhibitor maintenance therapy in platinum sensitive sporadic ovarian cancers improves progression free survival.	Platinum	47-55	poly(ADP-ribose) polymerase 1	Homo sapiens	9-13
30954906-4	2019	Of note, the presence of both negative PD-L1 expression and low TMB may identify a subgroup of patients who has little benefit from immunotherapy combinations and for whom the best treatment option may still be platinum-based chemotherapy.	Platinum	211-219	CD274 molecule	Homo sapiens	39-44
31047858-8	2019	Loss of NKX2-8 resulted in reprogramming of FA metabolism of EOC cells in an adipose microenvironment and leading to platinum resistance.	Platinum	117-125	NK2 homeobox 8	Homo sapiens	8-14
30989314-7	2019	Apoptosis induced by the C60-Cis-Pt nanocomplex was confirmed by caspase 3/7 activation and externalization of phosphatidylserine on the outer surface of LLC cells with the double Annexin V-FITC/PI staining.	Platinum	32-35	caspase 3	Mus musculus	65-76
30989314-7	2019	Apoptosis induced by the C60-Cis-Pt nanocomplex was confirmed by caspase 3/7 activation and externalization of phosphatidylserine on the outer surface of LLC cells with the double Annexin V-FITC/PI staining.	Platinum	32-35	annexin A5	Mus musculus	180-189
31140829-0	2019	Downregulation of LINC00515 in high-grade serous ovarian cancer and its relationship with platinum resistance.	Platinum	90-98	long intergenic non-protein coding RNA 515	Homo sapiens	18-27
31140829-1	2019	Aim: To investigate the expression of long intergenic noncoding RNA 00515 (LINC00515) in high-grade serous ovarian cancer (HGSOC) and its potential correlation with platinum resistance.	Platinum	165-173	long intergenic non-protein coding RNA 515	Homo sapiens	75-84
31140829-3	2019	We further explored the statistical significance of the relationship between LINC00515 expression and platinum resistance in HGSOC.	Platinum	102-110	long intergenic non-protein coding RNA 515	Homo sapiens	77-86
31140829-4	2019	Results: LINC00515 was gradually downregulated in the order of normal &gt; platinum-sensitive &gt; platinum-resistant tissue (p &lt; 0.05).	Platinum	75-83	long intergenic non-protein coding RNA 515	Homo sapiens	9-18
31140829-4	2019	Results: LINC00515 was gradually downregulated in the order of normal &gt; platinum-sensitive &gt; platinum-resistant tissue (p &lt; 0.05).	Platinum	99-107	long intergenic non-protein coding RNA 515	Homo sapiens	9-18
31140829-5	2019	Results demonstrated that LINC00515 downregulation was correlated with platinum resistance and relapse-free survival (RFS) of HGSOC (p &lt; 0.05).	Platinum	71-79	long intergenic non-protein coding RNA 515	Homo sapiens	26-35
31140829-6	2019	Conclusion: LINC00515 downregulation is correlated with HGSOC development, platinum resistance and RFS, supporting its utility as a potential biomarker to predict platinum resistance and prognosis of RFS.	Platinum	75-83	long intergenic non-protein coding RNA 515	Homo sapiens	12-21
31140829-6	2019	Conclusion: LINC00515 downregulation is correlated with HGSOC development, platinum resistance and RFS, supporting its utility as a potential biomarker to predict platinum resistance and prognosis of RFS.	Platinum	163-171	long intergenic non-protein coding RNA 515	Homo sapiens	12-21
30852385-0	2019	Multifunctional platinum(IV) complexes as immunostimulatory agents to promote cancer immunochemotherapy by inhibiting tryptophan-2,3-dioxygenase.	Platinum	16-24	tryptophan 2,3-dioxygenase	Homo sapiens	118-144
30797591-3	2019	ERCC1-XPF heterodimer is a key player in nucleotide excision repair (NER) involved in the repair of platinum induced DNA damage.	Platinum	100-108	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
30797591-3	2019	ERCC1-XPF heterodimer is a key player in nucleotide excision repair (NER) involved in the repair of platinum induced DNA damage.	Platinum	100-108	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	6-9
30797591-6	2019	Pre-clinically, ERCC1 and XPF was depleted in A2780 (platinum sensitive) and A2780cis (platinum resistant) ovarian cancer cell lines and tested for platinum sensitivity as well as for Olaparib induced synthetic lethality.	Platinum	53-61	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	16-21
30689078-0	2019	STAT3 rs4796793 contributes to lung cancer risk and clinical outcomes of platinum-based chemotherapy.	Platinum	73-81	signal transducer and activator of transcription 3	Homo sapiens	0-5
30797591-6	2019	Pre-clinically, ERCC1 and XPF was depleted in A2780 (platinum sensitive) and A2780cis (platinum resistant) ovarian cancer cell lines and tested for platinum sensitivity as well as for Olaparib induced synthetic lethality.	Platinum	53-61	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	26-29
30797591-6	2019	Pre-clinically, ERCC1 and XPF was depleted in A2780 (platinum sensitive) and A2780cis (platinum resistant) ovarian cancer cell lines and tested for platinum sensitivity as well as for Olaparib induced synthetic lethality.	Platinum	87-95	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	16-21
30797591-6	2019	Pre-clinically, ERCC1 and XPF was depleted in A2780 (platinum sensitive) and A2780cis (platinum resistant) ovarian cancer cell lines and tested for platinum sensitivity as well as for Olaparib induced synthetic lethality.	Platinum	87-95	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	16-21
30797591-9	2019	Pre-clinically, ERCC1 or XPF depletion not only increased platinum sensitivity but also increased toxicity to Olaparib therapy.	Platinum	58-66	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	16-21
30797591-9	2019	Pre-clinically, ERCC1 or XPF depletion not only increased platinum sensitivity but also increased toxicity to Olaparib therapy.	Platinum	58-66	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	25-28
30797591-11	2019	CONCLUSION: The data provide evidence that low ERCC1 is not only a predictor of platinum sensitivity but is also a promising biomarker for Olaparib induced synthetic lethality in ovarian cancers.	Platinum	80-88	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
30816440-10	2019	Furthermore, the expression of GRP78, a master regulator of the UPR, was enhanced in the osteosarcoma tissues of patients that were resistant to double regimen of doxorubicin and a platinum-based drug.	Platinum	181-189	heat shock protein family A (Hsp70) member 5	Homo sapiens	31-36
30839285-1	2019	OBJECTIVE: Tumors arising in BRCA1/2 mutation carriers are characterized by increased platinum sensitivity; however, it is unknown whether this feature should be considered while choosing between primary surgical versus systemic treatment.	Platinum	86-94	BRCA1 DNA repair associated	Homo sapiens	29-34
31933990-0	2019	Dihydrofolate reductase as a predictor for poor response to platinum-based chemotherapy in epithelial ovarian cancer.	Platinum	60-68	dihydrofolate reductase	Homo sapiens	0-23
31933990-5	2019	The correlation between DHFR expression and platinum-based chemotherapy response was analyzed.	Platinum	44-52	dihydrofolate reductase	Homo sapiens	24-28
30683677-1	2019	INTRODUCTION: Poly(ADP-ribose) polymerase inhibitors significantly improve progression-free survival in platinum-sensitive high-grade serous and endometrioid ovarian carcinoma, with greatest benefits observed in women with a pathogenic BRCA1/2 variant.	Platinum	104-112	BRCA1 DNA repair associated	Homo sapiens	236-243
30664989-1	2019	INTRODUCTION: This randomized phase II trial aimed at evaluating the engineered programmed cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line platinum-etoposide chemotherapy.	Platinum	178-186	CD274 molecule	Homo sapiens	80-110
30826588-5	2019	The coumarin platinum(IV) complex could effectively induce apoptosis of SKOV-3 cells through up-regulating the expression of caspase3 and caspase9.	Platinum	13-21	caspase 3	Homo sapiens	125-133
30826588-5	2019	The coumarin platinum(IV) complex could effectively induce apoptosis of SKOV-3 cells through up-regulating the expression of caspase3 and caspase9.	Platinum	13-21	caspase 9	Homo sapiens	138-146
30914152-9	2019	33.3% were against the addition of platinum agents as neoadjuvant chemotherapy in BRCA-mutated patients with BCP.	Platinum	35-43	BRCA1 DNA repair associated	Homo sapiens	82-86
30990480-4	2019	Among them, the GaPd2 nanoparticles required only 24.3 mV overpotential to achieve a 10 mA cm-2 current density, which is outstanding compared to most Pt-based nanomaterials.	Platinum	151-153	glyceraldehyde-3-phosphate dehydrogenase, spermatogenic	Homo sapiens	16-21
31015207-8	2019	Prophylactic NAC intervention was safe and effective in preventing the occurrence of PGF and PT in EC &lt; 0.1% patients by promoting the dynamic reconstitution of BM ECs and CD34+ cells, along with reducing their ROS levels, which was further confirmed by in situ BM trephine biopsy analyses.	Platinum	93-95	X-linked Kx blood group	Homo sapiens	13-16
31028498-0	2019	Colorimetric tyrosinase assay based on catechol inhibition of the oxidase-mimicking activity of chitosan-stabilized platinum nanoparticles.	Platinum	116-124	tyrosinase	Homo sapiens	13-23
31028498-8	2019	It is based on the fact that catechol can inhibit the oxidase-like activity of chitosan-stabilized platinum nanoparticles (Ch-PtNPs) by competing with the substrate for the active sites and TYRase can catalyze the oxidation of catechol.	Platinum	99-107	tyrosinase	Homo sapiens	190-196
30999573-1	2019	Visible-light-driven photocatalytic supramolecular enantiodifferentiating dimerization of 2-anthracenecarboxylic acid (AC) through triplet-triplet annihilation (TTA), mediated by the Schiff base Pt(II) complex (Pt-1, Pt-2, and Pt-3) was studied.	Platinum	195-197	zinc finger protein 135	Homo sapiens	227-231
31015457-2	2019	Herein, we report that the ensemble of Pt single atoms coordinated with oxygen atoms in MIL-101 (Pt1@MIL) induces distinct reaction path to improve selective hydrogenation of CO2 into methanol.	Platinum	39-41	zinc finger protein 77	Homo sapiens	97-104
30724953-3	2019	Insulin is one of the prototypical protein targets of platinum drugs as it has been seen to be involved in bioavailability reduction and might also determine resistance in certain cancer lines.	Platinum	54-62	insulin	Homo sapiens	0-7
30999573-1	2019	Visible-light-driven photocatalytic supramolecular enantiodifferentiating dimerization of 2-anthracenecarboxylic acid (AC) through triplet-triplet annihilation (TTA), mediated by the Schiff base Pt(II) complex (Pt-1, Pt-2, and Pt-3) was studied.	Platinum	195-197	zinc finger protein 77	Homo sapiens	211-215
31114351-9	2019	Conclusion: This meta-analysis suggests that olaparib maintenance therapy is effective and well-tolerated for the patients with platinum-sensitive BRCA-mutated ovarian cancer.	Platinum	128-136	BRCA1 DNA repair associated	Homo sapiens	147-151
30879295-4	2019	The complex ( OC-6-44)-acetatodichlorido(cyclohexane-1 R,2 R-diamine)( rac-2-(2-propynyl)octanoato)platinum(IV) showed higher tumor mass Pt accumulation than oxaliplatin, due to its higher lipophilicity, with negligible nephro- and hepatotoxicities when administered intravenously.	Platinum	137-139	Rac family small GTPase 2	Mus musculus	71-76
30732749-7	2019	Also PEI-modified T-CNF exhibited high selectivity towards Pt in the presence of other metals.	Platinum	59-61	NPHS1 adhesion molecule, nephrin	Homo sapiens	20-23
30538112-1	2019	PURPOSE: ERCC1/XPF is a DNA endonuclease with variable expression in primary tumor specimens, and has been investigated as a predictive biomarker for efficacy of platinum-based chemotherapy.	Platinum	162-170	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	9-14
30538112-1	2019	PURPOSE: ERCC1/XPF is a DNA endonuclease with variable expression in primary tumor specimens, and has been investigated as a predictive biomarker for efficacy of platinum-based chemotherapy.	Platinum	162-170	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	15-18
30538112-6	2019	In addition, when p53 is disrupted by CRISPR-Cas9 (p53*) in ERCC1Delta/p53WT cells, there is reduced apoptosis and increased viability after platinum treatment.	Platinum	141-149	tumor protein p53	Homo sapiens	18-21
30538112-6	2019	In addition, when p53 is disrupted by CRISPR-Cas9 (p53*) in ERCC1Delta/p53WT cells, there is reduced apoptosis and increased viability after platinum treatment.	Platinum	141-149	tumor protein p53	Homo sapiens	51-54
30538112-10	2019	CONCLUSIONS: Our findings implicate p53 as a potential confounding variable in clinical assessments of ERCC1 as a platinum biomarker via promoting an environment in which error-prone mechanisms of ICL-R may be able to partially compensate for loss of ERCC1.See related commentary by Friboulet et al., p. 2369.	Platinum	114-122	tumor protein p53	Homo sapiens	36-39
30538112-10	2019	CONCLUSIONS: Our findings implicate p53 as a potential confounding variable in clinical assessments of ERCC1 as a platinum biomarker via promoting an environment in which error-prone mechanisms of ICL-R may be able to partially compensate for loss of ERCC1.See related commentary by Friboulet et al., p. 2369.	Platinum	114-122	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	103-108
31149035-5	2019	Considering its weak damage to normal cells combined with high toxicity to cancer cells, this NF-kappaB-binding platinum complex is a potential anti-cancer candidate and acts to verify the strategy of hijacking endogenous trans-nuclear proteins to achieve cancer-cell specificity and enhance therapeutic indices.	Platinum	112-120	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	94-103
31037158-13	2019	Determining the levels of HOXB13 and its target genes from needle biopsy specimens may help predict the sensitivity of lung adenocarcinoma patients to platinum-based chemotherapy and patient outcomes.	Platinum	151-159	homeobox B13	Homo sapiens	26-32
31157259-0	2019	Polymorphisms in microRNA let-7 binding sites of the HIF1AN and CLDN12 genes can predict pathologic complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer.	Platinum	133-141	hypoxia inducible factor 1 subunit alpha inhibitor	Homo sapiens	53-59
31001468-3	2019	Here, we found that the expression of CACNA2D3 was significantly associated with poor platinum response in ESCC patients from the Gene Expression Omnibus database.	Platinum	86-94	calcium voltage-gated channel auxiliary subunit alpha2delta 3	Homo sapiens	38-46
30584903-2	2019	Since targeting excision repair cross-complementing 1 (ERCC1) may be a viable strategy to reestablish the therapeutic sensitivity to platinum-based agents in chemoresistant cases, and low ERCC1 level is beneficial to metastatic lung cancer patients undergoing platinum-based chemotherapy, we hypothesized that metastasis-associated process is involved in ERCC1-dependent cisplatin-resistance in lung adenocarcinoma.	Platinum	133-141	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	16-53
30584903-2	2019	Since targeting excision repair cross-complementing 1 (ERCC1) may be a viable strategy to reestablish the therapeutic sensitivity to platinum-based agents in chemoresistant cases, and low ERCC1 level is beneficial to metastatic lung cancer patients undergoing platinum-based chemotherapy, we hypothesized that metastasis-associated process is involved in ERCC1-dependent cisplatin-resistance in lung adenocarcinoma.	Platinum	133-141	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	55-60
30584903-2	2019	Since targeting excision repair cross-complementing 1 (ERCC1) may be a viable strategy to reestablish the therapeutic sensitivity to platinum-based agents in chemoresistant cases, and low ERCC1 level is beneficial to metastatic lung cancer patients undergoing platinum-based chemotherapy, we hypothesized that metastasis-associated process is involved in ERCC1-dependent cisplatin-resistance in lung adenocarcinoma.	Platinum	133-141	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	188-193
30584903-2	2019	Since targeting excision repair cross-complementing 1 (ERCC1) may be a viable strategy to reestablish the therapeutic sensitivity to platinum-based agents in chemoresistant cases, and low ERCC1 level is beneficial to metastatic lung cancer patients undergoing platinum-based chemotherapy, we hypothesized that metastasis-associated process is involved in ERCC1-dependent cisplatin-resistance in lung adenocarcinoma.	Platinum	133-141	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	188-193
30584903-2	2019	Since targeting excision repair cross-complementing 1 (ERCC1) may be a viable strategy to reestablish the therapeutic sensitivity to platinum-based agents in chemoresistant cases, and low ERCC1 level is beneficial to metastatic lung cancer patients undergoing platinum-based chemotherapy, we hypothesized that metastasis-associated process is involved in ERCC1-dependent cisplatin-resistance in lung adenocarcinoma.	Platinum	260-268	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	16-53
30584903-2	2019	Since targeting excision repair cross-complementing 1 (ERCC1) may be a viable strategy to reestablish the therapeutic sensitivity to platinum-based agents in chemoresistant cases, and low ERCC1 level is beneficial to metastatic lung cancer patients undergoing platinum-based chemotherapy, we hypothesized that metastasis-associated process is involved in ERCC1-dependent cisplatin-resistance in lung adenocarcinoma.	Platinum	260-268	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	55-60
30584903-2	2019	Since targeting excision repair cross-complementing 1 (ERCC1) may be a viable strategy to reestablish the therapeutic sensitivity to platinum-based agents in chemoresistant cases, and low ERCC1 level is beneficial to metastatic lung cancer patients undergoing platinum-based chemotherapy, we hypothesized that metastasis-associated process is involved in ERCC1-dependent cisplatin-resistance in lung adenocarcinoma.	Platinum	260-268	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	188-193
30584903-2	2019	Since targeting excision repair cross-complementing 1 (ERCC1) may be a viable strategy to reestablish the therapeutic sensitivity to platinum-based agents in chemoresistant cases, and low ERCC1 level is beneficial to metastatic lung cancer patients undergoing platinum-based chemotherapy, we hypothesized that metastasis-associated process is involved in ERCC1-dependent cisplatin-resistance in lung adenocarcinoma.	Platinum	260-268	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	188-193
31157259-0	2019	Polymorphisms in microRNA let-7 binding sites of the HIF1AN and CLDN12 genes can predict pathologic complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer.	Platinum	133-141	claudin 12	Homo sapiens	64-70
30892024-1	2019	Novel hetero-binuclear platinum complexes (HBC-Pt(II)-M(II), M = Ca(II), Mg(II), Zn(II), and Cd(II)) have been synthesized by the reaction of the corresponding precursors [Pt(ppy)(mu-Cl)]2 with (2-(1 H-tetrazol-5-yl)phenyl)diphenylphosphine oxide (TTPPO).	Platinum	23-31	keratin 88, pseudogene	Homo sapiens	43-46
30796464-0	2019	ABCB1 c.3435C&gt;T polymorphism is associated with platinum toxicity: a preliminary study.	Platinum	51-59	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
30796464-15	2019	CONCLUSIONS: The present study reveals that ABCB1 c.3435C&gt;T polymorphism influences platinum toxicity.	Platinum	87-95	ATP binding cassette subfamily B member 1	Homo sapiens	44-49
30731264-0	2019	A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.	Platinum	18-26	hematopoietic prostaglandin D synthase	Mus musculus	52-77
30672100-3	2019	Homologous recombination deficiency (HRD) and platinum sensitivity are prospective biomarkers for predicting the response to PARP inhibitors in ovarian cancers.	Platinum	46-54	poly(ADP-ribose) polymerase 1	Homo sapiens	125-129
30885350-1	2019	PURPOSE: This study aims to understand the effects and long-term survival of 1st generation epithelial growth factor receptor tyrosine kinase inhibitors(EGFR-TKI)or platinum-based chemotherapy as first-line therapy in advanced lung adenocarcinoma patients with uncommon EGFR mutations.	Platinum	165-173	epidermal growth factor receptor	Homo sapiens	270-274
30885350-9	2019	CONCLUSIONS: Compared with chemotherapy, use of the 1st generation of EGFR-TKIs as first-line therapy can improve the short-term efficacy of patients with EGFR uncommon mutations advanced lung adenocarcinoma, but platinum-based chemotherapy showed a longer overall survival.	Platinum	213-221	epidermal growth factor receptor	Homo sapiens	70-74
30478887-0	2019	EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer.	Platinum	93-101	epidermal growth factor receptor	Homo sapiens	0-4
30478887-0	2019	EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer.	Platinum	93-101	Kruppel like factor 5	Homo sapiens	52-56
30478887-10	2019	Our study indicates that the EGFR to KLF5 pathway is predictive of patient progression on platinum-based therapy.	Platinum	90-98	epidermal growth factor receptor	Homo sapiens	29-33
30478887-10	2019	Our study indicates that the EGFR to KLF5 pathway is predictive of patient progression on platinum-based therapy.	Platinum	90-98	Kruppel like factor 5	Homo sapiens	37-41
30886344-2	2019	Here, we show that targeting tumour-associated macrophages by colony-stimulating factor-1 receptor (CSF-1R) blockade in the K14cre;Cdh1F/F;Trp53F/F transgenic mouse model for breast cancer stimulates intratumoural type I interferon (IFN) signalling, which enhances the anticancer efficacy of platinum-based chemotherapeutics.	Platinum	292-300	colony stimulating factor 1 receptor	Mus musculus	62-98
30886344-2	2019	Here, we show that targeting tumour-associated macrophages by colony-stimulating factor-1 receptor (CSF-1R) blockade in the K14cre;Cdh1F/F;Trp53F/F transgenic mouse model for breast cancer stimulates intratumoural type I interferon (IFN) signalling, which enhances the anticancer efficacy of platinum-based chemotherapeutics.	Platinum	292-300	colony stimulating factor 1 receptor	Mus musculus	100-106
30731264-4	2019	By effectively inhibiting GSTs, complex 1 was found to be able to promote higher platinum uptake and cause more severe DNA damage in both A549 cells and A549/DDP cells as compared with cisplatin.	Platinum	81-89	hematopoietic prostaglandin D synthase	Mus musculus	26-30
29662106-11	2019	In conclusion, our results suggest that ERCC1 rs3212986, XRCC1 rs25487, MDM2 rs1690924, MTR rs1805087, and SLC19A1 rs1051266 gene polymorphisms may significantly act as predictive factors in NSCLC patients treated with platinum-based chemotherapy.	Platinum	219-227	solute carrier family 19 member 1	Homo sapiens	107-114
30720106-8	2019	IHC analysis showed an inverse profile, with positivity for PGD2 strongly associated with an increase in disease-free survival (P=0.009), the absence of relapse (P=0.039) and sensitivity to platinum-based therapy (P=0.016).	Platinum	190-198	prostaglandin D2 synthase	Homo sapiens	60-64
30923328-3	2019	Pectin capped platinum nanoparticles (PtNPs) at sub MIC (20 microM) concentration was effective, in causing loss of Extended Spectrum Beta Lactamase (ESBL) harboring plasmid as evidenced by, absence of plasmid in agarose gel and by a concomitant (16-64 fold) drop in MIC for cell wall inhibitors ceftriaxone and meropenem, in carbapenem resistant Escherichia coli (CREC).	Platinum	14-22	EsbL	Escherichia coli	116-148
29662106-3	2019	ERCC1, ERCC2, XRCC1, MDM2, MTHFR, MTR, and SLC19A1 gene polymorphisms may contribute to individual variation in response and survival to platinum-based chemotherapy.	Platinum	137-145	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
29662106-3	2019	ERCC1, ERCC2, XRCC1, MDM2, MTHFR, MTR, and SLC19A1 gene polymorphisms may contribute to individual variation in response and survival to platinum-based chemotherapy.	Platinum	137-145	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	7-12
29662106-3	2019	ERCC1, ERCC2, XRCC1, MDM2, MTHFR, MTR, and SLC19A1 gene polymorphisms may contribute to individual variation in response and survival to platinum-based chemotherapy.	Platinum	137-145	X-ray repair cross complementing 1	Homo sapiens	14-19
29662106-3	2019	ERCC1, ERCC2, XRCC1, MDM2, MTHFR, MTR, and SLC19A1 gene polymorphisms may contribute to individual variation in response and survival to platinum-based chemotherapy.	Platinum	137-145	MDM2 proto-oncogene	Homo sapiens	21-25
29662106-3	2019	ERCC1, ERCC2, XRCC1, MDM2, MTHFR, MTR, and SLC19A1 gene polymorphisms may contribute to individual variation in response and survival to platinum-based chemotherapy.	Platinum	137-145	methylenetetrahydrofolate reductase	Homo sapiens	27-32
29662106-3	2019	ERCC1, ERCC2, XRCC1, MDM2, MTHFR, MTR, and SLC19A1 gene polymorphisms may contribute to individual variation in response and survival to platinum-based chemotherapy.	Platinum	137-145	solute carrier family 19 member 1	Homo sapiens	43-50
29662106-11	2019	In conclusion, our results suggest that ERCC1 rs3212986, XRCC1 rs25487, MDM2 rs1690924, MTR rs1805087, and SLC19A1 rs1051266 gene polymorphisms may significantly act as predictive factors in NSCLC patients treated with platinum-based chemotherapy.	Platinum	219-227	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	40-45
31049278-5	2019	Patients with abnormality of FOLR1, DHFR, and MTRR tend to have a higher percentage of platinum resistance.	Platinum	87-95	folate receptor alpha	Homo sapiens	29-34
31049278-5	2019	Patients with abnormality of FOLR1, DHFR, and MTRR tend to have a higher percentage of platinum resistance.	Platinum	87-95	dihydrofolate reductase	Homo sapiens	36-40
31049278-5	2019	Patients with abnormality of FOLR1, DHFR, and MTRR tend to have a higher percentage of platinum resistance.	Platinum	87-95	5-methyltetrahydrofolate-homocysteine methyltransferase reductase	Homo sapiens	46-50
31049278-7	2019	The combination of FOLR1, DHFR, and MTRR could produce an area of 0.864 under the receiver-operating characteristic curve in distinguishing platinum-resistant patients from platinum-sensitive patients (P &lt; 0.0001).	Platinum	140-148	folate receptor alpha	Homo sapiens	19-24
31049278-7	2019	The combination of FOLR1, DHFR, and MTRR could produce an area of 0.864 under the receiver-operating characteristic curve in distinguishing platinum-resistant patients from platinum-sensitive patients (P &lt; 0.0001).	Platinum	140-148	dihydrofolate reductase	Homo sapiens	26-30
31049278-7	2019	The combination of FOLR1, DHFR, and MTRR could produce an area of 0.864 under the receiver-operating characteristic curve in distinguishing platinum-resistant patients from platinum-sensitive patients (P &lt; 0.0001).	Platinum	140-148	5-methyltetrahydrofolate-homocysteine methyltransferase reductase	Homo sapiens	36-40
31049278-7	2019	The combination of FOLR1, DHFR, and MTRR could produce an area of 0.864 under the receiver-operating characteristic curve in distinguishing platinum-resistant patients from platinum-sensitive patients (P &lt; 0.0001).	Platinum	173-181	folate receptor alpha	Homo sapiens	19-24
31049278-7	2019	The combination of FOLR1, DHFR, and MTRR could produce an area of 0.864 under the receiver-operating characteristic curve in distinguishing platinum-resistant patients from platinum-sensitive patients (P &lt; 0.0001).	Platinum	173-181	5-methyltetrahydrofolate-homocysteine methyltransferase reductase	Homo sapiens	36-40
30919167-4	2019	These defects confer increased sensitivity to platinum chemotherapy or poly (ADP-ribose) polymerase (PARP) inhibitors.	Platinum	46-54	poly(ADP-ribose) polymerase 1	Homo sapiens	101-105
30673164-0	2019	Controlled Synthesis of Surfactant-Free Water-Dispersible Colloidal Platinum Nanoparticles by the Co4Cat Process.	Platinum	68-76	complement C4A (Rodgers blood group)	Homo sapiens	98-101
30909992-0	2019	[Association between the HER2 Gene Status and the Efficacy of First-line Pemetrexed Combined with Platinum Chemotherapy in Patients with Advanced Lung  : Adenocarcinoma].	Platinum	98-106	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-29
30909992-3	2019	The aim of this study is to investigate the efficacy of pemetrexed combined with platinum chemotherapy in patients with HER2-mutant and HER2 wild-type lung adenocarcinoma.	Platinum	81-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
30962858-0	2019	The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis.	Platinum	26-34	BRCA1 DNA repair associated	Homo sapiens	57-61
30909992-3	2019	The aim of this study is to investigate the efficacy of pemetrexed combined with platinum chemotherapy in patients with HER2-mutant and HER2 wild-type lung adenocarcinoma.	Platinum	81-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	136-140
30962858-3	2019	BRCA status is being studied as a predictive biomarker of response to platinum agents.	Platinum	70-78	BRCA1 DNA repair associated	Homo sapiens	0-4
30909992-13	2019	CONCLUSIONS: HER2-mutant lung adenocarcinoma patients with first-line pemetrexed combined with platinum chemotherapy have greater clinical benefit than HER2 wild-type patients.	Platinum	95-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-17
30962858-6	2019	This study aims to establish if the presence of a germline BRCA mutation in women with TNBC improves the pathologic complete response (pCR) after neoadjuvant chemotherapy with platinum compounds.	Platinum	176-184	BRCA1 DNA repair associated	Homo sapiens	59-63
30870501-10	2019	We identified both known and novel somatic copy number aberrations (12p, MDM2, and RHBDD1) and mutations (XRCC2, PIK3CA, RITA1) including candidate markers for platinum resistance that were present in a primary tumor of mixed histology and that remained after tandem autologous stem cell transplant.	Platinum	160-168	X-ray repair cross complementing 2	Homo sapiens	106-111
30962858-11	2019	Conclusions: This meta-analysis shows that the addition of platinum to chemotherapy regimens in the neoadjuvant setting increases pCR rate in BRCA - mutated as compared to wild-type TNBC patients.	Platinum	59-67	BRCA1 DNA repair associated	Homo sapiens	142-146
30842342-11	2019	These findings suggest that the TSC1 gene variant is an important predictive marker for platinum doublet chemotherapy outcomes in NSCLC patients.	Platinum	88-96	TSC complex subunit 1	Homo sapiens	32-36
30870501-10	2019	We identified both known and novel somatic copy number aberrations (12p, MDM2, and RHBDD1) and mutations (XRCC2, PIK3CA, RITA1) including candidate markers for platinum resistance that were present in a primary tumor of mixed histology and that remained after tandem autologous stem cell transplant.	Platinum	160-168	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	113-119
30871108-6	2019	Poly ADP-ribose polymerase (PARP) inhibitors and platinum-based chemotherapy have proven to be effective in the treatment of other tumor types linked to BRCA1 and BRCA2 alterations and several trials are currently evaluating their efficacy in prostate cancer.	Platinum	49-57	BRCA1 DNA repair associated	Homo sapiens	153-158
30758372-1	2019	Reaction of AsCl3 with Pt(0) complexes [Pt(PCy3)2], [Pt(PCy3)(IMes)] and [Pt(IMes)2] (IMes = 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene) resulted in oxidative addition of As-Cl bonds at the Pt centres to form complexes of the form trans-[PtCl(AsCl2)L2].	Platinum	23-28	achaete-scute family bHLH transcription factor 3	Homo sapiens	12-17
30871186-1	2019	Dysfunctional homologous recombination DNA repair (HRR), frequently due to BRCA mutations, is a determinant of sensitivity to platinum chemotherapy and poly(ADP-ribose) polymerase inhibitors (PARPi).	Platinum	126-134	BRCA1 DNA repair associated	Homo sapiens	75-79
30871108-6	2019	Poly ADP-ribose polymerase (PARP) inhibitors and platinum-based chemotherapy have proven to be effective in the treatment of other tumor types linked to BRCA1 and BRCA2 alterations and several trials are currently evaluating their efficacy in prostate cancer.	Platinum	49-57	BRCA2 DNA repair associated	Homo sapiens	163-168
30648820-2	2019	Thus, deficiency of MCM8-9 sensitizes cells to replication stress caused, for example, by platinum compounds that induce interstrand cross-links.	Platinum	90-98	minichromosome maintenance 8 homologous recombination repair factor	Homo sapiens	20-24
30633424-10	2019	Our data indicate that ZNF671 functions as a tumor suppressor in ovarian cancer and that the DNA methylation status of ZNF671 might be an effective biomarker for the recurrence of serous ovarian cancer after platinum-based adjuvant chemotherapy.	Platinum	208-216	zinc finger protein 671	Homo sapiens	119-125
29988075-1	2019	Platinum-based chemotherapies can result in ovarian insufficiency by reducing the ovarian reserve, a reduction believed to result from apoptosis of immature oocytes via activation/phosphorylation of TAp63alpha by multiple kinases including CHEK2, CK1, and ABL1.	Platinum	0-8	checkpoint kinase 2	Mus musculus	240-245
29988075-1	2019	Platinum-based chemotherapies can result in ovarian insufficiency by reducing the ovarian reserve, a reduction believed to result from apoptosis of immature oocytes via activation/phosphorylation of TAp63alpha by multiple kinases including CHEK2, CK1, and ABL1.	Platinum	0-8	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	256-260
30648820-4	2019	Therefore, it is possible that inhibiting MCM8-9 selectively hypersensitizes cancer cells to platinum compounds and poly(ADP-ribose) polymerase inhibitors, both of which hamper replication fork progression.	Platinum	93-101	minichromosome maintenance 8 homologous recombination repair factor	Homo sapiens	42-48
30648820-10	2019	Taken together, the data suggest that conceptual MCM8-9 inhibitors will be powerful cancer-specific chemosensitizers for platinum compounds and poly(ADP-ribose) polymerase inhibitors, thereby opening new avenues to the design of novel cancer chemotherapeutic strategies.	Platinum	121-129	minichromosome maintenance 8 homologous recombination repair factor	Homo sapiens	49-55
30328531-0	2019	Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer.	Platinum	51-59	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	13-19
30589566-7	2019	Unexpectedly, following Van treatment, PKC-delta expression was found to be highest among the 4 genes related to cell death, which was remarkably suppressed in vitro and in PT-Atg7-KO mice.	Platinum	173-175	protein kinase C, delta	Mus musculus	39-48
30589566-7	2019	Unexpectedly, following Van treatment, PKC-delta expression was found to be highest among the 4 genes related to cell death, which was remarkably suppressed in vitro and in PT-Atg7-KO mice.	Platinum	173-175	autophagy related 7	Mus musculus	176-180
30589566-10	2019	Furthermore, the data showed that PT-Atg7-KO exerted a renoprotective effect against Van-induced nephrotoxicity, but this effect was lost after injection with myc-tagged PKCdelta.	Platinum	34-36	autophagy related 7	Homo sapiens	37-41
30589566-10	2019	Furthermore, the data showed that PT-Atg7-KO exerted a renoprotective effect against Van-induced nephrotoxicity, but this effect was lost after injection with myc-tagged PKCdelta.	Platinum	34-36	protein kinase C delta	Homo sapiens	170-178
30504425-1	2019	PURPOSE: Despite the clinical advantage of the combination of trastuzumab and platinum-based chemotherapy in HER2-amplified tumors, resistance will eventually develop.	Platinum	78-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-113
30608899-7	2019	Based on the survival analyses, the advanced-stage patients with high SOX30 expression can receive the platin and/or taxol based chemotherapy, whereas should not receive chemotherapy containing gemcitabine or topotecan.	Platinum	103-109	SRY-box transcription factor 30	Homo sapiens	70-75
30640563-2	2019	Areas covered: The identification of genetic driver alterations led to the selection of patients who are most likely to benefit from epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) and rat osteosarcoma (ROS-1) tyrosine kinase inhibitors; on the other hand, in the absence of oncogenic alterations, platinum-based doublet chemotherapy regimens were the cornerstone of treatment.	Platinum	327-335	epidermal growth factor receptor	Homo sapiens	133-165
30640563-2	2019	Areas covered: The identification of genetic driver alterations led to the selection of patients who are most likely to benefit from epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) and rat osteosarcoma (ROS-1) tyrosine kinase inhibitors; on the other hand, in the absence of oncogenic alterations, platinum-based doublet chemotherapy regimens were the cornerstone of treatment.	Platinum	327-335	ROS proto-oncogene 1 , receptor tyrosine kinase	Rattus norvegicus	232-237
30328531-2	2019	The aim of this study was to assess the association between uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene polymorphism and severe hematologic toxicities in Japanese patients receiving etoposide plus platinum chemotherapy for small-cell lung cancer.	Platinum	215-223	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	60-107
30833436-11	2019	CONCLUSION: S-1 plus irinotecan in a 3 weekly setting is safe and active in women with advanced or recurrent cervical cancer previously treated with platinum based chemotherapy.	Platinum	149-157	proteasome 26S subunit, non-ATPase 1	Homo sapiens	12-15
30328531-2	2019	The aim of this study was to assess the association between uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene polymorphism and severe hematologic toxicities in Japanese patients receiving etoposide plus platinum chemotherapy for small-cell lung cancer.	Platinum	215-223	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	109-115
33014516-2	2019	Pembrolizumab and nivolumab, which are classified as immune checkpoint inhibitors of programmed cell death protein 1, have shown clinically significant activity in patients who progressed on or after platinum-based regimens, and these agents are now US Food and Drug Administration approved for this indication.	Platinum	200-208	programmed cell death 1	Homo sapiens	85-116
30823644-5	2019	Seamless BiOCl functions like a noble metal, with platinum-like behavior, accelerating the oxidizing ability of fabricated BiOCl/Bi2WO6 hybrids, which was favorable for the photocatalytic decomposition of organic compounds (3.2 times greater for Rhodamine B (RhB) and 4 times greater for Ciprofloxacin (CIP)) over the Bi2WO6 catalysts.	Platinum	50-58	muscular LMNA interacting protein	Homo sapiens	288-308
30854066-0	2019	GSTP1 as a potential predictive factor for adverse events associated with platinum-based antitumor agent-induced peripheral neuropathy.	Platinum	74-82	glutathione S-transferase pi 1	Homo sapiens	0-5
30518877-11	2019	Anti-PD-L1 alone in a platinum-sensitive model or with cisplatin in a platinum-resistant model increases survival.	Platinum	22-30	CD274 antigen	Mus musculus	5-10
30518877-11	2019	Anti-PD-L1 alone in a platinum-sensitive model or with cisplatin in a platinum-resistant model increases survival.	Platinum	70-78	CD274 antigen	Mus musculus	5-10
30854066-1	2019	Glutathione S-transferase (GST) exhibits antidotal effects on numerous drugs, including platinum-based antineoplastic drugs.	Platinum	88-96	glutathione S-transferase kappa 1	Homo sapiens	0-25
30854066-1	2019	Glutathione S-transferase (GST) exhibits antidotal effects on numerous drugs, including platinum-based antineoplastic drugs.	Platinum	88-96	glutathione S-transferase kappa 1	Homo sapiens	27-30
30854066-3	2019	In the present study, it was determined whether GSTP1 can predict adverse events associated with platinum-based antitumor agent-induced peripheral neuropathy among Japanese patients.	Platinum	97-105	glutathione S-transferase pi 1	Homo sapiens	48-53
30628188-12	2019	ERCC1 messenger RNA levels may be a predictive factor for response to platinum-containing regimens.	Platinum	70-78	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
30709915-3	2019	The Pt-GpG tolerance by translesion DNA synthesis (TLS) polymerases contributes to the resistance of tumors to platinum-based chemotherapy.	Platinum	111-119	FUS RNA binding protein	Homo sapiens	51-54
30709915-10	2019	Overall, the Poleta-oxaliplatin-GpG structure provides a structural basis for TLS-mediated bypass of the major oxaliplatin-DNA adducts and insights into resistance to platinum-based chemotherapy in humans.	Platinum	167-175	FUS RNA binding protein	Homo sapiens	78-81
30776030-4	2019	When the Pd(111) surface is heated to room temperature, the HCN is converted to the aminocarbyne species, CNH2, which was also observed on the Pt(111) surface.	Platinum	143-145	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	60-63
30408550-0	2019	miR-509-3p enhances platinum drug sensitivity in ovarian cancer.	Platinum	20-28	microRNA 5093	Homo sapiens	0-10
30408550-10	2019	Altogether, our data provide preliminary evidence, supporting that targeting miR-509-3p might be a potential therapeutic strategy for patients with platinum-resistant ovarian cancer.	Platinum	148-156	microRNA 5093	Homo sapiens	77-87
30628188-0	2019	Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA.	Platinum	24-32	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	121-126
30862140-0	2019	[Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].	Platinum	87-95	DNA polymerase kappa	Homo sapiens	22-42
30862140-1	2019	Objective: To investigate the associations between genetic variations of DNA polymerase kappa (POLK) and treatment response to platinum-based chemotherapy of small cell lung cancer (SCLC), and to analyze the influencing factors on survival.	Platinum	127-135	DNA polymerase kappa	Homo sapiens	73-93
30862140-1	2019	Objective: To investigate the associations between genetic variations of DNA polymerase kappa (POLK) and treatment response to platinum-based chemotherapy of small cell lung cancer (SCLC), and to analyze the influencing factors on survival.	Platinum	127-135	DNA polymerase kappa	Homo sapiens	95-99
30408550-4	2019	In present study, we compared the expression profiles of miRNAs between three pairs of platinum-resistant and platinum-sensitive ovarian tissues and found that miR-509-3p was significantly down-regulated in cisplatin-resistant ovarian cancer tissues.	Platinum	87-95	microRNA 5093	Homo sapiens	160-170
30408550-4	2019	In present study, we compared the expression profiles of miRNAs between three pairs of platinum-resistant and platinum-sensitive ovarian tissues and found that miR-509-3p was significantly down-regulated in cisplatin-resistant ovarian cancer tissues.	Platinum	110-118	microRNA 5093	Homo sapiens	160-170
30638658-11	2019	FAM84B-AS promotes gastric cancer proliferation through inhibition of apoptosis signaling pathways and promotes drug resistance of gastric cancer cells to platinum drugs through its apoptosis-inhibiting functions.	Platinum	155-163	LRAT domain containing 2	Homo sapiens	0-6
30259975-5	2019	Furthermore, BET inhibition impaired the ability of TNBC cells to overcome the increase in DNA damage after platinum salts (i.e., CDDP) exposure, leading to massive cell death, and triggered synthetic lethality when combined with PARP inhibitors (i.e., AZD2281).	Platinum	130-134	delta/notch like EGF repeat containing	Homo sapiens	13-16
30778772-5	2019	Subgroup analysis of patients with mutations in the epidermal growth factor receptor (EGFR) gene and rearrangements in the anaplastic lymphoma kinase (ALK) gene also demonstrated benefit with combined anti-PD-L1, bevacizumab, and platinum chemotherapy.	Platinum	230-238	epidermal growth factor receptor	Homo sapiens	52-84
30778772-5	2019	Subgroup analysis of patients with mutations in the epidermal growth factor receptor (EGFR) gene and rearrangements in the anaplastic lymphoma kinase (ALK) gene also demonstrated benefit with combined anti-PD-L1, bevacizumab, and platinum chemotherapy.	Platinum	230-238	ALK receptor tyrosine kinase	Homo sapiens	123-149
30778772-5	2019	Subgroup analysis of patients with mutations in the epidermal growth factor receptor (EGFR) gene and rearrangements in the anaplastic lymphoma kinase (ALK) gene also demonstrated benefit with combined anti-PD-L1, bevacizumab, and platinum chemotherapy.	Platinum	230-238	ALK receptor tyrosine kinase	Homo sapiens	151-154
30259975-5	2019	Furthermore, BET inhibition impaired the ability of TNBC cells to overcome the increase in DNA damage after platinum salts (i.e., CDDP) exposure, leading to massive cell death, and triggered synthetic lethality when combined with PARP inhibitors (i.e., AZD2281).	Platinum	108-116	delta/notch like EGF repeat containing	Homo sapiens	13-16
30279231-0	2019	Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/beta-catenin/CBP signaling.	Platinum	22-30	RNA binding motif single stranded interacting protein 3	Homo sapiens	8-13
30367340-6	2019	The results highlighted a different behavior between the two series of complexes being platinum compounds more reactive toward RNase and cyt c than palladium compounds.	Platinum	87-95	cytochrome c, somatic	Homo sapiens	137-142
30367340-7	2019	Based on the obtained results, it is proposed that in presence of RNase A and cyt c, the platinum complexes undergo activation through release of labile ligands followed by binding to the protein.	Platinum	89-97	ribonuclease A family member 1, pancreatic	Homo sapiens	66-73
30367340-7	2019	Based on the obtained results, it is proposed that in presence of RNase A and cyt c, the platinum complexes undergo activation through release of labile ligands followed by binding to the protein.	Platinum	89-97	cytochrome c, somatic	Homo sapiens	78-83
30439368-0	2019	Electrochemiluminescent immunosensor for prostate specific antigen based upon luminol functionalized platinum nanoparticles loaded on graphene.	Platinum	101-109	kallikrein related peptidase 3	Homo sapiens	41-66
30425037-1	2019	A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in BRCA-mutant cancers is the acquisition of BRCA reversion mutations that restore protein function.	Platinum	30-38	BRCA1 DNA repair associated	Homo sapiens	83-87
30425037-1	2019	A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in BRCA-mutant cancers is the acquisition of BRCA reversion mutations that restore protein function.	Platinum	30-38	BRCA1 DNA repair associated	Homo sapiens	125-129
30425037-3	2019	BRCA reversion mutations were identified in pretreatment cfDNA from 18% (2/11) of platinum-refractory and 13% (5/38) of platinum-resistant cancers, compared with 2% (1/48) of platinum-sensitive cancers (P = 0.049).	Platinum	82-90	BRCA1 DNA repair associated	Homo sapiens	0-4
30425037-3	2019	BRCA reversion mutations were identified in pretreatment cfDNA from 18% (2/11) of platinum-refractory and 13% (5/38) of platinum-resistant cancers, compared with 2% (1/48) of platinum-sensitive cancers (P = 0.049).	Platinum	120-128	BRCA1 DNA repair associated	Homo sapiens	0-4
30425037-3	2019	BRCA reversion mutations were identified in pretreatment cfDNA from 18% (2/11) of platinum-refractory and 13% (5/38) of platinum-resistant cancers, compared with 2% (1/48) of platinum-sensitive cancers (P = 0.049).	Platinum	120-128	BRCA1 DNA repair associated	Homo sapiens	0-4
30425037-6	2019	SIGNIFICANCE: BRCA reversion mutations are detected in cfDNA from platinum-resistant or platinum-refractory HGOC and are associated with decreased clinical benefit from rucaparib treatment.	Platinum	66-74	BRCA1 DNA repair associated	Homo sapiens	14-18
30425037-6	2019	SIGNIFICANCE: BRCA reversion mutations are detected in cfDNA from platinum-resistant or platinum-refractory HGOC and are associated with decreased clinical benefit from rucaparib treatment.	Platinum	88-96	BRCA1 DNA repair associated	Homo sapiens	14-18
30279231-0	2019	Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/beta-catenin/CBP signaling.	Platinum	22-30	microRNA 126	Homo sapiens	89-96
30279231-0	2019	Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/beta-catenin/CBP signaling.	Platinum	22-30	catenin beta 1	Homo sapiens	100-112
30279231-0	2019	Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/beta-catenin/CBP signaling.	Platinum	22-30	CREB binding protein	Homo sapiens	113-116
30279231-9	2019	Importantly, cotherapy of CBP/beta-catenin antagonist PRI-724 induced sensitization of RBMS3-deleted EOC to platinum therapy.	Platinum	108-116	CREB binding protein	Homo sapiens	26-29
30279231-9	2019	Importantly, cotherapy of CBP/beta-catenin antagonist PRI-724 induced sensitization of RBMS3-deleted EOC to platinum therapy.	Platinum	108-116	catenin beta 1	Homo sapiens	30-42
30279231-9	2019	Importantly, cotherapy of CBP/beta-catenin antagonist PRI-724 induced sensitization of RBMS3-deleted EOC to platinum therapy.	Platinum	108-116	RNA binding motif single stranded interacting protein 3	Homo sapiens	87-92
30270052-0	2019	Tumor Lysis Syndrome After Platinum-based Chemotherapy in Castration-resistant Prostate Cancer With a BRCA2 Mutation: A Case Report.	Platinum	27-35	BRCA2 DNA repair associated	Homo sapiens	102-107
30540581-2	2019	RECENT FINDINGS: PARP inhibitors have been most studied in patients with breast and ovarian cancers associated with deleterious germline BRCA1 or BRCA2 mutations, though their role has expanded to include use as maintenance therapy in women with platinum-sensitive high-grade serous ovarian cancer due to the high propensity of such cancers to have defects in DNA repair by homologous recombination.	Platinum	246-254	poly(ADP-ribose) polymerase 1	Homo sapiens	17-21
30414698-12	2019	We additionally found an association between low MSH2 in bladder tumors and poorer patient survival when treated with platinum-based chemotherapy.	Platinum	118-126	mutS homolog 2	Homo sapiens	49-53
30414698-15	2019	MSH2 has potential as a biomarker predictive of response to platinum-based therapy.	Platinum	60-68	mutS homolog 2	Homo sapiens	0-4
30472259-0	2019	Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.	Platinum	51-59	partner and localizer of BRCA2	Homo sapiens	15-20
30295925-10	2019	The knockdown of Octn1 in DRG ameliorated peripheral neuropathy, and decreased platinum accumulation in DRG, whereas the knockdown of Octn2 did not.	Platinum	79-87	solute carrier family 22 member 4	Rattus norvegicus	17-22
30295925-12	2019	These results indicate that Octn1 and Mate1 are involved in platinum accumulation at DRG and oxaliplatin-induced peripheral neuropathy.	Platinum	60-68	solute carrier family 22 member 4	Rattus norvegicus	28-33
30295925-12	2019	These results indicate that Octn1 and Mate1 are involved in platinum accumulation at DRG and oxaliplatin-induced peripheral neuropathy.	Platinum	60-68	solute carrier family 47 member 1	Rattus norvegicus	38-43
30672383-0	2019	Polymorphisms in IGF2/H19 gene locus are associated with platinum-based chemotherapeutic response in Chinese patients with epithelial ovarian cancer.	Platinum	57-65	insulin like growth factor 2	Homo sapiens	17-21
30478151-0	2019	Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.	Platinum	83-91	AXL receptor tyrosine kinase	Homo sapiens	55-58
30478151-3	2019	This study aims to determine whether and how inhibition of the receptor tyrosine kinase AXL can restore sensitivity to first-line platinum and taxane therapy in ovarian cancer.	Platinum	130-138	AXL receptor tyrosine kinase	Homo sapiens	88-91
30478151-11	2019	AXL inhibition increased platinum accumulation by 2-fold (*, P &lt; 0.05).	Platinum	25-33	AXL receptor tyrosine kinase	Homo sapiens	0-3
30478151-13	2019	AXL contributes to platinum and taxane resistance in ovarian cancer, and inhibition of AXL improves chemoresponse and accumulation of chemotherapy drugs.	Platinum	19-27	AXL receptor tyrosine kinase	Homo sapiens	0-3
30190521-6	2019	Among miRNA, combination of miR-1290, miR-196b and miR-135a in tumor tissue, and miR-21, miR-25, miR27b, and miR-326 in plasma were predictive for response to platinum-based chemotherapy in advanced NSCLC.	Platinum	159-167	microRNA 1290	Homo sapiens	28-36
30190521-6	2019	Among miRNA, combination of miR-1290, miR-196b and miR-135a in tumor tissue, and miR-21, miR-25, miR27b, and miR-326 in plasma were predictive for response to platinum-based chemotherapy in advanced NSCLC.	Platinum	159-167	microRNA 196b	Homo sapiens	38-46
30190521-6	2019	Among miRNA, combination of miR-1290, miR-196b and miR-135a in tumor tissue, and miR-21, miR-25, miR27b, and miR-326 in plasma were predictive for response to platinum-based chemotherapy in advanced NSCLC.	Platinum	159-167	microRNA 21	Homo sapiens	81-87
30190521-6	2019	Among miRNA, combination of miR-1290, miR-196b and miR-135a in tumor tissue, and miR-21, miR-25, miR27b, and miR-326 in plasma were predictive for response to platinum-based chemotherapy in advanced NSCLC.	Platinum	159-167	microRNA 25	Homo sapiens	89-95
30190521-6	2019	Among miRNA, combination of miR-1290, miR-196b and miR-135a in tumor tissue, and miR-21, miR-25, miR27b, and miR-326 in plasma were predictive for response to platinum-based chemotherapy in advanced NSCLC.	Platinum	159-167	microRNA 27b	Homo sapiens	97-103
30672383-0	2019	Polymorphisms in IGF2/H19 gene locus are associated with platinum-based chemotherapeutic response in Chinese patients with epithelial ovarian cancer.	Platinum	57-65	H19 imprinted maternally expressed transcript	Homo sapiens	22-25
30190521-6	2019	Among miRNA, combination of miR-1290, miR-196b and miR-135a in tumor tissue, and miR-21, miR-25, miR27b, and miR-326 in plasma were predictive for response to platinum-based chemotherapy in advanced NSCLC.	Platinum	159-167	microRNA 326	Homo sapiens	109-116
30672383-1	2019	AIM: The present study aimed to assess the association between IGF2/H19 genetic variants and susceptibility to platinum-based chemotherapy in epithelial ovarian cancer (EOC).	Platinum	111-119	insulin like growth factor 2	Homo sapiens	63-67
30672383-1	2019	AIM: The present study aimed to assess the association between IGF2/H19 genetic variants and susceptibility to platinum-based chemotherapy in epithelial ovarian cancer (EOC).	Platinum	111-119	H19 imprinted maternally expressed transcript	Homo sapiens	68-71
30709250-9	2019	The decrease in the required overpotential (eta) for the alloys with respect to the unstrained Pt(111) surface is found to be in the range (0.04 V-0.25 V) assuming the dissociative mechanism and (0.02 V-0.10 V) assuming the associative mechanism, where the variation depends on the thickness of Pt overlayers.	Platinum	95-97	endothelin receptor type A	Homo sapiens	44-47
30745873-0	2018	Anti-tumorigenic and Platinum-Sensitizing Effects of Apolipoprotein A1 and Apolipoprotein A1 Mimetic Peptides in Ovarian Cancer.	Platinum	21-29	apolipoprotein A1	Homo sapiens	53-70
30668408-1	2019	BACKGROUND: Excision repair cross-complementary 1 (ERCC1) overexpression in lung cancer cells is strongly correlated with its resistance to platinum-based chemotherapy.	Platinum	140-148	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	51-56
30774376-0	2019	Reversing platinum resistance in ovarian cancer multicellular spheroids by targeting Bcl-2.	Platinum	10-18	BCL2 apoptosis regulator	Homo sapiens	85-90
30745873-0	2018	Anti-tumorigenic and Platinum-Sensitizing Effects of Apolipoprotein A1 and Apolipoprotein A1 Mimetic Peptides in Ovarian Cancer.	Platinum	21-29	apolipoprotein A1	Homo sapiens	75-92
30520205-2	2019	A cost-effective carbon-supported carbon-defect-anchored platinum single-atom electrocatalysts (Pt1 /C) with remarkable ORR performance is reported.	Platinum	57-65	zinc finger protein 77	Homo sapiens	96-99
30745873-4	2018	We aimed to disclose the effects of ApoA1 and a mimetic peptide on the malignant phenotype of ovarian cancer cells, particularly regarding cell viability, invasiveness and platinum sensitization.	Platinum	172-180	apolipoprotein A1	Homo sapiens	36-41
30660106-1	2019	We report here a supercatalyst for oxygen reduction of Pt/CNx/Ni in a unique ternary heterostructure, in which the Pt and the underlying Ni nanoparticles are separated by two to three layers of nitrogen-doped carbon (CNx), which mediates the transfer of electrons from the inner Ni to the outer Pt and protects the Ni against corrosion at the same time.	Platinum	55-57	calnexin	Homo sapiens	58-61
30660106-1	2019	We report here a supercatalyst for oxygen reduction of Pt/CNx/Ni in a unique ternary heterostructure, in which the Pt and the underlying Ni nanoparticles are separated by two to three layers of nitrogen-doped carbon (CNx), which mediates the transfer of electrons from the inner Ni to the outer Pt and protects the Ni against corrosion at the same time.	Platinum	55-57	calnexin	Homo sapiens	217-220
30624436-1	2019	Inspired by the fascinating result that NbN-related species can possess a similar electronic structure to noble metal atoms (e.g. Pt), in this work we have proposed for the first time a new strategy, through embedding the transition metal (TM) Nb atom in the in-plane cavity of g-C3N4, for constructing the nonprecious Nb-C3N4 configuration comprising the NbN unit exhibiting noble-metal-like characteristics.	Platinum	130-132	nibrin	Homo sapiens	40-43
30520205-3	2019	An acidic H2 /O2 single cell with Pt1 /C as cathode delivers a maximum power density of 520 mW cm-2 at 80  C, corresponding to a superhigh platinum utilization of 0.09 gPt  kW-1 .	Platinum	139-147	zinc finger protein 77	Homo sapiens	34-37
30520205-4	2019	Further physical characterization and density functional theory computations reveal that single Pt atoms anchored stably by four carbon atoms in carbon divacancies (Pt-C4 ) are the main active centers for the observed high ORR performance.	Platinum	96-98	pericentriolar material 1	Homo sapiens	165-170
30997004-5	2019	Compared with commercial platinum/carbon, the synthesized atomically dispersed Pt catalyst, as a superior HER catalyst, exhibited a lower overpotential of approximately 55 mV at a current density of 100 mA cm-2 and a lower Tafel slope of 26 mV dec-1 and had higher stability in 0.5 M H2SO4.	Platinum	79-81	deleted in esophageal cancer 1	Homo sapiens	244-249
30886796-2	2019	Here, a sacrificial-counter-electrode method to synthesize a MoS x /carbon nanotubes/Pt catalyst (0.55 wt% Pt loading) is developed, which exhibits a low overpotential of 25 mV at a current density of 10 mA cm-2, a low Tafel slope of 27 mV dec-1, and excellent stability under acidic conditions.	Platinum	85-87	MOS proto-oncogene, serine/threonine kinase	Homo sapiens	61-64
30637494-4	2019	Under the optimized conditions, the limits of detection for Pt, Au and Bi are 8.6, 4.4 and 3.4 ng L-1, respectively.	Platinum	60-62	immunoglobulin kappa variable 1-16	Homo sapiens	98-101
30886796-2	2019	Here, a sacrificial-counter-electrode method to synthesize a MoS x /carbon nanotubes/Pt catalyst (0.55 wt% Pt loading) is developed, which exhibits a low overpotential of 25 mV at a current density of 10 mA cm-2, a low Tafel slope of 27 mV dec-1, and excellent stability under acidic conditions.	Platinum	85-87	deleted in esophageal cancer 1	Homo sapiens	240-245
30886796-3	2019	The theory calculations and experimental results confirm the high hydrogen evolution activity that is likely due to the fact that the S atoms in MoS x can be substituted with O atoms during a potential cycling process when using Pt as a counter-electrode, where the O atoms act as bridges between the catalytic PtO x particles and the MoS x support to generate a MoS x -O-PtO x structure, allowing the Pt atoms to donate more electrons thus facilitating the hydrogen evolution reaction process.	Platinum	229-231	MOS proto-oncogene, serine/threonine kinase	Homo sapiens	145-148
30631938-0	2019	Colorimetric and electrochemical (dual) thrombin assay based on the use of a platinum nanoparticle modified metal-organic framework (type Fe-MIL-88) acting as a peroxidase mimic.	Platinum	77-85	coagulation factor II, thrombin	Homo sapiens	40-48
30631938-7	2019	Graphical abstract Schematic representation of a colorimetric and electrochemical (dual) thrombin assay based on the use of a platinum nanoparticle modified metal-organic framework for color development and hybridization chain reaction for electrochemical signal.	Platinum	126-134	coagulation factor II, thrombin	Homo sapiens	89-97
30124494-1	2019	BACKGROUND: Combination therapy with fluorouracil, platinum, and trastuzumab (Tmab) is the first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer, and there is currently no established second-line therapy.	Platinum	51-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-156
30376305-4	2019	X-ray protein crystallography of the {[Pt(ppy)(PPh3)]/ubiquitin} conjugate revealed direct bonding of the platinum center to unique histidine-68 residue through the nitrogen atom of imidazole function, the coordination being also supported by noncovalent interaction of the ligands with the protein secondary structure.	Platinum	106-114	protein phosphatase 4 catalytic subunit	Homo sapiens	47-51
30755819-0	2019	Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer.	Platinum	95-103	mucin 16, cell surface associated	Homo sapiens	6-11
30755819-0	2019	Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer.	Platinum	95-103	leptin	Homo sapiens	24-30
30124494-1	2019	BACKGROUND: Combination therapy with fluorouracil, platinum, and trastuzumab (Tmab) is the first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer, and there is currently no established second-line therapy.	Platinum	51-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
30228154-10	2019	CONCLUSIONS: Our study highlights circulating exosomal miR-425-3p as a potential biomarker for improved predictions of the clinical response to platinum-based chemotherapy in patients with NSCLC.	Platinum	144-152	microRNA 4253	Homo sapiens	55-65
30228154-11	2019	IMPACT: This study provides the first evidence that miR-425-3p in NSCLC patient-derived exosomes can be a marker for predicating the clinical response to platinum-based chemotherapy.	Platinum	154-162	microRNA 4253	Homo sapiens	52-62
30228154-0	2019	Prognostic Role of Circulating Exosomal miR-425-3p for the Response of NSCLC to Platinum-Based Chemotherapy.	Platinum	80-88	microRNA 4253	Homo sapiens	40-50
30259082-0	2019	CD19+ tumor-infiltrating B-cells prime CD4+ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer.	Platinum	72-80	CD19 molecule	Homo sapiens	0-26
30339780-3	2019	This organometallic complex induced p53-independent cytotoxicity and reduced size and vascularization of patients-derived tumor explants that are resistant to platinum drugs.	Platinum	159-167	tumor protein p53	Homo sapiens	36-39
30259082-4	2019	We evaluated the survival benefit of platinum-based chemotherapy according to CD19+ TIB.	Platinum	37-45	CD19 molecule	Homo sapiens	78-82
30259082-12	2019	CONCLUSION: CD19+ TIB was identified as an independent prognostic factor, which could predict for post-surgery survival and platinum-based ACT benefits in MIBC.	Platinum	124-132	CD19 molecule	Homo sapiens	12-16
30565086-8	2019	In cases of progression after platinum-based therapy, PD-1/PD-L1 inhibitors are standard alternatives.	Platinum	30-38	programmed cell death 1	Homo sapiens	54-58
30565086-8	2019	In cases of progression after platinum-based therapy, PD-1/PD-L1 inhibitors are standard alternatives.	Platinum	30-38	CD274 molecule	Homo sapiens	59-64
31798335-0	2019	The endogenous erythropoietin in correlation with other erythrocytic parameters in patients with head and neck squamous cell carcinoma treated with platinum-based induction chemotherapy.	Platinum	148-156	erythropoietin	Homo sapiens	15-29
30220072-8	2019	RESULTS: Peak platinum urinary concentrations correlated with urinary levels of KIM-1, calbindin, clusterin, GST-pi, beta2M, albumin, NGAL, osteopontin, clusterin, cystatin C, and TFF3 at day 10.	Platinum	14-22	hepatitis A virus cellular receptor 1	Homo sapiens	80-85
29984656-0	2019	Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors.	Platinum	76-84	protein tyrosine kinase 2	Homo sapiens	0-21
29984656-3	2019	Most recently, a new role has emerged for FAK in promoting resistance to taxane and platinum-based therapy in ovarian and other cancers.	Platinum	84-92	protein tyrosine kinase 2	Homo sapiens	42-45
30220072-8	2019	RESULTS: Peak platinum urinary concentrations correlated with urinary levels of KIM-1, calbindin, clusterin, GST-pi, beta2M, albumin, NGAL, osteopontin, clusterin, cystatin C, and TFF3 at day 10.	Platinum	14-22	calbindin 1	Homo sapiens	87-96
30220072-8	2019	RESULTS: Peak platinum urinary concentrations correlated with urinary levels of KIM-1, calbindin, clusterin, GST-pi, beta2M, albumin, NGAL, osteopontin, clusterin, cystatin C, and TFF3 at day 10.	Platinum	14-22	clusterin	Homo sapiens	98-107
30220072-8	2019	RESULTS: Peak platinum urinary concentrations correlated with urinary levels of KIM-1, calbindin, clusterin, GST-pi, beta2M, albumin, NGAL, osteopontin, clusterin, cystatin C, and TFF3 at day 10.	Platinum	14-22	lipocalin 2	Homo sapiens	134-138
30220072-8	2019	RESULTS: Peak platinum urinary concentrations correlated with urinary levels of KIM-1, calbindin, clusterin, GST-pi, beta2M, albumin, NGAL, osteopontin, clusterin, cystatin C, and TFF3 at day 10.	Platinum	14-22	secreted phosphoprotein 1	Homo sapiens	140-151
30220072-8	2019	RESULTS: Peak platinum urinary concentrations correlated with urinary levels of KIM-1, calbindin, clusterin, GST-pi, beta2M, albumin, NGAL, osteopontin, clusterin, cystatin C, and TFF3 at day 10.	Platinum	14-22	clusterin	Homo sapiens	153-162
30220072-8	2019	RESULTS: Peak platinum urinary concentrations correlated with urinary levels of KIM-1, calbindin, clusterin, GST-pi, beta2M, albumin, NGAL, osteopontin, clusterin, cystatin C, and TFF3 at day 10.	Platinum	14-22	cystatin C	Homo sapiens	164-174
30220072-8	2019	RESULTS: Peak platinum urinary concentrations correlated with urinary levels of KIM-1, calbindin, clusterin, GST-pi, beta2M, albumin, NGAL, osteopontin, clusterin, cystatin C, and TFF3 at day 10.	Platinum	14-22	trefoil factor 3	Homo sapiens	180-184
30220072-9	2019	Unbound platinum plasma concentrations at 2 h also correlated with urinary clusterin, beta2M, cystatin C, NGAL, osteopontin, and TFF3 at day 3.	Platinum	8-16	clusterin	Homo sapiens	75-84
30220072-9	2019	Unbound platinum plasma concentrations at 2 h also correlated with urinary clusterin, beta2M, cystatin C, NGAL, osteopontin, and TFF3 at day 3.	Platinum	8-16	cystatin C	Homo sapiens	94-104
30220072-9	2019	Unbound platinum plasma concentrations at 2 h also correlated with urinary clusterin, beta2M, cystatin C, NGAL, osteopontin, and TFF3 at day 3.	Platinum	8-16	lipocalin 2	Homo sapiens	106-110
30220072-9	2019	Unbound platinum plasma concentrations at 2 h also correlated with urinary clusterin, beta2M, cystatin C, NGAL, osteopontin, and TFF3 at day 3.	Platinum	8-16	secreted phosphoprotein 1	Homo sapiens	112-123
30220072-9	2019	Unbound platinum plasma concentrations at 2 h also correlated with urinary clusterin, beta2M, cystatin C, NGAL, osteopontin, and TFF3 at day 3.	Platinum	8-16	trefoil factor 3	Homo sapiens	129-133
29961768-1	2019	PURPOSE: Germline variants in double-strand DNA damage repair (dsDDR) genes (e.g., BRCA1/2) predispose to pancreatic adenocarcinoma (PDAC) and may predict sensitivity to platinum-based chemotherapy and poly(ADP) ribose polymerase (PARP) inhibitors.	Platinum	170-178	BRCA1 DNA repair associated	Homo sapiens	83-90
30522358-0	2019	XPG polymorphisms and their association with lung cancer susceptibility, overall survival and response in North Indian patients treated with platinum-based doublet chemotherapy.	Platinum	141-149	ERCC excision repair 5, endonuclease	Homo sapiens	0-3
29961768-1	2019	PURPOSE: Germline variants in double-strand DNA damage repair (dsDDR) genes (e.g., BRCA1/2) predispose to pancreatic adenocarcinoma (PDAC) and may predict sensitivity to platinum-based chemotherapy and poly(ADP) ribose polymerase (PARP) inhibitors.	Platinum	170-178	poly(ADP-ribose) polymerase 1	Homo sapiens	202-229
29961768-1	2019	PURPOSE: Germline variants in double-strand DNA damage repair (dsDDR) genes (e.g., BRCA1/2) predispose to pancreatic adenocarcinoma (PDAC) and may predict sensitivity to platinum-based chemotherapy and poly(ADP) ribose polymerase (PARP) inhibitors.	Platinum	170-178	poly(ADP-ribose) polymerase 1	Homo sapiens	231-235
30719133-0	2019	High Expression Levels of AGGF1 and MFAP4 Predict Primary Platinum-Based Chemoresistance and are Associated with Adverse Prognosis in Patients with Serous Ovarian Cancer.	Platinum	58-66	angiogenic factor with G-patch and FHA domains 1	Homo sapiens	26-31
30640701-13	2019	Hormone antagonism was the preferred treatment for the first platinum resistant recurrence (54%), while a BRAF inhibitor was the preferred agent in platinum resistant recurrence in the presence of a known BRAF mutation (56%).	Platinum	148-156	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	106-110
30719133-0	2019	High Expression Levels of AGGF1 and MFAP4 Predict Primary Platinum-Based Chemoresistance and are Associated with Adverse Prognosis in Patients with Serous Ovarian Cancer.	Platinum	58-66	microfibril associated protein 4	Homo sapiens	36-41
30719133-7	2019	AGGF1 and MFAP4 were found highly expressed in patients with platinum-resistant SOC and independently predicted platinum resistance.	Platinum	61-69	angiogenic factor with G-patch and FHA domains 1	Homo sapiens	0-5
30719133-7	2019	AGGF1 and MFAP4 were found highly expressed in patients with platinum-resistant SOC and independently predicted platinum resistance.	Platinum	61-69	microfibril associated protein 4	Homo sapiens	10-15
30719133-7	2019	AGGF1 and MFAP4 were found highly expressed in patients with platinum-resistant SOC and independently predicted platinum resistance.	Platinum	112-120	angiogenic factor with G-patch and FHA domains 1	Homo sapiens	0-5
30719133-7	2019	AGGF1 and MFAP4 were found highly expressed in patients with platinum-resistant SOC and independently predicted platinum resistance.	Platinum	112-120	microfibril associated protein 4	Homo sapiens	10-15
30719133-12	2019	Therefore, AGGF1 and MFAP4 are potential predictive biomarkers for response to platinum-based chemotherapy and survival outcomes in SOC.	Platinum	79-87	angiogenic factor with G-patch and FHA domains 1	Homo sapiens	11-16
30719133-12	2019	Therefore, AGGF1 and MFAP4 are potential predictive biomarkers for response to platinum-based chemotherapy and survival outcomes in SOC.	Platinum	79-87	microfibril associated protein 4	Homo sapiens	21-26
30305342-8	2019	In TNBC cell line data, platinum sensitivity was recapitulated, and a sensitivity to the inhibition of the phosphatase PPM1D was revealed.	Platinum	24-32	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	119-124
31292359-2	2019	For advanced NSCLC harboring activating EGFR mutations, an EGFR-TKI is preferably prescribed as it provides a superior survival benefit over platinum-based chemotherapy.	Platinum	141-149	epidermal growth factor receptor	Homo sapiens	59-63
30301863-7	2019	Corroborating the basis of sensitivity, transcriptional profiling of platinum-resistant ARID1A-mutated HT1197 cells treated with panobinostat reveals negative enrichment for both cyto-proliferative (MYC and E2F targets) and DNA repair gene sets, and positive enrichment for TP53 and inflammatory gene sets.	Platinum	69-77	AT-rich interaction domain 1A	Homo sapiens	88-94
30359932-0	2019	A novel platinum complex containing a piplartine derivative exhibits enhanced cytotoxicity, causes oxidative stress and triggers apoptotic cell death by ERK/p38 pathway in human acute promyelocytic leukemia HL-60 cells.	Platinum	8-16	mitogen-activated protein kinase 3	Homo sapiens	153-156
30301863-7	2019	Corroborating the basis of sensitivity, transcriptional profiling of platinum-resistant ARID1A-mutated HT1197 cells treated with panobinostat reveals negative enrichment for both cyto-proliferative (MYC and E2F targets) and DNA repair gene sets, and positive enrichment for TP53 and inflammatory gene sets.	Platinum	69-77	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	199-202
30301863-7	2019	Corroborating the basis of sensitivity, transcriptional profiling of platinum-resistant ARID1A-mutated HT1197 cells treated with panobinostat reveals negative enrichment for both cyto-proliferative (MYC and E2F targets) and DNA repair gene sets, and positive enrichment for TP53 and inflammatory gene sets.	Platinum	69-77	tumor protein p53	Homo sapiens	274-278
32030362-3	2019	Tumors deficient in deoxyribonucleic acid (DNA) damage repair mechanisms such as BRCA mutants show better responses to platinum based agents, however, such tumors can utilize the poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) pathway as a salvage mechanism.	Platinum	119-127	BRCA1 DNA repair associated	Homo sapiens	81-85
30359932-0	2019	A novel platinum complex containing a piplartine derivative exhibits enhanced cytotoxicity, causes oxidative stress and triggers apoptotic cell death by ERK/p38 pathway in human acute promyelocytic leukemia HL-60 cells.	Platinum	8-16	mitogen-activated protein kinase 1	Homo sapiens	157-160
30359932-2	2019	In the present study, we synthesized a novel platinum complex containing a piplartine derivative cis-[PtCl(PIP-OH)(PPh3)2]PF6 (where, PIP-OH = piplartine demethylated derivative; and PPh3 = triphenylphosphine) with enhanced cytotoxicity in different cancer cells, and investigated its apoptotic action in human promyelocytic leukemia HL-60 cells.	Platinum	45-53	prolactin induced protein	Homo sapiens	107-110
30576195-1	2018	We report an observation of a quantum tunneling effect in a proton-transfer (PT) during potential-induced transformation of dioxygen on a platinum electrode in a low overpotential (eta) region at 298 K. However, this quantum process is converted to the classical PT scheme in the high eta region.	Platinum	138-146	endothelin receptor type A	Homo sapiens	181-184
30810094-1	2019	The objective of this study is to evaluate the relationship between discoidin domain receptor 2 (DDR2) and miR-182 expression with response to platinum-based chemotherapy and survival in women with high-grade serous ovarian cancer (HGSOC).	Platinum	143-151	discoidin domain receptor tyrosine kinase 2	Homo sapiens	68-95
30810094-1	2019	The objective of this study is to evaluate the relationship between discoidin domain receptor 2 (DDR2) and miR-182 expression with response to platinum-based chemotherapy and survival in women with high-grade serous ovarian cancer (HGSOC).	Platinum	143-151	discoidin domain receptor tyrosine kinase 2	Homo sapiens	97-101
30810094-1	2019	The objective of this study is to evaluate the relationship between discoidin domain receptor 2 (DDR2) and miR-182 expression with response to platinum-based chemotherapy and survival in women with high-grade serous ovarian cancer (HGSOC).	Platinum	143-151	microRNA 182	Homo sapiens	107-114
30643056-0	2018	[Research progress of copper transporter 1 in platinum-based chemotherapy].	Platinum	46-54	solute carrier family 31 member 1	Homo sapiens	22-42
30643056-3	2018	CTR1 is also the major platinum influx transporter and plays a key role in platinum resistance.	Platinum	23-31	solute carrier family 31 member 1	Homo sapiens	0-4
30643056-4	2018	The expression, polymorphism, and degradation of CTR1 affect platinum resistance in tumors.	Platinum	61-69	solute carrier family 31 member 1	Homo sapiens	49-53
30643056-5	2018	Therefore, CTR1 may be a potential predictive biomarker of platinum resistance and a therapeutic target for overcoming platinum resistance.	Platinum	59-67	solute carrier family 31 member 1	Homo sapiens	11-15
30643056-5	2018	Therefore, CTR1 may be a potential predictive biomarker of platinum resistance and a therapeutic target for overcoming platinum resistance.	Platinum	119-127	solute carrier family 31 member 1	Homo sapiens	11-15
30566445-9	2018	The addition of PT-2385 abolished the increase in lung volume and endothelial proliferation in response to VEGFR1.	Platinum	16-18	FMS-like tyrosine kinase 1	Mus musculus	107-113
30518684-3	2018	Inflammatory cytokine IL-6 is elevated in residual tumors after platinum treatment, and we hypothesized that IL-6 plays a critical role in platinum-induced OCSC enrichment.	Platinum	139-147	interleukin 6	Homo sapiens	109-113
30518684-5	2018	We show that platinum induces IL-6 secretion by cancer-associated fibroblasts in the tumor microenvironment, promoting OCSC enrichment in residual tumors after chemotherapy.	Platinum	13-21	interleukin 6	Homo sapiens	30-34
30359932-2	2019	In the present study, we synthesized a novel platinum complex containing a piplartine derivative cis-[PtCl(PIP-OH)(PPh3)2]PF6 (where, PIP-OH = piplartine demethylated derivative; and PPh3 = triphenylphosphine) with enhanced cytotoxicity in different cancer cells, and investigated its apoptotic action in human promyelocytic leukemia HL-60 cells.	Platinum	45-53	caveolin 1	Homo sapiens	115-119
30359932-2	2019	In the present study, we synthesized a novel platinum complex containing a piplartine derivative cis-[PtCl(PIP-OH)(PPh3)2]PF6 (where, PIP-OH = piplartine demethylated derivative; and PPh3 = triphenylphosphine) with enhanced cytotoxicity in different cancer cells, and investigated its apoptotic action in human promyelocytic leukemia HL-60 cells.	Platinum	45-53	sperm associated antigen 17	Homo sapiens	122-125
30359932-2	2019	In the present study, we synthesized a novel platinum complex containing a piplartine derivative cis-[PtCl(PIP-OH)(PPh3)2]PF6 (where, PIP-OH = piplartine demethylated derivative; and PPh3 = triphenylphosphine) with enhanced cytotoxicity in different cancer cells, and investigated its apoptotic action in human promyelocytic leukemia HL-60 cells.	Platinum	45-53	prolactin induced protein	Homo sapiens	134-137
30359932-2	2019	In the present study, we synthesized a novel platinum complex containing a piplartine derivative cis-[PtCl(PIP-OH)(PPh3)2]PF6 (where, PIP-OH = piplartine demethylated derivative; and PPh3 = triphenylphosphine) with enhanced cytotoxicity in different cancer cells, and investigated its apoptotic action in human promyelocytic leukemia HL-60 cells.	Platinum	45-53	caveolin 1	Homo sapiens	183-187
30359932-3	2019	The structure of PIP-OH ligand was characterized by X-ray crystallographic analysis and the resulting platinum complex was characterized by infrared, molar conductance measurements, elemental analysis and NMR experiments.	Platinum	102-110	prolactin induced protein	Homo sapiens	17-20
30236806-4	2018	In the presence of Hg2+, MBs-DNA1 can hybridize with platinum nanoparticles (PtNPs)-functionalized DNA2 (DNA2-PtNPs) via T-Hg2+-T binding.	Platinum	53-61	DNA replication helicase/nuclease 2	Homo sapiens	99-103
30236806-4	2018	In the presence of Hg2+, MBs-DNA1 can hybridize with platinum nanoparticles (PtNPs)-functionalized DNA2 (DNA2-PtNPs) via T-Hg2+-T binding.	Platinum	53-61	DNA replication helicase/nuclease 2	Homo sapiens	105-115
30512935-5	2018	As exemplified in this work, upon loading Pt nanoparticles into porous PIL microstructures, the hybrid sensor showed outstanding performance, bearing both a high sensitivity and a wide detection range.	Platinum	42-44	serpin family A member 2 (gene/pseudogene)	Homo sapiens	71-74
30518684-0	2018	IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells.	Platinum	14-22	interleukin 6	Homo sapiens	0-4
30518684-3	2018	Inflammatory cytokine IL-6 is elevated in residual tumors after platinum treatment, and we hypothesized that IL-6 plays a critical role in platinum-induced OCSC enrichment.	Platinum	64-72	interleukin 6	Homo sapiens	22-26
30518684-9	2018	We conclude that IL-6 signaling blockade combined with an HMA can eliminate OCSC after platinum treatment, supporting this strategy to prevent tumor recurrence after standard chemotherapy.	Platinum	87-95	interleukin 6	Homo sapiens	17-21
30576195-1	2018	We report an observation of a quantum tunneling effect in a proton-transfer (PT) during potential-induced transformation of dioxygen on a platinum electrode in a low overpotential (eta) region at 298 K. However, this quantum process is converted to the classical PT scheme in the high eta region.	Platinum	138-146	endothelin receptor type A	Homo sapiens	285-288
30278151-4	2018	These 2 anticancer Pd and Pt complexes were activated against chronic myelogenous leukemia cell line K562, so that 50% cytotoxic concentration values of 16 and 26 muM for Pd and Pt complexes, respectively, were observed, which were much lower than that of cisplatin (154 muM).	Platinum	26-28	latexin	Homo sapiens	163-166
30346805-0	2018	Genetic Variants in the Wingless Antagonist Genes (sFRP, DKK, and Axin2) Predict the Overall Survival and Prognosis of North Indian Lung Cancer Patients Treated with Platinum-Based Doublet Chemotherapy.	Platinum	166-174	axin 2	Homo sapiens	66-71
30396856-0	2018	Salidroside improves the hypoxic tumor microenvironment and reverses the drug resistance of platinum drugs via HIF-1alpha signaling pathway.	Platinum	92-100	hypoxia inducible factor 1 subunit alpha	Homo sapiens	111-121
30367559-0	2018	Single-cell RNA-seq analysis reveals the platinum resistance gene COX7B and the surrogate marker CD63.	Platinum	41-49	cytochrome c oxidase subunit 7B	Homo sapiens	66-71
30367559-3	2018	Here, mapping the transcriptome of cancers treated with CDDP by scRNA-seq, we uncovered a novel gene, COX7B, associated with platinum-resistance, and surrogate marker, CD63.	Platinum	125-133	cytochrome c oxidase subunit 7B	Homo sapiens	102-107
30367559-7	2018	Analyzing scRNA-seq data from platinum-naive cancer cells demonstrated a low-COX7B subclone that could be sorted out from bulk cancer cells by assaying CD63.	Platinum	30-38	cytochrome c oxidase subunit 7B	Homo sapiens	77-82
30367559-8	2018	This low-COX7B subclone behaved as cells with acquired platinum-resistance when challenged to CDDP.	Platinum	55-63	cytochrome c oxidase subunit 7B	Homo sapiens	9-14
30367559-9	2018	Our results offer a new transcriptome landscape of platinum-resistance that provides valuable insights into chemosensitivity and drug resistance in cancers, and we identify a novel platinum resistance gene, COX7B, and a surrogate marker, CD63.	Platinum	51-59	cytochrome c oxidase subunit 7B	Homo sapiens	207-212
30367559-9	2018	Our results offer a new transcriptome landscape of platinum-resistance that provides valuable insights into chemosensitivity and drug resistance in cancers, and we identify a novel platinum resistance gene, COX7B, and a surrogate marker, CD63.	Platinum	51-59	CD63 molecule	Homo sapiens	238-242
30367559-9	2018	Our results offer a new transcriptome landscape of platinum-resistance that provides valuable insights into chemosensitivity and drug resistance in cancers, and we identify a novel platinum resistance gene, COX7B, and a surrogate marker, CD63.	Platinum	181-189	cytochrome c oxidase subunit 7B	Homo sapiens	207-212
30278151-4	2018	These 2 anticancer Pd and Pt complexes were activated against chronic myelogenous leukemia cell line K562, so that 50% cytotoxic concentration values of 16 and 26 muM for Pd and Pt complexes, respectively, were observed, which were much lower than that of cisplatin (154 muM).	Platinum	26-28	latexin	Homo sapiens	271-274
30107189-1	2018	We explored the correlation of tumor necrosis factor alpha-induced protein 8 (TNFAIP8) with platinum resistance in ovarian cancers treated with neoadjuvant chemotherapy (NACT).	Platinum	92-100	TNF alpha induced protein 8	Homo sapiens	78-85
30109500-0	2018	MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance.	Platinum	99-107	mechanistic target of rapamycin kinase	Homo sapiens	41-45
30107189-1	2018	We explored the correlation of tumor necrosis factor alpha-induced protein 8 (TNFAIP8) with platinum resistance in ovarian cancers treated with neoadjuvant chemotherapy (NACT).	Platinum	92-100	TNF alpha induced protein 8	Homo sapiens	31-76
30527181-0	2018	Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.	Platinum	37-45	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	77-83
30265997-1	2018	Eight new platinum(II) complexes Pt1-Pt8 with substituted 3-(2"-benzimidazolyl) coumarins were successfully synthesized and characterized by single crystal X-ray diffraction analysis, nuclear magnetic resonance spectroscopy (NMR), electrospray ionization-mass spectrometry (ESI-MS), infrared spectrophotometry (IR) and elemental analysis.	Platinum	10-18	zinc finger protein 77	Homo sapiens	33-36
30527181-10	2018	CONCLUSION: Our results reveal an association between UGT1A1 polymorphisms and toxicity of platinum-etoposide doublet therapy in SCLC patients, suggesting that close monitoring for toxicity, especially nephrotoxicity, is warranted for patients with such variant alleles receiving this treatment.	Platinum	91-99	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	54-60
30482243-2	2018	Based on the mechanisms of CSCC carcinogenesis has been postulated that these tumors may be amenable to PD-1/PD-L1 blockade.This case illustrates a patient with CSCC with nodal involvement and pulmonary metastases, refractory to two lines of platinum-based regimens and salvage surgery, for whom treatment with nivolumab was recommended.	Platinum	242-250	programmed cell death 1	Homo sapiens	104-108
30076413-0	2018	RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients.	Platinum	117-125	RAN binding protein 9	Homo sapiens	0-6
30076413-3	2018	Here, we provide a molecular rationale for the stratification of NSCLC patients potentially benefitting from platinum compounds based on the expression levels of RANBP9, a recently identified player of the cellular DDR.	Platinum	109-117	RAN binding protein 9	Homo sapiens	162-168
30076413-5	2018	Moreover, a retrospective analysis of 132 platinum-treated patients from the multi-centric TAILOR trial showed that RANBP9 overexpression levels are associated with clinical response to platinum compounds [Progression Free Survival Hazard Ratio (RANBP9 high vs low) 1.73, 95% CI 1.15-2.59, p = 0.0084; Overall Survival HR (RANBP9 high vs low) 1.99, 95% CI 1.27-3.11, p = 0.003].	Platinum	42-50	RAN binding protein 9	Homo sapiens	116-122
30076413-5	2018	Moreover, a retrospective analysis of 132 platinum-treated patients from the multi-centric TAILOR trial showed that RANBP9 overexpression levels are associated with clinical response to platinum compounds [Progression Free Survival Hazard Ratio (RANBP9 high vs low) 1.73, 95% CI 1.15-2.59, p = 0.0084; Overall Survival HR (RANBP9 high vs low) 1.99, 95% CI 1.27-3.11, p = 0.003].	Platinum	42-50	RAN binding protein 9	Homo sapiens	246-252
30076413-5	2018	Moreover, a retrospective analysis of 132 platinum-treated patients from the multi-centric TAILOR trial showed that RANBP9 overexpression levels are associated with clinical response to platinum compounds [Progression Free Survival Hazard Ratio (RANBP9 high vs low) 1.73, 95% CI 1.15-2.59, p = 0.0084; Overall Survival HR (RANBP9 high vs low) 1.99, 95% CI 1.27-3.11, p = 0.003].	Platinum	42-50	RAN binding protein 9	Homo sapiens	246-252
30076413-5	2018	Moreover, a retrospective analysis of 132 platinum-treated patients from the multi-centric TAILOR trial showed that RANBP9 overexpression levels are associated with clinical response to platinum compounds [Progression Free Survival Hazard Ratio (RANBP9 high vs low) 1.73, 95% CI 1.15-2.59, p = 0.0084; Overall Survival HR (RANBP9 high vs low) 1.99, 95% CI 1.27-3.11, p = 0.003].	Platinum	186-194	RAN binding protein 9	Homo sapiens	116-122
30076413-5	2018	Moreover, a retrospective analysis of 132 platinum-treated patients from the multi-centric TAILOR trial showed that RANBP9 overexpression levels are associated with clinical response to platinum compounds [Progression Free Survival Hazard Ratio (RANBP9 high vs low) 1.73, 95% CI 1.15-2.59, p = 0.0084; Overall Survival HR (RANBP9 high vs low) 1.99, 95% CI 1.27-3.11, p = 0.003].	Platinum	186-194	RAN binding protein 9	Homo sapiens	246-252
30076413-5	2018	Moreover, a retrospective analysis of 132 platinum-treated patients from the multi-centric TAILOR trial showed that RANBP9 overexpression levels are associated with clinical response to platinum compounds [Progression Free Survival Hazard Ratio (RANBP9 high vs low) 1.73, 95% CI 1.15-2.59, p = 0.0084; Overall Survival HR (RANBP9 high vs low) 1.99, 95% CI 1.27-3.11, p = 0.003].	Platinum	186-194	RAN binding protein 9	Homo sapiens	246-252
30568487-0	2018	A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer.	Platinum	130-138	adrenoceptor beta 2	Homo sapiens	40-66
30568487-11	2018	Conclusion: rs1042713, which is located in the ADRB2 gene, could predict pCR to taxane-and platinum-based neoadjuvant chemotherapy in LABC.	Platinum	91-99	adrenoceptor beta 2	Homo sapiens	47-52
30482243-2	2018	Based on the mechanisms of CSCC carcinogenesis has been postulated that these tumors may be amenable to PD-1/PD-L1 blockade.This case illustrates a patient with CSCC with nodal involvement and pulmonary metastases, refractory to two lines of platinum-based regimens and salvage surgery, for whom treatment with nivolumab was recommended.	Platinum	242-250	CD274 molecule	Homo sapiens	109-114
30482243-2	2018	Based on the mechanisms of CSCC carcinogenesis has been postulated that these tumors may be amenable to PD-1/PD-L1 blockade.This case illustrates a patient with CSCC with nodal involvement and pulmonary metastases, refractory to two lines of platinum-based regimens and salvage surgery, for whom treatment with nivolumab was recommended.	Platinum	242-250	nodal growth differentiation factor	Homo sapiens	171-176
30478317-8	2018	Furthermore, CBX2 knockdown re-sensitized cells to platinum-based chemotherapy.	Platinum	51-59	chromobox 2	Homo sapiens	13-17
30498397-18	2018	Conclusions: gammaH2AX expression, but not wild type p53, may potentially serve as a biomarker of resistance to platinum therapeutics in soft tissue sarcomas.	Platinum	112-120	H2A.X variant histone	Mus musculus	13-22
30596104-3	2018	Therefore, the variable region of Pan was fused to a fragment of Pseudomonas exotoxin A (PE38) to create the immunotoxin, denoted as Ptoxin (PT).	Platinum	141-143	adenosine deaminase 2	Homo sapiens	34-37
30387603-1	2018	Four platinum(II) complexes Pt-1, Pt-2, Pt-3, and Pt-4 with the isomeric donor-acceptor (D-A) conjugated ligand framework are designed and prepared, and their thermal, photophysical, and electrochemical characteristics investigated.	Platinum	5-13	zinc finger protein 77	Homo sapiens	28-32
30280635-1	2018	BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on &gt;=50% of tumor cells).	Platinum	103-111	CD274 molecule	Homo sapiens	194-199
32254583-3	2018	Herein, a novel SMND of carboplatin-lauric acid nanoparticles (CBP-LA NPs) was developed for the first time to reduce GSH-mediated platinum resistance and improve the antitumor efficiency of platinum(ii).	Platinum	131-139	CREB binding protein	Homo sapiens	63-66
32254583-3	2018	Herein, a novel SMND of carboplatin-lauric acid nanoparticles (CBP-LA NPs) was developed for the first time to reduce GSH-mediated platinum resistance and improve the antitumor efficiency of platinum(ii).	Platinum	191-199	CREB binding protein	Homo sapiens	63-66
32254583-10	2018	The intracellular glutathione determination and the Pt-DNA adduct assay revealed that CBP-LA NPs could reduce the intracellular GSH levels and improve the efficiency of platinum chelating with DNA, which would overcome GSH-mediated platinum(ii) resistance.	Platinum	52-54	CREB binding protein	Homo sapiens	86-89
32254583-10	2018	The intracellular glutathione determination and the Pt-DNA adduct assay revealed that CBP-LA NPs could reduce the intracellular GSH levels and improve the efficiency of platinum chelating with DNA, which would overcome GSH-mediated platinum(ii) resistance.	Platinum	169-177	CREB binding protein	Homo sapiens	86-89
30387603-1	2018	Four platinum(II) complexes Pt-1, Pt-2, Pt-3, and Pt-4 with the isomeric donor-acceptor (D-A) conjugated ligand framework are designed and prepared, and their thermal, photophysical, and electrochemical characteristics investigated.	Platinum	5-13	zinc finger protein 135	Homo sapiens	40-44
30581498-10	2018	Conclusions: This meta-analysis suggested that the ERCC2 rs1799793 polymorphism might be a predictor of prognosis in gastric cancer patients subjected to platinum-based chemotherapy.	Platinum	154-162	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	51-56
30339378-2	2018	In this study, a highly sensitive sandwich enzyme-linked immunosorbent assay (sELISA) based on a specific polyclonal antibody against human IgE linear epitopes of BLG and an anti-BLG polyclonal antibody-platinum nanoparticles probe was described for detection of BLG.	Platinum	203-211	immunoglobulin heavy constant epsilon	Homo sapiens	140-143
30360067-0	2018	L12 Atomic Ordered Substrate Enhanced Pt-Skin Cu3Pt Catalyst for Efficient Oxygen Reduction Reaction.	Platinum	38-40	ribosomal protein L12	Homo sapiens	0-3
30360067-2	2018	However, there still lacks a systematic study on revealing the influence of low-Pt-content intermetallic substrates (L12-PtM3).	Platinum	80-82	ribosomal protein L12	Homo sapiens	117-120
30207020-1	2018	Infrared multiple photon dissociation spectroscopy (IR-MPD) has been employed to determine the nature of CO2 binding to size-selected platinum cluster anions, Ptn - (n=4-7).	Platinum	134-142	pleiotrophin	Homo sapiens	159-162
30360067-4	2018	The L12 substrate shows a contracted lattice structure and provides Pt-o-Cu3Pt/C with an excellent specific activity of 1.73 mA cm-2, which is 1.4- and 8.4-fold higher than that of Pt-d-Cu3Pt/C and commercial Pt/C, respectively.	Platinum	68-70	ribosomal protein L12	Homo sapiens	4-7
30360084-2	2018	Herein, hydrogen thermal pretreatment of the Pt single atoms on porous nanorods of CeO2 (Pt1/ PN-CeO2) induced the formation of isolated bimetallic PtCe sites as a new type of active center for CO oxidation.	Platinum	45-47	zinc finger protein 77	Homo sapiens	89-92
30318551-4	2018	By monitoring the surface-enhanced Raman signal change of isonitrile probes in the hot spot, it was revealed that gold and platinum nanoparticles show opposite directions of charge transfer over the same formaldehyde treatment.	Platinum	123-131	alcohol dehydrogenase iron containing 1	Homo sapiens	83-86
30217639-3	2018	PATIENTS AND METHODS: We retrospectively reviewed data from 1190 patients with KRAS mutations who underwent first-line platinum-based chemotherapy for stage IV NSCLC.	Platinum	119-127	KRAS proto-oncogene, GTPase	Homo sapiens	79-83
30167862-4	2018	Platinum-based chemotherapy synergizes with ErbB-targeted CAR T cells (named T4), significantly reducing tumor burden in mice.	Platinum	0-8	epidermal growth factor receptor	Mus musculus	44-48
30238677-2	2018	Significantly lower overpotentials are required for PdP2 @CB (27.5 mV in 0.5 m H2 SO4 ; 35.4 mV in 1 m KOH; 84.6 mV in 1 m PBS) to achieve a HER electrocatalytic current density of 10 mA cm-2 compared to commercial Pt/CB (30.1 mV in 0.5 m H2 SO4 ; 46.6 mV in 1 m KOH; 122.7 mV in 1 m PBS).	Platinum	215-217	pyruvate dehydrogenase phosphatase catalytic subunit 2	Homo sapiens	52-56
30564353-1	2018	Presented herein is the case of a heavily pretreated patient with high-grade neuroendocrine prostate cancer that achieved a complete metabolic response on platinum-based chemotherapy after treatment with the dual CD-47 and SIRP-alpha inhibitor, RRx-001, in a Phase II clinical trial.	Platinum	155-163	CD47 molecule	Homo sapiens	213-218
30564353-1	2018	Presented herein is the case of a heavily pretreated patient with high-grade neuroendocrine prostate cancer that achieved a complete metabolic response on platinum-based chemotherapy after treatment with the dual CD-47 and SIRP-alpha inhibitor, RRx-001, in a Phase II clinical trial.	Platinum	155-163	signal regulatory protein alpha	Homo sapiens	223-233
30228165-5	2018	OCs driven by BRCA1/2, FA-associated, and BRCAness germline mutations have a demonstrated sensitivity to PARP inhibitors due to underlying deficiencies in DNA homologous recombination; however, clinical responses are often partial and highly dependent on platinum sensitivity.	Platinum	255-263	poly(ADP-ribose) polymerase 1	Homo sapiens	105-109
30405211-0	2018	Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.	Platinum	79-87	cytidine deaminase	Homo sapiens	0-18
30405211-2	2018	In our previous retrospective study, CDA enzymatic activity was the strongest prognostic biomarker of the activity and efficacy of platinum/gemcitabine combinations.	Platinum	131-139	cytidine deaminase	Homo sapiens	37-40
29863757-4	2018	This review will introduce to you a few classes of phosphorescent materials based on tridentate and tetradentate cycloplatinated complexes and related material design strategies, a classical example of thermodynamic and kinetic control of reactions and related platinum-mediated competing sp2 /sp3 C-H activation reactions, an unprecedented regiospecific acylation of cycloplatinated complexes, and a unique platinum-catalyzed oxidant- and additive-free C-H acylation reaction.	Platinum	261-269	Sp2 transcription factor	Homo sapiens	289-292
30217639-10	2018	CONCLUSION: KRAS-specific AAS appears to induce different responses to chemotherapy regimens after first-line platinum-based chemotherapy in advanced NSCLC.	Platinum	110-118	KRAS proto-oncogene, GTPase	Homo sapiens	12-16
30278221-0	2018	PARP inhibition in platinum-based chemotherapy: Chemopotentiation and neuroprotection.	Platinum	19-27	poly(ADP-ribose) polymerase 1	Homo sapiens	0-4
30198802-2	2018	These mutations are mutually exclusive from the more common, epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements and have been associated with poor outcomes and a lower response to platinum-based chemotherapy.	Platinum	217-225	epidermal growth factor receptor	Homo sapiens	61-93
30238837-0	2018	Relationship between GSTP1 rs1695 gene polymorphism and myelosuppression induced by platinum-based drugs: a meta-analysis.	Platinum	84-92	glutathione S-transferase pi 1	Homo sapiens	21-26
30238837-1	2018	Although many previous studies have reported the relationship between GSTP1 rs1695 gene polymorphism and myelosuppression induced by platinum-based drugs, the conclusions are not consistent.	Platinum	133-141	glutathione S-transferase pi 1	Homo sapiens	70-75
30238837-2	2018	The aim of the study is to evaluate the association between granulocytopenia and thrombocytopenia induced by platinum-based drugs and GSTP1 rs1695 gene polymorphism by meta-analysis.	Platinum	109-117	glutathione S-transferase pi 1	Homo sapiens	134-139
30238837-5	2018	GSTP1 rs1695 gene polymorphism showed a significant correlation with granulocytopenia induced by platinum-based drugs (dominant genetic model: OR=1.60, 95% CI=1.19.	Platinum	97-105	glutathione S-transferase pi 1	Homo sapiens	0-5
30238837-11	2018	In conclusion, the GSTP1 rs1695 gene polymorphism is associated with granulocytopenia induced by platinum-based drugs.	Platinum	97-105	glutathione S-transferase pi 1	Homo sapiens	19-24
30610800-7	2018	In FIGO stage IIIC-IV patients with a platinum-free interval (PFI) &gt;12 months had, in comparison with patients with PFI &lt;=12 months, a higher CD68 density score (191.9 +- 95.2 vs. 152.7 +- 69.4, p=0.066) and a lower CD163 density score (106.7 +- 73.3 vs. 154.5 +- 73.9, p=0.011).	Platinum	38-46	CD68 molecule	Homo sapiens	148-152
30610800-7	2018	In FIGO stage IIIC-IV patients with a platinum-free interval (PFI) &gt;12 months had, in comparison with patients with PFI &lt;=12 months, a higher CD68 density score (191.9 +- 95.2 vs. 152.7 +- 69.4, p=0.066) and a lower CD163 density score (106.7 +- 73.3 vs. 154.5 +- 73.9, p=0.011).	Platinum	38-46	CD163 molecule	Homo sapiens	222-227
30149143-11	2018	This study lays the foundations for combining metformin with standard platinum-based chemotherapy in the treatment of KRAS/LKB1 co-mutated NSCLC.	Platinum	70-78	KRAS proto-oncogene, GTPase	Homo sapiens	118-122
30293710-3	2018	Among platinum-sensitive patients, 40% carry a germline or somatic BRCA1/2 mutation.	Platinum	6-14	BRCA1 DNA repair associated	Homo sapiens	67-74
30194007-0	2018	Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer.	Platinum	117-125	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	35-40
30194007-11	2018	CONCLUSION: In conclusion, ERCC1 was identified as a potential biomarker of platinum response overall survival in HGSOC undergoing neoadjuvant HGSOC treatment.	Platinum	76-84	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	27-32
30278221-6	2018	Inhibition of poly(ADP-ribose) polymerase (PARP), a nuclear enzyme activated upon DNA damage, has demonstrated substantial sensory and enteric neuroprotective capacity when administered in combination with platinum chemotherapeutics.	Platinum	206-214	poly(ADP-ribose) polymerase 1	Homo sapiens	14-41
30278221-6	2018	Inhibition of poly(ADP-ribose) polymerase (PARP), a nuclear enzyme activated upon DNA damage, has demonstrated substantial sensory and enteric neuroprotective capacity when administered in combination with platinum chemotherapeutics.	Platinum	206-214	poly(ADP-ribose) polymerase 1	Homo sapiens	43-47
30367052-4	2018	We synthesize gamma-alumina-supported platinum/copper SAA catalysts by incipient wetness co-impregnation method with a high copper to platinum ratio.	Platinum	38-46	serum amyloid A1 cluster	Homo sapiens	54-57
30407287-0	2018	XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy: A systematic review and MOOSE-compliant meta-analysis.	Platinum	80-88	X-ray repair cross complementing 1	Homo sapiens	0-5
30375398-9	2018	In addition, in platinum-treated patients with relapsed ovarian cancer, resistant period was positively correlated with the expression of PANDAR and SFRS2, and inversely associated with expression of p53-Ser15 and PUMA in these clinical tissues.	Platinum	16-24	promoter of CDKN1A antisense DNA damage activated RNA	Homo sapiens	138-144
30375398-9	2018	In addition, in platinum-treated patients with relapsed ovarian cancer, resistant period was positively correlated with the expression of PANDAR and SFRS2, and inversely associated with expression of p53-Ser15 and PUMA in these clinical tissues.	Platinum	16-24	serine and arginine rich splicing factor 2	Homo sapiens	149-154
30375398-9	2018	In addition, in platinum-treated patients with relapsed ovarian cancer, resistant period was positively correlated with the expression of PANDAR and SFRS2, and inversely associated with expression of p53-Ser15 and PUMA in these clinical tissues.	Platinum	16-24	tumor protein p53	Homo sapiens	200-203
30367052-4	2018	We synthesize gamma-alumina-supported platinum/copper SAA catalysts by incipient wetness co-impregnation method with a high copper to platinum ratio.	Platinum	134-142	serum amyloid A1 cluster	Homo sapiens	54-57
30287812-6	2018	Together, our results expose GTF2H1 as a potential novel predictive marker of platinum drug sensitivity in SWI/SNF-deficient cancer cells.	Platinum	78-86	general transcription factor IIH subunit 1	Homo sapiens	29-35
30347698-0	2018	Stereoselective Double Reduction of 3-Methyl-2-cyclohexenone, by Use of Palladium and Platinum Nanoparticles, in Tandem with Alcohol Dehydrogenase.	Platinum	86-94	aldo-keto reductase family 1 member A1	Homo sapiens	125-146
30326862-3	2018	We aimed to evaluate whether PBBPs could have predictive value in HER2-positive ABC treated with pertuzumab and trastuzumab (PT) combined with eribulin (ERI) or nab-paclitaxel (Nab-PTX).	Platinum	125-127	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
30099361-1	2018	A series of Pt nanoparticles (with size of 3-4 nm) decorated CdS nanorods were prepared via a simple solvothermal method.	Platinum	12-14	CDP-diacylglycerol synthase 1	Homo sapiens	61-64
30308991-7	2018	Platinum was more easily reducible in all of the P25 supported samples compared to those obtained from the more water-retentive homemade TiO2.	Platinum	0-8	tubulin polymerization promoting protein	Homo sapiens	49-52
30205260-0	2018	Novel tacrine platinum(II) complexes display high anticancer activity via inhibition of telomerase activity, dysfunction of mitochondria, and activation of the p53 signaling pathway.	Platinum	14-22	tumor protein p53	Homo sapiens	160-163
30443189-0	2018	Effect of RIF1 on response of non-small-cell lung cancer patients to platinum-based chemotherapy by regulating MYC signaling pathway.	Platinum	69-77	replication timing regulatory factor 1	Homo sapiens	10-14
30443189-0	2018	Effect of RIF1 on response of non-small-cell lung cancer patients to platinum-based chemotherapy by regulating MYC signaling pathway.	Platinum	69-77	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	111-114
30443189-6	2018	In this study, we found that RIF1 expression was correlated with the response of NSCLC patients to platinum-based chemotherapy (n=89, P=0.002).	Platinum	99-107	replication timing regulatory factor 1	Homo sapiens	29-33
30443189-7	2018	Among patients who have been treated with platinum chemo-therapy, those with high levels of RIF1 expression had significantly shorter survival than those with low RIF1 expression (P&lt;0.05).	Platinum	42-50	replication timing regulatory factor 1	Homo sapiens	92-96
30443189-7	2018	Among patients who have been treated with platinum chemo-therapy, those with high levels of RIF1 expression had significantly shorter survival than those with low RIF1 expression (P&lt;0.05).	Platinum	42-50	replication timing regulatory factor 1	Homo sapiens	163-167
30443189-12	2018	Taken together, these data revealed that RIF1 played an important role in regulating MYC and MYC-activated genes, which in turn contributes to cellular response to cisplatin and NSCLC patients" response to platinum-based chemotherapy.	Platinum	206-214	replication timing regulatory factor 1	Homo sapiens	41-45
30443189-12	2018	Taken together, these data revealed that RIF1 played an important role in regulating MYC and MYC-activated genes, which in turn contributes to cellular response to cisplatin and NSCLC patients" response to platinum-based chemotherapy.	Platinum	206-214	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	85-88
30443189-12	2018	Taken together, these data revealed that RIF1 played an important role in regulating MYC and MYC-activated genes, which in turn contributes to cellular response to cisplatin and NSCLC patients" response to platinum-based chemotherapy.	Platinum	206-214	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	93-96
30443189-13	2018	RIF1 might serve as a novel biomarker for predicting platinum-based chemo-sensitivity and the prognosis of NSCLC patients, so as to guide the chemotherapy regimen adjustment for individual patient with NSCLC and improve their clinical outcomes.	Platinum	53-61	replication timing regulatory factor 1	Homo sapiens	0-4
30072396-10	2018	Taken together, our findings indicate that RPA exhaustion represents a major determinant of cisplatin sensitivity in HGSOC cell lines.Significance: The influence of replication protein A exhaustion on cisplatin sensitivity harbors important implications toward improving therapy of various cancers that initially respond to platinum-based agents but later relapse due to intrinsic or acquired drug resistance.	Platinum	324-332	replication protein A1	Homo sapiens	43-46
30119207-3	2018	In this study, we intended to investigate the effect of miR-1294 on platinum-resistant OC.	Platinum	68-76	microRNA 1294	Homo sapiens	56-64
30586539-1	2018	Currently, platinum-based chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) that is not driven by identifiable genetic events, such as sensitizing mutations of epidermal growth factor receptor (EGFR) and translocations of anaplastic lymphoma kinase (ALK).	Platinum	11-19	epidermal growth factor receptor	Homo sapiens	208-240
30586539-1	2018	Currently, platinum-based chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) that is not driven by identifiable genetic events, such as sensitizing mutations of epidermal growth factor receptor (EGFR) and translocations of anaplastic lymphoma kinase (ALK).	Platinum	11-19	epidermal growth factor receptor	Homo sapiens	242-246
30586539-1	2018	Currently, platinum-based chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) that is not driven by identifiable genetic events, such as sensitizing mutations of epidermal growth factor receptor (EGFR) and translocations of anaplastic lymphoma kinase (ALK).	Platinum	11-19	ALK receptor tyrosine kinase	Homo sapiens	270-296
30586539-1	2018	Currently, platinum-based chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) that is not driven by identifiable genetic events, such as sensitizing mutations of epidermal growth factor receptor (EGFR) and translocations of anaplastic lymphoma kinase (ALK).	Platinum	11-19	ALK receptor tyrosine kinase	Homo sapiens	298-301
30173384-0	2018	Interaction of metals from group 10 (Ni, Pd, and Pt) and 11 (Cu, Ag, and Au) with human blood delta-ALA-D: in vitro and in silico studies.	Platinum	49-51	aminolevulinate dehydratase	Homo sapiens	94-105
30207369-3	2018	In this contribution, a platinum-based metallomesogen containing a mesogenic biphenyl (Pt1) was prepared and characterised.	Platinum	24-32	zinc finger protein 77	Homo sapiens	87-90
30429951-3	2018	Herein, we propose a less toxic platinum complex, namely oxa/cis-platin, as hSOD1 antiaggregation lead compound.	Platinum	32-40	superoxide dismutase 1	Homo sapiens	76-81
30072396-10	2018	Taken together, our findings indicate that RPA exhaustion represents a major determinant of cisplatin sensitivity in HGSOC cell lines.Significance: The influence of replication protein A exhaustion on cisplatin sensitivity harbors important implications toward improving therapy of various cancers that initially respond to platinum-based agents but later relapse due to intrinsic or acquired drug resistance.	Platinum	324-332	replication protein A1	Homo sapiens	165-186
30303135-2	2018	It has been seen that ALDH1 expression in non-small cell lung cancer (NSCLC) and the presence of marker was linked to a more tumorigenic potential in the in vivo assessment and shorter disease-free survival in NSCLC patients with platinum treatment.	Platinum	230-238	aldehyde dehydrogenase 1 family member A1	Homo sapiens	22-27
30306576-3	2018	For gynecologic cancers, drugs targeting angiogenesis such as anti-VEGF antibody have been used in the treatment of advanced or recurrent ovarian and cervical cancers, and the drugs targeting homologous recombination deficiency such as PARP inhibitors have been approved for maintenance after chemotherapy in platinum-sensitive ovarian cancer.	Platinum	309-317	vascular endothelial growth factor A	Homo sapiens	67-71
30364051-0	2018	Toxicological Implications of Platinum Nanoparticle Exposure: Stimulation of Intracellular Stress, Inflammatory Response, and Akt Signaling In Vitro.	Platinum	30-38	AKT serine/threonine kinase 1	Homo sapiens	126-129
30041154-10	2018	Sco1Delta mutants exhibited low copper transporter 1, reduced Pt accumulation suggesting that Sco1 mediated regulation of copper transporter 1 is responsible for altered sensitivity to cisplatin.	Platinum	62-64	high-affinity Cu transporter CTR1	Saccharomyces cerevisiae S288C	122-142
30041154-9	2018	Loss of synthesis of cytochrome coxidase 1 protein (Sco1) in rho0 cells deregulated copper transporter 1, impaired Pt uptake and lowered cytotoxicity, despite lowered glutathione levels.	Platinum	115-117	Cu-binding protein SCO1	Saccharomyces cerevisiae S288C	8-50
30041154-9	2018	Loss of synthesis of cytochrome coxidase 1 protein (Sco1) in rho0 cells deregulated copper transporter 1, impaired Pt uptake and lowered cytotoxicity, despite lowered glutathione levels.	Platinum	115-117	Cu-binding protein SCO1	Saccharomyces cerevisiae S288C	52-56
30041154-10	2018	Sco1Delta mutants exhibited low copper transporter 1, reduced Pt accumulation suggesting that Sco1 mediated regulation of copper transporter 1 is responsible for altered sensitivity to cisplatin.	Platinum	62-64	Cu-binding protein SCO1	Saccharomyces cerevisiae S288C	0-4
30313031-3	2018	This study investigates the relationship between the expression levels of lung resistance protein (LRP) and placental glutathione S-transferase-P1 (GSTP1), the resistance of primary epithelial ovarian cancer (PEOC) to chemotherapy, and the prognosis of patients with platinum drug-resistant PEOC.Quantitative PCR (QT-PCR) was used to detect the mRNA level of the resistance genes LRP, GSTP1 in all tissue and cell lines.The expression levels of resistance gene (LRP, GSTP1) in PEOC were the highest, followed by borderline adenoma tissues, and the lowest levels found in benign tumor tissues, the difference of genes expression between different tissues was statistically significant; the difference between the expression rates and relative expression level of drug resistance genes was statistically significant in platinum sensitive group compare with the platinum resistant group.	Platinum	817-825	LDL receptor related protein 1	Homo sapiens	99-102
30313031-3	2018	This study investigates the relationship between the expression levels of lung resistance protein (LRP) and placental glutathione S-transferase-P1 (GSTP1), the resistance of primary epithelial ovarian cancer (PEOC) to chemotherapy, and the prognosis of patients with platinum drug-resistant PEOC.Quantitative PCR (QT-PCR) was used to detect the mRNA level of the resistance genes LRP, GSTP1 in all tissue and cell lines.The expression levels of resistance gene (LRP, GSTP1) in PEOC were the highest, followed by borderline adenoma tissues, and the lowest levels found in benign tumor tissues, the difference of genes expression between different tissues was statistically significant; the difference between the expression rates and relative expression level of drug resistance genes was statistically significant in platinum sensitive group compare with the platinum resistant group.	Platinum	817-825	glutathione S-transferase pi 1	Homo sapiens	118-146
30313031-3	2018	This study investigates the relationship between the expression levels of lung resistance protein (LRP) and placental glutathione S-transferase-P1 (GSTP1), the resistance of primary epithelial ovarian cancer (PEOC) to chemotherapy, and the prognosis of patients with platinum drug-resistant PEOC.Quantitative PCR (QT-PCR) was used to detect the mRNA level of the resistance genes LRP, GSTP1 in all tissue and cell lines.The expression levels of resistance gene (LRP, GSTP1) in PEOC were the highest, followed by borderline adenoma tissues, and the lowest levels found in benign tumor tissues, the difference of genes expression between different tissues was statistically significant; the difference between the expression rates and relative expression level of drug resistance genes was statistically significant in platinum sensitive group compare with the platinum resistant group.	Platinum	267-275	LDL receptor related protein 1	Homo sapiens	99-102
30313031-3	2018	This study investigates the relationship between the expression levels of lung resistance protein (LRP) and placental glutathione S-transferase-P1 (GSTP1), the resistance of primary epithelial ovarian cancer (PEOC) to chemotherapy, and the prognosis of patients with platinum drug-resistant PEOC.Quantitative PCR (QT-PCR) was used to detect the mRNA level of the resistance genes LRP, GSTP1 in all tissue and cell lines.The expression levels of resistance gene (LRP, GSTP1) in PEOC were the highest, followed by borderline adenoma tissues, and the lowest levels found in benign tumor tissues, the difference of genes expression between different tissues was statistically significant; the difference between the expression rates and relative expression level of drug resistance genes was statistically significant in platinum sensitive group compare with the platinum resistant group.	Platinum	817-825	glutathione S-transferase pi 1	Homo sapiens	148-153
30313031-3	2018	This study investigates the relationship between the expression levels of lung resistance protein (LRP) and placental glutathione S-transferase-P1 (GSTP1), the resistance of primary epithelial ovarian cancer (PEOC) to chemotherapy, and the prognosis of patients with platinum drug-resistant PEOC.Quantitative PCR (QT-PCR) was used to detect the mRNA level of the resistance genes LRP, GSTP1 in all tissue and cell lines.The expression levels of resistance gene (LRP, GSTP1) in PEOC were the highest, followed by borderline adenoma tissues, and the lowest levels found in benign tumor tissues, the difference of genes expression between different tissues was statistically significant; the difference between the expression rates and relative expression level of drug resistance genes was statistically significant in platinum sensitive group compare with the platinum resistant group.	Platinum	267-275	glutathione S-transferase pi 1	Homo sapiens	118-146
30313031-3	2018	This study investigates the relationship between the expression levels of lung resistance protein (LRP) and placental glutathione S-transferase-P1 (GSTP1), the resistance of primary epithelial ovarian cancer (PEOC) to chemotherapy, and the prognosis of patients with platinum drug-resistant PEOC.Quantitative PCR (QT-PCR) was used to detect the mRNA level of the resistance genes LRP, GSTP1 in all tissue and cell lines.The expression levels of resistance gene (LRP, GSTP1) in PEOC were the highest, followed by borderline adenoma tissues, and the lowest levels found in benign tumor tissues, the difference of genes expression between different tissues was statistically significant; the difference between the expression rates and relative expression level of drug resistance genes was statistically significant in platinum sensitive group compare with the platinum resistant group.	Platinum	267-275	glutathione S-transferase pi 1	Homo sapiens	148-153
30313031-3	2018	This study investigates the relationship between the expression levels of lung resistance protein (LRP) and placental glutathione S-transferase-P1 (GSTP1), the resistance of primary epithelial ovarian cancer (PEOC) to chemotherapy, and the prognosis of patients with platinum drug-resistant PEOC.Quantitative PCR (QT-PCR) was used to detect the mRNA level of the resistance genes LRP, GSTP1 in all tissue and cell lines.The expression levels of resistance gene (LRP, GSTP1) in PEOC were the highest, followed by borderline adenoma tissues, and the lowest levels found in benign tumor tissues, the difference of genes expression between different tissues was statistically significant; the difference between the expression rates and relative expression level of drug resistance genes was statistically significant in platinum sensitive group compare with the platinum resistant group.	Platinum	817-825	LDL receptor related protein 1	Homo sapiens	99-102
30313031-3	2018	This study investigates the relationship between the expression levels of lung resistance protein (LRP) and placental glutathione S-transferase-P1 (GSTP1), the resistance of primary epithelial ovarian cancer (PEOC) to chemotherapy, and the prognosis of patients with platinum drug-resistant PEOC.Quantitative PCR (QT-PCR) was used to detect the mRNA level of the resistance genes LRP, GSTP1 in all tissue and cell lines.The expression levels of resistance gene (LRP, GSTP1) in PEOC were the highest, followed by borderline adenoma tissues, and the lowest levels found in benign tumor tissues, the difference of genes expression between different tissues was statistically significant; the difference between the expression rates and relative expression level of drug resistance genes was statistically significant in platinum sensitive group compare with the platinum resistant group.	Platinum	817-825	glutathione S-transferase pi 1	Homo sapiens	118-146
30313031-3	2018	This study investigates the relationship between the expression levels of lung resistance protein (LRP) and placental glutathione S-transferase-P1 (GSTP1), the resistance of primary epithelial ovarian cancer (PEOC) to chemotherapy, and the prognosis of patients with platinum drug-resistant PEOC.Quantitative PCR (QT-PCR) was used to detect the mRNA level of the resistance genes LRP, GSTP1 in all tissue and cell lines.The expression levels of resistance gene (LRP, GSTP1) in PEOC were the highest, followed by borderline adenoma tissues, and the lowest levels found in benign tumor tissues, the difference of genes expression between different tissues was statistically significant; the difference between the expression rates and relative expression level of drug resistance genes was statistically significant in platinum sensitive group compare with the platinum resistant group.	Platinum	817-825	glutathione S-transferase pi 1	Homo sapiens	148-153
30106452-7	2018	Platinum increased p53 and p-p53 (ser15) in a time-dependent manner in 3D cultures.	Platinum	0-8	tumor protein p53	Homo sapiens	19-22
30076277-1	2018	LESSONS LEARNED: NGR-hTNF was safely combined with doxorubicin, showing a promising antitumor activity in unselected patients with relapsed small cell lung cancer.Similar antitumor activity was observed in platinum-sensitive and platinum-resistant patient cohorts.	Platinum	206-214	reticulon 4 receptor	Homo sapiens	17-20
30076277-1	2018	LESSONS LEARNED: NGR-hTNF was safely combined with doxorubicin, showing a promising antitumor activity in unselected patients with relapsed small cell lung cancer.Similar antitumor activity was observed in platinum-sensitive and platinum-resistant patient cohorts.	Platinum	206-214	tumor necrosis factor	Homo sapiens	21-25
30106452-7	2018	Platinum increased p53 and p-p53 (ser15) in a time-dependent manner in 3D cultures.	Platinum	0-8	tumor protein p53	Homo sapiens	29-32
30076277-1	2018	LESSONS LEARNED: NGR-hTNF was safely combined with doxorubicin, showing a promising antitumor activity in unselected patients with relapsed small cell lung cancer.Similar antitumor activity was observed in platinum-sensitive and platinum-resistant patient cohorts.	Platinum	229-237	reticulon 4 receptor	Homo sapiens	17-20
30106452-9	2018	Under 3D culture condition, knockdown of integrin beta4 did not detectably change the basal p53 protein level but increased p53 and p-p53 (ser15) protein accumulation induced by platinum.	Platinum	178-186	integrin subunit beta 4	Homo sapiens	41-55
30076277-1	2018	LESSONS LEARNED: NGR-hTNF was safely combined with doxorubicin, showing a promising antitumor activity in unselected patients with relapsed small cell lung cancer.Similar antitumor activity was observed in platinum-sensitive and platinum-resistant patient cohorts.	Platinum	229-237	tumor necrosis factor	Homo sapiens	21-25
30106452-9	2018	Under 3D culture condition, knockdown of integrin beta4 did not detectably change the basal p53 protein level but increased p53 and p-p53 (ser15) protein accumulation induced by platinum.	Platinum	178-186	tumor protein p53	Homo sapiens	124-127
30106452-9	2018	Under 3D culture condition, knockdown of integrin beta4 did not detectably change the basal p53 protein level but increased p53 and p-p53 (ser15) protein accumulation induced by platinum.	Platinum	178-186	tumor protein p53	Homo sapiens	124-127
30106452-11	2018	Knockdown of wild-type p53 decreased sensitivity to platinum in 3D cultures.	Platinum	52-60	tumor protein p53	Homo sapiens	23-26
30106452-12	2018	Since it has been proven that platinum damages DNA to kill cells and p53 plays a key role in the DNA damage response, our results indicated that integrin beta4 reduced DNA damage-induced p53 activation to decrease chemosensitivity in CRC.	Platinum	30-38	integrin subunit beta 4	Homo sapiens	145-159
30106452-12	2018	Since it has been proven that platinum damages DNA to kill cells and p53 plays a key role in the DNA damage response, our results indicated that integrin beta4 reduced DNA damage-induced p53 activation to decrease chemosensitivity in CRC.	Platinum	30-38	tumor protein p53	Homo sapiens	187-190
30029446-4	2018	The Cu-MOF (copper metallic framework) crosslinking of 0.25U LOx in a chitosan layer, allows to determine the enzymatic product generated on a platinum modified working electrode, at 0.15 V (vs SPE Ag/AgCl).	Platinum	143-151	lysyl oxidase	Homo sapiens	61-64
29857117-10	2018	Specifically, Nrf2 plays an indispensable role in NSCLC cell sensitivity to platinum-based treatments and we found that combination of CP-673451 and cisplatin produced a synergistic anticancer effect and substantial ROS production in vitro.	Platinum	76-84	NFE2 like bZIP transcription factor 2	Homo sapiens	14-18
30312060-1	2018	Transport calculations based on ab initio band structures reveal large interface-generated spin currents at Co/Pt, Co/Cu, and Pt/Cu interfaces.	Platinum	111-113	spindlin 1	Homo sapiens	91-95
30056367-6	2018	Moreover, we demonstrated that high levels of ROR2 in platinum-resistant samples were associated with upregulation of Wnt5a, STAT3 and NF-kB levels, suggesting that a crosstalk between the non-canonical Wnt5a-ROR2 and STAT3/NF-kB signaling pathways.	Platinum	54-62	signal transducer and activator of transcription 3	Homo sapiens	218-223
30056367-7	2018	Upregulation of ROR2, Wnt5a, STAT3 and NF-kB was further detected in a platinum-resistant cell-line model.	Platinum	71-79	receptor tyrosine kinase like orphan receptor 2	Homo sapiens	16-20
30056367-7	2018	Upregulation of ROR2, Wnt5a, STAT3 and NF-kB was further detected in a platinum-resistant cell-line model.	Platinum	71-79	Wnt family member 5A	Homo sapiens	22-27
30056367-7	2018	Upregulation of ROR2, Wnt5a, STAT3 and NF-kB was further detected in a platinum-resistant cell-line model.	Platinum	71-79	signal transducer and activator of transcription 3	Homo sapiens	29-34
30053382-3	2018	We have recently reported that microRNA-7 is silenced by DNA methylation and is involved in the resistance to platinum in cancer cells through the action of the musculoaponeurotic fibrosarcoma oncogene family, protein G (MAFG).	Platinum	110-118	MAF bZIP transcription factor G	Homo sapiens	161-219
30053382-3	2018	We have recently reported that microRNA-7 is silenced by DNA methylation and is involved in the resistance to platinum in cancer cells through the action of the musculoaponeurotic fibrosarcoma oncogene family, protein G (MAFG).	Platinum	110-118	MAF bZIP transcription factor G	Homo sapiens	221-225
30053382-9	2018	We report first the specific nuclear identification of MAFG as a novel detection method for diagnosis in NSCLC, and then we report that MAFG modulates the redox response and confers cell protection against free radicals generated after platinum administration, thus also being a promising therapeutic target.	Platinum	236-244	MAF bZIP transcription factor G	Homo sapiens	136-140
30056367-5	2018	We showed that the development of platinum resistance correlated with upregulation of ROR2, whereas GREB1 was downregulated.	Platinum	34-42	receptor tyrosine kinase like orphan receptor 2	Homo sapiens	86-90
30056367-6	2018	Moreover, we demonstrated that high levels of ROR2 in platinum-resistant samples were associated with upregulation of Wnt5a, STAT3 and NF-kB levels, suggesting that a crosstalk between the non-canonical Wnt5a-ROR2 and STAT3/NF-kB signaling pathways.	Platinum	54-62	receptor tyrosine kinase like orphan receptor 2	Homo sapiens	46-50
30056367-6	2018	Moreover, we demonstrated that high levels of ROR2 in platinum-resistant samples were associated with upregulation of Wnt5a, STAT3 and NF-kB levels, suggesting that a crosstalk between the non-canonical Wnt5a-ROR2 and STAT3/NF-kB signaling pathways.	Platinum	54-62	Wnt family member 5A	Homo sapiens	118-123
30056367-6	2018	Moreover, we demonstrated that high levels of ROR2 in platinum-resistant samples were associated with upregulation of Wnt5a, STAT3 and NF-kB levels, suggesting that a crosstalk between the non-canonical Wnt5a-ROR2 and STAT3/NF-kB signaling pathways.	Platinum	54-62	signal transducer and activator of transcription 3	Homo sapiens	125-130
30056367-6	2018	Moreover, we demonstrated that high levels of ROR2 in platinum-resistant samples were associated with upregulation of Wnt5a, STAT3 and NF-kB levels, suggesting that a crosstalk between the non-canonical Wnt5a-ROR2 and STAT3/NF-kB signaling pathways.	Platinum	54-62	Wnt family member 5A	Homo sapiens	203-213
30266954-5	2018	Analysis of 21 BRCA1-methylated platinum-sensitive recurrent HGSOC (ARIEL2 Part 1 trial) confirmed that homozygous or hemizygous BRCA1 methylation predicts rucaparib clinical response, and that methylation loss can occur after exposure to chemotherapy.	Platinum	32-40	BRCA1 DNA repair associated	Homo sapiens	15-20
30266954-5	2018	Analysis of 21 BRCA1-methylated platinum-sensitive recurrent HGSOC (ARIEL2 Part 1 trial) confirmed that homozygous or hemizygous BRCA1 methylation predicts rucaparib clinical response, and that methylation loss can occur after exposure to chemotherapy.	Platinum	32-40	ADP-ribosyltransferase 1	Homo sapiens	68-81
30312060-1	2018	Transport calculations based on ab initio band structures reveal large interface-generated spin currents at Co/Pt, Co/Cu, and Pt/Cu interfaces.	Platinum	126-128	spindlin 1	Homo sapiens	91-95
30312060-4	2018	The Co/Cu and Co/Pt interfaces additionally generate spin currents with polarization along m[over ^]x(z[over ^]xE), where m[over ^] gives the magnetization direction of Co.	Platinum	17-19	spindlin 1	Homo sapiens	53-57
30310510-0	2018	Gene expression and single nucleotide polymorphism of ATP7B are associated with platinum-based chemotherapy response in non-small cell lung cancer patients.	Platinum	80-88	ATPase copper transporting beta	Homo sapiens	54-59
30319427-8	2018	A variation in SLC22A2 rs316019, a gene involved in platinum uptake by the kidney, was associated with different measures of nephrotoxicity in four independent studies.	Platinum	52-60	solute carrier family 22 member 2	Homo sapiens	15-22
30310317-5	2018	Gal-3 expression was related to the grade (P=0.037), clinical stage (P=0.034), platinum resistance (P=0.030), and recurrence (P=0.001) in SEOC.	Platinum	79-87	galectin 3	Homo sapiens	0-5
30298127-0	2018	Protected and De-protected Platinum(IV) Glycoconjugates With GLUT1 and OCT2-Mediated Selective Cancer Targeting: Demonstrated Enhanced Transporter-Mediated Cytotoxic Properties in vitro and in vivo.	Platinum	27-35	solute carrier family 2 member 1	Homo sapiens	61-66
30298127-0	2018	Protected and De-protected Platinum(IV) Glycoconjugates With GLUT1 and OCT2-Mediated Selective Cancer Targeting: Demonstrated Enhanced Transporter-Mediated Cytotoxic Properties in vitro and in vivo.	Platinum	27-35	solute carrier family 22 member 2	Homo sapiens	71-75
30275702-8	2018	The results demonstrated that OPN expression levels significantly correlated with cancer differentiation, distant metastasis and the efficacy of platinum-based treatment.	Platinum	145-153	secreted phosphoprotein 1	Homo sapiens	30-33
30275702-9	2018	Notably, the results identified OPN expression levels as a potential factor for predicting the response of cells to first-line platinum-based chemotherapy using multivariate analysis, as well as predicting cancer differentiation and distant metastasis.	Platinum	127-135	secreted phosphoprotein 1	Homo sapiens	32-35
30275703-7	2018	Results: The approved checkpoint inhibitors (PD1 and PDL1 inhibitors) have similar efficacy and safety profiles in metastatic platinum-refractory bladder cancer, but they vary in dose and frequency and cost burden.	Platinum	126-134	programmed cell death 1	Homo sapiens	45-48
30241606-5	2018	In vitro, CT45 regulated PP4 activity, and its high expression led to increased DNA damage and platinum sensitivity.	Platinum	95-103	G antigen 5	Homo sapiens	10-14
30241606-5	2018	In vitro, CT45 regulated PP4 activity, and its high expression led to increased DNA damage and platinum sensitivity.	Platinum	95-103	protein phosphatase 4 catalytic subunit	Homo sapiens	25-28
30141818-4	2018	In particular, it is demonstrated that the charge transfer mechanism of SnO/TiO2 can be switched from the Z-scheme to type II by Pt loading, leading to a significant enhancement of photocatalytic performances.	Platinum	129-131	strawberry notch homolog 2	Homo sapiens	72-75
30310510-3	2018	Recent studies suggest that ATP7B, a copper efflux transporter, may be involved in platinum resistance.	Platinum	83-91	ATPase copper transporting beta	Homo sapiens	28-33
30310510-5	2018	Moreover, the effects of single nucleotide polymorphisms (SNPs) in ATP7B gene on the response to platinum-based chemotherapy are scarcely understood.	Platinum	97-105	ATPase copper transporting beta	Homo sapiens	67-72
30310510-14	2018	Conclusion: Our findings indicate that ATP7B rs9526814 may contribute to platinum resistance by influencing ATP7B gene expression and can be used as a potential biomarker to predict the sensitivity of platinum-based chemotherapy in NSCLC patients.	Platinum	73-81	ATPase copper transporting beta	Homo sapiens	39-44
30310510-14	2018	Conclusion: Our findings indicate that ATP7B rs9526814 may contribute to platinum resistance by influencing ATP7B gene expression and can be used as a potential biomarker to predict the sensitivity of platinum-based chemotherapy in NSCLC patients.	Platinum	73-81	ATPase copper transporting beta	Homo sapiens	108-113
30310510-14	2018	Conclusion: Our findings indicate that ATP7B rs9526814 may contribute to platinum resistance by influencing ATP7B gene expression and can be used as a potential biomarker to predict the sensitivity of platinum-based chemotherapy in NSCLC patients.	Platinum	201-209	ATPase copper transporting beta	Homo sapiens	39-44
30310510-14	2018	Conclusion: Our findings indicate that ATP7B rs9526814 may contribute to platinum resistance by influencing ATP7B gene expression and can be used as a potential biomarker to predict the sensitivity of platinum-based chemotherapy in NSCLC patients.	Platinum	201-209	ATPase copper transporting beta	Homo sapiens	108-113
30181600-0	2018	Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer.	Platinum	40-48	tyrosine kinase with immunoglobulin like and EGF like domains 1	Homo sapiens	25-30
30237852-2	2018	mTORC1/2 inhibitors, which impair mRNA translation, can re-sensitize resistant ovarian cancer cells to platinum chemotherapy but the mechanism remains poorly described.	Platinum	103-111	CREB regulated transcription coactivator 1	Mus musculus	0-6
30104402-6	2018	Additionally, PRDX5 predicted a lower PFS in all ovarian cancer patients treated with Platin, Taxol, and Taxol+Platin chemotherapy.	Platinum	86-92	peroxiredoxin 5	Homo sapiens	14-19
30104402-6	2018	Additionally, PRDX5 predicted a lower PFS in all ovarian cancer patients treated with Platin, Taxol, and Taxol+Platin chemotherapy.	Platinum	111-117	peroxiredoxin 5	Homo sapiens	14-19
30104402-7	2018	PRDX3 and PRDX6 also showed poor PFS in patients treated with Platin chemotherapy.	Platinum	62-68	peroxiredoxin 3	Homo sapiens	0-5
30104402-7	2018	PRDX3 and PRDX6 also showed poor PFS in patients treated with Platin chemotherapy.	Platinum	62-68	peroxiredoxin 6	Homo sapiens	10-15
30104402-9	2018	PRDX6 predicted a poorer OS in patients treated with Taxol and Taxol+Platin chemotherapy.Conclusion: These results suggest that there are distinct prognostic values of PRDX family members in patients with ovarian cancer, and that the expression of PRDX3, PRDX5, and PRDX6 mRNAs are a useful prognostic indicator in the effect of chemotherapy in ovarian cancer patients.	Platinum	69-75	peroxiredoxin 6	Homo sapiens	0-5
30234108-3	2018	New intriguing scenarios are opening nowadays for the management of prostate cancer in patients with germline or somatic mutations in components of DNA repair pathways (e.g., BRCA1 and BRCA2 genes), such as specific screening policies and new therapeutic strategies involving PARP inhibitors or platinum-based chemotherapy.	Platinum	295-303	BRCA1 DNA repair associated	Homo sapiens	175-180
30234108-3	2018	New intriguing scenarios are opening nowadays for the management of prostate cancer in patients with germline or somatic mutations in components of DNA repair pathways (e.g., BRCA1 and BRCA2 genes), such as specific screening policies and new therapeutic strategies involving PARP inhibitors or platinum-based chemotherapy.	Platinum	295-303	BRCA2 DNA repair associated	Homo sapiens	185-190
30237852-3	2018	Using platinum-resistant OVCAR-3 cells treated with the selective mTORC1/2 inhibitor INK128/MLN128, we conducted genome-wide transcription and translation studies and analyzed the effect on cell proliferation, AKT-mTOR signaling and cell survival, to determine whether carboplatin resistance involves selective mRNA translational reprogramming, and whether it is sensitive to mTORC1/2 inhibition.	Platinum	6-14	CREB regulated transcription coactivator 2	Mus musculus	66-74
30237852-3	2018	Using platinum-resistant OVCAR-3 cells treated with the selective mTORC1/2 inhibitor INK128/MLN128, we conducted genome-wide transcription and translation studies and analyzed the effect on cell proliferation, AKT-mTOR signaling and cell survival, to determine whether carboplatin resistance involves selective mRNA translational reprogramming, and whether it is sensitive to mTORC1/2 inhibition.	Platinum	6-14	mechanistic target of rapamycin kinase	Homo sapiens	66-70
30237852-3	2018	Using platinum-resistant OVCAR-3 cells treated with the selective mTORC1/2 inhibitor INK128/MLN128, we conducted genome-wide transcription and translation studies and analyzed the effect on cell proliferation, AKT-mTOR signaling and cell survival, to determine whether carboplatin resistance involves selective mRNA translational reprogramming, and whether it is sensitive to mTORC1/2 inhibition.	Platinum	6-14	CREB regulated transcription coactivator 1	Mus musculus	66-72
30181600-5	2018	Importantly potentiation of therapeutic efficacy by TIE-1 inhibition was selective to DNA-adduct-type chemotherapeutic platinum reagents.	Platinum	119-127	tyrosine kinase with immunoglobulin like and EGF like domains 1	Homo sapiens	52-57
30181600-6	2018	Therefore, TIE-1 is suggested to promote XPC-dependent NER, rendering ovarian cancer cells resistant to platinum.	Platinum	104-112	tyrosine kinase with immunoglobulin like and EGF like domains 1	Homo sapiens	11-16
30015866-3	2018	However, the association between GOLPH3 gene overexpression and resistance to platinum-based drugs in colon cancer remains unknown.	Platinum	78-86	golgi phosphoprotein 3	Homo sapiens	33-39
30237852-8	2018	These data suggest a clinical path to re-sensitize platinum resistant ovarian cancer to platinum chemotherapy through partial inhibition of mTORC1/2, resulting in selective translation inhibition of DDR and anti-apoptosis protective mRNAs.	Platinum	51-59	CREB regulated transcription coactivator 2	Mus musculus	140-148
30237852-8	2018	These data suggest a clinical path to re-sensitize platinum resistant ovarian cancer to platinum chemotherapy through partial inhibition of mTORC1/2, resulting in selective translation inhibition of DDR and anti-apoptosis protective mRNAs.	Platinum	88-96	CREB regulated transcription coactivator 2	Mus musculus	140-148
27941566-7	2018	METHODS: FRA expression was evaluated in tissue samples in an epithelial ovarian tumor microarray and 2 study groups: platinum resistant ovarian cancer and primary EAC.	Platinum	118-126	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	9-12
27941566-10	2018	In the platinum resistant ovarian cancer group, FRA was expressed in all 30 samples with moderate to strong staining.	Platinum	7-15	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	48-51
30111871-1	2018	BACKGROUND: Mutations in BRCA1 and BRCA2 are associated with better survival in ovarian cancer (OC) patients due to a better response to platinum-based chemotherapy.	Platinum	137-145	BRCA1 DNA repair associated	Homo sapiens	25-30
30111871-1	2018	BACKGROUND: Mutations in BRCA1 and BRCA2 are associated with better survival in ovarian cancer (OC) patients due to a better response to platinum-based chemotherapy.	Platinum	137-145	BRCA2 DNA repair associated	Homo sapiens	35-40
30111871-10	2018	Fully platinum-sensitivity was characterized by lower BRCA1/2 mRNA-expression in BRCA1-wildtype cancers in comparison to platinum-refractory OC.	Platinum	6-14	BRCA1 DNA repair associated	Homo sapiens	54-61
30111871-11	2018	CONCLUSION: Our findings may reflect higher platinum-sensitivity due to reduced capacity of DNA damage repair in tissues with low BRCA1/2-expression.	Platinum	44-52	BRCA1 DNA repair associated	Homo sapiens	130-135
29871906-2	2018	PARP inhibitors are now approved for recurrent ovarian cancer as maintenance following response to platinum chemotherapy and BRCA-mutated (BRCAm) cancer treatment.	Platinum	99-107	poly(ADP-ribose) polymerase 1	Homo sapiens	0-4
30194207-6	2018	CONCLUSION: TTF-1 expression may serve as a predictive marker to identify patients who may benefit from the addition of bevacizumab to platinum doublet therapy.	Platinum	135-143	transcription termination factor 1	Homo sapiens	12-17
30397885-3	2018	A high expression level of both ERalpha (&gt;= 25%) and ERbeta (&gt;= 44%) in the tumor predicts a significantly longer progression-free survival time (p &lt; 0.01) in the patients after the first line of platinum and taxane-based adjuvant chemotherapy.	Platinum	205-213	estrogen receptor 1	Homo sapiens	32-39
30397885-3	2018	A high expression level of both ERalpha (&gt;= 25%) and ERbeta (&gt;= 44%) in the tumor predicts a significantly longer progression-free survival time (p &lt; 0.01) in the patients after the first line of platinum and taxane-based adjuvant chemotherapy.	Platinum	205-213	estrogen receptor 2	Homo sapiens	56-62
30466712-10	2018	Checkpoint inhibitors such as anti-PD-1 and anti-PD-L1 antibodies, were shown to significantly improve disease free survival and overall survival after failure of platinum-based chemotherapy.	Platinum	163-171	CD274 molecule	Homo sapiens	49-54
30202628-7	2018	Platinum-sensitive patients had significantly elevated levels of YKL-40 compared with platinum-resistant or refractory patients.	Platinum	0-8	chitinase 3 like 1	Homo sapiens	65-71
29807243-1	2018	A novel compound, Cou-platin, composed of 7-hydroxycoumarin and a platinum(IV) moiety derived from cisplatin was designed and synthesized.	Platinum	66-74	brachyury, T-box transcription factor T	Mus musculus	18-21
30181415-8	2018	This report presents 2 patients with high-grade colorectal NECs who had different responses to treatment with combined BRAF/MEK inhibition after experiencing disease progression through first-line platinum-based chemotherapy.	Platinum	197-205	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	119-123
30181415-8	2018	This report presents 2 patients with high-grade colorectal NECs who had different responses to treatment with combined BRAF/MEK inhibition after experiencing disease progression through first-line platinum-based chemotherapy.	Platinum	197-205	mitogen-activated protein kinase kinase 7	Homo sapiens	124-127
30209370-7	2018	We control the flow of spin current across a haematite-platinum interface-at which spins accumulate, generating the spin current-by tuning the antiferromagnetic resonance frequency using an external magnetic field12.	Platinum	55-63	spindlin 1	Homo sapiens	23-27
30209370-7	2018	We control the flow of spin current across a haematite-platinum interface-at which spins accumulate, generating the spin current-by tuning the antiferromagnetic resonance frequency using an external magnetic field12.	Platinum	55-63	spindlin 1	Homo sapiens	83-87
29997033-1	2018	INTRODUCTION: Platinum-based neoadjvant chemotherapy (NAC) before radical cystectomy (RC) is the gold standard in the treatment of muscle invasive bladder cancer (MIBC).	Platinum	14-22	X-linked Kx blood group	Homo sapiens	54-57
29027501-1	2018	The aim of this study was synthesis of two new water-soluble fluorescent palladium and platinum complexes with formulas of [Pt(DACH)(FIP)](NO3)2 and [Pd(DACH)(FIP)](NO3)2, respectively, where FIP is 2-(furan-2-yl)-1H-imidazo[4,5-f][1,10] phenanthroline and DACH is 1R,2R-diaminocyclohexane.	Platinum	87-95	upstream transcription factor 2, c-fos interacting	Homo sapiens	133-136
29027501-1	2018	The aim of this study was synthesis of two new water-soluble fluorescent palladium and platinum complexes with formulas of [Pt(DACH)(FIP)](NO3)2 and [Pd(DACH)(FIP)](NO3)2, respectively, where FIP is 2-(furan-2-yl)-1H-imidazo[4,5-f][1,10] phenanthroline and DACH is 1R,2R-diaminocyclohexane.	Platinum	87-95	upstream transcription factor 2, c-fos interacting	Homo sapiens	159-162
29027501-1	2018	The aim of this study was synthesis of two new water-soluble fluorescent palladium and platinum complexes with formulas of [Pt(DACH)(FIP)](NO3)2 and [Pd(DACH)(FIP)](NO3)2, respectively, where FIP is 2-(furan-2-yl)-1H-imidazo[4,5-f][1,10] phenanthroline and DACH is 1R,2R-diaminocyclohexane.	Platinum	87-95	upstream transcription factor 2, c-fos interacting	Homo sapiens	159-162
29775808-1	2018	OBJECTIVE: The aim of this study was to assess the efficacy of maintenance pembrolizumab in patients with extensive-stage SCLC after treatment with platinum and etoposide.	Platinum	148-156	SCLC1	Homo sapiens	122-126
30202628-10	2018	Further studies are needed to understand the relationship between YKL-40 and platinum sensitivity.	Platinum	77-85	chitinase 3 like 1	Homo sapiens	66-72
29998548-2	2018	The Pt0 complex Pt(PPh3 )4 regioselectively cleaves two C-C sigma bonds of [5] CPP and [6]CPP to give cyclic dinuclear platinum complexes in high yields.	Platinum	4-7	caveolin 1	Homo sapiens	19-23
29998548-2	2018	The Pt0 complex Pt(PPh3 )4 regioselectively cleaves two C-C sigma bonds of [5] CPP and [6]CPP to give cyclic dinuclear platinum complexes in high yields.	Platinum	119-127	caveolin 1	Homo sapiens	19-23
30105344-2	2018	Herein, two new kinds of Ni (POxN3-x)2/NPC and Co (POxN3-x)2/NPC (NPC: N, P-co-doped carbon) are synthesized through a facile post-treatment of nickel- or cobalt-phytic acid xerogel, followed by an annealing procedure under an argon and ammonia atmosphere at 800  C. The as-prepared catalysts exhibit outstanding catalytic activities for both the oxygen reduction and evolution reactions, which are comparable to those of Pt/C and IrO2.	Platinum	422-424	NPC intracellular cholesterol transporter 1	Homo sapiens	29-49
30192570-2	2018	Here, we investigate the unidirectional magnetoresistance (UMR) caused by the current-induced spin accumulation in Co/Pt and CoCr/Pt bilayers.	Platinum	118-120	spindlin 1	Homo sapiens	94-98
30105344-2	2018	Herein, two new kinds of Ni (POxN3-x)2/NPC and Co (POxN3-x)2/NPC (NPC: N, P-co-doped carbon) are synthesized through a facile post-treatment of nickel- or cobalt-phytic acid xerogel, followed by an annealing procedure under an argon and ammonia atmosphere at 800  C. The as-prepared catalysts exhibit outstanding catalytic activities for both the oxygen reduction and evolution reactions, which are comparable to those of Pt/C and IrO2.	Platinum	422-424	NPC intracellular cholesterol transporter 1	Homo sapiens	29-42
29888872-6	2018	The Volmer-Tafel mechanism is indicated on Ru2 P nanoparticles with the typical Tafel slope of 30 mV dec-1 of Pt metal indicating a Pt-like catalytic ability.	Platinum	110-112	deleted in esophageal cancer 1	Homo sapiens	101-106
30082520-9	2018	Conclusions: The PARP1 2444 mutation allele C might be associated with the decreased sensitivity to platinum-based chemotherapy in advanced NSCLC.	Platinum	100-108	poly(ADP-ribose) polymerase 1	Homo sapiens	17-22
29942974-5	2018	The application of the synthetic strategy was also successfully extended to other metal ions of biomedical interest, such as gold(i) and platinum(ii), to obtain [AuI(SSC-Inp-GlcN)(PPh3)] and [PtII(SSC-Inp-GlcN)2], respectively.	Platinum	137-145	protein phosphatase 4 catalytic subunit	Homo sapiens	180-184
30147334-4	2018	Platinum-based postoperative adjuvant chemotherapy for at least four cycles can significantly improve the survival in stage III patients with ASC.	Platinum	0-8	PYD and CARD domain containing	Homo sapiens	142-145
30119639-9	2018	CONCLUSIONS: Our results indicate a potential prognostic role for MAP17 in lung tumours, with particular relevance in lung adenocarcinomas, and highlight the predictive pot0065ntial of this membrane-associated protein for platinum-based therapy and EGFR inhibitor efficacy.	Platinum	222-230	PDZK1 interacting protein 1	Homo sapiens	66-71
30119639-9	2018	CONCLUSIONS: Our results indicate a potential prognostic role for MAP17 in lung tumours, with particular relevance in lung adenocarcinomas, and highlight the predictive pot0065ntial of this membrane-associated protein for platinum-based therapy and EGFR inhibitor efficacy.	Platinum	222-230	epidermal growth factor receptor	Homo sapiens	249-253
29656068-4	2018	The Pt3/Ni@CN-doped with low Pt contents cannot form the electron transfer structure and the Pt1/Ni@CN-doped with high Pt contents show an obvious aggregation of Pt nanoparticles.	Platinum	29-31	zinc finger protein 135	Homo sapiens	4-7
29784373-0	2018	Alpha fetoprotein assessment by using a nano optical sensor thin film binuclear Pt-2-aminobenzimidazole-Bipyridine for early diagnosis of liver cancer.	Platinum	80-82	alpha fetoprotein	Homo sapiens	0-17
30119639-0	2018	MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma.	Platinum	30-38	PDZK1 interacting protein 1	Homo sapiens	0-5
30083668-5	2018	Our results show that the presence of the hydrogen atom on the Pt catalyst can efficiently induce the H-diffusion process through the C-C surface, and the Pt-H bond significantly facilitates the H-migration from C-H bonds near to the active Pt catalyst to the adjacent carbon atom with an energy barrier &lt;0.5 eV under ambient conditions.	Platinum	63-65	parathyroid hormone	Homo sapiens	155-159
30049372-0	2018	Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer.	Platinum	38-46	CD274 molecule	Homo sapiens	133-138
30103829-4	2018	The aim of this study was to identify the frequency and spectrum of germline BRCA1/2 pathogenic alterations in a cohort of patients with ovarian serous carcinoma, with a view to adequately selecting patients for prevention through family counseling and correlating this frequency with platinum sensitivity as a guidance to identify patients eligible for iPARP in our population.	Platinum	285-293	BRCA1 DNA repair associated	Homo sapiens	77-82
30087340-0	2018	Tunable inverse spin Hall effect in nanometer-thick platinum films by ionic gating.	Platinum	52-60	spindlin 1	Homo sapiens	16-20
29807697-6	2018	Among patients with a platinum-free interval (PFI) of 3-6 months, OS2 in patients treated with platinum was significantly longer compared to individuals receiving non-platinum-based treatment (median 17.67 months, 95% CI: 14.79-20.75 vs. 10.62 months, 95% CI: 8.02-12.72, P = 0.022).	Platinum	22-30	matrilin 3	Homo sapiens	66-69
29807697-6	2018	Among patients with a platinum-free interval (PFI) of 3-6 months, OS2 in patients treated with platinum was significantly longer compared to individuals receiving non-platinum-based treatment (median 17.67 months, 95% CI: 14.79-20.75 vs. 10.62 months, 95% CI: 8.02-12.72, P = 0.022).	Platinum	95-103	matrilin 3	Homo sapiens	66-69
29807697-6	2018	Among patients with a platinum-free interval (PFI) of 3-6 months, OS2 in patients treated with platinum was significantly longer compared to individuals receiving non-platinum-based treatment (median 17.67 months, 95% CI: 14.79-20.75 vs. 10.62 months, 95% CI: 8.02-12.72, P = 0.022).	Platinum	95-103	matrilin 3	Homo sapiens	66-69
30151275-3	2018	Herein we report a case of a patient with metastatic pancreatic adenocarcinoma to the lung and liver who was found to have a deleterious germline mutation in RAD51C who had a remarkable response to chemotherapy with FOLFIRINOX, a platinum-containing regimen.	Platinum	230-238	RAD51 paralog C	Homo sapiens	158-164
30033091-4	2018	We show clinical evidence that expression of MAST1, both initial and cisplatin-induced, contributes to platinum resistance and worse clinical outcome.	Platinum	103-111	microtubule associated serine/threonine kinase 1	Homo sapiens	45-50
29532557-0	2018	A prolonged response to platinum-based therapy in a patient with metastatic urothelial carcinoma harboring a single rearranged and truncated NF2 gene.	Platinum	24-32	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	141-144
29532557-10	2018	Although our patient"s tumor demonstrated unique acquired genetic features including both loss of heterozygosity and truncation of the NF2 locus, he still achieved a meaningful response to platinum-based chemotherapy.	Platinum	189-197	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	135-138
29749482-6	2018	In in vitro experiments, ZBED3-AS1, F11-AS1 and GAS5 were differentially expressed in cell lines that are known to be resistant and non-resistant to platinum-based drugs, which was consistent with the results in the present study.	Platinum	149-157	zinc finger BED-type containing 3	Homo sapiens	25-30
29749482-6	2018	In in vitro experiments, ZBED3-AS1, F11-AS1 and GAS5 were differentially expressed in cell lines that are known to be resistant and non-resistant to platinum-based drugs, which was consistent with the results in the present study.	Platinum	149-157	prostaglandin D2 receptor	Homo sapiens	31-34
29749482-6	2018	In in vitro experiments, ZBED3-AS1, F11-AS1 and GAS5 were differentially expressed in cell lines that are known to be resistant and non-resistant to platinum-based drugs, which was consistent with the results in the present study.	Platinum	149-157	prostaglandin D2 receptor	Homo sapiens	40-43
29749482-6	2018	In in vitro experiments, ZBED3-AS1, F11-AS1 and GAS5 were differentially expressed in cell lines that are known to be resistant and non-resistant to platinum-based drugs, which was consistent with the results in the present study.	Platinum	149-157	growth arrest specific 5	Homo sapiens	48-52
29777302-7	2018	RESULTS: There is accumulating evidence of increased sensitivity to platinum-based therapy and poly-ADP-ribose polymerase inhibitors (PARPi) in BRCA-associated PDAC.	Platinum	68-76	BRCA1 DNA repair associated	Homo sapiens	144-148
29777302-11	2018	Patients with unresectable metastatic BRCA-positive PDAC may benefit from platinum-based therapy.	Platinum	74-82	BRCA1 DNA repair associated	Homo sapiens	38-42
30021972-2	2018	A nitrogen-rich polymer of an intrinsic microporosity (PIM) precursor is impregnated with PtCl62- to give (after vacuum carbonization at 700  C) a nitrogen-containing heterocarbon with embedded Pt nanoparticles of typically 1-4 nm diameter (with some particles up to 20 nm diameter).	Platinum	90-92	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	55-58
29660381-8	2018	Both ARID1A and MRP2 expression levels are correlated with sensitivity to platinum.	Platinum	74-82	AT-rich interaction domain 1A	Homo sapiens	5-11
29660381-8	2018	Both ARID1A and MRP2 expression levels are correlated with sensitivity to platinum.	Platinum	74-82	ATP binding cassette subfamily C member 2	Homo sapiens	16-20
30045976-2	2018	Using a whole-genome synthetic lethal RNA interference screen, we identified activin signaling as a critical mediator of innate platinum resistance.	Platinum	128-136	inhibin subunit beta E	Homo sapiens	77-84
30112115-13	2018	To conclude, deletion of GSTT1, rs1695 and rs1799793 may constitute potential predictors of platinum-induced ototoxicity.	Platinum	92-100	glutathione S-transferase theta 1	Homo sapiens	25-30
30080919-4	2018	More recently, these two and a third PARP inhibitor, niraparib, were approved by the FDA as maintenance therapy following platinum-based chemotherapy for recurrent ovarian cancer.	Platinum	122-130	poly(ADP-ribose) polymerase 1	Homo sapiens	37-41
30018331-5	2018	By targeting both the MHC class I complex (beta-2-microglobulin) and a broadly expressed sodium-potassium ATPase-subunit (CD298) with platinum-conjugated antibodies, human immune cells, stem cells as well as tumor cells could be multiplexed in the same single-cell assay.	Platinum	134-142	ATPase Na+/K+ transporting subunit beta 3	Homo sapiens	122-127
29908438-3	2018	Here we modified cisplatin with an analogue of the selective inhibitor of RNA polymerase I-mediated transcription BMH-21 to develop a novel platinum-based Pol I selective inhibitor.	Platinum	140-148	DNA polymerase iota	Homo sapiens	155-160
29996917-3	2018	In cancer patients, loss of BRCA1 function in tumor tissue has been associated with an increased sensitivity to platinum agents and to poly-(ADP-ribose) polymerase (PARP) inhibitors.	Platinum	112-120	BRCA1 DNA repair associated	Homo sapiens	28-33
29932199-3	2018	Owing to its favorable composition and structure, the PtCo-Co/TiM can deliver an ultrahigh current density of 46.5 mA cm-2 at an overpotential of 70 mV in 1.0 M KOH, superior to recently reported Pt-based electrocatalysts.	Platinum	54-56	Rho guanine nucleotide exchange factor 5	Homo sapiens	62-65
29904761-5	2018	An unexpected extensive platination of the protein is clearly observed: Pt containing fragments bind close to the NZ atom of Lys1 and OE1 atom of Glu7, NE2 atom of His15 and NH1 atom of Arg14, ND1 atom of His15, NZ atom of Lys96, NZ atom of Lys97 and ND1 atom of Asn93, NZ atom of Lys13 and the C-terminal carboxylate, and the N-terminal amine.	Platinum	72-74	mitochondrially encoded NADH dehydrogenase 1	Homo sapiens	193-196
29916690-5	2018	The redox reactions, induced by photogenerated holes and electrons on the TiO2/Pt Janus micromotor surfaces, produce a local electric field that propels the micromotors as well as oxidative species that are able to photodegrade 2,4-DNT and 2,4,6-TNT.	Platinum	79-81	5', 3'-nucleotidase, cytosolic	Homo sapiens	232-235
29916690-5	2018	The redox reactions, induced by photogenerated holes and electrons on the TiO2/Pt Janus micromotor surfaces, produce a local electric field that propels the micromotors as well as oxidative species that are able to photodegrade 2,4-DNT and 2,4,6-TNT.	Platinum	79-81	chromosome 16 open reading frame 82	Homo sapiens	246-249
29904761-5	2018	An unexpected extensive platination of the protein is clearly observed: Pt containing fragments bind close to the NZ atom of Lys1 and OE1 atom of Glu7, NE2 atom of His15 and NH1 atom of Arg14, ND1 atom of His15, NZ atom of Lys96, NZ atom of Lys97 and ND1 atom of Asn93, NZ atom of Lys13 and the C-terminal carboxylate, and the N-terminal amine.	Platinum	72-74	mitochondrially encoded NADH dehydrogenase 1	Homo sapiens	251-254
29809169-0	2018	ATP11B mediates platinum resistance in ovarian cancer.	Platinum	16-24	ATPase phospholipid transporting 11B (putative)	Homo sapiens	0-6
29396858-8	2018	Correlation between disease course at tissue acquisition and response to PARP inhibitor (PARPi)/platinum was demonstrated in PDXs in vivo.	Platinum	96-104	poly(ADP-ribose) polymerase 1	Homo sapiens	73-77
29867226-3	2018	Emerging breast and ovarian cancer research indicate that BRCA status predicts responsiveness to platinum-based chemotherapy, as well as to inhibitors of poly(ADP-ribose) polymerase (PARP), owing to the ability of these interventions to inhibit DNA repair pathways.	Platinum	97-105	BRCA1 DNA repair associated	Homo sapiens	58-62
29870916-3	2018	Researches in investigating platinum-PARPi combination use compared with platinum monotherapy demonstrated promising benefit in metastatic BRCA mutated breast cancer or TNBC, while no such superiority was observed in the neoadjuvant setting of TNBC.	Platinum	28-36	BRCA1 DNA repair associated	Homo sapiens	139-143
29870916-8	2018	In this review, we summarized the utility of combining platinum-PARPi in BRCA mutated breast cancer or TNBC compared with platinum monotherapy and provided promising prospects of PARPi as maintenance therapy in breast cancer, as well as providing a strong rationale for testing immunotherapy combined with PARPi in breast cancer to expand the clinical utility of PARPi.	Platinum	55-63	BRCA1 DNA repair associated	Homo sapiens	73-77
29464975-1	2018	Until recently, palliative options for the treatment of platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have been cytotoxic chemotherapy and EGFR inhibitors.	Platinum	56-64	epidermal growth factor receptor	Homo sapiens	187-191
29767464-9	2018	This is the first report about marked prolongation of survival by BEV + GEM in a patient with platinum-resistant recurrent ovarian cancer.	Platinum	94-102	GTP binding protein overexpressed in skeletal muscle	Homo sapiens	72-75
29724815-0	2018	Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.	Platinum	150-158	cyclin E1	Homo sapiens	68-73
29782802-3	2018	Herein, we developed highly active and selective catalysts in selective hydrogenation by embedding Pt single atoms in the surface of Ni nanocrystals (denoted as Pt1/Ni nanocrystals).	Platinum	99-101	zinc finger protein 77	Homo sapiens	161-164
29662190-5	2018	Inhibition of JAK2 by LY2784544 or IL-11 by anti-IL-11 antibody overcomes the platinum resistance in vitro or in vivo.	Platinum	78-86	Janus kinase 2	Homo sapiens	14-18
29662190-5	2018	Inhibition of JAK2 by LY2784544 or IL-11 by anti-IL-11 antibody overcomes the platinum resistance in vitro or in vivo.	Platinum	78-86	interleukin 11	Homo sapiens	35-40
29662190-5	2018	Inhibition of JAK2 by LY2784544 or IL-11 by anti-IL-11 antibody overcomes the platinum resistance in vitro or in vivo.	Platinum	78-86	interleukin 11	Homo sapiens	49-54
29662190-7	2018	These findings not only identify a novel ROS-IL-11-JAK2-mediated platinum resistance mechanism but also provide a new strategy for using LY2784544- or IL-11-mediated immunotherapy to treat platinum-resistant ovarian cancer.	Platinum	65-73	interleukin 11	Homo sapiens	45-50
29662190-7	2018	These findings not only identify a novel ROS-IL-11-JAK2-mediated platinum resistance mechanism but also provide a new strategy for using LY2784544- or IL-11-mediated immunotherapy to treat platinum-resistant ovarian cancer.	Platinum	65-73	Janus kinase 2	Homo sapiens	51-55
29662190-7	2018	These findings not only identify a novel ROS-IL-11-JAK2-mediated platinum resistance mechanism but also provide a new strategy for using LY2784544- or IL-11-mediated immunotherapy to treat platinum-resistant ovarian cancer.	Platinum	189-197	interleukin 11	Homo sapiens	45-50
29662190-7	2018	These findings not only identify a novel ROS-IL-11-JAK2-mediated platinum resistance mechanism but also provide a new strategy for using LY2784544- or IL-11-mediated immunotherapy to treat platinum-resistant ovarian cancer.	Platinum	189-197	Janus kinase 2	Homo sapiens	51-55
29662190-7	2018	These findings not only identify a novel ROS-IL-11-JAK2-mediated platinum resistance mechanism but also provide a new strategy for using LY2784544- or IL-11-mediated immunotherapy to treat platinum-resistant ovarian cancer.	Platinum	189-197	interleukin 11	Homo sapiens	151-156
29572670-6	2018	Overall, the radiotherapy regime was changed in 55 of 120 cases (46%) based on the higher detection rate of [68Ga]PSMA PET/CT: in 15% of cases with PT, in 43% of cases with RL, and in 44% of cases with MD.	Platinum	148-150	folate hydrolase 1	Homo sapiens	114-118
29906086-8	2018	The ability to successfully conduct electrochemical measurements in biofouling solutions via a unique biosieving-like mechanism is demonstrated by exposure of the unique 3D bicontinuous nanoporous platinum-based electrode to fibrinogen in phosphate buffer and in a solution containing red blood cells.	Platinum	197-205	fibrinogen beta chain	Homo sapiens	225-235
30002902-1	2018	The title compound, [PtCl2(C26H22P2)] 2CHCl3 (I), is the third monoclinic polymorph of this platinum(II) complex involving the bidentate ligand cis-1,2-bis-(di-phenyl-phosphan-yl)ethyl-ene (cis-dppe) [for the others, see: Oberhauser et al.	Platinum	92-100	suppressor of cytokine signaling 1	Homo sapiens	144-149
29806464-6	2018	The strong inhibition of PT on PL in the gastrointestinal tract might be one mechanism for its lipid-lowering effect.	Platinum	25-27	pancreatic lipase	Homo sapiens	31-33
29977535-4	2018	The protein expressions evaluated were those of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and orotate phsphoribosyltransferase (OPRT), which were suspected to be associated with the effect of S-1 agents, excision repair cross-complementation group 1 (ERCC1), which was suspected to be associated with the effect of platinum-based agents, and class III beta-tubulin (TUBB3), which was suspected to be associated with the effect of taxane-based agents.	Platinum	338-346	uridine monophosphate synthetase	Homo sapiens	151-155
29977536-0	2018	Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition.	Platinum	25-33	epidermal growth factor receptor	Homo sapiens	86-90
29662190-4	2018	Using quantitative high-throughput combinational screen (qHTCS) and genomic sequencing, we show that in platinum-resistant ovarian cancer elevated ROS levels sustain high level of IL-11 by stimulating FRA1-mediated IL-11 expression and increased IL-11 causes resistance to platinum drugs by constitutively activating JAK2-STAT5 via an autocrine mechanism.	Platinum	104-112	interleukin 11	Homo sapiens	180-185
29662190-4	2018	Using quantitative high-throughput combinational screen (qHTCS) and genomic sequencing, we show that in platinum-resistant ovarian cancer elevated ROS levels sustain high level of IL-11 by stimulating FRA1-mediated IL-11 expression and increased IL-11 causes resistance to platinum drugs by constitutively activating JAK2-STAT5 via an autocrine mechanism.	Platinum	104-112	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	201-205
29662190-4	2018	Using quantitative high-throughput combinational screen (qHTCS) and genomic sequencing, we show that in platinum-resistant ovarian cancer elevated ROS levels sustain high level of IL-11 by stimulating FRA1-mediated IL-11 expression and increased IL-11 causes resistance to platinum drugs by constitutively activating JAK2-STAT5 via an autocrine mechanism.	Platinum	104-112	interleukin 11	Homo sapiens	215-220
29662190-4	2018	Using quantitative high-throughput combinational screen (qHTCS) and genomic sequencing, we show that in platinum-resistant ovarian cancer elevated ROS levels sustain high level of IL-11 by stimulating FRA1-mediated IL-11 expression and increased IL-11 causes resistance to platinum drugs by constitutively activating JAK2-STAT5 via an autocrine mechanism.	Platinum	104-112	interleukin 11	Homo sapiens	215-220
29662190-4	2018	Using quantitative high-throughput combinational screen (qHTCS) and genomic sequencing, we show that in platinum-resistant ovarian cancer elevated ROS levels sustain high level of IL-11 by stimulating FRA1-mediated IL-11 expression and increased IL-11 causes resistance to platinum drugs by constitutively activating JAK2-STAT5 via an autocrine mechanism.	Platinum	104-112	Janus kinase 2	Homo sapiens	317-321
29662190-4	2018	Using quantitative high-throughput combinational screen (qHTCS) and genomic sequencing, we show that in platinum-resistant ovarian cancer elevated ROS levels sustain high level of IL-11 by stimulating FRA1-mediated IL-11 expression and increased IL-11 causes resistance to platinum drugs by constitutively activating JAK2-STAT5 via an autocrine mechanism.	Platinum	104-112	signal transducer and activator of transcription 5A	Homo sapiens	322-327
29662190-4	2018	Using quantitative high-throughput combinational screen (qHTCS) and genomic sequencing, we show that in platinum-resistant ovarian cancer elevated ROS levels sustain high level of IL-11 by stimulating FRA1-mediated IL-11 expression and increased IL-11 causes resistance to platinum drugs by constitutively activating JAK2-STAT5 via an autocrine mechanism.	Platinum	273-281	interleukin 11	Homo sapiens	180-185
29905882-1	2018	Prior studies have demonstrated an association between excision repair cross-complementation group 1 (ERCC1) expression level and outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy.	Platinum	213-221	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	55-100
29905882-1	2018	Prior studies have demonstrated an association between excision repair cross-complementation group 1 (ERCC1) expression level and outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy.	Platinum	213-221	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	102-107
29782802-4	2018	During the hydrogenation of 3-nitrostyrene, the TOF numbers based on surface Pt atoms of Pt1/Ni nanocrystals reached ~1800 h-1 under 3 atm of H2 at 40  C, much higher than that of Pt single atoms supported on active carbon, TiO2, SiO2, and ZSM-5.	Platinum	77-79	zinc finger protein 77	Homo sapiens	89-92
29782802-5	2018	Mechanistic studies reveal that the remarkable activity of Pt1/Ni nanocrystals derived from sufficient hydrogen supply because of spontaneous dissociation of H2 on both Pt and Ni atoms as well as facile diffusion of H atoms on Pt1/Ni nanocrystals.	Platinum	59-61	zinc finger protein 77	Homo sapiens	227-230
29782802-6	2018	Moreover, the ensemble composed of the Pt single atom and nearby Ni atoms in Pt1/Ni nanocrystals leads to the adsorption configuration of 3-nitrostyrene favorable for the activation of nitro groups, accounting for the high selectivity for 3-vinylaniline.	Platinum	39-41	zinc finger protein 77	Homo sapiens	77-80
29463559-10	2018	Finally, RB1 knockdown in a cell line established from a capecitabine-responder PDX decreased sensitivity to 5-FU treatment.Conclusions: We identified capecitabine as efficient chemotherapy in TNBC PDX models established from residual disease and resistant to anthracyclines, taxanes, and platins.	Platinum	289-296	RB transcriptional corepressor 1	Homo sapiens	9-12
29866066-10	2018	In combination with either cisplatin or paclitaxel, 3PO (a novel PFKFB3 inhibitor) enhanced the cytotoxic effect in both platinum sensitive and platinum resistant ovarian cancer cells.	Platinum	121-129	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	65-71
29866066-10	2018	In combination with either cisplatin or paclitaxel, 3PO (a novel PFKFB3 inhibitor) enhanced the cytotoxic effect in both platinum sensitive and platinum resistant ovarian cancer cells.	Platinum	144-152	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	65-71
29930760-0	2018	Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.	Platinum	93-101	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	33-43
29930760-0	2018	Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.	Platinum	93-101	signal transducer and activator of transcription 3	Homo sapiens	61-66
29750420-3	2018	We review key trials that have led to the approval of three PARP inhibitors-olaparib, niraparib and rucaparib-as maintenance therapy for platinum-sensitive recurrent ovarian cancer.	Platinum	137-145	poly(ADP-ribose) polymerase 1	Homo sapiens	60-64
29750420-6	2018	Three phase III trials (NOVA, SOLO2 and ARIEL3) demonstrated remarkable improvement in progression-free survival (PFS) with PARP inhibitors given as maintenance therapy in patients with complete or partial response after platinum-based therapy for platinum-sensitive ovarian cancer.	Platinum	221-229	poly(ADP-ribose) polymerase 1	Homo sapiens	124-128
29848719-0	2018	Neoadjuvant Platinum-based Chemotherapy Followed by Radical Hysterectomy for Stage Ib2-IIb Adenocarcinoma of the Uterine Cervix - An Italian Multicenter Retrospective Study.	Platinum	12-20	mitogen-activated protein kinase 8 interacting protein 2	Homo sapiens	83-86
29630768-0	2018	Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation.	Platinum	79-87	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	0-27
29630768-3	2018	Here, we present data indicating that EZH2 overexpression is associated with cisplatin resistance and intracellular platinum drug accumulation.	Platinum	116-124	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	38-42
29630768-6	2018	Downregulation of EZH2 not only sensitized cellular reactions to cisplatin and increased cellular platinum accumulation when cells were exposed to both cisplatin and BODIPY-Pt (a fluorescent cisplatin complex) but also protected copper transporter 1, a high-affinity copper transporter closely related to cisplatin resistance, from cisplatin-induced proteasomal degradation.	Platinum	98-106	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	18-22
29856124-0	2018	LINC00857 expression predicts and mediates the response to platinum-based chemotherapy in muscle-invasive bladder cancer.	Platinum	59-67	long intergenic non-protein coding RNA 857	Homo sapiens	0-9
29856124-8	2018	Expression of the lncRNA, LINC00857, was found to be upregulated in tumors from patients that did not respond to platinum-based chemotherapy.	Platinum	113-121	long intergenic non-protein coding RNA 857	Homo sapiens	26-35
30067614-7	2018	PARP inhibitors, which inhibit DNA repair, have shown the greatest activity in those ovarian cancers that harbor deleterious BRCA mutations, and they have also demonstrated activity in the maintenance setting after a response to and completion of platinum-based chemotherapy in patients with sensitive recurrent ovarian cancer regardless of BRCA status.	Platinum	247-255	poly(ADP-ribose) polymerase 1	Homo sapiens	0-4
29856124-12	2018	Our data indicate that LINC00857 plays an important role in the regulation of response to platinum-based chemotherapy.	Platinum	90-98	long intergenic non-protein coding RNA 857	Homo sapiens	23-32
29540490-4	2018	In this study, we attempted to establish the correlation of PI3K/STAT3/HOTAIR signaling with the progression of HNSCC and its sensitivity toward platinum-based and targeted anti-EGFR combination therapy.Experimental Design: We first analyzed the STAT3/HOTAIR and PI3K/AKT level in human HNSCC samples.	Platinum	145-153	signal transducer and activator of transcription 3	Homo sapiens	65-70
29540490-4	2018	In this study, we attempted to establish the correlation of PI3K/STAT3/HOTAIR signaling with the progression of HNSCC and its sensitivity toward platinum-based and targeted anti-EGFR combination therapy.Experimental Design: We first analyzed the STAT3/HOTAIR and PI3K/AKT level in human HNSCC samples.	Platinum	145-153	HOX transcript antisense RNA	Homo sapiens	71-77
29928365-0	2018	Expression of UCP2 is associated with sensitivity to platinum-based chemotherapy for ovarian serous carcinoma.	Platinum	53-61	uncoupling protein 2	Homo sapiens	14-18
29910616-6	2018	In addition, treatment with Au@Pt-NSs led to upregulation of phospho-p38 MAPK and downregulation of phospho-AKT in EJ cells.	Platinum	31-33	AKT serine/threonine kinase 1	Homo sapiens	108-111
29998228-2	2018	EGFR-mutated NSCLC patients have an increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib or afatinib, showing superior response, progression-free survival and overall survival rates with EGFR-TKIs than with platinum doublet chemotherapy, which makes EGFR-TKIs the standard of care in this subgroup of NSCLC patients.	Platinum	248-256	epidermal growth factor receptor	Homo sapiens	0-4
29998228-2	2018	EGFR-mutated NSCLC patients have an increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib or afatinib, showing superior response, progression-free survival and overall survival rates with EGFR-TKIs than with platinum doublet chemotherapy, which makes EGFR-TKIs the standard of care in this subgroup of NSCLC patients.	Platinum	248-256	epidermal growth factor receptor	Homo sapiens	61-65
29998228-2	2018	EGFR-mutated NSCLC patients have an increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib or afatinib, showing superior response, progression-free survival and overall survival rates with EGFR-TKIs than with platinum doublet chemotherapy, which makes EGFR-TKIs the standard of care in this subgroup of NSCLC patients.	Platinum	248-256	epidermal growth factor receptor	Homo sapiens	61-65
29998228-2	2018	EGFR-mutated NSCLC patients have an increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib or afatinib, showing superior response, progression-free survival and overall survival rates with EGFR-TKIs than with platinum doublet chemotherapy, which makes EGFR-TKIs the standard of care in this subgroup of NSCLC patients.	Platinum	248-256	epidermal growth factor receptor	Homo sapiens	61-65
30069329-8	2018	The rs11614913 (miR-196a-2) C allele or rs9280508 (miR-30c-1) G allele carriers shown more sensitive to platinum both in additive (P=0.010, P=0.022, respectively) and dominant models (P=0.001, P=0.018, respectively).	Platinum	104-112	microRNA 196a-2	Homo sapiens	16-26
30069329-8	2018	The rs11614913 (miR-196a-2) C allele or rs9280508 (miR-30c-1) G allele carriers shown more sensitive to platinum both in additive (P=0.010, P=0.022, respectively) and dominant models (P=0.001, P=0.018, respectively).	Platinum	104-112	microRNA 30c-1	Homo sapiens	51-60
29748023-7	2018	RESULTS: Combining the EGFR test with each TKI, gefitinib, erlotinib and afatinib if M+ or otherwise platinum doublets, resulted in higher effectiveness than the use of platinum doublets for all by 0.15, 0.19 and 0.21 QALYs, respectively.	Platinum	101-109	epidermal growth factor receptor	Homo sapiens	23-27
29397516-0	2018	Role of polymorphic XRCC6 (Ku70)/XRCC7 (DNA-PKcs) genes towards susceptibility and prognosis of lung cancer patients undergoing platinum based doublet chemotherapy.	Platinum	128-136	X-ray repair cross complementing 6	Homo sapiens	20-25
29397516-0	2018	Role of polymorphic XRCC6 (Ku70)/XRCC7 (DNA-PKcs) genes towards susceptibility and prognosis of lung cancer patients undergoing platinum based doublet chemotherapy.	Platinum	128-136	X-ray repair cross complementing 6	Homo sapiens	27-31
29397516-0	2018	Role of polymorphic XRCC6 (Ku70)/XRCC7 (DNA-PKcs) genes towards susceptibility and prognosis of lung cancer patients undergoing platinum based doublet chemotherapy.	Platinum	128-136	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	33-38
29397516-0	2018	Role of polymorphic XRCC6 (Ku70)/XRCC7 (DNA-PKcs) genes towards susceptibility and prognosis of lung cancer patients undergoing platinum based doublet chemotherapy.	Platinum	128-136	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	40-48
29928365-7	2018	The present study investigated the association between UCP2 expression and platinum sensitivity.	Platinum	75-83	uncoupling protein 2	Homo sapiens	55-59
29928365-11	2018	The UCP2 weighted score was lower in the platinum-sensitive group than in the platinum resistant-group (P=0.005).	Platinum	41-49	uncoupling protein 2	Homo sapiens	4-8
29928365-11	2018	The UCP2 weighted score was lower in the platinum-sensitive group than in the platinum resistant-group (P=0.005).	Platinum	78-86	uncoupling protein 2	Homo sapiens	4-8
29928365-12	2018	In addition, patients in the low UCP2 expression group were more sensitive to platinum-based chemotherapy than those in the high UCP2 expression group (P=0.001).	Platinum	78-86	uncoupling protein 2	Homo sapiens	33-37
29928365-14	2018	UCP2 expression may be a predictive marker of the efficacy of platinum-based chemotherapy for patients with ovarian serous carcinoma.	Platinum	62-70	uncoupling protein 2	Homo sapiens	0-4
29802286-1	2018	Mutations in genes of the breast cancer susceptibility gene (BRCA) pathway, namely, BRCA1, BRCA2, and PALB2, can provide useful information for the efficacy of platinum-based or poly ADP-ribose polymerase inhibitors chemotherapeutic regimens.	Platinum	160-168	BRCA1 DNA repair associated	Homo sapiens	61-65
29673791-13	2018	Similarly, Huaier also had a good adjuvant therapeutic effect on enhancing platinum (L-OHP and DDP) and adriamycin (ADM).	Platinum	75-83	translocase of inner mitochondrial membrane 8A	Homo sapiens	85-98
29808239-1	2018	OPINION STATEMENT: A decade after the discovery of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (EML4-ALK) rearrangements in non-small cell lung cancer (NSCLC), several inhibitors have gained regulatory approval, and their sequential use has deferred platinum-based chemotherapy to later lines of therapy.	Platinum	289-297	EMAP like 4	Homo sapiens	101-105
29808239-1	2018	OPINION STATEMENT: A decade after the discovery of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (EML4-ALK) rearrangements in non-small cell lung cancer (NSCLC), several inhibitors have gained regulatory approval, and their sequential use has deferred platinum-based chemotherapy to later lines of therapy.	Platinum	289-297	EMAP like 4	Homo sapiens	135-139
29808239-1	2018	OPINION STATEMENT: A decade after the discovery of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (EML4-ALK) rearrangements in non-small cell lung cancer (NSCLC), several inhibitors have gained regulatory approval, and their sequential use has deferred platinum-based chemotherapy to later lines of therapy.	Platinum	289-297	ALK receptor tyrosine kinase	Homo sapiens	140-143
29899829-3	2018	Consistent with this, increased Fap1 expression is associated with resistance to Fas or platinum induced apoptosis in some human colon cancer tumors or cell lines.	Platinum	88-96	protein tyrosine phosphatase non-receptor type 13	Homo sapiens	32-36
29899829-9	2018	Our studies suggest that therapeutically targeting Fap1 may decrease persistence of colon cancer stem cells during treatment with platinum chemotherapy by activating Fap1 substrates.	Platinum	130-138	protein tyrosine phosphatase non-receptor type 13	Homo sapiens	51-55
29802286-1	2018	Mutations in genes of the breast cancer susceptibility gene (BRCA) pathway, namely, BRCA1, BRCA2, and PALB2, can provide useful information for the efficacy of platinum-based or poly ADP-ribose polymerase inhibitors chemotherapeutic regimens.	Platinum	160-168	BRCA1 DNA repair associated	Homo sapiens	84-89
29802286-1	2018	Mutations in genes of the breast cancer susceptibility gene (BRCA) pathway, namely, BRCA1, BRCA2, and PALB2, can provide useful information for the efficacy of platinum-based or poly ADP-ribose polymerase inhibitors chemotherapeutic regimens.	Platinum	160-168	BRCA2 DNA repair associated	Homo sapiens	91-96
29802286-1	2018	Mutations in genes of the breast cancer susceptibility gene (BRCA) pathway, namely, BRCA1, BRCA2, and PALB2, can provide useful information for the efficacy of platinum-based or poly ADP-ribose polymerase inhibitors chemotherapeutic regimens.	Platinum	160-168	partner and localizer of BRCA2	Homo sapiens	102-107
31458755-6	2018	A comparison between Pt/N-pGF and commercial Pt/C shows that Pt/N-pGF has superior performance, based on its more positive onset potential and higher limiting diffusion current at -0.5 V.	Platinum	21-23	placental growth factor	Homo sapiens	66-69
29745942-5	2018	The strongest antiparallel chelate-chelate stacking interaction is formed between two platinum chelates, with a CCSD(T)/CBS interaction energy of -9.70 kcal mol-1, while the strongest stacking between two palladium chelates and two nickel chelates has CCSD(T)/CBS energies of -9.21 kcal mol-1 and -9.50 kcal mol-1, respectively.	Platinum	86-94	cystathionine beta-synthase	Homo sapiens	120-123
29745942-5	2018	The strongest antiparallel chelate-chelate stacking interaction is formed between two platinum chelates, with a CCSD(T)/CBS interaction energy of -9.70 kcal mol-1, while the strongest stacking between two palladium chelates and two nickel chelates has CCSD(T)/CBS energies of -9.21 kcal mol-1 and -9.50 kcal mol-1, respectively.	Platinum	86-94	cystathionine beta-synthase	Homo sapiens	260-263
29783665-3	2018	Here, a commercial NGS cancer panel comprising 26 genes, including TP53, was used to identify new genetic markers of platinum resistance and patient prognosis in a retrospective set of patients diagnosed with epithelial ovarian cancer.	Platinum	117-125	tumor protein p53	Homo sapiens	67-71
29861877-5	2018	Contrasting results, however, have been reported on the capability of variants of other genes as MTHFR, TYMS, ERCC1, XRCC1, GSTP1, CYP3A4/3A5 and ABCB1, in predicting either therapy efficacy or toxicity in patients undergoing treatment with pyrimidine antimetabolites, platinum derivatives, irinotecan and taxanes.	Platinum	269-277	methylenetetrahydrofolate reductase	Homo sapiens	97-102
29861877-5	2018	Contrasting results, however, have been reported on the capability of variants of other genes as MTHFR, TYMS, ERCC1, XRCC1, GSTP1, CYP3A4/3A5 and ABCB1, in predicting either therapy efficacy or toxicity in patients undergoing treatment with pyrimidine antimetabolites, platinum derivatives, irinotecan and taxanes.	Platinum	269-277	thymidylate synthetase	Homo sapiens	104-108
29861877-5	2018	Contrasting results, however, have been reported on the capability of variants of other genes as MTHFR, TYMS, ERCC1, XRCC1, GSTP1, CYP3A4/3A5 and ABCB1, in predicting either therapy efficacy or toxicity in patients undergoing treatment with pyrimidine antimetabolites, platinum derivatives, irinotecan and taxanes.	Platinum	269-277	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	110-115
29861877-5	2018	Contrasting results, however, have been reported on the capability of variants of other genes as MTHFR, TYMS, ERCC1, XRCC1, GSTP1, CYP3A4/3A5 and ABCB1, in predicting either therapy efficacy or toxicity in patients undergoing treatment with pyrimidine antimetabolites, platinum derivatives, irinotecan and taxanes.	Platinum	269-277	ATP binding cassette subfamily B member 1	Homo sapiens	146-151
29872499-9	2018	These data support the important role of CDK12 in the response to a platinum based therapy in ovarian patients.	Platinum	68-76	cyclin dependent kinase 12	Homo sapiens	41-46
29844858-0	2018	Genetic polymorphism of SLC31A1 is associated with clinical outcomes of platinum-based chemotherapy in non-small-cell lung cancer patients through modulating microRNA-mediated regulation.	Platinum	72-80	solute carrier family 31 member 1	Homo sapiens	24-31
29513396-2	2018	In this study, highly active sputtered thin films of platinum alloyed with yttrium (Pt3 Y) are deposited on commercial gas diffusion layers and their performance in a proton exchange membrane fuel cell is measured.	Platinum	53-61	zinc finger protein 135	Homo sapiens	84-87
29844858-1	2018	SLC31A1 is the major transporter for platinum drug intake, its expression correlates with drug disposition and response.	Platinum	37-45	solute carrier family 31 member 1	Homo sapiens	0-7
29672168-6	2018	Expert opinion: The FDA has approved this drug for the treatment of recurrent BRCA-mutated ovarian cancers, which were previously treated with at least two chemotherapies and has accepted the supplemental new drug application for maintenance use in patients who respond to platinum-based chemotherapy via the Prescription Drug User Fee Act (PDUFA) on 6 April 2018.	Platinum	273-281	BRCA1 DNA repair associated	Homo sapiens	78-82
29507127-4	2018	Using platinum replica electron microscopy of endothelial cells, we show that vascular endothelial (VE)-cadherin colocalizes with Arp2/3 complex-positive actin networks at different AJ types and is positioned at the interface between two oppositely oriented branched networks from adjacent cells.	Platinum	6-14	cadherin 5	Homo sapiens	78-112
29688719-0	2018	A Photoactive Platinum(IV) Anticancer Complex Inhibits Thioredoxin-Thioredoxin Reductase System Activity by Induced Oxidization of the Protein.	Platinum	14-22	thioredoxin	Homo sapiens	55-66
29688719-0	2018	A Photoactive Platinum(IV) Anticancer Complex Inhibits Thioredoxin-Thioredoxin Reductase System Activity by Induced Oxidization of the Protein.	Platinum	14-22	peroxiredoxin 5	Homo sapiens	67-88
29688719-2	2018	We demonstrate herein that the photoactive platinum(IV) anticancer complex trans,trans,trans-[Pt(N3)2(OH)2(Py)2] (1) can bind to His, Glu, and Gln residues of Trx upon the irradiation of blue light.	Platinum	43-51	thioredoxin	Homo sapiens	159-162
29729664-5	2018	While a previous case report demonstrated a surprising cure of platinum-resistant ovarian cancer with BRCA2 mutation by orally administered melphalan.	Platinum	63-71	BRCA2 DNA repair associated	Homo sapiens	102-107
29675525-5	2018	Secondly, platinum nanoparticles of 1.5 nm and 7.1 nm in diameter were loaded into MCF-17, and characterized by TEM.	Platinum	10-18	MFT2	Homo sapiens	112-115
29641173-0	2018	Monodisperse Metal-Organic Framework Nanospheres with Encapsulated Core-Shell Nanoparticles Pt/Au@Pd@{Co2(oba)4(3-bpdh)2}4H2O for the Highly Selective Conversion of CO2 to CO.	Platinum	92-94	complement C2	Homo sapiens	102-105
29294407-3	2018	Afterward, target binding aptamer Iota (TBAIota) was modified on electrode to specially recognize target TB, which could further combine with TBAII and single-stranded DNA P1-modified platinum nanoparticles (TBAII-PtNPs-P1) for immobilizing DNA networks with abundant MnPP.	Platinum	184-192	coagulation factor II, thrombin	Homo sapiens	40-42
29713086-3	2018	Triple-negative breast cancers (TNBCs) harbor subpopulations with BRCA1/2 mutations, hypothesized to be especially platinum-sensitive.	Platinum	115-123	BRCA1 DNA repair associated	Homo sapiens	66-73
29741112-0	2018	XPF polymorphism toward lung cancer susceptibility and survival in patients treated with platinum-based chemotherapy.	Platinum	89-97	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	0-3
29699633-5	2018	We found that PT-deficient miR-17-92 mice had more severe renal dysfunction and renal structures than their littermates.	Platinum	14-16	Mir17 host gene (non-protein coding)	Mus musculus	27-36
29366462-11	2018	The results of this study suggest that incursion of mST was likely to be the main cause of the loss of "Platinum" status and confirm that mST can persist in pigs and their environment.	Platinum	104-112	mercaptopyruvate sulfurtransferase	Mus musculus	52-55
29572031-0	2018	Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.	Platinum	50-58	helicase, POLQ like	Homo sapiens	0-18
29572031-0	2018	Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.	Platinum	50-58	helicase, POLQ like	Homo sapiens	20-24
29572031-7	2018	RESULTS: HELQ expression associates with response of EOC patients to platinum-based chemotherapy and their overall survival (OS), disease free survival (DFS).	Platinum	69-77	helicase, POLQ like	Homo sapiens	9-13
29572031-9	2018	CONCLUSIONS: HELQ plays an important role in regulating the expression of DNA repair proteins NER pathway which, in turn, contributes to cellular response to cisplatin and patients" response to platinum-based chemotherapy.	Platinum	194-202	helicase, POLQ like	Homo sapiens	13-17
29710850-2	2018	Although its activity is required to maintain genome integrity in healthy cells, ERCC1-XPF can counteract the effect of DNA-damaging therapies such as platinum-based chemotherapy in cancer cells.	Platinum	151-159	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	81-86
29717803-3	2018	These tubular catalysts with both open ends deliver electrochemical active surface area (ECSA) of 91.43 m2 gpt-1 which results from multiple Pt atoms exposed on the inner and outer surfaces that doubled Pt atoms can participate in catalytic reactions, further with enhanced electrocatalytic performance for oxygen reduction reaction (ORR).	Platinum	141-143	glutamic--pyruvic transaminase	Homo sapiens	107-112
29650143-3	2018	The introduction of anti-programmed cell death protein 1/programmed death-ligand 1(PD1/PD-L1) checkpoint inhibitors has redefined the therapeutic landscape for platinum-resistant urothelial cancers; their clinical efficacy and favorable toxicity render these agents attractive therapeutic options either as monotherapy or in combination with other agents in earlier disease states, including muscle-invasive disease.	Platinum	160-168	programmed cell death 1	Homo sapiens	83-86
29650143-3	2018	The introduction of anti-programmed cell death protein 1/programmed death-ligand 1(PD1/PD-L1) checkpoint inhibitors has redefined the therapeutic landscape for platinum-resistant urothelial cancers; their clinical efficacy and favorable toxicity render these agents attractive therapeutic options either as monotherapy or in combination with other agents in earlier disease states, including muscle-invasive disease.	Platinum	160-168	CD274 molecule	Homo sapiens	87-92
29712898-0	2018	C/EBPbeta enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation.	Platinum	19-27	CCAAT enhancer binding protein beta	Homo sapiens	0-9
29710850-2	2018	Although its activity is required to maintain genome integrity in healthy cells, ERCC1-XPF can counteract the effect of DNA-damaging therapies such as platinum-based chemotherapy in cancer cells.	Platinum	151-159	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	87-90
29690507-1	2018	The compound APR-246 (PRIMA-1MET) is a known reactivator of (mutant) p53 and inducer of oxidative stress which can sensitize cancer cells to platinum-based chemotherapeutics.	Platinum	141-149	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	13-16
29472315-7	2018	Additionally, AQP3, AQP6, and AQP11 mRNA expression were correlated with better OS, whereas AQP0 and AQP1 showed poor OS in all ovarian cancer patients treated with Platin, Taxol, and Taxol + Platin chemotherapy.	Platinum	165-171	major intrinsic protein of lens fiber	Homo sapiens	92-96
29472315-8	2018	AQP5, AQP8, and AQP10 were associated with improved OS, however, AQP4 predicted unfavorable OS in all patients treated with Platin chemotherapy.	Platinum	124-130	aquaporin 4	Homo sapiens	65-69
29719582-1	2018	Background: There is increasing evidence of high platinum sensitivity in BRCA-associated breast cancer.	Platinum	49-57	BRCA1 DNA repair associated	Homo sapiens	73-77
29719582-12	2018	Conclusion: The results of the study confirm the high pCR rate in BRCA1-positive breast cancer after platinum-based neoadjuvant chemotherapy.	Platinum	101-109	BRCA1 DNA repair associated	Homo sapiens	66-71
29685168-7	2018	Silencing BMI1 could reduce cell growth and metastasis, promote cell apoptosis, and enhance the platinum sensitivity of EOC cells.	Platinum	96-104	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	10-14
29690507-1	2018	The compound APR-246 (PRIMA-1MET) is a known reactivator of (mutant) p53 and inducer of oxidative stress which can sensitize cancer cells to platinum-based chemotherapeutics.	Platinum	141-149	tumor protein p53	Homo sapiens	69-72
29325739-8	2018	Anti-PD-1/PD-L1 antibodies have shown favorable clinical activity and tolerability in patients with metastatic urothelial carcinoma refractory to platinum-based therapy or who are ineligible for cisplatin.	Platinum	146-154	programmed cell death 1	Homo sapiens	5-9
29714311-2	2018	We confirmed that a metal/metal oxide bilayer of Al2O3~10  nm and Pt ~20  nm was successfully deposited on the micropores whose width and depth are 20 mum and 300 mum, respectively.	Platinum	66-68	latexin	Homo sapiens	151-154
29714311-2	2018	We confirmed that a metal/metal oxide bilayer of Al2O3~10  nm and Pt ~20  nm was successfully deposited on the micropores whose width and depth are 20 mum and 300 mum, respectively.	Platinum	66-68	latexin	Homo sapiens	163-166
29617652-0	2018	Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.	Platinum	78-86	BRCA2 DNA repair associated	Homo sapiens	120-125
29617652-3	2018	Utilizing primary and recurrent BRCA1/2-mutated carcinomas from OC patients, patient-derived lines, and an in vivo BRCA2-mutated mouse model, we identified a microRNA, miR-493-5p, that induced platinum/PARPi resistance exclusively in BRCA2-mutated carcinomas.	Platinum	193-201	BRCA1 DNA repair associated	Homo sapiens	32-37
29617652-3	2018	Utilizing primary and recurrent BRCA1/2-mutated carcinomas from OC patients, patient-derived lines, and an in vivo BRCA2-mutated mouse model, we identified a microRNA, miR-493-5p, that induced platinum/PARPi resistance exclusively in BRCA2-mutated carcinomas.	Platinum	193-201	BRCA2 DNA repair associated	Homo sapiens	115-120
29617652-3	2018	Utilizing primary and recurrent BRCA1/2-mutated carcinomas from OC patients, patient-derived lines, and an in vivo BRCA2-mutated mouse model, we identified a microRNA, miR-493-5p, that induced platinum/PARPi resistance exclusively in BRCA2-mutated carcinomas.	Platinum	193-201	microRNA 493	Mus musculus	168-175
29617652-3	2018	Utilizing primary and recurrent BRCA1/2-mutated carcinomas from OC patients, patient-derived lines, and an in vivo BRCA2-mutated mouse model, we identified a microRNA, miR-493-5p, that induced platinum/PARPi resistance exclusively in BRCA2-mutated carcinomas.	Platinum	193-201	breast cancer 2, early onset	Mus musculus	234-239
29617652-7	2018	We conclude that impact of miR-493-5p on multiple pathways pertinent to genome stability cumulatively causes PARPi/platinum resistance in BRCA2 mutant carcinomas.	Platinum	115-123	microRNA 493	Homo sapiens	27-34
29617652-7	2018	We conclude that impact of miR-493-5p on multiple pathways pertinent to genome stability cumulatively causes PARPi/platinum resistance in BRCA2 mutant carcinomas.	Platinum	115-123	BRCA2 DNA repair associated	Homo sapiens	138-143
29599365-1	2018	BACKGROUND/AIM: The purpose of this trial was to evaluate the feasibility and efficacy of alternating platinum-based doublet chemotherapy with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with EGFR-mutant non-small cell lung cancer (NSCLC).	Platinum	102-110	epidermal growth factor receptor	Homo sapiens	232-236
29472240-1	2018	Researchers have presented a new model that uses six readily available clinical factors to predict whether a patient with advanced bladder cancer who has already received platinum chemotherapy will respond to treatment with the PD-L1 inhibitor atezolizumab.	Platinum	171-179	CD274 molecule	Homo sapiens	228-233
29624369-4	2018	Two hairpin DNA probes, H1 and H2, were ingeniously designed and functionalized with magnetic beads (MBs) and platinum nanoparticles (PtNPs), respectively, to form MBs-H1 and PtNPs-H2 complexes.	Platinum	110-118	H1.5 linker histone, cluster member	Homo sapiens	24-33
29577726-2	2018	To quantitatively detect mRNA expression levels in living cells, we have developed DNA-driven gold nanorod coated platinum-upconversion nanoparticle satellite assemblies (termed Au NR@Pt-UCNP satellites) for intracellular thymidine kinase 1 (TK1) mRNA analysis.	Platinum	114-122	thymidine kinase 1	Homo sapiens	222-240
29577726-2	2018	To quantitatively detect mRNA expression levels in living cells, we have developed DNA-driven gold nanorod coated platinum-upconversion nanoparticle satellite assemblies (termed Au NR@Pt-UCNP satellites) for intracellular thymidine kinase 1 (TK1) mRNA analysis.	Platinum	114-122	thymidine kinase 1	Homo sapiens	242-245
29194596-0	2018	Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response.	Platinum	126-134	vav guanine nucleotide exchange factor 3	Homo sapiens	18-22
29194596-13	2018	Notably, platinum-refractory cancers showed marked overexpression of Vav3.1 compared to other subsets of platinum-sensitivity (15.848 vs. 6.653, p = 0.0001).	Platinum	9-17	vav guanine nucleotide exchange factor 3	Homo sapiens	69-73
29644490-3	2018	RECENT FINDINGS: Since May 2016, five different agents targeting the PD-1/PD-L1 pathway (atezolizumab, pembrolizumab, nivolumab, avelumab, durvalumab) have received FDA approval for the treatment of aUC in the platinum-refractory setting, while pembrolizumab and atezolizumab are FDA-approved for cisplatin-ineligible patients in the first-line setting.	Platinum	210-218	CD274 molecule	Homo sapiens	74-79
29644491-5	2018	To date, PARPi seems less efficacious in metastatic breast cancer patients than those with BRCA mutated platinum-sensitive recurrent ovarian cancer, perhaps reflecting the biologic heterogeneity and low somatic BRCA mutation rate in breast cancer.	Platinum	104-112	BRCA1 DNA repair associated	Homo sapiens	91-95
29452344-0	2018	Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers.	Platinum	71-79	BLM RecQ like helicase	Homo sapiens	18-21
29452344-5	2018	Results: We identified two genes, the Bloom helicase (BLM) and Fanconi anemia complementation group I (FANCI), that have both increased DNA copy number and gene expression in the platinum-sensitive cases.	Platinum	179-187	BLM RecQ like helicase	Homo sapiens	38-52
29452344-5	2018	Results: We identified two genes, the Bloom helicase (BLM) and Fanconi anemia complementation group I (FANCI), that have both increased DNA copy number and gene expression in the platinum-sensitive cases.	Platinum	179-187	BLM RecQ like helicase	Homo sapiens	54-57
29452344-5	2018	Results: We identified two genes, the Bloom helicase (BLM) and Fanconi anemia complementation group I (FANCI), that have both increased DNA copy number and gene expression in the platinum-sensitive cases.	Platinum	179-187	FA complementation group I	Homo sapiens	63-101
29452344-5	2018	Results: We identified two genes, the Bloom helicase (BLM) and Fanconi anemia complementation group I (FANCI), that have both increased DNA copy number and gene expression in the platinum-sensitive cases.	Platinum	179-187	FA complementation group I	Homo sapiens	103-108
29452344-8	2018	Conclusions: A biomarker based on the expression levels of the BLM and FANCI genes is a potential predictor of platinum sensitivity in triple-negative breast cancer and ovarian cancer.	Platinum	111-119	BLM RecQ like helicase	Homo sapiens	63-66
29452344-8	2018	Conclusions: A biomarker based on the expression levels of the BLM and FANCI genes is a potential predictor of platinum sensitivity in triple-negative breast cancer and ovarian cancer.	Platinum	111-119	FA complementation group I	Homo sapiens	71-76
29325739-8	2018	Anti-PD-1/PD-L1 antibodies have shown favorable clinical activity and tolerability in patients with metastatic urothelial carcinoma refractory to platinum-based therapy or who are ineligible for cisplatin.	Platinum	146-154	CD274 molecule	Homo sapiens	10-15
29082457-10	2018	Both lncRNA RP5-1120P11.1 and ABCC10 were down-regulated in platinum-resistant HGS-OvCa patients, and RP5-1120P11.1 is located near ABCC10 on chromosome 6.	Platinum	60-68	ATP binding cassette subfamily C member 10	Homo sapiens	30-36
29397193-1	2018	Niraparib is an oral poly(ADP ribose) polymerase (PARP) inhibitor that is currently approved by the United States Food and Drug Administration (US FDA) as well as recently approved by the European Medicines Agency (EMA) for the maintenance treatment of women with recurrent ovarian cancer who are in complete or partial response to platinum-based chemotherapy.	Platinum	332-340	poly(ADP-ribose) polymerase 1	Homo sapiens	50-54
29082457-10	2018	Both lncRNA RP5-1120P11.1 and ABCC10 were down-regulated in platinum-resistant HGS-OvCa patients, and RP5-1120P11.1 is located near ABCC10 on chromosome 6.	Platinum	60-68	ATP binding cassette subfamily C member 10	Homo sapiens	132-138
29407906-7	2018	The mechanism starts with formation of Cpd 0 from the ferrous-dioxy reactant complex by PT from the C-ring heme propionate coupled with hole transfer to H4B through the highest occupied pi-orbital of NHA as a bridge.	Platinum	88-90	H4 clustered histone 4	Homo sapiens	153-156
29353085-10	2018	In addition, crystallographic data were obtained for the (PtL)4/Lysozyme and (PtL)4/RNase A adducts pointing at His side chains as the primary binding sites for monometallic Pt fragments.	Platinum	58-60	lysozyme C, tracheal isozyme	Bos taurus	64-72
29309945-9	2018	Within the BRCA1/BRCA2 mutated group, having had platinum-based adjuvant chemotherapy (n = 10) was associated with better survival than alternative chemotherapy (n = 8) or no adjuvant therapy (n = 4) (31.0 vs 17.8 vs 9.3 months, respectively, p &lt; 0.001).	Platinum	49-57	BRCA1 DNA repair associated	Homo sapiens	11-16
29309945-9	2018	Within the BRCA1/BRCA2 mutated group, having had platinum-based adjuvant chemotherapy (n = 10) was associated with better survival than alternative chemotherapy (n = 8) or no adjuvant therapy (n = 4) (31.0 vs 17.8 vs 9.3 months, respectively, p &lt; 0.001).	Platinum	49-57	BRCA2 DNA repair associated	Homo sapiens	17-22
29309945-11	2018	However, platinum-based chemotherapy regimens were associated with markedly improved survival in patients with BRCA1/BRCA2 mutations, with survival differences no longer appreciated with wild-type patients.	Platinum	9-17	BRCA1 DNA repair associated	Homo sapiens	111-116
29309945-11	2018	However, platinum-based chemotherapy regimens were associated with markedly improved survival in patients with BRCA1/BRCA2 mutations, with survival differences no longer appreciated with wild-type patients.	Platinum	9-17	BRCA2 DNA repair associated	Homo sapiens	117-122
29541174-2	2018	BRCA2-associated ovarian carcinomas predominantly possess a high-grade serous phenotype, which respond to platinum and targeted therapy with PARP inhibitors.	Platinum	106-114	BRCA2 DNA repair associated	Homo sapiens	0-5
29572009-9	2018	CONCLUSION: A combination of ERCC1 and ERCC2 polymorphisms may predict OS among pemetrexed/platinum treated advanced non-squamous NSCLC patients.	Platinum	91-99	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	29-34
29572009-9	2018	CONCLUSION: A combination of ERCC1 and ERCC2 polymorphisms may predict OS among pemetrexed/platinum treated advanced non-squamous NSCLC patients.	Platinum	91-99	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	39-44
29451289-5	2018	Owing to this trade-off, the Pt complex with a moderate hydrogen bonding acceptor, PF6-, most effectively shows dimer emission.	Platinum	29-31	sperm associated antigen 17	Homo sapiens	83-86
29552194-6	2018	In addition, significant differences were also revealed in the expression levels of SMO (P=0.013) and GLI1 (P=0.0005) between the platinum drug-sensitive and drug-resistant groups.	Platinum	130-138	smoothened, frizzled class receptor	Homo sapiens	84-87
29552194-6	2018	In addition, significant differences were also revealed in the expression levels of SMO (P=0.013) and GLI1 (P=0.0005) between the platinum drug-sensitive and drug-resistant groups.	Platinum	130-138	GLI family zinc finger 1	Homo sapiens	102-106
29527843-5	2018	METHODS: A total of 114 patients with EGFR-negative lung adenocarcinoma who were treated with platinum doublet were retrospectively enrolled.	Platinum	94-102	epidermal growth factor receptor	Homo sapiens	38-42
28540485-0	2018	XPC Polymorphism and Risk for Lung Cancer in North Indian Patients Treated with Platinum Based Chemotherapy and Its Association with Clinical Outcomes.	Platinum	80-88	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	0-3
28540485-7	2018	The treatment outcomes of 167 lung cancer patients treated with platinum based chemotherapy were evaluated.The mutant genotypic variant of XPC Lys939Gln has been associated with elevated risk of lung cancer(OR:2.30;95%CI:1.41-3.73;p=0.0007) whereas XPC Ala499Val showed a highly protective effect (OR:0.25;95%CI:0.10-0.63;p=0.003).	Platinum	64-72	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	139-142
28540485-7	2018	The treatment outcomes of 167 lung cancer patients treated with platinum based chemotherapy were evaluated.The mutant genotypic variant of XPC Lys939Gln has been associated with elevated risk of lung cancer(OR:2.30;95%CI:1.41-3.73;p=0.0007) whereas XPC Ala499Val showed a highly protective effect (OR:0.25;95%CI:0.10-0.63;p=0.003).	Platinum	64-72	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	249-252
29474082-1	2018	The vibrational dynamics of Pt-H on a nanostructured platinum surface has been examined by ultrafast infrared spectroscopy.	Platinum	53-61	parathyroid hormone	Homo sapiens	28-32
29580231-0	2018	GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer.	Platinum	14-22	growth differentiation factor 15	Homo sapiens	0-5
29134637-0	2018	An ERCC4 regulatory variant predicts grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy.	Platinum	126-134	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	3-8
29584739-4	2018	The HE4 value was assessed based on the PSF, OS, DFS, surgical outcome, two-year survival and platinum sensitivity.	Platinum	94-102	WAP four-disulfide core domain 2	Homo sapiens	4-7
29584739-5	2018	RESULTS: Preoperative HE4 levels were a predictor of platinum sensitivity (AUC- 0.644; p = 0.035) and DFS (AUC = 0.637; p = 0.0492).	Platinum	53-61	WAP four-disulfide core domain 2	Homo sapiens	22-25
29662625-0	2018	ADAM17 inhibition enhances platinum efficiency in ovarian cancer.	Platinum	27-35	ADAM metallopeptidase domain 17	Homo sapiens	0-6
29301826-0	2018	p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.	Platinum	75-83	tumor protein p53	Homo sapiens	0-3
29301826-0	2018	p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.	Platinum	75-83	tumor protein p53	Homo sapiens	143-146
29502288-3	2018	The anti PD1 agent, nivolumab, was recently approved by the FDA as a standard of care regimen for patients with platinum refractory recurrent/metastatic (R/M) HNSCC.	Platinum	112-120	programmed cell death 1	Homo sapiens	9-12
29466854-4	2018	Here, we show that the spin states of iron atoms adsorbed directly on a conductive platinum substrate have a surprisingly long spin-relaxation time in the nanosecond regime, which is comparable to that of a transition metal atom decoupled from the substrate electrons by a thin decoupling layer.	Platinum	83-91	spindlin 1	Homo sapiens	23-27
29466854-4	2018	Here, we show that the spin states of iron atoms adsorbed directly on a conductive platinum substrate have a surprisingly long spin-relaxation time in the nanosecond regime, which is comparable to that of a transition metal atom decoupled from the substrate electrons by a thin decoupling layer.	Platinum	83-91	spindlin 1	Homo sapiens	127-131
29441396-2	2018	Reaction of (PPh2)2BMes with Ni(COD)2 or Pt(COD)Me2 (COD = 1,5-cyclooctadiene) results in gradual COD displacement to give [eta3-P,B,P-(PPh2)2BMes]Ni(COD) (3) or [eta3-P,B,P-(PPh2)2BMes]Pt(CH3)2 (6).	Platinum	41-44	COD2	Homo sapiens	32-37
28481779-6	2018	The association between claudin-4 expression and platinum resistance was assessed using risk ratios and the Pearson chi test.	Platinum	49-57	claudin 4	Homo sapiens	24-33
28851663-12	2018	Our study supports that ALDH1A1 expression is associated with poor response to platinum-based therapy in patients with high-grade ovarian serous carcinoma.	Platinum	79-87	aldehyde dehydrogenase 1 family member A1	Homo sapiens	24-31
29397071-0	2018	DN604: A platinum(II) drug candidate with classic SAR can induce apoptosis via suppressing CK2-mediated p-cdc25C subcellular localization in cancer cells.	Platinum	9-17	sarcosine dehydrogenase	Homo sapiens	50-53
29397071-0	2018	DN604: A platinum(II) drug candidate with classic SAR can induce apoptosis via suppressing CK2-mediated p-cdc25C subcellular localization in cancer cells.	Platinum	9-17	cell division cycle 25C	Homo sapiens	106-112
29352572-15	2018	Combination therapy demonstrated promising preliminary antitumor activity in platinum-sensitive ovarian cancer patients with germline BRCA mutations.	Platinum	77-85	BRCA1 DNA repair associated	Homo sapiens	134-138
28481779-14	2018	The role of claudin-4 in the development of platinum resistance remains unclear.	Platinum	44-52	claudin 4	Homo sapiens	12-21
29707316-0	2018	Single nucleotide polymorphisms of casitas B-lineage lymphoma proto-oncogene-b predict outcomes of patients with advanced non-small cell lung cancer after first-line platinum based doublet chemotherapy.	Platinum	166-174	Cbl proto-oncogene B	Homo sapiens	35-78
29394468-0	2018	Copper efflux transporters ATP7A and ATP7B: Novel biomarkers for platinum drug resistance and targets for therapy.	Platinum	65-73	ATPase copper transporting alpha	Homo sapiens	27-32
29394468-0	2018	Copper efflux transporters ATP7A and ATP7B: Novel biomarkers for platinum drug resistance and targets for therapy.	Platinum	65-73	ATPase copper transporting beta	Homo sapiens	37-42
29394468-3	2018	Recent studies suggest that copper efflux transporters, which are encoded by ATP7A and ATP7B, play an important role in platinum drug resistance.	Platinum	120-128	ATPase copper transporting alpha	Homo sapiens	77-82
29394468-3	2018	Recent studies suggest that copper efflux transporters, which are encoded by ATP7A and ATP7B, play an important role in platinum drug resistance.	Platinum	120-128	ATPase copper transporting beta	Homo sapiens	87-92
29394468-7	2018	We also discuss the possible mechanisms of platinum drug resistance mediated by ATP7A/7B and provide novel strategies for overcoming resistance.	Platinum	43-51	ATPase copper transporting alpha	Homo sapiens	80-85
29153720-1	2018	Hierarchical nanoporous platinum-copper (hnp-PtCu) alloy nanoflowers with bimodal pore/ligament size are easily fabricated by selectively dissolving Al atoms and part of Cu atoms from PtCuAl ternary alloy.	Platinum	24-32	kallikrein related peptidase 8	Homo sapiens	41-44
29448753-7	2018	However, the anatase phase of Pt/TiO2 exhibited better degradation ability than the anatase/rutile junction of Pt/TiO2, and the degradation rate decreased with a decrease in the anatase composition of TiO2, indicating that anatase composition in the Pt/TiO2 system played an important role of enhancing the photocatalytic degradation of Acid Red 1 dye.	Platinum	30-32	adenosine deaminase RNA specific B1	Homo sapiens	342-347
29695698-6	2018	It has been shown that pT effectively inhibits the expression of CCR5 in both the HT1080 CCR5-EGFP model cell line and in human primary lymphocytes.	Platinum	23-25	C-C motif chemokine receptor 5	Homo sapiens	65-69
29496254-1	2018	PURPOSE: First-line treatment for patients with extensive-stage small cell lung cancer (SCLC) includes treatment with platinum-based combination chemotherapy.	Platinum	118-126	SCLC1	Homo sapiens	88-92
29695698-6	2018	It has been shown that pT effectively inhibits the expression of CCR5 in both the HT1080 CCR5-EGFP model cell line and in human primary lymphocytes.	Platinum	23-25	C-C motif chemokine receptor 5	Homo sapiens	89-93
29368506-0	2018	Panitumumab-Conjugated and Platinum-Cored pH-Sensitive Apoferritin Nanocages for Colorectal Cancer-Targeted Therapy.	Platinum	27-35	ferritin heavy chain 1	Homo sapiens	55-66
29531840-1	2018	Background: The North-East Japan Study Group (NEJ) 005/Tokyo Cooperative Oncology Group (TCOG) 0902 study has reported that first-line concurrent and sequential alternating combination therapies of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (gefitinib) plus platinum-based doublet chemotherapy (carboplatin/pemetrexed) offer promising efficacy with predictable toxicities for patients with EGFR-mutant non-small cell lung cancer.	Platinum	284-292	epidermal growth factor receptor	Homo sapiens	201-233
29531840-1	2018	Background: The North-East Japan Study Group (NEJ) 005/Tokyo Cooperative Oncology Group (TCOG) 0902 study has reported that first-line concurrent and sequential alternating combination therapies of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (gefitinib) plus platinum-based doublet chemotherapy (carboplatin/pemetrexed) offer promising efficacy with predictable toxicities for patients with EGFR-mutant non-small cell lung cancer.	Platinum	284-292	epidermal growth factor receptor	Homo sapiens	235-239
29435041-0	2018	TBX2 expression is associated with platinum-sensitivity of ovarian serous carcinoma.	Platinum	35-43	T-box transcription factor 2	Homo sapiens	0-4
29435041-7	2018	In the present study the association between TBX2 expression and platinum sensitivity was investigated.	Platinum	65-73	T-box transcription factor 2	Homo sapiens	45-49
29435041-11	2018	The TBX2-weighted score was significantly lower in the platinum-sensitive group than the platinum-resistant group (P=0.005) and the low TBX2 expression group was significantly more sensitive to platinum-based chemotherapy (P=0.004).	Platinum	55-63	T-box transcription factor 2	Homo sapiens	4-8
29435041-13	2018	TBX2 expression may serve as a predictive marker of the efficacy of platinum-based chemotherapy for patients with ovarian serous carcinoma.	Platinum	68-76	T-box transcription factor 2	Homo sapiens	0-4
29411604-1	2018	We report in this article a detailed study on how to stabilize a first-row transition metal (M) in an intermetallic L10-MPt alloy nanoparticle (NP) structure and how to surround the L10-MPt with an atomic layer of Pt to enhance the electrocatalysis of Pt for oxygen reduction reaction (ORR) in fuel cell operation conditions.	Platinum	121-123	immunoglobulin kappa variable 3-7 (non-functional)	Homo sapiens	116-119
29411604-1	2018	We report in this article a detailed study on how to stabilize a first-row transition metal (M) in an intermetallic L10-MPt alloy nanoparticle (NP) structure and how to surround the L10-MPt with an atomic layer of Pt to enhance the electrocatalysis of Pt for oxygen reduction reaction (ORR) in fuel cell operation conditions.	Platinum	187-189	immunoglobulin kappa variable 3-7 (non-functional)	Homo sapiens	182-185
29410996-5	2018	Numerous clinical metal-containing drugs, such as platinum- and gold-containing compounds, show inhibitory effects on the thioredoxin system, providing strategies to develop novel anti-cancer drugs.	Platinum	50-58	thioredoxin	Homo sapiens	122-133
29467390-3	2018	Overexpression of Fibroblast Growth Factor 1 (FGF1) is observed in various cancers, correlates with poor survival and could be responsible for resistance to platinum-based chemotherapy of serous ovarian cancers.	Platinum	157-165	fibroblast growth factor 1	Homo sapiens	18-44
29363680-1	2018	Based on choline oxidase immobilized by co-crosslinking on an overoxidised polypyrrole modified platinum electrode, a novel electrochemical assay for cholinesterase activity in human serum was developed.	Platinum	96-104	butyrylcholinesterase	Homo sapiens	150-164
29467390-3	2018	Overexpression of Fibroblast Growth Factor 1 (FGF1) is observed in various cancers, correlates with poor survival and could be responsible for resistance to platinum-based chemotherapy of serous ovarian cancers.	Platinum	157-165	fibroblast growth factor 1	Homo sapiens	46-50
29662657-10	2018	This is the first study demonstrating the role of cN-II as a predictor of response to gemcitabine/platinum combinations in NSCLC.	Platinum	98-106	5'-nucleotidase, cytosolic II	Homo sapiens	50-55
32913984-0	2018	Polyclonal BRCA2 Reversion Mutations Detected in Circulating Tumor DNA After Platinum Chemotherapy in a Patient With Metastatic Prostate Cancer.	Platinum	77-85	BRCA2 DNA repair associated	Homo sapiens	11-16
29192713-1	2018	Platinum complexes of the type [Pt(PL)(AL)]2+ where PL is a derivative of 1,10-phenanthroline and AL is cis-1,4-diaminocyclohexane (1,4-dach), have been synthesised and characterised by ultraviolet spectroscopy, elemental microanalysis, nuclear magnetic resonance and X-ray crystallography.	Platinum	0-8	suppressor of cytokine signaling 1	Homo sapiens	104-109
29662657-0	2018	5"-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.	Platinum	87-95	5'-nucleotidase ecto	Homo sapiens	0-15
29662657-0	2018	5"-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.	Platinum	87-95	5'-nucleotidase, cytosolic II	Homo sapiens	16-21
29459887-0	2018	Role of BRCA Mutations in the Modulation of Response to Platinum Therapy.	Platinum	56-64	BRCA1 DNA repair associated	Homo sapiens	8-12
29372745-5	2018	As a result, the enhanced hydrogen production of 3D OPG-C3N4-CN reaches up to 1590 mumol h-1 g-1 when using Pt as a cocatalyst, which is about six times as much as that of the bulk g-C3N4.	Platinum	108-110	basic transcription factor 3 pseudogene 11	Homo sapiens	52-55
29178431-3	2018	Metal ions such as cobalt(II), iron(III), platinum(IV) and nickel(II) are found to partition preferentially to one of the phases of the acidic aqueous biphasic system and it is here shown that it successfully allows the difficult separation of CoII from NiII , here studied at 24 and 50  C.	Platinum	42-50	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	244-248
29849936-1	2018	Introduction: Patients with advanced lung adenocarcinoma harboring epidermal growth factor receptor (EGFR)-activating mutations have good response rate and longer progression-free survival (PFS) when treated with the tyrosine kinase inhibitors (TKI) compared with platinum-based chemotherapy.	Platinum	264-272	epidermal growth factor receptor	Homo sapiens	67-99
29849936-1	2018	Introduction: Patients with advanced lung adenocarcinoma harboring epidermal growth factor receptor (EGFR)-activating mutations have good response rate and longer progression-free survival (PFS) when treated with the tyrosine kinase inhibitors (TKI) compared with platinum-based chemotherapy.	Platinum	264-272	epidermal growth factor receptor	Homo sapiens	101-105
31938179-2	2018	Human copper transporter 1 (hCTR1) was proven as crucial regulator for cellular platinum uptake in cancer cells and improving effect of cisplatin treatment.	Platinum	80-88	solute carrier family 31 member 1	Homo sapiens	6-26
29331492-10	2018	Furthermore, BRCA2 was an independent unfavorable prognostic factor for disease-free survival and overall survival (P &lt; 0.001) in GC patients who underwent platinum-based adjuvant chemotherapy.	Platinum	159-167	BRCA2 DNA repair associated	Homo sapiens	13-18
29716743-4	2018	In this research, we study whether FOXO3a was involved in the mechanism of platinum drug resistance.	Platinum	75-83	forkhead box O3	Homo sapiens	35-41
29716743-6	2018	RESULTS: We found that FOXO3a expression upregulated significantly in A2780 compared with A2780/DDP cells with the treatment of platinum.	Platinum	128-136	forkhead box O3	Homo sapiens	23-29
29716743-7	2018	Moreover, overexpression of FOXO3a in ovarian cancer inversed the platinum resistance in ovarian cancer.	Platinum	66-74	forkhead box O3	Homo sapiens	28-34
29716743-8	2018	CONCLUSION: These observations reminded that the role of FOXO3a might be one of the critical mechanisms in developing platinum drug resistance in ovarian cancer.	Platinum	118-126	forkhead box O3	Homo sapiens	57-63
29144983-0	2018	Albumin-coordinated assembly of clearable platinum nanodots for photo-induced cancer theranostics.	Platinum	42-50	albumin	Homo sapiens	0-7
29144983-3	2018	Here, we introduce albumin-coordinated assembly of clearable Pt nanodots (Pt-NDs) with monodisperse nanostructure as high-performance theranostic agents for imaging-guided photothermal tumor ablation.	Platinum	61-63	albumin	Homo sapiens	19-26
29187510-0	2018	ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas.	Platinum	33-41	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
29187510-2	2018	Excision repair cross complementing group 1 (ERCC1) plays a critical role in the repair of platinum-induced DNA damage.	Platinum	91-99	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-43
29187510-2	2018	Excision repair cross complementing group 1 (ERCC1) plays a critical role in the repair of platinum-induced DNA damage.	Platinum	91-99	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	45-50
29233532-12	2018	BRCA1 mutations were associated with increased sensitivity to platinum chemotherapy while BRCA1 methylation was not (P=0.034, P=0.803).	Platinum	62-70	BRCA1 DNA repair associated	Homo sapiens	0-5
29240605-0	2018	Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer.	Platinum	82-90	platelet derived growth factor D	Homo sapiens	0-32
31938179-2	2018	Human copper transporter 1 (hCTR1) was proven as crucial regulator for cellular platinum uptake in cancer cells and improving effect of cisplatin treatment.	Platinum	80-88	solute carrier family 31 member 1	Homo sapiens	28-33
29240605-1	2018	OBJECTIVE: This study aimed to investigate whether platelet-derived growth factor D (PDGF-D) is a prognostic biomarker and is associated with platinum resistance in epithelial ovarian cancer, which has not been studied by others previously.	Platinum	142-150	platelet derived growth factor D	Homo sapiens	51-83
31938179-3	2018	Thus, methods to detect expression of hCTR1 in patients in biopsy specimens with certain rapidity and accuracy are essential to evaluate platinum drug sensitivity and perform further individualized treatment.	Platinum	137-145	solute carrier family 31 member 1	Homo sapiens	38-43
29240605-1	2018	OBJECTIVE: This study aimed to investigate whether platelet-derived growth factor D (PDGF-D) is a prognostic biomarker and is associated with platinum resistance in epithelial ovarian cancer, which has not been studied by others previously.	Platinum	142-150	platelet derived growth factor D	Homo sapiens	85-91
29240605-6	2018	Platelet-derived growth factor D in platinum-resistant cases is overexpressed compared with that in platinum-sensitive cases (P &lt; 0.001).	Platinum	36-44	platelet derived growth factor D	Homo sapiens	0-32
28150532-0	2018	Spectroscopic investigation of Bovine Liver Catalase interactions with a novel phen-imidazole derivative of platinum.	Platinum	108-116	catalase	Bos taurus	44-52
29240605-6	2018	Platelet-derived growth factor D in platinum-resistant cases is overexpressed compared with that in platinum-sensitive cases (P &lt; 0.001).	Platinum	100-108	platelet derived growth factor D	Homo sapiens	0-32
29240605-7	2018	Obstetrics stage (P = 0.029) and PDGF-D overexpression (P &lt; 0.001) are independently correlated with platinum resistance.	Platinum	104-112	platelet derived growth factor D	Homo sapiens	33-39
29240605-8	2018	CONCLUSIONS: Our study indicates that PDGF-D overexpression is an independent predictor of platinum-based chemotherapy resistance and that it may also be a potential biomarker for targeted therapy and poor prognosis.	Platinum	91-99	platelet derived growth factor D	Homo sapiens	38-44
28150532-4	2018	On the other hand, the fluorescence quenching measurements revealed that despite slight changes in activity, catalase experiences notable alterations in three-dimensional environment around the chromophores of the enzyme structure with increasing platinum complex concentration.	Platinum	247-255	catalase	Bos taurus	109-117
29133939-4	2018	For example, DNA repair pathway mutations in genes such as ERCC2, FANCC, ATM, RB1, and others can predict responses to neoadjuvant platinum-based chemotherapies and to targeted therapies on the basis of mutation status.	Platinum	131-139	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	59-64
29133939-4	2018	For example, DNA repair pathway mutations in genes such as ERCC2, FANCC, ATM, RB1, and others can predict responses to neoadjuvant platinum-based chemotherapies and to targeted therapies on the basis of mutation status.	Platinum	131-139	FA complementation group C	Homo sapiens	66-71
29133939-4	2018	For example, DNA repair pathway mutations in genes such as ERCC2, FANCC, ATM, RB1, and others can predict responses to neoadjuvant platinum-based chemotherapies and to targeted therapies on the basis of mutation status.	Platinum	131-139	ATM serine/threonine kinase	Homo sapiens	73-76
29133939-4	2018	For example, DNA repair pathway mutations in genes such as ERCC2, FANCC, ATM, RB1, and others can predict responses to neoadjuvant platinum-based chemotherapies and to targeted therapies on the basis of mutation status.	Platinum	131-139	RB transcriptional corepressor 1	Homo sapiens	78-81
29231705-4	2018	Thrombin was selected as a model target, and its two aptamers recognizing different sites of the protein were used (one aptamer was immobilized on the surface of magnetic microparticles and the other aptamer was functionalized with platinum nanoparticles).	Platinum	232-240	coagulation factor II, thrombin	Homo sapiens	0-8
30154286-1	2018	OBJECTIVE: To determine mechanisms for the role of high mobility group box-1 (HMGB1) to platinum based chemo-sensitivity in cervical cancer.	Platinum	88-96	high mobility group box 1	Homo sapiens	51-76
30154286-1	2018	OBJECTIVE: To determine mechanisms for the role of high mobility group box-1 (HMGB1) to platinum based chemo-sensitivity in cervical cancer.	Platinum	88-96	high mobility group box 1	Homo sapiens	78-83
29251623-5	2018	Spheroid spreading is altered by the PIP-platin, which was a novel platinum based drug previously reported by us with an inhibitory effect on cell migration.	Platinum	67-75	prolactin induced protein	Homo sapiens	37-40
29254797-7	2018	The association between IKK2 and NF-kappaB positivity predicted a subgroup with shorter overall survival (p = 0.004), disease-free survival (p = 0.003) and resistance to platinum-based chemotherapy (p = 0.036).	Platinum	170-178	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	24-28
29254797-7	2018	The association between IKK2 and NF-kappaB positivity predicted a subgroup with shorter overall survival (p = 0.004), disease-free survival (p = 0.003) and resistance to platinum-based chemotherapy (p = 0.036).	Platinum	170-178	nuclear factor kappa B subunit 1	Homo sapiens	33-42
29254797-11	2018	IKK2 and NF-kappaB are related to poor prognosis and are potential predictors of response to platinum-based chemotherapy in HGSC.	Platinum	93-101	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	0-4
29254797-11	2018	IKK2 and NF-kappaB are related to poor prognosis and are potential predictors of response to platinum-based chemotherapy in HGSC.	Platinum	93-101	nuclear factor kappa B subunit 1	Homo sapiens	9-18
29102254-11	2018	NAC significantly increased the rate of pT0 from 20.2% to 34.3% (P = 0.007) in cT2 and from 3.8% to 23.9% (P&lt;0.001) in cT3-4.	Platinum	40-43	cancer/testis antigen 2	Homo sapiens	79-82
29849942-3	2018	Persistent activation of STAT3 is associated with cancer growth and progression and is also involved in cell resistance to platinum and taxane treatment.	Platinum	123-131	signal transducer and activator of transcription 3	Homo sapiens	25-30
29307819-4	2018	In this study, the fluorescence lifetime of the metabolic coenzyme NADH reveals that the absence of REV3L can promote the p53-mediated upregulation of oxidative phosphorylation in cisplatin-treated H1299 lung carcinoma cells and increases cancer cell sensitivity to this platinum-based chemotherapy.	Platinum	271-279	tumor protein p53	Homo sapiens	122-125
29293312-0	2018	Hypochlorous Acid Promoted Platinum Drug Chemotherapy by Myeloperoxidase-Encapsulated Therapeutic Metal Phenolic Nanoparticles.	Platinum	27-35	myeloperoxidase	Homo sapiens	57-72
29215207-3	2018	The spatial separation of Pt and Au particles by the MOF further steers the formation of charge flow and expedites the charge migration.	Platinum	26-28	lysine acetyltransferase 8	Homo sapiens	53-56
29215207-4	2018	As a result, the Pt@MOF/Au presents an exceptionally high photocatalytic H2 production rate by water splitting under visible light irradiation, far superior to Pt/MOF/Au, MOF/Au and other counterparts with similar Pt or Au contents, highlighting the important role of each component and the Pt location in the catalyst.	Platinum	17-19	lysine acetyltransferase 8	Homo sapiens	20-23
29215207-4	2018	As a result, the Pt@MOF/Au presents an exceptionally high photocatalytic H2 production rate by water splitting under visible light irradiation, far superior to Pt/MOF/Au, MOF/Au and other counterparts with similar Pt or Au contents, highlighting the important role of each component and the Pt location in the catalyst.	Platinum	17-19	lysine acetyltransferase 8	Homo sapiens	163-166
29215207-4	2018	As a result, the Pt@MOF/Au presents an exceptionally high photocatalytic H2 production rate by water splitting under visible light irradiation, far superior to Pt/MOF/Au, MOF/Au and other counterparts with similar Pt or Au contents, highlighting the important role of each component and the Pt location in the catalyst.	Platinum	17-19	lysine acetyltransferase 8	Homo sapiens	163-166
29231705-5	2018	The two aptamers were specifically bound with the thrombin to form a sandwich structure; thus, the platinum nanoparticles were linked to the magnetic microparticles, and they were separated by a magnet easily.	Platinum	99-107	coagulation factor II, thrombin	Homo sapiens	50-58
29116491-2	2018	O6-methylguanine methyltransferase (MGMT) is involved in DNA repair and is found to affect the efficacy of platinum-based chemotherapy.	Platinum	107-115	O-6-methylguanine-DNA methyltransferase	Homo sapiens	0-34
29335501-0	2018	Dual functional dinuclear platinum complex with selective reactivity towards c-myc G-quadruplex.	Platinum	26-34	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	77-82
29515788-5	2018	These results demonstrate the importance of the association between platinum resistance and CD44s during EMT induction in oral cancer cells.	Platinum	68-76	CD44 molecule (Indian blood group)	Homo sapiens	92-96
29089357-8	2018	Co-mutation of KRAS and KEAP1/ NFE2L2 is an independent prognostic factor, predicting shorter survival, duration of response to initial platinum-based chemotherapy, and survival from the start of immune therapy.	Platinum	136-144	KRAS proto-oncogene, GTPase	Homo sapiens	15-19
29089357-8	2018	Co-mutation of KRAS and KEAP1/ NFE2L2 is an independent prognostic factor, predicting shorter survival, duration of response to initial platinum-based chemotherapy, and survival from the start of immune therapy.	Platinum	136-144	kelch like ECH associated protein 1	Homo sapiens	24-29
29089357-8	2018	Co-mutation of KRAS and KEAP1/ NFE2L2 is an independent prognostic factor, predicting shorter survival, duration of response to initial platinum-based chemotherapy, and survival from the start of immune therapy.	Platinum	136-144	NFE2 like bZIP transcription factor 2	Homo sapiens	31-37
29311703-1	2018	In this study, we integrated bilayer structure of covered Pt on nickel zinc ferrite (NZFO) and CoFe/Pt/NZFO tri-layer structure by pulsed laser deposition system for a spin Hall magnetoresistance (SMR) study.	Platinum	58-60	spindlin 1	Homo sapiens	168-172
29311703-3	2018	Moreover, the spin Hall angle and the spin diffusion length, which were 0.0648 and 1.31 nm, respectively, can be fitted by changing the Pt thickness in the longitudinal SMR function.	Platinum	136-138	spindlin 1	Homo sapiens	14-18
29311703-3	2018	Moreover, the spin Hall angle and the spin diffusion length, which were 0.0648 and 1.31 nm, respectively, can be fitted by changing the Pt thickness in the longitudinal SMR function.	Platinum	136-138	spindlin 1	Homo sapiens	38-42
29311703-6	2018	Additionally, comparison between the tri-layer structure with Pt/NZFO and CoFe/Pt bilayer systems suggests that the SMR ratio can be enhanced by more than 70%, indicating that additional spin current should be injected into Pt layer.	Platinum	62-64	spindlin 1	Homo sapiens	187-191
29116491-2	2018	O6-methylguanine methyltransferase (MGMT) is involved in DNA repair and is found to affect the efficacy of platinum-based chemotherapy.	Platinum	107-115	O-6-methylguanine-DNA methyltransferase	Homo sapiens	36-40
29116491-6	2018	RESULTS: In our cohorts, high MGMT expression was significantly correlated with shorter overall survival (OS) in patients with platinum-based adjuvant chemotherapy [hazard ratio (HR) 2.386, p = 0.048; HR 2.920, p = 0.007; HR 2.324, p = 0.004, respectively, in FUSCC, ZS, and combination sets], but not in patients without chemotherapy.	Platinum	127-135	O-6-methylguanine-DNA methyltransferase	Homo sapiens	30-34
29116491-9	2018	CONCLUSIONS: We demonstrated that high MGMT expression is an independent poor prognostic factor in MIBC patients with platinum-based adjuvant chemotherapy, but not in patients without chemotherapy.	Platinum	118-126	O-6-methylguanine-DNA methyltransferase	Homo sapiens	39-43
28969563-4	2018	Platinum drug-cisplatin interacts covalently and alters the function of the key plasma protease inhibitor molecule -alpha-2-macroglobulin and induces the conformational changes in the protein molecule and inactivates it.	Platinum	0-8	alpha-2-macroglobulin	Homo sapiens	116-137
29155058-2	2018	XPO1 participates in the nuclear export of FoxO-1, which we previously found to be decreased in platinum-resistant ovarian carcinoma.	Platinum	96-104	exportin 1	Homo sapiens	0-4
29155058-2	2018	XPO1 participates in the nuclear export of FoxO-1, which we previously found to be decreased in platinum-resistant ovarian carcinoma.	Platinum	96-104	forkhead box O1	Homo sapiens	43-49
29491212-7	2018	Ex vivo platinum drug treatment of the primary culture obtained from naive patients over seven days also revealed a significant increase in MRP1 (7/9), XRCC1 (4/9) and ERCC1 (4/9).	Platinum	8-16	ATP binding cassette subfamily C member 1	Homo sapiens	140-144
29491212-7	2018	Ex vivo platinum drug treatment of the primary culture obtained from naive patients over seven days also revealed a significant increase in MRP1 (7/9), XRCC1 (4/9) and ERCC1 (4/9).	Platinum	8-16	X-ray repair cross complementing 1	Homo sapiens	152-157
29491212-7	2018	Ex vivo platinum drug treatment of the primary culture obtained from naive patients over seven days also revealed a significant increase in MRP1 (7/9), XRCC1 (4/9) and ERCC1 (4/9).	Platinum	8-16	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	168-173
29491212-9	2018	Clinical treatment by platinum-based anti-cancer drug can develop acquired drug resistance in Thai gastric cancer patients through upregulation in the expression of drug transporter MRP1 and DNA repair XRCC1 and ERCC1.	Platinum	22-30	ATP binding cassette subfamily C member 1	Homo sapiens	182-186
29491212-9	2018	Clinical treatment by platinum-based anti-cancer drug can develop acquired drug resistance in Thai gastric cancer patients through upregulation in the expression of drug transporter MRP1 and DNA repair XRCC1 and ERCC1.	Platinum	22-30	X-ray repair cross complementing 1	Homo sapiens	202-207
29491212-9	2018	Clinical treatment by platinum-based anti-cancer drug can develop acquired drug resistance in Thai gastric cancer patients through upregulation in the expression of drug transporter MRP1 and DNA repair XRCC1 and ERCC1.	Platinum	22-30	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	212-217
29719287-0	2018	Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.	Platinum	47-55	replication timing regulatory factor 1	Homo sapiens	18-22
29719287-10	2018	RESULTS: RIF1 expression was significantly associated with the response of ovarian patients to platinum-based chemotherapy (P&lt; 0.01).	Platinum	95-103	replication timing regulatory factor 1	Homo sapiens	9-13
29719287-11	2018	In cohorts from online databases, high expression of RIF1 was associated with higher mortality of EOC patients based on platinum chemotherapy (P &lt; 0.01).	Platinum	120-128	replication timing regulatory factor 1	Homo sapiens	53-57
29719287-15	2018	CONCLUSIONS: RIF1 plays an important role in regulating the expression of NER proteins, which in turn contributes to cellular response to cisplatin and EOC patients" response to platinum-based chemotherapy.	Platinum	178-186	replication timing regulatory factor 1	Homo sapiens	13-17
29719287-17	2018	RIF1 may serve as a novel biomarker for predicting platinum-based chemosensitivity and the prognosis of EOC patients.	Platinum	51-59	replication timing regulatory factor 1	Homo sapiens	0-4
29063235-5	2018	RESULTS: Among seven MMR genes, high mRNA levels of MSH6, MLH1 and PMS2 were significantly associated with a better overall survival for all ovarian cancer patients treated with platinum-based chemotherapy, especially in late-stage and poor-differentiated ovarian cancer patients.	Platinum	178-186	mutS homolog 6	Homo sapiens	52-56
29063235-5	2018	RESULTS: Among seven MMR genes, high mRNA levels of MSH6, MLH1 and PMS2 were significantly associated with a better overall survival for all ovarian cancer patients treated with platinum-based chemotherapy, especially in late-stage and poor-differentiated ovarian cancer patients.	Platinum	178-186	mutL homolog 1	Homo sapiens	58-62
29063235-5	2018	RESULTS: Among seven MMR genes, high mRNA levels of MSH6, MLH1 and PMS2 were significantly associated with a better overall survival for all ovarian cancer patients treated with platinum-based chemotherapy, especially in late-stage and poor-differentiated ovarian cancer patients.	Platinum	178-186	PMS1 homolog 2, mismatch repair system component	Homo sapiens	67-71
30207284-0	2018	Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.	Platinum	77-85	SET and MYND domain containing 2	Homo sapiens	159-164
30207284-6	2018	CONCLUSION: Germline SMYD2 alleles are associated with bad clinical outcome of first-line platinum-based treatment in advanced NSCLC patients.	Platinum	90-98	SET and MYND domain containing 2	Homo sapiens	21-26
30207284-8	2018	MICROABSTRACT: A two-Stage Genome wide association study in Caucasian population reveals germline genetic variation in SMYD2 associated to progression disease in first-line platinum-based treatment in advanced NSCLC patients.	Platinum	173-181	SET and MYND domain containing 2	Homo sapiens	119-124
29226731-0	2018	Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.	Platinum	20-28	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	119-124
29066501-2	2018	Here, we demonstrated that platinum-resistant cancer had a higher percentage of high BRCA2 level (87.5% vs 43.6%, P = 0.001), and that patients with a low BRCA2 level in cancer tissues had longer progression-free survival (with a median time of 28.0 vs 12.0 months, P &lt; 0.001) and platinum-free duration (with a median time of 19.0 vs 5.0 months, P &lt; 0.001) compared with those with a high BRCA2 level.	Platinum	27-35	BRCA2 DNA repair associated	Homo sapiens	85-90
29066501-2	2018	Here, we demonstrated that platinum-resistant cancer had a higher percentage of high BRCA2 level (87.5% vs 43.6%, P = 0.001), and that patients with a low BRCA2 level in cancer tissues had longer progression-free survival (with a median time of 28.0 vs 12.0 months, P &lt; 0.001) and platinum-free duration (with a median time of 19.0 vs 5.0 months, P &lt; 0.001) compared with those with a high BRCA2 level.	Platinum	27-35	BRCA2 DNA repair associated	Homo sapiens	155-160
29066501-2	2018	Here, we demonstrated that platinum-resistant cancer had a higher percentage of high BRCA2 level (87.5% vs 43.6%, P = 0.001), and that patients with a low BRCA2 level in cancer tissues had longer progression-free survival (with a median time of 28.0 vs 12.0 months, P &lt; 0.001) and platinum-free duration (with a median time of 19.0 vs 5.0 months, P &lt; 0.001) compared with those with a high BRCA2 level.	Platinum	27-35	BRCA2 DNA repair associated	Homo sapiens	155-160
29066501-2	2018	Here, we demonstrated that platinum-resistant cancer had a higher percentage of high BRCA2 level (87.5% vs 43.6%, P = 0.001), and that patients with a low BRCA2 level in cancer tissues had longer progression-free survival (with a median time of 28.0 vs 12.0 months, P &lt; 0.001) and platinum-free duration (with a median time of 19.0 vs 5.0 months, P &lt; 0.001) compared with those with a high BRCA2 level.	Platinum	284-292	BRCA2 DNA repair associated	Homo sapiens	155-160
29066501-2	2018	Here, we demonstrated that platinum-resistant cancer had a higher percentage of high BRCA2 level (87.5% vs 43.6%, P = 0.001), and that patients with a low BRCA2 level in cancer tissues had longer progression-free survival (with a median time of 28.0 vs 12.0 months, P &lt; 0.001) and platinum-free duration (with a median time of 19.0 vs 5.0 months, P &lt; 0.001) compared with those with a high BRCA2 level.	Platinum	284-292	BRCA2 DNA repair associated	Homo sapiens	155-160
29066501-6	2018	These data suggest that a low BRCA2 level can predict better platinum sensitivity and prognosis, and that the modulation of autophagy can be a chemosensitizer for certain cancers.	Platinum	61-69	BRCA2 DNA repair associated	Homo sapiens	30-35
29226731-5	2018	Area covered: Among the polymorphisms of proteins involved in uptake, metabolism, cytotoxicity and efflux of platinum drugs, codon 118 C/T and C8092A in ERCC1 are the best characterized SNPs studied for their predictive power.	Platinum	109-117	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	153-158
31501807-6	2018	Within the germline BRCA2-positive cases exposed to platinum chemotherapy or PARP inhibition, the prevalence of reversion mutations was 40%.	Platinum	52-60	BRCA2 DNA repair associated	Homo sapiens	20-25
29157627-8	2018	We found a strong ER expression via IHC in both the primary and matched recurrent HGSOC, particularly in the Platinum-resistant subgroup.	Platinum	109-117	estrogen receptor 1	Homo sapiens	18-20
29194191-2	2018	The objective of this study was to compare the hematologic adverse effect profiles associated with platinum-based chemotherapy in ovarian cancer patients with and without germline BRCA mutations.	Platinum	99-107	BRCA1 DNA repair associated	Homo sapiens	180-184
29970670-0	2018	ATP7B rs9535826 is associated with gastrointestinal toxicity of platinum-based chemotherapy in nonsmall cell lung cancer patients.	Platinum	64-72	ATPase copper transporting beta	Homo sapiens	0-5
29970670-3	2018	The two P-type ATPases ATP7A and ATP7B have been identified to play an essential role in the transport of platinum.	Platinum	106-114	ATPase copper transporting alpha	Homo sapiens	23-28
29970670-3	2018	The two P-type ATPases ATP7A and ATP7B have been identified to play an essential role in the transport of platinum.	Platinum	106-114	ATPase copper transporting beta	Homo sapiens	33-38
29970670-5	2018	In this study, we aimed to investigate the association of ATP7A and ATP7B genetic polymorphisms with clinical outcome and toxicity of platinum-based chemotherapy in NSCLC patients.	Platinum	134-142	ATPase copper transporting alpha	Homo sapiens	58-63
29970670-5	2018	In this study, we aimed to investigate the association of ATP7A and ATP7B genetic polymorphisms with clinical outcome and toxicity of platinum-based chemotherapy in NSCLC patients.	Platinum	134-142	ATPase copper transporting beta	Homo sapiens	68-73
29970670-13	2018	Conclusion: The genotypes of ATP7B gene may be novel and significant biomarkers for predicting the gastrointestinal toxicity of platinum-based chemotherapy in NSCLC patients.	Platinum	128-136	ATPase copper transporting beta	Homo sapiens	29-34
29399172-9	2018	These results indicated that loss of BECN1 expression in ovarian carcinoma is a negative prognosticator in patients receiving platinum-based chemotherapy.	Platinum	126-134	beclin 1	Homo sapiens	37-42
29369176-0	2018	Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma.	Platinum	10-18	epidermal growth factor receptor	Homo sapiens	41-45
29369176-1	2018	The aim of this study was to detect the epidermal growth factor receptor (EGFR) gene type at pre- and postchemotherapy to evaluate the impact of platinum-based chemotherapy on EGFR gene mutations and provide a theoretical foundation for clinical treatment.Around 40 serum DNA samples were collected from advanced nonsmall cell lung cancer patients who received platinum-based chemotherapy as first-line treatment in our hospital from August 1, 2014 to June 1, 2015.	Platinum	145-153	epidermal growth factor receptor	Homo sapiens	40-72
29369176-1	2018	The aim of this study was to detect the epidermal growth factor receptor (EGFR) gene type at pre- and postchemotherapy to evaluate the impact of platinum-based chemotherapy on EGFR gene mutations and provide a theoretical foundation for clinical treatment.Around 40 serum DNA samples were collected from advanced nonsmall cell lung cancer patients who received platinum-based chemotherapy as first-line treatment in our hospital from August 1, 2014 to June 1, 2015.	Platinum	145-153	epidermal growth factor receptor	Homo sapiens	74-78
29369176-1	2018	The aim of this study was to detect the epidermal growth factor receptor (EGFR) gene type at pre- and postchemotherapy to evaluate the impact of platinum-based chemotherapy on EGFR gene mutations and provide a theoretical foundation for clinical treatment.Around 40 serum DNA samples were collected from advanced nonsmall cell lung cancer patients who received platinum-based chemotherapy as first-line treatment in our hospital from August 1, 2014 to June 1, 2015.	Platinum	145-153	epidermal growth factor receptor	Homo sapiens	176-180
29369176-1	2018	The aim of this study was to detect the epidermal growth factor receptor (EGFR) gene type at pre- and postchemotherapy to evaluate the impact of platinum-based chemotherapy on EGFR gene mutations and provide a theoretical foundation for clinical treatment.Around 40 serum DNA samples were collected from advanced nonsmall cell lung cancer patients who received platinum-based chemotherapy as first-line treatment in our hospital from August 1, 2014 to June 1, 2015.	Platinum	361-369	epidermal growth factor receptor	Homo sapiens	74-78
29369176-8	2018	EGFR mutation positive patients had a disease control rate (DCR) of 88.2% (15/17), whereas it was only 57.1% in EGFR mutation negative patients, which was statistically significant (P = 0.01) indicating a better curative effect in EGFR mutation positive patients.Platinum-based chemotherapy may change the serum EGFR gene type in advanced lung adenocarcinoma.	Platinum	263-271	epidermal growth factor receptor	Homo sapiens	0-4
29631257-4	2018	The vascular endothelial growth factor (VEGF)-A antibody bevacizumab is approved for first-line treatment of advanced-stage patients in combination with platinum-based chemotherapy.	Platinum	153-161	vascular endothelial growth factor A	Homo sapiens	4-38
29631257-4	2018	The vascular endothelial growth factor (VEGF)-A antibody bevacizumab is approved for first-line treatment of advanced-stage patients in combination with platinum-based chemotherapy.	Platinum	153-161	vascular endothelial growth factor A	Homo sapiens	40-44
29387232-2	2018	Previous studies have identified that targeting NEDD8-activating enzyme (NAE) with MLN4924 effectively overcomes platinum resistance in preclinical models of ovarian cancer.	Platinum	113-121	NEDD8 ubiquitin like modifier	Homo sapiens	48-53
29399172-10	2018	Assessment of BECN1 expression may be useful for predicting an unfavorable response to platinum-based chemotherapy in ovarian carcinoma.	Platinum	87-95	beclin 1	Homo sapiens	14-19
30048976-1	2018	The nucleotide excision repair protein excision repair cross-complementation group 1 (ERCC1) has been repeatedly shown to be involved in the sensitivity of cancer cells to platinum derivatives.	Platinum	172-180	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	39-84
29694959-0	2018	Prognostic Impact of DNA Repair Protein Expression in Non-Small Cell Lung Cancers Treated with Platinum-Based Chemotherapy and Subsequent Curative Lung Resection.	Platinum	95-103	X-ray repair cross complementing 6 pseudogene 5	Homo sapiens	21-39
29694959-2	2018	This study aimed to investigate the predictive value of DNA repair protein expression in surgically resected NSCLCs in terms of prognosis and responses to platinum-containing chemotherapy.	Platinum	155-163	X-ray repair cross complementing 6 pseudogene 5	Homo sapiens	56-74
29694959-5	2018	RESULTS: SIRT1 expression correlated significantly with improved responses to platinum-based chemotherapy (odds ratio, 2.28; p = 0.024), progression-free survival (hazard ratio [HR], 0.74; p = 0.036), overall survival (HR, 0.63; p = 0.006), and tumor-bearing survival (HR, 0.62; p = 0.014).	Platinum	78-86	sirtuin 1	Homo sapiens	9-14
30048976-1	2018	The nucleotide excision repair protein excision repair cross-complementation group 1 (ERCC1) has been repeatedly shown to be involved in the sensitivity of cancer cells to platinum derivatives.	Platinum	172-180	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	86-91
28989055-0	2017	Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.	Platinum	92-100	HECT domain E3 ubiquitin protein ligase 3	Homo sapiens	19-25
28989055-0	2017	Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.	Platinum	92-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
28989055-5	2017	Moreover, high HECTD3 expression is significantly associated with poor platinum response and prognosis in ovarian cancer patients.	Platinum	71-79	HECT domain E3 ubiquitin protein ligase 3	Homo sapiens	15-21
28989055-9	2017	HECTD3 may be considered a promising molecular predictor of platinum chemosensitivity and prognosis for serous ovarian cancer.	Platinum	60-68	HECT domain E3 ubiquitin protein ligase 3	Homo sapiens	0-6
29464038-6	2018	Chemotherapeutic drugs had variable effects; while platinum-based chemotherapy decreased the expression of CD39, methotrexate led to a functional increase in CD39 expression and increased production of immunosuppressive ADO.	Platinum	51-59	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	107-111
29594375-7	2017	Next, an antibody against MPO was immobilized on the modified GCE via the stable conjunction between Cu, Pt, Pd and amino groups.	Platinum	105-107	myeloperoxidase	Homo sapiens	26-29
28278082-0	2017	Caspase 8 polymorphisms contribute to the prognosis of advanced lung adenocarcinoma patients after platinum-based chemotherapy.	Platinum	99-107	caspase 8	Homo sapiens	0-9
29594375-13	2017	Antibody against MPO was immobilized on the network via conjugation between Cu, Pt, Pd and amino groups.	Platinum	80-82	myeloperoxidase	Homo sapiens	17-20
28654887-2	2017	CEA aptamer loaded onto Pt@CuMOFs was bound with hemin to form hemin@G-quadruplex (hGq) with mimicking peroxidase activity.	Platinum	24-26	CEA cell adhesion molecule 3	Homo sapiens	0-3
29246904-6	2017	Elevated HRDetect was also significantly associated with CI on platinum-based therapy (AUC = 0.89; P = 0.006) with the same optimal threshold, even after adjusting for BRCA1/2 mutation status and treatment timing.	Platinum	63-71	BRCA1 DNA repair associated	Homo sapiens	168-175
29290694-5	2017	The greatest benefit in terms of progression-free survival, in all three PARPi maintenance registration studies, was seen in women with platinum-sensitive BRCA mutation-associated HGSOC.	Platinum	136-144	BRCA1 DNA repair associated	Homo sapiens	155-159
28278082-3	2017	To explore the relationship between tagSNPs or haplotypes of CASP8 and the efficacy of platinum-based chemotherapy in advanced lung adenocarcinoma patients of China, we recruited 555 advanced adenocarcinoma patients.	Platinum	87-95	caspase 8	Homo sapiens	61-66
29353977-0	2017	Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy.	Platinum	103-111	epidermal growth factor receptor	Homo sapiens	9-13
29187479-9	2017	In the group of patients who received adjuvant chemotherapy based on platinum derivatives in combination with paclitaxel or gemcitabine, we found shorter DFI (p=0.0473) and OS (p=0.0053) in those with high expression of TS.	Platinum	69-77	thymidylate synthetase	Homo sapiens	220-222
29100168-6	2017	Combined data suggested that GSTM1-null genotype patients have a lower risk of death compared to GSTM1-wt carriers, specifically in advanced stages (hazard ratio (HR), 0.68; 95% CI, 0.48-0.97) and when submitted to platinum-based chemotherapy (aHR, 0.61; 95% CI, 0.39-0.94).	Platinum	215-223	glutathione S-transferase mu 1	Homo sapiens	29-34
29353977-2	2017	This study aimed to investigate the effect of first-line EGFR-TKIs or platinum-based chemotherapy in NSCLC patients with uncommon EGFR mutations.	Platinum	70-78	epidermal growth factor receptor	Homo sapiens	130-134
28994323-3	2017	Atezolizumab is an engineered humanized anti-PD-L1 monoclonal antibody that inhibits PD-L1 binding to PD-1 and B7.1, enhancing immune-mediated tumor killing and is currently approved as second-line treatment after failure of platinum-based chemotherapy as well as first-line in cisplatin-ineligible patients.	Platinum	225-233	CD274 molecule	Homo sapiens	45-50
29198325-0	2017	ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis.	Platinum	99-107	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
29198325-1	2017	BACKGROUND: The predictive role of excision repair cross-complementing group 1 (ERCC1) as a predictive factor in patients with advanced urothelial cancer (AUC) treated with platinum-based treatment is not well defined.	Platinum	173-181	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	35-78
29198325-1	2017	BACKGROUND: The predictive role of excision repair cross-complementing group 1 (ERCC1) as a predictive factor in patients with advanced urothelial cancer (AUC) treated with platinum-based treatment is not well defined.	Platinum	173-181	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	80-85
29198325-2	2017	Here, we evaluate the role of ERCC1 in patients with AUC treated with platinum-based treatment.	Platinum	70-78	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	30-35
29517083-6	2017	Currently, the only FDA-approved indication for the anti-PD-L1 monoclonal antibody durvalumab (MEDI-4736) is locally advanced or metastatic urothelial carcinoma that has progressed during or following platinum-based chemotherapy within 12 months of treatment.	Platinum	201-209	CD274 molecule	Homo sapiens	57-62
27873337-10	2017	Taken together, our results revealed that polymorphisms of miR-5197, miR-605, miR-146a, and miR-27a contributed to the chemotherapy toxicity of lung cancer, which may serve as a predictive tool for toxicity evaluation of platinum-based chemotherapy in lung cancer patients.	Platinum	221-229	microRNA 5197	Homo sapiens	59-67
28994323-3	2017	Atezolizumab is an engineered humanized anti-PD-L1 monoclonal antibody that inhibits PD-L1 binding to PD-1 and B7.1, enhancing immune-mediated tumor killing and is currently approved as second-line treatment after failure of platinum-based chemotherapy as well as first-line in cisplatin-ineligible patients.	Platinum	225-233	CD274 molecule	Homo sapiens	85-90
29035087-0	2017	Xeroderma pigmentosum complementation group D polymorphism toward lung cancer susceptibility survival and response in patients treated with platinum chemotherapy.	Platinum	140-148	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	0-45
28520216-10	2017	ERCC1(rs11615), XRCC1(rs25487, rs1799782) and XPD(rs13181) polymorphisms were better predictors in evaluating the efficacy of platinum-based chemotherapy in NSCLC patients.	Platinum	126-134	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
28972404-0	2017	The prognostic role of MAC30 in advanced gastric cancer patients receiving platinum-based chemotherapy.	Platinum	75-83	transmembrane protein 97	Homo sapiens	23-28
28972404-5	2017	GC with enhanced MAC30 exhibited poorer survival by Kaplan-Meier analysis and poor response to adjuvant platinum-based chemotherapy.	Platinum	104-112	transmembrane protein 97	Homo sapiens	17-22
28972404-6	2017	A multivariate analysis showed that MAC30 was an independent prognostic factor of overall survival in GC receiving platinum-based chemotherapy.	Platinum	115-123	transmembrane protein 97	Homo sapiens	36-41
28972404-7	2017	CONCLUSION: MAC30 could play as a potential biomarker for prognosis of GC with platinum-based chemotherapy.	Platinum	79-87	transmembrane protein 97	Homo sapiens	12-17
28520216-10	2017	ERCC1(rs11615), XRCC1(rs25487, rs1799782) and XPD(rs13181) polymorphisms were better predictors in evaluating the efficacy of platinum-based chemotherapy in NSCLC patients.	Platinum	126-134	X-ray repair cross complementing 1	Homo sapiens	16-21
29129443-2	2017	Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC.	Platinum	90-98	vascular endothelial growth factor A	Homo sapiens	52-56
28797868-12	2017	CONCLUSION: Serum NGF increases in cancer patients receiving taxane or platinum with painful CIPN, suggesting that it might be a potential biomarker of the presence and severity of neuropathic pain in this population.	Platinum	71-79	nerve growth factor	Homo sapiens	18-21
29169523-0	2017	Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and EGFR-Mutated Lung Adenocarcinoma.	Platinum	67-75	epidermal growth factor receptor	Homo sapiens	151-155
29172280-2	2017	SKOV3 cells displayed platinum-inducedIL-6 and IL-8 overproduction whereas wild type A2780 displayed no detectable cytokine production.	Platinum	22-30	C-X-C motif chemokine ligand 8	Homo sapiens	47-51
29390553-0	2017	ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy.	Platinum	128-136	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
29390553-1	2017	The deoxyribonucleic acid (DNA) repair gene encoding the excision-repair cross-complementation group 1 (ERCC1) protein is known to predict the response to platinum-based chemotherapy.	Platinum	155-163	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	57-102
29390553-1	2017	The deoxyribonucleic acid (DNA) repair gene encoding the excision-repair cross-complementation group 1 (ERCC1) protein is known to predict the response to platinum-based chemotherapy.	Platinum	155-163	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	104-109
29390553-2	2017	Our aim was to explore whether ERCC1 expression predicted tumor response and survival in patients with recurrent or metastatic cervical cancer treated via platinum-based chemotherapy.	Platinum	155-163	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	31-36
29390553-9	2017	Thus, pretreatment ERCC1 expression status can be used to predict tumor response and survival of patients with recurrent or metastatic uterine cervical cancer receiving platinum-based chemotherapy.	Platinum	169-177	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	19-24
29163686-0	2017	Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer.	Platinum	81-89	KRAS proto-oncogene, GTPase	Homo sapiens	38-42
29163686-1	2017	We performed this retrospective study to investigate whether the KRAS mutation status and its subtypes could predict the effect of first-line platinum-based chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC).	Platinum	142-150	KRAS proto-oncogene, GTPase	Homo sapiens	65-69
29163686-11	2017	In conclusion, KRAS mutation was a negative predictive factor of PFS in Chinese patients with advanced NSCLC who received first platinum-based chemotherapy.	Platinum	128-136	KRAS proto-oncogene, GTPase	Homo sapiens	15-19
32454631-8	2017	In the current review, recent findings with respect to the role of mainly CYP1A1, CYP1B1, CYP2D6, CYP2E1 and CYP3A4 gene polymorphisms in response to chemotherapy and survival in patients with NSCLC have been provided, which could be useful for clinicians in the prognosis of these patients who are mainly treated with platinum-based chemotherapy.	Platinum	319-327	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	109-115
29035505-5	2017	To our knowledge, {(PW9)2Ni7}/{Cu(ethylenediamine)2}/TTF-F represents the first example of POM-based noble-metal-free ORR electrocatalyst possessing both comparable ORR electrocatalytic activity and much higher stability than that of Pt/C in neutral medium.	Platinum	234-236	ras homolog family member H	Homo sapiens	53-58
29169370-0	2017	Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-kappaB-TNFalpha-PIK3CA loop.	Platinum	50-58	tumor necrosis factor	Homo sapiens	93-101
29169370-0	2017	Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-kappaB-TNFalpha-PIK3CA loop.	Platinum	50-58	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	102-108
28834763-5	2017	In vitro and in vivo results provide strong evidence that GSTs inhibitor-modified cisplatin prodrug combined with nanoparticle encapsulation favor high effective platinum accumulation, significantly enhanced antitumor efficacy against cisplatin-resistant cancer and decreased system toxicity.	Platinum	162-170	glutathione S-transferase kappa 1	Homo sapiens	58-62
29138580-0	2017	S100A16, a promising candidate as a prognostic marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinoma.	Platinum	58-66	S100 calcium binding protein A16	Homo sapiens	0-7
29138580-4	2017	The aim of this study was to evaluate the use of S100A16 expression as a prognostic marker in patients with completely resected lung adenocarcinoma receiving platinum-based adjuvant chemotherapy.	Platinum	158-166	S100 calcium binding protein A16	Homo sapiens	49-56
29138580-5	2017	Methods: S100A16 expression was immunohistochemically studied in 65 consecutive lung adenocarcinoma patients who underwent complete resection and received platinum-based adjuvant chemotherapy.	Platinum	155-163	S100 calcium binding protein A16	Homo sapiens	9-16
29138580-10	2017	Conclusion: The present study revealed that S100A16 is a promising candidate as a prognostic marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinoma.	Platinum	104-112	S100 calcium binding protein A16	Homo sapiens	44-51
29020447-0	2017	Efficiently Synergistic Hydrogen Evolution Realized by Trace Amount of Pt-Decorated Defect-Rich SnS2 Nanosheets.	Platinum	71-73	sodium voltage-gated channel alpha subunit 11	Homo sapiens	96-100
29020447-3	2017	Herein, we demonstrate the successful structural engineering and simultaneous integration of trace amount Pt in SnS2 nanosheets via a facile and effective in situ cycling voltammetry activation process, leading to the efficiently synergistic HER.	Platinum	106-108	sodium voltage-gated channel alpha subunit 11	Homo sapiens	112-116
29232464-11	2017	The presence of germline or somatic BRCA mutations allows platinum-responsive patients to optimize chemotherapy efficacy and prolonging PFS by the use of olaparib (PARP inhibitor) given as maintenance therapy until progression.	Platinum	58-66	BRCA1 DNA repair associated	Homo sapiens	36-40
29232464-11	2017	The presence of germline or somatic BRCA mutations allows platinum-responsive patients to optimize chemotherapy efficacy and prolonging PFS by the use of olaparib (PARP inhibitor) given as maintenance therapy until progression.	Platinum	58-66	poly(ADP-ribose) polymerase 1	Homo sapiens	164-168
29109859-1	2017	Inhibitors of poly(ADP-ribose) polymerase (PARP) are new types of personalized treatment of relapsed platinum-sensitive ovarian cancer harboring BRCA1/2 mutations.	Platinum	101-109	poly(ADP-ribose) polymerase 1	Homo sapiens	14-41
29109859-1	2017	Inhibitors of poly(ADP-ribose) polymerase (PARP) are new types of personalized treatment of relapsed platinum-sensitive ovarian cancer harboring BRCA1/2 mutations.	Platinum	101-109	poly(ADP-ribose) polymerase 1	Homo sapiens	43-47
29109859-1	2017	Inhibitors of poly(ADP-ribose) polymerase (PARP) are new types of personalized treatment of relapsed platinum-sensitive ovarian cancer harboring BRCA1/2 mutations.	Platinum	101-109	BRCA1 DNA repair associated	Homo sapiens	145-152
28875225-1	2017	PURPOSES: To assess the methodological quality of systematic reviews (SRs) or meta-analysis concerning the predictive value of ERCC1 in platinum chemotherapy of non-small cell lung cancer.	Platinum	136-144	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	127-132
28765325-1	2017	Purpose: Resistance to platinum-based chemotherapy or PARP inhibition in germline BRCA1 or BRCA2 mutation carriers may occur through somatic reversion mutations or intragenic deletions that restore BRCA1 or BRCA2 function.	Platinum	23-31	BRCA1 DNA repair associated	Homo sapiens	82-87
28765325-1	2017	Purpose: Resistance to platinum-based chemotherapy or PARP inhibition in germline BRCA1 or BRCA2 mutation carriers may occur through somatic reversion mutations or intragenic deletions that restore BRCA1 or BRCA2 function.	Platinum	23-31	BRCA2 DNA repair associated	Homo sapiens	91-96
28765325-1	2017	Purpose: Resistance to platinum-based chemotherapy or PARP inhibition in germline BRCA1 or BRCA2 mutation carriers may occur through somatic reversion mutations or intragenic deletions that restore BRCA1 or BRCA2 function.	Platinum	23-31	BRCA1 DNA repair associated	Homo sapiens	198-203
28765325-1	2017	Purpose: Resistance to platinum-based chemotherapy or PARP inhibition in germline BRCA1 or BRCA2 mutation carriers may occur through somatic reversion mutations or intragenic deletions that restore BRCA1 or BRCA2 function.	Platinum	23-31	BRCA2 DNA repair associated	Homo sapiens	207-212
29048667-9	2017	The results of this study implied that TF2a and TF2b might help prevent and treat platinum-resistant ovarian cancer.	Platinum	82-90	general transcription factor IIB	Homo sapiens	48-52
28934637-4	2017	In addition, anti-IGF-1R targeted strategies potentiated the efficacy of platinum based chemotherapy.	Platinum	73-81	insulin like growth factor 1 receptor	Homo sapiens	18-24
28608263-12	2017	The platinum-DNA adducts were observed in HeLa cell in apoptosis; however, in the tumor samples, the platinum-DNA adducts were observed in morphologically healthy tumor cells; these cells displayed nuclear HSPB1/p.	Platinum	4-12	heat shock protein family B (small) member 1	Homo sapiens	206-213
28608263-12	2017	The platinum-DNA adducts were observed in HeLa cell in apoptosis; however, in the tumor samples, the platinum-DNA adducts were observed in morphologically healthy tumor cells; these cells displayed nuclear HSPB1/p.	Platinum	101-109	heat shock protein family B (small) member 1	Homo sapiens	206-213
28790113-2	2017	As chemoresistance and tumor aggressiveness are often related, we decided to study the role of the NTSR1 complex within platinum-based chemotherapy responses.	Platinum	120-128	neurotensin receptor 1	Homo sapiens	99-104
28790113-8	2017	Furthermore, in a large series of high-grade ovarian cancer, NTSR1 mRNA was shown to correlate with higher stages and platinum resistance.Conclusions: This study strongly suggests that the addition of NTSR1 inhibitor in combination with platinum salt-based therapy will improve the response to the drug.	Platinum	118-126	neurotensin receptor 1	Homo sapiens	61-66
28790113-8	2017	Furthermore, in a large series of high-grade ovarian cancer, NTSR1 mRNA was shown to correlate with higher stages and platinum resistance.Conclusions: This study strongly suggests that the addition of NTSR1 inhibitor in combination with platinum salt-based therapy will improve the response to the drug.	Platinum	118-126	neurotensin receptor 1	Homo sapiens	201-206
28790117-8	2017	Clinical data suggest that NSCLC and ovarian cancer patients with low PAPSS1 expression survive longer following platinum-based chemotherapy.Conclusions: These results suggest that PAPSS1 inhibition enhances cisplatin activity in multiple preclinical model systems and that low PAPSS1 expression may serve as a biomarker for platin sensitivity in cancer patients.	Platinum	113-121	3'-phosphoadenosine 5'-phosphosulfate synthase 1	Homo sapiens	70-76
28790117-8	2017	Clinical data suggest that NSCLC and ovarian cancer patients with low PAPSS1 expression survive longer following platinum-based chemotherapy.Conclusions: These results suggest that PAPSS1 inhibition enhances cisplatin activity in multiple preclinical model systems and that low PAPSS1 expression may serve as a biomarker for platin sensitivity in cancer patients.	Platinum	113-121	3'-phosphoadenosine 5'-phosphosulfate synthase 1	Homo sapiens	181-187
28790117-8	2017	Clinical data suggest that NSCLC and ovarian cancer patients with low PAPSS1 expression survive longer following platinum-based chemotherapy.Conclusions: These results suggest that PAPSS1 inhibition enhances cisplatin activity in multiple preclinical model systems and that low PAPSS1 expression may serve as a biomarker for platin sensitivity in cancer patients.	Platinum	113-121	3'-phosphoadenosine 5'-phosphosulfate synthase 1	Homo sapiens	181-187
29163216-1	2017	Oxaliplatin, a third-generation platinum-based chemotherapeutic agent, displays unique acute peripheral neuropathy triggered or enhanced by cold, and accumulating evidence suggests that transient receptor potential ankyrin 1 (TRPA1) is responsible.	Platinum	32-40	transient receptor potential cation channel subfamily A member 1	Homo sapiens	186-224
28902979-3	2017	The Au@M (M = Pd or Pt) nanoparticle clusters (NPCs) with a high density of sub-1 nm interparticle gaps are successfully prepared by the deposition of M shells onto thermally activated Au NPCs.	Platinum	20-22	SUB1 regulator of transcription	Homo sapiens	76-81
29027395-5	2017	RESULTS: Overall, high PD-L1 expression (PD-L1(high)) was observed in 44.7% (55/123) of OCCC patients, and was strongly associated with advanced stages (p=0.020), positive ascitic fluid (p=0.016), platinum-resistant (PR) disease (p=0.045), and recurrence (p=0.038).	Platinum	197-205	CD274 molecule	Homo sapiens	23-28
29027395-5	2017	RESULTS: Overall, high PD-L1 expression (PD-L1(high)) was observed in 44.7% (55/123) of OCCC patients, and was strongly associated with advanced stages (p=0.020), positive ascitic fluid (p=0.016), platinum-resistant (PR) disease (p=0.045), and recurrence (p=0.038).	Platinum	197-205	CD274 molecule	Homo sapiens	41-46
29145241-0	2017	The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy.	Platinum	140-148	enolase 2	Homo sapiens	34-57
29145241-10	2017	In addition, multivariate Cox regression analysis showed that NSE level &gt; 50.324 ng/mL and distant metastasis were independently correlated with worse OS.Serum NSE and LDH could be promising biomarkers for predicting therapy response and survival of SCLC patients receiving first-line platinum-based chemotherapy.	Platinum	288-296	enolase 2	Homo sapiens	62-65
29145241-10	2017	In addition, multivariate Cox regression analysis showed that NSE level &gt; 50.324 ng/mL and distant metastasis were independently correlated with worse OS.Serum NSE and LDH could be promising biomarkers for predicting therapy response and survival of SCLC patients receiving first-line platinum-based chemotherapy.	Platinum	288-296	enolase 2	Homo sapiens	163-166
29093822-6	2017	Several phase 1 and 2 clinical trials of EZH2 inhibitors are ongoing currently and there is considerable promise in translational trials for utilization of this new targeted therapy, both to capitalize on ARID1A loss of function and to increase sensitivity to platinum-based adjuvant chemotherapies.	Platinum	260-268	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	41-45
28608017-1	2017	BACKGROUND: Platinum resistance enhances DNA damage repair through nucleotide excision repair mechanisms involving the excision repair cross-complementing group 1 (ERCC1), X-ray cross-complementing group 1 (XRCC1), and excision repair cross-complementing group 2 (ERCC2).	Platinum	12-20	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	119-162
28608017-1	2017	BACKGROUND: Platinum resistance enhances DNA damage repair through nucleotide excision repair mechanisms involving the excision repair cross-complementing group 1 (ERCC1), X-ray cross-complementing group 1 (XRCC1), and excision repair cross-complementing group 2 (ERCC2).	Platinum	12-20	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	164-169
28608017-1	2017	BACKGROUND: Platinum resistance enhances DNA damage repair through nucleotide excision repair mechanisms involving the excision repair cross-complementing group 1 (ERCC1), X-ray cross-complementing group 1 (XRCC1), and excision repair cross-complementing group 2 (ERCC2).	Platinum	12-20	X-ray repair cross complementing 1	Homo sapiens	172-205
28608017-1	2017	BACKGROUND: Platinum resistance enhances DNA damage repair through nucleotide excision repair mechanisms involving the excision repair cross-complementing group 1 (ERCC1), X-ray cross-complementing group 1 (XRCC1), and excision repair cross-complementing group 2 (ERCC2).	Platinum	12-20	X-ray repair cross complementing 1	Homo sapiens	207-212
28608017-1	2017	BACKGROUND: Platinum resistance enhances DNA damage repair through nucleotide excision repair mechanisms involving the excision repair cross-complementing group 1 (ERCC1), X-ray cross-complementing group 1 (XRCC1), and excision repair cross-complementing group 2 (ERCC2).	Platinum	12-20	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	219-262
28608017-1	2017	BACKGROUND: Platinum resistance enhances DNA damage repair through nucleotide excision repair mechanisms involving the excision repair cross-complementing group 1 (ERCC1), X-ray cross-complementing group 1 (XRCC1), and excision repair cross-complementing group 2 (ERCC2).	Platinum	12-20	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	264-269
28787544-3	2017	We demonstrate a potential-cycling method to synthesize a catalyst comprising single Pt atoms on CoP-based nanotube arrays supported by a Ni foam, termed PtSA-NT-NF.	Platinum	85-87	caspase recruitment domain family member 16	Homo sapiens	97-100
29123433-12	2017	In the nonsquamous EGFR/ALK-negative/unknown cohort, most received first-line platinum combinations, particularly younger patients (78% &gt;=75 years vs 93% &lt;75 years old).	Platinum	78-86	epidermal growth factor receptor	Homo sapiens	19-23
29093254-6	2017	Aberration in eIF3A, the largest subunit of eIF3, is known to contribute to carcinogenesis and protection against evolution into higher-grade malignancy, and the altered expression or mutation of eIF3A affects the responses of cancer patients to platinum-based chemotherapy.	Platinum	246-254	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	14-19
29093254-6	2017	Aberration in eIF3A, the largest subunit of eIF3, is known to contribute to carcinogenesis and protection against evolution into higher-grade malignancy, and the altered expression or mutation of eIF3A affects the responses of cancer patients to platinum-based chemotherapy.	Platinum	246-254	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	14-18
29093254-6	2017	Aberration in eIF3A, the largest subunit of eIF3, is known to contribute to carcinogenesis and protection against evolution into higher-grade malignancy, and the altered expression or mutation of eIF3A affects the responses of cancer patients to platinum-based chemotherapy.	Platinum	246-254	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	196-201
29123433-12	2017	In the nonsquamous EGFR/ALK-negative/unknown cohort, most received first-line platinum combinations, particularly younger patients (78% &gt;=75 years vs 93% &lt;75 years old).	Platinum	78-86	ALK receptor tyrosine kinase	Homo sapiens	24-27
28692638-1	2017	OBJECTIVE: Subjects with germline BRCA1/2 mutations (gBRCAm) have an increased risk of developing ovarian cancer and enhanced sensitivity to platinum-containing agents and PARP (poly[ADP-ribose] polymerase) inhibitors.	Platinum	141-149	BRCA1 DNA repair associated	Homo sapiens	34-41
29375966-4	2018	These photocathodes with subsequent deposition of Pt nanoparticles generate a photovoltage of 300 mV and a photocurrent density of 2.4 mA cm-2 at 0 V versus reversible hydrogen electrode (RHE) for water splitting under simulated visible-light illumination (lambda &gt; 500 nm, Pin = 80 mW cm-2).	Platinum	50-52	dynein light chain LC8-type 1	Homo sapiens	277-280
29151951-13	2017	Conclusion: The synergistic effect of PDE inhibitors with platinum-based agents has been demonstrated in lung cancer.	Platinum	58-66	aldehyde dehydrogenase 7 family member A1	Homo sapiens	38-41
28978336-10	2017	CONCLUSIONS: Our findings suggest that GOLPH3L is a potential therapeutic target for the treatment of ovarian cancer: targeting GOLPH3L signaling may represent a promising strategy to enhance platinum response in patients with chemoresistant ovarian cancer.	Platinum	192-200	golgi phosphoprotein 3 like	Homo sapiens	39-46
28978336-10	2017	CONCLUSIONS: Our findings suggest that GOLPH3L is a potential therapeutic target for the treatment of ovarian cancer: targeting GOLPH3L signaling may represent a promising strategy to enhance platinum response in patients with chemoresistant ovarian cancer.	Platinum	192-200	golgi phosphoprotein 3 like	Homo sapiens	128-135
28969705-2	2017	First identified in association with the maturation of thymocytes, SLFN11 was later causally associated, by two independent groups, with the resistance to DNA damaging agents such as topoisomerase I and II inhibitors, platinum compounds, and other alkylators, making it an attractive molecule for biomarker development.	Platinum	218-226	schlafen family member 11	Homo sapiens	67-73
28778953-0	2017	CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation.	Platinum	45-53	cyclin dependent kinase 6	Homo sapiens	0-4
28778953-0	2017	CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation.	Platinum	45-53	forkhead box O3	Homo sapiens	72-77
28778953-3	2017	Here, we report that silencing or pharmacological inhibition of CDK6 increases EOC cell sensitivity to platinum.	Platinum	103-111	cyclin dependent kinase 6	Homo sapiens	64-68
28778953-4	2017	We observed that, upon platinum treatment, CDK6 phosphorylated and stabilized the transcription factor FOXO3, eventually inducing ATR transcription.	Platinum	23-31	cyclin dependent kinase 6	Homo sapiens	43-47
28778953-4	2017	We observed that, upon platinum treatment, CDK6 phosphorylated and stabilized the transcription factor FOXO3, eventually inducing ATR transcription.	Platinum	23-31	forkhead box O3	Homo sapiens	103-108
28778953-4	2017	We observed that, upon platinum treatment, CDK6 phosphorylated and stabilized the transcription factor FOXO3, eventually inducing ATR transcription.	Platinum	23-31	ATR serine/threonine kinase	Homo sapiens	130-133
28778953-8	2017	Our data suggest that CDK6 represents an actionable target that can be exploited to improve platinum efficacy in EOC patients.	Platinum	92-100	cyclin dependent kinase 6	Homo sapiens	22-26
28737129-0	2017	Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer.	Platinum	70-78	calcitonin receptor	Homo sapiens	37-41
28737129-0	2017	Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer.	Platinum	70-78	solute carrier family 31 member 2	Homo sapiens	43-47
28737129-0	2017	Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer.	Platinum	70-78	ATPase copper transporting beta	Homo sapiens	60-65
28737129-1	2017	The copper transporters &lt;italic&gt;CTR1&lt;/italic&gt;, &lt;italic&gt;CTR2&lt;/italic&gt;, &lt;italic&gt;ATP7A&lt;/italic&gt;, and &lt;italic&gt;ATP7B&lt;/italic&gt; regulate intracellular concentration of platinum by mediating its uptake and efflux in cells.	Platinum	209-217	calcitonin receptor	Homo sapiens	38-42
28737129-1	2017	The copper transporters &lt;italic&gt;CTR1&lt;/italic&gt;, &lt;italic&gt;CTR2&lt;/italic&gt;, &lt;italic&gt;ATP7A&lt;/italic&gt;, and &lt;italic&gt;ATP7B&lt;/italic&gt; regulate intracellular concentration of platinum by mediating its uptake and efflux in cells.	Platinum	209-217	solute carrier family 31 member 2	Homo sapiens	73-77
28737129-2	2017	We sought to explore the effect of genetic polymorphisms in &lt;italic&gt;CTR1&lt;/italic&gt;, &lt;italic&gt;CTR2&lt;/italic&gt;, &lt;italic&gt;ATP7A&lt;/italic&gt;, and &lt;italic&gt;ATP7B&lt;/italic&gt; on platinum resistance in patients suffering from epithelial ovarian cancer (EOC).	Platinum	208-216	calcitonin receptor	Homo sapiens	74-78
28737129-7	2017	Our findings suggest that the &lt;italic&gt;CTR1&lt;/italic&gt; and &lt;italic&gt;ATP7A&lt;/italic&gt; genetic polymorphisms could affect platinum resistance.	Platinum	138-146	calcitonin receptor	Homo sapiens	44-48
28737129-7	2017	Our findings suggest that the &lt;italic&gt;CTR1&lt;/italic&gt; and &lt;italic&gt;ATP7A&lt;/italic&gt; genetic polymorphisms could affect platinum resistance.	Platinum	138-146	ATPase copper transporting alpha	Homo sapiens	82-87
29057957-4	2017	Here, we show that Pt2 dimers can be fabricated with a bottom-up approach on graphene using atomic layer deposition, through proper nucleation sites creation, Pt1 single-atom deposition and attaching a secondary Pt atom selectively on the preliminary one.	Platinum	19-21	zinc finger protein 77	Homo sapiens	159-162
29151966-0	2017	Polymorphisms of CCNB1 Associated With the Clinical Outcomes of Platinum-Based Chemotherapy in Chinese NSCLC Patients.	Platinum	64-72	cyclin B1	Homo sapiens	17-22
29151966-3	2017	We aim to investigate the correlation of CCNB1 polymorphisms to the efficiency of platinum-based chemotherapy in Chinese advanced NSCLC patients.	Platinum	82-90	cyclin B1	Homo sapiens	41-46
29151966-5	2017	We analyzed the association of CCNB1 four tagSNPs with efficiency of platinum-based chemotherapy.	Platinum	69-77	cyclin B1	Homo sapiens	31-36
29151966-12	2017	In summary, CCNB1 polymorphisms may contribute to the clinical efficiency of platinum-based chemotherapy in advanced NSCLC patients, and it is helpful for the personalized treatment.	Platinum	77-85	cyclin B1	Homo sapiens	12-17
29262602-0	2017	Dihydroartemisinin inhibits EMT induced by platinum-based drugs via Akt-Snail pathway.	Platinum	43-51	AKT serine/threonine kinase 1	Homo sapiens	68-71
29262602-0	2017	Dihydroartemisinin inhibits EMT induced by platinum-based drugs via Akt-Snail pathway.	Platinum	43-51	snail family transcriptional repressor 1	Homo sapiens	72-77
28930439-3	2017	The resultant Ni0.9Pt0.1/MOF core-shell composite with a low Pt content exerted exceedingly high activity and durability for complete H2 evolution (100% hydrogen selectivity) from alkaline N2H4BH3 and N2H4 H2O solution.	Platinum	19-21	lysine acetyltransferase 8	Homo sapiens	25-28
28982859-5	2017	RESULTS: Some CDDP-resistant HepG2 cell lines exhibited changes in the expression of copper transporter 1, multidrug resistant protein (MRP)2, and/or MRP3, resulting in decreased intracellular platinum amounts, while others showed no change in platinum accumulation.	Platinum	193-201	ATP binding cassette subfamily C member 2	Homo sapiens	136-141
28982859-5	2017	RESULTS: Some CDDP-resistant HepG2 cell lines exhibited changes in the expression of copper transporter 1, multidrug resistant protein (MRP)2, and/or MRP3, resulting in decreased intracellular platinum amounts, while others showed no change in platinum accumulation.	Platinum	193-201	ATP binding cassette subfamily C member 3	Homo sapiens	150-154
28857726-3	2017	The NuDEL  comprises a covered Cheatham-Platinum stent mounted on a balloon-in-balloon and pre-loaded in a long delivery sheath.	Platinum	40-48	nudE neurodevelopment protein 1 like 1	Homo sapiens	4-9
28604461-1	2017	OBJECTIVE: Serous adenocarcinomas that arise in patients with inherited mutations in the tumor suppressor genes BRCA1 and BRCA2 are initially well treatable with platinum/paclitaxel.	Platinum	162-170	BRCA1 DNA repair associated	Homo sapiens	112-117
28604461-1	2017	OBJECTIVE: Serous adenocarcinomas that arise in patients with inherited mutations in the tumor suppressor genes BRCA1 and BRCA2 are initially well treatable with platinum/paclitaxel.	Platinum	162-170	BRCA2 DNA repair associated	Homo sapiens	122-127
29191602-12	2017	CONCLUSIONS: In our cohort enriched for advanced NSCLC patients who received platinum-based chemotherapy, STK11 mutations were not specifically associated with clinico-pathological features and they did not impact upon survival.	Platinum	77-85	serine/threonine kinase 11	Homo sapiens	106-111
28629012-1	2017	In this study, a novel bio-adsorbent (PT-GO) was prepared by functionalization persimmon tannin (PT) with graphene oxide (GO) and the effective adsorption behaviors of Au3+, Pd2+ and Ag+ ions from aqueous solution was investigated.	Platinum	38-40	PAF1 homolog, Paf1/RNA polymerase II complex component	Homo sapiens	174-177
28629012-7	2017	Combination of ion exchange, electrostatic interaction and physical adsorption was the mechanism for adsorption of Au3+, Pd2+ and Ag+ onto PT-GO bio-adsorbent.	Platinum	139-141	PAF1 homolog, Paf1/RNA polymerase II complex component	Homo sapiens	121-124
29254192-0	2017	Inhibition of coiled coil domain containing protein 69 enhances platinum-induced apoptosis in ovarian cancer cells.	Platinum	64-72	coiled-coil domain containing 69	Homo sapiens	14-54
28888100-0	2017	Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells.	Platinum	74-82	checkpoint kinase 1	Homo sapiens	0-4
28888100-2	2017	Here we newly demonstrate the ability of one of the most specific Chk1 inhibitors, SCH900776 (MK-8776), to enhance human colon cancer cell sensitivity to the cytotoxic effects of platinum(II) cisplatin and platinum(IV)- LA-12 complexes.	Platinum	179-187	checkpoint kinase 1	Homo sapiens	66-70
28888100-2	2017	Here we newly demonstrate the ability of one of the most specific Chk1 inhibitors, SCH900776 (MK-8776), to enhance human colon cancer cell sensitivity to the cytotoxic effects of platinum(II) cisplatin and platinum(IV)- LA-12 complexes.	Platinum	206-214	checkpoint kinase 1	Homo sapiens	66-70
29254192-12	2017	Our results showed that CCDC69 inhibition might interfere with the effectiveness of combination therapy with platinum drugs.	Platinum	109-117	coiled-coil domain containing 69	Homo sapiens	24-30
28934230-10	2017	In particular, higher E-cadherin mRNA levels were associated with cancer antigen 125 levels more than 500 U/mL and platinum-free intervals less than 6 months.	Platinum	115-123	cadherin 1	Homo sapiens	22-32
29033581-0	2017	NANOG as an adverse predictive marker in advanced non-small cell lung cancer treated with platinum-based chemotherapy.	Platinum	90-98	Nanog homeobox	Homo sapiens	0-5
28723093-4	2017	This Au-TiO2/Pt arrangement in three dimensions effectively utilizes conduction-band electrons injected into the TiO2 aerogel network upon exciting the Au SPR at the Au TiO2 interface.	Platinum	13-15	sepiapterin reductase	Homo sapiens	155-158
28723093-6	2017	We compare the photocatalytic rates of H2 generation with and without Pt cocatalysts added to Au-TiO2 aerogels and demonstrate electrochemical linkage of the SPR-generated carriers at the Au TiO2 interfaces to downfield Pt nanoparticle cocatalysts.	Platinum	70-72	sepiapterin reductase	Homo sapiens	158-161
29033581-4	2017	The aim of this study was to investigate whether NANOG levels are associated with clinical outcomes of patients with non-small cell lung cancer (NSCLC) who were treated with platinum-based chemotherapy.	Platinum	174-182	Nanog homeobox	Homo sapiens	49-54
29033581-5	2017	METHODS: NANOG levels were evaluated immunohistochemically using the histologic score (H-score) in tumor tissues from patients with advanced NSCLC who received platinum-based doublet treatment.	Platinum	160-168	Nanog homeobox	Homo sapiens	9-14
29033581-10	2017	CONCLUSION: NANOG overexpression was associated with poor response and short overall survival in patients with advanced NSCLC who were treated with platinum-based chemotherapy, suggesting that NANOG could be a potential adverse predictive marker in this setting.	Platinum	148-156	Nanog homeobox	Homo sapiens	12-17
29033581-10	2017	CONCLUSION: NANOG overexpression was associated with poor response and short overall survival in patients with advanced NSCLC who were treated with platinum-based chemotherapy, suggesting that NANOG could be a potential adverse predictive marker in this setting.	Platinum	148-156	Nanog homeobox	Homo sapiens	193-198
28608931-0	2017	The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.	Platinum	67-75	BRCA2 DNA repair associated	Homo sapiens	33-38
28928375-6	2017	These results obtained in this study indicate that the Co3S4/CoP hybrid nanorod is promising replacement to the Pt-based catalysts for H2 production.	Platinum	112-114	caspase recruitment domain family member 16	Homo sapiens	61-64
28608931-1	2017	BACKGROUND: Breast cancer 2 (BRCA2)-associated breast and ovarian cancers are sensitive to platinum-based chemotherapy.	Platinum	91-99	BRCA2 DNA repair associated	Homo sapiens	12-27
28608931-1	2017	BACKGROUND: Breast cancer 2 (BRCA2)-associated breast and ovarian cancers are sensitive to platinum-based chemotherapy.	Platinum	91-99	BRCA2 DNA repair associated	Homo sapiens	29-34
28916831-6	2017	Expression of a non-phosphorylatable ATR-S435A construct or deletion of A kinase-anchoring protein 12 (AKAP12) impeded platinum adduct clearance and prevented cAMP-mediated enhancement of ATR and XPA"s associations with cisplatin-damaged DNA, indicating that ATR phosphorylation at S435 is necessary for cAMP-enhanced repair of platinum-induced damage and protection against cisplatin-induced mutagenesis.	Platinum	328-336	A-kinase anchoring protein 12	Homo sapiens	72-101
28870319-0	2017	Ultrasensitive electrochemical immunosensor for alpha fetoprotein detection based on platinum nanoparticles anchored on cobalt oxide/graphene nanosheets for signal amplification.	Platinum	85-93	alpha fetoprotein	Homo sapiens	48-65
28918032-5	2017	Although miR-31 re-expression increased chemoresistance, paradoxically, a higher relative intracellular accumulation of platinum was detected.	Platinum	120-128	microRNA 31	Homo sapiens	9-15
28918032-7	2017	Linked with a downregulation of OCT1, a bipotential transcriptional regulator with multiple miR-31 target binding sites, we subsequently identified an indirect miR-31-mediated upregulation of ABCB9, a transporter associated with drug accumulation in lysosomes, and increased uptake of platinum to lysosomes.	Platinum	285-293	solute carrier family 22 member 1	Homo sapiens	32-36
28918032-7	2017	Linked with a downregulation of OCT1, a bipotential transcriptional regulator with multiple miR-31 target binding sites, we subsequently identified an indirect miR-31-mediated upregulation of ABCB9, a transporter associated with drug accumulation in lysosomes, and increased uptake of platinum to lysosomes.	Platinum	285-293	microRNA 31	Homo sapiens	92-98
28916831-3	2017	MC1R antagonists human beta-defensin 3 and agouti signaling protein blocked MSH- but not forskolin-mediated enhancement of platinum-induced DNA damage.	Platinum	123-131	melanocortin 1 receptor	Homo sapiens	0-4
28916831-6	2017	Expression of a non-phosphorylatable ATR-S435A construct or deletion of A kinase-anchoring protein 12 (AKAP12) impeded platinum adduct clearance and prevented cAMP-mediated enhancement of ATR and XPA"s associations with cisplatin-damaged DNA, indicating that ATR phosphorylation at S435 is necessary for cAMP-enhanced repair of platinum-induced damage and protection against cisplatin-induced mutagenesis.	Platinum	328-336	A-kinase anchoring protein 12	Homo sapiens	103-109
28916831-6	2017	Expression of a non-phosphorylatable ATR-S435A construct or deletion of A kinase-anchoring protein 12 (AKAP12) impeded platinum adduct clearance and prevented cAMP-mediated enhancement of ATR and XPA"s associations with cisplatin-damaged DNA, indicating that ATR phosphorylation at S435 is necessary for cAMP-enhanced repair of platinum-induced damage and protection against cisplatin-induced mutagenesis.	Platinum	119-127	ATR serine/threonine kinase	Homo sapiens	37-40
28918032-7	2017	Linked with a downregulation of OCT1, a bipotential transcriptional regulator with multiple miR-31 target binding sites, we subsequently identified an indirect miR-31-mediated upregulation of ABCB9, a transporter associated with drug accumulation in lysosomes, and increased uptake of platinum to lysosomes.	Platinum	285-293	microRNA 31	Homo sapiens	160-166
28916799-6	2017	While the intersection of potential energy curves of S0 and S1 states result in the nonradiation transition from S1 to S0 state, which successfully explain why the emission peak of the proton-transfer PIP-C-MeOH-PT form could not be reported in previous experiment.	Platinum	212-214	prolactin induced protein	Homo sapiens	201-204
28918032-7	2017	Linked with a downregulation of OCT1, a bipotential transcriptional regulator with multiple miR-31 target binding sites, we subsequently identified an indirect miR-31-mediated upregulation of ABCB9, a transporter associated with drug accumulation in lysosomes, and increased uptake of platinum to lysosomes.	Platinum	285-293	ATP binding cassette subfamily B member 9	Homo sapiens	192-197
29137324-4	2017	The aim of this study was to evaluate the stability of BRCA1 promoter hypermethylation in recurrent disease after platinum based chemotherapy.	Platinum	114-122	BRCA1 DNA repair associated	Homo sapiens	55-60
28916831-6	2017	Expression of a non-phosphorylatable ATR-S435A construct or deletion of A kinase-anchoring protein 12 (AKAP12) impeded platinum adduct clearance and prevented cAMP-mediated enhancement of ATR and XPA"s associations with cisplatin-damaged DNA, indicating that ATR phosphorylation at S435 is necessary for cAMP-enhanced repair of platinum-induced damage and protection against cisplatin-induced mutagenesis.	Platinum	119-127	A-kinase anchoring protein 12	Homo sapiens	72-101
28916831-6	2017	Expression of a non-phosphorylatable ATR-S435A construct or deletion of A kinase-anchoring protein 12 (AKAP12) impeded platinum adduct clearance and prevented cAMP-mediated enhancement of ATR and XPA"s associations with cisplatin-damaged DNA, indicating that ATR phosphorylation at S435 is necessary for cAMP-enhanced repair of platinum-induced damage and protection against cisplatin-induced mutagenesis.	Platinum	119-127	A-kinase anchoring protein 12	Homo sapiens	103-109
28878296-0	2017	Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy.	Platinum	111-119	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	20-25
28853487-4	2017	Our investigations revealed that the electrical conductivity of the (011)-La0.7Sr0.3CoO3/PMN-PT film changes continuously from metallicity to insulativity under repeated transport measurements below room temperature, which indicates the transformation of the Co4+ state to Co3+ in the film.	Platinum	93-95	complement C4A (Rodgers blood group)	Homo sapiens	259-262
29254172-1	2017	Introduction: Trastuzumab in combination with platinum-based chemotherapy is the standard first-line regimen in HER2-positive advanced gastric cancer.	Platinum	46-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-116
28878296-0	2017	Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy.	Platinum	111-119	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	30-33
28588062-1	2017	High-grade epithelial ovarian carcinomas containing mutated BRCA1 or BRCA2 (BRCA1/2) homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and PARP inhibitors (PARPi), while restoration of HR function due to secondary mutations in BRCA1/2 has been recognized as an important resistance mechanism.	Platinum	138-146	BRCA1 DNA repair associated	Homo sapiens	60-65
27689466-0	2017	Activation of estrogen receptor alpha by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells.	Platinum	73-81	estrogen receptor 1	Homo sapiens	14-37
27689466-11	2017	Collectively, our findings suggest that activation of ERalpha by E2 and cisplatin can induce platinum-resistance by increasing the expression of anti-apoptotic protein in ovarian cancer cells.	Platinum	93-101	estrogen receptor 1	Homo sapiens	54-61
28588062-1	2017	High-grade epithelial ovarian carcinomas containing mutated BRCA1 or BRCA2 (BRCA1/2) homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and PARP inhibitors (PARPi), while restoration of HR function due to secondary mutations in BRCA1/2 has been recognized as an important resistance mechanism.	Platinum	138-146	BRCA2 DNA repair associated	Homo sapiens	69-74
28588062-1	2017	High-grade epithelial ovarian carcinomas containing mutated BRCA1 or BRCA2 (BRCA1/2) homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and PARP inhibitors (PARPi), while restoration of HR function due to secondary mutations in BRCA1/2 has been recognized as an important resistance mechanism.	Platinum	138-146	BRCA2 DNA repair associated	Homo sapiens	76-83
28588062-1	2017	High-grade epithelial ovarian carcinomas containing mutated BRCA1 or BRCA2 (BRCA1/2) homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and PARP inhibitors (PARPi), while restoration of HR function due to secondary mutations in BRCA1/2 has been recognized as an important resistance mechanism.	Platinum	138-146	BRCA2 DNA repair associated	Homo sapiens	258-265
28601656-2	2017	Src activation has been associated with a more aggressive neoplastic phenotype and induces resistance to platinum agents in preclinical models.	Platinum	105-113	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
29234489-2	2017	The current treatment paradigm has shifted to personalized treatment strategies with tyrosine kinase inhibitors (TKIs) or anaplastic lymphoma kinase (ALK) inhibitors, due to low survival rates in non-small cell lung cancer (NSCLC) in terms of the prevailing platinum-based therapy.	Platinum	258-266	ALK receptor tyrosine kinase	Homo sapiens	122-148
28927067-8	2017	Lower levels of miR-146a in primary tumor tissue samples were correlated with a shorter progression-free survival (P=0.04) and platinum-resistance of metastases (P=0.006).	Platinum	127-135	microRNA 146a	Homo sapiens	16-24
28713952-10	2017	The study indicated that c-Jun and CCNB1 may be the prognostic biomarkers of EOC treated with carboplatin, and certain pathways (such as p53 signaling pathway, cell cycle and mitogen-activation protein kinase signaling pathway) may be involved in carbo-platin-resistant EOC.	Platinum	99-105	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	25-30
28713952-10	2017	The study indicated that c-Jun and CCNB1 may be the prognostic biomarkers of EOC treated with carboplatin, and certain pathways (such as p53 signaling pathway, cell cycle and mitogen-activation protein kinase signaling pathway) may be involved in carbo-platin-resistant EOC.	Platinum	99-105	cyclin B1	Homo sapiens	35-40
28927101-14	2017	The results of the present study suggest that ERCC1 expression is an important prognostic indicator for NSCLC, particularly for patients with stage II-III tumors who receive systematic platinum-based adjuvant chemotherapy.	Platinum	185-193	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	46-51
28842710-4	2017	Additionally, the area under the receiver operating characteristic curve (AUC) was used to predict platinum resistance and prognosis by comparing the predictive ability of PNI and cancer antigen (CA)-125.	Platinum	99-107	mucin 16, cell surface associated	Homo sapiens	180-203
28807247-1	2017	BACKGROUND: Surgery is the standard treatment for early-stage NSCLC, and platinum-based chemotherapy remains as the treatment of choice for advanced-stage NSCLC patients with naive EGFR status.	Platinum	73-81	epidermal growth factor receptor	Homo sapiens	181-185
28455360-0	2017	Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study.	Platinum	60-68	KRAS proto-oncogene, GTPase	Homo sapiens	12-16
28928874-0	2017	ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy.	Platinum	103-111	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
28928874-1	2017	Purpose: To develop a qPCR method to examine the 202 isoform of excision repair cross-complementation group 1 (ERCC1_202) and to evaluate its clinical utility as a predictive biomarker for platinum-based chemotherapy in non-small cell lung cancer (NSCLC).	Platinum	189-197	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	111-116
28928874-8	2017	Conclusions: This study suggests that the efficacy of platinum-based chemotherapy can be improved when customized according to the expression of ERCC1_202.	Platinum	54-62	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	145-150
28525843-4	2017	Platinum drug release was pH rate controlled, with more rapid release (t1/2 20 h) at acidic pH similar to the tumor microenvironment yet slower release (t1/2 35 h) at normal physiological pH.	Platinum	0-8	interleukin 1 receptor like 1	Homo sapiens	71-80
28525843-4	2017	Platinum drug release was pH rate controlled, with more rapid release (t1/2 20 h) at acidic pH similar to the tumor microenvironment yet slower release (t1/2 35 h) at normal physiological pH.	Platinum	0-8	interleukin 1 receptor like 1	Homo sapiens	153-162
28860885-2	2017	First- and second-generation EGFR TKIs, including erlotinib, gefitinib and afatinib, have consistently shown superior efficacy and better toxicity compared with first-line platinum-based chemotherapy and currently represent the standard of care for EGFR-mutated advanced NSCLC patients.	Platinum	172-180	epidermal growth factor receptor	Homo sapiens	29-33
28805881-4	2017	Further, characteristics of CNF resonators after platinum deposition and intensive electron beam exposure are investigated, and resonance frequency shifts due to mass loading on the CNFs are clearly observed.	Platinum	49-57	NPHS1 adhesion molecule, nephrin	Homo sapiens	28-31
29156754-7	2017	Our data suggested that larger ERCC1 transcript levels correlated with the outcome of platinum-based chemotherapy.	Platinum	86-94	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	31-36
28441021-2	2017	The substitution of PPh3 into Pt(PPh3)2(C CR)2 (R = aryl) with rac- or meso-dpmppe gives Pt(rac-dpmppe)(C CR)2 or Pt(meso-dpmppe)(C CR)2, respectively.	Platinum	30-32	caveolin 1	Homo sapiens	20-24
28441021-2	2017	The substitution of PPh3 into Pt(PPh3)2(C CR)2 (R = aryl) with rac- or meso-dpmppe gives Pt(rac-dpmppe)(C CR)2 or Pt(meso-dpmppe)(C CR)2, respectively.	Platinum	30-32	caveolin 1	Homo sapiens	33-37
28455360-8	2017	When we stratified PanNEN-G3 with Rb and KRAS, PanNENs-G3 with Rb loss and those with mutated KRAS showed significantly higher RRs to platinum-based chemotherapy than those without (Rb loss, 80% vs. normal Rb, 24%, P = 0.006; mutated KRAS, 77% versus wild type, 23%, P = 0.023).	Platinum	134-142	KRAS proto-oncogene, GTPase	Homo sapiens	41-45
28455360-8	2017	When we stratified PanNEN-G3 with Rb and KRAS, PanNENs-G3 with Rb loss and those with mutated KRAS showed significantly higher RRs to platinum-based chemotherapy than those without (Rb loss, 80% vs. normal Rb, 24%, P = 0.006; mutated KRAS, 77% versus wild type, 23%, P = 0.023).	Platinum	134-142	KRAS proto-oncogene, GTPase	Homo sapiens	94-98
28455360-8	2017	When we stratified PanNEN-G3 with Rb and KRAS, PanNENs-G3 with Rb loss and those with mutated KRAS showed significantly higher RRs to platinum-based chemotherapy than those without (Rb loss, 80% vs. normal Rb, 24%, P = 0.006; mutated KRAS, 77% versus wild type, 23%, P = 0.023).	Platinum	134-142	KRAS proto-oncogene, GTPase	Homo sapiens	94-98
28455360-11	2017	Rb and KRAS are promising predictors of response to platinum-based chemotherapy for PanNEN-G3, and Rb for NEC-G3.	Platinum	52-60	KRAS proto-oncogene, GTPase	Homo sapiens	7-11
29100359-9	2017	Transcriptome analysis showed early up-regulation of CDKN1A and c-Fos in both, platinum-resistant and -sensitive cells after 5-FdU-ECyd treatment and de-regulation of distinct cellular pathways involved in cell cycle regulation, apoptosis, DNA-damage response and RNA-metabolism.	Platinum	79-87	cyclin dependent kinase inhibitor 1A	Homo sapiens	53-59
29100359-9	2017	Transcriptome analysis showed early up-regulation of CDKN1A and c-Fos in both, platinum-resistant and -sensitive cells after 5-FdU-ECyd treatment and de-regulation of distinct cellular pathways involved in cell cycle regulation, apoptosis, DNA-damage response and RNA-metabolism.	Platinum	79-87	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	64-69
28800641-1	2017	BACKGROUND: High expression of the RNA-binding motif protein 3 (RBM3) has been shown to correlate, with prolonged survival in several malignant diseases and with the benefit of platinum-based chemotherapy in ovarian cancer.	Platinum	177-185	RNA binding motif protein 3	Homo sapiens	35-62
28800641-1	2017	BACKGROUND: High expression of the RNA-binding motif protein 3 (RBM3) has been shown to correlate, with prolonged survival in several malignant diseases and with the benefit of platinum-based chemotherapy in ovarian cancer.	Platinum	177-185	RNA binding motif protein 3	Homo sapiens	64-68
28749491-1	2017	Highly efficient Pt-Fe/gamma-Al2O3 catalysts for preferential oxidation of CO in excess of H2 (CO-PROX) were prepared by utilizing single-atom Fe species as active sites for O2 activation, which exhibited high catalytic activity and selectivity from 25  C to 200  C, with the highest Pt specific rate of Pt-based catalysts for CO-PROX.	Platinum	17-19	pyruvate dehydrogenase complex component X	Homo sapiens	98-102
28749491-1	2017	Highly efficient Pt-Fe/gamma-Al2O3 catalysts for preferential oxidation of CO in excess of H2 (CO-PROX) were prepared by utilizing single-atom Fe species as active sites for O2 activation, which exhibited high catalytic activity and selectivity from 25  C to 200  C, with the highest Pt specific rate of Pt-based catalysts for CO-PROX.	Platinum	17-19	pyruvate dehydrogenase complex component X	Homo sapiens	330-334
28467918-9	2017	77% of BRCA1 and 31% of BRCA2 carriers were platinum-pretreated.	Platinum	44-52	BRCA1 DNA repair associated	Homo sapiens	7-12
29163831-8	2017	Significant associations were also found in patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) (HR = 3.16, 95% CI: 2.21-4.52, P &lt; 0.001) and with a platinum-based regimen (HR = 4.35, 95% CI: 2.45-7.72, P &lt; 0.001).	Platinum	194-202	epidermal growth factor receptor	Homo sapiens	127-131
28467918-9	2017	77% of BRCA1 and 31% of BRCA2 carriers were platinum-pretreated.	Platinum	44-52	BRCA2 DNA repair associated	Homo sapiens	24-29
28264872-10	2017	Among 98 patients, 5 (5.1%) discontinued because of an adverse event (excluding disease progression).Conclusions: Rucaparib was tolerable and had activity in patients with platinum-sensitive germline BRCA1/2-mutated HGOC.	Platinum	172-180	BRCA1 DNA repair associated	Homo sapiens	200-205
28860445-1	2017	We report a case of TNBC treated effectively with a platinum-based regimen after developing resistance to anthracycline and taxane-based neoadjuvant chemotherapy(NAC).	Platinum	52-60	synuclein alpha	Homo sapiens	162-165
28760152-10	2017	DISCUSSION: MATEO will be the first trial to define the role of a S-1 based maintenance therapy in patients having received a platinum-based firstline chemotherapy.	Platinum	126-134	proteasome 26S subunit, non-ATPase 1	Homo sapiens	66-69
28623073-0	2017	Commentary on "Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer".	Platinum	50-58	BRCA2 DNA repair associated	Homo sapiens	41-46
28623073-8	2017	Biallelic BRCA2 inactivation in mCRPC warrants further exploration as a predictive biomarker for sensitivity to platinum chemotherapy.	Platinum	112-120	BRCA2 DNA repair associated	Homo sapiens	10-15
28645807-1	2017	BACKGROUND: Excision repair cross complement group 1 (ERCC1) expression is a predictive biomarker for platinum-containing treatment in squamous cell carcinoma of head and neck (SCCHN).	Platinum	102-110	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	12-52
28645807-1	2017	BACKGROUND: Excision repair cross complement group 1 (ERCC1) expression is a predictive biomarker for platinum-containing treatment in squamous cell carcinoma of head and neck (SCCHN).	Platinum	102-110	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	54-59
28651933-9	2017	Nuclear expression of beta-catenin in advanced ovarian cancer of LTS patients proved to be not only an independent favourable predictor of OS (univariate analysis: p=0.025, multivariate analysis: p=0.041) but also showed strong correlation with platinum sensitivity and platinum re-induction.	Platinum	245-253	catenin beta 1	Homo sapiens	22-34
28651933-9	2017	Nuclear expression of beta-catenin in advanced ovarian cancer of LTS patients proved to be not only an independent favourable predictor of OS (univariate analysis: p=0.025, multivariate analysis: p=0.041) but also showed strong correlation with platinum sensitivity and platinum re-induction.	Platinum	270-278	catenin beta 1	Homo sapiens	22-34
28651933-10	2017	CONCLUSIONS: Translocation of stabilized beta-catenin from cytoplasm to the nucleus plays an important role in predicting platinum sensitivity.	Platinum	122-130	catenin beta 1	Homo sapiens	41-53
28758939-9	2017	Moreover, patients with STON2 protein overexpression were more likely to exhibit platinum resistance and to have undergone neoadjuvant chemotherapy.	Platinum	81-89	stonin 2	Homo sapiens	24-29
29209522-7	2017	One option for patients with PD-L1 expression lower than 50% may be the combination of ICI with platinum-based chemotherapy or with ICIs against different targets.	Platinum	96-104	CD274 molecule	Homo sapiens	29-34
28977945-0	2017	Genetic polymorphisms of long non-coding RNA GAS5 predict platinum-based concurrent chemoradiotherapy response in nasopharyngeal carcinoma patients.	Platinum	58-66	growth arrest specific 5	Homo sapiens	45-49
28758939-12	2017	In conclusion, STON2 plays an important role in the progression and prognosis of ovarian carcinoma, especially in platinum resistance, intraperitoneal metastasis, and recurrence.	Platinum	114-122	stonin 2	Homo sapiens	15-20
28415744-8	2017	CONCLUSIONS: Platinum-based chemotherapy seems to select for EMT-like CTCs in ovarian cancer patients and provokes a shift towards PI3Kalpha and Twist expressing CTCs, which may reflect clonal tumor evolution towards therapy resistance.	Platinum	13-21	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	131-140
28743242-0	2017	Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement.	Platinum	97-105	X-ray repair cross complementing 1	Homo sapiens	24-29
28743242-4	2017	To explore the relationship between XRCC1 polymorphisms and platinum-based chemotherapy in advanced NSCLC patients, we performed this meta-analysis.	Platinum	60-68	X-ray repair cross complementing 1	Homo sapiens	36-41
28743242-12	2017	CONCLUSIONS: Our results indicated that in NSCLC patients treated with platinum-based regimen, XRCC1 194Arg allele suggest poor objective response rate, the GlnGln genotype of XRCC1 399 suggest poorer overall survival in Caucasian patients, and longer PFS in Asian patients.	Platinum	71-79	X-ray repair cross complementing 1	Homo sapiens	95-100
28743242-12	2017	CONCLUSIONS: Our results indicated that in NSCLC patients treated with platinum-based regimen, XRCC1 194Arg allele suggest poor objective response rate, the GlnGln genotype of XRCC1 399 suggest poorer overall survival in Caucasian patients, and longer PFS in Asian patients.	Platinum	71-79	X-ray repair cross complementing 1	Homo sapiens	176-181
28747739-0	2017	Spin pump and probe in lanthanum strontium manganite/platinum bilayers.	Platinum	53-61	spindlin 1	Homo sapiens	0-4
28747739-5	2017	The thickness dependences of ISHE voltage allow to extract the values of spin mixing conductance and spin Hall angle of LSMO/Pt bilayers, which are (1.8 +- 0.4) x 1019 m-2 and (1.2 +- 0.1) % respectively.	Platinum	125-127	spindlin 1	Homo sapiens	73-77
28747739-5	2017	The thickness dependences of ISHE voltage allow to extract the values of spin mixing conductance and spin Hall angle of LSMO/Pt bilayers, which are (1.8 +- 0.4) x 1019 m-2 and (1.2 +- 0.1) % respectively.	Platinum	125-127	spindlin 1	Homo sapiens	101-105
28454085-3	2017	Although platinum sensitivity has been suggested as a marker of response to PARP inhibitors, patients with platinum-resistant disease still respond to olaparib.	Platinum	9-17	collagen type XI alpha 2 chain	Homo sapiens	76-80
28660264-5	2017	Compared with Me-Por-RB, Pt-Por-RB was not only internalized in the organelles, but also in the nuclei of HeLa cells, probably due to the presence of platinum complexes, as analyzed using the confocal laser scanning microscope.	Platinum	150-158	solute carrier family 25 member 3	Homo sapiens	25-34
28678257-5	2017	Based on conductance and break-off distance data, we demonstrate that a PPh3 supporting ligand in the platinum complexes can provide an alternative contact point for the STM tip in the molecular junctions, orthogonal to the terminal C[triple bond, length as m-dash]CSiMe3 group.	Platinum	102-110	caveolin 1	Homo sapiens	72-76
28737170-3	2017	The acidic single-cell with such a catalyst as cathode delivers high performance, with power density up to 680 mW cm-2 at 80  C with a low platinum loading of 0.09 mgPt cm-2, corresponding to a platinum utilization of 0.13 gPt kW-1 in the fuel cell.	Platinum	194-202	glutamic--pyruvic transaminase	Homo sapiens	165-168
28454085-10	2017	CONCLUSION: PTPI may be used to refine the prediction of response to PARP inhibition based on the conventional categorization of platinum sensitivity.	Platinum	129-137	collagen type XI alpha 2 chain	Homo sapiens	69-73
28404378-4	2017	We found that mRNA and protein levels of Axl were increased in the platinum-resistant IGROV-1/Pt1 and IGROV-1/OHP cell lines compared to the parental IGROV-1 cells.	Platinum	67-75	AXL receptor tyrosine kinase	Homo sapiens	41-44
28744017-3	2017	The heat-driven dynamics is observed in Y3Fe5O12/Pt bilayer nanowires where ohmic heating of the Pt layer results in injection of pure spin current into the Y3Fe5O12 layer.	Platinum	49-51	spindlin 1	Homo sapiens	135-139
28944120-6	2017	Here, we describe the case of a 64-year-old man with Stage IIB (tumor size 2 to 5 cm with involvement of axillary lymph nodes), high-grade estrogen receptor, progesterone receptor, and HER2-positive invasive ductal carcinoma with a germline breast cancer susceptibility gene 1 (BRCA1) mutation who was treated in a neoadjuvant fashion with dual HER2 blockade and platinum-based chemotherapy regimen.	Platinum	363-371	erb-b2 receptor tyrosine kinase 2	Homo sapiens	185-189
28682064-7	2017	All Pt(N(R)-1,1"-Me2dma)G adducts exhibit two new downfield-shifted G H8 signals, consistent with G bound to platinum by N7 and a syn/anti rotamer mixture.	Platinum	4-6	synemin	Homo sapiens	130-133
28339098-1	2017	BACKGROUND: The ICON6 trial showed that cediranib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, improved clinical outcomes for patients with platinum-sensitive relapsed ovarian cancer when it was used with chemotherapy and was continued as maintenance therapy.	Platinum	175-183	fms related receptor tyrosine kinase 1	Homo sapiens	72-128
28404378-4	2017	We found that mRNA and protein levels of Axl were increased in the platinum-resistant IGROV-1/Pt1 and IGROV-1/OHP cell lines compared to the parental IGROV-1 cells.	Platinum	67-75	zinc finger protein 77	Homo sapiens	86-109
28761342-0	2017	Transferrin-functionalized nanographene oxide for delivery of platinum complexes to enhance cancer-cell selectivity and apoptosis-inducing efficacy.	Platinum	62-70	transferrin	Homo sapiens	0-11
28977941-3	2017	CCNE1 amplification, occurring in ~20% of the high grade serous ovarian tumors, was previously proposed as a marker for platinum resistance and poor prognosis as well as for CDK2 inhibition.	Platinum	120-128	cyclin E1	Homo sapiens	0-5
28977941-4	2017	The current study aimed to examine the role of CCNE1 positive-immunostain as a predictor of first-line taxane-platinum chemoresistance.	Platinum	110-118	cyclin E1	Homo sapiens	47-52
28570761-2	2017	A block copolymer with attached fructose, which interacts with GLUT5 receptor, was used and conjugated with a low and a high amount of platinum drugs.	Platinum	135-143	solute carrier family 2 member 5	Homo sapiens	63-68
28698656-7	2017	We found that HSPD1 rs17730989-SUMF1 rs2633851 interaction was associated with platinum-based chemotherapy-induced hematologic toxicity (adjusted OR = 0.233, P = 0.018).	Platinum	79-87	heat shock protein family D (Hsp60) member 1	Homo sapiens	14-19
28698656-7	2017	We found that HSPD1 rs17730989-SUMF1 rs2633851 interaction was associated with platinum-based chemotherapy-induced hematologic toxicity (adjusted OR = 0.233, P = 0.018).	Platinum	79-87	sulfatase modifying factor 1	Homo sapiens	31-36
28698656-9	2017	Besides, the model of ARHGAP26 rs3776332-ERCC6 rs2228528-SLC2A1 rs4658-histology was associated with platinum-based chemotherapeutic response.	Platinum	101-109	Rho GTPase activating protein 26	Homo sapiens	22-30
28698656-9	2017	Besides, the model of ARHGAP26 rs3776332-ERCC6 rs2228528-SLC2A1 rs4658-histology was associated with platinum-based chemotherapeutic response.	Platinum	101-109	ERCC excision repair 6, chromatin remodeling factor	Homo sapiens	41-46
28698656-9	2017	Besides, the model of ARHGAP26 rs3776332-ERCC6 rs2228528-SLC2A1 rs4658-histology was associated with platinum-based chemotherapeutic response.	Platinum	101-109	solute carrier family 2 member 1	Homo sapiens	57-63
27918237-0	2017	GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer.	Platinum	35-43	glutathione peroxidase 3	Homo sapiens	0-4
31457650-7	2017	Alternatively, when the metal-metal interaction dominates, larger clusters such as Pt5, Pt6, Pt7, Pt8, and Pt13 exhibit a two-layer structure with one or more Pt atoms on the top layer not interacting directly with the support.	Platinum	83-85	zinc finger protein 79	Homo sapiens	93-96
28574829-6	2017	Furthermore, in an in vivo mouse model, platinum agents preferentially eliminated EpCAM-negative cells in comparison with EpCAM-positive cells, suggesting that the remaining subpopulation of EpCAM-positive cells contributes to tumor recurrence after chemotherapy.	Platinum	40-48	epithelial cell adhesion molecule	Mus musculus	82-87
29416691-0	2018	Chinese C allele carriers of the ERCC5 rs1047768 polymorphism are more sensitive to platinum-based chemotherapy: a meta-analysis.	Platinum	84-92	ERCC excision repair 5, endonuclease	Homo sapiens	33-38
29416691-1	2018	It is suspected that ERCC5 rs1047768 and rs17655 polymorphisms influence the response to platinum-based chemotherapy.	Platinum	89-97	ERCC excision repair 5, endonuclease	Homo sapiens	21-26
27918237-3	2017	GPX3 role in oxidative damage has been associated with sensitivity to platinums in other tumors but its importance in colorectal cancer (CRC) has not been determined.	Platinum	70-79	glutathione peroxidase 3	Homo sapiens	0-4
27918237-4	2017	We examined the role of GPX3 methylation in colorectal carcinoma in determining sensitivity to platinum drugs using primary tumor specimens, cell lines, knockdown cell lines, and tumor cell line xenografts.	Platinum	95-103	glutathione peroxidase 3	Homo sapiens	24-28
27918237-6	2017	In contrast, in cell lines with high baseline levels of GPX3 expression or with the ability to increase GPX3 expression, platinum resistance is increased.	Platinum	121-129	glutathione peroxidase 3	Homo sapiens	56-60
27918237-6	2017	In contrast, in cell lines with high baseline levels of GPX3 expression or with the ability to increase GPX3 expression, platinum resistance is increased.	Platinum	121-129	glutathione peroxidase 3	Homo sapiens	104-108
27918237-9	2017	In vivo, GPX3 methylation predicts tumor xenograft sensitivity to platinum with regression of GPX3 knockdown xenografts with platinum treatment but continued growth of GPX3 wild type xenografts in the presence of platinum.	Platinum	66-74	glutathione peroxidase 3	Homo sapiens	9-13
27918237-9	2017	In vivo, GPX3 methylation predicts tumor xenograft sensitivity to platinum with regression of GPX3 knockdown xenografts with platinum treatment but continued growth of GPX3 wild type xenografts in the presence of platinum.	Platinum	66-74	glutathione peroxidase 3	Homo sapiens	94-98
27918237-9	2017	In vivo, GPX3 methylation predicts tumor xenograft sensitivity to platinum with regression of GPX3 knockdown xenografts with platinum treatment but continued growth of GPX3 wild type xenografts in the presence of platinum.	Platinum	66-74	glutathione peroxidase 3	Homo sapiens	94-98
27918237-9	2017	In vivo, GPX3 methylation predicts tumor xenograft sensitivity to platinum with regression of GPX3 knockdown xenografts with platinum treatment but continued growth of GPX3 wild type xenografts in the presence of platinum.	Platinum	125-133	glutathione peroxidase 3	Homo sapiens	9-13
27918237-9	2017	In vivo, GPX3 methylation predicts tumor xenograft sensitivity to platinum with regression of GPX3 knockdown xenografts with platinum treatment but continued growth of GPX3 wild type xenografts in the presence of platinum.	Platinum	125-133	glutathione peroxidase 3	Homo sapiens	94-98
27918237-9	2017	In vivo, GPX3 methylation predicts tumor xenograft sensitivity to platinum with regression of GPX3 knockdown xenografts with platinum treatment but continued growth of GPX3 wild type xenografts in the presence of platinum.	Platinum	125-133	glutathione peroxidase 3	Homo sapiens	94-98
27918237-9	2017	In vivo, GPX3 methylation predicts tumor xenograft sensitivity to platinum with regression of GPX3 knockdown xenografts with platinum treatment but continued growth of GPX3 wild type xenografts in the presence of platinum.	Platinum	125-133	glutathione peroxidase 3	Homo sapiens	9-13
27918237-9	2017	In vivo, GPX3 methylation predicts tumor xenograft sensitivity to platinum with regression of GPX3 knockdown xenografts with platinum treatment but continued growth of GPX3 wild type xenografts in the presence of platinum.	Platinum	125-133	glutathione peroxidase 3	Homo sapiens	94-98
27918237-9	2017	In vivo, GPX3 methylation predicts tumor xenograft sensitivity to platinum with regression of GPX3 knockdown xenografts with platinum treatment but continued growth of GPX3 wild type xenografts in the presence of platinum.	Platinum	125-133	glutathione peroxidase 3	Homo sapiens	94-98
27737534-1	2017	PURPOSE: We evaluated the clinical utility of excision repair cross-complementation group 1 (ERCC1) expression as a predictive biomarker for platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).	Platinum	141-149	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	46-91
27737534-1	2017	PURPOSE: We evaluated the clinical utility of excision repair cross-complementation group 1 (ERCC1) expression as a predictive biomarker for platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).	Platinum	141-149	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	93-98
28436941-0	2017	INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer.	Platinum	54-62	insulin receptor	Homo sapiens	0-4
28082048-13	2017	Four patients with tumors harboring CCDC6-RET and KIF5B-RET fusions showed pronounced and durable responses to platinum-based chemotherapy that lasted for 8 to 15 months.	Platinum	111-119	coiled-coil domain containing 6	Homo sapiens	36-41
28082048-13	2017	Four patients with tumors harboring CCDC6-RET and KIF5B-RET fusions showed pronounced and durable responses to platinum-based chemotherapy that lasted for 8 to 15 months.	Platinum	111-119	ret proto-oncogene	Homo sapiens	42-45
28082048-13	2017	Four patients with tumors harboring CCDC6-RET and KIF5B-RET fusions showed pronounced and durable responses to platinum-based chemotherapy that lasted for 8 to 15 months.	Platinum	111-119	kinesin family member 5B	Homo sapiens	50-55
28082048-13	2017	Four patients with tumors harboring CCDC6-RET and KIF5B-RET fusions showed pronounced and durable responses to platinum-based chemotherapy that lasted for 8 to 15 months.	Platinum	111-119	ret proto-oncogene	Homo sapiens	56-59
28087643-0	2017	Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.	Platinum	58-66	BRCA1 DNA repair associated	Homo sapiens	6-11
28087643-1	2017	Purpose: In germline BRCA1 or BRCA2 (BRCA1/2) mutation carriers, restoration of tumor BRCA1/2 function by a secondary mutation is recognized as a mechanism of resistance to platinum and PARP inhibitors, primarily in ovarian cancer.	Platinum	173-181	BRCA1 DNA repair associated	Homo sapiens	21-26
28087643-1	2017	Purpose: In germline BRCA1 or BRCA2 (BRCA1/2) mutation carriers, restoration of tumor BRCA1/2 function by a secondary mutation is recognized as a mechanism of resistance to platinum and PARP inhibitors, primarily in ovarian cancer.	Platinum	173-181	BRCA2 DNA repair associated	Homo sapiens	30-35
28087643-1	2017	Purpose: In germline BRCA1 or BRCA2 (BRCA1/2) mutation carriers, restoration of tumor BRCA1/2 function by a secondary mutation is recognized as a mechanism of resistance to platinum and PARP inhibitors, primarily in ovarian cancer.	Platinum	173-181	BRCA2 DNA repair associated	Homo sapiens	37-44
28087643-1	2017	Purpose: In germline BRCA1 or BRCA2 (BRCA1/2) mutation carriers, restoration of tumor BRCA1/2 function by a secondary mutation is recognized as a mechanism of resistance to platinum and PARP inhibitors, primarily in ovarian cancer.	Platinum	173-181	BRCA2 DNA repair associated	Homo sapiens	86-93
28087643-9	2017	A local relapse biopsy 4 months later revealed the identical reversion mutation, and the patient subsequently died from metastatic breast cancer.Conclusions: We report a BRCA1 reversion mutation in a patient newly diagnosed with triple-negative breast cancer that developed over 18 weeks of platinum-based neoadjuvant therapy.	Platinum	291-299	BRCA1 DNA repair associated	Homo sapiens	170-175
28436941-1	2017	This study aimed to investigate the correlation between INSR gene polymorphisms on platinum-based chemotherapy sensitivity and prognosis in epithelial ovarian cancer (EOC).	Platinum	83-91	insulin receptor	Homo sapiens	56-60
28436941-9	2017	These findings indicate that INSR rs2252673 and rs3745546 polymorphisms were associated with sensitivity to platinum-based chemotherapy in EOC patients and rs2252673 polymorphism may be an independent risk factor for EOC prognosis.	Platinum	108-116	insulin receptor	Homo sapiens	29-33
28746220-2	2017	Our study evaluated the correlation between copy number variations (CNVs) of neurotrophic tyrosine receptor kinase 3 (NTRK3) and the prognosis of ovarian cancer, which might predict platinum resistance in ovarian cancer patients.Array comparative genomic hybridization (CGH) was used to test gene backgrounds between platinum-sensitive and platinum-resistant relapsed populations and CNVs of NTRK3 were indicated by cluster analysis.	Platinum	182-190	neurotrophic receptor tyrosine kinase 3	Homo sapiens	77-116
28541631-8	2017	BRCA1/2-mutation carriers had favorable platinum sensitivity (relative risk, 1.57, p&lt;0.05), resulting in a 100% remission probability and survival rate.	Platinum	40-48	BRCA1 DNA repair associated	Homo sapiens	0-5
29456299-8	2017	Methodology used for studying the bacteria through AFM includes the following: (1) Probe type: Platinum coated silicon nitrate tip.	Platinum	95-103	TOR signaling pathway regulator	Homo sapiens	127-130
28300598-0	2017	Palladium and Platinum Nanoparticles Activate AHR and NRF2 in Human Keratinocytes-Implications in Vitiligo Therapy.	Platinum	14-22	aryl hydrocarbon receptor	Homo sapiens	46-49
28300598-0	2017	Palladium and Platinum Nanoparticles Activate AHR and NRF2 in Human Keratinocytes-Implications in Vitiligo Therapy.	Platinum	14-22	NFE2 like bZIP transcription factor 2	Homo sapiens	54-58
28369553-2	2017	Data are presented from the phase II trial (ASCEND-2) evaluating efficacy and safety in a subset of Japanese patients with ALK-rearranged non-small cell lung cancer previously treated with platinum-based chemotherapy, who experienced disease progression on crizotinib.	Platinum	189-197	ALK receptor tyrosine kinase	Homo sapiens	123-126
28577956-0	2017	Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.	Platinum	21-29	epidermal growth factor receptor	Homo sapiens	87-91
28577956-0	2017	Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.	Platinum	21-29	epidermal growth factor receptor	Homo sapiens	151-155
28746220-2	2017	Our study evaluated the correlation between copy number variations (CNVs) of neurotrophic tyrosine receptor kinase 3 (NTRK3) and the prognosis of ovarian cancer, which might predict platinum resistance in ovarian cancer patients.Array comparative genomic hybridization (CGH) was used to test gene backgrounds between platinum-sensitive and platinum-resistant relapsed populations and CNVs of NTRK3 were indicated by cluster analysis.	Platinum	182-190	neurotrophic receptor tyrosine kinase 3	Homo sapiens	118-123
28746220-2	2017	Our study evaluated the correlation between copy number variations (CNVs) of neurotrophic tyrosine receptor kinase 3 (NTRK3) and the prognosis of ovarian cancer, which might predict platinum resistance in ovarian cancer patients.Array comparative genomic hybridization (CGH) was used to test gene backgrounds between platinum-sensitive and platinum-resistant relapsed populations and CNVs of NTRK3 were indicated by cluster analysis.	Platinum	317-325	neurotrophic receptor tyrosine kinase 3	Homo sapiens	77-116
28746220-2	2017	Our study evaluated the correlation between copy number variations (CNVs) of neurotrophic tyrosine receptor kinase 3 (NTRK3) and the prognosis of ovarian cancer, which might predict platinum resistance in ovarian cancer patients.Array comparative genomic hybridization (CGH) was used to test gene backgrounds between platinum-sensitive and platinum-resistant relapsed populations and CNVs of NTRK3 were indicated by cluster analysis.	Platinum	317-325	neurotrophic receptor tyrosine kinase 3	Homo sapiens	118-123
28746220-4	2017	Spearman"s rank correlation analysis and chi test were used to evaluate the accuracy of CNVs of NTRK3 which predicted platinum-sensitive or platinum-resistant recurrence.We detected CNVs of NTRK3 between 2 groups by array CGH, and amplification of NTRK3 was confirmed by FISH in the platinum-sensitive recurrence group with enlarged samples.	Platinum	118-126	neurotrophic receptor tyrosine kinase 3	Homo sapiens	96-101
28746220-8	2017	According to the above standard, 15 cases with NTRK3 amplification were platinum-sensitive and 12 cases without NTRK3 amplification were platinum-resistant recurrences which demonstrated that the accuracy of NTRK3 amplification/nonamplification to predict recurrent types was 65.9% (27/41).CNVs of NTRK3 were associated with platinum-sensitive and platinum-resistant recurrences.	Platinum	72-80	neurotrophic receptor tyrosine kinase 3	Homo sapiens	47-52
28746220-9	2017	Amplification of NTRK3 perfectly predicted platinum-sensitive relapse of ovarian cancer.	Platinum	43-51	neurotrophic receptor tyrosine kinase 3	Homo sapiens	17-22
28685075-3	2017	The aim of the present study was to evaluate the efficacy and adverse events (AE) of combination therapy with irinotecan and platinum (CPT-Pt) for ROC.	Platinum	125-133	choline phosphotransferase 1	Homo sapiens	135-138
28685075-4	2017	A total of 28 platinum-resistant or refractory patients with ROC treated with CPT-Pt at the National Defense Medical College Hospital institution between 2002 and 2012 were identified.	Platinum	14-22	choline phosphotransferase 1	Homo sapiens	78-81
28623887-0	2017	Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis.	Platinum	47-55	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	24-29
28647964-11	2017	The risk of BRCA1 mutation in Val507Met and Arg378Ser were more evident in subjects with negative family history, positive menopause history, negative tubal ligation, onset age (&lt;=60 years old) and sensitivity to platinum-based chemotherapy in EOC (all P&lt;0.05), while Pro24Ser was only more evident in positive menopause history of EOC (P&lt;0.05).	Platinum	216-224	BRCA1 DNA repair associated	Homo sapiens	12-17
28647964-13	2017	The family history, menopause history, tubal ligation, onset age and sensitivity to platinum-based chemotherapy have effects on BARD1 SNP in the risk of BRCA1 gene mutation.	Platinum	84-92	BRCA1 associated RING domain 1	Homo sapiens	128-133
28647964-13	2017	The family history, menopause history, tubal ligation, onset age and sensitivity to platinum-based chemotherapy have effects on BARD1 SNP in the risk of BRCA1 gene mutation.	Platinum	84-92	BRCA1 DNA repair associated	Homo sapiens	153-158
28597888-3	2017	The common method to investigate oxidative stability of LIB electrolytes is related to determination of the electrochemical stability window (ESW), on e.g. Pt or LiMn2O4 electrodes.	Platinum	156-158	leucine rich repeat containing 15	Homo sapiens	56-59
28562428-10	2017	CONCLUSION: We identified a variant in the 3"-UTR region Nup107 unique to sensitivity to platinum in ovarian cancer.	Platinum	89-97	nucleoporin 107	Homo sapiens	57-63
28721084-0	2017	Urinary TIMP2 IGFBP7 for the prediction of platinum-induced acute renal injury.	Platinum	43-51	TIMP metallopeptidase inhibitor 2	Homo sapiens	8-13
28721084-0	2017	Urinary TIMP2 IGFBP7 for the prediction of platinum-induced acute renal injury.	Platinum	43-51	insulin like growth factor binding protein 7	Homo sapiens	14-20
28721084-13	2017	CONCLUSION: Urinary TIMP2 IGFBP7 measured in specimens gathered after PBC may be a useful tool to early identify patients who are at risk for developing platinum-induced AKI.	Platinum	153-161	TIMP metallopeptidase inhibitor 2	Homo sapiens	20-25
28721084-13	2017	CONCLUSION: Urinary TIMP2 IGFBP7 measured in specimens gathered after PBC may be a useful tool to early identify patients who are at risk for developing platinum-induced AKI.	Platinum	153-161	insulin like growth factor binding protein 7	Homo sapiens	26-32
28490629-7	2017	The compromised DNA repair and chemosensitization induced by SMI#9 or RAD6B depletion were associated with decreased platinum drug-induced proliferating cell nuclear antigen (PCNA) and FANCD2 monoubiquitinations (surrogate markers of TLS and FA pathway activation, respectively) and with attenuated FANCD2, RAD6, gammaH2AX, and POL eta foci formation and cisplatin-adduct removal.	Platinum	117-125	ubiquitin conjugating enzyme E2 B	Homo sapiens	70-75
28490629-7	2017	The compromised DNA repair and chemosensitization induced by SMI#9 or RAD6B depletion were associated with decreased platinum drug-induced proliferating cell nuclear antigen (PCNA) and FANCD2 monoubiquitinations (surrogate markers of TLS and FA pathway activation, respectively) and with attenuated FANCD2, RAD6, gammaH2AX, and POL eta foci formation and cisplatin-adduct removal.	Platinum	117-125	proliferating cell nuclear antigen	Homo sapiens	139-180
28490629-7	2017	The compromised DNA repair and chemosensitization induced by SMI#9 or RAD6B depletion were associated with decreased platinum drug-induced proliferating cell nuclear antigen (PCNA) and FANCD2 monoubiquitinations (surrogate markers of TLS and FA pathway activation, respectively) and with attenuated FANCD2, RAD6, gammaH2AX, and POL eta foci formation and cisplatin-adduct removal.	Platinum	117-125	FA complementation group D2	Homo sapiens	299-305
28549213-4	2017	Cisplatin interactions with Atox1 and other copper transporters are linked to cancer resistance to platinum-based chemotherapy.	Platinum	99-107	antioxidant 1 copper chaperone	Homo sapiens	28-33
28549213-8	2017	Analysis of simultaneous binding of copper and cisplatin to Atox1 under physiological conditions shows that both metals are bound to the protein through copper-sulfur-platinum bridges.	Platinum	167-175	antioxidant 1 copper chaperone	Homo sapiens	60-65
28623887-4	2017	A meta-analysis was conducted to explore whether platinum-based chemotherapy effectiveness could be attributed to the ERCC1 C19007T polymorphisms.	Platinum	49-57	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	118-123
28488871-4	2017	BLZ-945SCNs/Pt undergo supersensitive structure collapse in the prevascular regions of tumor tissues and enable the simultaneous release of platinum (Pt)-prodrug conjugated small particles and BLZ-945, a small molecule inhibitor of colony stimulating factor 1 receptor (CSF-1R) of TAMs.	Platinum	140-148	colony stimulating factor 1 receptor	Homo sapiens	232-268
28617432-8	2017	Moreover, an analysis of clinical data revealed that a high BST2 level might serve as an independent indicator of poor prognosis in patients with locally advanced NPC treated with platinum-based chemoradiotherapy.	Platinum	180-188	bone marrow stromal cell antigen 2	Homo sapiens	60-64
28617432-9	2017	These findings suggest that BST2 likely mediates platinum resistance in NPC, offering guidance for personalized and precise treatment strategies for patients with NPC.	Platinum	49-57	bone marrow stromal cell antigen 2	Homo sapiens	28-32
28619062-8	2017	RESULTS: PtPT is a chemically well-characterized synthetic complex of platinum that potently inhibits proteasome-associated deubiquitinases USP14 and UCHL5 activity and shows selective cytotoxicity to multiple cancer cells without damaging DNA.	Platinum	70-78	ubiquitin specific peptidase 14	Homo sapiens	140-145
28619062-8	2017	RESULTS: PtPT is a chemically well-characterized synthetic complex of platinum that potently inhibits proteasome-associated deubiquitinases USP14 and UCHL5 activity and shows selective cytotoxicity to multiple cancer cells without damaging DNA.	Platinum	70-78	ubiquitin C-terminal hydrolase L5	Homo sapiens	150-155
28488871-4	2017	BLZ-945SCNs/Pt undergo supersensitive structure collapse in the prevascular regions of tumor tissues and enable the simultaneous release of platinum (Pt)-prodrug conjugated small particles and BLZ-945, a small molecule inhibitor of colony stimulating factor 1 receptor (CSF-1R) of TAMs.	Platinum	140-148	colony stimulating factor 1 receptor	Homo sapiens	270-276
28488871-4	2017	BLZ-945SCNs/Pt undergo supersensitive structure collapse in the prevascular regions of tumor tissues and enable the simultaneous release of platinum (Pt)-prodrug conjugated small particles and BLZ-945, a small molecule inhibitor of colony stimulating factor 1 receptor (CSF-1R) of TAMs.	Platinum	12-14	colony stimulating factor 1 receptor	Homo sapiens	232-268
28488871-4	2017	BLZ-945SCNs/Pt undergo supersensitive structure collapse in the prevascular regions of tumor tissues and enable the simultaneous release of platinum (Pt)-prodrug conjugated small particles and BLZ-945, a small molecule inhibitor of colony stimulating factor 1 receptor (CSF-1R) of TAMs.	Platinum	12-14	colony stimulating factor 1 receptor	Homo sapiens	270-276
28467806-6	2017	GLUT inhibitor mediated cell viability analysis, GLUT1 knockdown cell line-based cytotoxicity evaluation, and platinum accumulation study demonstrated that the cellular uptake of the sugar-conjugates was regulated by GLUT1.	Platinum	110-118	solute carrier family 2 member 1	Homo sapiens	217-222
28494179-5	2017	The homologous recombination deficiency (HRD) resulting from the loss of BRCA function is the main rationale of platinum efficacy in TNBC.	Platinum	112-120	BRCA1 DNA repair associated	Homo sapiens	73-77
28510422-2	2017	Here mass spectrometric proof of entrapment of the group VIII transition-metal platinum (Pt) in fullerenes is first reported.	Platinum	79-87	cytochrome c oxidase subunit 8A	Homo sapiens	57-61
28510422-2	2017	Here mass spectrometric proof of entrapment of the group VIII transition-metal platinum (Pt) in fullerenes is first reported.	Platinum	89-91	cytochrome c oxidase subunit 8A	Homo sapiens	57-61
29228656-0	2017	Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients.	Platinum	82-90	platelet derived growth factor receptor beta	Homo sapiens	10-20
29228656-0	2017	Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients.	Platinum	82-90	kinase insert domain receptor	Homo sapiens	25-32
29228656-6	2017	Platinum-resistant ovarian cancers (56/192) demonstrated significantly higher intratumoral levels of the angiogenesis-associated growth-factor receptors PDGFR-beta and VEGFR2 compared to platinum-sensitive tumors.	Platinum	0-8	platelet derived growth factor receptor beta	Homo sapiens	153-163
29228656-6	2017	Platinum-resistant ovarian cancers (56/192) demonstrated significantly higher intratumoral levels of the angiogenesis-associated growth-factor receptors PDGFR-beta and VEGFR2 compared to platinum-sensitive tumors.	Platinum	0-8	kinase insert domain receptor	Homo sapiens	168-174
29228656-9	2017	High intratumoral levels of the angiogenesis-related growth-factor receptors PDGFR-beta and VEGFR2 might serve as novel predictive biomarkers to identify primary resistance to platinum-based chemotherapy.	Platinum	176-184	platelet derived growth factor receptor beta	Homo sapiens	77-87
29228656-9	2017	High intratumoral levels of the angiogenesis-related growth-factor receptors PDGFR-beta and VEGFR2 might serve as novel predictive biomarkers to identify primary resistance to platinum-based chemotherapy.	Platinum	176-184	kinase insert domain receptor	Homo sapiens	92-98
28494179-9	2017	Taken together, all findings suggest that HR deficiency profile encompassed by BRCA mutation and high HRD score could predict response to platinum, even to other DNA-damage inducing agents.	Platinum	138-146	BRCA1 DNA repair associated	Homo sapiens	79-83
28494179-10	2017	p53 family members and molecular subtypes of TNBC are also important alternative considerations for predicting platinum response based on the preclinical trials.	Platinum	111-119	tumor protein p53	Homo sapiens	0-3
28272630-2	2017	The H2 production rates are dependent on the Pt-loading level, and the optimum production rate in the Pt/CdS/TNTs is approximately six times higher than that in Pt/CdS/TiO2.	Platinum	45-47	CDP-diacylglycerol synthase 1	Homo sapiens	105-108
28272630-2	2017	The H2 production rates are dependent on the Pt-loading level, and the optimum production rate in the Pt/CdS/TNTs is approximately six times higher than that in Pt/CdS/TiO2.	Platinum	45-47	troponin T1, slow skeletal type	Homo sapiens	109-113
28288951-11	2017	Haploidentical related donor HSCT with PT/Cy represents an effective therapeutic approach for patients with DOCK8 deficiency who lack a matched related or unrelated donor.	Platinum	39-41	dedicator of cytokinesis 8	Homo sapiens	108-113
28272630-2	2017	The H2 production rates are dependent on the Pt-loading level, and the optimum production rate in the Pt/CdS/TNTs is approximately six times higher than that in Pt/CdS/TiO2.	Platinum	45-47	CDP-diacylglycerol synthase 1	Homo sapiens	164-167
28272630-2	2017	The H2 production rates are dependent on the Pt-loading level, and the optimum production rate in the Pt/CdS/TNTs is approximately six times higher than that in Pt/CdS/TiO2.	Platinum	102-104	CDP-diacylglycerol synthase 1	Homo sapiens	105-108
28272630-2	2017	The H2 production rates are dependent on the Pt-loading level, and the optimum production rate in the Pt/CdS/TNTs is approximately six times higher than that in Pt/CdS/TiO2.	Platinum	102-104	troponin T1, slow skeletal type	Homo sapiens	109-113
28272630-2	2017	The H2 production rates are dependent on the Pt-loading level, and the optimum production rate in the Pt/CdS/TNTs is approximately six times higher than that in Pt/CdS/TiO2.	Platinum	102-104	CDP-diacylglycerol synthase 1	Homo sapiens	164-167
28272630-2	2017	The H2 production rates are dependent on the Pt-loading level, and the optimum production rate in the Pt/CdS/TNTs is approximately six times higher than that in Pt/CdS/TiO2.	Platinum	102-104	CDP-diacylglycerol synthase 1	Homo sapiens	105-108
28272630-2	2017	The H2 production rates are dependent on the Pt-loading level, and the optimum production rate in the Pt/CdS/TNTs is approximately six times higher than that in Pt/CdS/TiO2.	Platinum	102-104	troponin T1, slow skeletal type	Homo sapiens	109-113
28272630-2	2017	The H2 production rates are dependent on the Pt-loading level, and the optimum production rate in the Pt/CdS/TNTs is approximately six times higher than that in Pt/CdS/TiO2.	Platinum	102-104	CDP-diacylglycerol synthase 1	Homo sapiens	164-167
28272630-4	2017	This indicates that the Pt/CdS/TNTs composites enable H2 production via true water splitting under our typical experimental conditions.	Platinum	24-26	CDP-diacylglycerol synthase 1	Homo sapiens	27-30
28272630-4	2017	This indicates that the Pt/CdS/TNTs composites enable H2 production via true water splitting under our typical experimental conditions.	Platinum	24-26	troponin T1, slow skeletal type	Homo sapiens	31-35
28272630-5	2017	X-ray photoelectron spectroscopy (XPS) analyses of the as-synthesized Pt/CdS/TNTs and those used for 6 and 12 h show that metallic Pt on the CdS/TNTs is less susceptible to oxidation than Pt on CdS/TiO2.	Platinum	70-72	CDP-diacylglycerol synthase 1	Homo sapiens	141-144
28272630-5	2017	X-ray photoelectron spectroscopy (XPS) analyses of the as-synthesized Pt/CdS/TNTs and those used for 6 and 12 h show that metallic Pt on the CdS/TNTs is less susceptible to oxidation than Pt on CdS/TiO2.	Platinum	70-72	troponin T1, slow skeletal type	Homo sapiens	145-149
28272630-5	2017	X-ray photoelectron spectroscopy (XPS) analyses of the as-synthesized Pt/CdS/TNTs and those used for 6 and 12 h show that metallic Pt on the CdS/TNTs is less susceptible to oxidation than Pt on CdS/TiO2.	Platinum	70-72	CDP-diacylglycerol synthase 1	Homo sapiens	141-144
28272630-5	2017	X-ray photoelectron spectroscopy (XPS) analyses of the as-synthesized Pt/CdS/TNTs and those used for 6 and 12 h show that metallic Pt on the CdS/TNTs is less susceptible to oxidation than Pt on CdS/TiO2.	Platinum	131-133	CDP-diacylglycerol synthase 1	Homo sapiens	73-76
28272630-5	2017	X-ray photoelectron spectroscopy (XPS) analyses of the as-synthesized Pt/CdS/TNTs and those used for 6 and 12 h show that metallic Pt on the CdS/TNTs is less susceptible to oxidation than Pt on CdS/TiO2.	Platinum	131-133	troponin T1, slow skeletal type	Homo sapiens	77-81
28272630-5	2017	X-ray photoelectron spectroscopy (XPS) analyses of the as-synthesized Pt/CdS/TNTs and those used for 6 and 12 h show that metallic Pt on the CdS/TNTs is less susceptible to oxidation than Pt on CdS/TiO2.	Platinum	131-133	CDP-diacylglycerol synthase 1	Homo sapiens	141-144
28272630-5	2017	X-ray photoelectron spectroscopy (XPS) analyses of the as-synthesized Pt/CdS/TNTs and those used for 6 and 12 h show that metallic Pt on the CdS/TNTs is less susceptible to oxidation than Pt on CdS/TiO2.	Platinum	131-133	troponin T1, slow skeletal type	Homo sapiens	145-149
28272630-5	2017	X-ray photoelectron spectroscopy (XPS) analyses of the as-synthesized Pt/CdS/TNTs and those used for 6 and 12 h show that metallic Pt on the CdS/TNTs is less susceptible to oxidation than Pt on CdS/TiO2.	Platinum	131-133	CDP-diacylglycerol synthase 1	Homo sapiens	141-144
28272630-5	2017	X-ray photoelectron spectroscopy (XPS) analyses of the as-synthesized Pt/CdS/TNTs and those used for 6 and 12 h show that metallic Pt on the CdS/TNTs is less susceptible to oxidation than Pt on CdS/TiO2.	Platinum	131-133	CDP-diacylglycerol synthase 1	Homo sapiens	73-76
28272630-5	2017	X-ray photoelectron spectroscopy (XPS) analyses of the as-synthesized Pt/CdS/TNTs and those used for 6 and 12 h show that metallic Pt on the CdS/TNTs is less susceptible to oxidation than Pt on CdS/TiO2.	Platinum	131-133	troponin T1, slow skeletal type	Homo sapiens	77-81
28272630-5	2017	X-ray photoelectron spectroscopy (XPS) analyses of the as-synthesized Pt/CdS/TNTs and those used for 6 and 12 h show that metallic Pt on the CdS/TNTs is less susceptible to oxidation than Pt on CdS/TiO2.	Platinum	131-133	CDP-diacylglycerol synthase 1	Homo sapiens	141-144
28272630-5	2017	X-ray photoelectron spectroscopy (XPS) analyses of the as-synthesized Pt/CdS/TNTs and those used for 6 and 12 h show that metallic Pt on the CdS/TNTs is less susceptible to oxidation than Pt on CdS/TiO2.	Platinum	131-133	troponin T1, slow skeletal type	Homo sapiens	145-149
28272630-5	2017	X-ray photoelectron spectroscopy (XPS) analyses of the as-synthesized Pt/CdS/TNTs and those used for 6 and 12 h show that metallic Pt on the CdS/TNTs is less susceptible to oxidation than Pt on CdS/TiO2.	Platinum	131-133	CDP-diacylglycerol synthase 1	Homo sapiens	141-144
28272630-6	2017	In addition, photocorrosion of CdS (i.e., sulfate formation) is significantly inhibited during the photocatalytic H2 production reactions in the Pt/CdS/TNTs because of the efficient charge transfer via the TNTs framework.	Platinum	145-147	CDP-diacylglycerol synthase 1	Homo sapiens	31-34
28272630-6	2017	In addition, photocorrosion of CdS (i.e., sulfate formation) is significantly inhibited during the photocatalytic H2 production reactions in the Pt/CdS/TNTs because of the efficient charge transfer via the TNTs framework.	Platinum	145-147	CDP-diacylglycerol synthase 1	Homo sapiens	148-151
28272630-6	2017	In addition, photocorrosion of CdS (i.e., sulfate formation) is significantly inhibited during the photocatalytic H2 production reactions in the Pt/CdS/TNTs because of the efficient charge transfer via the TNTs framework.	Platinum	145-147	troponin T1, slow skeletal type	Homo sapiens	152-156
28272630-6	2017	In addition, photocorrosion of CdS (i.e., sulfate formation) is significantly inhibited during the photocatalytic H2 production reactions in the Pt/CdS/TNTs because of the efficient charge transfer via the TNTs framework.	Platinum	145-147	troponin T1, slow skeletal type	Homo sapiens	206-210
28272630-7	2017	The Pt/CdS/TNTs samples are thermally more stable than Pt/CdS/TiO2 and CdS/TNTs, effectively inhibiting the formation of CdO during the thermal synthesis.	Platinum	4-6	CDP-diacylglycerol synthase 1	Homo sapiens	7-10
28272630-7	2017	The Pt/CdS/TNTs samples are thermally more stable than Pt/CdS/TiO2 and CdS/TNTs, effectively inhibiting the formation of CdO during the thermal synthesis.	Platinum	4-6	troponin T1, slow skeletal type	Homo sapiens	11-15
28272630-7	2017	The Pt/CdS/TNTs samples are thermally more stable than Pt/CdS/TiO2 and CdS/TNTs, effectively inhibiting the formation of CdO during the thermal synthesis.	Platinum	4-6	CDP-diacylglycerol synthase 1	Homo sapiens	58-61
28272630-7	2017	The Pt/CdS/TNTs samples are thermally more stable than Pt/CdS/TiO2 and CdS/TNTs, effectively inhibiting the formation of CdO during the thermal synthesis.	Platinum	4-6	CDP-diacylglycerol synthase 1	Homo sapiens	58-61
28272630-7	2017	The Pt/CdS/TNTs samples are thermally more stable than Pt/CdS/TiO2 and CdS/TNTs, effectively inhibiting the formation of CdO during the thermal synthesis.	Platinum	4-6	troponin T1, slow skeletal type	Homo sapiens	75-79
28272630-7	2017	The Pt/CdS/TNTs samples are thermally more stable than Pt/CdS/TiO2 and CdS/TNTs, effectively inhibiting the formation of CdO during the thermal synthesis.	Platinum	4-6	cell adhesion associated, oncogene regulated	Homo sapiens	121-124
28272630-7	2017	The Pt/CdS/TNTs samples are thermally more stable than Pt/CdS/TiO2 and CdS/TNTs, effectively inhibiting the formation of CdO during the thermal synthesis.	Platinum	55-57	CDP-diacylglycerol synthase 1	Homo sapiens	7-10
28272630-7	2017	The Pt/CdS/TNTs samples are thermally more stable than Pt/CdS/TiO2 and CdS/TNTs, effectively inhibiting the formation of CdO during the thermal synthesis.	Platinum	55-57	troponin T1, slow skeletal type	Homo sapiens	11-15
28272630-7	2017	The Pt/CdS/TNTs samples are thermally more stable than Pt/CdS/TiO2 and CdS/TNTs, effectively inhibiting the formation of CdO during the thermal synthesis.	Platinum	55-57	CDP-diacylglycerol synthase 1	Homo sapiens	58-61
28272630-7	2017	The Pt/CdS/TNTs samples are thermally more stable than Pt/CdS/TiO2 and CdS/TNTs, effectively inhibiting the formation of CdO during the thermal synthesis.	Platinum	55-57	CDP-diacylglycerol synthase 1	Homo sapiens	58-61
28272630-7	2017	The Pt/CdS/TNTs samples are thermally more stable than Pt/CdS/TiO2 and CdS/TNTs, effectively inhibiting the formation of CdO during the thermal synthesis.	Platinum	55-57	cell adhesion associated, oncogene regulated	Homo sapiens	121-124
28416482-8	2017	Notably, treatment with a gamma-secretase inhibitor that blunts NOTCH1 function ablated self-renewing LCSC activity and restored platinum sensitivity in vitro and in vivo Overall, our results define the pathogenic characters of a cancer stem-like subpopulation in lung cancer, the targeting of which may relieve platinum resistance in this disease.	Platinum	129-137	notch receptor 1	Homo sapiens	64-70
28416482-8	2017	Notably, treatment with a gamma-secretase inhibitor that blunts NOTCH1 function ablated self-renewing LCSC activity and restored platinum sensitivity in vitro and in vivo Overall, our results define the pathogenic characters of a cancer stem-like subpopulation in lung cancer, the targeting of which may relieve platinum resistance in this disease.	Platinum	312-320	notch receptor 1	Homo sapiens	64-70
28498256-4	2017	METHODS: Postmenopausal women who had estrogen and/or progesterone receptor-positive platinum-resistant or platinum-refractory recurrent ovarian cancer and disease measurable by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or GCIG (Gynecologic Cancer InterGroup) CA-125 criteria were eligible.	Platinum	85-93	progesterone receptor	Homo sapiens	54-75
28477743-1	2017	Hereditary epithelial ovarian cancer [EOC] in germline BRCA mutation (gBRCAm) carriers has a distinct clinical behavior characterized by younger age, high- grade serous histology, advanced stage, visceral distribution of disease, high response to platinum and other non-platinum agents and better clinical outcome.	Platinum	247-255	BRCA1 DNA repair associated	Homo sapiens	55-59
28477743-1	2017	Hereditary epithelial ovarian cancer [EOC] in germline BRCA mutation (gBRCAm) carriers has a distinct clinical behavior characterized by younger age, high- grade serous histology, advanced stage, visceral distribution of disease, high response to platinum and other non-platinum agents and better clinical outcome.	Platinum	270-278	BRCA1 DNA repair associated	Homo sapiens	55-59
28471247-2	2017	Areas covered: This review focuses on the main hematologic and non-hematologic toxicities correlated with the use of licensed antiangiogenic agents and PARP inhibitors in recurrent platinum-sensitive EOC, providing recommendations for their management.	Platinum	181-189	poly(ADP-ribose) polymerase 1	Homo sapiens	152-156
28534248-4	2017	In those who have progressed after receiving platinum-based chemotherapy in the first-line, multiple PD-1/PD-L1 agents are available and currently approved, including nivolumab, pembrolizumab, and atezolizumab.	Platinum	45-53	CD274 molecule	Homo sapiens	106-111
28405842-3	2017	As platinum(II) drugs are still the most important therapeutics against lung cancer, we synthesized in this study the first platinum(IV) complexes coupled to the EGFR-targeting peptide LARLLT (and the shuffled RTALLL as reference).	Platinum	124-132	epidermal growth factor receptor	Homo sapiens	162-166
28497832-7	2017	We used this hybrid structure as a counter electrode by casting it on an FTO substrate to form a film, which displayed better photovoltaic conversion efficiency (8.91%) than the commercial Pt counterpart (7.67%).	Platinum	189-191	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	73-76
28736628-6	2017	In pancreatic cancer, BRCA is a tool used to differentiate patients who are likely to respond to platinum-based combination therapies and to benefit from poly (ADP-ribose) polymerase (PARP) inhibitors.	Platinum	97-105	BRCA1 DNA repair associated	Homo sapiens	22-26
28572675-1	2017	The influences of glutathione s-transferase P1, M1, and T1 variants on the efficacy of platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients were inconsistent in previous studies.	Platinum	87-95	glutathione S-transferase pi 1	Homo sapiens	18-46
28572675-4	2017	The Asian patients bearing the favorable GSTM1 null genotype were more likely to have better response rates to platinum-based chemotherapy compared to those patients with the unfavorable GSTM1 present genotype (OR = 1.493 (1.192-1.870), P &lt; 0.001).	Platinum	111-119	glutathione S-transferase mu 1	Homo sapiens	41-46
28572675-6	2017	Our meta-analysis suggested that the GSTP1 IIe105Val, GSTM1 and GSTT1 null variants might be predictive factors for the efficacy of platinum-based chemotherapy to NSCLC patients.	Platinum	132-140	glutathione S-transferase pi 1	Homo sapiens	37-42
28572675-6	2017	Our meta-analysis suggested that the GSTP1 IIe105Val, GSTM1 and GSTT1 null variants might be predictive factors for the efficacy of platinum-based chemotherapy to NSCLC patients.	Platinum	132-140	glutathione S-transferase mu 1	Homo sapiens	54-59
28572675-6	2017	Our meta-analysis suggested that the GSTP1 IIe105Val, GSTM1 and GSTT1 null variants might be predictive factors for the efficacy of platinum-based chemotherapy to NSCLC patients.	Platinum	132-140	glutathione S-transferase theta 1	Homo sapiens	64-69
28572675-7	2017	The use of GSTP1 IIe105Val, GSTM1 and GSTT1 null polymorphisms as predictive factors of efficacy of personalized platinum-based chemotherapy to NSCLC patients requires further verification with multi-center, multi-ethnic and large-sample-size pharmacogenetic studies.	Platinum	113-121	glutathione S-transferase pi 1	Homo sapiens	11-16
28572675-7	2017	The use of GSTP1 IIe105Val, GSTM1 and GSTT1 null polymorphisms as predictive factors of efficacy of personalized platinum-based chemotherapy to NSCLC patients requires further verification with multi-center, multi-ethnic and large-sample-size pharmacogenetic studies.	Platinum	113-121	glutathione S-transferase theta 1	Homo sapiens	38-43
28513693-3	2017	The average IC50 values of the platinum(iv) derivatives ranged from 1.26 to 5.39 muM, compared with 1.24 muM for Pt56MeSS, suggesting that the axial ligands have a relatively minor effect on the potency of the compounds.	Platinum	31-39	latexin	Homo sapiens	81-84
28545541-10	2017	In HGSOC patients, MAL was significantly overexpressed in platinum-resistant compared to platinum-sensitive patients and resulted as an independent prognostic marker of survival.	Platinum	58-66	mal, T cell differentiation protein	Homo sapiens	19-22
28545541-10	2017	In HGSOC patients, MAL was significantly overexpressed in platinum-resistant compared to platinum-sensitive patients and resulted as an independent prognostic marker of survival.	Platinum	89-97	mal, T cell differentiation protein	Homo sapiens	19-22
28008860-10	2017	Moreover, basal neurokinin B level was different between ICPP and PT groups (p&lt;0.01).	Platinum	66-68	tachykinin precursor 3	Homo sapiens	16-28
28008860-11	2017	A serum neurokinin B level of 2.42 ng/mL provided the most appropriate level to differentiate ICPP from PT, with a sensitivity of 84% and specificity of 77.1%.	Platinum	104-106	tachykinin precursor 3	Homo sapiens	8-20
29228641-6	2017	Deficiencies in DNA repair pathways that arise as a result of BRCA mutations make them hypersensitive to DNA-damaging treatments such as platinum chemotherapy and PARP inhibitors.	Platinum	137-145	BRCA1 DNA repair associated	Homo sapiens	62-66
27802183-0	2017	Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.	Platinum	119-127	fibroblast growth factor receptor 2	Homo sapiens	21-56
28383086-0	2017	Platinum transfer from hCTR1 to Atox1 is dependent on the type of platinum complex.	Platinum	0-8	solute carrier family 31 member 1	Homo sapiens	23-28
28383086-0	2017	Platinum transfer from hCTR1 to Atox1 is dependent on the type of platinum complex.	Platinum	0-8	antioxidant 1 copper chaperone	Homo sapiens	32-37
28383086-0	2017	Platinum transfer from hCTR1 to Atox1 is dependent on the type of platinum complex.	Platinum	66-74	solute carrier family 31 member 1	Homo sapiens	23-28
28383086-0	2017	Platinum transfer from hCTR1 to Atox1 is dependent on the type of platinum complex.	Platinum	66-74	antioxidant 1 copper chaperone	Homo sapiens	32-37
28383086-4	2017	It is still unknown how the platinum drugs in hCTR1 transfer to cytoplasmic media, and whether various platinum complexes possess different activities in this process.	Platinum	28-36	solute carrier family 31 member 1	Homo sapiens	46-51
28383086-8	2017	These results demonstrated that the platinated intracellular-domain of hCTR1 is reactive to Atox1, and the reactivity is dependent on the ligand and the coordination structure of platinum complexes.	Platinum	179-187	solute carrier family 31 member 1	Homo sapiens	71-76
28383086-8	2017	These results demonstrated that the platinated intracellular-domain of hCTR1 is reactive to Atox1, and the reactivity is dependent on the ligand and the coordination structure of platinum complexes.	Platinum	179-187	antioxidant 1 copper chaperone	Homo sapiens	92-97
28385528-0	2017	Mannose-conjugated platinum complexes reveals effective tumor targeting mediated by glucose transporter 1.	Platinum	19-27	solute carrier family 2 member 1	Homo sapiens	84-105
32264286-0	2017	Albumin-mediated platinum nanocrystals for in vivo enhanced computed tomography imaging.	Platinum	17-25	albumin	Homo sapiens	0-7
32264286-3	2017	Herein, a simple albumin-directed fabrication of platinum (Pt) nanocrystals was achieved for exploring the utilization in CT imaging.	Platinum	49-57	albumin	Homo sapiens	17-24
32264286-3	2017	Herein, a simple albumin-directed fabrication of platinum (Pt) nanocrystals was achieved for exploring the utilization in CT imaging.	Platinum	59-61	albumin	Homo sapiens	17-24
28001032-4	2017	Such greatly enhanced activity is due to the various valence states of Pt (Ptn+, n = 0, 2, or 3), forming Pt-O bonds embedded in the framework of TiO2 and ultrafine Pt metal nanoparticles on the surface of TiO2.	Platinum	71-73	pleiotrophin	Homo sapiens	75-78
28636292-3	2017	Indeed, in a recent phase 3 study, the PD1 inhibitor nivolumab has recently demonstrated a significant improvement in overall survival for platin-resistant recurrent and/or metastatic HNSCC.	Platinum	139-145	programmed cell death 1	Homo sapiens	39-42
28932630-14	2017	Conclusion: Low-dose DAC/paclitaxel/carboplatin regimen demonstrates disease benefit, especially in patients with platinum-resistant/refractory ovarian cancer, and might show remarkable clinical response when combined with adoptive immunotherapy in platinum-resistant/refractory ovarian cancer patients.	Platinum	114-122	arylacetamide deacetylase	Homo sapiens	21-24
28932630-14	2017	Conclusion: Low-dose DAC/paclitaxel/carboplatin regimen demonstrates disease benefit, especially in patients with platinum-resistant/refractory ovarian cancer, and might show remarkable clinical response when combined with adoptive immunotherapy in platinum-resistant/refractory ovarian cancer patients.	Platinum	249-257	arylacetamide deacetylase	Homo sapiens	21-24
28263384-2	2017	VCAM-1 imaging suggests expression during treatment is an indicator of platinum resistance.	Platinum	71-79	vascular cell adhesion molecule 1	Homo sapiens	0-6
27984705-2	2017	Here we report a platinum nanoparticles (PtNPs)-decorated reduced graphene oxide (rGO) field effect transistor (FET) biosensor coupled with a microfilter system for label-free and highly sensitive detection of BNP in whole blood.	Platinum	17-25	natriuretic peptide B	Homo sapiens	210-213
28263384-12	2017	This is especially compelling in light of previous data suggesting that persistent VCAM-1 expression during treatment is an indicator of platinum resistance.	Platinum	137-145	vascular cell adhesion molecule 1	Homo sapiens	83-89
28626402-0	2017	Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer.	Platinum	120-128	BRCA2 DNA repair associated	Homo sapiens	82-87
28626402-14	2017	CONCLUSIONS: Second-line chemotherapy with a nonplatinum combination - trabectedin plus PLD - was effective in a BRCA2 mutation carrier with recurrent partially platinum-sensitive ovarian cancer.	Platinum	48-56	BRCA2 DNA repair associated	Homo sapiens	113-118
28404895-10	2017	In conclusion, in nasopharyngeal carcinoma patients, ERCC1 and BRCA1 may be a predictor of response to platinum-based chemotherapy and concurrent radiochemotherapy.	Platinum	103-111	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	53-58
28404895-10	2017	In conclusion, in nasopharyngeal carcinoma patients, ERCC1 and BRCA1 may be a predictor of response to platinum-based chemotherapy and concurrent radiochemotherapy.	Platinum	103-111	BRCA1 DNA repair associated	Homo sapiens	63-68
28978016-7	2017	Finally, Kaplan-Maier survival analyses identified significant MEOX2-dependent GLI-1 protein expression associated with clinical progression and poorer overall survival using an independent cohort of NSCLC patients undergoing platinum-based oncological therapy with both epidermal growth factor receptor (EGFR)-non-mutated and EGFR-mutated status.	Platinum	226-234	mesenchyme homeobox 2	Homo sapiens	63-68
28978016-7	2017	Finally, Kaplan-Maier survival analyses identified significant MEOX2-dependent GLI-1 protein expression associated with clinical progression and poorer overall survival using an independent cohort of NSCLC patients undergoing platinum-based oncological therapy with both epidermal growth factor receptor (EGFR)-non-mutated and EGFR-mutated status.	Platinum	226-234	GLI family zinc finger 1	Homo sapiens	79-84
27663594-2	2017	DNA mismatch repair proteins bind to platinum DNA adducts and at sites of DNA damage can recruit the DNA methylating enzyme DNMT1, resulting in aberrant methylation.	Platinum	37-45	DNA methyltransferase 1	Homo sapiens	124-129
28482906-12	2017	Multivariate analyses confirmed FOXM1 protein overexpression as an independent indicator of worse disease specific survival in non-serous EOCs, and of shorter time to progression in platinum-resistant cases.	Platinum	182-190	forkhead box M1	Homo sapiens	32-37
28482906-13	2017	FOXM1 downregulation in EOC cell lines inhibited cell growth and clonogenicity, and promoted the cytotoxic effects of platinum compounds, doxorubicin hydrochloride and olaparib.	Platinum	118-126	forkhead box M1	Homo sapiens	0-5
28324784-1	2017	New Pt(II) complexes (Pt-1-3) bearing 1,2,5-oxadiazole ligands (1-3) were synthesized, characterized and evaluated for their ability to disrupt STAT3 dimerization.	Platinum	4-6	signal transducer and activator of transcription 3	Mus musculus	144-149
28324784-3	2017	Its corresponding platinum complex Pt-3 exhibited an increased cytotoxicity (IC50 = 18.4 muM) and a stronger interaction with STAT3 (IC50 = 1.4 muM), leading to inhibition of its signaling pathway.	Platinum	18-26	latexin	Homo sapiens	89-92
28324784-3	2017	Its corresponding platinum complex Pt-3 exhibited an increased cytotoxicity (IC50 = 18.4 muM) and a stronger interaction with STAT3 (IC50 = 1.4 muM), leading to inhibition of its signaling pathway.	Platinum	18-26	signal transducer and activator of transcription 3	Mus musculus	126-131
28324784-3	2017	Its corresponding platinum complex Pt-3 exhibited an increased cytotoxicity (IC50 = 18.4 muM) and a stronger interaction with STAT3 (IC50 = 1.4 muM), leading to inhibition of its signaling pathway.	Platinum	18-26	latexin	Homo sapiens	144-147
27663594-4	2017	We used an ovarian cancer cell line model to investigate the role of the DNA mismatch repair gene MLH1 in platinum-induced methylation changes.Results: Specific CpG methylation changes in blood at relapse are observed following platinum-based chemotherapy and are associated with patient survival, independent of other clinical factors [hazard ratio, 3.7; 95% confidence interval, 1.8-7.6, P = 2.8 x 10-4].	Platinum	106-114	mutL homolog 1	Homo sapiens	98-102
27663594-4	2017	We used an ovarian cancer cell line model to investigate the role of the DNA mismatch repair gene MLH1 in platinum-induced methylation changes.Results: Specific CpG methylation changes in blood at relapse are observed following platinum-based chemotherapy and are associated with patient survival, independent of other clinical factors [hazard ratio, 3.7; 95% confidence interval, 1.8-7.6, P = 2.8 x 10-4].	Platinum	228-236	mutL homolog 1	Homo sapiens	98-102
28388072-1	2017	Two new amphiphilic platinum(II) complexes, [Pt(2-(4-fluorophenyl)-5-(4-dodecyloxyphenyl)pyridine) (acac)] (Pt-1) and [Pt(2-(4-dodecyloxyphenyl)-5-(thien-2-yl)-c-cyclopentenepyridine) (acac)] (Pt-2), where acac is acetylacetonate, were synthesized and characterized.	Platinum	45-47	zinc finger protein 77	Homo sapiens	108-112
28487881-3	2017	This would not have been detected by standard BRCA testing, and it led to additional treatment with a maintenance poly ADP ribose polymerase (PARP) inhibitor following platinum-based chemotherapy.	Platinum	168-176	poly(ADP-ribose) polymerase 1	Homo sapiens	114-140
28487881-3	2017	This would not have been detected by standard BRCA testing, and it led to additional treatment with a maintenance poly ADP ribose polymerase (PARP) inhibitor following platinum-based chemotherapy.	Platinum	168-176	poly(ADP-ribose) polymerase 1	Homo sapiens	142-146
28730758-6	2017	This paper summarizes data about platinum derivatives through a multidisciplinary approach, starting from a chemical point of view and on to their mechanism of action, mechanism of cellular resistance, predictive factors for the outcome of chemotherapy such as micro RNAs (miRNAs), tumor suppressor protein p53, and the excision repair cross-complementing 1 protein (ERCC1).	Platinum	33-41	tumor protein p53	Homo sapiens	307-310
27914067-12	2017	Thus, MDS with der(5;19)(p10;q10) may represent a platinum agent-related t-MDS that is highly resistant to chemotherapy.	Platinum	50-58	S100 calcium binding protein A10	Homo sapiens	25-28
28730758-6	2017	This paper summarizes data about platinum derivatives through a multidisciplinary approach, starting from a chemical point of view and on to their mechanism of action, mechanism of cellular resistance, predictive factors for the outcome of chemotherapy such as micro RNAs (miRNAs), tumor suppressor protein p53, and the excision repair cross-complementing 1 protein (ERCC1).	Platinum	33-41	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	367-372
28521419-3	2017	The present study examined the protein expression of excision repair cross-complementation group 1 (ERCC1) and class III beta-tubulin (TUBB3), which are consider to be indicators of the anticancer activity of platinum-based and taxane-based chemotherapy, respectively.	Platinum	209-217	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	53-98
28382796-8	2017	CONCLUSION: High expression of LC3A proteins was associated with lower response to platinum therapy, leading to worse prognoses in CCC.	Platinum	83-91	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	31-35
28350120-7	2017	Downregulation of OVGP1 was significantly associated with shorter OS in all subgroups of OC patients, including subgroups of 752 patients treated with chemotherapy regimens containing taxol, 763 with both platin and taxol, 1364 with platin, 371 patients with grade 1-2 disease, 968 with grade 3 disease, 1148 with stage III-IV disease, and 439 with TP53 mutations.	Platinum	205-211	oviductal glycoprotein 1	Homo sapiens	18-23
28350120-7	2017	Downregulation of OVGP1 was significantly associated with shorter OS in all subgroups of OC patients, including subgroups of 752 patients treated with chemotherapy regimens containing taxol, 763 with both platin and taxol, 1364 with platin, 371 patients with grade 1-2 disease, 968 with grade 3 disease, 1148 with stage III-IV disease, and 439 with TP53 mutations.	Platinum	233-239	oviductal glycoprotein 1	Homo sapiens	18-23
28521419-3	2017	The present study examined the protein expression of excision repair cross-complementation group 1 (ERCC1) and class III beta-tubulin (TUBB3), which are consider to be indicators of the anticancer activity of platinum-based and taxane-based chemotherapy, respectively.	Platinum	209-217	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	100-105
28521419-3	2017	The present study examined the protein expression of excision repair cross-complementation group 1 (ERCC1) and class III beta-tubulin (TUBB3), which are consider to be indicators of the anticancer activity of platinum-based and taxane-based chemotherapy, respectively.	Platinum	209-217	tubulin beta 3 class III	Homo sapiens	135-140
28420874-7	2017	Treatment of mice harboring platinum-resistant ovarian tumor xenografts with pHLIP-PNA constructs suppressed HOTAIR activity, reduced tumor formation and improved survival.	Platinum	28-36	HOX transcript antisense RNA (non-protein coding)	Mus musculus	109-115
28056499-1	2017	Peptide triazole (PT) antagonists interact with gp120 subunits of HIV-1 Env trimers to block host cell receptor interactions, trigger gp120 shedding, irreversibly inactivate virus and inhibit infection.	Platinum	18-20	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	48-53
28056499-1	2017	Peptide triazole (PT) antagonists interact with gp120 subunits of HIV-1 Env trimers to block host cell receptor interactions, trigger gp120 shedding, irreversibly inactivate virus and inhibit infection.	Platinum	18-20	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	72-75
28056499-1	2017	Peptide triazole (PT) antagonists interact with gp120 subunits of HIV-1 Env trimers to block host cell receptor interactions, trigger gp120 shedding, irreversibly inactivate virus and inhibit infection.	Platinum	18-20	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	134-139
28213255-0	2017	Amperometric flow injection analysis of glucose using immobilized glucose oxidase on nano-composite carbon nanotubes-platinum nanoparticles carbon paste electrode.	Platinum	117-125	hydroxyacid oxidase 1	Homo sapiens	66-81
28213255-1	2017	We report a novel amperometric glucose biosensor based on glucose oxidase (GOx) immobilized on a carbon nanotube (CNTs)-poly(diallyldimethyl-ammonium chloride) (PDDA)-platinum nanoparticle (PtNPs) modified carbon-paste electrode (CNTs-PDDA-PtNPs/CPE).	Platinum	167-175	hydroxyacid oxidase 1	Homo sapiens	58-73
28213255-1	2017	We report a novel amperometric glucose biosensor based on glucose oxidase (GOx) immobilized on a carbon nanotube (CNTs)-poly(diallyldimethyl-ammonium chloride) (PDDA)-platinum nanoparticle (PtNPs) modified carbon-paste electrode (CNTs-PDDA-PtNPs/CPE).	Platinum	167-175	hydroxyacid oxidase 1	Homo sapiens	75-78
28213255-1	2017	We report a novel amperometric glucose biosensor based on glucose oxidase (GOx) immobilized on a carbon nanotube (CNTs)-poly(diallyldimethyl-ammonium chloride) (PDDA)-platinum nanoparticle (PtNPs) modified carbon-paste electrode (CNTs-PDDA-PtNPs/CPE).	Platinum	167-175	carboxypeptidase E	Homo sapiens	246-249
27819677-0	2017	InFlo: a novel systems biology framework identifies cAMP-CREB1 axis as a key modulator of platinum resistance in ovarian cancer.	Platinum	90-98	cAMP responsive element binding protein 1	Homo sapiens	57-62
27819677-8	2017	InFlo was the only algorithm to identify hyperactivation of the cAMP-CREB1 axis as a key mechanism associated with resistance to platinum-based therapy, a finding that we subsequently experimentally validated.	Platinum	129-137	cAMP responsive element binding protein 1	Homo sapiens	69-74
27819677-9	2017	We confirmed that inhibition of CREB1 phosphorylation potently sensitized resistant cells to platinum therapy and was effective in killing ovarian cancer stem cells that contribute to both platinum-resistance and tumour recurrence.	Platinum	93-101	cAMP responsive element binding protein 1	Homo sapiens	32-37
27819677-9	2017	We confirmed that inhibition of CREB1 phosphorylation potently sensitized resistant cells to platinum therapy and was effective in killing ovarian cancer stem cells that contribute to both platinum-resistance and tumour recurrence.	Platinum	189-197	cAMP responsive element binding protein 1	Homo sapiens	32-37
28442702-7	2017	CONCLUSIONS Polymorphisms of GSTP1 rs1695 and ABCC2 rs717620 can be used to predict the outcomes of Uygur patients with advanced NSCLC who have received platinum-based chemotherapy.	Platinum	153-161	glutathione S-transferase pi 1	Homo sapiens	29-34
28442702-7	2017	CONCLUSIONS Polymorphisms of GSTP1 rs1695 and ABCC2 rs717620 can be used to predict the outcomes of Uygur patients with advanced NSCLC who have received platinum-based chemotherapy.	Platinum	153-161	ATP binding cassette subfamily C member 2	Homo sapiens	46-51
28410578-10	2017	Patients with high LDL or LDLR expression level may benefit from treatment that modulates lipoprotein combined with platinum-based chemotherapy.	Platinum	116-124	low density lipoprotein receptor	Homo sapiens	26-30
28026870-12	2017	Compared with VVMs that had KIT mutations, wild-type KIT VVMs were more likely to express molecular markers suggestive of platinum resistance (ERCC1), alkylating sensitivity (MGMT), and anthracycline sensitivity (TOP2A).	Platinum	122-130	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	53-56
28291774-0	2017	BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.	Platinum	48-56	BRCA2 DNA repair associated	Homo sapiens	0-5
28881640-0	2017	MicroRNA-200c as a prognostic and sensitivity marker for platinum chemotherapy in advanced gastric cancer.	Platinum	57-65	microRNA 200c	Homo sapiens	0-13
28881640-7	2017	Patients with higher miR-200c expression had better treatment outcomes with platinum chemotherapy and longer progression-free survival and overall survival than patients with lower miR-200c expression.	Platinum	76-84	microRNA 200c	Homo sapiens	21-29
28291774-6	2017	RESULTS: Initially, the patient had an exceptional response to platinum and PARP inhibitor therapy, most likely due to the BRCA2 mutation.	Platinum	63-71	BRCA2 DNA repair associated	Homo sapiens	123-128
28390395-7	2017	CONCLUSIONS: Given increasing evidence suggesting RB1 loss is associated with responsiveness to conventional chemotherapies, particularly platinum-based regimens, we hypothesize that this genetic feature predisposed chemosensitivity in our patient"s tumor.	Platinum	138-146	RB transcriptional corepressor 1	Homo sapiens	50-53
28445986-6	2017	We found high BMI1 mRNA expression in blood was associated with longer progression-free survival (PFS) (P=0.049) and overall survival (OS) (P=0.012) in advanced NSCLC patients treated with first-line platinum-based chemotherapy.	Platinum	200-208	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	14-18
28388557-0	2017	ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.	Platinum	99-107	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
28388557-1	2017	BACKGROUND: We recently showed that the presence of ERCC1+CTCs is an independent predictive biomarker for platinum-resistance and poor prognosis of ovarian cancer.	Platinum	106-114	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	52-57
28388557-9	2017	The presence of ERCC1+CTCs after chemotherapy correlated with platinum-resistance (P=0.01), reduced PFS (P=0.0293) and OS (P=0.0008) and their persistence indicated poor post-therapeutic outcome (PFS: P=0.005; OS: P=0.0058).	Platinum	62-70	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	16-21
28388557-11	2017	CONCLUSION: Auxiliary assessment of ERCC1-transcripts expands the phenotypic spectrum of CTC detection and defines an additional overlapping fraction of ERCC1-expressing CTCs, which are potentially selected by platinum-based chemotherapy.	Platinum	210-218	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	36-41
28388557-11	2017	CONCLUSION: Auxiliary assessment of ERCC1-transcripts expands the phenotypic spectrum of CTC detection and defines an additional overlapping fraction of ERCC1-expressing CTCs, which are potentially selected by platinum-based chemotherapy.	Platinum	210-218	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	153-158
28388557-12	2017	Specifically, we suggest that ERCC1+CTCs could additionally be useful as a surrogate for monitoring platinum-based chemotherapy and to assess the post-therapeutic outcome of ovarian cancer.	Platinum	100-108	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	30-35
28430518-4	2017	The negative SMR is found to persist even when NiO blocks the spin transmission between Pt and YIG, indicating it is governed by the spin current response of the NiO layer.	Platinum	88-90	spindlin 1	Homo sapiens	62-66
28430518-4	2017	The negative SMR is found to persist even when NiO blocks the spin transmission between Pt and YIG, indicating it is governed by the spin current response of the NiO layer.	Platinum	88-90	spindlin 1	Homo sapiens	133-137
28260796-14	2017	In conclusion, ANRIL and MEG3 genetic polymorphisms are associated with severe platinum toxicity and could be considered as biomarkers for pretreatment evaluation in Chinese patients with lung cancer.	Platinum	79-87	CDKN2B antisense RNA 1	Homo sapiens	15-20
28260796-14	2017	In conclusion, ANRIL and MEG3 genetic polymorphisms are associated with severe platinum toxicity and could be considered as biomarkers for pretreatment evaluation in Chinese patients with lung cancer.	Platinum	79-87	maternally expressed 3	Homo sapiens	25-29
28314991-0	2017	XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.	Platinum	106-114	ERCC excision repair 5, endonuclease	Homo sapiens	0-3
28186269-10	2017	In summary, two variants in RPA1 and EXO1 were associated with poor survival in NSCLC patients treated by platinum-based chemotherapy.	Platinum	106-114	replication protein A1	Homo sapiens	28-32
28186269-10	2017	In summary, two variants in RPA1 and EXO1 were associated with poor survival in NSCLC patients treated by platinum-based chemotherapy.	Platinum	106-114	exonuclease 1	Homo sapiens	37-41
27943282-1	2017	BRCA1/2-associated breast cancers are sensitive to poly(ADPribose) polymerase (PARP) inhibitors and platinum compounds mainly due to their deficiency in DNA repair via homologous recombination (HR).	Platinum	100-108	BRCA1 DNA repair associated	Homo sapiens	0-5
28391420-10	2017	At progression despite available TKIs, we use pemetrexed-based platinum doublet chemotherapy or immunotherapy if the tumor has high expression of PDL-1.	Platinum	63-71	CD274 molecule	Homo sapiens	146-151
28260069-11	2017	Additional studies are needed to determine the mechanism of ERCC1-induced platinum resistance in lung adenoma patients from Xuanwei.	Platinum	74-82	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	60-65
28164426-8	2017	Platinum anticancer drugs activate ATP7A/B and are subjected to ATP-dependent vectorial displacement with a mechanism analogous to that of copper.	Platinum	0-8	ATPase copper transporting alpha	Homo sapiens	35-40
28332164-0	2017	Polymorphism in XRCC1 gene modulates survival and clinical outcomes of advanced North Indian lung cancer patients treated with platinum-based doublet chemotherapy.	Platinum	127-135	X-ray repair cross complementing 1	Homo sapiens	16-21
28356150-17	2017	CONCLUSIONS: PXR is a potential biomarker for predicting outcome and activates MRP3 transcription by directly binding to its promoter resulting in an increased L-OHP efflux capacity, and resistance to L-OHP or platinum drugs in CRC.	Platinum	210-218	nuclear receptor subfamily 1 group I member 2	Homo sapiens	13-16
28529902-2	2017	Platinum-based doublet chemotherapy is the standard first-line treatment for metastatic NSCLC when genomic testing reveals no targetable alteration such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) or ROS1 translocation/re-arrangements.	Platinum	0-8	epidermal growth factor receptor	Homo sapiens	190-194
28529902-2	2017	Platinum-based doublet chemotherapy is the standard first-line treatment for metastatic NSCLC when genomic testing reveals no targetable alteration such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) or ROS1 translocation/re-arrangements.	Platinum	0-8	ALK receptor tyrosine kinase	Homo sapiens	207-233
28529902-2	2017	Platinum-based doublet chemotherapy is the standard first-line treatment for metastatic NSCLC when genomic testing reveals no targetable alteration such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) or ROS1 translocation/re-arrangements.	Platinum	0-8	ALK receptor tyrosine kinase	Homo sapiens	235-238
28529902-2	2017	Platinum-based doublet chemotherapy is the standard first-line treatment for metastatic NSCLC when genomic testing reveals no targetable alteration such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) or ROS1 translocation/re-arrangements.	Platinum	0-8	ROS proto-oncogene 1, receptor tyrosine kinase	Homo sapiens	243-247
28321449-0	2017	Catalysts of self-assembled Pt@CeO2-delta-rich core-shell nanoparticles on 3D ordered macroporous Ce1-xZrxO2 for soot oxidation: nanostructure-dependent catalytic activity.	Platinum	28-30	carboxylesterase 1	Homo sapiens	98-101
28356150-17	2017	CONCLUSIONS: PXR is a potential biomarker for predicting outcome and activates MRP3 transcription by directly binding to its promoter resulting in an increased L-OHP efflux capacity, and resistance to L-OHP or platinum drugs in CRC.	Platinum	210-218	ATP binding cassette subfamily C member 3	Homo sapiens	79-83
27649553-0	2017	Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.	Platinum	75-83	exportin 1	Homo sapiens	42-46
28265633-1	2017	Cyclometalation of dibenzothienyl-pyridine (HPyDBT) afforded a series of platinum(ii) complexes Pt(PyDBT)(L)Cl (L = DMSO, 1; P(p-C6H4-X)3 (X = H, 2; CF3, 3; OMe, 4; NPh2, 5); 1,3,5-triaza-7-phosphaadamantane, 6; 2,6-dimethylphenyl isocyanide, 7).	Platinum	73-81	neurexophilin 2	Homo sapiens	165-169
28121629-7	2017	Four proteins (CYFRA21.1, CRP, SAA and NSE) are severely reduced and three proteins (OPN, MIF and NSE) are moderately decreased after platinum-based chemotherapy.	Platinum	134-142	secreted phosphoprotein 1	Homo sapiens	85-88
28121629-7	2017	Four proteins (CYFRA21.1, CRP, SAA and NSE) are severely reduced and three proteins (OPN, MIF and NSE) are moderately decreased after platinum-based chemotherapy.	Platinum	134-142	macrophage migration inhibitory factor	Homo sapiens	90-93
28121629-7	2017	Four proteins (CYFRA21.1, CRP, SAA and NSE) are severely reduced and three proteins (OPN, MIF and NSE) are moderately decreased after platinum-based chemotherapy.	Platinum	134-142	enolase 2	Homo sapiens	98-101
29029536-9	2017	According to the subgroup analysis, platinum-based chemotherapy resulted in an improved 3-year disease-free survival compared with TS-1 treatment (66.8% vs. 57.8%, P = 0.015) for patients with high-risk features (any two or more of pT4, pN3, and lymphovascular invasion positivity).	Platinum	36-44	sodium voltage-gated channel alpha subunit 10	Homo sapiens	237-240
27649553-5	2017	Seven patients with late-stage, recurrent, and heavily pretreated ovarian cancer were treated with an oral XPO1 inhibitor.Results: XPO1 RNA overexpression and protein nuclear localization were correlated with decreased survival and platinum resistance in ovarian cancer.	Platinum	232-240	exportin 1	Homo sapiens	107-111
27649553-5	2017	Seven patients with late-stage, recurrent, and heavily pretreated ovarian cancer were treated with an oral XPO1 inhibitor.Results: XPO1 RNA overexpression and protein nuclear localization were correlated with decreased survival and platinum resistance in ovarian cancer.	Platinum	232-240	exportin 1	Homo sapiens	131-135
27649553-6	2017	Targeted XPO1 inhibition decreased cell viability and synergistically restored platinum sensitivity in both immortalized ovarian cancer cells and PDCL.	Platinum	79-87	exportin 1	Homo sapiens	9-13
27649553-9	2017	In selinexor-treated patients, tumor growth was halted in 3 of 5 patients, including one with a partial response, and was safely tolerated by all.Conclusions: Taken together, these results provide evidence that XPO1 inhibition represents a new therapeutic strategy for overcoming platinum resistance in women with ovarian cancer.	Platinum	280-288	exportin 1	Homo sapiens	211-215
28225095-0	2017	High-index {hk0} faceted platinum concave nanocubes with enhanced peroxidase-like activity for an ultrasensitive colorimetric immunoassay of the human prostate-specific antigen.	Platinum	25-33	kallikrein related peptidase 3	Homo sapiens	151-176
28183138-13	2017	BRCA-associated PDAC patients received neoadjuvant, or adjuvant platinum-based treatment more frequently than controls (7 out of 8 vs 6 out of 14) and (7 out of 21 vs 3 out of 44), respectively.	Platinum	64-72	BRCA1 DNA repair associated	Homo sapiens	0-4
28183138-15	2017	A trend to increased DFS was observed among BRCA-positive cases treated with neoadjuvant/adjuvant platinum-containing regimens (n=10) compared with similarly treated controls (n=7) (39.1 vs 12.4 months, P=0.255).	Platinum	98-106	BRCA1 DNA repair associated	Homo sapiens	44-48
28225095-3	2017	Herein, we for the first time propose a novel colorimetric immunoassay for the ultrasensitive detection of the human prostate-specific antigen (PSA) based on using a unique type of nanolabel - high-index {hk0} faceted platinum concave nanocubes (HIF-Pt-CNCs).	Platinum	218-226	kallikrein related peptidase 3	Homo sapiens	117-148
27443420-1	2017	OBJECTIVE: Homologous recombination (HR) is frequently impaired in sporadic high-grade serous ovarian carcinoma (sHGSOC) due to deficiencies in BRCA1/2 genes, a situation associated with hypersensitivity to platinum compounds.	Platinum	207-215	BRCA1 DNA repair associated	Homo sapiens	144-151
29071009-2	2017	It is found that a platinum bound NTf2 radical (NTf2 ) formed by the oxidation of NTf2- at anodic potential can catalyze the oxidation of hydrogen and enhance its reaction rate.	Platinum	19-27	nuclear transport factor 2	Homo sapiens	34-38
29071009-2	2017	It is found that a platinum bound NTf2 radical (NTf2 ) formed by the oxidation of NTf2- at anodic potential can catalyze the oxidation of hydrogen and enhance its reaction rate.	Platinum	19-27	nuclear transport factor 2	Homo sapiens	48-52
29071009-2	2017	It is found that a platinum bound NTf2 radical (NTf2 ) formed by the oxidation of NTf2- at anodic potential can catalyze the oxidation of hydrogen and enhance its reaction rate.	Platinum	19-27	nuclear transport factor 2	Homo sapiens	48-52
27443420-6	2017	METHODS: mRNA expression of RAP80 was analyzed in tumor samples from 35 patients who postoperatively received standard platinum-based chemotherapy.	Platinum	119-127	ubiquitin interaction motif containing 1	Homo sapiens	28-33
27669169-1	2017	RATIONALE: Patients with non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR) are relatively sensitive to EGFR-tyrosine kinase inhibitor (TKI) treatment and have longer progression-free survival (PFS) when treated with EGFR-TKI compared with platinum-based chemotherapy.	Platinum	277-285	epidermal growth factor receptor	Homo sapiens	73-105
28440968-0	2017	The Effects of Active Hexose Correlated Compound (AHCC) on Levels of CD4+ and CD8+ in Patients with Epithelial Ovarian Cancer or Peritoneal Cancer Receiving Platinum Based Chemotherapy Background: Adjuvant chemotherapy is a required treatment for most patients with epithelial ovarian cancer(EOC) or peritoneal cancer.	Platinum	157-165	CD4 molecule	Homo sapiens	69-72
27506489-1	2017	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy for patients with EGFR-mutated non-small-cell lung cancer (NSCLC) have shown a significantly better objective response rate and progression-free survival than platinum doublet therapy.	Platinum	255-263	epidermal growth factor receptor	Homo sapiens	0-32
27506489-1	2017	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy for patients with EGFR-mutated non-small-cell lung cancer (NSCLC) have shown a significantly better objective response rate and progression-free survival than platinum doublet therapy.	Platinum	255-263	epidermal growth factor receptor	Homo sapiens	34-38
27506489-1	2017	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy for patients with EGFR-mutated non-small-cell lung cancer (NSCLC) have shown a significantly better objective response rate and progression-free survival than platinum doublet therapy.	Platinum	255-263	epidermal growth factor receptor	Homo sapiens	114-118
27669169-1	2017	RATIONALE: Patients with non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR) are relatively sensitive to EGFR-tyrosine kinase inhibitor (TKI) treatment and have longer progression-free survival (PFS) when treated with EGFR-TKI compared with platinum-based chemotherapy.	Platinum	277-285	epidermal growth factor receptor	Homo sapiens	107-111
27669169-1	2017	RATIONALE: Patients with non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR) are relatively sensitive to EGFR-tyrosine kinase inhibitor (TKI) treatment and have longer progression-free survival (PFS) when treated with EGFR-TKI compared with platinum-based chemotherapy.	Platinum	277-285	epidermal growth factor receptor	Homo sapiens	141-145
27669169-1	2017	RATIONALE: Patients with non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR) are relatively sensitive to EGFR-tyrosine kinase inhibitor (TKI) treatment and have longer progression-free survival (PFS) when treated with EGFR-TKI compared with platinum-based chemotherapy.	Platinum	277-285	epidermal growth factor receptor	Homo sapiens	141-145
28166401-4	2017	After 3 h of exposure to these platinum(II) agents, &gt;50% of BCL-2 siRNA transcripts were platinated and unable to effectively suppress mRNA levels.	Platinum	31-39	BCL2 apoptosis regulator	Homo sapiens	63-68
28109627-17	2017	The single observed objective response was in a germline BRCA mutated, platinum-sensitive patient.	Platinum	71-79	BRCA1 DNA repair associated	Homo sapiens	57-61
28073598-3	2017	We hypothesized that the loss of HDAC10 would sensitize cells to platinum therapy.	Platinum	65-73	histone deacetylase 10	Homo sapiens	33-39
28073598-6	2017	From the TCGA data we found that low HDAC10 mRNA levels correlated with platinum sensitivity of the tumors.	Platinum	72-80	histone deacetylase 10	Homo sapiens	37-43
28073598-9	2017	CONCLUSIONS: From the results of this study, we suggest that the inhibition of HDAC10 may potentiate the effects of platinum therapies in ovarian tumors.	Platinum	116-124	histone deacetylase 10	Homo sapiens	79-85
28089377-4	2017	METHODS: Recurrent platinum-resistant ovarian, peritoneal, or fallopian tube cancer patients received nab-paclitaxel, 100mg/m2 days 1, 8, 15 followed by GM-CSF 250mug days 16-26 every 28days for 6 planned cycles.	Platinum	19-27	colony stimulating factor 2	Homo sapiens	153-159
28166401-9	2017	Coincorporation of BCL-2 siRNA and platinum(IV) analogues in a single micelle enabled maximal suppression of BCL-2 mRNA levels (to &lt;10% of baseline), augmented the intracellular levels of platinum (by ~4x) and the numbers of resultant Pt-DNA adducts (by &gt;5x), increased the cellular fractions that underwent apoptosis (by ~4x), and enhanced the in vitro antiproliferative activity of the corresponding platinum(II) agent (by 10-100x, depending on the cancer cell line).	Platinum	191-199	BCL2 apoptosis regulator	Homo sapiens	19-24
28166401-9	2017	Coincorporation of BCL-2 siRNA and platinum(IV) analogues in a single micelle enabled maximal suppression of BCL-2 mRNA levels (to &lt;10% of baseline), augmented the intracellular levels of platinum (by ~4x) and the numbers of resultant Pt-DNA adducts (by &gt;5x), increased the cellular fractions that underwent apoptosis (by ~4x), and enhanced the in vitro antiproliferative activity of the corresponding platinum(II) agent (by 10-100x, depending on the cancer cell line).	Platinum	35-43	BCL2 apoptosis regulator	Homo sapiens	109-114
28166401-9	2017	Coincorporation of BCL-2 siRNA and platinum(IV) analogues in a single micelle enabled maximal suppression of BCL-2 mRNA levels (to &lt;10% of baseline), augmented the intracellular levels of platinum (by ~4x) and the numbers of resultant Pt-DNA adducts (by &gt;5x), increased the cellular fractions that underwent apoptosis (by ~4x), and enhanced the in vitro antiproliferative activity of the corresponding platinum(II) agent (by 10-100x, depending on the cancer cell line).	Platinum	191-199	BCL2 apoptosis regulator	Homo sapiens	19-24
28245188-5	2017	RESULTS: AMH levels were significantly higher in the PT group than the prepubertal control group and similar to the CPP group.	Platinum	53-55	anti-Mullerian hormone	Homo sapiens	9-12
27943283-3	2017	In particular, DNA-damaging agents such as platinum drugs and poly(ADP-ribose) polymerase (PARP) inhibitors show strong activity against BRCA1-mutated tumours.	Platinum	43-51	breast cancer 1, early onset	Mus musculus	137-142
28245188-10	2017	CONCLUSIONS: Serum AMH levels in girls with PT was found to be higher than in prepubertal girls.	Platinum	44-46	anti-Mullerian hormone	Homo sapiens	19-22
28031409-0	2017	Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation.	Platinum	39-47	tumor protein p53	Homo sapiens	32-35
28236982-11	2017	CONCLUSION: RAD51 loss has an unfavourable prognostic impact in NSCLC patients undergoing curative surgical resection, but it may have a favourable predictive value in the subgroup of patients receiving perioperative platinum-based CT or RT, most likely as a consequence of deficient DNA repair.	Platinum	217-225	RAD51 recombinase	Homo sapiens	12-17
28031409-3	2017	The current study demonstrates that, unlike cisplatin, platinum analogues oxaliplatin and DACH-diacetato-dichloro-Pt(IV) (DAP) strongly stabilize and activate p53v172F in resistant cells, as indicated by prolonged p53 half-life and transactivation of targets p21 (CDKN1A) and MDM2.	Platinum	55-63	tumor protein p53	Homo sapiens	159-162
28031409-3	2017	The current study demonstrates that, unlike cisplatin, platinum analogues oxaliplatin and DACH-diacetato-dichloro-Pt(IV) (DAP) strongly stabilize and activate p53v172F in resistant cells, as indicated by prolonged p53 half-life and transactivation of targets p21 (CDKN1A) and MDM2.	Platinum	55-63	cyclin dependent kinase inhibitor 1A	Homo sapiens	264-270
28031409-3	2017	The current study demonstrates that, unlike cisplatin, platinum analogues oxaliplatin and DACH-diacetato-dichloro-Pt(IV) (DAP) strongly stabilize and activate p53v172F in resistant cells, as indicated by prolonged p53 half-life and transactivation of targets p21 (CDKN1A) and MDM2.	Platinum	55-63	MDM2 proto-oncogene	Homo sapiens	276-280
28031409-3	2017	The current study demonstrates that, unlike cisplatin, platinum analogues oxaliplatin and DACH-diacetato-dichloro-Pt(IV) (DAP) strongly stabilize and activate p53v172F in resistant cells, as indicated by prolonged p53 half-life and transactivation of targets p21 (CDKN1A) and MDM2.	Platinum	55-63	tumor protein p53	Homo sapiens	214-217
28031409-3	2017	The current study demonstrates that, unlike cisplatin, platinum analogues oxaliplatin and DACH-diacetato-dichloro-Pt(IV) (DAP) strongly stabilize and activate p53v172F in resistant cells, as indicated by prolonged p53 half-life and transactivation of targets p21 (CDKN1A) and MDM2.	Platinum	55-63	cyclin dependent kinase inhibitor 1A	Homo sapiens	259-262
27980217-7	2017	The relationship of CTR1 to cancer prognosis remained significant in the subgroup of patients who underwent platinum-based chemotherapy, the patients with ovarian cancer and those with lung cancer.	Platinum	108-116	solute carrier family 31 member 1	Homo sapiens	20-24
28454268-0	2017	TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells.	Platinum	36-44	family with sequence similarity 168 member A	Homo sapiens	0-5
28454268-6	2017	However, the contribution of TCRP1 to the resistance of platinum agents in human lung and ovarian cancer cells remains to be elucidated.	Platinum	56-64	family with sequence similarity 168 member A	Homo sapiens	29-34
28454268-9	2017	Knockdown of TCRP1 resensitized the cells to the platinum-based agents.	Platinum	49-57	family with sequence similarity 168 member A	Homo sapiens	13-18
28454268-13	2017	These findings identify TCRP1 as a potential predictor of platinum resistance in the treatment of lung and ovarian cancer.	Platinum	58-66	family with sequence similarity 168 member A	Homo sapiens	24-29
27823977-1	2017	We aimed to evaluate the efficacy of dual inhibition of epidermal growth factor receptor (EGFR) with nimotuzumab (EGFR monoclonal antibody) plus gefitinib (EGFR-tyrosine kinase inhibitor) in advanced non-small cell lung cancer (NSCLC) after platinum-based chemotherapy.	Platinum	241-249	epidermal growth factor receptor	Homo sapiens	56-88
27823977-1	2017	We aimed to evaluate the efficacy of dual inhibition of epidermal growth factor receptor (EGFR) with nimotuzumab (EGFR monoclonal antibody) plus gefitinib (EGFR-tyrosine kinase inhibitor) in advanced non-small cell lung cancer (NSCLC) after platinum-based chemotherapy.	Platinum	241-249	epidermal growth factor receptor	Homo sapiens	90-94
28280362-0	2017	Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trials.	Platinum	54-62	epidermal growth factor receptor	Homo sapiens	93-97
28264456-1	2017	A series of nanostructured Pt-Au/MOx-CeO2 (M = Mn, Fe, Ti) catalysts were prepared and their catalytic performance for the co-oxidation of carbon monoxide (CO) and hydrogen (H2) were evaluated at room temperature.	Platinum	27-29	monooxygenase DBH like 1	Homo sapiens	33-36
28219202-2	2017	The discovery of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) has transformed the treatment of NSCLC from platinum based doublet chemotherapy into era of target therapy.	Platinum	132-140	epidermal growth factor receptor	Homo sapiens	78-82
28219206-0	2017	[Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].	Platinum	92-100	glutathione synthetase	Homo sapiens	44-66
28219206-1	2017	Objective: To explore the associations between genetic variations of glutathione synthetase gene (GSS) and response to platinum-based chemotherapy of small cell lung cancer(SCLC), and to analyze the influencing factors on survival.	Platinum	119-127	glutathione synthetase	Homo sapiens	69-91
28219206-1	2017	Objective: To explore the associations between genetic variations of glutathione synthetase gene (GSS) and response to platinum-based chemotherapy of small cell lung cancer(SCLC), and to analyze the influencing factors on survival.	Platinum	119-127	glutathione synthetase	Homo sapiens	98-101
28219206-2	2017	Methods: Four haplotype-tagging single nucleotide polymorphisms (htSNPs) of GSS were genotyped by Sequenom MassARRAY methods in 903 SCLC patients who received platinum-based chemotherapy, and had different response and survival time.	Platinum	159-167	glutathione synthetase	Homo sapiens	76-79
28219206-10	2017	Rs7265992 and rs725521 of GSS were associated with the overall survival (OS) of SCLC patients who received platinum-based chemotherapy (HR=1.16, 95% CI=1.02-1.33, P=0.027; HR=1.17, 95% CI=1.05-1.31, P=0.006, respectively).	Platinum	107-115	glutathione synthetase	Homo sapiens	26-29
28219206-14	2017	Conclusions: These results suggest that GSS genetic polymorphism rs725521 plays an important role in the response to platinum-based chemotherapy, while rs7265992 and rs725521 have important effect on the prognosis of SCLC patients, which may be potential genetic biomarkers for personalized treatment of SCLC.	Platinum	117-125	glutathione synthetase	Homo sapiens	40-43
27997127-3	2017	Carboplatin was selected as the comparative platinum complex, since the Pt-Mal-LHRH malonate linker chelates platinum in a similar manner to carboplatin.	Platinum	44-52	gonadotropin releasing hormone 1	Mus musculus	79-83
28025447-1	2017	INTRODUCTION: The efficacy of platinum-based adjuvant chemotherapy (PBAC) for pathological stage II and stage III squamous cell carcinoma (SCC) of the lung was analyzed retrospectively.	Platinum	30-38	serpin family B member 3	Homo sapiens	139-142
27977146-1	2017	In this study, we have shown that substitution of chloride ligand for imidazole (Im) ring in the cyclometalated platinum complex Pt(phpy)(PPh3)Cl (1; phpy, 2-phenylpyridine; PPh3, triphenylphosphine), which is nonemissive in solution, switches on phosphorescence of the resulting compound.	Platinum	112-120	caveolin 1	Homo sapiens	138-142
27977146-1	2017	In this study, we have shown that substitution of chloride ligand for imidazole (Im) ring in the cyclometalated platinum complex Pt(phpy)(PPh3)Cl (1; phpy, 2-phenylpyridine; PPh3, triphenylphosphine), which is nonemissive in solution, switches on phosphorescence of the resulting compound.	Platinum	112-120	caveolin 1	Homo sapiens	174-178
28187748-11	2017	AURKA and PD-L1 correlated with the resistance to platinum-based chemotherapy in CCC patients (P = 0.043, 0.028, respectively) while no similar results were observed in HGSC patients.	Platinum	50-58	aurora kinase A	Homo sapiens	0-5
28060758-6	2017	DNA sequencing of EOC cell lines revealed previously unreported somatic mutations in the Mothers Against Decapentaplegic Homolog 4 (SMAD4) within platinum-resistant cells.	Platinum	146-154	SMAD family member 4	Homo sapiens	89-130
28060758-6	2017	DNA sequencing of EOC cell lines revealed previously unreported somatic mutations in the Mothers Against Decapentaplegic Homolog 4 (SMAD4) within platinum-resistant cells.	Platinum	146-154	SMAD family member 4	Homo sapiens	132-137
28060758-8	2017	These studies provide the first evidence that acquired SMAD4 mutations enhance the chemo-resistance profile of EOC and present a novel mechanism in which exchange of tumor-derived exosomes perpetuates an EMT phenotype, leading to the development of subpopulations of platinum-refractory cells.	Platinum	267-275	SMAD family member 4	Homo sapiens	55-60
28187748-11	2017	AURKA and PD-L1 correlated with the resistance to platinum-based chemotherapy in CCC patients (P = 0.043, 0.028, respectively) while no similar results were observed in HGSC patients.	Platinum	50-58	CD274 molecule	Homo sapiens	10-15
28179355-3	2017	PATIENTS AND METHODS: We retrospectively screened 100 chemotherapy-naive patients with advanced non-squamous NSCLC treated with pemetrexed plus a platinum-derivative in relation to the pretreatment level of cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA).	Platinum	146-154	keratin 19	Homo sapiens	207-221
28102711-0	2017	Higher Expression of ERCC1 May Be Associated with Resistance to Adjuvant Platinum-Based Chemotherapy in Gastric Cancer.	Platinum	73-81	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	21-26
28102711-3	2017	Here, we investigated the expression of ERCC1 in gastric cancer with platinum-based chemotherapy after surgery, and the association between ERCC1 expression and clinical parameters was analyzed.	Platinum	69-77	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	40-45
28102711-4	2017	Our data showed that high levels of ERCC1 expression were positively associated with resistance to platinum-based chemotherapy but not with lymph node metastasis and pathological stage.	Platinum	99-107	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	36-41
28154416-8	2017	This finding suggested that ZFAS1 may participate in platinum resistance.	Platinum	53-61	ZNFX1 antisense RNA 1	Homo sapiens	28-33
27726966-0	2017	Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).	Platinum	116-124	serine carboxypeptidase 1	Homo sapiens	226-230
28345838-0	2017	ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy Background: Possible targeted therapies for metastatic triple negative breast cancer (TNBC) include cytotoxicchemotherapy that causes interstrand breaks (platinum-based drugs).	Platinum	83-91	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
28345838-0	2017	ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy Background: Possible targeted therapies for metastatic triple negative breast cancer (TNBC) include cytotoxicchemotherapy that causes interstrand breaks (platinum-based drugs).	Platinum	265-273	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
28345838-1	2017	The excision repair cross-complementation 1(ERCC1) enzyme plays an essential role in the nucleotide excision repair pathway, removing platinum-induced DNAadducts and contributing to cisplatin resistance.	Platinum	134-142	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	44-49
28345838-10	2017	High expression of ERCC1 was thereby fond to be significantly associated with poor outcome in patientstreated with platinum based chemotherapy.	Platinum	115-123	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	19-24
28120035-0	2017	The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy.	Platinum	43-51	NFE2 like bZIP transcription factor 2	Homo sapiens	12-16
28120035-0	2017	The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy.	Platinum	43-51	activating transcription factor 2	Homo sapiens	21-25
28120035-1	2017	PURPOSE: Nrf2 and its role in controlling levels of the AKR family of aldo-keto reductases which have been implicated in resistance to platinum-based chemotherapy was studied in ovarian, cervical and lung cell lines.	Platinum	135-143	NFE2 like bZIP transcription factor 2	Homo sapiens	9-13
28027876-0	2017	ERCC2/XPD Lys751Gln alter DNA repair efficiency of platinum-induced DNA damage through P53 pathway.	Platinum	51-59	general transcription and DNA repair factor IIH helicase subunit XPD	Cricetulus griseus	0-5
28027876-0	2017	ERCC2/XPD Lys751Gln alter DNA repair efficiency of platinum-induced DNA damage through P53 pathway.	Platinum	51-59	general transcription and DNA repair factor IIH helicase subunit XPD	Cricetulus griseus	6-9
28027876-0	2017	ERCC2/XPD Lys751Gln alter DNA repair efficiency of platinum-induced DNA damage through P53 pathway.	Platinum	51-59	cellular tumor antigen p53	Cricetulus griseus	87-90
28027876-2	2017	The platinum-induced DNA damage is recognized and repaired by the nucleotide excision repair (NER) system of which ERCC2/XPD is a critical enzyme.	Platinum	4-12	general transcription and DNA repair factor IIH helicase subunit XPD	Cricetulus griseus	115-120
28027876-2	2017	The platinum-induced DNA damage is recognized and repaired by the nucleotide excision repair (NER) system of which ERCC2/XPD is a critical enzyme.	Platinum	4-12	general transcription and DNA repair factor IIH helicase subunit XPD	Cricetulus griseus	121-124
28027876-3	2017	Single nucleotide polymorphisms in ERCC2/XPD have been found to be associated with platinum resistance.	Platinum	83-91	general transcription and DNA repair factor IIH helicase subunit XPD	Cricetulus griseus	35-40
28027876-3	2017	Single nucleotide polymorphisms in ERCC2/XPD have been found to be associated with platinum resistance.	Platinum	83-91	general transcription and DNA repair factor IIH helicase subunit XPD	Cricetulus griseus	41-44
28027876-4	2017	The aim of the present study was to investigate whether ERCC2/XPD Lys751Gln (rs13181) polymorphism is causally related to DNA repair capacity of platinum-induced DNA damage.	Platinum	145-153	general transcription and DNA repair factor IIH helicase subunit XPD	Cricetulus griseus	56-61
28027876-4	2017	The aim of the present study was to investigate whether ERCC2/XPD Lys751Gln (rs13181) polymorphism is causally related to DNA repair capacity of platinum-induced DNA damage.	Platinum	145-153	general transcription and DNA repair factor IIH helicase subunit XPD	Cricetulus griseus	62-65
28027876-15	2017	We concluded that ERCC2/XPD rs13181 polymorphism is possibly related to the DNA repair capacity of platinum-induced DNA damage.	Platinum	99-107	general transcription and DNA repair factor IIH helicase subunit XPD	Cricetulus griseus	18-23
28027876-15	2017	We concluded that ERCC2/XPD rs13181 polymorphism is possibly related to the DNA repair capacity of platinum-induced DNA damage.	Platinum	99-107	general transcription and DNA repair factor IIH helicase subunit XPD	Cricetulus griseus	24-27
28097688-1	2017	By engineering multidomain formation in Co/Pt multilayers, it is demonstrated how multilevel storage can be achieved by spin-orbit torque switching.	Platinum	43-45	spindlin 1	Homo sapiens	120-124
28223671-1	2017	Nedaplatin(NDP)is a platinum derivative anticancer drug.An NDP dose of 100mg/m2 every 4 weeks is recommended in non-elderly Japanese patient because a higher dose may lead to myelosuppression, such as thrombocytopenia.In a pharmacokinetic analysis, thrombocytopenia was significantly correlated with renal function.However, the correct dose in patients with impaired renal function remains unclear.To evaluate the usefulness of dose reduction in patients with renal dysfunction, we conducted a retrospective study.This study included Japanese solid cancer patients who received NDP monotherapy in Nagoya University Hospital between April 2011 and March 2014.	Platinum	20-28	norrin cystine knot growth factor NDP	Homo sapiens	11-14
27739325-2	2017	Tumor cells with deleterious BRCA1 or BRCA2 mutations are deficient in homologous recombination DNA repair and are intrinsically sensitive to platinum therapy and poly(ADP-ribose) polymerase inhibitors.	Platinum	142-150	BRCA1 DNA repair associated	Homo sapiens	29-34
27739325-2	2017	Tumor cells with deleterious BRCA1 or BRCA2 mutations are deficient in homologous recombination DNA repair and are intrinsically sensitive to platinum therapy and poly(ADP-ribose) polymerase inhibitors.	Platinum	142-150	BRCA2 DNA repair associated	Homo sapiens	38-43
27574722-9	2017	The disease stage-stratified ICER analysis found that the pemetrexed/platinum incurred total Medicare costs of $536,424 and $283,560 per observed additional year of life relative to platinum monotherapy and paclitaxel/carboplatin, respectively.	Platinum	69-77	cAMP responsive element modulator	Homo sapiens	29-33
27818289-1	2017	This study aims to investigate the expression of the hematopoietic pre-B-cell leukemia transcription factor-interacting protein (HPIP) and its association with platinum resistance in epithelial ovarian cancer (EOC).	Platinum	160-168	PBX homeobox interacting protein 1	Homo sapiens	53-127
27818289-1	2017	This study aims to investigate the expression of the hematopoietic pre-B-cell leukemia transcription factor-interacting protein (HPIP) and its association with platinum resistance in epithelial ovarian cancer (EOC).	Platinum	160-168	PBX homeobox interacting protein 1	Homo sapiens	129-133
27818289-4	2017	High HPIP expression was correlated with platinum resistance in EOCs.	Platinum	41-49	PBX homeobox interacting protein 1	Homo sapiens	5-9
27818289-5	2017	HPIP in platinum-resistant cases was overexpressed compared with that in platinum-sensitive cases (P&lt;.001).	Platinum	8-16	PBX homeobox interacting protein 1	Homo sapiens	0-4
27818289-5	2017	HPIP in platinum-resistant cases was overexpressed compared with that in platinum-sensitive cases (P&lt;.001).	Platinum	73-81	PBX homeobox interacting protein 1	Homo sapiens	0-4
27818289-6	2017	Platinum resistance was independently correlated with the International Federation of Gynecology and Obstetrics stage and HPIP overexpression.	Platinum	0-8	PBX homeobox interacting protein 1	Homo sapiens	122-126
27818289-8	2017	Our findings indicate that HPIP overexpression is an independent predictor of platinum-based chemotherapy resistance and that it may also be a potential biomarker for targeted therapy.	Platinum	78-86	PBX homeobox interacting protein 1	Homo sapiens	27-31
28096358-0	2017	Repair shielding of platinum-DNA lesions in testicular germ cell tumors by high-mobility group box protein 4 imparts cisplatin hypersensitivity.	Platinum	20-28	high mobility group box 4	Homo sapiens	75-108
27893323-0	2017	ERCC1 as Predictor of Platinum Benefit in Non-Small-Cell Lung Cancer.	Platinum	22-30	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
27893326-0	2017	Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).	Platinum	62-70	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	42-47
27893326-1	2017	Purpose Retrospective studies indicate that expression of excision repair cross complementing group 1 (ERCC1) protein is associated with platinum resistance and survival in non-small-cell lung cancer (NSCLC).	Platinum	137-145	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	58-101
27893326-1	2017	Purpose Retrospective studies indicate that expression of excision repair cross complementing group 1 (ERCC1) protein is associated with platinum resistance and survival in non-small-cell lung cancer (NSCLC).	Platinum	137-145	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	103-108
28143445-0	2017	HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.	Platinum	52-58	heat shock protein 90 alpha family class A member 1	Homo sapiens	0-5
28139737-6	2017	These results establish a novel mechanism by which NF-kappaB and Akt contribute to chemoresistance involving a signaling pathway consisting of histone H4, DNA-PK, RIP1 and IAPs that attenuates ROS-mediated apoptosis, and targeting this pathway may improve the anticancer efficacy of platinum-based chemotherapy.	Platinum	283-291	AKT serine/threonine kinase 1	Homo sapiens	65-68
28139737-6	2017	These results establish a novel mechanism by which NF-kappaB and Akt contribute to chemoresistance involving a signaling pathway consisting of histone H4, DNA-PK, RIP1 and IAPs that attenuates ROS-mediated apoptosis, and targeting this pathway may improve the anticancer efficacy of platinum-based chemotherapy.	Platinum	283-291	H4 clustered histone 9	Homo sapiens	143-153
28096358-8	2017	Collectively, these data provide convincing evidence that HMGB4 plays a major role in sensitizing TGCTs to cisplatin, consistent with shielding of platinum-DNA adducts from excision repair.	Platinum	147-155	high mobility group box 4	Homo sapiens	58-63
28149933-2	2017	On average, 30-40% of patients achieve a complete pathologic response (i.e., stage pT0) after receiving NAC.	Platinum	83-86	X-linked Kx blood group	Homo sapiens	104-107
28128193-11	2017	Positive ERCC1 expression was identified as a negative prognostic marker in patients treated with platinum-based chemotherapy.	Platinum	98-106	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	9-14
28176920-0	2017	Elevated serum levels of vascular endothelial growth factor predict a poor prognosis of platinum-based chemotherapy in non-small cell lung cancer.	Platinum	88-96	vascular endothelial growth factor A	Homo sapiens	25-59
28176920-1	2017	AIM: This study was designed to investigate the predictive and prognostic values of serum vascular endothelial growth factor (VEGF) level in non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.	Platinum	198-206	vascular endothelial growth factor A	Homo sapiens	90-124
28176920-1	2017	AIM: This study was designed to investigate the predictive and prognostic values of serum vascular endothelial growth factor (VEGF) level in non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.	Platinum	198-206	vascular endothelial growth factor A	Homo sapiens	126-130
28176920-9	2017	CONCLUSION: In conclusion, the serum VEGF levels were found to be a poor prognostic biomarker for the efficacy of platinum-based chemotherapy in terms of PFS, but it was not shown to be a suitable predictive marker for clinical response to platinum-based chemotherapy.	Platinum	114-122	vascular endothelial growth factor A	Homo sapiens	37-41
28176920-9	2017	CONCLUSION: In conclusion, the serum VEGF levels were found to be a poor prognostic biomarker for the efficacy of platinum-based chemotherapy in terms of PFS, but it was not shown to be a suitable predictive marker for clinical response to platinum-based chemotherapy.	Platinum	240-248	vascular endothelial growth factor A	Homo sapiens	37-41
32263549-0	2017	Upconversion nanoparticles loaded with eIF4E siRNA and platinum(iv) prodrug to sensitize platinum based chemotherapy for laryngeal cancer and bioimaging.	Platinum	89-97	eukaryotic translation initiation factor 4E	Homo sapiens	39-44
28026182-0	2017	Directing Energy Transfer in Panchromatic Platinum Complexes for Dual Vis-Near-IR or Dual Visible Emission from sigma-Bonded BODIPY Dyes.	Platinum	42-50	long intergenic non-protein coding RNA 1191	Homo sapiens	70-81
27688191-8	2017	The intrinsic DNA reactivity of the platinum(II)-sugar conjugates was found as Gal-Me-Pt &gt; Glu-Me-Pt &gt; Man-Me-Pt   oxaliplatin by kinetic study on the formation of platinum(II) adducts with guanosine-5"-monophosphate (5"-GMP).	Platinum	86-88	5'-nucleotidase, cytosolic II	Homo sapiens	227-230
28074905-1	2017	Our previous studied indicated that eukaryotic translation initiation factor 3a (eIF3a) increases the sensitive of platinum-based chemotherapy in lung cancer.	Platinum	115-123	eukaryotic translation initiation factor 6	Homo sapiens	36-79
28074905-1	2017	Our previous studied indicated that eukaryotic translation initiation factor 3a (eIF3a) increases the sensitive of platinum-based chemotherapy in lung cancer.	Platinum	115-123	eukaryotic translation initiation factor 3 subunit J	Homo sapiens	81-86
28073261-3	2017	We demonstrate here the excitation and detection of spin dynamics in Y3Fe5O12/Pt nanowires by spin-torque ferromagnetic resonance.	Platinum	78-80	spindlin 1	Homo sapiens	52-56
28073261-3	2017	We demonstrate here the excitation and detection of spin dynamics in Y3Fe5O12/Pt nanowires by spin-torque ferromagnetic resonance.	Platinum	78-80	spindlin 1	Homo sapiens	94-98
27688191-8	2017	The intrinsic DNA reactivity of the platinum(II)-sugar conjugates was found as Gal-Me-Pt &gt; Glu-Me-Pt &gt; Man-Me-Pt   oxaliplatin by kinetic study on the formation of platinum(II) adducts with guanosine-5"-monophosphate (5"-GMP).	Platinum	101-103	5'-nucleotidase, cytosolic II	Homo sapiens	227-230
27688191-8	2017	The intrinsic DNA reactivity of the platinum(II)-sugar conjugates was found as Gal-Me-Pt &gt; Glu-Me-Pt &gt; Man-Me-Pt   oxaliplatin by kinetic study on the formation of platinum(II) adducts with guanosine-5"-monophosphate (5"-GMP).	Platinum	101-103	5'-nucleotidase, cytosolic II	Homo sapiens	227-230
26919453-9	2017	In vitro, platinum-based chemotherapy induced TF/phosphatidylserine microparticle shedding from A549 and A427 lung cancers cells, which enhanced thrombin generation in plasma in a FVII-dependent manner.	Platinum	10-18	coagulation factor III	Mus musculus	46-48
27697601-13	2017	Our results show that Mad2 gene silencing using targeted chitosan nanoparticles has tremendous potential in overcoming platinum resistance in NSCLC.	Platinum	119-127	mitotic arrest deficient 2 like 1	Homo sapiens	22-26
28674258-4	2017	In this review, we focus on the specific roles of redox-sensitive TRP ankyrin 1 (TRPA1), which was first reported to be a cold nociceptor, in acute cold hypersensitivity induced by oxaliplatin, a platinum-based agent, because it induces a peculiar cold-triggered CIPN during or within hours after its infusion.	Platinum	196-204	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	66-79
28674258-4	2017	In this review, we focus on the specific roles of redox-sensitive TRP ankyrin 1 (TRPA1), which was first reported to be a cold nociceptor, in acute cold hypersensitivity induced by oxaliplatin, a platinum-based agent, because it induces a peculiar cold-triggered CIPN during or within hours after its infusion.	Platinum	196-204	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	81-86
27773744-6	2017	In addition, loss of Wwox significantly reduced progression free survival in a cohort of ovarian cancer patients treated with platin-based chemotherapies.	Platinum	126-132	WW domain containing oxidoreductase	Homo sapiens	21-25
28270080-6	2017	This review provides a comprehensive overview of various metal complexes (gold, platinum, ruthenium, rhodium, iridium, iron, palladium, silver, antimony, bismuth, tin) targeting mammalian TrxR and discusses their cytotoxicity in tumor cells.	Platinum	80-88	peroxiredoxin 5	Homo sapiens	188-192
29027523-10	2017	CONCLUSION: Immunohistochemical analysis shows that the unique association between the CD44+/CD24low/- phenotype and the pronounced production of tenascin C may have a prognostic potential, prospectively indicating the inefficiency of neoadjuvant PCT, in particular that with platinum derivatives, which is used for the standard treatment of triple-negative BC.	Platinum	276-284	CD44 molecule (Indian blood group)	Homo sapiens	87-91
29027523-10	2017	CONCLUSION: Immunohistochemical analysis shows that the unique association between the CD44+/CD24low/- phenotype and the pronounced production of tenascin C may have a prognostic potential, prospectively indicating the inefficiency of neoadjuvant PCT, in particular that with platinum derivatives, which is used for the standard treatment of triple-negative BC.	Platinum	276-284	tenascin C	Homo sapiens	146-156
26919453-9	2017	In vitro, platinum-based chemotherapy induced TF/phosphatidylserine microparticle shedding from A549 and A427 lung cancers cells, which enhanced thrombin generation in plasma in a FVII-dependent manner.	Platinum	10-18	coagulation factor II	Mus musculus	145-153
26919453-14	2017	Platinum-based chemotherapy induces the shedding of TF/phosphatidylserine microparticles from tumour cells and the release of CFDNA from host neutrophils.	Platinum	0-8	coagulation factor III	Mus musculus	52-54
29199672-1	2017	OBJECTIVE: Several clinical trials have shown that advanced nonsmall cell lung cancer (NSCLC) patients can benefit from treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy than receiving platinum-based doublets chemotherapy in the first-line treatment of advanced NSCLC; the objective of this study was to evaluate whether patients could be treated with EGFR-TKI for advanced NSCLC in the first-line setting.	Platinum	232-240	epidermal growth factor receptor	Homo sapiens	195-199
28178720-0	2017	ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy.	Platinum	58-66	erb-b2 receptor tyrosine kinase 4	Homo sapiens	0-5
27188201-0	2017	Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy.	Platinum	128-136	reactive oxygen species modulator 1	Homo sapiens	0-35
27188201-0	2017	Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy.	Platinum	128-136	reactive oxygen species modulator 1	Homo sapiens	37-42
27188201-3	2017	We evaluated the association of Romo1 expression with clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.	Platinum	141-149	reactive oxygen species modulator 1	Homo sapiens	32-37
27188201-11	2017	CONCLUSION: Romo1 overexpression was associated with poor response to treatment and shorter survival in advanced NSCLC patients treated with platinum-based chemotherapy.	Platinum	141-149	reactive oxygen species modulator 1	Homo sapiens	12-17
27978798-8	2017	Recent studies have shown that the use of PARP inhibitors together with platinum-based agents is a promising therapy strategy for ovarian cancer patients with "BRCAness", i.e., a phenotypic characteristic of tumors that not only can involve loss-of-function mutations in either BRCA1 or BRCA2, but also encompasses the molecular features of BRCA-mutant tumors.	Platinum	72-80	BRCA1 DNA repair associated	Homo sapiens	160-164
27817932-9	2017	Significant associations with worse survival were found for advanced stages (RR 2.63, P&lt;0.001), moderate (RR 1.90, P&lt;0.047) and poor differentiation (RR 2.20, P&lt;0.009), neoadjuvant chemotherapy (RR1.33, P&lt;0.022), residual tumor (RR 2.65, P&lt;0.001) and platinum single (2.34, P&lt;0.001) compared to platinum combination chemotherapy.	Platinum	266-274	ribonucleotide reductase regulatory subunit M2	Homo sapiens	156-160
27817932-9	2017	Significant associations with worse survival were found for advanced stages (RR 2.63, P&lt;0.001), moderate (RR 1.90, P&lt;0.047) and poor differentiation (RR 2.20, P&lt;0.009), neoadjuvant chemotherapy (RR1.33, P&lt;0.022), residual tumor (RR 2.65, P&lt;0.001) and platinum single (2.34, P&lt;0.001) compared to platinum combination chemotherapy.	Platinum	266-274	ribonucleotide reductase regulatory subunit M2	Homo sapiens	156-160
27817932-9	2017	Significant associations with worse survival were found for advanced stages (RR 2.63, P&lt;0.001), moderate (RR 1.90, P&lt;0.047) and poor differentiation (RR 2.20, P&lt;0.009), neoadjuvant chemotherapy (RR1.33, P&lt;0.022), residual tumor (RR 2.65, P&lt;0.001) and platinum single (2.34, P&lt;0.001) compared to platinum combination chemotherapy.	Platinum	313-321	ribonucleotide reductase regulatory subunit M2	Homo sapiens	156-160
27817932-9	2017	Significant associations with worse survival were found for advanced stages (RR 2.63, P&lt;0.001), moderate (RR 1.90, P&lt;0.047) and poor differentiation (RR 2.20, P&lt;0.009), neoadjuvant chemotherapy (RR1.33, P&lt;0.022), residual tumor (RR 2.65, P&lt;0.001) and platinum single (2.34, P&lt;0.001) compared to platinum combination chemotherapy.	Platinum	313-321	ribonucleotide reductase regulatory subunit M2	Homo sapiens	156-160
27908594-25	2017	Our results suggest that assessment of tumour LOH can be used to identify patients with BRCA wild-type platinum-sensitive ovarian cancers who might benefit from rucaparib.	Platinum	103-111	BRCA2 DNA repair associated	Homo sapiens	88-92
27550472-11	2017	Importantly, administration of Vit E reduced kidney total platinum concentration indicating a role of platinum renal accumulation on the ability of Vit E to protect against CP nephrotoxicity.	Platinum	58-66	vitrin	Rattus norvegicus	31-34
27550472-11	2017	Importantly, administration of Vit E reduced kidney total platinum concentration indicating a role of platinum renal accumulation on the ability of Vit E to protect against CP nephrotoxicity.	Platinum	102-110	vitrin	Rattus norvegicus	31-34
28034549-8	2017	RESULTS: BAT was positive to CD203c or CD63 in 11 out of 15 patients allergic to platinum compounds (73%), with increased expression of CD203c and CD63 in 11 (73%) and 6 (40%) patients, respectively.	Platinum	81-89	ectonucleotide pyrophosphatase/phosphodiesterase 3	Homo sapiens	29-35
28034549-8	2017	RESULTS: BAT was positive to CD203c or CD63 in 11 out of 15 patients allergic to platinum compounds (73%), with increased expression of CD203c and CD63 in 11 (73%) and 6 (40%) patients, respectively.	Platinum	81-89	CD63 molecule	Homo sapiens	39-43
28034549-14	2017	CONCLUSIONS: BAT identified patients allergic to platinum compounds with an increased risk of reactions during desensitization and higher CD63 expression was observed in severe reactions.	Platinum	49-57	CD63 molecule	Homo sapiens	138-142
27376191-0	2016	A sensitive sandwich-type electrochemical aptasensor for thrombin detection based on platinum nanoparticles decorated carbon nanocages as signal labels.	Platinum	85-93	coagulation factor II, thrombin	Homo sapiens	57-65
27629824-5	2017	In this article, we present an overview of thio-and semicarbazones associated with heterocycles, indanones, and styryl and aryl skeletons, including their metal complexes with antimony, platinum, palladium, copper, ruthenium, rhenium, manganese and vanadium.	Platinum	186-194	acetyl-CoA acyltransferase 1	Homo sapiens	43-47
27061377-7	2017	However, knocking down CHOP reversed E Platinum-induced apoptosis by blocking mitochondrial apoptotic pathway.	Platinum	39-47	DNA damage inducible transcript 3	Homo sapiens	23-27
28342452-3	2017	Polymorphisms in genes involved in DNA repair and others such as PI3K/PTEN/AKT and TGF-beta pathways have been demonstrated to be associated with response, survival and toxicity in advanced NSCLC patients treated with platinum-based chemotherapy.	Platinum	218-226	phosphatase and tensin homolog	Homo sapiens	70-74
28342452-3	2017	Polymorphisms in genes involved in DNA repair and others such as PI3K/PTEN/AKT and TGF-beta pathways have been demonstrated to be associated with response, survival and toxicity in advanced NSCLC patients treated with platinum-based chemotherapy.	Platinum	218-226	AKT serine/threonine kinase 1	Homo sapiens	75-78
28342452-3	2017	Polymorphisms in genes involved in DNA repair and others such as PI3K/PTEN/AKT and TGF-beta pathways have been demonstrated to be associated with response, survival and toxicity in advanced NSCLC patients treated with platinum-based chemotherapy.	Platinum	218-226	transforming growth factor beta 1	Homo sapiens	83-91
28126916-3	2017	To better understand the obstacles to successful biomarker development, we systematically mapped research activities for a biomarker that has been in development for at least 12 years: excision repair cross-complement group 1 protein (ERCC1) as a biomarker for predicting clinical benefit with platinum-based chemotherapy in non-small cell lung cancer.	Platinum	294-302	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	235-240
27821802-4	2016	Homologous Recombination deficiency has been assumed to be a Germ Cell Tumor characteristic underlying platinum-sensitivity, whereby Poly(ADP-ribose) polymerase (PARP), an enzyme involved in HR DNA repair, is an intriguing target: PARP inhibitors have already entered in clinical practice of other malignancies and trials are recruiting TGCT patients in order to validate their role in this disease.	Platinum	103-111	poly(ADP-ribose) polymerase 1	Homo sapiens	133-160
27980207-2	2016	We report on a class of platinum-lead/platinum (PtPb/Pt) core/shell nanoplate catalysts that exhibit large biaxial strains.	Platinum	24-32	protein tyrosine phosphatase receptor type B	Homo sapiens	48-52
27980207-2	2016	We report on a class of platinum-lead/platinum (PtPb/Pt) core/shell nanoplate catalysts that exhibit large biaxial strains.	Platinum	38-46	protein tyrosine phosphatase receptor type B	Homo sapiens	48-52
27980207-5	2016	The intermetallic core and uniform four layers of Pt shell of the PtPb/Pt nanoplates appear to underlie the high endurance of these catalysts, which can undergo 50,000 voltage cycles with negligible activity decay and no apparent structure and composition changes.	Platinum	50-52	protein tyrosine phosphatase receptor type B	Homo sapiens	66-70
27399934-1	2016	We report on a bimetallic, bifunctional electrode where a platinum (Pt) surface was patterned with nanostructured gold (Au) fingers with different film thicknesses, which was functionalized with glucose oxidase (GOx) to yield a highly sensitive glucose biosensor.	Platinum	58-66	hydroxyacid oxidase 1	Homo sapiens	212-215
27399934-1	2016	We report on a bimetallic, bifunctional electrode where a platinum (Pt) surface was patterned with nanostructured gold (Au) fingers with different film thicknesses, which was functionalized with glucose oxidase (GOx) to yield a highly sensitive glucose biosensor.	Platinum	68-70	hydroxyacid oxidase 1	Homo sapiens	195-210
27399934-1	2016	We report on a bimetallic, bifunctional electrode where a platinum (Pt) surface was patterned with nanostructured gold (Au) fingers with different film thicknesses, which was functionalized with glucose oxidase (GOx) to yield a highly sensitive glucose biosensor.	Platinum	68-70	hydroxyacid oxidase 1	Homo sapiens	212-215
27399934-4	2016	Optimized electrocatalytic activity was reached for the architecture Pt/Au-SAM/GOx with 50nm thickness of Au, where synergy between Pt and Au allowed for detection of hydrogen peroxide (H2O2) at a low applied potential (0V vs. Ag/AgCl).	Platinum	69-71	hydroxyacid oxidase 1	Homo sapiens	79-82
27376191-1	2016	In this work, a novel and sensitive sandwich-type electrochemical aptasensor has been developed for thrombin detection based on platinum nanoparticles (Pt NPs) decorated carbon nanocages (CNCs) as signal tags.	Platinum	128-136	coagulation factor II, thrombin	Homo sapiens	100-108
27399934-1	2016	We report on a bimetallic, bifunctional electrode where a platinum (Pt) surface was patterned with nanostructured gold (Au) fingers with different film thicknesses, which was functionalized with glucose oxidase (GOx) to yield a highly sensitive glucose biosensor.	Platinum	58-66	hydroxyacid oxidase 1	Homo sapiens	195-210
27977010-3	2016	We recently demonstrated that lower expression of the molecular chaperone TRAP1 in OC patients correlates with higher tumor grade and stage, and platinum resistance.	Platinum	145-153	TNF receptor associated protein 1	Homo sapiens	74-79
27610644-1	2016	CONTEXT: - Excision repair cross-complementation 1 (ERCC1) is a key enzyme in nuclear excision repair pathway and has a critical role in helping remove DNA adducts caused by cross-linking agents, such as platinum-containing cancer chemotherapies and other DNA-damaging therapeutic modalities.	Platinum	204-212	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	52-57
27998224-3	2016	We conducted a proof-of-principle phase II study in patients with p53 tumor suppressor gene ( TP53)-mutated ovarian cancer refractory or resistant (&lt; 3 months) to first-line platinum-based therapy to determine overall response rate, progression-free and overall survival, pharmacokinetics, and modulation of phosphorylated cyclin-dependent kinase (CDK1) in skin biopsies.	Platinum	177-185	tumor protein p53	Homo sapiens	66-69
27998224-3	2016	We conducted a proof-of-principle phase II study in patients with p53 tumor suppressor gene ( TP53)-mutated ovarian cancer refractory or resistant (&lt; 3 months) to first-line platinum-based therapy to determine overall response rate, progression-free and overall survival, pharmacokinetics, and modulation of phosphorylated cyclin-dependent kinase (CDK1) in skin biopsies.	Platinum	177-185	tumor protein p53	Homo sapiens	94-98
27623999-2	2016	In patients with NSCLC harboring specific genetic alterations the anti EGFR TKIs and the ALK TKIs have improved the response rate and the quality of life compared to standard platinum-based chemotherapy.	Platinum	175-183	epidermal growth factor receptor	Homo sapiens	71-75
27917619-1	2016	Olaparib is the first oral poly(ADP-ribose) polymerase inhibitor to be approved as maintenance monotherapy for treatment of patients with platinum-sensitive relapsed BRCA-mutated (BRCAm) serous ovarian cancer.	Platinum	138-146	BRCA1 DNA repair associated	Homo sapiens	166-170
27920140-2	2016	It is the first PD-L1 inhibitor approved for use in patients with metastatic non-small cell lung cancer that has advanced in spite of treatment with platinum-based chemotherapy.	Platinum	149-157	CD274 molecule	Homo sapiens	16-21
27623999-2	2016	In patients with NSCLC harboring specific genetic alterations the anti EGFR TKIs and the ALK TKIs have improved the response rate and the quality of life compared to standard platinum-based chemotherapy.	Platinum	175-183	ALK receptor tyrosine kinase	Homo sapiens	89-92
27748801-7	2016	Among the genes involved in platinum or taxane resistance (MDR1, ABCG2, MRP2 or ATP7B), MDR1 was uniquely overexpressed in all the resistant cells.	Platinum	28-36	ATP binding cassette subfamily B member 1	Homo sapiens	59-63
27748801-7	2016	Among the genes involved in platinum or taxane resistance (MDR1, ABCG2, MRP2 or ATP7B), MDR1 was uniquely overexpressed in all the resistant cells.	Platinum	28-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	65-70
27748801-7	2016	Among the genes involved in platinum or taxane resistance (MDR1, ABCG2, MRP2 or ATP7B), MDR1 was uniquely overexpressed in all the resistant cells.	Platinum	28-36	ATP binding cassette subfamily C member 2	Homo sapiens	72-76
27748801-7	2016	Among the genes involved in platinum or taxane resistance (MDR1, ABCG2, MRP2 or ATP7B), MDR1 was uniquely overexpressed in all the resistant cells.	Platinum	28-36	ATPase copper transporting beta	Homo sapiens	80-85
27748801-7	2016	Among the genes involved in platinum or taxane resistance (MDR1, ABCG2, MRP2 or ATP7B), MDR1 was uniquely overexpressed in all the resistant cells.	Platinum	28-36	ATP binding cassette subfamily B member 1	Homo sapiens	88-92
27614750-0	2016	Association of p53 codon 72 polymorphism and survival of North Indian lung cancer patients treated with platinum-based chemotherapy.	Platinum	104-112	tumor protein p53	Homo sapiens	15-18
27987582-0	2016	A folylpoly-gamma-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer.	Platinum	131-139	folylpolyglutamate synthase	Homo sapiens	2-36
27295257-2	2016	The presence of Pt nanoparticles with different sizes and distributions on the walls of microengines fabricated from bilayer nanomembranes with different materials results in promoted catalytic reaction efficiency, which leads to an ultrafast speed (the highest speed 3200 mum/s).	Platinum	16-18	latexin	Homo sapiens	273-276
28101226-13	2016	These results indicate that overexpression of plasma miR-25, miR-21, miR-27b and miR-326, prior to treatment, in patients with advanced LAC is predictive of non-benefit from first-line pemetrexed and platinum-based chemotherapy, and is associated with decreased PFS.	Platinum	200-208	microRNA 25	Homo sapiens	53-59
27599718-3	2016	Structural characterization by X-ray diffraction and scanning electron microscopy showed that there are no other impurity phases but BNF and NZF, and the nucleation barrier caused that it is easier for NZF and BNF to grow on each other rather than on the surface of Pt/Ti/SiO2/Si.	Platinum	266-268	PHD finger protein 20	Homo sapiens	202-205
27905094-4	2016	Based on the Pt-modified PEDOT:PSS layer, the efficiency of the silicon/PEDOT:PSS cell can be increased to 11.46%, corresponding to ~20% enhancement to the one without platinum (Pt) modification.	Platinum	168-176	PSS	Homo sapiens	31-34
27905094-4	2016	Based on the Pt-modified PEDOT:PSS layer, the efficiency of the silicon/PEDOT:PSS cell can be increased to 11.46%, corresponding to ~20% enhancement to the one without platinum (Pt) modification.	Platinum	168-176	PSS	Homo sapiens	78-81
27905094-4	2016	Based on the Pt-modified PEDOT:PSS layer, the efficiency of the silicon/PEDOT:PSS cell can be increased to 11.46%, corresponding to ~20% enhancement to the one without platinum (Pt) modification.	Platinum	13-15	PSS	Homo sapiens	31-34
27905094-4	2016	Based on the Pt-modified PEDOT:PSS layer, the efficiency of the silicon/PEDOT:PSS cell can be increased to 11.46%, corresponding to ~20% enhancement to the one without platinum (Pt) modification.	Platinum	13-15	PSS	Homo sapiens	78-81
27528390-3	2016	In this study, we have evaluated the cytotoxic activity of lipid (C6 and C8)-modified platinum compounds in combination with a survivin-silencing siRNA against cisplatin resistant tumors.	Platinum	86-94	complement component 6	Mus musculus	66-75
28101226-13	2016	These results indicate that overexpression of plasma miR-25, miR-21, miR-27b and miR-326, prior to treatment, in patients with advanced LAC is predictive of non-benefit from first-line pemetrexed and platinum-based chemotherapy, and is associated with decreased PFS.	Platinum	200-208	microRNA 27b	Homo sapiens	69-76
28101226-13	2016	These results indicate that overexpression of plasma miR-25, miR-21, miR-27b and miR-326, prior to treatment, in patients with advanced LAC is predictive of non-benefit from first-line pemetrexed and platinum-based chemotherapy, and is associated with decreased PFS.	Platinum	200-208	microRNA 326	Homo sapiens	81-88
26376695-0	2016	Overexpression of MAC30 is Resistant to Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.	Platinum	40-48	transmembrane protein 97	Homo sapiens	18-23
27905519-3	2016	We here report the retrospective analysis of polymorphisms in 5 genes (ATM, ATR, Chk1, Chk2 and CDK12) involved in the cellular response to platinum in a cohort of 240 cancer patients with late stage ovarian cancer.	Platinum	140-148	ATM serine/threonine kinase	Homo sapiens	71-74
27905519-3	2016	We here report the retrospective analysis of polymorphisms in 5 genes (ATM, ATR, Chk1, Chk2 and CDK12) involved in the cellular response to platinum in a cohort of 240 cancer patients with late stage ovarian cancer.	Platinum	140-148	ATR serine/threonine kinase	Homo sapiens	76-79
27905519-3	2016	We here report the retrospective analysis of polymorphisms in 5 genes (ATM, ATR, Chk1, Chk2 and CDK12) involved in the cellular response to platinum in a cohort of 240 cancer patients with late stage ovarian cancer.	Platinum	140-148	checkpoint kinase 1	Homo sapiens	81-85
27905519-3	2016	We here report the retrospective analysis of polymorphisms in 5 genes (ATM, ATR, Chk1, Chk2 and CDK12) involved in the cellular response to platinum in a cohort of 240 cancer patients with late stage ovarian cancer.	Platinum	140-148	checkpoint kinase 2	Homo sapiens	87-91
27905519-3	2016	We here report the retrospective analysis of polymorphisms in 5 genes (ATM, ATR, Chk1, Chk2 and CDK12) involved in the cellular response to platinum in a cohort of 240 cancer patients with late stage ovarian cancer.	Platinum	140-148	cyclin dependent kinase 12	Homo sapiens	96-101
26376695-2	2016	The objective of this study was to investigate the prognostic value of meningioma-associated protein (MAC30) on adjuvant platinum-based chemotherapeutic response and survival in patients with NSCLC.	Platinum	121-129	transmembrane protein 97	Homo sapiens	102-107
26376695-6	2016	Patients having NSCLC with MAC30 overexpression showed a poorer response to platinum-based chemotherapy, while there was no prognostic value of MAC30 expression on molecularly targeted therapy.	Platinum	76-84	transmembrane protein 97	Homo sapiens	27-32
26376695-7	2016	Further, patients receiving platinum-based chemotherapy with enhanced MAC30 expression exhibited shorter survival.	Platinum	28-36	transmembrane protein 97	Homo sapiens	70-75
26376695-8	2016	A multivariate analysis exhibited that increased MAC30 expression was an independent prognostic factor for overall survival in patients having NSCLC with platinum-based chemotherapy.	Platinum	154-162	transmembrane protein 97	Homo sapiens	49-54
26376695-9	2016	In conclusion, patients having NSCLC with higher MAC30 expression resisted to platinum-based chemotherapy and exhibited worse survival.	Platinum	78-86	transmembrane protein 97	Homo sapiens	49-54
27711734-6	2016	By replacing P25 with Pt co-catalyst-loaded P25, the apparent quantum yield of the mixture increased from 23 to 73%, although an extremely small amount (below 0.06%) of Pt was used in the system.	Platinum	22-24	tubulin polymerization promoting protein	Homo sapiens	44-47
27835790-0	2016	The P38alpha rs3804451 Variant Predicts Chemotherapy Response and Survival of Patients with Non-Small Cell Lung Cancer Treated with Platinum-Based Chemotherapy.	Platinum	132-140	mitogen-activated protein kinase 14	Homo sapiens	4-12
27748779-0	2016	Platinum(0)-mediated C-O bond activation of ethers via an SN2 mechanism.	Platinum	0-8	solute carrier family 38 member 5	Homo sapiens	58-61
27748779-1	2016	A computational study of the C(methyl)-O bond activation of fluorinated aryl methyl ethers by a platinum(0) complex Pt(PCyp3)2 (Cyp = cyclopentyl) (N. A. Jasim, R. N. Perutz, B. Procacci and A. C. Whitwood, Chem.	Platinum	96-104	peptidylprolyl isomerase G	Homo sapiens	120-123
27826607-4	2016	While the complexes Ni(CNArMes2)3, Pd(CNArDipp2)2 and Pt(CNArDipp2)2 were initially targeted as analogues to unstable, low-coordinate metal carbonyls, it soon became apparent that these zero-valent metal centers bore appreciable Lewis basic qualities due largely to the enhanced sigma-donor/pi-acid ratio of isocyanides compared to CO.	Platinum	54-56	nudix hydrolase 4	Homo sapiens	57-66
27813497-0	2016	Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients.	Platinum	38-46	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	6-10
27813497-1	2016	PURPOSE: To define the role of the DNA repair protein apurinic/apyrimidinic endonuclease 1 (APE1) in predicting the prognosis and chemotherapeutic response of non-small cell lung cancer patients receiving platinum-containing chemotherapy.	Platinum	205-213	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	92-96
27813497-5	2016	EXPERIMENTAL DESIGN: We measured APE1 protein levels in biopsy tissue from 172 NSCLC patients and sera of 412 NSCLC patients receiving platinum-based chemotherapy by immunohistochemistry and a newly established sensitive and specific enzyme-linked immunosorbent assay, respectively.	Platinum	135-143	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	33-37
27813497-8	2016	The chemotherapy-naive serum APE1 level, which correlated with its tissue level inversely associated with progression-free survival of platinum-containing doublet chemotherapy, whereas post-treatment serum APE1 level was inversely associated with overall survival.	Platinum	135-143	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	29-33
27884198-5	2016	The PARP inhibitor Olaparib [AZD2281] has been approved by the FDA for use in pretreated ovarian cancer patients with defective BRCA1/2 genes, and by the EMEA for maintenance therapy in platinum sensitive ovarian cancer patients with defective BRCA1/2 genes.	Platinum	186-194	poly(ADP-ribose) polymerase 1	Homo sapiens	4-8
27998448-1	2016	Objective: BRCA1 (breast cancer susceptibility gene 1) and RAP80 (receptor-associated protein 80) play key roles in predicting chemosensitivity of platinum and taxanes.	Platinum	147-155	BRCA1 DNA repair associated	Homo sapiens	11-16
27998448-1	2016	Objective: BRCA1 (breast cancer susceptibility gene 1) and RAP80 (receptor-associated protein 80) play key roles in predicting chemosensitivity of platinum and taxanes.	Platinum	147-155	ubiquitin interaction motif containing 1	Homo sapiens	59-64
27998448-1	2016	Objective: BRCA1 (breast cancer susceptibility gene 1) and RAP80 (receptor-associated protein 80) play key roles in predicting chemosensitivity of platinum and taxanes.	Platinum	147-155	ubiquitin interaction motif containing 1	Homo sapiens	66-96
27655641-6	2016	We also demonstrated that silencing PARP1 enhanced the cell death induced by the platinum-based chemotherapy drug carboplatin in lung cancer cells (CL1-5 and H1975).	Platinum	81-89	poly(ADP-ribose) polymerase 1	Homo sapiens	36-41
27819360-4	2016	Previously we showed that upregulated IGF-1R expression is essential to initiate platinum-taxol resistance at early stage which declines with elevated levels of activated AKT at late resistant stage in ovarian cancer cells.	Platinum	81-89	insulin like growth factor 1 receptor	Homo sapiens	38-44
27736844-6	2016	PARP inhibitors have demonstrated durable antitumour activity in BRCA-mutated advanced OC as a single agent in the treatment and maintenance setting, particularly in platinum-sensitive disease.	Platinum	166-174	poly(ADP-ribose) polymerase 1	Homo sapiens	0-4
27793850-0	2016	Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.	Platinum	114-122	mucin 16, cell surface associated	Homo sapiens	57-62
27853379-12	2016	CONCLUSION: The results of this study suggest that FASL-844 C/T polymorphism could predict PFS in MPM patients receiving platinum-based chemotherapy; therefore, this should be further evaluated as a potential marker for the prediction of clinical outcome in patients with MPM.	Platinum	121-129	Fas ligand	Homo sapiens	51-55
27812204-9	2016	However, stratified by chemotherapy regimen, inverse correlation between high ABCB1 status and poor OS, PFS and TR were only found in patients underwent platinum-based chemotherapy but not in patients received standard platinum/paclitaxel-based chemotherapy.	Platinum	153-161	ATP binding cassette subfamily B member 1	Homo sapiens	78-83
27502726-5	2016	RESULTS: The best-validated predictive biomarkers for efficacy are currently ERCC1, RRM1, and TS for platinum agents, gemcitabine and pemetrexed, respectively.	Platinum	101-109	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	77-82
27819259-1	2016	A functionalized nanohydrogel siRNA delivery system and a mouse model of serous ovarian cancer were used to test predictions from previous cell line studies that knockdown of EGFR (epidermal growth factor receptor) may be of clinical significance in the treatment of epithelial tumors especially with respect to the enhancement of platinum based therapies.	Platinum	331-339	epidermal growth factor receptor	Mus musculus	175-179
27819259-1	2016	A functionalized nanohydrogel siRNA delivery system and a mouse model of serous ovarian cancer were used to test predictions from previous cell line studies that knockdown of EGFR (epidermal growth factor receptor) may be of clinical significance in the treatment of epithelial tumors especially with respect to the enhancement of platinum based therapies.	Platinum	331-339	epidermal growth factor receptor	Mus musculus	181-213
27819259-2	2016	Our results support these predictions and suggest that targeted delivery of EGFR siRNA may be an effective strategy for the treatment of ovarian and other epithelial tumors associated with elevated levels of EGFR and especially those demonstrating resistance to platinum-based therapies.	Platinum	262-270	epidermal growth factor receptor	Mus musculus	76-80
27812537-0	2016	Acquired platinum resistance involves epithelial to mesenchymal transition through ubiquitin ligase FBXO32 dysregulation.	Platinum	9-17	F-box protein 32	Homo sapiens	100-106
27812537-2	2016	Four invasive UC cell lines, T24, 5637, and their corresponding sublines T24PR and 5637PR with acquired platinum resistance, were assessed by microarray, and the ubiquitin E3 ligase FBXO32 was newly identified as a negative regulator of EMT in UC tumors after acquisition of platinum resistance.	Platinum	104-112	F-box protein 32	Homo sapiens	182-188
27812537-2	2016	Four invasive UC cell lines, T24, 5637, and their corresponding sublines T24PR and 5637PR with acquired platinum resistance, were assessed by microarray, and the ubiquitin E3 ligase FBXO32 was newly identified as a negative regulator of EMT in UC tumors after acquisition of platinum resistance.	Platinum	275-283	F-box protein 32	Homo sapiens	182-188
28032496-0	2016	Effect of the ERCC1 (C118T) Polymorphism on Treatment Response in Advanced Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy For advanced non-small-cell lung cancer (NSCLC) cases, a platinum-based regimen is the first-line chemotherapytreatment.	Platinum	122-130	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-19
28032496-0	2016	Effect of the ERCC1 (C118T) Polymorphism on Treatment Response in Advanced Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy For advanced non-small-cell lung cancer (NSCLC) cases, a platinum-based regimen is the first-line chemotherapytreatment.	Platinum	207-215	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-19
28032496-2	2016	This study aimed to investigate the effects of the ERCC1(C118T) polymorphism on treatment response in 26 Thai advanced NSCLC patients receiving first line platinum-basedchemotherapy during January to July 2015 at King Chulalongkorn Memorial Hospital (KCMH).	Platinum	155-163	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	51-56
28032496-5	2016	The response rate to platinum-based chemotherapy in the wild type (C/C) of ERCC1 (C118T) wasbetter than with the variant types (C/T and T/T) but the difference was not statistically significant (29.7% vs 9.1%,P=0.274).	Platinum	21-29	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	75-80
27882231-0	2016	Organic cation transporter 6 directly confers resistance to anticancer platinum drugs.	Platinum	71-79	solute carrier family 22 member 16	Homo sapiens	0-28
27882231-7	2016	The findings suggested that a reduced OCT6 expression confers platinum drug resistance in the sublines by decreasing the uptake of platinum drugs.	Platinum	62-70	solute carrier family 22 member 16	Homo sapiens	38-42
27882231-7	2016	The findings suggested that a reduced OCT6 expression confers platinum drug resistance in the sublines by decreasing the uptake of platinum drugs.	Platinum	131-139	solute carrier family 22 member 16	Homo sapiens	38-42
27882231-10	2016	Taken together with the previous results, the present findings indicate that OCT6 is directly involved in platinum drug resistance by mediating platinum drug uptake in cancer cells.	Platinum	106-114	solute carrier family 22 member 16	Homo sapiens	77-81
27882231-10	2016	Taken together with the previous results, the present findings indicate that OCT6 is directly involved in platinum drug resistance by mediating platinum drug uptake in cancer cells.	Platinum	144-152	solute carrier family 22 member 16	Homo sapiens	77-81
27590741-5	2016	In tumor cells with low endogenous levels of PBX1, its enforced expression promoted cancer stem cell-like phenotypes, including most notably an increase in resistance to platinum-based therapy used most commonly for treating this disease.	Platinum	170-178	PBX homeobox 1	Homo sapiens	45-49
27665847-0	2016	RAD18 polymorphisms are associated with platinum-based chemotherapy toxicity in Chinese patients with non-small cell lung cancer.	Platinum	40-48	RAD18 E3 ubiquitin protein ligase	Homo sapiens	0-5
27665847-2	2016	The aim of the present study is to evaluate the contribution of RAD18 polymorphisms to platinum-chemotherapy response and its potential side effects in Chinese patients with non-small cell lung cancer (NSCLC).	Platinum	87-95	RAD18 E3 ubiquitin protein ligase	Homo sapiens	64-69
27665847-11	2016	CONCLUSION: RAD18 polymorphisms are correlated with the side effects of platinum-chemotherapy in Chinese patients with advanced NSCLC.	Platinum	72-80	RAD18 E3 ubiquitin protein ligase	Homo sapiens	12-17
26940054-7	2016	The lowest CPR that changed PI, PT, or SS by &gt;=6  (the highest reported error of measurement of these parameters) was considered as unacceptable.	Platinum	32-34	cytochrome p450 oxidoreductase	Homo sapiens	11-14
27590741-6	2016	Conversely, silencing PBX1 in platinum-resistant cells that overexpressed PBX1 sensitized them to platinum treatment and reduced their stem-like properties.	Platinum	30-38	PBX homeobox 1	Homo sapiens	22-26
27590741-6	2016	Conversely, silencing PBX1 in platinum-resistant cells that overexpressed PBX1 sensitized them to platinum treatment and reduced their stem-like properties.	Platinum	30-38	PBX homeobox 1	Homo sapiens	74-78
27590741-6	2016	Conversely, silencing PBX1 in platinum-resistant cells that overexpressed PBX1 sensitized them to platinum treatment and reduced their stem-like properties.	Platinum	98-106	PBX homeobox 1	Homo sapiens	22-26
27590741-6	2016	Conversely, silencing PBX1 in platinum-resistant cells that overexpressed PBX1 sensitized them to platinum treatment and reduced their stem-like properties.	Platinum	98-106	PBX homeobox 1	Homo sapiens	74-78
27590741-9	2016	We further demonstrated that a STAT3/JAK2 inhibitor could potently sensitize platinum-resistant cells to carboplatin and suppress their growth in vivo Our findings offer a mechanistic rationale to target the PBX1/STAT3 axis to antagonize a key mechanism of chemoresistance in ovarian cancers and possibly other human cancers.	Platinum	77-85	signal transducer and activator of transcription 3	Homo sapiens	31-36
27590741-9	2016	We further demonstrated that a STAT3/JAK2 inhibitor could potently sensitize platinum-resistant cells to carboplatin and suppress their growth in vivo Our findings offer a mechanistic rationale to target the PBX1/STAT3 axis to antagonize a key mechanism of chemoresistance in ovarian cancers and possibly other human cancers.	Platinum	77-85	Janus kinase 2	Homo sapiens	37-41
27590741-9	2016	We further demonstrated that a STAT3/JAK2 inhibitor could potently sensitize platinum-resistant cells to carboplatin and suppress their growth in vivo Our findings offer a mechanistic rationale to target the PBX1/STAT3 axis to antagonize a key mechanism of chemoresistance in ovarian cancers and possibly other human cancers.	Platinum	77-85	PBX homeobox 1	Homo sapiens	208-212
27590741-9	2016	We further demonstrated that a STAT3/JAK2 inhibitor could potently sensitize platinum-resistant cells to carboplatin and suppress their growth in vivo Our findings offer a mechanistic rationale to target the PBX1/STAT3 axis to antagonize a key mechanism of chemoresistance in ovarian cancers and possibly other human cancers.	Platinum	77-85	signal transducer and activator of transcription 3	Homo sapiens	213-218
27591123-8	2016	In ligand exchange experiments using both Pt atomic absorption and 31P NMR spectroscopies, we show that phosphaplatins most likely bind to VEGFR-2 through metal-ligand coordination rather than electrostatic interactions.	Platinum	42-44	kinase insert domain receptor	Homo sapiens	139-146
27899771-9	2016	HNF1B mediates resistance to oxidative stress and platinum in OCCC cells.	Platinum	50-58	HNF1 homeobox B	Homo sapiens	0-5
27617661-1	2016	BACKGROUND: In patients with platinum-sensitive recurrent serous ovarian cancer, maintenance monotherapy with the PARP inhibitor olaparib significantly improves progression-free survival versus placebo.	Platinum	29-37	collagen type XI alpha 2 chain	Homo sapiens	114-118
27617661-21	2016	INTERPRETATION: Despite not reaching statistical significance, patients with BRCA-mutated platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy after platinum-based chemotherapy appeared to have longer overall survival, supporting the reported progression-free survival benefit.	Platinum	90-98	BRCA1 DNA repair associated	Homo sapiens	77-81
27617661-23	2016	Taken together, these data support both the long-term clinical benefit and tolerability of maintenance olaparib in patients with BRCA-mutated platinum-sensitive recurrent serous ovarian cancer.	Platinum	142-150	BRCA1 DNA repair associated	Homo sapiens	129-133
27554045-3	2016	MiR-483-3p, which may participate in apoptosis and cell proliferation regulation, was found up-regulated in 4 platinum resistant variants, particularly in the IGROV-1/Pt1 subline, versus parental cells.	Platinum	110-118	microRNA 483	Homo sapiens	0-7
27554045-3	2016	MiR-483-3p, which may participate in apoptosis and cell proliferation regulation, was found up-regulated in 4 platinum resistant variants, particularly in the IGROV-1/Pt1 subline, versus parental cells.	Platinum	110-118	zinc finger protein 77	Homo sapiens	167-170
27554045-6	2016	Predicted targets of miR-483-3p included PRKCA (encoding PKC-alpha), previously reported to be associated to platinum-resistance in ovarian carcinoma.	Platinum	109-117	microRNA 483	Homo sapiens	21-28
27554045-6	2016	Predicted targets of miR-483-3p included PRKCA (encoding PKC-alpha), previously reported to be associated to platinum-resistance in ovarian carcinoma.	Platinum	109-117	protein kinase C alpha	Homo sapiens	41-46
27554045-6	2016	Predicted targets of miR-483-3p included PRKCA (encoding PKC-alpha), previously reported to be associated to platinum-resistance in ovarian carcinoma.	Platinum	109-117	protein kinase C alpha	Homo sapiens	57-66
27554045-9	2016	Overall, our results suggest that overexpression of miR-483-3p by ovarian carcinoma platinum-resistant cells may interfere with their proliferation, thus protecting them from DNA damage induced by platinum compounds and ultimately representing a drug-resistance mechanism.	Platinum	84-92	microRNA 483	Homo sapiens	52-59
27554045-9	2016	Overall, our results suggest that overexpression of miR-483-3p by ovarian carcinoma platinum-resistant cells may interfere with their proliferation, thus protecting them from DNA damage induced by platinum compounds and ultimately representing a drug-resistance mechanism.	Platinum	197-205	microRNA 483	Homo sapiens	52-59
27756336-1	2016	BACKGROUND: Triple-negative breast cancer (TNBC) with a BRCA1-like molecular signature has been demonstrated to remarkably respond to platinum-based chemotherapy and might be suited for a future treatment with poly(ADP-ribose)polymerase (PARP) inhibitors.	Platinum	134-142	BRCA1 DNA repair associated	Homo sapiens	56-61
27690263-4	2016	We investigated the platinum-catalyzed reduction of 4-nitrothiophenol to 4-aminothiophenol in aqueous sodium borohydride solution as a prominent model reaction, by using label-free SERS monitoring in a microfluidic reactor.	Platinum	20-28	seryl-tRNA synthetase 2, mitochondrial	Homo sapiens	181-185
27609519-3	2016	Mass spectrometric and crystallographic studies of Pt(II) binding to the RecA intein revealed a complex in which two platinum atoms bind at N- and C-terminal catalytic cysteine residues.	Platinum	117-125	RAD51 recombinase	Homo sapiens	73-77
27788210-2	2016	In vitro studies revealed that COMMD1 plays a role in sensitizing cancer cell lines to cisplatin, however, the mechanism and its role in platinum sensitivity in cancer has yet to be established.	Platinum	137-145	copper metabolism domain containing 1	Homo sapiens	31-37
27877224-0	2016	The role of copper transporter ATP7A in platinum-resistance of esophageal squamous cell cancer (ESCC).	Platinum	40-48	ATPase copper transporting alpha	Homo sapiens	31-36
27877224-1	2016	Purpose: Platinum derivatives, such as cisplatin (DDP), carboplatin and oxaliplatin, are widely used components of modern cancer chemotherapy including esophageal squamous cell cancer (ESCC).	Platinum	9-17	translocase of inner mitochondrial membrane 8A	Homo sapiens	50-53
27877224-5	2016	To determine whether knockdown the expression of ATP7A could reverse the platinum-resistance of EC109/DDP cells or not, we used RNA interference system to explore the role of ATP7A in platinum resistance.	Platinum	73-81	ATPase copper transporting alpha	Homo sapiens	49-54
27877224-5	2016	To determine whether knockdown the expression of ATP7A could reverse the platinum-resistance of EC109/DDP cells or not, we used RNA interference system to explore the role of ATP7A in platinum resistance.	Platinum	73-81	translocase of inner mitochondrial membrane 8A	Homo sapiens	102-105
27756336-1	2016	BACKGROUND: Triple-negative breast cancer (TNBC) with a BRCA1-like molecular signature has been demonstrated to remarkably respond to platinum-based chemotherapy and might be suited for a future treatment with poly(ADP-ribose)polymerase (PARP) inhibitors.	Platinum	134-142	poly(ADP-ribose) polymerase 1	Homo sapiens	210-236
27756336-1	2016	BACKGROUND: Triple-negative breast cancer (TNBC) with a BRCA1-like molecular signature has been demonstrated to remarkably respond to platinum-based chemotherapy and might be suited for a future treatment with poly(ADP-ribose)polymerase (PARP) inhibitors.	Platinum	134-142	poly(ADP-ribose) polymerase 1	Homo sapiens	238-242
27822420-0	2016	Genetic variants of BCL2 gene predict clinical outcomes of non-small-cell lung cancer patients treated with platinum-based chemotherapy in a Chinese population.	Platinum	108-116	BCL2 apoptosis regulator	Homo sapiens	20-24
27041570-2	2016	In this study, we show that upregulation of HOTAIR induced platinum resistance in ovarian cancer, and increased HOTAIR levels were observed in recurrent platinum-resistant ovarian tumors vs primary ovarian tumors.	Platinum	59-67	HOX transcript antisense RNA	Homo sapiens	44-50
27041570-2	2016	In this study, we show that upregulation of HOTAIR induced platinum resistance in ovarian cancer, and increased HOTAIR levels were observed in recurrent platinum-resistant ovarian tumors vs primary ovarian tumors.	Platinum	153-161	HOX transcript antisense RNA	Homo sapiens	44-50
27041570-2	2016	In this study, we show that upregulation of HOTAIR induced platinum resistance in ovarian cancer, and increased HOTAIR levels were observed in recurrent platinum-resistant ovarian tumors vs primary ovarian tumors.	Platinum	153-161	HOX transcript antisense RNA	Homo sapiens	112-118
27041570-3	2016	To investigate the role of HOTAIR during DNA damage induced by platinum, we monitored double-strand breaks and show that HOTAIR expression results in sustained activation of DNA damage response (DDR) after platinum treatment.	Platinum	63-71	HOX transcript antisense RNA	Homo sapiens	27-33
27041570-3	2016	To investigate the role of HOTAIR during DNA damage induced by platinum, we monitored double-strand breaks and show that HOTAIR expression results in sustained activation of DNA damage response (DDR) after platinum treatment.	Platinum	63-71	HOX transcript antisense RNA	Homo sapiens	121-127
27041570-3	2016	To investigate the role of HOTAIR during DNA damage induced by platinum, we monitored double-strand breaks and show that HOTAIR expression results in sustained activation of DNA damage response (DDR) after platinum treatment.	Platinum	206-214	HOX transcript antisense RNA	Homo sapiens	27-33
27041570-3	2016	To investigate the role of HOTAIR during DNA damage induced by platinum, we monitored double-strand breaks and show that HOTAIR expression results in sustained activation of DNA damage response (DDR) after platinum treatment.	Platinum	206-214	HOX transcript antisense RNA	Homo sapiens	121-127
27041570-5	2016	We show that HOTAIR regulates activation of NF-kappaB by decreasing Ikappa-Balpha (NF-kappaB inhibitor) and establish that by inducing prolonged NF-kappaB activation and expression of NF-kappaB target genes during DNA damage, HOTAIR has a critical role in cellular senescence and platinum sensitivity.	Platinum	280-288	HOX transcript antisense RNA	Homo sapiens	13-19
27041570-5	2016	We show that HOTAIR regulates activation of NF-kappaB by decreasing Ikappa-Balpha (NF-kappaB inhibitor) and establish that by inducing prolonged NF-kappaB activation and expression of NF-kappaB target genes during DNA damage, HOTAIR has a critical role in cellular senescence and platinum sensitivity.	Platinum	280-288	nuclear factor kappa B subunit 1	Homo sapiens	44-53
27041570-5	2016	We show that HOTAIR regulates activation of NF-kappaB by decreasing Ikappa-Balpha (NF-kappaB inhibitor) and establish that by inducing prolonged NF-kappaB activation and expression of NF-kappaB target genes during DNA damage, HOTAIR has a critical role in cellular senescence and platinum sensitivity.	Platinum	280-288	NFKB inhibitor alpha	Homo sapiens	68-81
27041570-5	2016	We show that HOTAIR regulates activation of NF-kappaB by decreasing Ikappa-Balpha (NF-kappaB inhibitor) and establish that by inducing prolonged NF-kappaB activation and expression of NF-kappaB target genes during DNA damage, HOTAIR has a critical role in cellular senescence and platinum sensitivity.	Platinum	280-288	nuclear factor kappa B subunit 1	Homo sapiens	83-92
27041570-5	2016	We show that HOTAIR regulates activation of NF-kappaB by decreasing Ikappa-Balpha (NF-kappaB inhibitor) and establish that by inducing prolonged NF-kappaB activation and expression of NF-kappaB target genes during DNA damage, HOTAIR has a critical role in cellular senescence and platinum sensitivity.	Platinum	280-288	nuclear factor kappa B subunit 1	Homo sapiens	83-92
27041570-5	2016	We show that HOTAIR regulates activation of NF-kappaB by decreasing Ikappa-Balpha (NF-kappaB inhibitor) and establish that by inducing prolonged NF-kappaB activation and expression of NF-kappaB target genes during DNA damage, HOTAIR has a critical role in cellular senescence and platinum sensitivity.	Platinum	280-288	nuclear factor kappa B subunit 1	Homo sapiens	83-92
27041570-5	2016	We show that HOTAIR regulates activation of NF-kappaB by decreasing Ikappa-Balpha (NF-kappaB inhibitor) and establish that by inducing prolonged NF-kappaB activation and expression of NF-kappaB target genes during DNA damage, HOTAIR has a critical role in cellular senescence and platinum sensitivity.	Platinum	280-288	HOX transcript antisense RNA	Homo sapiens	226-232
27546519-0	2016	Efficient Synthesis of MCu (M = Pd, Pt, and Au) Aerogels with Accelerated Gelation Kinetics and their High Electrocatalytic Activity.	Platinum	36-38	mitochondrial calcium uniporter	Homo sapiens	23-26
27546519-1	2016	To accelerate hydrogel formation and further simplify the synthetic procedure, a series of MCu (M = Pd, Pt, and Au) bimetallic aerogels is synthesized from the in situ reduction of metal precursors through enhancement of the gelation kinetics at elevated temperature.	Platinum	104-106	mitochondrial calcium uniporter	Homo sapiens	91-94
27716873-6	2016	Olaparib, the first and most extensively investigated PARP inhibitor, is now licensed in Europe for maintenance treatment of patients with platinum-sensitive relapsed BRCA-mutated (germline or somatic) high-grade serous ovarian cancer who have responded to platinum-based chemotherapy.	Platinum	139-147	BRCA1 DNA repair associated	Homo sapiens	167-172
27602952-3	2016	The CEBPA gene sequence was analyzed in 118 ovarian cancer patients (44 platinum/cyclophosphamide (PC)-treated and 74 taxane/platinum (TP)-treated), both in tumors and blood samples, and in blood from 236 healthy women, using PCR-Sanger sequencing and Real-Time quantitative PCR (qPCR)-based genotyping methods, respectively.	Platinum	72-80	CCAAT enhancer binding protein alpha	Homo sapiens	4-9
27602952-3	2016	The CEBPA gene sequence was analyzed in 118 ovarian cancer patients (44 platinum/cyclophosphamide (PC)-treated and 74 taxane/platinum (TP)-treated), both in tumors and blood samples, and in blood from 236 healthy women, using PCR-Sanger sequencing and Real-Time quantitative PCR (qPCR)-based genotyping methods, respectively.	Platinum	125-133	CCAAT enhancer binding protein alpha	Homo sapiens	4-9
27822420-1	2016	Platinum agents induce cancer cell death through BCL2-dependent intrinsic apoptotic pathway and are commonly used as anti-tumor drug.	Platinum	0-8	BCL2 apoptosis regulator	Homo sapiens	49-53
27822420-2	2016	In this study, we evaluated whether single nucleotide polymorphism (SNPs) of BCL2 can affect the overall survival (OS) and progression-free survival (PFS) in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.	Platinum	215-223	BCL2 apoptosis regulator	Homo sapiens	77-81
27822420-3	2016	We genotyped 48 SNPs of BCL2 gene by Illumina Custom Designed Chip in 972 advanced NSCLC patients treated with platinum-based chemotherapy.	Platinum	111-119	BCL2 apoptosis regulator	Homo sapiens	24-28
27822420-7	2016	As representative, the G allele of rs949037 was associated with longer OS in NSCLC patients with platinum-based chemotherapy.	Platinum	97-105	Moloney sarcoma oncogene	Mus musculus	71-73
27822420-10	2016	To conclude, polymorphisms of BCL2 gene may have an impact on the OS of platinum-based chemotherapy in NSCLC patients, which may be prognostic biomarkers of chemotherapy if validated in larger studies.	Platinum	72-80	BCL2 apoptosis regulator	Homo sapiens	30-34
27822420-10	2016	To conclude, polymorphisms of BCL2 gene may have an impact on the OS of platinum-based chemotherapy in NSCLC patients, which may be prognostic biomarkers of chemotherapy if validated in larger studies.	Platinum	72-80	Moloney sarcoma oncogene	Mus musculus	66-68
27511924-7	2016	Increasing evidence on the molecular role of the BRCA2 protein in the homologous recombination of DNA damages suggest that BRCA2-related PDAC are sensitive to agents causing DNA cross-linking damage, such as platinum salts, and treatments targeting rescue DNA repair pathways, such as poly(ADP-ribose) polymerase inhibitors that are currently under investigation.	Platinum	208-216	BRCA2 DNA repair associated	Homo sapiens	49-54
27541962-6	2016	Mixing of Pt and Au enhances the reactivity of the cationic Pd2 dimers, decreases it for their neutral counterparts, and does not affect much in the anionic states.	Platinum	10-12	PAF1 homolog, Paf1/RNA polymerase II complex component	Homo sapiens	60-63
27511924-7	2016	Increasing evidence on the molecular role of the BRCA2 protein in the homologous recombination of DNA damages suggest that BRCA2-related PDAC are sensitive to agents causing DNA cross-linking damage, such as platinum salts, and treatments targeting rescue DNA repair pathways, such as poly(ADP-ribose) polymerase inhibitors that are currently under investigation.	Platinum	208-216	BRCA2 DNA repair associated	Homo sapiens	123-128
27869444-8	2016	Platinum-based agents and PARP inhibitors are effective not only against tumors with germinal and somatic BRCA1/2 mutations but also against sporadic carcinomas with epigenetic BRCA1/2 inactivation or with defects of other independent genes involved in the control of homologous recombination.	Platinum	0-8	BRCA1 DNA repair associated	Homo sapiens	106-113
27869444-8	2016	Platinum-based agents and PARP inhibitors are effective not only against tumors with germinal and somatic BRCA1/2 mutations but also against sporadic carcinomas with epigenetic BRCA1/2 inactivation or with defects of other independent genes involved in the control of homologous recombination.	Platinum	0-8	BRCA1 DNA repair associated	Homo sapiens	106-111
27869446-10	2016	Tumors with BRCA1/2 inactivation show a better therapeutic response to platinum-based chemotherapeutic compounds and a more favorable prognosis.	Platinum	71-79	BRCA1 DNA repair associated	Homo sapiens	12-17
27747088-8	2016	Small series and case reports have suggested that pancreatic cancers harboring BRCA1/2 or other homologous repair gene mutations demonstrate enhanced response to platinum-based chemotherapy although this has not been prospectively validated.	Platinum	162-170	BRCA1 DNA repair associated	Homo sapiens	79-86
27626838-2	2016	In patients harbouring EGFR mutations, the treatment with different available EGFR tyrosine kinase inhibitors (TKIs) showed to be more effective and safe than platinum-based chemotherapy regimens.	Platinum	159-167	epidermal growth factor receptor	Homo sapiens	23-27
27225067-8	2016	Overexpression of HOXB4 and HOXB9 was identified in high grade serous cell lines after platinum resistance developed.	Platinum	87-95	homeobox B4	Homo sapiens	18-23
27225067-8	2016	Overexpression of HOXB4 and HOXB9 was identified in high grade serous cell lines after platinum resistance developed.	Platinum	87-95	homeobox B9	Homo sapiens	28-33
28065997-0	2016	Rapid evaporation at the superheat limit of methanol, ethanol, butanol and n-heptane on platinum films supported by low-stress SiN membranes.	Platinum	88-96	embryonal Fyn-associated substrate	Homo sapiens	127-130
28065997-1	2016	The bubble nucleation temperatures of several organic liquids (methanol, ethanol, butanol, n-heptane) on stress-minimized platinum (Pt) films supported by SiN membranes is examined by pulse-heating the membranes for times ranging from 1 micros to 10 micros.	Platinum	122-130	embryonal Fyn-associated substrate	Homo sapiens	155-158
27423378-11	2016	Low IL-8 level (p=0.053) was marginally associated with platinum resistant disease.	Platinum	56-64	C-X-C motif chemokine ligand 8	Homo sapiens	4-8
26785283-4	2016	Retrospective studies have shown an improved prognosis, higher response rates to platinum-containing regimens, and longer treatment-free intervals between relapses in patients with BRCA 1 and BRCA 2 (BRCA1/2)-mutated ovarian cancer (BMOC) compared with patients who are not carriers of this mutation.	Platinum	81-89	BRCA1 DNA repair associated	Homo sapiens	181-187
27557979-1	2016	Platinum complexes bearing phosphane ligands in cis configuration with deprotonated flavonoids (3-hydroxyflavone, quercetin) and deprotonated ethyl gallate were synthesized starting from cis-[PtCl2(PPh3)2].	Platinum	0-8	caveolin 1	Homo sapiens	198-202
26785283-4	2016	Retrospective studies have shown an improved prognosis, higher response rates to platinum-containing regimens, and longer treatment-free intervals between relapses in patients with BRCA 1 and BRCA 2 (BRCA1/2)-mutated ovarian cancer (BMOC) compared with patients who are not carriers of this mutation.	Platinum	81-89	BRCA2 DNA repair associated	Homo sapiens	192-198
26785283-4	2016	Retrospective studies have shown an improved prognosis, higher response rates to platinum-containing regimens, and longer treatment-free intervals between relapses in patients with BRCA 1 and BRCA 2 (BRCA1/2)-mutated ovarian cancer (BMOC) compared with patients who are not carriers of this mutation.	Platinum	81-89	BRCA1 DNA repair associated	Homo sapiens	200-207
26799758-4	2016	For example, studies support the use of platinum salts chemotherapy in BRCA mutated cancers.	Platinum	40-48	BRCA1 DNA repair associated	Homo sapiens	71-75
27732999-5	2016	Limited-stage (LS) SCLC is a potentially curable disease with long-term survival of 20 to 25% when treated with platinum-based chemotherapy plus concurrent thoracic radiation.	Platinum	112-120	SCLC1	Homo sapiens	19-23
27676404-0	2016	RICTOR polymorphisms affect efficiency of platinum-based chemotherapy in Chinese non-small-cell lung cancer patients.	Platinum	42-50	RPTOR independent companion of MTOR complex 2	Homo sapiens	0-6
27676404-1	2016	AIM: We investigated the association between RICTOR polymorphisms and clinical outcomes of platinum-based chemotherapy for Chinese non-small-cell lung cancer patients.	Platinum	91-99	RPTOR independent companion of MTOR complex 2	Homo sapiens	45-51
27676404-6	2016	CONCLUSION: The study showed evidences for RICTOR polymorphisms" role in platinum-based chemotherapy efficiency, which could provide new insight to lung cancer management.	Platinum	73-81	RPTOR independent companion of MTOR complex 2	Homo sapiens	43-49
27677313-0	2016	Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer.	Platinum	74-82	mucin 16, cell surface associated	Homo sapiens	6-11
27677313-4	2016	In addition, the HE4 value of 115 pmol/L is the best cut-off level for identifying platinum-sensitive patients.	Platinum	83-91	WAP four-disulfide core domain 2	Homo sapiens	17-20
27677313-5	2016	CONCLUSIONS: The introduction of HE4 as a new tool for predicting platinum-sensitivity and interval optimal cytoreduction is promising.	Platinum	66-74	WAP four-disulfide core domain 2	Homo sapiens	33-36
27677313-0	2016	Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer.	Platinum	74-82	WAP four-disulfide core domain 2	Homo sapiens	16-19
27677586-8	2016	We apply TDJGL to the PI3K/AKT/mTOR pathway in ovarian tumors to build differential networks associated with platinum resistance.	Platinum	109-117	AKT serine/threonine kinase 1	Homo sapiens	27-30
27677586-8	2016	We apply TDJGL to the PI3K/AKT/mTOR pathway in ovarian tumors to build differential networks associated with platinum resistance.	Platinum	109-117	mechanistic target of rapamycin kinase	Homo sapiens	31-35
27677313-0	2016	Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer.	Platinum	113-121	mucin 16, cell surface associated	Homo sapiens	6-11
27713639-3	2016	It has been approved by the US Food and Drug Administration for the treatment of patients with metastatic NSCLC, whose tumors express PD-1 ligand 1 (PD-L1), with disease progression on or after platinum-containing chemotherapy.	Platinum	194-202	CD274 molecule	Homo sapiens	149-154
27363542-2	2016	A direct comparison demonstrates that depending on the metallation either efficient (Pt-por) or stable (Zn-por) devices are achieved, demonstrating that the choice of the metal core is a key aspect for future developments.	Platinum	85-87	cytochrome p450 oxidoreductase	Homo sapiens	88-91
26650486-1	2016	PURPOSE: Chemotherapy with platinum compounds and gemcitabine is frequently used in first-line treatment of advanced non-small cell lung cancer (NSCLC) patients in which tyrosine kinase inhibitors (EGFR or ALK) cannot be administered.	Platinum	27-35	ALK receptor tyrosine kinase	Homo sapiens	206-209
27517495-2	2016	However, the mechanisms of microenvironment-mediated drug resistance for nonspecific conventional chemotherapeutic agents, such as platinum compounds or antimetabolites, are still unclear.Here we describe a mechanism induced by soluble factors released by carcinoma-associated fibroblasts (CAFs) that induce the translocation of AKT, Survivin and P38 to the nucleus of tumor cells.	Platinum	131-139	AKT serine/threonine kinase 1	Homo sapiens	329-332
27517495-2	2016	However, the mechanisms of microenvironment-mediated drug resistance for nonspecific conventional chemotherapeutic agents, such as platinum compounds or antimetabolites, are still unclear.Here we describe a mechanism induced by soluble factors released by carcinoma-associated fibroblasts (CAFs) that induce the translocation of AKT, Survivin and P38 to the nucleus of tumor cells.	Platinum	131-139	mitogen-activated protein kinase 14	Homo sapiens	347-350
27601007-0	2016	Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.	Platinum	16-24	kelch like ECH associated protein 1	Homo sapiens	40-45
27601007-0	2016	Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.	Platinum	16-24	NFE2 like bZIP transcription factor 2	Homo sapiens	46-50
27601007-1	2016	BACKGROUND: The objective of this study was to evaluate the effect of platinum-based drugs on nuclear-factor erythroid2 like 2 (NRF2) signaling in non-small cell lung cancer cell lines with or without Kelch-like ECH-associated protein 1 (KEAP1) mutations and to determine the role of NRF2 and KEAP1 on platinum-based drug treatment.	Platinum	70-78	NFE2 like bZIP transcription factor 2	Homo sapiens	94-126
27601007-1	2016	BACKGROUND: The objective of this study was to evaluate the effect of platinum-based drugs on nuclear-factor erythroid2 like 2 (NRF2) signaling in non-small cell lung cancer cell lines with or without Kelch-like ECH-associated protein 1 (KEAP1) mutations and to determine the role of NRF2 and KEAP1 on platinum-based drug treatment.	Platinum	70-78	NFE2 like bZIP transcription factor 2	Homo sapiens	128-132
27601007-1	2016	BACKGROUND: The objective of this study was to evaluate the effect of platinum-based drugs on nuclear-factor erythroid2 like 2 (NRF2) signaling in non-small cell lung cancer cell lines with or without Kelch-like ECH-associated protein 1 (KEAP1) mutations and to determine the role of NRF2 and KEAP1 on platinum-based drug treatment.	Platinum	70-78	kelch like ECH associated protein 1	Homo sapiens	238-243
27601007-1	2016	BACKGROUND: The objective of this study was to evaluate the effect of platinum-based drugs on nuclear-factor erythroid2 like 2 (NRF2) signaling in non-small cell lung cancer cell lines with or without Kelch-like ECH-associated protein 1 (KEAP1) mutations and to determine the role of NRF2 and KEAP1 on platinum-based drug treatment.	Platinum	70-78	NFE2 like bZIP transcription factor 2	Homo sapiens	284-288
27593081-1	2016	BACKGROUND The aim of the study was to assess whether HIF-1alpha polymorphisms have an effect on the response to chemotherapy of locally advanced cervical cancer (LACC) patients treated with platinum-based neoadjuvant chemotherapy (NACT) and radical surgery.	Platinum	191-199	hypoxia inducible factor 1 subunit alpha	Homo sapiens	54-64
27590272-0	2016	Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.	Platinum	195-203	solute carrier family 22 member 2	Homo sapiens	58-86
27590272-0	2016	Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.	Platinum	195-203	solute carrier family 22 member 2	Homo sapiens	88-92
27590272-0	2016	Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.	Platinum	195-203	solute carrier family 47 member 1	Homo sapiens	95-126
27590272-0	2016	Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.	Platinum	195-203	solute carrier family 47 member 1	Homo sapiens	128-133
27590272-0	2016	Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.	Platinum	195-203	ATP binding cassette subfamily C member 2	Homo sapiens	140-181
27590272-0	2016	Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.	Platinum	195-203	ATP binding cassette subfamily C member 2	Homo sapiens	183-188
27601007-1	2016	BACKGROUND: The objective of this study was to evaluate the effect of platinum-based drugs on nuclear-factor erythroid2 like 2 (NRF2) signaling in non-small cell lung cancer cell lines with or without Kelch-like ECH-associated protein 1 (KEAP1) mutations and to determine the role of NRF2 and KEAP1 on platinum-based drug treatment.	Platinum	70-78	kelch like ECH associated protein 1	Homo sapiens	293-298
27601007-1	2016	BACKGROUND: The objective of this study was to evaluate the effect of platinum-based drugs on nuclear-factor erythroid2 like 2 (NRF2) signaling in non-small cell lung cancer cell lines with or without Kelch-like ECH-associated protein 1 (KEAP1) mutations and to determine the role of NRF2 and KEAP1 on platinum-based drug treatment.	Platinum	302-310	NFE2 like bZIP transcription factor 2	Homo sapiens	128-132
27601007-5	2016	RESULTS: We found that platinum-based therapies modified the NRF2 signaling pathway differently in KEAP1-mutated non-small cell lung cancer (NSCLC) cell lines compared with wild-type KEAP1 cell lines.	Platinum	23-31	NFE2 like bZIP transcription factor 2	Homo sapiens	61-65
27601007-5	2016	RESULTS: We found that platinum-based therapies modified the NRF2 signaling pathway differently in KEAP1-mutated non-small cell lung cancer (NSCLC) cell lines compared with wild-type KEAP1 cell lines.	Platinum	23-31	kelch like ECH associated protein 1	Homo sapiens	99-104
27601007-5	2016	RESULTS: We found that platinum-based therapies modified the NRF2 signaling pathway differently in KEAP1-mutated non-small cell lung cancer (NSCLC) cell lines compared with wild-type KEAP1 cell lines.	Platinum	23-31	kelch like ECH associated protein 1	Homo sapiens	183-188
27601007-7	2016	The modification of NRF2 or KEAP1 expression in NSCLC cell lines disrupted downstream gene expression and cell sensitivity to platinum-based drugs.	Platinum	126-134	NFE2 like bZIP transcription factor 2	Homo sapiens	20-24
27601007-7	2016	The modification of NRF2 or KEAP1 expression in NSCLC cell lines disrupted downstream gene expression and cell sensitivity to platinum-based drugs.	Platinum	126-134	kelch like ECH associated protein 1	Homo sapiens	28-33
27601007-9	2016	CONCLUSIONS: Our findings suggest that NRF2 signaling plays an indispensable role in NSCLC cell sensitivity to platinum-based treatments and provides a rationale for using NRF2 as a specific biomarker for predicting which patients will be most likely to benefit from platinum-based treatment.	Platinum	111-119	NFE2 like bZIP transcription factor 2	Homo sapiens	39-43
27601007-9	2016	CONCLUSIONS: Our findings suggest that NRF2 signaling plays an indispensable role in NSCLC cell sensitivity to platinum-based treatments and provides a rationale for using NRF2 as a specific biomarker for predicting which patients will be most likely to benefit from platinum-based treatment.	Platinum	111-119	NFE2 like bZIP transcription factor 2	Homo sapiens	172-176
27601007-9	2016	CONCLUSIONS: Our findings suggest that NRF2 signaling plays an indispensable role in NSCLC cell sensitivity to platinum-based treatments and provides a rationale for using NRF2 as a specific biomarker for predicting which patients will be most likely to benefit from platinum-based treatment.	Platinum	267-275	NFE2 like bZIP transcription factor 2	Homo sapiens	39-43
27601007-9	2016	CONCLUSIONS: Our findings suggest that NRF2 signaling plays an indispensable role in NSCLC cell sensitivity to platinum-based treatments and provides a rationale for using NRF2 as a specific biomarker for predicting which patients will be most likely to benefit from platinum-based treatment.	Platinum	267-275	NFE2 like bZIP transcription factor 2	Homo sapiens	172-176
27590272-2	2016	Four important transporter genes are expressed in the kidney, including organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), ATP-binding cassette subfamily B member 1 (ABCB1), and ATP-binding cassette subfamily C member 2 (ABCC2), and genetic polymorphisms in these genes may alter the efficacy and adverse effects of platinum drugs.	Platinum	343-351	solute carrier family 22 member 2	Homo sapiens	72-100
27590272-2	2016	Four important transporter genes are expressed in the kidney, including organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), ATP-binding cassette subfamily B member 1 (ABCB1), and ATP-binding cassette subfamily C member 2 (ABCC2), and genetic polymorphisms in these genes may alter the efficacy and adverse effects of platinum drugs.	Platinum	343-351	solute carrier family 22 member 2	Homo sapiens	102-106
27590272-2	2016	Four important transporter genes are expressed in the kidney, including organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), ATP-binding cassette subfamily B member 1 (ABCB1), and ATP-binding cassette subfamily C member 2 (ABCC2), and genetic polymorphisms in these genes may alter the efficacy and adverse effects of platinum drugs.	Platinum	343-351	ATP binding cassette subfamily B member 1	Homo sapiens	193-198
27590272-2	2016	Four important transporter genes are expressed in the kidney, including organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), ATP-binding cassette subfamily B member 1 (ABCB1), and ATP-binding cassette subfamily C member 2 (ABCC2), and genetic polymorphisms in these genes may alter the efficacy and adverse effects of platinum drugs.	Platinum	343-351	ATP binding cassette subfamily C member 2	Homo sapiens	205-246
27590272-9	2016	In addition, ABCC2 rs717620 was significantly associated with the platinum-based chemotherapy response (P = 0.031).	Platinum	66-74	ATP binding cassette subfamily C member 2	Homo sapiens	13-18
27590272-11	2016	CONCLUSION: OCT2 rs316019, MATE1 rs2289669, and ABCC2 rs717620 might be potential clinical markers for predicting chemotherapy toxicity and response induced by platinum-based treatment in NSCLC patients.	Platinum	160-168	solute carrier family 22 member 2	Homo sapiens	12-16
27590272-11	2016	CONCLUSION: OCT2 rs316019, MATE1 rs2289669, and ABCC2 rs717620 might be potential clinical markers for predicting chemotherapy toxicity and response induced by platinum-based treatment in NSCLC patients.	Platinum	160-168	solute carrier family 47 member 1	Homo sapiens	27-32
27590272-11	2016	CONCLUSION: OCT2 rs316019, MATE1 rs2289669, and ABCC2 rs717620 might be potential clinical markers for predicting chemotherapy toxicity and response induced by platinum-based treatment in NSCLC patients.	Platinum	160-168	ATP binding cassette subfamily C member 2	Homo sapiens	48-53
26650486-5	2016	The aim of this study was to determine the association between single nucleotide polymorphisms (SNPs) of the RRM1 promoter (-37C&gt;A, -524C&gt;T) and the effectiveness of first-line chemotherapy based on platinum compounds and gemcitabine in NSCLC patients.	Platinum	205-213	ribonucleotide reductase catalytic subunit M1	Homo sapiens	109-113
26179868-0	2016	The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.	Platinum	174-182	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	39-84
26179868-0	2016	The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.	Platinum	174-182	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	86-91
26179868-1	2016	Excision repair cross-complementation group 1 (ERCC1) protein has been extensively investigated as a prognostic and predictive factor for platinum-based treatment in head and neck squamous cell carcinoma (HNSCC) but with inconsistent results.	Platinum	138-146	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-45
26179868-1	2016	Excision repair cross-complementation group 1 (ERCC1) protein has been extensively investigated as a prognostic and predictive factor for platinum-based treatment in head and neck squamous cell carcinoma (HNSCC) but with inconsistent results.	Platinum	138-146	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
28003870-0	2016	New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes.	Platinum	45-53	BRCA1 DNA repair associated	Homo sapiens	138-143
28003870-0	2016	New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes.	Platinum	45-53	BRCA2 DNA repair associated	Homo sapiens	148-153
28003870-5	2016	Loss-of-function mutations in genes in the homologous recombination pathway, especially BRCA1 and BRCA2, predict higher rates of platinum sensitivity, better overall survival (OS), and better response to PARPi in women with OC.	Platinum	129-137	BRCA1 DNA repair associated	Homo sapiens	88-93
28003870-5	2016	Loss-of-function mutations in genes in the homologous recombination pathway, especially BRCA1 and BRCA2, predict higher rates of platinum sensitivity, better overall survival (OS), and better response to PARPi in women with OC.	Platinum	129-137	BRCA2 DNA repair associated	Homo sapiens	98-103
28003870-6	2016	Among patients with platinum-sensitive recurrent OC, a BRCA mutation is the first genetically defined predictive marker for targeted therapy, since these patients are most likely to benefit from treatment with a PARPi, such as olaparib.	Platinum	20-28	BRCA1 DNA repair associated	Homo sapiens	55-59
27381982-3	2016	Increased phosphorylation promoted 14-3-3 binding to BLNK (37-fold) and SYK (2.5-fold) in a pS/pT-concentration dependent manner.	Platinum	95-97	B cell linker	Homo sapiens	53-57
27374141-0	2016	Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.	Platinum	78-86	transmembrane protein 88	Homo sapiens	0-24
27374141-0	2016	Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.	Platinum	78-86	transmembrane protein 88	Homo sapiens	26-32
27374141-6	2016	We confirmed that TMEM88 and DAXX mRNA expression levels were increased in platinum resistant compared to control xenografts, inversely correlated with promoter methylation levels.	Platinum	75-83	transmembrane protein 88	Homo sapiens	18-24
27374141-6	2016	We confirmed that TMEM88 and DAXX mRNA expression levels were increased in platinum resistant compared to control xenografts, inversely correlated with promoter methylation levels.	Platinum	75-83	death domain associated protein	Homo sapiens	29-33
27374141-8	2016	TMEM88 was detectable by IHC in all histological types of ovarian tumors and its knock-down by using siRNA promoted OC cell proliferation and colony formation and re-sensitized cells to platinum.	Platinum	186-194	transmembrane protein 88	Homo sapiens	0-6
27374141-10	2016	CONCLUSIONS: Overall, our results support that OC platinum resistance was correlated with TMEM88 overexpression regulated through decreased promoter methylation.	Platinum	50-58	transmembrane protein 88	Homo sapiens	90-96
27374141-11	2016	Our data suggest that TMEM88 functions as an inhibitor of Wnt signaling, contributing to the development of platinum resistance.	Platinum	108-116	transmembrane protein 88	Homo sapiens	22-28
27381982-3	2016	Increased phosphorylation promoted 14-3-3 binding to BLNK (37-fold) and SYK (2.5-fold) in a pS/pT-concentration dependent manner.	Platinum	95-97	spleen associated tyrosine kinase	Homo sapiens	72-75
27747004-0	2016	Association of CHEK2 polymorphisms with the efficacy of platinum-based chemotherapy for advanced non-small-cell lung cancer in Chinese never-smoking women.	Platinum	56-64	checkpoint kinase 2	Homo sapiens	15-20
27484966-9	2016	The investigations on how picoplatin interacts with HSA are important for the understanding of the anticancer mechanism and toxicity of platinum-based anticancer drug.	Platinum	136-144	albumin	Homo sapiens	52-55
27603388-2	2016	The aim of this study was to compare platinum-resistant recurrence following treatment with NACT-IDS or PDS in patients with stage IIIC and IV EOC.We retrospectively reviewed the records of 341 patients who underwent PDS or NACT-IDS for Federation of Gynecology and Obstetrics stage IIIC or IV EOC between March 1990 and December 2010.	Platinum	37-45	solute carrier family 13 member 5	Homo sapiens	92-96
27603388-2	2016	The aim of this study was to compare platinum-resistant recurrence following treatment with NACT-IDS or PDS in patients with stage IIIC and IV EOC.We retrospectively reviewed the records of 341 patients who underwent PDS or NACT-IDS for Federation of Gynecology and Obstetrics stage IIIC or IV EOC between March 1990 and December 2010.	Platinum	37-45	solute carrier family 13 member 5	Homo sapiens	224-228
27643650-0	2016	Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy.	Platinum	125-133	proteasome 26S subunit, non-ATPase 1	Homo sapiens	42-45
27643650-12	2016	CONCLUSIONS: In women with advanced or recurrent cervical cancer previously treated with platinum-based chemotherapy, S-1 plus irinotecan in a triweekly setting is a reasonable treatment regimen with an acceptable toxicity profile.	Platinum	89-97	proteasome 26S subunit, non-ATPase 1	Homo sapiens	118-121
27211249-2	2016	While the first-line chemotherapy (CT1) has been established as gemcitabine-platinum doublet in advanced GBC, there is no standard recommendation or guidelines regarding feasibility of second-line therapy.	Platinum	76-84	cardiotrophin 1	Homo sapiens	35-38
27567201-0	2016	The molecular shape and the field similarities as criteria to interpret SAR studies for fragment-based design of platinum(IV) anticancer agents.	Platinum	113-121	sarcosine dehydrogenase	Homo sapiens	72-75
27460845-0	2016	ACE2 overexpression inhibits acquired platinum resistance-induced tumor angiogenesis in NSCLC.	Platinum	38-46	angiotensin converting enzyme 2	Homo sapiens	0-4
27460845-4	2016	In the present study, we investigated the effect of ACE2 on tumor-associated angiogen-esis after the development of acquired platinum resistance in non-small cell lung cancer (NSCLC).	Platinum	125-133	angiotensin converting enzyme 2	Homo sapiens	52-56
27460845-7	2016	These platinum-resistant cells showed significantly higher angiotensin II type 1 receptor (AT1R), ACE and VEGF production and lower ACE2 expression than their corresponding parent cells.	Platinum	6-14	angiotensin II receptor type 1	Homo sapiens	59-89
27460845-7	2016	These platinum-resistant cells showed significantly higher angiotensin II type 1 receptor (AT1R), ACE and VEGF production and lower ACE2 expression than their corresponding parent cells.	Platinum	6-14	angiotensin II receptor type 1	Homo sapiens	91-95
27460845-7	2016	These platinum-resistant cells showed significantly higher angiotensin II type 1 receptor (AT1R), ACE and VEGF production and lower ACE2 expression than their corresponding parent cells.	Platinum	6-14	angiotensin I converting enzyme	Homo sapiens	98-101
27460845-7	2016	These platinum-resistant cells showed significantly higher angiotensin II type 1 receptor (AT1R), ACE and VEGF production and lower ACE2 expression than their corresponding parent cells.	Platinum	6-14	vascular endothelial growth factor A	Homo sapiens	106-110
27460845-7	2016	These platinum-resistant cells showed significantly higher angiotensin II type 1 receptor (AT1R), ACE and VEGF production and lower ACE2 expression than their corresponding parent cells.	Platinum	6-14	angiotensin converting enzyme 2	Homo sapiens	132-136
27460845-11	2016	Our findings indicate that ACE2 overexpression may potentially suppress angiogenesis in NSCLC after the development of acquired platinum resistance.	Platinum	128-136	angiotensin converting enzyme 2	Homo sapiens	27-31
27603388-6	2016	In the multivariate logistic regression analyses, NACT-IDS and postoperative residual tumor mass &gt;1 cm were risk factors for platinum-resistant recurrence (adjusted odds ratios 2.950 and 2.915; 95% confidence intervals [CIs] 1.572-5.537 and 1.780-4.771, P = 0.001 and 0.000, respectively).	Platinum	128-136	solute carrier family 13 member 5	Homo sapiens	50-54
27603388-7	2016	Postoperative residual tumor mass &gt;1 cm and platinum-resistant disease were significantly correlated with shorter OS (adjusted hazard ratios 1.579 and 4.078; 95% CI 1.193-2.089 and 3.074-5.412, P = 0.001 and 0.000, respectively), whereas NACT-IDS did not extend OS.NACT-IDS increases the risk of platinum-resistant recurrence in patients with stage IIIC and IV EOC.	Platinum	47-55	solute carrier family 13 member 5	Homo sapiens	241-245
27603388-7	2016	Postoperative residual tumor mass &gt;1 cm and platinum-resistant disease were significantly correlated with shorter OS (adjusted hazard ratios 1.579 and 4.078; 95% CI 1.193-2.089 and 3.074-5.412, P = 0.001 and 0.000, respectively), whereas NACT-IDS did not extend OS.NACT-IDS increases the risk of platinum-resistant recurrence in patients with stage IIIC and IV EOC.	Platinum	47-55	solute carrier family 13 member 5	Homo sapiens	268-272
27747004-3	2016	This study aimed to investigate the relationship between polymorphisms in the CHEK2 gene and efficacy of platinum-based doublet chemotherapy in never-smoking Chinese female patients with advanced non-small-cell lung cancer (NSCLC).	Platinum	105-113	checkpoint kinase 2	Homo sapiens	78-83
27747004-4	2016	METHODS: Using DNA from blood samples of 272 Chinese advanced NSCLC non-smoking female patients treated with first-line platinum-based chemotherapy, we have analyzed the relationships between four SNPs in the CHEK2 gene and clinical outcomes.	Platinum	120-128	checkpoint kinase 2	Homo sapiens	209-214
27747004-9	2016	CONCLUSIONS: Our findings indicate that SNPs in CHEK2 are related to Chinese advanced NSCLC never-smoking female patients receiving platinum-based doublet chemotherapy in China.	Platinum	132-140	checkpoint kinase 2	Homo sapiens	48-53
27574114-5	2016	Using gel-mobility-shift assays and surface plasmon resonance spectroscopy we examined the interactions of NF-kappaB proteins with oligodeoxyribonucleotide duplexes containing kappaB site damaged by DNA adducts of three platinum complexes.	Platinum	220-228	nuclear factor kappa B subunit 1	Homo sapiens	107-116
27498158-1	2016	Platinum-based chemotherapy is the standard treatment for NSCLC patients with EGFR wild-type, and as alternative to failure to EGFR inhibitors.	Platinum	0-8	epidermal growth factor receptor	Homo sapiens	78-82
27498158-7	2016	Patients with ERCC1 C118T-T allele (p=0.00345; RR=26.05; CI95%=4.33, 515.77) and ERCC2 rs50872-CC genotype (p=0.00291; RR=4.06; CI95%=1.66, 10.65) had higher risk of general toxicity for platinum-based chemotherapy.	Platinum	187-195	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-19
27498158-7	2016	Patients with ERCC1 C118T-T allele (p=0.00345; RR=26.05; CI95%=4.33, 515.77) and ERCC2 rs50872-CC genotype (p=0.00291; RR=4.06; CI95%=1.66, 10.65) had higher risk of general toxicity for platinum-based chemotherapy.	Platinum	187-195	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	81-86
27498158-11	2016	In conclusion, ERCC1 C118T, ERCC2 rs50872, ERCC2 Asp312Asn, ABCB1 C1236T, IL1B rs12621220 and IL16 rs7170924 polymorphisms may substantially act as prognostic factors in NSCLC patients treated with platinum-based chemotherapy.	Platinum	198-206	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	15-20
27155850-6	2016	High PARP activity was associated with platinum sensitivity both in the entire study cohort (p = 0.022) and in the high-grade subgroup (p = 0.017).	Platinum	39-47	poly(ADP-ribose) polymerase 1	Homo sapiens	5-9
27155850-9	2016	In conclusion, we present a novel finding of high PARP activity associated with platinum sensitivity and improved PFS in EOC.	Platinum	80-88	poly(ADP-ribose) polymerase 1	Homo sapiens	50-54
27766772-7	2016	Combined gefitinib with platinum-based chemotherapy as first-line treatment probably benefits non-small cell cancer patients in stage IV harboring sensitive EGFR gene mutations with a better local control rate, longer survival, and tolerable side effects.	Platinum	24-32	epidermal growth factor receptor	Homo sapiens	157-161
27574114-7	2016	The results indicate that structurally different DNA adducts of these platinum complexes exhibit a different efficiency to affect the affinity of the platinated DNA (kappaB sites) to NF-kappaB proteins.	Platinum	70-78	nuclear factor kappa B subunit 1	Homo sapiens	183-192
27555886-2	2016	For example, tumors in BRCA1/2 mutation carriers usually arise via somatic inactivation of the remaining BRCA allele, which makes them particularly sensitive to platinum-based drugs, PARP inhibitors (PARPi), mitomycin C, liposomal doxorubicin, etc.	Platinum	161-169	BRCA1 DNA repair associated	Homo sapiens	23-28
27248474-6	2016	Patients carrying CT or TT genotypes of XRCC1 C580T could be more sensitive to platinum-based chemotherapy compared to patients with CC genotype (OR = 0.54, 95%CI: 0.37-0.80, P = 0.002).	Platinum	79-87	X-ray repair cross complementing 1	Homo sapiens	40-45
27248474-7	2016	CC genotype of XRCC3 C18067T carriers showed more resistance to platinum-based chemotherapy when compared to those with CT or TT genotypes (OR = 0.69, 95%CI: 0.52-0.91, P = 0.009).	Platinum	64-72	X-ray repair cross complementing 3	Homo sapiens	15-20
27248474-8	2016	Our study indicated that XRCC1 G1196A/ C580T and XRCC3 C18067T should be paid attention for personalized platinum-based chemotherapy in NSCLC patients.	Platinum	105-113	X-ray repair cross complementing 1	Homo sapiens	25-30
27248474-8	2016	Our study indicated that XRCC1 G1196A/ C580T and XRCC3 C18067T should be paid attention for personalized platinum-based chemotherapy in NSCLC patients.	Platinum	105-113	X-ray repair cross complementing 3	Homo sapiens	49-54
27561236-1	2016	We report on the out-of-plane thermal conductivities of tetragonal L10 FePt (001) easy-axis and cubic A1 FePt thin films via time-domain thermoreflectance over a temperature range from 133 K to 500 K. The out-of-plane thermal conductivity of the chemically ordered L10 phase with alternating Fe and Pt layers is ~23% greater than the thermal conductivity of the disordered A1 phase at room temperature and below.	Platinum	73-75	immunoglobulin kappa variable 3-7 (non-functional)	Homo sapiens	67-70
27404114-4	2016	Specifically, we explored the use of gold and platinum nanoparticles to increase the binding affinity of Abeta-specific small molecules to inhibit Abeta peptide aggregation into fibrils in vitro.	Platinum	46-54	succinate-CoA ligase ADP-forming subunit beta	Homo sapiens	105-110
27404114-4	2016	Specifically, we explored the use of gold and platinum nanoparticles to increase the binding affinity of Abeta-specific small molecules to inhibit Abeta peptide aggregation into fibrils in vitro.	Platinum	46-54	succinate-CoA ligase ADP-forming subunit beta	Homo sapiens	147-152
27487151-0	2016	ABCC2-24C &gt; T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients.	Platinum	65-73	ATP binding cassette subfamily C member 2	Homo sapiens	0-5
27555886-2	2016	For example, tumors in BRCA1/2 mutation carriers usually arise via somatic inactivation of the remaining BRCA allele, which makes them particularly sensitive to platinum-based drugs, PARP inhibitors (PARPi), mitomycin C, liposomal doxorubicin, etc.	Platinum	161-169	BRCA1 DNA repair associated	Homo sapiens	23-27
27439590-5	2016	Results show that the photocatalytic turnover frequency (TOF), defined as moles of hydrogen produced per surface mole of Pt-Pd metal atom per second, for Pt-Pd nanocubes/CdS (Pt-Pd NCs/CdS) photocatalyst can be 3.4 times more effective than Pt-Pd nano-octahedra/CdS (Pt-Pd NOTa/CdS) nanocomposite photocatalyst.	Platinum	154-156	CDP-diacylglycerol synthase 1	Homo sapiens	185-188
27439590-2	2016	The activity of Pt-Pd nanoparticles loaded Pt-Pd/CdS photocatalysts are affected based on both the Pt-Pd alloy nanoparticles" shape and their compositions.	Platinum	16-18	CDP-diacylglycerol synthase 1	Homo sapiens	49-52
27439590-2	2016	The activity of Pt-Pd nanoparticles loaded Pt-Pd/CdS photocatalysts are affected based on both the Pt-Pd alloy nanoparticles" shape and their compositions.	Platinum	43-45	CDP-diacylglycerol synthase 1	Homo sapiens	49-52
27439590-2	2016	The activity of Pt-Pd nanoparticles loaded Pt-Pd/CdS photocatalysts are affected based on both the Pt-Pd alloy nanoparticles" shape and their compositions.	Platinum	43-45	CDP-diacylglycerol synthase 1	Homo sapiens	49-52
27439590-5	2016	Results show that the photocatalytic turnover frequency (TOF), defined as moles of hydrogen produced per surface mole of Pt-Pd metal atom per second, for Pt-Pd nanocubes/CdS (Pt-Pd NCs/CdS) photocatalyst can be 3.4 times more effective than Pt-Pd nano-octahedra/CdS (Pt-Pd NOTa/CdS) nanocomposite photocatalyst.	Platinum	121-123	CDP-diacylglycerol synthase 1	Homo sapiens	170-173
27439590-5	2016	Results show that the photocatalytic turnover frequency (TOF), defined as moles of hydrogen produced per surface mole of Pt-Pd metal atom per second, for Pt-Pd nanocubes/CdS (Pt-Pd NCs/CdS) photocatalyst can be 3.4 times more effective than Pt-Pd nano-octahedra/CdS (Pt-Pd NOTa/CdS) nanocomposite photocatalyst.	Platinum	154-156	CDP-diacylglycerol synthase 1	Homo sapiens	170-173
27439590-5	2016	Results show that the photocatalytic turnover frequency (TOF), defined as moles of hydrogen produced per surface mole of Pt-Pd metal atom per second, for Pt-Pd nanocubes/CdS (Pt-Pd NCs/CdS) photocatalyst can be 3.4 times more effective than Pt-Pd nano-octahedra/CdS (Pt-Pd NOTa/CdS) nanocomposite photocatalyst.	Platinum	154-156	CDP-diacylglycerol synthase 1	Homo sapiens	170-173
27439590-5	2016	Results show that the photocatalytic turnover frequency (TOF), defined as moles of hydrogen produced per surface mole of Pt-Pd metal atom per second, for Pt-Pd nanocubes/CdS (Pt-Pd NCs/CdS) photocatalyst can be 3.4 times more effective than Pt-Pd nano-octahedra/CdS (Pt-Pd NOTa/CdS) nanocomposite photocatalyst.	Platinum	154-156	CDP-diacylglycerol synthase 1	Homo sapiens	185-188
27439590-5	2016	Results show that the photocatalytic turnover frequency (TOF), defined as moles of hydrogen produced per surface mole of Pt-Pd metal atom per second, for Pt-Pd nanocubes/CdS (Pt-Pd NCs/CdS) photocatalyst can be 3.4 times more effective than Pt-Pd nano-octahedra/CdS (Pt-Pd NOTa/CdS) nanocomposite photocatalyst.	Platinum	154-156	CDP-diacylglycerol synthase 1	Homo sapiens	185-188
27439590-5	2016	Results show that the photocatalytic turnover frequency (TOF), defined as moles of hydrogen produced per surface mole of Pt-Pd metal atom per second, for Pt-Pd nanocubes/CdS (Pt-Pd NCs/CdS) photocatalyst can be 3.4 times more effective than Pt-Pd nano-octahedra/CdS (Pt-Pd NOTa/CdS) nanocomposite photocatalyst.	Platinum	154-156	CDP-diacylglycerol synthase 1	Homo sapiens	185-188
27439590-5	2016	Results show that the photocatalytic turnover frequency (TOF), defined as moles of hydrogen produced per surface mole of Pt-Pd metal atom per second, for Pt-Pd nanocubes/CdS (Pt-Pd NCs/CdS) photocatalyst can be 3.4 times more effective than Pt-Pd nano-octahedra/CdS (Pt-Pd NOTa/CdS) nanocomposite photocatalyst.	Platinum	154-156	CDP-diacylglycerol synthase 1	Homo sapiens	185-188
27439590-5	2016	Results show that the photocatalytic turnover frequency (TOF), defined as moles of hydrogen produced per surface mole of Pt-Pd metal atom per second, for Pt-Pd nanocubes/CdS (Pt-Pd NCs/CdS) photocatalyst can be 3.4 times more effective than Pt-Pd nano-octahedra/CdS (Pt-Pd NOTa/CdS) nanocomposite photocatalyst.	Platinum	154-156	CDP-diacylglycerol synthase 1	Homo sapiens	185-188
27439590-6	2016	Along with the shape effect, the atomic ratio of Pt to Pd can also impact the efficiency of Pt-Pd/CdS photocatalysts.	Platinum	49-51	CDP-diacylglycerol synthase 1	Homo sapiens	98-101
27439590-6	2016	Along with the shape effect, the atomic ratio of Pt to Pd can also impact the efficiency of Pt-Pd/CdS photocatalysts.	Platinum	92-94	CDP-diacylglycerol synthase 1	Homo sapiens	98-101
27397134-5	2016	In the present study we have investigated the adsorption on and the release from biomimetic HA nanoparticles of two platinum derivatives of cis-1,4-diaminocyclohexane ([PtX2(cis-1,4-DACH)], X2 = Cl2 (1) and 1,1-cyclobutanedicarboxylate (CBDCA, 2)).	Platinum	116-124	paired like homeodomain 2	Homo sapiens	169-173
27358387-0	2016	Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?	Platinum	44-52	mucin 16, cell surface associated	Homo sapiens	3-8
26950035-3	2016	Multidrug resistance-associated protein 1 (MRP1) and Multidrug resistance-associated protein 4 (MRP4) play a role in irinotecan-resistance, and Excision Repair Cross-Complementation group 1 (ERCC1) expression can confer resistance to platinum compounds.	Platinum	234-242	ATP binding cassette subfamily C member 1	Homo sapiens	0-41
26950035-3	2016	Multidrug resistance-associated protein 1 (MRP1) and Multidrug resistance-associated protein 4 (MRP4) play a role in irinotecan-resistance, and Excision Repair Cross-Complementation group 1 (ERCC1) expression can confer resistance to platinum compounds.	Platinum	234-242	ATP binding cassette subfamily C member 1	Homo sapiens	43-47
26950035-3	2016	Multidrug resistance-associated protein 1 (MRP1) and Multidrug resistance-associated protein 4 (MRP4) play a role in irinotecan-resistance, and Excision Repair Cross-Complementation group 1 (ERCC1) expression can confer resistance to platinum compounds.	Platinum	234-242	ATP binding cassette subfamily C member 4	Homo sapiens	53-94
26950035-3	2016	Multidrug resistance-associated protein 1 (MRP1) and Multidrug resistance-associated protein 4 (MRP4) play a role in irinotecan-resistance, and Excision Repair Cross-Complementation group 1 (ERCC1) expression can confer resistance to platinum compounds.	Platinum	234-242	ATP binding cassette subfamily C member 4	Homo sapiens	96-100
26950035-3	2016	Multidrug resistance-associated protein 1 (MRP1) and Multidrug resistance-associated protein 4 (MRP4) play a role in irinotecan-resistance, and Excision Repair Cross-Complementation group 1 (ERCC1) expression can confer resistance to platinum compounds.	Platinum	234-242	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	144-189
26950035-3	2016	Multidrug resistance-associated protein 1 (MRP1) and Multidrug resistance-associated protein 4 (MRP4) play a role in irinotecan-resistance, and Excision Repair Cross-Complementation group 1 (ERCC1) expression can confer resistance to platinum compounds.	Platinum	234-242	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	191-196
27135783-4	2016	Both the presence of multiple sharp tips and charge transfer between Pt and Co enabled the accumulation of negative charges on the Pt atoms in the vertices of the Pt3 Co octapods.	Platinum	69-71	zinc finger protein 135	Homo sapiens	163-166
27135783-4	2016	Both the presence of multiple sharp tips and charge transfer between Pt and Co enabled the accumulation of negative charges on the Pt atoms in the vertices of the Pt3 Co octapods.	Platinum	131-133	zinc finger protein 135	Homo sapiens	163-166
27135783-5	2016	Moreover, infrared reflection absorption spectroscopy confirmed that the high negative charge density at the Pt atoms in the vertices of the Pt3 Co octapods promotes the activation of CO2 and accordingly enhances the catalytic activity.	Platinum	109-111	zinc finger protein 135	Homo sapiens	141-144
27485273-6	2016	High FOLR1 expression was found to predict increased platinum sensitivity in type I cancers (odds ratio = 3.288; 1.256-10.75; p = 0.020).	Platinum	53-61	folate receptor alpha	Homo sapiens	5-10
27485273-12	2016	In type I cancers, however, strong FOLR1 expression has been found to be a reliable indicator of improved platinum responsiveness reflecting a transient better one-year follow up outcome in highly FOLR1 expressing type I cancers.	Platinum	106-114	folate receptor alpha	Homo sapiens	35-40
27485273-12	2016	In type I cancers, however, strong FOLR1 expression has been found to be a reliable indicator of improved platinum responsiveness reflecting a transient better one-year follow up outcome in highly FOLR1 expressing type I cancers.	Platinum	106-114	folate receptor alpha	Homo sapiens	197-202
27384479-5	2016	Decrement of human copper transporter 1 (hCtr1) and transferrin receptor 1 (TfR1) expression involved in the development of platinum resistance in S3 cells.	Platinum	124-132	solute carrier family 31 member 1	Homo sapiens	19-39
27384479-5	2016	Decrement of human copper transporter 1 (hCtr1) and transferrin receptor 1 (TfR1) expression involved in the development of platinum resistance in S3 cells.	Platinum	124-132	solute carrier family 31 member 1	Homo sapiens	41-46
27384479-5	2016	Decrement of human copper transporter 1 (hCtr1) and transferrin receptor 1 (TfR1) expression involved in the development of platinum resistance in S3 cells.	Platinum	124-132	transferrin receptor	Homo sapiens	52-74
27384479-5	2016	Decrement of human copper transporter 1 (hCtr1) and transferrin receptor 1 (TfR1) expression involved in the development of platinum resistance in S3 cells.	Platinum	124-132	transferrin receptor	Homo sapiens	76-80
27407100-1	2016	BACKGROUND: Data on CA-125 as a predictor of disease progression (PD) in ovarian cancer come predominantly from patients with platinum-sensitive disease receiving chemotherapy alone.	Platinum	126-134	mucin 16, cell surface associated	Homo sapiens	20-26
27407100-12	2016	CONCLUSIONS: In this platinum-resistant population, PD was typically detected earlier by imaging than by CA-125, irrespective of bevacizumab treatment.	Platinum	21-29	mucin 16, cell surface associated	Homo sapiens	105-111
27449101-2	2016	miR-770-5p expression was reduced in platinum-resistant patients.	Platinum	37-45	microRNA 7705	Homo sapiens	0-10
29179445-0	2017	ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy.	Platinum	53-61	ADAM metallopeptidase with thrombospondin type 1 motif 16	Homo sapiens	0-8
29179445-3	2017	Our recent analysis of genomics and clinical data from the Cancer Genome Atlas demonstrated that somatic mutations of ADAMTS 1, 6, 8, 9, 15, 16, 18 and L1 genes were associated with higher sensitivity to platinum and longer progression-free survival, overall survival, and platinum-free survival duration in 512 patients with high-grade serous ovarian carcinoma.	Platinum	204-212	ADAM metallopeptidase with thrombospondin type 1 motif 1	Homo sapiens	118-126
29179445-3	2017	Our recent analysis of genomics and clinical data from the Cancer Genome Atlas demonstrated that somatic mutations of ADAMTS 1, 6, 8, 9, 15, 16, 18 and L1 genes were associated with higher sensitivity to platinum and longer progression-free survival, overall survival, and platinum-free survival duration in 512 patients with high-grade serous ovarian carcinoma.	Platinum	273-281	ADAM metallopeptidase with thrombospondin type 1 motif 1	Homo sapiens	118-126
29179445-7	2017	We also used a well-characterized in vivo mouse model to evaluate the response of ovarian cancer cells with ADAMTS16 mutations to platinum-based therapy.	Platinum	130-138	a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 16	Mus musculus	108-116
27622063-8	2016	We show that both platinum drugs triggered translocation of calreticulin and HSP70, as well as the release of ATP and HMGB1.	Platinum	18-26	calreticulin	Homo sapiens	60-72
27622063-8	2016	We show that both platinum drugs triggered translocation of calreticulin and HSP70, as well as the release of ATP and HMGB1.	Platinum	18-26	heat shock protein family A (Hsp70) member 4	Homo sapiens	77-82
27622063-8	2016	We show that both platinum drugs triggered translocation of calreticulin and HSP70, as well as the release of ATP and HMGB1.	Platinum	18-26	ATPase phospholipid transporting 8A2	Homo sapiens	110-113
27622063-8	2016	We show that both platinum drugs triggered translocation of calreticulin and HSP70, as well as the release of ATP and HMGB1.	Platinum	18-26	high mobility group box 1	Homo sapiens	118-123
27622063-10	2016	Moreover, upon interaction with platinum-treated tumor cells, CD1c(+) DCs efficiently stimulated allogeneic proliferation of T lymphocytes.	Platinum	32-40	CD1c molecule	Homo sapiens	62-66
27299748-0	2016	Rho GTPases: RAC1 polymorphisms affected platinum-based chemotherapy toxicity in lung cancer patients.	Platinum	41-49	Rac family small GTPase 1	Homo sapiens	13-17
27299748-9	2016	RESULTS: We found that the polymorphisms of RAC1 rs836554, rs4720672, and rs12536544 were significantly associated with platinum-based chemotherapy toxicity (p = 0.018, p = 0.044, and p = 0.021, respectively).	Platinum	120-128	Rac family small GTPase 1	Homo sapiens	44-48
27299748-10	2016	CONCLUSIONS: RAC1 rs836554, rs4720672, and rs12536544 polymorphisms may be novel and useful genetic markers to predict the toxicity induced by platinum-based chemotherapy in lung cancer patients.	Platinum	143-151	Rac family small GTPase 1	Homo sapiens	13-17
26957554-10	2016	CONCLUSIONS: HR deficiency identifies TNBC tumors, including BRCA1/2 nonmutated tumors more likely to respond to platinum-containing therapy.	Platinum	113-121	BRCA1 DNA repair associated	Homo sapiens	61-66
26896377-4	2016	In the present research, beta-lactoglobulin-pectin nanoparticles were designed to transfer a newly synthesized, anticancer platinum complex (bipyridine ethyl dithiocarbamate Pt(II) nitrate), to the colon.	Platinum	123-131	beta-lactoglobulin	Bos taurus	25-43
27454289-1	2016	Patients with cancers that harbor breast cancer 1 (BRCA1) mutations initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; however, resistance invariably arises in these patients and is a major clinical problem.	Platinum	94-102	BRCA1 DNA repair associated	Homo sapiens	34-49
26778300-13	2016	CONCLUSION: A high percentage of nuclear staining of ERCC1, RAD51, and PAR, assessed by immunohistochemistry, correlated with worse OS for patients with mUC treated with first-line platinum combination chemotherapy, supporting the evidence of the DNA repair pathways" role in the prognosis of mUC.	Platinum	181-189	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	53-58
26778300-13	2016	CONCLUSION: A high percentage of nuclear staining of ERCC1, RAD51, and PAR, assessed by immunohistochemistry, correlated with worse OS for patients with mUC treated with first-line platinum combination chemotherapy, supporting the evidence of the DNA repair pathways" role in the prognosis of mUC.	Platinum	181-189	RAD51 recombinase	Homo sapiens	60-65
26778300-13	2016	CONCLUSION: A high percentage of nuclear staining of ERCC1, RAD51, and PAR, assessed by immunohistochemistry, correlated with worse OS for patients with mUC treated with first-line platinum combination chemotherapy, supporting the evidence of the DNA repair pathways" role in the prognosis of mUC.	Platinum	181-189	jumping translocation breakpoint	Homo sapiens	71-74
26778300-14	2016	We also report new evidence that RAD51 and PAR might play a role in the platinum response.	Platinum	72-80	RAD51 recombinase	Homo sapiens	33-38
26778300-14	2016	We also report new evidence that RAD51 and PAR might play a role in the platinum response.	Platinum	72-80	jumping translocation breakpoint	Homo sapiens	43-46
27142971-8	2016	Platinum concentrations from surfaces of bags and floors ranged from 0.01 to 439 pg/cm(2) (median: urine bag 2.77 pg/cm(2), drainage bag 0.22 pg/cm(2), floor left 0.14 pg/cm(2), floor right 0.24 pg/cm(2)), with the highest contamination found on the outer surface of the urine bags.	Platinum	0-8	BAG cochaperone 2	Homo sapiens	105-110
27329924-1	2016	Results from a phase II study indicate that the PD-L1 inhibitor atezolizumab, recently approved for advanced bladder cancer that"s refractory to standard platinum chemotherapy, is effective as first-line therapy for this disease.	Platinum	154-162	CD274 molecule	Homo sapiens	48-53
27454289-1	2016	Patients with cancers that harbor breast cancer 1 (BRCA1) mutations initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; however, resistance invariably arises in these patients and is a major clinical problem.	Platinum	94-102	BRCA1 DNA repair associated	Homo sapiens	51-56
27454289-5	2016	PARPi- and cisplatin-resistant clones did not harbor secondary reversion mutations; rather, PARPi and platinum resistance required increased expression of a really interesting gene (RING) domain-deficient BRCA1 protein (Rdd-BRCA1).	Platinum	102-110	BRCA1 DNA repair associated	Homo sapiens	205-210
27454289-5	2016	PARPi- and cisplatin-resistant clones did not harbor secondary reversion mutations; rather, PARPi and platinum resistance required increased expression of a really interesting gene (RING) domain-deficient BRCA1 protein (Rdd-BRCA1).	Platinum	102-110	BRCA1 DNA repair associated	Homo sapiens	224-229
27446360-0	2016	High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer.	Platinum	41-49	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	5-10
27233943-2	2016	Unbiased genomic and proteomic screenings using ovarian cancer cell lines of different genetic backgrounds and sensitivities to platinum led to the identification of two key genes upregulated by mifepristone and involved in the unfolded protein response (UPR): the master chaperone of the endoplasmic reticulum (ER), glucose regulated protein (GRP) of 78 kDa, and the CCAAT/enhancer binding protein homologous transcription factor (CHOP).	Platinum	128-136	gastrin releasing peptide	Homo sapiens	317-342
27233943-2	2016	Unbiased genomic and proteomic screenings using ovarian cancer cell lines of different genetic backgrounds and sensitivities to platinum led to the identification of two key genes upregulated by mifepristone and involved in the unfolded protein response (UPR): the master chaperone of the endoplasmic reticulum (ER), glucose regulated protein (GRP) of 78 kDa, and the CCAAT/enhancer binding protein homologous transcription factor (CHOP).	Platinum	128-136	gastrin releasing peptide	Homo sapiens	344-347
27233943-2	2016	Unbiased genomic and proteomic screenings using ovarian cancer cell lines of different genetic backgrounds and sensitivities to platinum led to the identification of two key genes upregulated by mifepristone and involved in the unfolded protein response (UPR): the master chaperone of the endoplasmic reticulum (ER), glucose regulated protein (GRP) of 78 kDa, and the CCAAT/enhancer binding protein homologous transcription factor (CHOP).	Platinum	128-136	DNA damage inducible transcript 3	Homo sapiens	368-430
27233943-2	2016	Unbiased genomic and proteomic screenings using ovarian cancer cell lines of different genetic backgrounds and sensitivities to platinum led to the identification of two key genes upregulated by mifepristone and involved in the unfolded protein response (UPR): the master chaperone of the endoplasmic reticulum (ER), glucose regulated protein (GRP) of 78 kDa, and the CCAAT/enhancer binding protein homologous transcription factor (CHOP).	Platinum	128-136	DNA damage inducible transcript 3	Homo sapiens	432-436
27446360-1	2016	The present study aimed to investigate the association between excision repair cross-complementation group 1 (ERCC1) expression and clinical resistance to platinum-based chemotherapy or clinical characteristics, including survival time, in patients with epithelial ovarian cancer (EOC).	Platinum	155-163	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	63-108
27446360-1	2016	The present study aimed to investigate the association between excision repair cross-complementation group 1 (ERCC1) expression and clinical resistance to platinum-based chemotherapy or clinical characteristics, including survival time, in patients with epithelial ovarian cancer (EOC).	Platinum	155-163	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	110-115
27446360-9	2016	These results demonstrate that high ERCC1 expression is associated with resistance to platinum-based chemotherapy, but not with survival time, and ERCC1 protein expression is not an independent factor or the only factor affecting the prognosis of patients with EOC.	Platinum	86-94	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	36-41
27323405-6	2016	Suppression of ABHD2 in OVCA420 cells increased phosphorylated p38 and ERK, platinum resistance, and side population cells (p&lt;0.01, respectively).	Platinum	76-84	abhydrolase domain containing 2, acylglycerol lipase	Homo sapiens	15-20
27302373-3	2016	Samples with monolayer and above platinum coverages exhibit maximum electrochemically active surface areas values of ~100 m(2)/gpt and specific activities that are ~4x to 6x of a reference platinum nanoparticle bilayer array.	Platinum	33-41	glutamic--pyruvic transaminase	Homo sapiens	127-130
27465688-3	2016	Patients with BRCA mutant EOC, and thus a defect in the homologous recombination (HR) repair pathway, demonstrate greater clinical response to platinum and olaparib therapy than patients with BRCA wild-type EOC.	Platinum	143-151	BRCA1 DNA repair associated	Homo sapiens	14-18
27476577-4	2016	The prepared CJ-Pt/Au colloidal catalysts characterized by UV-Vis, TEM, HR-TEM and HAADF-STEM-EELS showed a high catalytic activity for aerobic glucose oxidation, and the top Au atoms decorating the Pt NCs were about 15 times more active than the Au atoms of Au NCs with similar particle size.	Platinum	16-18	MFT2	Homo sapiens	67-70
27191893-6	2016	However, when stratified by chemotherapy regimen, patients whose tumors had TP53 and HR mutations demonstrated a marked survival advantage when treated with platinum and paclitaxel vs. platinum +/- cyclophosphamide (median OS of 90 months (95% CI 50-NA) vs. 29.5 months (95% CI 17.7-50.5), p = 0.0005).	Platinum	157-165	tumor protein p53	Homo sapiens	76-80
27191893-6	2016	However, when stratified by chemotherapy regimen, patients whose tumors had TP53 and HR mutations demonstrated a marked survival advantage when treated with platinum and paclitaxel vs. platinum +/- cyclophosphamide (median OS of 90 months (95% CI 50-NA) vs. 29.5 months (95% CI 17.7-50.5), p = 0.0005).	Platinum	185-193	tumor protein p53	Homo sapiens	76-80
27323405-8	2016	In clinical serous ovarian cancer specimens, low expression of ABHD2 was associated with platinum resistance and poor prognosis (p&lt;0.05, respectively).	Platinum	89-97	abhydrolase domain containing 2, acylglycerol lipase	Homo sapiens	63-68
27411790-13	2016	High-performance liquid chromatography (HPLC) showed that the total platinum level was lower in A549-EHD1 cells than in control cells, and the concentration of CDDP was higher in the EHD1 knockdown cells than in the A549/DDP control cells.	Platinum	68-76	EH domain containing 1	Homo sapiens	101-105
27465871-18	2016	The diagnosis value of ORM1 protein in ovarian cancer patients with platinum resistance performance is significantly higher than that of FN1 and SERPINA1 protein(P=0.000) CONCLUSIONS: The differentially express level of FN1, SERPINA1 and ORM1 between PTS and PTR play a essential role in measuring subtle changes in response to platinum-based chemotherapy and may be involved in biological processes of platinum resistance.	Platinum	68-76	orosomucoid 1	Homo sapiens	23-27
27465871-18	2016	The diagnosis value of ORM1 protein in ovarian cancer patients with platinum resistance performance is significantly higher than that of FN1 and SERPINA1 protein(P=0.000) CONCLUSIONS: The differentially express level of FN1, SERPINA1 and ORM1 between PTS and PTR play a essential role in measuring subtle changes in response to platinum-based chemotherapy and may be involved in biological processes of platinum resistance.	Platinum	68-76	fibronectin 1	Homo sapiens	220-223
27465871-18	2016	The diagnosis value of ORM1 protein in ovarian cancer patients with platinum resistance performance is significantly higher than that of FN1 and SERPINA1 protein(P=0.000) CONCLUSIONS: The differentially express level of FN1, SERPINA1 and ORM1 between PTS and PTR play a essential role in measuring subtle changes in response to platinum-based chemotherapy and may be involved in biological processes of platinum resistance.	Platinum	328-336	orosomucoid 1	Homo sapiens	23-27
27465871-18	2016	The diagnosis value of ORM1 protein in ovarian cancer patients with platinum resistance performance is significantly higher than that of FN1 and SERPINA1 protein(P=0.000) CONCLUSIONS: The differentially express level of FN1, SERPINA1 and ORM1 between PTS and PTR play a essential role in measuring subtle changes in response to platinum-based chemotherapy and may be involved in biological processes of platinum resistance.	Platinum	328-336	orosomucoid 1	Homo sapiens	23-27
27465871-19	2016	ORM1 has higher diagnostic efficiency of platinum resistance in ovarian cancer patients.	Platinum	41-49	orosomucoid 1	Homo sapiens	0-4
27305454-2	2016	We investigated the reaction of the chaperone Atox1 with an activated form of oxaliplatin, the third platinum drug to reach worldwide approval.	Platinum	101-109	antioxidant 1 copper chaperone	Homo sapiens	46-51
27191653-4	2016	In contrast, platinum-resistant cells revealed a significant dependency on the presence of glutamine, with an upregulated expression of glutamine transporter ASCT2 and glutaminase.	Platinum	13-21	solute carrier family 1 member 5	Homo sapiens	158-163
27305454-4	2016	In solution, one or two {Pt(DACH)(2+)} moieties bind to the conserved CXXC metal-binding motif of Atox1; in the latter case the two sulfur atoms likely bridging the two platinum units.	Platinum	25-27	antioxidant 1 copper chaperone	Homo sapiens	98-103
27305454-4	2016	In solution, one or two {Pt(DACH)(2+)} moieties bind to the conserved CXXC metal-binding motif of Atox1; in the latter case the two sulfur atoms likely bridging the two platinum units.	Platinum	169-177	antioxidant 1 copper chaperone	Homo sapiens	98-103
27305454-8	2016	However, while in the latter case there was only one Pt-binding site (0.4 occupancy) made of four sulfur atoms of the CXXC motifs of the two Atox1 chains in a tetrahedral arrangement, we found, in addition, a secondary Pt-binding site involving Cys41 of the B chain (0.25 occupancy).	Platinum	53-55	antioxidant 1 copper chaperone	Homo sapiens	141-146
27305454-11	2016	Since full occupancy of the tetrahedral cavity is a common feature of all Atox1 dimeric structures obtained with other metal ions (Cu(+), Cd(2+), and Hg(2+)), we propose that in the case of platinum, where the occupancy is only 0.4, the remaining cavities are occupied by Cu(+) ions.	Platinum	190-198	antioxidant 1 copper chaperone	Homo sapiens	74-79
27343437-2	2016	Pre-clinical and clinical data suggest that TNBC could be more sensitive to platinum-based chemotherapy, especially among BRCA1/2-mutated patients.	Platinum	76-84	BRCA1 DNA repair associated	Homo sapiens	122-127
27354603-7	2016	Negative pre-treatment expression of cytoplasmic ALDH1 predicted sensitivity to platinum (p=0.017).	Platinum	80-88	aldehyde dehydrogenase 1 family member A1	Homo sapiens	49-54
27040953-2	2016	X-ray structures were also solved for the adducts formed at 20 and 55  C. Data demonstrate that high temperature facilitates the formation of CDDP-HEWL adducts, where Pt atoms bind ND1 atom of His15 or NE2 atom of His15 and NH1 atom of Arg14.	Platinum	167-169	mitochondrially encoded NADH dehydrogenase 1	Homo sapiens	181-184
26762562-0	2016	Sonic Hedgehog Pathway Activation Is Associated With Resistance to Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Carcinoma.	Platinum	67-75	sonic hedgehog signaling molecule	Homo sapiens	0-14
26762562-13	2016	CONCLUSION: The Shh pathway is associated with resistance to platinum-based chemotherapy in NSCLC.	Platinum	61-69	sonic hedgehog signaling molecule	Homo sapiens	16-19
27044931-14	2016	CONCLUSION: Afatinib demonstrated significant activity in patients with platinum-refractory UC with HER2 or ERBB3 alterations.	Platinum	72-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-104
27428214-1	2016	The aim of this study was to investigate the efficacy and safety of the extended use of platinum-based doublet chemotherapy (PT-DC) plus endostatin in patients with advanced nonsmall cell lung cancer (NSCLC).We performed a retrospective analysis of 200 newly diagnosed advanced NSCLC patients who had received at least 1 cycle of endostatin plus PT-DC between September 2009 and November 2014.	Platinum	88-96	collagen type XVIII alpha 1 chain	Homo sapiens	330-340
27196780-0	2016	Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.	Platinum	86-94	CREB regulated transcription coactivator 2	Mus musculus	5-13
27196780-2	2016	Because mTORC1 and its downstream mRNA translation effectors may protect against genotoxic DNA damage, we investigated the inhibition of mTORC1 and mTORC1/2 in the ability to reverse platinum resistance in tissue culture and in animal tumor models of serous ovarian cancer.	Platinum	183-191	CREB regulated transcription coactivator 1	Mus musculus	137-143
27196780-2	2016	Because mTORC1 and its downstream mRNA translation effectors may protect against genotoxic DNA damage, we investigated the inhibition of mTORC1 and mTORC1/2 in the ability to reverse platinum resistance in tissue culture and in animal tumor models of serous ovarian cancer.	Platinum	183-191	CREB regulated transcription coactivator 2	Mus musculus	148-156
27196780-4	2016	We show that platinum-resistant OVCAR-3 ovarian cancer cells are resensitized to low levels of carboplatin in culture by mTOR inhibition, demonstrating reduced survival after treatment with either mTORC1 inhibitor everolimus or mTORC1/2 inhibitor PP242.	Platinum	13-21	mechanistic target of rapamycin kinase	Homo sapiens	121-125
27196780-4	2016	We show that platinum-resistant OVCAR-3 ovarian cancer cells are resensitized to low levels of carboplatin in culture by mTOR inhibition, demonstrating reduced survival after treatment with either mTORC1 inhibitor everolimus or mTORC1/2 inhibitor PP242.	Platinum	13-21	CREB regulated transcription coactivator 1	Mus musculus	197-203
27196780-4	2016	We show that platinum-resistant OVCAR-3 ovarian cancer cells are resensitized to low levels of carboplatin in culture by mTOR inhibition, demonstrating reduced survival after treatment with either mTORC1 inhibitor everolimus or mTORC1/2 inhibitor PP242.	Platinum	13-21	CREB regulated transcription coactivator 2	Mus musculus	228-236
27196780-5	2016	Platinum resistance is shown to be associated with activating phosphorylation of AKT and CHK1, inactivating phosphorylation of 4E-BP1, the negative regulator of eIF4E, which promotes increased cap-dependent mRNA translation and increased levels of CHK1 and BRCA1 proteins.	Platinum	0-8	AKT serine/threonine kinase 1	Homo sapiens	81-84
27196780-5	2016	Platinum resistance is shown to be associated with activating phosphorylation of AKT and CHK1, inactivating phosphorylation of 4E-BP1, the negative regulator of eIF4E, which promotes increased cap-dependent mRNA translation and increased levels of CHK1 and BRCA1 proteins.	Platinum	0-8	checkpoint kinase 1	Homo sapiens	89-93
27196780-5	2016	Platinum resistance is shown to be associated with activating phosphorylation of AKT and CHK1, inactivating phosphorylation of 4E-BP1, the negative regulator of eIF4E, which promotes increased cap-dependent mRNA translation and increased levels of CHK1 and BRCA1 proteins.	Platinum	0-8	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	127-133
27196780-5	2016	Platinum resistance is shown to be associated with activating phosphorylation of AKT and CHK1, inactivating phosphorylation of 4E-BP1, the negative regulator of eIF4E, which promotes increased cap-dependent mRNA translation and increased levels of CHK1 and BRCA1 proteins.	Platinum	0-8	eukaryotic translation initiation factor 4E	Homo sapiens	161-166
27196780-5	2016	Platinum resistance is shown to be associated with activating phosphorylation of AKT and CHK1, inactivating phosphorylation of 4E-BP1, the negative regulator of eIF4E, which promotes increased cap-dependent mRNA translation and increased levels of CHK1 and BRCA1 proteins.	Platinum	0-8	checkpoint kinase 1	Homo sapiens	248-252
27196780-5	2016	Platinum resistance is shown to be associated with activating phosphorylation of AKT and CHK1, inactivating phosphorylation of 4E-BP1, the negative regulator of eIF4E, which promotes increased cap-dependent mRNA translation and increased levels of CHK1 and BRCA1 proteins.	Platinum	0-8	BRCA1 DNA repair associated	Homo sapiens	257-262
27196780-6	2016	Animals with platinum-resistant OVCAR-3 tumors treated with carboplatin plus mTORC1/2 inhibition had significantly longer median survival and strikingly reduced metastasis compared with animals treated with carboplatin plus everolimus, which inhibits only mTORC1.	Platinum	13-21	CREB regulated transcription coactivator 1	Mus musculus	77-83
27196780-6	2016	Animals with platinum-resistant OVCAR-3 tumors treated with carboplatin plus mTORC1/2 inhibition had significantly longer median survival and strikingly reduced metastasis compared with animals treated with carboplatin plus everolimus, which inhibits only mTORC1.	Platinum	13-21	CREB regulated transcription coactivator 1	Mus musculus	256-262
27196780-8	2016	We conclude that mTORC1/2 inhibition is superior to mTORC1 inhibition in reversing platinum resistance in tumors and strongly impairs AKT activation, DNA repair responses, and translation, promoting improved survival in the background of platinum resistance.	Platinum	83-91	CREB regulated transcription coactivator 2	Mus musculus	17-25
27196780-8	2016	We conclude that mTORC1/2 inhibition is superior to mTORC1 inhibition in reversing platinum resistance in tumors and strongly impairs AKT activation, DNA repair responses, and translation, promoting improved survival in the background of platinum resistance.	Platinum	83-91	CREB regulated transcription coactivator 1	Mus musculus	17-23
27196780-8	2016	We conclude that mTORC1/2 inhibition is superior to mTORC1 inhibition in reversing platinum resistance in tumors and strongly impairs AKT activation, DNA repair responses, and translation, promoting improved survival in the background of platinum resistance.	Platinum	238-246	CREB regulated transcription coactivator 2	Mus musculus	17-25
27196780-8	2016	We conclude that mTORC1/2 inhibition is superior to mTORC1 inhibition in reversing platinum resistance in tumors and strongly impairs AKT activation, DNA repair responses, and translation, promoting improved survival in the background of platinum resistance.	Platinum	238-246	CREB regulated transcription coactivator 1	Mus musculus	17-23
27196780-8	2016	We conclude that mTORC1/2 inhibition is superior to mTORC1 inhibition in reversing platinum resistance in tumors and strongly impairs AKT activation, DNA repair responses, and translation, promoting improved survival in the background of platinum resistance.	Platinum	238-246	AKT serine/threonine kinase 1	Homo sapiens	134-137
27531263-0	2016	[Genetic variation in DNA repair gene RAD52 is associated with the response to platinum-based chemotherapy in SCLC patients].	Platinum	79-87	RAD52 homolog, DNA repair protein	Homo sapiens	38-43
27531263-1	2016	OBJECTIVE: To explore the associations between genetic variations of DNA repair gene RAD52 and response to platinum-based chemotherapy of small cell lung cancer (SCLC), and to analyze the influencing factors on survival.	Platinum	107-115	RAD52 homolog, DNA repair protein	Homo sapiens	85-90
27531263-15	2016	CONCLUSIONS: These results suggest that RAD52 genetic polymorphism rs10774474 plays an important role in the response to platinum-based chemotherapy, and may be a potential genetic biomarker for SCLC personalized treatment.	Platinum	121-129	RAD52 homolog, DNA repair protein	Homo sapiens	40-45
27112899-4	2016	We also find that cisplatin (Pt) accumulation correlates with LRRC8A protein expression and channel activity, i.e., the cellular Pt content is high when VSOAC is activated by depolarization of the plasma membrane or hypoosmotic cell swelling, and reduced when channel activity/LRRC8A expression is reduced by genetically silencing/pharmacological inhibition, or the cells have acquired a resistant phenotype with low LRRC8A protein expression.	Platinum	29-31	leucine rich repeat containing 8 VRAC subunit A	Homo sapiens	62-68
27112899-4	2016	We also find that cisplatin (Pt) accumulation correlates with LRRC8A protein expression and channel activity, i.e., the cellular Pt content is high when VSOAC is activated by depolarization of the plasma membrane or hypoosmotic cell swelling, and reduced when channel activity/LRRC8A expression is reduced by genetically silencing/pharmacological inhibition, or the cells have acquired a resistant phenotype with low LRRC8A protein expression.	Platinum	29-31	leucine rich repeat containing 8 VRAC subunit A	Homo sapiens	277-283
27112899-4	2016	We also find that cisplatin (Pt) accumulation correlates with LRRC8A protein expression and channel activity, i.e., the cellular Pt content is high when VSOAC is activated by depolarization of the plasma membrane or hypoosmotic cell swelling, and reduced when channel activity/LRRC8A expression is reduced by genetically silencing/pharmacological inhibition, or the cells have acquired a resistant phenotype with low LRRC8A protein expression.	Platinum	29-31	leucine rich repeat containing 8 VRAC subunit A	Homo sapiens	277-283
27196765-4	2016	Inhibition of mitotic kinase WEE1 was found to have the most effective response in combination with platinum compounds in lung cancer cell lines.	Platinum	100-108	WEE1 G2 checkpoint kinase	Homo sapiens	29-33
27196765-9	2016	In summary, PAXIP1 is involved in sensitizing lung cancer cells to the WEE1 inhibitor AZD1775 in combination with platinum-based treatment.	Platinum	114-122	PAX interacting protein 1	Homo sapiens	12-18
26964942-1	2016	In this study, we report on the potential use of platinum nanoparticles (Pt-NPs), a superoxide dismutase (SOD)/catalase mimetic antioxidant, in combination with 1MHz ultrasound (US) at an intensity of 0.4 W/cm(2), 10% duty factor, 100 Hz PRF, for 2 min.	Platinum	49-57	catalase	Homo sapiens	111-119
27356090-17	2016	MAIN RESULTS: Two studies, including 97 women, met our inclusion criteria: one assessed LHRH agonist (leuprorelin) use in relapsed (platinum-resistant and platinum-refractory) EOC in comparison with a chemotherapeutic agent (treosulfan) (Du Bois 2002); the other examined LHRH agonist (decapeptyl) versus a placebo (Currie 1994).	Platinum	132-140	gonadotropin releasing hormone 1	Homo sapiens	88-92
27351382-4	2016	A miR panel based on relevance for platinum sensitivity and UC was studied by quantitative reverse transcription quantitative PCR (RT-qPCR).	Platinum	35-43	membrane associated ring-CH-type finger 8	Homo sapiens	2-5
26763252-0	2016	Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.	Platinum	64-72	msh homeobox 1	Homo sapiens	43-47
27147577-3	2016	We retrospectively analyzed expression of excision repair cross-complementing group-1 (ERCC1) - involved in the repair of platinum induced damage - in patients affected by mPC treated with FOLFIRINOX in order to evaluate its predictive role.	Platinum	122-130	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	42-85
27366083-0	2016	The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer.	Platinum	56-64	BRCA1 DNA repair associated	Homo sapiens	28-33
27366083-0	2016	The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer.	Platinum	56-64	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	18-23
27276062-8	2016	Overall, based on the strength of further analysis, CD24 presents a strong rationale to be utilized as a predictive indicator to stratify head and neck cancer patients for platinum-based therapy.	Platinum	172-180	CD24 molecule	Homo sapiens	52-56
27147577-3	2016	We retrospectively analyzed expression of excision repair cross-complementing group-1 (ERCC1) - involved in the repair of platinum induced damage - in patients affected by mPC treated with FOLFIRINOX in order to evaluate its predictive role.	Platinum	122-130	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	87-92
27172134-1	2016	The substituted imidazolate-based MOF (SIM-1) easily forms a homogeneous layer at the surface of millimetric platinum-loaded alumina beads.	Platinum	109-117	lysine acetyltransferase 8	Homo sapiens	34-37
26706102-6	2016	The research presenting a prospective concept for targeted therapy anticancer drug design, and with the analysis of the synthesis, water solubility, antitumor activity, and the transportability of the platinum(II) glycoconjugates, this study provides fundamental data supporting the inherent potential of these designed conjugates as lead compounds for GLUT-mediated tumor targeting.	Platinum	201-209	solute carrier family 2 member 1	Homo sapiens	353-357
26862009-0	2016	Impact of UGT1A1 genotype upon toxicities of combination with low-dose irinotecan plus platinum.	Platinum	87-95	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	10-16
26862009-2	2016	However, the correlation between UGT1A1 polymorphisms and the risk of toxicities induced by low-dose irinotecan plus platinum combination therapy still remains controversial.	Platinum	117-125	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	33-39
26862009-11	2016	UGT1A1 genotypes are useful biomarkers for predicting severe hematological toxicities in patients treated with irinotecan plus platinum analog.	Platinum	127-135	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	0-6
25131817-0	2016	Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.	Platinum	128-136	prostaglandin-endoperoxide synthase 2	Homo sapiens	20-36
25131817-2	2016	The aim of this study is to investigate the association between COX-2 polymorphisms and clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy.	Platinum	186-194	prostaglandin-endoperoxide synthase 2	Homo sapiens	64-69
27100737-1	2016	PURPOSE: This meta-analysis aimed to evaluate whether an association exists between the ERCC1 rs11615 (C&gt;T) polymorphism and patient response to platinum-based chemotherapy and radiation-based chemotherapy.	Platinum	148-156	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	88-93
27100737-5	2016	In the subgroup analyses by ethnicity, the ERCC1 rs11615 (C&gt;T) polymorphism was shown to be significantly associated with objective response in Caucasian patients treated with platinum-based chemotherapy in the recessive model (TT vs. CT/CC: OR 0.696, 95 % CI 0.508-0.954, heterogeneity = 0.330), but the association was not observed in the Asian population.	Platinum	179-187	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	43-48
27060747-3	2016	Despite multiple clinical trials in SCLC, platinum-based chemotherapy remains the mainstay of treatment in the first line advanced disease setting; good initial responses are nevertheless inevitably followed by disease relapse and survival ultimately remains poor.	Platinum	42-50	SCLC1	Homo sapiens	36-40
27478321-1	2016	OBJECTIVE: The aim of this study is to identify the prognostic significance of X-ray cross-complementing gene 1 (XRCC1) in patients with gastric cancer undergoing surgery and platinum-based adjuvant chemotherapy.	Platinum	175-183	X-ray repair cross complementing 1	Homo sapiens	79-111
27478321-1	2016	OBJECTIVE: The aim of this study is to identify the prognostic significance of X-ray cross-complementing gene 1 (XRCC1) in patients with gastric cancer undergoing surgery and platinum-based adjuvant chemotherapy.	Platinum	175-183	X-ray repair cross complementing 1	Homo sapiens	113-118
27478321-7	2016	And the patients with negative XRCC1 expression benefited more from platinum-based adjuvant chemotherapy (P = 0.049).	Platinum	68-76	X-ray repair cross complementing 1	Homo sapiens	31-36
27478321-11	2016	The patients with negative XRCC1 expression can benefit more from platinum-based adjuvant chemotherapy.	Platinum	66-74	X-ray repair cross complementing 1	Homo sapiens	27-32
27087632-4	2016	Rucaparib received US FDA Breakthrough Therapy designation for treatment of platinum-sensitive BRCA-mutated advanced ovarian cancer patients who received greater than two lines of platinum-based therapy.	Platinum	76-84	BRCA1 DNA repair associated	Homo sapiens	95-99
26724258-0	2016	Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.	Platinum	35-43	BRCA2 DNA repair associated	Homo sapiens	26-31
26724258-6	2016	Biallelic BRCA2 inactivation in mCRPC warrants further exploration as a predictive biomarker for sensitivity to platinum chemotherapy.	Platinum	112-120	BRCA2 DNA repair associated	Homo sapiens	10-15
27100483-6	2016	In contrast, knockdown of ANXA4 increased susceptibility to platinum in ovarian cancer and malignant mesothelioma cells.	Platinum	60-68	annexin A4	Homo sapiens	26-31
27306810-3	2016	METHODS: Consecutive patients with advanced/recurrent non-small cell lung cancer (NSCLC)harboring activating EGFR mutations were treated with platinum combined with PEM at our institute.	Platinum	142-150	epidermal growth factor receptor	Homo sapiens	109-113
27240366-0	2016	A Micro-Platinum Wire Biosensor for Fast and Selective Detection of Alanine Aminotransferase.	Platinum	8-16	glutamic--pyruvic transaminase	Homo sapiens	68-92
27108527-3	2016	Similar tendency was observed in platinum treated patients, suggesting an IL-6 associated cisplatin resistance.	Platinum	33-41	interleukin 6	Homo sapiens	74-78
26729200-9	2016	CCAT2 rs6983267, H19 rs2839698, MALAT1 rs619586, and HOTAIR rs7958904 were associated with platinum-based chemotherapy response in dominant model ((P = 0.02, P = 0.04, P = 0.04, P = 0.01, respectively).	Platinum	91-99	colon cancer associated transcript 2	Homo sapiens	0-5
26729200-9	2016	CCAT2 rs6983267, H19 rs2839698, MALAT1 rs619586, and HOTAIR rs7958904 were associated with platinum-based chemotherapy response in dominant model ((P = 0.02, P = 0.04, P = 0.04, P = 0.01, respectively).	Platinum	91-99	H19 imprinted maternally expressed transcript	Homo sapiens	17-20
26729200-9	2016	CCAT2 rs6983267, H19 rs2839698, MALAT1 rs619586, and HOTAIR rs7958904 were associated with platinum-based chemotherapy response in dominant model ((P = 0.02, P = 0.04, P = 0.04, P = 0.01, respectively).	Platinum	91-99	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	32-38
26729200-9	2016	CCAT2 rs6983267, H19 rs2839698, MALAT1 rs619586, and HOTAIR rs7958904 were associated with platinum-based chemotherapy response in dominant model ((P = 0.02, P = 0.04, P = 0.04, P = 0.01, respectively).	Platinum	91-99	HOX transcript antisense RNA	Homo sapiens	53-59
26729200-10	2016	ANRIL rs10120688 (P = 0.02, adenocarcinoma) and rs1333049 (P = 0.04, small-cell lung cancer), H19 rs2107425 (P = 0.02, small-cell lung cancer) and HOTAIR rs1899663 (P = 0.03, male; P = 0.03, smoker) were associated with response to platinum-based chemotherapy.	Platinum	232-240	CDKN2B antisense RNA 1	Homo sapiens	0-5
26729200-11	2016	HOTTIP, CCAT2, H19, HOTAIR, MALATI, ANRIL genetic polymorphisms were significantly associated with lung cancer susceptibility or platinum-based chemotherapy response.	Platinum	129-137	HOXA distal transcript antisense RNA	Homo sapiens	0-6
27249003-0	2016	Clinical Significance of Long Non-Coding RNA CASC8 rs10505477 Polymorphism in Lung Cancer Susceptibility, Platinum-Based Chemotherapy Response, and Toxicity.	Platinum	106-114	cancer susceptibility 8	Homo sapiens	45-50
27249003-1	2016	Long non-coding RNA (lncRNA) CASC8 rs10505477 polymorphism has been identified to be related to risk of many kinds of cancers, such as colorectal cancer, gastric cancer, and invasive ovarian cancer, and it may be involved in the prognosis of gastric cancer patients who have received platinum-based chemotherapy after surgical treatment.	Platinum	284-292	cancer susceptibility 8	Homo sapiens	29-34
27249003-9	2016	Thus, lncRNA CASC8 rs10505477 could serve as a possible risk marker for diagnosing lung cancer, and could be used to forecast the response and toxicity of platinum-based treatment in lung cancer patients.	Platinum	155-163	cancer susceptibility 8	Homo sapiens	13-18
27114072-1	2016	The reaction of Fe(eta-C5H4NHC(O)PPh2)2 () with PtX2(PPh3)2 selectively formed cage-shaped complexes formulated as [(PtX)4()6]X4 CHCl3 (X = Cl, Br), in which the four square-planar Pt fragments were situated at each vertex and the six s were located in each side of a tetrahedral framework and hydrogen bonds existed between the NH groups in s and X(-) ions inside the cage.	Platinum	48-50	endothelin receptor type A	Homo sapiens	19-22
27114072-1	2016	The reaction of Fe(eta-C5H4NHC(O)PPh2)2 () with PtX2(PPh3)2 selectively formed cage-shaped complexes formulated as [(PtX)4()6]X4 CHCl3 (X = Cl, Br), in which the four square-planar Pt fragments were situated at each vertex and the six s were located in each side of a tetrahedral framework and hydrogen bonds existed between the NH groups in s and X(-) ions inside the cage.	Platinum	48-50	protein phosphatase 4 catalytic subunit	Homo sapiens	53-57
26695147-0	2016	PTEN polymorphisms contribute to clinical outcomes of advanced lung adenocarcinoma patients treated with platinum-based chemotherapy.	Platinum	105-113	phosphatase and tensin homolog	Homo sapiens	0-4
26695147-1	2016	This study aimed to elucidate the impact of PTEN single nucleotide polymorphism (SNP) on clinical outcomes for advanced lung adenocarcinoma (LAC) patients treated with platinum-based chemotherapy.	Platinum	168-176	phosphatase and tensin homolog	Homo sapiens	44-48
26695147-7	2016	Taken together, PTEN polymorphisms may contribute to survival and chemotherapy efficacy of advanced LAC patients treated with platinum-based agents.	Platinum	126-134	phosphatase and tensin homolog	Homo sapiens	16-20
27313464-3	2016	Nivolumab is the first PD-1 inhibitor approved for the treatment of advanced-stage squamous cell non-small-cell lung cancer following platinum-based chemotherapy.	Platinum	134-142	programmed cell death 1	Homo sapiens	23-27
27323074-0	2016	ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer.	Platinum	50-58	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
27323074-1	2016	This study aims to investigate the association between ERCC1 codon C118T polymorphism and the response rate of platinum-based chemotherapy in patients with late-stage bladder cancer.	Platinum	111-119	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	55-60
27149014-4	2016	The decrease of the spin-crossover temperature of {Fe(pz)[Pt(CN)4]} upon water adsorption predicted by the simulations is in agreement with the available experimental data and is traced back to the elongation of the bonds between the Fe(II) atoms and the organic linkers induced by interactions of the adsorbed water molecules with the framework.	Platinum	58-60	spindlin 1	Homo sapiens	20-24
27209210-0	2016	Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.	Platinum	36-44	aurora kinase A	Homo sapiens	0-15
27209210-5	2016	In this retrospective study, an immunohistochemical evaluation of Aurora Kinase A (AURKA) was performed on 41 cases of HGSOC according to platinum-status.	Platinum	138-146	aurora kinase A	Homo sapiens	66-81
27209210-5	2016	In this retrospective study, an immunohistochemical evaluation of Aurora Kinase A (AURKA) was performed on 41 cases of HGSOC according to platinum-status.	Platinum	138-146	aurora kinase A	Homo sapiens	83-88
27209210-6	2016	Taking into account the number and intensity of AURKA positive cells we built a predictive score able to discriminate with high accuracy platinum-sensitive patients from platinum-resistant patients (p &lt; 0.001).	Platinum	137-145	aurora kinase A	Homo sapiens	48-53
27209210-6	2016	Taking into account the number and intensity of AURKA positive cells we built a predictive score able to discriminate with high accuracy platinum-sensitive patients from platinum-resistant patients (p &lt; 0.001).	Platinum	170-178	aurora kinase A	Homo sapiens	48-53
27209210-9	2016	Particularly, our results indicate that AURKA has a role both as predictor of platinum-resistance and as prognostic factor, that deserves further investigation in prospective clinical trials.	Platinum	78-86	aurora kinase A	Homo sapiens	40-45
27128813-3	2016	When paired with a platinum wire counter electrode and an Ag/AgCl reference electrode these sensitized films exhibited photocurrent densities on the order of 350 nA/cm(2) under 0 V applied bias conditions versus a normal hydrogen electrode (NHE) and 75 mW/cm(2) illumination at a wavelength of 445 nm.	Platinum	19-27	solute carrier family 9 member C1	Homo sapiens	241-244
27135196-0	2016	Methyl 6-Amino-6-deoxy-d-pyranoside-Conjugated Platinum(II) Complexes for Glucose Transporter (GLUT)-Mediated Tumor Targeting: Synthesis, Cytotoxicity, and Cellular Uptake Mechanism.	Platinum	47-55	solute carrier family 2 member 1	Homo sapiens	74-93
27135196-0	2016	Methyl 6-Amino-6-deoxy-d-pyranoside-Conjugated Platinum(II) Complexes for Glucose Transporter (GLUT)-Mediated Tumor Targeting: Synthesis, Cytotoxicity, and Cellular Uptake Mechanism.	Platinum	47-55	solute carrier family 2 member 1	Homo sapiens	95-99
26671993-2	2016	We hypothesized that decreased expression of SMARCA4/BRG1, a known regulator of transcription and DNA repair, is a novel predictive biomarker of increased sensitivity to adjuvant platinum-based therapies in non-small cell lung cancer (NSCLC).	Platinum	179-187	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Homo sapiens	45-52
26716514-2	2016	To identify novel target genes the modulation of which could modify platinum resistance, we performed a high-throughput RNAi screen and identified Yes-associated protein (YAP1), a transcription coactivator and a known oncogene, as a potential actionable candidate.	Platinum	68-76	Yes1 associated transcriptional regulator	Homo sapiens	171-175
26716514-8	2016	Taken together, our study is the first to indicate the potential role of YAP1 as a common modulator of resistance mechanisms and a potential novel, actionable target that can improve responses to platinum, radiation and EGFR-targeted therapy in lung cancer.	Platinum	196-204	Yes1 associated transcriptional regulator	Homo sapiens	73-77
26671993-11	2016	CONCLUSIONS: Low expression of SMARCA4/BRG1 is significantly associated with worse prognosis; however, it is a novel significant predictive biomarker for increased sensitivity to platinum-based chemotherapy in NSCLC.	Platinum	179-187	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Homo sapiens	31-38
26671993-11	2016	CONCLUSIONS: Low expression of SMARCA4/BRG1 is significantly associated with worse prognosis; however, it is a novel significant predictive biomarker for increased sensitivity to platinum-based chemotherapy in NSCLC.	Platinum	179-187	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Homo sapiens	39-43
26671993-2	2016	We hypothesized that decreased expression of SMARCA4/BRG1, a known regulator of transcription and DNA repair, is a novel predictive biomarker of increased sensitivity to adjuvant platinum-based therapies in non-small cell lung cancer (NSCLC).	Platinum	179-187	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Homo sapiens	53-57
26993769-0	2016	Genetic variants of GADD45A, GADD45B and MAPK14 predict platinum-based chemotherapy-induced toxicities in Chinese patients with non-small cell lung cancer.	Platinum	56-64	growth arrest and DNA damage inducible alpha	Homo sapiens	20-27
27179933-9	2016	Moreover, APR-246 sensitized TP53 mutant primary ovarian cancer cells, isolated from a clinically platinum-resistant patient, to cisplatin; the IC50 value of cisplatin decreased 3.6 fold from 6.5 to 1.8 muM in the presence of clinically relevant concentration of APR-246.	Platinum	98-106	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	10-13
27179511-1	2016	BACKGROUND: BRCA1 is a main component of homologous recombination and induces resistance to platinum in preclinical models.	Platinum	92-100	BRCA1 DNA repair associated	Homo sapiens	12-17
26993769-0	2016	Genetic variants of GADD45A, GADD45B and MAPK14 predict platinum-based chemotherapy-induced toxicities in Chinese patients with non-small cell lung cancer.	Platinum	56-64	growth arrest and DNA damage inducible beta	Homo sapiens	29-36
26993769-0	2016	Genetic variants of GADD45A, GADD45B and MAPK14 predict platinum-based chemotherapy-induced toxicities in Chinese patients with non-small cell lung cancer.	Platinum	56-64	mitogen-activated protein kinase 14	Homo sapiens	41-47
27072580-4	2016	An immunohistochemical study revealed that a high expression level of MMP10 is a marker for poor prognosis and platinum resistance in multivariate analysis.	Platinum	111-119	matrix metallopeptidase 10	Homo sapiens	70-75
26993769-1	2016	The JNK and P38alpha pathways play a crucial role in tissue homeostasis, apoptosis and autophagy under genotoxic stresses, but it is unclear whether single nucleotide polymorphisms (SNPs) of genes in these pathways play a role in platinum-based chemotherapy-induced toxicities in patients with advanced non-small cell lung cancer (NSCLC).	Platinum	230-238	mitogen-activated protein kinase 8	Homo sapiens	4-7
27049921-4	2016	High miR-520g expression promoted tumor progression and chemoresistance to platinum-based chemotherapy, and reduced survival in EOC patients.	Platinum	75-83	microRNA 520g	Homo sapiens	5-13
26993769-1	2016	The JNK and P38alpha pathways play a crucial role in tissue homeostasis, apoptosis and autophagy under genotoxic stresses, but it is unclear whether single nucleotide polymorphisms (SNPs) of genes in these pathways play a role in platinum-based chemotherapy-induced toxicities in patients with advanced non-small cell lung cancer (NSCLC).	Platinum	230-238	mitogen-activated protein kinase 14	Homo sapiens	12-20
26993769-2	2016	We genotyped 11 selected, independent, potentially functional SNPs of nine genes in the JNK and P38alpha pathways in 689 patients with advanced NSCLC treated with platinum-combination chemotherapy regimens.	Platinum	163-171	mitogen-activated protein kinase 8	Homo sapiens	88-91
26993769-2	2016	We genotyped 11 selected, independent, potentially functional SNPs of nine genes in the JNK and P38alpha pathways in 689 patients with advanced NSCLC treated with platinum-combination chemotherapy regimens.	Platinum	163-171	mitogen-activated protein kinase 14	Homo sapiens	96-104
26993769-6	2016	The present study provides evidence that genetic variants in genes involved in the JNK and P38alpha pathways may predict platinum-based chemotherapy toxicity outcomes in patients with advanced NSCLC.	Platinum	121-129	mitogen-activated protein kinase 8	Homo sapiens	83-86
26993769-6	2016	The present study provides evidence that genetic variants in genes involved in the JNK and P38alpha pathways may predict platinum-based chemotherapy toxicity outcomes in patients with advanced NSCLC.	Platinum	121-129	mitogen-activated protein kinase 14	Homo sapiens	91-99
27197267-1	2016	Breast and ovarian cancer patients harboring BRCA1/2 germline mutations have clinically benefitted from therapy with PARP inhibitor (PARPi) or platinum compounds, but acquired resistance limits clinical impact.	Platinum	143-151	BRCA1 DNA repair associated	Homo sapiens	45-52
27127105-5	2016	More research is needed to assesses whether inhibitors of PARP have any role as maintenance treatment after first-line chemotherapy and as palliative treatment of platinum-resistant disease.	Platinum	163-171	poly(ADP-ribose) polymerase 1	Homo sapiens	58-62
26964893-5	2016	These signatures predict platinum-sensitivity and survival in EOC, as it was previously shown for germline mutations of BRCA1/BRCA2.	Platinum	25-33	BRCA1 DNA repair associated	Homo sapiens	120-125
26964893-5	2016	These signatures predict platinum-sensitivity and survival in EOC, as it was previously shown for germline mutations of BRCA1/BRCA2.	Platinum	25-33	BRCA2 DNA repair associated	Homo sapiens	126-131
27249597-7	2016	For platinum-sensitive EOC patients, positive expression of Beclin1 and BRCA1 was lower, and positive P62 expression was higher than in platinum-resistant patients (p&lt;0.05).	Platinum	4-12	beclin 1	Homo sapiens	60-67
26984416-2	2016	Demonstration of anti-cancer activity has led to the European Medicines Agency (EMA) approval of the PARP inhibitor (PARPi) olaparib as maintenance therapy in women with BRCA-mutated (BRCAm) ovarian cancer with platinum-sensitive recurrence following response to platinum therapy and the US Food and Drug Administration (US FDA) approval of olaparib in relapsed germline BRCA-mutated (gBRCAm) ovarian cancer in women who have received at least three prior chemotherapy treatments, both occurring in 2014.	Platinum	211-219	poly(ADP-ribose) polymerase 1	Homo sapiens	101-105
26984416-2	2016	Demonstration of anti-cancer activity has led to the European Medicines Agency (EMA) approval of the PARP inhibitor (PARPi) olaparib as maintenance therapy in women with BRCA-mutated (BRCAm) ovarian cancer with platinum-sensitive recurrence following response to platinum therapy and the US Food and Drug Administration (US FDA) approval of olaparib in relapsed germline BRCA-mutated (gBRCAm) ovarian cancer in women who have received at least three prior chemotherapy treatments, both occurring in 2014.	Platinum	263-271	poly(ADP-ribose) polymerase 1	Homo sapiens	101-105
26803611-0	2016	Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile.	Platinum	74-82	glutathione S-transferase kappa 1	Homo sapiens	121-124
26803611-2	2016	This heterogeneous response might result from inter-individual variations in the platinum-detoxification pathway due to the expression of glutathione-S-transferase (GST) enzymes.	Platinum	81-89	glutathione S-transferase kappa 1	Homo sapiens	138-163
26803611-2	2016	This heterogeneous response might result from inter-individual variations in the platinum-detoxification pathway due to the expression of glutathione-S-transferase (GST) enzymes.	Platinum	81-89	glutathione S-transferase kappa 1	Homo sapiens	165-168
26803611-7	2016	Multivariate Cox regression analysis indicates that the inclusion of genetic information regarding GSTM1 polymorphism increased the predictive ability of risk of death after OC platinum-based chemotherapy (c-index from 0.712 to 0.833).	Platinum	177-185	cytochrome c oxidase subunit 8A	Homo sapiens	13-16
26803611-7	2016	Multivariate Cox regression analysis indicates that the inclusion of genetic information regarding GSTM1 polymorphism increased the predictive ability of risk of death after OC platinum-based chemotherapy (c-index from 0.712 to 0.833).	Platinum	177-185	glutathione S-transferase mu 1	Homo sapiens	99-104
26803611-10	2016	CONCLUSION: GSTM1 polymorphism seems to have an impact in OC prognosis as it predicts a better response to platinum-based chemotherapy and hence an improved survival.	Platinum	107-115	glutathione S-transferase mu 1	Homo sapiens	12-17
27249597-7	2016	For platinum-sensitive EOC patients, positive expression of Beclin1 and BRCA1 was lower, and positive P62 expression was higher than in platinum-resistant patients (p&lt;0.05).	Platinum	4-12	BRCA1 DNA repair associated	Homo sapiens	72-77
27249597-9	2016	CONCLUSIONS: Inhibition of expression of beclin1 may suppress autophagy to enhance the efficiency of platinum-sensitive ovarian cancer.	Platinum	101-109	beclin 1	Homo sapiens	41-48
27239233-11	2016	CONCLUSIONS: Gemcitabine plus S-1 offers a satisfactory clinical activity and an acceptable safety profile for recurrent and metastatic NPC patients after failure of platinum-based chemotherapy.	Platinum	166-174	proteasome 26S subunit, non-ATPase 1	Homo sapiens	30-33
26649489-1	2016	In this work, a nanohybrid of platinum nanoparticles-porous ZnO spheres-hemin (Pt-pZnO-hemin) was synthesized for construction of alkaline phosphatase-based immunosensor for detection of influenza.	Platinum	30-38	alkaline phosphatase, placental	Homo sapiens	130-150
27239233-0	2016	Phase II study of gemcitabine plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy.	Platinum	131-139	proteasome 26S subunit, non-ATPase 1	Homo sapiens	35-38
27330954-2	2016	This report presents the case of a 71-year-old Asian female never smoker with EGFR mutated T790M negative non squamous cell lung cancer (NSCLC) pre-treated with the experimental epi-immunotherapeutic agent, RRx-001, that re-responded to single agent carboplatin after failure of platinum doublets, TKIs, pemetrexed and nivolumab.	Platinum	279-287	epidermal growth factor receptor	Homo sapiens	78-82
26619847-13	2016	In subgroup analysis, a significant improvement of CR by the addition of anti-VEGF/VEGFR drugs was observed in patients with colorectal cancer (RR, 2.10, 95 % CI 1.21-3.63, P = 0.008), ovarian cancer (RR, 3.07; 95 % CI, 1.68-5.62, P = 0.000), and patients who are treated with platinum-based regimens (RR, 1.78, 95 % CI, 1.23-2.59, P = 0.002).	Platinum	277-285	vascular endothelial growth factor A	Homo sapiens	78-82
26619847-13	2016	In subgroup analysis, a significant improvement of CR by the addition of anti-VEGF/VEGFR drugs was observed in patients with colorectal cancer (RR, 2.10, 95 % CI 1.21-3.63, P = 0.008), ovarian cancer (RR, 3.07; 95 % CI, 1.68-5.62, P = 0.000), and patients who are treated with platinum-based regimens (RR, 1.78, 95 % CI, 1.23-2.59, P = 0.002).	Platinum	277-285	kinase insert domain receptor	Homo sapiens	83-88
27313779-5	2016	Platinum increased p53 in a dose-dependent and time-dependent manner.	Platinum	0-8	tumor protein p53	Homo sapiens	19-22
27313779-8	2016	Knockdown of p53 significantly decreased sensitivity to platinum in 3D cultures.	Platinum	56-64	tumor protein p53	Homo sapiens	13-16
27313779-13	2016	Taken together, our results suggest that p53 is involved in a 3D architecture-mediated decrease in chemosensitivity to platinum in colon cancer.	Platinum	119-127	tumor protein p53	Homo sapiens	41-44
27071465-2	2016	Using the prepared N-PGR as the supporting material, a novel nitrogen doped porous graphene/Pt nanoflower material (Pt/N-PGR) was obtained by a green and simple method.	Platinum	92-94	progesterone receptor	Homo sapiens	21-24
27071465-2	2016	Using the prepared N-PGR as the supporting material, a novel nitrogen doped porous graphene/Pt nanoflower material (Pt/N-PGR) was obtained by a green and simple method.	Platinum	92-94	progesterone receptor	Homo sapiens	121-124
27071465-7	2016	The superior catalytic activity and selectivity make Pt/N-PGR a promising nanomaterial for application in electrochemical biosensing studies.	Platinum	53-56	progesterone receptor	Homo sapiens	58-61
27098511-8	2016	We also found that high expression of KIAA1522 is a significant risk factor for decreased overall survival of the patients who received platinum-based chemotherapy.	Platinum	136-144	KIAA1522	Homo sapiens	38-46
27098511-10	2016	Taken together, high expression of KIAA1522 can be used as an independent biomarker for predication of poor survival and platinum-resistance of NSCLC patients, and aberrant KIAA1522 might be a new target for the therapy of the disease.	Platinum	121-129	KIAA1522	Homo sapiens	35-43
26977772-6	2016	Reaction of 2 with CS2 affords the crystalline complex 4, in which the PPtP framework is bent, the CS2 molecule is eta(2)-coordinated to Pt, and one S atom interacts with Al.	Platinum	72-74	chorionic somatomammotropin hormone 2	Homo sapiens	19-22
26902386-2	2016	We demonstrate that it enables the fabrication of homogeneous Janus MOF particles according to the MOF (ZIF-8, UiO-66 or UiO-66-SH), the metal (Au, Co or Pt), the MOF particle size (from the micrometer to the submicrometer regime) and the metal-film thickness (from 5 nm to 50 nm) employed.	Platinum	154-156	lysine acetyltransferase 8	Homo sapiens	68-71
26724920-5	2016	The laser-induced dissociation of the monoadduct obtained in MALDI source was carried out and one platinum was found to bind to insulin B chain was determined.	Platinum	98-106	insulin	Homo sapiens	128-135
26938929-0	2016	Platinum-Containing Polyoxometalates: syn- and anti-[Pt(II)2(alpha-PW11O39)2](10-) and Formation of the Metal-Metal-Bonded di-Pt(III) Derivatives.	Platinum	0-8	synemin	Homo sapiens	38-41
27016235-9	2016	All patients (42.7%) who are platinum-sensitive had HR germline mutations (RAD50, NBN, ATM).	Platinum	29-37	RAD50 double strand break repair protein	Homo sapiens	75-80
26810463-4	2016	Therefore, we have used a biodegradable polymer carrier to conjugate with DACH-Pt and dichloroacetate, a PDK inhibitor that can reverse the Warburg effect and derepress the resistance to apoptosis, thus sensitizing cancer cells to platinum.	Platinum	231-239	dachshund family transcription factor 1	Homo sapiens	74-78
26961971-5	2016	My practice pattern for patients with EGFR wild-type NSCLC is platinum-based chemotherapy as first-line therapy, immunotherapy as second-line therapy, and single-agent chemotherapy as third-line therapy for patients with preserved performance status who want to pursue further therapy.	Platinum	62-70	epidermal growth factor receptor	Homo sapiens	38-42
27069172-0	2016	Dynamic Analysis of CA125 Decline During Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer as a Predictor for Platinum Sensitivity.	Platinum	128-136	mucin 16, cell surface associated	Homo sapiens	20-25
27069172-1	2016	AIM: Our objective was to evaluate the kinetic parameters of serum CA125 during neoadjuvant platinum-based chemotherapy (NAC), in patients with epithelial ovarian cancer, in order to identify a surrogate marker of sensitivity to platinum.	Platinum	92-100	mucin 16, cell surface associated	Homo sapiens	67-72
27069172-1	2016	AIM: Our objective was to evaluate the kinetic parameters of serum CA125 during neoadjuvant platinum-based chemotherapy (NAC), in patients with epithelial ovarian cancer, in order to identify a surrogate marker of sensitivity to platinum.	Platinum	229-237	mucin 16, cell surface associated	Homo sapiens	67-72
27069172-7	2016	CONCLUSION: A CA125 level after the 3rd NAC &lt;35 UI/ml is an independent predictor for tumor platinum-sensitivity.	Platinum	95-103	mucin 16, cell surface associated	Homo sapiens	14-19
26816351-0	2016	ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.	Platinum	121-129	ATP binding cassette subfamily C member 2	Homo sapiens	0-5
26816351-1	2016	BACKGROUND: The drug transporter ABCC2 is upregulated in non-small cell lung cancer (NSCLC) and implicated in platinum resistance.	Platinum	110-118	ATP binding cassette subfamily C member 2	Homo sapiens	33-38
26816351-2	2016	We evaluated the association between germline polymorphisms in the ABCC2 gene and survival outcomes of platinum-treated advanced NSCLC patients.	Platinum	103-111	ATP binding cassette subfamily C member 2	Homo sapiens	67-72
26816351-3	2016	MATERIAL AND METHODS: Ten candidate and tagging germline polymorphisms in the ABCC2 gene were genotyped in a discovery cohort of 170 platinum-treated stage IV NSCLC patients from the Princess Margaret Cancer Centre.	Platinum	133-141	ATP binding cassette subfamily C member 2	Homo sapiens	78-83
26816351-9	2016	CONCLUSION: The ABCC2 polymorphism, rs8187710 (4544G&gt;A), is associated with overall survival in platinum-treated advanced NSCLC patients.	Platinum	99-107	ATP binding cassette subfamily C member 2	Homo sapiens	16-21
27016235-9	2016	All patients (42.7%) who are platinum-sensitive had HR germline mutations (RAD50, NBN, ATM).	Platinum	29-37	nibrin	Homo sapiens	82-85
27016235-9	2016	All patients (42.7%) who are platinum-sensitive had HR germline mutations (RAD50, NBN, ATM).	Platinum	29-37	ATM serine/threonine kinase	Homo sapiens	87-90
27016235-10	2016	Patients with HER2 overexpression (2/7, 28.6%) had germline HR mutations and were platinum-sensitive.	Platinum	82-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-18
26979124-3	2016	MATERIALS &amp; METHODS: Functionalized (PEG or IgG) carbon-encapsulated platinum-spiked iron carbide nanoparticles were injected intravenously in mice (single or repeated dose administration).	Platinum	73-81	immunoglobulin heavy chain (V7183 family)	Mus musculus	41-51
26939044-10	2016	The findings described here form a milestone in discovering novel inhibitors for the NER pathway aiming at improving the efficacy of current platinum-based therapy, by modulating the XPA-ERCC1 interaction.	Platinum	141-149	XPA, DNA damage recognition and repair factor	Homo sapiens	183-186
26939044-10	2016	The findings described here form a milestone in discovering novel inhibitors for the NER pathway aiming at improving the efficacy of current platinum-based therapy, by modulating the XPA-ERCC1 interaction.	Platinum	141-149	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	187-192
26856458-0	2016	Aneurysm Organization Effects of Gellan Sulfate Core Platinum Coil with Tenascin-C in a Simulated Clinical Setting and the Possible Mechanism.	Platinum	53-61	tenascin	Oryctolagus cuniculus	72-82
26856458-1	2016	BACKGROUND: This study aimed to deliver gellan sulfate core platinum coil with tenascin-C (GSCC-TNC) into rabbit side-wall aneurysms endovascularly and to evaluate the organization effects in a simulated clinical setting.	Platinum	60-68	coilin	Oryctolagus cuniculus	69-73
26856458-1	2016	BACKGROUND: This study aimed to deliver gellan sulfate core platinum coil with tenascin-C (GSCC-TNC) into rabbit side-wall aneurysms endovascularly and to evaluate the organization effects in a simulated clinical setting.	Platinum	60-68	tenascin	Oryctolagus cuniculus	79-89
26856458-1	2016	BACKGROUND: This study aimed to deliver gellan sulfate core platinum coil with tenascin-C (GSCC-TNC) into rabbit side-wall aneurysms endovascularly and to evaluate the organization effects in a simulated clinical setting.	Platinum	60-68	tenascin	Oryctolagus cuniculus	96-99
26828315-6	2016	With the aid of two prototype systems, in which the molecules are contacted by either Ag or Pt electrodes, we find two different possible origins for conductance saturation.	Platinum	92-94	activation induced cytidine deaminase	Homo sapiens	9-12
27073511-1	2016	The effects of platinum-based drugs are controlled by genes that are involved in DNA detoxification, including glutathione S-transferase (GST)P1 and GSTM1, which have been associated with increased benefits in the chemotherapeutic treatment of patients with ovarian cancer.	Platinum	15-23	glutathione S-transferase kappa 1	Homo sapiens	111-136
27073511-1	2016	The effects of platinum-based drugs are controlled by genes that are involved in DNA detoxification, including glutathione S-transferase (GST)P1 and GSTM1, which have been associated with increased benefits in the chemotherapeutic treatment of patients with ovarian cancer.	Platinum	15-23	glutathione S-transferase pi 1	Homo sapiens	138-144
27073578-0	2016	Association of single nucleotide polymorphisms in the MVP gene with platinum resistance and survival in patients with epithelial ovarian cancer.	Platinum	68-76	major vault protein	Homo sapiens	54-57
27073578-2	2016	The aim of the present study was to investigate the association between single nucleotide polymorphisms (SNPs) in the MVP gene and the tumor response to platinum-based chemotherapy and survival of patients affected by epithelial ovarian cancer (EOC), in addition to confirm whether tetra-primer amplification-refractory mutation system (ARMS)-polymerase chain reaction (PCR) is an accurate genotyping method.	Platinum	153-161	major vault protein	Homo sapiens	118-121
27073511-1	2016	The effects of platinum-based drugs are controlled by genes that are involved in DNA detoxification, including glutathione S-transferase (GST)P1 and GSTM1, which have been associated with increased benefits in the chemotherapeutic treatment of patients with ovarian cancer.	Platinum	15-23	glutathione S-transferase mu 1	Homo sapiens	149-154
26513282-0	2016	Detection of prostate specific antigen based on electrocatalytic platinum nanoparticles conjugated to a recombinant scFv antibody.	Platinum	65-73	kallikrein related peptidase 3	Homo sapiens	13-38
32263178-2	2016	To this, 6-azide-6-deoxy-beta-cyclodextrin (N3-beta-CD) was clicked creating a hosting environment for a hydrophobic small molecule platinum pro-drug.	Platinum	132-140	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	47-54
27058088-0	2016	Spin Torque Study of the Spin Hall Conductivity and Spin Diffusion Length in Platinum Thin Films with Varying Resistivity.	Platinum	77-85	spindlin 1	Homo sapiens	0-4
27058088-0	2016	Spin Torque Study of the Spin Hall Conductivity and Spin Diffusion Length in Platinum Thin Films with Varying Resistivity.	Platinum	77-85	spindlin 1	Homo sapiens	25-29
27058088-0	2016	Spin Torque Study of the Spin Hall Conductivity and Spin Diffusion Length in Platinum Thin Films with Varying Resistivity.	Platinum	77-85	spindlin 1	Homo sapiens	25-29
26870872-5	2016	The latter species are likely to be involved as intermediates in the platinum-mediated large-scale production of HCN from CH4/NH3 (the DEGUSSA process).	Platinum	69-77	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	113-116
27033785-0	2016	[Effect of polymorphisms of NF-kappaB and PXR on platinum-based chemotherapy for non-small cell lung cancer].	Platinum	49-57	nuclear factor kappa B subunit 1	Homo sapiens	28-37
27033785-0	2016	[Effect of polymorphisms of NF-kappaB and PXR on platinum-based chemotherapy for non-small cell lung cancer].	Platinum	49-57	nuclear receptor subfamily 1 group I member 2	Homo sapiens	42-45
27033785-7	2016	:  CONCLUSION: Patients with NF-kappaB rs230521 CC, PXR rs3814058 CC and CT had higher risk to suffer hematological toxicity during platinum-based chemotherapy for non-small cell lung cancer.	Platinum	132-140	nuclear factor kappa B subunit 1	Homo sapiens	29-38
27033785-7	2016	:  CONCLUSION: Patients with NF-kappaB rs230521 CC, PXR rs3814058 CC and CT had higher risk to suffer hematological toxicity during platinum-based chemotherapy for non-small cell lung cancer.	Platinum	132-140	nuclear receptor subfamily 1 group I member 2	Homo sapiens	52-55
27004793-0	2016	BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.	Platinum	49-57	BRCA1 DNA repair associated	Homo sapiens	0-4
27034988-2	2016	A common linear correlation between hydrogen binding energy (HBE) and pH is observed for four supported platinum-group metal catalysts (Pt/C, Ir/C, Pd/C, and Rh/C) over a broad pH range (0 to 13), suggesting that the pH dependence of HBE is metal-independent.	Platinum	104-112	HCL2	Homo sapiens	142-162
27051298-0	2016	Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment.	Platinum	142-150	epidermal growth factor receptor	Homo sapiens	117-121
27051298-8	2016	Furthermore, patients who received platinum-based doublet had a trend for better PFS2 and a significantly better OS2 than those who received chemotherapy without platinum (PFS2: 4.9 months vs 2.6 months, P=0.0584; OS2: 16.1 months vs 6.7 months, P=0.0007).	Platinum	35-43	GINS complex subunit 2	Homo sapiens	81-85
27051298-8	2016	Furthermore, patients who received platinum-based doublet had a trend for better PFS2 and a significantly better OS2 than those who received chemotherapy without platinum (PFS2: 4.9 months vs 2.6 months, P=0.0584; OS2: 16.1 months vs 6.7 months, P=0.0007).	Platinum	35-43	matrilin 3	Homo sapiens	113-116
27051298-8	2016	Furthermore, patients who received platinum-based doublet had a trend for better PFS2 and a significantly better OS2 than those who received chemotherapy without platinum (PFS2: 4.9 months vs 2.6 months, P=0.0584; OS2: 16.1 months vs 6.7 months, P=0.0007).	Platinum	35-43	GINS complex subunit 2	Homo sapiens	172-176
27051298-8	2016	Furthermore, patients who received platinum-based doublet had a trend for better PFS2 and a significantly better OS2 than those who received chemotherapy without platinum (PFS2: 4.9 months vs 2.6 months, P=0.0584; OS2: 16.1 months vs 6.7 months, P=0.0007).	Platinum	35-43	matrilin 3	Homo sapiens	214-217
27051298-9	2016	Analyses of the patients receiving platinum-based doublet showed that patients receiving pemetrexed had a significantly better PFS2 (6.4 months vs 4.1 months, P=0.0083) and a trend for better OS2 than those without pemetrexed treatment.	Platinum	35-43	GINS complex subunit 2	Homo sapiens	127-131
27051298-9	2016	Analyses of the patients receiving platinum-based doublet showed that patients receiving pemetrexed had a significantly better PFS2 (6.4 months vs 4.1 months, P=0.0083) and a trend for better OS2 than those without pemetrexed treatment.	Platinum	35-43	matrilin 3	Homo sapiens	192-195
26513282-0	2016	Detection of prostate specific antigen based on electrocatalytic platinum nanoparticles conjugated to a recombinant scFv antibody.	Platinum	65-73	immunglobulin heavy chain variable region	Homo sapiens	116-120
26513282-2	2016	In this paper, we propose a sensitive electrochemical immunosensor based on electrocatalytic platinum nanoparticles conjugated to a recombinant scFv antibody.	Platinum	93-101	immunglobulin heavy chain variable region	Homo sapiens	144-148
26513282-5	2016	Furthermore, highly specific in-house generated scFv fragments as receptor proteins were utilised for one step site-directed immobilisation on the surface of platinum nanoparticles (PtNPs).	Platinum	158-166	immunglobulin heavy chain variable region	Homo sapiens	48-52
26881895-6	2016	Experimental results demonstrated that the Ti/CeO2:Al/Pt sandwich structure exhibits significantly better switching characteristics including lower forming voltage, improved and stable SET/RESET voltages, enhanced endurance of more than 10(4) repetitive switching cycles and large memory window (ROFF/RON &gt; 10(2)) as compared to undoped Ti/CeOx/Pt device.	Platinum	54-56	macrophage stimulating 1 receptor	Homo sapiens	301-304
26964739-7	2016	RESULTS: Carboplatin treatment in the platinum-sensitive OV1002 model triggered up-regulation of cell cycle, mTOR and DDR pathways, while at late time points WNT, invasion, EMT and MAPK pathways were modulated.	Platinum	38-46	mechanistic target of rapamycin kinase	Homo sapiens	109-113
26964739-7	2016	RESULTS: Carboplatin treatment in the platinum-sensitive OV1002 model triggered up-regulation of cell cycle, mTOR and DDR pathways, while at late time points WNT, invasion, EMT and MAPK pathways were modulated.	Platinum	38-46	IL2 inducible T cell kinase	Homo sapiens	173-176
26862592-1	2016	Low-loadings of Pt supported over six transition metal carbide (Pt/TMC) powder catalysts were synthesized and evaluated for hydrogen oxidation and evolution reactions in an alkaline electrolyte.	Platinum	16-18	STT3 oligosaccharyltransferase complex catalytic subunit A	Homo sapiens	67-70
26837279-4	2016	trans-[PtH(sarp)(PPh3)] was evaluated as a preformed, tin-free hydroformylation catalyst on styrene and found active at 100  C, at pressures over 75 bar, yielding phenylpropanal (regioselectivities up to 83% in 2-phenylpropanal), with total conversions to aldehydes up to 100% at styrene/platinum ratios from 400/1 to 1000/1 and minimal hydrogenation products.	Platinum	288-296	caveolin 1	Homo sapiens	17-21
26879473-1	2016	Carbenes of platinum and palladium, PtC3 and PdC3 , were generated in the gas phase through laser vaporization of a metal target in the presence of a low concentration of a hydrocarbon precursor undergoing supersonic expansion.	Platinum	12-20	nuclear receptor coactivator 4	Homo sapiens	36-40
27478275-1	2016	Carbenes of platinum and palladium, PtC3 and PdC3, were generated in the gas phase through laser vaporization of a metal target in the presence of a low concentration of a hydrocarbon precursor undergoing supersonic expansion.	Platinum	12-20	nuclear receptor coactivator 4	Homo sapiens	36-40
26915599-4	2016	The optimized Co@NCN-800 exhibits outstanding HER activity with an onset potential of -89 mV (vs RHE), a large exchange current density of 62.2 muA cm(-2), and small Tafel slope of 82 mV dec(-1), as well as excellent stability (5000 cycles) in acid media, demonstrating the potential for the replacement of Pt-based catalysts.	Platinum	307-309	factor interacting with PAPOLA and CPSF1	Homo sapiens	97-100
27014726-2	2016	This data article describes the possible circumvention of resistance to specifically platinum (Pt)-based anticancer drugs by vatalanib via inhibition of two other efflux transporters ABCC2 and ATP7A.	Platinum	85-93	ATP binding cassette subfamily C member 2	Homo sapiens	183-188
27014726-2	2016	This data article describes the possible circumvention of resistance to specifically platinum (Pt)-based anticancer drugs by vatalanib via inhibition of two other efflux transporters ABCC2 and ATP7A.	Platinum	85-93	ATPase copper transporting alpha	Homo sapiens	193-198
27014726-2	2016	This data article describes the possible circumvention of resistance to specifically platinum (Pt)-based anticancer drugs by vatalanib via inhibition of two other efflux transporters ABCC2 and ATP7A.	Platinum	95-97	ATP binding cassette subfamily C member 2	Homo sapiens	183-188
27014726-2	2016	This data article describes the possible circumvention of resistance to specifically platinum (Pt)-based anticancer drugs by vatalanib via inhibition of two other efflux transporters ABCC2 and ATP7A.	Platinum	95-97	ATPase copper transporting alpha	Homo sapiens	193-198
26915599-4	2016	The optimized Co@NCN-800 exhibits outstanding HER activity with an onset potential of -89 mV (vs RHE), a large exchange current density of 62.2 muA cm(-2), and small Tafel slope of 82 mV dec(-1), as well as excellent stability (5000 cycles) in acid media, demonstrating the potential for the replacement of Pt-based catalysts.	Platinum	307-309	deleted in esophageal cancer 1	Homo sapiens	187-193
29997781-3	2016	ctc-[Pt(NH3)2(PhB)2Cl2] inhibits 60-70% HDAC activity in cancer cells, at levels below the IC50 values of PhB, suggesting synergism between Pt and PhB.	Platinum	5-7	prohibitin 1	Homo sapiens	14-17
26842788-13	2016	RRM1 may be a prognostic and predictive biomarker for PFS in patients with NSCLC who received platinum-based adjuvant chemotherapy, and combining EGFR mutation and RRM1 expression or combining ERCC1 and RRM1 expression can enhance prognostic and predictive power for PFS.	Platinum	94-102	ribonucleotide reductase catalytic subunit M1	Homo sapiens	0-4
26423401-0	2016	PMS2 expression in epithelial ovarian cancer is posttranslationally regulated by Akt and essential for platinum-induced apoptosis.	Platinum	103-111	PMS1 homolog 2, mismatch repair system component	Homo sapiens	0-4
26898616-2	2016	Patients harbouring these sensitizing mutations treated with EGFR TKI have derived significant clinical outcome when compared with standard platinum based chemotherapy doublets.	Platinum	140-148	epidermal growth factor receptor	Homo sapiens	61-65
26856379-0	2016	Spin-orbit torque in Pt/CoNiCo/Pt symmetric devices.	Platinum	21-23	spindlin 1	Homo sapiens	0-4
26804625-2	2016	The active channel of the OTF-PTs was fabricated by blending a UV responsive 2,7-dipenty-[1]benzothieno[2,3-b][1]benzothiophene (C5-BTBT) as small molecule semiconductor and a branched unsaturated polyester (B-upe) as dielectric binder (ratio 1:1).	Platinum	30-33	complement C5	Homo sapiens	129-136
26867799-4	2016	Western blot and laser scanning confocal microscopy studies indicated that beta-elemene enhanced the sensitivity of HCC cells to oxaliplatin by upregulating copper transporter 1 (CTR1), a major controller of intracellular platinum accumulation.	Platinum	222-230	solute carrier family 31, member 1	Mus musculus	157-177
26867799-4	2016	Western blot and laser scanning confocal microscopy studies indicated that beta-elemene enhanced the sensitivity of HCC cells to oxaliplatin by upregulating copper transporter 1 (CTR1), a major controller of intracellular platinum accumulation.	Platinum	222-230	solute carrier family 31, member 1	Mus musculus	179-183
26784023-2	2016	Reported herein is a novel three-dimensional hierarchical architectured electrocatalyst, consisting of platinum-copper-nickel nanoparticles-decorated carbon nanofiber arrays, which are conformally assembled on carbon felt fabrics (PtCuNi/CNF@CF) by an ambient-pressure chemical vapor deposition coupled with a spontaneous galvanic replacement reaction.	Platinum	103-111	NPHS1 adhesion molecule, nephrin	Homo sapiens	238-241
26784023-3	2016	The free-standing PtCuNi/CNF@CF monolith exhibits high porosities, a well-defined geometry shape, outstanding electron conductivity, and a unique characteristic of localizing platinum-copper-nickel nanoparticles in the tips of carbon nanofibers.	Platinum	175-183	NPHS1 adhesion molecule, nephrin	Homo sapiens	25-28
26784023-5	2016	Electrochemical measurements demonstrate that the PtCuNi/CNF@CF possesses superior intrinsic activity as well as mass-specific activity in comparison with the state-of-the-art Pt/C catalysts, both in acidic and alkaline solutions.	Platinum	50-52	NPHS1 adhesion molecule, nephrin	Homo sapiens	57-60
26851002-0	2016	Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.	Platinum	64-72	solute carrier family 31 member 1	Homo sapiens	19-23
26870698-9	2016	This dual mechanism of action may account for the striking synergy between APR-246 and platinum compounds.	Platinum	87-95	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	75-78
26588239-3	2016	In the present study, we performed a retrospective investigation of the association between TOP2A, HER2 overexpression, and disease-free and overall survival in patients with endometrial cancer receiving taxane and platinum.	Platinum	215-223	DNA topoisomerase II alpha	Homo sapiens	92-97
26588239-3	2016	In the present study, we performed a retrospective investigation of the association between TOP2A, HER2 overexpression, and disease-free and overall survival in patients with endometrial cancer receiving taxane and platinum.	Platinum	215-223	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
26264211-0	2016	STAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancer.	Platinum	70-78	signal transducer and activator of transcription 3	Homo sapiens	0-5
26588239-11	2016	CONCLUSIONS: Patients with TOP2A overexpression have a worse prognosis compared with those with TOP2A nonexpression, and TOP2A may be a useful biomarker in patients receiving adjuvant taxane-platinum regimens with moderate- to high-risk endometrial cancer.	Platinum	191-199	DNA topoisomerase II alpha	Homo sapiens	27-32
26933421-0	2016	Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization.	Platinum	20-28	epidermal growth factor receptor	Homo sapiens	52-56
26775588-2	2016	As a case study we evaluated how a particular predictive biomarker, ERCC1, was assessed in research on platinum-based chemotherapy in non-small-cell lung cancer and what motivated the choice of procedure.	Platinum	103-111	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	68-73
26775588-5	2016	RESULTS: Thirty-three studies of platinum-based chemotherapy in non-small-cell lung cancer using ERCC1 were identified.	Platinum	33-41	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	97-102
26893752-8	2016	Platinum-based drugs were provided for patients with wild-type EGFR.	Platinum	0-8	epidermal growth factor receptor	Homo sapiens	63-67
26740498-0	2016	Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.	Platinum	17-25	KRAS proto-oncogene, GTPase	Homo sapiens	64-68
26740498-0	2016	Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.	Platinum	17-25	thymidylate synthetase	Homo sapiens	122-126
26551017-6	2016	Here, we use Kerr microscopy to examine spin-orbit torque-driven domain wall motion in Co/AlOx wires with different shapes and orientations on top of a current-carrying Pt layer.	Platinum	169-171	spindlin 1	Homo sapiens	40-44
26893680-0	2016	Role of BCL2-associated athanogene in resistance to platinum-based chemotherapy in non-small-cell lung cancer.	Platinum	52-60	BCL2 apoptosis regulator	Homo sapiens	8-12
26893680-1	2016	The present study aimed to address the pharmacogenetic role of BAG1 in platinum-based chemotherapy in advanced non-small-cell lung cancer (NSCLC) and in cultured human lung adenocarcinoma A549 cells.	Platinum	71-79	BAG cochaperone 1	Homo sapiens	63-67
26893702-10	2016	Additional analysis of the expression of S100A14 and corresponding clinical and pathological data revealed the correlation between the elevated expression of S100A14 and resistance to platinum-based chemotherapy.	Platinum	184-192	S100 calcium binding protein A14	Homo sapiens	41-48
26893702-10	2016	Additional analysis of the expression of S100A14 and corresponding clinical and pathological data revealed the correlation between the elevated expression of S100A14 and resistance to platinum-based chemotherapy.	Platinum	184-192	S100 calcium binding protein A14	Homo sapiens	158-165
26893702-12	2016	Overall, the present results demonstrate that S100A14 is likely to be involved in the resistance of SOC to platinum-based chemotherapy.	Platinum	107-115	S100 calcium binding protein A14	Homo sapiens	46-53
26958497-3	2016	Although the activity of platinum-based doublets has been shown in EGFR mutated NSCLC patients after progression to first-line TKIs, PFS is rather short.	Platinum	25-33	epidermal growth factor receptor	Homo sapiens	67-71
26774475-4	2016	We uncover a resistance mechanism by which a microRNA, miR-622, induces resistance to PARPis and platinum in BRCA1 mutant HGSOCs by targeting the Ku complex and restoring HR-mediated DSB repair.	Platinum	97-105	BRCA1 DNA repair associated	Homo sapiens	109-114
26774475-3	2016	Although BRCA1/2-reversion mutations are a clinically validated resistance mechanism, they account for less than half of platinum-resistant BRCA1/2-mutated HGSOCs.	Platinum	121-129	BRCA1 DNA repair associated	Homo sapiens	9-14
26774475-6	2016	Importantly, high expression of miR-622 in BRCA1-deficient HGSOCs is associated with worse outcome after platinum chemotherapy, indicating microRNA-mediated resistance through HR rescue.	Platinum	105-113	microRNA 622	Homo sapiens	32-39
26774475-3	2016	Although BRCA1/2-reversion mutations are a clinically validated resistance mechanism, they account for less than half of platinum-resistant BRCA1/2-mutated HGSOCs.	Platinum	121-129	BRCA1 DNA repair associated	Homo sapiens	140-145
26675258-9	2016	Interestingly, ectopic expression of miR-30a re-sensitized platinum-resistant EOC cells to cisplatinum-induced apoptosis.	Platinum	59-67	microRNA 30a	Homo sapiens	37-44
26774475-4	2016	We uncover a resistance mechanism by which a microRNA, miR-622, induces resistance to PARPis and platinum in BRCA1 mutant HGSOCs by targeting the Ku complex and restoring HR-mediated DSB repair.	Platinum	97-105	microRNA 622	Homo sapiens	55-62
26625211-0	2016	Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.	Platinum	102-110	DEAH-box helicase 16	Homo sapiens	44-56
26716408-0	2016	Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.	Platinum	74-82	periostin	Homo sapiens	0-9
26716408-7	2016	Taken together, we found high POSTN expression in cancer microenvironment is correlated with poor prognosis in EOC patients and associated with platinum resistance.	Platinum	144-152	periostin	Homo sapiens	30-35
26660293-1	2016	A Pt/TiO2-modified carbon nitride nanofiber (Pt/TiO2-CNx) catalyst has been synthesized by a chemical method for the oxygen reduction reaction (ORR).	Platinum	2-4	calnexin	Homo sapiens	53-56
26660293-8	2016	The high durability of Pt/0.2 g TiO2-CNx is attributed to the corrosion-resistance of 0.2 g TiO2-CNx nanowires support and the good interaction between the 0.2 g TiO2-CNx support and the Pt nanoparticles.	Platinum	23-25	calnexin	Homo sapiens	37-40
26660293-8	2016	The high durability of Pt/0.2 g TiO2-CNx is attributed to the corrosion-resistance of 0.2 g TiO2-CNx nanowires support and the good interaction between the 0.2 g TiO2-CNx support and the Pt nanoparticles.	Platinum	23-25	calnexin	Homo sapiens	97-100
26660293-8	2016	The high durability of Pt/0.2 g TiO2-CNx is attributed to the corrosion-resistance of 0.2 g TiO2-CNx nanowires support and the good interaction between the 0.2 g TiO2-CNx support and the Pt nanoparticles.	Platinum	23-25	calnexin	Homo sapiens	97-100
26660293-8	2016	The high durability of Pt/0.2 g TiO2-CNx is attributed to the corrosion-resistance of 0.2 g TiO2-CNx nanowires support and the good interaction between the 0.2 g TiO2-CNx support and the Pt nanoparticles.	Platinum	187-189	calnexin	Homo sapiens	37-40
26625211-7	2016	Overall, these results identify SLFN11 epigenetic inactivation as a predictor of resistance to platinum drugs in human cancer.	Platinum	95-103	schlafen family member 11	Homo sapiens	32-38
26625211-0	2016	Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.	Platinum	102-110	schlafen family member 11	Homo sapiens	57-63
26625211-3	2016	Using this approach, we have found promoter CpG island hypermethylation-associated silencing of the putative DNA/RNA helicase Schlafen-11 (SLFN11) to be associated with increased resistance to platinum compounds.	Platinum	193-201	DEAH-box helicase 16	Homo sapiens	113-125
26625211-3	2016	Using this approach, we have found promoter CpG island hypermethylation-associated silencing of the putative DNA/RNA helicase Schlafen-11 (SLFN11) to be associated with increased resistance to platinum compounds.	Platinum	193-201	schlafen family member 11	Homo sapiens	139-145
26653115-3	2016	We observe a substantial frequency shift of spin waves depending on the spin chirality in Pt/Co/MgO structures.	Platinum	90-92	spindlin 1	Homo sapiens	44-48
26677728-1	2016	This study reports on the synthesis of Pt nanourchins (PtNUs) on FTO glass surfaces and their application as an efficient and robust counter electrode (CE) in dye-sensitized solar cells (DSCs).	Platinum	39-41	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	65-68
26653115-3	2016	We observe a substantial frequency shift of spin waves depending on the spin chirality in Pt/Co/MgO structures.	Platinum	90-92	spindlin 1	Homo sapiens	72-76
26573238-1	2016	A redox series of cyclometalated platinum complexes based on a dinuclear motif linked by acetamidato (aam) bridging ligands, [Pt2 (mu-aam)2 (ppy)2 ] (ppy(-) =2-phenylpyridinate ion), has been synthesized.	Platinum	33-41	pancreatic polypeptide 2, pseudogene	Homo sapiens	141-146
26745875-1	2016	BRCA mutated ovarian cancers respond better to platinum-based therapy and to the recently approved PARP-inhibitors.	Platinum	47-55	BRCA1 DNA repair associated	Homo sapiens	0-4
26745623-1	2016	A highly active and stable nano structured Pt/Mg1-xNixO catalysts was developed by a simple co-precipitation method.	Platinum	43-45	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	46-49
26745623-2	2016	The obtained Pt/Mg1-xNixO catalyst exhibited cubic structure nanocatalyst with a size of 50-80 nm and realized CH4 and CO2 conversions as high as 98% at 900 C with excellent stability in the dry reforming of methane.	Platinum	13-15	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	16-19
26629888-0	2016	A Systems Oncology Approach Identifies NT5E as a Key Metabolic Regulator in Tumor Cells and Modulator of Platinum Sensitivity.	Platinum	105-113	5'-nucleotidase ecto	Homo sapiens	39-43
26572935-1	2016	Directly 2,12- and 2,8-linked Zn(II) porphyrin oligomers were prepared from 2,12- and 2,8-diborylated Zn(II) porphyrin by a cross platinum-induced coupling with a 2-borylated Zn(II) porphyrin end unit followed by a triphenylphosphine (PPh3 )-mediated reductive elimination.	Platinum	130-138	caveolin 1	Homo sapiens	235-239
26629888-3	2016	NT5E expression and associated metabolome variations were also correlated with sensitivity to several chemotherapeutics including platinum-based treatment.	Platinum	130-138	5'-nucleotidase ecto	Homo sapiens	0-4
26629888-4	2016	NT5E mRNA levels were observed to be elevated in cells upon in vitro and in vivo acquisition of platinum resistance in ovarian cancer cells, and specific targeting of NT5E increased tumor cell sensitivity to platinum.	Platinum	96-104	5'-nucleotidase ecto	Homo sapiens	0-4
26629888-4	2016	NT5E mRNA levels were observed to be elevated in cells upon in vitro and in vivo acquisition of platinum resistance in ovarian cancer cells, and specific targeting of NT5E increased tumor cell sensitivity to platinum.	Platinum	208-216	5'-nucleotidase ecto	Homo sapiens	167-171
26629888-5	2016	We observed that tumor NT5E levels were prognostic for outcomes in ovarian cancer and were elevated after treatment with platinum, supporting the translational relevance of our findings.	Platinum	121-129	5'-nucleotidase ecto	Homo sapiens	23-27
26629888-7	2016	We experimentally validated the main findings of the NT5E gene being involved in both intrinsic and acquired resistance to platinum-based drugs.	Platinum	123-131	5'-nucleotidase ecto	Homo sapiens	53-57
27165214-0	2016	ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases.	Platinum	41-49	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
28078200-0	2016	Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy.	Platinum	86-94	cystatin C	Homo sapiens	21-31
28078200-3	2016	The aim of this work was to explore the possibility of using serum cystatin C instead of serum creatinine to early predict renal failure in cancer patients who received platinum based chemotherapy.	Platinum	169-177	cystatin C	Homo sapiens	67-77
27039774-0	2016	Investigating the Frequency of the ERCC1 Gene C8092A Polymorphism in Iranian Patients with Advanced Gastric Cancer Receiving Platinum-based Chemotherapy.	Platinum	125-133	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	35-40
27797249-2	2016	One possible factor appears to be resistance involving polymorphisms in the CTR1 gene which plays an importance role in accumulation of platinum in the cytoplasm.	Platinum	136-144	solute carrier family 31 member 1	Homo sapiens	76-80
27797249-9	2016	CONCLUSIONS: This is the first study suggesting that polymorphism at CTR1 rs12686377 may be associated with toxicity from platinum-based regimens.	Platinum	122-130	solute carrier family 31 member 1	Homo sapiens	69-73
27039774-2	2016	Previous studies have shown that clinical outcome with platinum-based compounds depends on ERCC1 polymorphisms.	Platinum	55-63	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	91-96
27165214-1	2016	To investigate whether excision repair cross complementing-group1 (ERCC1) expression status could serve as a bio-predictor of response to platinum-based induction chemotherapy for head and neck cancers (HNCs) patients with a diagnosis of epithelial HNC were studied retrospectively.	Platinum	138-146	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	23-65
27039774-3	2016	The aim of this study was to investigate the frequency of a common polymorphism of ERCC1 gene (C8092A) in Iranian patients with advanced gastric cancer receiving platinum chemotherapy.	Platinum	162-170	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	83-88
27165214-1	2016	To investigate whether excision repair cross complementing-group1 (ERCC1) expression status could serve as a bio-predictor of response to platinum-based induction chemotherapy for head and neck cancers (HNCs) patients with a diagnosis of epithelial HNC were studied retrospectively.	Platinum	138-146	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	67-72
27165214-7	2016	Our study indicates that ERCC1 expression status detected by RT-PCR might serve as a bio-predictor of response to platinum-based induction chemotherapy for epithelial HNCs.	Platinum	114-122	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	25-30
26499899-0	2016	Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer.	Platinum	119-127	C-C motif chemokine ligand 2	Homo sapiens	21-55
26499899-0	2016	Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer.	Platinum	119-127	C-C motif chemokine ligand 2	Homo sapiens	57-62
26499899-0	2016	Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer.	Platinum	119-127	C-C motif chemokine ligand 2	Homo sapiens	63-68
26499899-13	2016	CONCLUSION: Elevated circulating MCP-1/CCL-2 level may be an unfavorable predictive factor to chemotherapy based on platinum and taxane in patients with gastric cancer.	Platinum	116-124	C-C motif chemokine ligand 2	Homo sapiens	33-38
26589409-7	2016	RESULTS: Absolute count of CD19+ and the CD4/CD8 ratio were significantly lower in NSCLC patients than in age-paired controls, while highly differentiated T cells increased in NSCLC patients treated with platinum-based chemotherapy.	Platinum	204-212	CD19 molecule	Homo sapiens	27-31
26499899-13	2016	CONCLUSION: Elevated circulating MCP-1/CCL-2 level may be an unfavorable predictive factor to chemotherapy based on platinum and taxane in patients with gastric cancer.	Platinum	116-124	C-C motif chemokine ligand 2	Homo sapiens	39-44
26589409-7	2016	RESULTS: Absolute count of CD19+ and the CD4/CD8 ratio were significantly lower in NSCLC patients than in age-paired controls, while highly differentiated T cells increased in NSCLC patients treated with platinum-based chemotherapy.	Platinum	204-212	CD4 molecule	Homo sapiens	41-44
26589409-7	2016	RESULTS: Absolute count of CD19+ and the CD4/CD8 ratio were significantly lower in NSCLC patients than in age-paired controls, while highly differentiated T cells increased in NSCLC patients treated with platinum-based chemotherapy.	Platinum	204-212	CD8a molecule	Homo sapiens	45-48
27057082-0	2016	A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis.	Platinum	111-119	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	66-71
26636903-8	2016	MCT4 concomitant positivity in hypoxic tumor cells and in the tumor stroma, as well as positivity in each of these regions concomitant with MCT1 positivity in normoxic tumor cells, was significantly associated with an unfavourable clinicopathological profile, and predicted lower overall survival rates among patients receiving platinum-based chemotherapy.	Platinum	328-336	solute carrier family 16 member 3	Homo sapiens	0-4
26517706-1	2016	BACKGROUND: Despite the development of molecular research and targeted therapy, patients with wild-type epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) still receive platinum doublet chemotherapy as the standard first-line treatment.	Platinum	193-201	epidermal growth factor receptor	Homo sapiens	104-136
26517706-1	2016	BACKGROUND: Despite the development of molecular research and targeted therapy, patients with wild-type epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) still receive platinum doublet chemotherapy as the standard first-line treatment.	Platinum	193-201	epidermal growth factor receptor	Homo sapiens	138-142
26517706-10	2016	CONCLUSION: Our data showed that the efficacy of various platinum doublet regimens was similar in patients with wild-type EGFR nonsquamous NSCLC.	Platinum	57-65	epidermal growth factor receptor	Homo sapiens	122-126
28373819-1	2016	AIM OF THE STUDY: The presence of BRCA germline mutations in patients with ovarian cancer has been shown to have predictive and prognostic significance, including increased platinum-sensitivity.	Platinum	173-181	BRCA1 DNA repair associated	Homo sapiens	34-38
27057082-7	2016	ERCC1 C118T and C8092A could predict both ORR and OS for platinum-based chemotherapy in Asian NSCLC patients (CT + TT versus CC, ORR: OR = 0.80, 95% CI = 0.67-0.94; OS: HR = 1.24, 95% CI = 1.01-1.53) (CA + AA versus CC, ORR: OR = 0.76, 95% CI = 0.60-0.96; OS: HR = 1.37, 95% CI = 1.06-1.75).	Platinum	57-65	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
27057082-8	2016	CONCLUSIONS: Current evidence strongly indicated the prospect of ERCC1 C118T and C8092A as predictive biomarkers for platinum-based chemotherapy in Asian NSCLC patients.	Platinum	117-125	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	65-70
27172742-1	2016	PURPOSE OF INVESTIGATION: To correlate serum CA125 at relapse with survival in ovarian cancer patients who achieved a complete response after primary cytoreduction and paclitaxel- and platinum-based chemotherapy.	Platinum	184-192	mucin 16, cell surface associated	Homo sapiens	45-50
26774150-0	2016	Overexpression of filamin-A protein is associated with aggressive phenotype and poor survival outcomes in NSCLC patients treated with platinum-based combination chemotherapy.	Platinum	134-142	filamin A	Homo sapiens	18-27
26693899-2	2016	Re-activating BRCA1 or MDR1 mutations can underlie platinum resistance in end-stage patients.	Platinum	51-59	BRCA1 DNA repair associated	Homo sapiens	14-19
26693899-2	2016	Re-activating BRCA1 or MDR1 mutations can underlie platinum resistance in end-stage patients.	Platinum	51-59	ATP binding cassette subfamily B member 1	Homo sapiens	23-27
26693899-8	2016	Instead, a platinum score of 13 copy number regions, among other genes including MECOM, CCNE1 and ERBB2, correlated with platinum-free interval (PFI) after first-line therapy, whereas an increase of this score in recurrent tumours predicted the change in PFI during subsequent therapy.	Platinum	11-19	MDS1 and EVI1 complex locus	Homo sapiens	81-86
26693899-8	2016	Instead, a platinum score of 13 copy number regions, among other genes including MECOM, CCNE1 and ERBB2, correlated with platinum-free interval (PFI) after first-line therapy, whereas an increase of this score in recurrent tumours predicted the change in PFI during subsequent therapy.	Platinum	11-19	cyclin E1	Homo sapiens	88-93
26693899-8	2016	Instead, a platinum score of 13 copy number regions, among other genes including MECOM, CCNE1 and ERBB2, correlated with platinum-free interval (PFI) after first-line therapy, whereas an increase of this score in recurrent tumours predicted the change in PFI during subsequent therapy.	Platinum	11-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-103
26693899-8	2016	Instead, a platinum score of 13 copy number regions, among other genes including MECOM, CCNE1 and ERBB2, correlated with platinum-free interval (PFI) after first-line therapy, whereas an increase of this score in recurrent tumours predicted the change in PFI during subsequent therapy.	Platinum	121-129	MDS1 and EVI1 complex locus	Homo sapiens	81-86
26693899-8	2016	Instead, a platinum score of 13 copy number regions, among other genes including MECOM, CCNE1 and ERBB2, correlated with platinum-free interval (PFI) after first-line therapy, whereas an increase of this score in recurrent tumours predicted the change in PFI during subsequent therapy.	Platinum	121-129	cyclin E1	Homo sapiens	88-93
26693899-8	2016	Instead, a platinum score of 13 copy number regions, among other genes including MECOM, CCNE1 and ERBB2, correlated with platinum-free interval (PFI) after first-line therapy, whereas an increase of this score in recurrent tumours predicted the change in PFI during subsequent therapy.	Platinum	121-129	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-103
26693899-10	2016	Nevertheless, all primary platinum-sensitive HGSOCs remained HR-deficient, irrespective of whether they became resistant to second-line platinum, further suggesting these tumours qualify for second-line Poly APD ribose polymerase (PARP) inhibitor treatment.	Platinum	26-34	poly(ADP-ribose) polymerase 1	Homo sapiens	231-235
26443214-0	2016	Engineering Customized TALENs Using the Platinum Gate TALEN Kit.	Platinum	40-48	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	60-63
26443214-3	2016	Here, we describe the protocols for Golden Gate assembly-based TALEN construction using the Platinum Gate TALEN Kit, which allows generation of highly active Platinum TALENs.	Platinum	92-100	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	112-115
26578208-6	2016	RESULTS: Anti-HER2 affisome demonstrated a higher amount of platinum intracellularly, and affected HER2(+)-SK-BR-3 cell death was at lower concentrations compared with its liposome counterparts.	Platinum	60-68	erb-b2 receptor tyrosine kinase 2	Mus musculus	14-18
26909102-11	2016	Second, SHBG was the variable which best discriminated PT from PP.	Platinum	55-57	sex hormone binding globulin	Homo sapiens	8-12
26774150-9	2016	Increased filamin A protein expression was significantly related with poor survival outcomes in patients with adjuvant platinum-based chemotherapy: OS (HR=1.005, 95%CI[1.000;1.010], p=0.037), DFS (HR=1.004, 95%CI [1.001:1.008], p=0,017).	Platinum	119-127	filamin A	Homo sapiens	10-19
26870274-0	2016	Prognostic implications of survivin and lung resistance protein in advanced non-small cell lung cancer treated with platinum-based chemotherapy.	Platinum	116-124	major vault protein	Homo sapiens	40-63
26534836-6	2016	Thus, our findings highlight for the first time the possible differential roles of the basal and induced JNK activities in the chemoresistance of ovarian cancer cells and also suggest that time-staggered JNK inhibition may be a rational and promising strategy to overcome the resistance of ovarian cancer to platinum- and taxane-based chemotherapy.	Platinum	308-316	mitogen-activated protein kinase 8	Homo sapiens	204-207
26870274-2	2016	The present study aimed to explore the prognostic implications of survivin and lung resistance protein (LRP) in advanced NSCLC treated with platinum-based chemotherapy.	Platinum	140-148	major vault protein	Homo sapiens	104-107
26870274-10	2016	Either the expression of survivin or the combined expression of LRP and survivin is associated with a poor prognosis in advanced NSCLC treated with platinum-based chemotherapy.	Platinum	148-156	major vault protein	Homo sapiens	64-67
27226269-10	2016	In addition, we succeeded to demonstrate a predictive value of miR221, miR224, miR520 and miR375 microRNA levels for a therapeutic effect of chemotherapy based on platinum derivates.	Platinum	163-171	microRNA 221	Homo sapiens	63-69
27226269-10	2016	In addition, we succeeded to demonstrate a predictive value of miR221, miR224, miR520 and miR375 microRNA levels for a therapeutic effect of chemotherapy based on platinum derivates.	Platinum	163-171	microRNA 224	Homo sapiens	71-77
27226269-10	2016	In addition, we succeeded to demonstrate a predictive value of miR221, miR224, miR520 and miR375 microRNA levels for a therapeutic effect of chemotherapy based on platinum derivates.	Platinum	163-171	microRNA 375	Homo sapiens	90-96
26342406-0	2015	High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation.	Platinum	35-43	BRCA1 DNA repair associated	Homo sapiens	104-108
27062783-0	2016	[Expression of MiR-130a in Serum Samples of Patients with Epithelial Ovarian Cancer and Its Association with Platinum Resistance].	Platinum	109-117	microRNA 130a	Homo sapiens	15-23
27062783-1	2016	OBJECTIVE: To determine the expression of miR-130a in patients with epithelial ovarian cancer and its association with platinum resistance.	Platinum	119-127	microRNA 130a	Homo sapiens	42-50
27062783-5	2016	RESULTS: Platinum-resistant patients had significantly higher levels of expression of miR-130a and BCL-2, and lower level of PTEN than platinum-sensitive patients (P &lt; 0.05).	Platinum	9-17	microRNA 130a	Homo sapiens	86-94
27062783-5	2016	RESULTS: Platinum-resistant patients had significantly higher levels of expression of miR-130a and BCL-2, and lower level of PTEN than platinum-sensitive patients (P &lt; 0.05).	Platinum	9-17	BCL2 apoptosis regulator	Homo sapiens	99-104
27062783-5	2016	RESULTS: Platinum-resistant patients had significantly higher levels of expression of miR-130a and BCL-2, and lower level of PTEN than platinum-sensitive patients (P &lt; 0.05).	Platinum	9-17	phosphatase and tensin homolog	Homo sapiens	125-129
27062783-6	2016	The expression level of miR-130a increased with increased severity in histological classification and appearance of lymph node metastasis in the platinum-resistant patients (P &lt; 0.05).	Platinum	145-153	microRNA 130a	Homo sapiens	24-32
27062783-7	2016	CONCLUSION: MiR-130a may mediate the generation of platinum resistance in epithelial ovarian cancer through inhibiting PTEN to activate PI3K/AKT signaling pathway and increasing BCL-2 to inhibit tumor cell apoptosis.	Platinum	51-59	microRNA 130a	Homo sapiens	12-20
27062783-7	2016	CONCLUSION: MiR-130a may mediate the generation of platinum resistance in epithelial ovarian cancer through inhibiting PTEN to activate PI3K/AKT signaling pathway and increasing BCL-2 to inhibit tumor cell apoptosis.	Platinum	51-59	phosphatase and tensin homolog	Homo sapiens	119-123
27062783-7	2016	CONCLUSION: MiR-130a may mediate the generation of platinum resistance in epithelial ovarian cancer through inhibiting PTEN to activate PI3K/AKT signaling pathway and increasing BCL-2 to inhibit tumor cell apoptosis.	Platinum	51-59	BCL2 apoptosis regulator	Homo sapiens	178-183
26342406-2	2015	Testing for Slavic founder BRCA mutations was performed for 225 ovarian cancer (OC) patients, who were treated by platinum-based neoadjuvant therapy.	Platinum	114-122	BRCA1 DNA repair associated	Homo sapiens	27-31
26675567-8	2015	In particular, we focus on the mechanism of platinum resistance in clear cell carcinoma, including the role of annexin A4, one of the most investigated factors of platinum resistance, as well as the mutant genes and overexpressed proteins such as VEGF, PI3K/AKT/mTOR signaling pathway, ARID1A, hepatocyte nuclear factor-1beta, ZNF217.	Platinum	44-52	AT-rich interaction domain 1A	Homo sapiens	286-292
26715866-10	2015	Limited outcomes data support the use of mitotane and platinum therapies for patients with low levels of the proteins RRM1 and ERCC1.	Platinum	54-62	ribonucleotide reductase catalytic subunit M1	Homo sapiens	118-122
26715866-10	2015	Limited outcomes data support the use of mitotane and platinum therapies for patients with low levels of the proteins RRM1 and ERCC1.	Platinum	54-62	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	127-132
26675567-8	2015	In particular, we focus on the mechanism of platinum resistance in clear cell carcinoma, including the role of annexin A4, one of the most investigated factors of platinum resistance, as well as the mutant genes and overexpressed proteins such as VEGF, PI3K/AKT/mTOR signaling pathway, ARID1A, hepatocyte nuclear factor-1beta, ZNF217.	Platinum	44-52	HNF1 homeobox B	Homo sapiens	294-325
26675567-8	2015	In particular, we focus on the mechanism of platinum resistance in clear cell carcinoma, including the role of annexin A4, one of the most investigated factors of platinum resistance, as well as the mutant genes and overexpressed proteins such as VEGF, PI3K/AKT/mTOR signaling pathway, ARID1A, hepatocyte nuclear factor-1beta, ZNF217.	Platinum	44-52	vascular endothelial growth factor A	Homo sapiens	247-251
26675567-8	2015	In particular, we focus on the mechanism of platinum resistance in clear cell carcinoma, including the role of annexin A4, one of the most investigated factors of platinum resistance, as well as the mutant genes and overexpressed proteins such as VEGF, PI3K/AKT/mTOR signaling pathway, ARID1A, hepatocyte nuclear factor-1beta, ZNF217.	Platinum	44-52	AKT serine/threonine kinase 1	Homo sapiens	258-261
26669450-8	2015	Based on the evidence presented, patients who will receive the greatest benefit from PARP inhibition are those with platinum-sensitive relapsed ovarian cancer and a BRCA mutation.	Platinum	116-124	poly(ADP-ribose) polymerase 1	Homo sapiens	85-89
26675567-8	2015	In particular, we focus on the mechanism of platinum resistance in clear cell carcinoma, including the role of annexin A4, one of the most investigated factors of platinum resistance, as well as the mutant genes and overexpressed proteins such as VEGF, PI3K/AKT/mTOR signaling pathway, ARID1A, hepatocyte nuclear factor-1beta, ZNF217.	Platinum	44-52	mechanistic target of rapamycin kinase	Homo sapiens	262-266
26675567-8	2015	In particular, we focus on the mechanism of platinum resistance in clear cell carcinoma, including the role of annexin A4, one of the most investigated factors of platinum resistance, as well as the mutant genes and overexpressed proteins such as VEGF, PI3K/AKT/mTOR signaling pathway, ARID1A, hepatocyte nuclear factor-1beta, ZNF217.	Platinum	44-52	zinc finger protein 217	Homo sapiens	327-333
26585822-0	2015	Genetic variations in the PI3K/AKT pathway predict platinum-based neoadjuvant chemotherapeutic sensitivity in squamous cervical cancer.	Platinum	51-59	AKT serine/threonine kinase 1	Homo sapiens	31-34
26319330-0	2015	Pt-decorated GaN nanowires with significant improvement in H2 gas-sensing performance at room temperature.	Platinum	0-2	gigaxonin	Homo sapiens	13-16
26585822-2	2015	The PI3K/Akt pathway plays a role in chemoresistance to platinum-based neoadjuvant chemotherapy (NAC).	Platinum	56-64	AKT serine/threonine kinase 1	Homo sapiens	9-12
26694397-6	2015	The sensor output of the micro-TGS decreased with increasing Pt content in the Pt/alpha-Al2O3 catalyst, by cancelling out the combustion heat from the AuPtPd/SnO2 catalyst.	Platinum	61-63	strawberry notch homolog 1	Homo sapiens	158-161
26585822-3	2015	The objective of this study was to evaluate the association between genetic polymorphisms in the PI3K/Akt pathway and chemotherapeutic outcomes following platinum-based NAC in Northwestern Chinese Han patients with squamous cervical cancer (SCC).	Platinum	154-162	AKT serine/threonine kinase 1	Homo sapiens	102-105
26585822-12	2015	SIGNIFICANCE: The findings from this study demonstrate that genetic polymorphisms in the PI3K/Akt pathway are associated with sensitivity to platinum-based chemotherapy in SCC patients.	Platinum	141-149	AKT serine/threonine kinase 1	Homo sapiens	94-97
32263029-2	2015	Due to the physico-chemical properties of Pt-NPs (electroactivity) and MIL-100(Fe) (high specific surface area and pore volume, biocompatibility), the resulting GOx-MIL-100(Fe)-PtNP bioelectrode exhibits excellent electrocatalytic performances for glucose detection.	Platinum	42-44	hydroxyacid oxidase 1	Homo sapiens	161-164
26531239-2	2015	To this end, the single extraction of platinum in [OMIM][NTf2] has been investigated as a function of the initial concentration of Pt(IV) ions dissolved in 1 M HCl.	Platinum	38-46	nuclear transport factor 2	Homo sapiens	57-61
26646960-6	2015	The PARP inhibitor olaparib is recommended as maintenance treatment of women with platinum sensitive relapsed BRCA mutated high-grade serous EOC who have responded to platinum-based chemotherapy.	Platinum	82-90	poly(ADP-ribose) polymerase 1	Homo sapiens	4-8
26656462-0	2015	Polymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy.	Platinum	121-129	BCL2 apoptosis regulator	Homo sapiens	17-21
26656462-0	2015	Polymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy.	Platinum	121-129	BCL2 associated X, apoptosis regulator	Homo sapiens	26-29
26656462-5	2015	The data from the current study provide evidence that BCL2-938C&gt;A and BAX-248G&gt;A polymorphisms may be useful in predicting clinical outcomes of patients with advanced inoperable NSCLC to platinum-based chemotherapy.	Platinum	193-201	BCL2 apoptosis regulator	Homo sapiens	54-58
26656462-5	2015	The data from the current study provide evidence that BCL2-938C&gt;A and BAX-248G&gt;A polymorphisms may be useful in predicting clinical outcomes of patients with advanced inoperable NSCLC to platinum-based chemotherapy.	Platinum	193-201	BCL2 associated X, apoptosis regulator	Homo sapiens	73-76
26497682-1	2015	Our identification of dysregulation of the AKT pathway in ovarian cancer as a platinum resistance specific event led to a comprehensive analysis of in vitro, in vivo and clinical behaviour of the AKT inhibitor GSK2141795.	Platinum	78-86	AKT serine/threonine kinase 1	Homo sapiens	43-46
26497682-1	2015	Our identification of dysregulation of the AKT pathway in ovarian cancer as a platinum resistance specific event led to a comprehensive analysis of in vitro, in vivo and clinical behaviour of the AKT inhibitor GSK2141795.	Platinum	78-86	AKT serine/threonine kinase 1	Homo sapiens	196-199
26497682-8	2015	Development of this signature represents an opportunity to demonstrate the clinical importance of AKT inhibition for re-sensitisation of platinum resistant ovarian cancer to platinum.	Platinum	137-145	AKT serine/threonine kinase 1	Homo sapiens	98-101
26497682-8	2015	Development of this signature represents an opportunity to demonstrate the clinical importance of AKT inhibition for re-sensitisation of platinum resistant ovarian cancer to platinum.	Platinum	174-182	AKT serine/threonine kinase 1	Homo sapiens	98-101
26646960-6	2015	The PARP inhibitor olaparib is recommended as maintenance treatment of women with platinum sensitive relapsed BRCA mutated high-grade serous EOC who have responded to platinum-based chemotherapy.	Platinum	82-90	BRCA1 DNA repair associated	Homo sapiens	110-114
26235215-0	2015	The reaction of a platinated methionine motif of CTR1 with cysteine and histidine is dependent upon the type of precursor platinum complex.	Platinum	122-130	solute carrier family 31 member 1	Homo sapiens	49-53
26662220-3	2015	Photoactivation of the platinum-guanidinoneomycin conjugate in the presence of 5"-guanosine monophosphate (5"-GMP) led to the formation of trans-[Pt(N3 )(py)2 (5"-GMP)](+) , as does the parent platinum(IV) complex.	Platinum	23-31	5'-nucleotidase, cytosolic II	Homo sapiens	110-113
26662220-3	2015	Photoactivation of the platinum-guanidinoneomycin conjugate in the presence of 5"-guanosine monophosphate (5"-GMP) led to the formation of trans-[Pt(N3 )(py)2 (5"-GMP)](+) , as does the parent platinum(IV) complex.	Platinum	23-31	5'-nucleotidase, cytosolic II	Homo sapiens	163-166
26631692-6	2015	The integrity of endothelial cells (ECs) monolayer was destroyed by tumor necrosis factor-alpha (TNF-alpha) in a hemodynamic background, which facilitated the tumor cell adhesion, this situation was recovered by the administration of platinum nanoparticles (Pt-NPs).	Platinum	234-242	tumor necrosis factor	Homo sapiens	68-95
26631692-6	2015	The integrity of endothelial cells (ECs) monolayer was destroyed by tumor necrosis factor-alpha (TNF-alpha) in a hemodynamic background, which facilitated the tumor cell adhesion, this situation was recovered by the administration of platinum nanoparticles (Pt-NPs).	Platinum	234-242	tumor necrosis factor	Homo sapiens	97-106
26399480-0	2015	Glutathione selectively modulates the binding of platinum drugs to human copper chaperone Cox17.	Platinum	49-57	cytochrome c oxidase copper chaperone COX17	Homo sapiens	90-95
26399480-6	2015	In the present study, we found that GSH significantly modulates the reaction of platinum complexes with Cox17.	Platinum	80-88	cytochrome c oxidase copper chaperone COX17	Homo sapiens	104-109
26399480-8	2015	Surprisingly, the pre-formed cisplatin-GSH adducts are highly reactive to Cox17; over 90% platinum transfers from GSH to Cox17.	Platinum	90-98	cytochrome c oxidase copper chaperone COX17	Homo sapiens	74-79
26399480-8	2015	Surprisingly, the pre-formed cisplatin-GSH adducts are highly reactive to Cox17; over 90% platinum transfers from GSH to Cox17.	Platinum	90-98	cytochrome c oxidase copper chaperone COX17	Homo sapiens	121-126
26523837-0	2015	Combinatorial-Designed Epidermal Growth Factor Receptor-Targeted Chitosan Nanoparticles for Encapsulation and Delivery of Lipid-Modified Platinum Derivatives in Wild-Type and Resistant Non-Small-Cell Lung Cancer Cells.	Platinum	137-145	epidermal growth factor receptor	Homo sapiens	23-55
26239547-3	2015	Pt(N(H)6-Medpa)G adducts form syn and anti rotamers with the guanine O6 and the central N-H of N(H)6-Medpa on the same or opposite side of the coordination plane, respectively.	Platinum	0-2	synemin	Homo sapiens	30-33
26239547-5	2015	However, in comparison, the syn rotamer of Pt(N(H)6-Medpa)G adducts has an unexpectedly high abundance.	Platinum	43-45	synemin	Homo sapiens	28-31
26644081-0	2015	Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells.	Platinum	58-66	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	106-113
27844009-1	2015	The interactions between platinum complexes and human serum albumin (HSA) play crucial roles in the distribution, metabolism, and activity of platinum-based anticancer drugs.	Platinum	25-33	albumin	Homo sapiens	54-67
27844009-1	2015	The interactions between platinum complexes and human serum albumin (HSA) play crucial roles in the distribution, metabolism, and activity of platinum-based anticancer drugs.	Platinum	142-150	albumin	Homo sapiens	54-67
26644081-3	2015	In this study, we showed that combination of imatinib with platinum (Pt)-based anticancer agents, including cisplatin and oxaliplatin, exhibited synergistic cytotoxic effect specifically in Bcr-Abl+ human chronic myeloid leukemia cell line K562 but not in Bcr-Abl- RPMI8226 cells.	Platinum	59-67	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	190-197
26644081-3	2015	In this study, we showed that combination of imatinib with platinum (Pt)-based anticancer agents, including cisplatin and oxaliplatin, exhibited synergistic cytotoxic effect specifically in Bcr-Abl+ human chronic myeloid leukemia cell line K562 but not in Bcr-Abl- RPMI8226 cells.	Platinum	59-67	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	256-263
26644081-3	2015	In this study, we showed that combination of imatinib with platinum (Pt)-based anticancer agents, including cisplatin and oxaliplatin, exhibited synergistic cytotoxic effect specifically in Bcr-Abl+ human chronic myeloid leukemia cell line K562 but not in Bcr-Abl- RPMI8226 cells.	Platinum	69-71	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	190-197
26644081-3	2015	In this study, we showed that combination of imatinib with platinum (Pt)-based anticancer agents, including cisplatin and oxaliplatin, exhibited synergistic cytotoxic effect specifically in Bcr-Abl+ human chronic myeloid leukemia cell line K562 but not in Bcr-Abl- RPMI8226 cells.	Platinum	69-71	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	256-263
26248472-10	2015	CONCLUSION: Urinary KIM-1 measured 24 h after the start of drug infusion has the potential to detect early AKI in pediatric patients treated with MTX or platinum-class drugs.	Platinum	153-161	hepatitis A virus cellular receptor 1	Homo sapiens	20-25
26351349-0	2015	Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.	Platinum	81-89	programmed cell death 1	Homo sapiens	38-42
26124006-13	2015	In conclusion, our research demonstrated the combined effects of BAG-1 and XPD polymorphisms on chemotherapy sensitivity and survival in patients with advanced NSCLC, which might be the important predictive markers for platinum-based chemotherapy efficacy.	Platinum	219-227	BAG cochaperone 1	Homo sapiens	65-70
26004768-1	2015	BACKGROUND: In this work, we aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarkers in patients with ovarian cancer who were treated within the phase III randomized European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG) 55041 study comparing erlotinib with observation in patients with no evidence of disease progression after first-line platinum-based chemotherapy.	Platinum	413-421	epidermal growth factor receptor	Homo sapiens	57-89
26004768-1	2015	BACKGROUND: In this work, we aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarkers in patients with ovarian cancer who were treated within the phase III randomized European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG) 55041 study comparing erlotinib with observation in patients with no evidence of disease progression after first-line platinum-based chemotherapy.	Platinum	413-421	epidermal growth factor receptor	Homo sapiens	91-95
26124006-13	2015	In conclusion, our research demonstrated the combined effects of BAG-1 and XPD polymorphisms on chemotherapy sensitivity and survival in patients with advanced NSCLC, which might be the important predictive markers for platinum-based chemotherapy efficacy.	Platinum	219-227	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	75-78
26585370-0	2015	Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy.	Platinum	123-131	X-ray repair cross complementing 1	Homo sapiens	45-50
26585370-1	2015	Published data have shown inconsistent results about the pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy.	Platinum	155-163	X-ray repair cross complementing 1	Homo sapiens	77-82
26210103-5	2015	In addition, it was recently shown that aberrations in DNA repair genes, such as BRCA2 and ATM, are present in both somatic and germline form in a significant minority of prostate cancer; these abnormalities can be targeted by drugs such as platinums and PARP inhibitors.	Platinum	241-250	BRCA2 DNA repair associated	Homo sapiens	81-86
32262868-1	2015	Flexible films of polytungstate (PT) as active ingredients were fabricated in PDMS as a "band-Aid" to achieve controllable H2O2 release.	Platinum	33-35	activation induced cytidine deaminase	Homo sapiens	94-97
26561172-3	2015	We confirmed that the damage threshold of the platinum/carbon multilayer with a bilayer period of 3 nm was 0.051 muJ/mum(2), which is sufficiently higher than that in practical applications.	Platinum	46-54	latexin	Homo sapiens	117-120
26302232-5	2015	We further found that siRNA-mediated inhibition of Notch1 suppression can increase the sensitivity of HCC cells to platinum drugs and decrease the percentage of HCC CSCs, and consequently resulting in enhanced proliferation inhibition and apoptosis induction in HCC cells in vitro.	Platinum	115-123	notch receptor 1	Homo sapiens	51-57
26210103-5	2015	In addition, it was recently shown that aberrations in DNA repair genes, such as BRCA2 and ATM, are present in both somatic and germline form in a significant minority of prostate cancer; these abnormalities can be targeted by drugs such as platinums and PARP inhibitors.	Platinum	241-250	ATM serine/threonine kinase	Homo sapiens	91-94
26210103-5	2015	In addition, it was recently shown that aberrations in DNA repair genes, such as BRCA2 and ATM, are present in both somatic and germline form in a significant minority of prostate cancer; these abnormalities can be targeted by drugs such as platinums and PARP inhibitors.	Platinum	241-250	collagen type XI alpha 2 chain	Homo sapiens	255-259
31973370-3	2015	The cathode assembly consisting of 54 atom % Pt showed enhanced reactivity both in binary (Pt-Pd; k1  10.7x10-3  min-1 ) and ternary (Cu-Pt-Pd; k1  28.6x10-3  min-1 ) states.	Platinum	45-47	CD59 molecule (CD59 blood group)	Homo sapiens	159-164
26400460-15	2015	Platinum-based therapies increase the expression of MnSOD, which may result in an abundance of hydrogen peroxide, a reactive oxygen species.	Platinum	0-8	superoxide dismutase 2	Homo sapiens	52-57
31973370-3	2015	The cathode assembly consisting of 54 atom % Pt showed enhanced reactivity both in binary (Pt-Pd; k1  10.7x10-3  min-1 ) and ternary (Cu-Pt-Pd; k1  28.6x10-3  min-1 ) states.	Platinum	45-47	CD59 molecule (CD59 blood group)	Homo sapiens	113-118
26510880-5	2015	Furthermore, QYG reduced platinum accumulation in the kidney by decreasing the expression of copper transporter 1 and organic cation transporter 2.	Platinum	25-33	solute carrier family 31, member 1	Mus musculus	93-146
26823845-0	2015	Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.	Platinum	97-105	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	20-25
26823845-0	2015	Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.	Platinum	97-105	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	30-35
26371700-1	2015	OBJECTIVES: After failure of first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC) harboring EGFR-activating mutation, platinum based combination chemotherapy is recommended.	Platinum	200-208	epidermal growth factor receptor	Homo sapiens	101-105
26371700-1	2015	OBJECTIVES: After failure of first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC) harboring EGFR-activating mutation, platinum based combination chemotherapy is recommended.	Platinum	200-208	epidermal growth factor receptor	Homo sapiens	174-178
26371700-10	2015	CONCLUSIONS: Based on this retrospective analysis, platinum combination with pemetrexed resulted in a better disease control rate and a tendency toward prolongation of progression-free survival in NSCLC patients who progressed after first-line EGFR TKIs.	Platinum	51-59	epidermal growth factor receptor	Homo sapiens	244-248
25263481-8	2015	Moreover, when selecting patients who received platinum-based chemotherapy, the prognosis was significantly worse for those with MCT1 and CD147 positive tumors.	Platinum	47-55	solute carrier family 16 member 1	Homo sapiens	129-133
25263481-8	2015	Moreover, when selecting patients who received platinum-based chemotherapy, the prognosis was significantly worse for those with MCT1 and CD147 positive tumors.	Platinum	47-55	basigin (Ok blood group)	Homo sapiens	138-143
26415993-0	2015	Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.	Platinum	48-56	KRAS proto-oncogene, GTPase	Homo sapiens	98-102
26499264-0	2015	Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.	Platinum	136-144	cyclin A1	Homo sapiens	22-31
26579492-6	2015	DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a core component of NHEJ and it has shown considerable promise as a chemosensitization target in numerous cancer types, including ovarian cancer where it functions to promote platinum-induced survival signaling, via AKT activation.	Platinum	236-244	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	0-46
26579492-6	2015	DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a core component of NHEJ and it has shown considerable promise as a chemosensitization target in numerous cancer types, including ovarian cancer where it functions to promote platinum-induced survival signaling, via AKT activation.	Platinum	236-244	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	48-56
26579492-6	2015	DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a core component of NHEJ and it has shown considerable promise as a chemosensitization target in numerous cancer types, including ovarian cancer where it functions to promote platinum-induced survival signaling, via AKT activation.	Platinum	236-244	AKT serine/threonine kinase 1	Homo sapiens	277-280
26406962-3	2015	The WW domain of human Pin1 can recognize the phosphoserine/phosphothreonine-proline (pS/pT-P) motifs, while its PPIase domain catalyzes the cis/trans isomerization of prolyl bonds to regulate the cell cycle.	Platinum	89-91	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	23-27
26492315-0	2015	Loss of PTEN Facilitates Rosiglitazone-Mediated Enhancement of Platinum(IV) Complex LA-12-Induced Apoptosis in Colon Cancer Cells.	Platinum	63-71	phosphatase and tensin homolog	Homo sapiens	8-12
26416458-0	2015	KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.	Platinum	95-103	KRAS proto-oncogene, GTPase	Homo sapiens	0-4
26416458-2	2015	The aim of this planned ancillary study within the TAILOR trial was to assess the prognostic value of KRAS mutations in advanced NSCLC patients treated with platinum-based first-line chemotherapy.	Platinum	157-165	KRAS proto-oncogene, GTPase	Homo sapiens	102-106
26416458-6	2015	This study, with all consecutive patients genotyped, indicates that the presence of KRAS mutations has a mild negative impact on OS in advanced NSCLC patient treated with a first-line platinum-containing regimen.	Platinum	184-192	KRAS proto-oncogene, GTPase	Homo sapiens	84-88
26267317-0	2015	The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma.	Platinum	55-63	C-X-C motif chemokine ligand 8	Homo sapiens	37-41
26482648-8	2015	Moreover, we demonstrate that the expressions of miR-17 and miR-92 families in NSCLC tissues are significantly associated with platinum-based chemotherapy response.	Platinum	127-135	microRNA 17	Homo sapiens	49-55
26482648-8	2015	Moreover, we demonstrate that the expressions of miR-17 and miR-92 families in NSCLC tissues are significantly associated with platinum-based chemotherapy response.	Platinum	127-135	microRNA 9-2	Homo sapiens	60-66
26482648-9	2015	CONCLUSION: Our study indicates that miR-17 and miR-92 families play important roles in cisplatin resistance and can be used as potential biomarkers for better predicting the clinical response to platinum-based chemotherapy in NSCLC.	Platinum	196-204	microRNA 17	Homo sapiens	37-43
26482648-9	2015	CONCLUSION: Our study indicates that miR-17 and miR-92 families play important roles in cisplatin resistance and can be used as potential biomarkers for better predicting the clinical response to platinum-based chemotherapy in NSCLC.	Platinum	196-204	microRNA 9-2	Homo sapiens	48-54
26267317-3	2015	We studied the expression of IL-8 and IL-8 receptors in platinum sensitive and resistant cell lines.	Platinum	56-64	C-X-C motif chemokine ligand 8	Homo sapiens	29-33
26351341-5	2015	The only regimen to demonstrate survival superiority is platinum, fluorouracil, and cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor (EGFR).	Platinum	56-64	epidermal growth factor receptor	Homo sapiens	138-170
26267317-3	2015	We studied the expression of IL-8 and IL-8 receptors in platinum sensitive and resistant cell lines.	Platinum	56-64	C-X-C motif chemokine ligand 8	Homo sapiens	38-42
26267317-4	2015	Using qRT-PCR and immunohistochemistry, both platinum sensitive (PEA1, PEO14) and resistant (PEA2, PEO23) show increased expression of IL-8 and IL-8 receptors.	Platinum	45-53	C-X-C motif chemokine ligand 8	Homo sapiens	135-139
26267317-4	2015	Using qRT-PCR and immunohistochemistry, both platinum sensitive (PEA1, PEO14) and resistant (PEA2, PEO23) show increased expression of IL-8 and IL-8 receptors.	Platinum	45-53	C-X-C motif chemokine ligand 8	Homo sapiens	144-148
26267317-6	2015	Knockdown of IL-8 increased sensitivity to cisplatin in platinum sensitive and reversed platinum resistance in resistant cell lines, decreased the expression of anti-apoptotic Bcl-2 and decreased inhibitory phosphorylation of pro-apoptotic Bad.	Platinum	56-64	C-X-C motif chemokine ligand 8	Homo sapiens	13-17
26267317-6	2015	Knockdown of IL-8 increased sensitivity to cisplatin in platinum sensitive and reversed platinum resistance in resistant cell lines, decreased the expression of anti-apoptotic Bcl-2 and decreased inhibitory phosphorylation of pro-apoptotic Bad.	Platinum	88-96	C-X-C motif chemokine ligand 8	Homo sapiens	13-17
26267317-7	2015	IL-8 receptor antagonist treatment also enhanced platinum sensitivity.	Platinum	49-57	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
26267317-9	2015	Inhibition of IL-8 signalling can enhance response in platinum sensitive and resistant disease.	Platinum	54-62	C-X-C motif chemokine ligand 8	Homo sapiens	14-18
26334096-0	2015	A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.	Platinum	88-96	tumor protein p53	Homo sapiens	55-58
26351341-5	2015	The only regimen to demonstrate survival superiority is platinum, fluorouracil, and cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor (EGFR).	Platinum	56-64	epidermal growth factor receptor	Homo sapiens	172-176
26372676-3	2015	A single-cell, two-step SLRR protocol based on the galvanic replacement of underpotentially deposited monolayers of Pb with Pt was used to grow epitaxial Pt1-xPbx (x &lt; 0.1) alloys of up to 10 ML thickness on Au substrates.	Platinum	124-126	zinc finger protein 77	Homo sapiens	154-157
26309119-2	2015	Here we report a composite photocatalyst, in which graphene and Pt particles act as cocatalysts to modify CdS nanowires.	Platinum	64-66	CDP-diacylglycerol synthase 1	Homo sapiens	106-109
26309119-5	2015	The graphene and Pt comodified CdS nanowires gain a high hydrogen evolution rate of 3984 mumol h(-1) g(-1), which is almost 4 times higher than that of bare CdS nanowires and also higher than the sum of graphene-CdS and Pt-CdS nanowires.	Platinum	17-19	CDP-diacylglycerol synthase 1	Homo sapiens	31-34
26309119-5	2015	The graphene and Pt comodified CdS nanowires gain a high hydrogen evolution rate of 3984 mumol h(-1) g(-1), which is almost 4 times higher than that of bare CdS nanowires and also higher than the sum of graphene-CdS and Pt-CdS nanowires.	Platinum	17-19	CDP-diacylglycerol synthase 1	Homo sapiens	157-160
26309119-5	2015	The graphene and Pt comodified CdS nanowires gain a high hydrogen evolution rate of 3984 mumol h(-1) g(-1), which is almost 4 times higher than that of bare CdS nanowires and also higher than the sum of graphene-CdS and Pt-CdS nanowires.	Platinum	17-19	CDP-diacylglycerol synthase 1	Homo sapiens	157-160
26309119-5	2015	The graphene and Pt comodified CdS nanowires gain a high hydrogen evolution rate of 3984 mumol h(-1) g(-1), which is almost 4 times higher than that of bare CdS nanowires and also higher than the sum of graphene-CdS and Pt-CdS nanowires.	Platinum	17-19	CDP-diacylglycerol synthase 1	Homo sapiens	157-160
26353932-7	2015	Systematic analysis of drug uptake, DNA adduct formation and DNA damage responses implicated in cisplatin adducts removal revealed that the KRAS(G12C) mutation might be particular because it stimulates Base Excision Repair to rapidly remove platinum from DNA even before the formation of cross-links.	Platinum	241-249	KRAS proto-oncogene, GTPase	Homo sapiens	140-144
26209642-4	2015	Wild-type EGFR patients (N = 218) received first-line platinum-based chemotherapy and were randomly allocated at progression to erlotinib or docetaxel.	Platinum	54-62	epidermal growth factor receptor	Homo sapiens	10-14
26471290-0	2015	Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.	Platinum	133-141	KRAS proto-oncogene, GTPase	Homo sapiens	30-34
25687850-0	2015	Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.	Platinum	46-54	epidermal growth factor receptor	Homo sapiens	142-146
26141368-5	2015	We found that the percentage of CD8(+) T cells in BM was higher in the patients with PT than in the controls.	Platinum	85-87	CD8a molecule	Homo sapiens	32-35
26186063-3	2015	In this work, we described the design, synthesis, and characterization of conjugates combining trastuzumab with a platinum (IV) analog of oxaliplatin, in which the trastuzumab acted as an active targeting agent for HER2-positive cancer cells.	Platinum	114-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	215-219
25687850-1	2015	PURPOSE: Platinum-based doublet chemotherapy is the treatment of choice for patients with non-small cell lung cancer (NSCLC); however, the role of a platinum-based doublet as second-line therapy after failure of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for NSCLC patients has not yet been elucidated.	Platinum	9-17	epidermal growth factor receptor	Homo sapiens	249-253
26306784-2	2015	The aim of our study was to (i) first determine the sensitivity of cytokeratin-7 (KRT7) mRNA expression levels for the molecular detection of CTCs using spiked-in lung adenocarcinoma (AC)-derived A549 cells and (ii) evaluate the impact of KRT7 mRNA expression in peripheral whole blood on the response to treatment and prognosis of patients with advanced lung AC who were treated with first-line platinum-based chemotherapy.	Platinum	396-404	keratin 7	Homo sapiens	67-80
26395808-14	2015	The absence of BRCA1 in 41 % of tumors reveals a BRCAness phenotype, constituting an excellent marker for therapy sensitivity, to platinum drugs or PARP inhibitors.	Platinum	130-138	BRCA1 DNA repair associated	Homo sapiens	15-20
26288241-0	2015	Association of MDR1 gene (C3435T) polymorphism and gene expression profiling in lung cancer patients treated with platinum-based chemotherapy.	Platinum	114-122	ATP binding cassette subfamily B member 1	Homo sapiens	15-19
25182391-8	2015	The PTH level was fully recovered to its preoperative range on the day 84 as 6 of 8 rats (75%) of the PT group and 7 of 9 rats (77.8%) of the PT + SIS group were recovered; the PTH levels were 117.84 and 178.36 pg/ml, respectively.	Platinum	4-6	parathyroid hormone	Rattus norvegicus	177-180
26208523-5	2015	In this study, we found that oxaliplatin and dachplatin, platinum-based drugs containing the 1,2-diaminocyclohexane (DACH) carrier ligand, repressed the expression of nuclear isoform of dUTPase (DUT-N), whereas cisplatin and carboplatin did not.	Platinum	57-65	Deoxyuridine triphosphatase	Drosophila melanogaster	186-193
26208523-5	2015	In this study, we found that oxaliplatin and dachplatin, platinum-based drugs containing the 1,2-diaminocyclohexane (DACH) carrier ligand, repressed the expression of nuclear isoform of dUTPase (DUT-N), whereas cisplatin and carboplatin did not.	Platinum	57-65	deoxyuridine triphosphatase	Homo sapiens	195-198
26303225-0	2015	PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.	Platinum	53-61	collagen type XI alpha 2 chain	Homo sapiens	0-4
26125441-0	2015	Critical role of Wnt/beta-catenin signaling in driving epithelial ovarian cancer platinum resistance.	Platinum	81-89	catenin beta 1	Homo sapiens	21-33
26622894-10	2015	High hCtr1 expression combined with low ATP7A expression was associated with an improved prognosis in patients with resected NSCLC that received platinum-based chemotherapy.	Platinum	145-153	solute carrier family 31 member 1	Homo sapiens	5-10
26143638-0	2015	Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.	Platinum	138-146	vascular endothelial growth factor A	Homo sapiens	0-34
26156020-0	2015	High expression of XPA confers poor prognosis for nasopharyngeal carcinoma patients treated with platinum-based chemoradiotherapy.	Platinum	97-105	XPA, DNA damage recognition and repair factor	Homo sapiens	19-22
26156020-1	2015	In this study, we tried to explore if xeroderma pigmentosum complementation group-A (XPA) expression is likely a prognostic prediction factor for locally advanced nasopharyngeal carcinoma (NPC) patients treated with platinum-based chemoradiotherapy, which was considered to bring chemotherapy-related severe toxicity compared with radiotherapy alone.	Platinum	216-224	XPA, DNA damage recognition and repair factor	Homo sapiens	38-83
26156020-1	2015	In this study, we tried to explore if xeroderma pigmentosum complementation group-A (XPA) expression is likely a prognostic prediction factor for locally advanced nasopharyngeal carcinoma (NPC) patients treated with platinum-based chemoradiotherapy, which was considered to bring chemotherapy-related severe toxicity compared with radiotherapy alone.	Platinum	216-224	XPA, DNA damage recognition and repair factor	Homo sapiens	85-88
26156020-3	2015	XPA expression was detected by immunohistochemistry in cancer tissues from locally advanced NPC patients treated with platinum-based chemoradiotherapy.	Platinum	118-126	XPA, DNA damage recognition and repair factor	Homo sapiens	0-3
26156020-7	2015	Combining XPA levels and T/N classifications, we successfully classified these patients into low, medium and high risk groups for platinum-based chemoradiotherapy.	Platinum	130-138	XPA, DNA damage recognition and repair factor	Homo sapiens	10-13
26156020-8	2015	These findings suggest that XPA levels may be a potential predictor of prognosis in locally advanced NPC patients treated with platinum-based chemoradiotherapy, and helpful for selecting patients likely to need and benefit from this treatment in future.	Platinum	127-135	XPA, DNA damage recognition and repair factor	Homo sapiens	28-31
26213845-3	2015	The current study aims to test the hypothesis that eIF3a may affect the drug response and prognosis of ovarian cancer patients receiving platinum-based chemotherapy by regulating xeroderma pigmentosum complementation group C (XPC) and p27(Kip1).	Platinum	137-145	eukaryotic translation initiation factor 3 subunit J	Homo sapiens	51-56
26213845-3	2015	The current study aims to test the hypothesis that eIF3a may affect the drug response and prognosis of ovarian cancer patients receiving platinum-based chemotherapy by regulating xeroderma pigmentosum complementation group C (XPC) and p27(Kip1).	Platinum	137-145	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	179-224
26213845-3	2015	The current study aims to test the hypothesis that eIF3a may affect the drug response and prognosis of ovarian cancer patients receiving platinum-based chemotherapy by regulating xeroderma pigmentosum complementation group C (XPC) and p27(Kip1).	Platinum	137-145	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	226-229
26213845-3	2015	The current study aims to test the hypothesis that eIF3a may affect the drug response and prognosis of ovarian cancer patients receiving platinum-based chemotherapy by regulating xeroderma pigmentosum complementation group C (XPC) and p27(Kip1).	Platinum	137-145	interferon alpha inducible protein 27	Homo sapiens	235-238
26125441-10	2015	Taken together, our data is the first report providing evidence that the Wnt/beta-catenin signaling pathway maintains stem-like properties and drug resistance of primary HGSOC PDX derived platinum resistant models, and therapeutic targeting of this pathway with iCG-001/PRI-724, which has been shown to be well tolerated in Phase I trials, may be an effective treatment option.	Platinum	188-196	catenin beta 1	Homo sapiens	77-89
26351843-11	2015	These findings suggest that activation of EGFR during platinum treatment contributes to the development of platinum resistance.	Platinum	54-62	epidermal growth factor receptor	Homo sapiens	42-46
26353782-9	2015	Knockdown of DKK1 by siRNA sensitized for cisplatin in two different NSCLC cell lines and in ovarian A2780 cells, but not in the A2780 cis subline made resistant to cisplatin by chronic exposure, suggesting a role of DKK1 in intrinsic but not acquired platinum refractoriness.	Platinum	252-260	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	13-17
26353782-10	2015	CONCLUSIONS: We identified DKK1 as a possible marker of a cisplatin-refractory phenotype and as a potential novel therapeutic target to improve platinum response of NSCLC cells.	Platinum	144-152	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	27-31
26351843-0	2015	Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells.	Platinum	72-80	epidermal growth factor receptor	Homo sapiens	21-53
26351843-4	2015	Others have shown that EGFR activation is linked to cisplatin treatment and platinum resistance.	Platinum	76-84	epidermal growth factor receptor	Homo sapiens	23-27
26351843-5	2015	We hypothesized that cisplatin induced activation of the EGFR mediates changes in DNA methylation associated with the development of platinum resistance.	Platinum	133-141	epidermal growth factor receptor	Homo sapiens	57-61
26351843-11	2015	These findings suggest that activation of EGFR during platinum treatment contributes to the development of platinum resistance.	Platinum	107-115	epidermal growth factor receptor	Homo sapiens	42-46
26351843-12	2015	Furthermore, EGFR inhibition may be an effective strategy at attenuating the development of platinum resistance thereby enhancing the effectiveness of chemotherapeutic treatment in ovarian cancer.	Platinum	92-100	epidermal growth factor receptor	Homo sapiens	13-17
26220844-0	2015	Predictive value of STMN1 gene promoter polymorphism (-2166T&gt;C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine.	Platinum	131-139	stathmin 1	Homo sapiens	20-25
26550452-5	2015	MTRR over-expression in OC tissue was correlated with pathologic type (P=0.005), grade (P=0.037), FIGO stage (P=0.001), organ metastasis (P=0.009) and platinum resistance (P=0.038).	Platinum	151-159	5-methyltetrahydrofolate-homocysteine methyltransferase reductase	Homo sapiens	0-4
26220844-11	2015	CONCLUSION: Rare TT genotype of STMN1 gene may be an unfavorable predictive factor of chemotherapy based on platinum compounds and vinorelbine, in patients with NSCLC.	Platinum	108-116	stathmin 1	Homo sapiens	32-37
25922216-0	2015	What can platinum offer yet in the treatment of PS2 NSCLC patients?	Platinum	9-17	taste 2 receptor member 64 pseudogene	Homo sapiens	48-51
25818095-10	2015	CONCLUSION: The results of our study suggest that SNPs in MDM2 might be used to predict the toxicities of platinum-based chemotherapy and overall survival in patients with advanced NSCLC.	Platinum	106-114	MDM2 proto-oncogene	Homo sapiens	58-62
25990507-0	2015	Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.	Platinum	12-20	epidermal growth factor receptor	Homo sapiens	142-146
25990507-3	2015	Therefore, we here aimed to investigate the efficacy of platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations.	Platinum	56-64	epidermal growth factor receptor	Homo sapiens	165-169
25990507-10	2015	CONCLUSIONS: Second-line platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations was effective and showed equivalent outcomes to first-line platinum combination chemotherapy.	Platinum	25-33	epidermal growth factor receptor	Homo sapiens	134-138
25922216-3	2015	This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients.	Platinum	66-74	taste 2 receptor member 64 pseudogene	Homo sapiens	117-120
26181684-11	2015	The influence of hot charge carriers on the chemistry at the metal-oxide interface are discussed for the cases of Au, Ag, and Pt nanoparticles on oxide supports and Pt-CdSe-Pt nanodumbbells.	Platinum	126-128	alcohol dehydrogenase iron containing 1	Homo sapiens	17-20
26100858-9	2015	CONCLUSIONS: These data show that TOP2A gene gain and protein over-expression might predict activity of PLD in platinum resistant/refractory EOC.	Platinum	111-119	DNA topoisomerase II alpha	Homo sapiens	34-39
26123645-9	2015	ERCC1 and MGMT were absent in 81% and 46% of tumors analyzed, respectively, suggesting potential benefit from platinum and alkylating agents.	Platinum	110-118	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
26123645-9	2015	ERCC1 and MGMT were absent in 81% and 46% of tumors analyzed, respectively, suggesting potential benefit from platinum and alkylating agents.	Platinum	110-118	O-6-methylguanine-DNA methyltransferase	Homo sapiens	10-14
26164266-0	2015	APE1, the DNA base excision repair protein, regulates the removal of platinum adducts in sensory neuronal cultures by NER.	Platinum	69-77	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	0-4
25894372-11	2015	The findings demonstrated that paclitaxel effect may be interfered with stathmin; overexpression of stathmin is a predictive marker for a worse prognosis in patients with NSCLC who were treated by both platinum and paclitaxel chemotherapy.	Platinum	202-210	stathmin 1	Homo sapiens	100-108
26181684-11	2015	The influence of hot charge carriers on the chemistry at the metal-oxide interface are discussed for the cases of Au, Ag, and Pt nanoparticles on oxide supports and Pt-CdSe-Pt nanodumbbells.	Platinum	165-167	alcohol dehydrogenase iron containing 1	Homo sapiens	17-20
26269716-6	2015	We found that IL6, TNF, CXCL8, IL1B and ERK1/2 were the top genes in terms of the number of connections in platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for combined taxane-platinum-induced neuropathy.	Platinum	107-115	interleukin 6	Homo sapiens	14-17
25946469-1	2015	BACKGROUND: Single nucleotide polymorphism (SNP) of the excision repair cross-complementing group 1 (ERCC1) gene has been linked with sensitivity to platinum and radiation.	Platinum	149-157	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	56-99
25946469-1	2015	BACKGROUND: Single nucleotide polymorphism (SNP) of the excision repair cross-complementing group 1 (ERCC1) gene has been linked with sensitivity to platinum and radiation.	Platinum	149-157	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	101-106
26148430-3	2015	Once the PNN ligands were coordinated to platinum, the resulting complexes proved to be very effective as catalysts in a domino reaction, where a Pt-catalyzed reduction of nitrobenzene was followed by a Paal-Knorr pyrrole reaction.	Platinum	41-49	pinin, desmosome associated protein	Homo sapiens	9-12
26269716-6	2015	We found that IL6, TNF, CXCL8, IL1B and ERK1/2 were the top genes in terms of the number of connections in platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for combined taxane-platinum-induced neuropathy.	Platinum	107-115	tumor necrosis factor	Homo sapiens	19-22
26269716-6	2015	We found that IL6, TNF, CXCL8, IL1B and ERK1/2 were the top genes in terms of the number of connections in platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for combined taxane-platinum-induced neuropathy.	Platinum	107-115	C-X-C motif chemokine ligand 8	Homo sapiens	24-29
26269716-6	2015	We found that IL6, TNF, CXCL8, IL1B and ERK1/2 were the top genes in terms of the number of connections in platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for combined taxane-platinum-induced neuropathy.	Platinum	107-115	interleukin 1 beta	Homo sapiens	31-35
26269716-6	2015	We found that IL6, TNF, CXCL8, IL1B and ERK1/2 were the top genes in terms of the number of connections in platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for combined taxane-platinum-induced neuropathy.	Platinum	107-115	mitogen-activated protein kinase 3	Homo sapiens	40-46
26269716-6	2015	We found that IL6, TNF, CXCL8, IL1B and ERK1/2 were the top genes in terms of the number of connections in platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for combined taxane-platinum-induced neuropathy.	Platinum	107-115	tumor protein p53	Homo sapiens	139-143
26269716-6	2015	We found that IL6, TNF, CXCL8, IL1B and ERK1/2 were the top genes in terms of the number of connections in platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for combined taxane-platinum-induced neuropathy.	Platinum	107-115	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	145-148
26269716-6	2015	We found that IL6, TNF, CXCL8, IL1B and ERK1/2 were the top genes in terms of the number of connections in platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for combined taxane-platinum-induced neuropathy.	Platinum	107-115	poly(ADP-ribose) polymerase 1	Homo sapiens	150-155
26269716-6	2015	We found that IL6, TNF, CXCL8, IL1B and ERK1/2 were the top genes in terms of the number of connections in platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for combined taxane-platinum-induced neuropathy.	Platinum	107-115	tumor necrosis factor	Homo sapiens	170-173
26269716-6	2015	We found that IL6, TNF, CXCL8, IL1B and ERK1/2 were the top genes in terms of the number of connections in platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for combined taxane-platinum-induced neuropathy.	Platinum	194-202	interleukin 6	Homo sapiens	14-17
26269716-6	2015	We found that IL6, TNF, CXCL8, IL1B and ERK1/2 were the top genes in terms of the number of connections in platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for combined taxane-platinum-induced neuropathy.	Platinum	194-202	tumor necrosis factor	Homo sapiens	19-22
26269716-6	2015	We found that IL6, TNF, CXCL8, IL1B and ERK1/2 were the top genes in terms of the number of connections in platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for combined taxane-platinum-induced neuropathy.	Platinum	194-202	C-X-C motif chemokine ligand 8	Homo sapiens	24-29
26269716-6	2015	We found that IL6, TNF, CXCL8, IL1B and ERK1/2 were the top genes in terms of the number of connections in platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for combined taxane-platinum-induced neuropathy.	Platinum	194-202	interleukin 1 beta	Homo sapiens	31-35
26269716-6	2015	We found that IL6, TNF, CXCL8, IL1B and ERK1/2 were the top genes in terms of the number of connections in platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for combined taxane-platinum-induced neuropathy.	Platinum	194-202	mitogen-activated protein kinase 3	Homo sapiens	40-46
26269716-6	2015	We found that IL6, TNF, CXCL8, IL1B and ERK1/2 were the top genes in terms of the number of connections in platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for combined taxane-platinum-induced neuropathy.	Platinum	194-202	tumor protein p53	Homo sapiens	139-143
26233609-3	2015	A number of different platinum-based chemotherapy regimens and non-platinum-based chemotherapy regimens have been used for the treatment of SCLC, with varying results.	Platinum	22-30	SCLC1	Homo sapiens	140-144
26309405-2	2015	Copper transporter 1 (CTR1) and organic cation transporter 2 (OCT2) critically affect the uptake and cytotoxicity of platinum drugs.	Platinum	117-125	solute carrier family 31 member 1	Homo sapiens	0-20
26309405-2	2015	Copper transporter 1 (CTR1) and organic cation transporter 2 (OCT2) critically affect the uptake and cytotoxicity of platinum drugs.	Platinum	117-125	solute carrier family 31 member 1	Homo sapiens	22-26
26309405-2	2015	Copper transporter 1 (CTR1) and organic cation transporter 2 (OCT2) critically affect the uptake and cytotoxicity of platinum drugs.	Platinum	117-125	solute carrier family 22 member 2	Homo sapiens	32-60
26309405-2	2015	Copper transporter 1 (CTR1) and organic cation transporter 2 (OCT2) critically affect the uptake and cytotoxicity of platinum drugs.	Platinum	117-125	solute carrier family 22 member 2	Homo sapiens	62-66
26233609-3	2015	A number of different platinum-based chemotherapy regimens and non-platinum-based chemotherapy regimens have been used for the treatment of SCLC, with varying results.	Platinum	67-75	SCLC1	Homo sapiens	140-144
26233609-5	2015	OBJECTIVES: To determine the effectiveness of platinum chemotherapy regimens compared with non-platinum chemotherapy regimens in the treatment of SCLC with respect to survival, tumour response, toxicity and quality of life.	Platinum	46-54	SCLC1	Homo sapiens	146-150
26124480-9	2015	CRS 3 also predicted sensitivity to first-line platinum therapy (94.3% negative predictive value for progression &lt; 6 months).	Platinum	47-55	CRSA	Homo sapiens	0-5
26164623-1	2015	OBJECTIVE: Using TCGA database, we had demonstrated that aberrantly activated Forkhead box M1 (FOXM1) correlates to worse overall survival in a subgroup of platinum resistant patients.	Platinum	156-164	forkhead box M1	Homo sapiens	78-93
26164623-1	2015	OBJECTIVE: Using TCGA database, we had demonstrated that aberrantly activated Forkhead box M1 (FOXM1) correlates to worse overall survival in a subgroup of platinum resistant patients.	Platinum	156-164	forkhead box M1	Homo sapiens	95-100
26099969-1	2015	PURPOSE: The use of trastuzumab, a monoclonal antibody targeting the HER2 protein, in combination with 5-fluorouracil/platinum-based chemotherapy improves survival in patients with HER2-positive advanced gastric cancer.	Platinum	118-126	erb-b2 receptor tyrosine kinase 2	Homo sapiens	181-185
26049123-14	2015	CONCLUSION: Weekly paclitaxel/carboplatin with G-CSF is an effective treatment with acceptable toxicity in patients with platinum-resistant or platinum-refractory OC, advanced or recurrent EC and CC.	Platinum	121-129	colony stimulating factor 3	Homo sapiens	47-52
26079827-7	2015	Finally, we observed sensitivity to cisplatin in cN-II silenced cells and resistance to this same drug in cN-II over-expressing cells indicating an involvement of cN-II in the mechanism of action of platinum derivatives, and most probably in DNA repair.	Platinum	199-207	5'-nucleotidase, cytosolic II	Homo sapiens	106-111
26079827-7	2015	Finally, we observed sensitivity to cisplatin in cN-II silenced cells and resistance to this same drug in cN-II over-expressing cells indicating an involvement of cN-II in the mechanism of action of platinum derivatives, and most probably in DNA repair.	Platinum	199-207	5'-nucleotidase, cytosolic II	Homo sapiens	106-111
26323924-0	2015	The genotype of ribonucleotidereductase M1 -269C &gt; A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer.	Platinum	91-99	ribonucleotide reductase catalytic subunit M1	Homo sapiens	16-42
26323924-1	2015	PURPOSE: Genetic polymorphisms of ribonucleotidereductase M1 (RRM1) was a DNA repair gene, which may affect patients" response to platinum-based chemotherapy or gemcitabine-based chemotherapy.	Platinum	130-138	ribonucleotide reductase catalytic subunit M1	Homo sapiens	34-60
26323924-1	2015	PURPOSE: Genetic polymorphisms of ribonucleotidereductase M1 (RRM1) was a DNA repair gene, which may affect patients" response to platinum-based chemotherapy or gemcitabine-based chemotherapy.	Platinum	130-138	ribonucleotide reductase catalytic subunit M1	Homo sapiens	62-66
26323924-2	2015	We retrospectively assessed whether single nucleotide polymorphisms (SNPs) of RRM1 can be used to predict overall survival (OS), progression free survival and response in nonsmall cell lung cancer (NSCLC) patients treated with platinum-based regimens as first-line chemotherapy.	Platinum	227-235	ribonucleotide reductase catalytic subunit M1	Homo sapiens	78-82
26323924-8	2015	CONCLUSION: The genotype of RRM1 -269C &gt; A was significantly associated with platinum-based chemotherapy sensitivity in smoking patients and can be used to predict OS in advanced NSCLC patients who received platinum-based chemotherapy or gemcitabine-based chemotherapy.	Platinum	80-88	ribonucleotide reductase catalytic subunit M1	Homo sapiens	28-32
26323924-8	2015	CONCLUSION: The genotype of RRM1 -269C &gt; A was significantly associated with platinum-based chemotherapy sensitivity in smoking patients and can be used to predict OS in advanced NSCLC patients who received platinum-based chemotherapy or gemcitabine-based chemotherapy.	Platinum	210-218	ribonucleotide reductase catalytic subunit M1	Homo sapiens	28-32
26158423-6	2015	Knockdown of IMP3 or Lin28B decreased cell proliferation, migration, and invasion, and increased the platinum sensitivity, but not taxol sensitivity, of ovarian cancer cells through increased expression of hCTR1, a copper transporter involved in platinum uptake.	Platinum	246-254	IMP U3 small nucleolar ribonucleoprotein 3	Homo sapiens	13-17
25825120-4	2015	This classification is indicative of patients" response to high dose alkylating and platinum containing chemotherapy regimens, which targets the inability of BRCA1 deficient cells to repair DNA double strand breaks.	Platinum	84-92	BRCA1 DNA repair associated	Homo sapiens	158-163
26063585-7	2015	Further analysis revealed that high expression of IGF2 was an unfavorable factor for the prognosis of the ovarian cancer patients at clinical stage I + II, stage III, histological grade 2, grade 3 or those treated with chemotherapy containing platin and Taxol.	Platinum	243-249	insulin like growth factor 2	Homo sapiens	50-54
26063687-4	2015	Results of large phase III randomized trials clearly established that EGFR TKIs are superior to chemotherapy as frontline treatment in patients with EGFR(mut+), whereas in the EGFR wild-type (EGFR(WT)) or EGFR unknown population, platinum-based chemotherapy remains the standard of care, with no consistent benefit produced by the addition of EGFR TKI.	Platinum	230-238	epidermal growth factor receptor	Homo sapiens	70-74
26158423-6	2015	Knockdown of IMP3 or Lin28B decreased cell proliferation, migration, and invasion, and increased the platinum sensitivity, but not taxol sensitivity, of ovarian cancer cells through increased expression of hCTR1, a copper transporter involved in platinum uptake.	Platinum	101-109	IMP U3 small nucleolar ribonucleoprotein 3	Homo sapiens	13-17
26158423-6	2015	Knockdown of IMP3 or Lin28B decreased cell proliferation, migration, and invasion, and increased the platinum sensitivity, but not taxol sensitivity, of ovarian cancer cells through increased expression of hCTR1, a copper transporter involved in platinum uptake.	Platinum	101-109	lin-28 homolog B	Homo sapiens	21-27
26158423-6	2015	Knockdown of IMP3 or Lin28B decreased cell proliferation, migration, and invasion, and increased the platinum sensitivity, but not taxol sensitivity, of ovarian cancer cells through increased expression of hCTR1, a copper transporter involved in platinum uptake.	Platinum	246-254	lin-28 homolog B	Homo sapiens	21-27
26158423-6	2015	Knockdown of IMP3 or Lin28B decreased cell proliferation, migration, and invasion, and increased the platinum sensitivity, but not taxol sensitivity, of ovarian cancer cells through increased expression of hCTR1, a copper transporter involved in platinum uptake.	Platinum	246-254	calcitonin receptor	Homo sapiens	206-211
26200905-0	2015	Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.	Platinum	211-219	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	35-131
26205780-3	2015	While HIF-1alpha has been associated with platinum resistance in a variety of cancers, including ovarian, relatively little is known about the importance of the duration of hypoxia.	Platinum	42-50	hypoxia inducible factor 1 subunit alpha	Homo sapiens	6-16
26200905-11	2015	RRM1 expression was predictive and prognostic of clinical outcome in advanced UC treated with gemcitabine plus platinum combination chemotherapy.	Platinum	111-119	ribonucleotide reductase catalytic subunit M1	Homo sapiens	0-4
26191776-3	2015	In 1 M HClO4 at 23  C, a CTR as low as 0.04 Omega cm(-2) was obtained with only 20 mug cm(-2) Pt and 11 mug cm(-2) Ru using the carbon-supported Ru@Pt with 1:1 Ru:Pt atomic ratio.	Platinum	94-96	calcitonin receptor	Homo sapiens	25-28
26196284-6	2015	Our studies showed that triple-negative breast cancer patients with attenuated iNOS levels in tumor cells after treatment showed better responses to platinum-based neoadjuvant chemotherapy than other triple-negative breast cancer patients.	Platinum	149-157	nitric oxide synthase 2	Homo sapiens	79-83
26196284-8	2015	Our data suggest that aberrant high level of iNOS/NO are associated with less effectiveness of platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.	Platinum	95-103	nitric oxide synthase 2	Homo sapiens	45-49
26196284-9	2015	Therefore, we propose to monitor iNOS levels as a new predictor for triple-negative breast cancer patient"s response to platinum-based neoadjuvant chemotherapy.	Platinum	120-128	nitric oxide synthase 2	Homo sapiens	33-37
26085466-3	2015	The CdS/Pt/TiO2 NTAs exhibited a much higher photocatalytic activity compared to pure TiO2 NTAs and binary CdS (or Pt)/TiO2 NTAs under visible light irradiation.	Platinum	8-10	CDP-diacylglycerol synthase 1	Homo sapiens	4-7
26085466-3	2015	The CdS/Pt/TiO2 NTAs exhibited a much higher photocatalytic activity compared to pure TiO2 NTAs and binary CdS (or Pt)/TiO2 NTAs under visible light irradiation.	Platinum	8-10	CDP-diacylglycerol synthase 1	Homo sapiens	107-110
26085466-3	2015	The CdS/Pt/TiO2 NTAs exhibited a much higher photocatalytic activity compared to pure TiO2 NTAs and binary CdS (or Pt)/TiO2 NTAs under visible light irradiation.	Platinum	115-117	CDP-diacylglycerol synthase 1	Homo sapiens	4-7
26085466-4	2015	A kinetic study showed that the rate constants of Pt/TiO2, CdS/TiO2 and CdS/Pt/TiO2 NTAs are 0.00736, 0.01717 and 0.02077 min(-1), respectively, revealing a remarkable kinetic enhancement in the ternary heteronanostructures due to the synergistic effect of the three components.	Platinum	50-52	CDP-diacylglycerol synthase 1	Homo sapiens	59-62
26085466-4	2015	A kinetic study showed that the rate constants of Pt/TiO2, CdS/TiO2 and CdS/Pt/TiO2 NTAs are 0.00736, 0.01717 and 0.02077 min(-1), respectively, revealing a remarkable kinetic enhancement in the ternary heteronanostructures due to the synergistic effect of the three components.	Platinum	50-52	CDP-diacylglycerol synthase 1	Homo sapiens	72-75
26085466-4	2015	A kinetic study showed that the rate constants of Pt/TiO2, CdS/TiO2 and CdS/Pt/TiO2 NTAs are 0.00736, 0.01717 and 0.02077 min(-1), respectively, revealing a remarkable kinetic enhancement in the ternary heteronanostructures due to the synergistic effect of the three components.	Platinum	76-78	CDP-diacylglycerol synthase 1	Homo sapiens	59-62
26085466-4	2015	A kinetic study showed that the rate constants of Pt/TiO2, CdS/TiO2 and CdS/Pt/TiO2 NTAs are 0.00736, 0.01717 and 0.02077 min(-1), respectively, revealing a remarkable kinetic enhancement in the ternary heteronanostructures due to the synergistic effect of the three components.	Platinum	76-78	CDP-diacylglycerol synthase 1	Homo sapiens	72-75
26085466-5	2015	Besides, the CdS/Pt/TiO2 NTAs exhibit high stability after being used 22 times.	Platinum	17-19	CDP-diacylglycerol synthase 1	Homo sapiens	13-16
25656821-0	2015	Association of Wnt-Inducible Signaling Pathway Protein 1 Genetic Polymorphisms With Lung Cancer Susceptibility and Platinum-Based Chemotherapy Response.	Platinum	115-123	cellular communication network factor 4	Homo sapiens	15-56
26211591-4	2015	Here we describe a nover conjugate comprising of Herceptin (an anti-HER2 antibody) and platinum drug via a cathepsin B cleavable dipetide for enhancing drug accumulation and HER2-positive cancer cell specific delivery.	Platinum	87-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-72
26211591-4	2015	Here we describe a nover conjugate comprising of Herceptin (an anti-HER2 antibody) and platinum drug via a cathepsin B cleavable dipetide for enhancing drug accumulation and HER2-positive cancer cell specific delivery.	Platinum	87-95	cathepsin B	Homo sapiens	107-118
26211591-4	2015	Here we describe a nover conjugate comprising of Herceptin (an anti-HER2 antibody) and platinum drug via a cathepsin B cleavable dipetide for enhancing drug accumulation and HER2-positive cancer cell specific delivery.	Platinum	87-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	174-178
26003539-0	2015	Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.	Platinum	120-128	BRCA1 DNA repair associated	Homo sapiens	20-25
26003539-0	2015	Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.	Platinum	120-128	DNA topoisomerase II binding protein 1	Homo sapiens	30-36
26003539-1	2015	PURPOSE: To investigate the correlation between protein expression of breast cancer susceptibility gene 1 (BRCA1) and topoisomerase IIbeta-binding protein 1 (TopBP1) and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.	Platinum	230-238	BRCA1 DNA repair associated	Homo sapiens	107-112
26003539-1	2015	PURPOSE: To investigate the correlation between protein expression of breast cancer susceptibility gene 1 (BRCA1) and topoisomerase IIbeta-binding protein 1 (TopBP1) and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.	Platinum	230-238	DNA topoisomerase II binding protein 1	Homo sapiens	118-156
26003539-1	2015	PURPOSE: To investigate the correlation between protein expression of breast cancer susceptibility gene 1 (BRCA1) and topoisomerase IIbeta-binding protein 1 (TopBP1) and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.	Platinum	230-238	DNA topoisomerase II binding protein 1	Homo sapiens	158-164
26328013-0	2015	HOTAIR is a predictive and prognostic biomarker for patients with advanced gastric adenocarcinoma receiving fluorouracil and platinum combination chemotherapy.	Platinum	125-133	HOX transcript antisense RNA	Homo sapiens	0-6
26328013-4	2015	This study aimed to evaluate the association of HOTAIR expression with the prognosis of patients with advanced gastric adenocarcinoma (GA) receiving fluorouracil and platinum based chemotherapy.	Platinum	166-174	HOX transcript antisense RNA	Homo sapiens	48-54
26328013-5	2015	We examined the levels of HOTAIR in 168 GA samples using quantitative real-time PCR and analyzed its relationship with clinical features and prognosis of patients with advanced GA treated with fluorouracil and platinum based chemotherapy.	Platinum	210-218	HOX transcript antisense RNA	Homo sapiens	26-32
26328013-8	2015	In conclusion, our results provide first evidence that HOTAIR may be served as a biomarker that predicts which patient with advanced GA will benefit from fluorouracil and platinum combination chemotherapy.	Platinum	171-179	HOX transcript antisense RNA	Homo sapiens	55-61
25656821-3	2015	In this study, we aimed to investigate the relationship of WISP1 genetic polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response in Chinese lung cancer patients.	Platinum	123-131	cellular communication network factor 4	Homo sapiens	59-64
25656821-7	2015	CONCLUSION: Genotypes of WISP1 may be novel and useful biomarkers for diagnosis of lung cancer and evaluation of platinum-based chemotherapy response in lung cancer patients.	Platinum	113-121	cellular communication network factor 4	Homo sapiens	25-30
25956741-2	2015	Based on mouse xenograft experiments, where ERCC1-deficient melanomas were cured by cisplatin therapy, we proposed that inhibition of ERCC1-XPF could enhance the effectiveness of platinum-based chemotherapy.	Platinum	179-187	excision repair cross-complementing rodent repair deficiency, complementation group 4	Mus musculus	140-143
25956741-1	2015	ERCC1-XPF is a structure-specific endonuclease that is required for the repair of DNA lesions, generated by the widely used platinum-containing cancer chemotherapeutics such as cisplatin, through the Nucleotide Excision Repair and Interstrand Crosslink Repair pathways.	Platinum	124-132	excision repair cross-complementing rodent repair deficiency, complementation group 1	Mus musculus	0-5
26458583-6	2015	RESULTS: In this meta-analysis, we found that XRCC1 Arg194Trp polymorphism was significantly associated with the efficacy of platinum-based chemotherapy.	Platinum	125-133	X-ray repair cross complementing 1	Homo sapiens	46-51
25956741-1	2015	ERCC1-XPF is a structure-specific endonuclease that is required for the repair of DNA lesions, generated by the widely used platinum-containing cancer chemotherapeutics such as cisplatin, through the Nucleotide Excision Repair and Interstrand Crosslink Repair pathways.	Platinum	124-132	excision repair cross-complementing rodent repair deficiency, complementation group 4	Mus musculus	6-9
25956741-2	2015	Based on mouse xenograft experiments, where ERCC1-deficient melanomas were cured by cisplatin therapy, we proposed that inhibition of ERCC1-XPF could enhance the effectiveness of platinum-based chemotherapy.	Platinum	179-187	excision repair cross-complementing rodent repair deficiency, complementation group 1	Mus musculus	44-49
26458583-0	2015	Effect of X-ray repair cross complementing group 1 polymorphisms on the efficacy of platinum-based chemotherapy in patients with nonsmall cell lung cancer.	Platinum	84-92	X-ray repair cross complementing 1	Homo sapiens	10-50
26458583-1	2015	AIMS: X-ray repair cross complementing group 1 (XRCC1) has been indicated to be correlated with the efficacy of platinum-based chemotherapy.	Platinum	112-120	X-ray repair cross complementing 1	Homo sapiens	6-46
26458583-1	2015	AIMS: X-ray repair cross complementing group 1 (XRCC1) has been indicated to be correlated with the efficacy of platinum-based chemotherapy.	Platinum	112-120	X-ray repair cross complementing 1	Homo sapiens	48-53
26458583-8	2015	CONCLUSION: This meta-analysis suggested that the XRCC1 Arg194Trp polymorphism may be associated with efficacy of platinum-based chemotherapy.	Platinum	114-122	X-ray repair cross complementing 1	Homo sapiens	50-55
26131551-7	2015	MRP2 inhibitors (myricetin and MK571) reduced the ATP-dependent accumulation of oxaliplatin-derived platinum in MRP2-expressing membrane vesicles in a concentration-dependent manner.	Platinum	100-108	ATP binding cassette subfamily C member 2	Homo sapiens	0-4
26181256-13	2015	Follow-up experiments established that loss of FANCA function was associated with platinum hypersensitivity both in vitro and in patient-derived xenografts, thus providing biologic rationale and functional evidence for his extreme clinical response.	Platinum	82-90	FA complementation group A	Homo sapiens	47-52
25263447-0	2015	p53 protein aggregation promotes platinum resistance in ovarian cancer.	Platinum	33-41	tumor protein p53	Homo sapiens	0-3
25263447-9	2015	With in vitro and in vivo models, we demonstrated that the inhibition of p14ARF could suppress p53 aggregation and sensitize cancer cells to platinum treatment.	Platinum	141-149	cyclin dependent kinase inhibitor 2A	Homo sapiens	73-79
26131551-0	2015	Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles.	Platinum	91-99	ATP binding cassette subfamily C member 2	Homo sapiens	0-41
26131551-7	2015	MRP2 inhibitors (myricetin and MK571) reduced the ATP-dependent accumulation of oxaliplatin-derived platinum in MRP2-expressing membrane vesicles in a concentration-dependent manner.	Platinum	100-108	ATP binding cassette subfamily C member 2	Homo sapiens	112-116
26131551-0	2015	Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles.	Platinum	91-99	ATP binding cassette subfamily C member 2	Homo sapiens	43-47
26131551-3	2015	In the current study, preparations of MRP2-expressing and control membrane vesicles, containing inside-out orientated vesicles, were used to directly characterise the membrane transport of oxaliplatin-derived platinum measured by inductively coupled plasma mass spectrometry.	Platinum	209-217	ATP binding cassette subfamily C member 2	Homo sapiens	38-42
26131551-5	2015	MRP2-expressing membrane vesicles accumulated up to 19-fold more platinum during their incubation with oxaliplatin and ATP as compared to control membrane vesicles and in the absence of ATP.	Platinum	65-73	ATP binding cassette subfamily C member 2	Homo sapiens	0-4
26131551-9	2015	In conclusion, MRP2 mediates the ATP-dependent active membrane transport of oxaliplatin-derived platinum.	Platinum	96-104	ATP binding cassette subfamily C member 2	Homo sapiens	15-19
25847936-11	2015	CONCLUSION: Platinum agents are active in mTNBC, especially in patients with germline BRCA1/2 mutations.	Platinum	12-20	BRCA1 DNA repair associated	Homo sapiens	86-93
25999351-6	2015	The enrichment of ALDH1 expression after treatment was associated with a poor response to chemotherapy, with platinum resistance and independently prognosticated unfavorable outcome.	Platinum	109-117	aldehyde dehydrogenase 1 family member A1	Homo sapiens	18-23
25892674-8	2015	Finally, it is important to note that HE4 identifies platinum non-responders thus enabling a switch to second line chemotherapy and improved survival.	Platinum	53-61	WAP four-disulfide core domain 2	Homo sapiens	38-41
26086967-1	2015	Two main causes of platinum resistance are mutation in the tumor suppressor gene TP53 and drug-induced increase in intracellular glutathione concentration.	Platinum	19-27	tumor protein p53	Homo sapiens	81-85
26086967-7	2015	We propose that this unique ability of APR-246/MQ to bind to cysteines in both mutant p53 and glutathione has a key role in the resensitization as well as in the outstanding synergistic effects observed with APR-246 in combination with platinum compounds in ovarian cancer cell lines and primary cancer cells.	Platinum	236-244	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	39-42
26086967-7	2015	We propose that this unique ability of APR-246/MQ to bind to cysteines in both mutant p53 and glutathione has a key role in the resensitization as well as in the outstanding synergistic effects observed with APR-246 in combination with platinum compounds in ovarian cancer cell lines and primary cancer cells.	Platinum	236-244	tumor protein p53	Homo sapiens	86-89
26086967-7	2015	We propose that this unique ability of APR-246/MQ to bind to cysteines in both mutant p53 and glutathione has a key role in the resensitization as well as in the outstanding synergistic effects observed with APR-246 in combination with platinum compounds in ovarian cancer cell lines and primary cancer cells.	Platinum	236-244	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	208-211
26086967-10	2015	Our results provide a strong rationale for the ongoing clinical study with APR-246 in combination with platinum-based therapy in patients with p53-mutant recurrent high-grade serous (HGS) ovarian cancer.	Platinum	103-111	tumor protein p53	Homo sapiens	143-146
26086967-12	2015	Combined treatment with APR-246 and platinum or other DNA-damaging drugs could allow dramatically improved therapy of a wide range of therapy refractory p53 mutant tumors.	Platinum	36-44	tumor protein p53	Homo sapiens	153-156
26039708-0	2015	Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors.	Platinum	126-134	AKT serine/threonine kinase 1	Homo sapiens	56-59
26078799-0	2015	Annexin A3 Is a Potential Predictor of Platinum Resistance in Epithelial Ovarian Cancer Patients in a Prospective Cohort.	Platinum	39-47	annexin A3	Homo sapiens	0-10
26078799-2	2015	In our previous studies, the platinum-resistance-related protein, annexin A3, was selected by comparative proteomics.	Platinum	29-37	annexin A3	Homo sapiens	66-76
26078799-4	2015	We also evaluated the capacity of serum annexin A3 levels to predict platinum resistance.	Platinum	69-77	annexin A3	Homo sapiens	40-50
26078799-7	2015	Residual disease after primary surgery (p=0.004) and serum annexin A3 levels (p=0.036) were both independent factors associated with platinum resistance.	Platinum	133-141	annexin A3	Homo sapiens	59-69
26078799-10	2015	Multivariate logistic analysis showed that expression of annexin A3 as assessed by immunohistochemistry (P=0.005) and residual tumor size (P=0.000) had a significant influence on platinum resistance.	Platinum	179-187	annexin A3	Homo sapiens	57-67
26078799-13	2015	Serum annexin A3 levels may be a potential predictor of platinum resistance in epithelial ovarian cancer patients.	Platinum	56-64	annexin A3	Homo sapiens	6-16
26057002-4	2015	WEE1 rs3910384 genotype correlated to overall survival (OS) and progress-free survival (PFS) of NSCLC patients treated with platinum-based chemotherapy.	Platinum	124-132	WEE1 G2 checkpoint kinase	Homo sapiens	0-4
26057002-6	2015	NSCLC patients with the WEE1 rs3910384 G/G homozygote genotype showed 13.5 months extended OS, 3.2 months extended PFS, and a 274% relative increase in their 3-year survival rate (from 7.4% to 27.7%) compared to the A/A+A/G genotype after treatment with platinum-gemcitabine regimen.	Platinum	254-262	WEE1 G2 checkpoint kinase	Homo sapiens	24-28
26057002-9	2015	In conclusion, the WEE1 rs3910384 G/G homozygote genotype can be used as a selective biomarker for NSCLC patients to indicate treatment with platinum and gemcitabine regimen.	Platinum	141-149	WEE1 G2 checkpoint kinase	Homo sapiens	19-23
25132263-2	2015	This study investigates whether BRCA1-IRIS is a novel treatment target for ovarian cancers and in platinum-resistant recurrences.	Platinum	98-106	breast cancer 1, early onset	Mus musculus	32-37
26039708-0	2015	Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors.	Platinum	126-134	mechanistic target of rapamycin kinase	Homo sapiens	60-64
23689644-0	2015	Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.	Platinum	162-170	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	25-30
23689644-10	2015	CONCLUSIONS: Our data suggest ABCG2 htSNPs rs2725264 (overall group and taxane-platinum combination group) and rs4148149 (gemcitabine-platinum combination group) were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy.	Platinum	79-87	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	30-35
23689644-10	2015	CONCLUSIONS: Our data suggest ABCG2 htSNPs rs2725264 (overall group and taxane-platinum combination group) and rs4148149 (gemcitabine-platinum combination group) were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy.	Platinum	134-142	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	30-35
23689644-10	2015	CONCLUSIONS: Our data suggest ABCG2 htSNPs rs2725264 (overall group and taxane-platinum combination group) and rs4148149 (gemcitabine-platinum combination group) were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy.	Platinum	134-142	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	30-35
23689644-11	2015	Thus, the ABCG2 htSNP rs2725264 may be independently associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy.	Platinum	127-135	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	10-15
25935221-2	2015	The CdS QDs preparations were applied onto a platinum electrode to obtain solid films.	Platinum	45-53	CDP-diacylglycerol synthase 1	Homo sapiens	4-7
26082895-15	2015	CONCLUSION: Our exploratory correlative studies indicate that CEC and IL-8 changes may be predictive for response to O + C and prognostic in recurrent platinum-sensitive OvCa, requiring prospective validation.	Platinum	151-159	C-X-C motif chemokine ligand 8	Homo sapiens	70-74
25678479-4	2015	Coil retrieval was performed by placing a Trevo ProVue stent retriever over the coil and trying to trap a part of the platinum coil within the stent mesh by advancing the microcatheter over the stent or simply by retrieving the stent without trying to trap the coil by advancing the microcatheter.	Platinum	118-126	coilin	Homo sapiens	0-4
25678479-4	2015	Coil retrieval was performed by placing a Trevo ProVue stent retriever over the coil and trying to trap a part of the platinum coil within the stent mesh by advancing the microcatheter over the stent or simply by retrieving the stent without trying to trap the coil by advancing the microcatheter.	Platinum	118-126	coilin	Homo sapiens	127-131
25678479-4	2015	Coil retrieval was performed by placing a Trevo ProVue stent retriever over the coil and trying to trap a part of the platinum coil within the stent mesh by advancing the microcatheter over the stent or simply by retrieving the stent without trying to trap the coil by advancing the microcatheter.	Platinum	118-126	coilin	Homo sapiens	127-131
26247532-8	2015	CK19 was significantly up-regulated in PNENs, having higher pT (p=0.018), pR (p=0.025), vascular (p=0.020), perineural (p=0.026) and lymphatic invasion (p=0.043).	Platinum	60-62	keratin 19	Homo sapiens	0-4
25846650-5	2015	Moreover, IL-33 at these low concentrations protected against platinum-induced apoptosis in various gastric cancer cell lines, yet not in normal gastric epithelial cells.	Platinum	62-70	interleukin 33	Homo sapiens	10-15
25846650-9	2015	In conclusion, the present study demonstrated that IL-33 protected against platinum-induced apoptosis and promoted cell invasion via activation of the JNK pathway in gastric cancer cells.	Platinum	75-83	interleukin 33	Homo sapiens	51-56
25846650-9	2015	In conclusion, the present study demonstrated that IL-33 protected against platinum-induced apoptosis and promoted cell invasion via activation of the JNK pathway in gastric cancer cells.	Platinum	75-83	mitogen-activated protein kinase 8	Homo sapiens	151-154
25846650-10	2015	In light of the prevalence of platinum-based chemotherapeutics in the treatment of gastric cancer, our results suggest that the level of IL-33 should be monitored during the treatment of gastric cancer, particularly when using platinum-based chemotherapeutics.	Platinum	30-38	interleukin 33	Homo sapiens	137-142
25846650-10	2015	In light of the prevalence of platinum-based chemotherapeutics in the treatment of gastric cancer, our results suggest that the level of IL-33 should be monitored during the treatment of gastric cancer, particularly when using platinum-based chemotherapeutics.	Platinum	227-235	interleukin 33	Homo sapiens	137-142
25866324-5	2015	Mean levels of serum CA125 and HE4 decreased comparably in patients during initial treatment regardless of their primary platinum response, but mean urine HE4 levels decreased only 7% in primary platinum resistant patients while decreasing 68% in those who were sensitive.	Platinum	195-203	WAP four-disulfide core domain 2	Homo sapiens	155-158
25866324-6	2015	By 7months after diagnosis, urine HE4 levels were higher in primary platinum resistant patients compared to those who proved to be sensitive (p=0.051) and persisted 12months after diagnosis (p=0.014).	Platinum	68-76	WAP four-disulfide core domain 2	Homo sapiens	34-37
25866324-8	2015	CONCLUSIONS: Measuring HE4 in urine complements serum assays for the detection of ovarian cancer and may allow identification of patients at high risk for primary platinum resistance.	Platinum	163-171	WAP four-disulfide core domain 2	Homo sapiens	23-26
25359574-5	2015	Furthermore, in NSCLC cell lines, ATF2 expression levels were evaluated and correlated to platinum (CDDP) resistance.	Platinum	90-98	activating transcription factor 2	Homo sapiens	34-38
25991068-19	2015	AUTHORS" CONCLUSIONS: PARP inhibitors appear to improve PFS in women with recurrent platinum-sensitive disease.	Platinum	84-92	poly(ADP-ribose) polymerase 1	Homo sapiens	22-26
26164510-0	2015	[eIF3a gene polymorphism and chemo-sensitivity to platinum-based drugs in ovarian cancer].	Platinum	50-58	eukaryotic translation initiation factor 3 subunit J	Homo sapiens	1-6
26164510-11	2015	The genotype of eIF3a rs10787899 GA was easier to resist platinum drug compared with the GG genotype and the odds ratio could be increased by 2.676 (95%CI: 0.544-13.159).	Platinum	57-65	eukaryotic translation initiation factor 3 subunit J	Homo sapiens	16-21
26164510-12	2015	The genotype of eIF3a rs10787899 AA was easier to resist platinum drug compared with the GG genotype and the odds ratio could be increased by 5.419(95%CI: 0.964-30.471).	Platinum	57-65	eukaryotic translation initiation factor 3 subunit J	Homo sapiens	16-21
26020272-4	2015	This study aimed to investigate the association of TERT polymorphisms with clinical outcome of advanced non-small cell lung cancer (NSCLC) patients receiving first-line platinum-based chemotherapy, including response rate, clinical benefit, progression-free survival (PFS), overall survival (OS), and grade 3 or 4 toxicity.	Platinum	169-177	telomerase reverse transcriptase	Homo sapiens	51-55
26020272-9	2015	The results from the current study, for the first time to our knowledge, provide suggestive evidence of an effect of TERT polymorphisms on disease progression variability among Chinese patients with platinum-treated advanced NSCLC.	Platinum	199-207	telomerase reverse transcriptase	Homo sapiens	117-121
25770156-6	2015	Our data therefore provide a mechanistic association between HORMAD1 expression, a specific pattern of genomic instability, and an association with response to platinum-based chemotherapy in TNBC.	Platinum	160-168	HORMA domain containing 1	Homo sapiens	61-68
26024188-3	2015	The pure spin current is detected by using the inverse spin-Hall effect of either a Pt or Pd electrode on n-Ge.	Platinum	84-86	spindlin 1	Homo sapiens	9-13
26024188-3	2015	The pure spin current is detected by using the inverse spin-Hall effect of either a Pt or Pd electrode on n-Ge.	Platinum	84-86	spindlin 1	Homo sapiens	55-59
25529533-8	2015	The platinum plasma concentrations in the LLC tumor-bearing mice receiving NP10 remained up to 46-fold higher than that of mice receiving equivalent doses of free CDDP.	Platinum	4-12	nuclear receptor subfamily 4, group A, member 1	Mus musculus	75-79
25529533-10	2015	The platinum concentration ratio of NP10 to free CDDP in tumors reached as high as 9.4.	Platinum	4-12	nuclear receptor subfamily 4, group A, member 1	Mus musculus	36-40
26015868-1	2015	BACKGROUND: Ovarian and triple-negative breast cancers with BRCA1 or BRCA2 loss are highly sensitive to treatment with PARP inhibitors and platinum-based cytotoxic agents and show an accumulation of genomic scars in the form of gross DNA copy number aberrations.	Platinum	139-147	BRCA1 DNA repair associated	Homo sapiens	60-65
26015868-1	2015	BACKGROUND: Ovarian and triple-negative breast cancers with BRCA1 or BRCA2 loss are highly sensitive to treatment with PARP inhibitors and platinum-based cytotoxic agents and show an accumulation of genomic scars in the form of gross DNA copy number aberrations.	Platinum	139-147	BRCA2 DNA repair associated	Homo sapiens	69-74
26015868-2	2015	Cancers without BRCA1 or BRCA2 loss but with accumulation of similar genomic scars also show increased sensitivity to platinum-based chemotherapy.	Platinum	118-126	BRCA1 DNA repair associated	Homo sapiens	16-21
26015868-2	2015	Cancers without BRCA1 or BRCA2 loss but with accumulation of similar genomic scars also show increased sensitivity to platinum-based chemotherapy.	Platinum	118-126	BRCA2 DNA repair associated	Homo sapiens	25-30
25940438-9	2015	Thus, we present the novel TSN-S100A11-PLA(2) axis regulating superoxide-dependent apoptosis, triggered by platinum-based chemotherapeutic agents in NSCLC that may be targeted by innovative cancer therapies.	Platinum	107-115	translin	Homo sapiens	27-30
25940438-9	2015	Thus, we present the novel TSN-S100A11-PLA(2) axis regulating superoxide-dependent apoptosis, triggered by platinum-based chemotherapeutic agents in NSCLC that may be targeted by innovative cancer therapies.	Platinum	107-115	S100 calcium binding protein A11	Homo sapiens	31-38
25940438-9	2015	Thus, we present the novel TSN-S100A11-PLA(2) axis regulating superoxide-dependent apoptosis, triggered by platinum-based chemotherapeutic agents in NSCLC that may be targeted by innovative cancer therapies.	Platinum	107-115	phospholipase A2 group IB	Homo sapiens	39-45
25860784-1	2015	We used coordinated mutagenesis, synthetic design, and flexible docking to investigate the structural mechanism of Env gp120 encounter by peptide triazole (PT) inactivators of HIV-1.	Platinum	156-158	endogenous retrovirus group K member 20	Homo sapiens	115-118
25860784-1	2015	We used coordinated mutagenesis, synthetic design, and flexible docking to investigate the structural mechanism of Env gp120 encounter by peptide triazole (PT) inactivators of HIV-1.	Platinum	156-158	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	119-124
25772757-1	2015	PURPOSE: The purposes of this study were to determine whether organic cation transporters (OCTs) can mediate platinum uptake, and whether OCT down-regulation confers resistance against cisplatin (CDDP) in cancer cells.	Platinum	109-117	plexin A2	Homo sapiens	91-94
25772757-7	2015	Furthermore, OCT6 overexpression induced by transfection of the OCT6 gene (SLC22A16) forced expression vector-sensitized PC-14/CDDP cells to CDDP and oxaliplatin (L-OHP) concomitant with increased intracellular concentration of platinum.	Platinum	228-236	solute carrier family 22 member 16	Homo sapiens	13-17
25772757-7	2015	Furthermore, OCT6 overexpression induced by transfection of the OCT6 gene (SLC22A16) forced expression vector-sensitized PC-14/CDDP cells to CDDP and oxaliplatin (L-OHP) concomitant with increased intracellular concentration of platinum.	Platinum	228-236	solute carrier family 22 member 16	Homo sapiens	64-68
25772757-7	2015	Furthermore, OCT6 overexpression induced by transfection of the OCT6 gene (SLC22A16) forced expression vector-sensitized PC-14/CDDP cells to CDDP and oxaliplatin (L-OHP) concomitant with increased intracellular concentration of platinum.	Platinum	228-236	solute carrier family 22 member 16	Homo sapiens	75-83
25772757-8	2015	CONCLUSION: OCT6 is a mediator of platinum uptake in cancer cells, and down-regulation of OCT6 is possibly one of the mechanisms of resistance against cisplatin in lung cancer.	Platinum	34-42	solute carrier family 22 member 16	Homo sapiens	12-16
25926105-1	2015	BACKGROUND: No previous study has addressed the efficacy of NF-kappaB blockade when bladder tumors develop acquired resistance toward CDDP-treatments.	Platinum	134-138	nuclear factor kappa B subunit 1	Homo sapiens	60-69
25573098-0	2015	Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy.	Platinum	163-171	myoglobin	Homo sapiens	62-71
25573098-12	2015	Expression of ERCC1, TYMS, TUBB3, non-muscle myosin II, myoglobin and MyoD1 was also associated with decreased survival rates of patients with lung adenocarcinoma treated with platinum-based chemotherapy.	Platinum	176-184	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-19
25573098-12	2015	Expression of ERCC1, TYMS, TUBB3, non-muscle myosin II, myoglobin and MyoD1 was also associated with decreased survival rates of patients with lung adenocarcinoma treated with platinum-based chemotherapy.	Platinum	176-184	thymidylate synthetase	Homo sapiens	21-25
25573098-12	2015	Expression of ERCC1, TYMS, TUBB3, non-muscle myosin II, myoglobin and MyoD1 was also associated with decreased survival rates of patients with lung adenocarcinoma treated with platinum-based chemotherapy.	Platinum	176-184	tubulin beta 3 class III	Homo sapiens	27-32
25573098-12	2015	Expression of ERCC1, TYMS, TUBB3, non-muscle myosin II, myoglobin and MyoD1 was also associated with decreased survival rates of patients with lung adenocarcinoma treated with platinum-based chemotherapy.	Platinum	176-184	myoglobin	Homo sapiens	56-65
25573098-12	2015	Expression of ERCC1, TYMS, TUBB3, non-muscle myosin II, myoglobin and MyoD1 was also associated with decreased survival rates of patients with lung adenocarcinoma treated with platinum-based chemotherapy.	Platinum	176-184	myogenic differentiation 1	Homo sapiens	70-75
25926105-2	2015	We investigated the changes in NF-kappaB activation and therapeutic impact of NF-kappaB blockade by the novel NF-kappaB inhibitor dehydroxymethyl derivative of epoxyquinomicin (DHMEQ) in CDDP-resistant bladder cancer cells.	Platinum	187-191	nuclear factor kappa B subunit 1	Homo sapiens	78-87
25926105-2	2015	We investigated the changes in NF-kappaB activation and therapeutic impact of NF-kappaB blockade by the novel NF-kappaB inhibitor dehydroxymethyl derivative of epoxyquinomicin (DHMEQ) in CDDP-resistant bladder cancer cells.	Platinum	187-191	nuclear factor kappa B subunit 1	Homo sapiens	78-87
25966119-0	2015	Correlation of MSH3 polymorphisms with response and survival in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.	Platinum	133-141	mutS homolog 3	Homo sapiens	15-19
25901419-8	2015	Significant associations were also found in the patients treated with EGFR-TKIs (HR = 1.83; 95%CI = 1.31-2.58; P = 0.011) and platinum-based regimen (HR = 1.53; 95%CI = 1.18-1.99; P = 0.001).	Platinum	126-134	epidermal growth factor receptor	Homo sapiens	70-74
25779564-1	2015	Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease.	Platinum	128-136	poly(ADP-ribose) polymerase 1	Homo sapiens	0-28
25779564-1	2015	Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease.	Platinum	128-136	poly(ADP-ribose) polymerase 1	Homo sapiens	30-34
25966119-7	2015	Our results showed that single nucleotide polymorphisms in MSH3 had an impact on the chemotherapy response and prognosis of advanced NCSLC patients who were treated with platinum-based chemotherapy.	Platinum	170-178	mutS homolog 3	Homo sapiens	59-63
25779613-4	2015	A polysulfide electrolyte and a Pt-coated FTO glass count electrode were used to test the photovoltaic performance of the constructed devices.	Platinum	32-34	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	42-45
25768916-1	2015	Platinum-derivatized homopyrimidine triplex-forming oligonucleotides (Pt-TFOs) consisting of 2"-O-methyl-5-methyluridine, 2"-O-methyl-5-methylcytidine, and a single 3"-N7-trans-chlorodiammine platinum(II)-2"-deoxyguanosine were designed to cross-link to the transcribed strand at four different sequences in the human androgen receptor (AR) gene.	Platinum	0-8	androgen receptor	Homo sapiens	318-335
26574362-2	2015	In this study, the recently observed qualitative differences between the platinum and gold compounds in the magnitude and the sign of spin-orbit-induced (SO) nuclear magnetic shielding at the vicinal light atom ((13)C, (15)N), sigma(SO)(LA), are explained by the contractions of 6s and 6p atomic orbitals in Au complexes, originating in the larger Au nuclear charge and stronger scalar relativistic effects in gold complexes.	Platinum	73-81	spindlin 1	Homo sapiens	134-138
25768916-1	2015	Platinum-derivatized homopyrimidine triplex-forming oligonucleotides (Pt-TFOs) consisting of 2"-O-methyl-5-methyluridine, 2"-O-methyl-5-methylcytidine, and a single 3"-N7-trans-chlorodiammine platinum(II)-2"-deoxyguanosine were designed to cross-link to the transcribed strand at four different sequences in the human androgen receptor (AR) gene.	Platinum	0-8	androgen receptor	Homo sapiens	337-339
25768916-9	2015	Although the levels of knockdown of AR mRNA and protein were modest, the results suggest that Pt-TFOs hold potential as agents for controlling gene expression by cross-linking to DNA and disrupting transcription.	Platinum	94-96	androgen receptor	Homo sapiens	36-38
25647444-0	2015	ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.	Platinum	98-106	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
25627260-2	2015	We previously showed that Bcl-xL and Mcl-1 cooperatively protect platinum-resistant ovarian cancer cells from apoptosis.	Platinum	65-73	BCL2 like 1	Homo sapiens	26-32
25627260-2	2015	We previously showed that Bcl-xL and Mcl-1 cooperatively protect platinum-resistant ovarian cancer cells from apoptosis.	Platinum	65-73	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	37-42
25331442-0	2015	Stromal Expression of Fibroblast Activation Protein Alpha (FAP) Predicts Platinum Resistance and Shorter Recurrence in patients with Epithelial Ovarian Cancer.	Platinum	73-81	fibroblast activation protein alpha	Homo sapiens	22-57
25331442-0	2015	Stromal Expression of Fibroblast Activation Protein Alpha (FAP) Predicts Platinum Resistance and Shorter Recurrence in patients with Epithelial Ovarian Cancer.	Platinum	73-81	fibroblast activation protein alpha	Homo sapiens	59-62
25691460-0	2015	Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients.	Platinum	67-75	tumor protein p53	Homo sapiens	29-33
25331442-7	2015	FAP immunoexpression by tumor stroma was a significant predictive factor for platinum resistance (p = 0.0154).	Platinum	77-85	fibroblast activation protein alpha	Homo sapiens	0-3
25672916-1	2015	PURPOSE: Phosphatidylinositol-3-kinase I (PI3K) inhibition sensitizes a wide range of cancer cell lines to platinum/taxane-based chemotherapy.	Platinum	107-115	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	9-40
25765877-4	2015	Platinum derivatives, such as cisplatin and carboplatin, harm mainly peripheral nerves and dorsal root ganglia neurons, possibly because of progressive DNA-adduct accumulation and inhibition of DNA repair pathways (e.g., extracellular signal-regulated kinase 1/2, c-Jun N-terminal kinase/stress-activated protein kinase, and p38 mitogen-activated protein kinass), which finally mediate apoptosis.	Platinum	0-8	mitogen-activated protein kinase 3	Homo sapiens	221-262
25780441-8	2015	Furthermore, high/positive ERCC1 expression was found to be associated with poor survival in patients receiving platinum-based chemotherapy in the RT-PCR group (HR 2.13; 95% CI 1.06-4.27).	Platinum	112-120	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	27-32
25780441-10	2015	In addition, low mRNA levels of ERCC1 appear to be associated with a significant favorable OS benefit from platinum-based chemotherapy.	Platinum	107-115	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	32-37
25681684-0	2015	Differential activation of NF-kappaB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.	Platinum	66-74	nuclear factor kappa B subunit 1	Homo sapiens	27-36
25681684-5	2015	Using isogenic cellular matrices of cisplatin, paclitaxel and platinum-taxol resistant MyD88(negative) A2780 ovarian cancer cells expressing a NF-kappaB reporter sensor, we showed that enhanced NF-kappaB activity was required for cisplatin but not for paclitaxel resistance.	Platinum	62-70	MYD88 innate immune signal transduction adaptor	Homo sapiens	87-92
25681684-5	2015	Using isogenic cellular matrices of cisplatin, paclitaxel and platinum-taxol resistant MyD88(negative) A2780 ovarian cancer cells expressing a NF-kappaB reporter sensor, we showed that enhanced NF-kappaB activity was required for cisplatin but not for paclitaxel resistance.	Platinum	62-70	nuclear factor kappa B subunit 1	Homo sapiens	143-152
25681684-5	2015	Using isogenic cellular matrices of cisplatin, paclitaxel and platinum-taxol resistant MyD88(negative) A2780 ovarian cancer cells expressing a NF-kappaB reporter sensor, we showed that enhanced NF-kappaB activity was required for cisplatin but not for paclitaxel resistance.	Platinum	62-70	nuclear factor kappa B subunit 1	Homo sapiens	194-203
25681684-8	2015	In contrast, paclitaxel and the platinum-taxol resistant cells showed down regulation in NF-kappaB activity.	Platinum	32-40	nuclear factor kappa B subunit 1	Homo sapiens	89-98
25681684-9	2015	Intriguingly, silencing of MyD88 in cisplatin resistant and MyD88(positive) TOV21G and SKOV3 cells showed enhanced NF-kappaB activity after cisplatin but not after paclitaxel or platinum-taxol treatments.	Platinum	178-186	MYD88 innate immune signal transduction adaptor	Homo sapiens	27-32
25681684-9	2015	Intriguingly, silencing of MyD88 in cisplatin resistant and MyD88(positive) TOV21G and SKOV3 cells showed enhanced NF-kappaB activity after cisplatin but not after paclitaxel or platinum-taxol treatments.	Platinum	178-186	MYD88 innate immune signal transduction adaptor	Homo sapiens	60-65
25681684-9	2015	Intriguingly, silencing of MyD88 in cisplatin resistant and MyD88(positive) TOV21G and SKOV3 cells showed enhanced NF-kappaB activity after cisplatin but not after paclitaxel or platinum-taxol treatments.	Platinum	178-186	nuclear factor kappa B subunit 1	Homo sapiens	115-124
25519148-12	2015	IMPLICATIONS: AKT-targeted therapy has value in a first-line setting as well as a second-line treatment for recurrent disease developing after platinum-based chemotherapy or bevacizumab treatment.	Platinum	143-151	AKT serine/threonine kinase 1	Homo sapiens	14-17
26130472-6	2015	Platinum specific IgE measurement and basophil activation test (BAT) are emerging as new diagnostic tools and in combination with skin testing can help support the diagnosis and the cross-reactivity between the three most commonly used platinum drugs, namely carboplatin, cisplatin, and oxaliplatin.	Platinum	0-8	immunoglobulin heavy constant epsilon	Homo sapiens	18-21
25870375-8	2015	The patient was treated with platinum-based doublet chemotherapy and sorafenib, and his AFP level decreased to 25 ng/mL.	Platinum	29-37	alpha fetoprotein	Homo sapiens	88-91
25870375-9	2015	This case report presents the novel use of sorafenib in combination with platinum-based doublet chemotherapy in EGFR wild-type HAL, which led to a partial response.	Platinum	73-81	epidermal growth factor receptor	Homo sapiens	112-116
25870375-9	2015	This case report presents the novel use of sorafenib in combination with platinum-based doublet chemotherapy in EGFR wild-type HAL, which led to a partial response.	Platinum	73-81	histidine ammonia-lyase	Homo sapiens	127-130
25597412-3	2015	miR-197 is downregulated in platinum-resistant NSCLC specimens, resulting in the promotion of chemoresistance, tumorigenicity, and pulmonary metastasis in vitro and in vivo.	Platinum	28-36	microRNA 197	Homo sapiens	0-7
25108408-0	2015	Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.	Platinum	75-83	cadherin 1	Homo sapiens	20-30
25108408-1	2015	To analyze correlation between immunoexpression of E-cadherin and efficacy of first line platinum-based chemotherapy in patients with advanced-stage high-grade serous ovarian carcinoma.	Platinum	89-97	cadherin 1	Homo sapiens	51-61
25108408-5	2015	Positive E-cadherin expression predict significantly better response to first line platinum-based chemotherapy (p &lt; 0.001) and platinum sensitivity (p &lt; 0.001).	Platinum	83-91	cadherin 1	Homo sapiens	9-19
25194563-14	2015	We could confirm our previous data in a larger cohort that platinum-based chemotherapy affects the ERCC1 expression probably referring to an induction of tumor cell selection.	Platinum	59-67	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	99-104
25765877-4	2015	Platinum derivatives, such as cisplatin and carboplatin, harm mainly peripheral nerves and dorsal root ganglia neurons, possibly because of progressive DNA-adduct accumulation and inhibition of DNA repair pathways (e.g., extracellular signal-regulated kinase 1/2, c-Jun N-terminal kinase/stress-activated protein kinase, and p38 mitogen-activated protein kinass), which finally mediate apoptosis.	Platinum	0-8	mitogen-activated protein kinase 14	Homo sapiens	325-328
25108408-5	2015	Positive E-cadherin expression predict significantly better response to first line platinum-based chemotherapy (p &lt; 0.001) and platinum sensitivity (p &lt; 0.001).	Platinum	130-138	cadherin 1	Homo sapiens	9-19
25108408-7	2015	The multivariate analysis for OS showed that positive E-cadherin expression is predictor to platinum sensitivity (p &lt; 0.001) and longer OS (p = 0.01).	Platinum	92-100	cadherin 1	Homo sapiens	54-64
25730414-14	2015	The introduction of plasmonic Au probes into the Pt-CdS double-shell hollow particles facilitated the monitoring of photocatalytic hydrogen generation that occurred on an individual particle surface by single particle measurements.	Platinum	49-51	CDP-diacylglycerol synthase 1	Homo sapiens	52-55
25108408-8	2015	Positive E-cadherin expression seems to be a predictor of better response to first line platinum-based chemotherapy, platinum sensitivity and favorable clinical outcome in patients with advanced-stage serous ovarian cancer.	Platinum	88-96	cadherin 1	Homo sapiens	9-19
25108408-8	2015	Positive E-cadherin expression seems to be a predictor of better response to first line platinum-based chemotherapy, platinum sensitivity and favorable clinical outcome in patients with advanced-stage serous ovarian cancer.	Platinum	117-125	cadherin 1	Homo sapiens	9-19
25194563-0	2015	Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer.	Platinum	33-41	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	10-15
25194563-1	2015	We have already demonstrated in a small cohort of 17 non-small cell lung cancer patients that ERCC1 (excision repair cross-complementation group 1) protein expression decreased after platinum-based treatment, however, certain clinicopathological parameters, such as histologic subtypes, ERCC1 expression scores, chemotherapeutic combinations, response rate, gender and smoking history were not analyzed.	Platinum	183-191	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	94-99
25194563-1	2015	We have already demonstrated in a small cohort of 17 non-small cell lung cancer patients that ERCC1 (excision repair cross-complementation group 1) protein expression decreased after platinum-based treatment, however, certain clinicopathological parameters, such as histologic subtypes, ERCC1 expression scores, chemotherapeutic combinations, response rate, gender and smoking history were not analyzed.	Platinum	183-191	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	287-292
25542228-1	2015	We aimed to evaluate the clinical response to platinum-based chemotherapy and treatment outcome of gastric cancer patients in the present of ERCC1, ERCC2, NBN, RAD51, and XRCC3 gene polymorphisms.	Platinum	46-54	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	141-146
25542228-1	2015	We aimed to evaluate the clinical response to platinum-based chemotherapy and treatment outcome of gastric cancer patients in the present of ERCC1, ERCC2, NBN, RAD51, and XRCC3 gene polymorphisms.	Platinum	46-54	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	148-153
25542228-1	2015	We aimed to evaluate the clinical response to platinum-based chemotherapy and treatment outcome of gastric cancer patients in the present of ERCC1, ERCC2, NBN, RAD51, and XRCC3 gene polymorphisms.	Platinum	46-54	nibrin	Homo sapiens	155-158
25542228-1	2015	We aimed to evaluate the clinical response to platinum-based chemotherapy and treatment outcome of gastric cancer patients in the present of ERCC1, ERCC2, NBN, RAD51, and XRCC3 gene polymorphisms.	Platinum	46-54	RAD51 recombinase	Homo sapiens	160-165
25542228-1	2015	We aimed to evaluate the clinical response to platinum-based chemotherapy and treatment outcome of gastric cancer patients in the present of ERCC1, ERCC2, NBN, RAD51, and XRCC3 gene polymorphisms.	Platinum	46-54	X-ray repair cross complementing 3	Homo sapiens	171-176
25656569-1	2015	NHC adducts of the stannylene Trip2 Sn (Trip=2,4,6-triisopropylphenyl) were reacted with zero-valent Ni, Pd, and Pt precursor complexes to cleanly yield the respective metal complexes featuring a three-membered ring moiety Sn-Sn-M along with carbene transfer onto the metal and complete substitution of the starting ligands.	Platinum	113-115	mediator complex subunit 1	Homo sapiens	30-35
25719509-4	2015	On Cu/Pt(100), the selective conversion from NO3(-) to N2 may be achieved.	Platinum	6-8	NBL1, DAN family BMP antagonist	Homo sapiens	45-48
25679519-7	2015	Both Pd nanowires and Pd@Pt nanowires show a prompt and reversible increase in resistance upon exposure to H2 in air, caused by the conversion of Pd to more resistive PdHx.	Platinum	25-27	pyruvate dehydrogenase complex component X	Homo sapiens	167-171
25806091-2	2015	Platinum-resistant cells may have reduced expression of the copper/platinum transporter CTR1.	Platinum	0-8	solute carrier family 31 member 1	Homo sapiens	88-92
25488476-8	2015	RESULTS: Increments of INHBA transcript level was associated with higher pT status in both UTUC and UBUC.	Platinum	73-75	inhibin subunit beta A	Homo sapiens	23-28
25699480-4	2015	These (195)Pt NMR profiles constitute unique NMR "fingerprints", useful for the unambiguous assignment of the series of [PtCl6-n(OH)n](2-) anions including their possible cis/trans/fac/mer stereoisomers in such solutions, without a need for accurate chemical shift measurements.	Platinum	11-13	FA complementation group C	Homo sapiens	181-184
25209742-1	2015	This retrospective study was conducted to determine whether endostatin improves the efficacy and safety of platinum-based chemotherapy administered via both intravenous and arterial infusions for stage III/IV non-small-cell lung cancer (NSCLC).	Platinum	107-115	collagen type XVIII alpha 1 chain	Homo sapiens	60-70
25750333-10	2015	CONCLUSION: Increased cyclin A expression in EOC is related to a more aggressive tumor behavior and predicts the response of patients to first-line platinum-based chemotherapy.	Platinum	148-156	cyclin A2	Homo sapiens	22-30
25732572-0	2015	Association of positively selected eIF3a polymorphisms with toxicity of platinum-based chemotherapy in NSCLC patients.	Platinum	72-80	eukaryotic translation initiation factor 3 subunit J	Homo sapiens	35-40
25732572-2	2015	In this study, we investigated the association of the positively selected SNPs of eIF3a with the response to and toxicity of platinum-based chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC).	Platinum	125-133	eukaryotic translation initiation factor 3 subunit J	Homo sapiens	82-87
25732572-12	2015	CONCLUSION: The positively selected SNPs of eIF3a are significantly correlated with platinum-based chemotherapy toxicities in Chinese NSCLC patients.	Platinum	84-92	eukaryotic translation initiation factor 3 subunit J	Homo sapiens	44-49
25758301-7	2015	BRCA1-mutated tumours appear to be highly sensitive to platinum, in both the neoadjuvant and metastatic setting.	Platinum	55-63	BRCA1 DNA repair associated	Homo sapiens	0-5
25450871-1	2015	BACKGROUND: Platinum-based chemotherapy is the standard first-line therapy for patients with advanced lung squamous cell carcinoma (SCC).	Platinum	12-20	serpin family B member 3	Homo sapiens	132-135
25560806-0	2015	Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.	Platinum	94-102	ATR serine/threonine kinase	Homo sapiens	28-31
25667646-8	2015	In conclusion, patients with NSCLC with EGFR mutations tend to have a low expression of ERCC1 mRNA and may potentially benefit from platinum-based chemotherapy.	Platinum	132-140	epidermal growth factor receptor	Homo sapiens	40-44
25667646-8	2015	In conclusion, patients with NSCLC with EGFR mutations tend to have a low expression of ERCC1 mRNA and may potentially benefit from platinum-based chemotherapy.	Platinum	132-140	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	88-93
26000095-7	2015	Significant correlation was detected between the ex vivo sensitivity to platinum based drugs and gemcitabine and the level of ERCC1 and RRM1.	Platinum	72-80	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	126-131
26000095-7	2015	Significant correlation was detected between the ex vivo sensitivity to platinum based drugs and gemcitabine and the level of ERCC1 and RRM1.	Platinum	72-80	ribonucleotide reductase catalytic subunit M1	Homo sapiens	136-140
25560806-0	2015	Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.	Platinum	94-102	ATM serine/threonine kinase	Homo sapiens	36-39
25560806-4	2015	RESULTS: Pharmacologic inhibition of ATR significantly enhanced platinum drug response in all GYN cancer cell lines tested, whereas inhibition of ATM did not enhance the response to platinum drugs.	Platinum	64-72	ATR serine/threonine kinase	Homo sapiens	37-40
25881102-8	2015	Homozygous carriers of the rs1799793 (ERCC2, G &gt; A) G-allele had a prolonged platinum-free interval (p = 0.016).	Platinum	80-88	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	38-43
25579902-0	2015	Formation of platinum-coated templates of insulin nanowires used in reducing 4-nitrophenol.	Platinum	13-21	insulin	Homo sapiens	42-49
25640610-3	2015	Here, we report the demonstration of platinum decorated reduced graphene oxide intercalated polyanililne:poly(4-styrenesulfonate) (Pt_rGO/PANI:PSS) hybrid paste for flexible electric devices.	Platinum	37-45	PSS	Homo sapiens	143-146
25603057-0	2015	Cholesterol reduces the sensitivity to platinum-based chemotherapy via upregulating ABCG2 in lung adenocarcinoma.	Platinum	39-47	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	84-89
25615009-2	2015	These are newly synthesized cyclometalated complexes of general formula (PPy)M(O   N)(n) (H(PPy) = 2-phenylpyridine, M = Pd(II) or Pt(II), H(O   N)(n) = Schiff base).	Platinum	131-133	pancreatic polypeptide	Homo sapiens	73-76
25603057-5	2015	We propose that chemoresistance may be attributed to cholesterol-induced ABCG2 expression and hypothesize that blocking ABCG2 may increase the efficacy of platinum-based chemotherapeutic agents.	Platinum	155-163	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	120-125
25603057-6	2015	Using the MTT cell viability assay, we observed that cotreatment with ABCG2 blocker Nicardipine and platinum-based drugs Cisplatin, Oxaliplatin or Carboplatin significantly decreased cell viability of tumor cells.	Platinum	100-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	70-75
25557076-2	2015	The method implies the coupling of N-Boc-protected alkynamine derivatives and appropriate alkenes or alkynes in a process catalysed by a platinum/triflic acid catalytic binary system.	Platinum	137-145	BOC cell adhesion associated, oncogene regulated	Homo sapiens	37-40
25628093-5	2015	Furthermore, HtrA2 downregulation modulated sensitivity to platinum in serous ovarian cancer cells in vitro.	Platinum	59-67	HtrA serine peptidase 2	Homo sapiens	13-18
25823848-6	2015	DBC1 expression was significantly associated with advanced clinicopathological factors such as high tumor stage, latent distant metastasis, platinum-resistance, elevated serum levels of CA125, high histologic grade, and BRCA1 expression.	Platinum	140-148	cell cycle and apoptosis regulator 2	Homo sapiens	0-4
25582599-0	2015	The combination of thioxodihydroquinazolinones and platinum drugs reverses platinum resistance in tumor cells by inducing mitochondrial apoptosis independent of Bax and Bak.	Platinum	51-59	BCL2 associated X, apoptosis regulator	Homo sapiens	161-164
25582599-0	2015	The combination of thioxodihydroquinazolinones and platinum drugs reverses platinum resistance in tumor cells by inducing mitochondrial apoptosis independent of Bax and Bak.	Platinum	75-83	BCL2 associated X, apoptosis regulator	Homo sapiens	161-164
25582599-5	2015	We have identified the thioxodihydroquinazolinone mdivi-1 as a member of a novel class of small molecules that are able to induce Bax- and Bak-independent mitochondrial outer membrane permeabilization when combined with cisplatin, thereby efficiently triggering apoptosis in platinum-resistant tumor cells.	Platinum	275-283	BCL2 associated X, apoptosis regulator	Homo sapiens	130-133
25932258-0	2015	Correlation of rs1799793 polymorphism in ERCC2 and the clinical response to platinum-based chemotherapy in patients with triple negative breast cancer.	Platinum	76-84	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	41-46
25932258-3	2015	OBJECTIVES: The aim of this study was to investigate the association between ERCC2 single nucleotide polymorphisms (SNPs) and the response to platinum-based chemotherapy among patients with triple negative breast cancer.	Platinum	142-150	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	77-82
25932258-13	2015	CONCLUSIONS: ERCC2 rs1799793 polymorphism may be associated with the clinical sensitivity of platinum-based chemotherapy and could be a potential predictive biomarker for triple negative breast cancer patients treated with platinum compounds.	Platinum	93-101	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	13-18
25932258-13	2015	CONCLUSIONS: ERCC2 rs1799793 polymorphism may be associated with the clinical sensitivity of platinum-based chemotherapy and could be a potential predictive biomarker for triple negative breast cancer patients treated with platinum compounds.	Platinum	223-231	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	13-18
25901207-0	2015	SOD2 rs4880 CT/CC genotype predicts poor survival for Chinese gastric cancer patients received platinum and fluorouracil based adjuvant chemotherapy.	Platinum	95-103	superoxide dismutase 2	Homo sapiens	0-4
25823848-8	2015	BRCA1 expression was significantly associated with latent distant metastasis, platinum-resistance, and higher histologic grade.	Platinum	78-86	BRCA1 DNA repair associated	Homo sapiens	0-5
25667499-1	2015	AIM: To correlate CA125 levels after platinum- and paclitaxel-based chemotherapy with progression-free survival (PFS) and overall survival (OS) in advanced ovarian carcinoma following primary cytoreduction.	Platinum	37-45	mucin 16, cell surface associated	Homo sapiens	18-23
25888998-0	2015	Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.	Platinum	116-124	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-16
25537514-6	2015	Our work highlights that a proportion of patients with wild-type BRCA1/2 ovarian cancers benefit from platinum-based chemotherapy and that the patients who benefit could be predicted from BRCA1/2-directed miRNA signature.	Platinum	102-110	BRCA2 DNA repair associated	Homo sapiens	65-72
25304989-4	2015	Recent reports have suggested that in the setting of impaired DNA repair, chemotherapeutic agents that induce DNA damage, such as platinum-based antineoplastic drugs (platins) and poly(ADP-ribose) polymerase inhibitors (PARP inhibitors), have improved efficacy.	Platinum	130-138	poly(ADP-ribose) polymerase 1	Homo sapiens	220-224
25025933-0	2015	Preparation of Au-Pt nanostructures by combining top-down with bottom-up strategies and application in label-free electrochemical immunosensor for detection of NMP22.	Platinum	18-20	nuclear mitotic apparatus protein 1	Homo sapiens	160-165
25960722-4	2015	Targeted therapy for hereditary breast and ovarian cancer has become a reality with the approval of olaparib for platin-sensitive late relapsed BRCA-associated ovarian cancer in December 2014.	Platinum	113-119	BRCA1 DNA repair associated	Homo sapiens	144-148
25467313-2	2015	Platinum-containing NCT, particularly in patients with HER2+ and triple-negative breast cancers (TNBC) may increase pCR rates.	Platinum	0-8	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
25467313-8	2015	CONCLUSIONS: Prospective studies of anthracycline-free platinum-containing NCT are warranted in LABC patients with HER2+ and TNBC.	Platinum	55-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	115-119
25253429-7	2015	Taken together, all these results strongly demonstrate that MDR-1 overexpression in K-562 cells could be associated to a MDR phenotype, and moreover, it is also contributing to the platinum and structurally related compound, resistance in these cells.	Platinum	181-189	ATP binding cassette subfamily B member 1	Homo sapiens	60-65
25490861-0	2015	Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.	Platinum	13-21	growth differentiation factor 15	Homo sapiens	30-62
25490861-0	2015	Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.	Platinum	13-21	interferon alpha inducible protein 27	Homo sapiens	73-76
25385265-0	2015	TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.	Platinum	49-57	tumor protein p53	Homo sapiens	0-4
25462204-12	2015	CONCLUSION: These data suggest that brown algae phlorotannins may improve the efficacy of platinum drugs for ovarian cancer by enhancing cancer cell apoptosis via the ROS/Akt/NFkappaB pathway and reduce nephrotoxicity by protecting against normal kidney cell damage.	Platinum	90-98	AKT serine/threonine kinase 1	Homo sapiens	171-174
25462204-12	2015	CONCLUSION: These data suggest that brown algae phlorotannins may improve the efficacy of platinum drugs for ovarian cancer by enhancing cancer cell apoptosis via the ROS/Akt/NFkappaB pathway and reduce nephrotoxicity by protecting against normal kidney cell damage.	Platinum	90-98	nuclear factor kappa B subunit 1	Homo sapiens	175-183
25385265-9	2015	Patients with oncomorphic TP53 mutations demonstrated significantly worse PFS, a 60% higher risk of recurrence (HR=1.60, 95% confidence intervals 1.09, 2.33, p=0.015), and higher rates of platinum resistance (chi(2) test p=0.0024) when compared with single nucleotide mutations not categorized as oncomorphic.	Platinum	188-196	tumor protein p53	Homo sapiens	26-30
25494307-1	2015	In this work, a sensitive electrochemical aptasensor for the detection of thrombin (TB) is developed and demonstrated based on the co-catalysis of hemin/G-quadruplex, platinum nanoparticles (PtNPs) and flower-like MnO2 nanosphere functionalized multi-walled carbon nanotubes (MWCNT-MnO2).	Platinum	167-175	coagulation factor II, thrombin	Homo sapiens	74-82
25528679-3	2015	{(1)H, (15)N} HSQC NMR of (15)N-labeled compounds with the ZF2 showed the appearance of several new (15)N peaks, consistent with sulfur binding and formation of Pt-S species.	Platinum	161-163	zinc finger protein 274	Homo sapiens	59-62
25561341-1	2015	The use of platinum, palladium and rhodium (Platinum Group Elements - PGEs) and the possibility of exposure to their ultratrace levels is increasing.	Platinum	11-19	prostaglandin E synthase	Rattus norvegicus	70-74
25561341-1	2015	The use of platinum, palladium and rhodium (Platinum Group Elements - PGEs) and the possibility of exposure to their ultratrace levels is increasing.	Platinum	44-52	prostaglandin E synthase	Rattus norvegicus	70-74
25561341-3	2015	Like other metal-based nanoparticles, exposure to PGEs nanoparticles may result in a release of ultratrace amounts of Pt, Pd, Rh ions in the body whose metabolic fate and toxicity still need to be evaluated.	Platinum	118-120	prostaglandin E synthase	Rattus norvegicus	50-54
25558790-12	2015	CONCLUSION: Our findings suggested that only patients with rare EGFR mutations could receive platinum-based chemotherapy as a first-line treatment, due to their low response rates and short PFS in response to EGFR-TKIs.	Platinum	93-101	epidermal growth factor receptor	Homo sapiens	64-68
25558790-12	2015	CONCLUSION: Our findings suggested that only patients with rare EGFR mutations could receive platinum-based chemotherapy as a first-line treatment, due to their low response rates and short PFS in response to EGFR-TKIs.	Platinum	93-101	epidermal growth factor receptor	Homo sapiens	209-213
25624920-6	2015	The apoptotic effect of the platinum agents was evaluated by double-staining the GC cells with Annexin V-fluorescein isothiocyanate and propodium iodide.	Platinum	28-36	annexin A5	Homo sapiens	95-104
25301443-6	2015	For the EGFR-mutant patients treated with first-line platinum/pemetrexed combinations, the ORR was significantly higher than that of the wild-type patients treated with similar regimens (43 vs. 21%, p = 0.039).	Platinum	53-61	epidermal growth factor receptor	Homo sapiens	8-12
25494307-1	2015	In this work, a sensitive electrochemical aptasensor for the detection of thrombin (TB) is developed and demonstrated based on the co-catalysis of hemin/G-quadruplex, platinum nanoparticles (PtNPs) and flower-like MnO2 nanosphere functionalized multi-walled carbon nanotubes (MWCNT-MnO2).	Platinum	167-175	coagulation factor II, thrombin	Homo sapiens	84-86
25629706-2	2015	Various molar ratios of Au to Pt and different electrodeposition conditions were evaluated to control the morphology and electrocatalytic activity of the Pt-Au bimetallic nanoparticles.	Platinum	30-32	microtubule-associated protein tau	Rattus norvegicus	154-159
25729984-0	2015	XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy.	Platinum	100-108	ERCC excision repair 5, endonuclease	Homo sapiens	0-3
25729984-1	2015	We conducted a cohort study to investigate whether 3 potential single nucleotide polymorphisms (SNPs) in the xeroderma pigmentosum complementation group G (XPG) gene could predict the survival of advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based doublet chemotherapy.	Platinum	262-270	ERCC excision repair 5, endonuclease	Homo sapiens	109-154
25729984-1	2015	We conducted a cohort study to investigate whether 3 potential single nucleotide polymorphisms (SNPs) in the xeroderma pigmentosum complementation group G (XPG) gene could predict the survival of advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based doublet chemotherapy.	Platinum	262-270	ERCC excision repair 5, endonuclease	Homo sapiens	156-159
25482209-5	2015	We found that miR-136 expression was significantly reduced in primary platinum-resistant patients and the ovarian cancer OVC cell line.	Platinum	70-78	microRNA 136	Homo sapiens	14-21
25482209-8	2015	However, in the platinum-resistant C13 cell line, the overexpression of miR-136 markedly promoted an apoptotic response to cisplatin.	Platinum	16-24	microRNA 136	Homo sapiens	72-79
24531715-1	2015	High expression of Ankyrin Repeat Domain 1 (ANKRD1) in ovarian carcinoma is associated with poor survival, and in ovarian cancer cell lines is associated with platinum resistance.	Platinum	159-167	ankyrin repeat domain 1	Homo sapiens	19-42
24531715-1	2015	High expression of Ankyrin Repeat Domain 1 (ANKRD1) in ovarian carcinoma is associated with poor survival, and in ovarian cancer cell lines is associated with platinum resistance.	Platinum	159-167	ankyrin repeat domain 1	Homo sapiens	44-50
25973302-4	2015	We perform immunohistochemistry analysis to detect MK in EOC sample with postoperative platinum/paclitaxel combination therapy, we found that 71.4% (85 in 119 samples) of these samples were MK positive (&gt; 10% of the cells were stained), and the expression of MK was significantly associated with disease histology (P = 0.038) as well as differentiation grade (P &lt; 0.001).	Platinum	87-95	midkine	Homo sapiens	51-53
25557169-6	2015	Consequently, CDK2 inhibition sensitizes cyclin E1-driven but not RAS-driven ovarian cancer cells to platinum-based chemotherapy.	Platinum	101-109	cyclin dependent kinase 2	Homo sapiens	14-18
25371202-2	2015	A peptide triazole (PT) class of entry inhibitor has previously been shown to bind to HIV-1 gp120, suppress interactions of the Env protein at host cell receptor binding sites, inhibit cell infection, and cause envelope spike protein breakdown, including gp120 shedding and, for some variants, virus membrane lysis.	Platinum	20-22	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	92-97
25784983-0	2015	XRCC1 genetic polymorphisms and sensitivity to platinum-based drugs in non-small cell lung cancer: an update meta-analysis based on 4708 subjects.	Platinum	47-55	X-ray repair cross complementing 1	Homo sapiens	0-5
25784983-1	2015	OBJECTIVE: To evaluate the correlation between genetic polymorphisms in x-ray repair cross complementing group 1 (XRCC1) and sensitivity to platinum-based chemotherapy drugs in patients with non-small cell lung cancer.	Platinum	140-148	X-ray repair cross complementing 1	Homo sapiens	72-112
25784983-1	2015	OBJECTIVE: To evaluate the correlation between genetic polymorphisms in x-ray repair cross complementing group 1 (XRCC1) and sensitivity to platinum-based chemotherapy drugs in patients with non-small cell lung cancer.	Platinum	140-148	X-ray repair cross complementing 1	Homo sapiens	114-119
25784983-10	2015	CONCLUSION: Genetic polymorphisms in the XRCC1 gene are correlated with sensitivity to platinum-based chemotherapy in patients with non-small cell lung cancer.	Platinum	87-95	X-ray repair cross complementing 1	Homo sapiens	41-46
25371202-2	2015	A peptide triazole (PT) class of entry inhibitor has previously been shown to bind to HIV-1 gp120, suppress interactions of the Env protein at host cell receptor binding sites, inhibit cell infection, and cause envelope spike protein breakdown, including gp120 shedding and, for some variants, virus membrane lysis.	Platinum	20-22	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	255-260
25375839-4	2015	Spectroscopic studies of both platinum derivatives reveal their ability to interact unequivocally with DNA from calf thymus and DNA of low molecular weight from salmon sperms, and also with the most abundant protein in human blood plasma, human serum albumin (HSA).	Platinum	30-38	albumin	Homo sapiens	245-258
25407898-0	2015	Nucleolar targeting by platinum: p53-independent apoptosis follows rRNA inhibition, cell-cycle arrest, and DNA compaction.	Platinum	23-31	tumor protein p53	Homo sapiens	33-36
25371202-2	2015	A peptide triazole (PT) class of entry inhibitor has previously been shown to bind to HIV-1 gp120, suppress interactions of the Env protein at host cell receptor binding sites, inhibit cell infection, and cause envelope spike protein breakdown, including gp120 shedding and, for some variants, virus membrane lysis.	Platinum	20-22	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	128-131
26561252-2	2015	Glucose oxidase (GOx) was easily dissolved in this solution and GOx-immobilized electrode was easily fabricated by simple repetitious drops of GOx-cellulose solution on the surface of a platinum-iridium electrode.	Platinum	186-194	hydroxyacid oxidase 1	Homo sapiens	0-15
25382796-9	2015	However, in the presence of thrombomodulin, the ETP increased [from 542 nM*min (417-694) at baseline to 845 nM*min (789-1050) on post-operative day 3] to values higher than that in healthy subjects (558 nM*min (390-680); P &lt; 0.001), which contrasts with substantially prolonged PT levels.	Platinum	281-283	thrombomodulin	Homo sapiens	28-42
25993149-1	2015	Retrospective studies have shown an improved prognosis, higher response rates to platinum-containing regimens, and longer treatment-free intervals between relapses in patients with BRCA 1 and BRCA 2 (BRCA1/2)-mutated ovarian cancer (BMOC) compared with patients who are not carriers of this mutation.	Platinum	81-89	BRCA1 DNA repair associated	Homo sapiens	181-187
25993149-1	2015	Retrospective studies have shown an improved prognosis, higher response rates to platinum-containing regimens, and longer treatment-free intervals between relapses in patients with BRCA 1 and BRCA 2 (BRCA1/2)-mutated ovarian cancer (BMOC) compared with patients who are not carriers of this mutation.	Platinum	81-89	BRCA2 DNA repair associated	Homo sapiens	192-198
25993149-1	2015	Retrospective studies have shown an improved prognosis, higher response rates to platinum-containing regimens, and longer treatment-free intervals between relapses in patients with BRCA 1 and BRCA 2 (BRCA1/2)-mutated ovarian cancer (BMOC) compared with patients who are not carriers of this mutation.	Platinum	81-89	BRCA1 DNA repair associated	Homo sapiens	200-207
26561252-2	2015	Glucose oxidase (GOx) was easily dissolved in this solution and GOx-immobilized electrode was easily fabricated by simple repetitious drops of GOx-cellulose solution on the surface of a platinum-iridium electrode.	Platinum	186-194	hydroxyacid oxidase 1	Homo sapiens	17-20
26561252-2	2015	Glucose oxidase (GOx) was easily dissolved in this solution and GOx-immobilized electrode was easily fabricated by simple repetitious drops of GOx-cellulose solution on the surface of a platinum-iridium electrode.	Platinum	186-194	hydroxyacid oxidase 1	Homo sapiens	64-67
26561252-2	2015	Glucose oxidase (GOx) was easily dissolved in this solution and GOx-immobilized electrode was easily fabricated by simple repetitious drops of GOx-cellulose solution on the surface of a platinum-iridium electrode.	Platinum	186-194	hydroxyacid oxidase 1	Homo sapiens	64-67
26625826-0	2015	Serum Anti-Gal-3 Autoantibody is a Predictive Marker of the Efficacy of Platinum-Based Chemotherapy against Pulmonary Adenocarcinoma.	Platinum	72-80	galectin 3	Homo sapiens	11-16
25115278-3	2015	Recently high level of AKT was shown to be involved in platinum resistance and furthermore in resistance against Natural-killer (NK)-cell mediated killing in ovarian cancer.	Platinum	55-63	AKT serine/threonine kinase 1	Homo sapiens	23-26
26415382-1	2015	The review is concerned with the crucial marker of nucleotide excision repair ERCC1 and its contribution to platinum resistance of ovarian cancer.	Platinum	108-116	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	78-83
26415382-3	2015	Data on the prognostic and predictive value of ERCC1 as a marker of the response to platinum-based therapy in ovarian cancer are systematized.	Platinum	84-92	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
26625826-6	2015	Furthermore, pretreated biopsy specimens taken from patients evaluated as showing PD following platinum- based chemotherapy showed a tendency to have a higher positive rate of Gal-3 than those with PR and SD (p = 0.0601).	Platinum	95-103	galectin 3	Homo sapiens	176-181
26625826-7	2015	CONCLUSIONS: These results suggest that serum IgG levels of anti-Gal-3 autoantibody may be useful to predict the efficacy of platinum-based chemotherapy for patients with lung AC.	Platinum	125-133	galectin 3	Homo sapiens	65-70
25835177-0	2015	MMP-9/ANC score as a predictive biomarker for efficacy of bevacizumab plus platinum doublet chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer.	Platinum	75-83	matrix metallopeptidase 9	Homo sapiens	0-5
25602630-7	2015	Patients with high-grade serous ovarian cancer and high HER2 levels had poor overall survival; however, better survival in the low HER2 patient subgroup treated with platinum/taxane-based therapy correlated positively with PRP4K expression (HR = 0.37 [95% CI 0.15-0.88]; p = 0.03).	Platinum	166-174	erb-b2 receptor tyrosine kinase 2	Homo sapiens	131-135
25602630-7	2015	Patients with high-grade serous ovarian cancer and high HER2 levels had poor overall survival; however, better survival in the low HER2 patient subgroup treated with platinum/taxane-based therapy correlated positively with PRP4K expression (HR = 0.37 [95% CI 0.15-0.88]; p = 0.03).	Platinum	166-174	pre-mRNA processing factor 4B	Homo sapiens	223-228
26513874-7	2015	RESULTS: The author obtained 38 new SNPs after excluding 22 SNP from dbSNP database and 1000 Genomes Project and found ESRP1, LDHA, DDX5, and HEXA were associated with platinum resistance of ovarian cancer.	Platinum	168-176	epithelial splicing regulatory protein 1	Homo sapiens	119-124
25872328-2	2015	MATERIALS AND METHODS: The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray.	Platinum	96-104	translocase of inner mitochondrial membrane 8A	Homo sapiens	115-123
25732554-0	2015	Evaluation of interactions between platinum-/ruthenium-based anticancer agents and human serum albumin: development of HSA carrier for metal-based drugs.	Platinum	35-43	albumin	Homo sapiens	89-102
25732554-0	2015	Evaluation of interactions between platinum-/ruthenium-based anticancer agents and human serum albumin: development of HSA carrier for metal-based drugs.	Platinum	35-43	albumin	Homo sapiens	119-122
25732554-4	2015	This review not only provides a brief outline of the properties of HSA carriers but also provides an overview of the binding and anticancer characteristics of platinum-/ruthenium-based anticancer drugs to HSA that may guide the rational designing and development of metal-based drugs and HSA-based carriers for clinical applications.	Platinum	159-167	albumin	Homo sapiens	67-70
25732554-4	2015	This review not only provides a brief outline of the properties of HSA carriers but also provides an overview of the binding and anticancer characteristics of platinum-/ruthenium-based anticancer drugs to HSA that may guide the rational designing and development of metal-based drugs and HSA-based carriers for clinical applications.	Platinum	159-167	albumin	Homo sapiens	205-208
25732554-4	2015	This review not only provides a brief outline of the properties of HSA carriers but also provides an overview of the binding and anticancer characteristics of platinum-/ruthenium-based anticancer drugs to HSA that may guide the rational designing and development of metal-based drugs and HSA-based carriers for clinical applications.	Platinum	159-167	albumin	Homo sapiens	205-208
25872328-2	2015	MATERIALS AND METHODS: The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray.	Platinum	96-104	translocase of inner mitochondrial membrane 8A	Homo sapiens	120-123
26513874-7	2015	RESULTS: The author obtained 38 new SNPs after excluding 22 SNP from dbSNP database and 1000 Genomes Project and found ESRP1, LDHA, DDX5, and HEXA were associated with platinum resistance of ovarian cancer.	Platinum	168-176	lactate dehydrogenase A	Homo sapiens	126-130
26513874-7	2015	RESULTS: The author obtained 38 new SNPs after excluding 22 SNP from dbSNP database and 1000 Genomes Project and found ESRP1, LDHA, DDX5, and HEXA were associated with platinum resistance of ovarian cancer.	Platinum	168-176	DEAD-box helicase 5	Homo sapiens	132-136
26513874-7	2015	RESULTS: The author obtained 38 new SNPs after excluding 22 SNP from dbSNP database and 1000 Genomes Project and found ESRP1, LDHA, DDX5, and HEXA were associated with platinum resistance of ovarian cancer.	Platinum	168-176	hexosaminidase subunit alpha	Homo sapiens	142-146
24703712-0	2015	The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy.	Platinum	62-70	solute carrier family 31 member 1	Homo sapiens	12-16
26206420-8	2015	Studies are also being undertaken with inhibitors of poly(ADP-ribose) polymerase (PARP), targeting the DNA repair pathway as it is possible that the benefits seen with these agents in "platinum-sensitive" disease will apply to those with "platinum-resistant" disease.	Platinum	185-193	poly(ADP-ribose) polymerase 1	Homo sapiens	53-80
26206420-8	2015	Studies are also being undertaken with inhibitors of poly(ADP-ribose) polymerase (PARP), targeting the DNA repair pathway as it is possible that the benefits seen with these agents in "platinum-sensitive" disease will apply to those with "platinum-resistant" disease.	Platinum	185-193	poly(ADP-ribose) polymerase 1	Homo sapiens	82-86
26206420-8	2015	Studies are also being undertaken with inhibitors of poly(ADP-ribose) polymerase (PARP), targeting the DNA repair pathway as it is possible that the benefits seen with these agents in "platinum-sensitive" disease will apply to those with "platinum-resistant" disease.	Platinum	239-247	poly(ADP-ribose) polymerase 1	Homo sapiens	53-80
26206420-8	2015	Studies are also being undertaken with inhibitors of poly(ADP-ribose) polymerase (PARP), targeting the DNA repair pathway as it is possible that the benefits seen with these agents in "platinum-sensitive" disease will apply to those with "platinum-resistant" disease.	Platinum	239-247	poly(ADP-ribose) polymerase 1	Homo sapiens	82-86
26359224-4	2015	For human epidermal growth factor receptors 2 (HER2) negative cancer, standard treatments are combinations of fluoropyrimidine and platinum with or without epirubicin or docetaxel in first-line therapy.	Platinum	131-139	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-51
26638920-5	2015	Finally, thymidylate synthase protein cutoffs may predict mesothelioma response to the association of pemetrexed with a platinum derivative.	Platinum	120-128	thymidylate synthetase	Homo sapiens	9-29
25898678-1	2015	With the potential risks for the environment and human health, the concentration and distribution characteristics of platinum group element(PGEs) in road dust in Xiamen city were investigated.	Platinum	117-125	prostaglandin E synthase	Homo sapiens	140-144
25344342-7	2015	The results not only provide a rapid and efficient way to identify the platinum binding sites in proteins, but also indicate that the binding of cisplatin could promote the fragmentation of IGF-1 and the rupture of disulfide bond.	Platinum	71-79	insulin like growth factor 1	Homo sapiens	190-195
25735651-0	2015	Challenges in economic modeling of anticancer therapies: an example of modeling the survival benefit of olaparib maintenance therapy for patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer.	Platinum	164-172	BRCA1 DNA repair associated	Homo sapiens	151-155
24703712-6	2015	Here, we summarize and discuss current insights into the Ctr2 protein and its interaction with Ctr1, its functions in mammalian Cu homeostasis and platinum-based chemotherapy.	Platinum	147-155	solute carrier family 31 member 2	Homo sapiens	57-61
25938424-2	2015	The objective of the current study was to design a non-steroidal-platinum(II) derivative that would target the estrogen receptor alpha (ERalpha) without triggering estrogenic cell proliferation.	Platinum	65-73	estrogen receptor 1	Homo sapiens	111-134
25378648-11	2015	Further study is needed to confirm survival benefit of platinum-based chemotherapy for elderly non-small-cell lung cancer [UMIN-CTR (www.umin.ac.jp/ctr/) ID: C000000146].	Platinum	55-63	calcitonin receptor	Homo sapiens	128-131
25378648-11	2015	Further study is needed to confirm survival benefit of platinum-based chemotherapy for elderly non-small-cell lung cancer [UMIN-CTR (www.umin.ac.jp/ctr/) ID: C000000146].	Platinum	55-63	calcitonin receptor	Homo sapiens	148-151
25989663-8	2015	CONCLUSION: ERCC1 expression maybe regarded as indicator platinum based chemotherapy sensitivity prediction in nasopharyngeal carcinoma, and also helpful for formulating individualized treatment.	Platinum	57-65	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	12-17
25465061-0	2015	Correlation of apolipoprotein A-I kinetics with survival and response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer.	Platinum	84-92	apolipoprotein A1	Homo sapiens	15-33
25938424-2	2015	The objective of the current study was to design a non-steroidal-platinum(II) derivative that would target the estrogen receptor alpha (ERalpha) without triggering estrogenic cell proliferation.	Platinum	65-73	estrogen receptor 1	Homo sapiens	136-143
25465061-1	2015	The aim of this study was to determine whether apolipoprotein A-I (ApoA-I) kinetics predict the overall survival in patients with advanced-stage non-small cell lung cancer (NSCLC) during platinum-based first-line therapy.	Platinum	187-195	apolipoprotein A1	Homo sapiens	47-65
25465061-1	2015	The aim of this study was to determine whether apolipoprotein A-I (ApoA-I) kinetics predict the overall survival in patients with advanced-stage non-small cell lung cancer (NSCLC) during platinum-based first-line therapy.	Platinum	187-195	apolipoprotein A1	Homo sapiens	67-73
25591596-1	2015	UNLABELLED: The aim of this study was to determine the response of advanced-stage non-small cell lung cancer (NSCLC) patients with or without EGFR mutations to platinum-based chemotherapy with or without gefitinib maintenance.	Platinum	160-168	epidermal growth factor receptor	Homo sapiens	142-146
25469300-2	2015	According to numerous studies, ERCC1 gene expression correlates with overall survival and effectiveness of chemotherapy with platinum agents.	Platinum	125-133	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	31-36
25452171-6	2015	When data were stratified by postoperative treatments and CCND1 expression levels, the MST for patients treated with fluoropyrimidine plus platinum (n = 140) was significantly longer than for those treated with fluoropyrimidine only (n = 71) in both high and low CCND1 expression groups (65.0 vs. 29.0 months, P = 0.041; and 74.5 vs. 33.0 months, P = 0.003, respectively).	Platinum	139-147	cyclin D1	Homo sapiens	58-63
25452171-6	2015	When data were stratified by postoperative treatments and CCND1 expression levels, the MST for patients treated with fluoropyrimidine plus platinum (n = 140) was significantly longer than for those treated with fluoropyrimidine only (n = 71) in both high and low CCND1 expression groups (65.0 vs. 29.0 months, P = 0.041; and 74.5 vs. 33.0 months, P = 0.003, respectively).	Platinum	139-147	cyclin D1	Homo sapiens	263-268
25006690-7	2014	The observed size dependence of the Pt atoms inside the clusters may contribute to the size-dependent chemical reactivity of Ptn clusters on the Al2O3 surface.	Platinum	36-38	pleiotrophin	Homo sapiens	125-128
26374559-10	2015	Some resistant cancer cells continue to respond to platinum based drugs, encouraging further development of PARP inhibitors for cancer treatment.	Platinum	51-59	poly(ADP-ribose) polymerase 1	Homo sapiens	108-112
26273329-6	2015	A platinum-based regimen remains the mainstay of first-line systemic therapy for advanced NSCLC patients who are negative for EGFR mutation or ALK gene rearrangement.	Platinum	2-10	epidermal growth factor receptor	Homo sapiens	126-130
26278154-15	2015	The REV3 and REV7 polymorphisms are in a catalytic subunit and an accessory subunit of Pol zeta, respectively, and participate in platinum-chemotherapy tolerance and side effects.	Platinum	130-138	REV3 like, DNA directed polymerase zeta catalytic subunit	Homo sapiens	4-8
26278154-15	2015	The REV3 and REV7 polymorphisms are in a catalytic subunit and an accessory subunit of Pol zeta, respectively, and participate in platinum-chemotherapy tolerance and side effects.	Platinum	130-138	mitotic arrest deficient 2 like 2	Homo sapiens	13-17
25354091-15	2015	The present study indicates that the HE4 protein plays a promotive role in the proliferation and resistance to carboplatin in ovarian cancer cells, implicating the value of HE4 to predict tumor growth potential and resistance to platinum-based chemotherapy in epithelial ovarian cancer (EOC).	Platinum	229-237	WAP four-disulfide core domain 2	Homo sapiens	37-40
25476899-4	2014	Recently, we demonstrated that the reduced expression of base excision repair protein XRCC1 and its upstream regulator JWA in gastric cancerous tissues correlated with a significant survival benefit of adjuvant first-line platinum-based chemotherapy as well as XRCC1 playing an important role in the DNA repair of cisplatin-resistant gastric cancer cells.	Platinum	222-230	X-ray repair cross complementing 1	Homo sapiens	86-91
25426677-3	2014	The conductivity of PepA, a bacterial aminopeptidase used as a protein shell (PS), and the platinum nanoparticles (PtNPs) encapsulated by PepA was measured using a field effect transistor (FET) and a graphene-based FET (GFET).	Platinum	91-99	carnosine dipeptidase 2	Homo sapiens	138-142
25038538-0	2014	Choline and acetylcholine detection based on peroxidase-like activity and protein antifouling property of platinum nanoparticles in bovine serum albumin scaffold.	Platinum	106-114	albumin	Homo sapiens	139-152
25038538-1	2014	Platinum nanoparticles (PtNPs) in the scaffold of bovine serum albumin (BSA) through biomineralization are found to possess excellent peroxidase-like activity that can catalyze N-ethyl-N-(3-sulfopropyl)-3-methylaniline sodium salt (TOPS) coupled with 4-amino-antipyrine (4-AAP) by the action of hydrogen peroxide to give an obvious purple product.	Platinum	0-8	albumin	Homo sapiens	57-70
25316809-4	2014	RESULTS: We demonstrate in vitro that SGI-110 resensitized a range of platinum-resistant ovarian cancer cells to cisplatin (CDDP) and induced significant demethylation and reexpression of TSG, differentiation-associated genes, and putative drivers of ovarian cancer cisplatin resistance.	Platinum	70-78	chromogranin B	Homo sapiens	38-41
25520568-13	2014	CONCLUSION: ERCC1 negativity with platinum therapy, gemcitabine therapy, good PS, and female gender all correlated with improved overall survival in patients with advanced NSCLC.	Platinum	34-42	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	12-17
25501233-0	2014	ERCC1 mRNA expression is associated with the clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.	Platinum	105-113	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
25501233-11	2014	In summary, low ERCC1 mRNA expression was associated with better response to chemotherapy and correlated with longer survival in advanced NSCLC patients treated with platinum-based chemotherapy.	Platinum	166-174	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	16-21
25476899-4	2014	Recently, we demonstrated that the reduced expression of base excision repair protein XRCC1 and its upstream regulator JWA in gastric cancerous tissues correlated with a significant survival benefit of adjuvant first-line platinum-based chemotherapy as well as XRCC1 playing an important role in the DNA repair of cisplatin-resistant gastric cancer cells.	Platinum	222-230	ADP ribosylation factor like GTPase 6 interacting protein 5	Homo sapiens	119-122
25124282-5	2014	Mechanisms of differential sensitivity of SCLC cell lines to PARP inhibition were investigated by comparing protein and gene expression profiles of the platinum sensitive and the less sensitive cell lines.	Platinum	152-160	poly(ADP-ribose) polymerase 1	Homo sapiens	61-65
25503135-6	2014	For combinations of LH3 with the phytochemicals, platinum accumulation and the level of Pt-DNA binding were found to be greater in the resistant A2780(cisR) cell line than in the parental A2780 cell line.	Platinum	49-57	procollagen-lysine,2-oxoglutarate 5-dioxygenase 3	Homo sapiens	20-23
25285768-0	2014	Platinum(IV) complex LA-12 exerts higher ability than cisplatin to enhance TRAIL-induced cancer cell apoptosis via stimulation of mitochondrial pathway.	Platinum	0-8	TNF superfamily member 10	Homo sapiens	75-80
25124282-9	2014	Gene expression profiling identified differential expression of a 5-gene panel (GLS, UBEC2, HACL1, MSI2, and LOC100129585) in cell lines with relatively greater sensitivity to platinum and veliparib combination.	Platinum	176-184	2-hydroxyacyl-CoA lyase 1	Homo sapiens	92-97
25266736-6	2014	PACCs lacking RAF rearrangements were significantly enriched for genomic alterations, causing inactivation of DNA repair genes (45%); these genomic alterations have been associated with sensitivity to platinum-based therapies and PARP inhibitors.	Platinum	201-209	zinc fingers and homeoboxes 2	Homo sapiens	14-17
25124282-9	2014	Gene expression profiling identified differential expression of a 5-gene panel (GLS, UBEC2, HACL1, MSI2, and LOC100129585) in cell lines with relatively greater sensitivity to platinum and veliparib combination.	Platinum	176-184	musashi RNA binding protein 2	Homo sapiens	99-103
25303639-5	2014	Two distinct pathways by which the target compounds undergo effective ester hydrolysis, the proposed activating step, have been confirmed: platinum-assisted, self-immolative ester cleavage in a low-chloride environment (LC-ESMS, NMR spectroscopy) and enzymatic cleavage by human carboxylesterase-2 (hCES-2) (LC-ESMS).	Platinum	139-147	carboxylesterase 2	Homo sapiens	279-297
25303639-5	2014	Two distinct pathways by which the target compounds undergo effective ester hydrolysis, the proposed activating step, have been confirmed: platinum-assisted, self-immolative ester cleavage in a low-chloride environment (LC-ESMS, NMR spectroscopy) and enzymatic cleavage by human carboxylesterase-2 (hCES-2) (LC-ESMS).	Platinum	139-147	carboxylesterase 2	Homo sapiens	299-305
25266653-11	2014	It is registered for patients with the presence of ALK gene rearrangements after the failure of the first line of treatment based on platinum derivatives.	Platinum	133-141	ALK receptor tyrosine kinase	Homo sapiens	51-54
25674197-1	2014	BACKGROUND: Excision repair cross complementation group 1 (ERCC1) is a nucleotide excision repair pathway gene which provides protection against platinum-based chemotherapy-induced DNA damage.	Platinum	145-153	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	12-57
24729390-6	2014	The data from the current study provide evidence that OGG1 Ser326Cys, XRCC1 Arg399Gln, APE1 Asp148Glu, and APE1-141T/G polymorphisms may be useful in predicting clinical outcomes in patients with advanced inoperable NSCLC that will undergo platinum-based chemotherapy.	Platinum	240-248	8-oxoguanine DNA glycosylase	Homo sapiens	54-58
26759527-9	2014	Trabectedin + PLD is a non-platinum combination that is well tolerated, with a manageable safety profile, which is independent of age.	Platinum	27-35	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	14-17
25281495-12	2014	CONCLUSIONS: We established that amplifications in 14q32.33 were associated with reduced OS, PFS, PFI and platinum resistance in three independent cohorts, suggesting that AKT1 amplifications act as a potentially predictive marker for EOC treated with platinum-based chemotherapy.	Platinum	106-114	AKT serine/threonine kinase 1	Homo sapiens	172-176
25281495-12	2014	CONCLUSIONS: We established that amplifications in 14q32.33 were associated with reduced OS, PFS, PFI and platinum resistance in three independent cohorts, suggesting that AKT1 amplifications act as a potentially predictive marker for EOC treated with platinum-based chemotherapy.	Platinum	252-260	AKT serine/threonine kinase 1	Homo sapiens	172-176
24729390-0	2014	Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.	Platinum	99-107	8-oxoguanine DNA glycosylase	Homo sapiens	47-51
24729390-0	2014	Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.	Platinum	99-107	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	53-57
24729390-0	2014	Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.	Platinum	99-107	X-ray repair cross complementing 1	Homo sapiens	62-67
25674197-1	2014	BACKGROUND: Excision repair cross complementation group 1 (ERCC1) is a nucleotide excision repair pathway gene which provides protection against platinum-based chemotherapy-induced DNA damage.	Platinum	145-153	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	59-64
25674197-7	2014	CONCLUSIONS: High ERCC1 mRNA expression of the NSCLC tumor tissues was associated with poor disease-free survival (DFS), in both the surgery alone and postoperative platinum-containing chemotherapy subgroups.	Platinum	165-173	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	18-23
24994039-0	2014	Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis.	Platinum	81-89	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	20-65
25028118-0	2014	Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.	Platinum	79-87	methylenetetrahydrofolate reductase	Homo sapiens	21-26
25028118-0	2014	Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.	Platinum	79-87	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	31-36
24994039-1	2014	PURPOSE: The predictive value of excision repair cross-complementation group 1 (ERCC1) gene for survival and response to platinum-based chemotherapy in gastric cancer (GC) remains controversial.	Platinum	121-129	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	33-78
24994039-1	2014	PURPOSE: The predictive value of excision repair cross-complementation group 1 (ERCC1) gene for survival and response to platinum-based chemotherapy in gastric cancer (GC) remains controversial.	Platinum	121-129	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	80-85
25227663-10	2014	This study suggests that the efficacy of platinum-based chemotherapy can be improved when customized according to the mRNA expression of BRCA1, ERCC1, RRM1, and RRM2.	Platinum	41-49	BRCA1 DNA repair associated	Homo sapiens	137-142
25451143-1	2014	Using density functional theory, stability, chemical, and optical properties of small platinum clusters, Ptn (n = 2 to 10) have been investigated.	Platinum	86-94	pleiotrophin	Homo sapiens	105-108
24793378-1	2014	The aim of the study was to analyze the frequency of epidermal growth factor receptor (EGFR) mutations in Brazilian non-small cell lung cancer patients and to correlate these mutations with response to benefit of platinum-based chemotherapy in non-small cell lung cancer (NSCLC).	Platinum	213-221	epidermal growth factor receptor	Homo sapiens	53-85
24793378-1	2014	The aim of the study was to analyze the frequency of epidermal growth factor receptor (EGFR) mutations in Brazilian non-small cell lung cancer patients and to correlate these mutations with response to benefit of platinum-based chemotherapy in non-small cell lung cancer (NSCLC).	Platinum	213-221	epidermal growth factor receptor	Homo sapiens	87-91
24793378-6	2014	Patients with NSCLCs harboring EGFR exon 19 deletions or the exon 21 L858R mutation were found to have a higher chance of response to platinum-paclitaxel (OR 9.67 [95 % CI 1.03-90.41], p = 0.047).	Platinum	134-142	epidermal growth factor receptor	Homo sapiens	31-35
24793378-8	2014	EGFR mutations seem to be predictive of a response to platinum-paclitaxel, and additional studies are needed to confirm or refute this relationship.	Platinum	54-62	epidermal growth factor receptor	Homo sapiens	0-4
25227663-10	2014	This study suggests that the efficacy of platinum-based chemotherapy can be improved when customized according to the mRNA expression of BRCA1, ERCC1, RRM1, and RRM2.	Platinum	41-49	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	144-149
25227663-10	2014	This study suggests that the efficacy of platinum-based chemotherapy can be improved when customized according to the mRNA expression of BRCA1, ERCC1, RRM1, and RRM2.	Platinum	41-49	ribonucleotide reductase catalytic subunit M1	Homo sapiens	151-155
25227663-10	2014	This study suggests that the efficacy of platinum-based chemotherapy can be improved when customized according to the mRNA expression of BRCA1, ERCC1, RRM1, and RRM2.	Platinum	41-49	ribonucleotide reductase regulatory subunit M2	Homo sapiens	161-165
25157649-1	2014	The kinetics and effect of hyper activated IGF-1R signaling is not well investigated during acquirement of platinum and taxol resistance in ovarian cancer cells.	Platinum	107-115	insulin like growth factor 1 receptor	Homo sapiens	43-49
25408231-13	2014	CONCLUSION: We identified MEK1 as a promising prognostic biomarker candidate correlated to response to platinum based chemotherapy in ovarian cancer.	Platinum	103-111	mitogen-activated protein kinase kinase 1	Homo sapiens	26-30
25399490-6	2014	Absence of CD133 expression in primary tumors was significantly associated with high platinum sensitivity in both patient groups with and without CNS metastases.	Platinum	85-93	prominin 1	Homo sapiens	11-16
25399490-8	2014	CONCLUSIONS: These data suggest that there exist a positive association between CD133 expression in primary EOC, platinum resistance and the increased risk of CNS metastases, as well as a less favorable prognosis of EOC.	Platinum	113-121	prominin 1	Homo sapiens	80-85
24628382-1	2014	Three platinum(II) bipyridyl bis((7-R-fluoren-2-yl)acetylide) complexes (R = benzoyl (Pt-1), 2-(N-phenylbenzimidazoly) (Pt-2), or 2-(3-phenylquinoxalinyl) (Pt-3)) are synthesized and characterized.	Platinum	6-14	zinc finger protein 77	Homo sapiens	86-90
25405734-0	2014	WISP1 polymorphisms contribute to platinum-based chemotherapy toxicity in lung cancer patients.	Platinum	34-42	cellular communication network factor 4	Homo sapiens	0-5
25081901-12	2014	Conversely, KRAS-variant patients appeared to experience some improvement in disease control when cetuximab was added to their platinum-based regimen (log-rank P = 0.04).	Platinum	127-135	KRAS proto-oncogene, GTPase	Homo sapiens	12-16
25405734-2	2014	The genetic polymorphism of WISP1 was revealed to be associated with susceptibility and platinum-based chemotherapy response in our previous studies.	Platinum	88-96	cellular communication network factor 4	Homo sapiens	28-33
25405734-3	2014	In this study, we aimed to investigate the relationship of WISP1 genetic polymorphisms with platinum-based chemotherapy toxicity in lung cancer patients.	Platinum	92-100	cellular communication network factor 4	Homo sapiens	59-64
25405734-8	2014	Genotypes of WISP1 may be novel and useful biomarkers for predicting platinum-based chemotherapy toxicity in lung cancer patients.	Platinum	69-77	cellular communication network factor 4	Homo sapiens	13-18
25099161-8	2014	The data show that the PIM2 kinase plays a role in the response of ovarian cancer cells to platinum drugs and suggest that PIM inhibitors may find clinical application as an adjunct to platinum-based therapies.	Platinum	91-99	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	23-27
25099161-8	2014	The data show that the PIM2 kinase plays a role in the response of ovarian cancer cells to platinum drugs and suggest that PIM inhibitors may find clinical application as an adjunct to platinum-based therapies.	Platinum	91-99	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	23-26
25099161-8	2014	The data show that the PIM2 kinase plays a role in the response of ovarian cancer cells to platinum drugs and suggest that PIM inhibitors may find clinical application as an adjunct to platinum-based therapies.	Platinum	185-193	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	23-27
25099161-8	2014	The data show that the PIM2 kinase plays a role in the response of ovarian cancer cells to platinum drugs and suggest that PIM inhibitors may find clinical application as an adjunct to platinum-based therapies.	Platinum	185-193	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	23-26
25375151-0	2014	The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis.	Platinum	135-143	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	24-69
25375151-0	2014	The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis.	Platinum	135-143	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	71-76
25375151-1	2014	Recently, the correlation between the efficacy of platinum-based chemotherapy and ERCC1 expression in patients with SCLC has attracted wide-spread attention, and a lot of investigations have been conducted, whereas conflicting results were presented.	Platinum	50-58	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	82-87
25375151-2	2014	Therefore, we performed the present meta-analysis of eligible studies to derive a more precise evaluation of the association between ERCC1 expression and the clinical outcome in SCLC patients receiving platinum-based chemotherapy.	Platinum	202-210	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	133-138
25375151-10	2014	Our analysis suggested ERCC1 expression may be a prognostic factor in SCLC patients receiving platinum-based chemotherapy, especially for LS-SCLC.	Platinum	94-102	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	23-28
25382139-1	2014	We fabricated a highly efficient (with a solar-to-electricity conversion efficiency (eta) of 8.1%) Pt-free dye-sensitized solar cell (DSSC).	Platinum	99-101	endothelin receptor type A	Homo sapiens	85-88
25081901-13	2014	CONCLUSIONS: The TG/GG rs61764370 KRAS-variant is a potential predictive biomarker for poor platinum response in R/M HNSCC patients.	Platinum	92-100	KRAS proto-oncogene, GTPase	Homo sapiens	34-38
25295110-14	2014	Pt accumulation in the tumors was higher in the PL-CBP group than in the CBP group (PL-CBP vs. CBP, P&lt;0.05).	Platinum	0-2	CREB binding protein	Mus musculus	51-54
24889085-3	2014	For example, the transport of platinum-based anticancer drugs has been reported to be influenced by the expression and activities of OCT1-3 (SLC22A1-3), OCTN1/2 (SLC22A4/5), CTR1/2 (SLC31A1/2) and MATE1/2 (SLC47A1/2) solute carriers.	Platinum	30-38	solute carrier family 22 member 1	Homo sapiens	133-139
24889085-3	2014	For example, the transport of platinum-based anticancer drugs has been reported to be influenced by the expression and activities of OCT1-3 (SLC22A1-3), OCTN1/2 (SLC22A4/5), CTR1/2 (SLC31A1/2) and MATE1/2 (SLC47A1/2) solute carriers.	Platinum	30-38	solute carrier family 22 member 4	Homo sapiens	153-160
24889085-3	2014	For example, the transport of platinum-based anticancer drugs has been reported to be influenced by the expression and activities of OCT1-3 (SLC22A1-3), OCTN1/2 (SLC22A4/5), CTR1/2 (SLC31A1/2) and MATE1/2 (SLC47A1/2) solute carriers.	Platinum	30-38	solute carrier family 22 member 4	Homo sapiens	162-171
24889085-3	2014	For example, the transport of platinum-based anticancer drugs has been reported to be influenced by the expression and activities of OCT1-3 (SLC22A1-3), OCTN1/2 (SLC22A4/5), CTR1/2 (SLC31A1/2) and MATE1/2 (SLC47A1/2) solute carriers.	Platinum	30-38	solute carrier family 31 member 1	Homo sapiens	174-180
24889085-3	2014	For example, the transport of platinum-based anticancer drugs has been reported to be influenced by the expression and activities of OCT1-3 (SLC22A1-3), OCTN1/2 (SLC22A4/5), CTR1/2 (SLC31A1/2) and MATE1/2 (SLC47A1/2) solute carriers.	Platinum	30-38	solute carrier family 31 member 1	Homo sapiens	182-191
24889085-3	2014	For example, the transport of platinum-based anticancer drugs has been reported to be influenced by the expression and activities of OCT1-3 (SLC22A1-3), OCTN1/2 (SLC22A4/5), CTR1/2 (SLC31A1/2) and MATE1/2 (SLC47A1/2) solute carriers.	Platinum	30-38	solute carrier family 47 member 1	Homo sapiens	197-204
24889085-3	2014	For example, the transport of platinum-based anticancer drugs has been reported to be influenced by the expression and activities of OCT1-3 (SLC22A1-3), OCTN1/2 (SLC22A4/5), CTR1/2 (SLC31A1/2) and MATE1/2 (SLC47A1/2) solute carriers.	Platinum	30-38	solute carrier family 47 member 1	Homo sapiens	206-215
24948471-0	2014	Association of POLK polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.	Platinum	39-47	DNA polymerase kappa	Homo sapiens	15-19
25246386-0	2014	Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.	Platinum	80-88	thymidylate synthetase	Homo sapiens	20-22
25246386-0	2014	Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.	Platinum	80-88	methylenetetrahydrofolate reductase	Homo sapiens	24-29
25246386-0	2014	Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.	Platinum	80-88	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	35-40
25261232-0	2014	Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer.	Platinum	49-57	heat shock protein family A (Hsp70) member 4	Homo sapiens	0-21
25261232-2	2014	We evaluated whether the expression of heat shock protein 70 (Hsp70) is associated with clinical outcomes in patients with completely resected NSCLC who were treated with or without adjuvant platinum-based chemotherapy.	Platinum	191-199	heat shock protein family A (Hsp70) member 4	Homo sapiens	62-67
25261232-9	2014	CONCLUSION: Hsp70 is a positive predictive factor in completely resected NSCLC with received platinum-based adjuvant chemotherapy.	Platinum	93-101	heat shock protein family A (Hsp70) member 4	Homo sapiens	12-17
25262426-0	2014	Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.	Platinum	163-171	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	18-45
25262426-2	2014	The objective of this study was to investigate the correlation between EZH2 expression and platinum-based chemotherapy response as well as survival of patients with advanced non-small cell lung cancer (NSCLC).	Platinum	91-99	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	71-75
25674147-0	2014	ERCC1, RRM1 and TUBB3 mRNA expression on the tumor response and overall survival of non-small cell lung cancer treated with platinum-based chemotherapy.	Platinum	124-132	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
25674147-0	2014	ERCC1, RRM1 and TUBB3 mRNA expression on the tumor response and overall survival of non-small cell lung cancer treated with platinum-based chemotherapy.	Platinum	124-132	tubulin beta 3 class III	Homo sapiens	16-21
25295110-14	2014	Pt accumulation in the tumors was higher in the PL-CBP group than in the CBP group (PL-CBP vs. CBP, P&lt;0.05).	Platinum	0-2	CREB binding protein	Mus musculus	73-76
25295110-14	2014	Pt accumulation in the tumors was higher in the PL-CBP group than in the CBP group (PL-CBP vs. CBP, P&lt;0.05).	Platinum	0-2	CREB binding protein	Mus musculus	73-76
25295110-14	2014	Pt accumulation in the tumors was higher in the PL-CBP group than in the CBP group (PL-CBP vs. CBP, P&lt;0.05).	Platinum	0-2	CREB binding protein	Mus musculus	73-76
25233397-0	2014	PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.	Platinum	55-63	pyruvate kinase M1/2	Homo sapiens	0-4
25104092-0	2014	Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.	Platinum	166-174	methylenetetrahydrofolate reductase	Homo sapiens	26-61
25104092-8	2014	The results indicate that a heterozygous advantage may exist in certain MTHFR variants, and the polymorphisms (especially rs1537514) may play a predictive role of treatment efficacy and adverse effects in NSCLC patients treated with platinum-based chemotherapy.	Platinum	233-241	methylenetetrahydrofolate reductase	Homo sapiens	72-77
25489176-2	2014	This led to successful evidence of using tyrosine kinase inhibitors (TKIs) over the standard platinum doublet based chemotherapy as the first line treatment in the metastatic setting.The rearrangements of fusion protein EML4-ALK in NSCLC lead to the use of crizotinib for this class of tumors.	Platinum	93-101	EMAP like 4	Homo sapiens	220-224
25233397-2	2014	PKM2 expression levels have been correlated with the effect of platinum compounds in cancer cell lines and xenograft models.	Platinum	63-71	pyruvate kinase M1/2	Homo sapiens	0-4
25233397-3	2014	The potential predictive role of PKM2 in patients with metastatic/advanced non-small-cell lung cancer (NSCLC) receiving platinum-based chemotherapy as first-line was investigated.	Platinum	120-128	pyruvate kinase M1/2	Homo sapiens	33-37
25233397-11	2014	CONCLUSIONS: PKM2 expression may be a predictive biomarker of platinum sensitivity in advanced NSCLC patients treated with platinum-based chemotherapy.	Platinum	62-70	pyruvate kinase M1/2	Homo sapiens	13-17
25233397-11	2014	CONCLUSIONS: PKM2 expression may be a predictive biomarker of platinum sensitivity in advanced NSCLC patients treated with platinum-based chemotherapy.	Platinum	123-131	pyruvate kinase M1/2	Homo sapiens	13-17
25274682-0	2014	Testing the metal of ERCC2 in predicting the response to platinum-based therapy.	Platinum	57-65	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	21-26
25242165-8	2014	Cisplatin, a platinum-containing anti-cancer drug, binds to copper sites of ATP7A and ATP7B, and undergoes vectorial displacement in analogy with copper.	Platinum	13-21	ATPase copper transporting alpha	Homo sapiens	76-81
25242165-8	2014	Cisplatin, a platinum-containing anti-cancer drug, binds to copper sites of ATP7A and ATP7B, and undergoes vectorial displacement in analogy with copper.	Platinum	13-21	ATPase copper transporting beta	Homo sapiens	86-91
25333617-9	2014	Importantly, a mixture of Pd and Pt nanoparticles with a molar ratio of 3 or 4 to 1 continued to exhibit SOD and catalase activity after oxidation, indicating that Pd nanoparticles prevent the oxidative deterioration of Pt nanoparticles.	Platinum	33-35	superoxide dismutase 1, soluble	Mus musculus	105-108
25275083-0	2014	Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma.	Platinum	38-46	proteasome 26S subunit, non-ATPase 1	Homo sapiens	11-14
25275083-2	2014	PATIENTS AND METHODS: This study was a retrospective review of TC patients who had received S-1-based chemotherapy for patients with platinum- and antrathycline-failure TC.	Platinum	133-141	proteasome 26S subunit, non-ATPase 1	Homo sapiens	92-95
25107571-2	2014	The aim of this study was to evaluate the predictive value of APE1, BRCA1, ERCC1 and TUBB3 in advanced NSCLC patients who received platinum-paclitaxel treatment.	Platinum	131-139	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	62-66
25107571-5	2014	RESULTS: Patients with negative expression of APE1, ERCC1 or TUBB3 benefited from platinum plus paclitaxel regimen chemotherapy.	Platinum	82-90	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	46-50
25107571-5	2014	RESULTS: Patients with negative expression of APE1, ERCC1 or TUBB3 benefited from platinum plus paclitaxel regimen chemotherapy.	Platinum	82-90	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	52-57
25107571-5	2014	RESULTS: Patients with negative expression of APE1, ERCC1 or TUBB3 benefited from platinum plus paclitaxel regimen chemotherapy.	Platinum	82-90	tubulin beta 3 class III	Homo sapiens	61-66
25107571-9	2014	Moreover, patients with both APE1- and ERCC1-negative or both APE1- and TUBB3-negative tumors had significantly higher response rate, longer median PFS and OS following treatment with platinum and paclitaxel (P &lt; 0.05).	Platinum	184-192	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	29-33
25107571-9	2014	Moreover, patients with both APE1- and ERCC1-negative or both APE1- and TUBB3-negative tumors had significantly higher response rate, longer median PFS and OS following treatment with platinum and paclitaxel (P &lt; 0.05).	Platinum	184-192	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	39-44
25107571-9	2014	Moreover, patients with both APE1- and ERCC1-negative or both APE1- and TUBB3-negative tumors had significantly higher response rate, longer median PFS and OS following treatment with platinum and paclitaxel (P &lt; 0.05).	Platinum	184-192	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	62-66
25107571-9	2014	Moreover, patients with both APE1- and ERCC1-negative or both APE1- and TUBB3-negative tumors had significantly higher response rate, longer median PFS and OS following treatment with platinum and paclitaxel (P &lt; 0.05).	Platinum	184-192	tubulin beta 3 class III	Homo sapiens	72-77
25107571-10	2014	CONCLUSION: The data indicate that APE1, ERCC1 and TUBB3 could be a useful biomarker to predict clinical outcome in patients with advanced NSCLC receiving first-line platinum-paclitaxel chemotherapy.	Platinum	166-174	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	35-39
25107571-10	2014	CONCLUSION: The data indicate that APE1, ERCC1 and TUBB3 could be a useful biomarker to predict clinical outcome in patients with advanced NSCLC receiving first-line platinum-paclitaxel chemotherapy.	Platinum	166-174	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	41-46
25107571-10	2014	CONCLUSION: The data indicate that APE1, ERCC1 and TUBB3 could be a useful biomarker to predict clinical outcome in patients with advanced NSCLC receiving first-line platinum-paclitaxel chemotherapy.	Platinum	166-174	tubulin beta 3 class III	Homo sapiens	51-56
25093213-3	2014	At a platinum electrode in bis(trifluoromethylsulfonyl)imide (NTf2)-based ILs, methane is electro-oxidized to produce CO2 and water when an oxygen reduction process is included.	Platinum	5-13	nuclear transport factor 2	Homo sapiens	62-66
25300933-12	2014	CONCLUSIONS: In our population of Caucasian women with advanced lung adenocarcinoma we observed that the presence of EGFR activating mutations correlates with a significant reduction in the benefit from first-line platinum-based CT, emphasizing the importance of an upfront use of anti-EGFR TKIs in this patient subset.	Platinum	214-222	epidermal growth factor receptor	Homo sapiens	117-121
25300933-12	2014	CONCLUSIONS: In our population of Caucasian women with advanced lung adenocarcinoma we observed that the presence of EGFR activating mutations correlates with a significant reduction in the benefit from first-line platinum-based CT, emphasizing the importance of an upfront use of anti-EGFR TKIs in this patient subset.	Platinum	214-222	epidermal growth factor receptor	Homo sapiens	286-290
24879591-3	2014	Ab-CRP was covalently immobilized on mercaptopropionic acid (MPA)-capped Pt nanoparticles that were covalently anchored over the graphene to form a bioelectrode.	Platinum	73-75	C-reactive protein	Homo sapiens	3-6
25015375-0	2014	ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.	Platinum	109-117	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
25274682-2	2014	In this issue of Cancer Discovery, Van Allen and colleagues have analyzed responders and nonresponders to neoadjuvant platinum-based therapy with locally advanced urothelial cancer and identified a series of mutations in the nucleotide excision repair (NER) gene ERCC2 that correlate with the response to platinum-based therapy.	Platinum	118-126	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	263-268
25015375-8	2014	More interestingly, we discovered the presence of ERCC1(+)CTC at primary diagnosis to be likewise an independent predictor of platinum resistance (P = 0.010), whereas ERCC1 expression in corresponding primary tumor tissue predicted neither platinum resistance nor prognosis.	Platinum	126-134	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	50-55
25015375-9	2014	CONCLUSIONS: The presence of ERCC1(+)CTC can serve as a blood-based diagnostic biomarker for predicting platinum resistance at primary diagnosis of ovarian cancer.	Platinum	104-112	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	29-34
25274682-2	2014	In this issue of Cancer Discovery, Van Allen and colleagues have analyzed responders and nonresponders to neoadjuvant platinum-based therapy with locally advanced urothelial cancer and identified a series of mutations in the nucleotide excision repair (NER) gene ERCC2 that correlate with the response to platinum-based therapy.	Platinum	305-313	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	263-268
25070243-10	2014	Given that ATP7A plays a critical role in the resistance of platinum-drug (such as cisplatin) representing a first-line treatment for SCLC, PDTC could be a promising candidate of adjunct therapeutic reagent for the patients requiring treatment with platinum-based regimens.	Platinum	60-68	ATPase copper transporting alpha	Homo sapiens	11-16
24939607-1	2014	The aims of this study were to develop a new coil, gellan sulfate core platinum coil (GSCC), that delivers tenascin-C (TNC) to an aneurysm (GSCC-TNC) and to evaluate the effects on intra-aneurysmal organization.	Platinum	71-79	tenascin C	Rattus norvegicus	107-117
25248112-1	2014	OBJECTIVE: The aim of this study was to explore BRCA mutation frequency and to evaluate its impact on prognosis of advanced-stage ovarian cancer patients treated with debulking surgery and platinum-based chemotherapy.	Platinum	189-197	BRCA1 DNA repair associated	Homo sapiens	48-52
25248112-8	2014	CONCLUSIONS: Advanced ovarian cancer patients harboring BRCA1/2 mutation treated with debulking surgery and platinum-based adjuvant chemotherapy have a longer PFS.	Platinum	108-116	BRCA1 DNA repair associated	Homo sapiens	56-63
25186150-1	2014	Ovarian carcinomas (OC) arising in BRCA1 and BRCA2 mutation carriers demonstrate pronounced sensitivity to platinum-based therapy due to deficiency of double-strand break DNA repair.	Platinum	107-115	BRCA1 DNA repair associated	Homo sapiens	35-40
25186150-1	2014	Ovarian carcinomas (OC) arising in BRCA1 and BRCA2 mutation carriers demonstrate pronounced sensitivity to platinum-based therapy due to deficiency of double-strand break DNA repair.	Platinum	107-115	BRCA2 DNA repair associated	Homo sapiens	45-50
24939607-1	2014	The aims of this study were to develop a new coil, gellan sulfate core platinum coil (GSCC), that delivers tenascin-C (TNC) to an aneurysm (GSCC-TNC) and to evaluate the effects on intra-aneurysmal organization.	Platinum	71-79	tenascin C	Rattus norvegicus	119-122
25243473-6	2014	Interestingly, loss of PGC1alpha/TFAM and ERalpha was found also in a non-clear cell EOC cell line made highly resistant to platinum in vitro.	Platinum	124-132	PPARG coactivator 1 alpha	Homo sapiens	23-32
25253066-0	2014	ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy.	Platinum	84-92	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
25253066-2	2014	In the present study, we evaluated the prognostic role of the two most common ERCC1 polymorphisms in patients with T4 breast cancer receiving platinum-based chemotherapy.	Platinum	142-150	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	78-83
25253066-7	2014	The 8092A and 19007C genotypes in ERCC1 were significantly associated with overall survival in T4 breast cancer patients treated with chemotherapy containing platinum (p-values = 0.036 and 0.004, respectively).	Platinum	158-166	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	34-39
25253066-10	2014	CONCLUSIONS: The ERCC1 8092A and 19007C genotypes or their combination may predict a favorable prognosis in T4 breast cancer patients undergoing a platinum-based treatment.	Platinum	147-155	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	17-22
25243473-6	2014	Interestingly, loss of PGC1alpha/TFAM and ERalpha was found also in a non-clear cell EOC cell line made highly resistant to platinum in vitro.	Platinum	124-132	transcription factor A, mitochondrial	Homo sapiens	33-37
25243473-6	2014	Interestingly, loss of PGC1alpha/TFAM and ERalpha was found also in a non-clear cell EOC cell line made highly resistant to platinum in vitro.	Platinum	124-132	estrogen receptor 1	Homo sapiens	42-49
25142144-6	2014	Genotype data for the TP53-Arg72Pro polymorphism, which is associated with responses to platinum-based doublet chemotherapy, were subsequently incorporated into the prediction analysis.	Platinum	88-96	tumor protein p53	Homo sapiens	22-26
25058344-4	2014	The palladium(II), platinum(II) and bismuth(III) complexes inhibited TrxR at micromolar concentrations but not GR.	Platinum	19-27	peroxiredoxin 5	Homo sapiens	69-73
25222296-0	2014	Aberrant promoter methylation of caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC.	Platinum	92-100	caveolin 1	Homo sapiens	33-43
25222296-10	2014	CONCLUSIONS: CAV1 methylation is a predictor of disease stabilization and improved overall survival following chemotherapy with a taxane-platinum combination regimen in advanced NSCLC.	Platinum	137-145	caveolin 1	Homo sapiens	13-17
25277200-0	2014	Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner.	Platinum	19-27	annexin A4	Homo sapiens	0-10
25277200-2	2014	We previously reported that enhanced annexin A4 (ANXA4) expression, a Ca2+-regulated phospholipid-binding protein, induces chemoresistance to platinum-based drugs.	Platinum	142-150	annexin A4	Homo sapiens	37-47
25277200-2	2014	We previously reported that enhanced annexin A4 (ANXA4) expression, a Ca2+-regulated phospholipid-binding protein, induces chemoresistance to platinum-based drugs.	Platinum	142-150	annexin A4	Homo sapiens	49-54
25277200-4	2014	ANXA4 knockdown increased sensitivity to platinum-based drugs both in vitro and in vivo.	Platinum	41-49	annexin A4	Homo sapiens	0-5
25277200-6	2014	Platinum resistance was induced both in vitro and in vivo in cells expressing either full-length ANXA4 or the deletion mutants, containing at least one intact annexin repeat.	Platinum	0-8	annexin A4	Homo sapiens	97-102
25277200-8	2014	After cisplatin treatment, the intracellular chloride ion concentration, whose channel is partly regulated by ANXA4, significantly increased in the platinum-resistant cells.	Platinum	148-156	annexin A4	Homo sapiens	110-115
25216266-7	2014	ALDH1A1-knockdown significantly attenuated clonogenic potential, PARP-1 protein levels, and reversed inherent platinum resistance.	Platinum	110-118	aldehyde dehydrogenase 1 family member A1	Homo sapiens	0-7
25216266-11	2014	CONCLUSION: This data suggests that ovarian cancer cells expressing ALDH1A1 may maintain platinum resistance by altered regulation of cell cycle checkpoint and DNA repair network signaling.	Platinum	89-97	aldehyde dehydrogenase 1 family member A1	Homo sapiens	68-75
25072261-13	2014	CONCLUSION: Superior OS was observed for advanced-disease BRCA-associated PDAC with platinum exposure.	Platinum	84-92	BRCA1 DNA repair associated	Homo sapiens	58-62
25010864-0	2014	Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.	Platinum	57-65	glutathione S-transferase pi 1	Homo sapiens	0-28
25010864-0	2014	Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.	Platinum	57-65	glutathione S-transferase pi 1	Homo sapiens	30-35
25010864-2	2014	Platinum drugs are metabolised by glutathione S-transferase P1 (GSTP1), which is abundantly, but variably expressed in ovarian tumours.	Platinum	0-8	glutathione S-transferase pi 1	Homo sapiens	34-62
25010864-2	2014	Platinum drugs are metabolised by glutathione S-transferase P1 (GSTP1), which is abundantly, but variably expressed in ovarian tumours.	Platinum	0-8	glutathione S-transferase pi 1	Homo sapiens	64-69
24995581-0	2014	Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.	Platinum	62-70	interferon regulatory factor 1	Homo sapiens	0-30
25010864-11	2014	Inter-tumour differences in GSTP1 expression may therefore influence response to platinum-based chemotherapy in ovarian cancer patients.	Platinum	81-89	glutathione S-transferase pi 1	Homo sapiens	28-33
25191856-4	2014	Evidence suggests polymorphisms in genes encoding excision repair cross-complementing group 1 (ERCC1), a protein involved in nuclear excision repair (NER), may help predict response to cisplatin and other platinum-based chemotherapeutics.	Platinum	205-213	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	50-93
25191856-4	2014	Evidence suggests polymorphisms in genes encoding excision repair cross-complementing group 1 (ERCC1), a protein involved in nuclear excision repair (NER), may help predict response to cisplatin and other platinum-based chemotherapeutics.	Platinum	205-213	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	95-100
25129345-7	2014	Platinum-based chemotherapy is effective in a high proportion of patients with BRCA1-associated breast cancer.	Platinum	0-8	BRCA1 DNA repair associated	Homo sapiens	79-84
25145176-3	2014	Platinum-doped catalyst showed the best results in hydrogen generation, also producing methane, ethene and ethane, whereas the best oxygen production was exhibited by P25, followed by copper--and cobalt-containing photocatalysts.	Platinum	0-8	tubulin polymerization promoting protein	Homo sapiens	167-170
25017175-1	2014	Synergistic release of platinum anticancer drugs and O2 can be achieved in an H2O2-responsive nanocarrier incorporated with catalase.	Platinum	23-31	catalase	Homo sapiens	124-132
25035395-6	2014	Low-dose SGI-110 reduced the stem-like properties of ALDH(+) cells, including their tumor-initiating capacity, resensitized these OCSCs to platinum, and induced reexpression of differentiation-associated genes.	Platinum	139-147	semenogelin 1	Homo sapiens	9-12
24962727-0	2014	Platinum and palladium nanotubes based on genetically engineered elastin-mimetic fusion protein-fiber templates: synthesis and application in lithium-O2 batteries.	Platinum	0-8	elastin	Homo sapiens	65-72
25155628-3	2014	SNPs of DNA repair genes (ERCC1 and ERCC2) have been implicated in the causation of various cancers as well as inter-individual variability in the therapeutic outcomes of platinum based therapy.	Platinum	171-179	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	26-31
25155628-3	2014	SNPs of DNA repair genes (ERCC1 and ERCC2) have been implicated in the causation of various cancers as well as inter-individual variability in the therapeutic outcomes of platinum based therapy.	Platinum	171-179	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	36-41
24995581-6	2014	RESULTS: IPA and URA highlighted an IRF1-driven transcriptional program (P=0.0017; z-score of 3.091) in the platinum sensitive improved PFS group.	Platinum	108-116	interferon regulatory factor 1	Homo sapiens	36-40
24995581-9	2014	CONCLUSION: Transcriptome analysis identifies IRF1, a transcription factor that functions both in immune regulation and as a tumor suppressor, as being associated with platinum sensitivity and an independent predictor of both PFS and OS in HGSOC.	Platinum	168-176	interferon regulatory factor 1	Homo sapiens	46-50
24825122-0	2014	BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer.	Platinum	61-69	BRCA1 DNA repair associated	Homo sapiens	0-5
24825122-1	2014	BACKGROUND: The aim of the current study was to investigate the role of BRCA1 promoter methylation as predictive factor of response to platinum-taxane-based therapy in sporadic ovarian cancer.	Platinum	135-143	BRCA1 DNA repair associated	Homo sapiens	72-77
24825122-8	2014	CONCLUSIONS: BRCA1 promoter methylation is predictive for better response to platinum-taxane-based therapy in EOC.	Platinum	77-85	BRCA1 DNA repair associated	Homo sapiens	13-18
24968817-3	2014	On the basis of array data retrieved from Oncomine and Gene Expression Omnibus (GEO) online database, we found that the mRNA expression of HNF1B in 586 ovarian serous cystadenocarcinomas and in platinum-resistant A2780 epithelial ovarian cancer cells was significantly decreased, indicating a potential role of HNF1B in drug resistance in ovarian cancer.	Platinum	194-202	HNF1 homeobox B	Homo sapiens	139-144
25119504-11	2014	Furthermore, platinum-based chemotherapy was identified to improve the OS of PSCCB with EGFR + CK5/6+ (P = 0.027).	Platinum	13-21	epidermal growth factor receptor	Homo sapiens	88-92
25119504-11	2014	Furthermore, platinum-based chemotherapy was identified to improve the OS of PSCCB with EGFR + CK5/6+ (P = 0.027).	Platinum	13-21	keratin 5	Homo sapiens	95-98
25119504-13	2014	As the only independent prognostic factor for PSCCB, combined over-expression of EGFR and CK5/6 might be a potential indicator for the use of platinum-based chemotherapy.	Platinum	142-150	epidermal growth factor receptor	Homo sapiens	81-85
25119504-13	2014	As the only independent prognostic factor for PSCCB, combined over-expression of EGFR and CK5/6 might be a potential indicator for the use of platinum-based chemotherapy.	Platinum	142-150	keratin 5	Homo sapiens	90-95
25017423-2	2014	We demonstrated that overexpression of miR-224-5p in ovarian cancer patients is associated with platinum-based chemoresistance using miRNA microarray analysis and quantitative real-time polymerase chain reaction (qRT-PCR) validation in vivo, as well as in 4 human ovarian cancer cell lines (C13/OV2008; A2780CP/A2780S) in vitro.	Platinum	96-104	microRNA 224	Homo sapiens	39-46
25158060-0	2014	Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers.	Platinum	56-64	BRCA1 DNA repair associated	Homo sapiens	94-98
25017423-9	2014	Our findings suggest that miR-224-5p may function as an oncogene and induce platinum resistance in OPSC at least in part by downregulating PRKCD, thereby providing a biomarker for predicting chemosensitivity to cisplatin in patients with ovarian cancer.	Platinum	76-84	microRNA 224	Homo sapiens	26-33
25017423-9	2014	Our findings suggest that miR-224-5p may function as an oncogene and induce platinum resistance in OPSC at least in part by downregulating PRKCD, thereby providing a biomarker for predicting chemosensitivity to cisplatin in patients with ovarian cancer.	Platinum	76-84	protein kinase C delta	Homo sapiens	139-144
24643932-0	2014	Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer.	Platinum	64-72	epidermal growth factor receptor	Homo sapiens	15-19
24870596-0	2014	The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis.	Platinum	81-89	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	24-29
24870596-1	2014	Numerous studies examined the association between excision repair complementation group 1 (ERCC1) expression and the prognosis of gastric cancer patients receiving platinum-based chemotherapy but yielded controversial results.	Platinum	164-172	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	91-96
24870596-2	2014	We thus conducted a meta-analysis to quantitatively evaluate the prognostic value of ERCC1 expression in gastric cancer patients receiving platinum-based chemotherapy.	Platinum	139-147	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	85-90
24870596-8	2014	This meta-analysis suggested that ERCC1 expression might be a useful biomarker to predict response and survival for gastric cancer patients receiving platinum-based chemotherapy, particularly in Asians.	Platinum	150-158	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	34-39
25177362-1	2014	BACKGROUND: Electro-oxidation of methanol in acidic solution was investigated on a Pt/SnO2 based electrocatalyst obtained by the sol-gel method.	Platinum	83-85	strawberry notch homolog 2	Homo sapiens	86-89
25026285-9	2014	In these cells, CD157 expression was associated with increased activation of the mTOR signaling pathway, resulting in decreased platinum sensitivity.	Platinum	128-136	bone marrow stromal cell antigen 1	Homo sapiens	16-21
24983998-9	2014	Using this combined in silico-in vitro approach we provide here for the first time a quantitative 3D atomic view of the platinum binding to the first soluble domain of ATP7A.	Platinum	120-128	ATPase copper transporting alpha	Homo sapiens	168-173
24897557-0	2014	Lysozyme-directed synthesis of platinum nanoclusters as a mimic oxidase.	Platinum	31-39	lysozyme	Homo sapiens	0-8
24897557-1	2014	We present a simple, one-pot approach for synthesizing ultrafine platinum (Pt) nanoclusters (NCs) under alkaline conditions using lysozyme (Lys) as a template.	Platinum	75-77	lysozyme	Homo sapiens	130-138
24897557-1	2014	We present a simple, one-pot approach for synthesizing ultrafine platinum (Pt) nanoclusters (NCs) under alkaline conditions using lysozyme (Lys) as a template.	Platinum	75-77	lysozyme	Homo sapiens	140-143
25026285-9	2014	In these cells, CD157 expression was associated with increased activation of the mTOR signaling pathway, resulting in decreased platinum sensitivity.	Platinum	128-136	mechanistic target of rapamycin kinase	Homo sapiens	81-85
24797335-4	2014	Thus, the aim of this study is to evaluate the potential prognostic value of HORMAD2 polymorphisms in Han Chinese patients with advanced NSCLC and undergoing first-line platinum-based chemotherapy.	Platinum	169-177	HORMA domain containing 2	Homo sapiens	77-84
26674120-4	2014	RESULTS: High ATM protein expression was associated with serous cystadenocarcinomas (p = 0.021) and platinum resistance (p = 0.017).	Platinum	100-108	ATM serine/threonine kinase	Homo sapiens	14-17
25075026-0	2014	SOX18 expression predicts response to platinum-based chemotherapy in ovarian cancer.	Platinum	38-46	SRY-box transcription factor 18	Homo sapiens	0-5
25152614-0	2014	Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.	Platinum	119-127	proteasome 26S subunit, non-ATPase 1	Homo sapiens	23-26
25152614-1	2014	PURPOSE: This retrospective study evaluates the efficacy and safety of S-1 chemotherapy for recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy.	Platinum	168-176	proteasome 26S subunit, non-ATPase 1	Homo sapiens	71-74
25152614-10	2014	CONCLUSION: S-1 monotherapy is considered a safe and effective treatment option for recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy.	Platinum	160-168	proteasome 26S subunit, non-ATPase 1	Homo sapiens	12-15
24958519-0	2014	Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer.	Platinum	68-76	glutathione S-transferase pi 1	Homo sapiens	24-29
25085632-0	2014	Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent ) a VEGFR2/PDGFRbeta/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.	Platinum	39-47	kinase insert domain receptor	Homo sapiens	119-125
25085632-0	2014	Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent ) a VEGFR2/PDGFRbeta/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.	Platinum	39-47	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	136-141
25085632-0	2014	Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent ) a VEGFR2/PDGFRbeta/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.	Platinum	39-47	ret proto-oncogene	Homo sapiens	148-151
25085632-0	2014	Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent ) a VEGFR2/PDGFRbeta/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.	Platinum	39-47	colony stimulating factor 1 receptor	Homo sapiens	152-157
24958519-0	2014	Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer.	Platinum	68-76	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	34-39
24958519-1	2014	The study aims to investigate whether the glutathione S transferase P1 (GSTP1) and excision repair cross-complementing group 1 (ERCC1) polymorphism influence the response to treatment with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.	Platinum	189-197	glutathione S-transferase pi 1	Homo sapiens	42-70
24958519-1	2014	The study aims to investigate whether the glutathione S transferase P1 (GSTP1) and excision repair cross-complementing group 1 (ERCC1) polymorphism influence the response to treatment with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.	Platinum	189-197	glutathione S-transferase pi 1	Homo sapiens	72-77
24958519-1	2014	The study aims to investigate whether the glutathione S transferase P1 (GSTP1) and excision repair cross-complementing group 1 (ERCC1) polymorphism influence the response to treatment with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.	Platinum	189-197	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	83-126
24958519-1	2014	The study aims to investigate whether the glutathione S transferase P1 (GSTP1) and excision repair cross-complementing group 1 (ERCC1) polymorphism influence the response to treatment with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.	Platinum	189-197	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	128-133
24958519-16	2014	GSTP1 and ERCC1 polymorphism are correlated with response to platinum-based chemotherapy and have prognostic value for TTP.	Platinum	61-69	glutathione S-transferase pi 1	Homo sapiens	0-5
24958519-16	2014	GSTP1 and ERCC1 polymorphism are correlated with response to platinum-based chemotherapy and have prognostic value for TTP.	Platinum	61-69	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	10-15
24852429-0	2014	The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients.	Platinum	60-68	ATPase copper transporting beta	Homo sapiens	4-9
24824873-0	2014	Serum levels of vascular cell adhesion molecule-1 (VCAM-1) may have diagnostic, predictive, and prognostic roles in patients with lung cancer treated with platinum-based chemotherapy.	Platinum	155-163	vascular cell adhesion molecule 1	Homo sapiens	16-49
24852429-1	2014	This study aims to investigate the influence of ATP7B genetic polymorphism to platinum-based chemotherapy in Chinese Han lung cancer patients.	Platinum	78-86	ATPase copper transporting beta	Homo sapiens	48-53
24824873-0	2014	Serum levels of vascular cell adhesion molecule-1 (VCAM-1) may have diagnostic, predictive, and prognostic roles in patients with lung cancer treated with platinum-based chemotherapy.	Platinum	155-163	vascular cell adhesion molecule 1	Homo sapiens	51-57
24824873-2	2014	The objective of this study was to determine the clinical significance of the serum levels of vascular cell adhesion molecule-1 (VCAM-1) in lung cancer patients treated with platinum-based chemotherapy.	Platinum	174-182	vascular cell adhesion molecule 1	Homo sapiens	94-127
24852429-4	2014	Four tag SNPs of ATP7B (rs1061472, rs9535826, rs7999812, and rs9535828) were selected to evaluate their impacts to platinum-based chemotherapy in these patients.	Platinum	115-123	ATPase copper transporting beta	Homo sapiens	17-22
24824873-2	2014	The objective of this study was to determine the clinical significance of the serum levels of vascular cell adhesion molecule-1 (VCAM-1) in lung cancer patients treated with platinum-based chemotherapy.	Platinum	174-182	vascular cell adhesion molecule 1	Homo sapiens	129-135
24824873-13	2014	In conclusion, serum VCAM-1 concentrations may have diagnostic, predictive, and prognostic role in lung cancer patients treated with platinum-based chemotherapy.	Platinum	133-141	vascular cell adhesion molecule 1	Homo sapiens	21-27
24852429-5	2014	ATP7B rs9535828 and rs9535826 were found to be associated with platinum resistance in Chinese Han lung cancer patients.	Platinum	63-71	ATPase copper transporting beta	Homo sapiens	0-5
24852429-6	2014	Patients with A allele in ATP7B rs9535828 presented an increased susceptibility to platinum drugs (OR 1.96, 95 % CI 1.17-3.30, p &lt; 0.01).	Platinum	83-91	ATPase copper transporting beta	Homo sapiens	26-31
24852429-7	2014	Patients with G allele in ATP7B rs9535826 had the highest susceptibility to platinum drugs (OR 2.05, 95 % CI 1.19-3.52, p &lt; 0.01).	Platinum	76-84	ATPase copper transporting beta	Homo sapiens	26-31
24852429-8	2014	Our findings suggest that ATP7B genetic polymorphisms could affect the therapeutic efficacy of platinum-based chemotherapy, and ATP7B gene might be considered as predictive markers for the efficacy evaluation of platinum-based chemotherapy in Chinese Han lung cancer patients.	Platinum	95-103	ATPase copper transporting beta	Homo sapiens	26-31
24852429-8	2014	Our findings suggest that ATP7B genetic polymorphisms could affect the therapeutic efficacy of platinum-based chemotherapy, and ATP7B gene might be considered as predictive markers for the efficacy evaluation of platinum-based chemotherapy in Chinese Han lung cancer patients.	Platinum	212-220	ATPase copper transporting beta	Homo sapiens	128-133
24859833-0	2014	Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients.	Platinum	62-70	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	17-22
25007397-2	2014	The PE2 complex can be visualized as two branches containing two phenylacetylene units, each one linked by a platinum center, completely transparent in the visible region.	Platinum	109-117	ETS2 repressor factor	Homo sapiens	4-7
25223188-18	2014	The body weight, BMI, fat factor, IRI, TNF-alpha, and SOCS-3 all decreased in the PT group (P &lt; 0.05, P &lt; 0.01); leptin and adiponectin in the serum and the fat homogenate increased (P &lt; 0.05, P &lt; 0.01).	Platinum	82-84	tumor necrosis factor	Rattus norvegicus	39-48
25223188-18	2014	The body weight, BMI, fat factor, IRI, TNF-alpha, and SOCS-3 all decreased in the PT group (P &lt; 0.05, P &lt; 0.01); leptin and adiponectin in the serum and the fat homogenate increased (P &lt; 0.05, P &lt; 0.01).	Platinum	82-84	suppressor of cytokine signaling 3	Rattus norvegicus	54-60
25223188-18	2014	The body weight, BMI, fat factor, IRI, TNF-alpha, and SOCS-3 all decreased in the PT group (P &lt; 0.05, P &lt; 0.01); leptin and adiponectin in the serum and the fat homogenate increased (P &lt; 0.05, P &lt; 0.01).	Platinum	82-84	leptin	Rattus norvegicus	119-125
25223188-18	2014	The body weight, BMI, fat factor, IRI, TNF-alpha, and SOCS-3 all decreased in the PT group (P &lt; 0.05, P &lt; 0.01); leptin and adiponectin in the serum and the fat homogenate increased (P &lt; 0.05, P &lt; 0.01).	Platinum	82-84	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	130-141
24656855-0	2014	Effective anodic oxidation of naproxen by platinum nanoparticles coated FTO glass.	Platinum	42-50	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	72-75
25078585-1	2014	This study aimed to evaluate the association between RRM1 and BRCA1 expressions and the therapeutic efficacy of platinum-based chemotherapy in non-small cell lung cancer patients in terms of their response and prognosis.	Platinum	112-120	ribonucleotide reductase catalytic subunit M1	Homo sapiens	53-57
25076338-1	2014	Recent data suggests that treating patients with pancreatic cancer that express mutations in BRCA1, BRCA2, and PALB2 with chemotherapy which targets the DNA repair defect in these cells, such as platinum based therapies or PARPi [poly (ADP-ribose) polymerase inhibitor], may be more beneficial in these patients.	Platinum	195-203	BRCA1 DNA repair associated	Homo sapiens	93-98
25076338-1	2014	Recent data suggests that treating patients with pancreatic cancer that express mutations in BRCA1, BRCA2, and PALB2 with chemotherapy which targets the DNA repair defect in these cells, such as platinum based therapies or PARPi [poly (ADP-ribose) polymerase inhibitor], may be more beneficial in these patients.	Platinum	195-203	BRCA2 DNA repair associated	Homo sapiens	100-105
25076338-1	2014	Recent data suggests that treating patients with pancreatic cancer that express mutations in BRCA1, BRCA2, and PALB2 with chemotherapy which targets the DNA repair defect in these cells, such as platinum based therapies or PARPi [poly (ADP-ribose) polymerase inhibitor], may be more beneficial in these patients.	Platinum	195-203	partner and localizer of BRCA2	Homo sapiens	111-116
25078585-1	2014	This study aimed to evaluate the association between RRM1 and BRCA1 expressions and the therapeutic efficacy of platinum-based chemotherapy in non-small cell lung cancer patients in terms of their response and prognosis.	Platinum	112-120	BRCA1 DNA repair associated	Homo sapiens	62-67
25078585-5	2014	Patients with high RRM1 expression benefited more from a platinum-containing regimen, and patients with high BRCA1 expression showed a high response rate to a platinum-containing regimen and reduced disease progression.	Platinum	159-167	BRCA1 DNA repair associated	Homo sapiens	109-114
25047920-1	2014	BACKGROUND: Miriplatin (MPT) is a novel platinum complex used in TACE that shows promise for the treatment of hepatocellular carcinoma (HCC).	Platinum	40-48	ADAM metallopeptidase domain 17	Homo sapiens	65-69
24850841-0	2014	VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy.	Platinum	114-122	vascular endothelial growth factor A	Homo sapiens	0-4
24534575-0	2014	Porous platinum nanotubes labeled with hemin/G-quadruplex based electrochemical aptasensor for sensitive thrombin analysis via the cascade signal amplification.	Platinum	7-15	coagulation factor II, thrombin	Homo sapiens	105-113
24534575-1	2014	For the first time, a sensitive electrochemical aptasensor for thrombin (TB) was developed by using porous platinum nanotubes (PtNTs) labeled with hemin/G-quadruplex and glucose dehydrogenase (GDH) as labels.	Platinum	107-115	coagulation factor II, thrombin	Homo sapiens	63-71
24850841-0	2014	VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy.	Platinum	114-122	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	74-78
24850841-7	2014	In addition, high EZH2 expression was associated with poor overall survival in patients who received platinum-based adjuvant therapy, but not in patients who did not receive this therapy.	Platinum	101-109	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	18-22
24850841-10	2014	EZH2 depletion decreases the malignant potential of lung adenocarcinoma and sensitivity of the cells to both platinum-based and VEGFR-2-targeted therapy.	Platinum	109-117	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	0-4
24982391-1	2014	AIM: Expression of excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1) was suggested to be of predictive value for selecting patients with clinical benefit from platinum-based chemotherapy.	Platinum	203-211	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	106-111
24982391-5	2014	In contrast, patients with squamous cell carcinoma treated with adjuvant platinum-based chemotherapy who had a low ERCC1 expression had a survival benefit with respect to disease-free and overall survival.	Platinum	73-81	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	115-120
24982391-7	2014	CONCLUSION: Oour data point to a potential predictive value of ERCC1 expression for the selection of adjuvant platinum-based chemotherapy for patients with pulmonary squamous cell carcinomas but not for those with adenocarcinomas.	Platinum	110-118	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	63-68
24895096-1	2014	ZnIn(2)S(4) microspheres (ZIS MSs) were for the first time decorated with carbon quantum dots (CQDs) and platinum nanoparticles (NPs) as dual co-catalysts of for photocatalytic H(2) production.	Platinum	105-113	zinc finger RANBP2-type containing 2	Homo sapiens	26-29
25019640-4	2014	RESULTS: We found that XPF (an ERCC1 binding partner) and phospho-MAPKAP Kinase 2 (pMK2) are novel biomarkers for HNSCC patients undergoing platinum-based induction chemotherapy.	Platinum	140-148	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	23-26
25019640-4	2014	RESULTS: We found that XPF (an ERCC1 binding partner) and phospho-MAPKAP Kinase 2 (pMK2) are novel biomarkers for HNSCC patients undergoing platinum-based induction chemotherapy.	Platinum	140-148	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	31-36
25019640-4	2014	RESULTS: We found that XPF (an ERCC1 binding partner) and phospho-MAPKAP Kinase 2 (pMK2) are novel biomarkers for HNSCC patients undergoing platinum-based induction chemotherapy.	Platinum	140-148	MAPK activated protein kinase 2	Homo sapiens	66-81
25019640-7	2014	CONCLUSIONS: We identified XPF and pMK2 as novel DNA-repair biomarkers for locoregionally-advanced HNC patients undergoing platinum-based induction chemotherapy prior to definitive chemoradiation.	Platinum	123-131	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	27-30
24464627-1	2014	UNLABELLED: To investigate whether the NAD(P)H: quinone oxidoreductase 1 (NQO1) gene polymorphisms determine the Platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) in a Chinese cohort.	Platinum	113-121	NAD(P)H quinone dehydrogenase 1	Homo sapiens	39-72
24464627-1	2014	UNLABELLED: To investigate whether the NAD(P)H: quinone oxidoreductase 1 (NQO1) gene polymorphisms determine the Platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) in a Chinese cohort.	Platinum	113-121	NAD(P)H quinone dehydrogenase 1	Homo sapiens	74-78
24464627-10	2014	The NQO1 C609T polymorphism is an important molecular marker for advanced NSCLC, since it is associated with the NSCLC risk as well as the response status of platinum-based chemotherapy.	Platinum	158-166	NAD(P)H quinone dehydrogenase 1	Homo sapiens	4-8
24768329-0	2014	Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.	Platinum	112-120	KRAS proto-oncogene, GTPase	Homo sapiens	17-21
24742319-0	2014	Vintafolide (EC145) for the treatment of folate-receptor-alpha positive platinum-resistant ovarian cancer.	Platinum	72-80	folate receptor alpha	Homo sapiens	41-62
24802724-6	2014	CONCLUSIONS: Our findings indicate that the miR-200 family of microRNAs, and miR-429 in particular, play a critical role in the functioning of OC metastasizing cells and that targeted delivery of miR-429, and perhaps other miR-200 family members, in combination with platinum-based chemotherapies may be an effective strategy in reducing OC metastasis and tumor recurrence.	Platinum	267-275	microRNA 429	Homo sapiens	196-203
24038379-0	2014	miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A).	Platinum	72-80	microRNA 495	Homo sapiens	0-7
24792619-12	2014	In this subgroup, for those women who received paclitaxel and platinum agents combined (n = 57), reduced MAD2 intensity also identified women with a shorter RFS (P &lt; .007).	Platinum	62-70	mitotic arrest deficient 2 like 1	Homo sapiens	105-109
24802724-1	2014	OBJECTIVE: We recently determined that the ectopic over-expression of miR-429 and other members of the miR-200 family of microRNAs in ovarian cancer (OC) mesenchymal-like cell lines induces mesenchymal-to-epithelial transition (MET) with a concomitant increase in sensitivity to platinum drugs.	Platinum	279-287	microRNA 429	Homo sapiens	70-77
24038379-0	2014	miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A).	Platinum	72-80	ATPase copper transporting alpha	Homo sapiens	153-158
24038379-1	2014	Copper-transporting P-type adenosine triphosphatase A (ATP7A) is associated with platinum drug resistance in non-small cell lung cancer (NSCLC).	Platinum	81-89	ATPase copper transporting alpha	Homo sapiens	55-60
24038379-3	2014	In this study, the aim is to explore which miRNAs might participate in the platinum resistance by targeting ATP7A in NSCLC.	Platinum	75-83	ATPase copper transporting alpha	Homo sapiens	108-113
25051913-1	2014	Our aim was to evaluate the prognostic role of the pretreatment serum albumin level in patients with malignant pleural mesothelioma (MPM) receiving platinum-based systemic chemotherapy.	Platinum	148-156	albumin	Homo sapiens	70-77
25286685-12	2014	CONCLUSION: Hyperthermia can enhance the sensitivity of ovarian cancer SKOV3 cells to platinum-based drugs, which may be related to the down regulation of ERCC1 and Survivin expression.	Platinum	86-94	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	155-160
24729086-8	2014	We found that GSTM1 null/present but not GSTP1 A313G polymorphism was associated with platinum-based TR (for GSTM1, null vs present: OR = 1.77, 95% CI = 1.19-2.62).	Platinum	86-94	glutathione S-transferase mu 1	Homo sapiens	14-19
25045435-0	2014	Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.	Platinum	118-126	epithelial cell adhesion molecule	Homo sapiens	22-55
25045435-11	2014	EpCAM overexpression was significantly associated with a better progression free survival and higher response rates to platinum based chemotherapy (p=0.040 and p=0.048, respectively).	Platinum	119-127	epithelial cell adhesion molecule	Homo sapiens	0-5
24868108-0	2014	Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer.	Platinum	10-18	fms related receptor tyrosine kinase 1	Homo sapiens	115-118
24792335-3	2014	Furthermore, low expression of the copper transporter CTR1, a transporter of platinum uptake was associated with poor clinical outcome following platinum-based therapy in NSCLC patients.	Platinum	77-85	solute carrier family 31 member 1	Homo sapiens	54-58
24792335-3	2014	Furthermore, low expression of the copper transporter CTR1, a transporter of platinum uptake was associated with poor clinical outcome following platinum-based therapy in NSCLC patients.	Platinum	145-153	solute carrier family 31 member 1	Homo sapiens	54-58
24792335-4	2014	We investigated the relationship between tissue platinum concentrations and CTR1 expression in NSCLC specimens.	Platinum	48-56	solute carrier family 31 member 1	Homo sapiens	76-80
24792335-9	2014	A subset of patients with undetectable CTR1 expression in their tumors had reduced platinum concentrations (P=0.058) and tumor response (P=0.016) compared to those with any level of CTR1 expression.	Platinum	83-91	solute carrier family 31 member 1	Homo sapiens	39-43
24792335-12	2014	CTR1 expression may be necessary for therapeutic efficacy of platinum drugs, consistent with previous preclinical studies.	Platinum	61-69	solute carrier family 31 member 1	Homo sapiens	0-4
24792335-13	2014	A prospective clinical trial is necessary to develop CTR1 into a potential biomarker for platinum drugs.	Platinum	89-97	solute carrier family 31 member 1	Homo sapiens	53-57
25061320-0	2014	Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer.	Platinum	68-76	epidermal growth factor receptor	Homo sapiens	20-24
25061320-10	2014	CONCLUSION: Our data showed that the presence of EGFR mutations meant longer survival times for patients with advanced NSCLC who received platinum-based doublet first-line chemotherapy, especially in those with the exon 19 deletion mutation.	Platinum	138-146	epidermal growth factor receptor	Homo sapiens	49-53
24729086-0	2014	The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: a meta-analysis.	Platinum	111-119	glutathione S-transferase pi 1	Homo sapiens	28-33
24729086-0	2014	The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: a meta-analysis.	Platinum	111-119	glutathione S-transferase mu 1	Homo sapiens	44-49
24729086-1	2014	The relationship between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response (TR) of platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients have been extensively investigated by many studies, but the results were inconsistent and inconclusive.	Platinum	113-121	glutathione S-transferase pi 1	Homo sapiens	29-34
24729086-1	2014	The relationship between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response (TR) of platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients have been extensively investigated by many studies, but the results were inconsistent and inconclusive.	Platinum	113-121	glutathione S-transferase mu 1	Homo sapiens	45-50
24729086-11	2014	Our study suggested that the GSTP1 A313G and GSTM1 null/present polymorphisms could predict the treatment response of the platinum-based chemotherapy in NSCLC patients, especially in East-Asian patients.	Platinum	122-130	glutathione S-transferase pi 1	Homo sapiens	29-34
24729086-11	2014	Our study suggested that the GSTP1 A313G and GSTM1 null/present polymorphisms could predict the treatment response of the platinum-based chemotherapy in NSCLC patients, especially in East-Asian patients.	Platinum	122-130	glutathione S-transferase mu 1	Homo sapiens	45-50
24748235-0	2014	Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?	Platinum	16-24	WAP four-disulfide core domain 2	Homo sapiens	4-7
24748235-8	2014	At third chemotherapy cycle, in platinum-resistant patients, HE4 levels were &gt;70 pmol/L in 36 of 36 cases, although in platinum-sensitive/intermediate patients, HE4 levels were &gt;70 pmol/L only in six of 40 cases (sensitivity 100 %, specificity 85 %).	Platinum	32-40	WAP four-disulfide core domain 2	Homo sapiens	61-64
25051913-11	2014	The pretreatment serum albumin level is a simple, inexpensive and easily measurable marker with prognostic significance in MPM patients treated with platinum-based systemic chemotherapy.	Platinum	149-157	albumin	Homo sapiens	23-30
24760124-0	2014	Reactions of trinuclear platinum clusters with electrophiles: ionisation isomerism with [Pt3(mu2-I)(mu-PPh2)2(PPh3)3]I and [Pt3(mu-PPh2)2I2(PPh3)3].	Platinum	24-32	protein phosphatase 4 catalytic subunit	Homo sapiens	110-114
24975515-2	2014	Human epididymis protein 4 (HE4) is highly overexpressed in women with ovarian cancer and overexpression of HE4 has been found to correlate with platinum resistance.	Platinum	145-153	WAP four-disulfide core domain 2	Homo sapiens	28-31
24975515-2	2014	Human epididymis protein 4 (HE4) is highly overexpressed in women with ovarian cancer and overexpression of HE4 has been found to correlate with platinum resistance.	Platinum	145-153	WAP four-disulfide core domain 2	Homo sapiens	108-111
24760124-0	2014	Reactions of trinuclear platinum clusters with electrophiles: ionisation isomerism with [Pt3(mu2-I)(mu-PPh2)2(PPh3)3]I and [Pt3(mu-PPh2)2I2(PPh3)3].	Platinum	24-32	protein phosphatase 4 catalytic subunit	Homo sapiens	140-144
24763966-6	2014	When using flow injection analysis with a Pt/Pt-black electrode and standards derived from NO gas, a linear correlation (R(2) = 0.99) over a wide range of concentrations (7.6-190 muM) was obtained, with the LOD for NO being 1 muM.	Platinum	42-44	latexin	Homo sapiens	179-182
24763966-6	2014	When using flow injection analysis with a Pt/Pt-black electrode and standards derived from NO gas, a linear correlation (R(2) = 0.99) over a wide range of concentrations (7.6-190 muM) was obtained, with the LOD for NO being 1 muM.	Platinum	42-44	latexin	Homo sapiens	226-229
25018782-11	2014	CONCLUSION: Among the tested proteins the HE4 marker appears to be helpful in forecasting of optimal cytoreduction and possibly also of the prediction of response to platinum analogues used in first-line treatment of ovarian cancer.	Platinum	166-174	WAP four-disulfide core domain 2	Homo sapiens	42-45
24763966-6	2014	When using flow injection analysis with a Pt/Pt-black electrode and standards derived from NO gas, a linear correlation (R(2) = 0.99) over a wide range of concentrations (7.6-190 muM) was obtained, with the LOD for NO being 1 muM.	Platinum	45-47	latexin	Homo sapiens	179-182
24902769-2	2014	We present here a series of platinum(IV) prodrugs designed specifically to enhance interaction with human serum albumin (HSA) for drug delivery.	Platinum	28-36	albumin	Homo sapiens	106-119
24853184-2	2014	The aim of this study is to evaluate the impact of XIAP expression upon ovarian clear cell carcinoma (CCC) that has a platinum-resistant phenotype.	Platinum	118-126	X-linked inhibitor of apoptosis	Homo sapiens	51-55
24853184-6	2014	Cases with high XIAP expression had lower response rate to primary platinum-based chemotherapy (10% vs 65%, P=0.02).	Platinum	67-75	X-linked inhibitor of apoptosis	Homo sapiens	16-20
24801282-2	2014	We previously identified a class of broadly active peptide triazole (PT) dual antagonists that inhibit gp120 interactions at both its target receptor and coreceptor binding sites, induce shedding of gp120 from virus particles prior to host-cell encounter, and consequently can prevent viral entry and infection.	Platinum	69-71	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	103-108
24769605-2	2014	The Li-O bond on the surface of PT OCT nanocrystals is essential to the stability of such nanocrystals and also results in a dramatic high visible-light photocatalytic activity.	Platinum	32-34	plexin A2	Homo sapiens	35-38
24777448-5	2014	Aminopeptidase PepA-encapsulating 2 nm platinum nanoparticles (PepA-PtNPs) with the catalytic activities of hydrolysis and hydrogenation were employed as multifunctional nanobiocatalysts.	Platinum	39-47	carnosine dipeptidase 2	Homo sapiens	15-19
24777448-5	2014	Aminopeptidase PepA-encapsulating 2 nm platinum nanoparticles (PepA-PtNPs) with the catalytic activities of hydrolysis and hydrogenation were employed as multifunctional nanobiocatalysts.	Platinum	39-47	carnosine dipeptidase 2	Homo sapiens	63-67
24801282-2	2014	We previously identified a class of broadly active peptide triazole (PT) dual antagonists that inhibit gp120 interactions at both its target receptor and coreceptor binding sites, induce shedding of gp120 from virus particles prior to host-cell encounter, and consequently can prevent viral entry and infection.	Platinum	69-71	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	199-204
24534552-0	2014	Disposable amperometric biosensor based on lactate oxidase immobilised on platinum nanoparticle-decorated carbon nanofiber and poly(diallyldimethylammonium chloride) films.	Platinum	74-82	lysyl oxidase	Homo sapiens	43-58
24801282-4	2014	Here, we used a recently developed computational model of the PT-gp120 complex as a blueprint to design a covalently conjugated PT-gp120 recombinant protein.	Platinum	62-64	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	65-70
24801282-4	2014	Here, we used a recently developed computational model of the PT-gp120 complex as a blueprint to design a covalently conjugated PT-gp120 recombinant protein.	Platinum	62-64	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	131-136
24801282-8	2014	An N-terminally maleimido variant of this PEGylated PT, denoted AE21, was conjugated to E275C gp120 to produce the AE21-E275C covalent conjugate.	Platinum	52-54	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	94-99
24801282-10	2014	Similar to the noncovalent PT-gp120 complex, the covalent conjugate was able to bind the conformationally dependent mAb 2G12.	Platinum	27-29	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	30-35
25093514-1	2014	Poly (ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapies have been found to be particularly effective in tumors that harbor deleterious germline or somatic mutations in the BRCA1 or BRCA2 genes, the products of which contribute to the conservative homologous recombination repair of DNA double-strand breaks.	Platinum	51-59	BRCA1 DNA repair associated	Homo sapiens	197-202
25093514-1	2014	Poly (ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapies have been found to be particularly effective in tumors that harbor deleterious germline or somatic mutations in the BRCA1 or BRCA2 genes, the products of which contribute to the conservative homologous recombination repair of DNA double-strand breaks.	Platinum	51-59	BRCA2 DNA repair associated	Homo sapiens	206-211
24669010-10	2014	In the NAC arm and the RC arm, 34% and 9% of the patients had pT0, respectively (P &lt; 0.01).	Platinum	62-65	synuclein alpha	Homo sapiens	7-10
24781824-7	2014	Taken together all these results strongly demonstrate that MDR-1 over-expression in A549 cells could be associated to a MDR phenotype of these cells and moreover, it is also contributing to the platinum, and structurally-related compound, resistance in these cells.	Platinum	194-202	ATP binding cassette subfamily B member 1	Homo sapiens	59-64
24699848-10	2014	Among all the tested drugs, tetrasulfonated phthalocyanine of platinum resulted to be the molecule with the best cytostatic action on neoplastic cell lines at the concentration of 30 muM.	Platinum	62-70	latexin	Homo sapiens	183-186
24657486-0	2014	Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.	Platinum	51-59	checkpoint kinase 2	Homo sapiens	0-19
24684392-1	2014	The aim of the present study was to investigate the association of genetic polymorphisms in high mobility group box 1 and 2 (HMGB1 and HMGB2, respectively) with platinum-based chemotherapy responses in Chinese lung cancer patients.	Platinum	161-169	high mobility group box 1	Homo sapiens	92-123
24684392-1	2014	The aim of the present study was to investigate the association of genetic polymorphisms in high mobility group box 1 and 2 (HMGB1 and HMGB2, respectively) with platinum-based chemotherapy responses in Chinese lung cancer patients.	Platinum	161-169	high mobility group box 1	Homo sapiens	125-130
24684392-1	2014	The aim of the present study was to investigate the association of genetic polymorphisms in high mobility group box 1 and 2 (HMGB1 and HMGB2, respectively) with platinum-based chemotherapy responses in Chinese lung cancer patients.	Platinum	161-169	high mobility group box 2	Homo sapiens	135-140
24684392-5	2014	We found that rs1412125 and rs2249825 of HMGB1 were significantly associated with the platinum-based chemotherapy response in both recessive and genotypic models.	Platinum	86-94	high mobility group box 1	Homo sapiens	41-46
24684392-8	2014	The HMGB1 SNPs (rs1412125 and rs2249825) were associated with platinum-based chemotherapy responses in Chinese lung cancer patients.	Platinum	62-70	high mobility group box 1	Homo sapiens	4-9
24684392-9	2014	In conclusion, HMGB1 SNPs may serve as potential biomarkers for predicting the efficacy of platinum-based chemotherapy.	Platinum	91-99	high mobility group box 1	Homo sapiens	15-20
24657486-0	2014	Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.	Platinum	51-59	checkpoint kinase 2	Homo sapiens	21-25
24657486-10	2014	CONCLUSIONS: Chk2 is related to good response to platinum-based chemotherapy in advanced stage HGSOC patients.	Platinum	49-57	checkpoint kinase 2	Homo sapiens	13-17
24657486-11	2014	Chk2-depleted ovarian cancer cell lines have diminished platinum sensitivity, suggesting that Chk2 should not be considered a therapeutic target along with platinum-based treatment in HGSOC patients.	Platinum	56-64	checkpoint kinase 2	Homo sapiens	0-4
24730557-0	2014	Neuropilin-1-targeted gold nanoparticles enhance therapeutic efficacy of platinum(IV) drug for prostate cancer treatment.	Platinum	73-81	neuropilin 1	Homo sapiens	0-12
24306314-1	2014	PURPOSE: Preclinical data showed that trientine, a copper-lowering agent, re-sensitized cancer cells to carboplatin through enhanced human copper transporter 1 (hCtr1) -mediated platinum uptake.	Platinum	178-186	solute carrier family 31 member 1	Homo sapiens	139-159
24306314-1	2014	PURPOSE: Preclinical data showed that trientine, a copper-lowering agent, re-sensitized cancer cells to carboplatin through enhanced human copper transporter 1 (hCtr1) -mediated platinum uptake.	Platinum	178-186	solute carrier family 31 member 1	Homo sapiens	161-166
24785544-3	2014	Peak 2PA cross sections of neutral and ED-substituted Pt complexes occur at S0   Sn transitions to higher energy states, above the lowest-energy S0   S1 transition, and the corresponding values increase systematically with increasing ED strength, reaching maximum value, sigma2 ~ 300 GM (1 GM = 10-50 cm4 s), for R = NPh2.	Platinum	54-56	PEAK1 related, kinase-activating pseudokinase 1	Homo sapiens	0-6
24785544-3	2014	Peak 2PA cross sections of neutral and ED-substituted Pt complexes occur at S0   Sn transitions to higher energy states, above the lowest-energy S0   S1 transition, and the corresponding values increase systematically with increasing ED strength, reaching maximum value, sigma2 ~ 300 GM (1 GM = 10-50 cm4 s), for R = NPh2.	Platinum	54-56	neurexophilin 2	Homo sapiens	317-321
24785544-5	2014	Surprisingly, EW-substituted Pt complexes display a very different behavior, where the peak 2PA of the S0   S1 transition gradually increases with increasing EW strength, reaching values sigma2 = 700 GM for R = NO2, while in the S0   Sn transition region the peak 2PEF cross section decreases.	Platinum	29-31	PEAK1 related, kinase-activating pseudokinase 1	Homo sapiens	87-93
24767861-0	2014	TNFAIP8 overexpression is associated with platinum resistance in epithelial ovarian cancers with optimal cytoreduction.	Platinum	42-50	TNF alpha induced protein 8	Homo sapiens	0-7
24767861-4	2014	TNFAIP8 overexpression at both mRNA and protein levels in platinum-resistant disease was clearly higher than that in platinum-sensitive disease (P &lt; .05).	Platinum	58-66	TNF alpha induced protein 8	Homo sapiens	0-7
24767861-4	2014	TNFAIP8 overexpression at both mRNA and protein levels in platinum-resistant disease was clearly higher than that in platinum-sensitive disease (P &lt; .05).	Platinum	117-125	TNF alpha induced protein 8	Homo sapiens	0-7
24767861-5	2014	Platinum resistance was independently correlated with residual tumor size (P = .025), ascites (P = .027), and TNFAIP8 overexpression (P = .003).	Platinum	0-8	TNF alpha induced protein 8	Homo sapiens	110-117
24767861-6	2014	In particular, TNFAIP8 overexpression was correlated with platinum resistance in EOCs with optimal cytoreduction (P = .001).	Platinum	58-66	TNF alpha induced protein 8	Homo sapiens	15-22
24767861-8	2014	In conclusion, our findings indicate that TNFAIP8 overexpression is an independent predictor of platinum resistance and may be a potential biomarker for targeted therapy.	Platinum	96-104	TNF alpha induced protein 8	Homo sapiens	42-49
24615519-0	2014	Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer.	Platinum	63-71	ERCC excision repair 5, endonuclease	Homo sapiens	25-28
24809779-1	2014	BACKGROUND: Breast cancer susceptibility gene 1 (BRCA1) expression differentially affects outcome to platinum- and taxane-based chemotherapy.	Platinum	101-109	BRCA1 DNA repair associated	Homo sapiens	49-54
24730557-5	2014	Here, we exploit the advantages of both the antioxidant properties and high surface-area-to-volume ratio of Au@GSH NPs to demonstrate their potential for delivery of a platinum(IV) drug by targeting the neuropilin-1 receptor (Nrp-1).	Platinum	168-176	neuropilin 1	Homo sapiens	203-224
24730557-5	2014	Here, we exploit the advantages of both the antioxidant properties and high surface-area-to-volume ratio of Au@GSH NPs to demonstrate their potential for delivery of a platinum(IV) drug by targeting the neuropilin-1 receptor (Nrp-1).	Platinum	168-176	neuropilin 1	Homo sapiens	226-231
24730557-6	2014	A lethal dose of a platinum(IV) drug functionalized with the Nrp-1-targeting peptide (CRGDK) was delivered specifically to prostate cancer cells in vitro.	Platinum	19-27	neuropilin 1	Homo sapiens	61-66
24938464-0	2014	Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis.	Platinum	74-82	X-ray repair cross complementing 1	Homo sapiens	21-26
24920920-2	2014	The aim of this study was to evaluate the influence of prior EGFR TKI therapy on the efficacy of subsequent pemetrexed plus platinum (PP) in advanced chemonaive patients with EGFR-mutant lung adenocarcinoma.	Platinum	124-132	epidermal growth factor receptor	Homo sapiens	61-65
24920920-2	2014	The aim of this study was to evaluate the influence of prior EGFR TKI therapy on the efficacy of subsequent pemetrexed plus platinum (PP) in advanced chemonaive patients with EGFR-mutant lung adenocarcinoma.	Platinum	124-132	epidermal growth factor receptor	Homo sapiens	175-179
24938464-1	2014	X-ray repair cross complementing group 1(XRCC1) polymorphisms have been implicated in interindividual variability of efficacy of platinum chemotherapy for treating non-small cell lung cancer (NSCLC); however, results of different studies have been inconsistent.	Platinum	129-137	X-ray repair cross complementing 1	Homo sapiens	0-40
24971161-6	2013	Carbon cloth electrode ELAT HT 140 E-W with a platinum loading of 5 gm-2 was purchased by E-Tek.	Platinum	46-54	TEK receptor tyrosine kinase	Homo sapiens	92-95
24938464-1	2014	X-ray repair cross complementing group 1(XRCC1) polymorphisms have been implicated in interindividual variability of efficacy of platinum chemotherapy for treating non-small cell lung cancer (NSCLC); however, results of different studies have been inconsistent.	Platinum	129-137	X-ray repair cross complementing 1	Homo sapiens	41-46
24938464-2	2014	We conducted a meta-analysis to investigate the association between polymorphisms in the XRCC1 gene and response rate of platinum chemotherapy in advanced NSCLC patients.	Platinum	121-129	X-ray repair cross complementing 1	Homo sapiens	89-94
24938464-6	2014	For XRCC1 Arg399Gln, patients carrying two G alleles had a significantly increased response rate of platinum chemotherapy, when compared with those carrying the A allele [odds ratio (OR) = 2.05, 95% confidence interval CI = 1.62-2.60 for GG vs GA+AA].	Platinum	100-108	X-ray repair cross complementing 1	Homo sapiens	4-9
24938464-10	2014	Based on this meta-analysis, we conclude that XRCC1 polymorphisms are associated with treatment response to platinum chemotherapy in advanced NSCLC patients.	Platinum	108-116	X-ray repair cross complementing 1	Homo sapiens	46-51
24702224-3	2014	OBJECTIVES: Platinum-containing drugs are known to target the anti-oxidant selenoprotein TrxR in cancer cells.	Platinum	12-20	peroxiredoxin 5	Homo sapiens	89-93
24829859-7	2014	Platinum agents are effective in TNBC patients with BRCA1 mutation, either alone or in combination with poly adenosine diphosphate polymerase 1 inhibitors.	Platinum	0-8	BRCA1 DNA repair associated	Homo sapiens	52-57
24854656-0	2014	Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy.	Platinum	111-119	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-19
24854656-0	2014	Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy.	Platinum	111-119	BRCA1 DNA repair associated	Homo sapiens	24-29
24854656-5	2014	We found that low expression of ERCC1 and BRCA1 was associated with a good response to platinum-based chemotherapy, with an odds ratio [95% confidence interval (CI)] of 2.09 (1.33-3.27) and 2.92 (1.85-4.62), respectively.	Platinum	87-95	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	32-37
24854656-5	2014	We found that low expression of ERCC1 and BRCA1 was associated with a good response to platinum-based chemotherapy, with an odds ratio [95% confidence interval (CI)] of 2.09 (1.33-3.27) and 2.92 (1.85-4.62), respectively.	Platinum	87-95	BRCA1 DNA repair associated	Homo sapiens	42-47
24652390-3	2014	By using the NWA photoanodes with a hexagonal symmetry and FTO-Pt cathodes with an Al reflecting layer, the resulting DSSCs demonstrate a maxiumum efficiency of 2.09%, which is an improvement of 140% compared to the reference cells with line symmetry and no reflecting layer.	Platinum	63-65	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	59-62
24753635-0	2014	Influence of damping constant on inverse spin hall voltage of La0.7Sr0.3MnO3(x)/platinum bilayers.	Platinum	80-88	spindlin 1	Homo sapiens	41-45
24641901-5	2014	By 24 hours, twofold higher concentrations of platinum were detected in the kidneys and livers of Mrp2-null mice compared with wild types.	Platinum	46-54	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	98-102
24641901-6	2014	Enhanced platinum concentrations in Mrp2-null mice were observed in DNA and cytosolic fractions of the kidneys.	Platinum	9-17	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	36-40
24641901-10	2014	These data suggest that deficiency in Mrp2 lowers platinum excretion and increases susceptibility to kidney injury, which can be rescued by the human MRP2 ortholog.	Platinum	50-58	ATP binding cassette subfamily C member 2	Homo sapiens	38-42
24641901-10	2014	These data suggest that deficiency in Mrp2 lowers platinum excretion and increases susceptibility to kidney injury, which can be rescued by the human MRP2 ortholog.	Platinum	50-58	ATP binding cassette subfamily C member 2	Homo sapiens	150-154
24554028-0	2014	Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.	Platinum	134-142	thymidylate synthetase	Homo sapiens	0-20
24081797-1	2014	BACKGROUND: Ovarian cancer arising in women with BRCA mutations is known to have a more favorable outcome and to be more responsive to platinum-based regimens than in those without a hereditary background.	Platinum	135-143	BRCA1 DNA repair associated	Homo sapiens	49-53
24379240-1	2014	The E3 ubiquitin ligase EDD is overexpressed in recurrent, platinum-resistant ovarian cancers, suggesting a role in tumor survival and/or platinum resistance.	Platinum	59-67	ubiquitin protein ligase E3 component n-recognin 5	Mus musculus	24-27
24607283-5	2014	Pending review by the Food and Drug Administration (FDA) and the outcome of confirmatory phase III studies, PARP inhibitors could become the first FDA-approved biologic agent for ovarian cancer and also the first new FDA-approval in ovarian cancer since carboplatin and gemcitabine were approved for platinum sensitive ovarian cancer in 2006.	Platinum	300-308	poly(ADP-ribose) polymerase 1	Homo sapiens	108-112
24224851-0	2014	X-ray repair cross-complementing 1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis.	Platinum	65-73	X-ray repair cross complementing 1	Homo sapiens	0-34
24224851-1	2014	BACKGROUND AND AIM: The relationships between the X-ray repair cross-complementing 1 (XRCC1) Arg399Gln polymorphism (rs25487, G &gt; A) and responses to platinum-based chemotherapy of gastric and colorectal cancer patients are controversial.	Platinum	153-161	X-ray repair cross complementing 1	Homo sapiens	50-84
24224851-1	2014	BACKGROUND AND AIM: The relationships between the X-ray repair cross-complementing 1 (XRCC1) Arg399Gln polymorphism (rs25487, G &gt; A) and responses to platinum-based chemotherapy of gastric and colorectal cancer patients are controversial.	Platinum	153-161	X-ray repair cross complementing 1	Homo sapiens	86-91
24224851-8	2014	RESULTS: In the dominant model, the A allele of XRCC1 Arg399Gln polymorphism was associated with reduced RR to platinum-based chemotherapy in all gastric and colorectal cancer patients (A/G + A/A vs G/G OR, 0.73; 95% CI, 0.55-0.96) and in Asians (OR, 0.62; 95% CI, 0.44-0.89) but not in Caucasians (OR, 0.92; 95% CI, 0.60-1.42).	Platinum	111-119	X-ray repair cross complementing 1	Homo sapiens	48-53
24224851-11	2014	CONCLUSIONS: XRCC1 Arg399Gln polymorphism may be a valuable genetic marker for platinum-based chemotherapy of gastric and colorectal cancer patients, and more well-designed studies with large samples are needed to confirm our findings.	Platinum	79-87	X-ray repair cross complementing 1	Homo sapiens	13-18
24947259-0	2014	Association of CDC25 phosphatase family polymorphisms with the efficacy/toxicity of platinum-based chemotherapy in Chinese advanced NSCLC patients.	Platinum	84-92	cell division cycle 25C	Homo sapiens	15-20
24947259-2	2014	METHODS &amp; MATERIALS: We genotyped 14 SNPs of the CDC25 family in 663 Chinese patients with advanced NSCLC who were treated with first-line platinum-based chemotherapy and, in evaluable patients, analyzed relationships between the CDC25 family and the efficacy of platinum-based chemotherapy.	Platinum	143-151	cell division cycle 25C	Homo sapiens	53-58
24947259-2	2014	METHODS &amp; MATERIALS: We genotyped 14 SNPs of the CDC25 family in 663 Chinese patients with advanced NSCLC who were treated with first-line platinum-based chemotherapy and, in evaluable patients, analyzed relationships between the CDC25 family and the efficacy of platinum-based chemotherapy.	Platinum	267-275	cell division cycle 25C	Homo sapiens	53-58
24947259-4	2014	In addition, CDC25B rs3761218 and haplotype G/T/G/G were associated with the occurrence of severe toxicity with platinum-based chemotherapy, especially gastrointestinal and hematological toxicity.	Platinum	112-120	cell division cycle 25B	Homo sapiens	13-19
24947259-5	2014	CONCLUSION: These findings reveal a relationship between genetic variations of the CDC25 family and the efficacy and toxicity of platinum-based chemotherapy in patients with advanced NSCLC, especially in those with non-squamous-cell carcinoma.	Platinum	129-137	cell division cycle 25C	Homo sapiens	83-88
24585004-2	2014	Excision repair cross-complementation group 1 enzyme (ERCC1) has been proposed as a molecular predictor of clinical resistance to platinum-based chemotherapy.	Platinum	130-138	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-45
24585004-2	2014	Excision repair cross-complementation group 1 enzyme (ERCC1) has been proposed as a molecular predictor of clinical resistance to platinum-based chemotherapy.	Platinum	130-138	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	54-59
24585004-4	2014	Therefore, the combination of ERCC1 and Tau may be a valuable predictor of sensitivity to platinum/paclitaxel treatment.	Platinum	90-98	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	30-35
24722796-0	2014	The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer.	Platinum	46-54	DNA ligase 4	Homo sapiens	25-29
24722796-2	2014	The aim of this study was to investigate whether single-nucleotide polymorphisms (SNPs) in DNA repair genes NBS1, LIG4, and RAD51 were correlated with tumor response in advanced non-small cell lung cancer (NSCLC) patients in a Chinese population who received platinum-based chemotherapy.	Platinum	259-267	nibrin	Homo sapiens	108-112
24554028-2	2014	This study was conducted to evaluate the influence of TYMS polymorphisms on the survival of Portuguese patients with advanced non-small cell lung cancer (NSCLC) undergoing platinum-based chemotherapy.	Platinum	172-180	thymidylate synthetase	Homo sapiens	54-58
24722796-2	2014	The aim of this study was to investigate whether single-nucleotide polymorphisms (SNPs) in DNA repair genes NBS1, LIG4, and RAD51 were correlated with tumor response in advanced non-small cell lung cancer (NSCLC) patients in a Chinese population who received platinum-based chemotherapy.	Platinum	259-267	RAD51 recombinase	Homo sapiens	124-129
24554028-8	2014	According to our results, the TYMS polymorphisms may be useful tools to predict which advanced NSCLC patients could benefit more from platinum-based chemotherapy regimens.	Platinum	134-142	thymidylate synthetase	Homo sapiens	30-34
24765164-8	2014	In the present patient, the glutathione S-transferase P1 (GSTP1) gene polymorphism, which is involved in the detoxification of platinum drugs, was analyzed.	Platinum	127-135	glutathione S-transferase pi 1	Homo sapiens	28-56
24705979-1	2014	Excision repair cross-complementation group 1 (ERCC1) expression by non-small cell lung cancer (NSCLC) has been reported to predict resistance to platinum-based therapies.	Platinum	146-154	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
24560445-7	2014	In contrast, all three platinum refractory PDXs overexpressed dominant oncogenes (CCNE1, LIN28B and/or BCL2).	Platinum	23-31	cyclin E1	Homo sapiens	82-87
24560445-7	2014	In contrast, all three platinum refractory PDXs overexpressed dominant oncogenes (CCNE1, LIN28B and/or BCL2).	Platinum	23-31	lin-28 homolog B	Homo sapiens	89-95
24560445-7	2014	In contrast, all three platinum refractory PDXs overexpressed dominant oncogenes (CCNE1, LIN28B and/or BCL2).	Platinum	23-31	BCL2 apoptosis regulator	Homo sapiens	103-107
24765164-8	2014	In the present patient, the glutathione S-transferase P1 (GSTP1) gene polymorphism, which is involved in the detoxification of platinum drugs, was analyzed.	Platinum	127-135	glutathione S-transferase pi 1	Homo sapiens	58-63
24370899-2	2014	We conducted a cohort study to assess the associations of ERCC1 and XPF polymorphisms with response to platinum-based chemotherapy and clinical outcome of non-small-cell lung cancer (NSCLC).	Platinum	103-111	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	58-63
24443257-0	2014	ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.	Platinum	113-121	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
24443257-0	2014	ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.	Platinum	113-121	BRCA1 DNA repair associated	Homo sapiens	10-15
24948964-0	2014	ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy.	Platinum	102-110	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
24948964-0	2014	ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy.	Platinum	102-110	BRCA1 DNA repair associated	Homo sapiens	10-15
24948964-8	2014	CONCLUSION: ERCC1 and BRCA1 mRNA expression could be important predictive markers for individualized platinum-based chemotherapy for NSCLC patients.	Platinum	101-109	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	12-17
24948964-8	2014	CONCLUSION: ERCC1 and BRCA1 mRNA expression could be important predictive markers for individualized platinum-based chemotherapy for NSCLC patients.	Platinum	101-109	BRCA1 DNA repair associated	Homo sapiens	22-27
24370899-2	2014	We conducted a cohort study to assess the associations of ERCC1 and XPF polymorphisms with response to platinum-based chemotherapy and clinical outcome of non-small-cell lung cancer (NSCLC).	Platinum	103-111	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	68-71
24370899-4	2014	The predictive value of four SNPs in ERCC1 and two SNPs in XPF in patient"s response and survival related to platinum-based chemotherapy were analyzed using chi(2) tests, Kaplan-Meier method, log-rank test, and Cox proportional hazards regression.	Platinum	109-117	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	59-62
24370899-10	2014	This study reported that variants in ERCC1 can be used as a prognostic maker to platinum-based chemotherapy in NSCLC patients.	Platinum	80-88	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	37-42
24443257-7	2014	Our results suggest that ERCC1 and BRCA1 mRNA expressions are associated with PFS and OS in advanced NSCLC patients treated with platinum-based chemotherapy.	Platinum	129-137	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	25-30
24443257-7	2014	Our results suggest that ERCC1 and BRCA1 mRNA expressions are associated with PFS and OS in advanced NSCLC patients treated with platinum-based chemotherapy.	Platinum	129-137	BRCA1 DNA repair associated	Homo sapiens	35-40
24615460-7	2014	The spiky Pt nanosphere decorated G/S film was directly used as a H2O2 electrode with a sensitivity of 0.56 mA mM(-1) cm(-2), a linear range of 0-2.5 mM and an ultralow detection limit of 0.2 muM (S/N = 3).	Platinum	10-12	latexin	Homo sapiens	192-195
24841663-1	2014	Xeroderma pigmentosum group D (XPD) plays a key role in the repair of DNA and platinum resistance lesions.	Platinum	78-86	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	31-34
24841663-10	2014	These results provide suggestive evidence of a favorable effect for the XPD 312Asp/Asp and XPD 751Lys/Lys genotypes with respect to overall survival rates in platinum-treated NSCLC patients.	Platinum	158-166	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	72-75
24841663-10	2014	These results provide suggestive evidence of a favorable effect for the XPD 312Asp/Asp and XPD 751Lys/Lys genotypes with respect to overall survival rates in platinum-treated NSCLC patients.	Platinum	158-166	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	91-94
24640941-1	2014	A solvothermal method is used to deposit Pt nanoparticles on anodized TiO2 nanotubes (T_NT).	Platinum	41-43	troponin T1, slow skeletal type	Homo sapiens	86-90
24640941-5	2014	This boosting in the overall current is attributable to the enhanced oxidation of formic acid at the T_NT/Pt-electrolyte interface.	Platinum	106-108	troponin T1, slow skeletal type	Homo sapiens	101-105
24150977-4	2014	In this report, the in vitro mechanism of platinum resistance induced by Anx A4 was investigated in endometrial carcinoma cells (HEC1 cells) with low expression of Anx A4.	Platinum	42-50	annexin A4	Mus musculus	73-79
26269970-5	2014	The comparison suggests the use of the sudden approximation for treating the rotations even though CHD3 has large rotational constants and yields an estimated reaction barrier of 0.9 eV for CH4 + Pt(111).	Platinum	196-198	chromodomain helicase DNA binding protein 3	Homo sapiens	99-103
24150977-4	2014	In this report, the in vitro mechanism of platinum resistance induced by Anx A4 was investigated in endometrial carcinoma cells (HEC1 cells) with low expression of Anx A4.	Platinum	42-50	NDC80 kinetochore complex component	Mus musculus	129-133
24150977-0	2014	Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A.	Platinum	21-29	annexin A4	Mus musculus	0-10
24150977-0	2014	Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A.	Platinum	21-29	ATPase, Cu++ transporting, alpha polypeptide	Mus musculus	79-84
24150977-4	2014	In this report, the in vitro mechanism of platinum resistance induced by Anx A4 was investigated in endometrial carcinoma cells (HEC1 cells) with low expression of Anx A4.	Platinum	42-50	annexin A4	Mus musculus	164-170
24150977-3	2014	However, the precise mechanisms underlying that chemoresistance and the relationship of Anx A4 to platinum resistance in vivo remain unclear.	Platinum	98-106	annexin A4	Mus musculus	88-94
24150977-5	2014	Forced expression of Anx A4 in HEC1 cells resulted in chemoresistance to platinum drugs.	Platinum	73-81	annexin A4	Mus musculus	21-27
24150977-5	2014	Forced expression of Anx A4 in HEC1 cells resulted in chemoresistance to platinum drugs.	Platinum	73-81	NDC80 kinetochore complex component	Mus musculus	31-35
24150977-8	2014	Immunofluorescence analysis revealed that exposure to platinum drugs induced relocation of Anx A4 from the cytoplasm to the cellular membrane, where it became colocalized with ATP7A, a copper transporter also well known as a mechanism of platinum efflux.	Platinum	54-62	annexin A4	Mus musculus	91-97
24150977-8	2014	Immunofluorescence analysis revealed that exposure to platinum drugs induced relocation of Anx A4 from the cytoplasm to the cellular membrane, where it became colocalized with ATP7A, a copper transporter also well known as a mechanism of platinum efflux.	Platinum	54-62	ATPase, Cu++ transporting, alpha polypeptide	Mus musculus	176-181
24150977-8	2014	Immunofluorescence analysis revealed that exposure to platinum drugs induced relocation of Anx A4 from the cytoplasm to the cellular membrane, where it became colocalized with ATP7A, a copper transporter also well known as a mechanism of platinum efflux.	Platinum	238-246	annexin A4	Mus musculus	91-97
24150977-8	2014	Immunofluorescence analysis revealed that exposure to platinum drugs induced relocation of Anx A4 from the cytoplasm to the cellular membrane, where it became colocalized with ATP7A, a copper transporter also well known as a mechanism of platinum efflux.	Platinum	238-246	ATPase, Cu++ transporting, alpha polypeptide	Mus musculus	176-181
24150977-9	2014	ATP7A expression suppressed by small interfering RNA had no effect on HEC1 control cells in terms of chemosensitivity to platinum drugs.	Platinum	121-129	ATPase, Cu++ transporting, alpha polypeptide	Mus musculus	0-5
24686174-9	2014	Cumulatively, our study identifies a HOIP-regulated antiapoptotic signaling pathway, and we envisage HOIP as a potential target for the development of combinatorial chemotherapies to potentiate the efficacy of platinum-based anticancer drugs.	Platinum	210-218	ring finger protein 31	Homo sapiens	37-41
24686174-9	2014	Cumulatively, our study identifies a HOIP-regulated antiapoptotic signaling pathway, and we envisage HOIP as a potential target for the development of combinatorial chemotherapies to potentiate the efficacy of platinum-based anticancer drugs.	Platinum	210-218	ring finger protein 31	Homo sapiens	101-105
24150977-10	2014	However, suppression of ATP7A in Anx A4-overexpressing platinum-resistant cells improved chemosensitivity to platinum drugs (but not to 5-fluorouracil) to a level comparable to that of control cells.	Platinum	55-63	ATPase, Cu++ transporting, alpha polypeptide	Mus musculus	24-29
24150977-10	2014	However, suppression of ATP7A in Anx A4-overexpressing platinum-resistant cells improved chemosensitivity to platinum drugs (but not to 5-fluorouracil) to a level comparable to that of control cells.	Platinum	55-63	annexin A4	Mus musculus	33-39
24150977-10	2014	However, suppression of ATP7A in Anx A4-overexpressing platinum-resistant cells improved chemosensitivity to platinum drugs (but not to 5-fluorouracil) to a level comparable to that of control cells.	Platinum	109-117	ATPase, Cu++ transporting, alpha polypeptide	Mus musculus	24-29
24150977-10	2014	However, suppression of ATP7A in Anx A4-overexpressing platinum-resistant cells improved chemosensitivity to platinum drugs (but not to 5-fluorouracil) to a level comparable to that of control cells.	Platinum	109-117	annexin A4	Mus musculus	33-39
24150977-11	2014	These results indicate that enhanced expression of Anx A4 confers platinum resistance by promoting efflux of platinum drugs via ATP7A.	Platinum	66-74	annexin A4	Mus musculus	51-57
24150977-11	2014	These results indicate that enhanced expression of Anx A4 confers platinum resistance by promoting efflux of platinum drugs via ATP7A.	Platinum	66-74	ATPase, Cu++ transporting, alpha polypeptide	Mus musculus	128-133
24150977-11	2014	These results indicate that enhanced expression of Anx A4 confers platinum resistance by promoting efflux of platinum drugs via ATP7A.	Platinum	109-117	annexin A4	Mus musculus	51-57
24150977-11	2014	These results indicate that enhanced expression of Anx A4 confers platinum resistance by promoting efflux of platinum drugs via ATP7A.	Platinum	109-117	ATPase, Cu++ transporting, alpha polypeptide	Mus musculus	128-133
24607117-10	2014	The values of DeltaG and DeltaH were -3.5 and -26.1 kJ mol(-1), respectively, which indicate that the sorption of platinum onto CNF-PUFIX is spontaneous and exothermic.	Platinum	114-122	NPHS1 adhesion molecule, nephrin	Homo sapiens	128-131
24549179-1	2014	A new platinum-catalyzed anti-stereocontrolled ring-opening of oxabicyclic alkenes with various Grignard reagents was reported, which afforded the corresponding anti-2-substituted-1,2-dihydronaphthalen-1-ol products with moderate to good yields in the presence of a catalytic amount of Pt(PPh3)4 (2.5 mol%) under mild conditions.	Platinum	6-14	caveolin 1	Homo sapiens	289-293
24479491-4	2014	AREAS COVERED: This review gives an overview of the characteristics and functions of Annexin (Anx) A4, the mechanism of Anx A4-induced platinum resistance, the association between platinum resistance and platinum transporters, recent reports that Anx A4 overexpression promotes the efflux of platinum drugs via platinum transporters and the association between other Anxs and chemoresistance.	Platinum	135-143	annexin A4	Homo sapiens	120-126
24479491-7	2014	EXPERT OPINION: Anx A4 is overexpressed in ovarian clear cell carcinoma (CCC), and enhanced Anx A4 expression induces platinum resistance.	Platinum	118-126	annexin A4	Homo sapiens	92-98
24479491-8	2014	Recent studies showed that Anx A4 is also associated with platinum resistance in cancers other than ovarian CCC.	Platinum	58-66	annexin A4	Homo sapiens	27-33
24531842-7	2014	Our findings point to USP1-UAF1 as a key regulator of the DNA damage response and a target for overcoming resistance to the platinum-based anticancer drugs.	Platinum	124-132	ubiquitin specific peptidase 1	Homo sapiens	22-26
24531842-7	2014	Our findings point to USP1-UAF1 as a key regulator of the DNA damage response and a target for overcoming resistance to the platinum-based anticancer drugs.	Platinum	124-132	WD repeat domain 48	Homo sapiens	27-31
24607117-5	2014	The sorption properties of platinum (IV) onto CNF-PUFIX were investigated, the maximum sorption of platinum ions (~100%) was at the pH ranges 4-5, shaking for 18 min and sample flow rate 1.3 mL min(-1).	Platinum	27-35	NPHS1 adhesion molecule, nephrin	Homo sapiens	46-49
24607117-5	2014	The sorption properties of platinum (IV) onto CNF-PUFIX were investigated, the maximum sorption of platinum ions (~100%) was at the pH ranges 4-5, shaking for 18 min and sample flow rate 1.3 mL min(-1).	Platinum	99-107	NPHS1 adhesion molecule, nephrin	Homo sapiens	46-49
24635126-1	2014	Novel photochromic dithienylethene-based platinum(II) complexes (C^N^N)Pt(C C-DTE-C6H4-D) ((C^N^N) = 4,4"-di(n-hexyl)-6-phenyl-2,2"-bipyridine; D = H, NMe2) were prepared and characterized.	Platinum	41-49	NME/NM23 nucleoside diphosphate kinase 2	Homo sapiens	151-155
24737519-0	2014	Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.	Platinum	84-92	X-ray repair cross complementing 1	Homo sapiens	32-37
24338713-0	2014	The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.	Platinum	83-91	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	28-33
24338713-1	2014	The relationship between the ERCC1/2 single nucleotide polymorphisms (SNPs) and the clinical outcomes of the platinum-based chemotherapy in the non-small cell lung cancer (NSCLC) is still inconsistent and inconclusive despite extensive investigations have been conducted to address this question.	Platinum	109-117	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	29-34
24338713-10	2014	This meta-analysis suggested that the ERCC1 C118T, ERCC2 Asp312Asn, and Lys751Gln may be useful biomarkers to predict the clinical outcomes of the platinum-based chemotherapy in NSCLC patients.	Platinum	147-155	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	38-43
24338713-10	2014	This meta-analysis suggested that the ERCC1 C118T, ERCC2 Asp312Asn, and Lys751Gln may be useful biomarkers to predict the clinical outcomes of the platinum-based chemotherapy in NSCLC patients.	Platinum	147-155	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	51-56
24737519-0	2014	Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.	Platinum	84-92	X-ray repair cross complementing 3	Homo sapiens	39-44
24737519-0	2014	Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.	Platinum	84-92	ERCC excision repair 5, endonuclease	Homo sapiens	50-53
24737519-5	2014	Individuals with the XRCC1 399A/A genotype had a higher probability of responding well to platinum-based chemotherapy, indicated by an odds ratio (OR) of 2.27 [95% confidence interval (CI)=1.64-6.97].	Platinum	90-98	X-ray repair cross complementing 1	Homo sapiens	21-26
24737519-8	2014	Moreover, the XPG 46T/T genotype increased the likelihood of longer disease-free survival and overall survival of NSCLC patients treated with platinum-based chemotherapy (HR=0.47; 95%CI=0.22-0.82 and HR=0.52; 95%CI=0.31- 0.96, respectively).	Platinum	142-150	ERCC excision repair 5, endonuclease	Homo sapiens	14-17
24737519-9	2014	These results indicate that XRCC1 Arg399Gln and XPG His46His might significantly affect the clinical outcomes of platinum-based chemotherapy, highlighting the need for larger studies to confirm the role of these two SNPs in outcomes of NSCLC treatments.	Platinum	113-121	X-ray repair cross complementing 1	Homo sapiens	28-33
24737519-9	2014	These results indicate that XRCC1 Arg399Gln and XPG His46His might significantly affect the clinical outcomes of platinum-based chemotherapy, highlighting the need for larger studies to confirm the role of these two SNPs in outcomes of NSCLC treatments.	Platinum	113-121	ERCC excision repair 5, endonuclease	Homo sapiens	48-51
24481402-7	2014	RESULTS: High TGFBI levels were associated with longer overall survival (OS, P&lt;0.001) and progression-free survival (PFS, P&lt;0.001) in SCC patients who received adjuvant platinium-based chemotherapy.	Platinum	175-184	transforming growth factor beta induced	Homo sapiens	14-19
24508195-0	2014	A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and the chemosensitization of tumor cells to platinum.	Platinum	141-149	ERCC excision repair 3, TFIIH core complex helicase subunit	Homo sapiens	90-95
24647522-2	2014	This retrospective study was performed to evaluate the predictive value of ribonucleotide reductase regulatory subunit M1 (RRM1) on the therapeutic efficacy of platinum-based chemotherapy in patients with NSCLC.	Platinum	160-168	ribonucleotide reductase catalytic subunit M1	Homo sapiens	123-127
24675421-11	2014	Intervention targeting the RIP1/miR-940/MKP1/JNK pathway may be used to sensitize platinum-based chemotherapy.	Platinum	82-90	receptor interacting serine/threonine kinase 1	Homo sapiens	27-31
24211453-0	2014	Direct electrochemistry of myoglobin at reduced graphene oxide-multiwalled carbon nanotubes-platinum nanoparticles nanocomposite and biosensing towards hydrogen peroxide and nitrite.	Platinum	92-100	myoglobin	Homo sapiens	27-36
24532472-6	2014	Addition of 1-methylcytosine (1-MeC) to such a DMSO solution reveals coordination of 1-MeC to the central Pt.	Platinum	106-108	C-C motif chemokine ligand 28	Homo sapiens	32-35
24532472-6	2014	Addition of 1-methylcytosine (1-MeC) to such a DMSO solution reveals coordination of 1-MeC to the central Pt.	Platinum	106-108	C-C motif chemokine ligand 28	Homo sapiens	87-90
24554615-1	2014	Here, we demonstrate the use of Pt(0) nanoparticles immobilised on a polymeric monolithic support as a ligand-free heterogeneous catalytic system for the reduction of (13) CO2 at room temperature and atmospheric pressure.	Platinum	32-37	complement C2	Homo sapiens	172-175
24211453-1	2014	We described the preparation of a novel nanobiocomposite, reduced graphene oxide- multiwalled carbon nanotubes-platinum nanoparticles/myoglobin (RGO-MWCNT-Pt/Mb) for the direct electrochemistry of myoglobin and its application towards determination of hydrogen peroxide (H2O2) and nitrite (NO2(-)).	Platinum	111-119	myoglobin	Homo sapiens	197-206
24675421-11	2014	Intervention targeting the RIP1/miR-940/MKP1/JNK pathway may be used to sensitize platinum-based chemotherapy.	Platinum	82-90	microRNA 940	Homo sapiens	32-39
24442181-6	2014	In a similar manner, the analogous platinum complex, Pt(L)(PPh3), was synthesized.	Platinum	35-43	protein phosphatase 4 catalytic subunit	Homo sapiens	59-63
24675421-11	2014	Intervention targeting the RIP1/miR-940/MKP1/JNK pathway may be used to sensitize platinum-based chemotherapy.	Platinum	82-90	dual specificity phosphatase 1	Homo sapiens	40-44
24675421-11	2014	Intervention targeting the RIP1/miR-940/MKP1/JNK pathway may be used to sensitize platinum-based chemotherapy.	Platinum	82-90	mitogen-activated protein kinase 8	Homo sapiens	45-48
24681808-8	2014	CIC inhibition also enhances the chemotherapeutic potential of platinum-based agents.	Platinum	63-71	capicua transcriptional repressor	Homo sapiens	0-3
24497094-2	2014	By changing the condensation temperature, the degree of condensation and the loading of CNx can be controlled to give adjustable particle sizes of the Pt and Au NPs subsequently formed on the composites.	Platinum	151-153	calnexin	Homo sapiens	88-91
24603753-3	2014	The ERCC1-ERCC4 endonuclease plays a critical role in the repair of platinum-DNA damage and has widely been studied in relation to sensitivity to platinum chemotherapy.	Platinum	68-76	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	4-9
24603753-3	2014	The ERCC1-ERCC4 endonuclease plays a critical role in the repair of platinum-DNA damage and has widely been studied in relation to sensitivity to platinum chemotherapy.	Platinum	68-76	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	10-15
24603753-3	2014	The ERCC1-ERCC4 endonuclease plays a critical role in the repair of platinum-DNA damage and has widely been studied in relation to sensitivity to platinum chemotherapy.	Platinum	146-154	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	4-9
24603753-3	2014	The ERCC1-ERCC4 endonuclease plays a critical role in the repair of platinum-DNA damage and has widely been studied in relation to sensitivity to platinum chemotherapy.	Platinum	146-154	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	10-15
24473407-1	2014	Cox17 facilitates the platinum accumulation in mitochondria, which contributes to the overall cytotoxicity of cisplatin.	Platinum	22-30	cytochrome c oxidase copper chaperone COX17	Homo sapiens	0-5
24634242-0	2014	Pharmacogenetic role of XRCC1 polymorphisms on the clinical outcome of gastric cancer patients with platinum-based chemotherapy: a systematic review and meta-analysis.	Platinum	100-108	X-ray repair cross complementing 1	Homo sapiens	24-29
24634242-1	2014	It is still controversial whether X-ray repair cross-complementing group (XRCC1) gene polymorphisms (Arg194Trp and Arg399Gln) are associated with the clinical outcome of platinum-based chemotherapy in gastric cancer patients based on published studies.	Platinum	170-178	X-ray repair cross complementing 1	Homo sapiens	74-79
24634242-9	2014	The data suggest that the XRCC1 Arg399Gln polymorphism may be a prognostic biomarker of OS for platinum-based gastric cancer treatment.	Platinum	95-103	X-ray repair cross complementing 1	Homo sapiens	26-31
24457564-6	2014	RESULTS: BRCA mutation carriers treated with PLD (with or without platinum) or with gemcitabine + platinum had improved progression-free survival (PFS) and a lower risk for disease progression (adjusted for age, line of treatment, and platinum sensitivity) compared with patients with NH disease.	Platinum	66-74	BRCA1 DNA repair associated	Homo sapiens	9-13
24624361-0	2014	Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System.	Platinum	10-18	BRCA1 DNA repair associated	Homo sapiens	80-84
24624361-2	2014	Genetic and functional evidence points to the homologous recombination (HR) DNA repair system, and BRCA1 and BRCA2 in particular, as main determinants of response to platinum therapy.	Platinum	166-174	BRCA1 DNA repair associated	Homo sapiens	99-104
24624361-2	2014	Genetic and functional evidence points to the homologous recombination (HR) DNA repair system, and BRCA1 and BRCA2 in particular, as main determinants of response to platinum therapy.	Platinum	166-174	BRCA2 DNA repair associated	Homo sapiens	109-114
24624361-3	2014	BRCA-mutant ovarian cancers are especially sensitive to platinum, associated with better survival, and amenable to poly ADP ribose polymerase inhibitor treatment.	Platinum	56-64	BRCA1 DNA repair associated	Homo sapiens	0-4
24624361-4	2014	Here, we discuss a therapeutic concept that seeks to disrupt HR capacity via targeting of BRCA1 and BRCA2 functionality in order to reverse platinum resistance in BRCA-proficient high-grade serous ovarian cancers (HGSOC).	Platinum	140-148	BRCA1 DNA repair associated	Homo sapiens	90-95
24624361-4	2014	Here, we discuss a therapeutic concept that seeks to disrupt HR capacity via targeting of BRCA1 and BRCA2 functionality in order to reverse platinum resistance in BRCA-proficient high-grade serous ovarian cancers (HGSOC).	Platinum	140-148	BRCA2 DNA repair associated	Homo sapiens	100-105
24624361-4	2014	Here, we discuss a therapeutic concept that seeks to disrupt HR capacity via targeting of BRCA1 and BRCA2 functionality in order to reverse platinum resistance in BRCA-proficient high-grade serous ovarian cancers (HGSOC).	Platinum	140-148	BRCA1 DNA repair associated	Homo sapiens	90-94
24624361-6	2014	Several recent publications demonstrate efficient chemosensitization of BRCA-proficient cancers by combining targeted therapy with standard platinum-based agents.	Platinum	140-148	BRCA1 DNA repair associated	Homo sapiens	72-76
24300914-6	2014	Notably, this treatment combination induced downregulation of the excision repair cross-complementation group 1 (ERCC1) protein, which is involved in the key repair process of the oxaliplatin-DNA platinum adduct at the protein level.	Platinum	196-204	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	66-111
24300914-6	2014	Notably, this treatment combination induced downregulation of the excision repair cross-complementation group 1 (ERCC1) protein, which is involved in the key repair process of the oxaliplatin-DNA platinum adduct at the protein level.	Platinum	196-204	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	113-118
24366538-1	2014	The Hedgehog pathway is molecularly linked to increased resistance to cisplatin and increased repair of platinum-DNA damage, through C-JUN.	Platinum	104-112	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	133-138
24499239-0	2014	Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis.	Platinum	26-34	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	119-124
24499239-1	2014	BACKGROUND: In the present study, we performed this meta-analysis to estimate the association between excision repair cross-complementation group 1 (ERCC1) gene polymorphism and clinical resistance to platinum-based chemotherapy in the patients with epithelial ovarian cancer (EOC).	Platinum	201-209	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	102-147
24499239-1	2014	BACKGROUND: In the present study, we performed this meta-analysis to estimate the association between excision repair cross-complementation group 1 (ERCC1) gene polymorphism and clinical resistance to platinum-based chemotherapy in the patients with epithelial ovarian cancer (EOC).	Platinum	201-209	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	149-154
24499239-2	2014	METHODS: A total of 10 studies consist of 1479 EOC patients relating ERCC1 rs11615C/T and rs3212986C/A polymorphisms to the response of platinum-based chemotherapy were included in this meta-analysis.	Platinum	136-144	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	69-74
24499239-4	2014	CONCLUSIONS: The ERCC1 rs3212986C/A polymorphism may be a useful prognostic marker in platinum-based treatment of EOC.	Platinum	86-94	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	17-22
24463159-0	2014	TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.	Platinum	31-39	tumor protein p53	Homo sapiens	0-4
24463159-10	2014	CONCLUSIONS: TP53 K351N mutation may be associated with induction of platinum resistance after NACT in advanced EOC.	Platinum	69-77	tumor protein p53	Homo sapiens	13-17
24463159-10	2014	CONCLUSIONS: TP53 K351N mutation may be associated with induction of platinum resistance after NACT in advanced EOC.	Platinum	69-77	solute carrier family 13 member 5	Homo sapiens	95-99
24457564-6	2014	RESULTS: BRCA mutation carriers treated with PLD (with or without platinum) or with gemcitabine + platinum had improved progression-free survival (PFS) and a lower risk for disease progression (adjusted for age, line of treatment, and platinum sensitivity) compared with patients with NH disease.	Platinum	98-106	BRCA1 DNA repair associated	Homo sapiens	9-13
24457564-6	2014	RESULTS: BRCA mutation carriers treated with PLD (with or without platinum) or with gemcitabine + platinum had improved progression-free survival (PFS) and a lower risk for disease progression (adjusted for age, line of treatment, and platinum sensitivity) compared with patients with NH disease.	Platinum	98-106	BRCA1 DNA repair associated	Homo sapiens	9-13
24457564-8	2014	Under all treatment regimens, BRCA mutation carriers showed improved overall survival after adjusting for age, line of treatment, and platinum sensitivity.	Platinum	134-142	BRCA1 DNA repair associated	Homo sapiens	30-34
24457564-9	2014	CONCLUSIONS: This single-institution experience provides indications of an enhanced benefit in PFS for BRCA mutation carriers compared with patients with NH disease across a number of drug regimens (PLD, platinum, or gemcitabine + platinum) regardless of platinum sensitivity and line of therapy.	Platinum	231-239	BRCA1 DNA repair associated	Homo sapiens	103-107
24457564-9	2014	CONCLUSIONS: This single-institution experience provides indications of an enhanced benefit in PFS for BRCA mutation carriers compared with patients with NH disease across a number of drug regimens (PLD, platinum, or gemcitabine + platinum) regardless of platinum sensitivity and line of therapy.	Platinum	231-239	BRCA1 DNA repair associated	Homo sapiens	103-107
24342537-6	2014	RESULTS: aPS/PT were found in 41.3% and 46.7% of SLE patients by the aPS/PT(ih) and the aPS/PT(c), respectively.	Platinum	13-15	ret proto-oncogene	Homo sapiens	92-97
24439569-13	2014	CONCLUSIONS: KRAS mutant tumors had a lower DCR after the first-line platinum-based CT, but this difference did not translate in PFS or OS.	Platinum	69-77	KRAS proto-oncogene, GTPase	Homo sapiens	13-17
24469739-6	2014	Results indicate that, similar to the reaction of cisplatin, copper coordination also enhances the platination of Atox1 by two trans-platinum complexes, and platinum binds to the copper coordinating residues.	Platinum	133-141	antioxidant 1 copper chaperone	Homo sapiens	114-119
24469739-6	2014	Results indicate that, similar to the reaction of cisplatin, copper coordination also enhances the platination of Atox1 by two trans-platinum complexes, and platinum binds to the copper coordinating residues.	Platinum	157-165	antioxidant 1 copper chaperone	Homo sapiens	114-119
24469739-9	2014	Additionally, both apo- and Cu(I)-Atox1 react faster with trans-platinum complexes than with cisplatin, however, less protein aggregation is observed in the reaction of trans-platinum complexes.	Platinum	64-72	antioxidant 1 copper chaperone	Homo sapiens	34-39
24469739-9	2014	Additionally, both apo- and Cu(I)-Atox1 react faster with trans-platinum complexes than with cisplatin, however, less protein aggregation is observed in the reaction of trans-platinum complexes.	Platinum	175-183	antioxidant 1 copper chaperone	Homo sapiens	34-39
24469739-10	2014	These results indicate that the roles of Atox1 in the regulation of cellular trafficking of platinum drugs are dependent on the coordination configurations.	Platinum	92-100	antioxidant 1 copper chaperone	Homo sapiens	41-46
24468393-7	2014	The stability of platinum-protein complexes under the FASP tryptic digestion, either using TBP or DTT as reducing agents, was maintained, allowing the identification of several platinum-containing peptides from cisplatin-HSA.	Platinum	17-25	TATA box binding protein	Rattus norvegicus	91-94
24491227-1	2014	With the aid of TEM characterization, we describe two distinct Pt nanostructures generated via the electroless reduction of Pt(NH3)4(NO2)2 within Nafion.	Platinum	63-65	MFT2	Homo sapiens	16-19
24155212-4	2014	The low expression of RRM1 and RRM2 significantly increased the platinum-based chemotherapy response (For RRM1: odds ratio (OR) = 2.09, 95% confidence interval (CI) = 1.38-3.18; For RRM2: OR = 1.64, 95% CI = 1.09-2.48).	Platinum	64-72	ribonucleotide reductase catalytic subunit M1	Homo sapiens	22-26
24155212-4	2014	The low expression of RRM1 and RRM2 significantly increased the platinum-based chemotherapy response (For RRM1: odds ratio (OR) = 2.09, 95% confidence interval (CI) = 1.38-3.18; For RRM2: OR = 1.64, 95% CI = 1.09-2.48).	Platinum	64-72	ribonucleotide reductase regulatory subunit M2	Homo sapiens	31-35
24155212-4	2014	The low expression of RRM1 and RRM2 significantly increased the platinum-based chemotherapy response (For RRM1: odds ratio (OR) = 2.09, 95% confidence interval (CI) = 1.38-3.18; For RRM2: OR = 1.64, 95% CI = 1.09-2.48).	Platinum	64-72	ribonucleotide reductase catalytic subunit M1	Homo sapiens	106-110
24155212-4	2014	The low expression of RRM1 and RRM2 significantly increased the platinum-based chemotherapy response (For RRM1: odds ratio (OR) = 2.09, 95% confidence interval (CI) = 1.38-3.18; For RRM2: OR = 1.64, 95% CI = 1.09-2.48).	Platinum	64-72	ribonucleotide reductase regulatory subunit M2	Homo sapiens	182-186
24155212-7	2014	In conclusion, low expression of RRM1 and RRM2 could be used to predict the treatment response to platinum-based chemotherapy and survival in NSCLC.	Platinum	98-106	ribonucleotide reductase catalytic subunit M1	Homo sapiens	33-37
24155212-7	2014	In conclusion, low expression of RRM1 and RRM2 could be used to predict the treatment response to platinum-based chemotherapy and survival in NSCLC.	Platinum	98-106	ribonucleotide reductase regulatory subunit M2	Homo sapiens	42-46
24169734-10	2014	The activity of the apoptosis-promoting protein caspase 3/7 was determined; results proved that these novel platinum compounds, under the chosen experimental conditions, preferentially induce apoptosis over necrosis.	Platinum	108-116	caspase 3	Homo sapiens	48-57
24158589-1	2014	Excision repair cross complementation group 1 (ERCC1) is an important protein in the nucleotide excision repair (NER) pathway, which is responsible for removing DNA adducts induced by platinum based compounds.	Platinum	184-192	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-45
24398573-1	2014	Highly controlled "ship-in-a-bottle" platinum nanoparticles in silicalite-1 hollow single crystals have been prepared.	Platinum	37-45	inositol polyphosphate-5-phosphatase D	Homo sapiens	19-23
24055935-1	2014	This work presents a novel bienzymatic biosensor for the simultaneous determination of nitrite (NO2(-)) and nitrate (NO3(-)) ions using copper, zinc superoxide dismutase (SOD1) and nitrate reductase (NaR) coimmobilized on carbon nanotubes (CNT)-polypyrrole (PPy) nanocomposite modified platinum electrode.	Platinum	286-294	superoxide dismutase 1	Homo sapiens	171-175
24370425-4	2014	Compared with NiCo nanochains, the Pt-loaded NiCo nanochains present exceedingly high catalytic activity toward the hydrolytic dehydrogenation of ammonia borane aqueous under ambient atmosphere at room temperature, where the Ni16Co80/Pt4 nanochains exhibit high catalytic activity with a lower activation energy of 45.72 kJ mol(-1) and a superior dehydrogenation rate of 1.17 x 10(4) mL min(-1) g(-1), suggesting the potential application in hydrogen fuel and chemical industry.	Platinum	35-37	CD59 molecule (CD59 blood group)	Homo sapiens	387-393
24351980-1	2014	A highly sensitive electrochemical aptasensor for thrombin detection is developed and demonstrated by using porous platinum nanotubes modified with polyamidoamine dendrimers as nanocarriers and electrocatalysts.	Platinum	115-123	coagulation factor II, thrombin	Homo sapiens	50-58
24158589-1	2014	Excision repair cross complementation group 1 (ERCC1) is an important protein in the nucleotide excision repair (NER) pathway, which is responsible for removing DNA adducts induced by platinum based compounds.	Platinum	184-192	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
24525731-3	2014	We have recently shown that reduced expression of base excision repair protein XRCC1 (X-ray repair cross complementing group1) in gastric cancerous tissues correlates with a significant survival benefit from adjuvant first-line platinum-based chemotherapy.	Platinum	228-236	X-ray repair cross complementing 1	Homo sapiens	79-84
24525731-3	2014	We have recently shown that reduced expression of base excision repair protein XRCC1 (X-ray repair cross complementing group1) in gastric cancerous tissues correlates with a significant survival benefit from adjuvant first-line platinum-based chemotherapy.	Platinum	228-236	X-ray repair cross complementing 1	Homo sapiens	86-125
24499657-10	2014	Additionally, strong membranous beta-catenin expression was associated with resistance to platinum-based chemotherapy (p = 0.027).	Platinum	90-98	catenin beta 1	Homo sapiens	32-44
24581168-3	2014	The expression level of nuclear factor erythroid-2-related factor 2 (Nrf2) is related to chemoresistance against platinum drugs.	Platinum	113-121	NFE2 like bZIP transcription factor 2	Homo sapiens	24-67
24240112-8	2014	Somatic BRCA1/2 mutations and mutations in other homologous recombination genes have a similar positive impact on overall survival and platinum responsiveness as germline BRCA1/2 mutations.	Platinum	135-143	BRCA1 DNA repair associated	Homo sapiens	8-15
24581168-3	2014	The expression level of nuclear factor erythroid-2-related factor 2 (Nrf2) is related to chemoresistance against platinum drugs.	Platinum	113-121	NFE2 like bZIP transcription factor 2	Homo sapiens	69-73
24465544-1	2014	BACKGROUND: Many reports have shown inconsistent results on the relationship between single nucleotide polymorphisms (SNPs) of X-ray repair cross complementing protein (XRCC1) gene and platinum-based chemotherapeutic efficacy.	Platinum	185-193	X-ray repair cross complementing 1	Homo sapiens	169-174
24281000-8	2014	Furthermore, although CHKA silencing did not directly induce cell death, a significant increase of sensitivity to platinum, paclitaxel and doxorubicin was observed even in a drug-resistant context.	Platinum	114-122	choline kinase alpha	Homo sapiens	22-26
24484537-15	2014	Finally, we show that RNAi-mediated knockdown of STAG2 selectively sensitizes human PDA cell lines to platinum-based therapy.	Platinum	102-110	stromal antigen 2	Homo sapiens	49-54
25104919-3	2014	The current work benchmarks the SCC-DFTB/MM method against more accurate DFT/MM by simulating PT in a synthetic leucine-serine channel (LS2), which emulates the structure and function of biomolecular proton channels.	Platinum	94-96	serpin family D member 1	Homo sapiens	136-139
24364421-1	2014	Platinum-catalyzed diborylation of phenylethynyl MIDA boronate with Bpin-Bpin proceeds to yield 1,1,2-triboryl-2-phenylethene with two different classes of the boron functionalities.	Platinum	0-8	NADH:ubiquinone oxidoreductase complex assembly factor 7	Homo sapiens	49-53
24446315-11	2014	In conclusion, we found the polymorphisms of XRCC1 and XPD to be related to the efficacy of platinum-based chemotherapy in NSCLC patients.	Platinum	92-100	X-ray repair cross complementing 1	Homo sapiens	45-50
24241169-1	2014	The synthesis and full characterization of platinum nanoparticles (Pt NPs) prepared by decomposition of the Pt(dba)2 complex in the presence of CO and H2 and stabilized either sterically by a polymer, polyvinylpyrrolidone or chemically by a ligand, diphenylphosphinobutane, are reported.	Platinum	43-51	DBA2	Homo sapiens	108-116
24446315-11	2014	In conclusion, we found the polymorphisms of XRCC1 and XPD to be related to the efficacy of platinum-based chemotherapy in NSCLC patients.	Platinum	92-100	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	55-58
24400068-1	2014	Platinum drug-resistance in ovarian cancers mediated by anti-apoptotic proteins such as Bcl-xL is a major factor contributing to the chemotherapeutic resistance of recurrent disease.	Platinum	0-8	BCL2 like 1	Homo sapiens	88-94
24403499-3	2014	The combination of gemcitabine and cisplatin is based on gemcitabine-induced increased formation and retention of DNA-platinum adducts, which can be explained by a decrease of excision repair cross-complementing group-1 (ERCC1)-mediated DNA repair.	Platinum	118-126	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	176-219
24403493-0	2014	ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.	Platinum	49-57	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
24403493-1	2014	AIM: The purpose of the present study was to investigate the possible association between Excision repair cross-complementing group 1 (ERCC1) score and platinum resistance in first-line chemotherapy for ovarian cancer.	Platinum	152-160	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	90-133
24403493-1	2014	AIM: The purpose of the present study was to investigate the possible association between Excision repair cross-complementing group 1 (ERCC1) score and platinum resistance in first-line chemotherapy for ovarian cancer.	Platinum	152-160	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	135-140
24403493-2	2014	PATIENTS AND METHODS: ERCC1 Expression was determined using immunohisto-chemistry in 68 patients with platinum-responding tumor and 30 with platinum-resistant tumors.	Platinum	102-110	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	22-27
24403493-2	2014	PATIENTS AND METHODS: ERCC1 Expression was determined using immunohisto-chemistry in 68 patients with platinum-responding tumor and 30 with platinum-resistant tumors.	Platinum	140-148	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	22-27
24403493-3	2014	The primary end-point of this study was the association between the expression of ERCC1 protein with resistance to standard platinum-based chemotherapy in primary ovarian cancer.	Platinum	124-132	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	82-87
24025563-0	2014	ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis.	Platinum	47-55	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
24025563-1	2014	The objective of this study was to provide a precise evaluation of whether expression levels of excision repair cross-complementation group 1 (ERCC1) are associated with objective response, overall survival (OS), and median survival in patients with advanced bladder cancer treated with platinum-based chemotherapy.	Platinum	287-295	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	96-141
24025563-1	2014	The objective of this study was to provide a precise evaluation of whether expression levels of excision repair cross-complementation group 1 (ERCC1) are associated with objective response, overall survival (OS), and median survival in patients with advanced bladder cancer treated with platinum-based chemotherapy.	Platinum	287-295	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	143-148
24025563-9	2014	In conclusion, low/negative expression of ERCC1 was associated with higher objective response, median progression-free survival, and median OS in patients with advanced bladder cancer treated with platinum-based chemotherapy.	Platinum	197-205	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	42-47
24025563-10	2014	ERCC1 may be a suitable marker of prognosis and sensitivity to platinum-based chemotherapy in patients with advanced bladder cancer.	Platinum	63-71	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
24403493-4	2014	RESULTS: In pairwise comparisons, the overall survival (OS) for patients with ovarian cancer, who were non-responders to platinum-based chemotherapy with low or intermediate H-score for ERCC1 was better than that of non-responders with high H-score for ERCC1 [median OS=21 (16.8-25.2 months) and 28 (14.6-41.4 months) vs. 15 months (6.2-23.8 months), p-value=0.048, and p-value=0.017, respectively].	Platinum	121-129	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	186-191
24403493-4	2014	RESULTS: In pairwise comparisons, the overall survival (OS) for patients with ovarian cancer, who were non-responders to platinum-based chemotherapy with low or intermediate H-score for ERCC1 was better than that of non-responders with high H-score for ERCC1 [median OS=21 (16.8-25.2 months) and 28 (14.6-41.4 months) vs. 15 months (6.2-23.8 months), p-value=0.048, and p-value=0.017, respectively].	Platinum	121-129	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	253-258
24403499-3	2014	The combination of gemcitabine and cisplatin is based on gemcitabine-induced increased formation and retention of DNA-platinum adducts, which can be explained by a decrease of excision repair cross-complementing group-1 (ERCC1)-mediated DNA repair.	Platinum	118-126	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	221-226
24403507-7	2014	The most studied potential predictive markers of platinum-sensitivity are Excision Repair Cross Complementing-1 (ERCC1) and Brest Cancer Type-I Susceptibility protein (BRCA1); however, increasing biological knowledge about DNA repair pathways suggests the potential clinical usefulness of integrated analysis of multiple DNA repair components.	Platinum	49-57	BRCA1 DNA repair associated	Homo sapiens	168-173
24403514-6	2014	We have also used sequenced combinations of platinum drugs and bortezomib (a proteasome inhibitor that prevents cisplatin-induced proteasomal degration of copper transporter CTR1) to enhance cellular platinum accumulation and the level of platinum-DNA binding especially in the resistant human ovarian tumour models.	Platinum	44-52	solute carrier family 31 member 1	Homo sapiens	174-178
24521150-0	2014	The design and characterization of a novel beta-casein nano-vehicle loaded with platinum anticancer drug for drug delivery.	Platinum	80-88	casein beta	Homo sapiens	43-54
25250341-5	2014	RESULTS: ERCC1 118C and TP53 72Arg polymorphisms were associated with increased risks of platinum-induced nephrotoxicity.	Platinum	89-97	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	9-14
24521150-1	2014	We developed a drug-delivery system comprising a novel platinum drug (Pt(II) complex) entrapped within beta-Casein (beta-CN) nanoparticles referred to as nano-vehicles.	Platinum	55-63	casein beta	Homo sapiens	103-114
24521150-1	2014	We developed a drug-delivery system comprising a novel platinum drug (Pt(II) complex) entrapped within beta-Casein (beta-CN) nanoparticles referred to as nano-vehicles.	Platinum	55-63	casein beta	Homo sapiens	116-123
24521150-11	2014	These findings suggest that beta-CN is an excellent nano-vehicle for targeted delivery of platinum drugs, which are generally recognized as safe (GRAS) and potentially useful in pharmaceutical industries.	Platinum	90-98	casein beta	Homo sapiens	28-35
24521151-7	2014	Therefore, AURKB inhibitors could offer potential benefits if used after first-line platinum-based chemotherapy.	Platinum	84-92	aurora kinase B	Homo sapiens	11-16
24377810-7	2014	Platinum-based chemotherapy has been considered as a candidate for the treatment of BLBCs owing to their BRCA1 phenotype.	Platinum	0-8	BRCA1 DNA repair associated	Homo sapiens	105-110
24761869-0	2014	Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.	Platinum	112-120	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-19
24761869-0	2014	Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.	Platinum	112-120	poly(ADP-ribose) polymerase 1	Homo sapiens	30-35
24761869-9	2014	CONCLUSION: Patients with ERCC1 or PARP1 negative non-small cell lung cancer appear to benefit from platinum-based postoperative adjuvant chemotherapy.	Platinum	100-108	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	26-31
24761869-9	2014	CONCLUSION: Patients with ERCC1 or PARP1 negative non-small cell lung cancer appear to benefit from platinum-based postoperative adjuvant chemotherapy.	Platinum	100-108	poly(ADP-ribose) polymerase 1	Homo sapiens	35-40
24935384-1	2014	BACKGROUND: The aim of this work is to assess the frequency of BRCA1 protein immunohistochemical (IHC) expression in epithelial ovarian cancer (EOC) and to evaluate the association of BRCA1 expression with clinical and pathological characteristics and the overall survival (OS) of patients treated with postoperative platinum- based chemotherapeutic agents.	Platinum	317-325	BRCA1 DNA repair associated	Homo sapiens	63-68
25580427-0	2014	Emodin augments cisplatin cytotoxicity in platinum-resistant ovarian cancer cells via ROS-dependent MRP1 downregulation.	Platinum	42-50	ATP binding cassette subfamily C member 1	Homo sapiens	100-104
25580427-2	2014	Overexpression of ATP binding cassette transporter MRP1 is correlated with resistance to platinum drugs.	Platinum	89-97	ATP binding cassette subfamily C member 1	Homo sapiens	51-55
25250341-5	2014	RESULTS: ERCC1 118C and TP53 72Arg polymorphisms were associated with increased risks of platinum-induced nephrotoxicity.	Platinum	89-97	tumor protein p53	Homo sapiens	24-28
24779016-0	2014	BMP-4 genetic variants and protein expression are associated with platinum-based chemotherapy response and prognosis in NSCLC.	Platinum	66-74	bone morphogenetic protein 4	Homo sapiens	0-5
24779016-1	2014	To explore the role of genetic polymorphisms of bone morphogenic proteins 4 (BMP-4) in the response to platinum-based chemotherapy and the clinical outcome in patients with advanced nonsmall cell lung cancer (NSCLC), 938 patients with stage III (A+B) or IV NSCLC were enrolled in this study.	Platinum	103-111	bone morphogenetic protein 4	Homo sapiens	48-75
24779016-1	2014	To explore the role of genetic polymorphisms of bone morphogenic proteins 4 (BMP-4) in the response to platinum-based chemotherapy and the clinical outcome in patients with advanced nonsmall cell lung cancer (NSCLC), 938 patients with stage III (A+B) or IV NSCLC were enrolled in this study.	Platinum	103-111	bone morphogenetic protein 4	Homo sapiens	77-82
24934364-9	2014	mRNA expression levels were lower in patients who present three or less metastasis; higher CEA mRNA expression was associated a worse progression-free survival to platinum-based chemotherapy and overall survival.	Platinum	163-171	CEA cell adhesion molecule 3	Homo sapiens	91-94
24189460-7	2014	Furthermore, PARP-1 mutant overexpression in a pancreatic cancer cell line (MIA PaCa-2) increased sensitivity to platinum-based anticancer agents.	Platinum	113-121	poly(ADP-ribose) polymerase 1	Homo sapiens	13-19
24139827-9	2014	CONCLUSION: KRAS mutation appears to negatively affect sensitivity to first-line platinum-based chemotherapy in patients with advanced nonsquamous EGFR WT NSCLC.	Platinum	81-89	KRAS proto-oncogene, GTPase	Homo sapiens	12-16
25482940-2	2014	In this study, we investigated the role of the p53 and MDM2 genes in predicting adverse events in NSCLC patients treated with platinum-based chemotherapy.	Platinum	126-134	tumor protein p53	Homo sapiens	47-50
25482940-2	2014	In this study, we investigated the role of the p53 and MDM2 genes in predicting adverse events in NSCLC patients treated with platinum-based chemotherapy.	Platinum	126-134	MDM2 proto-oncogene	Homo sapiens	55-59
25482940-4	2014	We determine that MDM2 c.14 + 309T &gt; G was significantly associated with severe hematologic and overall toxicities for advanced NSCLC patients treated with platinum-based chemotherapy, especially for patients aged 57 and younger.	Platinum	159-167	MDM2 proto-oncogene	Homo sapiens	18-22
25482940-11	2014	In summary, we found that the p53 p. Pro72Arg, MDM2 c.14 + 309T &gt; G and MDM2 c.-461C &gt; G polymorphisms are associated with toxicity risks following platinum-based chemotherapy treatment in advanced NSCLC patients.	Platinum	154-162	MDM2 proto-oncogene	Homo sapiens	47-51
25482940-11	2014	In summary, we found that the p53 p. Pro72Arg, MDM2 c.14 + 309T &gt; G and MDM2 c.-461C &gt; G polymorphisms are associated with toxicity risks following platinum-based chemotherapy treatment in advanced NSCLC patients.	Platinum	154-162	MDM2 proto-oncogene	Homo sapiens	75-79
25482940-12	2014	We suggest that MDM2 c.14 + 309T &gt; G may be used as a candidate biomarker to predict adverse events in advanced NSCLC patients who had platinum-based chemotherapy treatment.	Platinum	138-146	MDM2 proto-oncogene	Homo sapiens	16-20
24139827-0	2014	Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.	Platinum	22-30	epidermal growth factor receptor	Homo sapiens	88-92
24139827-9	2014	CONCLUSION: KRAS mutation appears to negatively affect sensitivity to first-line platinum-based chemotherapy in patients with advanced nonsquamous EGFR WT NSCLC.	Platinum	81-89	epidermal growth factor receptor	Homo sapiens	147-151
24139827-0	2014	Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.	Platinum	22-30	KRAS proto-oncogene, GTPase	Homo sapiens	154-158
24139827-1	2014	BACKGROUND: We hypothesized that KRAS mutations function as a marker of poor sensitivity to first-line platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type (WT) non-small-cell lung cancer (NSCLC).	Platinum	103-111	KRAS proto-oncogene, GTPase	Homo sapiens	33-37
24220096-0	2014	Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.	Platinum	99-107	CD74 molecule	Homo sapiens	26-30
24139827-1	2014	BACKGROUND: We hypothesized that KRAS mutations function as a marker of poor sensitivity to first-line platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type (WT) non-small-cell lung cancer (NSCLC).	Platinum	103-111	epidermal growth factor receptor	Homo sapiens	169-173
24220096-3	2014	PATIENTS AND METHODS: We used a pathway-based approach to investigate the association between genetic polymorphisms in MIF-pathway genes and the outcomes of platinum-based chemotherapy in advanced non-small-cell lung cancer (NSCLC).	Platinum	157-165	macrophage migration inhibitory factor	Homo sapiens	119-122
24220096-10	2014	CONCLUSION: Our study is the first to suggest, to our knowledge, that polymorphisms in CD74 might be a marker of lower hematologic toxicity for patients with advanced NSCLC receiving platinum-based chemotherapy.	Platinum	183-191	CD74 molecule	Homo sapiens	87-91
24361480-2	2014	Here we describe a strategy to conveniently obtain metal-based PARP-1 inhibitors with enhanced biological activities by conjugating platinum moiety with an original inhibitor, e.g., benzonaphthyridone.	Platinum	132-140	poly(ADP-ribose) polymerase 1	Homo sapiens	63-69
24361480-7	2014	Our study implies that the conjugation of platinum with PARP-1 inhibitors could be a valid strategy to obtain more potent anticancer agents with improved biological activities.	Platinum	42-50	poly(ADP-ribose) polymerase 1	Homo sapiens	56-62
24211400-5	2014	After stratification, in patients with platinum-sensitive disease treated with the combination of trabectedin plus PLD, high levels of nibrin correlated with lower ORR (P=0.01) and shorter PFS (P=0.02).	Platinum	39-47	nibrin	Homo sapiens	135-141
24192511-0	2014	A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease.	Platinum	48-56	epidermal growth factor receptor	Homo sapiens	124-128
24696812-7	2014	The biosensor was created by immobilizing of uricase by a glutaraldehyde crosslinking procedure on PANI composite film on the surface of a platinum electrode while the polyelectrolyte layer of PAA were prepared via layer-by-layer assembly on the electrode, functioning as H2O2-selective film.	Platinum	139-147	urate oxidase (pseudogene)	Homo sapiens	45-52
24987709-9	2014	In conclusion, expression of HLA-G is an independent prognostic factor for improved survival in high grade epithelial ovarian cancer and a predictor for platinum sensitivity.	Platinum	153-161	major histocompatibility complex, class I, G	Homo sapiens	29-34
24148759-0	2014	Transport of platinum bonded nucleotides into proteoliposomes, mediated by Drosophila melanogaster thiamine pyrophosphate carrier protein (DmTpc1).	Platinum	13-21	Thiamine pyrophosphate carrier protein 1	Drosophila melanogaster	99-137
24148759-0	2014	Transport of platinum bonded nucleotides into proteoliposomes, mediated by Drosophila melanogaster thiamine pyrophosphate carrier protein (DmTpc1).	Platinum	13-21	Thiamine pyrophosphate carrier protein 1	Drosophila melanogaster	139-145
24148759-1	2014	The results of the present study suggest that DmTpc1 is actively implicated in the specific uptake of free cytoplasmic Pt bonded nucleotides, and therefore could be linked to the mechanism of action of some platinum-based antitumor drugs.	Platinum	207-215	Thiamine pyrophosphate carrier protein 1	Drosophila melanogaster	46-52
24148759-2	2014	Although DmTpc1 has a low affinity for model [Pt(dien)(N7-5"-dGTP)] and cis-[Pt(NH3)2(py)(N7-5"-dGTP)] compared to dATP it"s well known that DNA platination level of few metal atoms per double-stranded molecule may account for the pharmacological activity of platinum based antitumor drugs.	Platinum	259-267	Thiamine pyrophosphate carrier protein 1	Drosophila melanogaster	9-15
24401766-3	2014	Here we develop a sensitive spin-orbit torque magnetometer based on the magneto-optic Kerr effect that measures the spin-orbit torque vectors for cobalt iron boron/platinum bilayers over a wide thickness range.	Platinum	164-172	spindlin 1	Homo sapiens	28-32
24079350-8	2014	RESULTS: At both five and ten minutes after infusion, platinum concentrations in plasma were significantly lower for the thrombin group than for the control group.	Platinum	54-62	prothrombin	Oryctolagus cuniculus	121-129
24079350-9	2014	Platinum concentration in tumor tissue was significantly higher for the thrombin group than for the control group.	Platinum	0-8	prothrombin	Oryctolagus cuniculus	72-80
24401766-3	2014	Here we develop a sensitive spin-orbit torque magnetometer based on the magneto-optic Kerr effect that measures the spin-orbit torque vectors for cobalt iron boron/platinum bilayers over a wide thickness range.	Platinum	164-172	spindlin 1	Homo sapiens	116-120
23988033-9	2014	Analysis of extracted Atox1 with inductively coupled plasma mass spectrometry demonstrated the presence of Pt in the protein fraction.	Platinum	107-109	antioxidant 1 copper chaperone	Homo sapiens	22-27
23433892-12	2014	ERCC1 genotype maybe predictive of clinical benefit with platinum-based therapy in metastatic prostate cancer.	Platinum	57-65	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
24438715-8	2014	RESULTS: On comparing the platinum-based group versus no chemotherapy, we found that the ICER was $30,073/QALY and $58,151/QALY for early- and late-stage disease, respectively, while other nonplatinum and platinum plus taxane groups were dominated (less effective and more costly).	Platinum	26-34	cAMP responsive element modulator	Homo sapiens	89-93
24362578-0	2013	Interaction of classical platinum agents with the monomeric and dimeric Atox1 proteins: a molecular dynamics simulation study.	Platinum	25-33	antioxidant 1 copper chaperone	Homo sapiens	72-77
24438715-8	2014	RESULTS: On comparing the platinum-based group versus no chemotherapy, we found that the ICER was $30,073/QALY and $58,151/QALY for early- and late-stage disease, respectively, while other nonplatinum and platinum plus taxane groups were dominated (less effective and more costly).	Platinum	192-200	cAMP responsive element modulator	Homo sapiens	89-93
24438715-10	2014	For patients 85 years or older, platinum plus taxane, however, was not dominated by the platinum-based group, with an ICER of $133,892/QALY.	Platinum	32-40	cAMP responsive element modulator	Homo sapiens	118-122
25033687-0	2014	[Effectiveness of platinum-based chemotherapy in ovarian cancer patients with BRCA1/2 mutations].	Platinum	18-26	BRCA1 DNA repair associated	Homo sapiens	78-85
25033687-1	2014	The purpose of this study was to examine the clinical significance of mutations in BRCA1/2 in the formation of response to neoadjuvant platinum-based chemotherapy for ovarian cancer (OC).	Platinum	135-143	BRCA1 DNA repair associated	Homo sapiens	83-90
24362578-2	2013	All three platinum agents could respectively combine with the monomeric Atox1 protein and the dimeric Atox1 protein to form a stable binary and ternary complex due to the covalent interaction of the platinum center with the Atox1 protein.	Platinum	10-18	antioxidant 1 copper chaperone	Homo sapiens	72-77
24362578-2	2013	All three platinum agents could respectively combine with the monomeric Atox1 protein and the dimeric Atox1 protein to form a stable binary and ternary complex due to the covalent interaction of the platinum center with the Atox1 protein.	Platinum	10-18	antioxidant 1 copper chaperone	Homo sapiens	102-107
24362578-2	2013	All three platinum agents could respectively combine with the monomeric Atox1 protein and the dimeric Atox1 protein to form a stable binary and ternary complex due to the covalent interaction of the platinum center with the Atox1 protein.	Platinum	10-18	antioxidant 1 copper chaperone	Homo sapiens	102-107
24362578-2	2013	All three platinum agents could respectively combine with the monomeric Atox1 protein and the dimeric Atox1 protein to form a stable binary and ternary complex due to the covalent interaction of the platinum center with the Atox1 protein.	Platinum	199-207	antioxidant 1 copper chaperone	Homo sapiens	72-77
24362578-2	2013	All three platinum agents could respectively combine with the monomeric Atox1 protein and the dimeric Atox1 protein to form a stable binary and ternary complex due to the covalent interaction of the platinum center with the Atox1 protein.	Platinum	199-207	antioxidant 1 copper chaperone	Homo sapiens	102-107
24362578-2	2013	All three platinum agents could respectively combine with the monomeric Atox1 protein and the dimeric Atox1 protein to form a stable binary and ternary complex due to the covalent interaction of the platinum center with the Atox1 protein.	Platinum	199-207	antioxidant 1 copper chaperone	Homo sapiens	102-107
24362578-5	2013	However, the extra interactions to facilitate the stabilities of the ternary CisPt + 2Atox1 and OxaliPt + 2Atox1 models come from the alpha1 helices and alpha2-beta4 loops of the Atox1 protein-Atox1 protein interface due to the cis conformation of the platinum agents.	Platinum	252-260	antioxidant 1 copper chaperone	Homo sapiens	86-91
24362578-5	2013	However, the extra interactions to facilitate the stabilities of the ternary CisPt + 2Atox1 and OxaliPt + 2Atox1 models come from the alpha1 helices and alpha2-beta4 loops of the Atox1 protein-Atox1 protein interface due to the cis conformation of the platinum agents.	Platinum	252-260	antioxidant 1 copper chaperone	Homo sapiens	107-112
24362578-5	2013	However, the extra interactions to facilitate the stabilities of the ternary CisPt + 2Atox1 and OxaliPt + 2Atox1 models come from the alpha1 helices and alpha2-beta4 loops of the Atox1 protein-Atox1 protein interface due to the cis conformation of the platinum agents.	Platinum	252-260	antioxidant 1 copper chaperone	Homo sapiens	107-112
24362578-5	2013	However, the extra interactions to facilitate the stabilities of the ternary CisPt + 2Atox1 and OxaliPt + 2Atox1 models come from the alpha1 helices and alpha2-beta4 loops of the Atox1 protein-Atox1 protein interface due to the cis conformation of the platinum agents.	Platinum	252-260	antioxidant 1 copper chaperone	Homo sapiens	107-112
24362578-7	2013	These investigations might provide detailed information for understanding the interaction mechanism of the platinum agents binding to the Atox1 protein in the cytoplasm.	Platinum	107-115	antioxidant 1 copper chaperone	Homo sapiens	138-143
23835216-0	2013	Ultrasensitive thrombin detection based on direct electrochemistry of highly loaded hemoglobin spheres-encapsulated platinum nanoparticles as labels and electrocatalysts.	Platinum	116-124	coagulation factor II, thrombin	Homo sapiens	15-23
23835216-1	2013	For the first time, a sandwich-type electrochemical method was proposed for ultrasensitive thrombin (TB) detection based on direct electrochemistry of highly loaded hemoglobin spheres-encapsulated platinum nanoparticles (PtNPs@Hb) as labels and electrocatalysts.	Platinum	197-205	coagulation factor II, thrombin	Homo sapiens	91-99
23835216-1	2013	For the first time, a sandwich-type electrochemical method was proposed for ultrasensitive thrombin (TB) detection based on direct electrochemistry of highly loaded hemoglobin spheres-encapsulated platinum nanoparticles (PtNPs@Hb) as labels and electrocatalysts.	Platinum	197-205	coagulation factor II, thrombin	Homo sapiens	101-103
24526958-2	2014	The Pt-Cl bond lengths are comparable to those reported for other hexa-chlorido-platinate(IV) species.	Platinum	4-6	hexosaminidase subunit alpha	Homo sapiens	66-70
24281882-2	2013	It coordinates to palladium and platinum in a eta(2) -fashion giving complexes (red) with a trans-bent geometry, in contrast to eta(2) -alkyne complexes.	Platinum	32-40	DNA polymerase iota	Homo sapiens	46-52
24131953-0	2013	Study of underpotential deposited Cu layers on Pt(111) and their stability against CO and CO2 in perchloric acid.	Platinum	47-49	complement C2	Homo sapiens	90-93
24281882-2	2013	It coordinates to palladium and platinum in a eta(2) -fashion giving complexes (red) with a trans-bent geometry, in contrast to eta(2) -alkyne complexes.	Platinum	32-40	DNA polymerase iota	Homo sapiens	46-51
23455184-3	2013	The major aim of this study was to further define the expression pattern and the prognostic role of Bcl-2 together with BAG-1, BAG-3, and BAG-4 proteins in EOC patients receiving platinum/taxane-based chemotherapy.	Platinum	179-187	BCL2 apoptosis regulator	Homo sapiens	100-105
24349623-0	2013	Serum miR-200c and clinical outcome of patients with advanced esophageal squamous cancer receiving platinum-based chemotherapy.	Platinum	99-107	microRNA 200c	Homo sapiens	6-14
24349623-3	2013	The serum levels of miR-200c was assayed by quantitative RT-PCR in 157 healthy subjects and 157 patients with advanced ESCC who were treated with platinum-based chemotherapy.	Platinum	146-154	microRNA 200c	Homo sapiens	20-28
24335366-1	2013	OBJECTIVE: We evaluated the safety and efficacy of pegylated liposomal doxorubicin(PLD)and carboplatin(CBDCA)(CD) for platinum-sensitive recurrent epithelial ovarian cancer.	Platinum	118-126	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	83-86
24307601-6	2013	Maximum DEF values on the central transverse line, within the tumour, for Fe2O3, Ag, Gd, Pt and Au nanoparticles with 30 mg/ml concentration were 1.27, 1.15, 1.14, 1.32, 1.79, respectively.	Platinum	89-91	UTP25 small subunit processome component	Homo sapiens	8-11
24028849-0	2013	Beta-casein and its complexes with chitosan as nanovehicles for delivery of a platinum anticancer drug.	Platinum	78-86	casein beta	Homo sapiens	0-11
24028849-3	2013	Here, we describe a new drug-delivery system comprising a novel platinum complex (bipyridine morpholine dithiocarbamate Pt(II) nitrate) within nanoparticles composed of beta-casein (beta-CN) and chitosan (CS).	Platinum	64-72	casein beta	Homo sapiens	169-180
24028849-3	2013	Here, we describe a new drug-delivery system comprising a novel platinum complex (bipyridine morpholine dithiocarbamate Pt(II) nitrate) within nanoparticles composed of beta-casein (beta-CN) and chitosan (CS).	Platinum	64-72	casein beta	Homo sapiens	182-189
24028849-12	2013	The results obtained indicated that both the cytotoxicity and cellular uptake of platinum were enhanced by its entrapment in beta-CN-CS nanovehicles.	Platinum	81-89	casein beta	Homo sapiens	125-132
22821704-5	2013	Multi-loci analyses consistently indicated that interactions among XRCC1 Arg194Trp, XPC PAT, FAS G-1377A, and FASL T-844C were associated with sensitivity to platinum-based chemotherapy.	Platinum	158-166	X-ray repair cross complementing 1	Homo sapiens	67-72
22821704-5	2013	Multi-loci analyses consistently indicated that interactions among XRCC1 Arg194Trp, XPC PAT, FAS G-1377A, and FASL T-844C were associated with sensitivity to platinum-based chemotherapy.	Platinum	158-166	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	84-87
22821704-5	2013	Multi-loci analyses consistently indicated that interactions among XRCC1 Arg194Trp, XPC PAT, FAS G-1377A, and FASL T-844C were associated with sensitivity to platinum-based chemotherapy.	Platinum	158-166	Fas ligand	Homo sapiens	110-114
24389432-1	2013	INTRODUCTION: In a previous biomarker discovery project using gene-expression profiling we identified Serpin B3 (SB3) as a predictor of resistance to platinum doublet chemotherapy (PtC) in non-small-cell lung cancer (NSCLC).	Platinum	150-158	serpin family B member 3	Homo sapiens	102-111
24389432-1	2013	INTRODUCTION: In a previous biomarker discovery project using gene-expression profiling we identified Serpin B3 (SB3) as a predictor of resistance to platinum doublet chemotherapy (PtC) in non-small-cell lung cancer (NSCLC).	Platinum	150-158	serpin family B member 3	Homo sapiens	113-116
24171447-3	2013	In the reaction of 1 with ethylene bis(triphenylphosphine) platinum(0), a complete silicon-phosphorus bond breakage occurs, yielding the unprecedented dinuclear platinum complex 3 [LSi{Pt(PPh3)}2P(TMS)2].	Platinum	59-67	caveolin 1	Homo sapiens	188-192
25806266-4	2013	With regard to second-line tyrosine kinase inhibitors (TKIs) following platinum-based chemotherapy, its tumor response rate was less than first-line TKIs in patients with EGFR mutations.	Platinum	71-79	epidermal growth factor receptor	Homo sapiens	171-175
24144319-1	2013	Nanostructured novel Pt/Clay nanocomposites consisting of well-defined Pt nanoparticles prepared by clay-mediated in situ reduction displays very high thermal stability, large BET surface area and superior catalytic activity for CO oxidation as compared to a model reference Pt/SiO2 catalysts.	Platinum	21-23	delta/notch like EGF repeat containing	Homo sapiens	176-179
24090479-6	2013	CONCLUSION: VEGF-A rs25648 genotyping may help identify a patient subgroup unlikely to benefit from a first-line, platinum-based combination and potential candidates for alternative therapy choices.	Platinum	114-122	vascular endothelial growth factor A	Homo sapiens	12-18
23990458-0	2013	Predictive effect of XRCC3 Thr241Met polymorphism on platinum-based chemotherapy in lung cancer patients: meta-analysis.	Platinum	53-61	X-ray repair cross complementing 3	Homo sapiens	21-26
23990458-1	2013	Previous published data on the association between X-ray repair cross-complementing group 3 (XRCC3) Thr241Met polymorphism and clinical outcome of platinum-based chemotherapy in patients with lung cancer reported conflicting results.	Platinum	147-155	X-ray repair cross complementing 3	Homo sapiens	51-91
23990458-1	2013	Previous published data on the association between X-ray repair cross-complementing group 3 (XRCC3) Thr241Met polymorphism and clinical outcome of platinum-based chemotherapy in patients with lung cancer reported conflicting results.	Platinum	147-155	X-ray repair cross complementing 3	Homo sapiens	93-98
24144319-1	2013	Nanostructured novel Pt/Clay nanocomposites consisting of well-defined Pt nanoparticles prepared by clay-mediated in situ reduction displays very high thermal stability, large BET surface area and superior catalytic activity for CO oxidation as compared to a model reference Pt/SiO2 catalysts.	Platinum	71-73	delta/notch like EGF repeat containing	Homo sapiens	176-179
24171447-9	2013	The respective platinum intermediate 2 [LSi{Pt(TMS)(PPh3)}P(TMS)] was also experimentally observed.	Platinum	15-23	caveolin 1	Homo sapiens	52-56
24144319-1	2013	Nanostructured novel Pt/Clay nanocomposites consisting of well-defined Pt nanoparticles prepared by clay-mediated in situ reduction displays very high thermal stability, large BET surface area and superior catalytic activity for CO oxidation as compared to a model reference Pt/SiO2 catalysts.	Platinum	71-73	delta/notch like EGF repeat containing	Homo sapiens	176-179
24168967-1	2013	BACKGROUND: Expression of BRCA1 is commonly decreased in sporadic ovarian cancer, and this is associated with platinum sensitivity and favorable prognosis.	Platinum	110-118	BRCA1 DNA repair associated	Homo sapiens	26-31
24120429-8	2013	Abeta1-42-induced phosphorylation of JNK and p38 MAPK was inhibited by pretreatment with PT-3 in a dose-dependent manner.	Platinum	89-91	mitogen-activated protein kinase 8	Rattus norvegicus	37-40
24253929-0	2013	DNA polymerase eta modulates replication fork progression and DNA damage responses in platinum-treated human cells.	Platinum	86-94	DNA polymerase eta	Homo sapiens	0-18
24253929-1	2013	Human cells lacking DNA polymerase eta (poleta) are sensitive to platinum-based cancer chemotherapeutic agents.	Platinum	65-73	DNA polymerase eta	Homo sapiens	20-38
24253929-4	2013	Severe replication inhibition in individual platinum-treated poleta-deficient cells correlates with enhanced phosphorylation of the RPA2 subunit of replication protein A on serines 4 and 8, as determined using EdU labelling and immunofluorescence, consistent with formation of DNA strand breaks at arrested forks in the absence of poleta.	Platinum	44-52	replication protein A2	Homo sapiens	132-136
24218601-3	2013	Insensitivity of CCNE1-amplified tumors to platinum cross-linking agents may be partly because of an intact BRCA1/2 pathway.	Platinum	43-51	cyclin E1	Homo sapiens	17-22
32261059-6	2013	In addition, Nafion/Aurod@Pt/GCE was found to exhibit a low working potential, fast amperometric response, high sensitivity, good reproducibility, good long term stability, and a high specificity to glucose with negligible interference from uric acid, ascorbic acid, acetamidophenol, or chloride ions.	Platinum	26-28	aminomethyltransferase	Homo sapiens	29-32
24187992-5	2013	Upon investigation of the derivatives with L = PPh3, AsPh3, Me2S O, and (H2N)2C S, it has been concluded that an electrostatic interaction between the oxygen lone pair of the iminoether and the platinum center, fostered by the net positive charge of the complex and the low dielectric constant around the metal core provided by the hydrophobic L ligands, stabilizes the Z configuration.	Platinum	194-202	caveolin 1	Homo sapiens	47-51
24260311-0	2013	Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies.	Platinum	60-68	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	17-20
24260311-2	2013	Two commonly studied single nucleotide polymorphisms (SNPs) of XPD (Lys751Gln, A&gt;C, rs13181; Asp312Asn, G&gt;A, rs1799793) are implicated in the modulation of DNA repair capacity, thus related to the responses to platinum-based chemotherapy.	Platinum	216-224	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	63-66
24260311-3	2013	Here we performed a meta-analysis to better evaluate the association between the two XPD SNPs and clinical outcome of platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.	Platinum	118-126	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	85-88
24260311-11	2013	CONCLUSIONS: XPD Lys751Gln (A&gt;C) may have inverse predictive and prognostic role in platinum-based treatment of NSCLC according to different ethnicities.	Platinum	87-95	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	13-16
24008489-11	2013	CONCLUSIONS: Exposure to platinum, CRT, or steroids is associated with insulin resistance and cardiovascular risk factors and should be taken into consideration in the development of screening recommendations for cardiovascular risk.	Platinum	25-33	insulin	Homo sapiens	71-78
24209693-4	2013	Bortezomib, a proteasome inhibitor, has been reported to block this platinum-induced down-regulation of CTR1, so that in the presence of bortezomib, the cellular uptake of platinum drugs may be increased.	Platinum	68-76	solute carrier family 31 member 1	Homo sapiens	104-108
24209693-4	2013	Bortezomib, a proteasome inhibitor, has been reported to block this platinum-induced down-regulation of CTR1, so that in the presence of bortezomib, the cellular uptake of platinum drugs may be increased.	Platinum	172-180	solute carrier family 31 member 1	Homo sapiens	104-108
24209693-9	2013	RESULTS: Prevention of copper transporter 1 degradation by bortezomib is found to enhance the cellular accumulation of platinum, the level of Platinum - DNA binding and increases oxidative stress especially in the resistant cell lines.	Platinum	119-127	solute carrier family 31 member 1	Homo sapiens	23-43
24209693-9	2013	RESULTS: Prevention of copper transporter 1 degradation by bortezomib is found to enhance the cellular accumulation of platinum, the level of Platinum - DNA binding and increases oxidative stress especially in the resistant cell lines.	Platinum	142-150	solute carrier family 31 member 1	Homo sapiens	23-43
24209693-10	2013	CONCLUSIONS: The results suggest that the prevention of CTR1 degradation by bortezomib may be playing a major role in increasing the cellular uptake of platinum drugs and platinum-DNA binding level.	Platinum	152-160	solute carrier family 31 member 1	Homo sapiens	56-60
24209693-10	2013	CONCLUSIONS: The results suggest that the prevention of CTR1 degradation by bortezomib may be playing a major role in increasing the cellular uptake of platinum drugs and platinum-DNA binding level.	Platinum	171-179	solute carrier family 31 member 1	Homo sapiens	56-60
24067100-5	2013	It is demonstrated herein that increasing the internal electrolyte pH promotes oxidized platinum film formation, resulting in improved selectivity over CO. Selectivity coefficients (log KNO,j) for sensors assembled with internal solutions at various pH values range from -0.08 at pH 2.0 to -2.06 at pH 11.7, with average NO sensitivities of 1.24 nA/muM and a limit of detection (LOD) of &lt;1 nM.	Platinum	88-96	latexin	Homo sapiens	349-352
24223900-12	2013	Cox analyses confirmed that the SIRT 1 expression was a strong predictor for a poor OS and PFS in NSCLC patients underwent Platinum-based chemotherapy.	Platinum	123-131	cytochrome c oxidase subunit 8A	Homo sapiens	0-3
24223900-12	2013	Cox analyses confirmed that the SIRT 1 expression was a strong predictor for a poor OS and PFS in NSCLC patients underwent Platinum-based chemotherapy.	Platinum	123-131	sirtuin 1	Homo sapiens	32-38
24131965-4	2013	Patients with BRCA1/2 mutations have been reported to have improved chemosensitivity to platinum agents, longer disease-free intervals, and longer survivals than nonhereditary counterparts.	Platinum	88-96	BRCA1 DNA repair associated	Homo sapiens	14-21
24008489-8	2013	Compared with siblings, insulin resistance was significantly higher in CCS who received platinum plus cranial radiotherapy (CRT, 92% brain tumors) and in those who received steroids but no platinum (majority leukemia).	Platinum	88-96	insulin	Homo sapiens	24-31
24008489-8	2013	Compared with siblings, insulin resistance was significantly higher in CCS who received platinum plus cranial radiotherapy (CRT, 92% brain tumors) and in those who received steroids but no platinum (majority leukemia).	Platinum	189-197	insulin	Homo sapiens	24-31
23910066-11	2013	CONCLUSIONS: EGFR, but not K-RAS mutation, is associated with improved survival time to platinum-based chemotherapy.	Platinum	88-96	epidermal growth factor receptor	Homo sapiens	13-17
24243606-3	2013	On the other hand, due to a broad range of oxidation states under physiological conditions and a high affinity for protein binding, platinum and ruthenium coordination complexes are promising candidates for PLA2 inhibitors.	Platinum	132-140	phospholipase A2 group IIA	Homo sapiens	207-211
24045016-2	2013	Based on the literature, excision repair cross complementation group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) genes represent predictive biomarkers of response to platinum compound and gemcitabine, in NSCLC.	Platinum	171-179	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	25-70
24029657-3	2013	We investigated VCAM-1 expression as a marker of peritoneal metastasis and tumor response to platinum-based chemotherapy.	Platinum	93-101	vascular cell adhesion molecule 1	Homo sapiens	16-22
24029657-10	2013	Treatment of mesothelial cells in culture with carboplatin resulted in a transient decrease in VCAM-1 expression 4 h after treatment that returned to baseline within 16-24 h. In vivo imaging of VCAM-1 also demonstrated an acute decrease in expression 4 h after carboplatin administration that recovered within 48 h in mice harboring platinum-resistant tumors.	Platinum	333-341	vascular cell adhesion molecule 1	Mus musculus	194-200
24029657-11	2013	Chronic VCAM-1 expression reflected the effect of platinum-based treatment on tumor burden.	Platinum	50-58	vascular cell adhesion molecule 1	Homo sapiens	8-14
24029657-12	2013	Specifically, carboplatin treatment of mice with platinum-sensitive tumors showed reduced VCAM-1 expression, which correlated with reduced tumor burden; mice with platinum-resistant tumors retained elevated VCAM-1 expression and tumor burden after treatment.	Platinum	49-57	vascular cell adhesion molecule 1	Mus musculus	90-96
24029657-13	2013	CONCLUSION: Clinically relevant VCAM-1-specific imaging probes identify VCAM-1 expression as an indicator of ovarian cancer peritoneal metastasis and therapeutic response to platinum-based agents.	Platinum	174-182	vascular cell adhesion molecule 1	Homo sapiens	32-38
24029657-13	2013	CONCLUSION: Clinically relevant VCAM-1-specific imaging probes identify VCAM-1 expression as an indicator of ovarian cancer peritoneal metastasis and therapeutic response to platinum-based agents.	Platinum	174-182	vascular cell adhesion molecule 1	Homo sapiens	72-78
24221219-4	2013	Good results have also been reported for EGFR inhibitors in cases where platinum-based treatment has failed.	Platinum	72-80	epidermal growth factor receptor	Homo sapiens	41-45
24100590-0	2013	Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB.	Platinum	0-8	mitogen-activated protein kinase 8 interacting protein 2	Homo sapiens	151-154
23993732-0	2013	Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.	Platinum	132-140	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-34
23993732-1	2013	Excision-repair-cross-complement-1 (ERCC1) protein expression in tumor cells has been associated with resistance to platinum compounds, the backbone of treatment in NSCLC.	Platinum	116-124	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-34
24045016-2	2013	Based on the literature, excision repair cross complementation group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) genes represent predictive biomarkers of response to platinum compound and gemcitabine, in NSCLC.	Platinum	171-179	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	72-77
23993732-1	2013	Excision-repair-cross-complement-1 (ERCC1) protein expression in tumor cells has been associated with resistance to platinum compounds, the backbone of treatment in NSCLC.	Platinum	116-124	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	36-41
24045016-2	2013	Based on the literature, excision repair cross complementation group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) genes represent predictive biomarkers of response to platinum compound and gemcitabine, in NSCLC.	Platinum	171-179	ribonucleotide reductase catalytic subunit M1	Homo sapiens	83-110
23993732-2	2013	In the current study the impact of the tumoral ERCC1 protein expression on the outcome of patients with advanced stage NSCLC treated with platinum-based chemotherapy, was investigated.	Platinum	138-146	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
24045016-2	2013	Based on the literature, excision repair cross complementation group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) genes represent predictive biomarkers of response to platinum compound and gemcitabine, in NSCLC.	Platinum	171-179	ribonucleotide reductase catalytic subunit M1	Homo sapiens	112-116
24001328-4	2013	By the application of the best procedure, the virtual screening workflow was used to filter the Gold and Platinum database from Asinex to identify new Fyn inhibitors.	Platinum	105-113	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	151-154
23982437-0	2013	Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.	Platinum	87-95	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	20-25
23982437-0	2013	Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.	Platinum	87-95	ribonucleotide reductase catalytic subunit M1	Homo sapiens	30-34
23982437-1	2013	Platinum-based chemotherapy with third generation drugs (such as gemcitabine) is an efficacious regimen of first-line treatment of patients with advanced, unresectable non-small cell lung cancer (NSCLC), without activating EGFR mutations.	Platinum	0-8	epidermal growth factor receptor	Homo sapiens	223-227
23982437-11	2013	The analysis of RRM1 (-37C&gt;A) more than ERCC1 (19007C&gt;T) polymorphism may be a promising tool in the qualification of NSCLC patients for chemotherapy containing platinum compounds and gemcitabine.	Platinum	167-175	ribonucleotide reductase catalytic subunit M1	Homo sapiens	16-20
24142642-0	2013	Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced non-small cell lung cancer: an updated meta-analysis.	Platinum	124-132	methylenetetrahydrofolate reductase	Homo sapiens	13-48
24142642-1	2013	PURPOSE: Methylenetetrahydrofolate reductase (MTHFR) has been implicated in lung cancer risk and response to platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).	Platinum	109-117	methylenetetrahydrofolate reductase	Homo sapiens	9-44
24142642-1	2013	PURPOSE: Methylenetetrahydrofolate reductase (MTHFR) has been implicated in lung cancer risk and response to platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).	Platinum	109-117	methylenetetrahydrofolate reductase	Homo sapiens	46-51
24142642-3	2013	We performed meta-analysis to investigate the effect of MTHFR C677T polymorphism on lung cancer risk and response to platinum-based chemotherapy in advanced NSCLC.	Platinum	117-125	methylenetetrahydrofolate reductase	Homo sapiens	56-61
24142642-11	2013	In addition, MTHFR 677TT homozygote carriers had a better response to platinum-based chemotherapy in advanced NSCLC in the recessive model.	Platinum	70-78	methylenetetrahydrofolate reductase	Homo sapiens	13-18
24142642-12	2013	CONCLUSION: The MTHFR C677T polymorphism might be a genetic marker for lung cancer risk or response to platinum- based chemotherapy in advanced NSCLC.	Platinum	103-111	methylenetetrahydrofolate reductase	Homo sapiens	16-21
24104967-0	2013	Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents.	Platinum	122-130	proliferating cell nuclear antigen	Homo sapiens	24-58
24157868-7	2013	MT2A overexpression induced chemoresistance to cytotoxic drugs through direct chelation of platinum-containing drugs and indirect action on p53 zinc-dependent activity.	Platinum	91-99	metallothionein 2A	Homo sapiens	0-4
24144331-2	2013	ERCC1 and ERCC4 are involved in the removal of this damage and have previously been implicated in resistance to platinum compounds.	Platinum	112-120	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
24144331-2	2013	ERCC1 and ERCC4 are involved in the removal of this damage and have previously been implicated in resistance to platinum compounds.	Platinum	112-120	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	10-15
24151392-0	2013	Role of ABCG2 expression driven by cisplatin in platinum-containing chemotherapy for gastric cancer.	Platinum	48-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	8-13
24151392-1	2013	AIM: To investigate the relationship between increases in expression time of ABCG2 mRNA driven by cisplatin and efficacy of platinum-containing chemotherapy for gastric cancer.	Platinum	124-132	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	77-82
24113164-0	2013	Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells.	Platinum	60-68	fibroblast growth factor 13	Homo sapiens	26-31
24113006-10	2013	CONCLUSION: The patients with advanced lung adenocarcinoma might get benefits from pemetrexed-based or platinum-based chemotherapy after they were EGFR-TKIs resistace.	Platinum	103-111	epidermal growth factor receptor	Homo sapiens	147-151
24127322-1	2013	The platinum rule: Heterogeneous, additive-free C-3 selective alkylation of indoles by aliphatic and aromatic alcohols proceeded under transfer hydrogenation conditions with the reusable Pt/theta-Al2 O3 catalyst (see scheme; TON=turnover number).	Platinum	4-12	complement C3	Homo sapiens	48-51
23966292-1	2013	In patients with lung cancer whose tumors harbor activating mutations in the EGF receptor (EGFR), increased responses to platinum-based chemotherapies are seen compared with wild-type cancers.	Platinum	121-129	epidermal growth factor receptor	Homo sapiens	77-89
23966292-1	2013	In patients with lung cancer whose tumors harbor activating mutations in the EGF receptor (EGFR), increased responses to platinum-based chemotherapies are seen compared with wild-type cancers.	Platinum	121-129	epidermal growth factor receptor	Homo sapiens	91-95
24160625-0	2013	Spin excitations of individual Fe atoms on Pt(111): impact of the site-dependent giant substrate polarization.	Platinum	43-45	spindlin 1	Homo sapiens	0-4
24444563-0	2013	[Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].	Platinum	85-93	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	18-23
24444563-1	2013	OBJECTIVE: To explore the relationship among single nucleotide polymorphism (SNP) of excision repair cross-complementing 1(ERCC1) gene, chemotherapy sensitivity and clinical outcomes of epithelial ovarian cancer (EOC) patients treated with platinum.	Platinum	240-248	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	123-128
24444563-5	2013	RESULTS: The rs11615 C/T SNP of ERCC1, CC, CT and TT genotype frequencies were 53.1%, 45.6%, 1.4% in responders to platinum-based chemotherapy, while 52.0%, 35.6%, 12.3% in non-responders, respectively, in which there was significant difference between the two groups (P = 0.002) .	Platinum	115-123	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	32-37
24444563-12	2013	CONCLUSION: The rs11615 SNP of ERCC1 may become a valuable prognostic biomarker for EOC patients treated with platinum-based chemotherapy.	Platinum	110-118	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	31-36
24113164-0	2013	Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells.	Platinum	60-68	fibroblast growth factor 13	Homo sapiens	32-36
24113164-3	2013	When the FGF13 expression was suppressed, both the cells" resistance to platinum drugs and their ability to keep intracellular platinum low were abolished.	Platinum	72-80	fibroblast growth factor 13	Homo sapiens	9-14
24113164-3	2013	When the FGF13 expression was suppressed, both the cells" resistance to platinum drugs and their ability to keep intracellular platinum low were abolished.	Platinum	127-135	fibroblast growth factor 13	Homo sapiens	9-14
24113164-4	2013	Overexpression of FGF13 in parent cells led to greater resistance to cisplatin and reductions in the intracellular platinum concentration.	Platinum	115-123	fibroblast growth factor 13	Homo sapiens	18-23
23871345-6	2013	Microinjection of Ang II into the IML dose-dependently elevated mean blood pressure (MAP, employing a transducer-tipped catheter) and renal sympathetic nerve activity (RSNA, using a pair of platinum-iridium recording electrodes), which were completely abolished by Losartan, and attenuated by TEMPOL and apocynin.	Platinum	190-198	angiogenin	Rattus norvegicus	18-21
24113164-7	2013	These results suggest that FGF13 plays a pivotal role in mediating resistance to platinum drugs, possibly via a mechanism shared by platinum and copper.	Platinum	81-89	fibroblast growth factor 13	Homo sapiens	27-32
24113164-7	2013	These results suggest that FGF13 plays a pivotal role in mediating resistance to platinum drugs, possibly via a mechanism shared by platinum and copper.	Platinum	132-140	fibroblast growth factor 13	Homo sapiens	27-32
24124496-12	2013	Multivariate analysis revealed that SULF2 methylation was an independent prognostic factor of overall survival in gastric cancer patients treated with platinum-based chemotherapy.	Platinum	151-159	sulfatase 2	Homo sapiens	36-41
24116196-0	2013	XRCC3 Thr241Met is associated with response to platinum-based chemotherapy but not survival in advanced non-small cell lung cancer.	Platinum	47-55	X-ray repair cross complementing 3	Homo sapiens	0-5
24116196-8	2013	CONCLUSIONS: These findings suggest a predictive role of XRCC3 Thr241Met polymorphism on response to platinum-based chemotherapy in patients with advanced NSCLC.	Platinum	101-109	X-ray repair cross complementing 3	Homo sapiens	57-62
24116196-9	2013	Additionally, we first report that the XRCC3 Thr241Met polymorphism is associated with response to platinum-based chemotherapy and highlights the prognostic value of the XRCC3 Thr241Met polymorphism.	Platinum	99-107	X-ray repair cross complementing 3	Homo sapiens	39-44
24124496-14	2013	SULF2 methylation may be a novel prognostic biomarker for gastric cancer patients treated with platinum-based chemotherapy.	Platinum	95-103	sulfatase 2	Homo sapiens	0-5
24122978-3	2013	The human high-affinity copper (Cu) transporter-1 (hCtr1) can also transport Pt-based drugs including cisplatin (cDDP) and carboplatin.	Platinum	77-79	solute carrier family 31 member 1	Homo sapiens	51-56
23841470-1	2013	The remarkable success of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in patients with EGFR mutations and ALK rearrangements, respectively, introduced the era of targeted therapy in advanced non-small cell lung cancer (NSCLC), shifting treatment from platinum-based combination chemotherapy to molecularly tailored therapy.	Platinum	311-319	epidermal growth factor receptor	Homo sapiens	26-58
23841470-1	2013	The remarkable success of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in patients with EGFR mutations and ALK rearrangements, respectively, introduced the era of targeted therapy in advanced non-small cell lung cancer (NSCLC), shifting treatment from platinum-based combination chemotherapy to molecularly tailored therapy.	Platinum	311-319	epidermal growth factor receptor	Homo sapiens	60-64
23841470-1	2013	The remarkable success of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in patients with EGFR mutations and ALK rearrangements, respectively, introduced the era of targeted therapy in advanced non-small cell lung cancer (NSCLC), shifting treatment from platinum-based combination chemotherapy to molecularly tailored therapy.	Platinum	311-319	ALK receptor tyrosine kinase	Homo sapiens	70-96
23841470-1	2013	The remarkable success of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in patients with EGFR mutations and ALK rearrangements, respectively, introduced the era of targeted therapy in advanced non-small cell lung cancer (NSCLC), shifting treatment from platinum-based combination chemotherapy to molecularly tailored therapy.	Platinum	311-319	ALK receptor tyrosine kinase	Homo sapiens	98-101
23841470-1	2013	The remarkable success of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in patients with EGFR mutations and ALK rearrangements, respectively, introduced the era of targeted therapy in advanced non-small cell lung cancer (NSCLC), shifting treatment from platinum-based combination chemotherapy to molecularly tailored therapy.	Platinum	311-319	epidermal growth factor receptor	Homo sapiens	147-151
23982140-9	2013	Both the platinum compounds act early to alter the calbindin buffering system.	Platinum	9-17	calbindin 1	Rattus norvegicus	51-60
23922302-1	2013	PURPOSE: Preclinical data suggest that exposure to PARP inhibitors (PARPi) may compromise benefit to subsequent chemotherapy, particularly platinum-based regimens, in patients with BRCA1/2 mutation carrier ovarian cancer (PBMCOC), possibly through the acquisition of secondary BRCA1/2 mutations.	Platinum	139-147	collagen type XI alpha 2 chain	Homo sapiens	51-55
24197907-0	2013	The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.	Platinum	128-136	tumor protein p53 binding protein 1	Homo sapiens	24-29
23877012-7	2013	RESULTS: Phospho-AKT (serine473) expression correlated with survival from OVCA (P&lt;0.05) and platinum-response (P=0.004).	Platinum	95-103	AKT serine/threonine kinase 1	Homo sapiens	17-20
23973203-1	2013	This retrospective observational study evaluated cost effectiveness of first-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) with pemetrexed/platinum (Pem/Plat) relative to paclitaxel/carboplatin (Pac/Carbo) and paclitaxel/carboplatin/bevacizumab (Pac/Carbo/Bev).	Platinum	167-175	mucin 1, cell surface associated	Homo sapiens	177-180
24197907-0	2013	The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.	Platinum	128-136	BRCA1 DNA repair associated	Homo sapiens	34-39
24197907-5	2013	The expression of 53BP1 refines BRCA1-based predictive modeling to identify patients most likely to benefit from platinum-based chemotherapy.	Platinum	113-121	tumor protein p53 binding protein 1	Homo sapiens	18-23
24197907-5	2013	The expression of 53BP1 refines BRCA1-based predictive modeling to identify patients most likely to benefit from platinum-based chemotherapy.	Platinum	113-121	BRCA1 DNA repair associated	Homo sapiens	32-37
23617284-4	2013	Our previous studies have demonstrated the involvement of xeroderma pigmentosum group A (XPA) codon23 and xeroderma pigmentosum group D (XPD) codon751 single-nucleotide polymorphisms (SNPs) in clinical response to platinum based chemotherapy in advanced NSCLC patients.	Platinum	214-222	XPA, DNA damage recognition and repair factor	Homo sapiens	58-87
23617284-4	2013	Our previous studies have demonstrated the involvement of xeroderma pigmentosum group A (XPA) codon23 and xeroderma pigmentosum group D (XPD) codon751 single-nucleotide polymorphisms (SNPs) in clinical response to platinum based chemotherapy in advanced NSCLC patients.	Platinum	214-222	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	106-135
23617284-4	2013	Our previous studies have demonstrated the involvement of xeroderma pigmentosum group A (XPA) codon23 and xeroderma pigmentosum group D (XPD) codon751 single-nucleotide polymorphisms (SNPs) in clinical response to platinum based chemotherapy in advanced NSCLC patients.	Platinum	214-222	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	137-140
23727606-0	2013	Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.	Platinum	152-160	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	15-20
23727606-1	2013	The published data on the predictive role of ERCC1 polymorphisms in lung cancer risk and survival of patients with advanced non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy remains inconsistent.	Platinum	169-177	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	45-50
23727606-10	2013	Overall survival (OS) of patients with non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy was significantly related to ERCC1 C118T (HR: 1.29, 95% CI: 1.07-1.56, p=0.007, CT/TT vs. CC).	Platinum	84-92	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	141-146
23727606-12	2013	These findings suggest that ERCC1 C118T polymorphisms may serve as a biomarker for lung cancer risk and have prognostic value in patients with advanced non-small cell lung cancer (NSCLC) undergoing platinum-based treatment.	Platinum	198-206	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	28-33
24039787-0	2013	Epimorphin-induced MET sensitizes ovarian cancer cells to platinum.	Platinum	58-66	syntaxin 2	Homo sapiens	0-10
23045278-7	2013	We next correlated the expression level of miR-141 in 132 primary ovarian tumors (108 serous and 24 non-serous) with response to platinum-based chemotherapy.	Platinum	129-137	microRNA 141	Homo sapiens	43-50
23045278-8	2013	Although no differences were observed in the serous tumors, miR-141 levels were higher in non-serous ovarian tumors that did not respond well to therapy (platinum-free interval &lt;6 months).	Platinum	154-162	microRNA 141	Homo sapiens	60-67
23788751-1	2013	BACKGROUND: Combined inhibition of vascular, platelet-derived, and epidermal growth factor receptor (EGFR) pathways may overcome refractoriness to single agents in platinum-pretreated non-small-cell lung cancer (NSCLC).	Platinum	164-172	epidermal growth factor receptor	Homo sapiens	101-105
23962182-1	2013	The catalytic cleavage of two C-C single bonds is achieved by treatment of the hydrocarbon substrate spiro[bicyclo[2.2.1]hept-2-ene-7,1"-cyclopropane] with Pt(II) catalysts such as (Me2bpy)PtPh(NTf2) (Me2bpy = 4,4"-dimethyl-2,2"-bipyridine, NTf2(-) = N(SO2CF3)2(-)).	Platinum	156-158	nuclear transport factor 2	Homo sapiens	194-198
23962182-1	2013	The catalytic cleavage of two C-C single bonds is achieved by treatment of the hydrocarbon substrate spiro[bicyclo[2.2.1]hept-2-ene-7,1"-cyclopropane] with Pt(II) catalysts such as (Me2bpy)PtPh(NTf2) (Me2bpy = 4,4"-dimethyl-2,2"-bipyridine, NTf2(-) = N(SO2CF3)2(-)).	Platinum	156-158	nuclear transport factor 2	Homo sapiens	241-245
23942070-0	2013	Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial.	Platinum	14-22	epidermal growth factor receptor	Homo sapiens	74-106
23788751-1	2013	BACKGROUND: Combined inhibition of vascular, platelet-derived, and epidermal growth factor receptor (EGFR) pathways may overcome refractoriness to single agents in platinum-pretreated non-small-cell lung cancer (NSCLC).	Platinum	164-172	epidermal growth factor receptor	Homo sapiens	67-99
24023303-0	2013	Utility of ATP7B in prediction of response to platinum-based chemotherapy in urothelial bladder cancer.	Platinum	46-54	ATPase copper transporting beta	Homo sapiens	11-16
24023303-6	2013	Results were correlated with response to platinum-based chemotherapy: 65% of patients exhibited LOH of the ATP7B locus on chromosome 13q14.3, with a tendency to have a better response to chemotherapy.	Platinum	41-49	ATPase copper transporting beta	Homo sapiens	107-112
23787801-0	2013	KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.	Platinum	99-107	KRAS proto-oncogene, GTPase	Homo sapiens	0-4
23886447-3	2013	The main mechanism of action is related to a cellular transporter (CTR1) that plays a pivotal role in preserving the intra-cellular homeostasis, allowing at the same time the anti- tumor activity of platinum based therapies.	Platinum	199-207	solute carrier family 31 member 1	Homo sapiens	67-71
23810210-0	2013	ERCC1, MLH1, MSH2, MSH6, and betaIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.	Platinum	106-114	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
23810210-0	2013	ERCC1, MLH1, MSH2, MSH6, and betaIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.	Platinum	106-114	mutL homolog 1	Homo sapiens	7-11
23810210-0	2013	ERCC1, MLH1, MSH2, MSH6, and betaIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.	Platinum	106-114	mutS homolog 2	Homo sapiens	13-17
23810210-0	2013	ERCC1, MLH1, MSH2, MSH6, and betaIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.	Platinum	106-114	mutS homolog 6	Homo sapiens	19-23
23887170-1	2013	BACKGROUND: Data from seven recent randomized clinical trials have demonstrated that epidermal growth factor (EGFR) mutation status is predictive of improved progression-free survival and quality of life from first-line EGFR tyrosine kinase inhibitor therapy compared with platinum-based chemotherapy.	Platinum	273-281	epidermal growth factor	Homo sapiens	85-108
23887170-1	2013	BACKGROUND: Data from seven recent randomized clinical trials have demonstrated that epidermal growth factor (EGFR) mutation status is predictive of improved progression-free survival and quality of life from first-line EGFR tyrosine kinase inhibitor therapy compared with platinum-based chemotherapy.	Platinum	273-281	epidermal growth factor	Homo sapiens	110-114
24687344-4	2013	In regard to the clinical implications of MDR1 SNPs, it was found in large meta-analysis that C3435T SNP was associated with a slight increase in the susceptibility to ulcerative colitis and cancer and was related with slight modifications in tacrolimus pharmacokinetics and platinum-based chemotherapy response in lung cancer.	Platinum	275-283	ATP binding cassette subfamily B member 1	Homo sapiens	42-46
23887170-1	2013	BACKGROUND: Data from seven recent randomized clinical trials have demonstrated that epidermal growth factor (EGFR) mutation status is predictive of improved progression-free survival and quality of life from first-line EGFR tyrosine kinase inhibitor therapy compared with platinum-based chemotherapy.	Platinum	273-281	epidermal growth factor	Homo sapiens	220-224
24353711-4	2013	Our study showed response to platinum-containing regimen chemotherapy was high in those with high ERCC1 expression, and the OR (95% CI) were 1.73(1.06-2.81).	Platinum	29-37	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	98-103
23997830-6	2013	S-1 combined with CDDP or CBDCA was thought to be one of the standard platinum doublet regimens in the first-line setting for patients with advanced NSCLC in Japan.	Platinum	70-78	proteasome 26S subunit, non-ATPase 1	Homo sapiens	0-3
23751120-3	2013	In the present study, we demonstrate that cisplatin and a related platinum drug carboplatin produce the same adduct following reaction with MBD2 [metal-binding domain (repeat) 2], where platinum is bound to the side chains of the cysteine residues in the CxxC copper-binding motif.	Platinum	66-74	methyl-CpG binding domain protein 2	Homo sapiens	140-144
23500477-1	2013	A novel highly sensitive impedimetric Myelin Basic Protein (MBP) immunosensor for the determination of a Multiple Sclerosis (MS) autoantibody, Anti-Myelin Basic Protein (Anti-MBP) was developed by immobilization of MBP on Gelatin and Gelatin-Titanium Dioxide (TiO2) modified platinium electrode.	Platinum	275-284	myelin basic protein	Homo sapiens	38-58
23500477-1	2013	A novel highly sensitive impedimetric Myelin Basic Protein (MBP) immunosensor for the determination of a Multiple Sclerosis (MS) autoantibody, Anti-Myelin Basic Protein (Anti-MBP) was developed by immobilization of MBP on Gelatin and Gelatin-Titanium Dioxide (TiO2) modified platinium electrode.	Platinum	275-284	myelin basic protein	Homo sapiens	60-63
23500477-1	2013	A novel highly sensitive impedimetric Myelin Basic Protein (MBP) immunosensor for the determination of a Multiple Sclerosis (MS) autoantibody, Anti-Myelin Basic Protein (Anti-MBP) was developed by immobilization of MBP on Gelatin and Gelatin-Titanium Dioxide (TiO2) modified platinium electrode.	Platinum	275-284	myelin basic protein	Homo sapiens	148-168
23500477-1	2013	A novel highly sensitive impedimetric Myelin Basic Protein (MBP) immunosensor for the determination of a Multiple Sclerosis (MS) autoantibody, Anti-Myelin Basic Protein (Anti-MBP) was developed by immobilization of MBP on Gelatin and Gelatin-Titanium Dioxide (TiO2) modified platinium electrode.	Platinum	275-284	myelin basic protein	Homo sapiens	175-178
23500477-1	2013	A novel highly sensitive impedimetric Myelin Basic Protein (MBP) immunosensor for the determination of a Multiple Sclerosis (MS) autoantibody, Anti-Myelin Basic Protein (Anti-MBP) was developed by immobilization of MBP on Gelatin and Gelatin-Titanium Dioxide (TiO2) modified platinium electrode.	Platinum	275-284	myelin basic protein	Homo sapiens	175-178
23500477-3	2013	Gelatin-MBP and gelatin-TiO2-MBP electrodes were prepared by chemical immobilization of the substrates onto the platinium electrodes.	Platinum	112-121	myelin basic protein	Homo sapiens	29-32
23977265-0	2013	Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis.	Platinum	41-49	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	20-23
23977265-1	2013	BACKGROUND: The correlation between xeroderma pigmentosum group D (XPD) polymorphisms (Lys751Gln and Asp312Asn) and clinical outcomes of non-small cell lung cancer (NSCLC) patients, who received platinum-based chemotherapy (Pt-chemotherapy), is still inconclusive.	Platinum	195-203	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	67-70
23977265-10	2013	CONCLUSIONS: These results suggest that XPD Asp312Asn polymorphism may function as a predictive biomarker on platinum-based chemotherapy in NSCLC and further studies are warranted.	Platinum	109-117	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	40-43
23751120-5	2013	Platinum can also be transferred to MBD2 from copper chaperone Atox1, which was shown previously to bind cisplatin.	Platinum	0-8	antioxidant 1 copper chaperone	Homo sapiens	63-68
23751120-6	2013	Binding of the free cisplatin and reaction with the cisplatin-loaded Atox1 produce the same protein-bound platinum intermediate.	Platinum	106-114	antioxidant 1 copper chaperone	Homo sapiens	69-74
23751120-7	2013	Transfer of platinum along the copper-transport pathways in the cell may serve as a mechanism of drug delivery to its target in the cell nucleus, and explain tumour-cell resistance to cisplatin associated with the overexpression of copper transporters ATP7B and ATP7A.	Platinum	12-20	ATPase copper transporting beta	Homo sapiens	252-257
23751120-7	2013	Transfer of platinum along the copper-transport pathways in the cell may serve as a mechanism of drug delivery to its target in the cell nucleus, and explain tumour-cell resistance to cisplatin associated with the overexpression of copper transporters ATP7B and ATP7A.	Platinum	12-20	ATPase copper transporting alpha	Homo sapiens	262-267
23751120-5	2013	Platinum can also be transferred to MBD2 from copper chaperone Atox1, which was shown previously to bind cisplatin.	Platinum	0-8	methyl-CpG binding domain protein 2	Homo sapiens	36-40
23806103-4	2013	When cycled reductively in 0.1 M HClO4, FTO electrodes derivatized with Pt and Pd reached current densities for hydrogen evolution of 18.3 and 13.2 mA/cm(2), respectively, at -0.6 V vs normal hydrogen electrode (NHE).	Platinum	72-74	solute carrier family 9 member C1	Homo sapiens	212-215
23833300-10	2013	Patients with advanced NSCLC with BRAF mutations and wild-type tumors showed similar response rates and progression-free survival (PFS) to platinum-based combination chemotherapy and no difference in overall survival.	Platinum	139-147	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	34-38
23833300-11	2013	Within the BRAF cohort, patients with V600E-mutated tumors had a shorter PFS to platinum-based chemotherapy compared with those with non-V600E mutations, although this did not reach statistical significance (4.1 vs. 8.9 months; P = 0.297).	Platinum	80-88	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	11-15
23771151-7	2013	In a full cell testing, the fabricated novel electrode with extra-low Pt loading (0.043 mg cm(-2)) generated power as 1.21 kW g(-1)Pt when it is used as the cathode in a fuel cell.	Platinum	70-72	dolichyl-phosphate N-acetylglucosaminephosphotransferase 1	Homo sapiens	126-133
23964347-1	2013	PURPOSE: BRCA1/BRCA2 germline mutations appear to enhance the platinum-sensitivity, but little is known about the prognostic relevance of polymorphisms in BRCA1/BRCA2 in epithelial ovarian cancer (EOC).	Platinum	62-70	BRCA1 DNA repair associated	Homo sapiens	9-14
23964347-1	2013	PURPOSE: BRCA1/BRCA2 germline mutations appear to enhance the platinum-sensitivity, but little is known about the prognostic relevance of polymorphisms in BRCA1/BRCA2 in epithelial ovarian cancer (EOC).	Platinum	62-70	BRCA2 DNA repair associated	Homo sapiens	15-20
23951333-11	2013	RECQL1-siRNA may offer a new therapeutic strategy against various subtypes of OC, including platinum-resistant cancers, or in recurrent cancers that gain platinum resistance.	Platinum	92-100	RecQ like helicase	Homo sapiens	0-6
23951333-11	2013	RECQL1-siRNA may offer a new therapeutic strategy against various subtypes of OC, including platinum-resistant cancers, or in recurrent cancers that gain platinum resistance.	Platinum	154-162	RecQ like helicase	Homo sapiens	0-6
23576093-7	2013	These results provide some solid experimental evidence for the associative reaction mechanism of WGS and PROX reactions catalyzed by Pt/oxide catalysts.	Platinum	133-135	pyruvate dehydrogenase complex component X	Homo sapiens	105-109
23940523-0	2013	XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis.	Platinum	79-87	X-ray repair cross complementing 3	Homo sapiens	0-5
23940523-2	2013	Published evidence has shown controversial results about the relationship between XRCC3 Thr241Met polymorphism and clinical outcomes of non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy.	Platinum	190-198	X-ray repair cross complementing 3	Homo sapiens	82-87
23940741-0	2013	Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy.	Platinum	99-107	epidermal growth factor receptor	Homo sapiens	20-24
23940523-3	2013	METHODS: A systematic review and meta-analysis was performed to evaluate the predictive value of XRCC3 Thr241Met polymorphism on clinical outcomes of advanced NSCLC receiving platinum-based chemotherapy.	Platinum	175-183	X-ray repair cross complementing 3	Homo sapiens	97-102
23940741-0	2013	Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy.	Platinum	99-107	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	38-43
23940523-6	2013	Carriers of the variant XRCC3 241Met allele were significantly associated with good response to platinum-based chemotherapy (ThrMet/MetMet vs. ThrThr: OR  = 1.509, 95% CI: 1.099-2.072, Pheterogeneity  = 0.618).	Platinum	96-104	X-ray repair cross complementing 3	Homo sapiens	24-29
23940741-2	2013	The aim of this study was to assess the role of EGFR mutations and ERCC1 in predicting the efficacy of platinum-based chemotherapy and the outcome of patients with NSCLC.	Platinum	103-111	epidermal growth factor receptor	Homo sapiens	48-52
23940741-2	2013	The aim of this study was to assess the role of EGFR mutations and ERCC1 in predicting the efficacy of platinum-based chemotherapy and the outcome of patients with NSCLC.	Platinum	103-111	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	67-72
23940523-9	2013	CONCLUSIONS: This systematic review and meta-analysis shows that carriers of the XRCC3 241Met allele are associated with good response to platinum-based chemotherapy in advanced NSCLC, while the XRCC3 Thr241Met polymorphism is not associated with OS or PFS.	Platinum	138-146	X-ray repair cross complementing 3	Homo sapiens	81-86
23940741-3	2013	METHODS: We conducted a retrospective study to analyze the relationships between EGFR mutations or ERCC1 expression and progression-free survival (PFS) in patients with NSCLC who received platinum-based chemotherapy.	Platinum	188-196	epidermal growth factor receptor	Homo sapiens	81-85
23940741-3	2013	METHODS: We conducted a retrospective study to analyze the relationships between EGFR mutations or ERCC1 expression and progression-free survival (PFS) in patients with NSCLC who received platinum-based chemotherapy.	Platinum	188-196	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	99-104
23969971-6	2013	The STAT3 pathway responded early to platinum drugs associated with cisplatin resistance in epithelial ovarian cancer and provided a rationale for new therapeutic strategies to reverse cisplatin resistance.	Platinum	37-45	signal transducer and activator of transcription 3	Homo sapiens	4-9
23940741-9	2013	Our findings suggest that platinum-based chemotherapy is more effective against ERCC1-negative and exon 19-positive NSCLC.	Platinum	26-34	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	80-85
23720056-0	2013	TR3 modulates platinum resistance in ovarian cancer.	Platinum	14-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-3
23720056-4	2013	Moreover, TR3 expression was significantly lower in platinum-resistant tumors in patients with metastatic disease, and low TR3 staining was associated with poorer overall and progression-free survival.	Platinum	52-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	10-13
23720056-11	2013	Our results suggest that disruption of TR3 activity, via downregulation or nuclear sequestration, likely contributes to platinum resistance in ovarian cancer.	Platinum	120-128	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-42
23720056-12	2013	Moreover, we have described a treatment strategy aimed at overcoming platinum resistance by targeting TR3.	Platinum	69-77	nuclear receptor subfamily 4 group A member 1	Homo sapiens	102-105
23969971-0	2013	Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer.	Platinum	40-48	signal transducer and activator of transcription 3	Homo sapiens	23-28
23598363-0	2013	Rescue of platinum-damaged oocytes from programmed cell death through inactivation of the p53 family signaling network.	Platinum	10-18	transformation related protein 53, pseudogene	Mus musculus	90-93
23697579-2	2013	Here we describe the development of a polymeric NP, termed M-NP, comprising poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-PEG), stabilized with poly(vinyl alcohol) (PVA), and loaded with a water-soluble platinum(IV) [Pt(IV)] prodrug, mitaplatin.	Platinum	225-233	modifier of Niemann Pick type C1	Mus musculus	59-63
23595127-11	2013	Among these factors, only LRP, P-gp and TNF-alpha were associated with response to platinum-based chemotherapy.	Platinum	83-91	protein tyrosine phosphatase receptor type A	Homo sapiens	26-29
23595127-11	2013	Among these factors, only LRP, P-gp and TNF-alpha were associated with response to platinum-based chemotherapy.	Platinum	83-91	phosphoglycolate phosphatase	Homo sapiens	31-35
23595127-11	2013	Among these factors, only LRP, P-gp and TNF-alpha were associated with response to platinum-based chemotherapy.	Platinum	83-91	tumor necrosis factor	Homo sapiens	40-49
23564483-0	2013	Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer.	Platinum	56-64	peroxiredoxin 3	Homo sapiens	0-17
23564483-4	2013	PRX III expression was immunohistochemically determined in paraffin-embedded specimens from platinum-resistant (Pt-resistant) and platinum-sensitive (Pt-sensitive) patients.	Platinum	92-100	peroxiredoxin 3	Homo sapiens	0-7
23564483-4	2013	PRX III expression was immunohistochemically determined in paraffin-embedded specimens from platinum-resistant (Pt-resistant) and platinum-sensitive (Pt-sensitive) patients.	Platinum	112-114	peroxiredoxin 3	Homo sapiens	0-7
23564483-4	2013	PRX III expression was immunohistochemically determined in paraffin-embedded specimens from platinum-resistant (Pt-resistant) and platinum-sensitive (Pt-sensitive) patients.	Platinum	130-138	peroxiredoxin 3	Homo sapiens	0-7
23564483-4	2013	PRX III expression was immunohistochemically determined in paraffin-embedded specimens from platinum-resistant (Pt-resistant) and platinum-sensitive (Pt-sensitive) patients.	Platinum	150-152	peroxiredoxin 3	Homo sapiens	0-7
23564483-7	2013	PRX III protein was significantly higher in the Pt-resistant serous carcinomas, in moderately and poorly differentiated, and in stage III and IV ovarian cancer tissues compared to the Pt-sensitive group.	Platinum	48-50	peroxiredoxin 3	Homo sapiens	0-7
23084098-5	2013	According to the results of available meta-analyses, platinum-based chemotherapy should be considered the standard of care for the treatment of SCLC.	Platinum	53-61	SCLC1	Homo sapiens	144-148
23084098-6	2013	Cisplatin and carboplatin have shown similar efficacy, and the choice of the platinum compound for the treatment of patients with extensive stage SCLC should consider the expected toxicity profile, organ function, performance status, and comorbidities.	Platinum	77-85	SCLC1	Homo sapiens	146-150
23632208-0	2013	The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.	Platinum	87-95	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	51-56
23632208-1	2013	OBJECTIVE: This study aims to assess the role of polymorphisms in DNA repair genes, excision repair cross-complementation group 1 (ERCC1) and methyl-methanesulfonate sensitivity 19 (MMS19), in tumor response to platinum-based chemotherapy and survival in advanced epithelial ovarian cancer (EOC).	Platinum	211-219	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	84-129
23632208-1	2013	OBJECTIVE: This study aims to assess the role of polymorphisms in DNA repair genes, excision repair cross-complementation group 1 (ERCC1) and methyl-methanesulfonate sensitivity 19 (MMS19), in tumor response to platinum-based chemotherapy and survival in advanced epithelial ovarian cancer (EOC).	Platinum	211-219	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	131-136
23624523-12	2013	Higher frequency of IL-17-positive TICI might persist in recurrent tumor tissues of chemosensitive biopsies, suggesting repetitive platinum-based chemotherapy as an appropriate therapy for patients with IL-17-positive recurrences.	Platinum	131-139	interleukin 17A	Homo sapiens	20-25
23624523-12	2013	Higher frequency of IL-17-positive TICI might persist in recurrent tumor tissues of chemosensitive biopsies, suggesting repetitive platinum-based chemotherapy as an appropriate therapy for patients with IL-17-positive recurrences.	Platinum	131-139	interleukin 17A	Homo sapiens	203-208
23757163-4	2013	In addition, overexpression of OATP1B3 in mammalian cells increased cellular accumulation of platinum agents and decreased cell survival.	Platinum	93-101	solute carrier organic anion transporter family member 1B3	Homo sapiens	31-38
23936210-0	2013	Determinants for simultaneous binding of copper and platinum to human chaperone Atox1: hitchhiking not hijacking.	Platinum	52-60	antioxidant 1 copper chaperone	Homo sapiens	80-85
23697579-4	2013	An optimized preparation of M-NP by double emulsion and its physical characterization are reported, and the influence of encapsulation on the properties of the platinum agent is evaluated in vivo.	Platinum	160-168	modifier of Niemann Pick type C1	Mus musculus	28-32
23583215-0	2013	Class III beta-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.	Platinum	124-132	tubulin beta 3 class III	Homo sapiens	0-22
23585021-0	2013	Tubulin-beta-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.	Platinum	105-113	tubulin beta 3 class III	Homo sapiens	0-16
24125975-1	2013	CONTEXT: The excision repair cross-complementation group 1 (ERCC1) codon 118 C/T polymorphism has been associated with clinical outcome in cancer patients treated with platinum chemotherapy.	Platinum	168-176	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	13-58
23522953-1	2013	BACKGROUND: The aim of this study was to explore the association between vitamin D receptor (VDR) genetic polymorphisms and platinum-based chemotherapy response as well as the prognosis of non-small-cell lung cancer (NSCLC) in a Chinese cohort.	Platinum	124-132	vitamin D receptor	Homo sapiens	73-91
23522953-1	2013	BACKGROUND: The aim of this study was to explore the association between vitamin D receptor (VDR) genetic polymorphisms and platinum-based chemotherapy response as well as the prognosis of non-small-cell lung cancer (NSCLC) in a Chinese cohort.	Platinum	124-132	vitamin D receptor	Homo sapiens	93-96
23636450-1	2013	PURPOSE: Defective expression of the mismatch repair protein MSH3 is frequently detected in colon cancer, and down-regulation of its expression was found to decrease sensitivity to platinum compounds or poly(ADP-ribose) polymerase inhibitors (PARPi) monotherapy.	Platinum	181-189	mutS homolog 3	Homo sapiens	61-65
23636450-7	2013	MSH3-proficient HCT116+5 or HCT116+3+5 cells, which were more resistant to oxaliplatin and PARPi in comparison with their MSH3-deficient counterparts, expressed higher levels of the nucleotide excision repair ERCC1 and XPF proteins, involved in the resistance to platinum compounds, and lower PARP-1 levels.	Platinum	263-271	mutS homolog 3	Homo sapiens	0-4
23649003-2	2013	We sought to determine the efficacy of platinum-based chemotherapy in patients meeting at least one of seven prospectively defined "anaplastic" clinical criteria, including exclusive visceral or predominantly lytic bone metastases, bulky tumor masses, low prostate-specific antigen levels relative to tumor burden, or short response to androgen deprivation therapy.	Platinum	39-47	kallikrein related peptidase 3	Homo sapiens	256-281
23680713-5	2013	The anti-HER-2 antibody, trastuzumab, when added to a chemotherapeutic regimen combining a fluoropyrimidine and platinum, provides a survival benefit for those patients with HER-2 overexpression and/or amplification.	Platinum	112-120	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-14
24125975-1	2013	CONTEXT: The excision repair cross-complementation group 1 (ERCC1) codon 118 C/T polymorphism has been associated with clinical outcome in cancer patients treated with platinum chemotherapy.	Platinum	168-176	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	60-65
23763463-2	2013	This transformation is brought about by Pt-catalyzed asymmetric addition of B2(pin)2 across the imine double bond.	Platinum	40-42	telomeric repeat binding factor 1	Homo sapiens	76-84
23853482-7	2013	Among patients who received palliative platinum-based doublet chemotherapy, progression free survival (PFS) was longer in the low-TG2 group than in the high-TG2 group (11.0 vs. 7.0 months; P=0.330).	Platinum	39-47	transglutaminase 2	Homo sapiens	130-133
23853482-7	2013	Among patients who received palliative platinum-based doublet chemotherapy, progression free survival (PFS) was longer in the low-TG2 group than in the high-TG2 group (11.0 vs. 7.0 months; P=0.330).	Platinum	39-47	transglutaminase 2	Homo sapiens	157-160
23816907-4	2013	A quantum efficiency (QE) as high as 93 per cent at 420 nm for H2 production has been achieved for Pt-PdS/CdS, where Pt and PdS, respectively, act as reduction and oxidation cocatalysts and CdS as a photo-harvester.	Platinum	99-101	CDP-diacylglycerol synthase 1	Homo sapiens	106-109
23816907-4	2013	A quantum efficiency (QE) as high as 93 per cent at 420 nm for H2 production has been achieved for Pt-PdS/CdS, where Pt and PdS, respectively, act as reduction and oxidation cocatalysts and CdS as a photo-harvester.	Platinum	99-101	CDP-diacylglycerol synthase 1	Homo sapiens	190-193
23523421-2	2013	Excision repair cross-complementation group 1 (ERCC1) is a predictive marker for platinum-based chemotherapy.	Platinum	81-89	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-45
23523421-2	2013	Excision repair cross-complementation group 1 (ERCC1) is a predictive marker for platinum-based chemotherapy.	Platinum	81-89	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
23225521-6	2013	In ovarian cancer, 48% of the tumors were positive for XRCC1 expression and significantly associated with higher stage (p = 0.006), serous type tumors (p = 0.008), suboptimal de-bulking (p = 0.004) and platinum resistance (p &lt; 0.0001).	Platinum	202-210	X-ray repair cross complementing 1	Homo sapiens	55-60
23800275-7	2013	CONCLUSION: Altogether, these results suggest that the levels of RPS4X could be a good indicator for resistance to platinum-based therapy and a prognostic marker for ovarian cancer.	Platinum	115-123	ribosomal protein S4 X-linked	Homo sapiens	65-70
23499967-1	2013	A sensitive amperometric acetylcholinesterase (AChE) biosensor based on platinum nanoparticles (Pt NPs), carboxylic graphene (CGR), and nafion (NF)-modified glassy carbon electrode (GCE) has been developed.	Platinum	72-80	acetylcholinesterase (Cartwright blood group)	Homo sapiens	47-51
23660647-1	2013	An X-ray investigation has been performed with the aim of characterizing the binding sites of a platinum-based inhibitor (K[PtCl3(DMSO)]) of matrix metalloproteinase-3 (stromelysin-1).	Platinum	96-104	matrix metallopeptidase 3	Homo sapiens	169-182
23611190-4	2013	Co3O4 nanorods anchoring Pt atoms (Pt/Co3O4) are active for WGS with a low Ea of 50.1 +- 5.0 kJ mol(-1) in the temperature range of 150-200  C. The active surface of this catalyst is singly dispersed Pt1Co(n) nanoclusters anchored on Co3O4 (Pt1/Co3O4), evidenced by in situ studies of extended X-ray absorption fine structure spectroscopy.	Platinum	25-27	zinc finger protein 77	Homo sapiens	241-250
23762305-11	2013	CONCLUSION: PPI and EVO both could inhibit the activity of freshly-removed gastric tumor, and they could enhance the anticancer effect of Pt and 5-FU by reducing the mRNA expression levels of ERCC1 and TS.	Platinum	138-140	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	192-197
26283119-3	2013	Using the CoS2 counter electrode, CdS/CdSe-sensitized QDSSCs display improved short-circuit photocurrent density and fill factor, achieving solar light-to-electricity conversion efficiencies as high as 4.16%, with an average efficiency improvement of 54 (+-14)% over equivalent devices assembled with a traditional platinum counter electrode.	Platinum	315-323	CDP-diacylglycerol synthase 1	Homo sapiens	34-37
23611190-4	2013	Co3O4 nanorods anchoring Pt atoms (Pt/Co3O4) are active for WGS with a low Ea of 50.1 +- 5.0 kJ mol(-1) in the temperature range of 150-200  C. The active surface of this catalyst is singly dispersed Pt1Co(n) nanoclusters anchored on Co3O4 (Pt1/Co3O4), evidenced by in situ studies of extended X-ray absorption fine structure spectroscopy.	Platinum	35-37	zinc finger protein 77	Homo sapiens	241-250
22623275-1	2013	Cetuximab, a chimeric IgG1 monoclonal antibody against the epidermal growth factor receptor, is indicated for the treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer and recurrent or metastatic squamous cell cancer of the head and neck after failure of platinum-based therapy.	Platinum	287-295	epidermal growth factor receptor	Homo sapiens	59-91
23474348-0	2013	Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.	Platinum	79-87	folate receptor alpha	Homo sapiens	44-65
23556474-0	2013	Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo.	Platinum	91-99	solute carrier family 31 member 1	Rattus norvegicus	45-65
23556474-1	2013	The purpose of the present study was to determine whether copper histidine could inhibit copper transporter 1 (Ctr1)-mediated transport of oxaliplatin in vitro and thereby limit the accumulation of platinum and neurotoxicity of oxaliplatin in dorsal root ganglion (DRG) tissue in vivo.	Platinum	198-206	solute carrier family 31 member 1	Rattus norvegicus	89-109
23556474-1	2013	The purpose of the present study was to determine whether copper histidine could inhibit copper transporter 1 (Ctr1)-mediated transport of oxaliplatin in vitro and thereby limit the accumulation of platinum and neurotoxicity of oxaliplatin in dorsal root ganglion (DRG) tissue in vivo.	Platinum	198-206	solute carrier family 31 member 1	Rattus norvegicus	111-115
22740347-1	2013	BACKGROUND: High expression of excision repair cross-complementation 1 (ERCC1) predicts for resistance to platinum-based chemotherapy or chemoradiotherapy.	Platinum	106-114	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	31-70
22740347-1	2013	BACKGROUND: High expression of excision repair cross-complementation 1 (ERCC1) predicts for resistance to platinum-based chemotherapy or chemoradiotherapy.	Platinum	106-114	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	72-77
22358390-2	2013	METHODS: Immunohistochemistal staining was used to examine the expression of TUBB3 in resected lung tumor specimens obtained from 56 patients treated with platinum-based chemotherapy against recurrent tumors after curative resections.	Platinum	155-163	tubulin beta 3 class III	Homo sapiens	77-82
23666017-1	2013	OBJECTIVES: (1) To determine whether use of a PARP inhibitor or (2) BRCA1/2 mutation testing followed by a PARP inhibitor for test positives is potentially cost-effective for maintenance treatment of platinum-sensitive recurrent high-grade serous ovarian cancer.	Platinum	200-208	BRCA1 DNA repair associated	Homo sapiens	68-73
23666017-1	2013	OBJECTIVES: (1) To determine whether use of a PARP inhibitor or (2) BRCA1/2 mutation testing followed by a PARP inhibitor for test positives is potentially cost-effective for maintenance treatment of platinum-sensitive recurrent high-grade serous ovarian cancer.	Platinum	200-208	collagen type XI alpha 2 chain	Homo sapiens	107-111
23494670-8	2013	The MVD of PECAM-1 is also a potential predictor for NSCLC patients treated with first-line platinum-based doublet chemotherapy, as high PECAM-1 MVD correlated with worse overall survival.	Platinum	92-100	platelet and endothelial cell adhesion molecule 1	Homo sapiens	11-18
23510626-0	2013	XBP1 promoter polymorphism modulates platinum-based chemotherapy gastrointestinal toxicity for advanced non-small cell lung cancer patients.	Platinum	37-45	X-box binding protein 1	Homo sapiens	0-4
23510626-2	2013	Here, we investigated whether the regulatory variant rs2269577 of the XBP1 gene influences clinical outcome in advanced non-small cell lung cancer (NSCLC) patients undergoing platinum-based chemotherapy.	Platinum	175-183	X-box binding protein 1	Homo sapiens	70-74
23510626-8	2013	CONCLUSION: This is the first study to evaluate the effect of XBP1 polymorphism on severe chemotherapy-related adverse outcomes in platinum-treated advanced NSCLC patients using both pharmacogenomics and functional molecular analyses.	Platinum	131-139	X-box binding protein 1	Homo sapiens	62-66
23543413-0	2013	A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells.	Platinum	85-93	solute carrier family 31 member 1	Homo sapiens	31-36
23543413-7	2013	We confirm the correlation between higher hCTR1 levels and higher platinum drug uptake in tumor cells sensitive to the drug.	Platinum	66-74	solute carrier family 31 member 1	Homo sapiens	42-47
23702380-1	2013	The excision repair cross-complementation 1 (ERCC1) enzyme plays an essential role in the nucleotide excision repair pathway and is associated with resistance to platinum-based chemotherapy in different types of cancer.	Platinum	162-170	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	45-50
23494670-8	2013	The MVD of PECAM-1 is also a potential predictor for NSCLC patients treated with first-line platinum-based doublet chemotherapy, as high PECAM-1 MVD correlated with worse overall survival.	Platinum	92-100	platelet and endothelial cell adhesion molecule 1	Homo sapiens	137-144
23652306-7	2013	CONCLUSION: Steroid receptor coactivator 3 is a poor prognostic factor in EOCs and appears to identify a population of patients who would benefit from the addition of taxanes to their chemotherapy regimen, due to intrinsic resistance to platinum therapy.	Platinum	237-245	nuclear receptor coactivator 3	Homo sapiens	12-42
23408559-4	2013	Exact cone angles were evaluated for a wide array of phosphine and amine ligands bound to palladium, nickel, or platinum by optimizing structures using B3LYP/6-31G* density functional theory with effective core potentials for the transition metals.	Platinum	112-120	protein tyrosine phosphatase non-receptor type 22	Homo sapiens	154-157
25806229-1	2013	The backbone of first-line treatment for Epidermal Growth Factor (EGFR) wild-type (wt) advanced Non-small cell lung cancer (NSCLC) patients is the use of a platinum-based chemotherapy combination.	Platinum	156-164	epidermal growth factor	Homo sapiens	41-64
25806229-1	2013	The backbone of first-line treatment for Epidermal Growth Factor (EGFR) wild-type (wt) advanced Non-small cell lung cancer (NSCLC) patients is the use of a platinum-based chemotherapy combination.	Platinum	156-164	epidermal growth factor	Homo sapiens	66-70
23408298-1	2013	BACKGROUND: Activation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in head and neck cancers, and it has been demonstrated that inhibition of mTOR complex 1 sensitizes cell lines to platinum and taxane chemotherapy.	Platinum	240-248	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	30-59
23642142-0	2013	Interaction between platinum complexes and the C-terminal motif of human copper transporter 1.	Platinum	20-28	solute carrier family 31 member 1	Homo sapiens	73-93
23642142-10	2013	These findings provide insight into the mechanism of the C-terminus of hCTR1 in the transfer of platinum drugs from the trimeric pore of hCTR1 to the cytoplasm.	Platinum	96-104	solute carrier family 31 member 1	Homo sapiens	71-76
23642142-10	2013	These findings provide insight into the mechanism of the C-terminus of hCTR1 in the transfer of platinum drugs from the trimeric pore of hCTR1 to the cytoplasm.	Platinum	96-104	solute carrier family 31 member 1	Homo sapiens	137-142
26282962-1	2013	ATR-SEIRAS is extended for the first time to study potential-induced surface and interface structure variation of a CO-covered Pt electrode in a room-temperature ionic liquid of N-butyl-N-methyl-piperidinium bis((trifluoromethyl)sulfonyl)imide (or [Pip14][TNf2]).	Platinum	127-129	ATR serine/threonine kinase	Homo sapiens	0-3
23720710-3	2013	Pre-clinical models have demonstrated that many chemotherapy drugs, such as platinum-based agents, antracyclines, and taxanes, promote the activation of the NF-kappaB pathway.	Platinum	76-84	nuclear factor kappa B subunit 1	Homo sapiens	157-166
23408298-1	2013	BACKGROUND: Activation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in head and neck cancers, and it has been demonstrated that inhibition of mTOR complex 1 sensitizes cell lines to platinum and taxane chemotherapy.	Platinum	240-248	AKT serine/threonine kinase 1	Homo sapiens	67-70
23408298-1	2013	BACKGROUND: Activation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in head and neck cancers, and it has been demonstrated that inhibition of mTOR complex 1 sensitizes cell lines to platinum and taxane chemotherapy.	Platinum	240-248	mechanistic target of rapamycin kinase	Homo sapiens	71-100
23408298-1	2013	BACKGROUND: Activation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in head and neck cancers, and it has been demonstrated that inhibition of mTOR complex 1 sensitizes cell lines to platinum and taxane chemotherapy.	Platinum	240-248	mechanistic target of rapamycin kinase	Homo sapiens	102-106
23408298-1	2013	BACKGROUND: Activation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in head and neck cancers, and it has been demonstrated that inhibition of mTOR complex 1 sensitizes cell lines to platinum and taxane chemotherapy.	Platinum	240-248	mechanistic target of rapamycin kinase	Homo sapiens	200-204
23277484-12	2013	Furthermore, tumors with EML4-ALK fusions had significantly higher levels of ERCC1, a molecule with a key role in platinum drug efficacy, than tumors without EML4-ALK fusions.	Platinum	114-122	EMAP like 4	Homo sapiens	25-29
23549423-5	2013	When the photocatalytic properties of m-Pt-WO3 nanohybrids were systematically investigated, it was revealed that the m-Pt-WO3 nanohybrids showed great promise for degrading the organic dye under visible light irradiation, which shows an excellent photocatalytic activity that far exceeded those of pure phase mesoporous WO3 and commercial TiO2 (P25), and was 10-fold more active than that of the bulk Pt-WO3 catalyst.	Platinum	40-42	tubulin polymerization promoting protein	Homo sapiens	346-349
23277484-12	2013	Furthermore, tumors with EML4-ALK fusions had significantly higher levels of ERCC1, a molecule with a key role in platinum drug efficacy, than tumors without EML4-ALK fusions.	Platinum	114-122	ALK receptor tyrosine kinase	Homo sapiens	30-33
23277484-12	2013	Furthermore, tumors with EML4-ALK fusions had significantly higher levels of ERCC1, a molecule with a key role in platinum drug efficacy, than tumors without EML4-ALK fusions.	Platinum	114-122	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	77-82
23585472-7	2013	In vitro mechanistic studies on cellular platinum content and cisplatin efflux kinetics indicated that ATP11B enhances the export of cisplatin from cells.	Platinum	41-49	ATPase phospholipid transporting 11B (putative)	Homo sapiens	103-109
23479135-5	2013	RESULTS: Logistic regression analysis showed that subjects with the XRCC1-399 A allele had a significantly better response to platinum-based chemotherapy than those with the XRCC1-399 GG genotype (AA/AG vs. GG: adjusted OR = 2.35, 95 % CI = 1.11-5.00).	Platinum	126-134	X-ray repair cross complementing 1	Homo sapiens	68-73
23479135-8	2013	CONCLUSIONS: We found that XRCC1 Arg399Gln, PARP1 Va1762Ala and APE1 Asp148Glu SNPs in the BER pathway may influence the prognosis of advanced NSCLC patients following platinum-based chemotherapy.	Platinum	168-176	X-ray repair cross complementing 1	Homo sapiens	27-32
23479135-8	2013	CONCLUSIONS: We found that XRCC1 Arg399Gln, PARP1 Va1762Ala and APE1 Asp148Glu SNPs in the BER pathway may influence the prognosis of advanced NSCLC patients following platinum-based chemotherapy.	Platinum	168-176	poly(ADP-ribose) polymerase 1	Homo sapiens	44-49
23479135-8	2013	CONCLUSIONS: We found that XRCC1 Arg399Gln, PARP1 Va1762Ala and APE1 Asp148Glu SNPs in the BER pathway may influence the prognosis of advanced NSCLC patients following platinum-based chemotherapy.	Platinum	168-176	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	64-68
23683257-7	2013	Platinum-based doublet chemotherapy continues to be the standard of care for those treatment-naive patients with EGFR wild -type tumor or unknown EGFR status.	Platinum	0-8	epidermal growth factor receptor	Homo sapiens	113-117
23683257-7	2013	Platinum-based doublet chemotherapy continues to be the standard of care for those treatment-naive patients with EGFR wild -type tumor or unknown EGFR status.	Platinum	0-8	epidermal growth factor receptor	Homo sapiens	146-150
23645741-4	2013	Moreover, TYMS copy number was significantly lower in clinical NSCLC samples responsive to treatment with pemetrexed combined with platinum drugs (p=0.0067).	Platinum	131-139	thymidylate synthetase	Homo sapiens	10-14
23645741-5	2013	Furthermore, the decrease in the baseline CT size measurement of pemetrexed combined with platinum drug treatment correlated significantly with TYMS copy number (r=0.7967, p=0.0011).	Platinum	90-98	thymidylate synthetase	Homo sapiens	144-148
23518861-1	2013	OBJECTIVE: Protein phosphatase 2A (PP2A) is a target for cisplatin, which is a widely used platinum drug to treat various cancer, including ovarian cancer.	Platinum	91-99	protein phosphatase 2 phosphatase activator	Homo sapiens	19-33
23518861-1	2013	OBJECTIVE: Protein phosphatase 2A (PP2A) is a target for cisplatin, which is a widely used platinum drug to treat various cancer, including ovarian cancer.	Platinum	91-99	protein phosphatase 2 phosphatase activator	Homo sapiens	35-39
23585472-0	2013	ATP11B mediates platinum resistance in ovarian cancer.	Platinum	16-24	ATPase phospholipid transporting 11B (putative)	Homo sapiens	0-6
23436796-9	2013	Hence, concomitant therapy with COX inhibitors and/or IL-6R antibodies might increase the clinical effect of platinum-based chemotherapy in otherwise resistant tumors.	Platinum	109-117	interleukin 6 receptor	Homo sapiens	54-59
23633922-10	2013	Moreover, DA or the DR1 agonist SKF 82958 increased platinum concentration in SKOV3ip1 tumor xenografts following cisplatin administration.	Platinum	52-60	down-regulator of transcription 1	Mus musculus	20-23
24353624-2	2013	We investigated the impact of several potential SNPs of XPG on the efficacy of platinum-based chemotherapy in NSCLC patients.	Platinum	79-87	ERCC excision repair 5, endonuclease	Homo sapiens	56-59
23620771-0	2013	The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy.	Platinum	135-143	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	24-29
23620771-3	2013	This study aimed at investigating the association between COX-2 polymorphisms and the occurrence of grade 3 or 4 toxicity in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.	Platinum	183-191	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	58-63
23410825-0	2013	PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.	Platinum	30-38	poly(ADP-ribose) polymerase 1	Homo sapiens	0-5
23410825-7	2013	Further, the pharmacological inhibition of PARP induced a 1.7 to 2.3-fold increase in platinum adduct accumulation (24h) in A549 cell line suggesting a slow-down of platinum DNA-adduct repair capacity.	Platinum	86-94	poly(ADP-ribose) polymerase 1	Homo sapiens	43-47
23410825-7	2013	Further, the pharmacological inhibition of PARP induced a 1.7 to 2.3-fold increase in platinum adduct accumulation (24h) in A549 cell line suggesting a slow-down of platinum DNA-adduct repair capacity.	Platinum	165-173	poly(ADP-ribose) polymerase 1	Homo sapiens	43-47
23410825-13	2013	In conclusion, our data confirm that platinum DNA adduct accumulation is linked to chemosensitivity, which increase by pharmacological PARP inhibitors points to a role of PARP-dependent DNA repair in the process.	Platinum	37-45	poly(ADP-ribose) polymerase 1	Homo sapiens	135-139
23410825-13	2013	In conclusion, our data confirm that platinum DNA adduct accumulation is linked to chemosensitivity, which increase by pharmacological PARP inhibitors points to a role of PARP-dependent DNA repair in the process.	Platinum	37-45	poly(ADP-ribose) polymerase 1	Homo sapiens	171-175
23631819-1	2013	BACKGROUND: The aim of the study was to evaluate predictive and prognostic significance of microtubule-associated protein Tau in epithelial ovarian cancer (EOC) patients treated with paclitaxel and platinum-based chemotherapy.	Platinum	198-206	microtubule associated protein tau	Homo sapiens	91-125
23469757-5	2013	The platinum drug, oxoplatin, was then subsequently attached to the polymer via ester formation leading to platinum loading of 12 wt % as determined by TGA.	Platinum	4-12	T-box transcription factor 1	Homo sapiens	152-155
23447415-4	2013	Compounds syn-1-3 were employed as multidentate ligands for silver(I) and platinum(II) centres in apolar solvents.	Platinum	74-82	synapsin I	Homo sapiens	10-15
23478149-11	2013	In copper, silver, palladium, platinum, and rhodium, the WC and PBEsol frequencies match the experimental inelastic neutron scattering data better than the LDA or PBE.	Platinum	30-38	enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase	Homo sapiens	64-67
23469757-5	2013	The platinum drug, oxoplatin, was then subsequently attached to the polymer via ester formation leading to platinum loading of 12 wt % as determined by TGA.	Platinum	107-115	T-box transcription factor 1	Homo sapiens	152-155
23429864-0	2013	The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.	Platinum	117-125	BRCA1 DNA repair associated	Homo sapiens	24-29
23470147-1	2013	Peptide triazole (PT) entry inhibitors prevent HIV-1 infection by blocking the binding of viral gp120 to both the HIV-1 receptor and the coreceptor on target cells.	Platinum	18-20	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	96-101
23462720-2	2013	Reduced BRCA1 expression is associated with enhanced sensitivity to platinum-based chemotherapy.	Platinum	68-76	BRCA1 DNA repair associated	Homo sapiens	8-13
23462720-3	2013	We sought to examine the prognostic relevance of BRCA1 expression in EOC patients treated with intraperitoneal platinum/taxane.	Platinum	111-119	BRCA1 DNA repair associated	Homo sapiens	49-54
23344663-0	2013	Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.	Platinum	0-8	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	85-90
23344663-0	2013	Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.	Platinum	0-8	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	91-95
23344663-7	2013	Platinum compounds also sensitize to ABT-737 by dose-dependently decreasing Mcl-1 expression or by increasing the expression of pro-apoptotic BH3-only proteins Noxa and, to a lower extent, Bim.	Platinum	0-8	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	76-81
23344663-7	2013	Platinum compounds also sensitize to ABT-737 by dose-dependently decreasing Mcl-1 expression or by increasing the expression of pro-apoptotic BH3-only proteins Noxa and, to a lower extent, Bim.	Platinum	0-8	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	160-164
23429864-0	2013	The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.	Platinum	117-125	ubiquitin interaction motif containing 1	Homo sapiens	34-39
23275151-4	2013	Therefore, we hypothesized that combining PARP inhibition with platinum compounds may be an approach to improve platinum-based therapy for NSCLC.	Platinum	112-120	poly(ADP-ribose) polymerase 1	Homo sapiens	42-46
23344663-8	2013	Furthermore, we demonstrated that Noxa accumulation was involved in apoptosis occurring in response to the combination of ABT-737 and platinum compounds, since cells were protected from apoptosis by its silencing.	Platinum	134-142	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	34-38
23344663-11	2013	Therefore, we have revealed that the modulation of the Mcl-1/Noxa axis by platinum compounds results in a strong sensitization of chemoresistant ovarian carcinoma cells to ABT-737, which could constitute a promising therapeutic in these cancers.	Platinum	74-82	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	55-60
23344663-11	2013	Therefore, we have revealed that the modulation of the Mcl-1/Noxa axis by platinum compounds results in a strong sensitization of chemoresistant ovarian carcinoma cells to ABT-737, which could constitute a promising therapeutic in these cancers.	Platinum	74-82	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	61-65
23564780-8	2013	CONCLUSION: These data suggest that CTR2 contributes to platinum resistance in ovarian cancer.	Platinum	56-64	solute carrier family 31 member 2	Homo sapiens	36-40
23564780-9	2013	The CTR2/CTR1 ratio is a useful marker for platinum sensitivity and a potential prognostic factor in patients with ovarian cancer.	Platinum	43-51	solute carrier family 31 member 2	Homo sapiens	4-8
23564780-9	2013	The CTR2/CTR1 ratio is a useful marker for platinum sensitivity and a potential prognostic factor in patients with ovarian cancer.	Platinum	43-51	calcitonin receptor	Homo sapiens	9-13
23299407-8	2013	Additionally, the increased TNFAIP8 protein expression may predict platinum resistance and clinical outcomes in cervical cancer patients.	Platinum	67-75	TNF alpha induced protein 8	Homo sapiens	28-35
23450835-6	2013	Furthermore, fabricated Pt nanoparticles with a diameter of 3.4 nm are located uniformly around the pretreated H-TNT support.	Platinum	24-26	chromosome 16 open reading frame 82	Homo sapiens	113-116
23265709-1	2013	INTRODUCTION: Preclinical data suggest that BRCA1 and BRCA2 (BRCA1/2)-mutated ovarian cancers (BMOC) are exquisitely sensitive to platinum-salts, but resistant to microtubule-stabilizing anticancer agents.	Platinum	130-138	BRCA1 DNA repair associated	Homo sapiens	44-49
23265709-1	2013	INTRODUCTION: Preclinical data suggest that BRCA1 and BRCA2 (BRCA1/2)-mutated ovarian cancers (BMOC) are exquisitely sensitive to platinum-salts, but resistant to microtubule-stabilizing anticancer agents.	Platinum	130-138	BRCA2 DNA repair associated	Homo sapiens	54-59
23265709-1	2013	INTRODUCTION: Preclinical data suggest that BRCA1 and BRCA2 (BRCA1/2)-mutated ovarian cancers (BMOC) are exquisitely sensitive to platinum-salts, but resistant to microtubule-stabilizing anticancer agents.	Platinum	130-138	BRCA2 DNA repair associated	Homo sapiens	61-68
23412975-0	2013	VCP gene variation predicts outcome of advanced non-small-cell lung cancer platinum-based chemotherapy.	Platinum	75-83	valosin containing protein	Homo sapiens	0-3
23337490-3	2013	It remains unresolved whether NACT-IDS increases the risk of platinum resistance.	Platinum	61-69	solute carrier family 13 member 5	Homo sapiens	30-34
23337490-3	2013	It remains unresolved whether NACT-IDS increases the risk of platinum resistance.	Platinum	61-69	iduronate 2-sulfatase	Homo sapiens	35-38
23337490-9	2013	After the initial platinum-based chemotherapy, 42 (44.2%) women in the NACT-IDS group were considered to have platinum resistant disease, compared to 103 (31.2%) in the PDS group (P=0.01).	Platinum	110-118	solute carrier family 13 member 5	Homo sapiens	71-75
23337490-9	2013	After the initial platinum-based chemotherapy, 42 (44.2%) women in the NACT-IDS group were considered to have platinum resistant disease, compared to 103 (31.2%) in the PDS group (P=0.01).	Platinum	110-118	iduronate 2-sulfatase	Homo sapiens	76-79
23337490-10	2013	When multivariate logistic regression was used to control for factors independently associated with platinum resistance, NACT-IDS was no longer associated with an initial increased risk.	Platinum	100-108	iduronate 2-sulfatase	Homo sapiens	126-129
23337490-11	2013	However, in women that had a recurrence and were retreated with platinum-based chemotherapy, 32 (88.8%) in the NACT-IDS group had developed a recurrence within six months and were considered platinum resistant, compared to 62 (55.3%) in the PDS (P&lt;0.001).	Platinum	64-72	solute carrier family 13 member 5	Homo sapiens	111-115
23337490-11	2013	However, in women that had a recurrence and were retreated with platinum-based chemotherapy, 32 (88.8%) in the NACT-IDS group had developed a recurrence within six months and were considered platinum resistant, compared to 62 (55.3%) in the PDS (P&lt;0.001).	Platinum	64-72	iduronate 2-sulfatase	Homo sapiens	116-119
23337490-11	2013	However, in women that had a recurrence and were retreated with platinum-based chemotherapy, 32 (88.8%) in the NACT-IDS group had developed a recurrence within six months and were considered platinum resistant, compared to 62 (55.3%) in the PDS (P&lt;0.001).	Platinum	191-199	solute carrier family 13 member 5	Homo sapiens	111-115
23337490-12	2013	CONCLUSION: In women with EOC that have a recurrence and are treated again with platinum-based chemotherapy, NACT-IDS appears to increase the risk of platinum resistance.	Platinum	80-88	solute carrier family 13 member 5	Homo sapiens	109-113
23337490-12	2013	CONCLUSION: In women with EOC that have a recurrence and are treated again with platinum-based chemotherapy, NACT-IDS appears to increase the risk of platinum resistance.	Platinum	80-88	iduronate 2-sulfatase	Homo sapiens	114-117
23337490-12	2013	CONCLUSION: In women with EOC that have a recurrence and are treated again with platinum-based chemotherapy, NACT-IDS appears to increase the risk of platinum resistance.	Platinum	150-158	solute carrier family 13 member 5	Homo sapiens	109-113
23337490-12	2013	CONCLUSION: In women with EOC that have a recurrence and are treated again with platinum-based chemotherapy, NACT-IDS appears to increase the risk of platinum resistance.	Platinum	150-158	iduronate 2-sulfatase	Homo sapiens	114-117
22158331-4	2013	The Asp1104His polymorphism in xpg, a gene important for removal of platinum adducts, was associated with progression-free survival in early- and late-stage ovarian cancer.	Platinum	68-76	ERCC excision repair 5, endonuclease	Homo sapiens	31-34
23412975-3	2013	We investigated the association between VCP polymorphisms and clinical outcome in advanced NSCLC patients undergoing platinum-based chemotherapy.	Platinum	117-125	valosin containing protein	Homo sapiens	40-43
23412975-10	2013	Our study is the first to provide evidence that VCP polymorphisms are associated with a severe chemotherapy-related adverse outcome in platinum-treated advanced NSCLC patients.	Platinum	135-143	valosin containing protein	Homo sapiens	48-51
23417092-0	2013	A dinuclear platinum complex featuring the diboran(4)-1,2-diyl ligand in a mu2-bridging coordination mode.	Platinum	12-20	adaptor related protein complex 1 subunit mu 2	Homo sapiens	75-78
23437824-4	2013	The absorption positions of these two molecules are completely different: CO2 is located between two Pt atoms, whereas one S atom of CS2 is located between two Pz ligands and the other S atom is between two Pt atoms.	Platinum	207-209	chorionic somatomammotropin hormone 2	Homo sapiens	133-136
23437824-6	2013	To elucidate the reasons for these differences, we performed an energy decomposition analysis and found that (i) both the large binding energy and the absorption position of CS2 arise from a large dispersion interaction between CS2 and the PCP, (ii) the absorption position of CO2 is mainly determined by the electrostatic interaction between CO2 and the Pt moiety, and (iii) the small binding energy of CO2 comes from the weak dispersion interaction between CO2 and the PCP.	Platinum	355-357	chorionic somatomammotropin hormone 2	Homo sapiens	174-177
23396495-5	2013	Such reconstruction resulted in the formation of more plated Pt particles on the CNF than on the carbon-black and exposure of more Pt atoms with relatively high co-ordination numbers, and thereby higher specific activity.	Platinum	61-63	NPHS1 adhesion molecule, nephrin	Homo sapiens	81-84
23401439-5	2013	Although low ERCC1 and/or RRM1 expression is generally associated with sensitivity to platinum, the results published in retrospective and prospective studies are not always consistent.	Platinum	86-94	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	13-18
23497550-5	2013	In 17 platinum-based studies, low/negative BRCA1 was in favor of better ORR (OR=1.70, 95%CI=1.32-2.18), longer OS and EFS (HR=1.58, 95%CI=1.27-1.97, and HR=1.60, 95%CI=1.07-2.39 for OS and EFS, respectively).	Platinum	6-14	BRCA1 DNA repair associated	Homo sapiens	43-48
23514287-5	2013	We mapped the epitope recognized by 16 commercially available ERCC1 antibodies and investigated the capacity of the different ERCC1 isoforms to repair platinum-induced DNA damage.	Platinum	151-159	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	126-131
23497550-0	2013	Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis.	Platinum	72-80	BRCA1 DNA repair associated	Homo sapiens	37-42
23497550-1	2013	The recent studies have evaluated the relationship between BRCA1 expression and clinical outcome of chemotherapy (mainly focused on platinum-based and toxal-based treatment) in NSCLC patients, but the results were inconclusive and controversial.	Platinum	132-140	BRCA1 DNA repair associated	Homo sapiens	59-64
23401439-5	2013	Although low ERCC1 and/or RRM1 expression is generally associated with sensitivity to platinum, the results published in retrospective and prospective studies are not always consistent.	Platinum	86-94	ribonucleotide reductase catalytic subunit M1	Homo sapiens	26-30
23211354-0	2013	Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.	Platinum	52-60	ERCC excision repair 5, endonuclease	Homo sapiens	8-13
23211354-1	2013	The ERCC5 gene plays an important role in the nucleotide excision repair pathway that recognizes and removes platinum-DNA adducts.	Platinum	109-117	ERCC excision repair 5, endonuclease	Homo sapiens	4-9
23211354-2	2013	We aimed to examine whether ERCC5 promoter polymorphisms contribute toward intervariations in the platinum treatment response in patients with advanced non-small-cell lung cancer (NSCLC).	Platinum	98-106	ERCC excision repair 5, endonuclease	Homo sapiens	28-33
23211354-7	2013	Further and larger scale studies are still required to provide more comprehensive information on ERCC5 promoter variations in the clinical outcome of NSCLC patients treated with platinum regimens.	Platinum	178-186	ERCC excision repair 5, endonuclease	Homo sapiens	97-102
23263187-0	2013	Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix.	Platinum	31-39	mitogen-activated protein kinase 8 interacting protein 2	Homo sapiens	83-86
22052826-4	2013	Cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), significantly improved median survival in combination with platinum/5-FU compared with chemotherapy alone, establishing it as a new standard for patients with recurrent or metastatic disease.	Platinum	141-149	epidermal growth factor receptor	Homo sapiens	75-79
23292835-2	2013	The aim of this study is to identify the prognostic significance of BRCA1 in patients with gastric cancer undergoing surgery and platinum-based adjuvant chemotherapy.	Platinum	129-137	BRCA1 DNA repair associated	Homo sapiens	68-73
23507588-4	2013	Several clinical trials clearly demonstrated that progression-free survival of patients treated with EGFR-TKI is significantly longer than that of those treated by conventional platinum doublet chemotherapy.	Platinum	177-185	epidermal growth factor receptor	Homo sapiens	101-105
23640560-9	2013	The RT-PCR analysis revealed that the expression of PARP-1 mRNA was decreased when platinum (Pt) and 3-AB were combined.	Platinum	83-91	poly(ADP-ribose) polymerase 1	Homo sapiens	52-58
23640560-9	2013	The RT-PCR analysis revealed that the expression of PARP-1 mRNA was decreased when platinum (Pt) and 3-AB were combined.	Platinum	93-95	poly(ADP-ribose) polymerase 1	Homo sapiens	52-58
23052480-0	2013	Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2.	Platinum	0-8	interleukin 6	Homo sapiens	59-63
23052480-0	2013	Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2.	Platinum	0-8	baculoviral IAP repeat containing 3	Homo sapiens	117-123
23052480-12	2013	Here, we present cIAP-2 as a novel inducer of platinum resistance in ovarian carcinoma cells, and suggest an axis beginning with an encounter between cisplatin and these cells, mediated sequentially by IL-6 and cIAP-2, resulting in cisplatin resistance.	Platinum	46-54	baculoviral IAP repeat containing 3	Homo sapiens	17-23
23463763-8	2013	CONCLUSIONS: Our data suggest the value of MTHFR C677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLC patients treated with gemcitabine/platinum.	Platinum	172-180	methylenetetrahydrofolate reductase	Homo sapiens	43-48
23292835-9	2013	The patients with BRCA1-negative expression benefited more from platinum-based adjuvant chemotherapy (p = 0.024).	Platinum	64-72	BRCA1 DNA repair associated	Homo sapiens	18-23
23443244-6	2013	The results revealed that a putative Pt-NAC complex was formed in plasma with NAC : CP molar ratios &gt;= 50 : 1 and that plasma protein binding of CP-derived Pt-species was marginally affected by NAC.	Platinum	37-39	X-linked Kx blood group	Homo sapiens	40-43
23443244-6	2013	The results revealed that a putative Pt-NAC complex was formed in plasma with NAC : CP molar ratios &gt;= 50 : 1 and that plasma protein binding of CP-derived Pt-species was marginally affected by NAC.	Platinum	37-39	X-linked Kx blood group	Homo sapiens	78-81
23443244-6	2013	The results revealed that a putative Pt-NAC complex was formed in plasma with NAC : CP molar ratios &gt;= 50 : 1 and that plasma protein binding of CP-derived Pt-species was marginally affected by NAC.	Platinum	37-39	X-linked Kx blood group	Homo sapiens	78-81
23292835-13	2013	Patients without BRCA1 expression can benefit from platinum-based adjuvant chemotherapy.	Platinum	51-59	BRCA1 DNA repair associated	Homo sapiens	17-22
23426424-0	2013	The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.	Platinum	90-98	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	15-20
23426424-1	2013	Excision repair cross-complementing 1 (ERCC1) is reported to be involved in the sensitivity of cancer cells to platinum-based chemotherapy.	Platinum	111-119	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-37
23426861-2	2013	There are no specific treatment guidelines for TNBC patients, however, it has been postulated that their phenotypic and molecular similarity to BRCA1-associated cancers would confer sensitivity to certain cytotoxic agents, including platinum.	Platinum	233-241	BRCA1 DNA repair associated	Homo sapiens	144-149
23426424-1	2013	Excision repair cross-complementing 1 (ERCC1) is reported to be involved in the sensitivity of cancer cells to platinum-based chemotherapy.	Platinum	111-119	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	39-44
23426424-2	2013	The present study was designed to evaluate the effects of ERCC1 expression on the chemosensitivity of platinum agents in gastric cancer cell lines, and on survival in gastric cancer patients treated with surgery followed by oxaliplatin-based adjuvant chemotherapy.	Platinum	102-110	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	58-63
23426424-6	2013	The results demonstrated that the expression levels of ERCC1 mRNA were correlated with the chemosensitivity of platinum agents, and depletion of ERCC1 sensitized the relatively resistant MKN45 cells to cisplatin and oxaliplatin.	Platinum	111-119	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	55-60
23426424-9	2013	These results suggest that overexpression of ERCC1 is correlated with platinum drug resistance in gastric cancer cells, and that depletion of ERCC1 sensitizes gastric cancer cell lines to cisplatin and oxaliplatin.	Platinum	70-78	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	45-50
23052861-1	2013	This study focuses on the identification of the products that are formed upon binding of therapeutically relevant platinum complexes to proteins like beta-lactoglobulin A (LGA), human serum albumin (HSA), or human hemoglobin (HB).	Platinum	114-122	albumin	Homo sapiens	184-197
23228696-3	2013	High expression levels of excision repair cross-complementary 1 (ERCC1) in cancers have been positively associated with the DNA repair capacity and a poor prognosis in NSCLC patients treated with platinum-containing chemotherapy.	Platinum	196-204	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	65-70
23356208-2	2013	This compound displays amphiphilic behavior and reacts easily with nucleophiles L, yielding the saturated complexes [(C(6)F(5))(2)Pt(II)(mu-PPh(2))(2)Pt(II)(mu-PPh(2))(2)Pt(II)(PPh(3))L] [L = PPh(3) (2), py (3)].	Platinum	130-132	protein phosphatase 4 catalytic subunit	Homo sapiens	177-183
23356208-2	2013	This compound displays amphiphilic behavior and reacts easily with nucleophiles L, yielding the saturated complexes [(C(6)F(5))(2)Pt(II)(mu-PPh(2))(2)Pt(II)(mu-PPh(2))(2)Pt(II)(PPh(3))L] [L = PPh(3) (2), py (3)].	Platinum	130-132	protein phosphatase 4 catalytic subunit	Homo sapiens	192-198
23356208-2	2013	This compound displays amphiphilic behavior and reacts easily with nucleophiles L, yielding the saturated complexes [(C(6)F(5))(2)Pt(II)(mu-PPh(2))(2)Pt(II)(mu-PPh(2))(2)Pt(II)(PPh(3))L] [L = PPh(3) (2), py (3)].	Platinum	150-152	protein phosphatase 4 catalytic subunit	Homo sapiens	177-183
23356208-2	2013	This compound displays amphiphilic behavior and reacts easily with nucleophiles L, yielding the saturated complexes [(C(6)F(5))(2)Pt(II)(mu-PPh(2))(2)Pt(II)(mu-PPh(2))(2)Pt(II)(PPh(3))L] [L = PPh(3) (2), py (3)].	Platinum	150-152	protein phosphatase 4 catalytic subunit	Homo sapiens	192-198
23356208-4	2013	The nucleophilic nature of 1 is also demonstrated through its reaction with cis-[Pt(C(6)F(5))(2)(THF)(2)], which results in the formation of [Pt(4)(mu-PPh(2))(4)(C(6)F(5))(4)(PPh(3))] (4).	Platinum	81-83	protein phosphatase 4 catalytic subunit	Homo sapiens	175-181
23344263-1	2013	PURPOSE: Results of multiple clinical trials suggest that EGF receptor (EGFR) tyrosine kinase inhibitors (TKI) exhibit negative effects on platinum-based chemotherapy in patients with lung cancer with wild-type (WT) EGFR, but the underlying molecular mechanisms are still uncertain.	Platinum	139-147	epidermal growth factor receptor	Homo sapiens	58-70
23344263-1	2013	PURPOSE: Results of multiple clinical trials suggest that EGF receptor (EGFR) tyrosine kinase inhibitors (TKI) exhibit negative effects on platinum-based chemotherapy in patients with lung cancer with wild-type (WT) EGFR, but the underlying molecular mechanisms are still uncertain.	Platinum	139-147	epidermal growth factor receptor	Homo sapiens	72-76
23388584-16	2013	Furthermore, we investigated survival endpoints in platinum-refractory patients who received PLD at least once during the course of disease.	Platinum	51-59	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	93-96
23178313-12	2013	Higher plasma HE4 levels correlated with poor surgery outcome in terms of macroscopically residual tumor mass (p&lt;0.001) and platinum-resistance (p=0.009).	Platinum	127-135	WAP four-disulfide core domain 2	Homo sapiens	14-17
22804784-0	2013	Association between eIF3alpha polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients.	Platinum	73-81	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	20-29
22804784-5	2013	The purpose of this study was to investigate whether eIF3alpha polymorphism is associated with severe platinum toxicity in patients with non-small cell lung cancer (NSCLC).	Platinum	102-110	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	53-62
22804784-12	2013	CONCLUSION: eIF3alpha Arg803Lys was associated with platinum toxicity in NSCLC patients and could be considered as a predictor for pretreatment evaluation in lung cancer patients.	Platinum	52-60	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	12-21
23271326-7	2013	Analyses combining DT-/PT TDLUs within subjects demonstrated that ER levels were significantly lower in premenopausal women versus postmenopausal women (odds ratio [OR] = 0.38, 95 % confidence interval [CI] = 0.19, 0.76, P = 0.0064) and among recent or current menopausal hormone therapy users compared with never users (OR = 0.14, 95 % CI = 0.046-0.43, P                 (trend) = 0.0006).	Platinum	23-25	estrogen receptor 1	Homo sapiens	66-68
22721387-7	2013	Finally, mesothelin expression promotes resistance to certain chemotherapy drugs such as TNF-alpha, paclitaxel, and a combination of platinum and cyclophosphamide.	Platinum	133-141	mesothelin	Homo sapiens	9-19
23110522-5	2013	More importantly, the sulfur-containing SGnP and CSGnP were found to have a superior ORR performance to commercially available platinum-based electrocatalyst.	Platinum	127-135	spermatogenesis associated serine rich 2 like	Homo sapiens	40-44
23011758-2	2013	Dual antagonist peptide triazoles (PT) are a novel class of HIV-1 inhibitors that specifically target the gp120 component of the viral spike and inhibit its interaction with both of its cell surface protein ligands, namely the initial receptor CD4 and the co-receptor (CCR5/CXCR4), thus preventing viral entry.	Platinum	35-37	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	106-111
23011758-2	2013	Dual antagonist peptide triazoles (PT) are a novel class of HIV-1 inhibitors that specifically target the gp120 component of the viral spike and inhibit its interaction with both of its cell surface protein ligands, namely the initial receptor CD4 and the co-receptor (CCR5/CXCR4), thus preventing viral entry.	Platinum	35-37	CD4 molecule	Homo sapiens	244-247
23340649-0	2013	Pre-Treatment of platinum resistant ovarian cancer cells with an MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as determined by high content screening.	Platinum	17-25	matrix metallopeptidase 9	Homo sapiens	65-70
23147001-4	2013	This review describes the advances that have been achieved in using transition metal (Ag, Au, Pt, Pd, Cu, Ni, and Ru) complexes containing NHC ligands as antitumor agents.	Platinum	94-96	high mobility group nucleosomal binding domain 4	Homo sapiens	139-142
23259819-1	2013	As advanced electrodes for direct alcohol fuel cells, graphene-Pd and graphene-Pt composites with a trace of SnO(2) have been successfully synthesized by a modified electroless plating technique.	Platinum	79-81	strawberry notch homolog 1	Homo sapiens	109-112
23340649-0	2013	Pre-Treatment of platinum resistant ovarian cancer cells with an MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as determined by high content screening.	Platinum	17-25	matrix metallopeptidase 2	Homo sapiens	71-76
23165642-0	2013	Platinum complexes bearing a boron-based PBP pincer ligand: synthesis, structure, and application as a catalyst for hydrosilylation of 1-decene.	Platinum	0-8	dedicator of cytokinesis 3	Homo sapiens	41-44
23123662-0	2013	Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons.	Platinum	67-75	solute carrier family 31 member 1	Rattus norvegicus	21-25
22833464-2	2013	Because PTCLs over express multidrug resistance gene 1/P-glycoprotein (MDR-1/P-gp), we devised platinum, etoposide, gemcitabine, and methylprednisolone (PEGS) with agents that are not substrates of the efflux pump.	Platinum	95-103	ATP binding cassette subfamily B member 1	Homo sapiens	71-76
22906713-2	2013	By combining laccase with catalase enzymes electrophoretically deposited by means of AC electric fields on multiple walled carbon nanotubes modified platinum black and, then stabilized by an outer layer of polypyrrole in the construction of GC/MWCNTs/Ptb/LAc-CAt/PPy biocathode, we can take advantage of the H(2)O(2) present in the solution or body tissue to increase the level of the dissolved O(2).	Platinum	149-157	catalase	Homo sapiens	26-34
22906713-2	2013	By combining laccase with catalase enzymes electrophoretically deposited by means of AC electric fields on multiple walled carbon nanotubes modified platinum black and, then stabilized by an outer layer of polypyrrole in the construction of GC/MWCNTs/Ptb/LAc-CAt/PPy biocathode, we can take advantage of the H(2)O(2) present in the solution or body tissue to increase the level of the dissolved O(2).	Platinum	149-157	polypyrimidine tract binding protein 1	Homo sapiens	251-254
22906713-2	2013	By combining laccase with catalase enzymes electrophoretically deposited by means of AC electric fields on multiple walled carbon nanotubes modified platinum black and, then stabilized by an outer layer of polypyrrole in the construction of GC/MWCNTs/Ptb/LAc-CAt/PPy biocathode, we can take advantage of the H(2)O(2) present in the solution or body tissue to increase the level of the dissolved O(2).	Platinum	149-157	pancreatic polypeptide	Homo sapiens	263-266
23123662-2	2013	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and platinum drugs.	Platinum	246-254	solute carrier family 31 member 1	Rattus norvegicus	193-197
23123662-2	2013	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and platinum drugs.	Platinum	246-254	solute carrier family 31 member 1	Rattus norvegicus	199-204
23123662-2	2013	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and platinum drugs.	Platinum	112-120	solute carrier family 31 member 1	Rattus norvegicus	43-63
23123662-7	2013	The accumulation of platinum by both cultured rat DRG neurons and HEK/rCtr1 cells, during oxaliplatin exposure, was saturable and temperature dependent, but was inhibited by copper only in HEK/rCtr1 cells.	Platinum	20-28	solute carrier family 31 member 1	Rattus norvegicus	70-75
23123662-2	2013	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and platinum drugs.	Platinum	112-120	solute carrier family 31 member 1	Rattus norvegicus	65-69
23123662-7	2013	The accumulation of platinum by both cultured rat DRG neurons and HEK/rCtr1 cells, during oxaliplatin exposure, was saturable and temperature dependent, but was inhibited by copper only in HEK/rCtr1 cells.	Platinum	20-28	solute carrier family 31 member 1	Rattus norvegicus	193-198
23123662-8	2013	In conclusion, rCtr1 can transport copper and platinum drugs, and sensitizes cells to their cytotoxicities.	Platinum	46-54	solute carrier family 31 member 1	Rattus norvegicus	15-20
23270953-0	2013	Electrochemical degradation of PNP at boron-doped diamond and platinum electrodes.	Platinum	62-70	purine nucleoside phosphorylase	Homo sapiens	31-34
23089594-8	2013	However, the key to the observed foamed product is the in situ platinum-catalyzed hydrosilylation of the allyl group, prior to or concomitant with silicone cure, leading to PEG-silicone copolymers that are able to stabilize both dispersed PEG droplets and bubbles.	Platinum	63-71	progestagen associated endometrial protein	Homo sapiens	173-176
23089594-8	2013	However, the key to the observed foamed product is the in situ platinum-catalyzed hydrosilylation of the allyl group, prior to or concomitant with silicone cure, leading to PEG-silicone copolymers that are able to stabilize both dispersed PEG droplets and bubbles.	Platinum	63-71	progestagen associated endometrial protein	Homo sapiens	239-242
23270953-1	2013	The electrochemical degradation of p-nitrophenol (PNP) at boron-doped diamond (BDD) and platinum (Pt) anodes was studied by varying the parameters such as Cl(-) concentration, pH of aqueous medium and applied current density.	Platinum	88-96	purine nucleoside phosphorylase	Homo sapiens	50-53
23270953-1	2013	The electrochemical degradation of p-nitrophenol (PNP) at boron-doped diamond (BDD) and platinum (Pt) anodes was studied by varying the parameters such as Cl(-) concentration, pH of aqueous medium and applied current density.	Platinum	98-100	purine nucleoside phosphorylase	Homo sapiens	50-53
23107767-5	2013	RESULTS: The genotypes of GGH-401C&gt;T were significantly associated with the response to platinum-based chemoradiotherapy.	Platinum	91-99	gamma-glutamyl hydrolase	Homo sapiens	26-29
23267165-7	2013	After chemotherapy, mesothelin as well as CA125 levels, were significantly associated with FIGO stage (p=0.041 and p=0.017) and residual tumor (p=0.022 and p=0.002) while L1CAM correlated with platinum sensitivity (p=0.041).	Platinum	193-201	mesothelin	Homo sapiens	20-30
22887466-11	2013	PFS on first-line platinum/pemetrexed may be prolonged in never/light-smoking patients regardless of ALK status.	Platinum	18-26	ALK receptor tyrosine kinase	Homo sapiens	101-104
22887466-6	2013	RESULTS: Among 70 ALK-positive patients treated with a platinum/pemetrexed regimen, the median PFS (mPFS) was 7.3 months (95% confidence interval (CI) 5.5-9.5).	Platinum	55-63	ALK receptor tyrosine kinase	Homo sapiens	18-21
24289594-3	2013	In this study, we confirmed that overexpression of SEMA4D in primary tumors and ascites was related to low differentiation, platinum resistance and a refractory status (P&lt;0.05), while high M2 macrophage count and percentage were evident in EOC patients with advanced FIGO stage and platinum resistance (P&lt;0.05), using immunohistochemistry, enzyme-linked immunosorbent assay (ELISA), and fluorescence-activated cell sorting (FACS), respectively.	Platinum	124-132	semaphorin 4D	Homo sapiens	51-57
24083725-1	2013	BACKGROUND: ERCC1 is considered as a promising molecular marker that may predict platinum based chemotherapy response in non small cell lung cancer patients.	Platinum	81-89	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	12-17
24289594-3	2013	In this study, we confirmed that overexpression of SEMA4D in primary tumors and ascites was related to low differentiation, platinum resistance and a refractory status (P&lt;0.05), while high M2 macrophage count and percentage were evident in EOC patients with advanced FIGO stage and platinum resistance (P&lt;0.05), using immunohistochemistry, enzyme-linked immunosorbent assay (ELISA), and fluorescence-activated cell sorting (FACS), respectively.	Platinum	285-293	semaphorin 4D	Homo sapiens	51-57
23534713-2	2013	We investigated the impact of XPD Arg156Arg, XPD Asp312Asn, XPD Asp711Asp and XPD Lys751Gln gene polymorphisms on the efficacy of platinum-based chemotherapy in NSCLC patients.	Platinum	130-138	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	30-33
23534713-2	2013	We investigated the impact of XPD Arg156Arg, XPD Asp312Asn, XPD Asp711Asp and XPD Lys751Gln gene polymorphisms on the efficacy of platinum-based chemotherapy in NSCLC patients.	Platinum	130-138	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	45-48
23534713-2	2013	We investigated the impact of XPD Arg156Arg, XPD Asp312Asn, XPD Asp711Asp and XPD Lys751Gln gene polymorphisms on the efficacy of platinum-based chemotherapy in NSCLC patients.	Platinum	130-138	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	45-48
23534713-2	2013	We investigated the impact of XPD Arg156Arg, XPD Asp312Asn, XPD Asp711Asp and XPD Lys751Gln gene polymorphisms on the efficacy of platinum-based chemotherapy in NSCLC patients.	Platinum	130-138	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	45-48
23534713-7	2013	CONCLUSION: We found polymorphisms in XPD to be associated with response to platinum-based chemotherapy in NSCLC, and our findings provide information for therapeutic decisions for individualized therapy.	Platinum	76-84	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	38-41
23621222-0	2013	XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy.	Platinum	87-95	ERCC excision repair 5, endonuclease	Homo sapiens	0-3
23621222-2	2013	We aimed to investigate the role of five potential SNPs of XPG gene on the response to platinum-based chemotherapy in advanced Chinese NSCLC patients.	Platinum	87-95	ERCC excision repair 5, endonuclease	Homo sapiens	59-62
23621222-8	2013	In conclusion, our study found that polymorphisms in rs1047768 C/T and rs2296147 C/T are associated with response to platinum-based chemotherapy in advanced NSCLC, and XPG polymorphisms could be predictive of prognosis.	Platinum	117-125	ERCC excision repair 5, endonuclease	Homo sapiens	168-171
23621265-7	2013	CONCLUSION: Our results indicated that the XPC Lys939Gln polymorphism may correlate with clinical outcome of patients with epithelial ovarian cancer when treated with platinum-based chemotherapy in Northern China.	Platinum	167-175	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	43-46
23936861-2	2013	Taking into account the side effects of surgery, radiation, platinum-based doublet chemotherapy, and the growth self-sufficiency characteristic of cancer cells, drugs have been discovered toward growth factor receptor (GFR) to treat NSCLC.	Platinum	60-68	Rap guanine nucleotide exchange factor 5	Homo sapiens	195-217
23936861-2	2013	Taking into account the side effects of surgery, radiation, platinum-based doublet chemotherapy, and the growth self-sufficiency characteristic of cancer cells, drugs have been discovered toward growth factor receptor (GFR) to treat NSCLC.	Platinum	60-68	Rap guanine nucleotide exchange factor 5	Homo sapiens	219-222
23736016-8	2013	Intracellular accumulation of platinum increased in cells with overexpressed S100P, and decreased in cells with S100P downregulation.	Platinum	30-38	S100 calcium binding protein P	Homo sapiens	77-82
24460276-2	2013	The objective of this study was to evaluate whether ERCC1 expression is associated with response to platinum-based chemotherapy in ovarian cancers.	Platinum	100-108	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	52-57
24460276-8	2013	Compared to patients with positive ERCC1 expression, those with negative ERCC1 expression had a better response to platinum-based chemotherapy.	Platinum	115-123	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	35-40
24460276-8	2013	Compared to patients with positive ERCC1 expression, those with negative ERCC1 expression had a better response to platinum-based chemotherapy.	Platinum	115-123	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	73-78
24460276-11	2013	ERCC1 protein expression status is significantly associated with response to platinum-based chemotherapy in ovarian cancers.	Platinum	77-85	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
24460276-0	2013	Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer.	Platinum	100-108	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	17-62
24460276-0	2013	Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer.	Platinum	100-108	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	64-69
24460276-1	2013	Recent studies suggested that the ovarian cancers with negative excision repair cross-complementation group 1 enzyme (ERCC1) expression have a better response to platinum-based chemotherapy than those with positive ERCC1 expression.	Platinum	162-170	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	64-109
24460276-1	2013	Recent studies suggested that the ovarian cancers with negative excision repair cross-complementation group 1 enzyme (ERCC1) expression have a better response to platinum-based chemotherapy than those with positive ERCC1 expression.	Platinum	162-170	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	118-123
23736016-8	2013	Intracellular accumulation of platinum increased in cells with overexpressed S100P, and decreased in cells with S100P downregulation.	Platinum	30-38	S100 calcium binding protein P	Homo sapiens	112-117
22796779-1	2013	We describe a simple method for preparing the hybrid material of Pt nanoparticles (NPs) supported on carbon-coated SnO(2) nanospheres (Pt-SnO(2)@C).	Platinum	65-67	strawberry notch homolog 2	Homo sapiens	138-141
24335195-0	2013	HIF1alpha genetic variants and protein expressions determine the response to platinum based chemotherapy and clinical outcome in patients with advanced NSCLC.	Platinum	77-85	hypoxia inducible factor 1 subunit alpha	Homo sapiens	0-9
24335195-10	2013	CONCLUSION: The results of our study suggest that HIF1alpha genetic variants and protein expression may be used as marker to screen NSCLC patients who are more likely to be responder to platinum based chemotherapy.	Platinum	186-194	hypoxia inducible factor 1 subunit alpha	Homo sapiens	50-59
23147994-0	2013	Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.	Platinum	32-40	endoglin	Mus musculus	0-8
23147994-0	2013	Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.	Platinum	32-40	endoglin	Mus musculus	10-15
23147994-9	2013	BARD1 was also associated with platinum resistance, and was induced by platinum exposure.	Platinum	31-39	BRCA1 associated RING domain 1	Mus musculus	0-5
23147994-9	2013	BARD1 was also associated with platinum resistance, and was induced by platinum exposure.	Platinum	71-79	BRCA1 associated RING domain 1	Mus musculus	0-5
23147994-12	2013	CONCLUSIONS: Endoglin downregulation promotes apoptosis, induces significant DNA damage through modulation of numerous DNA repair genes, and improves platinum sensitivity both in vivo and in vitro.	Platinum	150-158	endoglin	Mus musculus	13-21
23211422-2	2013	The aim of this study was to investigate the response rate in platinum-resistant, KRAS wild-type ovarian cancer patients treated with pegylated liposomal doxorubicin (PLD) supplemented with panitumumab.	Platinum	62-70	KRAS proto-oncogene, GTPase	Homo sapiens	82-86
23041051-7	2013	Since RSK2 is frequently amplified in a growing number of cancers, this may have implications for the sensitivity of these tumours to platinum-based cytotoxics.	Platinum	134-142	ribosomal protein S6 kinase A3	Homo sapiens	6-10
23199019-3	2013	An antibody to VEGF-A, bevacizumab, has demonstrated a survival benefit in conjunction with platinum-based doublet chemotherapy in non-small-cell lung cancer (NSCLC).	Platinum	92-100	vascular endothelial growth factor A	Homo sapiens	15-21
23017820-8	2013	PPIC positive CTCs during follow-up were significantly more often detected in the platinum resistant than in the platinum sensitive patient group, and indicated poor outcome independent from classical prognostic parameters.	Platinum	82-90	peptidylprolyl isomerase C	Homo sapiens	0-4
23017820-8	2013	PPIC positive CTCs during follow-up were significantly more often detected in the platinum resistant than in the platinum sensitive patient group, and indicated poor outcome independent from classical prognostic parameters.	Platinum	113-121	peptidylprolyl isomerase C	Homo sapiens	0-4
23377057-6	2013	Specimens of Au-Pt cast on gold cylinders in one piece showed higher strain development than the other groups used in this study, with strains ranging from 223.1 to 2,198.1 Mum/m.	Platinum	16-18	latexin	Homo sapiens	173-176
24204135-1	2013	The platinum (Pt)-group elements (PGEs) represent a new kind of environmental pollutant and a new hazard for human health.	Platinum	4-12	prostaglandin E synthase	Homo sapiens	34-38
24204135-1	2013	The platinum (Pt)-group elements (PGEs) represent a new kind of environmental pollutant and a new hazard for human health.	Platinum	14-16	prostaglandin E synthase	Homo sapiens	34-38
23225421-8	2012	The fact that MIF levels in serum of patients at primary diagnosis correlate with platinum sensibility supports the hypothesis that serum MIF levels should be evaluated as a parameter reflecting tumor sensibility towards chemotherapy in early stages of the disease.	Platinum	82-90	macrophage migration inhibitory factor	Homo sapiens	14-17
22546942-10	2013	SRP + PT group also showed a significant reduction in TNF-alpha and RANKL/OPG ratio at 8 weeks post-treatment compared with the SRP group (p &lt; 0.05).	Platinum	6-8	tumor necrosis factor	Homo sapiens	54-63
22546942-10	2013	SRP + PT group also showed a significant reduction in TNF-alpha and RANKL/OPG ratio at 8 weeks post-treatment compared with the SRP group (p &lt; 0.05).	Platinum	6-8	TNF superfamily member 11	Homo sapiens	68-73
22546942-10	2013	SRP + PT group also showed a significant reduction in TNF-alpha and RANKL/OPG ratio at 8 weeks post-treatment compared with the SRP group (p &lt; 0.05).	Platinum	6-8	TNF receptor superfamily member 11b	Homo sapiens	74-77
22983827-0	2013	Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population.	Platinum	92-100	X-ray repair cross complementing 1	Homo sapiens	37-42
22983827-0	2013	Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population.	Platinum	92-100	poly(ADP-ribose) polymerase 1	Homo sapiens	47-52
22983827-2	2013	We conducted a prospective study to determine whether associations exist between two polymorphisms in XRCC1 and ADPRT and the outcomes of Chinese ovarian cancer patients treated with platinum-based chemotherapy.	Platinum	183-191	X-ray repair cross complementing 1	Homo sapiens	102-107
22983827-2	2013	We conducted a prospective study to determine whether associations exist between two polymorphisms in XRCC1 and ADPRT and the outcomes of Chinese ovarian cancer patients treated with platinum-based chemotherapy.	Platinum	183-191	poly(ADP-ribose) polymerase 1	Homo sapiens	112-117
23053666-5	2013	The net accumulation of platinum (Pt) and the Pt-DNA adduct levels were reduced in CLDN3KD and CLDN4KD cells.	Platinum	24-32	claudin 4	Homo sapiens	95-100
23053666-5	2013	The net accumulation of platinum (Pt) and the Pt-DNA adduct levels were reduced in CLDN3KD and CLDN4KD cells.	Platinum	34-36	claudin 4	Homo sapiens	95-100
23591893-0	2013	Spin wave-assisted reduction in switching field of highly coercive iron-platinum magnets.	Platinum	72-80	spindlin 1	Homo sapiens	0-4
23127338-0	2013	The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients.	Platinum	43-51	eukaryotic translation initiation factor 3 subunit J	Homo sapiens	18-23
23127338-2	2013	The purpose of this study was to investigate possible mutations in promoter and exon regions of eIF3a gene and to assess whether eIF3a mutation status have prognostic and predictive significance in platinum-based chemotherapeutic lung cancer patients.	Platinum	198-206	eukaryotic translation initiation factor 3 subunit J	Homo sapiens	129-134
23127338-7	2013	eIF3a genetic polymorphisms can be considered as predictive tools for pretreatment evaluation of platinum-based chemotherapy.	Platinum	97-105	eukaryotic translation initiation factor 3 subunit J	Homo sapiens	0-5
24327053-4	2013	Noble metals such as Pt and Pd, and also Cu-based alloys, have been regarded as potential materials for a spin-current injector, owing to the large direct spin Hall effect.	Platinum	21-23	spindlin 1	Homo sapiens	106-110
24327053-4	2013	Noble metals such as Pt and Pd, and also Cu-based alloys, have been regarded as potential materials for a spin-current injector, owing to the large direct spin Hall effect.	Platinum	21-23	spindlin 1	Homo sapiens	155-159
24051929-3	2013	Since the introduction of the reversible EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib, patients with metastatic EGFR mutation-positive lung cancer can be offered a therapeutic alternative that has proven its superiority over standard platinum-based chemotherapy.	Platinum	252-260	epidermal growth factor receptor	Homo sapiens	41-45
23484053-5	2013	Accordingly, hsa-miR-302b expression was significantly associated with time to relapse or overall survival in two data sets of platinum-treated ovarian cancer patients.	Platinum	127-135	microRNA 302b	Homo sapiens	13-25
22982619-2	2012	We hypothesize that the anticancer drug nedaplatin (NDP), an analogue of cisplatin and a second-generation platinum complex, also targets TrxR.	Platinum	107-115	peroxiredoxin 2	Mus musculus	138-142
23224552-3	2012	The surface was reactivated for further Pt deposition by stepping the potential to more positive values, where H(upd) is oxidized and fresh sites for the adsorption of PtCl(4)(2-) become available.	Platinum	40-42	uroporphyrinogen decarboxylase	Homo sapiens	113-116
22252310-5	2012	The EGFR-targeted monoclonal antibody cetuximab is approved for the treatment of locally advanced SCCHN in combination with radiotherapy, for first-line treatment of recurrent or metastatic SCCHN in combination with platinum-based chemotherapy and 5-fluorouracil, and for recurrent or metastatic SCCHN following progression with platinum-based chemotherapy.	Platinum	216-224	epidermal growth factor receptor	Homo sapiens	4-8
22795264-0	2012	Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.	Platinum	96-104	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	10-15
22795264-1	2012	INTRODUCTION: The excision repair cross-complementing 1 (ERCC1) protein is an extensively investigated molecular marker because it may decrease sensitivity to platinum-based chemotherapy.	Platinum	159-167	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	18-55
22795264-1	2012	INTRODUCTION: The excision repair cross-complementing 1 (ERCC1) protein is an extensively investigated molecular marker because it may decrease sensitivity to platinum-based chemotherapy.	Platinum	159-167	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	57-62
22795264-2	2012	Low ERCC1 expression has already been correlated with better treatment efficacy in non-small-cell lung cancer patients treated with platinum-based chemotherapy.	Platinum	132-140	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	4-9
22795264-4	2012	METHODS: This retrospective pilot study evaluated the impact of ERCC1 expression levels on response to first-line platinum-based chemotherapy with or without radiotherapy and survival outcomes of 77 SCLC patients.	Platinum	114-122	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	64-69
22252310-5	2012	The EGFR-targeted monoclonal antibody cetuximab is approved for the treatment of locally advanced SCCHN in combination with radiotherapy, for first-line treatment of recurrent or metastatic SCCHN in combination with platinum-based chemotherapy and 5-fluorouracil, and for recurrent or metastatic SCCHN following progression with platinum-based chemotherapy.	Platinum	329-337	epidermal growth factor receptor	Homo sapiens	4-8
23197882-4	2012	In patients with advanced or metastatic gastric/GOJ cancer systemic chemotherapy with fluoropyrimidine/platinum-based regimens (+/-human epidermal growth factor receptor-2 antibody) is the mainstay of treatment.	Platinum	103-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-171
22484552-3	2012	RESULTS: The AKT inhibitor, API-2, resensitized platinum-resistant PEO4 tumors to cisplatin, leading to a markedly lower Ki67 labeling index (p &lt;= 0.006, n = 6 per group).	Platinum	48-56	AKT serine/threonine kinase 1	Homo sapiens	13-16
22484552-3	2012	RESULTS: The AKT inhibitor, API-2, resensitized platinum-resistant PEO4 tumors to cisplatin, leading to a markedly lower Ki67 labeling index (p &lt;= 0.006, n = 6 per group).	Platinum	48-56	baculoviral IAP repeat containing 3	Homo sapiens	28-33
22484552-7	2012	CONCLUSIONS: Therapeutic inhibition of AKT activation in acquired platinum-resistant disease can be imaged noninvasively by [(18)F]FDG-PET and [(18)F]FLT-PET warranting further assessment.	Platinum	66-74	AKT serine/threonine kinase 1	Homo sapiens	39-42
21826087-6	2012	This study suggests that XPD rs1799793 could be a marker of osteosarcoma associated with features conferring either a better prognosis or a better outcome after platinum therapy, or both.	Platinum	161-169	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	25-28
22992944-0	2012	Downregulation of AKT reverses platinum resistance of human ovarian             cancers in vitro.	Platinum	31-39	AKT serine/threonine kinase 1	Homo sapiens	18-21
22992944-7	2012	AKT overexpression             (confirmed by western blotting) converted platinum-sensitive A2780 into platinum-resistant             cells as shown by MTT assay.	Platinum	73-81	AKT serine/threonine kinase 1	Homo sapiens	0-3
22992944-7	2012	AKT overexpression             (confirmed by western blotting) converted platinum-sensitive A2780 into platinum-resistant             cells as shown by MTT assay.	Platinum	103-111	AKT serine/threonine kinase 1	Homo sapiens	0-3
22992944-8	2012	Importantly, platinum resistance of A2780cis cells             could be reversed by downregulation of AKT, as demonstrated by MTT and clonogenicity             assays and FACS analysis.	Platinum	13-21	AKT serine/threonine kinase 1	Homo sapiens	102-105
23146216-0	2012	Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?	Platinum	0-8	BRCA1 DNA repair associated	Homo sapiens	26-31
23066035-8	2012	We therefore suggest that HRD as predicted by a functional RAD51 assay correlates with in vitro PARPi sensitivity, clinical platinum sensitivity, and improved survival outcome.	Platinum	124-132	RAD51 recombinase	Homo sapiens	59-64
22949159-5	2012	Additionally, electrochemical pretreatment of platinum working electrodes aiming at surface oxidation improves the limit of detection of the sensor and the linearity of the calibration curve at low H2O2 concentrations (&lt;10 muM).	Platinum	46-54	latexin	Homo sapiens	226-229
23084051-4	2012	Initially, the added glucose was oxidized to gluconolactone and H(2)O(2) by the labeled GOx, and then the generated H(2)O(2) was reduced with the help of platinum nanoparticles, leading to the production of oxygen.	Platinum	154-162	hydroxyacid oxidase 1	Homo sapiens	88-91
22771825-0	2012	Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.	Platinum	113-121	EMAP like 4	Homo sapiens	21-25
22771825-0	2012	Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.	Platinum	113-121	ALK receptor tyrosine kinase	Homo sapiens	26-29
22771825-2	2012	Limited data have been available, however, on the outcome of first-line platinum-based chemotherapy in patients with EML4-ALK-positive advanced NSCLC who have not been treated with an ALK kinase inhibitor.	Platinum	72-80	EMAP like 4	Homo sapiens	117-121
22771825-2	2012	Limited data have been available, however, on the outcome of first-line platinum-based chemotherapy in patients with EML4-ALK-positive advanced NSCLC who have not been treated with an ALK kinase inhibitor.	Platinum	72-80	ALK receptor tyrosine kinase	Homo sapiens	122-125
22771825-2	2012	Limited data have been available, however, on the outcome of first-line platinum-based chemotherapy in patients with EML4-ALK-positive advanced NSCLC who have not been treated with an ALK kinase inhibitor.	Platinum	72-80	ALK receptor tyrosine kinase	Homo sapiens	184-187
22771825-5	2012	Platinum-based combination chemotherapy showed similar efficacies in the EML4-ALK, EGFR mutation, and wild-type cohorts in terms of response rate and progression-free survival, and overall survival in the EML4-ALK cohort closely resembled that in the wild-type cohort.	Platinum	0-8	EMAP like 4	Homo sapiens	73-77
22771825-5	2012	Platinum-based combination chemotherapy showed similar efficacies in the EML4-ALK, EGFR mutation, and wild-type cohorts in terms of response rate and progression-free survival, and overall survival in the EML4-ALK cohort closely resembled that in the wild-type cohort.	Platinum	0-8	ALK receptor tyrosine kinase	Homo sapiens	78-81
22771825-5	2012	Platinum-based combination chemotherapy showed similar efficacies in the EML4-ALK, EGFR mutation, and wild-type cohorts in terms of response rate and progression-free survival, and overall survival in the EML4-ALK cohort closely resembled that in the wild-type cohort.	Platinum	0-8	epidermal growth factor receptor	Homo sapiens	83-87
22771825-5	2012	Platinum-based combination chemotherapy showed similar efficacies in the EML4-ALK, EGFR mutation, and wild-type cohorts in terms of response rate and progression-free survival, and overall survival in the EML4-ALK cohort closely resembled that in the wild-type cohort.	Platinum	0-8	EMAP like 4	Homo sapiens	205-209
22771825-5	2012	Platinum-based combination chemotherapy showed similar efficacies in the EML4-ALK, EGFR mutation, and wild-type cohorts in terms of response rate and progression-free survival, and overall survival in the EML4-ALK cohort closely resembled that in the wild-type cohort.	Platinum	0-8	ALK receptor tyrosine kinase	Homo sapiens	210-213
23011948-1	2012	The synthesis and characterisation of a novel isomeric family of closo-carborane-containing Pt(II) complexes ((R/S)-(1-4) 2 NO(3)) are reported.	Platinum	92-94	retinoschisin 1	Homo sapiens	110-120
23094695-5	2012	Because the Pt(N(H)dpa) moiety contains a mirror plane but is unsymmetrical with respect to the coordination plane, Pt(N(H)dpa)(G) adducts can form anti or syn rotamers with the guanine O6 and the central N-H of N(H)dpa on the opposite or the same side of the coordination plane, respectively.	Platinum	12-14	synemin	Homo sapiens	156-159
23162726-7	2012	We anticipate that the demonstrated in vivo PT-OCT sensitivity to GNR contrast agents is sufficient to image molecular expression in vivo.	Platinum	44-46	plexin A2	Mus musculus	47-50
23143626-0	2012	Hsa-miR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population.	Platinum	70-78	microRNA 196a-2	Homo sapiens	4-13
23069641-0	2012	BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.	Platinum	54-62	BRCA1 DNA repair associated	Homo sapiens	0-5
23148636-0	2012	Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study.	Platinum	42-50	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	15-20
23010323-11	2012	Upon its transport across the plasma membrane by CTR1 the platinum drug is likely to be internalised along with the protein.	Platinum	58-66	solute carrier family 31 member 1	Homo sapiens	49-53
23125080-0	2012	XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies.	Platinum	40-48	X-ray repair cross complementing 1	Homo sapiens	0-5
23125080-2	2012	To obtain the association between XRCC1 polymorphism and clinical outcome of platinum-based treatment for NSCLC, a meta-analysis was conducted.	Platinum	77-85	X-ray repair cross complementing 1	Homo sapiens	34-39
23125080-4	2012	A fixed effect model was used to estimate pooled odds ratio (OR) and hazard ratio (HR) with 95% confidence interval (CI) for the association between XRCC1 Arg399Gln and response or survival of platinum-based treatment for advanced NSCLC.	Platinum	193-201	X-ray repair cross complementing 1	Homo sapiens	149-154
23125080-7	2012	RESULTS: Seventeen published case-control studies that focus on the association between XRCC1 Arg399Gln and response or survival of platinum-based treatment for advanced NSCLC in 2256 subjects were included in this meta-analysis, of whom 522 were AA genotypes (23.2% frequency), 916 AG genotypes (40.6% frequency), and 818 GG genotypes (36.2% frequency).	Platinum	132-140	X-ray repair cross complementing 1	Homo sapiens	88-93
23125080-12	2012	CONCLUSIONS: Our meta-analysis suggested that XRCC1 Arg399Gln is related with the sensitivity of NSCLC patients to platinum-based treatment.	Platinum	115-123	X-ray repair cross complementing 1	Homo sapiens	46-51
22941649-5	2012	In a number of different cancers, high expression of ERCC1 has been linked to a poor response to platinum-based chemotherapy.	Platinum	97-105	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	53-58
23095772-12	2012	CONCLUSIONS: The combination of HE4 and CA-125 levels at baseline just before initiation of chemotherapy was significantly associated with decreased progression-free and overall survival and to some extent with platinum resistance.	Platinum	211-219	WAP four-disulfide core domain 2	Homo sapiens	32-35
23148636-1	2012	AIM: The association between two polymorphisms of ERCC1 and treatment outcomes after platinum-based chemotherapy in patients with advanced urothelial cancer (UC) was examined.	Platinum	85-93	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	50-55
23127410-1	2012	AIM: To investigate the influence on platinum-based chemotherapy sensitivity by silencing xeroderma pigmentosum group A (XPA) gene expression in non-small cell lung cancer (NSCLC) drug resistance cell lines (A549/DDP).	Platinum	37-45	XPA, DNA damage recognition and repair factor	Homo sapiens	90-119
23127410-1	2012	AIM: To investigate the influence on platinum-based chemotherapy sensitivity by silencing xeroderma pigmentosum group A (XPA) gene expression in non-small cell lung cancer (NSCLC) drug resistance cell lines (A549/DDP).	Platinum	37-45	XPA, DNA damage recognition and repair factor	Homo sapiens	121-124
22929863-4	2012	In this study, we show that the electrocatalytic oxidation of hydrogen peroxide on a platinum electrode generates reactive oxygen species, presumably surface-bound platinum-oxo species, which are capable of oxygen insertion reactions in analogy to oxo-ferryl radical cations in the active site of Cytochrome P450.	Platinum	85-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	297-312
23019585-3	2012	This study demonstrates that the Notch signaling pathway and Notch3 in particular are critical for the regulation of CSCs and tumor resistance to platinum.	Platinum	146-154	notch receptor 3	Homo sapiens	61-67
23019585-6	2012	Similarly, a Notch3 siRNA knockdown increases the response to platinum therapy, further demonstrating that modulation of tumor chemosensitivity by GSI is Notch specific.	Platinum	62-70	notch receptor 3	Homo sapiens	13-19
22929863-4	2012	In this study, we show that the electrocatalytic oxidation of hydrogen peroxide on a platinum electrode generates reactive oxygen species, presumably surface-bound platinum-oxo species, which are capable of oxygen insertion reactions in analogy to oxo-ferryl radical cations in the active site of Cytochrome P450.	Platinum	164-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	297-312
22727794-12	2012	SIGNIFICANCE: These data provide in vivo evidence that ET-1 directly increases glomerular permeability to albumin and that albuminuria is prevented by increased PT albumin uptake in the rat.	Platinum	161-163	endothelin 1	Rattus norvegicus	55-59
22139083-11	2012	Perhaps explaining this finding, EOC patients with the KRAS variant were significantly more likely to be platinum resistant (odds ratio=3.18, confidence interval: 1.31-7.72, P=0.0106, n=291).	Platinum	105-113	KRAS proto-oncogene, GTPase	Homo sapiens	55-59
22139083-13	2012	These findings confirm the importance of the KRAS variant in EOC, and indicate that the KRAS variant is a biomarker of poor outcome in EOC likely due to platinum resistance.	Platinum	153-161	KRAS proto-oncogene, GTPase	Homo sapiens	88-92
23010708-4	2012	Notch3 overexpression correlated with shorter progression-free/overall survival in patients with advanced stage (stage III, IV) ovarian carcinoma treated with platinum and taxane.	Platinum	159-167	notch receptor 3	Homo sapiens	0-6
22990650-0	2012	Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer.	Platinum	58-66	fibroblast growth factor 1	Homo sapiens	17-21
22990650-7	2012	MDM2 (P=0.032) and ERBB2 (P=0.064) expression was increased in platinum-sensitive patients, and FGF1 (adjusted log-rank test P=0.006), FGFR2 (P=0.04) and PDRFRB expression (P=0.037) significantly inversely influenced progression-free survival.	Platinum	63-71	MDM2 proto-oncogene	Homo sapiens	0-4
22990650-7	2012	MDM2 (P=0.032) and ERBB2 (P=0.064) expression was increased in platinum-sensitive patients, and FGF1 (adjusted log-rank test P=0.006), FGFR2 (P=0.04) and PDRFRB expression (P=0.037) significantly inversely influenced progression-free survival.	Platinum	63-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-24
22990650-8	2012	Stable FGF1 gene knockdown in platinum-resistant A2780DPP cells re-sensitised cells to both cisplatin and carboplatin.	Platinum	30-38	fibroblast growth factor 1	Homo sapiens	7-11
23141325-4	2012	The Cu,ZnSOD (SOD1) immobilized on the carbon nanotubes in polypyrrole modified platinum electrode was used as the NO biosensor.	Platinum	80-88	superoxide dismutase 1	Homo sapiens	14-18
22972432-1	2012	Myoglobin single-electron transistors were investigated using nanometer-gap platinum electrodes fabricated by electromigration at cryogenic temperatures.	Platinum	76-84	myoglobin	Homo sapiens	0-9
22966761-2	2012	The resultant POMC with a small amount of P doping is demonstrated as a metal-free electrode with excellent electrocatalytic activity for oxygen reduction reaction (ORR), coupled with much enhanced stability and alcohol tolerance compared to those of platinum via four-electron pathway in alkaline medium.	Platinum	251-259	proopiomelanocortin	Homo sapiens	14-18
22540929-1	2012	In this study, a novel amperometric glucose biosensor was developed by immobilizing glucose oxidase (GOX) by cross-linking via glutaraldehyde on electrochemically polymerized polypyrrole-poly(vinyl sulphonate) (PPy-PVS) films on the surface of a platinum (Pt) electrode.	Platinum	246-254	hydroxyacid oxidase 1	Homo sapiens	84-99
22540929-1	2012	In this study, a novel amperometric glucose biosensor was developed by immobilizing glucose oxidase (GOX) by cross-linking via glutaraldehyde on electrochemically polymerized polypyrrole-poly(vinyl sulphonate) (PPy-PVS) films on the surface of a platinum (Pt) electrode.	Platinum	246-254	hydroxyacid oxidase 1	Homo sapiens	101-104
22540929-1	2012	In this study, a novel amperometric glucose biosensor was developed by immobilizing glucose oxidase (GOX) by cross-linking via glutaraldehyde on electrochemically polymerized polypyrrole-poly(vinyl sulphonate) (PPy-PVS) films on the surface of a platinum (Pt) electrode.	Platinum	256-258	hydroxyacid oxidase 1	Homo sapiens	84-99
22540929-1	2012	In this study, a novel amperometric glucose biosensor was developed by immobilizing glucose oxidase (GOX) by cross-linking via glutaraldehyde on electrochemically polymerized polypyrrole-poly(vinyl sulphonate) (PPy-PVS) films on the surface of a platinum (Pt) electrode.	Platinum	256-258	hydroxyacid oxidase 1	Homo sapiens	101-104
22435971-0	2012	Calpain-2 expression is associated with response to platinum based chemotherapy, progression-free and overall survival in ovarian cancer.	Platinum	52-60	calpain 2	Homo sapiens	0-9
22456757-11	2012	Instead, higher FOXP3(+)/CD8(+) ratio in tumor sites was an independent factor for poor response to platinum-based chemotherapy in overall cohort.	Platinum	100-108	forkhead box P3	Homo sapiens	16-21
22456757-11	2012	Instead, higher FOXP3(+)/CD8(+) ratio in tumor sites was an independent factor for poor response to platinum-based chemotherapy in overall cohort.	Platinum	100-108	CD8a molecule	Homo sapiens	25-28
22456757-12	2012	These findings suggest that immunological CD8(+) and FOXP3(+)Tregs cell infiltrate within tumor environment is predictive of response to platinum-based neoadjuvant chemotherapy in advanced NSCLC patients.	Platinum	137-145	CD8a molecule	Homo sapiens	42-45
22794121-4	2012	Recently, several members of the ATP-binding cassette (ABC), solute carrier (SLC) and ATPase membrane protein superfamilies have been found to contribute to the net accumulation of platinum drugs in malignant and normal tissues.	Platinum	181-189	C-C motif chemokine ligand 21	Homo sapiens	61-81
22926640-10	2012	A PARP inhibitor, olaparib, applied as maintenance treatment also improved PFS in platinum-sensitive relapsed ovarian cancer.	Platinum	82-90	poly(ADP-ribose) polymerase 1	Homo sapiens	2-6
22435971-6	2012	The association between calpain-2 expression and overall survival remained significant in multivariate analysis accounting for tumour grade, stage, optimal debulking and platinum sensitivity (hazard ratio = 2.174; 95% confidence interval = 1.144-4.130; P = 0.018).	Platinum	170-178	calpain 2	Homo sapiens	24-33
22435971-7	2012	The results suggest that determining calpain-2 expression in ovarian carcinomas may allow prognostic stratification of patients treated with surgery and platinum-based chemotherapy.	Platinum	153-161	calpain 2	Homo sapiens	37-46
22456757-12	2012	These findings suggest that immunological CD8(+) and FOXP3(+)Tregs cell infiltrate within tumor environment is predictive of response to platinum-based neoadjuvant chemotherapy in advanced NSCLC patients.	Platinum	137-145	forkhead box P3	Homo sapiens	53-58
22982660-9	2012	CONCLUSIONS: Our results support the hypothesis that DNA repair gene polymorphisms, particularly XRCC1 Arg399Gln, may modify the response to gemcitabine-platinum combination chemotherapy and, for the first time, show this effect in patients with MM.	Platinum	153-161	X-ray repair cross complementing 1	Homo sapiens	97-102
22953987-1	2012	Platinum(IV) prodrug diaminedichlorodihydroxyplatinum (ACHP) conjugated with a histone deacetylase (HDAC) inhibitor valproic acid (VA), VAAP, exhibited strong synergistic cytotoxicity, about 50-100 times more cytotoxic than ACHP or its simple mixture with VA, against various human carcinoma cell lines.	Platinum	0-8	limb development membrane protein 1	Homo sapiens	55-59
22953987-1	2012	Platinum(IV) prodrug diaminedichlorodihydroxyplatinum (ACHP) conjugated with a histone deacetylase (HDAC) inhibitor valproic acid (VA), VAAP, exhibited strong synergistic cytotoxicity, about 50-100 times more cytotoxic than ACHP or its simple mixture with VA, against various human carcinoma cell lines.	Platinum	0-8	histone deacetylase 9	Homo sapiens	79-98
22953987-1	2012	Platinum(IV) prodrug diaminedichlorodihydroxyplatinum (ACHP) conjugated with a histone deacetylase (HDAC) inhibitor valproic acid (VA), VAAP, exhibited strong synergistic cytotoxicity, about 50-100 times more cytotoxic than ACHP or its simple mixture with VA, against various human carcinoma cell lines.	Platinum	0-8	histone deacetylase 9	Homo sapiens	100-104
22953987-1	2012	Platinum(IV) prodrug diaminedichlorodihydroxyplatinum (ACHP) conjugated with a histone deacetylase (HDAC) inhibitor valproic acid (VA), VAAP, exhibited strong synergistic cytotoxicity, about 50-100 times more cytotoxic than ACHP or its simple mixture with VA, against various human carcinoma cell lines.	Platinum	0-8	limb development membrane protein 1	Homo sapiens	224-228
23020798-0	2012	Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review.	Platinum	109-117	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	17-22
23075683-2	2012	The aim of this study is to investigate the protein expression levels of Keap1 in non-small cell lung cancer (NSCLC) patients as well as to correlate its expression with the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients treated with platinum-based first-line chemotherapy.	Platinum	278-286	kelch like ECH associated protein 1	Homo sapiens	73-78
23075683-5	2012	The Keap1 expression was significantly correlated with the RR and PFS after platinum-based chemotherapy (P&lt;0.05) but not with the gender, age, smoking, pathology type, differentiation, metastasis, and OS (P&gt;0.05).	Platinum	76-84	kelch like ECH associated protein 1	Homo sapiens	4-9
23075683-7	2012	Furthermore, the level of Keap1 expression was an independent predictive factor of PFS after platinum-based first-line chemotherapy (P=0.007).	Platinum	93-101	kelch like ECH associated protein 1	Homo sapiens	26-31
23075683-8	2012	CONCLUSIONS: The expression of Keap1 was significantly correlated with the RR and PFS of platinum-based first-line chemotherapy.	Platinum	89-97	kelch like ECH associated protein 1	Homo sapiens	31-36
22766400-1	2012	We assessed whether single nucleotide polymorphisms (SNPs) in MDR1 gene C3435T predicted the outcome of platinum-based chemotherapies and survival in our non small cell lung cancer (NSCLC) patients.	Platinum	104-112	ATP binding cassette subfamily B member 1	Homo sapiens	62-66
22962276-5	2012	Because hCtr1 can also transport platinum drugs, this finding underscores the important role of hCtr1 in platinum-drug sensitivity in cancer chemotherapy.	Platinum	33-41	solute carrier family 31 member 1	Homo sapiens	8-13
22891266-6	2012	The relationship between tissue platinum concentration and survival was assessed by univariate and multicovariate Cox proportional hazards regression model analysis and Kaplan-Meier analysis.	Platinum	32-40	cytochrome c oxidase subunit 8A	Homo sapiens	114-117
22891266-10	2012	Patients with higher platinum concentration had longer time to recurrence (P = .034), progression-free survival (P = .018), and overall survival (P = .005) in the multicovariate Cox model analysis after adjusting for number of cycles.	Platinum	21-29	cytochrome c oxidase subunit 8A	Homo sapiens	178-181
23020798-0	2012	Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review.	Platinum	109-117	hematopoietic prostaglandin D synthase	Homo sapiens	24-28
23020798-0	2012	Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review.	Platinum	109-117	methylenetetrahydrofolate reductase	Homo sapiens	37-42
23020798-9	2012	CONCLUSION: Polymorphisms of ERCC1, GSTs, TS and MTHFR were closely associated with clinical outcomes of GC patients treated with platinum/5-Fu-based chemotherapy.	Platinum	130-138	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	29-34
23020798-9	2012	CONCLUSION: Polymorphisms of ERCC1, GSTs, TS and MTHFR were closely associated with clinical outcomes of GC patients treated with platinum/5-Fu-based chemotherapy.	Platinum	130-138	hematopoietic prostaglandin D synthase	Homo sapiens	36-40
22962276-5	2012	Because hCtr1 can also transport platinum drugs, this finding underscores the important role of hCtr1 in platinum-drug sensitivity in cancer chemotherapy.	Platinum	105-113	solute carrier family 31 member 1	Homo sapiens	8-13
23020798-9	2012	CONCLUSION: Polymorphisms of ERCC1, GSTs, TS and MTHFR were closely associated with clinical outcomes of GC patients treated with platinum/5-Fu-based chemotherapy.	Platinum	130-138	methylenetetrahydrofolate reductase	Homo sapiens	49-54
22962276-5	2012	Because hCtr1 can also transport platinum drugs, this finding underscores the important role of hCtr1 in platinum-drug sensitivity in cancer chemotherapy.	Platinum	105-113	solute carrier family 31 member 1	Homo sapiens	96-101
22987969-6	2012	The suggested benefit of neoadjuvant platinum, mainly in BRCA1-related cancers, needs to be confirmed in large randomized trials.	Platinum	37-45	BRCA1 DNA repair associated	Homo sapiens	57-62
22684743-0	2012	DNA repair protein expression in resected NSCLC: a different predictive value for platinum benefit in adenocarcinoma versus squamous-cell carcinoma?	Platinum	82-90	X-ray repair cross complementing 6 pseudogene 5	Homo sapiens	0-18
22791366-4	2012	Tumors arising in patients with BRCA mutations were shown to be particularly sensitive to platinum compounds or inhibitors of poly(ADP-ribose) polymerase.	Platinum	90-98	BRCA1 DNA repair associated	Homo sapiens	32-36
22725681-0	2012	Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients.	Platinum	67-75	solute carrier family 31 member 1	Homo sapiens	24-52
22725681-5	2012	Copper transporter protein 1 (CTR1) plays an essential role in cisplatin influx and is closely related to platinum resistance by influencing platinum uptake and accumulation.	Platinum	106-114	solute carrier family 31 member 1	Homo sapiens	0-28
22441531-0	2012	Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment.	Platinum	97-105	caspase 7	Homo sapiens	15-20
22441531-2	2012	We, therefore, explored whether single nucleotide polymorphisms (SNPs) of the CASP7 gene can modulate outcomes of patients with advanced non-small cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapy.	Platinum	196-204	caspase 7	Homo sapiens	78-83
22441531-3	2012	METHODS: We systematically genotyped 17 SNPs of CASP7 first in a discovery set of 279 patients with advanced NSCLC treated with platinum-based chemotherapy and then replicated the results in an independent set of 384 patients, in whom we evaluated associations with overall survival (OS) and progress-free survival (PFS) by Kaplan-Meier analysis and Cox hazards regression analysis.	Platinum	128-136	caspase 7	Homo sapiens	48-53
22725681-5	2012	Copper transporter protein 1 (CTR1) plays an essential role in cisplatin influx and is closely related to platinum resistance by influencing platinum uptake and accumulation.	Platinum	106-114	solute carrier family 31 member 1	Homo sapiens	30-34
22441531-6	2012	CONCLUSIONS: This study provides evidence that genetic variations of CASP7 may modulate OS and PFS of patients with advanced NSCLC treated with platinum-based chemotherapy.	Platinum	144-152	caspase 7	Homo sapiens	69-74
22725681-5	2012	Copper transporter protein 1 (CTR1) plays an essential role in cisplatin influx and is closely related to platinum resistance by influencing platinum uptake and accumulation.	Platinum	141-149	solute carrier family 31 member 1	Homo sapiens	0-28
22725681-5	2012	Copper transporter protein 1 (CTR1) plays an essential role in cisplatin influx and is closely related to platinum resistance by influencing platinum uptake and accumulation.	Platinum	141-149	solute carrier family 31 member 1	Homo sapiens	30-34
22725681-6	2012	The aim of the present study was to determine whether CTR1 polymorphisms are associated with platinum resistance in non-small cell lung carcinoma (NSCLC) patients.	Platinum	93-101	solute carrier family 31 member 1	Homo sapiens	54-58
22725681-12	2012	Genetic polymorphisms of CTR1 at rs7851395 and rs12686377 were associated with platinum resistance in NSCLC patients.	Platinum	79-87	solute carrier family 31 member 1	Homo sapiens	25-29
22725681-16	2012	Thus, CTR1 plays an essential role in platinum resistance and could be considered a predictive marker for the pretreatment evaluation of NSCLC patients.	Platinum	38-46	solute carrier family 31 member 1	Homo sapiens	6-10
22609620-3	2012	Much attention has focused on ERCC1 as a potential predictor of response to therapy because of its essential role in the repair of platinum-induced DNA damage.	Platinum	131-139	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	30-35
22609596-0	2012	Highly sensitive electrochemical impedance sensing of PEP gene based on integrated Au-Pt alloy nanoparticles and polytyramine.	Platinum	86-88	phosphoenolpyruvate carboxykinase 1	Homo sapiens	54-57
22609620-4	2012	The purpose of this study was to accurately measure protein levels of ERCC1 and its essential binding partner XPF from patients with EOC treated with platinum-based therapy and determine if protein levels correlate with mRNA levels, patient genotypes or clinical outcomes.	Platinum	150-158	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	70-75
21805378-1	2012	This study aimed to investigate association between single-nucleotide polymorphisms (SNPs) of excision repair cross-complementing gene 1 (ERCC1), excision repair cross-complementing gene 2 (ERCC2), and X-ray repair cross-complementing group 1 (XRCC1) with sensitivity of advanced non-small cell lung cancer (NSCLC) patients to platinum-based chemotherapy.	Platinum	327-335	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	138-143
21805378-1	2012	This study aimed to investigate association between single-nucleotide polymorphisms (SNPs) of excision repair cross-complementing gene 1 (ERCC1), excision repair cross-complementing gene 2 (ERCC2), and X-ray repair cross-complementing group 1 (XRCC1) with sensitivity of advanced non-small cell lung cancer (NSCLC) patients to platinum-based chemotherapy.	Platinum	327-335	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	190-195
22608006-0	2012	Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.	Platinum	162-170	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	25-30
21805378-1	2012	This study aimed to investigate association between single-nucleotide polymorphisms (SNPs) of excision repair cross-complementing gene 1 (ERCC1), excision repair cross-complementing gene 2 (ERCC2), and X-ray repair cross-complementing group 1 (XRCC1) with sensitivity of advanced non-small cell lung cancer (NSCLC) patients to platinum-based chemotherapy.	Platinum	327-335	X-ray repair cross complementing 1	Homo sapiens	202-242
22608006-6	2012	Therefore, we evaluated the impact of ERCC2 haplotype-tagging SNPs (htSNPs) on the clinical parameters of first-line platinum-based chemotherapy in unresectable NSCLC.	Platinum	117-125	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	38-43
22608006-15	2012	CONCLUSIONS: ERCC2 htSNPs rs50872 (overall), rs238405 (taxane-platinum doublets group), and rs238416 (gemcitabine-platinum doublets group) and infection related to first-line chemotherapy were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy.	Platinum	114-122	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	13-18
21805378-9	2012	The combined polymorphisms of ERCC1, ERCC2, and XRCC1 may be associated with sensitivity of NSCLC to platinum-based chemotherapy.	Platinum	101-109	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	30-35
22608006-15	2012	CONCLUSIONS: ERCC2 htSNPs rs50872 (overall), rs238405 (taxane-platinum doublets group), and rs238416 (gemcitabine-platinum doublets group) and infection related to first-line chemotherapy were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy.	Platinum	114-122	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	13-18
21805378-9	2012	The combined polymorphisms of ERCC1, ERCC2, and XRCC1 may be associated with sensitivity of NSCLC to platinum-based chemotherapy.	Platinum	101-109	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	37-42
21805378-9	2012	The combined polymorphisms of ERCC1, ERCC2, and XRCC1 may be associated with sensitivity of NSCLC to platinum-based chemotherapy.	Platinum	101-109	X-ray repair cross complementing 1	Homo sapiens	48-53
25806180-12	2012	The MET/HGF axis plays a major role in development of radioresistance and chemoresistance to platinums, taxanes, camtothecins and anthracyclines by inhibiting apoptosis via activation of PI3K-AKT pathway.	Platinum	93-102	hepatocyte growth factor	Homo sapiens	8-11
22710939-0	2012	Sec61beta controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A.	Platinum	34-42	SEC61 translocon subunit beta	Homo sapiens	0-9
22710939-0	2012	Sec61beta controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A.	Platinum	34-42	ATPase copper transporting alpha	Homo sapiens	131-136
22710939-2	2012	We discovered that the Sec61beta subunit modulates cellular sensitivity to chemotherapeutic agents, particularly the platinum drugs.	Platinum	117-125	SEC61 translocon subunit beta	Homo sapiens	23-40
22710939-10	2012	We conclude that Sec61beta modulates the cytotoxicity of many chemotherapeutic agents, with the largest effect being on the platinum drugs.	Platinum	124-132	SEC61 translocon subunit beta	Homo sapiens	17-26
22710939-11	2012	This modulation occurs through effects of Sec61beta on the expression and distribution of ATP7A, which was shown previously to control platinum drug sequestration and cytotoxicity.	Platinum	135-143	SEC61 translocon subunit beta	Homo sapiens	42-51
22710939-11	2012	This modulation occurs through effects of Sec61beta on the expression and distribution of ATP7A, which was shown previously to control platinum drug sequestration and cytotoxicity.	Platinum	135-143	ATPase copper transporting alpha	Homo sapiens	90-95
22733664-9	2012	Finally, flexibility analysis also indicates that the crosslinking of platinum to pairs of Met residues will effectively close the nonpolar groove and thus will likely interfere with the binding of CaM to its protein targets, as was proved by comparing assays for cisplatin-modified/unmodified CaM binding to melittin.	Platinum	70-78	calmodulin 1	Homo sapiens	198-201
22733664-9	2012	Finally, flexibility analysis also indicates that the crosslinking of platinum to pairs of Met residues will effectively close the nonpolar groove and thus will likely interfere with the binding of CaM to its protein targets, as was proved by comparing assays for cisplatin-modified/unmodified CaM binding to melittin.	Platinum	70-78	calmodulin 1	Homo sapiens	294-297
22281752-2	2012	Recent research has shown that expression of ERCC1 may predict resistance to treatment with platinum agents.	Platinum	92-100	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	45-50
22869732-1	2012	Expression of functional breast cancer susceptibility gene 1 (BRCA1) in human breast and ovarian cancers is associated with resistance to platinum-based chemotherapeutics and poly(ADP ribose) polymerase (PARP) inhibitors.	Platinum	138-146	BRCA1 DNA repair associated	Homo sapiens	62-67
22869732-1	2012	Expression of functional breast cancer susceptibility gene 1 (BRCA1) in human breast and ovarian cancers is associated with resistance to platinum-based chemotherapeutics and poly(ADP ribose) polymerase (PARP) inhibitors.	Platinum	138-146	poly(ADP-ribose) polymerase 1	Homo sapiens	175-202
22869732-1	2012	Expression of functional breast cancer susceptibility gene 1 (BRCA1) in human breast and ovarian cancers is associated with resistance to platinum-based chemotherapeutics and poly(ADP ribose) polymerase (PARP) inhibitors.	Platinum	138-146	poly(ADP-ribose) polymerase 1	Homo sapiens	204-208
22869732-6	2012	We demonstrate that the heat-shock protein 90 (HSP90) inhibitor 17-allylamino-17-demethoxygeldanamycin [17-AAG (Tanespimycin)], currently in Phase II/III clinical evaluation for several cancers, induces BRCA1 ubiquitination and proteasomal degradation, resulting in compromised repair of ionizing radiation- and platinum-induced DNA damage.	Platinum	312-320	heat shock protein 90 alpha family class A member 1	Homo sapiens	24-45
22869732-6	2012	We demonstrate that the heat-shock protein 90 (HSP90) inhibitor 17-allylamino-17-demethoxygeldanamycin [17-AAG (Tanespimycin)], currently in Phase II/III clinical evaluation for several cancers, induces BRCA1 ubiquitination and proteasomal degradation, resulting in compromised repair of ionizing radiation- and platinum-induced DNA damage.	Platinum	312-320	heat shock protein 90 alpha family class A member 1	Homo sapiens	47-52
22752226-0	2012	Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility.	Platinum	32-40	microRNA 193b	Homo sapiens	73-81
22752226-5	2012	Examining the relationships among rs1649942, its gene expression targets, genome-wide miRNA expression, and cellular sensitivity to carboplatin and cisplatin, we identified 2 platinum-associated miRNAs (miR-193b* and miR-320) that inhibit the expression of 5 platinum-associated genes (CRIM1, IFIT2, OAS1, KCNMA1, and GRAMD1B).	Platinum	175-183	microRNA 193b	Homo sapiens	203-211
22752226-5	2012	Examining the relationships among rs1649942, its gene expression targets, genome-wide miRNA expression, and cellular sensitivity to carboplatin and cisplatin, we identified 2 platinum-associated miRNAs (miR-193b* and miR-320) that inhibit the expression of 5 platinum-associated genes (CRIM1, IFIT2, OAS1, KCNMA1, and GRAMD1B).	Platinum	175-183	cysteine rich transmembrane BMP regulator 1	Homo sapiens	286-291
22752226-5	2012	Examining the relationships among rs1649942, its gene expression targets, genome-wide miRNA expression, and cellular sensitivity to carboplatin and cisplatin, we identified 2 platinum-associated miRNAs (miR-193b* and miR-320) that inhibit the expression of 5 platinum-associated genes (CRIM1, IFIT2, OAS1, KCNMA1, and GRAMD1B).	Platinum	175-183	interferon induced protein with tetratricopeptide repeats 2	Homo sapiens	293-298
22752226-5	2012	Examining the relationships among rs1649942, its gene expression targets, genome-wide miRNA expression, and cellular sensitivity to carboplatin and cisplatin, we identified 2 platinum-associated miRNAs (miR-193b* and miR-320) that inhibit the expression of 5 platinum-associated genes (CRIM1, IFIT2, OAS1, KCNMA1, and GRAMD1B).	Platinum	175-183	2'-5'-oligoadenylate synthetase 1	Homo sapiens	300-304
22752226-5	2012	Examining the relationships among rs1649942, its gene expression targets, genome-wide miRNA expression, and cellular sensitivity to carboplatin and cisplatin, we identified 2 platinum-associated miRNAs (miR-193b* and miR-320) that inhibit the expression of 5 platinum-associated genes (CRIM1, IFIT2, OAS1, KCNMA1, and GRAMD1B).	Platinum	175-183	potassium calcium-activated channel subfamily M alpha 1	Homo sapiens	306-312
22752226-5	2012	Examining the relationships among rs1649942, its gene expression targets, genome-wide miRNA expression, and cellular sensitivity to carboplatin and cisplatin, we identified 2 platinum-associated miRNAs (miR-193b* and miR-320) that inhibit the expression of 5 platinum-associated genes (CRIM1, IFIT2, OAS1, KCNMA1, and GRAMD1B).	Platinum	175-183	GRAM domain containing 1B	Homo sapiens	318-325
22752226-6	2012	We further replicated the relationship between the expression of miR-193b*, CRIM1, IFIT2, KCNMA1, and GRAMD1B, and platinum sensitivity in a separate HapMap CEU III dataset.	Platinum	115-123	microRNA 193b	Homo sapiens	65-73
22752226-6	2012	We further replicated the relationship between the expression of miR-193b*, CRIM1, IFIT2, KCNMA1, and GRAMD1B, and platinum sensitivity in a separate HapMap CEU III dataset.	Platinum	115-123	potassium calcium-activated channel subfamily M alpha 1	Homo sapiens	90-96
22752226-10	2012	Further examination of miR-193b* in platinum sensitivity in ovarian cancer is warranted.	Platinum	36-44	microRNA 193b	Homo sapiens	23-31
22634097-6	2012	MATERIAL AND METHODS: We analyzed RAD51 G172T polymorphism genotypes in cervical cancer patients who underwent a platinum-based chemotherapy in combination with radiotherapy.	Platinum	113-121	RAD51 recombinase	Homo sapiens	34-39
22860255-0	2012	Removal notice to: "A polymorphism in the 5" untranslated region of ERCC5 determines effectiveness of platinum-based chemotherapeutics" [Toxicology 290 (2011) 118].	Platinum	102-110	ERCC excision repair 5, endonuclease	Homo sapiens	68-73
26592130-1	2012	The cellular uptake of cisplatin and of other platinum-based drugs is mediated by the high-affinity copper transporter Ctr1.	Platinum	46-54	solute carrier family 31 member 1	Homo sapiens	119-123
26592130-3	2012	It is an excellent model for investigating the interaction of platinum drugs with Ctr1 under in vitro and in vivo conditions.	Platinum	62-70	solute carrier family 31 member 1	Homo sapiens	82-86
22034009-0	2012	Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer.	Platinum	95-103	fibroblast growth factor receptor 4	Homo sapiens	0-35
22034009-0	2012	Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer.	Platinum	95-103	fibroblast growth factor receptor 4	Homo sapiens	42-47
22034009-9	2012	Furthermore, the FGFR4 388Arg genotype significantly correlated with platinum sensitivity in the same subgroup (multivariate OR 3.81 p = 0.004).	Platinum	69-77	fibroblast growth factor receptor 4	Homo sapiens	17-22
22034009-10	2012	FGFR4 Arg388Gly genotype is an independent and strong context specific prognostic factor in patients with advanced ovarian cancer and could be used to predict platinum-sensitivity.	Platinum	159-167	fibroblast growth factor receptor 4	Homo sapiens	0-5
22696230-10	2012	Galectin-1 knockdown sensitized lung cancer cells to platinum-based chemotherapy (cisplatin).	Platinum	53-61	galectin 1	Homo sapiens	0-10
22733161-0	2012	CO oxidation on nanostructured SnO(x)/Pt(111) surfaces: unique properties of reduced SnO(x).	Platinum	38-40	strawberry notch homolog 1	Homo sapiens	85-88
22852778-3	2012	The purposes of this study were to: 1) analyze the association between chemotherapy-induced changes in plasma fibrinogen level and the chemotherapeutic response after the first two courses of standard first-line platinum-based chemotherapy; and 2) evaluate the prognostic significance of the basal plasma fibrinogen level in patients with advanced NSCLC.	Platinum	212-220	fibrinogen beta chain	Homo sapiens	110-120
22119437-2	2012	The most common mutations (L858R and exon 19 deletions) predict an improved clinical response to first-line oral EGFR-TKIs compared with standard platinum-based chemotherapy in patients with advanced NSCLC.	Platinum	146-154	epidermal growth factor receptor	Homo sapiens	113-117
22568453-0	2012	Association of CASP3 polymorphism with hematologic toxicity in patients with advanced non-small-cell lung carcinoma treated with platinum-based chemotherapy.	Platinum	129-137	caspase 3	Homo sapiens	15-20
22932088-0	2012	A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer.	Platinum	74-82	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	26-31
22866924-17	2012	With this approach, NSCLC patients with aberrant intratumoral TYMS expression will probably fare better with platinum-based treatments.	Platinum	109-117	thymidylate synthetase	Homo sapiens	62-66
22784773-0	2012	Re: Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer.	Platinum	13-21	angiotensin II receptor type 1	Homo sapiens	70-100
23012300-6	2012	In particular, the substantial proportion of TNBC tumours associated with BRCA1 mutations is driving clinical research into the use of DNA-damaging agents such as platinums, as well as of potentiators of DNA damage such as the investigational agent iniparib and inhibitors of poly-ADP ribose polymerase such as olaparib.	Platinum	163-172	BRCA1 DNA repair associated	Homo sapiens	74-79
23012302-5	2012	Platinum-based regimens are an emerging option for patients with BRCA1 mutation, and newer targeted agents such as anti-angiogenic treatment with bevacizumab or anti-epidermal growth factor receptor treatment with cetuximab, have shown some benefit in combination therapy.	Platinum	0-8	BRCA1 DNA repair associated	Homo sapiens	65-70
22932088-10	2012	CONCLUSIONS: The results indicated that platinum-based chemotherapy sensitivity was significantly associated with polymorphism of ERCC1 C118T and MDR1 C3435T SNP.	Platinum	40-48	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	130-135
22932088-10	2012	CONCLUSIONS: The results indicated that platinum-based chemotherapy sensitivity was significantly associated with polymorphism of ERCC1 C118T and MDR1 C3435T SNP.	Platinum	40-48	ATP binding cassette subfamily B member 1	Homo sapiens	146-150
22932088-11	2012	In further perspective studies, the ERCC1/MDR1 SNPs might serve as simple and less invasive biomarkers for personalized chemotherapy with platinum-based anticancer drugs.	Platinum	138-146	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	36-41
22932088-11	2012	In further perspective studies, the ERCC1/MDR1 SNPs might serve as simple and less invasive biomarkers for personalized chemotherapy with platinum-based anticancer drugs.	Platinum	138-146	ATP binding cassette subfamily B member 1	Homo sapiens	42-46
22516052-5	2012	The purpose of this study is to investigate whether CTR1 polymorphism is associated with platinum toxicity in non-small cell lung cancer (NSCLC) patients.	Platinum	89-97	solute carrier family 31 member 1	Homo sapiens	52-56
22883407-13	2012	Down-regulation of expression of ATP7B and ATP7A, and up-regulation of hCTR1 may cause the increase of intracellular platinum content in HCT116/L-OHP cells.	Platinum	117-125	solute carrier family 31 member 1	Homo sapiens	71-76
22521649-11	2012	CONCLUSIONS: Our current data indicate that lung cancer patients with EGFR-mutations had longer PFS with taxane than gemcitabine when receiving a platinum-based doublet regimen.	Platinum	146-154	epidermal growth factor receptor	Homo sapiens	70-74
22938324-7	2012	Specifically, we show that by using appropriate instrumentation and a 10 kOmega platinum resistance thermometer it is possible to measure modulated temperatures (0.5-20 Hz) with a resolution of about 20-100 muK.	Platinum	80-88	mitogen-activated protein kinase kinase kinase 12	Homo sapiens	207-210
22555222-0	2012	ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.	Platinum	205-213	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
22555222-1	2012	PURPOSE: To utilize a novel circulating tumor cell (CTC) technology to quantify ERCC1 expression on CTCs and determine whether ERCC1 expression levels predict efficacy of platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer (NSCLC).	Platinum	171-179	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	127-132
22555222-2	2012	EXPERIMENTAL DESIGN: ERCC1 expression was measured in 17 metastatic NSCLC patients who received platinum-based therapy and had &gt;=2 intact CTCs with acceptable ERCC1 expression assay results.	Platinum	96-104	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	21-26
22555222-10	2012	CONCLUSION: Low expression of ERCC1 on CTCs correlates with PFS in patients with metastatic NSCLC receiving platinum-based therapy.	Platinum	108-116	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	30-35
22752467-5	2012	A strong expression of AGR2 was seen in 15 HGSCs (12.1 %) and was significantly linked to shortened overall survival (OS, p = 0.011) and also for progression-free survival (PFS, p = 0.001) in the setting of adjuvant platinum-based chemotherapy (CTX).	Platinum	216-224	anterior gradient 2, protein disulphide isomerase family member	Homo sapiens	23-27
22752467-11	2012	Our data strongly support the further evaluation of AGR2 as a therapeutic target and a potential marker for response to platinum-based CTX in this tumor entity.	Platinum	120-128	anterior gradient 2, protein disulphide isomerase family member	Homo sapiens	52-56
22714952-0	2012	A general and high-yield galvanic displacement approach to Au-M (M = Au, Pd, and Pt) core-shell nanostructures with porous shells and enhanced electrocatalytic performances.	Platinum	81-83	phosphoglycolate phosphatase	Homo sapiens	59-63
22714952-1	2012	In this work, we utilize the galvanic displacement synthesis and make it a general and efficient method for the preparation of Au-M (M = Au, Pd, and Pt) core-shell nanostructures with porous shells, which consist of multilayer nanoparticles.	Platinum	149-151	phosphoglycolate phosphatase	Homo sapiens	127-131
22714952-7	2012	Thus, porous Au-M (M = Au, Pd, and Pt) core-shell nanostructures may provide many opportunities in the fields of organic catalysis, direct alcohol fuel cells, surface-enhanced Raman scattering, and so forth.	Platinum	35-37	phosphoglycolate phosphatase	Homo sapiens	13-17
22742927-0	2012	Insulin amyloid fibrils: an excellent platform for controlled synthesis of ultrathin superlong platinum nanowires with high electrocatalytic activity.	Platinum	95-103	insulin	Homo sapiens	0-7
22711857-7	2012	Mutation-negative patients who responded to multiple cycles of platin-based treatment were more likely to carry somatic BRCA1/2 mutations.	Platinum	63-69	BRCA1 DNA repair associated	Homo sapiens	120-125
22705987-0	2012	Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis.	Platinum	48-56	X-ray repair cross complementing 1	Homo sapiens	20-25
22072145-0	2012	Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy.	Platinum	138-146	matrix metallopeptidase 2	Homo sapiens	0-26
22072145-12	2012	CONCLUSIONS: To the authors" knowledge, this study provides the first evidence for a predictive role of MMP-2 polymorphisms in the variability of severe chemotherapy-related neutropenia among Chinese patients with platinum-treated, advanced NSCLC.	Platinum	214-222	matrix metallopeptidase 2	Homo sapiens	104-109
22734825-5	2012	Another isomer containing both S- and N-coordinated thiocyanato ligands, [Pt(SCN)(NCS)(H(2)dcbpy)] (1SN), was obtained as a nonluminescent yellow solid simply by exposure of 1SS H(2)O to acetone vapor at room temperature, and about 80% of 1SS H(2)O was found to be converted to 1SN.	Platinum	74-76	sorcin	Homo sapiens	77-80
22705987-1	2012	PURPOSE: Published data have shown conflicting results about the relationship between X-ray repair cross-complementing group 1 (XRCC1) gene polymorphisms (Arg399Gln and Arg194Trp) and clinical outcome of platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).	Platinum	204-212	X-ray repair cross complementing 1	Homo sapiens	86-126
22705987-1	2012	PURPOSE: Published data have shown conflicting results about the relationship between X-ray repair cross-complementing group 1 (XRCC1) gene polymorphisms (Arg399Gln and Arg194Trp) and clinical outcome of platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).	Platinum	204-212	X-ray repair cross complementing 1	Homo sapiens	128-133
22751260-6	2012	Consequently, characters of platinum clusters adsorbed on the sp2 surface can be changed by introducing vacancy-type defects.	Platinum	28-36	Sp2 transcription factor	Homo sapiens	62-65
22072307-11	2012	CONCLUSIONS: Both cDC and sDC regimens have activity in recurrent platinum-sensitive EOC with acceptable toxicity profiles.	Platinum	66-74	syndecan 1	Homo sapiens	26-29
22801507-2	2012	BRCA-mutated ovarian cancer often presents at an advanced stage, however, tend to have better response to platinum-based chemotherapy as compared with sporadic cases of epithelial ovarian cancer (EOC).	Platinum	106-114	BRCA1 DNA repair associated	Homo sapiens	0-4
22743243-7	2012	Optimal chemotherapy regimens is not yet determined and platin based chemotherapy could offer an effective alternative as the developpement of specific targeted therapies (anti Her1) could do.	Platinum	56-62	epidermal growth factor receptor	Homo sapiens	177-181
22356895-0	2012	MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.	Platinum	42-50	MDM2 proto-oncogene	Homo sapiens	0-4
22696244-0	2012	Microwave decoration of Pt nanoparticles on entangled 3D carbon nanotube architectures as PEM fuel cell cathode.	Platinum	24-26	mucin 1, cell surface associated	Homo sapiens	90-93
22615137-1	2012	The human copper transporter 1 (hCtr1) mediates cellular uptake of copper and Pt-based chemotherapeutic anticancer drugs.	Platinum	78-80	solute carrier family 31 member 1	Homo sapiens	10-30
22615137-1	2012	The human copper transporter 1 (hCtr1) mediates cellular uptake of copper and Pt-based chemotherapeutic anticancer drugs.	Platinum	78-80	solute carrier family 31 member 1	Homo sapiens	32-37
21739480-4	2012	Furthermore, a significant effect of SNPs in nucleotide excision repair pathway on lung cancer survival was observed among 185 stages III-IV patients treated with platinum-based chemotherapy without surgical operation: XPC rs2228000 (Ala499Val; P = 0.002) and ERCC1 rs11615 (Asn118Asn; P = 0.012).	Platinum	163-171	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	260-265
22595458-8	2012	Global demethylation in a platinum drug-resistant human gastric cancer cell line reversed Casp8AP2 methylation and diminished drug resistance.	Platinum	26-34	caspase 8 associated protein 2	Homo sapiens	90-98
24198494-3	2012	Different nanostructures of iron-platinum alloy and chemically disordered iron-platinum L10 phase were obtained without annealing.	Platinum	79-87	immunoglobulin kappa variable 3-7 (non-functional)	Homo sapiens	88-91
22524464-1	2012	The performance of a single platinum (Pt) nanowire for detecting H(2) in air is reported.	Platinum	28-36	relaxin 2	Homo sapiens	65-69
22524464-1	2012	The performance of a single platinum (Pt) nanowire for detecting H(2) in air is reported.	Platinum	38-40	relaxin 2	Homo sapiens	65-69
22524464-3	2012	The amplitude of the resistance change induced by H(2) exposure and the time rate of change of the nanowire resistance both increased with increasing temperature from 298 to 550 K. This resistance decrease of the Pt nanowire in the presence of H(2) results from reduced electron diffuse scattering at hydrogen-covered Pt surfaces as compared with oxygen-covered platinum surfaces, we hypothesize.	Platinum	213-215	relaxin 2	Homo sapiens	50-54
22524464-3	2012	The amplitude of the resistance change induced by H(2) exposure and the time rate of change of the nanowire resistance both increased with increasing temperature from 298 to 550 K. This resistance decrease of the Pt nanowire in the presence of H(2) results from reduced electron diffuse scattering at hydrogen-covered Pt surfaces as compared with oxygen-covered platinum surfaces, we hypothesize.	Platinum	213-215	relaxin 2	Homo sapiens	244-248
22524464-4	2012	The properties for the detection of H(2) in air of single Pt and Pd nanowires of similar size are compared in this study.	Platinum	58-60	relaxin 2	Homo sapiens	36-40
22596241-10	2012	CONCLUSION: The identification of the Transcription/CREB pathway (associated with OVCA cell line platinum sensitivity and overall survival) could improve patient stratification for treatment with current therapies and the rational selection of future OVCA therapy agents targeted to these pathways.	Platinum	97-105	cAMP responsive element binding protein 1	Homo sapiens	52-56
22494465-1	2012	We examined the mechanism of accumulation of charged polynuclear platinum complexes (PPCs) based on analogy of polyarginine interactions with the cell surface heparan sulfate proteoglycan (HSPG) family of protein-linked glycosoaminoglycan polysaccharides (GAGs).	Platinum	65-73	syndecan 2	Homo sapiens	189-193
22494465-4	2012	Furthermore, detection of platinum accumulation in wt CHO, mutant CHO-pgsD-677 (lacking HS), and CHO-pgsA (lacking HS/CS) cells confirms that HSPG-mediated interactions are an important mechanism for PPC internalization but not so for uncharged cisplatin and oxaliplatin.	Platinum	26-34	syndecan 2	Homo sapiens	142-146
22371153-0	2012	The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum.	Platinum	167-175	GNAS complex locus	Homo sapiens	26-31
22371153-2	2012	The aim of this study was to evaluate whether the T393C polymorphism of the GNAS1 gene could be used as a chemotherapy sensitivity and prognosis predictive marker of advanced non-small-cell lung cancer (NSCLC) treated with gemcitabine plus platinum (GP).	Platinum	240-248	GNAS complex locus	Homo sapiens	76-81
22617130-11	2012	CONCLUSION: S-1+paclitaxel was suggested to be a feasible and effective non-platinum-based regimen for chemotherapy in patients with advanced gastric cancer.	Platinum	76-84	proteasome 26S subunit, non-ATPase 1	Homo sapiens	12-15
22139760-8	2012	Multivariate analysis revealed ZNF217 gene amplification to be an independent prognostic factor for progression-free and overall survival after standard platinum agent-based chemotherapy (P = .0339 and P = .031, respectively).	Platinum	153-161	zinc finger protein 217	Homo sapiens	31-37
22406760-0	2012	BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.	Platinum	46-54	BRCA1 DNA repair associated	Homo sapiens	0-7
21940774-2	2012	We hypothesized that an intronic polymorphism (rs430397G&gt;A) in GRP78 affects survival among patients with NSCLC treated with platinum-based chemotherapy.	Platinum	128-136	heat shock protein family A (Hsp70) member 5	Homo sapiens	66-71
21940774-12	2012	CONCLUSIONS: The rs430397 AA genotype of GRP78 is associated with reduced survival and higher prevalence of early relapses in patients with advanced NSCLC treated with platinum-based chemotherapy.	Platinum	168-176	heat shock protein family A (Hsp70) member 5	Homo sapiens	41-46
22476961-0	2012	Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC.	Platinum	48-56	galectin 3	Homo sapiens	0-10
22476961-1	2012	AIM: To explore the association between the galectin-3 genetic polymorphisms and Platinum-based chemotherapy response as well as the prognosis of non-small cell lung cancer (NSCLC).	Platinum	81-89	galectin 3	Homo sapiens	44-54
22406760-2	2012	METHODS: BRCA1/2 mutation analysis was performed in 29 patients with platinum-sensitive EOC and 24 patients with platinum-resistant disease.	Platinum	69-77	BRCA1 DNA repair associated	Homo sapiens	9-14
22406760-10	2012	The majority of BRCA mutations (73%) were identified in patients with platinum-sensitive disease.	Platinum	70-78	BRCA1 DNA repair associated	Homo sapiens	16-20
22406760-11	2012	In total, 38% of platinum-sensitive tumors were found to have a BRCA mutation, compared to 17% of the platinum-resistant patients.	Platinum	17-25	BRCA1 DNA repair associated	Homo sapiens	64-68
22406760-12	2012	A statistical trend toward platinum-sensitive disease was seen in BRCA mutation carriers (p=0.079).	Platinum	27-35	BRCA1 DNA repair associated	Homo sapiens	66-70
22406760-14	2012	CONCLUSIONS: BRCA mutations occurred more frequently in platinum-sensitive EOC than platinum-resistant disease.	Platinum	56-64	BRCA1 DNA repair associated	Homo sapiens	13-17
22344449-8	2012	A significant association was found between the inmunohistochemistry             expression of ERCC1 and the lack of platinum response (p=0.001).	Platinum	117-125	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	95-100
22551904-0	2012	Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.	Platinum	132-140	X-ray repair cross complementing 1	Homo sapiens	24-29
22551904-7	2012	In the validation set, only XRCC1 399 CONCLUSIONS: Genetic polymorphism of XRCC1 Arg399Gln may be a candidate for contributing interindividual difference in the OS of gemcitabine/platinum-treated advanced NSCLC patients.	Platinum	179-187	X-ray repair cross complementing 1	Homo sapiens	28-33
22588152-0	2012	A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer.	Platinum	111-119	KRAS proto-oncogene, GTPase	Homo sapiens	62-66
22551904-7	2012	In the validation set, only XRCC1 399 CONCLUSIONS: Genetic polymorphism of XRCC1 Arg399Gln may be a candidate for contributing interindividual difference in the OS of gemcitabine/platinum-treated advanced NSCLC patients.	Platinum	179-187	X-ray repair cross complementing 1	Homo sapiens	75-80
22302397-1	2012	It is hypothesized that high expression of the excision repair cross-complementation group 1 (ERCC1) gene might be a positive prognostic factor, but predict decreased sensitivity to platinum-based chemotherapy.	Platinum	182-190	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-92
22302397-1	2012	It is hypothesized that high expression of the excision repair cross-complementation group 1 (ERCC1) gene might be a positive prognostic factor, but predict decreased sensitivity to platinum-based chemotherapy.	Platinum	182-190	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	94-99
22491798-1	2012	Low levels of human copper transporter 1 (hCtr1) mRNA are associated with a shorter progression-free survival after platinum-based therapy.	Platinum	116-124	solute carrier family 31 member 1	Homo sapiens	20-40
22387291-3	2012	Because oxaliplatin, satraplatin, and picoplatin contain bulkier chemical groups attached to the platinum core compared with cisplatin, we hypothesized that these chemical additions may impede replicative bypass by TLS polymerases and reduce tolerance to platinum-containing adducts.	Platinum	97-105	FUS RNA binding protein	Homo sapiens	215-218
22387291-3	2012	Because oxaliplatin, satraplatin, and picoplatin contain bulkier chemical groups attached to the platinum core compared with cisplatin, we hypothesized that these chemical additions may impede replicative bypass by TLS polymerases and reduce tolerance to platinum-containing adducts.	Platinum	255-263	FUS RNA binding protein	Homo sapiens	215-218
22387291-6	2012	REV1 and Polzeta were necessary for tolerance to all four platinum analogs and prevention of hyperactivation of the DNA damage response after treatment.	Platinum	58-66	REV1 DNA directed polymerase	Homo sapiens	0-4
22387291-7	2012	In addition, REV1 and Polzeta were important for the resolution of DNA double-stranded breaks created during replication-associated repair of platinum-containing ICLs.	Platinum	142-150	REV1 DNA directed polymerase	Homo sapiens	13-17
22387291-9	2012	Together, our data suggest that REV1 and Polzeta are critical for promoting resistance to all four clinically relevant platinum-based drugs by promoting both translesion DNA synthesis and DNA repair.	Platinum	119-127	REV1 DNA directed polymerase	Homo sapiens	32-36
22491798-2	2012	Pretreatment with a copper-lowering agent such as trientine enhanced hCtr1-mediated platinum uptake.	Platinum	84-92	solute carrier family 31 member 1	Homo sapiens	69-74
22491798-1	2012	Low levels of human copper transporter 1 (hCtr1) mRNA are associated with a shorter progression-free survival after platinum-based therapy.	Platinum	116-124	solute carrier family 31 member 1	Homo sapiens	42-47
22452940-9	2012	CONCLUSIONS: JWA and XRCC1 protein expressions in tumor are novel candidate prognostic markers and predictive factors for benefit from adjuvant platinum-based chemotherapy (FLO or FLP) in resectable human gastric carcinoma.	Platinum	144-152	ADP ribosylation factor like GTPase 6 interacting protein 5	Homo sapiens	13-16
22249976-0	2012	Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients.	Platinum	72-80	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	24-29
22249976-1	2012	The excision repair cross-complementation group 1 (ERCC1) plays an essential role in DNA repair and has been linked to resistance to platinum-based anticancer drugs among advanced non-small cell lung cancer (NSCLC) patients.	Platinum	133-141	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	4-49
22249976-1	2012	The excision repair cross-complementation group 1 (ERCC1) plays an essential role in DNA repair and has been linked to resistance to platinum-based anticancer drugs among advanced non-small cell lung cancer (NSCLC) patients.	Platinum	133-141	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	51-56
22249976-2	2012	We systematically evaluate whether ERCC1 Asn118Asn and C8092A genetic variants are associated with treatment response of platinum chemotherapy.	Platinum	121-129	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	35-40
22249976-3	2012	We preformed a meta-analysis using ten eligible cohort studies (including 11 datasets) with a total of 1,252 NSCLC patients to summarize the existing data on the association between the ERCC1 Asn118Asn and C8092A polymorphisms and response to platinum regiments.	Platinum	243-251	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	186-191
22741034-10	2012	It is to be defined if Bax predicts sensitivity to platinum analogs or to whatever chemotherapy regimen.	Platinum	51-59	BCL2 associated X, apoptosis regulator	Homo sapiens	23-26
22736131-13	2012	CONCLUSIONS: Triplets regimens (epirubicin, platins and fluorouracil) show benefit on disease-free survival for the stage III( gastric cancer patients staged by TNM staging 2010 edition.	Platinum	44-51	teneurin transmembrane protein 1	Homo sapiens	161-164
22509843-4	2012	At concentrations greater than 100 muM and low temperature, different behavior is observed, suggesting the growth rate to be limited by the deposition reaction of platinum at the nanowire tip.	Platinum	163-171	latexin	Homo sapiens	35-38
22452940-9	2012	CONCLUSIONS: JWA and XRCC1 protein expressions in tumor are novel candidate prognostic markers and predictive factors for benefit from adjuvant platinum-based chemotherapy (FLO or FLP) in resectable human gastric carcinoma.	Platinum	144-152	X-ray repair cross complementing 1	Homo sapiens	21-26
22261301-1	2012	OBJECTIVE: Excision repair cross-complementation group 1 (ERCC1) is required for the repair of platinum-induced DNA damage.	Platinum	95-103	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	11-56
22704851-0	2012	Role of ABCB1 C3435T in platinum-based therapy.	Platinum	24-32	ATP binding cassette subfamily B member 1	Homo sapiens	8-13
22031394-8	2012	Patients who carried the homozygous mutant glutathione S-transferase pi 1(GSTP1) GG genotype were at considerable risk for severe platinum-associated polyneuropathy (18% vs 3% in wild-type vs heterozygous mutant patients, respectively; P = .01).	Platinum	130-138	glutathione S-transferase pi 1	Homo sapiens	43-73
22031394-8	2012	Patients who carried the homozygous mutant glutathione S-transferase pi 1(GSTP1) GG genotype were at considerable risk for severe platinum-associated polyneuropathy (18% vs 3% in wild-type vs heterozygous mutant patients, respectively; P = .01).	Platinum	130-138	glutathione S-transferase pi 1	Homo sapiens	74-79
22396490-7	2012	For example, low expression of the Xist gene correlated with cisplatin hypersensitivity in most tumors, and it also predicted long recurrence-free survival of HER2-negative, stage III breast cancer patients treated with intensive platinum-based chemotherapy.	Platinum	230-238	X inactive specific transcript	Homo sapiens	35-39
22396490-7	2012	For example, low expression of the Xist gene correlated with cisplatin hypersensitivity in most tumors, and it also predicted long recurrence-free survival of HER2-negative, stage III breast cancer patients treated with intensive platinum-based chemotherapy.	Platinum	230-238	erb-b2 receptor tyrosine kinase 2	Homo sapiens	159-163
22333992-2	2012	METHODS: Using the Cancer Registry databases from our institutions, a retrospective review of patients with FIGO stage IIIC and IV EOC who were treated with platinum-based NACT-IDS between January 2006 and December 2009 was conducted.	Platinum	157-165	solute carrier family 13 member 5	Homo sapiens	172-176
22333992-2	2012	METHODS: Using the Cancer Registry databases from our institutions, a retrospective review of patients with FIGO stage IIIC and IV EOC who were treated with platinum-based NACT-IDS between January 2006 and December 2009 was conducted.	Platinum	157-165	iduronate 2-sulfatase	Homo sapiens	177-180
22583667-0	2012	DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.	Platinum	101-109	TNF receptor superfamily member 6b	Homo sapiens	0-4
22583667-2	2012	In our previous work Decoy Receptor 3 (DcR3) was found to be related to platinum resistance.	Platinum	72-80	TNF receptor superfamily member 6b	Homo sapiens	21-37
22583667-2	2012	In our previous work Decoy Receptor 3 (DcR3) was found to be related to platinum resistance.	Platinum	72-80	TNF receptor superfamily member 6b	Homo sapiens	39-43
22583667-3	2012	The major objective of this work was to define the cellular interaction of DcR3 with EOC and to explore its effects on platinum responsiveness.	Platinum	119-127	TNF receptor superfamily member 6b	Homo sapiens	75-79
22583667-8	2012	RESULTS: High DcR3 in the peritoneal cavity of women with EOC is associated with significantly shorter time to first recurrence after platinum based therapy (p = 0.02).	Platinum	134-142	TNF receptor superfamily member 6b	Homo sapiens	14-18
22583667-13	2012	After DcR3 exposure both SKOV-3 and OVCAR-3 became more resistant to platinum with 15% more cells surviving at high doses.	Platinum	69-77	TNF receptor superfamily member 6b	Homo sapiens	6-10
21855113-8	2012	Higher SCARA3 expression was found in disease recurrence postchemotherapy compared with primary diagnosis prechemotherapy OC effusions (P = .001), and this difference was significant for treatment with both platinum agents (P = .006) and paclitaxel (P = .002).	Platinum	207-215	scavenger receptor class A member 3	Homo sapiens	7-13
22261301-1	2012	OBJECTIVE: Excision repair cross-complementation group 1 (ERCC1) is required for the repair of platinum-induced DNA damage.	Platinum	95-103	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	58-63
22261301-2	2012	This study sought to assess the prognostic value of ERCC1 expression, measured by immunohistochemistry (IHC) using a highly specific antibody, in advanced epithelial ovarian cancer (EOC) patients treated with platinum-based chemotherapy.	Platinum	209-217	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	52-57
22367368-3	2012	Stage IB2 to IIB patients were treated with platinum-based neoadjuvant chemotherapy.	Platinum	44-52	mitogen-activated protein kinase 8 interacting protein 2	Homo sapiens	6-9
22459168-3	2012	Platinum measurement showed that cDDP bound to wild type MBD6 but not to the SXXS variant.	Platinum	0-8	methyl-CpG binding domain protein 6	Homo sapiens	57-61
22176813-2	2012	Increasing evidence demonstrates that patients with sensitizing mutations in the epidermal growth factor receptor (EGFR) experience improved progression-free survival and response rates with first-line gefitinib or erlotinib therapy relative to traditional platinum-based chemotherapy, while patients with EGFR-mutation negative tumors gain greater benefit from platinum-based chemotherapy.	Platinum	257-265	epidermal growth factor receptor	Homo sapiens	81-113
22176813-2	2012	Increasing evidence demonstrates that patients with sensitizing mutations in the epidermal growth factor receptor (EGFR) experience improved progression-free survival and response rates with first-line gefitinib or erlotinib therapy relative to traditional platinum-based chemotherapy, while patients with EGFR-mutation negative tumors gain greater benefit from platinum-based chemotherapy.	Platinum	257-265	epidermal growth factor receptor	Homo sapiens	115-119
22176813-2	2012	Increasing evidence demonstrates that patients with sensitizing mutations in the epidermal growth factor receptor (EGFR) experience improved progression-free survival and response rates with first-line gefitinib or erlotinib therapy relative to traditional platinum-based chemotherapy, while patients with EGFR-mutation negative tumors gain greater benefit from platinum-based chemotherapy.	Platinum	362-370	epidermal growth factor receptor	Homo sapiens	81-113
22176813-2	2012	Increasing evidence demonstrates that patients with sensitizing mutations in the epidermal growth factor receptor (EGFR) experience improved progression-free survival and response rates with first-line gefitinib or erlotinib therapy relative to traditional platinum-based chemotherapy, while patients with EGFR-mutation negative tumors gain greater benefit from platinum-based chemotherapy.	Platinum	362-370	epidermal growth factor receptor	Homo sapiens	115-119
22331493-0	2012	Sodium arsenite +- hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses.	Platinum	112-120	tumor protein p53	Homo sapiens	43-46
22331493-3	2012	P53 plays a critical role in cellular response to DNA damage and has been implicated in EOC response to platinum chemotherapy.	Platinum	104-112	tumor protein p53	Homo sapiens	0-3
22331493-11	2012	Hyperthermia +- sodium arsenite enhanced cellular and DNA accumulation of platinum in wild-type p53-expressing cells.	Platinum	74-82	tumor protein p53	Homo sapiens	96-99
22532140-0	2012	Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.	Platinum	79-87	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	20-25
22331493-12	2012	Only hyperthermia enhanced platinum accumulation in p53-null cells.	Platinum	27-35	tumor protein p53	Homo sapiens	52-55
22532140-8	2012	Uncommon TT genotype of ERCC1 19007 T&amp;gt;C polymorphism could predict poor response and shortening of progression free survival in NSCLC patients treated with platinum-based I-line chemotherapy.	Platinum	163-171	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	24-29
22532140-2	2012	The excision repair cross-complementation group 1 (ERCC1) is an enzyme that executes the incision of the damaged DNA strand and removes platinum-induced DNA adducts.	Platinum	136-144	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	4-49
22532140-2	2012	The excision repair cross-complementation group 1 (ERCC1) is an enzyme that executes the incision of the damaged DNA strand and removes platinum-induced DNA adducts.	Platinum	136-144	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	51-56
22322152-8	2012	Moreover, RNA interference targeting Beclin 1, inhibition of autophagy by 3-methyladenine (3-MA) and chloroquine significantly suppressed the above process as well as the BGC-823 cells growth inhibition triggered by 12.5 muM E Platinum.	Platinum	227-235	beclin 1	Homo sapiens	37-45
22322152-0	2012	E Platinum, a newly synthesized platinum compound, induces autophagy via inhibiting phosphorylation of mTOR in gastric carcinoma BGC-823 cells.	Platinum	2-10	mechanistic target of rapamycin kinase	Homo sapiens	103-107
22322152-0	2012	E Platinum, a newly synthesized platinum compound, induces autophagy via inhibiting phosphorylation of mTOR in gastric carcinoma BGC-823 cells.	Platinum	32-40	mechanistic target of rapamycin kinase	Homo sapiens	103-107
22322152-5	2012	Our results showed that autophagy induced by 12.5 muM E Platinum in gastric carcinoma BGC-823 cells was significantly characterized by the FITC-fluorescent microtubule associated protein 1 light chain 3 (MAP-LC3), lysosomal-rich/acidic compartments visualized with Lysotracker red (LTR-red) and an accumulation of numerous large autophagic vesicles within the cytoplasm, but not in the control cells.	Platinum	56-64	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	208-211
22322152-6	2012	Meanwhile treatment of cells with 12.5 muM E Platinum resulted in conversion of water soluble LC3 (LC3-I) to lipidated and autophagosome-associated form (LC3-II) as well as increasing expression of autophagy protein Beclin 1.	Platinum	45-53	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	94-97
22322152-6	2012	Meanwhile treatment of cells with 12.5 muM E Platinum resulted in conversion of water soluble LC3 (LC3-I) to lipidated and autophagosome-associated form (LC3-II) as well as increasing expression of autophagy protein Beclin 1.	Platinum	45-53	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	99-104
22322152-6	2012	Meanwhile treatment of cells with 12.5 muM E Platinum resulted in conversion of water soluble LC3 (LC3-I) to lipidated and autophagosome-associated form (LC3-II) as well as increasing expression of autophagy protein Beclin 1.	Platinum	45-53	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	99-102
22322152-6	2012	Meanwhile treatment of cells with 12.5 muM E Platinum resulted in conversion of water soluble LC3 (LC3-I) to lipidated and autophagosome-associated form (LC3-II) as well as increasing expression of autophagy protein Beclin 1.	Platinum	45-53	beclin 1	Homo sapiens	216-224
25992206-2	2012	Platinum containing combination regimens are superior to non-platinum regimens in limited stage-SCLC and possibly also in extensive stage-SCLC as first and second-line treatments.	Platinum	0-8	SCLC1	Homo sapiens	96-100
25992206-2	2012	Platinum containing combination regimens are superior to non-platinum regimens in limited stage-SCLC and possibly also in extensive stage-SCLC as first and second-line treatments.	Platinum	0-8	SCLC1	Homo sapiens	138-142
21765044-6	2012	In the group of platinum-treated patients with MM, ERCC1 8092C/C wild-type genotype significantly influenced progression-free survival (PFS) in multivariable analysis accounting for clinical variables (P = 0.034).	Platinum	16-24	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	51-56
22576213-8	2012	SIGNIFICANCE: Mutations in BRCA genes cause defects in DNA repair that predict sensitivity to DNA damaging agents, including platinum; however, some patients without BRCA mutations also benefit from these agents.	Platinum	125-133	BRCA1 DNA repair associated	Homo sapiens	27-31
22284908-1	2012	BACKGROUND: The nucleotide excision repair pathway is crucial for cellular DNA integrity and the ERCC1 helicase is also potentially involved in resistance to platinum-based chemotherapy, and high levels of ERCC1 mRNA in tumours have been associated with cisplatin resistance in different human cancers.	Platinum	158-166	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	97-102
22284908-1	2012	BACKGROUND: The nucleotide excision repair pathway is crucial for cellular DNA integrity and the ERCC1 helicase is also potentially involved in resistance to platinum-based chemotherapy, and high levels of ERCC1 mRNA in tumours have been associated with cisplatin resistance in different human cancers.	Platinum	158-166	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	206-211
22322152-9	2012	Studies of mechanism revealed that E Platinum suppressed activation of mTOR and p70S6K by decreasing phosphorylation of Akt, ERK1/2, JNK and p38 involved in mitogen-activated protein kinase signaling.	Platinum	37-45	mechanistic target of rapamycin kinase	Homo sapiens	71-75
22504675-5	2012	Inhibition of PARP potentiates the activity of DNA-damaging agents, such as alkylators, platinums, topoisomerase inhibitors, and radiation both in vitro and in vivo.	Platinum	88-97	poly(ADP-ribose) polymerase 1	Homo sapiens	14-18
22322152-9	2012	Studies of mechanism revealed that E Platinum suppressed activation of mTOR and p70S6K by decreasing phosphorylation of Akt, ERK1/2, JNK and p38 involved in mitogen-activated protein kinase signaling.	Platinum	37-45	ribosomal protein S6 kinase B1	Homo sapiens	80-86
22322152-9	2012	Studies of mechanism revealed that E Platinum suppressed activation of mTOR and p70S6K by decreasing phosphorylation of Akt, ERK1/2, JNK and p38 involved in mitogen-activated protein kinase signaling.	Platinum	37-45	AKT serine/threonine kinase 1	Homo sapiens	120-123
22322152-9	2012	Studies of mechanism revealed that E Platinum suppressed activation of mTOR and p70S6K by decreasing phosphorylation of Akt, ERK1/2, JNK and p38 involved in mitogen-activated protein kinase signaling.	Platinum	37-45	mitogen-activated protein kinase 3	Homo sapiens	125-131
22322152-9	2012	Studies of mechanism revealed that E Platinum suppressed activation of mTOR and p70S6K by decreasing phosphorylation of Akt, ERK1/2, JNK and p38 involved in mitogen-activated protein kinase signaling.	Platinum	37-45	mitogen-activated protein kinase 8	Homo sapiens	133-136
22322152-9	2012	Studies of mechanism revealed that E Platinum suppressed activation of mTOR and p70S6K by decreasing phosphorylation of Akt, ERK1/2, JNK and p38 involved in mitogen-activated protein kinase signaling.	Platinum	37-45	mitogen-activated protein kinase 1	Homo sapiens	141-144
22183581-5	2012	The first case (PEO1/PEO4), with HR deficiency, acquired translocations and small deletions through its early evolution, but a revertant BRCA2 mutation restoring HR function in the resistant lineage re-stabilized its genome and reduced platinum sensitivity.	Platinum	236-244	twinkle mtDNA helicase	Homo sapiens	16-20
22740205-1	2012	PURPOSE: Excision repair cross-complementation group 1 (ERCC1), which is a component of nucleotide excision repair (NER) pathway, removes platinum-induced DNA adducts.	Platinum	138-146	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	9-54
22740205-1	2012	PURPOSE: Excision repair cross-complementation group 1 (ERCC1), which is a component of nucleotide excision repair (NER) pathway, removes platinum-induced DNA adducts.	Platinum	138-146	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	56-61
22740205-2	2012	Overexpression of ERCC1 has been associated with resistance to platinum-based chemotherapy in ovarian and lung cancers.	Platinum	63-71	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	18-23
22740205-11	2012	CONCLUSION: Our study demonstrated that about two thirds of the TNBC showed positive expression of ERCC1, which may be predictive of a poor response to platinum-based chemotherapy.	Platinum	152-160	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	99-104
22781116-0	2012	[Effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum].	Platinum	136-144	ERCC excision repair 5, endonuclease	Homo sapiens	11-14
22179630-0	2012	The role of expression and polymorphism of the BAG-1 gene in response             to platinum-based chemotherapeutics in NSCLC.	Platinum	85-93	BAG cochaperone 1	Homo sapiens	47-52
22179630-1	2012	We investigated the correlation between BAG-1 expression and sensitivity to platinum-based chemotherapeutics in patients with non-small cell lung cancer (NSCLC).	Platinum	76-84	BAG cochaperone 1	Homo sapiens	40-45
22179630-14	2012	Compared to patients carrying the C/T genotype of BAG-1, patients carrying the C/C genotype at Bag-1 codon 324 exhibited better responses to platinum-based chemotherapy.	Platinum	141-149	BAG cochaperone 1	Homo sapiens	50-55
22179630-14	2012	Compared to patients carrying the C/T genotype of BAG-1, patients carrying the C/C genotype at Bag-1 codon 324 exhibited better responses to platinum-based chemotherapy.	Platinum	141-149	BAG cochaperone 1	Homo sapiens	95-100
22179630-15	2012	Hence, the expression of BAG-1 was closely associated with the sensitivity to platinum-based chemotherapeutics in NSCLC patients.	Platinum	78-86	BAG cochaperone 1	Homo sapiens	25-30
22425915-1	2012	INTRODUCTION: The potential predictive role of BRCA1 and ERCC1 expression levels in patients with metastatic non-small cell lung cancer (NSCLC) receiving second-line platinum-based chemotherapy was investigated.	Platinum	166-174	BRCA1 DNA repair associated	Homo sapiens	47-52
22425915-2	2012	METHODS: Real-time quantitative polymerase chain reaction after reverse transcription was used to assess the expression levels of BRCA1 and ERCC1 in 100 microdissected primary tumors from platinum-naive NSCLC patients treated with platinum-based chemotherapy in the second-line setting.	Platinum	188-196	BRCA1 DNA repair associated	Homo sapiens	130-135
22425915-2	2012	METHODS: Real-time quantitative polymerase chain reaction after reverse transcription was used to assess the expression levels of BRCA1 and ERCC1 in 100 microdissected primary tumors from platinum-naive NSCLC patients treated with platinum-based chemotherapy in the second-line setting.	Platinum	188-196	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	140-145
22425915-2	2012	METHODS: Real-time quantitative polymerase chain reaction after reverse transcription was used to assess the expression levels of BRCA1 and ERCC1 in 100 microdissected primary tumors from platinum-naive NSCLC patients treated with platinum-based chemotherapy in the second-line setting.	Platinum	231-239	BRCA1 DNA repair associated	Homo sapiens	130-135
22425915-2	2012	METHODS: Real-time quantitative polymerase chain reaction after reverse transcription was used to assess the expression levels of BRCA1 and ERCC1 in 100 microdissected primary tumors from platinum-naive NSCLC patients treated with platinum-based chemotherapy in the second-line setting.	Platinum	231-239	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	140-145
22425915-7	2012	CONCLUSIONS: These results suggest that the ERCC1 and BRCA1 mRNA expression levels in the primary tumor at the time of diagnosis could be used for the prediction of platinum sensitivity in the treatment of NSCLC in the second-line setting.	Platinum	165-173	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	44-49
22425915-7	2012	CONCLUSIONS: These results suggest that the ERCC1 and BRCA1 mRNA expression levels in the primary tumor at the time of diagnosis could be used for the prediction of platinum sensitivity in the treatment of NSCLC in the second-line setting.	Platinum	165-173	BRCA1 DNA repair associated	Homo sapiens	54-59
22322243-4	2012	Treatment of [M(Cl)(C(dppm)(2)-kappa3P,C,P)]Cl (M = Pd, Pt) with hydrochloric acid results in protonation at the CDP carbon atom and the formation of the PCP pincer complexes [M(Cl)(CH(dppm)(2)-kappa3P,C,P)]Cl(2) (M = Pd, Pt).	Platinum	56-58	cut like homeobox 1	Homo sapiens	113-116
22781116-1	2012	OBJECTIVE: To investigate the effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum.	Platinum	165-173	ERCC excision repair 5, endonuclease	Homo sapiens	40-43
22364571-4	2012	Our experimental results revealed that the relationship between the Hammett constant and rate constant for the electrochemical oxidation of phenolic compounds at the RuO(2)-SnO(2)-Sb(2)O(5) electrode was different from the results obtained at a platinum electrode.	Platinum	245-253	strawberry notch homolog 1	Homo sapiens	173-176
22439756-6	2012	Patients with negative ERCC1 and BAG-1 expression benefited more from platinum regimen (P = 0.001 and P = 0.002).	Platinum	70-78	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	23-28
22439756-6	2012	Patients with negative ERCC1 and BAG-1 expression benefited more from platinum regimen (P = 0.001 and P = 0.002).	Platinum	70-78	BAG cochaperone 1	Homo sapiens	33-38
21652582-0	2012	Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients.	Platinum	99-107	cytidine deaminase	Homo sapiens	15-33
22230694-0	2012	Amperometric acetylcholine biosensor based on self-assembly of gold nanoparticles and acetylcholinesterase on the sol-gel/multi-walled carbon nanotubes/choline oxidase composite-modified platinum electrode.	Platinum	187-195	acetylcholinesterase (Cartwright blood group)	Homo sapiens	86-106
22237007-0	2012	MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer.	Platinum	37-45	microRNA 21	Homo sapiens	0-8
21756279-11	2012	One BRCA2 carrier treated with docetaxel plus platinum survived 37 months.	Platinum	46-54	BRCA2 DNA repair associated	Homo sapiens	4-9
21652582-1	2012	BACKGROUND: The aim of this study was to evaluate whether cytidine deaminase (CDA) polymorphisms 79A&gt;C and 435C&gt;T and/or CDA enzymatic activity influenced clinical outcome in 126 advanced non-small-cell lung cancer patients treated with gemcitabine-platinum-regimens.	Platinum	255-263	cytidine deaminase	Homo sapiens	78-81
21652582-1	2012	BACKGROUND: The aim of this study was to evaluate whether cytidine deaminase (CDA) polymorphisms 79A&gt;C and 435C&gt;T and/or CDA enzymatic activity influenced clinical outcome in 126 advanced non-small-cell lung cancer patients treated with gemcitabine-platinum-regimens.	Platinum	255-263	cytidine deaminase	Homo sapiens	127-130
21652582-8	2012	CONCLUSIONS: CDA enzymatic activity appears to be the strongest candidate biomarker of activity and efficacy of platinum-gemcitabine-based chemotherapy and should be validated in a prospective study.	Platinum	112-120	cytidine deaminase	Homo sapiens	13-16
22237007-3	2012	Increased miR-21 expression significantly increased the resistance of A549 cell to platinum, whereas reduced miR-21 decreased the resistance of A549/CDDP cell.	Platinum	83-91	microRNA 21	Homo sapiens	10-16
22237007-3	2012	Increased miR-21 expression significantly increased the resistance of A549 cell to platinum, whereas reduced miR-21 decreased the resistance of A549/CDDP cell.	Platinum	149-153	microRNA 21	Homo sapiens	109-115
22237007-4	2012	This finding was further validated in the tissue samples of 58 patients and it was found that miR-21 expression was significantly increased in platinum based chemotherapy-resistant patients (n = 58, p = 0.000).	Platinum	143-151	microRNA 21	Homo sapiens	94-100
22237007-10	2012	The effect of a differently expressed miRNA (miR-21) was examined on the sensitivity of cells to platinum.	Platinum	97-105	microRNA 21	Homo sapiens	45-51
22237007-12	2012	CONCLUSION: Our data suggests that the expression level of miR-21 in tumor tissue and plasma might be used as a biomarker to predict adjuvant platinum based chemotherapy response and disease free survival in patients with NSCLC.	Platinum	142-150	microRNA 21	Homo sapiens	59-65
22374424-0	2012	Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients.	Platinum	53-61	X-ray repair cross complementing 3	Homo sapiens	15-20
22333583-0	2012	Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin.	Platinum	72-80	tumor protein p53	Homo sapiens	45-48
22374424-1	2012	INTRODUCTION: The aim of this study was to investigate whe- ther X-ray repair cross-complementing group 3 (XRCC3) and xeroderma pigmentosum group D (XPD) single nucleotide polymorphism (SNP) affects the outcome of platinum- based chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients.	Platinum	214-222	X-ray repair cross complementing 3	Homo sapiens	65-105
22374424-1	2012	INTRODUCTION: The aim of this study was to investigate whe- ther X-ray repair cross-complementing group 3 (XRCC3) and xeroderma pigmentosum group D (XPD) single nucleotide polymorphism (SNP) affects the outcome of platinum- based chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients.	Platinum	214-222	X-ray repair cross complementing 3	Homo sapiens	107-112
22374424-1	2012	INTRODUCTION: The aim of this study was to investigate whe- ther X-ray repair cross-complementing group 3 (XRCC3) and xeroderma pigmentosum group D (XPD) single nucleotide polymorphism (SNP) affects the outcome of platinum- based chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients.	Platinum	214-222	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	149-152
22374424-8	2012	XPD 751 Lys/ Lys might be a better prognostic marker of elderly or noncarcinoma NSCLC subgroup treated with platinum-based chemotherapy.	Platinum	108-116	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	0-3
25806150-2	2012	Phase III randomized studies have clearly demonstrated that a reversible EGFR-TKI is significantly superior in terms of response rate, progression-free survival and quality of life to platinum-based chemotherapy in advanced NSCLC patients who carry an activating EGFR mutation, thus resulting into a new standard of care for this biologically selected group of patients.	Platinum	184-192	epidermal growth factor receptor	Homo sapiens	73-77
22112610-0	2012	Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.	Platinum	130-138	ATP binding cassette subfamily B member 1	Homo sapiens	19-24
22112610-0	2012	Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.	Platinum	130-138	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	36-41
22112610-2	2012	This study examined associations between functional variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes in patients with epithelial ovarian/primary peritoneal cancer (EOC/PPC) following platinum and taxane-based chemotherapy.	Platinum	197-205	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	81-86
22112610-9	2012	CONCLUSION: The C421A variant in ABCG2, previously shown to be associated with enhanced protein degradation and drug sensitivity, was associated with longer PFS in advanced stage EOC/PPC patents treated with platinum+taxane-based chemotherapy.	Platinum	208-216	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	33-38
22755133-4	2012	CNF encapsulating platinum nanoparticles (Pt@CNF) is formed when a mixture of graphite, platinum, and hexadecanoic acid is used as a target.	Platinum	18-26	NPHS1 adhesion molecule, nephrin	Homo sapiens	0-3
22755133-4	2012	CNF encapsulating platinum nanoparticles (Pt@CNF) is formed when a mixture of graphite, platinum, and hexadecanoic acid is used as a target.	Platinum	18-26	NPHS1 adhesion molecule, nephrin	Homo sapiens	45-48
22755133-4	2012	CNF encapsulating platinum nanoparticles (Pt@CNF) is formed when a mixture of graphite, platinum, and hexadecanoic acid is used as a target.	Platinum	88-96	NPHS1 adhesion molecule, nephrin	Homo sapiens	0-3
22755133-4	2012	CNF encapsulating platinum nanoparticles (Pt@CNF) is formed when a mixture of graphite, platinum, and hexadecanoic acid is used as a target.	Platinum	88-96	NPHS1 adhesion molecule, nephrin	Homo sapiens	45-48
22755133-6	2012	The platinum nanoparticles in the CNF are 9 +/- 4 nm in diameter.	Platinum	4-12	NPHS1 adhesion molecule, nephrin	Homo sapiens	34-37
22755133-7	2012	The annealing of the Pt@CNF at 300 degrees C for a week in vacuum reveals that the CNF effectively prevents the platinum nanoparticles from aggregating.	Platinum	112-120	NPHS1 adhesion molecule, nephrin	Homo sapiens	24-27
22755133-7	2012	The annealing of the Pt@CNF at 300 degrees C for a week in vacuum reveals that the CNF effectively prevents the platinum nanoparticles from aggregating.	Platinum	112-120	NPHS1 adhesion molecule, nephrin	Homo sapiens	83-86
22258474-0	2012	Hypoxia-inducible factor-1alpha and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.	Platinum	138-146	hypoxia inducible factor 1 subunit alpha	Homo sapiens	0-31
22258474-2	2012	Furthermore, a relationship between excision repair cross-complementing 1 (ERCC1) expression and platinum resistance has been reported in patients with various malignancies.	Platinum	97-105	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	36-73
22258474-2	2012	Furthermore, a relationship between excision repair cross-complementing 1 (ERCC1) expression and platinum resistance has been reported in patients with various malignancies.	Platinum	97-105	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	75-80
22258474-3	2012	The aim of this study was to investigate the expression of HIF-1alpha and ERCC1 and to elucidate the clinical significance of their expression in patients with small cell lung cancer (SCLC) treated with front-line platinum-based chemotherapy.	Platinum	214-222	hypoxia inducible factor 1 subunit alpha	Homo sapiens	59-69
22258474-3	2012	The aim of this study was to investigate the expression of HIF-1alpha and ERCC1 and to elucidate the clinical significance of their expression in patients with small cell lung cancer (SCLC) treated with front-line platinum-based chemotherapy.	Platinum	214-222	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	74-79
22258474-9	2012	Multivariate analysis revealed that response to front-line platinum-based chemotherapy (p &lt; 0.001), good Eastern Cooperative Oncology Group performance status (0-1) (p = 0.002), and low expression of HIF-1alpha (p = 0.004) were independent predictors of better overall survival in ED-SCLC.	Platinum	59-67	hypoxia inducible factor 1 subunit alpha	Homo sapiens	203-213
22258474-10	2012	CONCLUSIONS: Low expression of HIF-1alpha may be a useful predictor of better overall survival in ED-SCLC patients treated with front-line platinum-based chemotherapy.	Platinum	139-147	hypoxia inducible factor 1 subunit alpha	Homo sapiens	31-41
22670529-2	2012	At present there is no rational explanation how CTR1 can transfer platinum group, which is different by coordination properties from highly similar Cu(I) and Ag(I).	Platinum	66-74	solute carrier family 31, member 1	Mus musculus	48-52
22670529-8	2012	Basing on structural and functional peculiarities of N-terminal part of CTR1 a hypothesis of coupled transport of copper and cisplatin has been suggested, which avoids the disagreement between CTR1-mediated cisplatin transport in vitro, and irreversible binding of platinum to Met-rich peptides.	Platinum	265-273	solute carrier family 31, member 1	Mus musculus	72-76
25806155-9	2012	Thus platinum-based chemotherapy combined with cetuximab represents a new treatment option for patients with advanced NSCLC and high EGFR expression in their tumors.	Platinum	5-13	epidermal growth factor receptor	Homo sapiens	133-137
22780973-8	2012	BRCA1 and ERCC1 expression level is negatively correlated with platinum-based chemosensitivity.	Platinum	63-71	BRCA1 DNA repair associated	Homo sapiens	0-5
22329723-1	2012	AIM: We evaluated whether the ERCC1 polymorphisms had an effect on survival in epithelial ovarian cancer (EOC) patients with platinum-based chemotherapy.	Platinum	125-133	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	30-35
22780973-8	2012	BRCA1 and ERCC1 expression level is negatively correlated with platinum-based chemosensitivity.	Platinum	63-71	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	10-15
22780973-13	2012	CONCLUSIONS: BRCA1 and ERCC1 mRNA expression has a negative correlation with the clinical sensitivity of platinum-based chemotherapy.	Platinum	105-113	BRCA1 DNA repair associated	Homo sapiens	13-18
22780973-13	2012	CONCLUSIONS: BRCA1 and ERCC1 mRNA expression has a negative correlation with the clinical sensitivity of platinum-based chemotherapy.	Platinum	105-113	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	23-28
22330686-4	2012	Optimizing treatment according to tumor status for DNA-repair biomarkers, such as ERCC1, BRCA1 or RRM1, could predict response to platinum, taxanes and gemcitabine-based therapies, respectively, and might improve substantially the response of individual patients" tumors.	Platinum	130-138	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	82-87
22142828-8	2012	In tumors collected from recurrent platinum-resistant patients, only CD133 was significantly increased.	Platinum	35-43	prominin 1	Homo sapiens	69-74
22339849-15	2012	CONCLUSIONS: Genetic polymorphisms in XRCC1 gene might be associated with overall survival and response to platinum-based chemotherapy in lung cancer patients.	Platinum	107-115	X-ray repair cross complementing 1	Homo sapiens	38-43
22225466-4	2012	The reactivity of these platinum compounds with a number of biomolecules, including cytochrome c, two sulfur containing modified amino acids, 9-ethylguanine, and a single strand oligonucleotide, was analyzed in depth by mass spectrometry and NMR spectroscopy.	Platinum	24-32	cytochrome c, somatic	Homo sapiens	84-96
21751198-14	2012	SNPs in the XPC gene may represent novel markers of ovarian cancer response to platinum-based chemotherapy.	Platinum	79-87	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	12-15
22154340-7	2012	The fastest nitrate reduction by GR-F with Pt was achieved at pH 9 among 7.5 to 11.	Platinum	43-45	growth hormone releasing hormone	Homo sapiens	33-37
22330686-4	2012	Optimizing treatment according to tumor status for DNA-repair biomarkers, such as ERCC1, BRCA1 or RRM1, could predict response to platinum, taxanes and gemcitabine-based therapies, respectively, and might improve substantially the response of individual patients" tumors.	Platinum	130-138	BRCA1 DNA repair associated	Homo sapiens	89-94
22330686-4	2012	Optimizing treatment according to tumor status for DNA-repair biomarkers, such as ERCC1, BRCA1 or RRM1, could predict response to platinum, taxanes and gemcitabine-based therapies, respectively, and might improve substantially the response of individual patients" tumors.	Platinum	130-138	ribonucleotide reductase catalytic subunit M1	Homo sapiens	98-102
22304828-0	2012	Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC).	Platinum	79-87	ATPase copper transporting alpha	Homo sapiens	53-58
22304828-3	2012	The goal of this study was to determine the role of ATP7A in the platinum-resistance of non-small cell lung cancer (NSCLC).	Platinum	65-73	ATPase copper transporting alpha	Homo sapiens	52-57
22304828-9	2012	ATP7A-positive patients had a significantly poorer histological grade (p = 0.039) and poorer response to platinum-basing chemotherapy (p = 0.001) compared with ATP7A-negative patients.	Platinum	105-113	ATPase copper transporting alpha	Homo sapiens	0-5
22304828-11	2012	CONCLUSIONS: ATP7A overexpression played an important role in platinum-resistance of NSCLC, and was a negative prognostic factor of NSCLC patients treated with platinum-based chemotherapy.	Platinum	62-70	ATPase copper transporting alpha	Homo sapiens	13-18
22304828-11	2012	CONCLUSIONS: ATP7A overexpression played an important role in platinum-resistance of NSCLC, and was a negative prognostic factor of NSCLC patients treated with platinum-based chemotherapy.	Platinum	160-168	ATPase copper transporting alpha	Homo sapiens	13-18
21479552-7	2012	In the NCI-60 cell line dataset, overexpression of the kinesin KIFC3 is significantly correlated with resistance to both docetaxel (P &lt; 0.001) and paclitaxel (P &lt; 0.001), but not to platinum-based chemotherapy, including carboplatin (P = 0.49) and cisplatin (P = 0.10).	Platinum	188-196	kinesin family member C3	Homo sapiens	63-68
21788094-0	2012	Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy.	Platinum	145-153	solute carrier family 31 member 1	Homo sapiens	41-61
22209414-2	2012	In the course of efforts to develop 17beta-estradiol-linked to anticancer agents targeting estrogen-dependent tissue, we identified three estradiol-linked platinum(II) complex analogs to cisplatin (E-CDDP) derivatives namely: VP-128 (1), CD-38 (2) and JMP-39 (3) that exhibit potent in vitro and in vivo (for derivative VP-128) activity along with interaction with the estrogen receptor alpha (ERalpha).	Platinum	155-163	estrogen receptor 1	Homo sapiens	369-392
22209414-2	2012	In the course of efforts to develop 17beta-estradiol-linked to anticancer agents targeting estrogen-dependent tissue, we identified three estradiol-linked platinum(II) complex analogs to cisplatin (E-CDDP) derivatives namely: VP-128 (1), CD-38 (2) and JMP-39 (3) that exhibit potent in vitro and in vivo (for derivative VP-128) activity along with interaction with the estrogen receptor alpha (ERalpha).	Platinum	155-163	estrogen receptor 1	Homo sapiens	394-401
21435174-0	2012	Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients.	Platinum	75-83	annexin A3	Homo sapiens	13-23
21435174-2	2012	We have previously found that increased expression of annexin A3 is a mechanism for platinum resistance in ovarian cancer cells.	Platinum	84-92	annexin A3	Homo sapiens	54-64
21435174-6	2012	Furthermore, serum levels of annexin A3 were significantly higher in platinum-resistant patients than in platinum-sensitive patients.	Platinum	69-77	annexin A3	Homo sapiens	29-39
21435174-6	2012	Furthermore, serum levels of annexin A3 were significantly higher in platinum-resistant patients than in platinum-sensitive patients.	Platinum	105-113	annexin A3	Homo sapiens	29-39
22033034-0	2012	CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study.	Platinum	92-100	mucin 16, cell surface associated	Homo sapiens	0-5
21831476-1	2012	INTRODUCTION: In small cell lung cancer (SCLC), despite the high response rates induced by platinum-based first line chemotherapies, relapse happens in 85% of the first-line responding tumors.	Platinum	91-99	SCLC1	Homo sapiens	41-45
21788094-0	2012	Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy.	Platinum	145-153	solute carrier family 31 member 1	Homo sapiens	63-68
22109568-9	2012	Moreover, patients with deficient-type GSTM1 were superior responders to platinum drugs than those carrying wild-type GSTM1 (P = 0.014).	Platinum	73-81	glutathione S-transferase mu 1	Homo sapiens	39-44
21788094-1	2012	BACKGROUND: Recent studies have shown that human copper transporter 1 (hCtr1), the major copper influx transporter, is involved in the transport of platinum-based antitumor agents.	Platinum	148-156	solute carrier family 31 member 1	Homo sapiens	49-69
21788094-1	2012	BACKGROUND: Recent studies have shown that human copper transporter 1 (hCtr1), the major copper influx transporter, is involved in the transport of platinum-based antitumor agents.	Platinum	148-156	solute carrier family 31 member 1	Homo sapiens	71-76
21788094-9	2012	CONCLUSION: This is the first report to state that hCtr1 is not only an independent predictor of platinum-based chemotherapy response but also a prognostic factor in stage III NSCLC.	Platinum	97-105	solute carrier family 31 member 1	Homo sapiens	51-56
28920258-0	2012	Response to gemcitabine-platinum chemotherapy by single nucleotide polymorphisms of RRM1 and ERCC1 genes in patients with non-small-cell lung cancer.	Platinum	24-32	ribonucleotide reductase catalytic subunit M1	Homo sapiens	84-88
22101352-11	2012	Loss of ARID1A correlated with shorter progression-free survival of patients with clear cell carcinomas treated with platinum-based chemotherapy (P&lt;0.01).	Platinum	117-125	AT-rich interaction domain 1A	Homo sapiens	8-14
22101352-12	2012	Loss of ARID1A expression tended to correlate with shorter overall survival in patients with ovarian clear cell carcinomas treated with platinum-based chemotherapy.	Platinum	136-144	AT-rich interaction domain 1A	Homo sapiens	8-14
22101352-16	2012	This study demonstrates that loss of ARID1A in ovarian clear cell carcinoma is a negative prognostic factor in patients treated with platinum-based chemotherapy.	Platinum	133-141	AT-rich interaction domain 1A	Homo sapiens	37-43
22101352-17	2012	Measurement of ARID1A expression may be a method to predict resistance to platinum-based chemotherapy in patients with ovarian clear cell carcinoma.	Platinum	74-82	AT-rich interaction domain 1A	Homo sapiens	15-21
22740902-2	2012	The measured-CrCl prior and subsequent to platinum-based chemotherapy of lung cancer patients was retrospectively analyzed.	Platinum	42-50	CRCL	Homo sapiens	13-17
22740902-7	2012	In cases with pre-treatment measured-CrCl levels of &gt;90 ml/min, favorable renal function is necessary in order to carry out platinum-based chemotherapy in lung cancer patients, including the elderly.	Platinum	127-135	CRCL	Homo sapiens	37-41
28920258-0	2012	Response to gemcitabine-platinum chemotherapy by single nucleotide polymorphisms of RRM1 and ERCC1 genes in patients with non-small-cell lung cancer.	Platinum	24-32	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	93-98
28920258-3	2012	The excision repair cross-complementation group 1 protein (ERCC1) is associated with platinum resistance.	Platinum	85-93	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	59-64
28920258-4	2012	A SNP of the ERCC1 gene (T19007C) has been reported as a prognostic marker in platinum-treated non-small-cell lung cancer (NSCLC).	Platinum	78-86	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	13-18
22336232-3	2012	The aim of this study is to investigate the relationship of IGF-1R+1013(G/A) and IGF-2R+1619(G/A) single nucleotide polymorphism (SNP) with platinum-based chemotherapy outcomes in advanced non-small cell lung cancer (NSCLC).	Platinum	140-148	insulin like growth factor 1 receptor	Homo sapiens	60-66
22173232-0	2012	Ferroxidase activity of apoferritin is increased in the presence of platinum nanoparticles.	Platinum	68-76	ferritin heavy chain	Equus caballus	24-35
22336232-3	2012	The aim of this study is to investigate the relationship of IGF-1R+1013(G/A) and IGF-2R+1619(G/A) single nucleotide polymorphism (SNP) with platinum-based chemotherapy outcomes in advanced non-small cell lung cancer (NSCLC).	Platinum	140-148	insulin like growth factor 2 receptor	Homo sapiens	81-87
22336232-14	2012	CONCLUSIONS: IGF-1R+1013(G/A) polymorphism alone or in combination with IGF-2R +1619(G/A) polymorphism was associated with the overall survival period in patients with advanced NSCLC after treatment with platin-based chemotherapy, which might be a prognostic factor in platin-treated patients with advanced NSCLC.	Platinum	204-210	insulin like growth factor 1 receptor	Homo sapiens	13-19
22336232-14	2012	CONCLUSIONS: IGF-1R+1013(G/A) polymorphism alone or in combination with IGF-2R +1619(G/A) polymorphism was associated with the overall survival period in patients with advanced NSCLC after treatment with platin-based chemotherapy, which might be a prognostic factor in platin-treated patients with advanced NSCLC.	Platinum	269-275	insulin like growth factor 1 receptor	Homo sapiens	13-19
22077595-12	2012	The result is consistent with the spin-orbit coupling caused by the central platinum heavy atom decreasing with larger nFAR.	Platinum	76-84	interleukin enhancer binding factor 3	Homo sapiens	119-123
22233925-11	2012	Silencing p57(Kip)2 decreased the apoptotic response to the effects of platinum but produced sensitisation to seliciclib.	Platinum	71-79	cyclin dependent kinase inhibitor 1C	Homo sapiens	10-19
22233925-13	2012	CONCLUSION: We conclude that p57(Kip2) is a candidate biomarker of platinum sensitivity/resistance in EOC and such cases may show preferential response to the cyclin-dependent kinase inhibitor seliciclib.	Platinum	67-75	cyclin dependent kinase inhibitor 1C	Homo sapiens	29-32
22233925-13	2012	CONCLUSION: We conclude that p57(Kip2) is a candidate biomarker of platinum sensitivity/resistance in EOC and such cases may show preferential response to the cyclin-dependent kinase inhibitor seliciclib.	Platinum	67-75	cyclin dependent kinase inhibitor 1C	Homo sapiens	33-37
22173232-1	2012	The ferroxidase activity of horse spleen apoferritin (HSAF) is increased by nine-fold in the presence of platinum nanoparticles.	Platinum	105-113	ferritin heavy chain	Equus caballus	41-52
22173299-1	2012	We report thermoelectric voltage measurements between the platinum-coated tip of a heated atomic force microscope (AFM) cantilever and a gold-coated substrate.	Platinum	58-66	TOR signaling pathway regulator	Homo sapiens	74-77
22631660-0	2012	Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese.	Platinum	53-61	nibrin	Homo sapiens	20-24
22085845-1	2012	Cyclometalated platinum(II) complexes [Pt(II)(C^N^N)(C NR)](+) (HC^N^N = 6-phenyl-2,2"-bipyridyl) display significant inhibition towards TNF-alpha stimulated NF-kappaB-dependent gene transcription at concentrations down to the micromolar range.	Platinum	15-23	tumor necrosis factor	Homo sapiens	137-146
22085845-1	2012	Cyclometalated platinum(II) complexes [Pt(II)(C^N^N)(C NR)](+) (HC^N^N = 6-phenyl-2,2"-bipyridyl) display significant inhibition towards TNF-alpha stimulated NF-kappaB-dependent gene transcription at concentrations down to the micromolar range.	Platinum	15-23	nuclear factor kappa B subunit 1	Homo sapiens	158-167
22631660-2	2012	We conducted this study to investigate the effect of two critical polymorphisms (rs1805794 and rs13312840) in NBS1 on treatment response and prognosis of advanced non-small cell lung cancer (NSCLC) patients with platinum-based chemotherapy.	Platinum	212-220	nibrin	Homo sapiens	110-114
22631660-11	2012	CONCLUSIONS: Our findings suggest that NBS1 polymorphisms may be genetic biomarkers for NSCLC prognosis especially PFS with platinum-based chemotherapy in the Chinese population.	Platinum	124-132	nibrin	Homo sapiens	39-43
22901187-0	2012	Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.	Platinum	59-67	phosphatase and tensin homolog	Homo sapiens	29-33
22901187-0	2012	Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.	Platinum	59-67	AKT serine/threonine kinase 1	Homo sapiens	34-37
22901187-0	2012	Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.	Platinum	59-67	mechanistic target of rapamycin kinase	Homo sapiens	38-42
22901187-7	2012	CONCLUSIONS: Our findings suggest that genetic variants in the PI3K/PTEN/AKT/mTOR pathway may predict platinum-based chemotherapy response in advanced NSCLC patients in a Chinese population.	Platinum	102-110	phosphatase and tensin homolog	Homo sapiens	68-72
22901187-7	2012	CONCLUSIONS: Our findings suggest that genetic variants in the PI3K/PTEN/AKT/mTOR pathway may predict platinum-based chemotherapy response in advanced NSCLC patients in a Chinese population.	Platinum	102-110	AKT serine/threonine kinase 1	Homo sapiens	73-76
22901187-7	2012	CONCLUSIONS: Our findings suggest that genetic variants in the PI3K/PTEN/AKT/mTOR pathway may predict platinum-based chemotherapy response in advanced NSCLC patients in a Chinese population.	Platinum	102-110	mechanistic target of rapamycin kinase	Homo sapiens	77-81
22938418-1	2012	OBJECTIVE: To investigate any association between XRCC1 and XRCC3 polymorphisms and outcome of platinum-based chemotherapy in ovarian cancer patients.	Platinum	95-103	X-ray repair cross complementing 1	Homo sapiens	50-55
22938418-1	2012	OBJECTIVE: To investigate any association between XRCC1 and XRCC3 polymorphisms and outcome of platinum-based chemotherapy in ovarian cancer patients.	Platinum	95-103	X-ray repair cross complementing 3	Homo sapiens	60-65
23098477-1	2012	AIM: SNPs of ERCC1 and ERCC2 genes have been found to be associated with response to platinum therapy in different clinical settings.	Platinum	85-93	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	13-18
23098477-1	2012	AIM: SNPs of ERCC1 and ERCC2 genes have been found to be associated with response to platinum therapy in different clinical settings.	Platinum	85-93	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	23-28
21706317-6	2012	Platinum was quantified in plasma UF and CSF using a validated atomic absorption spectroscopy assay with lower limit of quantification (LLQ) of 0.025 muM in UF and 0.006 muM after concentration in CSF.	Platinum	0-8	latexin	Homo sapiens	170-173
23464469-2	2012	Additionally, recent studies suggested that XRCC1 polymorphisms could be a biomarker of response to platinum-based chemotherapy.	Platinum	100-108	X-ray repair cross complementing 1	Homo sapiens	44-49
23464469-6	2012	As for response to platinum- based chemotherapy, the variant XRCC1 399Gln allele (Gln vs. Arg, OR=0.345, 95% CI: 0.163, 0.729) was linked with a poor response; however, the Arg194Trp polymorphism (TrpArg vs. ArgArg, OR=6.421, 95% CI: 1.573, 26.205) predicted a good response.	Platinum	19-27	X-ray repair cross complementing 1	Homo sapiens	61-66
23464469-7	2012	CONCLUSION: The Arg194Trp polymorphism of XRCC1 increases risk of cervical cancer; the variant 399Gln allele predicts poor response to platinum-based chemotherapy, while the Arg194Trp polymorphism indicates a good response.	Platinum	135-143	X-ray repair cross complementing 1	Homo sapiens	42-47
23167352-8	2012	CONCLUSION: This study indicated that GSTP1 Ile105Val, XRCC1 Arg194Trp and XRCC1Arg399Gln genes have a role in modifying the effect of platinum-based chemotherapy for NSCLC patients in a Chinese population.	Platinum	135-143	glutathione S-transferase pi 1	Homo sapiens	38-43
23167352-8	2012	CONCLUSION: This study indicated that GSTP1 Ile105Val, XRCC1 Arg194Trp and XRCC1Arg399Gln genes have a role in modifying the effect of platinum-based chemotherapy for NSCLC patients in a Chinese population.	Platinum	135-143	X-ray repair cross complementing 1	Homo sapiens	55-60
23167352-8	2012	CONCLUSION: This study indicated that GSTP1 Ile105Val, XRCC1 Arg194Trp and XRCC1Arg399Gln genes have a role in modifying the effect of platinum-based chemotherapy for NSCLC patients in a Chinese population.	Platinum	135-143	X-ray repair cross complementing 1	Homo sapiens	75-80
22668011-7	2012	The platinum-sensitive group had a statistically significant tendency for high Bax expression (p=0.04).	Platinum	4-12	BCL2 associated X, apoptosis regulator	Homo sapiens	79-82
22915856-10	2012	Furthermore, mice injected with PSMA-targeted SPMs showed significantly more paclitaxel and platinum in tumors, compared with nontargeted SPM-injected and paclitaxel-injected mice.	Platinum	92-100	folate hydrolase 1	Homo sapiens	32-36
22355465-7	2012	RESULTS: OVCA patient samples that demonstrated complete responses to primary platinum-based therapy demonstrated 4-fold higher CDK1 (p&lt;0.0001) and 2-fold lower PP2C (p=0.14) protein levels than samples that demonstrated incomplete responses.	Platinum	78-86	cyclin dependent kinase 1	Homo sapiens	128-132
22355465-11	2012	CONCLUSION: BAD pathway kinases and phosphatases, including CDK1 and PP2C, are associated with OVCA sensitivity to platinum and may represent therapeutic opportunities to enhance cytotoxic efficacy.	Platinum	115-123	cyclin dependent kinase 1	Homo sapiens	60-64
21676483-10	2012	CONCLUSION: Present data indicates that ERCC1 118 C/T or T/T might provide a better prognostic predictive marker of NSCLC patients treated with platinum-based chemotherapy, mainly in elderly subgroup, male, squamous carcinoma, smoker and those treated with non-GP/GC regimen.	Platinum	144-152	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	40-45
23936624-1	2012	A texaphyrin-oxaliplatin conjugate, oxaliTEX, was designed to test the concept that a platinum analog can overcome defects in drug accumulation and p53-dependent DNA damage response in a tumor model expressing multifactorial mechanisms of cisplatin resistance.	Platinum	86-94	tumor protein p53	Homo sapiens	148-151
22176776-2	2012	Recent studies in the Cancer Genome Atlas project have demonstrated that BRCA2 mutation carriers are more responsive to platinum-based chemotherapy among high-grade serous ovarian cancer patients.	Platinum	120-128	BRCA2 DNA repair associated	Homo sapiens	73-78
22591419-11	2012	Recently, preliminary safety data from a phase 1 trial reported that the combination of farletuzumab, carboplatin and PLD has an acceptable safety profile in patients with platinum- sensitive EOC following first or second relapse.	Platinum	172-180	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	118-121
22567180-10	2012	CONCLUSIONS: ERCC1 C118T may be a predictive marker of treatment response to 5-FU/platinum chemotherapy for CRC.	Platinum	82-90	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	13-18
22619676-7	2012	Overexpressing tumors respond better to platinum-based chemotherapy, suggesting eIF3a as a putative predictive as well as prognostic tumor marker in OSCC.	Platinum	40-48	eukaryotic translation initiation factor 3 subunit J	Homo sapiens	80-85
23102199-4	2012	ERCC1 is involved in removal of platinum adducts and might be a potential predictive and prognostic marker in NSCLC (non-small-cell lung cancer) treated with a cisplatin-based regimen.	Platinum	32-40	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
23102199-17	2012	In patients with adenocarcinoma and squamous cell carcinoma, we could assume increased resistance to platinum-based therapy because of high expectation of ERCC1 protein expression.	Platinum	101-109	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	155-160
22668011-9	2012	Our data suggests that (H) Bax protein expression prolongs survival, predicts platinum sensitivity and can be used after confirmation of this hypothesis in further prospective studies.	Platinum	78-86	BCL2 associated X, apoptosis regulator	Homo sapiens	27-30
21993766-8	2012	ELISA and immunohistochemical methods were carried out after 48, 72, 120, 192             and 240 h. We detected a reliable trend towards significantly decreased cytosolic             and nuclear beta-catenin and c-kit expression levels in p16-positive SCC and non-HPV             HNSCC cells induced by imatinib exposure for an extended incubation period, whereas             platinum-based agents had no or, at best, a slight influence.	Platinum	377-385	catenin beta 1	Homo sapiens	196-208
21993766-8	2012	ELISA and immunohistochemical methods were carried out after 48, 72, 120, 192             and 240 h. We detected a reliable trend towards significantly decreased cytosolic             and nuclear beta-catenin and c-kit expression levels in p16-positive SCC and non-HPV             HNSCC cells induced by imatinib exposure for an extended incubation period, whereas             platinum-based agents had no or, at best, a slight influence.	Platinum	377-385	cyclin dependent kinase inhibitor 2A	Homo sapiens	240-243
23581229-0	2012	The relationship between EGFR gene mutation status and ERCC1 in lung adenocarcinoma of Chinese patients receiving platinum-based neoadjuvant chemotherapy.	Platinum	114-122	epidermal growth factor receptor	Homo sapiens	25-29
22843554-0	2012	Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.	Platinum	78-86	caspase 8	Homo sapiens	20-25
22843554-0	2012	Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.	Platinum	78-86	caspase 10	Homo sapiens	30-36
22843554-2	2012	In this study, we aimed to comprehensively assess single nucleotide polymorphisms (SNPs) of the caspase-8 (CASP8) and caspase-10 (CASP10) genes in relation to toxicity outcomes with first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).	Platinum	193-201	caspase 8	Homo sapiens	96-105
22843554-2	2012	In this study, we aimed to comprehensively assess single nucleotide polymorphisms (SNPs) of the caspase-8 (CASP8) and caspase-10 (CASP10) genes in relation to toxicity outcomes with first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).	Platinum	193-201	caspase 8	Homo sapiens	107-112
22843554-2	2012	In this study, we aimed to comprehensively assess single nucleotide polymorphisms (SNPs) of the caspase-8 (CASP8) and caspase-10 (CASP10) genes in relation to toxicity outcomes with first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).	Platinum	193-201	caspase 10	Homo sapiens	118-128
22843554-9	2012	Our results provide novel evidence that polymorphisms in CASP8 and CASP10 may modulate toxicity outcomes in patients with advanced NSCLC treated with platinum-based chemotherapy.	Platinum	150-158	caspase 8	Homo sapiens	57-62
22843554-9	2012	Our results provide novel evidence that polymorphisms in CASP8 and CASP10 may modulate toxicity outcomes in patients with advanced NSCLC treated with platinum-based chemotherapy.	Platinum	150-158	caspase 10	Homo sapiens	67-73
22843554-2	2012	In this study, we aimed to comprehensively assess single nucleotide polymorphisms (SNPs) of the caspase-8 (CASP8) and caspase-10 (CASP10) genes in relation to toxicity outcomes with first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).	Platinum	193-201	caspase 10	Homo sapiens	130-136
23581229-0	2012	The relationship between EGFR gene mutation status and ERCC1 in lung adenocarcinoma of Chinese patients receiving platinum-based neoadjuvant chemotherapy.	Platinum	114-122	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	55-60
22843554-3	2012	We genotyped 13 tag SNPs of CASP8 and CASP10 in 663 patients with advanced NSCLC treated with platinum-based chemotherapy regimens.	Platinum	94-102	caspase 8	Homo sapiens	28-33
23581229-1	2012	The specific aim of this study was to assess the relationship between the mutation status of the epidermal growth factor receptor (EGFR) gene and excision repair cross-complementation group 1 (ERCC1) in lung adenocarcinoma of patients that received platinum-based neoadjuvant chemotherapy.	Platinum	249-257	epidermal growth factor receptor	Homo sapiens	97-129
23581229-1	2012	The specific aim of this study was to assess the relationship between the mutation status of the epidermal growth factor receptor (EGFR) gene and excision repair cross-complementation group 1 (ERCC1) in lung adenocarcinoma of patients that received platinum-based neoadjuvant chemotherapy.	Platinum	249-257	epidermal growth factor receptor	Homo sapiens	131-135
23581229-1	2012	The specific aim of this study was to assess the relationship between the mutation status of the epidermal growth factor receptor (EGFR) gene and excision repair cross-complementation group 1 (ERCC1) in lung adenocarcinoma of patients that received platinum-based neoadjuvant chemotherapy.	Platinum	249-257	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	146-191
22289679-2	2012	The methylation status of the PLK2 CpG island varies with sensitivity to paclitaxel and platinum in ovarian cancer cell lines.	Platinum	88-96	polo like kinase 2	Homo sapiens	30-34
23581229-1	2012	The specific aim of this study was to assess the relationship between the mutation status of the epidermal growth factor receptor (EGFR) gene and excision repair cross-complementation group 1 (ERCC1) in lung adenocarcinoma of patients that received platinum-based neoadjuvant chemotherapy.	Platinum	249-257	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	193-198
23272099-2	2012	Resistance to platinum-based therapy correlates with high expression of ERCC1, a major element of the NER machinery.	Platinum	14-22	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	72-77
23209746-0	2012	RAD52 variants predict platinum resistance and prognosis of cervical cancer.	Platinum	23-31	RAD52 homolog, DNA repair protein	Homo sapiens	0-5
23209746-2	2012	To evaluate the role of RAD52 variants in the response of tumor cells to platinum agents, we investigated their associations with platinum resistance and prognosis in cervical cancer patients.	Platinum	73-81	RAD52 homolog, DNA repair protein	Homo sapiens	24-29
23209746-2	2012	To evaluate the role of RAD52 variants in the response of tumor cells to platinum agents, we investigated their associations with platinum resistance and prognosis in cervical cancer patients.	Platinum	130-138	RAD52 homolog, DNA repair protein	Homo sapiens	24-29
23118991-2	2012	In this study, we assessed whether polymorphisms in genes of nucleotide excision repair (NER) pathway, including ERCC5, ERCC6, MMS19L, CCNH, XPC, RRM1, can affect the tolerability of platinum-based chemotherapy in NSCLC patients.	Platinum	183-191	ERCC excision repair 5, endonuclease	Homo sapiens	113-118
23285001-6	2012	Furthermore, patients with high p53 expression in tumors acquired remarkable survival benefit from adjuvant first-line platinum-based-chemotherapy.	Platinum	119-127	tumor protein p53	Homo sapiens	32-35
23285001-8	2012	Thus, p53 expression is a potent prognostic and predictive factor for resectable gastric cancer with adjuvant platinum-based chemotherapy.	Platinum	110-118	tumor protein p53	Homo sapiens	6-9
23185467-10	2012	Strong expression of SERPINB3 protein was a prognostic factor for platinum resistance (adjusted OR; odds ratio, 5.94; 95% Confidence Limits, 1.21-29.15), and for poor progression-free survival (PFS; adjusted HR; hazard ratio, 2.07; 95% CI; confidence interval, 1.03-4.41).	Platinum	66-74	serpin family B member 3	Homo sapiens	21-29
23185467-11	2012	Therefore, SERPINB3 may play an important role in ovarian carcinogenesis and be a novel biomarker for predicting platinum resistance and a poor prognosis for survival in patients with EOC.	Platinum	113-121	serpin family B member 3	Homo sapiens	11-19
22905093-8	2012	Proteins and genes related to DNA damage response, elongation and telomere extension and repair related directly and indirectly to platinum resistance were overexpressed, as the CHK1 protein and the genes CHEK2, LIG3, POLD1, POLA2, FANCD2, PRPF19, RECQ5 respectively, the last two not previously described in mesothelioma.	Platinum	131-139	checkpoint kinase 1	Homo sapiens	178-182
22905093-8	2012	Proteins and genes related to DNA damage response, elongation and telomere extension and repair related directly and indirectly to platinum resistance were overexpressed, as the CHK1 protein and the genes CHEK2, LIG3, POLD1, POLA2, FANCD2, PRPF19, RECQ5 respectively, the last two not previously described in mesothelioma.	Platinum	131-139	checkpoint kinase 2	Homo sapiens	205-210
22905093-8	2012	Proteins and genes related to DNA damage response, elongation and telomere extension and repair related directly and indirectly to platinum resistance were overexpressed, as the CHK1 protein and the genes CHEK2, LIG3, POLD1, POLA2, FANCD2, PRPF19, RECQ5 respectively, the last two not previously described in mesothelioma.	Platinum	131-139	DNA ligase 3	Homo sapiens	212-216
22905093-8	2012	Proteins and genes related to DNA damage response, elongation and telomere extension and repair related directly and indirectly to platinum resistance were overexpressed, as the CHK1 protein and the genes CHEK2, LIG3, POLD1, POLA2, FANCD2, PRPF19, RECQ5 respectively, the last two not previously described in mesothelioma.	Platinum	131-139	DNA polymerase delta 1, catalytic subunit	Homo sapiens	218-223
22905093-8	2012	Proteins and genes related to DNA damage response, elongation and telomere extension and repair related directly and indirectly to platinum resistance were overexpressed, as the CHK1 protein and the genes CHEK2, LIG3, POLD1, POLA2, FANCD2, PRPF19, RECQ5 respectively, the last two not previously described in mesothelioma.	Platinum	131-139	DNA polymerase alpha 2, accessory subunit	Homo sapiens	225-230
22905093-8	2012	Proteins and genes related to DNA damage response, elongation and telomere extension and repair related directly and indirectly to platinum resistance were overexpressed, as the CHK1 protein and the genes CHEK2, LIG3, POLD1, POLA2, FANCD2, PRPF19, RECQ5 respectively, the last two not previously described in mesothelioma.	Platinum	131-139	FA complementation group D2	Homo sapiens	232-238
22905093-8	2012	Proteins and genes related to DNA damage response, elongation and telomere extension and repair related directly and indirectly to platinum resistance were overexpressed, as the CHK1 protein and the genes CHEK2, LIG3, POLD1, POLA2, FANCD2, PRPF19, RECQ5 respectively, the last two not previously described in mesothelioma.	Platinum	131-139	pre-mRNA processing factor 19	Homo sapiens	240-246
22905093-8	2012	Proteins and genes related to DNA damage response, elongation and telomere extension and repair related directly and indirectly to platinum resistance were overexpressed, as the CHK1 protein and the genes CHEK2, LIG3, POLD1, POLA2, FANCD2, PRPF19, RECQ5 respectively, the last two not previously described in mesothelioma.	Platinum	131-139	RecQ like helicase 5	Homo sapiens	248-253
22761669-5	2012	MDR1 C3435T (OR = 1.97, 95% CI: 1.11-3.50, P = 0.02), G2677A/T (OR = 2.61, 95% CI: 1.44-4.74, P = 0.002) and GSTP1 A313G (OR = 0.32, 95% CI: 0.17-0.58, P = 0.0002) were significantly correlated with platinum-based chemotherapy in Asian NSCLC patients.	Platinum	199-207	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
22792399-10	2012	There was decreased expression of the sodium potassium pump (ATP1A), MRP1 and FBP which all have been previously associated with platinum accumulation defects in platinum-resistant cell lines.	Platinum	129-137	ATP binding cassette subfamily C member 1	Homo sapiens	69-73
22792399-10	2012	There was decreased expression of the sodium potassium pump (ATP1A), MRP1 and FBP which all have been previously associated with platinum accumulation defects in platinum-resistant cell lines.	Platinum	129-137	ECB2	Homo sapiens	78-81
22792399-10	2012	There was decreased expression of the sodium potassium pump (ATP1A), MRP1 and FBP which all have been previously associated with platinum accumulation defects in platinum-resistant cell lines.	Platinum	162-170	ATP binding cassette subfamily C member 1	Homo sapiens	69-73
22792399-10	2012	There was decreased expression of the sodium potassium pump (ATP1A), MRP1 and FBP which all have been previously associated with platinum accumulation defects in platinum-resistant cell lines.	Platinum	162-170	ECB2	Homo sapiens	78-81
22479369-0	2012	Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.	Platinum	55-63	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	27-30
22590594-2	2012	Deregulation of p53 and/or p73-associated apoptotic pathways contribute to the platinum-based resistance in ovarian cancer.	Platinum	79-87	tumor protein p53	Homo sapiens	16-19
22590594-2	2012	Deregulation of p53 and/or p73-associated apoptotic pathways contribute to the platinum-based resistance in ovarian cancer.	Platinum	79-87	tumor protein p73	Homo sapiens	27-30
22479369-1	2012	PURPOSE: Xeroderma pigmentosum group D (XPD) codes for a DNA helicase involved in nucleotide excision repair that removes platinum-induced DNA damage.	Platinum	122-130	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	40-43
22479369-3	2012	This study aims to identify whether XPD polymorphisms affect clinical efficacy among advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.	Platinum	151-159	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	36-39
22479369-11	2012	CONCLUSIONS: Our study provides evidence for the predictive role of XPD Asp(312)Asn, Asp(711)Asp and Lys(751)Gln polymorphisms/haplotype on NSCLC prognosis in inoperable advanced NSCLC patients treated with platinum-based chemotherapy.	Platinum	207-215	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	68-71
22032417-2	2011	CaM contains 9 methionine (Met), 1 histidine (His), 17 aspartic acid (Asp), and 23 glutamine acid (Glu) residues, all of which can potentially react with platinum compounds; thus, one-third of the CaM sequence is a possible binding target of platinum anticancer drugs, which represents a major challenge for identification of specific platinum modification sites.	Platinum	154-162	calmodulin 1	Homo sapiens	0-3
22077361-0	2011	Noncovalent interactions between a trinuclear monofunctional platinum complex and human serum albumin.	Platinum	61-69	albumin	Homo sapiens	88-101
22077361-1	2011	Interactions between platinum complexes and human serum albumin (HSA) play crucial roles in the metabolism, distribution, and efficacy of platinum-based anticancer drugs.	Platinum	21-29	albumin	Homo sapiens	50-63
22077361-1	2011	Interactions between platinum complexes and human serum albumin (HSA) play crucial roles in the metabolism, distribution, and efficacy of platinum-based anticancer drugs.	Platinum	138-146	albumin	Homo sapiens	50-63
22032417-2	2011	CaM contains 9 methionine (Met), 1 histidine (His), 17 aspartic acid (Asp), and 23 glutamine acid (Glu) residues, all of which can potentially react with platinum compounds; thus, one-third of the CaM sequence is a possible binding target of platinum anticancer drugs, which represents a major challenge for identification of specific platinum modification sites.	Platinum	154-162	calmodulin 1	Homo sapiens	197-200
22032417-2	2011	CaM contains 9 methionine (Met), 1 histidine (His), 17 aspartic acid (Asp), and 23 glutamine acid (Glu) residues, all of which can potentially react with platinum compounds; thus, one-third of the CaM sequence is a possible binding target of platinum anticancer drugs, which represents a major challenge for identification of specific platinum modification sites.	Platinum	242-250	calmodulin 1	Homo sapiens	0-3
22032417-2	2011	CaM contains 9 methionine (Met), 1 histidine (His), 17 aspartic acid (Asp), and 23 glutamine acid (Glu) residues, all of which can potentially react with platinum compounds; thus, one-third of the CaM sequence is a possible binding target of platinum anticancer drugs, which represents a major challenge for identification of specific platinum modification sites.	Platinum	242-250	calmodulin 1	Homo sapiens	0-3
22032417-6	2011	At a high molar ratio of cisplatin:CaM (8:1), up to 10 platinum(II) bind to Met, Asp, and Glu residues.	Platinum	55-63	calmodulin 1	Homo sapiens	35-38
24061133-2	2011	In this study two platinum(II) and palladium(II) complexes of the type [M(bpy)(pip-dtc)]NO3 (where M=Pt(II) or Pd(II), bpy=2,2"-bipyridine, pip-dtc=piperidinedithiocarbamate) were synthesized by reaction between diaquo-2,2"-bipyridine Pt(II)/Pd(II) nitrate and sodium salt of dithiocarbamate.	Platinum	18-26	prolactin induced protein	Bos taurus	79-82
22025407-2	2011	Ethacrynic acid (EA) is able to inhibit the detoxifying enzyme glutathione-S-transferase (GST), which catalyzes the conjugation between GSH and Pt-based drugs.	Platinum	144-146	glutathione S-transferase kappa 1	Homo sapiens	63-88
22025407-2	2011	Ethacrynic acid (EA) is able to inhibit the detoxifying enzyme glutathione-S-transferase (GST), which catalyzes the conjugation between GSH and Pt-based drugs.	Platinum	144-146	glutathione S-transferase kappa 1	Homo sapiens	90-93
22180399-10	2011	Use of CA125 to define progression could result in platinum-sensitive patients being falsely classified as platinum resistant.	Platinum	51-59	mucin 16, cell surface associated	Homo sapiens	7-12
22180399-10	2011	Use of CA125 to define progression could result in platinum-sensitive patients being falsely classified as platinum resistant.	Platinum	107-115	mucin 16, cell surface associated	Homo sapiens	7-12
22419895-9	2011	In patients harbouring BRCA-1 germline mutations, platinum derivatives are apparently promising.	Platinum	50-58	BRCA1 DNA repair associated	Homo sapiens	23-29
21529988-8	2011	Twenty of 34 serum proGRP-positive NSCLC patients received platinum-based chemotherapy, and the response rate was 55.0%.	Platinum	59-67	gastrin releasing peptide	Homo sapiens	19-25
21920589-1	2011	OBJECTIVES: We investigated the relationship between BRCA1 protein expression by immunohistochemistry (IHC) and clinical outcome following platinum and platinum/taxane chemotherapy in sporadic epithelial ovarian cancer (EOC).	Platinum	139-147	BRCA1 DNA repair associated	Homo sapiens	53-58
21920589-1	2011	OBJECTIVES: We investigated the relationship between BRCA1 protein expression by immunohistochemistry (IHC) and clinical outcome following platinum and platinum/taxane chemotherapy in sporadic epithelial ovarian cancer (EOC).	Platinum	152-160	BRCA1 DNA repair associated	Homo sapiens	53-58
21920589-5	2011	Patients with absent/low BRCA1 had a higher probability of clinical response following single agent platinum compared to high BRCA1 expressing patients (68.5% vs. 46.8%), while addition of a taxane increased response rates independent of BRCA1.	Platinum	100-108	BRCA1 DNA repair associated	Homo sapiens	25-30
21980053-0	2011	S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.	Platinum	110-118	proteasome 26S subunit, non-ATPase 1	Homo sapiens	0-3
21980053-2	2011	The objective was to evaluate the efficacy of S-1 monotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy.	Platinum	165-173	proteasome 26S subunit, non-ATPase 1	Homo sapiens	46-49
21980053-12	2011	CONCLUSIONS: S-1 monotherapy shows promising signs of efficacy and tolerability in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy in this retrospective cohort and warrants further investigation in this population.	Platinum	183-191	proteasome 26S subunit, non-ATPase 1	Homo sapiens	13-16
22152690-14	2011	CONCLUSIONS: The combination of the XRCC1 and XRCC3 polymorphisms may be associated with patient sensitivity to platinum-based chemotherapy in advanced NSCLC.	Platinum	112-120	X-ray repair cross complementing 1	Homo sapiens	36-41
20467918-8	2011	Patients with low ERCC1 expression benefited more from a platinum-containing regimen (P=0.094).	Platinum	57-65	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	18-23
22152690-14	2011	CONCLUSIONS: The combination of the XRCC1 and XRCC3 polymorphisms may be associated with patient sensitivity to platinum-based chemotherapy in advanced NSCLC.	Platinum	112-120	X-ray repair cross complementing 3	Homo sapiens	46-51
22152690-0	2011	[Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].	Platinum	72-80	X-ray repair cross complementing 1	Homo sapiens	15-20
22152690-0	2011	[Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].	Platinum	72-80	X-ray repair cross complementing 3	Homo sapiens	25-30
22029396-7	2011	Pt-1 is nonphosphorescent at RT in solution because of the acac-localized T(1) excited state [based on density functional theory (DFT) calculations and spin density analysis], but a structured emission band centered at 415 nm was observed at 77 K. Time-resolved transient absorption spectra and spin density analysis indicated a NI-localized intraligand triplet excited state ((3)IL) for complexes Pt-2, Pt-3, and Pt-4.	Platinum	0-2	zinc finger protein 135	Homo sapiens	404-408
22152690-3	2011	The aim of this study is to investigate the relationship between X-ray repair cross complementing protein 1 (XRCC1) and X-ray repair cross complementing protein 3 (XRCC3) gene polymorphisms and the chemosensitivity of platinum-based chemotherapy in patients with advanced NSCLC.	Platinum	218-226	X-ray repair cross complementing 1	Homo sapiens	65-107
22152690-3	2011	The aim of this study is to investigate the relationship between X-ray repair cross complementing protein 1 (XRCC1) and X-ray repair cross complementing protein 3 (XRCC3) gene polymorphisms and the chemosensitivity of platinum-based chemotherapy in patients with advanced NSCLC.	Platinum	218-226	X-ray repair cross complementing 1	Homo sapiens	109-114
22152690-3	2011	The aim of this study is to investigate the relationship between X-ray repair cross complementing protein 1 (XRCC1) and X-ray repair cross complementing protein 3 (XRCC3) gene polymorphisms and the chemosensitivity of platinum-based chemotherapy in patients with advanced NSCLC.	Platinum	218-226	X-ray repair cross complementing 3	Homo sapiens	120-162
22152690-3	2011	The aim of this study is to investigate the relationship between X-ray repair cross complementing protein 1 (XRCC1) and X-ray repair cross complementing protein 3 (XRCC3) gene polymorphisms and the chemosensitivity of platinum-based chemotherapy in patients with advanced NSCLC.	Platinum	218-226	X-ray repair cross complementing 3	Homo sapiens	164-169
22032259-0	2011	Reactivity of TCNE or TCNQ derivatives of quinonoid zwitterions: platinum-induced HCN elimination vs oxidative-addition.	Platinum	65-73	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	82-85
21970874-1	2011	BACKGROUND: Although pemetrexed, a potent thymidylate synthase (TS) inhibitor, enhances the cytoytoxic effect of platinum compounds against malignant pleural mesothelioma (MPM), novel combinations with effective targeted therapies are warranted.	Platinum	113-121	thymidylate synthetase	Homo sapiens	64-66
22007074-7	2011	We then demonstrated that MCP-1 (100 mug/mL)-releasing coils promote significantly greater aneurysm tissue in-growth than bare platinum or PLGA-only coils.	Platinum	127-135	chemokine (C-C motif) ligand 2	Mus musculus	26-31
22075440-8	2011	CONCLUSIONS: It appears that TP53 status determines the clinical importance of nuclear survivin expression in taxane-platinum treated ovarian cancer patients.	Platinum	117-125	tumor protein p53	Homo sapiens	29-33
22082649-9	2011	CONCLUSION This study provides support for the prognostic value of ERCC1 immunohistochemical expression in patients with NSCLC treated by adjuvant platinum-based chemotherapy.	Platinum	147-155	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	67-72
21952551-1	2011	We directly synthesized a platinum-nanoparticles/graphitic-nanofibers (PtNPs/GNFs) hybrid nanostructure on FTO glass.	Platinum	26-34	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	107-110
21958150-0	2011	Titanocene-phosphine derivatives as precursors to cytotoxic heterometallic TiAu2 and TiM (M = Pd, Pt) compounds.	Platinum	98-100	Rho guanine nucleotide exchange factor 5	Homo sapiens	85-88
21927014-0	2011	Platinum-(IV)-derivative satraplatin induced G2/M cell cycle perturbation via p53-p21(waf1/cip1)-independent pathway in human colorectal cancer cells.	Platinum	0-8	tumor protein p53	Homo sapiens	78-81
21927014-0	2011	Platinum-(IV)-derivative satraplatin induced G2/M cell cycle perturbation via p53-p21(waf1/cip1)-independent pathway in human colorectal cancer cells.	Platinum	0-8	cyclin dependent kinase inhibitor 1A	Homo sapiens	82-95
22110199-0	2011	Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence.	Platinum	53-61	solute carrier family 7 member 5	Homo sapiens	21-25
21723790-1	2011	UNLABELLED: Small observational studies have demonstrated an association between high ERCC1 expression level and poor prognosis in advanced NSCLC treated with platinum-based chemotherapy.	Platinum	159-167	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	86-91
21723790-5	2011	BACKGROUND: Observational studies have demonstrated an association between excision repair cross-complementation group 1 (ERCC1) expression level and health outcomes in patients with advanced non-small-cell lung cancer (NSCLC) treated with platinum-based regimens.	Platinum	240-248	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	75-120
21723790-5	2011	BACKGROUND: Observational studies have demonstrated an association between excision repair cross-complementation group 1 (ERCC1) expression level and health outcomes in patients with advanced non-small-cell lung cancer (NSCLC) treated with platinum-based regimens.	Platinum	240-248	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	122-127
21723790-12	2011	CONCLUSION: This study"s findings support the hypothesis that ERCC1 expression is associated with response rate and overall survival (OS) in patients with advanced NSCLC treated with platinum-based chemotherapy.	Platinum	183-191	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	62-67
21368065-1	2011	BACKGROUND: Breast cancer 1 (BRCA1) protein inactivation in sporadic ovarian carcinoma (OC) is common and low BRCA1 expression is linked with platinum sensitivity.	Platinum	142-150	BRCA1 DNA repair associated	Homo sapiens	12-27
21368065-1	2011	BACKGROUND: Breast cancer 1 (BRCA1) protein inactivation in sporadic ovarian carcinoma (OC) is common and low BRCA1 expression is linked with platinum sensitivity.	Platinum	142-150	BRCA1 DNA repair associated	Homo sapiens	29-34
21368065-1	2011	BACKGROUND: Breast cancer 1 (BRCA1) protein inactivation in sporadic ovarian carcinoma (OC) is common and low BRCA1 expression is linked with platinum sensitivity.	Platinum	142-150	BRCA1 DNA repair associated	Homo sapiens	110-115
21436186-2	2011	PATIENTS AND METHODS: We assessed the efficacy and toxicity of a platinum-based chemotherapy regimen in mCRPC patients with either neuroendocrine differentiation defined by high serum levels of chromogranin A (CgA) and neuron-specific enolase (NSE) or visceral metastases.	Platinum	65-73	chromogranin A	Homo sapiens	194-208
21436186-2	2011	PATIENTS AND METHODS: We assessed the efficacy and toxicity of a platinum-based chemotherapy regimen in mCRPC patients with either neuroendocrine differentiation defined by high serum levels of chromogranin A (CgA) and neuron-specific enolase (NSE) or visceral metastases.	Platinum	65-73	chromogranin A	Homo sapiens	210-213
21436186-2	2011	PATIENTS AND METHODS: We assessed the efficacy and toxicity of a platinum-based chemotherapy regimen in mCRPC patients with either neuroendocrine differentiation defined by high serum levels of chromogranin A (CgA) and neuron-specific enolase (NSE) or visceral metastases.	Platinum	65-73	enolase 2	Homo sapiens	219-242
21436186-2	2011	PATIENTS AND METHODS: We assessed the efficacy and toxicity of a platinum-based chemotherapy regimen in mCRPC patients with either neuroendocrine differentiation defined by high serum levels of chromogranin A (CgA) and neuron-specific enolase (NSE) or visceral metastases.	Platinum	65-73	enolase 2	Homo sapiens	244-247
22340169-2	2011	Previous studies indicated that certain EGFR mutations were associated with response and progression free survival following platinum based chemotherapy.	Platinum	125-133	epidermal growth factor receptor	Homo sapiens	40-44
21905963-2	2011	In the first-line setting, recent randomized Phase III trials comparing EGFR-TKIs versus platinum-based doublets demonstrated that in patients harboring an activating EGFR mutation, gefitinib is superior to chemotherapy in terms of response rate, progression-free survival, toxicity profile and quality of life, with a marginal positive effect on survival.	Platinum	89-97	epidermal growth factor receptor	Homo sapiens	167-171
21855118-2	2011	METHODS: A single-institution retrospective analysis of platinum-resistant patients characterized for the presence or absence of known deleterious BRCA mutations.	Platinum	56-64	BRCA1 DNA repair associated	Homo sapiens	147-151
21897273-11	2011	BRCA1 IHC negativity of sporadic EOC may be predictive of sensitivity to platinum-based chemotherapy and the poly-ADP-ribose-polymerase inhibitor-sensitive BRCAness phenotype.	Platinum	73-81	BRCA1 DNA repair associated	Homo sapiens	0-5
21720251-1	2011	OBJECTIVE: Several studies have suggested that excision repair cross-complementation group 1 (ERCC1), a protein involved in nucleotide excision repair, is associated with resistance to platinum agent-based chemotherapy or chemoradiotherapy with platinum agents in various types of cancer.	Platinum	185-193	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-92
21720251-1	2011	OBJECTIVE: Several studies have suggested that excision repair cross-complementation group 1 (ERCC1), a protein involved in nucleotide excision repair, is associated with resistance to platinum agent-based chemotherapy or chemoradiotherapy with platinum agents in various types of cancer.	Platinum	185-193	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	94-99
21964533-2	2011	We conducted a phase II study of the oral pan-VEGF receptor tyrosine kinase inhibitor, cediranib, in patients with MPM after platinum-based systemic chemotherapy.	Platinum	125-133	vascular endothelial growth factor A	Homo sapiens	46-50
22313299-0	2011	Synergism from combination of cisplatin and multicentred platinums coded as DH6Cl and TH1 in the human ovarian tumour models.	Platinum	57-66	negative elongation factor complex member C/D	Homo sapiens	86-89
21529986-9	2011	CONCLUSIONS: The study confirms tumor expression of ERCC1 as a predictor for clinical outcome in patients with advanced NSCLC receiving platinum-based chemotherapy, and found ABRX expression to be similarly predictive of clinical outcome.	Platinum	136-144	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	52-57
22313299-3	2011	In this study synergism in activity from the combinations of cisplatin (Cis) with two multicentred platinum complexes coded as TH1 and DH6Cl in the human ovarian A2780, A2780cisR and A27800473R cancer cell lines had been investigated.	Platinum	99-107	negative elongation factor complex member C/D	Homo sapiens	127-130
21681330-0	2011	Monofunctional platinum complexes containing a 4-nitrobenzo-2-oxa-1,3-diazole fluorophore: distribution in tumour cells.	Platinum	15-23	OXA1L mitochondrial inner membrane protein	Homo sapiens	62-67
22131882-0	2011	DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.	Platinum	79-87	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	0-6
22131882-0	2011	DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.	Platinum	79-87	AKT serine/threonine kinase 1	Homo sapiens	16-19
22131882-5	2011	The AKT pathway is central to cell survival and has been implicated in platinum resistance.	Platinum	71-79	AKT serine/threonine kinase 1	Homo sapiens	4-7
22131882-6	2011	Here, we show that platinum exposure induces an AKT-dependent, prosurvival, DNA damage response in clinically platinum-resistant but not platinum-sensitive cells.	Platinum	19-27	AKT serine/threonine kinase 1	Homo sapiens	48-51
22131882-6	2011	Here, we show that platinum exposure induces an AKT-dependent, prosurvival, DNA damage response in clinically platinum-resistant but not platinum-sensitive cells.	Platinum	110-118	AKT serine/threonine kinase 1	Homo sapiens	48-51
22131882-6	2011	Here, we show that platinum exposure induces an AKT-dependent, prosurvival, DNA damage response in clinically platinum-resistant but not platinum-sensitive cells.	Platinum	110-118	AKT serine/threonine kinase 1	Homo sapiens	48-51
22131882-8	2011	Inhibition of DNA-PK or AKT, but not mTORC2, restores platinum sensitivity in a panel of clinically resistant HGS ovarian cancer cell lines: we also demonstrate these effects in other tumor types.	Platinum	54-62	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	14-20
22131882-8	2011	Inhibition of DNA-PK or AKT, but not mTORC2, restores platinum sensitivity in a panel of clinically resistant HGS ovarian cancer cell lines: we also demonstrate these effects in other tumor types.	Platinum	54-62	AKT serine/threonine kinase 1	Homo sapiens	24-27
22104220-11	2011	The chemotherapeutic effect on patients carrying null-type GSTM1 was better than on those carrying the functional type when platinum drugs were administered.	Platinum	124-132	glutathione S-transferase mu 1	Homo sapiens	59-64
21990299-6	2011	Moreover, BRCA2 mutations were associated with a significantly higher primary chemotherapy sensitivity rate (100% for BRCA2-mutated vs 82% [P = .02] and 80% [P = .05] for BRCA wild-type and BRCA1-mutated cases, respectively) and longer platinum-free duration (median platinum-free duration, 18.0 months for BRCA2-mutated vs 11.7 [P = .02] and 12.5 [P = .04] months for BRCA wild-type and BRCA1-mutated cases, respectively).	Platinum	236-244	BRCA2 DNA repair associated	Homo sapiens	10-15
22040120-0	2011	The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo.	Platinum	8-16	retinol binding protein 4	Rattus norvegicus	54-79
21970881-0	2011	Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer.	Platinum	9-17	angiotensin II receptor type 1	Homo sapiens	66-96
21970881-1	2011	BACKGROUND: We investigated the changes in reactive oxygen species (ROS) and angiogenesis through angiotensin II (Ang II) type 1 receptor (AT1R) after the development of acquired platinum resistance in bladder cancer.	Platinum	179-187	angiotensin II receptor type 1	Homo sapiens	98-137
21970881-1	2011	BACKGROUND: We investigated the changes in reactive oxygen species (ROS) and angiogenesis through angiotensin II (Ang II) type 1 receptor (AT1R) after the development of acquired platinum resistance in bladder cancer.	Platinum	179-187	angiotensin II receptor type 1	Homo sapiens	139-143
21970881-5	2011	These platinum-resistant cells also showed significantly higher AT1R expression than their corresponding parent cells.	Platinum	6-14	angiotensin II receptor type 1	Homo sapiens	64-68
21970881-7	2011	We also demonstrated the efficacy of AT1R blockade at suppressing the growth of platinum-resistant xenograft model.	Platinum	80-88	angiotensin II receptor type 1	Homo sapiens	37-41
22009704-0	2011	Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients.	Platinum	76-84	glutathione S-transferase pi 1	Homo sapiens	25-30
22009704-0	2011	Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients.	Platinum	76-84	X-ray repair cross complementing 1	Homo sapiens	35-40
22009704-2	2011	Genetic polymorphisms of GSTP1 and XRCC1 involved in glutathione metabolic and DNA repair pathways may explain inter individual differences in chemosensitivity and clinical outcome in NSCLC patients treated with platinum-based regimens.	Platinum	212-220	glutathione S-transferase pi 1	Homo sapiens	25-30
22009704-2	2011	Genetic polymorphisms of GSTP1 and XRCC1 involved in glutathione metabolic and DNA repair pathways may explain inter individual differences in chemosensitivity and clinical outcome in NSCLC patients treated with platinum-based regimens.	Platinum	212-220	X-ray repair cross complementing 1	Homo sapiens	35-40
22009704-3	2011	METHODS: We used DNA sequencing methods to evaluate genetic polymorphisms of the GSTP1A313G and XRCC1G28152A in 111 patients with stage IV NSCLC treated with platinum-based chemotherapy.	Platinum	158-166	X-ray repair cross complementing 1	Homo sapiens	96-101
22009704-5	2011	RESULTS: GSTP1A313G and XRCC1G28152A polymorphisms, both alone and in combination, were significantly associated with response to treatment and clinical outcome (p &lt;0.05) in NSCLC patients treated with platinum-based chemotherapy.	Platinum	205-213	X-ray repair cross complementing 1	Homo sapiens	24-29
22009704-7	2011	CONCLUSION: Genetic polymorphisms of GSTP1 and XRCC1 may be important predictive factors in platinum-treated patients with advanced NSCLC.	Platinum	92-100	glutathione S-transferase pi 1	Homo sapiens	37-42
22009704-7	2011	CONCLUSION: Genetic polymorphisms of GSTP1 and XRCC1 may be important predictive factors in platinum-treated patients with advanced NSCLC.	Platinum	92-100	X-ray repair cross complementing 1	Homo sapiens	47-52
21763187-8	2011	The platinum complex (6) displays cytotoxicity (IC(50) = 12.4 muM) against breast cancer compared with that reported for cis-platin 9.91 muM.	Platinum	4-12	latexin	Homo sapiens	62-65
21763187-8	2011	The platinum complex (6) displays cytotoxicity (IC(50) = 12.4 muM) against breast cancer compared with that reported for cis-platin 9.91 muM.	Platinum	4-12	latexin	Homo sapiens	137-140
21856311-0	2011	HuCAL PLATINUM, a synthetic Fab library optimized for sequence diversity and superior performance in mammalian expression systems.	Platinum	6-14	FA complementation group B	Homo sapiens	28-31
21990299-6	2011	Moreover, BRCA2 mutations were associated with a significantly higher primary chemotherapy sensitivity rate (100% for BRCA2-mutated vs 82% [P = .02] and 80% [P = .05] for BRCA wild-type and BRCA1-mutated cases, respectively) and longer platinum-free duration (median platinum-free duration, 18.0 months for BRCA2-mutated vs 11.7 [P = .02] and 12.5 [P = .04] months for BRCA wild-type and BRCA1-mutated cases, respectively).	Platinum	267-275	BRCA2 DNA repair associated	Homo sapiens	10-15
21990299-6	2011	Moreover, BRCA2 mutations were associated with a significantly higher primary chemotherapy sensitivity rate (100% for BRCA2-mutated vs 82% [P = .02] and 80% [P = .05] for BRCA wild-type and BRCA1-mutated cases, respectively) and longer platinum-free duration (median platinum-free duration, 18.0 months for BRCA2-mutated vs 11.7 [P = .02] and 12.5 [P = .04] months for BRCA wild-type and BRCA1-mutated cases, respectively).	Platinum	267-275	BRCA1 DNA repair associated	Homo sapiens	10-14
21990299-6	2011	Moreover, BRCA2 mutations were associated with a significantly higher primary chemotherapy sensitivity rate (100% for BRCA2-mutated vs 82% [P = .02] and 80% [P = .05] for BRCA wild-type and BRCA1-mutated cases, respectively) and longer platinum-free duration (median platinum-free duration, 18.0 months for BRCA2-mutated vs 11.7 [P = .02] and 12.5 [P = .04] months for BRCA wild-type and BRCA1-mutated cases, respectively).	Platinum	267-275	BRCA1 DNA repair associated	Homo sapiens	190-195
21990299-6	2011	Moreover, BRCA2 mutations were associated with a significantly higher primary chemotherapy sensitivity rate (100% for BRCA2-mutated vs 82% [P = .02] and 80% [P = .05] for BRCA wild-type and BRCA1-mutated cases, respectively) and longer platinum-free duration (median platinum-free duration, 18.0 months for BRCA2-mutated vs 11.7 [P = .02] and 12.5 [P = .04] months for BRCA wild-type and BRCA1-mutated cases, respectively).	Platinum	236-244	BRCA1 DNA repair associated	Homo sapiens	10-14
21898612-12	2011	Finally, in the ion-molecule reactions with ammonia, both platinum complexes give rise to proton transfer to produce NH(4)(+); however, only the encounter complex generated with PtCH(+) undergoes efficient dehydrogenation of the substrate, and the rather minor formation of CNH(4)(+) indicates that C-N bond coupling is inefficient.	Platinum	58-66	patched 1	Homo sapiens	178-182
21990299-6	2011	Moreover, BRCA2 mutations were associated with a significantly higher primary chemotherapy sensitivity rate (100% for BRCA2-mutated vs 82% [P = .02] and 80% [P = .05] for BRCA wild-type and BRCA1-mutated cases, respectively) and longer platinum-free duration (median platinum-free duration, 18.0 months for BRCA2-mutated vs 11.7 [P = .02] and 12.5 [P = .04] months for BRCA wild-type and BRCA1-mutated cases, respectively).	Platinum	236-244	BRCA1 DNA repair associated	Homo sapiens	190-195
21910144-6	2011	Results indicated that the phenanthroline ligand could induce noncovalent interactions between Abeta peptide and platinum complexes, leading to rapid Abeta platination.	Platinum	113-121	amyloid beta precursor protein	Homo sapiens	95-100
21910144-6	2011	Results indicated that the phenanthroline ligand could induce noncovalent interactions between Abeta peptide and platinum complexes, leading to rapid Abeta platination.	Platinum	113-121	amyloid beta precursor protein	Homo sapiens	150-155
21879121-2	2011	We report on a templating method used to deposit highly ordered nanoporous platinum (Pt)-doped tin dioxide (SnO(2)) thin films that are crystallized by a 100  C water vapor hydrothermal treatment, with the low temperature process being compatible with a large variety of substrates including plastic.	Platinum	75-83	strawberry notch homolog 2	Homo sapiens	108-111
21879121-2	2011	We report on a templating method used to deposit highly ordered nanoporous platinum (Pt)-doped tin dioxide (SnO(2)) thin films that are crystallized by a 100  C water vapor hydrothermal treatment, with the low temperature process being compatible with a large variety of substrates including plastic.	Platinum	85-87	strawberry notch homolog 2	Homo sapiens	108-111
22039334-8	2011	Importantly, both cerium oxide and platinum nanoparticles reduce oxidant-mediated apoptosis in target cells as judged by the activation of caspase 3.	Platinum	35-43	caspase 3	Homo sapiens	139-148
21298384-1	2011	PURPOSE: The aim of this study is to evaluate the effect of excision repair cross-complementation group 1 (ERCC1) expression on treatment outcomes in advanced biliary tract adenocarcinoma (ABTA) patients treated with platinum-based chemotherapy.	Platinum	217-225	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	60-105
21298384-1	2011	PURPOSE: The aim of this study is to evaluate the effect of excision repair cross-complementation group 1 (ERCC1) expression on treatment outcomes in advanced biliary tract adenocarcinoma (ABTA) patients treated with platinum-based chemotherapy.	Platinum	217-225	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	107-112
21378390-2	2011	BRCA mutations are associated with an improved outcome and enhanced sensitivity to platinum chemotherapy, yet recurrence and platinum resistance remain a major problem and highly effective regimens following platinum failure do not yet exist.	Platinum	83-91	BRCA1 DNA repair associated	Homo sapiens	0-4
21378390-3	2011	Here we report a remarkable case of cure following platinum-resistant stage III ovarian carcinoma in a woman with a BRCA2 mutation.	Platinum	51-59	BRCA2 DNA repair associated	Homo sapiens	116-121
21899484-1	2011	Abstract: In this paper, a novel amperometric phenol biosensor with immobilization of polyphenol oxidase (tyrosinase) on electrochemically polymerized polypyrrole-polyvinylsulphonate (PPy-PVS) film has been accomplished via the entrapment technique on the surface of a platinum electrode.	Platinum	269-277	tyrosinase	Homo sapiens	106-116
21298384-0	2011	Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients.	Platinum	78-86	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	27-32
21683503-10	2011	An elevated serum level of HE4 is a poor prognostic factor for PFS in patients with epithelial ovarian cancer who were treated with debulking surgery and adjuvant taxane and platinum-based chemotherapy.	Platinum	174-182	WAP four-disulfide core domain 2	Homo sapiens	27-30
22331725-0	2011	TP53 gene status and human papilloma virus infection in response to platinum plus taxane-based chemotherapy of epithelial ovarian carcinomas.	Platinum	68-76	tumor protein p53	Homo sapiens	0-4
22331726-0	2011	Expression of ERCC1 protein in biopsy specimen predicts survival in advanced ovarian cancer patients treated with platinum-based chemotherapy.	Platinum	114-122	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-19
22331726-5	2011	Time to progression (TTP) and overall survival (OS) in EOC patients previously treated with platinum-based chemotherapy were significantly longer in those with low expression compared with patients showing high expression of ERCC1 protein.	Platinum	92-100	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	225-230
22331726-6	2011	CONCLUSION: Our results revealed that ERCC1 protein expression could potentially be used to customize chemotherapy by defining subsets of patients who would benefit the least from platinum-based chemotherapy.	Platinum	180-188	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	38-43
21909579-0	2011	Inhibitory effect of platinum and ruthenium bipyridyl complexes on porcine pancreatic phospholipase A2.	Platinum	21-29	phospholipase A2 group IB	Homo sapiens	86-102
21835933-1	2011	Epithelial ovarian cancer (EOC) patients with BRCA mutations (BRCA +) benefit from platinum-based treatment more than noncarriers.	Platinum	83-91	BRCA1 DNA repair associated	Homo sapiens	46-50
21835933-1	2011	Epithelial ovarian cancer (EOC) patients with BRCA mutations (BRCA +) benefit from platinum-based treatment more than noncarriers.	Platinum	83-91	BRCA1 DNA repair associated	Homo sapiens	62-68
21835933-9	2011	In this retrospective analysis, recurrent EOC BRCA mutation carriers treated with PLD had an improved outcome, and this result seemed to be independent of platinum sensitivity.	Platinum	155-163	BRCA1 DNA repair associated	Homo sapiens	46-50
21431178-1	2011	Ligand-metal cooperation in iridium and platinum complexes bearing tricyclic dibenzobarrelene-based PC(sp(3))P pincer ligands is discussed.	Platinum	40-48	Sp3 transcription factor pseudogene	Homo sapiens	100-110
22107222-3	2011	A dc current pulse was applied to the Pt layer and produced a spin current across the Pt thickness.	Platinum	38-40	spindlin 1	Homo sapiens	62-66
21725574-0	2011	Reaction of bis(o-phosphinophenyl)silane with M(PPh3)4 (M = Ni, Pd, Pt): synthesis and structural analysis of eta2-(Si-H) metal(0) and pentacoordinate silyl metal(II) hydride complexes of the Ni triad bearing a PSiP-pincer ligand.	Platinum	68-70	DNA polymerase iota	Homo sapiens	110-114
21795409-2	2011	EXPERIMENTAL DESIGN: We combined preclinical and in silico experiments with a phase 2 clinical trial of the anti-IL-6 antibody siltuximab in patients with platinum-resistant ovarian cancer.	Platinum	155-163	interleukin 6	Homo sapiens	113-117
21734577-2	2011	RECENT FINDINGS: Women with BRCA-associated epithelial ovarian cancer represent a unique group who commonly are diagnosed at a younger age, have advanced high-grade serous disease, have improved sensitivity to platinum-based chemotherapy in both the upfront and recurrent setting, and have an overall improved prognosis.	Platinum	210-218	BRCA1 DNA repair associated	Homo sapiens	28-32
21801891-7	2011	Thus Prussian Blue must act as an electron mediator between the FAD centre in CKX2 and the Pt surface.	Platinum	91-93	cytokinin oxidase 2	Arabidopsis thaliana	78-82
21750204-1	2011	PURPOSE: Excision repair cross-complementation group 1 (ERCC1) is a protein involved in repair of DNA platinum adducts and stalled DNA replication forks.	Platinum	102-110	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	9-54
21750204-1	2011	PURPOSE: Excision repair cross-complementation group 1 (ERCC1) is a protein involved in repair of DNA platinum adducts and stalled DNA replication forks.	Platinum	102-110	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	56-61
21732466-1	2011	Two near-infrared (NIR) absorbing metallopolyynes of platinum (P1 and P2) functionalized with a weakly electron-donating fluorene unit and two strong electron acceptors (viz.	Platinum	53-61	crystallin gamma F, pseudogene	Homo sapiens	63-72
21557512-8	2011	Analysis of the organization of actin filaments in actin patches using platinum replica electron microscopy reveals that patches consist of networks of actin filaments, and filaments in axonal filopodia exhibit an organization consistent with the Arp2/3-based convergent elongation mechanism.	Platinum	71-79	actin, beta	Gallus gallus	32-37
21557512-8	2011	Analysis of the organization of actin filaments in actin patches using platinum replica electron microscopy reveals that patches consist of networks of actin filaments, and filaments in axonal filopodia exhibit an organization consistent with the Arp2/3-based convergent elongation mechanism.	Platinum	71-79	actin, beta	Gallus gallus	51-56
21557512-8	2011	Analysis of the organization of actin filaments in actin patches using platinum replica electron microscopy reveals that patches consist of networks of actin filaments, and filaments in axonal filopodia exhibit an organization consistent with the Arp2/3-based convergent elongation mechanism.	Platinum	71-79	actin, beta	Gallus gallus	51-56
21734577-6	2011	SUMMARY: Patients with BRCA-associated epithelial ovarian cancer have improved response to platinum-based chemotherapy, improved survival, and may be appropriate candidates for treatment with novel targeted therapies.	Platinum	91-99	BRCA1 DNA repair associated	Homo sapiens	23-27
21640784-1	2011	To better understand species differences in cisplatin nephrotoxicity, we focused on renal cysteine-S-conjugate beta-lyase (C-S lyase), which may play a crucial role in the metabolism of platinum (Pt)-cysteine conjugates.	Platinum	186-194	kynurenine aminotransferase 1	Rattus norvegicus	90-121
21640784-1	2011	To better understand species differences in cisplatin nephrotoxicity, we focused on renal cysteine-S-conjugate beta-lyase (C-S lyase), which may play a crucial role in the metabolism of platinum (Pt)-cysteine conjugates.	Platinum	186-194	kynurenine aminotransferase 1	Rattus norvegicus	123-132
21640784-1	2011	To better understand species differences in cisplatin nephrotoxicity, we focused on renal cysteine-S-conjugate beta-lyase (C-S lyase), which may play a crucial role in the metabolism of platinum (Pt)-cysteine conjugates.	Platinum	196-198	kynurenine aminotransferase 1	Rattus norvegicus	90-121
21640784-1	2011	To better understand species differences in cisplatin nephrotoxicity, we focused on renal cysteine-S-conjugate beta-lyase (C-S lyase), which may play a crucial role in the metabolism of platinum (Pt)-cysteine conjugates.	Platinum	196-198	kynurenine aminotransferase 1	Rattus norvegicus	123-132
21687948-4	2011	Polymorphisms of MRP2, a protein involved in methotrexate, cisplatin and irinotecan active metabolite glucuronide transport, negatively affect platinum-based chemotherapy response.	Platinum	143-151	ATP binding cassette subfamily C member 2	Homo sapiens	17-21
21918337-7	2011	Recently, several tumor markers such as ERCC1 may have had a predictive value for selecting patients who will benefit from adjuvant platin-based chemotherapy.	Platinum	132-138	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	40-45
21804390-8	2011	Por(-) tumors showed an effective response to postoperative platinum-based first-line chemotherapy more frequently compared with Por(+) tumors (48% vs. 14%, P=0.042).	Platinum	60-68	cytochrome p450 oxidoreductase	Homo sapiens	0-3
21687948-2	2011	Recent studies have shown a correlation between the polymorphisms characterizing GSTM1-T1 detoxifying enzymes and poor outcome in advanced ovarian cancer patients treated with platinum/paclitaxel-based chemotherapy.	Platinum	176-184	glutathione S-transferase mu 1	Homo sapiens	81-86
21854619-7	2011	A2780s cells subjected to combination platinum and M344 treatment, demonstrated increased DNA damage as assessed by the presence of phosphorylated H2A.X foci in comparison to either treatment alone.	Platinum	38-46	H2A.X variant histone	Homo sapiens	147-152
21821001-3	2011	Galectin-3 expression was time- and transcription-dependently deregulated in K562 chronic myeloid leukemia cells stimulated for apoptosis by cisplatin (a platinum-based chemotherapy drug), sphingolipid ceramide analog C(2)-ceramide, and LY294002 (a phosphatidylinositol 3-kinase inhibitor).	Platinum	154-162	galectin 3	Homo sapiens	0-10
21854619-9	2011	CONCLUSIONS: The enhanced sensitivity of HDAC inhibition to platinum may be mediated through a BRCA1-dependent mechanism in breast and ovarian cancer cells.	Platinum	60-68	histone deacetylase 9	Homo sapiens	41-45
21854619-5	2011	RESULTS: With the addition of M344, the platinum-sensitive breast and ovarian cancer cell lines that displayed relatively high BRCA1 protein levels demonstrated significant potentiation of cisplatin cytotoxicity in association with a reduction of BRCA1 protein.	Platinum	40-48	BRCA1 DNA repair associated	Homo sapiens	127-132
21854619-5	2011	RESULTS: With the addition of M344, the platinum-sensitive breast and ovarian cancer cell lines that displayed relatively high BRCA1 protein levels demonstrated significant potentiation of cisplatin cytotoxicity in association with a reduction of BRCA1 protein.	Platinum	40-48	BRCA1 DNA repair associated	Homo sapiens	247-252
21854619-9	2011	CONCLUSIONS: The enhanced sensitivity of HDAC inhibition to platinum may be mediated through a BRCA1-dependent mechanism in breast and ovarian cancer cells.	Platinum	60-68	BRCA1 DNA repair associated	Homo sapiens	95-100
21676886-9	2011	Importantly, patients with evidence of Nrf2 pathway activation had fewer complete clinical responses to platinum-based therapy, were enriched for platinum resistance, and had shorter median overall survival compared with those who did not show evidence of Nrf2 pathway activation.	Platinum	104-112	NFE2 like bZIP transcription factor 2	Homo sapiens	39-43
21724587-4	2011	KDR CNGs were also associated with significantly increased risk of death (HR = 5.16; P = 0.003) in patients receiving adjuvant platinum-based chemotherapy, but no differences were observed in patients not receiving adjuvant therapy.	Platinum	127-135	kinase insert domain receptor	Homo sapiens	0-3
21724587-5	2011	To investigate potential mechanisms for these associations, we assessed NSCLC cell lines and found that KDR CNGs were significantly associated with in vitro resistance to platinum chemotherapy as well as increased levels of nuclear hypoxia inducible factor-1alpha (HIF-1alpha) in both NSCLC tumor specimens and cell lines.	Platinum	171-179	kinase insert domain receptor	Homo sapiens	104-107
21724587-6	2011	Furthermore, KDR knockdown experiments using small interfering RNA reduced platinum resistance, cell migration, and HIF-1alpha levels in cells bearing KDR CNGs, providing evidence for direct involvement of KDR.	Platinum	75-83	kinase insert domain receptor	Homo sapiens	13-16
22093929-9	2011	The CA125 level and lymph node metastasis rate of platinum-resistant patients were higher than those of platinum-sensitive patients (P &lt; 0.05, P &lt; 0.01).	Platinum	50-58	mucin 16, cell surface associated	Homo sapiens	4-9
21747163-5	2011	Besides, the gas-sensing properties of the sensor based on the In-doped SnO(2) with PT are greatly improved compared with sensors based on In-doped SnO(2) without PT and pure SnO(2).	Platinum	84-86	strawberry notch homolog 2	Homo sapiens	72-75
21819606-2	2011	Breast and ovarian neoplasms from BRCA1 or BRCA2 mutation carriers are characterized by deficient homologous recombination (HR) of DNA, that makes them particularly sensitive to platinum compounds or inhibitors of poly (ADP-ribose) polymerase (PARP).	Platinum	178-186	BRCA1 DNA repair associated	Homo sapiens	34-39
21819606-2	2011	Breast and ovarian neoplasms from BRCA1 or BRCA2 mutation carriers are characterized by deficient homologous recombination (HR) of DNA, that makes them particularly sensitive to platinum compounds or inhibitors of poly (ADP-ribose) polymerase (PARP).	Platinum	178-186	BRCA2 DNA repair associated	Homo sapiens	43-48
21819606-2	2011	Breast and ovarian neoplasms from BRCA1 or BRCA2 mutation carriers are characterized by deficient homologous recombination (HR) of DNA, that makes them particularly sensitive to platinum compounds or inhibitors of poly (ADP-ribose) polymerase (PARP).	Platinum	178-186	poly(ADP-ribose) polymerase 1	Homo sapiens	244-248
21676886-9	2011	Importantly, patients with evidence of Nrf2 pathway activation had fewer complete clinical responses to platinum-based therapy, were enriched for platinum resistance, and had shorter median overall survival compared with those who did not show evidence of Nrf2 pathway activation.	Platinum	146-154	NFE2 like bZIP transcription factor 2	Homo sapiens	39-43
21570711-1	2011	OBJECTIVE: CTR1 and CTR2 are copper transporters that have been associated with platinum sensitivity in several human cancers.	Platinum	80-88	solute carrier family 31 member 1	Homo sapiens	11-15
21570711-1	2011	OBJECTIVE: CTR1 and CTR2 are copper transporters that have been associated with platinum sensitivity in several human cancers.	Platinum	80-88	solute carrier family 31 member 2	Homo sapiens	20-24
21570711-8	2011	Of the 20 women with elevated CTR1 expression, 17 (85%) were sensitive to platinum-based chemotherapy.	Platinum	74-82	solute carrier family 31 member 1	Homo sapiens	30-34
21570711-9	2011	Of the 7 women with low CTR1 expression and high CTR2 expression, 6 (85.7%) were resistant to platinum-based chemotherapy and had the shortest progression-free survival of all women in our study sample.	Platinum	94-102	solute carrier family 31 member 2	Homo sapiens	49-53
21570711-10	2011	CONCLUSION: In our sample of 40 women with ovarian carcinoma, high CTR1 expression was significantly associated with sensitivity to platinum-based chemotherapy and longer progression-free survival.	Platinum	132-140	solute carrier family 31 member 1	Homo sapiens	67-71
21570711-11	2011	Conversely, low CTR1 expression and high CTR2 expression were significantly associated with resistance to platinum-based chemotherapy and the shortest survival.	Platinum	106-114	solute carrier family 31 member 1	Homo sapiens	16-20
21570711-11	2011	Conversely, low CTR1 expression and high CTR2 expression were significantly associated with resistance to platinum-based chemotherapy and the shortest survival.	Platinum	106-114	solute carrier family 31 member 2	Homo sapiens	41-45
21765211-0	2011	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.	Platinum	0-8	signal transducer and activator of transcription 6	Homo sapiens	29-34
21792013-1	2011	BACKGROUND: In non-small cell lung cancer, expression of excision repair cross-complementation group 1 (ERCC1) and p53 correlates with platinum resistance and class III beta-tubulin with resistance to taxanes.	Platinum	135-143	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	57-102
21792013-1	2011	BACKGROUND: In non-small cell lung cancer, expression of excision repair cross-complementation group 1 (ERCC1) and p53 correlates with platinum resistance and class III beta-tubulin with resistance to taxanes.	Platinum	135-143	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	104-109
21792013-1	2011	BACKGROUND: In non-small cell lung cancer, expression of excision repair cross-complementation group 1 (ERCC1) and p53 correlates with platinum resistance and class III beta-tubulin with resistance to taxanes.	Platinum	135-143	tumor protein p53	Homo sapiens	115-118
21765211-4	2011	We observed that exposure to platinum-based chemotherapeutics markedly reduced expression of the T cell inhibitory molecule programmed death receptor-ligand 2 (PD-L2) on both human DCs and human tumor cells.	Platinum	29-37	programmed cell death 1 ligand 2	Homo sapiens	160-165
21765211-7	2011	Consistent with these data, patients with STAT6-expressing head and neck cancer displayed enhanced recurrence-free survival upon treatment with cisplatin-based chemoradiation compared with patients with STAT6-negative tumors, demonstrating the clinical relevance of platinum-induced STAT6 modulation.	Platinum	266-274	signal transducer and activator of transcription 6	Homo sapiens	42-47
21709188-8	2011	Twelve (46.2%) of 26 (95% CI, 28.7% to 64.7%) platinum-resistant recurrences had secondary mutations restoring BRCA1/2, compared with one (5.3%) of 19 (95% CI, 1.2% to 24.8%) platinum-sensitive recurrences (P = .003, Fisher"s exact test).	Platinum	46-54	BRCA1 DNA repair associated	Homo sapiens	111-118
21709188-2	2011	In cell lines, BRCA2 restoration mediates resistance to platinum chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors.	Platinum	56-64	BRCA2 DNA repair associated	Homo sapiens	15-20
21458988-4	2011	PATIENTS AND METHODS: DNMT1/3b expression was analysed immunohistochemically in 127 pretherapeutic biopsies of neoadjuvant (platinum/5-fluorouracil)-treated GC patients and correlated with response and overall survival (OS).	Platinum	124-132	DNA methyltransferase 1	Homo sapiens	22-30
21665458-2	2011	Without using any stabilizer or pretreatment procedure, large amounts of Pt nanoparticles could be well deposited on the surface of the electrospun CNF electrode at room temperature, as revealed by scanning electron microscopy (SEM).	Platinum	73-75	NPHS1 adhesion molecule, nephrin	Homo sapiens	148-151
21458988-11	2011	CONCLUSION: Low DNMT1 expression defines a subgroup of GC patients with better outcomes following platinum/5FU-based neoadjuvant chemotherapy.	Platinum	98-106	DNA methyltransferase 1	Homo sapiens	16-21
21765407-3	2011	An N-terminal PEGylated version of this peptide containing a hydrolytically stable phosphothreonyl residue (pT) bound the Plk1 PBD with affinity equal to that of the non-PEGylated parent but showed markedly less interaction with the PBDs of the two closely related proteins Plk2 and Plk3.	Platinum	108-110	polo like kinase 1	Homo sapiens	122-126
21328523-8	2011	Exposure to platinum compounds was associated with an increased risk of problems hearing sounds (RR = 2.1; 95% CI: 1.3-3.2), tinnitus (RR = 2.8; 95% CI: 1.9-4.2), and hearing loss requiring an aid (RR = 4.1; 95% CI: 2.5-6.7).	Platinum	12-20	activation induced cytidine deaminase	Homo sapiens	193-196
21765407-3	2011	An N-terminal PEGylated version of this peptide containing a hydrolytically stable phosphothreonyl residue (pT) bound the Plk1 PBD with affinity equal to that of the non-PEGylated parent but showed markedly less interaction with the PBDs of the two closely related proteins Plk2 and Plk3.	Platinum	108-110	polo like kinase 2	Homo sapiens	274-278
21765407-3	2011	An N-terminal PEGylated version of this peptide containing a hydrolytically stable phosphothreonyl residue (pT) bound the Plk1 PBD with affinity equal to that of the non-PEGylated parent but showed markedly less interaction with the PBDs of the two closely related proteins Plk2 and Plk3.	Platinum	108-110	polo like kinase 3	Homo sapiens	283-287
21135055-0	2011	An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.	Platinum	85-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-120
21383688-0	2011	KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma.	Platinum	15-23	KiSS-1 metastasis suppressor	Homo sapiens	0-5
21571862-0	2011	HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.	Platinum	42-50	histone deacetylase 4	Homo sapiens	0-5
21461842-0	2011	Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.	Platinum	88-96	mucin 1, cell surface associated	Homo sapiens	8-12
21461842-0	2011	Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.	Platinum	88-96	mucin 1, cell surface associated	Homo sapiens	23-27
21461842-10	2011	Increased serum MUC1 and high anti-MUC1 antibody levels are prognostic for poor clinical response and reduced overall survival in platinum-resistant or platinum-refractory ovarian cancer.	Platinum	130-138	mucin 1, cell surface associated	Homo sapiens	16-20
21461842-10	2011	Increased serum MUC1 and high anti-MUC1 antibody levels are prognostic for poor clinical response and reduced overall survival in platinum-resistant or platinum-refractory ovarian cancer.	Platinum	130-138	mucin 1, cell surface associated	Homo sapiens	35-39
21827803-0	2011	Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis.	Platinum	71-79	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	17-22
21827803-0	2011	Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis.	Platinum	71-79	ATP binding cassette subfamily B member 1	Homo sapiens	40-44
21827803-2	2011	We performed this meta-analysis to compare outcome to platinum-based chemotherapies in advanced non-small cell lung cancer (NSCLC) with different ERCC1 C118T/C8092A and MDR1 C3435T polymorphisms.	Platinum	54-62	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	146-151
21827803-2	2011	We performed this meta-analysis to compare outcome to platinum-based chemotherapies in advanced non-small cell lung cancer (NSCLC) with different ERCC1 C118T/C8092A and MDR1 C3435T polymorphisms.	Platinum	54-62	ATP binding cassette subfamily B member 1	Homo sapiens	169-173
21515830-2	2011	The purpose of this study is to determine whether genetic variations in the transforming growth factor-beta (TGF-beta) pathway are associated with clinical outcomes in NSCLC patients receiving first-line platinum-based chemotherapy.	Platinum	204-212	transforming growth factor beta 1	Homo sapiens	76-107
21515830-2	2011	The purpose of this study is to determine whether genetic variations in the transforming growth factor-beta (TGF-beta) pathway are associated with clinical outcomes in NSCLC patients receiving first-line platinum-based chemotherapy.	Platinum	204-212	transforming growth factor beta 1	Homo sapiens	109-117
21515830-10	2011	These results suggest that genetic variations in the TGF-beta pathway are potential predictors of overall survival in NSCLC patients treated with platinum-based chemotherapy with or without radiation.	Platinum	146-154	transforming growth factor beta 1	Homo sapiens	53-61
21571862-5	2011	Significantly enhanced apoptotic response to platinum treatment in resistant cells was observed following knockdown of histone deacetylase (HDAC) 4, FOLR2, PIK3R1, or STAT1 (P &lt; 0.05).	Platinum	45-53	histone deacetylase 4	Homo sapiens	119-147
21571862-5	2011	Significantly enhanced apoptotic response to platinum treatment in resistant cells was observed following knockdown of histone deacetylase (HDAC) 4, FOLR2, PIK3R1, or STAT1 (P &lt; 0.05).	Platinum	45-53	folate receptor beta	Homo sapiens	149-154
21571862-0	2011	HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.	Platinum	42-50	signal transducer and activator of transcription 1	Homo sapiens	16-21
21571862-5	2011	Significantly enhanced apoptotic response to platinum treatment in resistant cells was observed following knockdown of histone deacetylase (HDAC) 4, FOLR2, PIK3R1, or STAT1 (P &lt; 0.05).	Platinum	45-53	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	156-162
21571862-5	2011	Significantly enhanced apoptotic response to platinum treatment in resistant cells was observed following knockdown of histone deacetylase (HDAC) 4, FOLR2, PIK3R1, or STAT1 (P &lt; 0.05).	Platinum	45-53	signal transducer and activator of transcription 1	Homo sapiens	167-172
20070981-1	2011	BACKGROUND: It has been reported that the expression of excision repair cross-complementation group 1 (ERCC1) protein predicts the effect of platinum-based chemotherapy and overall survival in the several cancers.	Platinum	141-149	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	56-101
21571862-7	2011	Acetyl-STAT1 was detected in platinum-sensitive cells but not in HDAC4 overexpressing platinum-resistant cells from the same patient.	Platinum	29-37	signal transducer and activator of transcription 1	Homo sapiens	7-12
21571862-8	2011	In resistant cells, STAT1 phosphorylation/nuclear translocation was seen following platinum exposure, whereas silencing of HDAC4 increased acetyl-STAT1 levels, prevented platinum-induced STAT1 activation, and restored cisplatin sensitivity.	Platinum	83-91	signal transducer and activator of transcription 1	Homo sapiens	20-25
21571862-9	2011	Conversely, matched sensitive cells were refractory to STAT1 phosphorylation on platinum treatment.	Platinum	80-88	signal transducer and activator of transcription 1	Homo sapiens	55-60
21571862-10	2011	Analysis of 16 paired tumor biopsies taken before and after development of clinical platinum resistance showed significantly increased HDAC4 expression in resistant tumors [n = 7 of 16 (44%); P = 0.04].	Platinum	84-92	histone deacetylase 4	Homo sapiens	135-140
21571862-12	2011	Together, our findings identify HDAC4 as a novel, therapeutically tractable target to counter platinum resistance in ovarian cancer.	Platinum	94-102	histone deacetylase 4	Homo sapiens	32-37
21610145-0	2011	Effect of eIF3a on response of lung cancer patients to platinum-based chemotherapy by regulating DNA repair.	Platinum	55-63	eukaryotic translation initiation factor 3 subunit J	Homo sapiens	10-15
21610145-2	2011	EXPERIMENTAL DESIGN: Immunohistochemistry was used to determine the expression of eIF3a in 211 human lung cancer tissues followed by association analysis of eIF3a expression with patient"s response to platinum-based chemotherapy.	Platinum	201-209	eukaryotic translation initiation factor 3 subunit J	Homo sapiens	82-87
21610145-2	2011	EXPERIMENTAL DESIGN: Immunohistochemistry was used to determine the expression of eIF3a in 211 human lung cancer tissues followed by association analysis of eIF3a expression with patient"s response to platinum-based chemotherapy.	Platinum	201-209	eukaryotic translation initiation factor 3 subunit J	Homo sapiens	157-162
21610145-6	2011	RESULTS: eIF3a expression associates with response of lung cancer patients to platinum-based chemotherapy.	Platinum	78-86	eukaryotic translation initiation factor 3 subunit J	Homo sapiens	9-14
21610145-8	2011	CONCLUSIONS: eIF3a plays an important role in regulating the expression of DNA repair proteins which, in turn, contributes to cellular response to DNA-damaging anticancer drugs and patients" response to platinum-based chemotherapy.	Platinum	203-211	eukaryotic translation initiation factor 3 subunit J	Homo sapiens	13-18
21496891-1	2011	OBJECTIVE: This study evaluated common polymorphisms in excision repair cross-complementation group 1 (ERCC1) involved in repair of platinum-induced DNA damage in advanced-stage, epithelial ovarian/peritoneal/tubal cancer (EOC/PPC/FTC) patients treated with intravenous carboplatin- and paclitaxel-based chemotherapy.	Platinum	132-140	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	103-108
21621119-2	2011	The expression of excision repair cross-complementation group 1 (ERCC1) has been reported to be associated with resistance to platinum-based chemotherapy.	Platinum	126-134	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	18-63
21621119-2	2011	The expression of excision repair cross-complementation group 1 (ERCC1) has been reported to be associated with resistance to platinum-based chemotherapy.	Platinum	126-134	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	65-70
21129812-0	2011	Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.	Platinum	119-127	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	14-17
21129812-0	2011	Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.	Platinum	119-127	X-ray repair cross complementing 1	Homo sapiens	32-37
21129812-2	2011	This study tested whether XPD Lys751Gln and XRCC1 T-77C polymorphisms were associated with survival in platinum-treated patients with advanced non-small-cell lung cancer (NSCLC).	Platinum	103-111	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	26-29
21129812-2	2011	This study tested whether XPD Lys751Gln and XRCC1 T-77C polymorphisms were associated with survival in platinum-treated patients with advanced non-small-cell lung cancer (NSCLC).	Platinum	103-111	X-ray repair cross complementing 1	Homo sapiens	44-49
21225901-3	2011	The hexane extract of PT (PT-H) inhibited apoptotic cell death in dexamethasone-induced osteoblastic cell lines, C3H10T1/2 and MC3T3-E1.	Platinum	22-24	parathyroid hormone	Mus musculus	26-30
21689426-6	2011	RESULTS: MGMT and XPD expression was directly and significantly related to resistance to platinum-containing treatment (p = 0.036 and p = 0.043, respectively).	Platinum	89-97	O-6-methylguanine-DNA methyltransferase	Homo sapiens	9-13
21689426-6	2011	RESULTS: MGMT and XPD expression was directly and significantly related to resistance to platinum-containing treatment (p = 0.036 and p = 0.043, respectively).	Platinum	89-97	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	18-21
20070981-1	2011	BACKGROUND: It has been reported that the expression of excision repair cross-complementation group 1 (ERCC1) protein predicts the effect of platinum-based chemotherapy and overall survival in the several cancers.	Platinum	141-149	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	103-108
20070981-2	2011	And there are some reports suggesting that the polymorphism of the ERCC1 may predict the effect of platinum-based chemotherapy and survival of the patients.	Platinum	99-107	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	67-72
20070981-3	2011	We have already reported that the expression of ERCC1 protein predicts survival after platinum-based chemotherapy for 90 completely resected non-small-cell lung cancers (NSCLC).	Platinum	86-94	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	48-53
20070981-9	2011	CONCLUSIONS: Our data seem to suggest that the ERCC1 protein expression and polymorphism of ERCC1 may predict the survival of patients who are treated with platinum-based chemotherapy.	Platinum	156-164	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
20070981-9	2011	CONCLUSIONS: Our data seem to suggest that the ERCC1 protein expression and polymorphism of ERCC1 may predict the survival of patients who are treated with platinum-based chemotherapy.	Platinum	156-164	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	92-97
21512709-3	2011	As a result, the 0.4 wt% Pt-loaded nanosheets exhibit superior catalytic activity in H(2)O(2) decomposition with an O(2) evolution rate of 342.5 mL g(-1) min(-1) in a clean aqueous system.	Platinum	25-27	CD59 molecule (CD59 blood group)	Homo sapiens	154-160
21435938-4	2011	METHODS: A systematic review was conducted to investigate whether two EGFR-TKIs, erlotinib and gefitinib, have efficacy in the platinum-resistance setting.	Platinum	127-135	epidermal growth factor receptor	Homo sapiens	70-74
21505707-5	2011	Thus, the heterodinuclear palladium/platinum complexes cis-[Pt(Ph2PN=CNN=CHS)2PdCl2]([Pt(2-H)2 PdCl2], 4a) and cis-[Pd(Ph2PN=CNN=CHS)2PtCl2]([Pd(2-H)2 PtCl2], 4b) were obtained by reaction with [PdCl2(NCPh)2] and [PtCl2(NCPh)2], respectively.	Platinum	36-44	phosducin like 2	Homo sapiens	78-83
21627863-2	2011	This study was to investigate whether plasma miRNA-21 (miR-21) can be used as a biomarker for the early detection of non-small cell lung cancer (NSCLC) and to explore its association with clinicopathologic features and sensitivity to platinum-based chemotherapy.	Platinum	234-242	microRNA 21	Homo sapiens	45-53
21636554-6	2011	In the stratified analysis on patients receiving platinum plus taxane treatment, we observed a hazardous effect on overall survival by the MAP3K1 variant (HR = 1.38; 95% CI = 1.11-1.72) and a protective effect by RAF1 (HR = 0.64; 95% CI = 0.50-0.82) in the EGFR pathway.	Platinum	49-57	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	139-145
21636554-6	2011	In the stratified analysis on patients receiving platinum plus taxane treatment, we observed a hazardous effect on overall survival by the MAP3K1 variant (HR = 1.38; 95% CI = 1.11-1.72) and a protective effect by RAF1 (HR = 0.64; 95% CI = 0.50-0.82) in the EGFR pathway.	Platinum	49-57	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	213-217
21636554-6	2011	In the stratified analysis on patients receiving platinum plus taxane treatment, we observed a hazardous effect on overall survival by the MAP3K1 variant (HR = 1.38; 95% CI = 1.11-1.72) and a protective effect by RAF1 (HR = 0.64; 95% CI = 0.50-0.82) in the EGFR pathway.	Platinum	49-57	epidermal growth factor receptor	Homo sapiens	257-261
21636554-9	2011	CONCLUSION: Common genetic variations in genes of EGFR and glutathione pathways may be associated with overall survival among patients with advanced stage NSCLC treated with platinum, taxane, and/or gemicitabine combinations.	Platinum	174-182	epidermal growth factor receptor	Homo sapiens	50-54
21435938-15	2011	Erlotinib and gefitinib are suitable for the treatment of platinum-pretreated NSCLC, particularly in patients with EGFR mutations or increases in copy number.	Platinum	58-66	epidermal growth factor receptor	Homo sapiens	115-119
21435938-5	2011	Preclinical studies of platinum-resistant cancer cell lines, which had been subsequently treated with EGFR-TKIs, were sought to establish proof-of-concept.	Platinum	23-31	epidermal growth factor receptor	Homo sapiens	102-106
21435938-8	2011	RESULTS: Preclinical models of platinum-resistant cancer were found which display a spectrum of cross-resistance profiles to EGFR-TKIs.	Platinum	31-39	epidermal growth factor receptor	Homo sapiens	125-129
21435938-10	2011	EGFR-TKIs show favourable response rates in platinum-pretreated NSCLC, 11.14% and 15.25% for 150mg/day erlotinib and 250mg/day gefitinib, respectively.	Platinum	44-52	epidermal growth factor receptor	Homo sapiens	0-4
21330665-2	2011	METHODS: Bulked segregant analysis and candidate gene sequencing revealed that the zebrafish platinum mutation is a single-nucleotide insertion in the vps11 (vacuolar protein sorting 11) gene.	Platinum	93-101	VPS11 core subunit of CORVET and HOPS complexes	Danio rerio	151-156
21513289-6	2011	For TEM, platinum nanoparticles (Pt nps) were formed in the PIM sample.	Platinum	9-17	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	60-63
21655476-0	2011	[Examination of ERCC1 expression in lung cancer patients treated with platinum-based chemotherapy].	Platinum	70-78	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	16-21
21655476-14	2011	The results of the present study suggest that platinum-based chemotherapy affects the expression of tissue biomarker (ERCC1) which may have predictive value, and probably induces a selection of tumor cells with more aggressive phenotype.	Platinum	46-54	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	118-123
21766907-4	2011	OBJECTIVE: The aim of our study was to evaluate the progression-free survival and tolerability of adjuvant treatment with platinum-based chemotherapy in patients with NSCLC, according to common DNA repair gene polymorphisms and ERCC1 expression.	Platinum	122-130	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	228-233
21605004-5	2011	In addition, we found that patients with the MTHFR 677 TT genotype showed a better response to platinum-based chemotherapy in the recessive model (TT vs CT + CC adjusted OR: 0.24; 95% CI: 0.09-0.68; p = 0.007), the generalized OR was 0.44 (0.22-0.88; p = 0.04).	Platinum	95-103	methylenetetrahydrofolate reductase	Homo sapiens	45-50
21605004-7	2011	Our results suggest that genetic polymorphisms of MTHFR 677 C T may contribute to NSCLC development in Chinese women and could also influence treatment response for advanced NSCLC patients with platinum-based chemotherapy.	Platinum	194-202	methylenetetrahydrofolate reductase	Homo sapiens	50-55
21627839-1	2011	BACKGROUND: Cyclooxygenase-2 overexpression is associated with poor outcome and resistance to platinum-based chemotherapy in ovarian cancer.	Platinum	94-102	prostaglandin-endoperoxide synthase 2	Homo sapiens	12-28
21678582-0	2011	Preparation and enhanced visible-light photocatalytic H2-production activity of CdS-sensitized Pt/TiO2 nanosheets with exposed (001) facets.	Platinum	95-97	CDP-diacylglycerol synthase 1	Homo sapiens	80-83
21678582-7	2011	After many replication experiments of the photocatalytic hydrogen production in the presence of lactic acid, the CdS-sensitized Pt/TiO(2) NSs did not show great loss in the photocatalytic activity, confirming that the CdS/Pt/TiO(2) NSs system is stable and not photocorroded.	Platinum	128-130	CDP-diacylglycerol synthase 1	Homo sapiens	113-116
21330665-2	2011	METHODS: Bulked segregant analysis and candidate gene sequencing revealed that the zebrafish platinum mutation is a single-nucleotide insertion in the vps11 (vacuolar protein sorting 11) gene.	Platinum	93-101	VPS11 core subunit of CORVET and HOPS complexes	Danio rerio	158-185
21330665-5	2011	RESULTS: Phenocopy and rescue experiments determined that a loss of Vps11 results in the platinum phenotype.	Platinum	89-97	VPS11 core subunit of CORVET and HOPS complexes	Danio rerio	68-73
21084428-6	2011	Thirty-one of 36 (86%) BRCA (+) and 60 of 74 (81%) BRCA (-) patients were platinum sensitive (P = 0.60).	Platinum	74-82	BRCA1 DNA repair associated	Homo sapiens	51-55
21227589-2	2011	In the present study, the evaporation behavior and accompanying artifacts are examined for the super-cell lattice structure of L1(0) FePt, where alternating Fe and Pt planes exist in the [0 0 1] orientation.	Platinum	135-137	immunoglobulin kappa variable 3-7 (non-functional)	Homo sapiens	127-132
21402713-7	2011	RNAi-dependent knockdown of Plk2 abrogated G(2)-M cell-cycle blockade by paclitaxel, conferring resistance to both paclitaxel and platinum.	Platinum	130-138	polo like kinase 2	Homo sapiens	28-32
21216588-6	2011	A tendency towards a better PFS was observed in patients with the highest level of ERCC1 and BRCA1 after platinum-based therapy than those given both platinum and taxol.	Platinum	105-113	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	83-88
21216588-6	2011	A tendency towards a better PFS was observed in patients with the highest level of ERCC1 and BRCA1 after platinum-based therapy than those given both platinum and taxol.	Platinum	105-113	BRCA1 DNA repair associated	Homo sapiens	93-98
21216588-6	2011	A tendency towards a better PFS was observed in patients with the highest level of ERCC1 and BRCA1 after platinum-based therapy than those given both platinum and taxol.	Platinum	150-158	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	83-88
20943283-0	2011	Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.	Platinum	40-48	ATP binding cassette subfamily C member 2	Homo sapiens	15-20
20943283-2	2011	In this study, we investigated the association of three putative functional polymorphisms of ABCC2 (C-24T, G1249A, and C3972T) with tumor response and occurrence of the grade 3 or 4 toxicity in 445 patients with stage III and IV NSCLC treated with platinum-based chemotherapy.	Platinum	248-256	ATP binding cassette subfamily C member 2	Homo sapiens	93-98
21623005-1	2011	Earlier we had shown that the MDM2 inhibitor (MI-219) belonging to the spiro-oxindole family can synergistically enhance the efficacy of platinum chemotherapeutics leading to 50% tumor free survival in a genetically complex pancreatic ductaladenocarcinoma (PDAC) xenograft model.	Platinum	137-145	MDM2 proto-oncogene	Homo sapiens	30-34
21497773-7	2011	Interestingly, these 2 SNPs are associated strongly with the baseline expression of &gt;20 genes (all P &lt;=10(-4)), and that 2 genes (SLC22A5 and SLCO4C1) are important organic cation/anion transporters known to affect platinum uptake and clearance.	Platinum	221-229	solute carrier family 22 member 5	Homo sapiens	136-143
21221762-0	2011	Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer.	Platinum	60-68	vascular endothelial growth factor A	Homo sapiens	34-38
21221762-4	2011	This study was undertaken to examine whether there is an association between VEGF-A expression in the tumour of EOC patients and their response to platinum based chemotherapy.	Platinum	147-155	vascular endothelial growth factor A	Homo sapiens	77-83
21221762-9	2011	Of the platinum resistant group, 18 (86%) patients had high VEGF score compared to only 1 (2%) with high VEGF score in the platinum sensitive group.	Platinum	7-15	vascular endothelial growth factor A	Homo sapiens	60-64
21221762-12	2011	CONCLUSION: We demonstrated that tumours of patients with platinum resistant EOC exhibit higher levels of VEGF expression compared to the platinum sensitive group.	Platinum	58-66	vascular endothelial growth factor A	Homo sapiens	106-110
21221762-12	2011	CONCLUSION: We demonstrated that tumours of patients with platinum resistant EOC exhibit higher levels of VEGF expression compared to the platinum sensitive group.	Platinum	138-146	vascular endothelial growth factor A	Homo sapiens	106-110
21663859-2	2011	The objective of this study was to elucidate the correlation between Nrf2 expression and platinum-based chemotherapy response as well as the prognostic significance of Nrf2 levels.	Platinum	89-97	NFE2 like bZIP transcription factor 2	Homo sapiens	69-73
21497773-7	2011	Interestingly, these 2 SNPs are associated strongly with the baseline expression of &gt;20 genes (all P &lt;=10(-4)), and that 2 genes (SLC22A5 and SLCO4C1) are important organic cation/anion transporters known to affect platinum uptake and clearance.	Platinum	221-229	solute carrier organic anion transporter family member 4C1	Homo sapiens	148-155
21370912-1	2011	The inhibition activity of a series of anticancer metal complexes based on platinum, ruthenium, and gold metal ions was evaluated on the zinc-finger protein PARP-1, either purified or directly on protein extracts from human breast cancer MCF7 cells.	Platinum	75-83	poly(ADP-ribose) polymerase 1	Homo sapiens	157-163
21372221-10	2011	CONCLUSIONS: Targeting PI3K and mTOR simultaneously using NVP-BEZ235 effectively inhibits ovarian cancer cell growth even in the presence of platinum resistance and prolongs survival of mice with intra-abdominal ovarian tumor disease.	Platinum	141-149	mechanistic target of rapamycin kinase	Mus musculus	32-36
21455266-5	2011	Active platinum efflux catalyzed by ATP7B is unlikely to significantly contribute to cisplatin resistance in vivo.	Platinum	7-15	ATPase copper transporting beta	Homo sapiens	36-41
21711804-1	2011	A series of Pt-loaded MS/ZnIn2S4 (MS = transition-metal sulfide: Ag2S, SnS, CoS, CuS, NiS, and MnS) photocatalysts was investigated to show various photocatalytic activities depending on different transition-metal sulfides.	Platinum	12-14	angiotensin II receptor type 1	Homo sapiens	65-69
21508375-8	2011	CONCLUSION: These data suggest that claudin-4 contributes to platinum resistance in ovarian cancer and may be a potential target in the treatment of platinum-resistant tumors.	Platinum	61-69	claudin 4	Homo sapiens	36-45
21508375-8	2011	CONCLUSION: These data suggest that claudin-4 contributes to platinum resistance in ovarian cancer and may be a potential target in the treatment of platinum-resistant tumors.	Platinum	149-157	claudin 4	Homo sapiens	36-45
21359394-0	2011	Nano-sized platinum as a mimic of uricase catalyzing the oxidative degradation of uric acid.	Platinum	11-19	urate oxidase (pseudogene)	Homo sapiens	34-41
21359394-3	2011	Herein, platinum nanoparticles (PtNPs) were found to be an effective mimic of uricase in the oxidation of UA.	Platinum	8-16	urate oxidase (pseudogene)	Homo sapiens	78-85
21447133-10	2011	CONCLUSIONS: Identification of HtrA1 in gastric cancer prior to chemotherapy indicates that levels of HtrA1 could be used to predict response to platinum-based combination therapies.	Platinum	145-153	HtrA serine peptidase 1	Homo sapiens	31-36
21276421-9	2011	The total MLC and phosphorylated MLC proteins and stress fibers were blocked after treatment with PT-262.	Platinum	98-100	modulator of VRAC current 1	Homo sapiens	10-13
21276421-9	2011	The total MLC and phosphorylated MLC proteins and stress fibers were blocked after treatment with PT-262.	Platinum	98-100	modulator of VRAC current 1	Homo sapiens	33-36
21134740-0	2011	High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma.	Platinum	64-72	claudin 7	Homo sapiens	5-14
21134740-4	2011	We assessed the association of CLDN-7 expressions with prognosis of the patients including sensitivity to platinum-based chemotherapy.	Platinum	106-114	claudin 7	Homo sapiens	31-37
21134740-8	2011	High CLDN-7 expression in primary tumour correlated with shorter progression-free survival (PFS) of the patients (P=0.005) and poor sensitivity to platinum-based chemotherapy (P=0.024).	Platinum	147-155	claudin 7	Homo sapiens	5-11
21134740-10	2011	CONCLUSION: These findings suggest CLDN-7 expression is an independent prognostic factor for PFS and it may play a role in regulating response to platinum-based chemotherapy in the treatment of EOC.	Platinum	146-154	claudin 7	Homo sapiens	35-41
21447133-10	2011	CONCLUSIONS: Identification of HtrA1 in gastric cancer prior to chemotherapy indicates that levels of HtrA1 could be used to predict response to platinum-based combination therapies.	Platinum	145-153	HtrA serine peptidase 1	Homo sapiens	102-107
21766492-3	2011	Polymorphisms within the GSTP1 may result in alterations in enzyme activity and change sensitivity to platinum-based chemotherapy.	Platinum	102-110	glutathione S-transferase pi 1	Homo sapiens	25-30
21318207-1	2011	In this study we report that fac-[Pt(IV)(dach)(9-EtG)Cl(3)](+) (dach = d,l-1,2-diaminocyclohexane, 9-EtG = 9-ethylguanine) in high pH (pH 12) or phosphate solution (pH 7.4) produces 8-oxo-9-EtG and Pt(II) species.	Platinum	34-36	FA complementation group C	Homo sapiens	29-32
21343649-2	2011	The J-V characteristics of the CdS nanorods show Shockley behaviour consistent with the energy band diagram of the platinum conducting atomic force microscope (CAFM) probe-CdS nanorod combination.	Platinum	115-123	CDP-diacylglycerol synthase 1	Homo sapiens	31-34
21387501-0	2011	The structure and behavior of platinum in SnO2-based sensors under working conditions.	Platinum	30-38	strawberry notch homolog 1	Homo sapiens	42-45
21315089-1	2011	Genetic polymorphisms in ERCC1 are thought to contribute to altered sensitivity to platinum-based chemotherapy.	Platinum	83-91	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	25-30
21293820-2	2011	When an electron-withdrawing [Ru(C(5)R(5))](+) fragment (R = H or Me) is eta(6)-coordinated to the phenyl ring of the NCN-pincer platinum fragment (cf.	Platinum	129-137	endothelin receptor type A	Homo sapiens	73-76
21293820-4	2011	However, when the ruthenium center is eta(6)-coordinated to a phenyl substituent linked in para-position to the carbon-to-platinum bond, i.e. complex [4](+), the SO(2)-binding property of the NCN-platinum center seems to be retained, as bubbling SO(2) into a solution of the latter complex produces the characteristic orange color.	Platinum	122-130	endothelin receptor type A	Homo sapiens	38-41
21293820-4	2011	However, when the ruthenium center is eta(6)-coordinated to a phenyl substituent linked in para-position to the carbon-to-platinum bond, i.e. complex [4](+), the SO(2)-binding property of the NCN-platinum center seems to be retained, as bubbling SO(2) into a solution of the latter complex produces the characteristic orange color.	Platinum	196-204	endothelin receptor type A	Homo sapiens	38-41
21293820-6	2011	We analyze this absence or weaker SO(2)-coordination in dichloromethane to be a consequence of the relative electron-poorness of the platinum center in the respective eta(6)-ruthenium coordinated NCN-pincer platinum complexes, that leads to a lower binding energy and an elongated calculated Pt-S bond distance.	Platinum	133-141	endothelin receptor type A	Homo sapiens	167-170
21293820-6	2011	We analyze this absence or weaker SO(2)-coordination in dichloromethane to be a consequence of the relative electron-poorness of the platinum center in the respective eta(6)-ruthenium coordinated NCN-pincer platinum complexes, that leads to a lower binding energy and an elongated calculated Pt-S bond distance.	Platinum	207-215	endothelin receptor type A	Homo sapiens	167-170
21315089-3	2011	This is the first study in which the functional impact of ERCC1 N118N on gene expression and platinum sensitivity was explored.	Platinum	93-101	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	58-63
21315089-7	2011	Cells complemented with ERCC1 showed significantly higher survival proportion than the parental cell line following platinum exposure (p&lt;0.0001), although no differences were observed between the cells transfected with the wild type or the polymorphic allele.	Platinum	116-124	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	24-29
21139574-10	2011	The addition of the anti-CD40L antibody to treated celiac biopsies significantly inhibited the PT-gliadin-induced production of IFN-gamma and IL-17, and mucosal T-bet.	Platinum	95-97	CD40 ligand	Homo sapiens	25-30
21139574-10	2011	The addition of the anti-CD40L antibody to treated celiac biopsies significantly inhibited the PT-gliadin-induced production of IFN-gamma and IL-17, and mucosal T-bet.	Platinum	95-97	interferon gamma	Homo sapiens	128-137
21139574-10	2011	The addition of the anti-CD40L antibody to treated celiac biopsies significantly inhibited the PT-gliadin-induced production of IFN-gamma and IL-17, and mucosal T-bet.	Platinum	95-97	interleukin 17A	Homo sapiens	142-147
21107700-6	2011	In summary, selection for platinum resistance is associated with a block of mitochondrial death signalling upstream of BAX/BAK activation.	Platinum	26-34	BCL2 associated X, apoptosis regulator	Homo sapiens	119-122
21144842-0	2011	Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents.	Platinum	125-133	plexin A2	Homo sapiens	27-30
20405296-0	2011	Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers.	Platinum	118-126	AKT serine/threonine kinase 1	Homo sapiens	52-55
21735691-7	2011	It probably results from dysfunction of BRCA1 gene, inducing better response to platinum-based cytostatic drugs.	Platinum	80-88	BRCA1 DNA repair associated	Homo sapiens	40-45
21586890-8	2011	As for the predictive marker of cisplatin, ERCC1 may predict survival in bladder cancer treated by platinum-based therapy.	Platinum	99-107	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	43-48
21289518-7	2011	We also found that overexpression of ERCC1 and TUBB3 was associated with resistance to platinum- and taxane-based chemotherapy.	Platinum	87-95	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	37-42
21047173-0	2011	SOD/catalase mimetic platinum nanoparticles inhibit heat-induced apoptosis in human lymphoma U937 and HH cells.	Platinum	21-29	catalase	Homo sapiens	4-12
21047173-1	2011	Platinum nanoparticles (Pt-NPs) are known to possess anti-tumouric activity and the ability to scavenge superoxides and peroxides indicating that they can act as superoxide dismutase (SOD)/catalase mimetics.	Platinum	0-8	catalase	Homo sapiens	189-197
21289518-7	2011	We also found that overexpression of ERCC1 and TUBB3 was associated with resistance to platinum- and taxane-based chemotherapy.	Platinum	87-95	tubulin beta 3 class III	Homo sapiens	47-52
21289518-9	2011	High-ERCC1 and TUBB3 expressions might be associated with resistance to platinum- and taxane-based chemotherapy, respectively.	Platinum	72-80	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	5-10
21258258-13	2011	The EGFR-tyrosine kinase inhibitor/platinum antagonism is a possible reason for the failure of those randomized trials.	Platinum	35-43	epidermal growth factor receptor	Homo sapiens	4-8
21289518-9	2011	High-ERCC1 and TUBB3 expressions might be associated with resistance to platinum- and taxane-based chemotherapy, respectively.	Platinum	72-80	tubulin beta 3 class III	Homo sapiens	15-20
21216099-7	2011	TPR patterns showed that by adding 1% platinum to support, the reducibility is highly increased.	Platinum	38-46	translocated promoter region, nuclear basket protein	Homo sapiens	0-3
21370501-0	2011	RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum.	Platinum	163-171	ribonucleotide reductase catalytic subunit M1	Homo sapiens	0-4
21370501-1	2011	OBJECTIVE: To evaluate the predictive values of gene expressions of ribonucleotide reductase M1 (RRM1) and breast cancer susceptibility gene 1 (BRCA1) in peripheral blood from Chinese patients with non-small-cell lung cancer (NSCLC) treated with gemcitabine plus platinum.	Platinum	263-271	ribonucleotide reductase catalytic subunit M1	Homo sapiens	97-101
21370501-9	2011	Advanced NSCLC patients with low RRM1 expression levels may benefit from gemcitabine plus platinum therapy.	Platinum	90-98	ribonucleotide reductase catalytic subunit M1	Homo sapiens	33-37
21370501-10	2011	RRM1 mRNA expression in peripheral blood could be used to predict the prognosis of NSCLC treated by gemcitabine and platinum.	Platinum	116-124	ribonucleotide reductase catalytic subunit M1	Homo sapiens	0-4
21575522-1	2011	OBJECTIVE: To investigate the relationship between the expression of ERCC1, BRCA1, beta-tubulin and K-ras and the clinical efficacy, prognosis in advanced non-small cell lung cancer treated by platinum-based chemotherapy.	Platinum	193-201	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	69-74
21575522-1	2011	OBJECTIVE: To investigate the relationship between the expression of ERCC1, BRCA1, beta-tubulin and K-ras and the clinical efficacy, prognosis in advanced non-small cell lung cancer treated by platinum-based chemotherapy.	Platinum	193-201	BRCA1 DNA repair associated	Homo sapiens	76-81
21575522-1	2011	OBJECTIVE: To investigate the relationship between the expression of ERCC1, BRCA1, beta-tubulin and K-ras and the clinical efficacy, prognosis in advanced non-small cell lung cancer treated by platinum-based chemotherapy.	Platinum	193-201	KRAS proto-oncogene, GTPase	Homo sapiens	100-105
20143185-0	2011	Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis.	Platinum	110-118	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	20-25
20143185-0	2011	Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis.	Platinum	110-118	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	30-33
20143185-1	2011	The published data on the predictive value of polymorphism of ERCC1 and XPD in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy are inconclusive.	Platinum	139-147	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	62-67
20143185-1	2011	The published data on the predictive value of polymorphism of ERCC1 and XPD in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy are inconclusive.	Platinum	139-147	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	72-75
20143185-8	2011	The results indicated that platinum-based chemotherapy sensitivity was significantly associated with polymorphism of ERCC1 C118T.	Platinum	27-35	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	117-122
21250674-5	2011	Analysis of the SPR signatures revealed two cluster groups corresponding to (i) sublethal pro-inflammatory responses to Al2O3, Au, Ag, SiO2 nanoparticles possibly related to ROS generation, and (ii) lethal genotoxic responses due to exposure to ZnO and Pt nanoparticles at a concentration range of 25-100 mug/mL at 12 h exposure.	Platinum	253-255	sepiapterin reductase	Mus musculus	16-19
21156845-6	2011	The poor prognosis of MLH1 AG/GG was the result of an increased risk of failing both R-CHOP21 (HR = 2.02; P = .007) and platinum-based second-line (HR = 2.26; P = .044) treatment.	Platinum	120-128	mutL homolog 1	Homo sapiens	22-26
21156845-8	2011	The effect on OS of MLH1, a component of the DNA mismatch repair system, is consistent with its role in regulating the genotoxic effects of doxorubicin and platinum compounds, which are a mainstay of DLBCL first- and second-line treatment.	Platinum	156-164	mutL homolog 1	Homo sapiens	20-24
21152644-0	2011	Platinum-catalyzed cyclization reaction of alkynes: synthesis of azepino[3,4-b]indol-1-ones.	Platinum	0-8	indoleamine 2,3-dioxygenase 2	Homo sapiens	79-86
20878461-0	2011	The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs.	Platinum	74-82	BRCA1 DNA repair associated	Homo sapiens	21-26
20705911-8	2011	One partial response (3.3%) and three CA125 responses (10%) were observed, all in platinum-sensitive patients using intermittent dosing.	Platinum	82-90	mucin 16, cell surface associated	Homo sapiens	38-43
21112084-0	2011	Direct evidence for catalase and peroxidase activities of ferritin-platinum nanoparticles.	Platinum	67-75	catalase	Homo sapiens	20-28
21112084-1	2011	Using apoferritin (apoFt) as a nucleation substrate, we have successfully synthesized 1-2 nm platinum nanoparticles (Pt-Ft) which are highly stable.	Platinum	93-101	ferritin heavy chain 1	Homo sapiens	6-17
20878461-0	2011	The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs.	Platinum	74-82	BRCA1 associated RING domain 1	Homo sapiens	27-32
20878461-5	2011	It is of interest to approach the BRCA1 RING domain as a potentially molecular target for platinum-based drugs for cancer therapy.	Platinum	90-98	BRCA1 DNA repair associated	Homo sapiens	34-39
20878461-6	2011	A previous study has shown that the anticancer drug cisplatin formed intramolecular and intermolecular BRCA1 adducts in which His117 was the primary platinum-binding site, and conferred conformational changes and induced thermostability.	Platinum	149-157	BRCA1 DNA repair associated	Homo sapiens	103-108
20878461-7	2011	Here, we have studied the functional consequence of the in vitro platination of the BRCA1 RING domain by a number of platinum complexes.	Platinum	117-125	BRCA1 DNA repair associated	Homo sapiens	84-89
20878461-9	2011	The consequences of the binding of the platinum complexes on the reactivity of the BRCA1 were also discussed.	Platinum	39-47	BRCA1 DNA repair associated	Homo sapiens	83-88
21268159-5	2011	The Zeise salt readily reacts with hUb crystals to afford an adduct with three platinum residues per protein molecule, Pt(3)-hUb.	Platinum	79-87	ELAV like RNA binding protein 2	Homo sapiens	35-38
20443003-1	2011	PURPOSE: To understand the mechanisms behind platinum drug/DENSPM-induced inhibition of cancer cell growth, we compared the effects of oxaliplatin and cisplatin when combined with DENSPM on the induction of SSAT mRNA, activity, polyamines and cell growth in A2780 human ovarian carcinoma cells and their oxaliplatin- and cisplatin-resistant variants A2780/C10B and A2780/CP, respectively.	Platinum	45-53	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	207-211
20443003-4	2011	RESULTS: Both platinum agents induced SSAT mRNA in parental A2780 cells, but not in resistant cells.	Platinum	14-22	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	38-42
20443003-5	2011	Platinum drug/DENSPM combinations produced high levels of SSAT activity in parental cells with significant depletion of spermine and spermidine, but not in resistant cells.	Platinum	0-8	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	58-62
20443003-11	2011	Reduced platinum uptake in Pt-resistant cells contributes to reduced SSAT mRNA induction and absence of synergy when combined with DENSPM.	Platinum	8-16	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	69-73
21268159-5	2011	The Zeise salt readily reacts with hUb crystals to afford an adduct with three platinum residues per protein molecule, Pt(3)-hUb.	Platinum	79-87	ELAV like RNA binding protein 2	Homo sapiens	125-128
20850517-7	2011	In occludin planimetric analysis the lengths of the integral uninterrupted cellular contour appeared longer in untreated than in PT-gliadin treated spheroids (71.8+-42.8 vs. 23.4+-25.9 mum, p&lt;0.01).	Platinum	129-131	occludin	Homo sapiens	3-11
21036364-8	2011	TPR profiles showed that the H(2) consumed was higher for Pt/FSM-16 than for Pt-Au/FSM-16 verifying the facile reduction of Pt moieties after addition of Au.	Platinum	58-60	translocated promoter region, nuclear basket protein	Homo sapiens	0-3
22471497-0	2011	HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.	Platinum	46-54	hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha	Homo sapiens	0-5
20877902-2	2011	It is based on the immobilization of glucose oxidase (GOx) in a poly(vinyl alcohol) (PVA) matrix directly drop casted on a platinum electrode surface (Pt/GOx-PVA).	Platinum	123-131	hydroxyacid oxidase 1	Homo sapiens	37-52
20877902-2	2011	It is based on the immobilization of glucose oxidase (GOx) in a poly(vinyl alcohol) (PVA) matrix directly drop casted on a platinum electrode surface (Pt/GOx-PVA).	Platinum	123-131	hydroxyacid oxidase 1	Homo sapiens	54-57
22296372-0	2011	Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer.	Platinum	62-70	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
22296372-1	2011	OBJECTIVE: To evaluate the influence of multi-drug resistance 1 (MDR1) gene codon 3435 polymorphisms on response to platinum-based chemotherapeutic regimens for advanced non small cell lung cancer (NSCLC).	Platinum	116-124	ATP binding cassette subfamily B member 1	Homo sapiens	40-63
22471497-4	2011	Furthermore, pre- treated biopsy specimens taken from patients who showed resistance to platinum-based treatment showed a significantly higher positive rate for HADHA in all cases (p=0.00367), including non-small cell lung carcinomas (p=0.002), small-cell lung carcinomas (p=0.038), and adenocarcinomas (p=0.008).	Platinum	88-96	hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha	Homo sapiens	161-166
22296372-1	2011	OBJECTIVE: To evaluate the influence of multi-drug resistance 1 (MDR1) gene codon 3435 polymorphisms on response to platinum-based chemotherapeutic regimens for advanced non small cell lung cancer (NSCLC).	Platinum	116-124	ATP binding cassette subfamily B member 1	Homo sapiens	65-69
22296372-7	2011	CONCLUSION: Our research suggested that patents with the C/C genotype in MDR1 codon 3435 could be more sensitive to platinum-based chemotherapy than patients with C/T and T/T; however, no significant difference was found between overall survival and MDR1 codon 3435 genetic polymorphisms.	Platinum	116-124	ATP binding cassette subfamily B member 1	Homo sapiens	73-77
22471497-5	2011	These results suggest that the expression of HADHA may be a useful marker to predict resistance to platinum-based chemotherapy in patients with lung cancer.	Platinum	99-107	hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha	Homo sapiens	45-50
22296372-7	2011	CONCLUSION: Our research suggested that patents with the C/C genotype in MDR1 codon 3435 could be more sensitive to platinum-based chemotherapy than patients with C/T and T/T; however, no significant difference was found between overall survival and MDR1 codon 3435 genetic polymorphisms.	Platinum	116-124	ATP binding cassette subfamily B member 1	Homo sapiens	250-254
21037225-0	2011	Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway.	Platinum	23-31	TNF superfamily member 10	Homo sapiens	68-73
21037225-3	2011	Combination therapy with platinum complexes may affect TRAIL-induced signaling via modulation of various steps in apoptotic pathways.	Platinum	25-33	TNF superfamily member 10	Homo sapiens	55-60
21057220-11	2011	Our results indicate that the Akt, but not necessarily EGFR, is one of the most important target in the response of the platinum-based chemotherapy and prognosis for ovarian cancer patients.	Platinum	120-128	AKT serine/threonine kinase 1	Homo sapiens	30-33
21037225-4	2011	Here, we show that cisplatin or a more potent platinum(IV) complex LA-12 used in 20-fold lower concentration enhanced killing effects of TRAIL in human colon and prostate cancer cell lines via stimulation of caspase activity and overall apoptosis.	Platinum	46-54	TNF superfamily member 10	Homo sapiens	137-142
21037225-4	2011	Here, we show that cisplatin or a more potent platinum(IV) complex LA-12 used in 20-fold lower concentration enhanced killing effects of TRAIL in human colon and prostate cancer cell lines via stimulation of caspase activity and overall apoptosis.	Platinum	46-54	caspase 8	Homo sapiens	208-215
21037225-5	2011	Both platinum complexes increased DR5 surface expression in colon cancer cells.	Platinum	5-13	TNF receptor superfamily member 10b	Homo sapiens	34-37
21037225-6	2011	Small interfering RNA-mediated DR5 silencing rescued cells from sensitizing effects of platinum drugs on TRAIL-induced caspase-8 activation and apoptosis, showing the functional importance of DR5 in the effects observed.	Platinum	87-95	TNF receptor superfamily member 10b	Homo sapiens	31-34
21037225-6	2011	Small interfering RNA-mediated DR5 silencing rescued cells from sensitizing effects of platinum drugs on TRAIL-induced caspase-8 activation and apoptosis, showing the functional importance of DR5 in the effects observed.	Platinum	87-95	TNF superfamily member 10	Homo sapiens	105-110
21037225-6	2011	Small interfering RNA-mediated DR5 silencing rescued cells from sensitizing effects of platinum drugs on TRAIL-induced caspase-8 activation and apoptosis, showing the functional importance of DR5 in the effects observed.	Platinum	87-95	caspase 8	Homo sapiens	119-128
21037225-6	2011	Small interfering RNA-mediated DR5 silencing rescued cells from sensitizing effects of platinum drugs on TRAIL-induced caspase-8 activation and apoptosis, showing the functional importance of DR5 in the effects observed.	Platinum	87-95	TNF receptor superfamily member 10b	Homo sapiens	192-195
21045685-6	2011	Additionally, the characterization of Wnt signaling through beta-catenin in adrenal development, the demonstration of the involvement of BMP signaling in adrenocortical carcinoma growth regulation, and the discovery that ERCC1 expression levels can predict therapeutic response to platinum are just a few of the recent advances that promise to shed light on adrenocortical carcinoma biology.	Platinum	281-289	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	221-226
22312557-0	2011	The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor.	Platinum	90-98	checkpoint kinase 2	Homo sapiens	117-121
22312557-12	2011	Our findings suggest that inhibition of platinum resistance can be achieved with a small-molecule inhibitor of Chk2, thus improving the therapeutic indices for platinum chemotherapy.	Platinum	40-48	checkpoint kinase 2	Homo sapiens	111-115
22312557-12	2011	Our findings suggest that inhibition of platinum resistance can be achieved with a small-molecule inhibitor of Chk2, thus improving the therapeutic indices for platinum chemotherapy.	Platinum	160-168	checkpoint kinase 2	Homo sapiens	111-115
21076302-5	2011	The IPASS study reported the predictive and prognostic impact of epidermal growth factor receptor (EGFR) mutations in stage IV patients treated with EGFR tyrosine kinase inhibitor or platinum-based chemotherapy.	Platinum	183-191	epidermal growth factor receptor	Homo sapiens	65-97
21076302-5	2011	The IPASS study reported the predictive and prognostic impact of epidermal growth factor receptor (EGFR) mutations in stage IV patients treated with EGFR tyrosine kinase inhibitor or platinum-based chemotherapy.	Platinum	183-191	epidermal growth factor receptor	Homo sapiens	99-103
20447721-0	2011	PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.	Platinum	121-129	phosphatase and tensin homolog	Homo sapiens	5-9
21863213-3	2011	The p53 mutation correlates significantly with resistance to platinum-based chemotherapy, early relapse and shortened overall survival in ovarian cancer patients.	Platinum	61-69	tumor protein p53	Homo sapiens	4-7
20803225-0	2011	Vitamin B12 as a carrier for targeted platinum delivery: in vitro cytotoxicity and mechanistic studies.	Platinum	38-46	NADH:ubiquinone oxidoreductase subunit B3	Homo sapiens	8-11
20803225-11	2011	We could show that the Pt(II) complexes cleaved from B12 exerted a cytotoxicity comparable to that of cisplatin itself.	Platinum	23-25	NADH:ubiquinone oxidoreductase subunit B3	Homo sapiens	53-56
22083043-3	2011	In the present study, we examined the direct effects of platinum nano-Pt on RANKL-induced osteoclast differentiation of murine pre-osteoclastic RAW 264.7 cells.	Platinum	56-64	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	76-81
20447721-0	2011	PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.	Platinum	121-129	AKT serine/threonine kinase 1	Homo sapiens	10-13
20447721-0	2011	PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.	Platinum	121-129	mechanistic target of rapamycin kinase	Homo sapiens	14-18
21934105-2	2011	Other BRCA-associated cancers have been shown to have greater sensitivity to platinum and poly(ADP-ribose) polymerase (PARP) inhibitors with better clinical outcomes than in sporadic cases; however, outcomes in BRCA-associated PAC have not been reported.	Platinum	77-85	BRCA1 DNA repair associated	Homo sapiens	6-10
21985855-1	2011	BACKGROUND: For patients with HER2-overexpressing gastric cancer, there is an improved prognosis with additional trastuzumab to chemotherapy with a platinum compound and a fluoropyrimidin in first-line therapy.	Platinum	148-156	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-34
21934105-2	2011	Other BRCA-associated cancers have been shown to have greater sensitivity to platinum and poly(ADP-ribose) polymerase (PARP) inhibitors with better clinical outcomes than in sporadic cases; however, outcomes in BRCA-associated PAC have not been reported.	Platinum	77-85	BRCA1 DNA repair associated	Homo sapiens	211-215
21355309-1	2011	OBJECTIVE: To investigate the protein expression of ERCC1 (excision repair cross complementation group 1) and survivin gene in platinum-resistant and platinum-sensitive epithelial ovarian carcinoma (EOC), and to explore the relationship among ERCC1 expression, survivin expression, the major clinicopathological characteristics as well as platinum sensitivity.	Platinum	127-135	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	52-57
22022380-8	2011	Meta-analysis of unadjusted estimates showed high ERCC1 was associated with significantly worse overall survival in platinum-treated NSCLC (average unadjusted HR = 1.61, 95%CI:1.23-2.1, p = 0.014), but not in NSCLC untreated with chemotherapy (average unadjusted HR = 0.82, 95%CI:0.51-1.31).	Platinum	116-124	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	50-55
22022380-10	2011	There was evidence that high ERCC1 was associated with reduced response to platinum (average RR = 0.80; 95%CI:0.64-0.99).	Platinum	75-83	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	29-34
22022380-12	2011	CONCLUSIONS: Current evidence suggests high ERCC1 may adversely influence survival and response in platinum-treated NSCLC patients, but not in non-platinum treated, although definitive evidence of a predictive influence is lacking.	Platinum	99-107	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	44-49
21087013-3	2010	The DFT calculations and observed spectra suggest that the side-chain CF3, CF2 groups (i.e., of the backbone and side chain) and the SO3(-) are ordered by the platinum surface.	Platinum	159-167	ATPase H+ transporting accessory protein 1	Homo sapiens	75-78
22715590-1	2011	Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are used as first-line agents for treating nonsquamous cell lung cancer with EGFR mutation, there are many patients who have to receive these drugs following platinum-based chemotherapy.	Platinum	239-247	epidermal growth factor receptor	Homo sapiens	70-74
21079146-5	2010	RESULTS: High TGF-alpha and amphiregulin were associated with poorer performance status (P=.06 and P&lt;.0001, respectively) and no prior platinum therapy (P=.06 and P=.02, respectively).	Platinum	138-146	transforming growth factor alpha	Homo sapiens	14-23
21079146-5	2010	RESULTS: High TGF-alpha and amphiregulin were associated with poorer performance status (P=.06 and P&lt;.0001, respectively) and no prior platinum therapy (P=.06 and P=.02, respectively).	Platinum	138-146	amphiregulin	Homo sapiens	28-40
21355309-1	2011	OBJECTIVE: To investigate the protein expression of ERCC1 (excision repair cross complementation group 1) and survivin gene in platinum-resistant and platinum-sensitive epithelial ovarian carcinoma (EOC), and to explore the relationship among ERCC1 expression, survivin expression, the major clinicopathological characteristics as well as platinum sensitivity.	Platinum	150-158	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	52-57
21355309-1	2011	OBJECTIVE: To investigate the protein expression of ERCC1 (excision repair cross complementation group 1) and survivin gene in platinum-resistant and platinum-sensitive epithelial ovarian carcinoma (EOC), and to explore the relationship among ERCC1 expression, survivin expression, the major clinicopathological characteristics as well as platinum sensitivity.	Platinum	150-158	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	52-57
21355309-5	2011	The positive rate of ERCC1 expression (67.85%, 19/28) in platinum-resistant patients" tissues was significantly higher than that in platinum-sensitive patients" tissues (25.00%, 9/36) (P = 0.001).	Platinum	57-65	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	21-26
21355309-5	2011	The positive rate of ERCC1 expression (67.85%, 19/28) in platinum-resistant patients" tissues was significantly higher than that in platinum-sensitive patients" tissues (25.00%, 9/36) (P = 0.001).	Platinum	132-140	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	21-26
21355309-8	2011	The proportion of platinum-resistant in patients with coexpression of ERCC1 and surviving (65.22%, 15/23) was insignificantly lower than that of in patients with single expression of ERCC1 (80.00%, 4/5) (P = 0.91).	Platinum	18-26	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	70-75
21355309-9	2011	CONCLUSION: Expression of ERCC1 in EOC patients" tumor tissue could be a predictive indicator for their platinum susceptibility and it might be helpful for prevention and reverse of platinum resistance in clinical practice.	Platinum	104-112	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	26-31
20504223-0	2010	High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.	Platinum	105-113	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	19-64
20802529-0	2010	An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs.	Platinum	67-75	mitogen-activated protein kinase 1	Homo sapiens	3-6
20802529-0	2010	An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs.	Platinum	67-75	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	28-32
20802529-3	2010	In this article, we show that the BH3-only protein Noxa is strongly transcriptionally upregulated in response to cisplatin and related platinum compounds.	Platinum	135-143	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	51-55
20802529-6	2010	These observations reveal a novel ERK-regulated route to Noxa expression that is important for the cell killing activity of platinum-based chemotherapeutic drugs.	Platinum	124-132	mitogen-activated protein kinase 1	Homo sapiens	34-37
20802529-6	2010	These observations reveal a novel ERK-regulated route to Noxa expression that is important for the cell killing activity of platinum-based chemotherapeutic drugs.	Platinum	124-132	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	57-61
20585871-4	2010	METHODS: HDAC1/2 expression was analyzed immunohistochemically in 127 pretherapeutic biopsy samples of neoadjuvant (platinum/5-fluorouracil) chemotherapy-treated GC patients and correlated with response and overall survival (OS).	Platinum	116-124	histone deacetylase 1	Homo sapiens	9-14
21091775-3	2010	Recent reports have suggested that ERCC1 is a predictive and prognostic marker in solid cancers treated with platinum-based chemotherapy.	Platinum	109-117	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	35-40
20504223-2	2010	The aim of this study was to investigate the relationship of the excision repair cross-complementation group 1 (ERCC1) mRNA level in fresh tumor tissue and the efficacy of platinum-based chemotherapy of NSCLC.	Platinum	172-180	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	65-110
20504223-2	2010	The aim of this study was to investigate the relationship of the excision repair cross-complementation group 1 (ERCC1) mRNA level in fresh tumor tissue and the efficacy of platinum-based chemotherapy of NSCLC.	Platinum	172-180	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	112-117
21118971-8	2010	These results suggest that YAP1 may play an important role in prognosis of small-cell lung cancer patients treated with platinum-based chemotherapy.	Platinum	120-128	Yes1 associated transcriptional regulator	Homo sapiens	27-31
20504223-10	2010	CONCLUSIONS: High level of ERCC1 mRNA may serve as a useful prognostic factor for poor outcome in advanced NSCLC patients treated with platinum-based third-generation doublet chemotherapy and may provide important information to guide tailored therapy of NSCLC patients.	Platinum	135-143	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	27-32
20851179-4	2010	Using salts of Pd, Pt, and Au as well as cisplatin and auranofin we found that Pd and Au were strikingly more potent inhibitors of recombinant TrxR1 than Pt.	Platinum	19-21	thioredoxin reductase 1	Homo sapiens	143-148
22166526-0	2010	XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.	Platinum	72-80	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	0-3
20851179-8	2010	These results reveal that Au and Pd are strong inhibitors of TrxR, but Pt and cisplatin trigger highly specific cellular effects on the Trx system, including covalent cross-linking of TrxR1 with Trx1 and TRP14.	Platinum	71-73	thioredoxin reductase 1	Homo sapiens	184-189
20851179-8	2010	These results reveal that Au and Pd are strong inhibitors of TrxR, but Pt and cisplatin trigger highly specific cellular effects on the Trx system, including covalent cross-linking of TrxR1 with Trx1 and TRP14.	Platinum	71-73	thioredoxin	Homo sapiens	195-199
20851179-8	2010	These results reveal that Au and Pd are strong inhibitors of TrxR, but Pt and cisplatin trigger highly specific cellular effects on the Trx system, including covalent cross-linking of TrxR1 with Trx1 and TRP14.	Platinum	71-73	thioredoxin domain containing 17	Homo sapiens	204-209
20889728-7	2010	In an in vivo orthotopic mouse model of ovarian cancer, ALDH1A1 silencing using nanoliposomal siRNA sensitized both taxane- and platinum-resistant cell lines to chemotherapy, significantly reducing tumor growth in mice compared with chemotherapy alone (a 74%-90% reduction; P &lt; 0.015).	Platinum	128-136	aldehyde dehydrogenase family 1, subfamily A1	Mus musculus	56-63
20951466-8	2010	CONCLUSIONS: We concluded that oral S-1 monotherapy is useful as second-line or later chemotherapy in previously treated patients with advanced thymic carcinoma and is a potential alternative choice for patients who cannot tolerate platinum-containing treatments.	Platinum	232-240	proteasome 26S subunit, non-ATPase 1	Homo sapiens	36-39
20562404-0	2010	Elevated phosphorylated tau pT-181 in a possible PRNP codon 129 MV vCJD case.	Platinum	28-30	prion protein	Homo sapiens	49-53
20975603-2	2010	Some clinical studies also suggest enhanced efficacy of platinum-based chemotherapy in patients with EGFR-mutant cancers.	Platinum	56-64	epidermal growth factor receptor	Homo sapiens	101-105
20889728-3	2010	In our analysis of multiple ovarian cancer cell lines, we found that ALDH1A1 expression and activity was significantly higher in taxane- and platinum-resistant cell lines.	Platinum	141-149	aldehyde dehydrogenase 1 family member A1	Homo sapiens	69-76
21110884-1	2010	BACKGROUND: DNA polymerase eta (pol eta) is capable of bypassing DNA adducts produced by cisplatin or oxaliplatin and is associated with cellular tolerance to platinum.	Platinum	159-167	DNA polymerase eta	Homo sapiens	12-30
20978714-8	2010	The rank order of a FXa inhibitor"s effect on PT ratio varied across thromboplastin reagents.	Platinum	46-48	coagulation factor X	Homo sapiens	20-23
21114867-0	2010	Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy.	Platinum	161-169	nitric oxide synthase 3	Homo sapiens	29-62
20940192-6	2010	CONCLUSION: Polymorphisms in the TP53 and PARP1 genes are involved in inter-individual differences in the response to platinum-based doublet chemotherapy in patients with NSCLC.	Platinum	118-126	tumor protein p53	Homo sapiens	33-37
20940192-6	2010	CONCLUSION: Polymorphisms in the TP53 and PARP1 genes are involved in inter-individual differences in the response to platinum-based doublet chemotherapy in patients with NSCLC.	Platinum	118-126	poly(ADP-ribose) polymerase 1	Homo sapiens	42-47
20957754-7	2010	There is a significant decrease of PHB in tumor tissues from ovarian cancer patients who were resistant to platinum-based chemotherapies.	Platinum	107-115	prohibitin 1	Homo sapiens	35-38
20666498-3	2010	The turnover rates (TORs), that is, rate normalized by the exposed platinum, on the two single crystals differ by less than a factor of 2 over the range of conditions studied and are also similar to the TOR on a supported catalyst with an average particle size of 9 nm.	Platinum	67-75	RAR related orphan receptor C	Homo sapiens	20-23
20814250-2	2010	The current study investigated whether single nucleotide polymorphisms (SNPs) in the X-ray repair cross complementing protein 1 (XRCC1) gene are associated with survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.	Platinum	230-238	X-ray repair cross complementing 1	Homo sapiens	85-127
20814250-2	2010	The current study investigated whether single nucleotide polymorphisms (SNPs) in the X-ray repair cross complementing protein 1 (XRCC1) gene are associated with survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.	Platinum	230-238	X-ray repair cross complementing 1	Homo sapiens	129-134
21166887-9	2010	PX24 also displayed sensitivity to other platinum drugs, oxaliplatin and ZD0473, whereas PX2 acquired significant resistance to both of them.	Platinum	41-49	pannexin 2	Homo sapiens	0-3
20728204-3	2010	However, the relevance of ERCC1 expression in ovarian cancer (OC) is the subject of controversy, both as a predictive parameter for platinum resistance and because of its association with poor prognosis.	Platinum	132-140	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	26-31
20957754-9	2010	These studies demonstrated that 2-D DIGE-based proteomic analysis could be a powerful tool to investigate limited mitochondrial proteins, and the association of PHB expression with platinum resistance indicates that mitochondria defects may contribute to platinum resistance in ovarian cancer cells.	Platinum	181-189	prohibitin 1	Homo sapiens	161-164
21036754-12	2010	CONCLUSION: The results of this study indicate that ERCC1 may predict survival in pancreatic cancer patients treated by platinum and fluoropyrimidine as second-line chemotherapy.	Platinum	120-128	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	52-57
20929239-5	2010	Under our optimized environment, a platinum-iridium probe tip can retain its write-read resolution over 5 km of sliding at a 5 mm/s velocity on a smooth ferroelectric film.	Platinum	35-43	TOR signaling pathway regulator	Homo sapiens	58-61
21223694-16	2010	CONCLUSION: Advanced NSCLC patients failed with the previous treatment of first-line platinum-based chemotherapy and EGFR-TKI may benefit from salvage chemotherapy, especially in patients who received &gt;= 6 months of EGFR-TKI.	Platinum	85-93	epidermal growth factor receptor	Homo sapiens	219-223
20708400-1	2010	In the present study, a new electrochemical probe-label-free aptasensor for thrombin (TB) based on the amplification of gold-platinum alloy nanoparticles (Au-PtNPs) and stearic acid was reported.	Platinum	125-133	coagulation factor II, thrombin	Homo sapiens	76-84
20708400-1	2010	In the present study, a new electrochemical probe-label-free aptasensor for thrombin (TB) based on the amplification of gold-platinum alloy nanoparticles (Au-PtNPs) and stearic acid was reported.	Platinum	125-133	coagulation factor II, thrombin	Homo sapiens	86-88
20875558-8	2010	The limit of detection (LOD) was 0.004 mgL(-1) of platinum in the original sample.	Platinum	50-58	LLGL scribble cell polarity complex component 1	Homo sapiens	39-45
20737065-5	2010	Electrochemical studies showed that, in [ML](PF(6))(2) (M = Pd and Pt), the half-wave potential of the 1,1"-ferrocenediyl group shifts to much more positive potentials due to the strong through-space interaction between the two metals (M...Fe).	Platinum	67-69	sperm associated antigen 17	Homo sapiens	45-50
20351547-0	2010	Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.	Platinum	76-84	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	37-42
20351547-0	2010	Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.	Platinum	76-84	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	47-50
20351547-2	2010	The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in polymorphisms of DNA repair gene ERCC1 (excision repair cross-complementation group 1) and XPD (ERCC2, excision repair cross-complementation group 2) were associated with the tumor response in advanced non-small-cell lung cancer (NSCLC) patients received platinum-based chemotherapy in Chinese population.	Platinum	346-354	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	124-129
20351547-2	2010	The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in polymorphisms of DNA repair gene ERCC1 (excision repair cross-complementation group 1) and XPD (ERCC2, excision repair cross-complementation group 2) were associated with the tumor response in advanced non-small-cell lung cancer (NSCLC) patients received platinum-based chemotherapy in Chinese population.	Platinum	346-354	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	182-185
20351547-2	2010	The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in polymorphisms of DNA repair gene ERCC1 (excision repair cross-complementation group 1) and XPD (ERCC2, excision repair cross-complementation group 2) were associated with the tumor response in advanced non-small-cell lung cancer (NSCLC) patients received platinum-based chemotherapy in Chinese population.	Platinum	346-354	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	187-192
20462983-0	2010	Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.	Platinum	57-65	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	22-27
21036717-8	2010	CONCLUSION: Binary combinations of platinum compounds Cs, Ox, YH12 and TH1 with plant compounds Tx and Co applied to ovarian cancer cell lines showed sequence- and concentration-dependent synergism.	Platinum	35-43	negative elongation factor complex member C/D	Homo sapiens	71-74
20735432-4	2010	Here we show that PDCD4 improves the sensitivity of ovarian cancer cells to platinum-based chemotherapy.	Platinum	76-84	programmed cell death 4	Homo sapiens	18-23
20423075-3	2010	Powdered Pt/CdS/TiO(2) photocatalysts of variable CdS content (0-100%) were synthesized by precipitation of CdS nanoparticles on TiO(2) (Degussa P25) followed by deposition of Pt (0.5 wt %) and were characterized with BET, XRD, and DRS.	Platinum	9-11	CDP-diacylglycerol synthase 1	Homo sapiens	50-53
20423075-3	2010	Powdered Pt/CdS/TiO(2) photocatalysts of variable CdS content (0-100%) were synthesized by precipitation of CdS nanoparticles on TiO(2) (Degussa P25) followed by deposition of Pt (0.5 wt %) and were characterized with BET, XRD, and DRS.	Platinum	9-11	CDP-diacylglycerol synthase 1	Homo sapiens	50-53
20423075-3	2010	Powdered Pt/CdS/TiO(2) photocatalysts of variable CdS content (0-100%) were synthesized by precipitation of CdS nanoparticles on TiO(2) (Degussa P25) followed by deposition of Pt (0.5 wt %) and were characterized with BET, XRD, and DRS.	Platinum	9-11	delta/notch like EGF repeat containing	Homo sapiens	218-221
20423075-3	2010	Powdered Pt/CdS/TiO(2) photocatalysts of variable CdS content (0-100%) were synthesized by precipitation of CdS nanoparticles on TiO(2) (Degussa P25) followed by deposition of Pt (0.5 wt %) and were characterized with BET, XRD, and DRS.	Platinum	9-11	sushi repeat containing protein X-linked	Homo sapiens	232-235
20619446-11	2010	Correlation studies showed stromal VCAN expression was associated with poorer overall and progression-free survival, platinum resistance, and increased MVD.	Platinum	117-125	versican	Homo sapiens	35-39
20619446-13	2010	CONCLUSIONS: VCAN overexpression is associated with increased MVD and invasion potential, which may lead to poorer overall and progression-free survival and platinum resistance.	Platinum	157-165	versican	Homo sapiens	13-17
20462983-0	2010	Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.	Platinum	57-65	X-ray repair cross complementing 3	Homo sapiens	32-37
20541281-0	2010	The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression?	Platinum	4-12	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	87-92
20541281-3	2010	This meta-analysis was performed to provide an assessment of whether expression variations of ERCC1 are associated with objective response and median survival in patients with advanced NSCLC treated with platinum-based chemotherapy.	Platinum	204-212	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	94-99
20541281-8	2010	Response to platinum-based chemotherapy was significantly higher in patients with ERCC1 low/negative expression (OR=0.48; 95% CI, 0.35-0.64; P&lt;0.00001).	Platinum	12-20	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	82-87
20541281-10	2010	CONCLUSIONS: Low/negative expression of ERCC1 was associated with higher objective response and median survival in advanced NSCLC patients treated with platinum-based chemotherapy.	Platinum	152-160	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	40-45
20541281-11	2010	ERCC1 may be a suitable marker of prognosis and sensitivity to platinum-based chemotherapy in patients with advanced NSCLC.	Platinum	63-71	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
20811683-4	2010	The established miriplatin-resistant cells showed clear cross-resistance to platinum complexes containing diaminocyclohexane as a carrier ligand, such as oxaliplatin and dichloro[(1R,2R)-1,2-cyclohexanediamine-N,N"]platinum (DPC), while three human cancer cell lines selected for resistance to cisplatin (A2780cis, NCI-H69/CPR, MOR/CPR) did not show cross-resistance to miriplatin.	Platinum	76-84	cytochrome p450 oxidoreductase	Homo sapiens	315-326
20811683-4	2010	The established miriplatin-resistant cells showed clear cross-resistance to platinum complexes containing diaminocyclohexane as a carrier ligand, such as oxaliplatin and dichloro[(1R,2R)-1,2-cyclohexanediamine-N,N"]platinum (DPC), while three human cancer cell lines selected for resistance to cisplatin (A2780cis, NCI-H69/CPR, MOR/CPR) did not show cross-resistance to miriplatin.	Platinum	76-84	opioid receptor mu 1	Homo sapiens	328-331
20811683-4	2010	The established miriplatin-resistant cells showed clear cross-resistance to platinum complexes containing diaminocyclohexane as a carrier ligand, such as oxaliplatin and dichloro[(1R,2R)-1,2-cyclohexanediamine-N,N"]platinum (DPC), while three human cancer cell lines selected for resistance to cisplatin (A2780cis, NCI-H69/CPR, MOR/CPR) did not show cross-resistance to miriplatin.	Platinum	76-84	cytochrome p450 oxidoreductase	Homo sapiens	323-326
20957220-0	2010	Effects of TAT-conjugated platinum nanoparticles on lifespan of mitochondrial electron transport complex I-deficient Caenorhabditis elegans, nuo-1.	Platinum	26-34	Tat	Human immunodeficiency virus 1	11-14
20970611-7	2010	RESULTS: The response of ITIH4 to PT was early, intense, and prolonged, with 2 peaks in serum concentration.	Platinum	34-36	inter-alpha-trypsin inhibitor heavy chain 4	Sus scrofa	25-30
20868484-9	2010	The reported methylation of XPG gene could be an important determinant of the response to platinum based therapy.	Platinum	90-98	ERCC excision repair 5, endonuclease	Homo sapiens	28-31
20596565-2	2010	The adsorption energies of both upd-H(ad) and OH(ad) decrease with increasing Pt content in the adsorption ensemble, shifting the onset of upd-H(ad) and OH(ad) formation to increasingly cathodic and anodic potentials, respectively.	Platinum	78-80	uroporphyrinogen decarboxylase	Homo sapiens	32-35
20596565-2	2010	The adsorption energies of both upd-H(ad) and OH(ad) decrease with increasing Pt content in the adsorption ensemble, shifting the onset of upd-H(ad) and OH(ad) formation to increasingly cathodic and anodic potentials, respectively.	Platinum	78-80	uroporphyrinogen decarboxylase	Homo sapiens	139-142
20957220-0	2010	Effects of TAT-conjugated platinum nanoparticles on lifespan of mitochondrial electron transport complex I-deficient Caenorhabditis elegans, nuo-1.	Platinum	26-34	NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial	Caenorhabditis elegans	141-146
20957220-1	2010	Platinum nanoparticle (Pt-np) species are superoxide dismutase/catalase mimetics and also have an activity similar to that of mitochondrial electron transport complex I.	Platinum	0-8	Catalase	Caenorhabditis elegans	63-71
20719524-3	2010	Four functionalized furyl-thiosemicarbazones (NT1-4) treated with divalent metals (Cu, Co, Pt, and Pd) to form the mononuclear metallic complexes of formula [M(L)2Cl2] or [M(L)Cl2] were examined.	Platinum	91-93	3'-nucleotidase	Homo sapiens	46-51
20836889-1	2010	BACKGROUND: ATP7A, ATP7B and CTR1 are metal transporting proteins that control the cellular disposition of copper and platinum drugs, but their expression in dorsal root ganglion (DRG) tissue and their role in platinum-induced neurotoxicity are unknown.	Platinum	118-126	ATPase copper transporting alpha	Rattus norvegicus	12-17
20538449-2	2010	The plant beta(1 3)-D-glucanase (betaG), glucose oxidase (GOD) or/and peroxidase (POD) in agarose-corn flour-gelatin (ACG) matrix were coated on platinum disc electrode to detect soluble beta(1 3)-D-glucan.	Platinum	145-153	peroxidase 1	Zea mays	70-80
20807817-3	2010	Although it is known that chemosensitivity in BRCA1-associated cancers is associated with unrepaired DNA damage, the specific effector pathway mediating the cellular response to platinum-induced damage in these tumors is poorly understood.	Platinum	178-186	BRCA1 DNA repair associated	Homo sapiens	46-51
20836889-1	2010	BACKGROUND: ATP7A, ATP7B and CTR1 are metal transporting proteins that control the cellular disposition of copper and platinum drugs, but their expression in dorsal root ganglion (DRG) tissue and their role in platinum-induced neurotoxicity are unknown.	Platinum	118-126	ATPase copper transporting beta	Rattus norvegicus	19-24
20836889-1	2010	BACKGROUND: ATP7A, ATP7B and CTR1 are metal transporting proteins that control the cellular disposition of copper and platinum drugs, but their expression in dorsal root ganglion (DRG) tissue and their role in platinum-induced neurotoxicity are unknown.	Platinum	118-126	solute carrier family 31 member 1	Rattus norvegicus	29-33
20836889-1	2010	BACKGROUND: ATP7A, ATP7B and CTR1 are metal transporting proteins that control the cellular disposition of copper and platinum drugs, but their expression in dorsal root ganglion (DRG) tissue and their role in platinum-induced neurotoxicity are unknown.	Platinum	210-218	ATPase copper transporting alpha	Rattus norvegicus	12-17
20836889-1	2010	BACKGROUND: ATP7A, ATP7B and CTR1 are metal transporting proteins that control the cellular disposition of copper and platinum drugs, but their expression in dorsal root ganglion (DRG) tissue and their role in platinum-induced neurotoxicity are unknown.	Platinum	210-218	ATPase copper transporting beta	Rattus norvegicus	19-24
20836889-1	2010	BACKGROUND: ATP7A, ATP7B and CTR1 are metal transporting proteins that control the cellular disposition of copper and platinum drugs, but their expression in dorsal root ganglion (DRG) tissue and their role in platinum-induced neurotoxicity are unknown.	Platinum	210-218	solute carrier family 31 member 1	Rattus norvegicus	29-33
20799737-2	2010	The [Pt{(+/-)-Me(2)dab}(9-EtG)(2)](NO(3))(2) (Me(2)dab = N,N"-dimethyl-2,3-diaminobutane, 9-EtG = 9-ethyl-guanine) complex crystallizes in the P2(1)/n space group, and the crystal contains a racemic mixture of complex molecules.	Platinum	5-7	H3 histone pseudogene 16	Homo sapiens	143-148
21331363-0	2010	Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial.	Platinum	51-59	erythropoietin	Homo sapiens	0-7
20944091-6	2010	In some types of cancer, high levels of ERCC1/XPF mRNA and protein correlate with poor overall survival and resistance to platinum-based chemotherapeutic treatments.	Platinum	122-130	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	40-45
21331363-10	2010	CONCLUSION: This small study showed, that Epoetin theta is a safe and effective treatment of symptomatic anaemia due to platinum-based chemotherapy in cancer patients.	Platinum	120-128	erythropoietin	Homo sapiens	42-49
20944091-6	2010	In some types of cancer, high levels of ERCC1/XPF mRNA and protein correlate with poor overall survival and resistance to platinum-based chemotherapeutic treatments.	Platinum	122-130	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	46-49
20047843-6	2010	Tumors expressing high BRCA1 may have increased resistance to platinums but increased sensitivity to taxanes.	Platinum	62-71	BRCA1 DNA repair associated	Homo sapiens	23-28
20047843-9	2010	While limited clinical data suggest that p53 mutations are associated with resistance to platinum-based therapies in NSCLC, data on p53 IHC positivity are equivocal.	Platinum	89-97	tumor protein p53	Homo sapiens	41-44
20855270-1	2010	OBJECTIVE: To study the association of positive expression of nucleotide excision repair cross complementary group 1 (ERCC1) in the tumor tissues with platinum resistance of the tumor cells and the clinical outcomes of neo-adjuvant chemotherapy in elderly patients with non-small cell lung cancer (NSCLC).	Platinum	151-159	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	118-123
20519567-1	2010	Mammalian copper transporter 1 (CTR1) is a high-affinity copper influx transporter that also mediates the uptake of platinum-containing chemotherapeutic agents including cisplatin (cDDP).	Platinum	116-124	solute carrier family 31 member 1	Homo sapiens	10-30
20519567-1	2010	Mammalian copper transporter 1 (CTR1) is a high-affinity copper influx transporter that also mediates the uptake of platinum-containing chemotherapeutic agents including cisplatin (cDDP).	Platinum	116-124	solute carrier family 31 member 1	Homo sapiens	32-36
20855270-2	2010	METHODS: ERCC1 expression was detected immunohistochemically in the tumor tissues from 113 elderly patients with NSCLC, of which 58 patients received platinum-containing neo-adjuvant chemotherapy, and the impact of ERCC1 expression on the outcomes of neo-adjuvant chemotherapy was analyzed.	Platinum	150-158	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	9-14
20451502-1	2010	The mammalian copper transporter 1 (CTR1) is responsible for the uptake of copper (Cu) from the extracellular space, and has been shown to play a major role in the initial accumulation of platinum-based drugs.	Platinum	188-196	solute carrier family 31 member 1	Homo sapiens	14-34
20058210-2	2010	The aim of this study was to evaluate the significance of clusterin expression to predict response to platinum-based neoadjuvant chemotherapy and survival of patients with invasive cervical cancer who subsequently underwent radical hysterectomy.	Platinum	102-110	clusterin	Homo sapiens	58-67
20058210-12	2010	We conclude that clusterin expression could be a new molecular marker to predict response to platinum-based chemotherapy and survival of patients with cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy.	Platinum	93-101	clusterin	Homo sapiens	17-26
20572187-0	2010	Proton-transfer reactions on hexanuclear platinum clusters: reversible heterolytic cleavage of H2 and C-H activation affording a linear, cluster-containing polymer.	Platinum	41-49	relaxin 2	Homo sapiens	95-103
22966390-1	2010	Expression of copper-transporting P-type adenosine triphosphatase A (ATP7A) is reportedly associated with platinum drug resistance in various types of solid tumors.	Platinum	106-114	ATPase copper transporting alpha	Homo sapiens	69-74
22966390-2	2010	However, the impact of ATP7A expression on platinum drug resistance in non-small cell lung cancer (NSCLC) has yet to be adequately elucidated.	Platinum	43-51	ATPase copper transporting alpha	Homo sapiens	23-28
20451502-1	2010	The mammalian copper transporter 1 (CTR1) is responsible for the uptake of copper (Cu) from the extracellular space, and has been shown to play a major role in the initial accumulation of platinum-based drugs.	Platinum	188-196	solute carrier family 31 member 1	Homo sapiens	36-40
20593813-1	2010	Geometry, electronic structure, and bonding analysis of the terminal neutral dihalogallyl complexes of nickel, palladium, and platinum trans-[X(PMe(3))(2)M(GaX(2))] (M = Ni, Pd, Pt; X = Cl, Br, I) were investigated at the BP86 level of theory.	Platinum	126-134	mesenchyme homeobox 2	Homo sapiens	156-159
20505878-1	2010	Electron transfer dissociation (ETD) and collision induced dissociation (CID) have been used to locate the precise binding sites for platinum and ruthenium anticancer complexes on the peptide Substance P.	Platinum	133-141	tachykinin precursor 1	Homo sapiens	192-203
20547053-6	2010	The prepared first-generation enzyme electrode (CS-GA-GOx/Pt(nano)/Au) exhibits a current sensitivity as high as 102 microA mM(-1) cm(-2) at 0.70 V vs SCE, being 13 times that of the CS-GOx/Pt(nano)/Au prepared similarly but without the GOx-CS precrosslinking.	Platinum	58-60	hydroxyacid oxidase 1	Homo sapiens	54-57
20547053-6	2010	The prepared first-generation enzyme electrode (CS-GA-GOx/Pt(nano)/Au) exhibits a current sensitivity as high as 102 microA mM(-1) cm(-2) at 0.70 V vs SCE, being 13 times that of the CS-GOx/Pt(nano)/Au prepared similarly but without the GOx-CS precrosslinking.	Platinum	58-60	hydroxyacid oxidase 1	Homo sapiens	186-189
20547053-6	2010	The prepared first-generation enzyme electrode (CS-GA-GOx/Pt(nano)/Au) exhibits a current sensitivity as high as 102 microA mM(-1) cm(-2) at 0.70 V vs SCE, being 13 times that of the CS-GOx/Pt(nano)/Au prepared similarly but without the GOx-CS precrosslinking.	Platinum	58-60	hydroxyacid oxidase 1	Homo sapiens	186-189
20681701-1	2010	Reaction of [PtCl(2)(dmso)(2)] with 2,5-(dialkoxyphenyl)pyridine in HOAc leads to a dinuclear, acetate-bridged, metal-metal bonded complex of platinum(III); dmso in the presence of acid is found to be responsible for the oxidation.	Platinum	142-150	hypoacusis 2 (autosomal recessive)	Homo sapiens	68-72
20593813-2	2010	The calculated geometries of platinum gallyl complexes trans-[X(PMe(3))(2)Pt(GaX(2))] (X = Br, I) are in excellent agreement with structurally characterized platinum complexes trans-[X(PCy(3))(2)M(GaX(2))].	Platinum	29-37	mesenchyme homeobox 2	Homo sapiens	77-80
20593813-2	2010	The calculated geometries of platinum gallyl complexes trans-[X(PMe(3))(2)Pt(GaX(2))] (X = Br, I) are in excellent agreement with structurally characterized platinum complexes trans-[X(PCy(3))(2)M(GaX(2))].	Platinum	29-37	mesenchyme homeobox 2	Homo sapiens	197-200
20593813-2	2010	The calculated geometries of platinum gallyl complexes trans-[X(PMe(3))(2)Pt(GaX(2))] (X = Br, I) are in excellent agreement with structurally characterized platinum complexes trans-[X(PCy(3))(2)M(GaX(2))].	Platinum	157-165	mesenchyme homeobox 2	Homo sapiens	77-80
20593813-8	2010	Thus, the [M]-GaX(2) bond in the studied gallyl complexes of Ni, Pd, and Pt has a greater degree of ionic character (65.7-72.5%).	Platinum	73-75	mesenchyme homeobox 2	Homo sapiens	14-17
20417484-0	2010	Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro.	Platinum	28-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	130-135
20434216-0	2010	The effect of TAT conjugated platinum nanoparticles on lifespan in a nematode Caenorhabditis elegans model.	Platinum	29-37	Tat	Human immunodeficiency virus 1	14-17
20417484-0	2010	Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro.	Platinum	28-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	136-139
20417484-4	2010	High HER-2/neu expressors were more sensitive to platinum compounds, manifesting a 5.22-fold decrease in carboplatin-IC(50) (P = .005) and a 5.37-fold decrease in cisplatin-IC(50) (P = .02).	Platinum	49-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-14
20417484-6	2010	CONCLUSION: USPC overexpressing HER-2/neu display greater in vitro sensitivity to platinum compounds when compared to low HER-2/neu expressors.	Platinum	82-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-37
20417484-6	2010	CONCLUSION: USPC overexpressing HER-2/neu display greater in vitro sensitivity to platinum compounds when compared to low HER-2/neu expressors.	Platinum	82-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-41
20417484-6	2010	CONCLUSION: USPC overexpressing HER-2/neu display greater in vitro sensitivity to platinum compounds when compared to low HER-2/neu expressors.	Platinum	82-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-41
20434216-1	2010	We have shown that platinum nanoparticle species (nano-Pt) is a superoxide dismutase/catalase mimetic that scavenges superoxide and hydrogen peroxide.	Platinum	19-27	Catalase	Caenorhabditis elegans	85-93
20730959-3	2010	Approaching the BRCA1 RING protein as a potentially molecular target for a platinum-based drug might be of interest in cancer therapy.	Platinum	75-83	BRCA1 DNA repair associated	Homo sapiens	16-21
19957335-12	2010	These effects are consistent with the poor response to platinum-based chemotherapy in patients with methylation of SFRP5.	Platinum	55-63	secreted frizzled related protein 5	Homo sapiens	115-120
19499188-0	2010	The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12.	Platinum	79-87	tumor protein p53	Homo sapiens	39-42
20631077-7	2010	Platinum incorporation into tumor DNA and the antitumor efficacy of transferrin-conjugated liposome-delivered oxaliplatin could be enhanced by drug administration at times when TfR1 expression increased.	Platinum	0-8	transferrin receptor	Mus musculus	177-181
20562210-10	2010	CONCLUSIONS: ALC was effective in enhancing the antitumor potential of platinum compounds in wild-type p53 tumors.	Platinum	71-79	allantoicase	Homo sapiens	13-16
20562210-10	2010	CONCLUSIONS: ALC was effective in enhancing the antitumor potential of platinum compounds in wild-type p53 tumors.	Platinum	71-79	tumor protein p53	Homo sapiens	103-106
20868591-0	2010	[Clinical significance of insulin-like growth factor-1 receptor in platinum-based chemotherapy for non-small cell lung cancer].	Platinum	67-75	insulin like growth factor 1 receptor	Homo sapiens	26-63
20547991-3	2010	Correlation with platinum responsiveness was assessed in platinum-sensitive and platinum-resistant tumor biopsy specimens from six patients with BRCA germline mutations.	Platinum	17-25	BRCA1 DNA repair associated	Homo sapiens	145-149
19962780-11	2010	In conclusion, ERCC1 protein protects NSCLC cells from synergistic cytotoxicity induced by emodin and platinum agents.	Platinum	102-110	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	15-20
20606085-12	2010	BRCA(1/2) mutations were associated with improved progression-free survival (PFS) after platinum-based chemotherapy in univariate (P = .032; hazard ratio [HR] = 0.65; 95% CI, 0.43 to 0.98) and multivariate (P = .019) analyses.	Platinum	88-96	BRCA1 DNA repair associated	Homo sapiens	0-8
20868591-2	2010	METHOD: The expression of IGF-1R was detected in 39 paraffin-embedded chemotherapy-naive non-small cell lung cancer tumor samples with immunohistochemical method,and the relationship between the outcomes of platinum-based chemotherapy and IGF-1R expression was analyzed.	Platinum	207-215	insulin like growth factor 1 receptor	Homo sapiens	26-32
20868591-5	2010	Better outcomes of platinum-based chemotherapy were observed in patients with negative IGF-1R expression.	Platinum	19-27	insulin like growth factor 1 receptor	Homo sapiens	87-93
20868591-6	2010	CONCLUSION: IGF-1R expression may be used to predict the effectiveness of the first-line platinum-based chemotherapy for end-stage non-small cell lung cancer.	Platinum	89-97	insulin like growth factor 1 receptor	Homo sapiens	12-18
20606680-5	2010	Loss of membranous CD166 and CD44s were linked to higher pT (P=0.002, P=0.014), pN (P=0.004, P=0.002), an infiltrating growth pattern (P&lt;0.001, P=0.002), and worse survival (P=0.015, P=0.019) in univariate analysis only.	Platinum	57-59	activated leukocyte cell adhesion molecule	Homo sapiens	19-24
20550106-0	2010	Recognition of platinum-DNA damage by poly(ADP-ribose) polymerase-1.	Platinum	15-23	poly(ADP-ribose) polymerase 1	Homo sapiens	38-67
20550106-2	2010	To investigate the properties of binding of PARP-1 to different platinum-DNA adducts in greater detail, biotinylated DNA probes containing a site-specific cisplatin 1,2-d(GpG) or 1,3-d(GpTpG) intrastrand cross-link or a cisplatin 5"-GC/5"-GC interstrand cross-link (ICL) were utilized in binding assays with cell-free extracts (CFEs) in vitro.	Platinum	64-72	poly(ADP-ribose) polymerase 1	Homo sapiens	44-50
20550106-6	2010	The role of poly(ADP-ribose) (pADPr) in mediating binding of PARP-1 to platinum damage was further investigated.	Platinum	71-79	poly(ADP-ribose) polymerase 1	Homo sapiens	61-67
20550106-9	2010	PARP-1 also binds to DNA damaged by other platinum compounds, including oxaliplatin and pyriplatin, indicating protein affinity for the damage in an adduct-specific manner rather than recognition of distorted DNA.	Platinum	42-50	poly(ADP-ribose) polymerase 1	Homo sapiens	0-6
20487263-4	2010	We used bisulfite sequencing, real-time polymerase chain reaction, and western blotting to check the methylation state and expression levels of BRCA1 of the following cell lines: platinum-sensitive human ovarian cancer cell line COC1, platinum-resistant cell line COC1/DDP, SKOV-3, and 5-Aza-dC treated COC1.	Platinum	179-187	BRCA1 DNA repair associated	Homo sapiens	144-149
20550106-10	2010	Our results reveal the unique binding properties for binding of PARP-1 to platinum-DNA damage, providing insights into, and a better understanding of, the cellular response to platinum-based anticancer drugs.	Platinum	74-82	poly(ADP-ribose) polymerase 1	Homo sapiens	64-70
20550106-10	2010	Our results reveal the unique binding properties for binding of PARP-1 to platinum-DNA damage, providing insights into, and a better understanding of, the cellular response to platinum-based anticancer drugs.	Platinum	176-184	poly(ADP-ribose) polymerase 1	Homo sapiens	64-70
20527800-10	2010	The reaction of 6 with Pt[P(t-Bu)(3)](2) in a hydrogen atmosphere yielded the new compound Pt(2)Re(2)(CO)(7)[P(t-Bu)(3)](2)(mu(3)-SbPh)(3) (7) by the cleavage of one phenyl ring from each of the two SbPh(2) ligands in 6 and the addition of a PtP(t-Bu)(3) group to the resultant SbPh ligands.	Platinum	23-25	protein tyrosine phosphatase receptor type U	Homo sapiens	242-245
20534738-10	2010	Nuclear expression of Nrf2 in malignant lung cancer cells may play a role in resistance to platinum-based treatment in squamous cell carcinoma.	Platinum	91-99	NFE2 like bZIP transcription factor 2	Homo sapiens	22-26
20631178-0	2010	Role of the copper transporter, CTR1, in platinum-induced ototoxicity.	Platinum	41-49	solute carrier family 31, member 1	Mus musculus	32-36
20631178-1	2010	The goal of this study was to determine the role of an influx copper transporter, CTR1, in the ototoxicity induced by cisplatin, a potent anticancer platinum analog used in the treatment of a variety of solid tumors.	Platinum	149-157	solute carrier family 31, member 1	Mus musculus	82-86
20487263-4	2010	We used bisulfite sequencing, real-time polymerase chain reaction, and western blotting to check the methylation state and expression levels of BRCA1 of the following cell lines: platinum-sensitive human ovarian cancer cell line COC1, platinum-resistant cell line COC1/DDP, SKOV-3, and 5-Aza-dC treated COC1.	Platinum	235-243	BRCA1 DNA repair associated	Homo sapiens	144-149
20878620-0	2010	Expression of ERCC1 and class III ss-tubulin in resected non-small cell lung cancer and its correlation with platinum-based adjuvant chemotherapy.	Platinum	109-117	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-19
20152903-3	2010	To remove this uncertainty, we introduce Fluorescence Detection of Heavy Atom Labeling (FD-HAL) using tetramethylrhodamine-5-maleimide (a fluorescent maleimide compound) to monitor in-gel cysteine residue accessibility and ascertain covalent modification by mercury, platinum and gold compounds.	Platinum	267-275	histidine ammonia-lyase	Homo sapiens	91-94
20427545-2	2010	We describe three cases of pregnant women with Stage Ib1 to IIa cervical cancer who were treated with paclitaxel plus platinum neoadjuvant chemotherapy followed by radical surgery.	Platinum	118-126	mitogen-activated protein kinase 8 interacting protein 1	Homo sapiens	53-56
20593550-0	2010	A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.	Platinum	89-97	vascular endothelial growth factor A	Homo sapiens	32-66
20648350-5	2010	The 2 nm Pt-modified SnO(2) nanorod sensors by sputtering showed the best sensing performance.	Platinum	9-11	strawberry notch homolog 2	Homo sapiens	21-24
20541702-2	2010	Here we show in human ovarian tumors that low levels of Ctr1 mRNA are associated with poor clinical response to platinum-based therapy.	Platinum	112-120	solute carrier family 31 member 1	Homo sapiens	56-60
20514439-1	2010	We have previously showed that platinum drugs up-regulate SSAT and SMO and down-regulate ODC and SAMDC in the polyamine pathway.	Platinum	31-39	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	58-62
20514439-1	2010	We have previously showed that platinum drugs up-regulate SSAT and SMO and down-regulate ODC and SAMDC in the polyamine pathway.	Platinum	31-39	smoothened, frizzled class receptor	Homo sapiens	67-70
20514439-1	2010	We have previously showed that platinum drugs up-regulate SSAT and SMO and down-regulate ODC and SAMDC in the polyamine pathway.	Platinum	31-39	ornithine decarboxylase 1	Homo sapiens	89-92
20514439-1	2010	We have previously showed that platinum drugs up-regulate SSAT and SMO and down-regulate ODC and SAMDC in the polyamine pathway.	Platinum	31-39	adenosylmethionine decarboxylase 1	Homo sapiens	97-102
20517311-6	2010	The combination of YM155 and platinum compounds also induced synergistic increases both in the number of apoptotic cells and in the activity of caspase-3.	Platinum	29-37	caspase 3	Homo sapiens	144-153
20104527-10	2010	In contrast, several platinum sensitive tumours, including primary ovarian, stomach and colorectal cancer, are characterised by ASS1 overexpression, which is regulated by proinflammatory cytokines.	Platinum	21-29	argininosuccinate synthase 1	Homo sapiens	128-132
20514439-2	2010	Several studies including our own established that platinum drugs combined with polyamine analog DENSPM produces synergistic increase in SSAT activity with polyamine depletion.	Platinum	51-59	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	137-141
20034732-4	2010	We found that FANCC- and FANCD2-mutant cells were unexpectedly more sensitive to platinum drugs than FANCA-mutant cells, and mono-ubiquitination of FANCD2, which is mediated by the FANCA and FANCC containing FA core complex was not required for platinum resistance.	Platinum	81-89	FA complementation group C	Homo sapiens	14-19
20550649-6	2010	Binding of LA-12 to Hsp90 was demonstrated by Hsp90 immunoprecipitation followed by platinum measurement using atomic absorption spectrometry (AAS).	Platinum	84-92	heat shock protein 90 alpha family class A member 1	Homo sapiens	20-25
19783226-1	2010	A biosensor based on a partially purified polyphenol oxidase (PPO) enzyme was developed by using electropolymerization of [(2,2"-bipyridine)(chloro)(p-cymene)rutenium(II)]chloride] mediator complex and 1,2-diamino benzene (DAB) on a screen printing Pt electrode (1mm diameter).	Platinum	249-251	protoporphyrinogen oxidase	Homo sapiens	33-60
19783226-1	2010	A biosensor based on a partially purified polyphenol oxidase (PPO) enzyme was developed by using electropolymerization of [(2,2"-bipyridine)(chloro)(p-cymene)rutenium(II)]chloride] mediator complex and 1,2-diamino benzene (DAB) on a screen printing Pt electrode (1mm diameter).	Platinum	249-251	protoporphyrinogen oxidase	Homo sapiens	62-65
20034732-4	2010	We found that FANCC- and FANCD2-mutant cells were unexpectedly more sensitive to platinum drugs than FANCA-mutant cells, and mono-ubiquitination of FANCD2, which is mediated by the FANCA and FANCC containing FA core complex was not required for platinum resistance.	Platinum	81-89	FA complementation group A	Homo sapiens	181-186
20034732-4	2010	We found that FANCC- and FANCD2-mutant cells were unexpectedly more sensitive to platinum drugs than FANCA-mutant cells, and mono-ubiquitination of FANCD2, which is mediated by the FANCA and FANCC containing FA core complex was not required for platinum resistance.	Platinum	81-89	FA complementation group C	Homo sapiens	191-196
20034732-4	2010	We found that FANCC- and FANCD2-mutant cells were unexpectedly more sensitive to platinum drugs than FANCA-mutant cells, and mono-ubiquitination of FANCD2, which is mediated by the FANCA and FANCC containing FA core complex was not required for platinum resistance.	Platinum	245-253	FA complementation group C	Homo sapiens	14-19
20034732-4	2010	We found that FANCC- and FANCD2-mutant cells were unexpectedly more sensitive to platinum drugs than FANCA-mutant cells, and mono-ubiquitination of FANCD2, which is mediated by the FANCA and FANCC containing FA core complex was not required for platinum resistance.	Platinum	245-253	FA complementation group D2	Homo sapiens	25-31
20424733-0	2010	Combined TPRx, in situ GISAXS and GIXAS studies of model semiconductor-supported platinum catalysts in the hydrogenation of ethene.	Platinum	81-89	tetrapeptide repeat homeobox 1	Homo sapiens	9-13
20034732-4	2010	We found that FANCC- and FANCD2-mutant cells were unexpectedly more sensitive to platinum drugs than FANCA-mutant cells, and mono-ubiquitination of FANCD2, which is mediated by the FANCA and FANCC containing FA core complex was not required for platinum resistance.	Platinum	245-253	FA complementation group A	Homo sapiens	101-106
20034732-4	2010	We found that FANCC- and FANCD2-mutant cells were unexpectedly more sensitive to platinum drugs than FANCA-mutant cells, and mono-ubiquitination of FANCD2, which is mediated by the FANCA and FANCC containing FA core complex was not required for platinum resistance.	Platinum	81-89	FA complementation group D2	Homo sapiens	25-31
20034732-4	2010	We found that FANCC- and FANCD2-mutant cells were unexpectedly more sensitive to platinum drugs than FANCA-mutant cells, and mono-ubiquitination of FANCD2, which is mediated by the FANCA and FANCC containing FA core complex was not required for platinum resistance.	Platinum	245-253	FA complementation group D2	Homo sapiens	148-154
20034732-4	2010	We found that FANCC- and FANCD2-mutant cells were unexpectedly more sensitive to platinum drugs than FANCA-mutant cells, and mono-ubiquitination of FANCD2, which is mediated by the FANCA and FANCC containing FA core complex was not required for platinum resistance.	Platinum	245-253	FA complementation group A	Homo sapiens	181-186
20191372-5	2010	We also report that platinum adducts cause a decrease in TRF2-dependent stimulation of telomeric invasion in vitro.	Platinum	20-28	telomeric repeat binding factor 2	Homo sapiens	57-61
20034732-4	2010	We found that FANCC- and FANCD2-mutant cells were unexpectedly more sensitive to platinum drugs than FANCA-mutant cells, and mono-ubiquitination of FANCD2, which is mediated by the FANCA and FANCC containing FA core complex was not required for platinum resistance.	Platinum	245-253	FA complementation group C	Homo sapiens	191-196
19488864-0	2010	Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer.	Platinum	47-55	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	23-28
19488864-10	2010	In conclusion, tumor ERCC1 expression is associated with tumor response and patients" survival in Chinese advanced NSCLC patients treated with platinum-based regimen and may serve as a biomarker in predicting tumor response and clinical outcome in the patient population.	Platinum	143-151	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	21-26
20461087-9	2010	CONCLUSIONS: We provide evidence that tumour regression and ERCC1 nuclear protein expression evaluated by immunohistochemistry are promising predictive markers in gastro-oesophageal cancer patients receiving neoadjuvant platinum-based chemotherapy.	Platinum	220-228	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	60-65
19683826-11	2010	However, only ERCC1 and betaIII-tubulin were prognostic factors after platinum- and taxane-based neoadjuvant chemotherapy following surgical resection.	Platinum	70-78	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-19
20159940-8	2010	Copper and platinum(II) have similar sulfur binding characteristics, and the presence of stacked rings of methionines and cysteines in the CTR1 trimer suggest a mechanism by which CTR1 selectively transports copper and the platinum-containing drugs via sequential transchelation reactions similar to the manner in which copper is passed from ATOX1 to the copper efflux transporters.	Platinum	11-19	solute carrier family 31 member 1	Homo sapiens	180-184
20159940-8	2010	Copper and platinum(II) have similar sulfur binding characteristics, and the presence of stacked rings of methionines and cysteines in the CTR1 trimer suggest a mechanism by which CTR1 selectively transports copper and the platinum-containing drugs via sequential transchelation reactions similar to the manner in which copper is passed from ATOX1 to the copper efflux transporters.	Platinum	11-19	antioxidant 1 copper chaperone	Homo sapiens	342-347
20159940-8	2010	Copper and platinum(II) have similar sulfur binding characteristics, and the presence of stacked rings of methionines and cysteines in the CTR1 trimer suggest a mechanism by which CTR1 selectively transports copper and the platinum-containing drugs via sequential transchelation reactions similar to the manner in which copper is passed from ATOX1 to the copper efflux transporters.	Platinum	223-231	solute carrier family 31 member 1	Homo sapiens	139-143
20159940-8	2010	Copper and platinum(II) have similar sulfur binding characteristics, and the presence of stacked rings of methionines and cysteines in the CTR1 trimer suggest a mechanism by which CTR1 selectively transports copper and the platinum-containing drugs via sequential transchelation reactions similar to the manner in which copper is passed from ATOX1 to the copper efflux transporters.	Platinum	223-231	solute carrier family 31 member 1	Homo sapiens	180-184
20159940-8	2010	Copper and platinum(II) have similar sulfur binding characteristics, and the presence of stacked rings of methionines and cysteines in the CTR1 trimer suggest a mechanism by which CTR1 selectively transports copper and the platinum-containing drugs via sequential transchelation reactions similar to the manner in which copper is passed from ATOX1 to the copper efflux transporters.	Platinum	223-231	antioxidant 1 copper chaperone	Homo sapiens	342-347
20458443-0	2010	Polymorphisms in hMSH2 and hMLH1 and response to platinum-based chemotherapy in advanced non-small-cell lung cancer patients.	Platinum	49-57	mutS homolog 2	Homo sapiens	17-22
20405851-11	2010	Comparison of the photophysics of F-1, F-2, and F-3 to those of their corresponding Pt complexes without the fluorenyl substituent discovers that F-1-F-3 exhibit larger molar extinction coefficients for their low-energy charge transfer absorption band, longer triplet excited-state lifetimes, higher emission quantum yields, and increased ratios of the excited-state absorption cross-section to that of the ground-state.	Platinum	84-86	coagulation factor II, thrombin	Homo sapiens	39-42
20405851-11	2010	Comparison of the photophysics of F-1, F-2, and F-3 to those of their corresponding Pt complexes without the fluorenyl substituent discovers that F-1-F-3 exhibit larger molar extinction coefficients for their low-energy charge transfer absorption band, longer triplet excited-state lifetimes, higher emission quantum yields, and increased ratios of the excited-state absorption cross-section to that of the ground-state.	Platinum	84-86	coagulation factor III, tissue factor	Homo sapiens	48-51
20405851-11	2010	Comparison of the photophysics of F-1, F-2, and F-3 to those of their corresponding Pt complexes without the fluorenyl substituent discovers that F-1-F-3 exhibit larger molar extinction coefficients for their low-energy charge transfer absorption band, longer triplet excited-state lifetimes, higher emission quantum yields, and increased ratios of the excited-state absorption cross-section to that of the ground-state.	Platinum	84-86	coagulation factor III, tissue factor	Homo sapiens	150-153
20406929-0	2010	Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.	Platinum	115-123	poly(ADP-ribose) polymerase 1	Homo sapiens	0-27
20406929-0	2010	Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.	Platinum	115-123	BRCA1 DNA repair associated	Homo sapiens	70-74
20406929-12	2010	CONCLUSION: Olaparib has antitumor activity in BRCA1/2 mutation ovarian cancer, which is associated with platinum sensitivity.	Platinum	105-113	BRCA1 DNA repair associated	Homo sapiens	47-52
20458443-7	2010	We found that there was a significantly increased chance of treatment response to platinum-based chemotherapy with the hMSH2 gIVS12-6T/C polymorphism.	Platinum	82-90	mutS homolog 2	Homo sapiens	119-124
20388977-2	2010	The biosensor was prepared by immobilizing glucose oxidase (GOx) on a platinum (Pt) electrode by a composite film consisting of GNRs, polyvinyl butyral (PVB) and glutaraldehyde.	Platinum	70-78	hydroxyacid oxidase 1	Homo sapiens	43-58
20386850-1	2010	2-(3-Benzyloxy)prop-1-ynyl)benzaldehyde with PtCl(2) in toluene would form Pt-pyryliums that underwent [3+2] cycloaddition with alkenes to the oxygen-bridged (5H-benzo[7]annulen-5-ylidene)platinum(ii) intermediates with good stereoselectivities.	Platinum	188-196	PROP paired-like homeobox 1	Homo sapiens	15-21
20388977-2	2010	The biosensor was prepared by immobilizing glucose oxidase (GOx) on a platinum (Pt) electrode by a composite film consisting of GNRs, polyvinyl butyral (PVB) and glutaraldehyde.	Platinum	70-78	hydroxyacid oxidase 1	Homo sapiens	60-63
20060649-9	2010	The aim of this review, that focuses on triple-negative breast cancer, is to summarize the most relevant knowledge on this particular type of cancer in terms of molecular features, pathogenesis, clinical characteristics, current treatments and the new therapeutic options that include the use of platinum compounds, EGFR antagonists, antiangiogenics and PARP inhibitors.	Platinum	296-304	epidermal growth factor receptor	Homo sapiens	316-320
20060649-9	2010	The aim of this review, that focuses on triple-negative breast cancer, is to summarize the most relevant knowledge on this particular type of cancer in terms of molecular features, pathogenesis, clinical characteristics, current treatments and the new therapeutic options that include the use of platinum compounds, EGFR antagonists, antiangiogenics and PARP inhibitors.	Platinum	296-304	collagen type XI alpha 2 chain	Homo sapiens	354-358
20224886-1	2010	Membrane proteins of the CTR family mediate cellular copper uptake in all eukaryotic cells and have been shown to participate in uptake of platinum-based anticancer drugs.	Platinum	139-147	calcitonin receptor	Homo sapiens	25-28
19941042-3	2010	Our goal in the current study was to use monocytic cytokine secretion to assess delivery of gold or platinum-based compounds from APT to human THP1 monocytes.	Platinum	100-108	GLI family zinc finger 2	Homo sapiens	143-147
20481911-0	2010	Spin-transfer-torque-assisted domain-wall creep in a Co/Pt multilayer wire.	Platinum	56-58	spindlin 1	Homo sapiens	0-4
20056675-10	2010	CONCLUSIONS: Our data suggest that assessment of survivin and second mitochondria-derived activator of caspase mRNA expression may be useful for predicting survival in non-small cell lung cancer patients receiving platinum-based chemotherapy after surgical resection and can provide valuable information for deciding better therapy strategy.	Platinum	214-222	diablo IAP-binding mitochondrial protein	Homo sapiens	62-110
20104194-1	2010	BACKGROUND: Excision repair cross-complementation group 1 (ERCC1) is a key component of the platinum-DNA repair mechanism.	Platinum	92-100	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	12-57
20104194-1	2010	BACKGROUND: Excision repair cross-complementation group 1 (ERCC1) is a key component of the platinum-DNA repair mechanism.	Platinum	92-100	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	59-64
20104194-14	2010	CONCLUSION: ERCC1 expression in SCLC treated with platinum-based chemotherapy has no impact on survival.	Platinum	50-58	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	12-17
20104194-15	2010	High expression of ERCC1 in TC might represent a clue to the failure of platinum-based therapy in these patients.	Platinum	72-80	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	19-24
20101229-4	2010	p53delta expression was associated with impaired response to primary platinum-based chemotherapy (P=0.032).	Platinum	69-77	tumor protein p53	Homo sapiens	0-3
20677561-1	2010	BACKGROUND AND OBJECTIVE: Results of studies on genetic polymorphisms of ERCC1 gene in DNA repair pathway which may affect response to platinum-based chemotherapy and survival in patients with non-small cell lung cancer are conflicting.	Platinum	135-143	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	73-78
20187069-2	2010	Recent studies have suggested that platinum-based chemotherapy may be of benefit in patients with advanced ovarian cancer prior to cytoreductive surgery (neoadjuvant chemotherapy, NACT).	Platinum	35-43	solute carrier family 13 member 5	Homo sapiens	180-184
20166687-3	2010	Reaction with the hexachloroantimonate(V) salt of tris(4-bromophenyl)aminium (TBPA(+)) results in complex redox chemistry, involving the platinum complex, SbCl(5)(2-) and TBPA(+).	Platinum	137-145	transthyretin	Homo sapiens	78-82
20166687-3	2010	Reaction with the hexachloroantimonate(V) salt of tris(4-bromophenyl)aminium (TBPA(+)) results in complex redox chemistry, involving the platinum complex, SbCl(5)(2-) and TBPA(+).	Platinum	137-145	transthyretin	Homo sapiens	171-175
20220845-5	2010	First, we show evidence for the transfer of spin angular momentum between an insulator magnet Y(3)Fe(5)O(12) and a platinum film.	Platinum	115-123	spindlin 1	Homo sapiens	44-48
20220845-6	2010	This transfer allows direct conversion of an electric current in the platinum film to a spin wave in the Y(3)Fe(5)O(12) via spin-Hall effects.	Platinum	69-77	spindlin 1	Homo sapiens	88-92
20220845-6	2010	This transfer allows direct conversion of an electric current in the platinum film to a spin wave in the Y(3)Fe(5)O(12) via spin-Hall effects.	Platinum	69-77	spindlin 1	Homo sapiens	124-128
20220845-8	2010	Specifically, the applied electric current is converted into spin angular momentum owing to the spin-Hall effect in the first platinum film; the angular momentum is then carried by a spin wave in the insulating Y(3)Fe(5)O(12) layer; at the distant platinum film, the spin angular momentum of the spin wave is converted back to an electric voltage.	Platinum	126-134	spindlin 1	Homo sapiens	61-65
19932554-1	2010	This study investigated the application of ozone in conjunction with Pt/Al(2)O(3) catalysts, called ozone-catalytic oxidation (OZCO) process, to destruct gaseous naphthalene (Nap).	Platinum	69-71	catenin beta like 1	Homo sapiens	175-178
20209131-3	2010	Furthermore, sporadic ovarian cancer patients with low levels of BRCA1 mRNA have longer survival following platinum-based chemotherapy than patients with high levels of BRCA1 mRNA.	Platinum	107-115	BRCA1 DNA repair associated	Homo sapiens	65-70
19642140-0	2010	Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.	Platinum	71-79	mal, T cell differentiation protein	Homo sapiens	9-12
19642140-6	2010	Since MAL transcripts are elevated in tumors from short-term survivors, all of whom were treated with platinum-based therapy, MAL may have a role in cisplatin response.	Platinum	102-110	mal, T cell differentiation protein	Homo sapiens	6-9
19642140-6	2010	Since MAL transcripts are elevated in tumors from short-term survivors, all of whom were treated with platinum-based therapy, MAL may have a role in cisplatin response.	Platinum	102-110	mal, T cell differentiation protein	Homo sapiens	126-129
19642140-9	2010	MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.	Platinum	58-66	mal, T cell differentiation protein	Homo sapiens	0-3
19642140-9	2010	MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer.	Platinum	182-190	mal, T cell differentiation protein	Homo sapiens	85-88
20141128-1	2010	A differentially protected diboron bearing the naphthalene-1,8-diaminato group on one of the two boron atoms undergoes highly regioselective diboration with terminal alkynes in the presence of Pt or Ir catalysts, giving 1-alkene-1,2-diboronic acid derivatives in which the less reactive B(dan) group is located at the terminal position.	Platinum	193-195	NBL1, DAN family BMP antagonist	Homo sapiens	289-292
20220845-8	2010	Specifically, the applied electric current is converted into spin angular momentum owing to the spin-Hall effect in the first platinum film; the angular momentum is then carried by a spin wave in the insulating Y(3)Fe(5)O(12) layer; at the distant platinum film, the spin angular momentum of the spin wave is converted back to an electric voltage.	Platinum	126-134	spindlin 1	Homo sapiens	96-100
20220845-8	2010	Specifically, the applied electric current is converted into spin angular momentum owing to the spin-Hall effect in the first platinum film; the angular momentum is then carried by a spin wave in the insulating Y(3)Fe(5)O(12) layer; at the distant platinum film, the spin angular momentum of the spin wave is converted back to an electric voltage.	Platinum	126-134	spindlin 1	Homo sapiens	96-100
20220845-8	2010	Specifically, the applied electric current is converted into spin angular momentum owing to the spin-Hall effect in the first platinum film; the angular momentum is then carried by a spin wave in the insulating Y(3)Fe(5)O(12) layer; at the distant platinum film, the spin angular momentum of the spin wave is converted back to an electric voltage.	Platinum	126-134	spindlin 1	Homo sapiens	96-100
20220845-8	2010	Specifically, the applied electric current is converted into spin angular momentum owing to the spin-Hall effect in the first platinum film; the angular momentum is then carried by a spin wave in the insulating Y(3)Fe(5)O(12) layer; at the distant platinum film, the spin angular momentum of the spin wave is converted back to an electric voltage.	Platinum	126-134	spindlin 1	Homo sapiens	96-100
20309916-0	2010	Generation of gold nanostructures at the surface of platinum electrode by electrodeposition for ECL detection for CE.	Platinum	52-60	C-C motif chemokine ligand 21	Homo sapiens	96-99
20108943-0	2010	Platinum complexes of eta2-thiophenes.	Platinum	0-8	DNA polymerase iota	Homo sapiens	22-26
19464815-1	2010	PURPOSE: The excision repair cross-complementation 1 (ERCC1) enzyme plays a rate-limiting role in the nucleotide excision repair pathway and is associated with resistance to platinum-based chemotherapy in cancers of the head and neck and the lung.	Platinum	174-182	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	13-52
19464815-1	2010	PURPOSE: The excision repair cross-complementation 1 (ERCC1) enzyme plays a rate-limiting role in the nucleotide excision repair pathway and is associated with resistance to platinum-based chemotherapy in cancers of the head and neck and the lung.	Platinum	174-182	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	54-59
20189873-11	2010	Our results suggested that gene polymorphisms in MDR1G2677T/A may be a predictive marker of platinum-based treatment response and of secondary effects, especially gastrointestinal toxicity for advanced NSCLC patients.	Platinum	92-100	ATP binding cassette subfamily B member 1	Homo sapiens	49-53
22966294-1	2010	Copper-transporting P-type adenosine triphosphatase (ATP7B) is reportedly associated with platinum drug resistance in various solid tumors.	Platinum	90-98	ATPase copper transporting beta	Homo sapiens	53-58
20065949-7	2010	Reexpression of FBXO32 markedly reduced proliferation of a platinum-resistant ovarian cancer cell line both in vitro and in vivo, due to increased apoptosis of the cells, and resensitized ovarian cancer cells to cisplatin.	Platinum	59-67	F-box protein 32	Homo sapiens	16-22
19529937-9	2010	CONCLUSION: The results demonstrate that co-exposure of tumor cells to emodin or DRB with cisplatin inhibits platinum drug uptake by impacting the hCtr1 transporter and, thereby, reduce the cytotoxicity of cisplatin.	Platinum	109-117	solute carrier family 31 member 1	Homo sapiens	147-152
20366900-3	2010	We relate this crossover to the difference in spin-orbit strength of Pt and Pd atoms and suggest that this phenomenon can be used for tuning the origins of the AHE in complex alloys.	Platinum	69-71	spindlin 1	Homo sapiens	46-50
19568750-7	2010	RESULTS: The C--&gt;T change of MRP2 C-24T and the A--&gt;G change of GSTP1 Ile105Val polymorphism significantly increased platinum-based chemotherapy response.	Platinum	123-131	ATP binding cassette subfamily C member 2	Homo sapiens	32-36
19568750-7	2010	RESULTS: The C--&gt;T change of MRP2 C-24T and the A--&gt;G change of GSTP1 Ile105Val polymorphism significantly increased platinum-based chemotherapy response.	Platinum	123-131	glutathione S-transferase pi 1	Homo sapiens	70-75
20103635-0	2010	Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer.	Platinum	53-61	annexin A3	Homo sapiens	24-34
20103635-3	2010	Anti-annexin A3 immunostaining indicated that cancers from platinum-resistant patients also possess higher levels of annexin A3 than those from platinum-sensitive patients.	Platinum	59-67	annexin A3	Homo sapiens	5-15
20103635-3	2010	Anti-annexin A3 immunostaining indicated that cancers from platinum-resistant patients also possess higher levels of annexin A3 than those from platinum-sensitive patients.	Platinum	59-67	annexin A3	Homo sapiens	117-127
20103635-3	2010	Anti-annexin A3 immunostaining indicated that cancers from platinum-resistant patients also possess higher levels of annexin A3 than those from platinum-sensitive patients.	Platinum	144-152	annexin A3	Homo sapiens	5-15
20103635-4	2010	Although expression of annexin A3 made susceptible ovarian cancer cells more resistant to platinum, expression of antisense annexin A3 downregulated its expression and rendered the resistant cells more sensitive to platinum.	Platinum	215-223	annexin A3	Homo sapiens	124-134
20103635-5	2010	In athymic mice, the growth of tumors from inoculated SKOV3 cells was inhibited by the administration of platinum, whereas tumors from annexin A3-expressing SKOV3/Ann were resistant to platinum treatment.	Platinum	185-193	annexin A3	Homo sapiens	135-145
20103635-6	2010	Interestingly, the intracellular platinum concentration and platinum-DNA binding are significantly lower in annexin A3-overexpressing cells than those in parental cells.	Platinum	33-41	annexin A3	Homo sapiens	108-118
20103635-6	2010	Interestingly, the intracellular platinum concentration and platinum-DNA binding are significantly lower in annexin A3-overexpressing cells than those in parental cells.	Platinum	60-68	annexin A3	Homo sapiens	108-118
20103635-8	2010	These results indicate that increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer.	Platinum	81-89	annexin A3	Homo sapiens	52-62
20057026-1	2010	Abnormal gas sensing characteristics are observed at low temperature in uniformly loaded Pt@SnO(2) nanorod gas sensors.	Platinum	89-91	strawberry notch homolog 1	Homo sapiens	92-95
20067471-0	2010	Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).	Platinum	26-34	solute carrier family 22 member 2	Homo sapiens	85-90
20067471-0	2010	Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).	Platinum	26-34	solute carrier family 22 member 2	Homo sapiens	92-100
20067471-4	2010	Here, we define the role of hSLC22A2 (OCT2) in the cellular uptake of platinum compounds.	Platinum	70-78	solute carrier family 22 member 2	Homo sapiens	28-36
20067471-4	2010	Here, we define the role of hSLC22A2 (OCT2) in the cellular uptake of platinum compounds.	Platinum	70-78	solute carrier family 22 member 2	Homo sapiens	38-42
20067471-5	2010	EXPERIMENTAL APPROACH: Human embryonic kidney (HEK) 293 cells stably expressing the hSLC22A2 gene (HEK293/hSLC22A2) were used in platinum accumulation studies.	Platinum	129-137	solute carrier family 22 member 2	Homo sapiens	84-92
20067471-12	2010	CONCLUSIONS AND IMPLICATIONS: The hSLC22A2 drug transporter is a critical determinant in the uptake and cytotoxicity of various platinum compounds, particularly oxaliplatin.	Platinum	128-136	solute carrier family 22 member 2	Homo sapiens	34-42
19568750-2	2010	We hypothesize that genetic polymorphisms in metabolising enzymes gene GSTP1 (glutathione S-transferase P1), and MRP2 (multidrug resistance-associated protein 2) (ABCC2), which result in inter-individual differences in metabolism and drug disposition, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients.	Platinum	285-293	glutathione S-transferase pi 1	Homo sapiens	71-76
19568750-2	2010	We hypothesize that genetic polymorphisms in metabolising enzymes gene GSTP1 (glutathione S-transferase P1), and MRP2 (multidrug resistance-associated protein 2) (ABCC2), which result in inter-individual differences in metabolism and drug disposition, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients.	Platinum	285-293	glutathione S-transferase pi 1	Homo sapiens	78-106
19690855-0	2010	A phase II trial of intraperitoneal interleukin-2 in patients  with platinum-resistant or platinum-refractory ovarian cancer.	Platinum	68-76	interleukin 2	Homo sapiens	36-49
19568750-2	2010	We hypothesize that genetic polymorphisms in metabolising enzymes gene GSTP1 (glutathione S-transferase P1), and MRP2 (multidrug resistance-associated protein 2) (ABCC2), which result in inter-individual differences in metabolism and drug disposition, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients.	Platinum	285-293	ATP binding cassette subfamily C member 2	Homo sapiens	113-117
19568750-2	2010	We hypothesize that genetic polymorphisms in metabolising enzymes gene GSTP1 (glutathione S-transferase P1), and MRP2 (multidrug resistance-associated protein 2) (ABCC2), which result in inter-individual differences in metabolism and drug disposition, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients.	Platinum	285-293	ATP binding cassette subfamily C member 2	Homo sapiens	119-160
19568750-2	2010	We hypothesize that genetic polymorphisms in metabolising enzymes gene GSTP1 (glutathione S-transferase P1), and MRP2 (multidrug resistance-associated protein 2) (ABCC2), which result in inter-individual differences in metabolism and drug disposition, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients.	Platinum	285-293	ATP binding cassette subfamily C member 2	Homo sapiens	163-168
19880164-3	2010	Here, we report long term follow-up of a group of patients with platinum-sensitive AOC who were treated with IL-2 and RA.	Platinum	64-72	interleukin 2	Homo sapiens	109-120
19922504-1	2010	Glutathione S-transferase P1 (GSTP1) participates in detoxification of potentially genotoxic compounds that may alter the efficacy and toxicity of platinum-based chemotherapy.	Platinum	147-155	glutathione S-transferase pi 1	Homo sapiens	0-28
19922504-1	2010	Glutathione S-transferase P1 (GSTP1) participates in detoxification of potentially genotoxic compounds that may alter the efficacy and toxicity of platinum-based chemotherapy.	Platinum	147-155	glutathione S-transferase pi 1	Homo sapiens	30-35
20181021-3	2010	A phase III trial (EXTREME) showed that adding the epidermal growth factor receptor (EGFR)-targeting IgG1 monoclonal antibody cetuximab to first-line platinum-based chemotherapy significantly prolongs progression-free and overall survival and increases response rate compared with platinum-based chemotherapy alone.	Platinum	150-158	epidermal growth factor receptor	Homo sapiens	51-83
20181021-3	2010	A phase III trial (EXTREME) showed that adding the epidermal growth factor receptor (EGFR)-targeting IgG1 monoclonal antibody cetuximab to first-line platinum-based chemotherapy significantly prolongs progression-free and overall survival and increases response rate compared with platinum-based chemotherapy alone.	Platinum	150-158	epidermal growth factor receptor	Homo sapiens	85-89
20181021-3	2010	A phase III trial (EXTREME) showed that adding the epidermal growth factor receptor (EGFR)-targeting IgG1 monoclonal antibody cetuximab to first-line platinum-based chemotherapy significantly prolongs progression-free and overall survival and increases response rate compared with platinum-based chemotherapy alone.	Platinum	281-289	epidermal growth factor receptor	Homo sapiens	51-83
20181021-3	2010	A phase III trial (EXTREME) showed that adding the epidermal growth factor receptor (EGFR)-targeting IgG1 monoclonal antibody cetuximab to first-line platinum-based chemotherapy significantly prolongs progression-free and overall survival and increases response rate compared with platinum-based chemotherapy alone.	Platinum	281-289	epidermal growth factor receptor	Homo sapiens	85-89
19889624-7	2010	However, PKR gene silencing or treatment with a specific PKR inhibitor significantly prevented the increase in pT(451)-PKR and pS(194)-FADD levels in SH-SY5Y nuclei and completely inhibited activities of caspase-3 and -8.	Platinum	111-113	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	9-12
19736245-9	2010	Direct inhibition of OCTN2 expressed in L6 cells by cisplatin, oxaliplatin or platinum(2+) could not be demonstrated, and experiments using urine from patients treated with cisplatin inhibited OCTN2 activity no more than expected from the carnitine content in the respective urine sample.	Platinum	78-86	solute carrier family 22 member 5	Homo sapiens	21-26
19889624-7	2010	However, PKR gene silencing or treatment with a specific PKR inhibitor significantly prevented the increase in pT(451)-PKR and pS(194)-FADD levels in SH-SY5Y nuclei and completely inhibited activities of caspase-3 and -8.	Platinum	111-113	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	57-60
19889624-7	2010	However, PKR gene silencing or treatment with a specific PKR inhibitor significantly prevented the increase in pT(451)-PKR and pS(194)-FADD levels in SH-SY5Y nuclei and completely inhibited activities of caspase-3 and -8.	Platinum	111-113	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	57-60
20013993-5	2010	The first oxidation of the highly electron-rich [(P2)Pt(dddt)] complex can be unambiguously assigned to the redox process affecting the Pt(dddt) moiety rather than the TTF core, a rare example in the coordination chemistry of tetrathiafulvalenes acting as ligands.	Platinum	53-55	ras homolog family member H	Homo sapiens	168-171
20593954-1	2010	BACKGROUND: Association of excision repair cross-complementing gene 1 (ERCC1) expression and treatment response and survival was evaluated in advanced stages of gastric cancer patients who were given different platinum-based chemotherapy.	Platinum	210-218	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	27-69
20356529-1	2010	OBJECTIVE: To study the expression of NASP in platinum resistance ovarian cancer cell clones (C0C1/DDP).	Platinum	46-54	nuclear autoantigenic sperm protein	Homo sapiens	38-42
20356529-1	2010	OBJECTIVE: To study the expression of NASP in platinum resistance ovarian cancer cell clones (C0C1/DDP).	Platinum	46-54	translocase of inner mitochondrial membrane 8A	Homo sapiens	94-102
20356529-5	2010	CONCLUSION: The identification of NASP in C0C1/DDP has laid a foundation for future in-depth researches into the mechanisms of ovarian cancer platinum resistance.	Platinum	142-150	nuclear autoantigenic sperm protein	Homo sapiens	34-38
20356529-5	2010	CONCLUSION: The identification of NASP in C0C1/DDP has laid a foundation for future in-depth researches into the mechanisms of ovarian cancer platinum resistance.	Platinum	142-150	translocase of inner mitochondrial membrane 8A	Homo sapiens	47-50
20494871-2	2010	Among the several candidate genes that have been proposed, many retrospective studies have indicated excision repair cross-complementing 1 (ERCC1), an endonuclease responsible for the repair of DNA damages, as a reliable biomarker of tumor sensitivity to platinum-based agents.	Platinum	255-263	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	101-138
20494871-2	2010	Among the several candidate genes that have been proposed, many retrospective studies have indicated excision repair cross-complementing 1 (ERCC1), an endonuclease responsible for the repair of DNA damages, as a reliable biomarker of tumor sensitivity to platinum-based agents.	Platinum	255-263	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	140-145
20593954-1	2010	BACKGROUND: Association of excision repair cross-complementing gene 1 (ERCC1) expression and treatment response and survival was evaluated in advanced stages of gastric cancer patients who were given different platinum-based chemotherapy.	Platinum	210-218	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	71-76
20593954-5	2010	Although the clinical benefit from platin based chemotherapy was the same for ERCC1 positive and negative patients, survival times were statistically significantly better in ERCC1 negative gastric cancer patients.	Platinum	35-41	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	78-83
20593954-6	2010	CONCLUSION: We suggest that IHC studies for ERCC1 may be useful in prediction of the clinical outcome of advanced gastric cancer patients treated with platin-based chemotherapy.	Platinum	151-157	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	44-49
20631827-2	2010	The last complex is, to the best of our knowledge, the first dinuclear compound of platinum(III) with axially bound 1-MeC.	Platinum	83-91	C-C motif chemokine ligand 28	Homo sapiens	118-121
19896793-7	2010	Since cisplatin-induced nephrotoxicity can be mediated by a glutathione-platinum conjugate catalyzed by gamma-glutamyl-transpeptidase (GGT) and glutathione is an endogenous substrate of GGT, the protective effect of NOV-002 in the kidney may be attributed to its ability to act as a competitive substrate for the enzyme.	Platinum	72-80	gamma-glutamyltransferase 1	Mus musculus	104-133
19896793-7	2010	Since cisplatin-induced nephrotoxicity can be mediated by a glutathione-platinum conjugate catalyzed by gamma-glutamyl-transpeptidase (GGT) and glutathione is an endogenous substrate of GGT, the protective effect of NOV-002 in the kidney may be attributed to its ability to act as a competitive substrate for the enzyme.	Platinum	72-80	gamma-glutamyltransferase 1	Mus musculus	135-138
19896793-7	2010	Since cisplatin-induced nephrotoxicity can be mediated by a glutathione-platinum conjugate catalyzed by gamma-glutamyl-transpeptidase (GGT) and glutathione is an endogenous substrate of GGT, the protective effect of NOV-002 in the kidney may be attributed to its ability to act as a competitive substrate for the enzyme.	Platinum	72-80	gamma-glutamyltransferase 1	Mus musculus	186-189
20693797-1	2010	The monoclonal epidermal growth factor receptor (EGFR) antibody cetuximab (Erbitux) was recently approved by the European Medicines Agency for the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in combination with a platinum-based chemotherapy.	Platinum	256-264	epidermal growth factor receptor	Homo sapiens	15-47
20693797-1	2010	The monoclonal epidermal growth factor receptor (EGFR) antibody cetuximab (Erbitux) was recently approved by the European Medicines Agency for the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in combination with a platinum-based chemotherapy.	Platinum	256-264	epidermal growth factor receptor	Homo sapiens	49-53
23136592-9	2010	The patient survival period of MGMT-positive glioblastomas treated with the platinum agents or the taxanes [median survival, 20.1 months (95% CI, 18.0-22.7)] was significantly longer than that of MGMT-positive tumors treated with nitrosoureas (p=0.0026), and was equivalent to that of MGMT-negative glioblastomas (p=0.3047).	Platinum	76-84	O-6-methylguanine-DNA methyltransferase	Homo sapiens	31-35
20164691-9	2010	TNBC is itself a heterogeneous group in which subgroups such as BRCA1 mutation carriers may have particular sensitivity to platinum agents and relatively less sensitivity to taxanes.	Platinum	123-131	BRCA1 DNA repair associated	Homo sapiens	64-69
20645920-2	2010	MRP1-5 can collectively confer resistance to natural product anticancer drugs and their conjugated metabolites, platinum compounds, folate antimetabolites, nucleoside and nucleotide analogs, and alkylating agents.	Platinum	112-120	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	0-4
23136592-10	2010	These results suggest that the platinum agents and the taxanes offer the best probability to be effective against immunohistochemically MGMT-positive glioblastomas.	Platinum	31-39	O-6-methylguanine-DNA methyltransferase	Homo sapiens	136-140
23136600-7	2010	The status of hMLH1 predicts the sensitivity of head and neck squamous cell carcinoma to platinum-based chemotherapy.	Platinum	89-97	mutL homolog 1	Homo sapiens	14-19
19830698-9	2010	These data support a role for FAU in the regulation of platinum-resistance in ovarian cancer.	Platinum	55-63	FAU ubiquitin like and ribosomal protein S30 fusion	Homo sapiens	30-33
19536777-8	2010	A second-line therapy with a gemcitabine/platinum combination regimen resulted in better overall survival than erlotinib in patients with EGFR mutations (p = 0.035) but not in patients with wild-type EGFR (p = 0.785).	Platinum	41-49	epidermal growth factor receptor	Homo sapiens	138-142
19536777-10	2010	The survival benefit of platinum-based combination regimens existed in patients with mutant EGFR but not wild-type EGFR.	Platinum	24-32	epidermal growth factor receptor	Homo sapiens	92-96
19854294-2	2010	Our explorative pathway analysis on seven published gene-sets associated with platinum resistance in ovarian cancer reveals TP53 and transforming growth factor beta as key genes.	Platinum	78-86	tumor protein p53	Homo sapiens	124-128
20377136-11	2010	While there is uncertainty about the potential involvement of CYP1A1 in the metabolism of platinum-containing agents, our findings suggest an association between the 462Val allele and the development of platinum resistance in ovarian tumors.	Platinum	90-98	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	62-68
19854294-2	2010	Our explorative pathway analysis on seven published gene-sets associated with platinum resistance in ovarian cancer reveals TP53 and transforming growth factor beta as key genes.	Platinum	78-86	transforming growth factor beta 1	Homo sapiens	133-164
19609560-2	2010	The objective of this study was to explore the value of the p53 mutational status, using four different techniques, in advanced OC patients as a predictive marker for responsiveness to platinum-based chemotherapy.	Platinum	185-193	tumor protein p53	Homo sapiens	60-63
21072377-4	2010	Human hCtr1 contains two methionine-rich Mets motifs on its extracellular N-terminus that are potential platinum-binding sites: the first one encompasses residues 7-14 with amino acid sequence Met-Gly-Met-Ser-Tyr-Met-Asp-Ser and the second one spans residues 39-46 with sequence Met-Met-Met-Met-Pro-Met-Thr-Phe.	Platinum	104-112	solute carrier family 31 member 1	Homo sapiens	6-11
19361884-2	2010	Two polymorphisms of ERCC1, T19007C (rs11615) and C8092A (rs3212986), have been reported to affect both the carcinogenesis and the survival of the patients who received platinum-based chemotherapy, but the mechanism by which these polymorphisms influence the survival is unclear.	Platinum	169-177	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	21-26
20017497-0	2010	Reducing stress on cells with apoferritin-encapsulated platinum nanoparticles.	Platinum	55-63	ferritin heavy chain 1	Homo sapiens	30-41
20017497-2	2010	To enable an uptake of such nanoparticles by cells without harming their membranes, platinum nanoparticles were synthesized within cavities of hollow protein nanospheres (apoferritin).	Platinum	84-92	ferritin heavy chain 1	Homo sapiens	171-182
20025464-0	2010	DNA damage and p53-mediated growth arrest in human cells treated with platinum nanoparticles.	Platinum	70-78	tumor protein p53	Homo sapiens	15-18
20377136-11	2010	While there is uncertainty about the potential involvement of CYP1A1 in the metabolism of platinum-containing agents, our findings suggest an association between the 462Val allele and the development of platinum resistance in ovarian tumors.	Platinum	203-211	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	62-68
20017670-4	2010	As GSTs participate in the metabolism of platinum metabolites, we also assessed the association between genetic variants in GST genes and survival of colorectal cancer patients who received treatment with oxaliplatin.	Platinum	41-49	glutathione S-transferase mu 1	Homo sapiens	3-7
22163553-1	2010	A novel potential treatment technique applied to a glucose biosensor that is based on pyrroloquinoline quinone (PQQ)-dependent glucose dehydrogenase (GDH) and chromium hexacyanoferrate (CrHCF) incorporated into a platinum (Pt) electrode was demonstrated.	Platinum	213-221	hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	Homo sapiens	127-148
22163553-1	2010	A novel potential treatment technique applied to a glucose biosensor that is based on pyrroloquinoline quinone (PQQ)-dependent glucose dehydrogenase (GDH) and chromium hexacyanoferrate (CrHCF) incorporated into a platinum (Pt) electrode was demonstrated.	Platinum	213-221	hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	Homo sapiens	150-153
22163553-1	2010	A novel potential treatment technique applied to a glucose biosensor that is based on pyrroloquinoline quinone (PQQ)-dependent glucose dehydrogenase (GDH) and chromium hexacyanoferrate (CrHCF) incorporated into a platinum (Pt) electrode was demonstrated.	Platinum	223-225	hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	Homo sapiens	127-148
22163553-1	2010	A novel potential treatment technique applied to a glucose biosensor that is based on pyrroloquinoline quinone (PQQ)-dependent glucose dehydrogenase (GDH) and chromium hexacyanoferrate (CrHCF) incorporated into a platinum (Pt) electrode was demonstrated.	Platinum	223-225	hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	Homo sapiens	150-153
22163559-5	2010	Further optimization showed that fabrication of Pt(C)/PoPD-GOx in the absence of added background electrolyte (i.e., electropolymerization in unbuffered enzyme-monomer solution) enhanced glucose selectivity 3-fold for this one-pot fabrication protocol which provided AA-rejection levels at least equal to recent multi-step polymer bilayer biosensor designs.	Platinum	48-50	hydroxyacid oxidase 1	Homo sapiens	59-62
22163564-1	2010	This study is an investigation of high-humidity aging effects on the total volatile organic compound (T-VOC) gas-sensing properties of platinum, palladium, and gold-loaded tin oxide (Pt,Pd,Au/SnO(2)) thick films.	Platinum	135-143	strawberry notch homolog 1	Homo sapiens	192-195
22163564-3	2010	The high-humidity aging is an effective treatment for resistance to humidity change for the Pt,Pd,Au/SnO(2) but not effective for the Pt/SnO(2).	Platinum	92-94	strawberry notch homolog 1	Homo sapiens	101-104
19709902-7	2009	Our results show that IL-21 therapy can be successfully combined with agents from different chemotherapeutic drug classes, i.e. topoisomerase II inhibitors (PLD), anti-metabolites (5-FU) and platinum analogs (oxaliplatin) provided that IL-21 therapy is delayed relative to chemotherapy.	Platinum	191-199	interleukin 21	Mus musculus	22-27
20008850-3	2009	Patients with sensitizing somatic mutations of EGFR treated with gefitinib or erlotinib have an initial clinical response of 60 to 80%, approximately twice as high as the responses associated with the administration of conventional platinum-based chemotherapy.	Platinum	232-240	epidermal growth factor receptor	Homo sapiens	47-51
20948186-9	2010	RESULTS: Analysis of variance always showed highly significant different PSA distributions for (1) the different PSA/FT, pT and pG groups; and (2) the pT and pG prognostic subgroups.	Platinum	121-123	aminopeptidase puromycin sensitive	Homo sapiens	73-76
19943199-7	2009	Targeting HMGB1 using platinum-containing compounds, ethyl pyruvate or glycyrrhizin has also been used to limit autophagy.	Platinum	22-30	high mobility group box 1	Homo sapiens	10-15
19304340-4	2009	This study was to investigate the relationship between polymorphisms of the RRM1 gene and sensitivity to platinum-based chemotherapy in non-small cell lung cancer (NSCLC).	Platinum	105-113	ribonucleotide reductase catalytic subunit M1	Homo sapiens	76-80
20021611-1	2009	It was recently reported that expression of excision repair cross-complementation group 1 (ERCC1), a DNA repair protein, predicts sensitivity to platinum-based chemotherapy drugs.	Platinum	145-153	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	44-89
20021611-1	2009	It was recently reported that expression of excision repair cross-complementation group 1 (ERCC1), a DNA repair protein, predicts sensitivity to platinum-based chemotherapy drugs.	Platinum	145-153	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	91-96
19815704-4	2009	Interestingly, GGH is a protein associated with methotrexate resistance, whereas emmprin, survivin, and DBI had been previously identified as predictors of outcome after platinum-containing chemotherapeutic regimens when assessed on tumor tissue.	Platinum	170-178	basigin (Ok blood group)	Homo sapiens	81-88
19598262-7	2009	Intracellular platinum levels were significantly lower in Anx A4-transfected cells compared with control cells after carboplatin treatment (p = 0.0020) and after an additional 360 min of carboplatin-free incubation (p = 0.0004), as measured by atomic absorption spectrophotometry.	Platinum	14-22	annexin A4	Felis catus	58-64
19815704-4	2009	Interestingly, GGH is a protein associated with methotrexate resistance, whereas emmprin, survivin, and DBI had been previously identified as predictors of outcome after platinum-containing chemotherapeutic regimens when assessed on tumor tissue.	Platinum	170-178	diazepam binding inhibitor, acyl-CoA binding protein	Homo sapiens	104-107
19540211-4	2009	Imatinib markedly reduced cisplatin-induced cytotoxicity and platinum accumulation in OCT2-expressing HEK293 cells, but almost no change was found in the cells expressing human MATE1, MATE2-K and rat MATE1.	Platinum	61-69	solute carrier family 22 member 2	Homo sapiens	86-90
19549713-1	2009	BACKGROUND: Nasopharyngeal carcinoma (NPC) is a platinum-sensitive cancer and excision repair cross-complementing group 1 (ERCC1) polymorphisms have been shown to predict survival in several cancers following platinum therapy.	Platinum	48-56	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	123-128
19549713-1	2009	BACKGROUND: Nasopharyngeal carcinoma (NPC) is a platinum-sensitive cancer and excision repair cross-complementing group 1 (ERCC1) polymorphisms have been shown to predict survival in several cancers following platinum therapy.	Platinum	209-217	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	78-121
19549713-1	2009	BACKGROUND: Nasopharyngeal carcinoma (NPC) is a platinum-sensitive cancer and excision repair cross-complementing group 1 (ERCC1) polymorphisms have been shown to predict survival in several cancers following platinum therapy.	Platinum	209-217	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	123-128
19779927-2	2009	The employed enzymes pyrroloquinoline quinone-dependent glucose dehydrogenase (PQQ-GDH) and hexokinase were entrapped, using pH-shift-induced precipitation of electrodeposition paint (EDP) at platinum microelectrodes (diameter of 25 microm).	Platinum	192-200	hexokinase 1	Homo sapiens	92-102
20032415-0	2009	The Akt and ERK activation by platinum-based chemotherapy in ovarian cancer is associated with favorable patient outcome.	Platinum	30-38	AKT serine/threonine kinase 1	Homo sapiens	4-7
20032415-0	2009	The Akt and ERK activation by platinum-based chemotherapy in ovarian cancer is associated with favorable patient outcome.	Platinum	30-38	mitogen-activated protein kinase 1	Homo sapiens	12-15
19888874-1	2009	BACKGROUND: In recent years, JM-216/satraplatin (GPC Biotech, Inc.) has emerged as a novel oral platinum analogue with a better toxicity profile than cisplatin.	Platinum	96-104	glycophorin C (Gerbich blood group)	Homo sapiens	49-52
19070448-2	2009	This study was designed to examine the interaction between the platinum-based anticancer drug, oxaliplatin, with human serum albumin (HSA) in aqueous solution at physiological pH with drug concentrations of 10 to 100 microM and a constant concentration of HSA (5.0 x 10(-5)M).	Platinum	63-71	albumin	Homo sapiens	125-132
19669174-0	2009	Reactivity of platinum-based antitumor drugs towards a Met- and His-rich 20mer peptide corresponding to the N-terminal domain of human copper transporter 1.	Platinum	14-22	solute carrier family 31 member 1	Homo sapiens	135-155
19669174-2	2009	Human copper transporter 1 (hCtr1), a copper influx protein, was recently found to facilitate the cellular entry of several platinum drugs.	Platinum	124-132	solute carrier family 31 member 1	Homo sapiens	6-26
19669174-2	2009	Human copper transporter 1 (hCtr1), a copper influx protein, was recently found to facilitate the cellular entry of several platinum drugs.	Platinum	124-132	solute carrier family 31 member 1	Homo sapiens	28-33
19787261-5	2009	Altered levels and subcellular APE1/Ref-1 expression was found in patients not responding to platinum-based chemotherapy comparing with those who responded to platinum-based chemotherapy.	Platinum	93-101	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	31-35
19787261-5	2009	Altered levels and subcellular APE1/Ref-1 expression was found in patients not responding to platinum-based chemotherapy comparing with those who responded to platinum-based chemotherapy.	Platinum	93-101	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	36-41
19787261-5	2009	Altered levels and subcellular APE1/Ref-1 expression was found in patients not responding to platinum-based chemotherapy comparing with those who responded to platinum-based chemotherapy.	Platinum	159-167	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	31-35
19787261-5	2009	Altered levels and subcellular APE1/Ref-1 expression was found in patients not responding to platinum-based chemotherapy comparing with those who responded to platinum-based chemotherapy.	Platinum	159-167	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	36-41
19775102-8	2009	Platinum uptake on PC-3 cells was 12-fold more for conjugate 7 and 3-fold more for conjugate 8 compared to that of the untargeted carboplatin, indicating selective activation of the CD13 receptors and delivery of the conjugates to CD13 positive cells.	Platinum	0-8	alanyl aminopeptidase, membrane	Homo sapiens	182-186
21475936-6	2009	Stromal expression of TOP2A increased in recurrent OvCa after platinum-based chemotherapy.	Platinum	62-70	DNA topoisomerase II alpha	Homo sapiens	22-27
21475919-10	2009	In conclusion, low ERCC1 levels were associated with platinum drug sensitivity in ESCC cell lines.	Platinum	53-61	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	19-24
19775102-8	2009	Platinum uptake on PC-3 cells was 12-fold more for conjugate 7 and 3-fold more for conjugate 8 compared to that of the untargeted carboplatin, indicating selective activation of the CD13 receptors and delivery of the conjugates to CD13 positive cells.	Platinum	0-8	alanyl aminopeptidase, membrane	Homo sapiens	231-235
19825178-4	2009	Enhanced sensitivity to platinum-based anticancer drugs has been related to BRCA1/2 functional loss.	Platinum	24-32	BRCA1 DNA repair associated	Homo sapiens	76-83
19755991-7	2009	HLA class I antigen was shown to be expressed at higher levels in patients with good overall survival in platinum-resistant patients (P=0.042).	Platinum	105-113	MHC class I polypeptide-related sequence A	Homo sapiens	0-19
19807176-2	2009	We have determined two crystal structures of cisplatin-Atox1 adducts that reveal platinum coordination by the conserved CXXC copper-binding motif.	Platinum	81-89	antioxidant 1 copper chaperone	Homo sapiens	55-60
19825178-5	2009	Retrospective studies disclosed differential chemosensitivity profiles of BRCA1/2-related as compared to "sporadic" ovarian cancer and led to the identification of a "BRCA-ness" phenotype of ovarian cancer, which includes inherited BRCA1/2 germ-line mutations, a serous high grade histology highly sensitive to platinum derivatives.	Platinum	311-319	BRCA1 DNA repair associated	Homo sapiens	74-79
19825178-5	2009	Retrospective studies disclosed differential chemosensitivity profiles of BRCA1/2-related as compared to "sporadic" ovarian cancer and led to the identification of a "BRCA-ness" phenotype of ovarian cancer, which includes inherited BRCA1/2 germ-line mutations, a serous high grade histology highly sensitive to platinum derivatives.	Platinum	311-319	BRCA1 DNA repair associated	Homo sapiens	74-81
19846981-5	2009	However, the platinum-sensitive subgroup by ATP-CRA showed a higher response rate than the empirical group (71 versus 38%; p=0.023) with a trend toward longer progression-free survival (8.7 versus 4.8 months for platinum-sensitive versus empirical; p=0.223) and overall survival (not reached versus 12.6 months for platinum-sensitive versus empirical for p=0.134).	Platinum	13-21	myotubularin related protein 11	Homo sapiens	48-51
19846981-5	2009	However, the platinum-sensitive subgroup by ATP-CRA showed a higher response rate than the empirical group (71 versus 38%; p=0.023) with a trend toward longer progression-free survival (8.7 versus 4.8 months for platinum-sensitive versus empirical; p=0.223) and overall survival (not reached versus 12.6 months for platinum-sensitive versus empirical for p=0.134).	Platinum	212-220	myotubularin related protein 11	Homo sapiens	48-51
19846981-5	2009	However, the platinum-sensitive subgroup by ATP-CRA showed a higher response rate than the empirical group (71 versus 38%; p=0.023) with a trend toward longer progression-free survival (8.7 versus 4.8 months for platinum-sensitive versus empirical; p=0.223) and overall survival (not reached versus 12.6 months for platinum-sensitive versus empirical for p=0.134).	Platinum	212-220	myotubularin related protein 11	Homo sapiens	48-51
19846981-6	2009	CONCLUSION: ATP-CRA may be helpful in selecting platinum-responsive patients in unresectable NSCLC.	Platinum	48-56	myotubularin related protein 11	Homo sapiens	16-19
19846981-7	2009	We consider that nonplatinum doublets in platinum-resistant patients by ATP-CRA may be a more adapted approach than platinum-based doublets in future clinical trials.	Platinum	20-28	myotubularin related protein 11	Homo sapiens	76-79
19846981-7	2009	We consider that nonplatinum doublets in platinum-resistant patients by ATP-CRA may be a more adapted approach than platinum-based doublets in future clinical trials.	Platinum	41-49	myotubularin related protein 11	Homo sapiens	76-79
19504048-0	2009	Biological synthesis of platinum nanoparticles with apoferritin.	Platinum	24-32	ferritin heavy chain	Equus caballus	52-63
19504048-1	2009	A novel biological method for the synthesis of platinum nanoparticles using the horse spleen apoferritin (HSAF) is reported.	Platinum	47-55	ferritin heavy chain	Equus caballus	93-104
19504048-3	2009	As the initial platinum concentration increased through 0.155, 0.31, 0.465 to 0.62 mM the efficiency of its removal from solution by the apoferritin was 99, 99, 84 and 71% respectively.	Platinum	15-23	ferritin heavy chain	Equus caballus	137-148
19741569-10	2009	Failure, after platinum-based chemotherapy, was associated with the GSTT1positive/GSTP-AA or GSTP-GG/GSTM1-positive genotype (P = 0.019, OR: 2.168, 95% CI: 1.130-4.160).	Platinum	15-23	glutathione S-transferase theta 1	Homo sapiens	68-73
19548140-1	2009	The aim was to determine whether promoter methylation of BRCA1, MGMT, MLH1, RASSF1A, and p16 genes could predict response to platinum-based chemotherapy.	Platinum	125-133	BRCA1 DNA repair associated	Homo sapiens	57-62
19548140-1	2009	The aim was to determine whether promoter methylation of BRCA1, MGMT, MLH1, RASSF1A, and p16 genes could predict response to platinum-based chemotherapy.	Platinum	125-133	O-6-methylguanine-DNA methyltransferase	Homo sapiens	64-68
19548140-1	2009	The aim was to determine whether promoter methylation of BRCA1, MGMT, MLH1, RASSF1A, and p16 genes could predict response to platinum-based chemotherapy.	Platinum	125-133	mutL homolog 1	Homo sapiens	70-74
19548140-1	2009	The aim was to determine whether promoter methylation of BRCA1, MGMT, MLH1, RASSF1A, and p16 genes could predict response to platinum-based chemotherapy.	Platinum	125-133	Ras association domain family member 1	Homo sapiens	76-83
19548140-1	2009	The aim was to determine whether promoter methylation of BRCA1, MGMT, MLH1, RASSF1A, and p16 genes could predict response to platinum-based chemotherapy.	Platinum	125-133	cyclin dependent kinase inhibitor 2A	Homo sapiens	89-92
19548140-4	2009	Response to platinum-based chemotherapy was documented clinically, radiologically, and by serial CA125 levels.	Platinum	12-20	mucin 16, cell surface associated	Homo sapiens	97-102
19570948-2	2009	hCtr1 is involved in the transport of platinum-based antitumor agents such as cisplatin (CDDP); however, the mechanisms that regulate hCtr1-mediated transport of these agents have not been well elucidated.	Platinum	38-46	solute carrier family 31 member 1	Homo sapiens	0-5
19724867-10	2009	These observations support the hypothesis that ASNA1 is a target to overcome platinum resistance in ovarian cancer.	Platinum	77-85	guided entry of tail-anchored proteins factor 3, ATPase	Homo sapiens	47-52
19342173-2	2009	In this study, the effect of anthraquinone-2,6-disulfonate (AQDS) bound into polypyrrole (PPy) on activated carbon felt (ACF) on anaerobic biodecolorization of azo dyes was investigated and compared with that immobilized on platinum (Pt).	Platinum	224-232	ACF	Homo sapiens	121-124
19805294-6	2009	A tendency toward shorter progression-free survival was observed in CD133+ NSCLC patients treated with platinum-containing regimens.	Platinum	103-111	prominin 1	Homo sapiens	68-73
19702329-0	2009	Pt-catalyzed enantioselective diboration of terminal alkenes with B2(pin)2.	Platinum	0-2	telomeric repeat binding factor 1	Homo sapiens	66-74
19713747-1	2009	Translesion synthesis by DNA polymerase eta (poleta) is one mechanism by which cancer cells can tolerate DNA damage by platinum-based anti-cancer drugs.	Platinum	119-127	DNA polymerase eta	Homo sapiens	25-43
19713747-5	2009	Compared to Chk1 and H2AX phosphorylation, RPA2 hyperphosphorylation on serine4/serine8 is a late event in response to platinum-induced DNA damage.	Platinum	119-127	replication protein A2	Homo sapiens	43-47
19655350-3	2009	Some important changes that occurred in the [(1)H,(13)C] HSQC NMR spectrum of cytochrome c treated with trans-[PtCl(2)(dma)(ma)] in water, after two days" incubation, most probably arose from direct platinum coordination to the protein side chain; this was proved conclusively by [(1)H,(1)H] NOESY NMR and [(1)H,(15)N] HSQC NMR measurements.	Platinum	199-207	LOC104968582	Bos taurus	78-90
19533750-6	2009	ASS1 silencing conferred selective resistance to platinum-based drugs and conferred arginine auxotrophy and sensitivity to arginine deprivation.	Platinum	49-57	argininosuccinate synthase 1	Homo sapiens	0-4
19533750-2	2009	Down-regulation of expression of argininosuccinate synthetase (ASS1), the rate-limiting enzyme in the biosynthesis of arginine, has been associated with the development of platinum resistance in ovarian cancer treated with platinum-based chemotherapy.	Platinum	172-180	argininosuccinate synthase 1	Homo sapiens	63-67
19533750-2	2009	Down-regulation of expression of argininosuccinate synthetase (ASS1), the rate-limiting enzyme in the biosynthesis of arginine, has been associated with the development of platinum resistance in ovarian cancer treated with platinum-based chemotherapy.	Platinum	223-231	argininosuccinate synthase 1	Homo sapiens	63-67
19655350-4	2009	Met65 was identified as the primary Pt binding site on cytochrome c.	Platinum	36-38	LOC104968582	Bos taurus	55-67
19466412-1	2009	PURPOSE: We report the neuronal expression of copper transporter 1 (CTR1) in rat dorsal root ganglia (DRG) and its association with the neurotoxicity of platinum-based drugs.	Platinum	153-161	solute carrier family 31 member 1	Rattus norvegicus	46-66
19658426-0	2009	Platinum(II) and palladium(II) complexes of chiral P-Cl functionalized bis-phosphino ortho-carbaboranes.	Platinum	0-8	polycystin 2 like 1, transient receptor potential cation channel	Homo sapiens	51-55
19745547-1	2009	Poly(dimethylsiloxane) (PDMS)-coated platinum electrodes modified with glucose oxidase (GOx) have been prepared from poly(L-lysine) (polymer backbone), glutaraldehyde (cross-linking agent) and poly(ethylene glycol) units.	Platinum	37-45	hydroxyacid oxidase 1	Homo sapiens	71-86
19745547-1	2009	Poly(dimethylsiloxane) (PDMS)-coated platinum electrodes modified with glucose oxidase (GOx) have been prepared from poly(L-lysine) (polymer backbone), glutaraldehyde (cross-linking agent) and poly(ethylene glycol) units.	Platinum	37-45	hydroxyacid oxidase 1	Homo sapiens	88-91
18571892-5	2009	Acquisition of platinum resistance in human ovarian cancer cells thus appeared to be related mainly to the expression of gamma-glutamylcysteine synthetase (gamma-GCS), topo II and metallothionein (hMT) genes, and partly to that of topo I and glutathione S-transferase--pi (GST-pi) genes, in addition to a decrease in platinum accumulation.	Platinum	15-23	glutamate-cysteine ligase catalytic subunit	Homo sapiens	121-154
18571892-5	2009	Acquisition of platinum resistance in human ovarian cancer cells thus appeared to be related mainly to the expression of gamma-glutamylcysteine synthetase (gamma-GCS), topo II and metallothionein (hMT) genes, and partly to that of topo I and glutathione S-transferase--pi (GST-pi) genes, in addition to a decrease in platinum accumulation.	Platinum	15-23	glutamate-cysteine ligase catalytic subunit	Homo sapiens	156-165
18571892-5	2009	Acquisition of platinum resistance in human ovarian cancer cells thus appeared to be related mainly to the expression of gamma-glutamylcysteine synthetase (gamma-GCS), topo II and metallothionein (hMT) genes, and partly to that of topo I and glutathione S-transferase--pi (GST-pi) genes, in addition to a decrease in platinum accumulation.	Platinum	15-23	histamine N-methyltransferase	Homo sapiens	197-200
18571892-11	2009	The siRNA directed to the TBCE gene and CBP/p300-interacting transactivator gene enhanced the cytotoxicity of diplatin to the platinum-resistant ovarian cancer cell line KFR.	Platinum	126-134	tubulin folding cofactor E	Homo sapiens	26-30
18571892-11	2009	The siRNA directed to the TBCE gene and CBP/p300-interacting transactivator gene enhanced the cytotoxicity of diplatin to the platinum-resistant ovarian cancer cell line KFR.	Platinum	126-134	CREB binding protein	Homo sapiens	40-48
19466412-0	2009	Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity.	Platinum	89-97	solute carrier family 31 member 1	Rattus norvegicus	23-43
19667264-11	2009	Patients in the EML4-ALK cohort and the WT/WT cohort showed similar response rates to platinum-based combination chemotherapy and no difference in overall survival.	Platinum	86-94	EMAP like 4	Homo sapiens	16-20
19667264-11	2009	Patients in the EML4-ALK cohort and the WT/WT cohort showed similar response rates to platinum-based combination chemotherapy and no difference in overall survival.	Platinum	86-94	ALK receptor tyrosine kinase	Homo sapiens	21-24
19466412-1	2009	PURPOSE: We report the neuronal expression of copper transporter 1 (CTR1) in rat dorsal root ganglia (DRG) and its association with the neurotoxicity of platinum-based drugs.	Platinum	153-161	solute carrier family 31 member 1	Rattus norvegicus	68-72
19466412-3	2009	The toxicity of platinum drugs to CTR1-positive and CTR1-negative neurons was compared in DRG from animals treated with maximum tolerated doses of oxaliplatin (1.85 mg/kg), cisplatin (1 mg/kg) or carboplatin (8 mg/kg) twice weekly for 8 weeks.	Platinum	16-24	solute carrier family 31 member 1	Rattus norvegicus	34-38
19466412-6	2009	After treatment with platinum drugs, the cell bodies of these CTR1-positive neurons became atrophied, with oxaliplatin causing the greatest percentage reduction in the mean cell body area relative to controls (42%; P &lt; 0.05), followed by cisplatin (18%; P &lt; 0.05) and carboplatin causing the least reduction (3.2%; P = NS).	Platinum	21-29	solute carrier family 31 member 1	Rattus norvegicus	62-66
19466412-8	2009	CONCLUSIONS: CTR1 is preferentially expressed by a subset of DRG neurons that are particularly vulnerable to the toxicity of platinum drugs.	Platinum	125-133	solute carrier family 31 member 1	Rattus norvegicus	13-17
19466412-9	2009	These findings, together with its neuronal membrane localization, are suggestive of CTR1-related mechanisms of platinum drug neuronal uptake and neurotoxicity.	Platinum	111-119	solute carrier family 31 member 1	Rattus norvegicus	84-88
19240185-0	2009	Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.	Platinum	122-130	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-57
19240185-3	2009	In other tumor entities, expression of excision repair cross complementing group 1 (ERCC1) predicts resistance to platinum compounds.	Platinum	114-122	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	39-82
19240185-3	2009	In other tumor entities, expression of excision repair cross complementing group 1 (ERCC1) predicts resistance to platinum compounds.	Platinum	114-122	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	84-89
19240185-10	2009	In platinum-treated patients (n=45), objective response to platinum compounds was observed in 3/21 patients (14.3%) with high ERCC1 expression and in 7/24 patients (29.2%) with low ERCC1 expression (P=0.23).	Platinum	3-11	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	126-131
19240185-10	2009	In platinum-treated patients (n=45), objective response to platinum compounds was observed in 3/21 patients (14.3%) with high ERCC1 expression and in 7/24 patients (29.2%) with low ERCC1 expression (P=0.23).	Platinum	3-11	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	181-186
19240185-10	2009	In platinum-treated patients (n=45), objective response to platinum compounds was observed in 3/21 patients (14.3%) with high ERCC1 expression and in 7/24 patients (29.2%) with low ERCC1 expression (P=0.23).	Platinum	59-67	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	126-131
19240185-10	2009	In platinum-treated patients (n=45), objective response to platinum compounds was observed in 3/21 patients (14.3%) with high ERCC1 expression and in 7/24 patients (29.2%) with low ERCC1 expression (P=0.23).	Platinum	59-67	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	181-186
19240185-11	2009	ERCC1 expression was strongly correlated with overall survival after platinum treatment (median: eight months in patients with high ERCC1 versus 24 months in low ERCC1 expression, hazard ratio (HR) 2.95 (95% confidence interval (CI) 1.4-6.2), P=0.004).	Platinum	69-77	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
19240185-11	2009	ERCC1 expression was strongly correlated with overall survival after platinum treatment (median: eight months in patients with high ERCC1 versus 24 months in low ERCC1 expression, hazard ratio (HR) 2.95 (95% confidence interval (CI) 1.4-6.2), P=0.004).	Platinum	69-77	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	132-137
19240185-11	2009	ERCC1 expression was strongly correlated with overall survival after platinum treatment (median: eight months in patients with high ERCC1 versus 24 months in low ERCC1 expression, hazard ratio (HR) 2.95 (95% confidence interval (CI) 1.4-6.2), P=0.004).	Platinum	69-77	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	132-137
19240185-12	2009	Multivariate analysis confirmed that high ERCC1 expression was a predictive factor for poor prognosis in platinum treated patients (HR 2.2, 95% CI 1.0-4.5, P=0.038).	Platinum	105-113	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	42-47
19240185-13	2009	Our findings suggest that ERCC1 expression is the first factor for predicting survival in ACC patients treated with platinum-based chemotherapy.	Platinum	116-124	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	26-31
19123003-1	2009	INTRODUCTION: The expression of excision repair cross-complementation group 1 (ERCC1) is reported to be correlated with resistance to platinum-based drugs.	Platinum	134-142	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	32-77
19150580-8	2009	CONCLUSIONS: High expression of ERCC1 may be a useful prognostic factor for poor outcome in advanced NSCLC patients treated with platinum and third-generation doublet chemotherapy.	Platinum	129-137	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	32-37
19253035-0	2009	Platinum-based chemotherapy in lung cancer affects the expression of certain biomarkers including ERCC1.	Platinum	0-8	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	98-103
19253035-12	2009	The results of the present study suggest that platinum-based chemotherapy probably induces a selection of tumor cells with more aggressive phenotype, and also affects the expression of tissue marker (ERCC1) that could have predictive value.	Platinum	46-54	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	200-205
20719167-9	2009	ERCC1, XRCC1 and XRCC3 gene polymorphisms were a useful marker for predicting better survival in advanced NSCLC patients treated with platinum-based chemotherapy.	Platinum	134-142	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
20719167-9	2009	ERCC1, XRCC1 and XRCC3 gene polymorphisms were a useful marker for predicting better survival in advanced NSCLC patients treated with platinum-based chemotherapy.	Platinum	134-142	X-ray repair cross complementing 1	Homo sapiens	7-12
20719167-9	2009	ERCC1, XRCC1 and XRCC3 gene polymorphisms were a useful marker for predicting better survival in advanced NSCLC patients treated with platinum-based chemotherapy.	Platinum	134-142	X-ray repair cross complementing 3	Homo sapiens	17-22
20719167-10	2009	XPA and XPD polymorphisms significantly increased response to platinum-based chemotherapy.	Platinum	62-70	XPA, DNA damage recognition and repair factor	Homo sapiens	0-3
20719167-10	2009	XPA and XPD polymorphisms significantly increased response to platinum-based chemotherapy.	Platinum	62-70	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	8-11
19330779-0	2009	A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer.	Platinum	2-10	DNA polymerase beta	Homo sapiens	34-38
19708784-1	2009	For the past 5 years, a radio-chemotherapy approach based on the photoactivation of platinum atoms (PAT-Plat) consisting of treating tumors with platinated compounds and irradiating them above the platinum K edge (78.4 keV) has been developed at the European Synchrotron Radiation Facility (Grenoble, France).	Platinum	84-92	plasminogen activator, tissue type	Rattus norvegicus	104-108
19515376-5	2009	TPR characterization suggests that the enhancement of Pt(75)Au(25)/C was attributed to the formation of an alloy surface, having a moderate oxophilicity and a Pt-related alloy surface species.	Platinum	54-56	translocated promoter region, nuclear basket protein	Homo sapiens	0-3
19123003-1	2009	INTRODUCTION: The expression of excision repair cross-complementation group 1 (ERCC1) is reported to be correlated with resistance to platinum-based drugs.	Platinum	134-142	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	79-84
19574032-0	2009	Dramatic response to platinum in a patient with cancer with a germline BRCA2 mutation.	Platinum	21-29	BRCA2 DNA repair associated	Homo sapiens	71-76
19661073-1	2009	Detoxification enzymes, especially glutathione S-transferase P1-1 (GSTP1-1), have been implicated in resistance to platinum-based chemotherapy.	Platinum	115-123	glutathione S-transferase pi 1	Homo sapiens	67-74
19249193-0	2009	Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer.	Platinum	0-8	BRCA1 DNA repair associated	Homo sapiens	26-31
19249193-2	2009	Recent in vitro data suggest a high sensitivity of BRCA1-associated carcinomas to platinum-based chemotherapy and a lower sensitivity to anthracyclines and taxanes.	Platinum	82-90	BRCA1 DNA repair associated	Homo sapiens	51-56
19249193-3	2009	This is explained by the key role of BRCA1 in DNA double-strand repair via homologous recombination, thereby leading to a higher sensitivity to DNA intercalating agents, such as platinum.	Platinum	178-186	BRCA1 DNA repair associated	Homo sapiens	37-42
19574032-1	2009	We present a case of dramatic response of poor prognosis cancer in a lady with a germline mutation in the BRCA2 gene who was exposed to platinum containing chemotherapy.	Platinum	136-144	BRCA2 DNA repair associated	Homo sapiens	106-111
19602291-2	2009	Restoration of BRCA1 and BRCA2 mediates resistance to platinum chemotherapy in recurrent BRCA1 and BRCA2 mutated hereditary ovarian carcinomas.	Platinum	54-62	BRCA1 DNA repair associated	Homo sapiens	15-20
19447480-12	2009	CONCLUSION: Earlier normalization of CA-125 levels during primary chemotherapy for EOC predicts improvement in platinum sensitivity, PFS, and OS.	Platinum	111-119	mucin 16, cell surface associated	Homo sapiens	37-43
19157633-7	2009	We found that there was a significantly increased chance of treatment response to platinum-based chemotherapy with the XRCC1 194Arg/Trp genotype (odds ratio 0.429; 95% CI 0.137-1.671; P=0.035).	Platinum	82-90	X-ray repair cross complementing 1	Homo sapiens	119-124
19383537-0	2009	The immediate early genes, c-fos, c-jun and AP-1, are early markers of platinum analogue toxicity in human proximal tubular cell primary cultures.	Platinum	71-79	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	27-32
19383537-0	2009	The immediate early genes, c-fos, c-jun and AP-1, are early markers of platinum analogue toxicity in human proximal tubular cell primary cultures.	Platinum	71-79	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	34-39
19383537-0	2009	The immediate early genes, c-fos, c-jun and AP-1, are early markers of platinum analogue toxicity in human proximal tubular cell primary cultures.	Platinum	71-79	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	44-48
19383537-1	2009	These studies tested the hypothesis that c-fos, c-jun and AP-1 are early markers of platinum analogue-induced proximal tubule nephrotoxicity in primary rat proximal tubule (RPT) and human proximal tubule (HPT) cell cultures.	Platinum	84-92	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	41-46
19383537-3	2009	Following a 2-h platinum analogue treatment, c-fos protein expression correlated with toxicity.	Platinum	16-24	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	45-50
19383537-4	2009	Maximal c-fos protein levels were observed at 8-h (RPT) and 4-h (HPT) post-platinum analogue treatment.	Platinum	75-83	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	8-13
19588000-1	2009	The loading of pre-treated amorphous silica with platinum or palladium was carried out by using the molecular precursors Pt2(micro-Cl)2Cl2(CO)2, or Pd2(micro-Cl)2Cl2(CO)2, respectively, which contain the required amount of coordinated CO to carry out the formation of the metal particles upon contact with moisture.	Platinum	49-57	PAF1 homolog, Paf1/RNA polymerase II complex component	Homo sapiens	148-151
19603033-3	2009	METHODS: In this study, hMLH1 expression was correlated with clinical response to platinum drugs and survival in advanced stage (III-IV) EOC patients.	Platinum	82-90	mutL homolog 1	Homo sapiens	24-29
19157633-0	2009	Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.	Platinum	47-55	X-ray repair cross complementing 1	Homo sapiens	17-22
19157633-0	2009	Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.	Platinum	47-55	ERCC excision repair 5, endonuclease	Homo sapiens	27-30
19157633-4	2009	In this study, we investigated whether single nucleotide polymorphisms (SNPs) in Xeroderma pigmentosum group G (XPG) and X-ray repair cross complementing group 1 (XRCC1) were associated with the tumor response in non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy in Chinese population.	Platinum	270-278	ERCC excision repair 5, endonuclease	Homo sapiens	81-110
19157633-4	2009	In this study, we investigated whether single nucleotide polymorphisms (SNPs) in Xeroderma pigmentosum group G (XPG) and X-ray repair cross complementing group 1 (XRCC1) were associated with the tumor response in non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy in Chinese population.	Platinum	270-278	ERCC excision repair 5, endonuclease	Homo sapiens	112-115
19157633-4	2009	In this study, we investigated whether single nucleotide polymorphisms (SNPs) in Xeroderma pigmentosum group G (XPG) and X-ray repair cross complementing group 1 (XRCC1) were associated with the tumor response in non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy in Chinese population.	Platinum	270-278	X-ray repair cross complementing 1	Homo sapiens	163-168
19602291-2	2009	Restoration of BRCA1 and BRCA2 mediates resistance to platinum chemotherapy in recurrent BRCA1 and BRCA2 mutated hereditary ovarian carcinomas.	Platinum	54-62	BRCA2 DNA repair associated	Homo sapiens	25-30
19602291-2	2009	Restoration of BRCA1 and BRCA2 mediates resistance to platinum chemotherapy in recurrent BRCA1 and BRCA2 mutated hereditary ovarian carcinomas.	Platinum	54-62	BRCA1 DNA repair associated	Homo sapiens	89-94
19602291-2	2009	Restoration of BRCA1 and BRCA2 mediates resistance to platinum chemotherapy in recurrent BRCA1 and BRCA2 mutated hereditary ovarian carcinomas.	Platinum	54-62	BRCA2 DNA repair associated	Homo sapiens	99-104
19602291-13	2009	Recurrent ovarian carcinomas commonly have increased BRCA1 and/or BRCA2 protein expression post chemotherapy exposure which could mediate resistance to platinum based therapies.	Platinum	152-160	BRCA1 DNA repair associated	Homo sapiens	53-58
19602291-13	2009	Recurrent ovarian carcinomas commonly have increased BRCA1 and/or BRCA2 protein expression post chemotherapy exposure which could mediate resistance to platinum based therapies.	Platinum	152-160	BRCA2 DNA repair associated	Homo sapiens	66-71
19588370-2	2009	OBJECTIVES: To evaluate the effectiveness and safety of platinum-based adjuvant chemotherapy after radical hysterectomy, radiotherapy, or both in the treatment of early stage cervical cancer (stages IA2, IB1 or IIA).	Platinum	56-64	protein tyrosine phosphatase receptor type N	Homo sapiens	199-202
19297315-1	2009	BACKGROUND: The expression levels of excision repair cross-complementation group 1 (ERCC1), replication protein A (RPA) and xeroderma pigmentosum group F (XPF) nucleotide excision repair proteins may be important in the response to platin-based therapy in lung cancer patients.	Platinum	232-238	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	37-82
19588370-2	2009	OBJECTIVES: To evaluate the effectiveness and safety of platinum-based adjuvant chemotherapy after radical hysterectomy, radiotherapy, or both in the treatment of early stage cervical cancer (stages IA2, IB1 or IIA).	Platinum	56-64	mitogen-activated protein kinase 8 interacting protein 1	Homo sapiens	204-207
19466729-0	2009	An amphiphilic resin-dispersion of nanoparticles of platinum (ARP-Pt): a highly active and recyclable catalyst for the aerobic oxidation of a variety of alcohols in water.	Platinum	52-60	arginine-glutamic acid dipeptide repeats	Homo sapiens	62-65
19466729-1	2009	An amphiphilic polystyrene-poly(ethylene glycol) (PS-PEG) resin-dispersion of nanoparticles of platinum (ARP-Pt, 4) was developed with a view towards use in catalysis in an aqueous environment under heterogeneous conditions.	Platinum	95-103	arginine-glutamic acid dipeptide repeats	Homo sapiens	105-108
19297315-1	2009	BACKGROUND: The expression levels of excision repair cross-complementation group 1 (ERCC1), replication protein A (RPA) and xeroderma pigmentosum group F (XPF) nucleotide excision repair proteins may be important in the response to platin-based therapy in lung cancer patients.	Platinum	232-238	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	84-89
19297315-1	2009	BACKGROUND: The expression levels of excision repair cross-complementation group 1 (ERCC1), replication protein A (RPA) and xeroderma pigmentosum group F (XPF) nucleotide excision repair proteins may be important in the response to platin-based therapy in lung cancer patients.	Platinum	232-238	replication protein A1	Homo sapiens	92-113
19297315-1	2009	BACKGROUND: The expression levels of excision repair cross-complementation group 1 (ERCC1), replication protein A (RPA) and xeroderma pigmentosum group F (XPF) nucleotide excision repair proteins may be important in the response to platin-based therapy in lung cancer patients.	Platinum	232-238	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	124-153
19297315-1	2009	BACKGROUND: The expression levels of excision repair cross-complementation group 1 (ERCC1), replication protein A (RPA) and xeroderma pigmentosum group F (XPF) nucleotide excision repair proteins may be important in the response to platin-based therapy in lung cancer patients.	Platinum	232-238	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	155-158
19432884-1	2009	Xeroderma pigmentosum group D (XPD) participates in DNA unwinding during nucleotide excision repair, which may alter the efficacy of platinum-based chemotherapy.	Platinum	133-141	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	31-34
19345990-3	2009	GP-Pt-bEGF with EGFR affinity produced much higher Pt concentrations in A549 cells (high EGFR expression) than in HFL1 cells (low EGFR expression).	Platinum	3-5	epidermal growth factor receptor	Mus musculus	16-20
19345990-3	2009	GP-Pt-bEGF with EGFR affinity produced much higher Pt concentrations in A549 cells (high EGFR expression) than in HFL1 cells (low EGFR expression).	Platinum	3-5	epidermal growth factor receptor	Mus musculus	89-93
19345990-3	2009	GP-Pt-bEGF with EGFR affinity produced much higher Pt concentrations in A549 cells (high EGFR expression) than in HFL1 cells (low EGFR expression).	Platinum	3-5	epidermal growth factor receptor	Mus musculus	89-93
19563645-10	2009	CONCLUSION: SNP of XRCC1 gene at codon 399 influences the response of cervical carcinoma to platinum-based NAC.	Platinum	92-100	X-ray repair cross complementing 1	Homo sapiens	19-24
19574766-2	2009	Preclinical and clinical data have suggested a potential use of excision repair cross-complementation group 1 enzyme (ERCC1) as a molecular predictor of clinical resistance to platinum-based chemotherapy.	Platinum	176-184	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	64-109
19552012-4	2009	A literature revision was done in order to define the role of ERCC1 e RRM1 genes in the response to chemotherapy based in platinum and gemcitabine respectively.	Platinum	122-130	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	62-67
19552012-4	2009	A literature revision was done in order to define the role of ERCC1 e RRM1 genes in the response to chemotherapy based in platinum and gemcitabine respectively.	Platinum	122-130	ribonucleotide reductase catalytic subunit M1	Homo sapiens	70-74
19509135-2	2009	Several other Cu transporters, including the influx transporter CTR1 and the two efflux transporters ATP7A and ATP7B, also regulate sensitivity to the platinum-containing drugs.	Platinum	151-159	solute carrier family 31 member 1	Homo sapiens	64-68
19509135-2	2009	Several other Cu transporters, including the influx transporter CTR1 and the two efflux transporters ATP7A and ATP7B, also regulate sensitivity to the platinum-containing drugs.	Platinum	151-159	ATPase copper transporting alpha	Homo sapiens	101-106
19509135-2	2009	Several other Cu transporters, including the influx transporter CTR1 and the two efflux transporters ATP7A and ATP7B, also regulate sensitivity to the platinum-containing drugs.	Platinum	151-159	ATPase copper transporting beta	Homo sapiens	111-116
19574766-2	2009	Preclinical and clinical data have suggested a potential use of excision repair cross-complementation group 1 enzyme (ERCC1) as a molecular predictor of clinical resistance to platinum-based chemotherapy.	Platinum	176-184	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	118-123
19574766-8	2009	Platinum resistance was found in 75% of the tumors with positive ERCC1 protein expression compared with 27% among the patients with negative tumor staining for ERCC1 (P = 0.0013).	Platinum	0-8	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	65-70
19574766-8	2009	Platinum resistance was found in 75% of the tumors with positive ERCC1 protein expression compared with 27% among the patients with negative tumor staining for ERCC1 (P = 0.0013).	Platinum	0-8	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	160-165
19574766-10	2009	CONCLUSIONS: The data presented suggest a positive association between positive ERCC1 protein expression and clinical resistance to platinum-based chemotherapy.	Platinum	132-140	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	80-85
19525010-0	2009	Terpyridine-platinum(II) complexes are effective inhibitors of mammalian topoisomerases and human thioredoxin reductase 1.	Platinum	12-20	thioredoxin reductase 1	Homo sapiens	98-121
19322891-0	2009	Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.	Platinum	82-90	stathmin 1	Homo sapiens	0-8
19362203-0	2009	Pt/Au bimetallic hierarchical structure with micro/nano-array via photolithography and electrochemical synthesis: From design to GOT and GPT biosensors.	Platinum	0-2	glutamic--pyruvic transaminase	Homo sapiens	137-140
19296535-1	2009	Recently, the copper efflux transporters ATP7B and ATP7A have been implicated in the transport of and resistance to platinum drugs in breast and ovarian cancers.	Platinum	116-124	ATPase copper transporting beta	Homo sapiens	41-46
19296535-1	2009	Recently, the copper efflux transporters ATP7B and ATP7A have been implicated in the transport of and resistance to platinum drugs in breast and ovarian cancers.	Platinum	116-124	ATPase copper transporting alpha	Homo sapiens	51-56
19438286-2	2009	Electrochemical study of carbon-supported Pt-on-Pd heteronanostructures shows not only enhancement in electrocatalytic activity for oxygen reduction reaction (ORR) but also much improved stability in comparison to a commercial platinum catalyst (E-TEK, 20 wt % Pt, diameter: 2.5 nm).	Platinum	42-44	TEK receptor tyrosine kinase	Homo sapiens	248-251
19322891-8	2009	This association was independent of patient age, disease stage, tumor grade, histology, and residual tumor size and was observed in patients who received platinum plus paclitaxel, but not in patients who received platinum without paclitaxel, suggesting that stathmin expression in tumor tissue may interfere with paclitaxel treatment.	Platinum	154-162	stathmin 1	Homo sapiens	258-266
19288144-6	2009	The platinum compounds were less reactive and considerably less selective in protein binding than RAPTA-C, which showed a high affinity towards ubiquitin and cytochrome c, but not superoxide dismutase.	Platinum	4-12	cytochrome c, somatic	Homo sapiens	158-170
19458053-9	2009	CONCLUSIONS: This investigation, for the first time, provides suggestive evidence of an effect of XPD p.Arg(156)Arg polymorphism on severe toxicity variability among platinum-treated non-small cell lung cancer patients.	Platinum	166-174	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	98-101
19470734-2	2009	Here, we examined the biological mechanisms and therapeutic potential of targeting a critical platinum resistance gene, ATP7B, using both in vitro and in vivo models.	Platinum	94-102	ATPase copper transporting beta	Homo sapiens	120-125
19470736-2	2009	Platinum-resistant cells may have reduced expression of the copper/platinum transporter CTR1.	Platinum	0-8	solute carrier family 31 member 1	Homo sapiens	88-92
19404210-0	2009	XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy.	Platinum	208-216	colony stimulating factor 3	Homo sapiens	27-32
18952980-1	2009	Glutathione S-transferases (GSTs) are polymorphic enzymes that catalyze the glutathione conjugation of alkylating agents, platinum compounds, and free radicals formed by radiation used to treat medulloblastoma.	Platinum	122-130	glutathione S-transferase mu 1	Homo sapiens	28-32
18977553-2	2009	The expression of excision repair cross-complementation group 1 (ERCC1) is reported to be correlated with resistance to platinum-based drugs.	Platinum	120-128	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	18-63
18977553-2	2009	The expression of excision repair cross-complementation group 1 (ERCC1) is reported to be correlated with resistance to platinum-based drugs.	Platinum	120-128	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	65-70
19434004-11	2009	Src inhibitors may be a promising therapy in melanoma, either by themselves or in combination with chemotherapy (especially with platinum compounds) or inhibitors of the Akt/PI3k pathway.	Platinum	129-137	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
19470246-0	2009	Effects of nanoparticulate saponin-platinum conjugates on 2,4-dinitrofluorobenzene-induced macrophage inflammatory protein-2 gene expression via reactive oxygen species production in RAW 264.7 cells.	Platinum	35-43	chemokine (C-X-C motif) ligand 2	Mus musculus	91-124
20719132-2	2009	It has been proven that ERCC1, RRM1, p53 expressions were related to resistance to platinum and prognosis of the patcents with lung cancer.	Platinum	83-91	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	24-29
20719132-2	2009	It has been proven that ERCC1, RRM1, p53 expressions were related to resistance to platinum and prognosis of the patcents with lung cancer.	Platinum	83-91	ribonucleotide reductase catalytic subunit M1	Homo sapiens	31-35
20719132-2	2009	It has been proven that ERCC1, RRM1, p53 expressions were related to resistance to platinum and prognosis of the patcents with lung cancer.	Platinum	83-91	tumor protein p53	Homo sapiens	37-40
19448737-5	2009	We found that mutations that remove positive charges in the 4th extracellular loop of CFTR (K892Q and R899Q) significantly alter the interaction between extracellular and intracellular Pt(NO2)42- ions.	Platinum	185-187	CF transmembrane conductance regulator	Homo sapiens	86-90
19356918-1	2009	An electrochemical method to determine alanine aminotransferase (ALT) activity over its normal and elevated physiological range was developed based upon detection of L-glutamate at a glutamate oxidase-modified platinum electrode.	Platinum	210-218	glutamic--pyruvic transaminase	Homo sapiens	39-63
19269451-6	2009	The practical utility of the electrode has been demonstrated by its use in determination of platinum ion in, alloy, tap, mineral and river water samples.	Platinum	92-100	nuclear RNA export factor 1	Homo sapiens	116-119
19269467-0	2009	Microbiosensor based on glucose oxidase and hexokinase co-immobilised on platinum microelectrode for selective ATP detection.	Platinum	73-81	hexokinase 1	Homo sapiens	44-54
19430706-0	2009	XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.	Platinum	66-74	XPA, DNA damage recognition and repair factor	Homo sapiens	0-3
19430706-2	2009	We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients.	Platinum	297-305	XPA, DNA damage recognition and repair factor	Homo sapiens	61-64
19430706-2	2009	We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients.	Platinum	297-305	XPA, DNA damage recognition and repair factor	Homo sapiens	66-95
19430706-2	2009	We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients.	Platinum	297-305	ERCC excision repair 5, endonuclease	Homo sapiens	101-104
19430706-2	2009	We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients.	Platinum	297-305	ERCC excision repair 5, endonuclease	Homo sapiens	106-135
19430706-3	2009	In this study, we find that the Aright curved arrow G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy.	Platinum	122-130	XPA, DNA damage recognition and repair factor	Homo sapiens	64-67
18649131-4	2009	CONCLUSIONS: Platinum-based chemotherapy appears to be effective in a high proportion of patients with BRCA1-associated breast cancers.	Platinum	13-21	BRCA1 DNA repair associated	Homo sapiens	103-108
21825468-0	2009	In situ x-ray reflectivity and grazing incidence x-ray diffraction study of L 1(0) ordering in (57)Fe/Pt multilayers.	Platinum	102-104	immunoglobulin kappa variable 3-7 (non-functional)	Homo sapiens	76-82
19270496-15	2009	The data provide the first evidence for direct interaction of cisplatin with BRCA1 and raise the possibility of BRCA1 as a therapeutic target for platinum drug-based chemotherapy.	Platinum	146-154	BRCA1 DNA repair associated	Homo sapiens	112-117
19349493-5	2009	However, the addition of a targeted agent (bevacizumab, an antiangioegenesis agent, or cetuximab, an antibody against the epidermal growth factor receptor [EGFR]) to platinum-based therapy has yielded an improvement in survival compared with platinum-based therapy alone.	Platinum	242-250	epidermal growth factor receptor	Homo sapiens	156-160
19289620-1	2009	PURPOSE: This study was designed to confirm the efficacy and safety of picoplatin, a cisplatin analog designed to overcome platinum resistance, in patients with small-cell lung cancer (SCLC) with platinum-refractory/-resistant disease.	Platinum	123-131	SCLC1	Homo sapiens	185-189
19289620-14	2009	CONCLUSION: Picoplatin demonstrated clinical efficacy in platinum-refractory SCLC.	Platinum	57-65	SCLC1	Homo sapiens	77-81
19349493-5	2009	However, the addition of a targeted agent (bevacizumab, an antiangioegenesis agent, or cetuximab, an antibody against the epidermal growth factor receptor [EGFR]) to platinum-based therapy has yielded an improvement in survival compared with platinum-based therapy alone.	Platinum	166-174	epidermal growth factor receptor	Homo sapiens	156-160
18804893-0	2009	Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.	Platinum	57-65	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-45
18804893-0	2009	Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.	Platinum	57-65	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
18804893-5	2009	MATERIALS AND METHODS: A literature review on ERCC1 was conducted as predictor in NSCLC patients receiving platinum-based treatment with emphasis on carboplatin.	Platinum	107-115	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	46-51
19379506-0	2009	Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?	Platinum	57-65	BRCA1 DNA repair associated	Homo sapiens	26-31
19379506-9	2009	For example, many thousands of BC patients around the world have already been subjected to second- or third-line therapy with platinum agents, but the association between BRCA status and response to the treatment has not been systematically evaluated in these women.	Platinum	126-134	BRCA1 DNA repair associated	Homo sapiens	171-175
19379506-11	2009	However, even elegantly-designed, small-sized, hypothesis-generating retrospective studies may require multicenter efforts and somewhat cumbersome logistics, that may explain the surprising lack of historical data on the platinum-based treatment of BC in BRCA1 carriers.	Platinum	221-229	BRCA1 DNA repair associated	Homo sapiens	255-260
19333003-12	2009	CONCLUSION: Our data suggest that BRCA1-defective in vivo HBCXs express a molecular scenario predictive of high sensitivity to platinum-derived compounds strongly supporting the rationale for prospective tailored clinical trials in hereditary breast cancer.	Platinum	127-135	BRCA1 DNA repair associated	Homo sapiens	34-39
19290672-6	2009	The potential influence of platinum nanoparticles on cellular redoxsystems was determined in the DCF assay, on the translocation of Nrf-2 and by monitoring the intracellular glutathione (GSH) levels.	Platinum	27-35	NFE2 like bZIP transcription factor 2	Homo sapiens	132-137
19168207-4	2009	This article reviews the preclinical and clinical evidence to support a role for BRCA1 as a potential predictive biomarker of response to both platinum and taxane based chemotherapy in EOC.	Platinum	143-151	BRCA1 DNA repair associated	Homo sapiens	81-86
19168207-8	2009	Evidence suggests that BRCA1 is a potential biomarker of response to platinum chemotherapy in EOC with BRCA1 deficiency predicting for enhanced response.	Platinum	69-77	BRCA1 DNA repair associated	Homo sapiens	23-28
19107936-9	2009	In an exploratory subgroup analysis significantly worse OS was seen for carriers of the ABCG2 421A-allele treated with platinum-based drugs (HR: 1.60; 95% CI 1.04-2.47; n = 256).	Platinum	119-127	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	88-93
18823676-8	2009	CONCLUSIONS: This study examined ERCC1 and BCRP expression in biopsy specimens as candidates for predictors of the survival of patients with advanced NSCLC treated with platinum-based chemotherapy.	Platinum	169-177	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	33-38
19347979-9	2009	CONCLUSIONS: Genotypes of glutathione-related enzymes, especially GCLC, may be used as host factors in predicting patients" survival after platinum-based chemotherapy.	Platinum	139-147	glutamate-cysteine ligase catalytic subunit	Homo sapiens	66-70
18823676-8	2009	CONCLUSIONS: This study examined ERCC1 and BCRP expression in biopsy specimens as candidates for predictors of the survival of patients with advanced NSCLC treated with platinum-based chemotherapy.	Platinum	169-177	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	43-47
19417476-0	2009	The influence of glancing angle deposited nano-rough platinum surfaces on the adsorption of fibrinogen and the proliferation of primary human fibroblasts.	Platinum	53-61	fibrinogen beta chain	Homo sapiens	92-102
19372558-8	2009	The predominant difference between the responses to the two platinum drugs was the presence of a drug-specific ATR-dependent S-phase arrest after cisplatin but not oxaliplatin.	Platinum	60-68	ATR serine/threonine kinase	Homo sapiens	111-114
19112013-1	2009	Nanoporous cerium oxide (CeO(2)) thin film deposited onto platinum (Pt) coated glass plate using pulsed laser deposition (PLD) has been utilized for immobilization of glucose oxidase (GOx).	Platinum	58-66	hydroxyacid oxidase 1	Homo sapiens	167-182
19112013-1	2009	Nanoporous cerium oxide (CeO(2)) thin film deposited onto platinum (Pt) coated glass plate using pulsed laser deposition (PLD) has been utilized for immobilization of glucose oxidase (GOx).	Platinum	58-66	hydroxyacid oxidase 1	Homo sapiens	184-187
19112013-1	2009	Nanoporous cerium oxide (CeO(2)) thin film deposited onto platinum (Pt) coated glass plate using pulsed laser deposition (PLD) has been utilized for immobilization of glucose oxidase (GOx).	Platinum	68-70	hydroxyacid oxidase 1	Homo sapiens	167-182
19112013-1	2009	Nanoporous cerium oxide (CeO(2)) thin film deposited onto platinum (Pt) coated glass plate using pulsed laser deposition (PLD) has been utilized for immobilization of glucose oxidase (GOx).	Platinum	68-70	hydroxyacid oxidase 1	Homo sapiens	184-187
19169248-0	2009	Ternary Pt/Rh/SnO2 electrocatalysts for oxidizing ethanol to CO2.	Platinum	8-10	strawberry notch homolog 2	Homo sapiens	14-17
19354063-6	2009	Platinum agents (cisplatin, carboplatin, oxaliplatin) are associated with IgE-mediated hypersensitivity reactions, and skin testing may be indicated.	Platinum	0-8	immunoglobulin heavy constant epsilon	Homo sapiens	74-77
18575867-3	2009	RESULTS: A decrease in ERCC1 protein expression and an increase in RAD51B foci activity was observed in association with the platinum induced cell cycle arrest but these changes did not correlate with resistance or altered DNA repair capacity.	Platinum	125-133	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	23-28
19396019-2	2009	Glutathione S-transferase-pi (GSTP1) belongs to a supergene family of detoxifying enzymes involved in the prevention of DNA damage and subsequent platinum resistance in numerous cancers.	Platinum	146-154	glutathione S-transferase pi 1	Homo sapiens	30-35
19396019-14	2009	Evaluation of promoter methylation and ERK activity may be useful for predicting tumor sensitivity to platinum-based chemotherapeutics.	Platinum	102-110	mitogen-activated protein kinase 1	Homo sapiens	39-42
18575867-3	2009	RESULTS: A decrease in ERCC1 protein expression and an increase in RAD51B foci activity was observed in association with the platinum induced cell cycle arrest but these changes did not correlate with resistance or altered DNA repair capacity.	Platinum	125-133	RAD51 paralog B	Homo sapiens	67-73
18575867-4	2009	The H69 cells and resistant cell lines have a p53 mutation and consequently decrease expression of p21 in response to platinum drug treatment, promoting progression of the cell cycle instead of increasing p21 to maintain the arrest.	Platinum	118-126	tumor protein p53	Homo sapiens	46-49
18575867-4	2009	The H69 cells and resistant cell lines have a p53 mutation and consequently decrease expression of p21 in response to platinum drug treatment, promoting progression of the cell cycle instead of increasing p21 to maintain the arrest.	Platinum	118-126	H3 histone pseudogene 16	Homo sapiens	99-102
18575867-7	2009	The novel mechanism of platinum resistance in the H69CIS200 and H69OX400 cells demonstrates the multifactorial nature of platinum resistance which can occur independently of alterations in DNA repair capacity and changes in ERCC1.	Platinum	23-31	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	224-229
18575867-7	2009	The novel mechanism of platinum resistance in the H69CIS200 and H69OX400 cells demonstrates the multifactorial nature of platinum resistance which can occur independently of alterations in DNA repair capacity and changes in ERCC1.	Platinum	121-129	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	224-229
19240170-1	2009	PURPOSE: This study aimed to test the hypothesis that elevated expression of antiapoptotic Bcl-2 family proteins predicts a poor therapeutic response of oropharyngeal squamous cell carcinoma (OPSCC) to concurrent platinum-based chemoradiation therapy.	Platinum	213-221	BCL2 apoptosis regulator	Homo sapiens	91-96
19240170-8	2009	CONCLUSIONS: Immunohistochemical assessment of Bcl-2 in pretreatment biopsy specimens can predict response of advanced OPSCC to concurrent platinum-based chemoradiation.	Platinum	139-147	BCL2 apoptosis regulator	Homo sapiens	47-52
19428505-5	2009	Regarding MAPKs, platinum derivatives activated p38 while they reduced the active form and the total amount of JNK/Sapk.	Platinum	17-25	mitogen-activated protein kinase 1	Homo sapiens	48-51
19362955-2	2009	We retrospectively assessed whether single nucleotide polymorphisms (SNP) of DNA-repair genes ERCC1, XPD, XRCC1 and glutathione S-transferase genes GSTP1, GSTT1 and GSTM1 predict overall survival (OS), response and toxicity in 119 non-small-cell lung cancer (NSCLC) patients treated with platinum-based regimens as first- or second-line chemotherapy.	Platinum	288-296	glutathione S-transferase pi 1	Homo sapiens	148-153
19362955-2	2009	We retrospectively assessed whether single nucleotide polymorphisms (SNP) of DNA-repair genes ERCC1, XPD, XRCC1 and glutathione S-transferase genes GSTP1, GSTT1 and GSTM1 predict overall survival (OS), response and toxicity in 119 non-small-cell lung cancer (NSCLC) patients treated with platinum-based regimens as first- or second-line chemotherapy.	Platinum	288-296	glutathione S-transferase mu 1	Homo sapiens	165-170
19150122-1	2009	OBJECTIVE: The aim of the study was to evaluate the prognostic significance of p53 and PTEN in patients with epithelial ovarian cancer who were treated with taxane and platinum-based chemotherapy.	Platinum	168-176	tumor protein p53	Homo sapiens	79-82
19150122-1	2009	OBJECTIVE: The aim of the study was to evaluate the prognostic significance of p53 and PTEN in patients with epithelial ovarian cancer who were treated with taxane and platinum-based chemotherapy.	Platinum	168-176	phosphatase and tensin homolog	Homo sapiens	87-91
18787840-0	2009	Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.	Platinum	179-187	epidermal growth factor receptor	Homo sapiens	0-32
19532012-4	2009	RECENT FINDINGS: Preliminary results of a phase II trial combining an anti-IGF-1R monoclonal antibody with platinum-based chemotherapy in untreated NSCLC patients have shown an encouraging response rate, particularly in those with squamous cell carcinoma, where IGFR expression is typically high.	Platinum	107-115	insulin like growth factor 1 receptor	Homo sapiens	262-266
19428505-5	2009	Regarding MAPKs, platinum derivatives activated p38 while they reduced the active form and the total amount of JNK/Sapk.	Platinum	17-25	mitogen-activated protein kinase 8	Homo sapiens	111-119
19428505-7	2009	By using specific inhibitors of the various MAPKs it was demonstrated that the platinum-induced neuronal apoptosis is mediated by early p38 and ERK1/2 activation, while JNK/Sapk has a neuroprotective role.	Platinum	79-87	mitogen-activated protein kinase 1	Homo sapiens	136-139
19428505-7	2009	By using specific inhibitors of the various MAPKs it was demonstrated that the platinum-induced neuronal apoptosis is mediated by early p38 and ERK1/2 activation, while JNK/Sapk has a neuroprotective role.	Platinum	79-87	mitogen-activated protein kinase 3	Homo sapiens	144-150
19072123-0	2009	Transformations and reactions of Re2(CO)8(mu-SbPh2)(mu-H) induced by the addition of a platinum(tri-t-butylphosphine) group.	Platinum	87-95	G protein-coupled receptor 161	Homo sapiens	33-36
19110234-7	2009	CONCLUSION: Azacitidine enhanced the sensitivity of platinum-resistant ovarian cancer cells to carboplatin associated with caspase-3- and -8-dependent apoptosis pathway and reexpression of DR4.	Platinum	52-60	caspase 3	Homo sapiens	123-140
19110234-7	2009	CONCLUSION: Azacitidine enhanced the sensitivity of platinum-resistant ovarian cancer cells to carboplatin associated with caspase-3- and -8-dependent apoptosis pathway and reexpression of DR4.	Platinum	52-60	major histocompatibility complex, class II, DR beta 4	Homo sapiens	189-192
19396000-9	2009	Despite the limited sample size and nonrandomized nature of this study, these results are provocative and suggest that advanced ovarian cancer patients who achieve an excellent response to primary platinum-based chemotherapy with a CA-125 serum level less than 10 U/mL may be more amenable to the benefits of paclitaxel maintenance therapy.	Platinum	197-205	mucin 16, cell surface associated	Homo sapiens	232-238
19148521-7	2009	Our results suggested that H-1 and H-1R cells may be useful in searching for candidate genes responsible for cross-resistance to platinum derivatives and for further studies to understand the mechanism of platinum resistance.	Platinum	129-137	H1.5 linker histone, cluster member	Homo sapiens	27-30
19148521-7	2009	Our results suggested that H-1 and H-1R cells may be useful in searching for candidate genes responsible for cross-resistance to platinum derivatives and for further studies to understand the mechanism of platinum resistance.	Platinum	205-213	H1.5 linker histone, cluster member	Homo sapiens	27-30
19256601-4	2009	The platinum-dihydrogen (Pt-H(2)) sigma complexes were formed only by occupation of the lowest electronic chemical potential sites associated with Pt-H antibonds (sigma(PtH) ( *)) in saturated platinum clusters.	Platinum	4-12	parathyroid hormone	Homo sapiens	25-29
19256601-4	2009	The platinum-dihydrogen (Pt-H(2)) sigma complexes were formed only by occupation of the lowest electronic chemical potential sites associated with Pt-H antibonds (sigma(PtH) ( *)) in saturated platinum clusters.	Platinum	4-12	parathyroid hormone	Homo sapiens	147-151
19256601-4	2009	The platinum-dihydrogen (Pt-H(2)) sigma complexes were formed only by occupation of the lowest electronic chemical potential sites associated with Pt-H antibonds (sigma(PtH) ( *)) in saturated platinum clusters.	Platinum	4-12	parathyroid hormone	Homo sapiens	169-172
19177209-0	2009	Does spin-orbit coupling effect favor planar structures for small platinum clusters?	Platinum	66-74	spindlin 1	Homo sapiens	5-9
18992864-6	2009	RESULTS: Forced expression of SPARC decreased growth of platinum-resistant ovarian cancer cell lines in vitro.	Platinum	56-64	secreted acidic cysteine rich glycoprotein	Mus musculus	30-35
18996970-0	2009	The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs.	Platinum	79-87	solute carrier family 31 member 1	Homo sapiens	26-46
19281127-0	2009	[K-ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non-small cell lung cancer].	Platinum	43-51	KRAS proto-oncogene, GTPase	Homo sapiens	1-6
20596495-2	2009	Thin film of Pt/Pd alloy on a Si substrate is melted and agglomerated into hemispheric nanodots by thermal dewetting process, and the array of the nanodots is used as etch mask for reactive ion etching (RIE) to form SAS on the Si surface.	Platinum	13-15	ankyrin repeat and KH domain containing 1	Homo sapiens	172-176
18836486-7	2009	CD133+ cells exhibit enhanced resistance to platinum-based therapy, drugs commonly used as first-line agents for the treatment of ovarian cancer.	Platinum	44-52	prominin 1	Homo sapiens	0-5
19147760-1	2009	PURPOSE: The copper transporter 1 (CTR1) is a major influx transporter for platinum drugs.	Platinum	75-83	solute carrier family 31 member 1	Homo sapiens	13-33
19147760-1	2009	PURPOSE: The copper transporter 1 (CTR1) is a major influx transporter for platinum drugs.	Platinum	75-83	solute carrier family 31 member 1	Homo sapiens	35-39
19129592-0	2009	(Di-tert-butylmethylphosphane)(eta2-di-tert-butylphosphanylphosphinidene)(triphenylphosphane)platinum(0).	Platinum	93-101	DNA polymerase iota	Homo sapiens	31-35
18467027-7	2009	The UV and Pt/gamma-Al2O3 combined in HG-OZ can enhance the TOC mineralization efficiency (eta(TOC)) to 56% (via HG-UV-OZ) and 57% (via HG-Pt-OZ), respectively, while only 45% with ozone only.	Platinum	11-13	rhomboid 5 homolog 2	Homo sapiens	60-63
18467027-7	2009	The UV and Pt/gamma-Al2O3 combined in HG-OZ can enhance the TOC mineralization efficiency (eta(TOC)) to 56% (via HG-UV-OZ) and 57% (via HG-Pt-OZ), respectively, while only 45% with ozone only.	Platinum	11-13	rhomboid 5 homolog 2	Homo sapiens	91-99
19053130-9	2009	The affinity of PARP-1 for platinum-modified DNA was established using this type of probe for the first time.	Platinum	27-35	poly(ADP-ribose) polymerase 1	Homo sapiens	16-22
18945793-3	2009	This study was conducted to evaluate the degree of endovascular histologic change associated with ultrathin gold- or vitronectin-coated platinum coils.	Platinum	136-144	vitronectin	Rattus norvegicus	117-128
19274496-3	2009	Data on how platinum-based combination chemotherapy affects Health Related Quality of Life (HRQOL) of patients with PS 2 are scarce and the treatment of this important group of patients is controversial.	Platinum	12-20	taste 2 receptor member 64 pseudogene	Homo sapiens	116-120
19274496-4	2009	METHODS: A national multicenter phase III study on platinum based chemotherapy to 432 advanced NSCLC patients included 123 patients with PS 2.	Platinum	51-59	taste 2 receptor member 64 pseudogene	Homo sapiens	137-141
19274496-10	2009	CONCLUSIONS: PS 2 NSCLC patients seem to achieve valuable HRQOL benefits from platinum-based combination therapy.	Platinum	78-86	taste 2 receptor member 64 pseudogene	Homo sapiens	13-17
19118055-10	2009	Interestingly, the subcohort of 6 SCLC patients with resistance to platinum/etoposide chemotherapy all scored positively for peripheral blood SCG3 transcript (P = 0.022).	Platinum	67-75	secretogranin III	Homo sapiens	142-146
20104979-3	2009	METHODS: From March 1, 2005 to December 31, 2008, the polymerase chain reaction-restriction fragment length polymorphism method was applied to evaluate genetic polymorphisms of the XRCC1 codon399 (Arg/Gln) and XPD codon751 (Lys/Gln) DNA repair genes in 108 patients with stage IIIB and IV NSCLCs treated with platinum-based chemotherapy in the Department of Chemotherapy of Jiangsu Cancer Hospital and Research Institute.	Platinum	309-317	X-ray repair cross complementing 1	Homo sapiens	181-186
19029838-10	2009	The PIK3CA amplification strongly diminished odds of complete remission (OR = 0.25, p = 0.033) and platinum sensitive response (PS, OR = 0.12, p = 0.004) in the taxane-platinum treated patients.	Platinum	99-107	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	4-10
19029838-10	2009	The PIK3CA amplification strongly diminished odds of complete remission (OR = 0.25, p = 0.033) and platinum sensitive response (PS, OR = 0.12, p = 0.004) in the taxane-platinum treated patients.	Platinum	168-176	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	4-10
19219875-3	2009	For all five presented crystal structures, the ECE-pincer-platinum or -palladium head group sticks out of the cutinase molecule and is exposed to the solvent.	Platinum	58-66	endothelin converting enzyme 1	Homo sapiens	47-50
19219875-4	2009	Depending on the nature of the ECE-pincer-metal head group, the ECE-pincer-platinum and -palladium guests occupy different pockets in the active site of cutinase, with concomitant different stereochemistries on the phosphorous atom for the cut-1 (S(P)) and cut-2 (R(P)) structures.	Platinum	75-83	endothelin converting enzyme 1	Homo sapiens	31-34
19219875-4	2009	Depending on the nature of the ECE-pincer-metal head group, the ECE-pincer-platinum and -palladium guests occupy different pockets in the active site of cutinase, with concomitant different stereochemistries on the phosphorous atom for the cut-1 (S(P)) and cut-2 (R(P)) structures.	Platinum	75-83	endothelin converting enzyme 1	Homo sapiens	64-67
19229369-6	2009	Following failure of platinum-based chemotherapy, the evidence suggests that second-line EGFR-TKIS or second-line chemotherapy result in similar survival.	Platinum	21-29	epidermal growth factor receptor	Homo sapiens	89-93
19252342-3	2009	In this study, to elucidate the haplotype structures of GSTT1 and GSTM1, genetic variations were identified in 194 Japanese cancer patients who received platinum-based chemotherapy.	Platinum	153-161	glutathione S-transferase theta 1	Homo sapiens	56-61
19252342-3	2009	In this study, to elucidate the haplotype structures of GSTT1 and GSTM1, genetic variations were identified in 194 Japanese cancer patients who received platinum-based chemotherapy.	Platinum	153-161	glutathione S-transferase mu 1	Homo sapiens	66-71
18937971-6	2009	Platinum highly sensitive response showed a positive association with TP53 accumulation (p=0.045).	Platinum	0-8	tumor protein p53	Homo sapiens	70-74
20045993-1	2009	ATP7A and ATP7B are involved in cellular resistance to platinum compounds such as cisplatin.	Platinum	55-63	ATPase copper transporting alpha	Homo sapiens	0-5
20045993-1	2009	ATP7A and ATP7B are involved in cellular resistance to platinum compounds such as cisplatin.	Platinum	55-63	ATPase copper transporting beta	Homo sapiens	10-15
19697632-0	2009	Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy.	Platinum	98-106	BRCA1 DNA repair associated	Homo sapiens	61-66
19697632-1	2009	We present here a case of a BRCA1 mutation carrier with repeat responsiveness of recurrent EOC to paclitaxel/platinum.	Platinum	109-117	BRCA1 DNA repair associated	Homo sapiens	28-33
19697632-5	2009	In conclusion, recurrent EOC in BRCA1 mutation carriers may retain sensitivity to paclitaxel/platinum combination chemotherapy, and this combination could be therapy of first choice in this patient population.	Platinum	93-101	BRCA1 DNA repair associated	Homo sapiens	32-37
19899409-1	2009	PURPOSE: The aim of the study was to assess whether COX-2 expression in epithelial ovarian carcinoma (EOC) tissue can distinguish between platin-sensitive and platin-resistant tumors.	Platinum	138-144	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	52-57
19899409-1	2009	PURPOSE: The aim of the study was to assess whether COX-2 expression in epithelial ovarian carcinoma (EOC) tissue can distinguish between platin-sensitive and platin-resistant tumors.	Platinum	159-165	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	52-57
19516889-10	2009	The effects may be associated with over-expression of MDR1, LRP, P-gp, and Bcl-2, which can increase the intracellular platinum accumulation and induce the cell apoptosis.	Platinum	119-127	ATP binding cassette subfamily B member 1	Homo sapiens	54-58
19258951-0	2009	Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany.	Platinum	127-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-60
19258951-0	2009	Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany.	Platinum	127-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	62-67
19258951-0	2009	Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany.	Platinum	127-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-72
19258951-2	2009	This exploratory analysis evaluates Her-2/neu as a prognostic factor in a large cohort of patients with advanced-stage ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy within a prospective randomized trial.	Platinum	147-155	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-45
19516889-10	2009	The effects may be associated with over-expression of MDR1, LRP, P-gp, and Bcl-2, which can increase the intracellular platinum accumulation and induce the cell apoptosis.	Platinum	119-127	major vault protein	Homo sapiens	60-63
19516889-10	2009	The effects may be associated with over-expression of MDR1, LRP, P-gp, and Bcl-2, which can increase the intracellular platinum accumulation and induce the cell apoptosis.	Platinum	119-127	ATP binding cassette subfamily B member 1	Homo sapiens	65-69
19516889-10	2009	The effects may be associated with over-expression of MDR1, LRP, P-gp, and Bcl-2, which can increase the intracellular platinum accumulation and induce the cell apoptosis.	Platinum	119-127	BCL2 apoptosis regulator	Homo sapiens	75-80
19538866-0	2009	[Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].	Platinum	104-112	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	28-33
19149760-2	2009	In the last 10 years the medical approach to platinum-resistant Non Small Cell Lung Cancer (NSCLC) has radically changed, passing from a lack of evidence of any primary treatment against the tumor, to the identification of chemotherapy or EGFR inhibitors as the gold standard for clinical practice.	Platinum	45-53	epidermal growth factor receptor	Homo sapiens	239-243
19149760-7	2009	Can the new EGFR inhibitors be considered an innovation in the treatment of platinum-resistant NSCLC, and should they be used in all patients with platinum-resistant NSCLC?	Platinum	76-84	epidermal growth factor receptor	Homo sapiens	12-16
19538866-1	2009	OBJECTIVE: To investigate the correlation of the mRNA expression level of excision repair cross-complementing group 1 (ERCC1) gene with clinicopathological parameters and clinical outcome in patients with non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy.	Platinum	250-258	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	74-117
19538866-1	2009	OBJECTIVE: To investigate the correlation of the mRNA expression level of excision repair cross-complementing group 1 (ERCC1) gene with clinicopathological parameters and clinical outcome in patients with non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy.	Platinum	250-258	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	119-124
19538866-8	2009	CONCLUSION: Our findings suggest that intratumoral ERCC1 mRNA expression level, although is uncorrelated with clinicopathological parameters, is an independent predictive marker for survival of the patients with NSCLC receiving platinum-based chemotherapy, and may provide critical information for personalized chemotherapy.	Platinum	228-236	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	51-56
18978032-3	2008	By using PLGA-b-PEG nanoparticles with PSMA targeting aptamers (Apt) on the surface as a vehicle for the platinum(IV) compound c,t,c-[Pt(NH(3))(2)(O(2)CCH(2)CH(2)CH(2)CH(2)CH(3))(2)Cl(2)] (1), a lethal dose of cisplatin was delivered specifically to prostate cancer cells.	Platinum	105-113	folate hydrolase 1	Homo sapiens	39-43
19018088-0	2008	Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy.	Platinum	90-98	BRCA1 DNA repair associated	Homo sapiens	10-15
19018088-1	2008	PURPOSE: To determine whether germ-line variations in BRCA1 affect outcome in non-small-cell lung cancer (NSCLC) patients treated with platinum combination chemotherapy.	Platinum	135-143	BRCA1 DNA repair associated	Homo sapiens	54-59
19018088-9	2008	CONCLUSION: These findings suggest that the AACC haplotype of the BRCA1 gene is an important prognostic marker in NSCLC patients treated with platinum combination chemotherapy.	Platinum	142-150	BRCA1 DNA repair associated	Homo sapiens	66-71
19074899-8	2008	Taken together, our results strongly suggest that let-7i might be used as a therapeutic target to modulate platinum-based chemotherapy and as a biomarker to predict chemotherapy response and survival in patients with ovarian cancer.	Platinum	107-115	microRNA let-7i	Homo sapiens	50-56
18977144-0	2008	Poly(ADP-ribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA.	Platinum	93-101	poly(ADP-ribose) polymerase 1	Homo sapiens	0-29
18977144-1	2008	The affinity of the poly(ADP-ribose) polymerase-1 (PARP-1) for platinum-damaged DNA was first discovered during photo-cross-linking experiments using the photoactive compound Pt-BP6 [J.	Platinum	63-71	poly(ADP-ribose) polymerase 1	Homo sapiens	20-49
18977144-1	2008	The affinity of the poly(ADP-ribose) polymerase-1 (PARP-1) for platinum-damaged DNA was first discovered during photo-cross-linking experiments using the photoactive compound Pt-BP6 [J.	Platinum	63-71	poly(ADP-ribose) polymerase 1	Homo sapiens	51-57
18977144-7	2008	We find that the activity of PARP proteins following exposure to platinum-modified DNA results in the dissociation of DNA-bound proteins.	Platinum	65-73	poly(ADP-ribose) polymerase 1	Homo sapiens	29-33
19079629-1	2008	BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIS) and chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung cancer (NSCLC) following failure of first-line platinum-based chemotherapy.	Platinum	224-232	epidermal growth factor receptor	Homo sapiens	73-77
19079629-13	2008	CONCLUSIONS: For patients with advanced nsclc who progressed following first-line platinum-based chemotherapy, the data demonstrate that second-line EGFR-TKI treatment is efficacious and well-tolerated and that it does not appear to diminish the benefit of third-line chemotherapy.	Platinum	82-90	epidermal growth factor receptor	Homo sapiens	149-153
18851872-0	2008	XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer.	Platinum	102-110	X-ray repair cross complementing 1	Homo sapiens	0-5
18851872-0	2008	XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer.	Platinum	102-110	gamma-glutamyl hydrolase	Homo sapiens	32-35
18955455-5	2008	RESULTS: Compared with controls, BRCA-positive patients had higher overall (95.5% v 59.1%; P = .002) and complete response rates (81.8% v 43.2%; P = .004) to first line treatment, higher responses to second and third line platinum-based chemotherapy (second line, 91.7% v 40.9% [P = .004]; third line, 100% v 14.3% [P = .005]) and longer TFIs.	Platinum	222-230	BRCA1 DNA repair associated	Homo sapiens	33-37
19060504-0	2008	Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer.	Platinum	88-96	C-reactive protein	Homo sapiens	15-33
19060504-1	2008	OBJECTIVE: This study was conducted to assess the prognostic role of regular measurements of C-reactive protein (CRP) in patients with advanced-stage non-small cell lung cancer (NSCLC) during platinum-based first-line therapy.	Platinum	192-200	C-reactive protein	Homo sapiens	93-111
19060504-1	2008	OBJECTIVE: This study was conducted to assess the prognostic role of regular measurements of C-reactive protein (CRP) in patients with advanced-stage non-small cell lung cancer (NSCLC) during platinum-based first-line therapy.	Platinum	192-200	C-reactive protein	Homo sapiens	113-116
19060504-8	2008	CONCLUSIONS: Measurement of CRP before initiation and during a platinum-based chemotherapy can provide prognostic information for the individual patient with advanced NSCLC and is able to support or even replace assessment of response by radiographic imaging in defined situations.	Platinum	63-71	C-reactive protein	Homo sapiens	28-31
18793687-4	2008	Two different kinase inhibitors (LY364947 and erlotinib, directed to either the TGF-beta receptor kinase or the EGF receptor) were individually conjugated to LZM via a novel platinum-based linker (Universal Linkage System; ULS).	Platinum	174-182	lysozyme	Homo sapiens	158-161
19175039-2	2008	The hMLH1 and hMSH2 proteins play a critical role in the maintenance of genome integrity and are involved in resistance to platinum-based therapy in colorectal cancer, which is deficient in hMLH1 protein and endometrial cancer, as well as in hMSH2 protein.	Platinum	123-131	mutL homolog 1	Homo sapiens	4-9
19175039-2	2008	The hMLH1 and hMSH2 proteins play a critical role in the maintenance of genome integrity and are involved in resistance to platinum-based therapy in colorectal cancer, which is deficient in hMLH1 protein and endometrial cancer, as well as in hMSH2 protein.	Platinum	123-131	mutS homolog 2	Homo sapiens	14-19
19175039-2	2008	The hMLH1 and hMSH2 proteins play a critical role in the maintenance of genome integrity and are involved in resistance to platinum-based therapy in colorectal cancer, which is deficient in hMLH1 protein and endometrial cancer, as well as in hMSH2 protein.	Platinum	123-131	mutL homolog 1	Homo sapiens	190-195
19175039-2	2008	The hMLH1 and hMSH2 proteins play a critical role in the maintenance of genome integrity and are involved in resistance to platinum-based therapy in colorectal cancer, which is deficient in hMLH1 protein and endometrial cancer, as well as in hMSH2 protein.	Platinum	123-131	mutS homolog 2	Homo sapiens	242-247
18801423-0	2008	Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP.	Platinum	35-43	ATP binding cassette subfamily G member 2	Canis lupus familiaris	10-15
18801423-2	2008	In this study, we examined possible interactions of ABCG2 transporter with platinum cytotoxic drugs.	Platinum	75-83	ATP binding cassette subfamily G member 2	Canis lupus familiaris	52-57
18823373-2	2008	The present study assessed the prognostic and predictive value of MMP-7 in tumors of patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy.	Platinum	156-164	matrix metallopeptidase 7	Homo sapiens	66-71
18956061-1	2008	Enhanced and rapid growth of lysozyme crystals at the surface of a platinum electrode, using an applied current and a simplified crystallizing solution, is demonstrated.	Platinum	67-75	lysozyme	Homo sapiens	29-37
18841938-1	2008	An integrated platinum nanoparticles (NPs)/glucose oxidase (GOx) composite film associated with a Au electrode is used to follow the biocatalytic activities of the enzyme.	Platinum	14-22	hydroxyacid oxidase 1	Homo sapiens	60-63
18823373-12	2008	These findings suggest that the expression level of MMP-7 in tumor cells is predictive of response to chemotherapy and outcome in patients with advanced NSCLC receiving platinum-based chemotherapy.	Platinum	169-177	matrix metallopeptidase 7	Homo sapiens	52-57
18980987-7	2008	ANKRD1 mRNA levels were correlated with platinum sensitivity in cell lines, and most significantly, decreasing ANKRD1 using siRNA increased cisplatin sensitivity &gt;2-fold.	Platinum	40-48	ankyrin repeat domain 1	Homo sapiens	0-6
18980987-9	2008	CONCLUSIONS: These findings suggest that ANKRD1, a gene not previously associated with ovarian cancer or with response to chemotherapy, is associated with treatment outcome, and decreasing ANKRD1 expression, or function, is a potential strategy to sensitize tumors to platinum-based drugs.	Platinum	268-276	ankyrin repeat domain 1	Homo sapiens	41-47
18980987-9	2008	CONCLUSIONS: These findings suggest that ANKRD1, a gene not previously associated with ovarian cancer or with response to chemotherapy, is associated with treatment outcome, and decreasing ANKRD1 expression, or function, is a potential strategy to sensitize tumors to platinum-based drugs.	Platinum	268-276	ankyrin repeat domain 1	Homo sapiens	189-195
19087571-0	2008	[Suppression of WWOX gene by RNA interference reverses platinum resistance acquired in SKOV3/SB cells].	Platinum	55-63	WW domain containing oxidoreductase	Homo sapiens	16-20
18723214-10	2008	HIGH DcR3 level was associated with stage IV disease and more than double the incidence of platinum resistant disease.	Platinum	91-99	TNF receptor superfamily member 6b	Homo sapiens	5-9
18710896-3	2008	In the present study, we examined whether hOCT3 was significantly involved in the oxaliplatin-induced cytotoxicity and accumulation of platinum in colorectal cancer.	Platinum	135-143	solute carrier family 22 member 3	Homo sapiens	42-47
18710896-6	2008	The release of lactate dehydrogenase (LDH) and accumulation of platinum with oxaliplatin treatment were increased in SW480 cells transfected with hOCT3 cDNA compared with empty vector-transfected cells.	Platinum	63-71	solute carrier family 22 member 3	Homo sapiens	146-151
18768214-0	2008	CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy.	Platinum	89-97	mucin 16, cell surface associated	Homo sapiens	0-5
19087571-6	2008	(2) After transfection of the WWOX interference fragment, the index of platinum resistance of SKOV3/SB decreased from 5.04 to 3.89.	Platinum	71-79	WW domain containing oxidoreductase	Homo sapiens	30-34
18800828-0	2008	Neglected bidentate sp2 N-donor carrier ligands with triazine nitrogen lone pairs: platinum complexes retromodeling cisplatin guanine nucleobase adducts.	Platinum	83-91	Sp2 transcription factor	Homo sapiens	20-23
19028616-4	2008	Moreover, platinum compounds have shown synergistic activity with trastuzumab, a monoclonal antibody against overexpressing HER2 breast cancer.	Platinum	10-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	124-128
18823085-10	2008	Further, in addition to the surface coordination behavior, we have also mimicked the chemisorption of the 1,2-dithiolane moiety onto the gold substrate in molecular coordination chemistry in oxidative addition reactions with the zero-valent platinum complex [Pt(PPh 3) 4].	Platinum	241-249	caveolin 1	Homo sapiens	262-267
18927287-5	2008	Recently, using cell-based experiments, we showed that platinum-based drugs and the antidiabetic drug rosiglitazone (PPARgamma ligand) interact synergistically to reduce cancer cell and tumor growth.	Platinum	55-63	peroxisome proliferator activated receptor gamma	Mus musculus	117-126
18927287-14	2008	CONCLUSIONS: These data show that the PPARgamma ligand/carboplatin combination is a new therapy worthy of clinical investigation in lung cancers, including those cancers that show primary resistance to platinum therapy or acquired resistance to targeted therapy.	Platinum	202-210	peroxisome proliferator activated receptor gamma	Mus musculus	38-47
18193228-0	2008	7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel synthetic compound induces lung carcinoma cell death associated with inhibiting ERK and CDC2 phosphorylation via a p53-independent pathway.	Platinum	47-50	mitogen-activated protein kinase 1	Homo sapiens	144-147
18193228-0	2008	7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel synthetic compound induces lung carcinoma cell death associated with inhibiting ERK and CDC2 phosphorylation via a p53-independent pathway.	Platinum	47-50	cyclin dependent kinase 1	Homo sapiens	152-156
18193228-0	2008	7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel synthetic compound induces lung carcinoma cell death associated with inhibiting ERK and CDC2 phosphorylation via a p53-independent pathway.	Platinum	47-50	tumor protein p53	Homo sapiens	179-182
18193228-8	2008	PT-262 induced the loss of mitochondrial membrane potential and elevated the caspase-3 activation and apoptosis.	Platinum	0-2	caspase 3	Homo sapiens	77-86
18193228-9	2008	Interestingly, the phosphorylation of ERK was inhibited by PT-262.	Platinum	59-61	mitogen-activated protein kinase 1	Homo sapiens	38-41
18193228-13	2008	PT-262 elicited the cytotoxicity and accumulated the G2/M fractions in both the p53-wild type and p53-null lung cancer cells.	Platinum	0-2	tumor protein p53	Homo sapiens	80-83
18193228-13	2008	PT-262 elicited the cytotoxicity and accumulated the G2/M fractions in both the p53-wild type and p53-null lung cancer cells.	Platinum	0-2	tumor protein p53	Homo sapiens	98-101
18193228-14	2008	The mitosis-regulated protein levels of cyclin B1 and phospho-CDC2 at Thr14, Tyr15, and Thr161 were repressed by PT-262 in these cells.	Platinum	113-115	cyclin B1	Homo sapiens	40-49
18193228-14	2008	The mitosis-regulated protein levels of cyclin B1 and phospho-CDC2 at Thr14, Tyr15, and Thr161 were repressed by PT-262 in these cells.	Platinum	113-115	cyclin dependent kinase 1	Homo sapiens	62-66
19007063-7	2008	The intracellular platinum was increased significantly in Tca8113/nm23-H1 group.	Platinum	18-26	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	66-73
19007063-10	2008	The mitochondrial membrane potential was decreased by nm23-H1 so that intracellular platinum was increased and finally increased the apoptosis or necrosis.	Platinum	84-92	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	54-61
18946749-9	2008	On the basis of in vitro studies, BRCA1-disrupted basal-like cancers may be sensitive to DNA-damaging agents including platinum-based compounds, topoisomerase I and II inhibitors, and alkylating agents.	Platinum	119-127	BRCA1 DNA repair associated	Homo sapiens	34-39
18803406-0	2008	Interaction of metallothionein-2 with platinum-modified 5"-guanosine monophosphate and DNA.	Platinum	38-46	metallothionein 2A	Homo sapiens	15-32
18803406-4	2008	Immunochemical analysis of MT-2 showed that the monofunctional platinum-DNA adducts formed DNA- cis/ trans-Pt-MT cross-links and that platinated MT-2 was released from the DNA- trans-Pt-MT cross-links with time.	Platinum	63-71	metallothionein 2A	Homo sapiens	27-31
18779603-0	2008	Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.	Platinum	128-136	secreted phosphoprotein 1	Homo sapiens	6-17
18586468-0	2008	Bovine serum albumin adsorption on nano-rough platinum surfaces studied by QCM-D.	Platinum	46-54	albumin	Homo sapiens	7-20
18690728-6	2008	In the photocatalytic dehydrogenation of neat ethanol, 1% Pt/TiO 2 (B) nanofiber calcined at 673 K was the most active catalyst and generated about the same amount of H 2 as did 1% Pt/P-25.	Platinum	58-60	tubulin polymerization promoting protein	Homo sapiens	184-188
18395930-1	2008	In this study, we examined the expression of excision repair cross-complementation group 1 (ERCC1) protein in 90 completely resected lung cancer samples from patients who received adjuvant or neo-adjuvant platinum-based chemotherapy.	Platinum	205-213	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	45-90
18395930-1	2008	In this study, we examined the expression of excision repair cross-complementation group 1 (ERCC1) protein in 90 completely resected lung cancer samples from patients who received adjuvant or neo-adjuvant platinum-based chemotherapy.	Platinum	205-213	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	92-97
18395930-3	2008	We also examined class III beta-tubulin protein expression in 50 patients treated with a platinum-based drug plus paclitaxel.	Platinum	89-97	tubulin beta 3 class III	Homo sapiens	17-39
18395930-4	2008	Among 90 patients treated with platinum-based chemotherapy, the loss of ERCC1 protein expression was associated with a better prognosis (p=0.0068).	Platinum	31-39	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	72-77
18395930-6	2008	Among 50 patients treated with a platinum-based drug plus paclitaxel, loss of class III beta-tubulin protein expression was also associated with a better prognosis (p=0.0303).	Platinum	33-41	tubulin beta 3 class III	Homo sapiens	78-100
18395930-9	2008	In conclusion, we found that the loss of ERCC1 and class III beta-tubulin protein expression were predictors of better survival in patients who received a platinum-based plus taxane chemotherapy.	Platinum	155-163	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	41-46
18395930-9	2008	In conclusion, we found that the loss of ERCC1 and class III beta-tubulin protein expression were predictors of better survival in patients who received a platinum-based plus taxane chemotherapy.	Platinum	155-163	tubulin beta 3 class III	Homo sapiens	51-73
18183478-3	2008	METHODS: TKI was conjugated to the protein Lysozyme (LZM) via a platinum-based linker.	Platinum	64-72	lysozyme	Homo sapiens	53-56
18572212-0	2008	Improved synthesis of unique estradiol-linked platinum(II) complexes showing potent cytocidal activity and affinity for the estrogen receptor alpha and beta.	Platinum	46-54	estrogen receptor 1	Homo sapiens	124-147
18623378-0	2008	ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.	Platinum	97-105	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
18623378-10	2008	CONCLUSIONS: These results suggest that N2-positive NSCLC patients with ERCC1 negative tumors show a survival benefit from neoadjuvant CCRT with a platinum-containing regimen.	Platinum	147-155	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	72-77
27873826-1	2008	A new amperometric uric acid biosensor was developed by immobilizing uricase by a glutaraldehyde crosslinking procedure on polyaniline-polypyrrole (pani-ppy) composite film on the surface of a platinum electrode.	Platinum	193-201	urate oxidase (pseudogene)	Homo sapiens	69-76
19031942-2	2008	MATERIALS AND METHODS: Activated (phosphorylated) p38-MAPK was immunohistochemically assessed in paraffin-embedded tumors obtained at primary debulking surgery from 45 patients treated with gemcitabine for platinum-resistant recurrence.	Platinum	206-214	mitogen-activated protein kinase 14	Homo sapiens	50-53
21479472-10	2008	Inhibition of the hRev3 gene may therefore prove to be a novel clinical strategy for reducing resistance to platinum-based chemotherapy in HNSCC.	Platinum	108-116	REV3 like, DNA directed polymerase zeta catalytic subunit	Homo sapiens	18-23
18719365-0	2008	Platinums sensitize human epithelial tumor cells to lymphotoxin alpha by inhibiting NFkappaB-dependent transcription.	Platinum	0-9	lymphotoxin alpha	Homo sapiens	52-69
18719365-0	2008	Platinums sensitize human epithelial tumor cells to lymphotoxin alpha by inhibiting NFkappaB-dependent transcription.	Platinum	0-9	nuclear factor kappa B subunit 1	Homo sapiens	84-92
18719365-5	2008	Further analysis revealed that the sensitization of platinums was associated with platinums-induced suppression of nuclear factor-kappaB (NFkappaB) and subsequent downregulation of X-linked inhibitor of apoptosis protein (XIAP), which rescued caspase-3 from inhibition.	Platinum	52-61	nuclear factor kappa B subunit 1	Homo sapiens	138-146
18719365-5	2008	Further analysis revealed that the sensitization of platinums was associated with platinums-induced suppression of nuclear factor-kappaB (NFkappaB) and subsequent downregulation of X-linked inhibitor of apoptosis protein (XIAP), which rescued caspase-3 from inhibition.	Platinum	52-61	X-linked inhibitor of apoptosis	Homo sapiens	181-220
18719365-5	2008	Further analysis revealed that the sensitization of platinums was associated with platinums-induced suppression of nuclear factor-kappaB (NFkappaB) and subsequent downregulation of X-linked inhibitor of apoptosis protein (XIAP), which rescued caspase-3 from inhibition.	Platinum	52-61	X-linked inhibitor of apoptosis	Homo sapiens	222-226
18719365-5	2008	Further analysis revealed that the sensitization of platinums was associated with platinums-induced suppression of nuclear factor-kappaB (NFkappaB) and subsequent downregulation of X-linked inhibitor of apoptosis protein (XIAP), which rescued caspase-3 from inhibition.	Platinum	52-61	caspase 3	Homo sapiens	243-252
18719365-5	2008	Further analysis revealed that the sensitization of platinums was associated with platinums-induced suppression of nuclear factor-kappaB (NFkappaB) and subsequent downregulation of X-linked inhibitor of apoptosis protein (XIAP), which rescued caspase-3 from inhibition.	Platinum	82-91	nuclear factor kappa B subunit 1	Homo sapiens	138-146
18719365-5	2008	Further analysis revealed that the sensitization of platinums was associated with platinums-induced suppression of nuclear factor-kappaB (NFkappaB) and subsequent downregulation of X-linked inhibitor of apoptosis protein (XIAP), which rescued caspase-3 from inhibition.	Platinum	82-91	X-linked inhibitor of apoptosis	Homo sapiens	181-220
18719365-5	2008	Further analysis revealed that the sensitization of platinums was associated with platinums-induced suppression of nuclear factor-kappaB (NFkappaB) and subsequent downregulation of X-linked inhibitor of apoptosis protein (XIAP), which rescued caspase-3 from inhibition.	Platinum	82-91	X-linked inhibitor of apoptosis	Homo sapiens	222-226
18719365-5	2008	Further analysis revealed that the sensitization of platinums was associated with platinums-induced suppression of nuclear factor-kappaB (NFkappaB) and subsequent downregulation of X-linked inhibitor of apoptosis protein (XIAP), which rescued caspase-3 from inhibition.	Platinum	82-91	caspase 3	Homo sapiens	243-252
18728395-8	2008	Promising drugs for treating BRCA1-mutated tumors include platinum compounds and PARP inhibitors, which are specifically toxic to DSB repair deficient cells.	Platinum	58-66	breast cancer 1, early onset	Mus musculus	29-34
18081788-0	2008	Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer.	Platinum	130-138	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	29-74
18081788-0	2008	Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer.	Platinum	130-138	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	79-102
18081788-1	2008	This study was undertaken to examine whether there is an association between excision repair cross-complementation group 1 (ERCC1) and xeroderma pigmentosum D (XPD) protein expression levels and response to platinum-based chemotherapy in epithelial ovarian cancer (EOC).	Platinum	207-215	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	77-122
18081788-1	2008	This study was undertaken to examine whether there is an association between excision repair cross-complementation group 1 (ERCC1) and xeroderma pigmentosum D (XPD) protein expression levels and response to platinum-based chemotherapy in epithelial ovarian cancer (EOC).	Platinum	207-215	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	124-129
18081788-1	2008	This study was undertaken to examine whether there is an association between excision repair cross-complementation group 1 (ERCC1) and xeroderma pigmentosum D (XPD) protein expression levels and response to platinum-based chemotherapy in epithelial ovarian cancer (EOC).	Platinum	207-215	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	135-158
18081788-1	2008	This study was undertaken to examine whether there is an association between excision repair cross-complementation group 1 (ERCC1) and xeroderma pigmentosum D (XPD) protein expression levels and response to platinum-based chemotherapy in epithelial ovarian cancer (EOC).	Platinum	207-215	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	160-163
18081788-7	2008	Upregulation of ERCC1 and XPD protein expression was associated with resistance process to platinum-based chemotherapy in advanced EOC.	Platinum	91-99	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	16-21
18081788-7	2008	Upregulation of ERCC1 and XPD protein expression was associated with resistance process to platinum-based chemotherapy in advanced EOC.	Platinum	91-99	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	26-29
18953187-0	2008	Raising the price of platinum: inhibition of NFkappaB in human tumor epithelial cells.	Platinum	21-29	nuclear factor kappa B subunit 1	Homo sapiens	45-53
18636185-1	2008	Copper-transporting P-type adenosine triphosphatase (ATP7B) is reportedly associated with platinum drug resistance in various solid carcinomas.	Platinum	90-98	ATPase copper transporting beta	Homo sapiens	53-58
18647348-2	2008	Saccharomyces cerevisiae with separate deletions of the genes encoding the trimeric protein serine/threonine phosphatase (Pph)3p-platinum sensitivity (Psy)4p-Psy2p complex, are more sensitive than the isogenic wild-type (WT) strain to cisplatin.	Platinum	129-137	protein phosphatase 4 regulatory subunit 3B	Homo sapiens	158-163
17645468-1	2008	AIM: The aim of the present study was to compare an inflammation-based prognostic score (Glasgow Prognostic Score, GPS) with performance status (ECOG-ps) in patients receiving platinum-based chemotherapy for palliation of gastroesophageal cancer.	Platinum	176-184	neurobeachin like 2	Homo sapiens	115-118
17645468-11	2008	CONCLUSION: The presence of a systemic inflammatory response, as evidenced by the GPS, appears to be superior to the subjective assessment of performance status (ECOG-ps) in predicting the response to platinum-based chemotherapy in patients with advanced gastroesophageal cancer.	Platinum	201-209	neurobeachin like 2	Homo sapiens	82-85
18687658-1	2008	Recombinant human erythropoietin is widely used to treat anemia associated with cancer and with the myelosuppressive effects of chemotherapy, particularly platinum-based regimens.	Platinum	155-163	erythropoietin	Homo sapiens	18-32
18280039-1	2008	Granular activated carbon-supported platinum (Pt/GAC) catalysts were prepared by microwave irradiation and characterized by scanning electron microscopy (SEM), energy-dispersive X-ray spectroscopy (EDX) and X-ray diffraction (XRD).	Platinum	36-44	glutaminase	Homo sapiens	49-52
18280039-2	2008	Pt particles dispersing onto the surface of GAC could be penetrated by microwave and acted as "reaction centre" in the degradations of p-nitrophenol (PNP) and pentachlorophenol (PCP) in aqueous solution by microwave-assisted catalytic oxidation.	Platinum	0-2	glutaminase	Homo sapiens	44-47
20641925-8	2004	PAP-1, a polypeptide (ELLLELELLELELLLE), has been found to transform from a hydrophilic form into a lipophilic form in acidic pH conditions in the milieu surrounding the tumor cells with a transition pH (pT) of 6.4, which allows PAP-1 to bind to the plasma membrane of tumor cells (9).	Platinum	204-206	regenerating islet-derived 3 beta	Mus musculus	0-5
18415044-8	2008	CONCLUSION: Pretreatment determination of DNA-PK/Ku86 activities might be helpful in identifying patients who will actually benefit from platinum-based treatment.	Platinum	137-145	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	42-48
18415044-8	2008	CONCLUSION: Pretreatment determination of DNA-PK/Ku86 activities might be helpful in identifying patients who will actually benefit from platinum-based treatment.	Platinum	137-145	X-ray repair cross complementing 5	Homo sapiens	49-53
18636185-2	2008	However, the impact of ATP7B on platinum drug resistance in non-small cell lung cancer (NSCLC) remains unknown.	Platinum	32-40	ATPase copper transporting beta	Homo sapiens	23-28
18507374-2	2008	By addition of AgX salts (X = Cl, Br, NO 3) an unexpected ring-opening reaction occurs with formation of the heteronuclear species PdAg(NP 3)X 3 [X = Cl (7), Br (8)], MAg(PP 3)X 3 [M = Pd, X = Cl (9), Br (10), NO 3 (13);M = Pt, X = Cl (11), Br (12), NO 3 (14)].	Platinum	224-226	NBL1, DAN family BMP antagonist	Homo sapiens	38-42
18594698-0	2008	Synthesis of eta1-borazine complexes of palladium and platinum.	Platinum	54-62	secreted phosphoprotein 1	Homo sapiens	13-17
18498153-5	2008	Likewise, 5 reacts with [AgOClO 3(PPh 3)] in CH 2Cl 2 forming the adduct [AgPdPt 2(mu-Br)(mu-PPh 2) 2(mu-Ph 2P-PPh 2)(R F) 4(PPh 3)] 8, which contains a Pt-Ag bond.	Platinum	78-80	protein phosphatase 4 catalytic subunit	Homo sapiens	34-39
18498153-5	2008	Likewise, 5 reacts with [AgOClO 3(PPh 3)] in CH 2Cl 2 forming the adduct [AgPdPt 2(mu-Br)(mu-PPh 2) 2(mu-Ph 2P-PPh 2)(R F) 4(PPh 3)] 8, which contains a Pt-Ag bond.	Platinum	78-80	protein phosphatase 4 catalytic subunit	Homo sapiens	125-130
18640939-1	2008	PURPOSE: We hypothesized that common polymorphisms in excision repair cross-complementation group 1 (ERCC1), involved in nucleotide excision repair of platinum-induced damage, would be associated with progression-free survival (PFS) and overall survival (OS) in women with optimally resected, stage III epithelial ovarian cancer (EOC) treated with cisplatin and paclitaxel (C+P).	Platinum	151-159	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	101-106
18594541-1	2008	The excision repair cross-complementation group 1 (ERCC1) enzyme plays a rate-limiting role in the nucleotide excision repair pathway and is associated with resistance to platinum-based chemotherapy.	Platinum	171-179	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	4-49
18594541-1	2008	The excision repair cross-complementation group 1 (ERCC1) enzyme plays a rate-limiting role in the nucleotide excision repair pathway and is associated with resistance to platinum-based chemotherapy.	Platinum	171-179	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	51-56
18720553-7	2008	Three recent studies demonstrated that acquired resistance to platinum analogues or PARP inhibitors in tumors carrying frame-shift BRCA1/2 mutations came from restored BRCA1/2 expression and HR function due to secondary intragenic mutations that corrected the open reading frames of mutated BRCA1/2.	Platinum	62-70	BRCA2 DNA repair associated	Homo sapiens	131-138
18720553-7	2008	Three recent studies demonstrated that acquired resistance to platinum analogues or PARP inhibitors in tumors carrying frame-shift BRCA1/2 mutations came from restored BRCA1/2 expression and HR function due to secondary intragenic mutations that corrected the open reading frames of mutated BRCA1/2.	Platinum	62-70	BRCA2 DNA repair associated	Homo sapiens	168-175
18720553-7	2008	Three recent studies demonstrated that acquired resistance to platinum analogues or PARP inhibitors in tumors carrying frame-shift BRCA1/2 mutations came from restored BRCA1/2 expression and HR function due to secondary intragenic mutations that corrected the open reading frames of mutated BRCA1/2.	Platinum	62-70	BRCA2 DNA repair associated	Homo sapiens	168-175
18575733-4	2008	Thirteen patients, whose tumors had an RQV of &gt;1.0 or who had an absolute value of MGMT of &gt;6.0x10(3) copies/microg RNA, were treated by platinum-based chemotherapy using cisplatin or carboplatin.	Platinum	143-151	O-6-methylguanine-DNA methyltransferase	Homo sapiens	86-90
18537815-7	2008	They were put on platinum-based chemotherapy and got APRT.	Platinum	17-25	adenine phosphoribosyltransferase	Homo sapiens	53-57
17961161-2	2008	Excision repair cross-complementation group 1 (ercc1) is one of the leading genes involved in DNA repair, and several studies have linked ercc1 to platinum resistance in cell lines and in human cancers.	Platinum	147-155	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-45
17961161-2	2008	Excision repair cross-complementation group 1 (ercc1) is one of the leading genes involved in DNA repair, and several studies have linked ercc1 to platinum resistance in cell lines and in human cancers.	Platinum	147-155	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
17961161-2	2008	Excision repair cross-complementation group 1 (ercc1) is one of the leading genes involved in DNA repair, and several studies have linked ercc1 to platinum resistance in cell lines and in human cancers.	Platinum	147-155	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	138-143
17961161-3	2008	A common single nucleotide polymorphism (SNP) of ercc1 at codon 118 has been proposed to impair ercc1 translation and reduce ERCC1 protein expression and consequently influence the response to platinum-based chemotherapy.	Platinum	193-201	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	49-54
17961161-3	2008	A common single nucleotide polymorphism (SNP) of ercc1 at codon 118 has been proposed to impair ercc1 translation and reduce ERCC1 protein expression and consequently influence the response to platinum-based chemotherapy.	Platinum	193-201	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	96-101
17961161-3	2008	A common single nucleotide polymorphism (SNP) of ercc1 at codon 118 has been proposed to impair ercc1 translation and reduce ERCC1 protein expression and consequently influence the response to platinum-based chemotherapy.	Platinum	193-201	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	125-130
17961161-4	2008	The primary aim of the present study was to evaluate ERCC1 expression and ercc1 codon 118 polymorphism in epithelial ovarian cancer (EOC) and their possible predictive value in patients treated with platinum-based chemotherapy.	Platinum	199-207	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	53-58
17961161-4	2008	The primary aim of the present study was to evaluate ERCC1 expression and ercc1 codon 118 polymorphism in epithelial ovarian cancer (EOC) and their possible predictive value in patients treated with platinum-based chemotherapy.	Platinum	199-207	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	74-79
17961161-10	2008	Patients with ERCC1-negative tumors appear to have significantly better response to platinum-based chemotherapy compared to patients with ERCC1-positive tumors, but the differences in response rates did not translate into differences in survival.	Platinum	84-92	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-19
18565881-9	2008	ERCC5 was identified as a candidate gene in this region because of its known function in the nucleotide excision repair pathway, the unique DNA repair pathway that removes platinum-DNA adducts.	Platinum	172-180	ERCC excision repair 5, endonuclease	Homo sapiens	0-5
18026990-8	2008	The SLN identification rate was 91.7% for the SA group and 80.9% for the PT group (P = 0.017).	Platinum	73-75	sarcolipin	Homo sapiens	4-7
18447329-7	2008	Values of IC50 were calculated for the new platinum complexes cis-[Pt(C6F5)2(HmtpO)2] and [Pt(dmba)(PPh3)(HmtpO)]ClO4 against a panel of human tumor cell lines representative of ovarian (A2780 and A2780 cisR), lung (NCI-H460), and breast cancers (T47D).	Platinum	43-51	protein phosphatase 4 catalytic subunit	Homo sapiens	100-104
18484750-3	2008	Owing to this unique structure, the Pt particles showed high resistance to sintering when subjected to thermal treatment at temperatures up to 800 degrees C. As a result, hydrogenation reactions using various heat-treated nPt@hCs as catalysts indicated that loss of catalytic activity was minimized.	Platinum	36-38	holocarboxylase synthetase	Homo sapiens	226-229
18484719-11	2008	The rate of reaction of MeI with complex 1 was some 3.5 times faster than that with complex A, indicating that dppf in the complex 1, as compared with PPh 3 in the complex A, has significantly enhanced the electron richness of the platinum centers.	Platinum	231-239	caveolin 1	Homo sapiens	151-156
19452042-4	2008	Among genes involved in the DNA repair system, the excision repair cross-complementing 1 (ERCC1) is a useful markers of clinical resistance to platinum-based chemotherapy.	Platinum	143-151	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	51-88
19452042-4	2008	Among genes involved in the DNA repair system, the excision repair cross-complementing 1 (ERCC1) is a useful markers of clinical resistance to platinum-based chemotherapy.	Platinum	143-151	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	90-95
19325796-1	2008	Photoinduced biohydrogen production systems, coupling saccharaides biomass such as sucrose, maltose, cellobiose, cellulose, or saccharides mixture hydrolysis by enzymes and glucose dehydrogenase (GDH), and hydrogen production with platinum colloid as a catalyst using the visible light-induced photosensitization of Mg chlorophyll-a (Mg Chl-a) from higher green plant or artificial chlorophyll analog, zinc porphyrin, are introduced.	Platinum	231-239	hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	Homo sapiens	196-199
18036700-1	2008	Expression of excision repair cross-complementation group 1 (ERCC1) is important for resistance to platinum agents.	Platinum	99-107	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-59
18350322-2	2008	We show here that horse heart cytochrome c reacts with CPT, leading to the formation of stable platinum/protein adducts.	Platinum	95-103	cytochrome c, somatic	Equus caballus	30-42
18036700-1	2008	Expression of excision repair cross-complementation group 1 (ERCC1) is important for resistance to platinum agents.	Platinum	99-107	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	61-66
18520795-1	2008	HYPOTHESIS: Aim of the study was to quantify ERCC1, RRM1, and TopoIIalpha mRNA expression profile as predictive factors for response and survival in SCLC patients treated with platinum/etoposide.	Platinum	176-184	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	45-50
18494946-1	2008	BACKGROUND AND OBJECTIVE: Expression of genes involved in DNA repair and/or DNA synthesis, including ribonucleotide reductase M1 (RRM1) and excision repair cross-complementation 1 (ERCC1) has been reported to be associated with chemosensitivity to platinum agents and gemcitabine.	Platinum	248-256	ribonucleotide reductase catalytic subunit M1	Homo sapiens	101-128
18520795-1	2008	HYPOTHESIS: Aim of the study was to quantify ERCC1, RRM1, and TopoIIalpha mRNA expression profile as predictive factors for response and survival in SCLC patients treated with platinum/etoposide.	Platinum	176-184	ribonucleotide reductase catalytic subunit M1	Homo sapiens	52-56
18494946-1	2008	BACKGROUND AND OBJECTIVE: Expression of genes involved in DNA repair and/or DNA synthesis, including ribonucleotide reductase M1 (RRM1) and excision repair cross-complementation 1 (ERCC1) has been reported to be associated with chemosensitivity to platinum agents and gemcitabine.	Platinum	248-256	ribonucleotide reductase catalytic subunit M1	Homo sapiens	130-134
18494946-1	2008	BACKGROUND AND OBJECTIVE: Expression of genes involved in DNA repair and/or DNA synthesis, including ribonucleotide reductase M1 (RRM1) and excision repair cross-complementation 1 (ERCC1) has been reported to be associated with chemosensitivity to platinum agents and gemcitabine.	Platinum	248-256	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	181-186
18494946-7	2008	CONCLUSIONS: These in vitro results suggest that further studies are needed to evaluate the expression of the RRM1, ERCC1 and ERCC2 genes as predictive biomarkers for sensitivity to platinum agents and gemcitabine.	Platinum	182-190	ribonucleotide reductase catalytic subunit M1	Homo sapiens	110-114
18494946-7	2008	CONCLUSIONS: These in vitro results suggest that further studies are needed to evaluate the expression of the RRM1, ERCC1 and ERCC2 genes as predictive biomarkers for sensitivity to platinum agents and gemcitabine.	Platinum	182-190	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	116-121
18494946-7	2008	CONCLUSIONS: These in vitro results suggest that further studies are needed to evaluate the expression of the RRM1, ERCC1 and ERCC2 genes as predictive biomarkers for sensitivity to platinum agents and gemcitabine.	Platinum	182-190	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	126-131
18463738-1	2008	Co@Pt-Au nanoparticles, which have enhanced magnetism and high stability in aqueous media, are utilized in conjunction with MRI to monitor the structural evolution of Abeta assemblies, especially Abeta protofibrils in the early reversible stages.	Platinum	3-5	amyloid beta precursor protein	Homo sapiens	167-172
18463738-1	2008	Co@Pt-Au nanoparticles, which have enhanced magnetism and high stability in aqueous media, are utilized in conjunction with MRI to monitor the structural evolution of Abeta assemblies, especially Abeta protofibrils in the early reversible stages.	Platinum	3-5	amyloid beta precursor protein	Homo sapiens	196-201
18483383-5	2008	RESULTS: Overexpression of NAC-1 correlated with shorter relapse-free survival in patients with advanced stage (stage III/IV) ovarian carcinoma treated with platinum and taxane chemotherapy.	Platinum	157-165	nucleus accumbens associated 1	Homo sapiens	27-32
19383331-9	2008	The anti-proliferative effects of low-dose platinum were strikingly potentiated also in resistant p53-deficient cells.	Platinum	43-51	transformation related protein 53, pseudogene	Mus musculus	98-101
18483383-6	2008	Furthermore, overexpression of NAC-1 in primary tumors predicted recurrence within 6 months after primary cytoreductive surgery followed by standard platinum and taxane chemotherapy.	Platinum	149-157	nucleus accumbens associated 1	Homo sapiens	31-36
18461196-2	2008	The same reactions with the analogous dimethyl complex [PtMe2(bpy)] gave the expected platinum(IV) complexes [PtRXMe2(bpy)], R = Et or nPr and X = Br or I; R = nBu and X = I, 4-8.	Platinum	86-94	neuronal pentraxin receptor	Homo sapiens	135-138
18463291-7	2008	This implies that the planar aromatic 1,10-phenanthroline ligands L confer some specificity for Abeta onto the platinum complexes.	Platinum	111-119	amyloid beta (A4) precursor protein	Mus musculus	96-101
18451150-2	2008	Using a spontaneous mouse mammary tumor model, we show that platinum compounds, which generate DNA breaks during the repair process, are more effective than doxorubicin in Brca1/p53-mutated tumors.	Platinum	60-68	breast cancer 1, early onset	Mus musculus	172-177
17661040-1	2008	We have previously demonstrated that overexpression of dihydrodiol dehydrogenase isoform 1 (DDH1) or DDH2 leads to the induction of drug resistance to platinum based drugs in human ovarian, lung, cervical and germ cell tumor cell lines.	Platinum	151-159	aldo-keto reductase family 1 member C1	Homo sapiens	55-90
17661040-1	2008	We have previously demonstrated that overexpression of dihydrodiol dehydrogenase isoform 1 (DDH1) or DDH2 leads to the induction of drug resistance to platinum based drugs in human ovarian, lung, cervical and germ cell tumor cell lines.	Platinum	151-159	aldo-keto reductase family 1 member C1	Homo sapiens	92-96
17661040-1	2008	We have previously demonstrated that overexpression of dihydrodiol dehydrogenase isoform 1 (DDH1) or DDH2 leads to the induction of drug resistance to platinum based drugs in human ovarian, lung, cervical and germ cell tumor cell lines.	Platinum	151-159	DDH2	Homo sapiens	101-105
18451150-2	2008	Using a spontaneous mouse mammary tumor model, we show that platinum compounds, which generate DNA breaks during the repair process, are more effective than doxorubicin in Brca1/p53-mutated tumors.	Platinum	60-68	transformation related protein 53, pseudogene	Mus musculus	178-181
18451150-7	2008	In partially platinum-responsive primary transplants, 6.6% to 11.0% (mean, 8.8%) tumor cells are CD29(hi)24(med); these populations significantly increase to 16.5% to 29.2% (mean, 22.8%; P &lt; 0.05) in platinum-refractory secondary tumor transplants.	Platinum	13-21	integrin beta 1 (fibronectin receptor beta)	Mus musculus	97-101
26621089-2	2008	Characterization of the platinum-containing species was achieved at the HF, MP2, and DFT (PBE1PBE, mPW1PW91, B3LYP, B3PW91, and B3P86) levels of theory, using two relativistic effective core potentials to treat the Pt atom (LanL2DZ and SBK), together with analytical Gaussian-type basis sets as implemented in Gaussian03.	Platinum	24-32	tryptase pseudogene 1	Homo sapiens	76-79
18342529-3	2008	Excision repair cross complementation 1 (ERCC1) is a key-enzyme in the repair of platinum-DNA adducts that has been demonstrated to influence the response to platinum-based therapy.	Platinum	81-89	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-39
18342529-3	2008	Excision repair cross complementation 1 (ERCC1) is a key-enzyme in the repair of platinum-DNA adducts that has been demonstrated to influence the response to platinum-based therapy.	Platinum	81-89	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	41-46
18342529-3	2008	Excision repair cross complementation 1 (ERCC1) is a key-enzyme in the repair of platinum-DNA adducts that has been demonstrated to influence the response to platinum-based therapy.	Platinum	158-166	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-39
18342529-3	2008	Excision repair cross complementation 1 (ERCC1) is a key-enzyme in the repair of platinum-DNA adducts that has been demonstrated to influence the response to platinum-based therapy.	Platinum	158-166	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	41-46
18342529-10	2008	ERCC1 expression might assist in selecting patients who will respond to adjuvant (neoadjuvant) platinum-based chemotherapy.	Platinum	95-103	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
18466065-0	2008	Galvano-spa-bath and health risks due to incorporation of chromium, nickel, and platinum released from electrodes.	Platinum	80-88	surfactant protein A2	Homo sapiens	8-11
18451256-1	2008	PURPOSE: The excision repair cross-complementation group 1 (ERCC1) plays a pivotal role in DNA repair and has been linked to protection against carcinogenesis and resistance to platinum-based anticancer drugs.	Platinum	177-185	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	13-58
18451256-1	2008	PURPOSE: The excision repair cross-complementation group 1 (ERCC1) plays a pivotal role in DNA repair and has been linked to protection against carcinogenesis and resistance to platinum-based anticancer drugs.	Platinum	177-185	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	60-65
18451256-2	2008	We tested whether genetic variants in the ERCC1 gene are associated with susceptibility to lung cancer and efficacy of platinum-chemotherapy in patients with small cell lung cancer (SCLC).	Platinum	119-127	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	42-47
18451256-11	2008	CONCLUSIONS: These findings are consistent with the notion that DNA repair is a double-edged sword in cancer and suggest that functional single-nucleotide polymorphisms in ERCC1 might serve as simple and less invasive biomarkers for personalized chemotherapy of platinum-based anticancer drugs.	Platinum	262-270	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	172-177
18329083-0	2008	Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.	Platinum	86-94	mucin 16, cell surface associated	Homo sapiens	26-32
18329083-2	2008	METHODS: A multicentric study of CA 125 kinetics under paclitaxel/platinum-based chemotherapy was performed in 130 stage IIc-IV patients.	Platinum	66-74	mucin 16, cell surface associated	Homo sapiens	33-39
18329083-11	2008	CONCLUSION: Characteristics of CA 125 kinetics during first line paclitaxel/platinum chemotherapy have a strong and independent prognostic value.	Platinum	76-84	mucin 16, cell surface associated	Homo sapiens	31-37
18425336-0	2008	ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy.	Platinum	107-115	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
18425336-1	2008	Excision repair cross-complementation 1 (ERCC1) has been reported to play a major role in the response to platinum-based therapies.	Platinum	106-114	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	41-46
18425336-9	2008	ERCC1 polymorphism may be a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy.	Platinum	101-109	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
19578506-0	2008	Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer.	Platinum	101-109	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-52
18414472-1	2008	The Fanconi gene family has a role in DNA repair and inactivation of FANCF has been proposed as a mechanism of sensitisation to platinum chemotherapy.	Platinum	128-136	FA complementation group F	Homo sapiens	69-74
19578506-7	2008	These data suggest the potent use of ERCC1 as a molecular predictor of clinical resistance to platinum-based chemotherapy in the adjuvant setting of NSCLC.	Platinum	94-102	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	37-42
20731911-1	2008	BACKGROUND: It has been proven that ERCC1(excision repair cross-complementation group 1)plays an important role in tumor sensitivity to platinum-based chemotherapy.This study was to examine the relationship between ERCC1 expression in NSCLCand efficacy of neoadjuvant chemotherapy.	Platinum	136-144	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	36-41
18338901-2	2008	Nanosized platinum particles dispersed on platelet-type CNF efficiently catalyze the reduction of functionalized nitroarenes to the corresponding substituted anilines in high turnover numbers with other functional groups remaining intact.	Platinum	10-18	NPHS1 adhesion molecule, nephrin	Homo sapiens	56-59
20731911-1	2008	BACKGROUND: It has been proven that ERCC1(excision repair cross-complementation group 1)plays an important role in tumor sensitivity to platinum-based chemotherapy.This study was to examine the relationship between ERCC1 expression in NSCLCand efficacy of neoadjuvant chemotherapy.	Platinum	136-144	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	215-220
18324837-5	2008	The association of the (3)-functionalized Pt NPs or CdS NPs to a boronic acid monolayer-modified electrode enables the electrochemical transduction of TR activity by the Pt-NPs-electrocatalyzed reduction of H2O2 or the photoelectrochemical transduction of TR activity by the generation of photocurrents in the presence of triethanolamine as a sacrificial electron donor.	Platinum	42-44	tyrosinase	Homo sapiens	151-153
18243683-6	2008	An electropolymerized meta-phenylenediamine (mPD) layer was used to exclude interfering substances from being recorded at the platinum recording sites.	Platinum	126-134	mevalonate (diphospho) decarboxylase	Mus musculus	45-48
18324837-5	2008	The association of the (3)-functionalized Pt NPs or CdS NPs to a boronic acid monolayer-modified electrode enables the electrochemical transduction of TR activity by the Pt-NPs-electrocatalyzed reduction of H2O2 or the photoelectrochemical transduction of TR activity by the generation of photocurrents in the presence of triethanolamine as a sacrificial electron donor.	Platinum	42-44	tyrosinase	Homo sapiens	256-258
18507046-6	2008	Platinum sensitivity was associated with heterozygosity at the TP53 locus (p = 0.006).	Platinum	0-8	tumor protein p53	Homo sapiens	63-67
18413725-0	2008	Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.	Platinum	67-75	BRCA1 DNA repair associated	Homo sapiens	10-15
18413725-0	2008	Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.	Platinum	67-75	BRCA1 DNA repair associated	Homo sapiens	29-34
18413725-1	2008	Although ovarian carcinomas with mutated BRCA1 or BRCA2 are sensitive to platinum compounds, such carcinomas eventually develop platinum resistance.	Platinum	73-81	BRCA1 DNA repair associated	Homo sapiens	41-46
18413725-1	2008	Although ovarian carcinomas with mutated BRCA1 or BRCA2 are sensitive to platinum compounds, such carcinomas eventually develop platinum resistance.	Platinum	73-81	BRCA2 DNA repair associated	Homo sapiens	50-55
18413725-3	2008	Here, we show that secondary mutations of BRCA1 also occur in BRCA1-mutated ovarian cancer with platinum resistance.	Platinum	96-104	BRCA1 DNA repair associated	Homo sapiens	42-47
18413725-3	2008	Here, we show that secondary mutations of BRCA1 also occur in BRCA1-mutated ovarian cancer with platinum resistance.	Platinum	96-104	BRCA1 DNA repair associated	Homo sapiens	62-67
18413725-5	2008	Four of the six recurrent platinum-resistant tumors had developed secondary genetic changes in BRCA1 that restored the reading frame of the BRCA1 protein, whereas none of the three platinum-sensitive recurrent tumors developed BRCA1 sequence alterations.	Platinum	26-34	BRCA1 DNA repair associated	Homo sapiens	95-100
18413725-5	2008	Four of the six recurrent platinum-resistant tumors had developed secondary genetic changes in BRCA1 that restored the reading frame of the BRCA1 protein, whereas none of the three platinum-sensitive recurrent tumors developed BRCA1 sequence alterations.	Platinum	26-34	BRCA1 DNA repair associated	Homo sapiens	140-145
18413725-5	2008	Four of the six recurrent platinum-resistant tumors had developed secondary genetic changes in BRCA1 that restored the reading frame of the BRCA1 protein, whereas none of the three platinum-sensitive recurrent tumors developed BRCA1 sequence alterations.	Platinum	26-34	BRCA1 DNA repair associated	Homo sapiens	140-145
18413725-7	2008	Intriguingly, the case with primary platinum resistance showed back mutation of BRCA1 in the primary tumor and showed another secondary mutation in the recurrent tumor.	Platinum	36-44	BRCA1 DNA repair associated	Homo sapiens	80-85
18413725-8	2008	Our results suggest that secondary mutations in BRCA1 can mediate resistance to platinum in BRCA1-mutated ovarian tumors.	Platinum	80-88	BRCA1 DNA repair associated	Homo sapiens	48-53
18413725-8	2008	Our results suggest that secondary mutations in BRCA1 can mediate resistance to platinum in BRCA1-mutated ovarian tumors.	Platinum	80-88	BRCA1 DNA repair associated	Homo sapiens	92-97
18421027-5	2008	Expression of LTB4-BLT2 correlated with advanced stage III/IV disease (P = .05), suboptimal debulking (P = .07), and platinum resistance (P = .03).	Platinum	117-125	leukotriene B4 receptor 2	Homo sapiens	19-23
18349819-3	2008	Given that DNA damage pathways are linked to platinum resistance, the aim of this study was to determine if EDD expression was associated with disease recurrence and platinum sensitivity in serous ovarian cancer.	Platinum	45-53	ubiquitin protein ligase E3 component n-recognin 5	Homo sapiens	108-111
18349819-3	2008	Given that DNA damage pathways are linked to platinum resistance, the aim of this study was to determine if EDD expression was associated with disease recurrence and platinum sensitivity in serous ovarian cancer.	Platinum	166-174	ubiquitin protein ligase E3 component n-recognin 5	Homo sapiens	108-111
18349819-5	2008	Although EDD expression was not directly correlated with relative cisplatin sensitivity of ovarian cancer cell lines, sensitivity to cisplatin was partially restored in platinum-resistant A2780-cp70 ovarian cancer cells following siRNA-mediated knockdown of EDD expression.	Platinum	169-177	ubiquitin protein ligase E3 component n-recognin 5	Homo sapiens	9-12
18349819-5	2008	Although EDD expression was not directly correlated with relative cisplatin sensitivity of ovarian cancer cell lines, sensitivity to cisplatin was partially restored in platinum-resistant A2780-cp70 ovarian cancer cells following siRNA-mediated knockdown of EDD expression.	Platinum	169-177	ubiquitin protein ligase E3 component n-recognin 5	Homo sapiens	258-261
18269242-1	2008	This paper describes a reinvestigation of the literature concerning the synthesis and structural characterization of the platinum(IV)-based anticancer drug known as CPA-7 and believed to be the compound fac-[PtCl3(NO2)(NH 3)2].	Platinum	121-129	cytochrome P450 family 2 subfamily A member 7	Homo sapiens	165-170
18269242-1	2008	This paper describes a reinvestigation of the literature concerning the synthesis and structural characterization of the platinum(IV)-based anticancer drug known as CPA-7 and believed to be the compound fac-[PtCl3(NO2)(NH 3)2].	Platinum	121-129	FA complementation group C	Homo sapiens	203-206
18316624-0	2008	Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.	Platinum	173-181	kinase insert domain protein receptor	Mus musculus	123-130
18316624-9	2008	Furthermore, the tumor cells also showed enhanced sensitivity to platinum-based chemotherapy in combination with PTK/ZK, indicating that autocrine VEGFRs are promoting tumor cell migration and survival.	Platinum	65-73	FMS-like tyrosine kinase 1	Mus musculus	147-153
18317076-1	2008	A 37-year-old female never smoker with metastatic large cell carcinoma of the lung had a partial response to a second line palliative therapy with the EGF-R tyrosine kinase inhibitor erlotinib after platinum based first line therapy failed.	Platinum	199-207	epidermal growth factor receptor	Homo sapiens	151-156
18060564-7	2008	Release of the platinum complexes from vitamin B12 is driven by intracellular reduction of Co(III) to Co(II) to Co(I) and subsequent adenosylation by the adenosyltransferase CobA.	Platinum	15-23	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	91-98
18060564-7	2008	Release of the platinum complexes from vitamin B12 is driven by intracellular reduction of Co(III) to Co(II) to Co(I) and subsequent adenosylation by the adenosyltransferase CobA.	Platinum	15-23	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	102-108
18060564-7	2008	Release of the platinum complexes from vitamin B12 is driven by intracellular reduction of Co(III) to Co(II) to Co(I) and subsequent adenosylation by the adenosyltransferase CobA.	Platinum	15-23	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	112-117
18264087-10	2008	Our results suggest that secondary mutations that restore the wild-type BRCA2 reading frame may be a major clinical mediator of acquired resistance to platinum-based chemotherapy.	Platinum	151-159	BRCA2 DNA repair associated	Homo sapiens	72-77
18347153-11	2008	In conclusion, our results indicate that the development of resistance to platinum drugs is associated with multiple alterations including deregulation of survival pathways activated by EGFR resulting in a reduced cellular response to gefitinib.	Platinum	74-82	epidermal growth factor receptor	Homo sapiens	186-190
18264087-1	2008	Ovarian carcinomas with mutations in the tumour suppressor BRCA2 are particularly sensitive to platinum compounds.	Platinum	95-103	BRCA2 DNA repair associated	Homo sapiens	59-64
20727282-8	2008	In the patients with platinum chemotherapy, the frequency of GSTM1-null genotype was 65.43%(53/81) in the response group of chemotherapy and 42%(21/50) in the non-response group.	Platinum	21-29	glutathione S-transferase mu 1	Homo sapiens	61-66
17922863-12	2008	CONCLUSION: These findings suggest that HMG1 induction as an enhancer of platinum sensitivity is mediated through interaction between oestrogen and ER-alpha.	Platinum	73-81	high mobility group box 1 pseudogene 5	Homo sapiens	40-44
18211000-2	2008	In the case of the C 3-symmetric trimer, each bpzph (-) ligand is bidentate with the metal bonded to a pyrazolyl group and to the phenyl group at the 6 position; the remaining pyrazolyl group bridges to an adjacent platinum center.	Platinum	215-223	complement C3	Homo sapiens	19-22
17922863-12	2008	CONCLUSION: These findings suggest that HMG1 induction as an enhancer of platinum sensitivity is mediated through interaction between oestrogen and ER-alpha.	Platinum	73-81	estrogen receptor 1	Homo sapiens	148-156
18036640-9	2008	Among patients receiving first-line chemotherapy, VEGF levels &lt;1900 pg/ml and TNFalpha levels &gt;35 pg/ml were associated with platinum sensitivity (p=0.021 and p=0.028, respectively) and improved progression-free survival (PFS) (p=0.007 and p=0.045, respectively).	Platinum	131-139	vascular endothelial growth factor A	Homo sapiens	50-54
18245530-6	2008	Patients with platinum-resistant EOC had significantly higher CRP serum levels compared with patients with platinum-sensitive EOC [6.0 (6.6) mg/dL versus 2.8 (3.8) mg/dL; P &lt; 0.001].	Platinum	14-22	C-reactive protein	Homo sapiens	62-65
18281754-3	2008	Na(+), K(+)-ATPase and multidrug resistance protein 1 were reported to be related to the accumulation of platinum drugs in tumor cells.	Platinum	105-113	ATP binding cassette subfamily B member 1	Homo sapiens	23-53
18281754-4	2008	Glutathione S-transferase-pi and metallo- thionein have been related to the metabolism of platinum drugs, excision repair cross-complementing 1/2 to DNA repair systems, and p53 to apoptosis.	Platinum	90-98	tumor protein p53	Homo sapiens	173-176
18036640-9	2008	Among patients receiving first-line chemotherapy, VEGF levels &lt;1900 pg/ml and TNFalpha levels &gt;35 pg/ml were associated with platinum sensitivity (p=0.021 and p=0.028, respectively) and improved progression-free survival (PFS) (p=0.007 and p=0.045, respectively).	Platinum	131-139	tumor necrosis factor	Homo sapiens	81-89
18095679-1	2008	Cyclization of 1,5-dienes bearing nucleophilic traps with electrophilic trisphosphine pincer ligated Pt(II) complexes results in the formation of a polycyclic Pt-alkyl via a Pt(eta2-alkene) intermediate.	Platinum	101-103	DNA polymerase iota	Homo sapiens	177-181
17875340-0	2008	Early intervention with epoetin beta prevents severe anaemia in lung cancer patients receiving platinum-based chemotherapy: a subgroup analysis of the NeoPrevent study.	Platinum	95-103	erythropoietin	Homo sapiens	24-31
17875340-1	2008	The NeoPrevent study showed that early intervention with epoetin beta could prevent severe anaemia in patients with solid tumours receiving platinum-based chemotherapy.	Platinum	140-148	erythropoietin	Homo sapiens	57-64
17875340-12	2008	Epoetin beta was effective in preventing severe anaemia in lung cancer patients receiving platinum-based chemotherapy.	Platinum	90-98	erythropoietin	Homo sapiens	0-7
18230133-6	2008	RESULTS: The advantage of taxane-platinum therapy over platinum-based therapy was seen in the TP53(+), and not in the TP53(-) group.	Platinum	55-63	tumor protein p53	Homo sapiens	94-98
18230133-7	2008	In the TP53(+) group taxane-platinum therapy enhanced the probability of complete remission (p = .018), platinum sensitivity (p = .014), platinum highly sensitive response (p = .038) and longer survival (OS, p = .008).	Platinum	28-36	tumor protein p53	Homo sapiens	7-11
18230133-7	2008	In the TP53(+) group taxane-platinum therapy enhanced the probability of complete remission (p = .018), platinum sensitivity (p = .014), platinum highly sensitive response (p = .038) and longer survival (OS, p = .008).	Platinum	104-112	tumor protein p53	Homo sapiens	7-11
18230133-7	2008	In the TP53(+) group taxane-platinum therapy enhanced the probability of complete remission (p = .018), platinum sensitivity (p = .014), platinum highly sensitive response (p = .038) and longer survival (OS, p = .008).	Platinum	104-112	tumor protein p53	Homo sapiens	7-11
18230133-8	2008	Poor tumor differentiation diminished the advantage from taxane-platinum therapy in the TP53(+) group.	Platinum	64-72	tumor protein p53	Homo sapiens	88-92
18230133-9	2008	In the TP53(-) group PC/PAC was at least equally efficient as taxane-platinum therapy and it enhanced the chance of platinum highly sensitive response (p = .010).	Platinum	116-124	tumor protein p53	Homo sapiens	7-11
18230133-10	2008	However, in the TP53(-) group taxane-platinum therapy possibly diminished the risk of death in patients over 53 yrs (p = .077).	Platinum	37-45	tumor protein p53	Homo sapiens	16-20
18230133-12	2008	CONCLUSION: Our results suggest that taxane-platinum therapy is particularly justified in patients with TP53(+) tumors or older than 53 years.	Platinum	44-52	tumor protein p53	Homo sapiens	104-108
18230133-13	2008	In the group of patients &lt; or =53 yrs and with TP53(-) tumors platinum-based therapy is possibly equally efficient.	Platinum	65-73	tumor protein p53	Homo sapiens	50-54
17970617-4	2008	The aim of this study was to examine the binding of a novel anticancer estradiol-platinum(II) hybrid molecule (CD-37) with calf-thymus DNA in vitro and to compare the results with those obtained with cisplatin drug.	Platinum	81-89	CD37 molecule	Bos taurus	111-116
17457342-2	2008	Megalin, a member of the low-density lipoprotein receptor family, is highly expressed in renal proximal tubular cells and marginal cells of the stria vascularis of the inner ear - tissues, which accumulate high levels of platinum-DNA adducts.	Platinum	221-229	LDL receptor related protein 2	Homo sapiens	0-7
18230133-6	2008	RESULTS: The advantage of taxane-platinum therapy over platinum-based therapy was seen in the TP53(+), and not in the TP53(-) group.	Platinum	33-41	tumor protein p53	Homo sapiens	94-98
18095679-2	2008	With electron-rich triphosphine ligands, an equilibrium between the Pt(eta2-alkene) and Pt-alkyl was observed.	Platinum	68-70	DNA polymerase iota	Homo sapiens	71-75
17845003-3	2008	Here, we describe the design, synthesis, and characterization of a series of mono- and difunctionalized platinum(IV) complexes in which a conjugated peptide motif, containing RGD, (CRGDC)c, (RGDfK)c, or NGR, is appended as a "tumor-homing device" to target tumor endothelial cells selectively over healthy cells.	Platinum	104-112	reticulon 4 receptor	Homo sapiens	203-206
18182978-4	2008	The major changes we found in HCT-8 were a stimulation of oxaliplatin-DNA adduct formation associated with reduced expression of the key enzyme (excision repair cross complementation group1: ERCC1) in the key repair process of oxaliplatin-DNA platinum adduct, the nucleotide excision repair (NER), both at the mRNA and protein levels.	Platinum	243-251	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	191-196
18179697-6	2008	Oxaliplatin is an antineoplastic platinum-based compound that generates DNA adducts which tightly bind HMGB1.	Platinum	33-41	high mobility group box 1	Mus musculus	103-108
17852557-10	2008	CONCLUSION: In accord with previously reported studies, high levels of the hypoxia regulated proteins HIF1alpha and CA9 in HNC predict resistance to platinum based radio-chemotherapy.	Platinum	149-157	hypoxia inducible factor 1 subunit alpha	Homo sapiens	102-111
18637648-5	2008	In the other complexes, both imine N atoms are coordinated to the Pt II, thus adopting a eta2-coordinational mode.	Platinum	66-68	DNA polymerase iota	Homo sapiens	89-93
18691054-8	2008	In vitro, the MRP/ABCC transporters can collectively confer resistance to natural product anticancer drugs and their conjugated metabolites, platinum compounds, folate antimetabolites, nucleoside and nucleotide analogs, arsenical and antimonial oxyanions, peptide-based agents, and in concert with alterations in phase II conjugating or biosynthetic enzymes, classical alkylating agents, alkylating agents.	Platinum	141-149	ATP binding cassette subfamily C member 1	Homo sapiens	14-17
18691054-8	2008	In vitro, the MRP/ABCC transporters can collectively confer resistance to natural product anticancer drugs and their conjugated metabolites, platinum compounds, folate antimetabolites, nucleoside and nucleotide analogs, arsenical and antimonial oxyanions, peptide-based agents, and in concert with alterations in phase II conjugating or biosynthetic enzymes, classical alkylating agents, alkylating agents.	Platinum	141-149	ATP binding cassette subfamily C member 1	Homo sapiens	18-22
17963210-1	2008	This paper describes the synthesis, characterisation, and cytotoxicity of a novel trinuclear platinum complex code named TH1.	Platinum	93-101	negative elongation factor complex member C/D	Homo sapiens	121-124
18172257-10	2008	CONCLUSION: Our study provides evidence that both germ line and somatic alterations of the p53 pathway influence the incidence and survival of ovarian carcinoma, and it underscores the importance of assessing the functionality of p53 in order to predict the sensitivity of platinum-based chemotherapies and patient outcome.	Platinum	273-281	tumor protein p53	Homo sapiens	91-94
18097614-4	2008	Western blot and immunohistochemical analysis demonstrated that the expression of N-cadherin, alpha- and beta-catenin is significantly reduced in cardiomyocyte intercalated disks of CMPH/FS vs. CMPH/PT and is lowered to levels similar to those found in healthy hamsters (GSH/PT), as well as transmission electron microscopy indicated that the cardiomyocyte intercalated disk ultrastructure is also re-established in CMPH/FS.	Platinum	199-201	cadherin 2	Homo sapiens	82-92
18097614-4	2008	Western blot and immunohistochemical analysis demonstrated that the expression of N-cadherin, alpha- and beta-catenin is significantly reduced in cardiomyocyte intercalated disks of CMPH/FS vs. CMPH/PT and is lowered to levels similar to those found in healthy hamsters (GSH/PT), as well as transmission electron microscopy indicated that the cardiomyocyte intercalated disk ultrastructure is also re-established in CMPH/FS.	Platinum	199-201	catenin beta 1	Homo sapiens	94-117
17852557-10	2008	CONCLUSION: In accord with previously reported studies, high levels of the hypoxia regulated proteins HIF1alpha and CA9 in HNC predict resistance to platinum based radio-chemotherapy.	Platinum	149-157	carbonic anhydrase 9	Homo sapiens	116-119
18020448-0	2007	The skeletal rearrangement of gold- and platinum-catalyzed cycloisomerization of cis-4,6-dien-1-yn-3-ols: pinacol rearrangement and formation of bicyclo[4.1.0]heptenone and reorganized styrene derivatives.	Platinum	40-48	suppressor of cytokine signaling 6	Homo sapiens	81-86
18414584-0	2008	Nuclear Factor-kappa B as a Resistance Factor to Platinum-Based Antineoplasic Drugs.	Platinum	49-57	nuclear factor kappa B subunit 1	Homo sapiens	0-22
18414584-5	2008	This factor is important in the final response of cells to platinum drugs, as exemplified by in vitro and in vivo models showing that inhibition of NF-kappaB sensitizes cancer cells to the effects of these drugs.	Platinum	59-67	nuclear factor kappa B subunit 1	Homo sapiens	148-157
18414584-6	2008	New approaches focusing on the inhibition of NF-kappaB could help to minimize or even eliminate intrinsic or acquired resistance to platinum drugs.	Platinum	132-140	nuclear factor kappa B subunit 1	Homo sapiens	45-54
18020448-1	2007	With gold and platinum catalysts, cis-4,6-dien-1-yn-3-ols undergo cycloisomerizations that enable structural reorganization of cyclized products chemoselectively.	Platinum	14-22	suppressor of cytokine signaling 6	Homo sapiens	34-39
17988661-12	2007	Based on previous PT developmental studies, we predicted that the assembly of PAWP is dependent on microtubule-manchette protein transport and manchette descent and independent of subacrosomal PT formation.	Platinum	18-20	WBP2 N-terminal like	Mus musculus	78-82
17988661-29	2007	The same temporal and manchette-based pattern of PAWP-PAS assembly during spermiogenesis was evident as in controls supporting our hypothesis that PAS assembly is independent of subacrosomal PT formation and that egg-activating ability resides within the PAS.	Platinum	191-193	WBP2 N-terminal like	Mus musculus	49-53
17999491-4	2007	Restricted phosphane rotation around the Pt-P bond impedes free dmphen oscillation in a 14-electron three-coordinate T-shaped intermediate, containing eta1-coordinated dmphen, generated by easy Pt-N bond dissociation from [Pt(Me)(dmphen)(P(o-tolyl)3)]+.	Platinum	41-43	secreted phosphoprotein 1	Homo sapiens	151-155
18094425-4	2007	RESULTS: We show that inhibition of endogenous BRCA1 expression in ovarian cancer cell lines results in increased sensitivity to platinum therapy and decreased sensitivity to antimicrotubule agents.	Platinum	129-137	BRCA1 DNA repair associated	Homo sapiens	47-52
18094425-5	2007	In addition, we show that patients with low/intermediate levels of BRCA1 mRNA have a significantly improved overall survival following treatment with platinum-based chemotherapy in comparison with patients with high levels of BRCA1 mRNA (57.2 versus 18.2 months; P = 0.0017; hazard ratio, 2.9).	Platinum	150-158	BRCA1 DNA repair associated	Homo sapiens	67-72
18094427-8	2007	In line with effects on DNA repair protein expression, cetuximab increased the accumulation of platinum and apurinic/apyrimidinic sites on DNA during oxaliplatin treatment.	Platinum	95-103	X-ray repair cross complementing 6 pseudogene 5	Homo sapiens	24-42
18085999-1	2007	INTRODUCTION: Glutathione S-transferase P1 (GSTP1) and excision-repair cross-complementing repair deficiency group 2 protein (ERCC2 or XPD) may modulate the activity of platinum derivatives.	Platinum	169-177	glutathione S-transferase pi 1	Homo sapiens	14-42
18085999-1	2007	INTRODUCTION: Glutathione S-transferase P1 (GSTP1) and excision-repair cross-complementing repair deficiency group 2 protein (ERCC2 or XPD) may modulate the activity of platinum derivatives.	Platinum	169-177	glutathione S-transferase pi 1	Homo sapiens	44-49
18085999-1	2007	INTRODUCTION: Glutathione S-transferase P1 (GSTP1) and excision-repair cross-complementing repair deficiency group 2 protein (ERCC2 or XPD) may modulate the activity of platinum derivatives.	Platinum	169-177	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	126-131
18085999-1	2007	INTRODUCTION: Glutathione S-transferase P1 (GSTP1) and excision-repair cross-complementing repair deficiency group 2 protein (ERCC2 or XPD) may modulate the activity of platinum derivatives.	Platinum	169-177	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	135-138
17992278-0	2007	Pre-association of polynuclear platinum anticancer agents on a protein, human serum albumin.	Platinum	31-39	albumin	Homo sapiens	78-91
17992278-2	2007	The interactions of polynuclear platinum complexes with human serum albumin were studied.	Platinum	32-40	albumin	Homo sapiens	62-75
18024864-1	2007	PURPOSE: To investigate the effect of excision repair cross-complementation group 1 (ERCC1) on treatment response and survival of patients treated with platinum chemotherapy with or without paclitaxel.	Platinum	152-160	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	38-83
17934097-8	2007	K(D)PT, a derivative of KPV corresponding to the amino acid 193-195 of IL-1beta, is currently emerging as another tripeptide with potent anti-inflammatory effects.	Platinum	4-6	interleukin 1 beta	Homo sapiens	71-79
18024864-1	2007	PURPOSE: To investigate the effect of excision repair cross-complementation group 1 (ERCC1) on treatment response and survival of patients treated with platinum chemotherapy with or without paclitaxel.	Platinum	152-160	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	85-90
18024864-5	2007	RESULTS: Among the 103 patients treated with platinum without paclitaxel, the C/C genotype, compared with C/T and T/T, was associated with greater risk of disease progression and death (hazard ratio [HR], 1.95, P = .051; HR, 2.01, P = .033, respectively); high levels of ERCC1 mRNA, compared with low levels, were associated with greater risk of disease progression (HR, 2.41; P = .014).	Platinum	45-53	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	271-276
18024864-7	2007	However, for the 75 patients treated with platinum plus paclitaxel, the C/C genotype and high ERCC1 expression were not associated with poor prognosis, suggesting that paclitaxel may help to alleviate ERCC1-related platinum resistance.	Platinum	215-223	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	201-206
18024864-8	2007	CONCLUSION: Ovarian cancer patients with high ERCC1 expression or the C/C genotype at codon 118 may benefit from the combination of platinum and paclitaxel, while those with low ERCC1 expression or the C/T or T/T genotype may respond well to platinum without paclitaxel.	Platinum	132-140	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	46-51
17956095-1	2007	Dinuclear square metallocycles 3a,b assemble spontaneously when M(en)(OTf)2 (M = Pd, Pt) and a 4,4"-bipyridinium ligand are mixed in acetonitrile.	Platinum	85-87	POU class 2 homeobox 2	Homo sapiens	70-75
18214043-0	2007	Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer.	Platinum	66-74	ATP binding cassette subfamily C member 2	Homo sapiens	34-38
18214043-8	2007	In 37 patients treated with platinum-based chemotherapy, the response rate of patients in the MRP2-negative group was significantly higher than that in the positive group (92% versus 50%).	Platinum	28-36	ATP binding cassette subfamily C member 2	Homo sapiens	94-98
17900114-1	2007	N,N"-Disubstituted imidazolium carboxylates, readily synthetically available, isolable, air- and water-stable reagents, efficiently transfer N-heterocyclic carbene (NHC) groups to Rh, Ir, Ru, Pt, and Pd, to give novel NHC complexes, e.g., [Pd(NHC)3OAc]OAc and [Pt(NHC)3Cl]Cl (NHC = 1,3-dimethyl imidazol-2-ylidene).	Platinum	192-194	high mobility group nucleosomal binding domain 4	Homo sapiens	141-163
18214043-10	2007	These results suggest that immunostaining of MRP2 for TBB specimens may help to predict clinical resistance to platinum agents.	Platinum	111-119	ATP binding cassette subfamily C member 2	Homo sapiens	45-49
18214043-11	2007	This is the first report which indicates that the immunohistochemical expression of MRP2 is positively related to a clinical resistance to platinum.	Platinum	139-147	ATP binding cassette subfamily C member 2	Homo sapiens	84-88
18066119-9	2007	This change was associated with cytotoxic properties in THP-1 cell that were related to alterations in cell membrane properties, which were also obtained with the pure ginsenosides PD, PT, and Rh2.	Platinum	185-187	GLI family zinc finger 2	Homo sapiens	56-61
17710451-6	2007	The reactions of [PtCl(bpma)]+ and [PtCl(gly-met-S,N,N)] with 5"-GMP were studied by using (1)H NMR spectroscopy at 298 K. The pK (a) value of the [Pt(gly-met-S,N,N)(H(2)O)]+ complex is 5.95.	Platinum	18-20	5'-nucleotidase, cytosolic II	Homo sapiens	65-68
17900114-1	2007	N,N"-Disubstituted imidazolium carboxylates, readily synthetically available, isolable, air- and water-stable reagents, efficiently transfer N-heterocyclic carbene (NHC) groups to Rh, Ir, Ru, Pt, and Pd, to give novel NHC complexes, e.g., [Pd(NHC)3OAc]OAc and [Pt(NHC)3Cl]Cl (NHC = 1,3-dimethyl imidazol-2-ylidene).	Platinum	192-194	high mobility group nucleosomal binding domain 4	Homo sapiens	165-168
17900114-1	2007	N,N"-Disubstituted imidazolium carboxylates, readily synthetically available, isolable, air- and water-stable reagents, efficiently transfer N-heterocyclic carbene (NHC) groups to Rh, Ir, Ru, Pt, and Pd, to give novel NHC complexes, e.g., [Pd(NHC)3OAc]OAc and [Pt(NHC)3Cl]Cl (NHC = 1,3-dimethyl imidazol-2-ylidene).	Platinum	192-194	high mobility group nucleosomal binding domain 4	Homo sapiens	218-221
17900114-1	2007	N,N"-Disubstituted imidazolium carboxylates, readily synthetically available, isolable, air- and water-stable reagents, efficiently transfer N-heterocyclic carbene (NHC) groups to Rh, Ir, Ru, Pt, and Pd, to give novel NHC complexes, e.g., [Pd(NHC)3OAc]OAc and [Pt(NHC)3Cl]Cl (NHC = 1,3-dimethyl imidazol-2-ylidene).	Platinum	192-194	high mobility group nucleosomal binding domain 4	Homo sapiens	218-221
17900114-1	2007	N,N"-Disubstituted imidazolium carboxylates, readily synthetically available, isolable, air- and water-stable reagents, efficiently transfer N-heterocyclic carbene (NHC) groups to Rh, Ir, Ru, Pt, and Pd, to give novel NHC complexes, e.g., [Pd(NHC)3OAc]OAc and [Pt(NHC)3Cl]Cl (NHC = 1,3-dimethyl imidazol-2-ylidene).	Platinum	192-194	high mobility group nucleosomal binding domain 4	Homo sapiens	218-221
17900114-1	2007	N,N"-Disubstituted imidazolium carboxylates, readily synthetically available, isolable, air- and water-stable reagents, efficiently transfer N-heterocyclic carbene (NHC) groups to Rh, Ir, Ru, Pt, and Pd, to give novel NHC complexes, e.g., [Pd(NHC)3OAc]OAc and [Pt(NHC)3Cl]Cl (NHC = 1,3-dimethyl imidazol-2-ylidene).	Platinum	192-194	high mobility group nucleosomal binding domain 4	Homo sapiens	218-221
17803325-2	2007	On such prepared and STM characterized Au(111)/Pt surfaces, we studied electrocatalytic oxidation of formic acid and methanol.	Platinum	47-49	sulfotransferase family 1A member 3	Homo sapiens	21-24
17678866-0	2007	A novel glucose biosensor based on immobilization of glucose oxidase in chitosan on a glassy carbon electrode modified with gold-platinum alloy nanoparticles/multiwall carbon nanotubes.	Platinum	129-137	hydroxyacid oxidase 1	Homo sapiens	53-68
17678866-1	2007	A novel glucose biosensor was constructed, based on the immobilization of glucose oxidase (GOx) with cross-linking in the matrix of biopolymer chitosan (CS) on a glassy carbon electrode (GCE), which was modified with gold-platinum alloy nanoparticles (Au-PtNPs) by electrodeposition on multiwall carbon nanotubes (CNTs) in CS film (CNTs/CS).	Platinum	222-230	hydroxyacid oxidase 1	Homo sapiens	74-89
17678866-1	2007	A novel glucose biosensor was constructed, based on the immobilization of glucose oxidase (GOx) with cross-linking in the matrix of biopolymer chitosan (CS) on a glassy carbon electrode (GCE), which was modified with gold-platinum alloy nanoparticles (Au-PtNPs) by electrodeposition on multiwall carbon nanotubes (CNTs) in CS film (CNTs/CS).	Platinum	222-230	hydroxyacid oxidase 1	Homo sapiens	91-94
17855454-5	2007	A role for variation in NER and BRCA2/FA pathway genes as determinants of OS was provided by an analysis restricted to the 456 patients treated with platinum-based agents.	Platinum	149-157	BRCA2 DNA repair associated	Homo sapiens	32-37
18153996-7	2007	Rate constants for photodegradation of benzylamine and aniline were found to be 1.4 x 10(-3) min(-1) and 0.7 x 10(-3) min(-1) for TiO2 as photocatalyst, while 2.7 x 10(-3) min(-1) and 1.7 x 10(-3) min(-1) for (5 wt.%) Pt/TiO2 as photocatalyst.	Platinum	218-220	CD59 molecule (CD59 blood group)	Homo sapiens	93-99
17885491-10	2007	Absent cyclin D3 expression was an important indicator of poor survival in univariate analysis in the entire cohort (P &gt; 0.00010) and in the platinum-treated patients (P = 0.001) and in multivariate analysis (P = 0.044).	Platinum	144-152	cyclin D3	Homo sapiens	7-16
17492463-0	2007	Biomonitoring of tram drivers exposed to airborne platinum, rhodium and palladium.	Platinum	50-58	translocation associated membrane protein 1	Homo sapiens	17-21
17909351-3	2007	We sought to determine the influence of ERCC1 mRNA expression in advanced NSCLC on chemotherapy response, toxicity, and survival after platinum-based chemotherapy.	Platinum	135-143	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	40-45
17639527-0	2007	In-situ flow-cell IRAS observation of intermediates during methanol oxidation on low-index platinum surfaces.	Platinum	91-99	nischarin	Homo sapiens	18-22
17903489-7	2007	Repeatability studies showed good precision (R.S.D.%, n=5): 3.7% (Rh); 2.6% (Pd) and 2.4% (Pt), for 10 ngL(-1); 2.4% (Rh); 1.4% (Pd) and 1.9% (Pt), for 50 ngL(-1); and 1.3% (Rh); 0.58% (Pd) and 0.62% (Pt), for 100 ngL(-1).	Platinum	91-93	leucine rich repeat containing 4C	Homo sapiens	103-109
17627943-2	2007	Ctr1 is also involved in cellular accumulation of cisplatin, a platinum-based anticancer drug.	Platinum	63-71	high-affinity Cu transporter CTR1	Saccharomyces cerevisiae S288C	0-4
17700879-0	2007	Encapsulation of platinum anticancer drugs by apoferritin.	Platinum	17-25	ferritin heavy chain 1	Homo sapiens	46-57
17640298-0	2007	Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy.	Platinum	145-153	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-45
17640298-1	2007	Expression of excision repair cross-complementation group 1 (ERCC1), p53, or thioredoxin (TRX) is reported to be correlated with resistance to platinum-based drugs.	Platinum	143-151	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-59
17640298-1	2007	Expression of excision repair cross-complementation group 1 (ERCC1), p53, or thioredoxin (TRX) is reported to be correlated with resistance to platinum-based drugs.	Platinum	143-151	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	61-66
17640298-1	2007	Expression of excision repair cross-complementation group 1 (ERCC1), p53, or thioredoxin (TRX) is reported to be correlated with resistance to platinum-based drugs.	Platinum	143-151	tumor protein p53	Homo sapiens	69-72
17640298-1	2007	Expression of excision repair cross-complementation group 1 (ERCC1), p53, or thioredoxin (TRX) is reported to be correlated with resistance to platinum-based drugs.	Platinum	143-151	thioredoxin	Homo sapiens	77-88
17640298-1	2007	Expression of excision repair cross-complementation group 1 (ERCC1), p53, or thioredoxin (TRX) is reported to be correlated with resistance to platinum-based drugs.	Platinum	143-151	thioredoxin	Homo sapiens	90-93
17640298-8	2007	This retrospective study indicates that immunostaining for ERCC1 may be useful for predicting survival in NSCLC patients receiving platinum-based chemotherapy against recurrent tumors after curative resection and can provide critical information for planning personalized chemotherapy.	Platinum	131-139	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	59-64
17417781-0	2007	Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer.	Platinum	70-78	RAD51 recombinase	Homo sapiens	23-28
17699862-5	2007	RESULTS: Plasma ultrafiltrate platinum clearance strongly correlated with CrCL (r2 = 0.712).	Platinum	30-38	CRCL	Homo sapiens	74-78
17417781-0	2007	Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer.	Platinum	70-78	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	33-38
17616122-4	2007	Both reagents serve to transfer PNP into the coordination sphere of divalent nickel, palladium, and platinum.	Platinum	100-108	purine nucleoside phosphorylase	Homo sapiens	32-35
17417781-9	2007	In conclusion, combined expression of Rad51 and ERCC1 expression is associated with resistance to platinum agents in the ex vivo study of clinical NSCLC, and evaluation of expression status of both DNA repair enzymes would be a predictor for clinical response to platinum-based chemotherapies.	Platinum	98-106	RAD51 recombinase	Homo sapiens	38-43
17417781-9	2007	In conclusion, combined expression of Rad51 and ERCC1 expression is associated with resistance to platinum agents in the ex vivo study of clinical NSCLC, and evaluation of expression status of both DNA repair enzymes would be a predictor for clinical response to platinum-based chemotherapies.	Platinum	98-106	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	48-53
17534174-0	2007	ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.	Platinum	30-38	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
17637991-11	2007	A single-crystal X-ray diffraction study of [23]PF6 shows that the cation has an approximately A-frame geometry, with a Pt-Pt separation of 2.7888(3) A and a Pt-H bond length of 1.62(1) A, and that the 5-methyl substituents have undergone partial exchange with the 4-hydrogen atoms of the PPh2 groups of the bridging carbanion.	Platinum	120-122	sperm associated antigen 17	Homo sapiens	48-51
17637991-11	2007	A single-crystal X-ray diffraction study of [23]PF6 shows that the cation has an approximately A-frame geometry, with a Pt-Pt separation of 2.7888(3) A and a Pt-H bond length of 1.62(1) A, and that the 5-methyl substituents have undergone partial exchange with the 4-hydrogen atoms of the PPh2 groups of the bridging carbanion.	Platinum	123-125	sperm associated antigen 17	Homo sapiens	48-51
17637991-11	2007	A single-crystal X-ray diffraction study of [23]PF6 shows that the cation has an approximately A-frame geometry, with a Pt-Pt separation of 2.7888(3) A and a Pt-H bond length of 1.62(1) A, and that the 5-methyl substituents have undergone partial exchange with the 4-hydrogen atoms of the PPh2 groups of the bridging carbanion.	Platinum	123-125	sperm associated antigen 17	Homo sapiens	48-51
17687196-9	2007	Based on this concept, phaseIII clinical trials comparing gefitinib monotherapy with standard platinum-based chemotherapy in lung cancer patients with EGFR mutations are ongoing.	Platinum	94-102	epidermal growth factor receptor	Homo sapiens	151-155
17583333-1	2007	Platinum complexes able to inhibit matrix metalloproteinases (MMPs) through a noncompetitive mechanism are reported for the first time in this study.	Platinum	0-8	matrix metallopeptidase 2	Homo sapiens	62-66
17580867-8	2007	Upon cleavage of the C-C bond in (dtbpe)Pt(eta2-(p-fluorophenyl-p-tolylacetylene) (9), both (dtbpe)Pt(p-fluorophenyl)(p-tolylacetylide) (10) and (dtbpe)Pt(p-tolyl)(p-fluorophenylacetylide) (11) were obtained.	Platinum	40-42	DNA polymerase iota	Homo sapiens	43-47
17534174-7	2007	SUMMARY: High ERCC1 expression is predictive of resistance to platinum-based therapy.	Platinum	62-70	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-19
17534174-8	2007	Thus, there is solid evidence to support ERCC1 as a useful marker of clinical resistance to platinum-based chemotherapy in the adjuvant setting of nonsmall-cell lung cancer.	Platinum	92-100	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	41-46
17433425-1	2007	Association of CD3+CD56+ cells with platinum resistance.	Platinum	36-44	neural cell adhesion molecule 1	Homo sapiens	19-23
17594186-6	2007	Platinum-based drugs have also been successfully combined with molecularly targeted drugs (e.g., the recent approval of the vascular endothelial growth factor monoclonal antibody bevacizumab with carboplatin and paclitaxel in patients with NSCLC).	Platinum	0-8	vascular endothelial growth factor A	Homo sapiens	124-158
17433425-11	2007	Higher tumor grade was associated with increased A/B CD4(+)CD25(+) ratio and reduced CD3(+)CD56(+) cells, while platinum resistance was associated with reduced A/B CD3(+)CD56(+) ratio.	Platinum	112-120	neural cell adhesion molecule 1	Homo sapiens	170-174
17433425-13	2007	The selective accumulation of CD3(+)CD56(+) population in ascites may be a predictive factor for platinum resistance.	Platinum	97-105	neural cell adhesion molecule 1	Homo sapiens	36-40
17602079-4	2007	Excision repair cross-complementing group 1 gene (ERCC1), a component of the nucleotide excision repair complex, is important for platinum-induced DNA adduct repair.	Platinum	130-138	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	50-55
17549342-1	2007	Tumor sensitivity to anticancer drugs such as CPT-11 and platinum derivatives was investigated by assessing Topo-1 and Bax/ERCC-1 expression in patients with stage I/II breast, lung, and gastric cancer who were positive for ONCs, and tumor sensitivity was compared between CPT-11 and platinum derivatives.	Platinum	57-65	BCL2 associated X, apoptosis regulator	Homo sapiens	119-122
17549342-1	2007	Tumor sensitivity to anticancer drugs such as CPT-11 and platinum derivatives was investigated by assessing Topo-1 and Bax/ERCC-1 expression in patients with stage I/II breast, lung, and gastric cancer who were positive for ONCs, and tumor sensitivity was compared between CPT-11 and platinum derivatives.	Platinum	57-65	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	123-129
17521178-0	2007	New approach for the preparation of efficient DNA cleaving agents: ditopic copper-platinum complexes based on 3-Clip-Phen and cisplatin.	Platinum	82-90	CAP-Gly domain containing linker protein 1	Homo sapiens	112-116
17577031-0	2007	Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer.	Platinum	72-80	annexin A5	Homo sapiens	42-51
17530758-15	2007	The LUMO of 17 exhibits an empty orbital on the platinum atom that appears to be the most likely site for PhC2H addition prior to its insertion into the Os-H bond.	Platinum	48-56	polyhomeotic homolog 2	Homo sapiens	106-110
17577031-7	2007	CONCLUSION: TAS is a promising test to predict tumor response in patients with advanced lung cancer early in the course of platinum-based chemotherapy.	Platinum	123-131	THAS	Homo sapiens	12-15
17469822-4	2007	First, liposomes containing either the dioleoyl MP or PT analogues bound to recombinant ING2 similar to liposomes containing dipalmitoyl PtdIns(5)P, indicating that the replacement of the hydrolyzable 5-phosphate group does not compromise the binding.	Platinum	54-56	inhibitor of growth family member 2	Homo sapiens	88-92
17541162-3	2007	CCl4 hepatotoxicity caused an increase in the sensitivity of mitochondria to Ca2+-stimulated PT in vitro.	Platinum	93-95	chemokine (C-C motif) ligand 4	Mus musculus	0-4
17415578-8	2007	In the multivariate Cox analysis, only the use of platinum-based chemotherapy was identified as an independent predictor of an increased survival (P = 0.01).	Platinum	50-58	cytochrome c oxidase subunit 8A	Homo sapiens	20-23
17444640-3	2007	These are mono- and bis-Pt(PBut3) adducts of 9 formed by the addition of a Pt(PBut3) group to the Os-Os bond in 11 and the Os-Os bond and Os-C bond to the sigma-bonded phenyl group in 12.	Platinum	23-26	lanosterol synthase	Homo sapiens	138-142
17215078-0	2007	Hypoxia inducible factor 1-alpha expression as a factor predictive of efficacy of taxane/platinum chemotherapy in advanced primary epithelial ovarian cancer.	Platinum	89-97	hypoxia inducible factor 1 subunit alpha	Homo sapiens	0-32
17469822-6	2007	Finally, molecular modeling and docking of the MP or PT analogues to the C-terminus PtdInsP-binding region of ING2 (consisting of a PHD finger and a polybasic region) revealed a number of complementary surface and electrostatic contacts between the lipids and ING2.	Platinum	53-55	inhibitor of growth family member 2	Homo sapiens	110-114
17469822-6	2007	Finally, molecular modeling and docking of the MP or PT analogues to the C-terminus PtdInsP-binding region of ING2 (consisting of a PHD finger and a polybasic region) revealed a number of complementary surface and electrostatic contacts between the lipids and ING2.	Platinum	53-55	inhibitor of growth family member 2	Homo sapiens	260-264
17021820-8	2007	Studies on the induction of SSAT by platinum drugs suggested by the Affymetrix data have been previously validated from this laboratory (Hector et al.	Platinum	36-44	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	28-32
17407274-3	2007	Here we reported the chemical and biological properties of seven platinum complexes with PPh3 or PMe2Ph in trans to several amines.	Platinum	65-73	caveolin 1	Homo sapiens	89-93
17595760-0	2007	A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer.	Platinum	79-87	mutL homolog 1	Homo sapiens	36-41
17686239-12	2007	CONCLUSION: Residual tumor, p53, and Pgp expression are predictive factors for the response to platinum/paclitaxel first-line adjuvant chemotherapy in advanced ovarian cancer.	Platinum	95-103	tumor protein p53	Homo sapiens	28-31
17686239-12	2007	CONCLUSION: Residual tumor, p53, and Pgp expression are predictive factors for the response to platinum/paclitaxel first-line adjuvant chemotherapy in advanced ovarian cancer.	Platinum	95-103	ATP binding cassette subfamily B member 1	Homo sapiens	37-40
17021820-11	2007	CONCLUSION: The data indicate a concerted effect of platinum drugs on the polyamine metabolic pathway with down-regulation in the expression of several enzyme genes involved in biosynthesis and many-fold up-regulation in expression of SSAT, an acetylating enzyme gene that is critically involved in polyamine catabolism and export.	Platinum	52-60	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	235-239
17337344-5	2007	RESULTS: Fluorodeoxyglucose uptake increased with pT, from 5/11 (45%) for pTis to 11/16 (69%) for pT1 (outer submucosa), P=0.07, as it did for standardized uptake value, median 0 for pTis to 2.7 for pT1 (outer submucosa), P=0.06.	Platinum	50-52	zinc finger protein 77	Homo sapiens	98-101
17366594-0	2007	Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer.	Platinum	74-82	myotubularin related protein 11	Homo sapiens	62-65
17366594-1	2007	BACKGROUND: The study investigated correlations between adenosine triphosphate / chemotherapy response assay (ATP-CRA) and clinical outcomes after ATP-CRA-guided platinum-based chemotherapy for unresectable nonsmall-cell lung cancer (NSCLC).	Platinum	162-170	myotubularin related protein 11	Homo sapiens	114-117
17366594-1	2007	BACKGROUND: The study investigated correlations between adenosine triphosphate / chemotherapy response assay (ATP-CRA) and clinical outcomes after ATP-CRA-guided platinum-based chemotherapy for unresectable nonsmall-cell lung cancer (NSCLC).	Platinum	162-170	myotubularin related protein 11	Homo sapiens	151-154
17366594-14	2007	CONCLUSIONS: Despite using bronchoscopic biopsied specimens, ATP-CRA and clinical outcomes correlated well after assay-guided platinum-based 2-drug chemotherapy for unresectable NSCLC.	Platinum	126-134	myotubularin related protein 11	Homo sapiens	65-68
17482130-5	2007	The effect appears to be due in part to PPARgamma-mediated downregulation of metallothioneins, proteins that have been shown to be involved in resistance to platinum-based therapy.	Platinum	157-165	peroxisome proliferator activated receptor gamma	Homo sapiens	40-49
17337344-5	2007	RESULTS: Fluorodeoxyglucose uptake increased with pT, from 5/11 (45%) for pTis to 11/16 (69%) for pT1 (outer submucosa), P=0.07, as it did for standardized uptake value, median 0 for pTis to 2.7 for pT1 (outer submucosa), P=0.06.	Platinum	50-52	zinc finger protein 77	Homo sapiens	199-202
17390039-1	2007	The sensitivity of LN metastases to anticancer drugs such as CPT-11 and platinum agents was investigated by assessing Topo-1 and Bax/ERCC-1 expression in patients who had stage III/Dukes" C colorectal cancer with ONCs.	Platinum	72-80	BCL2 associated X, apoptosis regulator	Homo sapiens	129-132
17390039-1	2007	The sensitivity of LN metastases to anticancer drugs such as CPT-11 and platinum agents was investigated by assessing Topo-1 and Bax/ERCC-1 expression in patients who had stage III/Dukes" C colorectal cancer with ONCs.	Platinum	72-80	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	133-139
17239941-11	2007	Therapy with platinum and taxane should be the treatment of choice in NAC.	Platinum	13-21	synuclein alpha	Homo sapiens	70-73
17465714-3	2007	The most recent update regarding gastric cancer pharmacogenetics highlights a prominent role of genetic polymorphisms of thymidylate synthase and glutathione S-transferase in the pharmacological treatment with commonly used drugs, such as 5-fluorouracil and platinum derivatives.	Platinum	258-266	thymidylate synthetase	Homo sapiens	121-141
17465714-3	2007	The most recent update regarding gastric cancer pharmacogenetics highlights a prominent role of genetic polymorphisms of thymidylate synthase and glutathione S-transferase in the pharmacological treatment with commonly used drugs, such as 5-fluorouracil and platinum derivatives.	Platinum	258-266	glutathione S-transferase kappa 1	Homo sapiens	146-171
17378557-1	2007	Sn94- reacts with Pt(PPh3)4 in ethylenediamine/toluene solvent mixtures in the presence of 2,2,2-cryptand to give four different complexes: "Rudolph"s complex" of proposed formula [Sn9Pt(PPh3)x]4- (2), the previously reported [Pt@Sn9Pt(PPh3)]2- ion (3), and the title complexes Pt2@Sn174- (4) and Pt@Sn9H3- (5).	Platinum	18-20	protein phosphatase 4 catalytic subunit	Homo sapiens	21-25
17378566-1	2007	Acetylplatinum(II) complexes trans-[Pt(COMe)Cl(L)2] (L = PPh3, 2a; P(4-FC6H4)3, 2b) were found to react with dialkyldisulfides R2S2 (R = Me, Et, Pr, Bu; Pr = n-propyl, Bu = n-butyl), yielding trinuclear 44 cve (cluster valence electrons) platinum clusters [(PtL)3(mu-SR)3]Cl (4).	Platinum	6-14	protein phosphatase 4 catalytic subunit	Homo sapiens	57-61
17084586-0	2007	Interleukin-1beta expression in murine J774A.1 macrophages exposed to platinum compounds: the role of p38 and ERK 1/2 mitogen-activated protein kinases.	Platinum	70-78	interleukin 1 beta	Mus musculus	0-17
17450904-3	2007	Similarly, trinuclear complexes (eta2 : eta2-C60) M(cis-dppet)M1 (dppr) (7-10; M, M1 = Pd, Pt; dppr = (eta5-Ph2PC5H4)2Ru) could be synthesized by reaction of the in situ prepared 3-6 with dppr.	Platinum	91-93	DNA polymerase iota	Homo sapiens	33-37
17450904-3	2007	Similarly, trinuclear complexes (eta2 : eta2-C60) M(cis-dppet)M1 (dppr) (7-10; M, M1 = Pd, Pt; dppr = (eta5-Ph2PC5H4)2Ru) could be synthesized by reaction of the in situ prepared 3-6 with dppr.	Platinum	91-93	DNA polymerase iota	Homo sapiens	40-44
17450904-5	2007	Cyclic voltammetric studies on 2 (M = Pt), 3 (M = Pd, M1 = Pd) and 9 (M = Pt, M1 = Pd) provided further evidence for the eta2-coordination of C60 to one metal fragment or two metal fragments in these complexes.	Platinum	38-40	DNA polymerase iota	Homo sapiens	121-125
17450904-5	2007	Cyclic voltammetric studies on 2 (M = Pt), 3 (M = Pd, M1 = Pd) and 9 (M = Pt, M1 = Pd) provided further evidence for the eta2-coordination of C60 to one metal fragment or two metal fragments in these complexes.	Platinum	74-76	ubiquinol-cytochrome c reductase complex assembly factor 2	Homo sapiens	54-68
17450904-5	2007	Cyclic voltammetric studies on 2 (M = Pt), 3 (M = Pd, M1 = Pd) and 9 (M = Pt, M1 = Pd) provided further evidence for the eta2-coordination of C60 to one metal fragment or two metal fragments in these complexes.	Platinum	74-76	DNA polymerase iota	Homo sapiens	121-125
17450933-1	2007	Platinum (Pt) nanoparticles were electrodeposited within multiwalled carbon nanotubes-Nafion-glucose oxidase (MWNTs-Nafion-GOx) nanobiocomposite by a potentiostatic method.	Platinum	0-8	hydroxyacid oxidase 1	Homo sapiens	123-126
17084586-10	2007	These data suggest that p38 MAPK and ERK 1/2 play an important role in induction of IL-1beta expression in J774A.1 macrophages exposed to test platinum compounds.	Platinum	143-151	mitogen-activated protein kinase 14	Mus musculus	24-27
17084586-10	2007	These data suggest that p38 MAPK and ERK 1/2 play an important role in induction of IL-1beta expression in J774A.1 macrophages exposed to test platinum compounds.	Platinum	143-151	mitogen-activated protein kinase 3	Mus musculus	37-44
17084586-10	2007	These data suggest that p38 MAPK and ERK 1/2 play an important role in induction of IL-1beta expression in J774A.1 macrophages exposed to test platinum compounds.	Platinum	143-151	interleukin 1 beta	Mus musculus	84-92
17229776-9	2007	CONCLUSION: The results of the study indicate that ERCC1 may predict survival in bladder cancer treated by platinum-based therapy.	Platinum	107-115	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	51-56
17251016-2	2007	Then, Ptns was introduced into the structure of BACE1 inhibitors at the P(1) position.	Platinum	6-10	beta-secretase 1	Homo sapiens	48-53
17332279-3	2007	Inhibition of PARP potentiates the activity of DNA-damaging agents, such as alkylators, platinums, topoisomerase inhibitors, and radiation in in vitro and in vivo models.	Platinum	88-97	poly(ADP-ribose) polymerase 1	Homo sapiens	14-18
17365305-0	2007	Induction of metallothionein in chick embryos as a mechanism of tolerance to platinum group metal exposure.	Platinum	77-85	metallothionein 4	Gallus gallus	13-28
17621943-3	2007	In artificial saliva containing 0.1% NaF at a pH of 4.0, the amounts of Ti dissolved from the Ti, Ti-6Al-4V, and Ti-6Al-7Nb alloys were about 50 times larger than those of the alloys containing 0.5 wt% Pt.	Platinum	202-204	C-X-C motif chemokine ligand 8	Homo sapiens	37-40
16698954-3	2007	METHODS: The immunoexpression of PPARgamma and its putative target cyclo-oxygenase 2 (COX2) was investigated in tumour tissues from 80 patients with primary and corresponding recurrent ovarian serous carcinomas after conventional platinum-based chemotherapy.	Platinum	230-238	peroxisome proliferator activated receptor gamma	Homo sapiens	33-42
17297971-2	2007	The sensor was constructed by the coimmobilization of two enzymes, i.e., N-acetylneuraminic acid aldolase and pyruvate oxidase, on a polyester microporous membrane, which was then mounted on top of a platinum disk electrode.	Platinum	200-208	N-acetylneuraminate pyruvate lyase	Homo sapiens	73-105
17365305-10	2007	The interaction of Pt, Pd and Rh in the mixture seems to favor metal accumulation and MT induction in the liver but not the brain.	Platinum	19-21	metallothionein 4	Gallus gallus	86-88
17214460-2	2007	For the first new compound ATP1, the inner phenyl rings (closer to the Pt atom) in Pt1 are replaced by thiophene rings bridging at the 2,5-positions.	Platinum	71-73	ATP synthase F1 subunit alpha	Homo sapiens	27-31
17290060-7	2007	In patients with platinum-resistant disease, we identified expression signatures consistent with activation of Src and Rb/E2F pathways, components of which were successfully targeted to increase response in ovarian cancer cell lines.	Platinum	17-25	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	111-114
17214460-2	2007	For the first new compound ATP1, the inner phenyl rings (closer to the Pt atom) in Pt1 are replaced by thiophene rings bridging at the 2,5-positions.	Platinum	71-73	zinc finger protein 77	Homo sapiens	83-86
17200349-14	2007	Furthermore, down-regulation of E2F7 may contribute to mechanisms underlying platinum resistance, and calculation of ratios of proliferation-promoting E2F1 to E2F7 could serve as a putative predictor of platinum resistance.	Platinum	203-211	E2F transcription factor 1	Homo sapiens	151-155
17160181-4	2007	Crystals were obtained of a product shown by X-ray crystallography to be the unusual dinuclear species [Pt2(BCl2)2(PMe3)4(micro-Cl)][BCl4] which reveals an arrangement in which two square planar platinum(II) centres are linked by a single bridging chloride which is trans to a BCl2 group on each platinum centre.	Platinum	195-203	BCL2 apoptosis regulator	Homo sapiens	108-112
17160181-4	2007	Crystals were obtained of a product shown by X-ray crystallography to be the unusual dinuclear species [Pt2(BCl2)2(PMe3)4(micro-Cl)][BCl4] which reveals an arrangement in which two square planar platinum(II) centres are linked by a single bridging chloride which is trans to a BCl2 group on each platinum centre.	Platinum	195-203	BCL3 transcription coactivator	Homo sapiens	133-137
17200349-11	2007	Tumors considered platinum resistant were associated with lower E2F4 and E2F7 expression (P = 0.012 and 0.009, respectively) compared with platinum-sensitive tumors.	Platinum	18-26	E2F transcription factor 4	Homo sapiens	64-68
17200349-11	2007	Tumors considered platinum resistant were associated with lower E2F4 and E2F7 expression (P = 0.012 and 0.009, respectively) compared with platinum-sensitive tumors.	Platinum	18-26	E2F transcription factor 7	Homo sapiens	73-77
18003544-8	2007	A platinum working electrode containing glucose oxidase (GOx) immobilized by poly-aniline (PA) and then modified by MPTMS was developed and evaluated.	Platinum	2-10	hydroxyacid oxidase 1	Homo sapiens	40-55
18003544-8	2007	A platinum working electrode containing glucose oxidase (GOx) immobilized by poly-aniline (PA) and then modified by MPTMS was developed and evaluated.	Platinum	2-10	hydroxyacid oxidase 1	Homo sapiens	57-60
18002547-1	2007	A Pyrroloquinoline quinone (PQQ)-dependent glucose dehydrogenase based platinum electrode was developed to detect glucose.	Platinum	71-79	hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	Homo sapiens	43-64
16874498-0	2007	Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: results of the NeoPrevent study.	Platinum	102-110	erythropoietin	Homo sapiens	24-31
16874498-2	2007	This study aimed to evaluate the efficacy and safety of epoetin beta in the prevention of severe anaemia in patients with solid tumours receiving concomitant platinum therapy.	Platinum	158-166	erythropoietin	Homo sapiens	56-63
16874498-9	2007	CONCLUSIONS: Epoetin beta effectively prevents anaemia in most patients with solid tumours receiving concurrent platinum-based chemotherapy.	Platinum	112-120	erythropoietin	Homo sapiens	13-20
17200349-12	2007	Again, ratios of E2F1 or E2F2 to E2F7 were the most favorable variables in predicting platinum resistance.	Platinum	86-94	E2F transcription factor 1	Homo sapiens	17-21
17200349-14	2007	Furthermore, down-regulation of E2F7 may contribute to mechanisms underlying platinum resistance, and calculation of ratios of proliferation-promoting E2F1 to E2F7 could serve as a putative predictor of platinum resistance.	Platinum	203-211	E2F transcription factor 7	Homo sapiens	159-163
17200349-12	2007	Again, ratios of E2F1 or E2F2 to E2F7 were the most favorable variables in predicting platinum resistance.	Platinum	86-94	E2F transcription factor 2	Homo sapiens	25-29
17200349-12	2007	Again, ratios of E2F1 or E2F2 to E2F7 were the most favorable variables in predicting platinum resistance.	Platinum	86-94	E2F transcription factor 7	Homo sapiens	33-37
17200349-14	2007	Furthermore, down-regulation of E2F7 may contribute to mechanisms underlying platinum resistance, and calculation of ratios of proliferation-promoting E2F1 to E2F7 could serve as a putative predictor of platinum resistance.	Platinum	77-85	E2F transcription factor 7	Homo sapiens	32-36
17584130-10	2007	The non-specific "superpotent" MC agonist, PT-141, which is the carboxylate derivative of MT-II, has reached phase II human trials.	Platinum	43-45	metallothionein 2A	Homo sapiens	90-95
19360146-5	2007	Src inhibition is also synergistic in vivo with platinum chemotherapeutics, further increasing the potential of combination regimens with Src inhibitors.	Platinum	48-56	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
17520586-3	2007	The chimeric anti- EGFR monoclonal antibody cetuximab has been approved for EGFR-expressing colorectal tumors in patients who progress after irinotecan-based chemotherapy in combination with irinotecan and in squamous cell head and neck carcinomas for patients with locally advanced disease in combination with radiation therapy or after failure of platinum-based chemotherapy in recurrent or metastatic disease (FDA).	Platinum	349-357	epidermal growth factor receptor	Homo sapiens	19-23
17436410-0	2007	Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients.	Platinum	137-145	matrix metallopeptidase 2	Homo sapiens	23-56
28207119-3	2007	The chimeric anti- EGFR monoclonal antibody cetuximab has been approved for EGFR-expressing colorectal tumors in patients who progress after irinotecan-based chemotherapy in combination with irinotecan and in squamous cell head and neck carcinomas for patients with locally advanced disease in combination with radiation therapy or after failure of platinum-based chemotherapy in recurrent or metastatic disease (FDA).	Platinum	349-357	epidermal growth factor receptor	Homo sapiens	19-23
17436410-0	2007	Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients.	Platinum	137-145	epidermal growth factor receptor	Homo sapiens	97-129
21182814-3	2006	The aim of this study is to investigate the relationship between genetic polymorphisms of MTHFR C677T or A1298C and the response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC).	Platinum	132-140	methylenetetrahydrofolate reductase	Homo sapiens	90-95
17181257-3	2006	The best performance for methanol electrooxidation was obtained on a ternary platinum based catalyst modified by upd-Ru and upd-Sn simultaneously.	Platinum	77-85	uroporphyrinogen decarboxylase	Homo sapiens	113-116
17181257-3	2006	The best performance for methanol electrooxidation was obtained on a ternary platinum based catalyst modified by upd-Ru and upd-Sn simultaneously.	Platinum	77-85	uroporphyrinogen decarboxylase	Homo sapiens	124-127
17225893-4	2006	The organometallic gold(I) and platinum(II) acetylide complexes [Pz2CH(C6H(4)-2-OCH2C[triple bond, length as m-dash]CAuPPh3)] and trans-[{Pz2CHC6H(4)-2-OCH2C[triple bond, length as m-dash]C}2Pt(PPh3)2] were prepared from and [AuCl(PPh3)] and trans-[PtCl2(PPh3)2], respectively.	Platinum	31-39	caveolin 1	Homo sapiens	119-123
21182814-11	2006	CONCLUSIONS: The results suggest that the synergic effect between MTHFR C677T and A1298C polymorphisms is associated with clinical response to platinum-based chemotherapy.	Platinum	143-151	methylenetetrahydrofolate reductase	Homo sapiens	66-71
21182814-12	2006	Detection of MTHFR genotypes may indicate the sensitivity of NSCLC patients to platinum-based chemotherapy.	Platinum	79-87	methylenetetrahydrofolate reductase	Homo sapiens	13-18
17088910-0	2006	Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21.	Platinum	97-105	interferon alpha inducible protein 27	Homo sapiens	16-19
17134213-1	2006	The adsorption and hydrogenation of carbon tetrachloride (CCl(4)) on a Pt (111) surface have been investigated using density functional theory (DFT).	Platinum	71-73	C-C motif chemokine ligand 4	Homo sapiens	58-64
17088910-0	2006	Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21.	Platinum	97-105	cyclin dependent kinase 2	Homo sapiens	42-46
17129015-6	2006	We also find that segmented nanorods with one Au end and one poly(pyrrole) end containing catalase, an enzyme that decomposes hydrogen peroxide nonelectrochemically, perform the overall catalytic reaction at a rate similar to that of nanorods containing Au and Pt segments.	Platinum	261-263	catalase	Homo sapiens	90-98
17088910-0	2006	Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21.	Platinum	97-105	H3 histone pseudogene 16	Homo sapiens	147-150
17088965-0	2006	A series of complexes of the phosphorus-based TTF ligand o-P2 with the metal ions Fe(II), Co(II), Ni(II), Pd(II), Pt(II), and Ag(I).	Platinum	114-116	bone morphogenetic protein 8b	Homo sapiens	57-61
16875718-0	2006	XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer.	Platinum	56-64	X-ray repair cross complementing 1	Homo sapiens	0-5
16875718-5	2006	RESULTS: The response to platinum-based NAC was higher in patients with SNP of XRCC1 R399Q (P=0.015), and there was a significant increased chance of treatment response in women with the G/G genotype (OR 38.0; 95% CI 1.66-870.45; P=0.023).	Platinum	25-33	X-ray repair cross complementing 1	Homo sapiens	79-84
16875718-7	2006	There were dose-dependent influence of the number of alleles on the response to platinum-based chemotherapy (chi2 test for linear-by-linear association; P=0.009 for XRCC1 R399Q and P=0.017 for SLC19A1 6318C/T, respectively).	Platinum	80-88	X-ray repair cross complementing 1	Homo sapiens	165-170
16875718-7	2006	There were dose-dependent influence of the number of alleles on the response to platinum-based chemotherapy (chi2 test for linear-by-linear association; P=0.009 for XRCC1 R399Q and P=0.017 for SLC19A1 6318C/T, respectively).	Platinum	80-88	solute carrier family 19 member 1	Homo sapiens	193-200
16875718-9	2006	CONCLUSIONS: Genetic polymorphism of XRCC1 R399Q is associated with response to platinum-based NAC in bulky cervical cancer, and MDR analysis documented association between gene-gene interaction of XRCC1 R399Q and treatment response.	Platinum	80-88	X-ray repair cross complementing 1	Homo sapiens	37-42
17145840-12	2006	Thus, ABCC2 localization can predict platinum therapy outcome.	Platinum	37-45	ATP binding cassette subfamily C member 2	Homo sapiens	6-11
17155762-3	2006	By comparing different contact materials (Al and/or Pt), we find, in agreement with theory, that the spin-related properties of the normal metal dictate the magnitude of the dc voltage.	Platinum	52-54	spindlin 1	Homo sapiens	101-105
17125375-1	2006	A highly efficient photocatalytic system for hydrogen evolution with dihydronicotinamide coenzyme (NADH) as a sacrificial agent in an aqueous solution has been constructed by using water-soluble platinum clusters functionalized with methyl viologen-alkanethiol (MVA2+) and a simple electron-donor dyad, 9-mesityl-10-methylacridinium ion (Acr+-Mes), which is capable of fast photoinduced electron transfer but extremely slow back electron transfer.	Platinum	195-203	centrosomal protein 57	Homo sapiens	262-266
17125375-1	2006	A highly efficient photocatalytic system for hydrogen evolution with dihydronicotinamide coenzyme (NADH) as a sacrificial agent in an aqueous solution has been constructed by using water-soluble platinum clusters functionalized with methyl viologen-alkanethiol (MVA2+) and a simple electron-donor dyad, 9-mesityl-10-methylacridinium ion (Acr+-Mes), which is capable of fast photoinduced electron transfer but extremely slow back electron transfer.	Platinum	195-203	acrosin	Homo sapiens	338-341
17125375-3	2006	As a result, the hydrogen-evolution rate of the photocatalytic system with MVA2+-modified platinum clusters (MVA2+-PtC) is 10 times faster than the photocatalytic system with the mixture of the same amount of MVA2+ and platinum clusters as that of MVA2+-PtC under otherwise the same experimental conditions.	Platinum	90-98	centrosomal protein 57	Homo sapiens	75-79
17125375-3	2006	As a result, the hydrogen-evolution rate of the photocatalytic system with MVA2+-modified platinum clusters (MVA2+-PtC) is 10 times faster than the photocatalytic system with the mixture of the same amount of MVA2+ and platinum clusters as that of MVA2+-PtC under otherwise the same experimental conditions.	Platinum	90-98	centrosomal protein 57	Homo sapiens	109-113
17125375-3	2006	As a result, the hydrogen-evolution rate of the photocatalytic system with MVA2+-modified platinum clusters (MVA2+-PtC) is 10 times faster than the photocatalytic system with the mixture of the same amount of MVA2+ and platinum clusters as that of MVA2+-PtC under otherwise the same experimental conditions.	Platinum	90-98	centrosomal protein 57	Homo sapiens	109-113
17125375-3	2006	As a result, the hydrogen-evolution rate of the photocatalytic system with MVA2+-modified platinum clusters (MVA2+-PtC) is 10 times faster than the photocatalytic system with the mixture of the same amount of MVA2+ and platinum clusters as that of MVA2+-PtC under otherwise the same experimental conditions.	Platinum	90-98	centrosomal protein 57	Homo sapiens	109-113
17125375-3	2006	As a result, the hydrogen-evolution rate of the photocatalytic system with MVA2+-modified platinum clusters (MVA2+-PtC) is 10 times faster than the photocatalytic system with the mixture of the same amount of MVA2+ and platinum clusters as that of MVA2+-PtC under otherwise the same experimental conditions.	Platinum	219-227	centrosomal protein 57	Homo sapiens	75-79
17125375-3	2006	As a result, the hydrogen-evolution rate of the photocatalytic system with MVA2+-modified platinum clusters (MVA2+-PtC) is 10 times faster than the photocatalytic system with the mixture of the same amount of MVA2+ and platinum clusters as that of MVA2+-PtC under otherwise the same experimental conditions.	Platinum	219-227	centrosomal protein 57	Homo sapiens	109-113
17125375-3	2006	As a result, the hydrogen-evolution rate of the photocatalytic system with MVA2+-modified platinum clusters (MVA2+-PtC) is 10 times faster than the photocatalytic system with the mixture of the same amount of MVA2+ and platinum clusters as that of MVA2+-PtC under otherwise the same experimental conditions.	Platinum	219-227	centrosomal protein 57	Homo sapiens	109-113
17125375-3	2006	As a result, the hydrogen-evolution rate of the photocatalytic system with MVA2+-modified platinum clusters (MVA2+-PtC) is 10 times faster than the photocatalytic system with the mixture of the same amount of MVA2+ and platinum clusters as that of MVA2+-PtC under otherwise the same experimental conditions.	Platinum	219-227	centrosomal protein 57	Homo sapiens	109-113
17020389-11	2006	During the platinum-catalyzed oxidation of carbon monoxide, we monitored the flow of hot electrons over several hours using a metal-semiconductor Schottky diode composed of Pt and TiO2.	Platinum	11-19	alcohol dehydrogenase iron containing 1	Homo sapiens	85-88
16931550-6	2006	At the single-fibre level, elevated PT was found in cells expressing fast myosin heavy chain (MyHC) isoforms, especially MyHC-IIx, but not in those expressing slow MyHC.	Platinum	36-38	myosin heavy chain 6	Homo sapiens	74-92
16931550-6	2006	At the single-fibre level, elevated PT was found in cells expressing fast myosin heavy chain (MyHC) isoforms, especially MyHC-IIx, but not in those expressing slow MyHC.	Platinum	36-38	myosin heavy chain 6	Homo sapiens	94-98
16931550-6	2006	At the single-fibre level, elevated PT was found in cells expressing fast myosin heavy chain (MyHC) isoforms, especially MyHC-IIx, but not in those expressing slow MyHC.	Platinum	36-38	myosin heavy chain 1	Homo sapiens	121-129
16931550-6	2006	At the single-fibre level, elevated PT was found in cells expressing fast myosin heavy chain (MyHC) isoforms, especially MyHC-IIx, but not in those expressing slow MyHC.	Platinum	36-38	myosin heavy chain 6	Homo sapiens	121-125
16616808-5	2006	MK-1 positivity tended to show significantly decreasing pT (P=0.0039), pN (P&lt;or=0.001), and pStage (P=0.001).	Platinum	56-58	potassium voltage-gated channel subfamily A member 1	Homo sapiens	0-4
17091993-5	2006	This important physical insight is evidenced by comparison of the rates of the Pt-catalyzed formation of gold nanoparticles in the presence and in the absence of hydrogen (H(2)), which adsorb dissociatively on a Pt nanocrystal surface forming Pt-H species.	Platinum	79-81	parathyroid hormone	Homo sapiens	243-247
16690105-10	2006	In this in vitro study, we determined the downregulation of intracellular GST activity and GSH concentration were the predominant mechanisms involved in the modulation of platinum resistance.	Platinum	171-179	glutathione S-transferase kappa 1	Homo sapiens	74-77
16934364-0	2006	Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy.	Platinum	130-138	kinesin family member 11	Homo sapiens	0-3
16934364-10	2006	CONCLUSIONS: Eg5 expression can predict a response to antimitotic agents combined with platinum chemotherapy among patients with advanced NSCLC.	Platinum	87-95	kinesin family member 11	Homo sapiens	13-16
17192989-3	2006	The material specificity, that is, the preferential adsorption, of GBP1 was also demonstrated using gold and platinum micropatterned on a silicon wafer containing native oxide.	Platinum	109-117	guanylate binding protein 1	Homo sapiens	67-71
16377083-7	2006	Treatment with two platinum compounds which bind the Stat3 protein and inhibit its activity without affecting its phosphorylation directly.	Platinum	19-27	signal transducer and activator of transcription 3	Mus musculus	53-58
17020389-11	2006	During the platinum-catalyzed oxidation of carbon monoxide, we monitored the flow of hot electrons over several hours using a metal-semiconductor Schottky diode composed of Pt and TiO2.	Platinum	173-175	alcohol dehydrogenase iron containing 1	Homo sapiens	85-88
17020389-12	2006	The thickness of the Pt film used as the catalyst was 5 nm, less than the electron mean free path, resulting in the ballistic transport of hot electrons through the metal.	Platinum	21-23	alcohol dehydrogenase iron containing 1	Homo sapiens	139-142
16647749-2	2006	We describe the "atypical platinum reactions" (APH) of 14 patients and our experience with skin testing and desensitization.	Platinum	26-34	acylaminoacyl-peptide hydrolase	Homo sapiens	47-50
16966686-0	2006	RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.	Platinum	64-72	ribonucleotide reductase catalytic subunit M1	Homo sapiens	0-4
17198586-0	2006	[Influences of PC cell-derived growth factor and breast cancer resistance protein on the curative effects of platinum-based chemotherapeutic regimens for advanced non-small cell lung cancer].	Platinum	109-117	granulin precursor	Homo sapiens	15-44
17198586-0	2006	[Influences of PC cell-derived growth factor and breast cancer resistance protein on the curative effects of platinum-based chemotherapeutic regimens for advanced non-small cell lung cancer].	Platinum	109-117	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	49-81
17198586-1	2006	OBJECTIVE: To investigate the influences of PC cell-derived growth factor (PCDGF) and breast cancer resistance protein (BCRP) on the curative effects of platinum-based chemotherapeutic regimens for advanced non-small cell lung cancer (NSCLC).	Platinum	153-161	granulin precursor	Homo sapiens	44-73
17198586-1	2006	OBJECTIVE: To investigate the influences of PC cell-derived growth factor (PCDGF) and breast cancer resistance protein (BCRP) on the curative effects of platinum-based chemotherapeutic regimens for advanced non-small cell lung cancer (NSCLC).	Platinum	153-161	granulin precursor	Homo sapiens	75-80
17198586-1	2006	OBJECTIVE: To investigate the influences of PC cell-derived growth factor (PCDGF) and breast cancer resistance protein (BCRP) on the curative effects of platinum-based chemotherapeutic regimens for advanced non-small cell lung cancer (NSCLC).	Platinum	153-161	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	86-118
17198586-1	2006	OBJECTIVE: To investigate the influences of PC cell-derived growth factor (PCDGF) and breast cancer resistance protein (BCRP) on the curative effects of platinum-based chemotherapeutic regimens for advanced non-small cell lung cancer (NSCLC).	Platinum	153-161	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	120-124
16966686-11	2006	CONCLUSION: The results strongly suggest that tumoral RRM1 expression is a major predictor of disease response to gemcitabine/platinum chemotherapy.	Platinum	126-134	ribonucleotide reductase catalytic subunit M1	Homo sapiens	54-58
16595148-8	2006	CONCLUSION: Reduction in the serum CA-125 concentration over the initial two cycles of platinum-based chemotherapy is a powerful independent predictor of survival for patients with suboptimal stage III or IV ovarian cancer.	Platinum	87-95	mucin 16, cell surface associated	Homo sapiens	35-41
16595148-9	2006	Patients without significant declines in CA-125 after two cycles of platinum-based chemotherapy have a particularly poor prognosis.	Platinum	68-76	mucin 16, cell surface associated	Homo sapiens	41-47
16913681-4	2006	In the reactions of platinum clusters Pt(n)()(+) (n = 2-4) with CH(4), the H(2) elimination from the dihydrogen complex is the rate-determining step.	Platinum	20-28	relaxin 2	Homo sapiens	75-79
17185181-8	2006	Recent evidence has shown that platinum-based chemotherapy with concurrent hyperfractionated radiotherapy followed by surgery is feasible and a promising strategy for highly selected patients with SCLC.	Platinum	31-39	SCLC1	Homo sapiens	197-201
17366786-8	2006	CONCLUSION: Breast cancer resistance protein (BCRP) is found to be expressed at high level in the serum of NSCLC patient, the intensity of BCRP expression may be correlated with chemotherapy resistance in NSCLC, and the high level expressing of BCRP may indicate resistance to the platinum-based chemotherapy regimen.	Platinum	281-289	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	12-44
17366786-8	2006	CONCLUSION: Breast cancer resistance protein (BCRP) is found to be expressed at high level in the serum of NSCLC patient, the intensity of BCRP expression may be correlated with chemotherapy resistance in NSCLC, and the high level expressing of BCRP may indicate resistance to the platinum-based chemotherapy regimen.	Platinum	281-289	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	46-50
17366786-8	2006	CONCLUSION: Breast cancer resistance protein (BCRP) is found to be expressed at high level in the serum of NSCLC patient, the intensity of BCRP expression may be correlated with chemotherapy resistance in NSCLC, and the high level expressing of BCRP may indicate resistance to the platinum-based chemotherapy regimen.	Platinum	281-289	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	139-143
17366786-8	2006	CONCLUSION: Breast cancer resistance protein (BCRP) is found to be expressed at high level in the serum of NSCLC patient, the intensity of BCRP expression may be correlated with chemotherapy resistance in NSCLC, and the high level expressing of BCRP may indicate resistance to the platinum-based chemotherapy regimen.	Platinum	281-289	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	139-143
16907658-7	2006	Successful implementation of oxaliplatin desensitisation protocols based on other platinum-containing compounds have been reported, which could enable a small number of patients who experience severe HSR to further receive an effective therapy for CRC.	Platinum	82-90	HSR	Homo sapiens	200-203
17409936-1	2006	BACKGROUND: Polymorphisms within the P1 isoenzyme of GST (GSTP1) are associated with alterations in enzyme activity and may change sensitivity to platinum-based chemotherapy.	Platinum	146-154	glutathione S-transferase pi 1	Homo sapiens	58-63
17409936-9	2006	CONCLUSIONS: GSTP1 haplotype can be used to stratify hematological toxicity after platinum-based chemotherapy, but the lack of significant associations with response or survival suggests that GSTP1 polymorphisms may not be strong pharmacogenomic markers in this population.	Platinum	82-90	glutathione S-transferase pi 1	Homo sapiens	13-18
16874833-0	2006	A synthetic breakthrough into an unanticipated stability regime: a series of isolable complexes in which C6, C8, C10, C12, C16, C20, C24, and C28 polyynediyl chains span two platinum atoms.	Platinum	174-182	chromosome 12 open reading frame 57	Homo sapiens	113-116
17051951-13	2006	CONCLUSIONS: Combined modality therapy using platinum-based combination chemotherapy and consolidation radiotherapy may provide effective local control and allow a bladder-preserving approach to the management of SCC of the bladder.	Platinum	45-53	serpin family B member 3	Homo sapiens	213-216
16847145-8	2006	There was an association between the effect of loss of CTR1 function on uptake of the platinum drugs and their cytotoxicity.	Platinum	86-94	solute carrier family 31, member 1	Mus musculus	55-59
16785472-6	2006	For patients receiving platinum drugs, the MDR1 C3435T variant allele was associated with significantly reduced recurrence risk (HR = 0.25; 95% CI, 0.10 to 0.64) and improved survival (HR = 0.44; 95% CI, 0.23 to 0.85).	Platinum	23-31	ATP binding cassette subfamily B member 1	Homo sapiens	43-47
16903734-12	2006	This stacking could explain the unprecedented, relatively low reactivity of a Pt complex bearing a dien-type ligand toward met vs 5"-GMP.	Platinum	78-80	5'-nucleotidase, cytosolic II	Homo sapiens	133-136
16793005-6	2006	The results of competitive ELISA demonstrated that PT could inhibit the binding of BCMA-Fc and anti-BLyS antibody to BLyS in vitro.	Platinum	51-53	tumor necrosis factor receptor superfamily, member 17	Mus musculus	83-87
16793005-6	2006	The results of competitive ELISA demonstrated that PT could inhibit the binding of BCMA-Fc and anti-BLyS antibody to BLyS in vitro.	Platinum	51-53	tumor necrosis factor (ligand) superfamily, member 13b	Mus musculus	100-104
16793005-6	2006	The results of competitive ELISA demonstrated that PT could inhibit the binding of BCMA-Fc and anti-BLyS antibody to BLyS in vitro.	Platinum	51-53	tumor necrosis factor (ligand) superfamily, member 13b	Mus musculus	117-121
16777483-4	2006	Platinums have also been found to downregulate MGMT expression and this approach is currently under exploration.	Platinum	0-9	O-6-methylguanine-DNA methyltransferase	Homo sapiens	47-51
16804928-7	2006	RESULTS: Using costs alone, BSC was the only definitive cost-effective treatment for platinum-resistant recurrent ovarian cancer patients, and second-line monotherapy was a reasonable cost-effective strategy with an incremental cost-effectiveness ratio (ICER) of 64,104 dollars.	Platinum	85-93	solute carrier family 12 member 2	Homo sapiens	28-31
16824042-0	2006	Deoxyribonuclease I footprinting reveals different DNA binding modes of bifunctional platinum complexes.	Platinum	85-93	deoxyribonuclease 1	Homo sapiens	0-19
16824042-3	2006	It was shown that various conformational perturbations induced by platinum binding in the major groove translated into the minor groove, allowing their detection by DNase I probing.	Platinum	66-74	deoxyribonuclease 1	Homo sapiens	165-172
16824042-4	2006	The results also demonstrate the very high sensitivity of DNase I to DNA conformational alterations induced by platinum complexes so that the platinum adducts which induce specific local conformational alterations in DNA are differently recognized by DNase I.	Platinum	111-119	deoxyribonuclease 1	Homo sapiens	58-65
16824042-4	2006	The results also demonstrate the very high sensitivity of DNase I to DNA conformational alterations induced by platinum complexes so that the platinum adducts which induce specific local conformational alterations in DNA are differently recognized by DNase I.	Platinum	111-119	deoxyribonuclease 1	Homo sapiens	251-258
16824042-4	2006	The results also demonstrate the very high sensitivity of DNase I to DNA conformational alterations induced by platinum complexes so that the platinum adducts which induce specific local conformational alterations in DNA are differently recognized by DNase I.	Platinum	142-150	deoxyribonuclease 1	Homo sapiens	58-65
16824042-4	2006	The results also demonstrate the very high sensitivity of DNase I to DNA conformational alterations induced by platinum complexes so that the platinum adducts which induce specific local conformational alterations in DNA are differently recognized by DNase I.	Platinum	142-150	deoxyribonuclease 1	Homo sapiens	251-258
16953177-2	2006	Tap water was electrolyzed in a water vessel using platinum cell technology.	Platinum	51-59	nuclear RNA export factor 1	Homo sapiens	0-3
17025126-6	2006	The electrocatalytic activity of the platinum catalyst supported on TiO2 nanotubes for methanol oxidation is found to be better than that of the standard commercial E-TEK catalyst.	Platinum	37-45	TEK receptor tyrosine kinase	Homo sapiens	167-170
16834391-1	2006	Ethylenediamine (en) solutions of K4Pb9 react with toluene solutions of ML4 (M = Pt, Pd, L = PPh3; M = Ni, L2= COD) and 2,2,2-crypt to give M@Pb12(2-) cluster anions (M = Pt (1), Pd (2), Ni (3)) as the [K(2,2,2-crypt)]+ salts in low (Ni) to good (Pt) yields.	Platinum	81-83	mucolipin TRP cation channel 1	Homo sapiens	72-75
16936459-2	2006	MGMT appears not to be linked to platinum resistance, so platinum chemotherapy should be used for MGMT-unmethylated tumors.	Platinum	57-65	O-6-methylguanine-DNA methyltransferase	Homo sapiens	98-102
17236555-8	2006	The intensity of PCDGF expression may be correlated with chemotherapy response and the high level expressing of PCDGF may indicate resistant to platinum-based chemotherapeutic regimen.	Platinum	144-152	granulin precursor	Homo sapiens	112-117
16805608-4	2006	Thus, higher catalytic activity was obtained with Pt0 dispersed in BMI.BF4 containing the less coordinating anion although these nanoparticles possess a larger mean diameter (3.4 nm) than those obtained in BMI.PF6 (2.3 nm).	Platinum	50-53	sperm associated antigen 17	Homo sapiens	210-213
16819291-2	2006	In this study we hypothesized that a polymorphism of ERCC1 Asn118Asn (C -&gt; T) might affect the platinum-resistance of epithelial ovarian cancer patients to platinum-taxane chemotherapy administered postoperatively.	Platinum	98-106	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	53-58
16819291-8	2006	Our results suggest that genotyping of the ERCC1 polymorphism Asn118Asn may be useful for predicting the platinum-resistance of epithelial ovarian cancer patients.	Platinum	105-113	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	43-48
16649224-0	2006	Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.	Platinum	92-100	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	0-29
16170571-7	2006	In the case of DDP, forced expression of either of the two Cu efflux transporters, ATP7A or ATP7B, in Me32a cells rendered them resistant to DDP, increased whole cell accumulation of Pt but reduced the amount of Pt in DNA.	Platinum	183-185	ATPase, Cu++ transporting, alpha polypeptide	Mus musculus	83-88
16649224-3	2006	Polymorphisms within the Xeroderma pigmentosum Group D protein (XPD), a member of the NER pathway, are associated with alterations in enzyme activity and may change sensitivity to platinum-based chemotherapy.	Platinum	180-188	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	25-54
16170571-7	2006	In the case of DDP, forced expression of either of the two Cu efflux transporters, ATP7A or ATP7B, in Me32a cells rendered them resistant to DDP, increased whole cell accumulation of Pt but reduced the amount of Pt in DNA.	Platinum	183-185	ATPase, Cu++ transporting, beta polypeptide	Mus musculus	92-97
16649224-3	2006	Polymorphisms within the Xeroderma pigmentosum Group D protein (XPD), a member of the NER pathway, are associated with alterations in enzyme activity and may change sensitivity to platinum-based chemotherapy.	Platinum	180-188	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	64-67
16170571-7	2006	In the case of DDP, forced expression of either of the two Cu efflux transporters, ATP7A or ATP7B, in Me32a cells rendered them resistant to DDP, increased whole cell accumulation of Pt but reduced the amount of Pt in DNA.	Platinum	212-214	ATPase, Cu++ transporting, alpha polypeptide	Mus musculus	83-88
16170571-7	2006	In the case of DDP, forced expression of either of the two Cu efflux transporters, ATP7A or ATP7B, in Me32a cells rendered them resistant to DDP, increased whole cell accumulation of Pt but reduced the amount of Pt in DNA.	Platinum	212-214	ATPase, Cu++ transporting, beta polypeptide	Mus musculus	92-97
16649224-8	2006	RESULTS: Significant correlations were observed between XPD haplotype and Grade 4 neutropenia and overall survival together with a greater response to platinum-based chemotherapy for the XPD *A haplotype.	Platinum	151-159	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	56-59
16170571-8	2006	In the case of JM118, forced expression of either ATP7A or ATP7B rendered Me32a cells resistant, increased not only whole cell Pt accumulation but also increased rather than decreased the amount of Pt in DNA.	Platinum	127-129	ATPase, Cu++ transporting, alpha polypeptide	Mus musculus	50-55
16170571-8	2006	In the case of JM118, forced expression of either ATP7A or ATP7B rendered Me32a cells resistant, increased not only whole cell Pt accumulation but also increased rather than decreased the amount of Pt in DNA.	Platinum	127-129	ATPase, Cu++ transporting, beta polypeptide	Mus musculus	59-64
16649224-8	2006	RESULTS: Significant correlations were observed between XPD haplotype and Grade 4 neutropenia and overall survival together with a greater response to platinum-based chemotherapy for the XPD *A haplotype.	Platinum	151-159	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	187-190
16170571-8	2006	In the case of JM118, forced expression of either ATP7A or ATP7B rendered Me32a cells resistant, increased not only whole cell Pt accumulation but also increased rather than decreased the amount of Pt in DNA.	Platinum	198-200	ATPase, Cu++ transporting, alpha polypeptide	Mus musculus	50-55
16649224-9	2006	CONCLUSIONS: The XPD haplotype may represent a useful pharmacogenomic marker of platinum-based chemotherapy in patients with advanced NSCLC and requires prospective validation.	Platinum	80-88	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	17-20
16170571-8	2006	In the case of JM118, forced expression of either ATP7A or ATP7B rendered Me32a cells resistant, increased not only whole cell Pt accumulation but also increased rather than decreased the amount of Pt in DNA.	Platinum	198-200	ATPase, Cu++ transporting, beta polypeptide	Mus musculus	59-64
16170571-12	2006	Second, ATP7A and ATP7B, while they both mediate resistance, have opposite effects on the accumulation of Pt in DNA following exposure to the two drugs.	Platinum	106-108	ATPase, Cu++ transporting, alpha polypeptide	Mus musculus	8-13
16170571-12	2006	Second, ATP7A and ATP7B, while they both mediate resistance, have opposite effects on the accumulation of Pt in DNA following exposure to the two drugs.	Platinum	106-108	ATPase, Cu++ transporting, beta polypeptide	Mus musculus	18-23
16764755-3	2006	The VEGF signaling pathway as a target in lung cancer therapy was validated by a randomized phase III study of platinum agent-based combination chemotherapy with or without bevacizumab, a recombinant humanized monoclonal antibody against VEGF-A, in first-line, nonsquamous, metastatic non-small-cell lung cancer.	Platinum	111-119	vascular endothelial growth factor A	Homo sapiens	4-8
16685392-11	2006	These results suggest that in vitro sensitivity to platinum-derived drugs, CDDP and CBDCA, is associated with PCNA-normalized mRNA expression of TS and DPD in human lung cancer tissues, as affected by the TS polymorphism.	Platinum	51-59	proliferating cell nuclear antigen	Homo sapiens	110-114
16685392-11	2006	These results suggest that in vitro sensitivity to platinum-derived drugs, CDDP and CBDCA, is associated with PCNA-normalized mRNA expression of TS and DPD in human lung cancer tissues, as affected by the TS polymorphism.	Platinum	51-59	dihydropyrimidine dehydrogenase	Homo sapiens	152-155
16700608-10	2006	The Pt(5)Fe(2)/SiO(2) sample was also more active than Pt/SiO(2) for PROX with a selectivity of approximately 92% at 50 degrees C. In this case, the deactivation with time on stream was substantially slower, indicating that the highly reducing environment under the PROX conditions helps maintain the properties of the active Pt-Fe bimetallic sites.	Platinum	4-6	pyruvate dehydrogenase complex component X	Homo sapiens	69-73
16700608-10	2006	The Pt(5)Fe(2)/SiO(2) sample was also more active than Pt/SiO(2) for PROX with a selectivity of approximately 92% at 50 degrees C. In this case, the deactivation with time on stream was substantially slower, indicating that the highly reducing environment under the PROX conditions helps maintain the properties of the active Pt-Fe bimetallic sites.	Platinum	4-6	pyruvate dehydrogenase complex component X	Homo sapiens	266-270
16803500-13	2006	We conclude that the combination chemotherapy with TIP yields a high response rate with acceptable toxicity for patients with recurrent cervical carcinoma, including those patients who have failed to respond to prior platinum-based chemotherapy.	Platinum	217-225	TOR signaling pathway regulator	Homo sapiens	51-54
16337112-1	2006	Multidrug resistance protein-5 (MRP5, ABCC5) is a member of the ATP-binding cassette transporter superfamily that effluxes a broad range of natural and xenobiotic compounds such as cyclic GMP, antiviral compounds, and cancer chemotherapeutic agents including nucleoside-based drugs, antifolate agents and platinum compounds.	Platinum	305-313	ATP binding cassette subfamily C member 5	Homo sapiens	0-30
26626686-5	2006	Energetic criteria show also that the STM tip (made from Pt and Ir alloys) immersed into a bromine solution may contain only dissociated bromine atoms that bind strongly with the surface Pt atoms.	Platinum	57-59	sulfotransferase family 1A member 3	Homo sapiens	38-41
16839218-3	2006	Our results suggest that the parent (H1-2), copper (C1-2)- and platinum (P1-2)-derivatized compounds were relatively more active in inducing apoptosis and cell killing in both human breast cancer cell lines, MDA-MB-231 cells being the more sensitive.	Platinum	63-71	H1.2 linker histone, cluster member	Homo sapiens	37-41
16839218-3	2006	Our results suggest that the parent (H1-2), copper (C1-2)- and platinum (P1-2)-derivatized compounds were relatively more active in inducing apoptosis and cell killing in both human breast cancer cell lines, MDA-MB-231 cells being the more sensitive.	Platinum	63-71	DNA polymerase epsilon 4, accessory subunit	Homo sapiens	73-77
16169242-6	2006	In addition, epoetin beta prevents severe anaemia and reduces transfusion requirements in patients with a high-risk of developing anaemia during chemotherapy, such as those receiving platinum-based regimens.	Platinum	183-191	erythropoietin	Homo sapiens	13-20
16570051-0	2006	Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial.	Platinum	16-24	erythropoietin	Homo sapiens	0-7
16536759-11	2006	CONCLUSIONS: These results indicate that GU SCC is an aggressive cancer; limited-stage SCC of the bladder or prostate, when treated with platinum/etoposide chemotherapy and radical radiotherapy, has a more favourable outcome than that of extensive GU SCC.	Platinum	137-145	serpin family B member 3	Homo sapiens	44-47
16536759-11	2006	CONCLUSIONS: These results indicate that GU SCC is an aggressive cancer; limited-stage SCC of the bladder or prostate, when treated with platinum/etoposide chemotherapy and radical radiotherapy, has a more favourable outcome than that of extensive GU SCC.	Platinum	137-145	serpin family B member 3	Homo sapiens	87-90
16536759-11	2006	CONCLUSIONS: These results indicate that GU SCC is an aggressive cancer; limited-stage SCC of the bladder or prostate, when treated with platinum/etoposide chemotherapy and radical radiotherapy, has a more favourable outcome than that of extensive GU SCC.	Platinum	137-145	serpin family B member 3	Homo sapiens	87-90
16892376-0	2006	Exploring metallodrug-protein interactions by ESI mass spectrometry: the reaction of anticancer platinum drugs with horse heart cytochrome c.	Platinum	96-104	cytochrome c, somatic	Equus caballus	128-140
16337112-1	2006	Multidrug resistance protein-5 (MRP5, ABCC5) is a member of the ATP-binding cassette transporter superfamily that effluxes a broad range of natural and xenobiotic compounds such as cyclic GMP, antiviral compounds, and cancer chemotherapeutic agents including nucleoside-based drugs, antifolate agents and platinum compounds.	Platinum	305-313	ATP binding cassette subfamily C member 5	Homo sapiens	32-36
16337112-1	2006	Multidrug resistance protein-5 (MRP5, ABCC5) is a member of the ATP-binding cassette transporter superfamily that effluxes a broad range of natural and xenobiotic compounds such as cyclic GMP, antiviral compounds, and cancer chemotherapeutic agents including nucleoside-based drugs, antifolate agents and platinum compounds.	Platinum	305-313	ATP binding cassette subfamily C member 5	Homo sapiens	38-43
16736773-4	2006	Electrochemical measurement by cyclic voltammetry (CV) demonstrated that the electrochemical surface area of PHSs was about twice higher than E-TEK platinum black.	Platinum	148-156	TEK receptor tyrosine kinase	Homo sapiens	144-147
16571898-4	2006	The two major reaction products of cisplatin, the guanine-guanine (Pt-[GG]) and adenine-guanine (Pt-[AG]) intrastrand crosslinks are recognized by Mab R-C18 and R-B3, respectively.	Platinum	67-69	stathmin-like 4	Mus musculus	161-165
16648566-2	2006	In the current study, we designed a cell-based screening strategy to identify small-molecule inhibitors of the FA/BRCA pathway with the hypothesis that such molecules could restore sensitivity to platinum agents.	Platinum	196-204	BRCA1 DNA repair associated	Homo sapiens	114-118
16571898-4	2006	The two major reaction products of cisplatin, the guanine-guanine (Pt-[GG]) and adenine-guanine (Pt-[AG]) intrastrand crosslinks are recognized by Mab R-C18 and R-B3, respectively.	Platinum	97-99	stathmin-like 4	Mus musculus	161-165
16494311-6	2006	X-ray photoelectron spectroscopy revealed that metallic Pt(0) (81.6%) predominated the Pt species in the heat-treated catalyst, which is more than the commercial E-TEK catalyst.	Platinum	56-58	TEK receptor tyrosine kinase	Homo sapiens	164-167
16519457-8	2006	The remaining S 2p component (approximately one-third of the sulfur layer), intermediate in binding energy between the other two components, is attributed to a chemisorbed species with a S binding configuration distinct from the majority alkylthiolate: for example, S bound to Pt bound to O, S with a different Pt coordination number, or S in an adsorbed disulfide.	Platinum	277-279	ribosomal protein S2	Homo sapiens	14-18
16568778-4	2006	The optimum calcination temperature was found to be around 200 degrees C. Additionally, platinum ion-doped TiO2 was prepared by impregnation using Pt(NH3)4(NO3)2 as a dopant, which improved the photocatalytic activity that degraded NO(x) in the visible light region.	Platinum	88-96	NBL1, DAN family BMP antagonist	Homo sapiens	156-159
16875604-0	2006	[XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].	Platinum	67-75	X-ray repair cross complementing 1	Homo sapiens	1-6
16875604-0	2006	[XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].	Platinum	67-75	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	11-14
16875604-2	2006	The purpose of this study was to examine the association between polymorphisms in XRCC1 and XPD, which are involved in DNA repair, and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).	Platinum	157-165	X-ray repair cross complementing 1	Homo sapiens	82-87
16875604-2	2006	The purpose of this study was to examine the association between polymorphisms in XRCC1 and XPD, which are involved in DNA repair, and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).	Platinum	157-165	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	92-95
16875604-3	2006	METHODS: XRCC1 Arg194Trp and XPD Lys751Gln were genotyped by PCR-RFLP method in 200 patients with advanced NSCLC who received platinum-based chemotherapy.	Platinum	126-134	X-ray repair cross complementing 1	Homo sapiens	9-14
16875604-9	2006	CONCLUSION: Those results suggest that the XRCC1 Arg194Trp and XPD Lys751Gln genetic polymorphisms may be associated with clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer.	Platinum	144-152	X-ray repair cross complementing 1	Homo sapiens	43-48
16875604-9	2006	CONCLUSION: Those results suggest that the XRCC1 Arg194Trp and XPD Lys751Gln genetic polymorphisms may be associated with clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer.	Platinum	144-152	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	63-66
16545208-22	2006	The ICER for PLDH compared with paclitaxel was pound 7033 per quality-adjusted life-year (QALY) in the overall patient population (comprising platinum-sensitive, -refractory and -resistant patients).	Platinum	142-150	cAMP responsive element modulator	Homo sapiens	4-8
16545208-23	2006	The ICER was more favourable in the platinum-sensitive group ( pound 5777 per QALY) and less favourable in the platinum-refractory/resistant group ( pound 9555 per QALY).	Platinum	36-44	cAMP responsive element modulator	Homo sapiens	4-8
16545208-23	2006	The ICER was more favourable in the platinum-sensitive group ( pound 5777 per QALY) and less favourable in the platinum-refractory/resistant group ( pound 9555 per QALY).	Platinum	111-119	cAMP responsive element modulator	Homo sapiens	4-8
16545208-26	2006	The ICER of PLDH compared with paclitaxel was pound 20,620 per QALY in the overall patient population, pound 16,183 per QALY in the platinum-sensitive population and pound 26,867 per QALY in the platinum-resistant and -refractory population.	Platinum	132-140	cAMP responsive element modulator	Homo sapiens	4-8
16545208-26	2006	The ICER of PLDH compared with paclitaxel was pound 20,620 per QALY in the overall patient population, pound 16,183 per QALY in the platinum-sensitive population and pound 26,867 per QALY in the platinum-resistant and -refractory population.	Platinum	195-203	cAMP responsive element modulator	Homo sapiens	4-8
16545208-34	2006	The ICER for paclitaxel-platinum combination therapy compared with CAP was pound 20,950 per QALY.	Platinum	24-32	cAMP responsive element modulator	Homo sapiens	4-8
16406195-0	2006	Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.	Platinum	101-109	cyclin D1	Homo sapiens	0-9
16406195-0	2006	Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.	Platinum	101-109	cyclin D1	Homo sapiens	11-16
16750013-0	2006	[Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms].	Platinum	77-85	tumor protein p53	Homo sapiens	110-113
16465328-1	2006	By chemically modifying the nucleation burst that generates monodisperse FePt nanocrystals, a mixture of Pt and Fe(x)Pt(1-x) nanoparticles forms during a one-pot reaction that includes a small amount of Cu as a catalyst; size-selective precipitation yields a bi-disperse population of Fe(x)Pt(1-x) nanoparticles, which can assemble into high-quality AB2, AB5, and AB13 superlattice structures.	Platinum	75-77	NBPF member 1	Homo sapiens	364-368
16213010-2	2006	The aim of this study was to determine the role of MRP2 in modulating cisplatin cytotoxicity in normal cells as well as the relationship between MRP2 expression and clinical response to platinum-based agents in ovarian cancer.	Platinum	186-194	ATP binding cassette subfamily C member 2	Homo sapiens	145-149
16213010-4	2006	We also examined MRP2 expression immunohistochemically in human ovarian tumors exhibiting extremes of clinical response to platinum-based chemotherapy, either absolute platin resistance or patients with residual disease after surgery who experienced extremely long complete response to primary platinum-based chemotherapy.	Platinum	123-131	ATP binding cassette subfamily C member 2	Homo sapiens	17-21
16213010-4	2006	We also examined MRP2 expression immunohistochemically in human ovarian tumors exhibiting extremes of clinical response to platinum-based chemotherapy, either absolute platin resistance or patients with residual disease after surgery who experienced extremely long complete response to primary platinum-based chemotherapy.	Platinum	123-129	ATP binding cassette subfamily C member 2	Homo sapiens	17-21
16213010-5	2006	RESULTS: Primary hepatocyte cultures from Mrp2-deficient TR- rats were over threefold more sensitive to cisplatin and accumulated a twofold greater amount of platinum on DNA that wild-type rat hepatocytes.	Platinum	158-166	ATP binding cassette subfamily C member 2	Rattus norvegicus	42-46
16213010-6	2006	In human ovarian carcinomas, MRP2 was detected by immunohistochemistry in 3/13 (23%) tumors from patients with absolute platin resistance compared with 5/9 (56%) tumors from patients with prolonged survival following treatment including a platinum-based agent.	Platinum	239-247	ATP binding cassette subfamily C member 2	Homo sapiens	29-33
16476840-0	2006	Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.	Platinum	44-52	erythropoietin	Homo sapiens	24-31
16476840-1	2006	OBJECTIVE: To evaluate the effect of epoetin alfa on quality of life (QOL) in patients with solid tumors and mild-to-moderate anemia receiving platinum-based chemotherapy relative to population norms.	Platinum	143-151	erythropoietin	Homo sapiens	37-44
16476841-0	2006	Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.	Platinum	44-52	erythropoietin	Homo sapiens	24-31
16476841-8	2006	CONCLUSION: In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels &gt;10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.	Platinum	46-54	erythropoietin	Homo sapiens	141-144
16750013-0	2006	[Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms].	Platinum	77-85	tumor protein p73	Homo sapiens	118-121
16750013-2	2006	This study examined the relationship between p53 and p73 genetic polymorphisms and the response to platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).	Platinum	99-107	tumor protein p53	Homo sapiens	45-48
16750013-2	2006	This study examined the relationship between p53 and p73 genetic polymorphisms and the response to platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).	Platinum	99-107	tumor protein p73	Homo sapiens	53-56
16750013-10	2006	CONCLUSION: Those results suggest that p53 and p73 polymorphisms may be associated with clinical responsiveness to platinum-based chemotherapy in advanced NSCLC.	Platinum	115-123	tumor protein p53	Homo sapiens	39-42
16750013-10	2006	CONCLUSION: Those results suggest that p53 and p73 polymorphisms may be associated with clinical responsiveness to platinum-based chemotherapy in advanced NSCLC.	Platinum	115-123	tumor protein p73	Homo sapiens	47-50
16342067-4	2006	In this study, the authors hypothesized that variant GSTP1 genotype would result in reduced inactivation of chemotherapy agents and improved survival in patients with advanced-stage nonsmall cell lung carcinoma (NSCLC), a population that is likely to receive platinum-based chemotherapy.	Platinum	259-267	glutathione S-transferase pi 1	Homo sapiens	53-58
15913978-6	2006	The 3D POA nano-networks coated platinum electrode gave a direct electrochemical behavior of horse heart cytochrome c (Cyt c) immobilized on this electrode surface, a pair of well-defined redox waves with formal potential (E( degrees ")) of -0.032 V (versus Ag/AgCl) was achieved.	Platinum	32-40	cytochrome c, somatic	Equus caballus	105-117
15913978-6	2006	The 3D POA nano-networks coated platinum electrode gave a direct electrochemical behavior of horse heart cytochrome c (Cyt c) immobilized on this electrode surface, a pair of well-defined redox waves with formal potential (E( degrees ")) of -0.032 V (versus Ag/AgCl) was achieved.	Platinum	32-40	cytochrome c, somatic	Equus caballus	119-124
15913978-10	2006	The quantitative determination of Cyt c by differential pulse voltammetry (DPV) using the fully sulfonated 3D POA nano-networks film coated platinum electrode was also studied.	Platinum	140-148	cytochrome c, somatic	Equus caballus	34-39
16375316-8	2005	Consequently, Pt/TiO2 shows substantially lower selectivities toward CO oxidation under PROX conditions than Pt/gamma-Al2O3.	Platinum	14-16	pyruvate dehydrogenase complex component X	Homo sapiens	88-92
16471509-1	2006	We report herewith the synthesis of hollow Pt nanospheres by using bis(p-sulfonatophenyl)phenylphosphine to selectively remove the Ag cores of Ag-Pt core-shell nanoparticles.	Platinum	43-45	angiopoietin 1	Homo sapiens	143-148
17163167-9	2006	Methylation of 14-3-3sigma is a new independent prognostic factor for survival in NSCLC patients receiving platinum-based chemotherapy.	Platinum	107-115	stratifin	Homo sapiens	15-26
16739339-0	2006	P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.	Platinum	119-127	tumor protein p53	Homo sapiens	0-3
16473140-0	2006	Molecular alterations of cells resistant to platinum drugs: role of PKCalpha.	Platinum	44-52	protein kinase C alpha	Homo sapiens	68-76
16473140-3	2006	Using display PCR, we found that acquisition of resistance to the multinuclear platinum complex BBR3464 was associated with modulation of several transcripts, including up-regulation of the major substrate of protein kinase C (PKC), the myristoylated alanine-rich C kinase substrate (MARCKS).	Platinum	79-87	protein kinase C alpha	Homo sapiens	227-230
16473140-3	2006	Using display PCR, we found that acquisition of resistance to the multinuclear platinum complex BBR3464 was associated with modulation of several transcripts, including up-regulation of the major substrate of protein kinase C (PKC), the myristoylated alanine-rich C kinase substrate (MARCKS).	Platinum	79-87	myristoylated alanine rich protein kinase C substrate	Homo sapiens	237-282
16473140-3	2006	Using display PCR, we found that acquisition of resistance to the multinuclear platinum complex BBR3464 was associated with modulation of several transcripts, including up-regulation of the major substrate of protein kinase C (PKC), the myristoylated alanine-rich C kinase substrate (MARCKS).	Platinum	79-87	myristoylated alanine rich protein kinase C substrate	Homo sapiens	284-290
16725267-1	2006	Patients with cancer receiving myelosuppressive chemotherapy frequently develop anaemia; platinum-based chemotherapy, in particular, leads to reduced production of the bone marrow-stimulating hormone erythropoietin.	Platinum	89-97	erythropoietin	Homo sapiens	200-214
16736282-5	2006	By contrast, most studies indicate that women developing a BRCA1/2-related ovarian cancer have an improved survival compared with non-carriers, particularly if they receive platinum-based therapy.	Platinum	173-181	BRCA1 DNA repair associated	Homo sapiens	59-64
16897574-8	2006	The PKA-dependent PT drop was substantially larger when fibers were pre-treated with protein phosphatase-1, indicating that inherent phosphorylation of titin is important for the basal myocardial PT level.	Platinum	18-20	titin	Homo sapiens	152-157
16787355-4	2006	In the present study we report that PARP-1 inhibitor 3-aminobenzamide (3-AB) increases the cytotoxic activity of the platinum compounds cisplatin, trans-[PtCl(2)(4-picoline)(piperazine)] and transplatin against CH1cisR cisplatin-resistant ovarian tumor cells.	Platinum	117-125	poly(ADP-ribose) polymerase 1	Homo sapiens	36-42
16787355-4	2006	In the present study we report that PARP-1 inhibitor 3-aminobenzamide (3-AB) increases the cytotoxic activity of the platinum compounds cisplatin, trans-[PtCl(2)(4-picoline)(piperazine)] and transplatin against CH1cisR cisplatin-resistant ovarian tumor cells.	Platinum	117-125	SUN domain containing ossification factor	Homo sapiens	211-214
16787355-6	2006	Altogether, these data suggest that pharmacological modulation of PARP-1 by inhibitors may be a suitable strategy to fight against tumor resistance to platinum drugs.	Platinum	151-159	poly(ADP-ribose) polymerase 1	Homo sapiens	66-72
16363819-0	2005	Synthesis and structural analysis of the first nanosized platinum-gold carbonyl/phosphine cluster, Pt13[Au2(PPh3)2]2(CO)10(PPh3)4, containing a Pt-centered [Ph3PAu-AuPPh3]-capped icosahedral Pt12 cage.	Platinum	57-65	caveolin 1	Homo sapiens	108-112
16363819-0	2005	Synthesis and structural analysis of the first nanosized platinum-gold carbonyl/phosphine cluster, Pt13[Au2(PPh3)2]2(CO)10(PPh3)4, containing a Pt-centered [Ph3PAu-AuPPh3]-capped icosahedral Pt12 cage.	Platinum	57-65	caveolin 1	Homo sapiens	123-127
16361617-9	2005	CONCLUSION Methylation of 14-3-3sigma is a new independent prognostic factor for survival in NSCLC patients receiving platinum-based chemotherapy.	Platinum	118-126	stratifin	Homo sapiens	26-37
16739308-0	2006	Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis.	Platinum	76-84	erythropoietin	Homo sapiens	0-7
16739308-0	2006	Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis.	Platinum	93-101	erythropoietin	Homo sapiens	0-7
16533424-5	2006	Very interestingly, specific change was found in recurrent ovarian cancer after platinum-based chemotherapy: TOP2A expression decreased in tumor epithelial cells of recurrent ovarian cancer compared to primary ovarian cancer (P = .056), whereas it increased in tumor-adjacent stromal cells in carboplatin-treated recurrent tumors compared to primary ovarian cancer (P = .023).	Platinum	80-88	DNA topoisomerase II alpha	Homo sapiens	109-114
16533424-6	2006	CONCLUSION: TOP2A mRNA and protein expression in ovarian cancer exhibits specific patterns in tumor epithelial and adjacent stromal cells, which are differentially modulated after platinum-based chemotherapy.	Platinum	180-188	DNA topoisomerase II alpha	Homo sapiens	12-17
16322298-1	2005	PURPOSE: We aimed to determine the clinical role of the p53 family members p53 and p73 in the responsiveness to platinum-based chemotherapy and survival in ovarian cancer, considering their cross-talk and the p53 polymorphism at codon 72.	Platinum	112-120	tumor protein p53	Homo sapiens	56-59
16351803-10	2005	CONCLUSION: The genetic polymorphisms of XPC-PAT, XPD Lys751Gln, and ERCC1 C8092A in nucleotide excision repair system may be associated with sensitivity of NSCLC patients to platinum-based chemotherapy.	Platinum	175-183	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	50-53
16351803-10	2005	CONCLUSION: The genetic polymorphisms of XPC-PAT, XPD Lys751Gln, and ERCC1 C8092A in nucleotide excision repair system may be associated with sensitivity of NSCLC patients to platinum-based chemotherapy.	Platinum	175-183	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	69-74
16242669-5	2005	The release of lactate dehydrogenase and the accumulation of platinum were greater in HEK-rOCT2 cells treated with cisplatin than in mock-transfected cells.	Platinum	61-69	solute carrier family 22 member 2	Rattus norvegicus	90-95
16322298-1	2005	PURPOSE: We aimed to determine the clinical role of the p53 family members p53 and p73 in the responsiveness to platinum-based chemotherapy and survival in ovarian cancer, considering their cross-talk and the p53 polymorphism at codon 72.	Platinum	112-120	tumor protein p53	Homo sapiens	75-78
16322298-1	2005	PURPOSE: We aimed to determine the clinical role of the p53 family members p53 and p73 in the responsiveness to platinum-based chemotherapy and survival in ovarian cancer, considering their cross-talk and the p53 polymorphism at codon 72.	Platinum	112-120	tumor protein p73	Homo sapiens	83-86
16322298-1	2005	PURPOSE: We aimed to determine the clinical role of the p53 family members p53 and p73 in the responsiveness to platinum-based chemotherapy and survival in ovarian cancer, considering their cross-talk and the p53 polymorphism at codon 72.	Platinum	112-120	tumor protein p53	Homo sapiens	75-78
16322298-10	2005	p53 mutational status was an important determinant of responsiveness to platinum-based chemotherapy in all patients with a residual tumor of &lt;2 cm in diameter after initial surgery (wild-type versus mutant, P = 0.029).	Platinum	72-80	tumor protein p53	Homo sapiens	0-3
16322298-17	2005	NH2-terminally truncated p73 isoforms were of significant clinical effect by providing an additional unfavorable factor for response to platinum-based chemotherapy and survival in p53 mutant ovarian cancers.	Platinum	136-144	tumor protein p73	Homo sapiens	25-28
16266050-0	2005	Tenascin-C-coated platinum coils for acceleration of organization of cavities and reduction of lumen size in a rat aneurysm model.	Platinum	18-26	tenascin C	Rattus norvegicus	0-10
16095677-8	2005	RESULTS: The rate constants of platinum diffusion from the peritoneal cavity to serum, serum to peritoneal cavity, serum to peripheral space, peripheral space to serum, and elimination were 0.94+/-0.79 (mean+/-SD), 1.28+/-2.50, 16.50+/-9.26, 0.99+/-0.62, and 4.14+/-1.45 (h-1), respectively.	Platinum	31-39	H1.5 linker histone, cluster member	Homo sapiens	272-275
16853891-4	2005	The so-prepared Pt/CNT composite materials show higher electrocatalytic activity and better tolerance to poisoning species in methanol oxidation than the commercial E-TEK catalyst, which can be ascribed to the high dispersion of Pt nanoparticles on the multiwalled carbon nanotube surface.	Platinum	16-18	TEK receptor tyrosine kinase	Homo sapiens	167-170
16273252-2	2005	A new therapeutic option for patients with non-small cell lung cancer (NSCLC) in these stages with progress or relapse after platinum-based chemotherapy exists in the inhibitors of the epidermal growth factor receptor (EGFR) tyrosine-kinase.	Platinum	125-133	epidermal growth factor receptor	Homo sapiens	185-217
16273252-2	2005	A new therapeutic option for patients with non-small cell lung cancer (NSCLC) in these stages with progress or relapse after platinum-based chemotherapy exists in the inhibitors of the epidermal growth factor receptor (EGFR) tyrosine-kinase.	Platinum	125-133	epidermal growth factor receptor	Homo sapiens	219-223
15900595-10	2005	RCN-positive cases showed a statistically significant better disease-free survival only in the cases receiving postoperative platinum-based adjuvant chemotherapy after curative resection (p = 0.007).	Platinum	125-133	reticulocalbin 1	Homo sapiens	0-3
16172647-2	2005	HL(1-4) react directly with M(II)Cl(2)(M = Pd, Pt) or Pt(II)I(2)(cod) affording neutral square-planar complexes of general formula [M(II)Cl(eta(3)-L(1-4))](M = Pd, Pt, 1-8) and [Pt(II)I(eta(3)-L(1-4))](M = Pd, Pt, 9-12).	Platinum	47-49	galectin 2	Homo sapiens	0-6
16172647-2	2005	HL(1-4) react directly with M(II)Cl(2)(M = Pd, Pt) or Pt(II)I(2)(cod) affording neutral square-planar complexes of general formula [M(II)Cl(eta(3)-L(1-4))](M = Pd, Pt, 1-8) and [Pt(II)I(eta(3)-L(1-4))](M = Pd, Pt, 9-12).	Platinum	54-56	galectin 2	Homo sapiens	0-6
16172647-2	2005	HL(1-4) react directly with M(II)Cl(2)(M = Pd, Pt) or Pt(II)I(2)(cod) affording neutral square-planar complexes of general formula [M(II)Cl(eta(3)-L(1-4))](M = Pd, Pt, 1-8) and [Pt(II)I(eta(3)-L(1-4))](M = Pd, Pt, 9-12).	Platinum	54-56	galectin 2	Homo sapiens	0-6
16853934-0	2005	Continuous hot electron generation in Pt/TiO2, Pd/TiO2, and Pt/GaN catalytic nanodiodes from oxidation of carbon monoxide.	Platinum	60-62	gigaxonin	Homo sapiens	63-66
16853934-1	2005	Thin films (&lt;10 nm) of platinum or palladium were deposited on TiO2 or GaN to form Schottky diodes.	Platinum	26-34	gigaxonin	Homo sapiens	74-77
16551521-7	2005	Numerous studies indicate that ERCC1 influences the repair of platinum DNA damage.	Platinum	62-70	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	31-36
16557672-8	2005	Numerous studies indicate that ERCC1 influences the repair of platinum DNA damage.	Platinum	62-70	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	31-36
16211296-0	2005	Down-regulation of O6-methylguanine-DNA methyltransferase gene expression in gliomas by platinum compounds.	Platinum	88-96	O-6-methylguanine-DNA methyltransferase	Homo sapiens	19-57
16211296-5	2005	The relative quantitation value (RQV) of MGMT mRNA normalized to the level of 2-microglobulin decreased after chemotherapy in all 5 patients treated with platinum compound.	Platinum	154-162	O-6-methylguanine-DNA methyltransferase	Homo sapiens	41-45
16211296-7	2005	The RQV of MGMT in these cells treated with platinum compounds obviously decreased, and these cells were more sensitive to ACNU than the control cells based on colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.	Platinum	44-52	O-6-methylguanine-DNA methyltransferase	Homo sapiens	11-15
16211296-8	2005	Both the clinical findings and laboratory results suggest that platinum compounds may play a role in the down-regulation of MGMT mRNA expression and up-regulation of the sensitivity to ACNU.	Platinum	63-71	O-6-methylguanine-DNA methyltransferase	Homo sapiens	124-128
16243820-4	2005	RNA expression levels of 5-FU metabolism-associated genes thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase, MAP7, and ELF3, of platinum- and taxane-related genes caldesmon, ERCC1, ERCC4, HER-2/neu, and GADD45, and of multidrug resistance gene MRP1 were determined using real-time reverse transcriptase-PCR.	Platinum	194-202	methylenetetrahydrofolate reductase	Homo sapiens	138-173
16266050-4	2005	METHODS: Platinum coils were prepared by successive coatings with cationic polyethyleneimine and anionic heparin and then TNC or basic fibroblast growth factor (bFGF) was immobilized by affinity binding to the heparin.	Platinum	9-17	tenascin C	Rattus norvegicus	122-125
16046414-0	2005	A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells.	Platinum	8-16	signal transducer and activator of transcription 3	Homo sapiens	48-53
15985306-1	2005	BACKGROUND: Gefitinib is the first approved EGFR tyrosine-kinase inhibitor indicated for the treatment of patients with locally advanced (IIIB) or metastatic NSCLC after failure of platinum-based first-line therapy and docetaxel chemotherapy.	Platinum	181-189	epidermal growth factor receptor	Homo sapiens	44-48
16046414-3	2005	Of these, a novel platinum (IV) compound, IS3 295, interacted with Stat3 and inhibited its binding to specific DNA-response elements.	Platinum	18-26	chromodomain helicase DNA binding protein 7	Homo sapiens	42-45
16046414-3	2005	Of these, a novel platinum (IV) compound, IS3 295, interacted with Stat3 and inhibited its binding to specific DNA-response elements.	Platinum	18-26	signal transducer and activator of transcription 3	Homo sapiens	67-72
16131066-2	2005	Impedance images of the pore openings were obtained by rastering a glass-sealed conically shaped Pt tip (approximately 1-microm radius) above the membrane surface, while measuring the total impedance between the tip and a large area Pt electrode located on the opposite side of the membrane.	Platinum	97-99	TOR signaling pathway regulator	Homo sapiens	100-103
16099064-2	2005	Catalase was entrapped in polyacrylamide gel and placed on the surface of platinum (working electrode) fixed in a Teflon holder with Ag-wire (auxiliary electrode), followed by addition of filter paper soaked in KCl.	Platinum	74-82	catalase	Homo sapiens	0-8
16144907-0	2005	ERCC1 and clinical resistance to platinum-based therapy.	Platinum	33-41	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
16096430-1	2005	Protein phosphatase 2A (PP2A) is a new target for platinum (Pt)-based cancer chemotherapeutic agents.	Platinum	50-58	protein phosphatase 2 phosphatase activator	Homo sapiens	24-28
16097757-11	2005	This mode of tip-dispensing SECM was used to obtain images of a platinum substrate electrode while monitoring both the substrate current and the feedback current at the probe.	Platinum	64-72	TOR signaling pathway regulator	Homo sapiens	13-16
16085187-0	2005	Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.	Platinum	108-116	peroxiredoxin 5	Homo sapiens	14-35
16085187-12	2005	These findings lead us to conclude that representative compounds of the major classes of clinically used anticancer alkylating agents and most platinum compounds may easily target TrxR, but not GR.	Platinum	143-151	peroxiredoxin 5	Homo sapiens	180-184
16101310-7	2005	This notion was further corroborated by efficient platinum-mediated photo-cross-linking of the drug-modified DNA to TBP.	Platinum	50-58	TATA-box binding protein	Homo sapiens	116-119
16097781-6	2005	Finally, submicrometer porous structures of alumina or polyethylene yielded intense molecular ion signals of angiotensin and insulin, in response to direct UV irradiation, when the surface was coated with Au or Pt.	Platinum	211-213	insulin	Homo sapiens	125-132
15975643-2	2005	METHODS: This is a multicenter phase II study of GEM/PLD regimen in recurrent ovarian cancer patients previously treated with at least one platinum/paclitaxel regimen, and with evidence of measurable disease.	Platinum	139-147	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	53-56
15975643-8	2005	In the group of platinum-sensitive patients, cases responsive to GEM/PLD combination showed a better OS with respect to patients unresponsive to GEM/PLD (median OS = 120 weeks versus median OS = 60 weeks, P value = 0.019).	Platinum	16-24	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	69-72
16098254-11	2005	CONCLUSION: Overall, our data suggest that gene polymorphisms active in the EGFR pathway may be associated with the sensitivity of colorectal cancer patients to platinum-based chemotherapy.	Platinum	161-169	epidermal growth factor receptor	Homo sapiens	76-80
15998045-3	2005	The reaction of soluble complexes 3 and 4 with 2 equiv of Ph3P=CHCO2Me in CH2Cl2 (40 degrees C, 5 h) leads to dehydrochlorination resulting in a chelate ring closure to furnish the platinum(IV) chelates [PtCl2{NH=C(R)NC(Ph)=NPh}2] (R = Ph, 5; R = NEt2, 6), accordingly, and the phosphonium salt [Ph3PCH2CO2Me]Cl.	Platinum	181-189	tetraspanin 12	Homo sapiens	247-251
15953714-9	2005	This study has shown that early intervention with EPO can result in a significant reduction of transfusion requirements and increases in Hb and QOL in patients with mild anemia during platinum-based chemotherapy.	Platinum	184-192	erythropoietin	Homo sapiens	50-53
15846115-4	2005	It was found that the Pt polymer Pt-7 gave rise to a considerably lower Pt concentration in serum and considerably higher concentration in liver and kidney than cisplatin.	Platinum	22-24	zinc finger protein 79	Homo sapiens	33-37
15886068-8	2005	Bryant, S. Hector, L. Pendyala, S.G. Chaney, M. Cordeiro-Stone, The role of DNA polymerase eta in translesion synthesis past platinum-DNA adducts in human fibroblasts, Cancer Res.	Platinum	125-133	DNA polymerase eta	Homo sapiens	76-94
21727458-5	2005	A typical Pt loading of 0.09 mg cm(-2) is achieved, that shows higher specific surface area of Pt than an E-TEK electrode with Pt loading of 0.075 mg cm(-2).	Platinum	10-12	TEK receptor tyrosine kinase	Homo sapiens	108-111
15688364-0	2005	Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.	Platinum	14-22	ATP binding cassette subfamily C member 2	Homo sapiens	89-93
15688364-4	2005	For reversal of platinum resistance, 2 anti-MRP2 hammerhead ribozymes were introduced into A2780RCIS cells.	Platinum	16-24	ATP binding cassette subfamily C member 2	Homo sapiens	44-48
15688364-8	2005	Kinetics of formation and elimination of platinum-DNA adducts suggest that the DNA repair capacity was not altered; the decrease in platinum-DNA adduct formation was rather a reflection of the protecting activity of MRP2.	Platinum	132-140	ATP binding cassette subfamily C member 2	Homo sapiens	216-220
15688364-9	2005	In conclusion, functional inhibition of MRP2 might be a promising strategy in the reversal of resistance to platinum-based anticancer drugs.	Platinum	108-116	ATP binding cassette subfamily C member 2	Homo sapiens	40-44
15688364-10	2005	This was reflected by the specific inhibition of MRP2 by ribozyme technology, indicating that this gene therapeutic approach may be applicable as a specific means to overcome platinum resistance in human neoplasms.	Platinum	175-183	ATP binding cassette subfamily C member 2	Homo sapiens	49-53
15958629-11	2005	However, because preclinical data indicate that UCN-01 potentiates response to platinum, further studies with alternative dose schedules of the combination, or with other platinum analogues, are warranted.	Platinum	79-87	urocortin	Homo sapiens	48-51
15839954-4	2005	Inhibition of specific exonucleases, such as excision repair cross-complementation group 1 (ERCC1), is integral to the platinum-gemcitabine synergy.	Platinum	119-127	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	92-97
15984515-1	2005	The treatment of choice for limited small-cell lung cancer (SCLC) is platinum-based chemotherapy combined with early, concurrent thoracic radiotherapy with a hyperfractionated regimen.	Platinum	69-77	SCLC1	Homo sapiens	60-64
16032878-1	2005	We report an experimental study of the variation of surface stress with surface charge density for nanoporous Pt immersed in aqueous solutions of NaF of various concentration.	Platinum	110-112	C-X-C motif chemokine ligand 8	Homo sapiens	146-149
16833774-0	2005	Hydrogenation of benzaldehyde and cinnamaldehyde in compressed CO2 medium with a Pt/C catalyst: a study on molecular interactions and pressure effects.	Platinum	81-83	complement C2	Homo sapiens	63-66
16852153-0	2005	Vibrational analysis of H2 and D2 adsorption on Pt/SiO2.	Platinum	48-50	relaxin 2	Homo sapiens	24-32
16852153-1	2005	Vibrational properties of surface species formed upon H2 and D2 exposure of silica supported platinum particles have been investigated with in situ diffuse reflection infrared Fourier transform spectroscopy.	Platinum	93-101	relaxin 2	Homo sapiens	54-63
15842772-5	2005	GS, however, decelerated HERG current deactivation in a concentration-dependent manner, which was more noticeable with panaxitriol (PT) than panaxidiol (PD).	Platinum	132-134	potassium voltage-gated channel subfamily H member 2	Homo sapiens	25-29
15739003-4	2005	The thioredoxin-platinum complex has no catalytic activity for the reduction of glutathione disulfide in the presence of NADPH and thioredoxin reductase, so that the platinum complex functions as an inhibitor.	Platinum	16-24	glutaredoxin family protein	Thermus thermophilus HB8	4-15
15826157-0	2005	Chelate and pincer carbene complexes of rhodium and platinum derived from hexaphenylcarbodiphosphorane, Ph3P=C=PPh3.	Platinum	52-60	protein phosphatase 4 catalytic subunit	Homo sapiens	111-115
16061005-0	2005	[Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].	Platinum	89-97	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	51-54
16061005-0	2005	[Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].	Platinum	89-97	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	59-62
16061005-2	2005	This study was to examine the association between genetic polymorphisms in XPC and XPD, two important components in nucleotide excision repair system, and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.	Platinum	176-184	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	75-78
16061005-2	2005	This study was to examine the association between genetic polymorphisms in XPC and XPD, two important components in nucleotide excision repair system, and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.	Platinum	176-184	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	83-86
16061005-3	2005	METHODS: Patients (n = 151) treated with platinum-based chemotherapy were genotyped for the AT dinucleotide insertion or deletion in intron 9 of XPC or Lys751Gln polymorphism in XPD.	Platinum	41-49	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	145-148
15756278-11	2005	In conclusion, in this phase I/II study, we defined the MTD and the dose recommended for the therapy with oral etoposide given over 10 days followed by s.c. GM-CSF in platinum-pretreated patients with advanced ovarian cancer.	Platinum	167-175	colony stimulating factor 2	Homo sapiens	157-163
15829328-0	2005	Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.	Platinum	115-123	prostaglandin-endoperoxide synthase 2	Homo sapiens	14-30
16851910-7	2005	Finally, at platinum electrodes, we directly observe (SCN)3-, a species analogous to I3- and (CN)3- that has been previously postulated but unverified.	Platinum	12-20	HCLS1 associated protein X-1	Homo sapiens	54-60
16851910-7	2005	Finally, at platinum electrodes, we directly observe (SCN)3-, a species analogous to I3- and (CN)3- that has been previously postulated but unverified.	Platinum	12-20	brain protein I3	Homo sapiens	85-98
16851921-0	2005	Ubiquitous strategy for probing ATR surface-enhanced infrared absorption at platinum group metal-electrolyte interfaces.	Platinum	76-84	ATR serine/threonine kinase	Homo sapiens	32-35
16851921-1	2005	A versatile two-step wet process to fabricate Pt, Pd, Rh, and Ru nanoparticle films (simplified as nanofilms hereafter) for in situ attenuated total reflection Fourier transform infrared (ATR-FTIR) study of electrochemical interfaces is presented, which incorporates an initial chemical deposition of a gold nanofilm on the basal plane of a silicon prism with the subsequent electrodepostion of desired platinum group metal overlayers.	Platinum	46-48	ATR serine/threonine kinase	Homo sapiens	188-191
16851921-1	2005	A versatile two-step wet process to fabricate Pt, Pd, Rh, and Ru nanoparticle films (simplified as nanofilms hereafter) for in situ attenuated total reflection Fourier transform infrared (ATR-FTIR) study of electrochemical interfaces is presented, which incorporates an initial chemical deposition of a gold nanofilm on the basal plane of a silicon prism with the subsequent electrodepostion of desired platinum group metal overlayers.	Platinum	403-411	ATR serine/threonine kinase	Homo sapiens	188-191
16851821-1	2005	The mechanism of NO interaction with nanosized Ru(Pd,Pt)-doped SnO(2) was studied by electron paramagnetic resonance, Mossbauer, and electric resistance measurements.	Platinum	53-55	strawberry notch homolog 2	Homo sapiens	63-66
15792471-7	2005	This 5% Pt-doped specimen shows an EPR signal (g = 2.0115, DeltaHpp = 114 G at 300 K) wider than the pure compound (DT-TTF)2[Au(mnt)2], denoting exchange between the donor spins and Pt(mnt)2- centers.	Platinum	8-10	ras homolog family member H	Homo sapiens	119-122
15739003-4	2005	The thioredoxin-platinum complex has no catalytic activity for the reduction of glutathione disulfide in the presence of NADPH and thioredoxin reductase, so that the platinum complex functions as an inhibitor.	Platinum	16-24	glutaredoxin family protein	Thermus thermophilus HB8	131-142
15739003-4	2005	The thioredoxin-platinum complex has no catalytic activity for the reduction of glutathione disulfide in the presence of NADPH and thioredoxin reductase, so that the platinum complex functions as an inhibitor.	Platinum	166-174	glutaredoxin family protein	Thermus thermophilus HB8	4-15
15739003-4	2005	The thioredoxin-platinum complex has no catalytic activity for the reduction of glutathione disulfide in the presence of NADPH and thioredoxin reductase, so that the platinum complex functions as an inhibitor.	Platinum	166-174	glutaredoxin family protein	Thermus thermophilus HB8	131-142
15732965-6	2005	Application of standard quantitative analysis of ligand effects (QALE) methodology enabled a quantitative separation of steric and electronic contributions of P-donor ligands to the values of the platinum-phosphorus 1J(PtP) coupling constants and of the free activation energies DeltaG++ of the fluxional motion of Me2-phen in 1-14.	Platinum	196-204	protein tyrosine phosphatase receptor type U	Homo sapiens	219-222
15865102-6	2005	Elevated HER-2 ECD concentration was related only to pT (p=0.0008), histological grade (p=0.0465), presence of comedonecrosis (p=0.0123) or comedo-type carcinoma (p=0.041) and was unrelated to the presence of an intraductal component.	Platinum	53-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-14
15913258-4	2005	The cyclic voltammogram of the tetrathiafulvalene-modified gold colloid on a Pt electrode showed two pair of redox peaks, at E1/2 = +0.67 V and at +0.87 V (vs. a saturated calomel electrode, in MeCN-0.1 M Bu4NClO4), corresponding to TTF/TTF*+ and TTF*+/TTF2+, respectively.	Platinum	77-79	ras homolog family member H	Homo sapiens	237-240
15725918-3	2005	RECENT FINDINGS: In the past, the results of randomized trials of comparative standard platinum-based combination chemotherapy regimens have demonstrated inferior survival rates in PS 2 patients compared with those with PS 0 or 1.	Platinum	87-95	taste 2 receptor member 64 pseudogene	Homo sapiens	181-185
15845181-0	2005	Clinical significance of hypoxia-inducible factor-1a messenger RNA expression in locally advanced non-small-cell lung cancer after platinum agent and gemcitabine chemotherapy followed by surgery.	Platinum	131-139	hypoxia inducible factor 1 subunit alpha	Homo sapiens	25-52
15845181-2	2005	This study analyzed HIF-1a messenger RNA expression levels using real-time quantitative polymerase chain reaction (PCR) in paraffin-embedded surgical specimens from 54 stage IIB-III patients with non-small-cell lung cancer (NSCLC) treated with induction platinum/gemcitabine followed by surgery between September 1998 and December 2002.	Platinum	254-262	hypoxia inducible factor 1 subunit alpha	Homo sapiens	20-26
15845181-11	2005	Hypoxia-inducible factor-1a expression levels analyzed by real-time quantitative PCR in surgery specimens after platinum/gemcitabine therapy do not correlate with the outcome of patients with stage II/III NSCLC.	Platinum	112-120	hypoxia inducible factor 1 subunit alpha	Homo sapiens	0-27
15913258-4	2005	The cyclic voltammogram of the tetrathiafulvalene-modified gold colloid on a Pt electrode showed two pair of redox peaks, at E1/2 = +0.67 V and at +0.87 V (vs. a saturated calomel electrode, in MeCN-0.1 M Bu4NClO4), corresponding to TTF/TTF*+ and TTF*+/TTF2+, respectively.	Platinum	77-79	ras homolog family member H	Homo sapiens	233-236
15913258-4	2005	The cyclic voltammogram of the tetrathiafulvalene-modified gold colloid on a Pt electrode showed two pair of redox peaks, at E1/2 = +0.67 V and at +0.87 V (vs. a saturated calomel electrode, in MeCN-0.1 M Bu4NClO4), corresponding to TTF/TTF*+ and TTF*+/TTF2+, respectively.	Platinum	77-79	ras homolog family member H	Homo sapiens	237-240
15913258-4	2005	The cyclic voltammogram of the tetrathiafulvalene-modified gold colloid on a Pt electrode showed two pair of redox peaks, at E1/2 = +0.67 V and at +0.87 V (vs. a saturated calomel electrode, in MeCN-0.1 M Bu4NClO4), corresponding to TTF/TTF*+ and TTF*+/TTF2+, respectively.	Platinum	77-79	transcription termination factor 2	Homo sapiens	253-257
15702175-1	2005	Diastereoisomerism in platinum(II) and palladium(II) complexes of helically chiral PAr3 ligands.	Platinum	22-30	par-3 family cell polarity regulator	Homo sapiens	83-87
15686959-7	2005	Our results show that NGF does not alter platination of DNA, indicating that it interrupts the platinum death pathway after adduct formation.	Platinum	95-103	nerve growth factor	Rattus norvegicus	22-25
15746057-7	2005	CONCLUSIONS: Adjusting for performance status and type of treatment regimen, carrying at least one ERCC1 8092A allele is associated with a &gt;2-fold increase in grade 3 or 4 gastrointestinal toxicity among platinum-treated non-small cell lung cancer patients.	Platinum	207-215	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	99-104
16833406-4	2005	We synthesized the platinum complex (Syd-PEn-Pt), the unmodified ligands (PEn-H), and the unmodified platinum complexes (PEn-Pt).	Platinum	19-27	mitogen-activated protein kinase 8 interacting protein 3	Homo sapiens	37-40
16833406-4	2005	We synthesized the platinum complex (Syd-PEn-Pt), the unmodified ligands (PEn-H), and the unmodified platinum complexes (PEn-Pt).	Platinum	19-27	proprotein convertase subtilisin/kexin type 1 inhibitor	Homo sapiens	41-44
15853154-7	2005	SEM and TEM investigations revealed silver and platinum nanowires between 10 nm and 100 nm in diameter.	Platinum	47-55	MFT2	Homo sapiens	8-11
15661210-3	2005	METHODS: We determined the expression of Bcl-x(L) in epithelial ovarian cancers from 28 patients at the time of initial staging laparotomy and in recurrent tumors in the same patients following treatment with platinum-based chemotherapy.	Platinum	209-217	BCL2 like 1	Homo sapiens	41-49
15629453-5	2005	The suppression of ERCC1 expression in the HeLa S3 cells led to a decrease in the repair activity of cisplatin-induced DNA damage along with a decrease in the cell viability against platinum-based drugs, such as cisplatin, carboplatin, and oxaliplatin.	Platinum	182-190	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	19-24
15655409-0	2005	The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.	Platinum	64-72	zinc fingers and homeoboxes 2	Homo sapiens	4-7
15987992-6	2005	The EGFR-directed monoclonal antibody (MAb) cetuximab (Erbitux) in combination with chemotherapy has shown some activity in the treatment of recurrent/metastatic disease both as first-line therapy and following cisplatin failure, and preliminary results suggest single-agent activity in platinum-resistant disease.	Platinum	287-295	epidermal growth factor receptor	Homo sapiens	4-8
15694018-5	2005	For this purpose, we assessed the expression of FANCD2 protein (a marker for FA pathway functioning) by immunohistochemistry in tumor specimens from 47 patients treated with platinum-based chemotherapy.	Platinum	174-182	FA complementation group D2	Homo sapiens	48-54
15613912-8	2005	With CADO-ES-1 and KCN cells, POM1 was found to be more effective than the platinum compounds cisplatin, carboplatin and Pt1.	Platinum	75-83	zinc finger protein 77	Homo sapiens	121-124
16285018-4	2005	Reaction of trans-[PtCl(S-Met1-Ub)(Am)(pip-pip)] with GSH resulted in the rapid formation of the ternary complex trans-[Pt(GS)(S-Met1-Ub)(Am)(pip-pip)] which was not stable and slowly lost the platinum moiety; after 7 days the platinum moiety was completely removed and the native ubiquitin was regenerated.	Platinum	193-201	granzyme M	Homo sapiens	26-30
15694018-0	2005	FANCD2 expression in advanced non-small-cell lung cancer and response to platinum-based chemotherapy.	Platinum	73-81	FA complementation group D2	Homo sapiens	0-6
16127286-7	2005	This outcome is consistent with the clinical observation that the efficacy of topotecan in the treatment of relapsed ovarian carcinoma patients is dependent on platinum sensitivity, because platinum-sensitive tumors are expected to carry wild-type p53.	Platinum	160-168	tumor protein p53	Homo sapiens	248-251
16127286-7	2005	This outcome is consistent with the clinical observation that the efficacy of topotecan in the treatment of relapsed ovarian carcinoma patients is dependent on platinum sensitivity, because platinum-sensitive tumors are expected to carry wild-type p53.	Platinum	190-198	tumor protein p53	Homo sapiens	248-251
15658103-0	2005	Immobilization of basic fibroblast growth factor on a platinum microcoil to enhance tissue organization in intracranial aneurysms.	Platinum	54-62	fibroblast growth factor 2	Canis lupus familiaris	18-48
15658103-1	2005	OBJECT: To enhance tissue organization in an aneurysm lumen, the authors prepared a platinum microcoil carrying basic fibroblast growth factor (bFGF) and analyzed its effectiveness in the treatment of aneurysms.	Platinum	84-92	fibroblast growth factor 2	Canis lupus familiaris	112-142
15658103-1	2005	OBJECT: To enhance tissue organization in an aneurysm lumen, the authors prepared a platinum microcoil carrying basic fibroblast growth factor (bFGF) and analyzed its effectiveness in the treatment of aneurysms.	Platinum	84-92	fibroblast growth factor 2	Canis lupus familiaris	144-148
15534626-1	2005	Excision Repair Cross-Complementing Rodent Repair Group 2 (ERCC2) plays an important role in DNA repair by eliminating bulky DNA adducts produced by platinum agents during the nucleotide excision repair pathway.	Platinum	149-157	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	59-64
15534626-2	2005	Several studies have associated polymorphisms in ERCC2 with response to platinum therapy, lung cancer risk, and DNA repair capacity.	Platinum	72-80	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	49-54
16285018-2	2005	The platinum complexes bind exclusively to Met1 of ubiquitin forming trans-[PtCl(S-Met1-Ub)(Am)(pip-pip)] adducts.	Platinum	4-12	granzyme M	Homo sapiens	43-47
16285018-2	2005	The platinum complexes bind exclusively to Met1 of ubiquitin forming trans-[PtCl(S-Met1-Ub)(Am)(pip-pip)] adducts.	Platinum	4-12	granzyme M	Homo sapiens	83-87
16285018-2	2005	The platinum complexes bind exclusively to Met1 of ubiquitin forming trans-[PtCl(S-Met1-Ub)(Am)(pip-pip)] adducts.	Platinum	4-12	prolactin induced protein	Homo sapiens	96-99
16285018-2	2005	The platinum complexes bind exclusively to Met1 of ubiquitin forming trans-[PtCl(S-Met1-Ub)(Am)(pip-pip)] adducts.	Platinum	4-12	prolactin induced protein	Homo sapiens	100-103
16285018-4	2005	Reaction of trans-[PtCl(S-Met1-Ub)(Am)(pip-pip)] with GSH resulted in the rapid formation of the ternary complex trans-[Pt(GS)(S-Met1-Ub)(Am)(pip-pip)] which was not stable and slowly lost the platinum moiety; after 7 days the platinum moiety was completely removed and the native ubiquitin was regenerated.	Platinum	193-201	prolactin induced protein	Homo sapiens	39-42
16285018-4	2005	Reaction of trans-[PtCl(S-Met1-Ub)(Am)(pip-pip)] with GSH resulted in the rapid formation of the ternary complex trans-[Pt(GS)(S-Met1-Ub)(Am)(pip-pip)] which was not stable and slowly lost the platinum moiety; after 7 days the platinum moiety was completely removed and the native ubiquitin was regenerated.	Platinum	193-201	prolactin induced protein	Homo sapiens	43-46
16285018-4	2005	Reaction of trans-[PtCl(S-Met1-Ub)(Am)(pip-pip)] with GSH resulted in the rapid formation of the ternary complex trans-[Pt(GS)(S-Met1-Ub)(Am)(pip-pip)] which was not stable and slowly lost the platinum moiety; after 7 days the platinum moiety was completely removed and the native ubiquitin was regenerated.	Platinum	193-201	granzyme M	Homo sapiens	129-133
16285018-4	2005	Reaction of trans-[PtCl(S-Met1-Ub)(Am)(pip-pip)] with GSH resulted in the rapid formation of the ternary complex trans-[Pt(GS)(S-Met1-Ub)(Am)(pip-pip)] which was not stable and slowly lost the platinum moiety; after 7 days the platinum moiety was completely removed and the native ubiquitin was regenerated.	Platinum	193-201	prolactin induced protein	Homo sapiens	43-46
16285018-4	2005	Reaction of trans-[PtCl(S-Met1-Ub)(Am)(pip-pip)] with GSH resulted in the rapid formation of the ternary complex trans-[Pt(GS)(S-Met1-Ub)(Am)(pip-pip)] which was not stable and slowly lost the platinum moiety; after 7 days the platinum moiety was completely removed and the native ubiquitin was regenerated.	Platinum	193-201	prolactin induced protein	Homo sapiens	43-46
16285018-4	2005	Reaction of trans-[PtCl(S-Met1-Ub)(Am)(pip-pip)] with GSH resulted in the rapid formation of the ternary complex trans-[Pt(GS)(S-Met1-Ub)(Am)(pip-pip)] which was not stable and slowly lost the platinum moiety; after 7 days the platinum moiety was completely removed and the native ubiquitin was regenerated.	Platinum	227-235	granzyme M	Homo sapiens	26-30
16285018-4	2005	Reaction of trans-[PtCl(S-Met1-Ub)(Am)(pip-pip)] with GSH resulted in the rapid formation of the ternary complex trans-[Pt(GS)(S-Met1-Ub)(Am)(pip-pip)] which was not stable and slowly lost the platinum moiety; after 7 days the platinum moiety was completely removed and the native ubiquitin was regenerated.	Platinum	227-235	prolactin induced protein	Homo sapiens	39-42
16285018-4	2005	Reaction of trans-[PtCl(S-Met1-Ub)(Am)(pip-pip)] with GSH resulted in the rapid formation of the ternary complex trans-[Pt(GS)(S-Met1-Ub)(Am)(pip-pip)] which was not stable and slowly lost the platinum moiety; after 7 days the platinum moiety was completely removed and the native ubiquitin was regenerated.	Platinum	227-235	prolactin induced protein	Homo sapiens	43-46
16285018-4	2005	Reaction of trans-[PtCl(S-Met1-Ub)(Am)(pip-pip)] with GSH resulted in the rapid formation of the ternary complex trans-[Pt(GS)(S-Met1-Ub)(Am)(pip-pip)] which was not stable and slowly lost the platinum moiety; after 7 days the platinum moiety was completely removed and the native ubiquitin was regenerated.	Platinum	227-235	granzyme M	Homo sapiens	129-133
16285018-4	2005	Reaction of trans-[PtCl(S-Met1-Ub)(Am)(pip-pip)] with GSH resulted in the rapid formation of the ternary complex trans-[Pt(GS)(S-Met1-Ub)(Am)(pip-pip)] which was not stable and slowly lost the platinum moiety; after 7 days the platinum moiety was completely removed and the native ubiquitin was regenerated.	Platinum	227-235	prolactin induced protein	Homo sapiens	43-46
16285018-4	2005	Reaction of trans-[PtCl(S-Met1-Ub)(Am)(pip-pip)] with GSH resulted in the rapid formation of the ternary complex trans-[Pt(GS)(S-Met1-Ub)(Am)(pip-pip)] which was not stable and slowly lost the platinum moiety; after 7 days the platinum moiety was completely removed and the native ubiquitin was regenerated.	Platinum	227-235	prolactin induced protein	Homo sapiens	43-46
15570087-8	2004	Studies using platinum-based chemotherapy had OS RRs of 1.30 (95% CI, 1.10 to 1.53; P = .002) and 1.35 (95% CI, 1.07 to 1.70; P = .01) at 2 and 3 years, respectively, favoring ERT.	Platinum	14-22	E74 like ETS transcription factor 3	Homo sapiens	176-179
15547660-0	2004	Excision repair cross complementing-group 1: gene expression and platinum resistance.	Platinum	65-73	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-43
15547660-7	2004	We summarized data from different cancer cell lines and human cancers showing that the high level of ERCC1-mRNA and/or ERCC1 protein is associated with resistance to platinum compounds with direct impact on cancer patient survival and finally we analyzed drugs interfering with ERCC1 gene expression and causing the reversal of the platinum resistance when given to cancer cells prior to platinum-based chemotherapy.	Platinum	166-174	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	101-106
15547660-7	2004	We summarized data from different cancer cell lines and human cancers showing that the high level of ERCC1-mRNA and/or ERCC1 protein is associated with resistance to platinum compounds with direct impact on cancer patient survival and finally we analyzed drugs interfering with ERCC1 gene expression and causing the reversal of the platinum resistance when given to cancer cells prior to platinum-based chemotherapy.	Platinum	166-174	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	119-124
15547660-7	2004	We summarized data from different cancer cell lines and human cancers showing that the high level of ERCC1-mRNA and/or ERCC1 protein is associated with resistance to platinum compounds with direct impact on cancer patient survival and finally we analyzed drugs interfering with ERCC1 gene expression and causing the reversal of the platinum resistance when given to cancer cells prior to platinum-based chemotherapy.	Platinum	166-174	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	119-124
15547660-7	2004	We summarized data from different cancer cell lines and human cancers showing that the high level of ERCC1-mRNA and/or ERCC1 protein is associated with resistance to platinum compounds with direct impact on cancer patient survival and finally we analyzed drugs interfering with ERCC1 gene expression and causing the reversal of the platinum resistance when given to cancer cells prior to platinum-based chemotherapy.	Platinum	332-340	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	101-106
15547660-7	2004	We summarized data from different cancer cell lines and human cancers showing that the high level of ERCC1-mRNA and/or ERCC1 protein is associated with resistance to platinum compounds with direct impact on cancer patient survival and finally we analyzed drugs interfering with ERCC1 gene expression and causing the reversal of the platinum resistance when given to cancer cells prior to platinum-based chemotherapy.	Platinum	332-340	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	101-106
15634646-0	2004	Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity.	Platinum	98-106	signal transducer and activator of transcription 3	Homo sapiens	27-77
15634646-6	2004	The novel platinum (IV) compounds, CPA-1, CPA-7, and platinum (IV) tetrachloride block Stat3 activity in vitro at low micromolar concentrations.	Platinum	10-18	signal transducer and activator of transcription 3	Homo sapiens	87-92
15634646-10	2004	Thus, the modulation of oncogenic signal transduction pathways, such as Stat3, may be one of the key molecular mechanisms for the antitumor effects of platinum (IV)-containing complexes.	Platinum	151-159	signal transducer and activator of transcription 3	Homo sapiens	72-77
15634646-5	2004	We report here that platinum-containing compounds disrupt Stat3 signaling and suppress its biological functions.	Platinum	20-28	signal transducer and activator of transcription 3	Homo sapiens	58-63
15634647-0	2004	Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.	Platinum	58-66	solute carrier family 31 member 1	Homo sapiens	33-37
15634646-6	2004	The novel platinum (IV) compounds, CPA-1, CPA-7, and platinum (IV) tetrachloride block Stat3 activity in vitro at low micromolar concentrations.	Platinum	10-18	carboxypeptidase A1	Homo sapiens	35-40
15634647-5	2004	Transfection of expression hemagglutinin-tagged hCtr1 cDNA into SCLC and SR2 cells enhanced the uptake of copper, cisplatin, carboplatin, and oxaliplatin, suggesting that hCtr1 transporter can transport these platinum-based drugs.	Platinum	209-217	solute carrier family 31 member 1	Homo sapiens	48-53
15634646-6	2004	The novel platinum (IV) compounds, CPA-1, CPA-7, and platinum (IV) tetrachloride block Stat3 activity in vitro at low micromolar concentrations.	Platinum	10-18	cytochrome P450 family 2 subfamily A member 7	Homo sapiens	42-47
15634647-5	2004	Transfection of expression hemagglutinin-tagged hCtr1 cDNA into SCLC and SR2 cells enhanced the uptake of copper, cisplatin, carboplatin, and oxaliplatin, suggesting that hCtr1 transporter can transport these platinum-based drugs.	Platinum	209-217	solute carrier family 31 member 1	Homo sapiens	171-176
15634647-6	2004	Whereas increased sensitivities to all these platinum drugs were observed in hCtr1-transfected SCLC cells, increased sensitivities to cisplatin and carboplatin but not to oxaliplatin were observed in hCtr1-transfected SR2 cells.	Platinum	45-53	solute carrier family 31 member 1	Homo sapiens	77-82
15634647-8	2004	Finally, using hCtr1 deletion mutants, we showed that the NH2-terminal domain of hCtr1 was involved in transporting all these platinum-based antitumor agents.	Platinum	126-134	solute carrier family 31 member 1	Homo sapiens	81-86
15326162-9	2004	Treatment with the metal chelator dimethyldithiocarbamate disassembled the hCtr1 multimer following cisplatin exposure, suggesting that platinum was an integral component of this complex.	Platinum	136-144	solute carrier family 31 member 1	Homo sapiens	75-80
15634647-9	2004	These results collectively show the importance of hCtr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant variants.	Platinum	76-84	solute carrier family 31 member 1	Homo sapiens	50-55
15685824-0	2004	Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.	Platinum	51-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-98
15545967-2	2004	We evaluated clinical significance of ERBB2 expression in relation to TP53 accumulation in ovarian carcinoma patients treated with platinum-based regimens.	Platinum	131-139	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-43
15547734-0	2004	Amplicon profiling reveals cytoplasmic overexpression of MUC1 protein as an indicator of resistance to platinum-based chemotherapy in patients with ovarian cancer.	Platinum	103-111	mucin 1, cell surface associated	Homo sapiens	57-61
15547734-7	2004	We concluded that the cytoplasmic overexpression of MUC1 might be an indicator of resistance to platinum-based chemotherapy and a prognostic marker in ovarian cancer.	Platinum	96-104	mucin 1, cell surface associated	Homo sapiens	52-56
15510290-4	2004	A similar reaction of fac(S)-[Co(aet)(3)] with [PtCl(4)](2-) or trans-[PtCl(2)(NH(3))(2)] produced an analogous Co(III)Pt(II)Co(III) trinuclear complex, [Pt[Co(aet)(3)](2)](2+)([2](2+)), but both the syn and anti forms were formed for [2](2+).	Platinum	48-50	synemin	Homo sapiens	200-203
15501963-2	2004	In cell lines derived from human non-small cell lung cancers (NSCLCs), Akt has been shown to confer chemoresistance by inhibition of apoptosis in response to different chemotherapeutic agents including platinum-based agents, which are often the first-line therapy for NSCLCs.	Platinum	202-210	AKT serine/threonine kinase 1	Homo sapiens	71-74
15486204-0	2004	Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin.	Platinum	111-119	tumor protein p53	Homo sapiens	57-60
15486204-5	2004	DNA is a major pharmacological target of platinum compounds and DNA binding activity of the p53 protein is crucial for its tumor suppressor function.	Platinum	41-49	tumor protein p53	Homo sapiens	92-95
15474662-5	2004	Epoetin beta is also effective for preventing the development of anaemia and decreasing transfusion requirements when administered with concomitant platinum-based chemotherapy.	Platinum	148-156	erythropoietin	Homo sapiens	0-7
15301704-0	2004	[Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer].	Platinum	67-73	X-ray repair cross complementing 1	Homo sapiens	36-41
15184995-5	2004	RESULTS: Preincubation of platinum-resistant A2780 cells with CSA reversed CBDCA resistance in a concentration-dependent and time-dependent manner.	Platinum	26-34	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	62-65
15184995-13	2004	Modest partial reversal of platinum resistance (in one patient with an objective response and in eight patients with stable disease noted) is achievable in vivo in patients pretreated with CSA.	Platinum	27-35	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	189-192
15375562-2	2004	This 42-bp segment seems to possess a regulatory function in ERCC1 expression and representing the level of clinical response to platinum-treatment in ovarian cancer patients.	Platinum	129-137	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	61-66
15229296-4	2004	The A2780/hCTR1 cells accumulated 46% more platinum after a 1-h exposure to 2 microM cisplatin, and 55% more after a 24 h exposure, than the control A2780/empty vector cells.	Platinum	43-51	solute carrier family 31 member 1	Homo sapiens	10-15
15379507-7	2004	This originates from the phase separation of PT-PEEGE, and PT-PEEGE molecules which remained to be soluble participate in the electrocatalytic reactions of GOx as mediators.	Platinum	45-47	hydroxyacid oxidase 1	Homo sapiens	156-159
15379507-7	2004	This originates from the phase separation of PT-PEEGE, and PT-PEEGE molecules which remained to be soluble participate in the electrocatalytic reactions of GOx as mediators.	Platinum	59-61	hydroxyacid oxidase 1	Homo sapiens	156-159
15361187-4	2004	The aim of our study was to evaluate the role of GnRH analogs in the management of platinum-resistant ovarian cancers.	Platinum	83-91	gonadotropin releasing hormone 1	Homo sapiens	49-53
19780241-2	2004	Recent clinical studies, however, suggest that regimens of taxane/platinum/trastuzumab are effective option for first-line treatment of HER2-overexpressing metastatic disease, and that docetaxel/carboplatin is viable in first-line treatment of HER2-negative metastatic disease, as well as in neoadjuvant therapy of locally advanced breast cancer.	Platinum	66-74	erb-b2 receptor tyrosine kinase 2	Homo sapiens	136-140
15261285-3	2004	A glucuronyl-platinum conjugate was designed and synthesised to test the compatibility of platinum compounds with beta-glucuronidase-based prodrug therapy.	Platinum	13-21	glucuronidase beta	Homo sapiens	114-132
15261285-4	2004	Instantaneous cleavage of the beta-glucuronic bond in the glucuronyl-platinum conjugate was observed upon addition of beta-glucuronidase resulting in Pt(II)(dach)(4-hydroxybenzylmalonate) and glucuronic acid.	Platinum	69-77	glucuronidase beta	Homo sapiens	118-136
15138708-0	2004	Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase.	Platinum	38-46	dihydrodiol dehydrogenase	Homo sapiens	157-182
15315423-3	2004	The presence of the polyoxometalate is presumed to allow the facile oxidation of a Pt(II) intermediate to a Pt(IV) intermediate and to aid in the addition of methane to the Pt catalytic center.	Platinum	83-85	activation induced cytidine deaminase	Homo sapiens	135-138
15301704-9	2004	CONCLUSION: Polymorphisms in the XRCC1 gene may have significant impact on the response of NSCLC patients to platin-based chemotherapy.	Platinum	109-115	X-ray repair cross complementing 1	Homo sapiens	33-38
15276680-12	2004	Together these data suggest that the Ahl allele in the C57 strain contributes to both the early onset AHL exhibited by these mice as well as their susceptibility to both TTS and PTS over-exposures.	Platinum	178-181	cadherin 23 (otocadherin)	Mus musculus	37-40
15297394-0	2004	Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.	Platinum	146-154	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-45
15297394-3	2004	Increased ERCC1 mRNA levels are related directly to platinum resistance in various cancers.	Platinum	52-60	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	10-15
15297394-4	2004	We examined the association between two polymorphisms of ERCC1, codon 118 C/T and C8092A, which are associated with altered ERCC1 mRNA levels and mRNA stability, and overall survival (OS) in 128 advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.	Platinum	253-261	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	57-62
15297394-4	2004	We examined the association between two polymorphisms of ERCC1, codon 118 C/T and C8092A, which are associated with altered ERCC1 mRNA levels and mRNA stability, and overall survival (OS) in 128 advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.	Platinum	253-261	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	124-129
15297394-8	2004	In conclusion, the ERCC1 C8092A polymorphism may be a useful predictor of OS in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.	Platinum	138-146	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	19-24
15284922-1	2004	A new procedure involving chemical polymerization of a monomer of m-phenylenediamine (m-ppd) containing glucose oxidase (GOx) and subsequent electro-synthesis of the functional GOx containing polymer onto platinum needle electrodes (PTNE) was used for the amperometric analysis of glucose concentration in brain dialysates.	Platinum	205-213	hydroxyacid oxidase 1	Homo sapiens	121-124
15284922-1	2004	A new procedure involving chemical polymerization of a monomer of m-phenylenediamine (m-ppd) containing glucose oxidase (GOx) and subsequent electro-synthesis of the functional GOx containing polymer onto platinum needle electrodes (PTNE) was used for the amperometric analysis of glucose concentration in brain dialysates.	Platinum	205-213	hydroxyacid oxidase 1	Homo sapiens	177-180
15271515-1	2004	Platinum compounds containing an aromatic diimine (1,10-phenanthroline or 2,9-dimethyl-1,10-phenanthroline; phen and Me(2)phen, respectively) and antiviral guanosine-type ligands (acyclovir or penciclovir; acy and pen, respectively) have been synthesised.	Platinum	0-8	proprotein convertase subtilisin/kexin type 1 inhibitor	Mus musculus	193-196
15252583-3	2004	Reaction between HL1 and labile Pt(II) and Pd(II) chlorides formed MCl2(HL1)2 complexes 4 (M = Pt) and 5 (M = Pd) in which a weak N-H...pi(aryl) hydrogen bonding interaction was identified in the solid-state structure of 4.	Platinum	32-34	intelectin 1	Homo sapiens	17-20
15142595-1	2004	The enzyme glucose oxidase (GOx) has been immobilized electrostatically onto carbon and platinum electrodes modified with mixed ferrocene-cobaltocenium dendrimers.	Platinum	88-96	hydroxyacid oxidase 1	Homo sapiens	11-26
15142595-1	2004	The enzyme glucose oxidase (GOx) has been immobilized electrostatically onto carbon and platinum electrodes modified with mixed ferrocene-cobaltocenium dendrimers.	Platinum	88-96	hydroxyacid oxidase 1	Homo sapiens	28-31
15252583-3	2004	Reaction between HL1 and labile Pt(II) and Pd(II) chlorides formed MCl2(HL1)2 complexes 4 (M = Pt) and 5 (M = Pd) in which a weak N-H...pi(aryl) hydrogen bonding interaction was identified in the solid-state structure of 4.	Platinum	32-34	intelectin 1	Homo sapiens	72-75
15237398-0	2004	Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: characterization of interactions between Pt(II) complexes and human serum albumin.	Platinum	0-8	albumin	Homo sapiens	188-201
15256455-0	2004	Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents.	Platinum	71-79	HRas proto-oncogene, GTPase	Homo sapiens	10-15
15256455-0	2004	Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents.	Platinum	71-79	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	43-48
15256455-6	2004	In addition, ERCC1 small interfering RNA expression was shown to reduce the oncogenic H-Ras-mediated increase in the DNA repair activity as well as to suppress the oncogenic H-Ras-mediated resistance of the cells to platinum-containing chemotherapeutic agents.	Platinum	216-224	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	13-18
15256455-6	2004	In addition, ERCC1 small interfering RNA expression was shown to reduce the oncogenic H-Ras-mediated increase in the DNA repair activity as well as to suppress the oncogenic H-Ras-mediated resistance of the cells to platinum-containing chemotherapeutic agents.	Platinum	216-224	HRas proto-oncogene, GTPase	Homo sapiens	174-179
15256455-7	2004	These results suggest that the oncogenic H-Ras-induced ERCC1, which activates the DNA repair capacity, may be involved in the protection of the cells against platinum-based anticancer agents.	Platinum	158-166	HRas proto-oncogene, GTPase	Homo sapiens	41-46
15256455-7	2004	These results suggest that the oncogenic H-Ras-induced ERCC1, which activates the DNA repair capacity, may be involved in the protection of the cells against platinum-based anticancer agents.	Platinum	158-166	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	55-60
15240550-5	2004	There was greater sequestration of Pt into intracellular vesicles in the 2008/ECFP-ATP7B cells than in the 2008/ECFP cells.	Platinum	35-37	ATPase copper transporting beta	Homo sapiens	83-88
15237398-1	2004	Characterizing how platinum metallocomplexes bind to human serum albumin (HSA) is essential in evaluating anticancer drug candidates.	Platinum	19-27	albumin	Homo sapiens	59-72
15253542-0	2004	Vascular endothelial growth factor immobilized on platinum microcoils for the treatment of intracranial aneurysms: experimental rat model study.	Platinum	50-58	vascular endothelial growth factor A	Homo sapiens	0-34
15252142-2	2004	Following our initial observation from gene expression profiling that platinum drugs induce SSAT, we undertook this present study to characterize platinum drug induction of SSAT and other polyamine catabolic enzymes and to examine how these responses might be enhanced with the well-known inducer of SSAT and clinically relevant polyamine analogue, N1,N11-diethylnorspermine (DENSPM).	Platinum	70-78	spermidine/spermine N1-acetyltransferase family member 2	Homo sapiens	92-96
15252142-2	2004	Following our initial observation from gene expression profiling that platinum drugs induce SSAT, we undertook this present study to characterize platinum drug induction of SSAT and other polyamine catabolic enzymes and to examine how these responses might be enhanced with the well-known inducer of SSAT and clinically relevant polyamine analogue, N1,N11-diethylnorspermine (DENSPM).	Platinum	146-154	spermidine/spermine N1-acetyltransferase family member 2	Homo sapiens	173-177
15252142-2	2004	Following our initial observation from gene expression profiling that platinum drugs induce SSAT, we undertook this present study to characterize platinum drug induction of SSAT and other polyamine catabolic enzymes and to examine how these responses might be enhanced with the well-known inducer of SSAT and clinically relevant polyamine analogue, N1,N11-diethylnorspermine (DENSPM).	Platinum	146-154	spermidine/spermine N1-acetyltransferase family member 2	Homo sapiens	173-177
15252142-10	2004	Taken together, the findings confirm potent induction of polyamine catabolic enzymes, such as SSAT by platinum drugs, and demonstrate that these biochemical responses as well as growth inhibition can be potentiated by co-treatment with the polyamine analogue DENSPM.	Platinum	102-110	spermidine/spermine N1-acetyltransferase family member 2	Homo sapiens	94-98
15256051-0	2004	Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1.	Platinum	14-22	SRSF protein kinase 1	Homo sapiens	134-139
15180418-4	2004	Consistent with the idea that electron-withdrawing R makes platinum(II) more resistant to oxidation (i.e., a proton on Pt), and thus less Bronsted basic, the (1)J(PtH) coupling constant falls in the series R = Me (90 Hz), R = C(6)H(5) (86 Hz), and R = C(6)F(5) (63 Hz).	Platinum	59-67	parathyroid hormone	Homo sapiens	163-166
15173006-4	2004	Finally, we identified three novel genes (PSY1-3, "platinum sensitivity") that, when deleted, demonstrate sensitivity to cisplatin and oxaliplatin, but not to mitomycin C.	Platinum	51-59	Psy2p	Saccharomyces cerevisiae S288C	42-48
15196859-12	2004	CONCLUSIONS: The results show that LNX might be of benefit in patients who have optimal primary cytoreductive surgery and who do not respond to platinum-based chemotherapy.	Platinum	144-152	ligand of numb-protein X 1	Homo sapiens	35-38
15173214-0	2004	XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.	Platinum	120-128	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	0-3
15173214-0	2004	XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.	Platinum	120-128	X-ray repair cross complementing 1	Homo sapiens	8-13
15173214-3	2004	METHODS: We used polymerase chain reaction-restriction fragment length polymorphism to evaluate genetic polymorphisms of the XPD (Asp312Asn) and XRCC1 (Arg399Gln) DNA repair genes in 103 patients with stage III (54%) and IV (46%) NSCLC treated with platinum-based chemotherapy.	Platinum	249-257	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	125-128
15173214-11	2004	CONCLUSION: Genetic polymorphisms in XPD and XRCC1 may be important prognostic factors in platinum-treated patients with advanced NSCLC.	Platinum	90-98	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	37-40
15173214-11	2004	CONCLUSION: Genetic polymorphisms in XPD and XRCC1 may be important prognostic factors in platinum-treated patients with advanced NSCLC.	Platinum	90-98	X-ray repair cross complementing 1	Homo sapiens	45-50
15213293-8	2004	These results demonstrate that both ATP7A and ATP7B modulate the pharmacodynamics of all three clinically used platinum drugs.	Platinum	111-119	ATPase copper transporting alpha	Homo sapiens	36-41
15213293-8	2004	These results demonstrate that both ATP7A and ATP7B modulate the pharmacodynamics of all three clinically used platinum drugs.	Platinum	111-119	ATPase copper transporting beta	Homo sapiens	46-51
15217965-3	2004	Using this dose and schedule, the response rate in a group of 57 patients with EGFR-positive non-small cell lung cancer after failure of platinum-containing chemotherapy was 12%.	Platinum	137-145	epidermal growth factor receptor	Homo sapiens	79-83
15253542-1	2004	Platinum microcoils coated with immobilized recombinant human vascular endothelial growth factor (rhVEGF) were prepared and the effectiveness for the embolization of aneurysms was investigated using a rat model.	Platinum	0-8	vascular endothelial growth factor A	Homo sapiens	62-96
14988228-8	2004	Titin-based PT was much lower (approximately 15 times) in fetal than adult rat cardiomyocytes, and measured PT levels were readily predictable with a model of worm-like chain titin elasticity.	Platinum	12-14	titin	Rattus norvegicus	0-5
15150622-0	2004	Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer.	Platinum	112-120	neurobeachin like 2	Homo sapiens	54-57
15042269-1	2004	Pulsed amperometric detection (PAD) of target DNA with platinum electrodes modified by single-stranded DNA (ssDNA) entrapped within polypyrrole (ssDNA/Ppy) is reported for the first time.	Platinum	55-63	pancreatic polypeptide	Bos taurus	151-154
15099972-9	2004	However, PAC-1 expression was significantly higher in effusions obtained before the institution of treatment with both platinum compounds (P = 0.029) and paclitaxel (P = 0.036).	Platinum	119-127	dual specificity phosphatase 2	Homo sapiens	9-14
15099111-1	2004	Density functional theory indicates that oxidative addition of the C-F and C-H bonds in C6F6 and C6H6 at zerovalent nickel and platinum fragments, M(H2PCH2CH2PH2), proceeds via initial exothermic formation of an eta2-coordinated arene complex.	Platinum	127-135	DNA polymerase iota	Homo sapiens	212-216
15204636-4	2004	The optimal vector, designated PT-cAu-TNF, consists of molecules of thiol-derivatized PEG (PT) and recombinant human TNF that are directly bound onto the surface of the gold nanoparticles.	Platinum	31-33	tumor necrosis factor	Homo sapiens	38-41
15204636-4	2004	The optimal vector, designated PT-cAu-TNF, consists of molecules of thiol-derivatized PEG (PT) and recombinant human TNF that are directly bound onto the surface of the gold nanoparticles.	Platinum	31-33	tumor necrosis factor	Homo sapiens	117-120
15931699-5	2004	RESULTS: A significant correlation was found between PT and AT-III (r= -0.631; p=0.000), between D-dimer and AT-III (r= -0.337; p=0.021) and between albumin and AT-III (r= 0.291; p-0.045).	Platinum	53-55	serpin family C member 1	Homo sapiens	60-66
15065292-0	2004	A chemically modified platinum electrode as a bidentate diamine ligand for forming well-defined, immobilized bis(eta 1-P-ether phosphane)(diamine)ruthenium(II) complexes.	Platinum	22-30	secreted phosphoprotein 1	Homo sapiens	113-118
15047226-0	2004	The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.	Platinum	80-88	mucin 16, cell surface associated	Homo sapiens	45-51
15047226-1	2004	OBJECTIVES: Serum CA 125 kinetics during early chemotherapy has a strong predictive and prognostic relevance for patients with advanced ovarian carcinoma who received a first-line platinum-based regimen, whereas the ability of serum CA 125 assay to reflect the response to paclitaxel-based chemotherapy has not yet been defined.	Platinum	180-188	mucin 16, cell surface associated	Homo sapiens	18-24
15047226-2	2004	The aim of the present paper is to calculate the serum CA 125 half-life during first-line paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma and to correlate this kinetic parameter with the response to treatment, progression-free survival and overall survival.	Platinum	101-109	mucin 16, cell surface associated	Homo sapiens	55-61
15047226-8	2004	CONCLUSIONS: Serum CA 125 assay represents a reliable biochemical tool for the management of advanced ovarian carcinoma patients who receive a first-line paclitaxel/platinum-based chemotherapy.	Platinum	165-173	mucin 16, cell surface associated	Homo sapiens	19-25
15072449-5	2004	In particular, as demonstrated by densitometric analysis, after exposure to both platinum compounds the total amount of the anti-apoptotic protein Bcl-2 was significantly reduced.	Platinum	81-89	BCL2 apoptosis regulator	Homo sapiens	147-152
15228233-4	2004	TNF-alpha release from PBMC was reduced by 10(-4) M (NH4)2[PtCl6] and INF-gamma release was reduced by 10(-4) and 10(-7) M hexa- and tetrachloroplatinate and 10(-4) M Na2PtI6, but not by other Pt salts.	Platinum	59-61	tumor necrosis factor	Homo sapiens	0-9
15014021-0	2004	Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.	Platinum	61-69	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	0-32
14735510-3	2004	cis-1 is converted slowly in solution into trans-[Pt(CZ=CZ-SiHPh(2))(SiHPh(2))(PMe(3))(2)] (trans-1) via intermediate 2 followed by reaction with H(2)SiPh(2).	Platinum	50-52	suppressor of cytokine signaling 1	Homo sapiens	0-5
14975213-0	2004	In vivo distribution of c-myc antisense oligodeoxynucleotides local delivered by gelatin-coated platinum-iridium stents in rabbits and its effect on apoptosis.	Platinum	96-104	myc proto-oncogene protein	Oryctolagus cuniculus	24-29
14960639-9	2004	At lymphoscintigraphy, SLN visualization required the acquisition of late images (3 h after the injection) in 20% of patients who received PA injections and 39.5% of patients who received SD/PT injections.	Platinum	191-193	sarcolipin	Homo sapiens	23-26
14735510-6	2004	Crystallographic and spectroscopic data of cis-1, trans-1, and 3 suggest the presence of an intramolecular interaction between the Si-H group of the 3-sila-1-propenyl ligand and Pt via an Si-H-Pt three-center-four-electron bond in the solid state and in solution.	Platinum	178-180	suppressor of cytokine signaling 1	Homo sapiens	43-48
15259856-0	2004	Influence of a novel platinum compound--cis-dichloro (dimethylsulphoxide) (1-beta-D-rybofuranosyl-1,2,4-triazolo-3-arboxyamide) platinum (II)--"Pt-rib-1"--on cell cycle and apoptosis in ClS91 and B16 mouse melanoma in vitro.	Platinum	21-29	ribonuclease, RNase A family, 1 (pancreatic)	Mus musculus	147-152
14737327-1	2004	Hydrophobic vitamin B(12) was covalently immobilized onto a platinum electrode surface, and the immobilized complex exhibits Co(ii)/Co(i) redox couple and in situ the Co(i) species reacts with phenethyl bromide to form styrene under irradiation with visible light with a turnover number of over 6000 for 1 h.	Platinum	60-68	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	125-131
14737327-1	2004	Hydrophobic vitamin B(12) was covalently immobilized onto a platinum electrode surface, and the immobilized complex exhibits Co(ii)/Co(i) redox couple and in situ the Co(i) species reacts with phenethyl bromide to form styrene under irradiation with visible light with a turnover number of over 6000 for 1 h.	Platinum	60-68	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	125-129
14737327-1	2004	Hydrophobic vitamin B(12) was covalently immobilized onto a platinum electrode surface, and the immobilized complex exhibits Co(ii)/Co(i) redox couple and in situ the Co(i) species reacts with phenethyl bromide to form styrene under irradiation with visible light with a turnover number of over 6000 for 1 h.	Platinum	60-68	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	132-136
15259856-3	2004	Aim of the study was to establish the influence of a platinum complex Pt-rib-1 on cell cycle and apoptosis occurrence in mouse melanoma B16 and ClS91 cells.	Platinum	53-61	ribonuclease, RNase A family, 1 (pancreatic)	Mus musculus	73-78
15259856-6	2004	The new platinum complex (Pt-rib-1); cis- dichloro (dimethylsulphoxide) (1- beta- D-ribofuranosyl- 1,2,4-triazolo -3- carboxyamide) platinum (II) was supplied.	Platinum	8-16	ribonuclease, RNase A family, 1 (pancreatic)	Mus musculus	29-34
15261162-3	2004	Immunofluorescence staining for the integrin subunits alphav and beta1 and the focal contact protein vinculin revealed that cells growing on gold and platinum expressed many focal contacts.	Platinum	150-158	hemoglobin, beta adult major chain	Mus musculus	65-70
14729645-6	2004	For example, the functionality of the p53-activated pathway appeared positively correlated with the cytotoxicity of all platinum compounds.	Platinum	120-128	tumor protein p53	Homo sapiens	38-41
14729645-8	2004	Among the parameters already known as related to the sensitivity to platinum compounds, we identified, in the complete set of 9400 genes, numerous significant relationships, such as the negative correlations between ERB-B2 and BCL-X(L) expressions and the cytotoxicity of the platinum compounds.	Platinum	68-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	216-222
14729645-8	2004	Among the parameters already known as related to the sensitivity to platinum compounds, we identified, in the complete set of 9400 genes, numerous significant relationships, such as the negative correlations between ERB-B2 and BCL-X(L) expressions and the cytotoxicity of the platinum compounds.	Platinum	68-76	BCL2 like 1	Homo sapiens	227-235
14729645-8	2004	Among the parameters already known as related to the sensitivity to platinum compounds, we identified, in the complete set of 9400 genes, numerous significant relationships, such as the negative correlations between ERB-B2 and BCL-X(L) expressions and the cytotoxicity of the platinum compounds.	Platinum	276-284	erb-b2 receptor tyrosine kinase 2	Homo sapiens	216-222
14729645-8	2004	Among the parameters already known as related to the sensitivity to platinum compounds, we identified, in the complete set of 9400 genes, numerous significant relationships, such as the negative correlations between ERB-B2 and BCL-X(L) expressions and the cytotoxicity of the platinum compounds.	Platinum	276-284	BCL2 like 1	Homo sapiens	227-235
15319547-5	2004	Caspase-3 activity after platinum complex exposure and uptake of the cation ASP+ (4-(4-(diethylamino)styryl)-N-methylpyridinium) of cells on filter membranes and impermeable supports (e.g. culture flasks) were compared.	Platinum	25-33	caspase 3	Canis lupus familiaris	0-9
15261162-3	2004	Immunofluorescence staining for the integrin subunits alphav and beta1 and the focal contact protein vinculin revealed that cells growing on gold and platinum expressed many focal contacts.	Platinum	150-158	vinculin	Mus musculus	101-109
14679524-7	2003	The increase in energy for Phi values below 65 degrees and 55 degrees (for 1 and 2, respectively) is mainly due to the short intramolecular contacts between C(8)H and the cis N-Me groups on the same side of the platinum coordination plane.	Platinum	211-219	glucose-6-phosphate isomerase	Homo sapiens	27-30
15331919-1	2004	OBJECTIVE: The protocol was designed to examine the biological effects and clinical activity of interferon-beta in patients with platinum/taxane-resistant ovarian cancer.	Platinum	129-137	interferon beta 1	Homo sapiens	96-111
14640687-6	2003	This finding suggested that pol eta could play a role in translesion synthesis past platinum-GG adducts in vivo.	Platinum	84-92	endothelin receptor type A	Homo sapiens	32-35
14640687-7	2003	On the other hand, translesion synthesis past platinum-GG adducts by pol beta was much less efficient.	Platinum	46-54	DNA polymerase beta	Homo sapiens	69-77
14735555-14	2003	Epoetin alfa therapy increased Hb levels, reduced transfusion requirements, and improved QOL in patients with anemia undergoing non-platinum chemotherapy for hematologic malignancies.	Platinum	132-140	erythropoietin	Homo sapiens	0-7
14676106-3	2003	EXPERIMENTAL DESIGN: ATP7A expression was quantified by immunohistochemical staining using microarrays containing normal and malignant tissues, and standard sections of 54 paired tumor samples obtained from ovarian carcinoma patients before and after at least two cycles of platinum-based therapy.	Platinum	274-282	ATPase copper transporting alpha	Homo sapiens	21-26
14513366-0	2003	Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.	Platinum	101-109	tumor protein p53	Homo sapiens	10-13
14513366-1	2003	PURPOSE: Resistance to chemotherapeutic drugs is a hallmark of many human cancers, which can occur independent of p53 gene status; however, the presence of wild-type p53 in chemorefractory tumors confers greater resistance to cisplatin, but such tumors do not display complete cross-resistance to the platinum analog (1R,2R-diaminocyclohexane)(trans-diacetato)(dichloro)platinumIV (DACH-Ac-Pt).	Platinum	301-309	tumor protein p53	Homo sapiens	166-169
14606852-4	2003	Chlorination of the platinum(II) complexes cis-1-3 and trans-1-4 gives the appropriate platinum(IV) complexes [PtCl(4)(NCNR(2))(2)] (cis-5-7 and trans-5-8).	Platinum	20-28	suppressor of cytokine signaling 1	Homo sapiens	43-48
14668599-2	2003	He was treated with platinum/etoposide/bleomycin chemotherapy with a decrease in serum alpha-fetoprotein and in the size of the primary tumor.	Platinum	20-28	alpha fetoprotein	Homo sapiens	87-104
14606852-4	2003	Chlorination of the platinum(II) complexes cis-1-3 and trans-1-4 gives the appropriate platinum(IV) complexes [PtCl(4)(NCNR(2))(2)] (cis-5-7 and trans-5-8).	Platinum	87-95	suppressor of cytokine signaling 1	Homo sapiens	43-48
14606852-10	2003	All the platinum compounds were additionally characterized by elemental analyses, FAB mass-spectrometry, and IR and (1)H and (13)C[(1)H] NMR spectroscopies.	Platinum	8-16	FA complementation group B	Homo sapiens	82-85
18969195-1	2003	Uricase (UOx) and polyelectrolyte were used for preparation of a permselective multilayer film and enzyme multilayer films on a platinum (Pt) electrode, allowing the detection of uric acid amperometrically.	Platinum	128-136	urate oxidase (pseudogene)	Homo sapiens	9-12
18969195-1	2003	Uricase (UOx) and polyelectrolyte were used for preparation of a permselective multilayer film and enzyme multilayer films on a platinum (Pt) electrode, allowing the detection of uric acid amperometrically.	Platinum	138-140	urate oxidase (pseudogene)	Homo sapiens	9-12
14599882-6	2003	After operation followed by six courses of platinum-based chemotherapy, serum levels of AFP dropped into normal range.	Platinum	43-51	alpha fetoprotein	Homo sapiens	88-91
14572312-0	2003	rIFN-gamma-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition.	Platinum	42-50	interferon gamma	Rattus norvegicus	0-10
14713361-10	2003	In summary, the pH shift caused by platinum electrodes had a significant influence on the permeation and stability of insulin.	Platinum	35-43	insulin	Homo sapiens	118-125
14728853-2	2003	METHODS: Forty-one patients with platinum-sensitive recurrent ovarian cancer from Jan. 1998 to Oct.	Platinum	33-41	plexin A2	Homo sapiens	95-98
14585501-4	2003	By applying differential display to cultures of mouse fibroblast, we have identified two transcripts (acute lymphoblastic leukemia-1, All-1, and a novel gene named metal-responsive gene, MERE-1) that were responsive to platinum and cadmium ions.	Platinum	219-227	lysine (K)-specific methyltransferase 2A	Mus musculus	134-139
14529671-5	2003	RESULTS: Overall, 7 of 30 patients experienced an objective response to platinum therapy (partial response, 23%; complete response, 0%) based on CT scan (2/21) and/or CA-125 (5/9) criteria.	Platinum	72-80	mucin 16, cell surface associated	Homo sapiens	167-173
14529677-6	2003	pan-JNK expression was higher in specimens treated with both platinum agents (P = 0.038) and paclitaxel (P = 0.033).	Platinum	61-69	mitogen-activated protein kinase 8	Homo sapiens	4-7
14650960-9	2003	In our experience, a non-platinum weekly regimen with GEM and TXL is well tolerated and effective, which suggests the possibility of induction chemotherapy and outpatient treatment.	Platinum	25-33	thioredoxin like 1	Homo sapiens	62-65
14572312-5	2003	rIFN-gamma reduced arginase activity in 3 EOC cell lines but increased activity in the 2008 cell line and its platinum-resistant subline, 2008.C13.	Platinum	110-118	interferon gamma	Rattus norvegicus	0-10
12888918-10	2003	A varying degree of splicing inhibition was observed for the other platinum analogs studied; the inhibitory activity decreased in the following order: ormaplatin &gt; cis-tetraplatin &gt; cis-DDP &gt; iproplatin &gt; carboplatin.	Platinum	67-75	translocase of inner mitochondrial membrane 8A	Homo sapiens	192-195
15601245-3	2003	The uptake rates of the two platinum species were studied, and also their effects on the expression of genes encoding metallothionein and heat-shock protein 70, which are known to be induced by several stress factors.	Platinum	28-36	metallothionein 4 L homeolog	Xenopus laevis	118-133
12870966-1	2003	The reaction of Pt(2)(dba)(3) (dba = bis-dibenzylidene acetone) dispersed in room temperature 1-n-butyl-3-methylimidazolium (BMI) hexafluorophosphate ionic liquid with molecular hydrogen (4 atm) at 75 degrees C leads to stable and isolable nanometric Pt(0) particles.	Platinum	16-18	ATM serine/threonine kinase	Homo sapiens	190-193
15369351-1	2003	The direct addition of a proton to a carbonyl oxygen in an eta2-enone complex of palladium and platinum led to the quantitative formation of eta3-1-hydroxyallyl complexes of palladium and platinum, of which X-ray diffraction analysis showed typical eta3-allyl structure.	Platinum	95-103	DNA polymerase iota	Homo sapiens	59-63
15369351-1	2003	The direct addition of a proton to a carbonyl oxygen in an eta2-enone complex of palladium and platinum led to the quantitative formation of eta3-1-hydroxyallyl complexes of palladium and platinum, of which X-ray diffraction analysis showed typical eta3-allyl structure.	Platinum	188-196	DNA polymerase iota	Homo sapiens	59-63
12883695-0	2003	Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy.	Platinum	123-131	erythropoietin	Homo sapiens	73-80
12914384-6	2003	XRCC1 (X-ray cross-complementing group 1), ERCC1 (excision cross-complementing gene) and GSTP1 (glutathione S-transferase) have a role in the development of pharmacoresistance to platinum derivatives.	Platinum	179-187	X-ray repair cross complementing 1	Homo sapiens	0-5
12914384-6	2003	XRCC1 (X-ray cross-complementing group 1), ERCC1 (excision cross-complementing gene) and GSTP1 (glutathione S-transferase) have a role in the development of pharmacoresistance to platinum derivatives.	Platinum	179-187	X-ray repair cross complementing 1	Homo sapiens	7-40
12914384-6	2003	XRCC1 (X-ray cross-complementing group 1), ERCC1 (excision cross-complementing gene) and GSTP1 (glutathione S-transferase) have a role in the development of pharmacoresistance to platinum derivatives.	Platinum	179-187	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	43-48
12914384-6	2003	XRCC1 (X-ray cross-complementing group 1), ERCC1 (excision cross-complementing gene) and GSTP1 (glutathione S-transferase) have a role in the development of pharmacoresistance to platinum derivatives.	Platinum	179-187	glutathione S-transferase pi 1	Homo sapiens	89-94
12914384-6	2003	XRCC1 (X-ray cross-complementing group 1), ERCC1 (excision cross-complementing gene) and GSTP1 (glutathione S-transferase) have a role in the development of pharmacoresistance to platinum derivatives.	Platinum	179-187	glutathione S-transferase kappa 1	Homo sapiens	96-121
12924882-1	2003	A heteronuclear complex of composition trans-[(NH(3))(2)Pt(N4-1-MeC(-)-N3)(2)Cu(H(2)O)(2)](ClO(4))(2) (1a), with 1-MeC(-) = 1-methylcytosinate, has been prepared and characterized by X-ray crystallography.	Platinum	56-58	C-C motif chemokine ligand 28	Homo sapiens	64-67
12924882-5	2003	In a modified procedure a third representative of this group of diplatinum(III) compounds, [(O(2)N)Pt(1-MeC(-)-N3,N4)(4)Pt](+) (2c) was isolated.	Platinum	99-101	C-C motif chemokine ligand 28	Homo sapiens	104-107
12924882-5	2003	In a modified procedure a third representative of this group of diplatinum(III) compounds, [(O(2)N)Pt(1-MeC(-)-N3,N4)(4)Pt](+) (2c) was isolated.	Platinum	120-122	C-C motif chemokine ligand 28	Homo sapiens	104-107
12924882-6	2003	All three compounds contain the four bridging 1-MeC ligands in a head,tail,head,tail arrangement with Pt-Pt distances (2.4516(7)-2.4976(9) A) that are the shortest ones among diplatinum(III) compounds containing nucleobases.	Platinum	102-104	C-C motif chemokine ligand 28	Homo sapiens	48-51
12893182-9	2003	This suggests that ovarian cancers that overexpress MDM2 may be amenable to treatment with platinum compounds.	Platinum	91-99	MDM2 proto-oncogene	Homo sapiens	52-56
12871780-0	2003	Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy.	Platinum	97-105	syndecan 1	Homo sapiens	19-29
12871780-8	2003	We conclude that high pretreatment serum syndecan-1 level is associated with poor prognosis in SCLC treated with platinum-based chemotherapy.	Platinum	113-121	syndecan 1	Homo sapiens	41-51
12925259-0	2003	Basic fibroblast growth factor released from a platinum coil with a polyvinyl alcohol core enhances cellular proliferation and vascular wall thickness: an in vitro and in vivo study.	Platinum	47-55	fibroblast growth factor 2	Rattus norvegicus	0-30
12821934-5	2003	Furthermore, other platinum compounds such as transplatin and platinum (IV) chloride can induce activation of p38 MAPK.	Platinum	19-27	mitogen-activated protein kinase 14	Homo sapiens	110-113
12853350-5	2003	RESULTS: High P21(WAF1) labeling index (LI) was an independent positive predictor of platinum-sensitive response (P = 0.02).	Platinum	85-93	cyclin dependent kinase inhibitor 1A	Homo sapiens	14-22
12839578-0	2003	Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin.	Platinum	79-87	ATP binding cassette subfamily C member 2	Homo sapiens	18-23
12839578-0	2003	Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin.	Platinum	79-87	ATP binding cassette subfamily C member 2	Homo sapiens	25-29
12839578-0	2003	Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin.	Platinum	79-87	ATP binding cassette subfamily C member 2	Homo sapiens	30-35
12886870-3	2003	Inhibition of the cyclooxygenase-2 (COX-2) enzyme, which is active in tumorigenesis, may augment efficacy and reduce toxicity of platinum/irinotecan combinations.	Platinum	129-137	prostaglandin-endoperoxide synthase 2	Homo sapiens	18-34
12886870-3	2003	Inhibition of the cyclooxygenase-2 (COX-2) enzyme, which is active in tumorigenesis, may augment efficacy and reduce toxicity of platinum/irinotecan combinations.	Platinum	129-137	prostaglandin-endoperoxide synthase 2	Homo sapiens	36-41
12808605-2	2003	With the use of an alternate soaking process a thin layer of hydroxyapatite (HAp) was formed on a platinum plate (Pt plate) which was used as a model for Guglielmi detachable coils (GDCs).	Platinum	98-106	reticulon 3	Homo sapiens	77-80
12808605-5	2003	The HAp layer was formed on the beta-mercaptopropionic acid-fixed Pt plate surface, and quantitative control of apatite formation was achieved by controlling the number of alternate soaking process cycles.	Platinum	66-68	reticulon 3	Homo sapiens	4-7
12808605-6	2003	The HAp formed on the Pt plate surface was confirmed by X-ray diffraction and X-ray photoelectron spectroscopy studies.	Platinum	22-24	reticulon 3	Homo sapiens	4-7
12839578-3	2003	In order to elucidate the role of the membrane adenosine triphosphate binding cassette-transporter cMOAT (canalicular multispecific anion transporter) (MRP2/ABCC2) in cisplatin resistance of melanoma, the expression of this protein was analyzed in the platinum drug-resistant cell line MeWo CIS 1.	Platinum	252-260	ATP binding cassette subfamily C member 2	Homo sapiens	99-104
12839578-3	2003	In order to elucidate the role of the membrane adenosine triphosphate binding cassette-transporter cMOAT (canalicular multispecific anion transporter) (MRP2/ABCC2) in cisplatin resistance of melanoma, the expression of this protein was analyzed in the platinum drug-resistant cell line MeWo CIS 1.	Platinum	252-260	ATP binding cassette subfamily C member 2	Homo sapiens	106-149
12839578-3	2003	In order to elucidate the role of the membrane adenosine triphosphate binding cassette-transporter cMOAT (canalicular multispecific anion transporter) (MRP2/ABCC2) in cisplatin resistance of melanoma, the expression of this protein was analyzed in the platinum drug-resistant cell line MeWo CIS 1.	Platinum	252-260	ATP binding cassette subfamily C member 2	Homo sapiens	152-156
12839578-3	2003	In order to elucidate the role of the membrane adenosine triphosphate binding cassette-transporter cMOAT (canalicular multispecific anion transporter) (MRP2/ABCC2) in cisplatin resistance of melanoma, the expression of this protein was analyzed in the platinum drug-resistant cell line MeWo CIS 1.	Platinum	252-260	ATP binding cassette subfamily C member 2	Homo sapiens	157-162
12839578-8	2003	The decrease in platinum-DNA adduct formation in cisplatin-resistant melanoma cells was rather a reflection of the protecting activity of the transporter cMOAT.	Platinum	16-24	ATP binding cassette subfamily C member 2	Homo sapiens	154-159
12839578-9	2003	In conclusion, the functional inhibition of cMOAT might be a promising strategy in the reversal of resistance to platinum-based anti-cancer drugs in human melanoma.	Platinum	113-121	ATP binding cassette subfamily C member 2	Homo sapiens	44-49
12673771-1	2003	A biohydrogen production system coupling the polysaccharide such as sucrose and maltose degradation with invertase and glucose dehydrognase (GDH) and hydrogen production with colloidal platinum as hydrogen-evolved catalyst using the visible light-induced photosensitization of water-soluble zinc porphyrin, zinc tetraphenylporphyrin tetrasulfonate (ZnTPPS) has been investigated.	Platinum	185-193	hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	Homo sapiens	141-144
12821934-5	2003	Furthermore, other platinum compounds such as transplatin and platinum (IV) chloride can induce activation of p38 MAPK.	Platinum	62-70	mitogen-activated protein kinase 14	Homo sapiens	110-113
12791187-3	2003	RESULTS: Serum platinum concentration-time curve after a single iv dose of KM-1 4.5 mg/kg in rats was fitted with an open three-compartment model.	Platinum	15-23	Kidney mass QTL 1	Rattus norvegicus	75-79
12791187-6	2003	Liver and spleen had the highest concentration of platinum after KM-1 treatment.	Platinum	50-58	Kidney mass QTL 1	Rattus norvegicus	65-69
12712470-12	2003	In vitro chemoresistance predicted tumor response to platinum chemotherapy correctly in BRCA heterozygotes (P = 0.0096).	Platinum	53-61	BRCA1 DNA repair associated	Homo sapiens	88-92
12851839-0	2003	Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome.	Platinum	0-8	glutathione S-transferase kappa 1	Homo sapiens	70-95
12720341-1	2003	A direct ionotropic gelation of the polycationic biopolymer chitosan (CHIT) with the polyanionic enzyme lactate oxidase (LOx) was used to form thin biopolymer-enzyme films on the surface of platinum electrodes.	Platinum	190-198	lysyl oxidase	Homo sapiens	104-119
12720341-1	2003	A direct ionotropic gelation of the polycationic biopolymer chitosan (CHIT) with the polyanionic enzyme lactate oxidase (LOx) was used to form thin biopolymer-enzyme films on the surface of platinum electrodes.	Platinum	190-198	lysyl oxidase	Homo sapiens	121-124
12757380-4	2003	In this work we attempted to develop long-circulating PEGylated carboplatin analogues with improved cell permeation abilities, by conjugating the platinum moiety to folate-targeted PEG carriers capable of utilizing the folate receptor-mediated endocytosis (FRME).	Platinum	146-154	progestagen associated endometrial protein	Homo sapiens	54-57
12757380-7	2003	Nontargeted PEG-Pt conjugates have a lower cellular uptake but produce higher levels of DNA binding and improved cytotoxicity.	Platinum	16-18	progestagen associated endometrial protein	Homo sapiens	12-15
12712470-16	2003	BRCA heterozygotes had a better response to platinum chemotherapy compared with women who had sporadic disease, which may have contributed to their improved prognosis.	Platinum	44-52	BRCA1 DNA repair associated	Homo sapiens	0-4
12824911-3	2003	Here, we investigated the predictive value of P53, Bcl-2 and lung resistance-related protein (LRP) expression for response to platinum-based chemotherapy, using transbronchial biopsy (TBB) specimens from patients with NSCLC.	Platinum	126-134	major vault protein	Homo sapiens	61-92
12684687-4	2003	We report that Brca1-deficiency in p53-null cells was associated with increased sensitivity to the topoisomerase I poisons camptothecin and topotecan, the topoisomerase II poisons doxorubicin, mitoxantrone and etoposide, and to the platinum compounds carboplatin and oxaliplatin, but not to the antimetabolites 5-fluorouracil and gemcitabine and the taxanes docetaxel and paclitaxel.	Platinum	232-240	tumor protein p53	Homo sapiens	35-38
12824911-3	2003	Here, we investigated the predictive value of P53, Bcl-2 and lung resistance-related protein (LRP) expression for response to platinum-based chemotherapy, using transbronchial biopsy (TBB) specimens from patients with NSCLC.	Platinum	126-134	major vault protein	Homo sapiens	94-97
12694661-0	2003	Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy.	Platinum	65-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-9
12694661-1	2003	OBJECTIVE: Our objective was to determine if the level of Her-2/neu expression in advanced ovarian cancer changed after platinum-based chemotherapy.	Platinum	120-128	erb-b2 receptor tyrosine kinase 2	Homo sapiens	58-67
12694661-5	2003	After platinum chemotherapy, Her-2/neu expression changed from 0 to 1+ in 7 patients, from 1+ to 0 in 4 patients, 0 to 2+ in 1 patient, and 1+ to 2+ in 2 patients and no change was seen in 29 patients.	Platinum	6-14	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-38
12646031-6	2003	On the other hand, the reaction of 3 with GMP results in the cleavage of one of the Pt-N(pyridazine) bonds to form an N7,O6-platinated polymer.	Platinum	84-86	5'-nucleotidase, cytosolic II	Homo sapiens	42-45
12663721-10	2003	CONCLUSION: Our data indicate that hTERT expression, measured by real-time RT-PCR, is a possible independent marker of response to platinum-based therapy in advanced stage ovarian cancer patients.	Platinum	131-139	telomerase reverse transcriptase	Homo sapiens	35-40
12644821-12	2003	BCL-2 and BAX, but not MEK1 expressions have predictive value in ovarian cancer patients treated with platinum-based chemotherapy.	Platinum	102-110	BCL2 apoptosis regulator	Homo sapiens	0-5
12644821-12	2003	BCL-2 and BAX, but not MEK1 expressions have predictive value in ovarian cancer patients treated with platinum-based chemotherapy.	Platinum	102-110	BCL2 associated X, apoptosis regulator	Homo sapiens	10-13
17472238-0	2003	Recombinant human erythropoietin for platinum-based chemotherapy-induced anaemia: A single-centre randomised study.	Platinum	37-45	erythropoietin	Homo sapiens	18-32
12622383-7	2003	In contrast, the i(cat) is almost constant for GOx-2-(10-phenothiazyl)propionic acid (PT-PA) hybrids with more than two PT groups synthesized by covalently modifying PT-PA to surface lysines, indicating that only a few key PT groups function as mediators.	Platinum	86-88	hydroxyacid oxidase 1	Homo sapiens	47-50
12626701-0	2003	Platinum cross-linking of adenines and guanines on the quadruplex structures of the AG3(T2AG3)3 and (T2AG3)4 human telomere sequences in Na+ and K+ solutions.	Platinum	0-8	CD58 molecule	Homo sapiens	84-87
16224397-0	2003	ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.	Platinum	112-120	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
16224397-3	2003	Previous studies have shown that ERCC1 gene expression is associated with clinical outcome to platinum chemotherapy in a variety of cancers.	Platinum	94-102	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	33-38
16224397-9	2003	We assessed the relationship between these ERCC1 gene polymorphism and clinical outcome to platinum-based chemotherapy in 106 patients with advanced refractory colorectal cancer.	Platinum	91-99	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	43-48
16224397-12	2003	The ERCC1 codon 118 polymorphism may be a useful predictor of clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.	Platinum	131-139	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	4-9
12740514-4	2003	OBJECTIVES: In this observational study, we have measured cellular and neutrophil-related inflammatory markers in induced sputum of COPD patients with unresectable non-small cell lung cancer (NSCLC) undergoing platinum-based chemotherapy.	Platinum	210-218	COPD	Homo sapiens	132-136
12619410-0	2003	The characterisation of supported platinum nanoparticles on carbon used for enantioselective hydrogenation: a combined electrochemical-STM approach.	Platinum	34-42	sulfotransferase family 1A member 3	Homo sapiens	135-138
12562205-3	2003	All the platinum compounds were characterized by elemental analyses, FAB mass spectrometry, and IR and (1)H, (13)C((1)H), and (195)Pt NMR spectroscopies, and three of them also by X-ray crystallography.	Platinum	8-16	FA complementation group B	Homo sapiens	69-72
12497586-12	2003	CONCLUSIONS: Results of the study highlight the importance of PKCalpha in the response of prostate cancer cells to mononuclear platinum compounds and indicate specific inhibition of the enzyme as a potential therapeutic strategy to sensitize androgen-independent prostate cancer cells to these drugs.	Platinum	127-135	protein kinase C alpha	Homo sapiens	62-70
12570658-0	2003	Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair.	Platinum	38-46	tumor protein p53	Homo sapiens	66-69
12570658-9	2003	Thus, platinum compounds are endowed with differential capability to activate pathways of p53-dependent or independent apoptosis, and differential recognition by specific cellular systems is likely to be the critical determinant of the cell fate (death/survival) after drug exposure.	Platinum	6-14	tumor protein p53	Homo sapiens	90-93
12565986-2	2003	A recently published clinical trial reported statistically significant (P&lt;0.001) increases in haemoglobin (Hb) levels and significantly (P&lt;0.01) increased HrQOL scores following the administration of recombinant human erythropoietin (r-HuEPO, epoetin alfa) versus placebo to anaemic cancer patients who received non-platinum chemotherapy.	Platinum	322-330	erythropoietin	Homo sapiens	224-238
12589033-1	2003	A transgenic mouse tumor model was used to investigate the role of p53 in tumor response to two different platinum-based chemotherapeutic agents: (a) cisplatin and (b) oxaliplatin, a diaminocyclohexane platine recently introduced into the clinic.	Platinum	106-114	transformation related protein 53, pseudogene	Mus musculus	67-70
12493571-0	2003	Palladium and platinum ions interfere with the measurement of erythrocyte vesiculation by inhibiting the acetylcholinesterase activity of the released spectrin-depleted microvesicles.	Platinum	14-22	acetylcholinesterase (Cartwright blood group)	Homo sapiens	105-125
12493571-1	2003	Palladium (Pd(2+)) and platinum (Pt(2+)) ions were found to inhibit erythrocyte membrane-bound acetylcholinesterase (AChE) with Ki values of 6.0 and 6.5 microg/ml, respectively.	Platinum	23-31	acetylcholinesterase (Cartwright blood group)	Homo sapiens	95-115
12493571-1	2003	Palladium (Pd(2+)) and platinum (Pt(2+)) ions were found to inhibit erythrocyte membrane-bound acetylcholinesterase (AChE) with Ki values of 6.0 and 6.5 microg/ml, respectively.	Platinum	23-31	acetylcholinesterase (Cartwright blood group)	Homo sapiens	117-121
12493571-1	2003	Palladium (Pd(2+)) and platinum (Pt(2+)) ions were found to inhibit erythrocyte membrane-bound acetylcholinesterase (AChE) with Ki values of 6.0 and 6.5 microg/ml, respectively.	Platinum	33-35	acetylcholinesterase (Cartwright blood group)	Homo sapiens	95-115
12493571-1	2003	Palladium (Pd(2+)) and platinum (Pt(2+)) ions were found to inhibit erythrocyte membrane-bound acetylcholinesterase (AChE) with Ki values of 6.0 and 6.5 microg/ml, respectively.	Platinum	33-35	acetylcholinesterase (Cartwright blood group)	Homo sapiens	117-121
15004974-0	2003	[Inhibition of ABC-transporter(s)" function in non-small cell lung cancer cells by platinum drugs].	Platinum	83-91	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	15-30
12574815-2	2003	Here, washed human platelets were used to characterize the binding of [(3)H]2-AG to CB(PT), showing a dissociation constant (Kd) of 140 +/- 31 nM and a maximum binding (Bmax) of 122 +/- 10 pmol.mg protein(-1).	Platinum	87-89	H2A clustered histone 11	Homo sapiens	74-80
12542303-3	2003	Photodeposition of platinum nanoparticles on dye-sensitized TiO2 (Pt/TiO2/Ru(II)L3) drastically enhanced the degradation rate of TCA and CCl4.	Platinum	19-27	C-C motif chemokine ligand 4	Homo sapiens	137-141
12542303-3	2003	Photodeposition of platinum nanoparticles on dye-sensitized TiO2 (Pt/TiO2/Ru(II)L3) drastically enhanced the degradation rate of TCA and CCl4.	Platinum	66-68	C-C motif chemokine ligand 4	Homo sapiens	137-141
14657531-4	2003	Randomized clinical trials of the EGFR-TK inhibitor gefitinib have demonstrated clinical benefits in patients with advanced non-small cell lung cancer whose disease had previously progressed on platinum- and docetaxel-based chemotherapy regimens.	Platinum	194-202	epidermal growth factor receptor	Homo sapiens	34-38
12566906-0	2003	Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group.	Platinum	61-69	erythropoietin	Homo sapiens	110-124
12566906-3	2003	We conducted a randomized, open label study to assess the efficacy of erythropoietin in preventing transfusions and significant anemia (hemoglobin &lt;10 g/dl) in patients with solid tumors receiving platinum-based chemotherapy.	Platinum	200-208	erythropoietin	Homo sapiens	70-84
12504621-2	2003	Platinum resistance is related to expression of excision repair proteins, one of which (ERCC-1) has been identified as playing a critical role in the synergy of gemcitabine and cisplatin.	Platinum	0-8	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	88-94
12459895-0	2003	Cooperative effects in long-range 1,4 DNA-DNA interstrand cross-links formed by polynuclear platinum complexes: an unexpected syn orientation of adenine bases outside the binding sites.	Platinum	92-100	synemin	Homo sapiens	126-129
12521176-3	2002	While the slow photocatalytic oxidation of NH3 to NO2-/NO3- is the only pathway for decomposition of NH3 on naked TiO2 and Au/TiO2, a new pathway, that of selective oxidation of ammonia to dinitrogen, opens up on Pt/TiO2.	Platinum	213-215	NBL1, DAN family BMP antagonist	Homo sapiens	55-58
12528808-9	2003	Suppression of cyclin D1 by cyclin D1 antisense mRNA expression was associated with growth inhibition and an increase in chemosensitivity to fluoropyrimidines and platinum compounds.	Platinum	163-171	cyclin D1	Homo sapiens	15-24
12528808-9	2003	Suppression of cyclin D1 by cyclin D1 antisense mRNA expression was associated with growth inhibition and an increase in chemosensitivity to fluoropyrimidines and platinum compounds.	Platinum	163-171	cyclin D1	Homo sapiens	28-37
12499281-0	2002	Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand.	Platinum	150-158	tumor protein p53	Homo sapiens	79-82
12499281-7	2002	Concomitant platinum treatment and IR led to poly(ADP-ribose) polymerase cleavage as a sign of caspase-3 activation and apoptosis.	Platinum	12-20	caspase 3	Homo sapiens	95-104
12436449-0	2002	Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.	Platinum	94-102	erythropoietin	Homo sapiens	49-63
12499281-11	2002	Taken together, p53 has a significant role in the cellular response to chemoradiation treatment in cervical cancer cell lines, but p53 activity may have a dramatically different effect on cell survival depending on the platinum carrier ligand.	Platinum	219-227	tumor protein p53	Homo sapiens	131-134
12405534-1	2002	Photoinduced hydrogen production with Mg chlorophyll-a from spirulina as a visible light photosensitizer by use of three component system consisting of nicotineamide adenine dinucleotide phosphate, reduced form (NADPH) as an electron donor, methylviologen as electron relay reagent and colloidal platinum as hydrogen evolution catalyst was investigated.	Platinum	296-304	2,4-dienoyl-CoA reductase 1	Homo sapiens	212-217
12478472-0	2002	Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response.	Platinum	39-47	tumor protein p53	Homo sapiens	143-146
12478472-1	2002	Mononuclear and multinuclear platinum complexes are known to induce distinct types of DNA lesions and exhibit different profiles of antitumor activity, in relation to p53 mutational status.	Platinum	29-37	tumor protein p53	Homo sapiens	167-170
12478472-8	2002	Multinuclear platinum complexes could be regarded as useful tools for investigating the p53-mediated process of cell cycle arrest in response to DNA damage.	Platinum	13-21	tumor protein p53	Homo sapiens	88-91
12436449-13	2002	CONCLUSIONS: Response to epoetin-alpha treatment in cancer patients receiving platinum chemotherapy can be predicted from changes in Hb level after 4 weeks of therapy.	Platinum	78-86	erythropoietin	Homo sapiens	25-32
12434296-5	2002	We report that lack of the Pms2 gene is associated with an increased sensitivity, ranging from 2-6-fold, to some types of anticancer agents including the topoisomerase II poisons doxorubicin, etoposide and mitoxantrone, the platinum compounds cisplatin and oxaliplatin, the taxanes docetaxel and paclitaxel, and the antimetabolite gemcitabine.	Platinum	224-232	PMS1 homolog 2, mismatch repair system component	Homo sapiens	27-31
12438251-1	2002	Impaired uptake of cisplatin (DDP) consistently accompanies the acquisition of resistance to the platinum drugs.	Platinum	97-105	translocase of inner mitochondrial membrane 8A	Homo sapiens	30-33
12142086-3	2002	The expression levels of messenger RNA for ZK7 in HNSCC clinical specimens exposed to platinum drugs and/or ionizing radiation were found to be higher than those in non-exposed specimens (P=0.0116).	Platinum	86-94	zinc finger protein 124	Homo sapiens	43-46
12391279-6	2002	Deletion of CTR1 resulted in a 16-fold reduction in the uptake of copper and an 8-fold reduction in the uptake of DDP measured at 1 h. The CTR1-deficient cells accumulated 2.3-fold (p &lt; 0.05) less platinum in their DNA and were 1.9-fold more resistant to the cytotoxic effect of DDP than the CTR1-replete cells.	Platinum	200-208	high-affinity Cu transporter CTR1	Saccharomyces cerevisiae S288C	12-16
12391279-6	2002	Deletion of CTR1 resulted in a 16-fold reduction in the uptake of copper and an 8-fold reduction in the uptake of DDP measured at 1 h. The CTR1-deficient cells accumulated 2.3-fold (p &lt; 0.05) less platinum in their DNA and were 1.9-fold more resistant to the cytotoxic effect of DDP than the CTR1-replete cells.	Platinum	200-208	high-affinity Cu transporter CTR1	Saccharomyces cerevisiae S288C	139-143
12391279-6	2002	Deletion of CTR1 resulted in a 16-fold reduction in the uptake of copper and an 8-fold reduction in the uptake of DDP measured at 1 h. The CTR1-deficient cells accumulated 2.3-fold (p &lt; 0.05) less platinum in their DNA and were 1.9-fold more resistant to the cytotoxic effect of DDP than the CTR1-replete cells.	Platinum	200-208	high-affinity Cu transporter CTR1	Saccharomyces cerevisiae S288C	139-143
12391279-11	2002	These results indicate that CTR1 function markedly influences the uptake of all of the clinically used platinum-containing drugs and suggest that this copper transporter may also transport DDP.	Platinum	103-111	high-affinity Cu transporter CTR1	Saccharomyces cerevisiae S288C	28-32
12370737-7	2002	In two cell line series sequentially derived from ovarian cancer patients pre- and post-cisplatin chemotherapy, BARX2 expression was downregulated in the cell lines established upon tumor recurrence after platinum therapy.	Platinum	205-213	BARX homeobox 2	Homo sapiens	112-117
12370737-8	2002	Transfection of BARX2 into a platinum resistant cell line significantly reversed cisplatin resistance compared with its isogenic platinum sensitive parent, in both growth inhibition and clonogenic assays.	Platinum	29-37	BARX homeobox 2	Homo sapiens	16-21
12370737-8	2002	Transfection of BARX2 into a platinum resistant cell line significantly reversed cisplatin resistance compared with its isogenic platinum sensitive parent, in both growth inhibition and clonogenic assays.	Platinum	129-137	BARX homeobox 2	Homo sapiens	16-21
12468337-1	2002	OBJECTIVE: The objective of this study was to verify the correlation between p53 immunostaining at initial diagnosis and at positive reassessment after completing platinum-based chemotherapy and to assess prognostic differences between patients whose tumors display positive immunostaining versus those that have negative immunostaining at such reassessment.	Platinum	163-171	tumor protein p53	Homo sapiens	77-80
12380828-3	2002	A model enzyme, glucose oxidase (GOx), was mixed with the CHIT-GDI-AY9 solution and cast on the surface of platinum electrodes to form robust CHIT-GDI-AY9-GOx films for glucose biosensing.	Platinum	107-115	hydroxyacid oxidase 1	Homo sapiens	16-31
12380828-3	2002	A model enzyme, glucose oxidase (GOx), was mixed with the CHIT-GDI-AY9 solution and cast on the surface of platinum electrodes to form robust CHIT-GDI-AY9-GOx films for glucose biosensing.	Platinum	107-115	hydroxyacid oxidase 1	Homo sapiens	33-36
12167163-1	2002	BACKGROUND: We have reported that protein imaging by transmission electron microscope observation based on low-angle platinum shadowing can reproduce characteristic ring structures of the replication clamp, proliferating cell nuclear antigen (PCNA), and the clamp loader protein, replication factor C (RFC).	Platinum	117-125	proliferating cell nuclear antigen	Homo sapiens	207-241
12181446-5	2002	Consistent with this finding, overexpression of the JNK target, c-Jun, significantly protected SCLC cells from platinum compounds, whereas expression of a c-Jun mutant encoding only the DNA binding domain increased the sensitivity of the SCLC cells to these drugs.	Platinum	111-119	mitogen-activated protein kinase 8	Homo sapiens	52-55
12181446-5	2002	Consistent with this finding, overexpression of the JNK target, c-Jun, significantly protected SCLC cells from platinum compounds, whereas expression of a c-Jun mutant encoding only the DNA binding domain increased the sensitivity of the SCLC cells to these drugs.	Platinum	111-119	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	64-69
12181446-6	2002	These findings support the hypothesis that activation of the JNKs by platinum compounds controls c-Jun-dependent transcriptional events that promote a protective response in SCLC cells.	Platinum	69-77	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	97-102
12181446-9	2002	The findings indicate that inhibition of the JNK pathway is a potential means to enhance the sensitivity of SCLC cells to platinum compounds.	Platinum	122-130	mitogen-activated protein kinase 8	Homo sapiens	45-48
12217742-9	2002	CONCLUSIONS: Older ovarian cancer patients (&gt;65 years) with low baseline Hb levels (&lt;10.5) at initiation of platinum-based chemotherapy are likely to become more anemic during treatment and should be considered for prophylactic erythropoietin therapy as an alternative to transfusion.	Platinum	114-122	erythropoietin	Homo sapiens	234-248
12217751-12	2002	CONCLUSION: This study showed that LH-RH agonist Leuprorelin has only a limited effect in patients pretreated with platinum-based chemotherapy.	Platinum	115-123	gonadotropin releasing hormone 1	Homo sapiens	35-40
12181446-0	2002	Regulation of platinum-compound cytotoxicity by the c-Jun N-terminal kinase and c-Jun signaling pathway in small-cell lung cancer cells.	Platinum	14-22	mitogen-activated protein kinase 8	Homo sapiens	52-75
12181446-0	2002	Regulation of platinum-compound cytotoxicity by the c-Jun N-terminal kinase and c-Jun signaling pathway in small-cell lung cancer cells.	Platinum	14-22	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	52-57
12200198-7	2002	Rasagiline prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF).	Platinum	25-27	glial cell derived neurotrophic factor	Homo sapiens	186-190
12167163-1	2002	BACKGROUND: We have reported that protein imaging by transmission electron microscope observation based on low-angle platinum shadowing can reproduce characteristic ring structures of the replication clamp, proliferating cell nuclear antigen (PCNA), and the clamp loader protein, replication factor C (RFC).	Platinum	117-125	proliferating cell nuclear antigen	Homo sapiens	243-247
12082455-19	2002	Intraperitoneal SCH 58500 is safe, well tolerated, and combined with platinum-based chemotherapy can be associated with a significant reduction of serum CA125 in heavily pretreated patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.	Platinum	69-77	mucin 16, cell surface associated	Homo sapiens	153-158
12101059-3	2002	Indirect electrochemical detection is accomplished at a 25 microm platinum electrode modified by cross-linking the enzymes choline oxidase and acetylcholinesterase with glutaraldehyde.	Platinum	66-74	acetylcholinesterase (Cartwright blood group)	Homo sapiens	143-163
12174899-0	2002	Mechanisms of actio of poly-plat, a novel platinum antineoplastic agent.	Platinum	42-50	plasminogen activator, tissue type	Homo sapiens	28-32
12216113-4	2002	Among phosphate analogues and their derivatives for PTP inhibition, Keggin compounds phosphomolybdate (PM) and phosphotungstate (PT) strongly inhibited both PTP-1B and SHP-1, with K(i) values of 0.06-1.2 micromM in the presence of EDTA.	Platinum	52-54	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	157-163
12216113-4	2002	Among phosphate analogues and their derivatives for PTP inhibition, Keggin compounds phosphomolybdate (PM) and phosphotungstate (PT) strongly inhibited both PTP-1B and SHP-1, with K(i) values of 0.06-1.2 micromM in the presence of EDTA.	Platinum	52-54	nuclear receptor subfamily 0 group B member 2	Homo sapiens	168-173
12121789-2	2002	In this manuscript we report on the interactions of cis-DDP (cisplatin, cis-diamminedichloroplatinum(II)) and trans-DDP (transplatin, trans-diamminedichloroplatinum(II)) with two model proteins, ubiquitin (Ub) and horse heart myoglobin (Mb), and attempt to answer the question whether proteins that have methionine-Pt adducts can transfer the platinum to biological nucleophiles and particularly to DNA.	Platinum	92-100	myoglobin	Equus caballus	226-235
12006509-2	2002	The purpose of this study was to examine p53 mutations in leukemias after ovarian cancer, for which treatment with platinum analogues was widely used.	Platinum	115-123	tumor protein p53	Homo sapiens	41-44
12214834-3	2002	Alpha-fetoprotein, which was elevated to 21236.6 ng/mL before the initial surgery, persisted within normal after the completion of adjuvant platinum-based chemotherapy.	Platinum	140-148	alpha fetoprotein	Homo sapiens	0-17
12093475-1	2002	The aim of this study is to establish anti-tumour potency of the new oral platinum drug JM216 and its metabolite JM118 in relation to the platinum (Pt)-DNA adduct formation, glutathione (GSH)-levels, and p53 status in human cancer cell lines with different sensitivities to cisplatin (CDDP).	Platinum	74-82	tumor protein p53	Homo sapiens	204-207
18968629-2	2002	The sensing film was prepared by electropolymerization of aniline into polyacrylonitrile (PAN)-coated platinum electrode in the presence of PPO.	Platinum	102-110	protoporphyrinogen oxidase	Homo sapiens	140-143
11862422-17	2002	OCC1-SEAP cells cultured in vitro were treated with the platinum-containing drug carboplatin.	Platinum	56-64	RIKEN cDNA 1500009L16 gene	Mus musculus	0-4
11841234-4	2002	Results of these studies demonstrate that both RPA and XPA are in close proximity to the adduct as measured by cross-linking of each protein directly to the platinum moiety.	Platinum	157-165	replication protein A1	Homo sapiens	47-50
11841234-4	2002	Results of these studies demonstrate that both RPA and XPA are in close proximity to the adduct as measured by cross-linking of each protein directly to the platinum moiety.	Platinum	157-165	XPA, DNA damage recognition and repair factor	Homo sapiens	55-58
11966428-0	2002	Optimisation of polystyrene resin-supported Pt catalysts in room temperature, solvent-less, oct-l-ene hydrosilylation using methyldichlorosilane.	Platinum	44-46	plexin A2	Homo sapiens	92-95
11966428-5	2002	The matrix of 18 resin-supported Pt complexes was then assessed for catalytic activity in the room temperature, solvent-less, hydrosilylation of oct-l-ene using methyldichlorosilane such that alkene: silane: Pt ratio was fixed at 2:1:1x10(-3).	Platinum	33-35	plexin A2	Homo sapiens	145-148
11966428-5	2002	The matrix of 18 resin-supported Pt complexes was then assessed for catalytic activity in the room temperature, solvent-less, hydrosilylation of oct-l-ene using methyldichlorosilane such that alkene: silane: Pt ratio was fixed at 2:1:1x10(-3).	Platinum	208-210	plexin A2	Homo sapiens	145-148
11972392-11	2002	CONCLUSIONS: COX-2 could represent a possible new marker of sensitivity to platin-based chemotherapy in ovarian cancer.	Platinum	75-81	prostaglandin-endoperoxide synthase 2	Homo sapiens	13-18
11960495-0	2002	Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.	Platinum	36-44	SUN domain containing ossification factor	Homo sapiens	195-198
11925162-12	2002	This trend is modified at low pH, and the palladium becomes 400 times more reactive than the platinum because of the formation of [Pd(CN)(3)HCN](-).	Platinum	93-101	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	140-143
11925164-0	2002	Bonding behavior of Co(CO)(3)L (L = CO, PPh(3)) building blocks in platinum-cobalt carbonyl clusters.	Platinum	67-75	protein phosphatase 4 catalytic subunit	Homo sapiens	40-46
11937055-2	2002	The structure of PDC-109 with bound phosphorylcholine was solved using MAD data of a single platinum site.	Platinum	92-100	seminal plasma protein PDC-109	Bos taurus	17-24
11881794-1	2002	In a single-center, case-control study the authors evaluated the efficacy and safety of epoetin alfa in pediatric cancer patients receiving platinum- or nonplatinum-based chemotherapy.	Platinum	140-148	erythropoietin	Homo sapiens	88-95
11885572-1	2002	The present paper describes the development of a simple, accurate and reproducible gas chromatographic method for the determination of hydrolyzed demethylcantharidin release from a novel series of traditional Chinese medicine (TCM)-platinum compounds possessing potent anticancer and protein phosphatase 2A (PP2A)-inhibition properties.	Platinum	232-240	protein phosphatase 2 phosphatase activator	Homo sapiens	292-306
11885572-1	2002	The present paper describes the development of a simple, accurate and reproducible gas chromatographic method for the determination of hydrolyzed demethylcantharidin release from a novel series of traditional Chinese medicine (TCM)-platinum compounds possessing potent anticancer and protein phosphatase 2A (PP2A)-inhibition properties.	Platinum	232-240	protein phosphatase 2 phosphatase activator	Homo sapiens	308-312
11862422-21	2002	OCC1 cells were injected intraperitoneally into nude mice and the mice were treated with the platinum-containing drugs cisplatin or carboplatin.	Platinum	93-101	chromosome 12 open reading frame 75	Homo sapiens	0-4
12057087-7	2002	Phase II studies evaluating other new agents, delivered singly or in combination, also have reported that gemcitabine, weekly paclitaxel, and the epidermal growth factor receptor (EGFR) inhibitors are active in a subset of patients who progress after first-line platinum-based therapy.	Platinum	262-270	epidermal growth factor receptor	Homo sapiens	146-178
12057087-7	2002	Phase II studies evaluating other new agents, delivered singly or in combination, also have reported that gemcitabine, weekly paclitaxel, and the epidermal growth factor receptor (EGFR) inhibitors are active in a subset of patients who progress after first-line platinum-based therapy.	Platinum	262-270	epidermal growth factor receptor	Homo sapiens	180-184
11998962-0	2002	Circulating CD34+ cells to predict the adequate harvest of peripheral blood progenitor cells in platinum-based chemotherapy.	Platinum	96-104	CD34 molecule	Homo sapiens	12-16
12120309-1	2002	The formation of a Pt skin layer with predominantly (111)-oriented facets induced by dissolution of Fe atoms in a Pt-Fe alloy for fuel cell applications is investigated for the first time by using in situ electrochemical STM in 0.1 M HClO4 solution.	Platinum	19-21	sulfotransferase family 1A member 3	Homo sapiens	221-224
11897340-1	2002	We have synthesised the complex [Pt(CH(3)SCH(2)CH(2)SCH(3))(5"-GMP-N7)(2)].6H(2)O (1), where 5"-GMP is 5"-guanosine monophosphate, and determined its X-ray crystal structure.	Platinum	33-35	5'-nucleotidase, cytosolic II	Homo sapiens	63-66
11897340-1	2002	We have synthesised the complex [Pt(CH(3)SCH(2)CH(2)SCH(3))(5"-GMP-N7)(2)].6H(2)O (1), where 5"-GMP is 5"-guanosine monophosphate, and determined its X-ray crystal structure.	Platinum	33-35	5'-nucleotidase, cytosolic II	Homo sapiens	96-99
11998962-6	2002	CONCLUSIONS: Harvesting procedure may be avoided when circulating CD34+ cells showed less than 0.10% after platinum-based mobilization chemotherapy.	Platinum	107-115	CD34 molecule	Homo sapiens	66-70
12440809-5	2002	In ovarian cancer p53 status is a strong predictor of response to platinum-based chemotherapy.	Platinum	66-74	tumor protein p53	Homo sapiens	18-21
11824623-2	2002	L-Methionine competes with 5"-GMP for the platinum binding site and forms as well as 5"-GMP adducts with oxaliplatin.	Platinum	42-50	5'-nucleotidase, cytosolic II	Homo sapiens	30-33
12440809-6	2002	Patients whose tumors have p53 mutations experience a lower chance of achieving a complete response following platinum-based regimens when compared to patients without p53 mutations.	Platinum	110-118	tumor protein p53	Homo sapiens	27-30
12440809-8	2002	Whereas patients with wild-type p53 tumors have a good chance to respond to platinum, patients with mutant p53 tumors may have a clinical benefit from the addition of paclitaxel to platinum-based chemotherapy.	Platinum	76-84	tumor protein p53	Homo sapiens	32-35
12440809-8	2002	Whereas patients with wild-type p53 tumors have a good chance to respond to platinum, patients with mutant p53 tumors may have a clinical benefit from the addition of paclitaxel to platinum-based chemotherapy.	Platinum	181-189	tumor protein p53	Homo sapiens	107-110
11733188-6	2002	The antitumor activity of the tested platinum compounds was found to correlate with the binding affinity of HMG1 to the respective drug-DNA adduct.	Platinum	37-45	high mobility group box 1 pseudogene 5	Homo sapiens	108-112
11766988-8	2001	The MRP5 mRNA levels in tumors from lung cancer patients treated with platinum regimen were significantly higher than in tumors from patients treated with non-platinum regimens, and the MRP5 expression levels were correlate with the GCS expression levels that is the rate-limiting step enzyme in glutathione biosynthesis.	Platinum	70-78	ATP binding cassette subfamily C member 5	Homo sapiens	4-8
11750714-2	2002	We tested PLD in locally advanced or metastatic NSCLC patients, progressed after a platinum-based first-line chemotherapy.	Platinum	83-91	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	10-13
11750714-17	2002	PLD at the doses employed in this study can be safely administered and has shown activity in platinum pretreated NSCLC patients.	Platinum	93-101	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	0-3
12239444-7	2002	As the prototype platinum compound, cisplatin has played a major role in the management of SCLC.	Platinum	17-25	SCLC1	Homo sapiens	91-95
12239444-10	2002	Several new platinum formulations or compounds are showing promising activity in SCLC.	Platinum	12-20	SCLC1	Homo sapiens	81-85
11751380-0	2001	A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.	Platinum	79-87	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	2-31
11751380-8	2001	We conclude that XPD Lys751Gln polymorphism may be an important marker in the prediction of clinical outcome to platinum-based chemotherapy.	Platinum	112-120	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	17-20
11752109-17	2002	These data support the hypothesis that the nephrotoxicity of cisplatin is due to the metabolism of a platinum-glutathione conjugate by GGT and cysteine S-conjugate beta-lyase to a potent nephrotoxin.	Platinum	101-109	gamma-glutamyltransferase 1	Mus musculus	135-138
11752109-17	2002	These data support the hypothesis that the nephrotoxicity of cisplatin is due to the metabolism of a platinum-glutathione conjugate by GGT and cysteine S-conjugate beta-lyase to a potent nephrotoxin.	Platinum	101-109	kynurenine aminotransferase 1	Mus musculus	143-174
11766988-8	2001	The MRP5 mRNA levels in tumors from lung cancer patients treated with platinum regimen were significantly higher than in tumors from patients treated with non-platinum regimens, and the MRP5 expression levels were correlate with the GCS expression levels that is the rate-limiting step enzyme in glutathione biosynthesis.	Platinum	70-78	ATP binding cassette subfamily C member 5	Homo sapiens	186-190
11766988-8	2001	The MRP5 mRNA levels in tumors from lung cancer patients treated with platinum regimen were significantly higher than in tumors from patients treated with non-platinum regimens, and the MRP5 expression levels were correlate with the GCS expression levels that is the rate-limiting step enzyme in glutathione biosynthesis.	Platinum	159-167	ATP binding cassette subfamily C member 5	Homo sapiens	4-8
11705695-0	2001	Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex.	Platinum	116-124	thioredoxin	Homo sapiens	40-51
11705695-0	2001	Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex.	Platinum	116-124	glutaredoxin	Homo sapiens	80-92
11720475-4	2001	Using molecular and immunohistochemical analyses we examined TP53 and its downstream genes p21, BAX and BCL-2 in ovarian tumour tissues and have evaluated the results in relation to clinico-pathological parameters, clinical outcome and response to platinum-based chemotherapy.	Platinum	248-256	tumor protein p53	Homo sapiens	61-65
11677602-5	2001	The spin-orbit coupling introduced by the platinum atom allows triplet-state emission, so optically and electrically generated luminescence from both singlet and triplet states can be compared directly.	Platinum	42-50	spindlin 1	Homo sapiens	4-8
11514569-0	2001	Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins.	Platinum	72-80	structure specific recognition protein 1	Homo sapiens	100-123
11514569-3	2001	Electrophoretic mobility shift assays show that both the A and B domains of HMGB1 as well as TBP discriminate between different platinum-DNA adducts.	Platinum	128-136	high mobility group box 1	Homo sapiens	76-81
11514569-3	2001	Electrophoretic mobility shift assays show that both the A and B domains of HMGB1 as well as TBP discriminate between different platinum-DNA adducts.	Platinum	128-136	TATA-box binding protein	Homo sapiens	93-96
11514569-4	2001	HMGB1 domain A is the most sensitive to the nature of the spectator ligands on platinum.	Platinum	79-87	high mobility group box 1	Homo sapiens	0-5
11759169-10	2001	Meso-1-PtCl2 does not inhibit the proliferation of tumor cells by direct interaction with their DNA, as is described for platinum complexes like cDDP.	Platinum	145-149	transcription factor 15	Mus musculus	0-6
11690209-3	2001	We find an unsuspected ground state at 50%-50% composition-the L1(1) structure, currently known in binary metallurgy only for the Cu(0.5)Pt(0.5) alloy system.	Platinum	137-139	immunoglobulin kappa variable 1-6	Homo sapiens	63-68
11759169-10	2001	Meso-1-PtCl2 does not inhibit the proliferation of tumor cells by direct interaction with their DNA, as is described for platinum complexes like cDDP.	Platinum	121-129	transcription factor 15	Mus musculus	0-6
11595686-0	2001	Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.	Platinum	48-56	tumor protein p53	Homo sapiens	15-18
11595686-9	2001	CONCLUSIONS: p53 alterations correlate significantly with resistance to platinum-based chemotherapy, early relapse, and shortened overall survival in ovarian cancer patients in univariate analysis.	Platinum	72-80	tumor protein p53	Homo sapiens	13-16
11681009-1	2001	The electrolytically detachable platinum coil (Guglielmi Detachable Coil: GDC) is a safe and efficient endovascular tool for treatment of cerebral aneurysms.	Platinum	32-40	solute carrier family 25 member 16	Homo sapiens	74-77
11899413-12	2001	Of greatest interest is the synergy between the platinum derivatives and the monoclonal antibody trastuzumab demonstrated in vitro in breast cancer cell lines overexpressing HER2/neu.	Platinum	48-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	174-178
11899413-12	2001	Of greatest interest is the synergy between the platinum derivatives and the monoclonal antibody trastuzumab demonstrated in vitro in breast cancer cell lines overexpressing HER2/neu.	Platinum	48-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	179-182
11899413-13	2001	Currently, several combinations of platinum compounds (either cisplatin or carboplatin) with docetaxel and trastuzumab are under clinical testing in patients with MBC who overexpress HER2/neu.	Platinum	35-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	183-187
11899413-13	2001	Currently, several combinations of platinum compounds (either cisplatin or carboplatin) with docetaxel and trastuzumab are under clinical testing in patients with MBC who overexpress HER2/neu.	Platinum	35-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	188-191
11899413-1	2001	Interest in platinum compounds for the treatment of breast cancer has been reawakened because of preclinical studies indicating synergy of platinum salts with the monoclonal antibody trastuzumab in human breast cancer cell lines that overexpress HER2/neu.	Platinum	12-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	246-250
11899413-1	2001	Interest in platinum compounds for the treatment of breast cancer has been reawakened because of preclinical studies indicating synergy of platinum salts with the monoclonal antibody trastuzumab in human breast cancer cell lines that overexpress HER2/neu.	Platinum	12-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	251-254
11583787-5	2001	Formation of [Pt(DACH)(L-Met-S,N)](+) inhibits coordination of 5"-GMP.	Platinum	14-16	5'-nucleotidase, cytosolic II	Homo sapiens	66-69
11798034-4	2001	In addition, the permeability transition or PT, which may also remove Ca2+ from the mitochondrial matrix, is intimately involved in other important functions such as apoptosis.	Platinum	44-46	carbonic anhydrase 2	Homo sapiens	70-73
11708058-1	2001	A modified platinum-disk electrode coated with a non-plasticized polyacrylamide (PAA) membrane was used to study electrochemically an enzymatic reaction between tyrosinase in the PAA membrane and catechol and 3,4-dihydroxytoluene in acetonitrile (AN).	Platinum	11-19	tyrosinase	Homo sapiens	161-171
11708058-2	2001	Tyrosinase, a hydrophilic biofunctional material, was immobilized in the thin PAA membrane, which adhered to the platinum-disk electrode and was stable in AN.	Platinum	113-121	tyrosinase	Homo sapiens	0-10
11588369-3	2001	In the trans compound, Pt is located on a centre of inversion and the Pt-Cl and Pt-S distances are 2.2786 (15) and 2.3002 (12) A, respectively.	Platinum	23-25	6-pyruvoyltetrahydropterin synthase	Homo sapiens	80-84
11477564-1	2001	To investigate the roles played by the multidrug resistance-associated protein (MRP1) homologues MRP3 and MRP4 in resistance to platinum drugs, we examined steady-state levels of mRNA for both MRP3 and MRP4 in normal lung and lung cancer specimens as well as peripheral mononuclear cells (PMN) after platinum drug exposure.	Platinum	128-136	ATP binding cassette subfamily C member 1	Homo sapiens	39-84
11496300-1	2001	The expression of the DNA mismatch repair proteins hMSH2 and hMLH1 and p21(waf1) the cyclin G1 inhibitor, may determine response of adult cancers to anti-cancer drugs, that include alkylating agents and platinum-based drugs.	Platinum	203-211	mutS homolog 2	Homo sapiens	51-56
11496300-1	2001	The expression of the DNA mismatch repair proteins hMSH2 and hMLH1 and p21(waf1) the cyclin G1 inhibitor, may determine response of adult cancers to anti-cancer drugs, that include alkylating agents and platinum-based drugs.	Platinum	203-211	mutL homolog 1	Homo sapiens	61-66
11496300-1	2001	The expression of the DNA mismatch repair proteins hMSH2 and hMLH1 and p21(waf1) the cyclin G1 inhibitor, may determine response of adult cancers to anti-cancer drugs, that include alkylating agents and platinum-based drugs.	Platinum	203-211	cyclin dependent kinase inhibitor 1A	Homo sapiens	71-74
11496300-1	2001	The expression of the DNA mismatch repair proteins hMSH2 and hMLH1 and p21(waf1) the cyclin G1 inhibitor, may determine response of adult cancers to anti-cancer drugs, that include alkylating agents and platinum-based drugs.	Platinum	203-211	cyclin dependent kinase inhibitor 1A	Homo sapiens	75-79
11496300-1	2001	The expression of the DNA mismatch repair proteins hMSH2 and hMLH1 and p21(waf1) the cyclin G1 inhibitor, may determine response of adult cancers to anti-cancer drugs, that include alkylating agents and platinum-based drugs.	Platinum	203-211	cyclin G1	Homo sapiens	85-94
11477564-1	2001	To investigate the roles played by the multidrug resistance-associated protein (MRP1) homologues MRP3 and MRP4 in resistance to platinum drugs, we examined steady-state levels of mRNA for both MRP3 and MRP4 in normal lung and lung cancer specimens as well as peripheral mononuclear cells (PMN) after platinum drug exposure.	Platinum	128-136	ATP binding cassette subfamily C member 3	Homo sapiens	97-101
11477564-1	2001	To investigate the roles played by the multidrug resistance-associated protein (MRP1) homologues MRP3 and MRP4 in resistance to platinum drugs, we examined steady-state levels of mRNA for both MRP3 and MRP4 in normal lung and lung cancer specimens as well as peripheral mononuclear cells (PMN) after platinum drug exposure.	Platinum	128-136	ATP binding cassette subfamily C member 4	Homo sapiens	106-110
11477564-1	2001	To investigate the roles played by the multidrug resistance-associated protein (MRP1) homologues MRP3 and MRP4 in resistance to platinum drugs, we examined steady-state levels of mRNA for both MRP3 and MRP4 in normal lung and lung cancer specimens as well as peripheral mononuclear cells (PMN) after platinum drug exposure.	Platinum	300-308	ATP binding cassette subfamily C member 1	Homo sapiens	39-84
11477564-6	2001	Furthermore, MRP3 expression levels in normal lung and tumor tissues from autopsy samples that had been exposed to platinum drugs while the patients were alive were significantly higher than those in unexposed tissues, but again MRP4 expression levels remained the same.	Platinum	115-123	ATP binding cassette subfamily C member 3	Homo sapiens	13-17
11477564-7	2001	These results suggest that platinum drugs and/or the physiological stress response to xenobiotics induce expression of the MRP3 gene.	Platinum	27-35	ATP binding cassette subfamily C member 3	Homo sapiens	123-127
11531279-0	2001	Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.	Platinum	126-134	thrombospondin 1	Homo sapiens	0-16
11599657-9	2001	Correlations were found between both peak free Pt concentrations in plasma and in urine and the maximum of urinary excretions of albumin and of N-acetyl-beta-D-glucosaminidase and the nadir of the glomerular filtration rate (P &lt; 0.05).	Platinum	47-49	O-GlcNAcase	Homo sapiens	144-175
11498439-0	2001	Delivery of human vascular endothelial growth factor with platinum coils enhances wall thickening and coil impregnation in a rat aneurysm model.	Platinum	58-66	vascular endothelial growth factor A	Homo sapiens	18-52
11712813-0	2001	A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.	Platinum	58-66	X-ray repair cross complementing 1	Homo sapiens	22-27
11473397-3	2001	Anion-exchange chromatography revealed the presence of isomers of two complexes which presumably result from the restricted rotation at the platinum-- N-7 (5"-GMP) bonds.	Platinum	140-148	5'-nucleotidase, cytosolic II	Homo sapiens	159-162
11488520-2	2001	Proposed mediators of platinum resistance include the protein kinase C (PKC) signal transduction pathway and associated c-FOS overexpression.	Platinum	22-30	protein kinase C alpha	Homo sapiens	72-75
11488520-2	2001	Proposed mediators of platinum resistance include the protein kinase C (PKC) signal transduction pathway and associated c-FOS overexpression.	Platinum	22-30	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	120-125
11410799-0	2001	Randomized study of dose or schedule modification of granulocyte colony-stimulating factor in platinum-based chemotherapy for elderly patients with lung cancer.	Platinum	94-102	colony stimulating factor 3	Homo sapiens	53-90
11459199-11	2001	These results provide evidence that changes in EGFR expression or function may play a role in determining chemosensitivity to platinum and topoisomerase I poisons in some human tumor systems, and that the EGFR-related changes in chemosensitivity may vary depending on the level of EGFR expression and/or function.	Platinum	126-134	epidermal growth factor receptor	Homo sapiens	47-51
11412107-6	2001	HMG1 domain B is superior to domain A for platinum-mediated photo-cross-linking, a result attributed to the different positioning of the proteins with respect to the platinum adduct and the greater ability of domain B to access photolabilized platinum in the major groove.	Platinum	42-50	high mobility group box 1 pseudogene 5	Homo sapiens	0-4
11412107-6	2001	HMG1 domain B is superior to domain A for platinum-mediated photo-cross-linking, a result attributed to the different positioning of the proteins with respect to the platinum adduct and the greater ability of domain B to access photolabilized platinum in the major groove.	Platinum	166-174	high mobility group box 1 pseudogene 5	Homo sapiens	0-4
11412107-6	2001	HMG1 domain B is superior to domain A for platinum-mediated photo-cross-linking, a result attributed to the different positioning of the proteins with respect to the platinum adduct and the greater ability of domain B to access photolabilized platinum in the major groove.	Platinum	166-174	high mobility group box 1 pseudogene 5	Homo sapiens	0-4
11465809-6	2001	Correlations were found between both peak free platinum concentrations in plasma and urine and maxima of urinary albumin and N-acetyl-beta-D-glucosaminidase excretion.	Platinum	47-55	O-GlcNAcase	Homo sapiens	125-156
11399173-2	2001	With TfOD the reaction gives selectively [Pt(3)(mu-PBu(t)(2))(2)(mu-D)(PBu(t)(2)H)(CO)(2)]OTf (2-D(1)), implying that the proton is transferred to a metal center while a P-H bond is formed by the reductive coupling of one of the bridging phosphides and the terminal hydride ligand of the reagent.	Platinum	42-44	adaptor related protein complex 5 subunit mu 1	Homo sapiens	65-69
11410504-7	2001	Furthermore, the response to platinum-based chemotherapy was independent from HIF-1alpha expression.	Platinum	29-37	hypoxia inducible factor 1 subunit alpha	Homo sapiens	78-88
11283915-5	2001	Avidin was also adsorbed onto bovine serum albumin (BSA)-coated surfaces of oxide and platinum.	Platinum	86-94	albumin	Homo sapiens	37-50
11410241-6	2001	The very large differential in IC(50) values between the CH-1 and CH-1cisR pair of cell lines for the 9-aminoacridine-4-carboxamide tethered platinum complexes indicates that repair of platinum-induced DNA damage may be a major determinant of the activity of these compounds.	Platinum	141-149	SUN domain containing ossification factor	Homo sapiens	57-61
11410241-6	2001	The very large differential in IC(50) values between the CH-1 and CH-1cisR pair of cell lines for the 9-aminoacridine-4-carboxamide tethered platinum complexes indicates that repair of platinum-induced DNA damage may be a major determinant of the activity of these compounds.	Platinum	185-193	SUN domain containing ossification factor	Homo sapiens	57-61
11279186-1	2001	The p53 gene encodes a nuclear phosphoprotein that is biologically activated in response to genotoxic stresses including treatment with anticancer platinum drugs.	Platinum	147-155	tumor protein p53	Homo sapiens	4-7
11316543-4	2001	METHODS AND MATERIALS: The nuclear expression of HAP1 and p53 proteins was studied by immunohistochemistry in paraffin-embedded material from 95 patients with locally advanced squamous cell head-and-neck cancer (HNC) treated with radical radiotherapy (38 cases with induction platinum-based chemotherapy and 57 with concurrent platinum chemoradiotherapy).	Platinum	276-284	huntingtin associated protein 1	Homo sapiens	49-53
11450990-9	2001	Only the clearance of filtered platinum was significantly related to urinary N-acetyl-beta-D-glucosaminidase and the other covariates were not related to these pharmacokinetic parameters with respect to unchanged cisplatin and total platinum concentrations.	Platinum	31-39	O-GlcNAcase	Homo sapiens	77-108
11346705-8	2001	CONCLUSION: The sequential administration of GM-CSF and G-CSF in combination with EPO is feasible and improves the PBPC collection efficiency after platinum-based intensive polychemotherapy, associating high PBPC mobilization to high collection efficiency during apheresis.	Platinum	148-156	colony stimulating factor 2	Homo sapiens	45-51
11346705-8	2001	CONCLUSION: The sequential administration of GM-CSF and G-CSF in combination with EPO is feasible and improves the PBPC collection efficiency after platinum-based intensive polychemotherapy, associating high PBPC mobilization to high collection efficiency during apheresis.	Platinum	148-156	colony stimulating factor 3	Homo sapiens	56-61
11346705-8	2001	CONCLUSION: The sequential administration of GM-CSF and G-CSF in combination with EPO is feasible and improves the PBPC collection efficiency after platinum-based intensive polychemotherapy, associating high PBPC mobilization to high collection efficiency during apheresis.	Platinum	148-156	erythropoietin	Homo sapiens	82-85
11316543-4	2001	METHODS AND MATERIALS: The nuclear expression of HAP1 and p53 proteins was studied by immunohistochemistry in paraffin-embedded material from 95 patients with locally advanced squamous cell head-and-neck cancer (HNC) treated with radical radiotherapy (38 cases with induction platinum-based chemotherapy and 57 with concurrent platinum chemoradiotherapy).	Platinum	327-335	huntingtin associated protein 1	Homo sapiens	49-53
11361338-13	2001	We reason that this is due to a cryptic PTS in native Eci1p that can function in a redundant system with the C-terminal HRL.	Platinum	40-43	dodecenoyl-CoA isomerase	Saccharomyces cerevisiae S288C	54-59
11301404-13	2001	The terminal plasma half-life of the total platinum after SKI 2053R administration ranged from 63.4 hours to 114.1 hours in dosages ranging from 40 mg/m(2) to 480 mg/m(2) without significant dose dependency.	Platinum	43-51	SKI proto-oncogene	Homo sapiens	58-61
11301404-15	2001	The renal excretion of SKI 2053R measured as platinum ranged from 49% to 75% of the administered dose.	Platinum	45-53	SKI proto-oncogene	Homo sapiens	23-26
11301404-1	2001	BACKGROUND: A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) (SKI 2053R), a new platinum derivative, was performed to determine the maximum tolerated dose (MTD), the dose limiting toxicities (DLTs), and the pharmacokinetic profile of SKI 2053R in patients with advanced, refractory malignancies.	Platinum	88-96	SKI proto-oncogene	Homo sapiens	102-105
11479892-3	2001	The standard management of limited-stage SCLC is concurrent platinum-based chemotherapy with thoracic radiotherapy (RT).	Platinum	60-68	SCLC1	Homo sapiens	41-45
11277967-5	2001	Slice cultures grown on a separate set of chips with platinum instead of silicon nitride surfaces also displayed normal MAP2 and GFAP immunostaining.	Platinum	53-61	microtubule-associated protein 2	Rattus norvegicus	120-124
11277967-6	2001	The width of the GFAP-rich zone (glia limitans) at the bottom surface of the slice cultures was the same ( approximately 20 microm) in cultures grown on chips with silicon nitride and platinum surfaces and on conventional insert membranes.	Platinum	184-192	glial fibrillary acidic protein	Rattus norvegicus	17-21
11261890-9	2001	This study showed that the LHRH agonist Triptorelin has only modest efficacy in patients pretreated with platinum-containing chemotherapy.	Platinum	105-113	gonadotropin releasing hormone 1	Homo sapiens	27-31
11332988-1	2001	The enhanced expression of the human ABC transporter, cMOAT (MRP2/ABCC2), is associated with resistance of tumor cells against platinum-containing compounds, such as cisplatin.	Platinum	127-135	ATP binding cassette subfamily C member 2	Homo sapiens	54-59
11332988-1	2001	The enhanced expression of the human ABC transporter, cMOAT (MRP2/ABCC2), is associated with resistance of tumor cells against platinum-containing compounds, such as cisplatin.	Platinum	127-135	ATP binding cassette subfamily C member 2	Homo sapiens	61-65
11332988-1	2001	The enhanced expression of the human ABC transporter, cMOAT (MRP2/ABCC2), is associated with resistance of tumor cells against platinum-containing compounds, such as cisplatin.	Platinum	127-135	ATP binding cassette subfamily C member 2	Homo sapiens	66-71
11462986-3	2001	This model is used to compare log P(oct) to cell uptake for five platinum drugs and hence to establish an exponential relation between these parameters.	Platinum	65-73	plexin A2	Homo sapiens	36-39
11233568-1	2001	We determined the number of single and double strand breaks (ssb and dsb) in a DNA-chloroterpyridine platinum complex induced by resonant photoabsorption in the L(III) innershell of a platinum atom.	Platinum	101-109	small RNA binding exonuclease protection factor La	Homo sapiens	61-64
11233568-1	2001	We determined the number of single and double strand breaks (ssb and dsb) in a DNA-chloroterpyridine platinum complex induced by resonant photoabsorption in the L(III) innershell of a platinum atom.	Platinum	184-192	small RNA binding exonuclease protection factor La	Homo sapiens	61-64
11077043-5	2000	Since these platinum-resistant tumors also show higher mRNA levels of ERCC1 and XPA, platinum resistance appears to be associated with concurrent up-regulation of four genes (XPA, ERCC1, XPB, and CSB).	Platinum	12-20	XPA, DNA damage recognition and repair factor	Homo sapiens	80-83
11878288-5	2001	We investigated the relation between P-glycoprotein and glutation S-transferase level for response to platinum-based chemotherapy in epithelial ovarian cancer.	Platinum	102-110	ATP binding cassette subfamily B member 1	Homo sapiens	37-51
11169653-0	2000	Synthesis and Reactions of Palladium and Platinum Complexes Bearing Diphosphinidenecyclobutene Ligands: A Thermally Stable Catalyst for Ethylene Polymerization This work was supported by a Grant-in-Aid for Scientific Research on Priority Area "The Chemistry of Inter-element Linkage" from the Ministry of Education, Science, Sports, and Culture, Japan.	Platinum	41-49	activation induced cytidine deaminase	Homo sapiens	198-201
11123991-8	2000	In contrast to the parasite enzyme, most (terpyridine)platinum complexes interact only reversibly with human glutathione reductase and an initial inhibition is completely abolished during the course of the assay.	Platinum	54-62	glutathione-disulfide reductase	Homo sapiens	109-130
11077043-2	2000	Higher mRNA levels of Xeroderma pigmentosum group B (XPB), which links DNA repair with DNA transcription, and of Cockayne"s syndrome group B (CSB), which is essential for gene-specific repair, were observed in tumor tissues that were clinically resistant to platinum-based chemotherapy, as compared with tissues from patients responding to therapy.	Platinum	258-266	ERCC excision repair 6, chromatin remodeling factor	Homo sapiens	113-140
11077043-5	2000	Since these platinum-resistant tumors also show higher mRNA levels of ERCC1 and XPA, platinum resistance appears to be associated with concurrent up-regulation of four genes (XPA, ERCC1, XPB, and CSB).	Platinum	12-20	XPA, DNA damage recognition and repair factor	Homo sapiens	175-178
11077043-2	2000	Higher mRNA levels of Xeroderma pigmentosum group B (XPB), which links DNA repair with DNA transcription, and of Cockayne"s syndrome group B (CSB), which is essential for gene-specific repair, were observed in tumor tissues that were clinically resistant to platinum-based chemotherapy, as compared with tissues from patients responding to therapy.	Platinum	258-266	ERCC excision repair 6, chromatin remodeling factor	Homo sapiens	142-145
11077043-5	2000	Since these platinum-resistant tumors also show higher mRNA levels of ERCC1 and XPA, platinum resistance appears to be associated with concurrent up-regulation of four genes (XPA, ERCC1, XPB, and CSB).	Platinum	12-20	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	180-185
11077043-5	2000	Since these platinum-resistant tumors also show higher mRNA levels of ERCC1 and XPA, platinum resistance appears to be associated with concurrent up-regulation of four genes (XPA, ERCC1, XPB, and CSB).	Platinum	12-20	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	70-75
11077043-5	2000	Since these platinum-resistant tumors also show higher mRNA levels of ERCC1 and XPA, platinum resistance appears to be associated with concurrent up-regulation of four genes (XPA, ERCC1, XPB, and CSB).	Platinum	12-20	ERCC excision repair 6, chromatin remodeling factor	Homo sapiens	196-199
11077043-5	2000	Since these platinum-resistant tumors also show higher mRNA levels of ERCC1 and XPA, platinum resistance appears to be associated with concurrent up-regulation of four genes (XPA, ERCC1, XPB, and CSB).	Platinum	85-93	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	70-75
11077043-5	2000	Since these platinum-resistant tumors also show higher mRNA levels of ERCC1 and XPA, platinum resistance appears to be associated with concurrent up-regulation of four genes (XPA, ERCC1, XPB, and CSB).	Platinum	85-93	XPA, DNA damage recognition and repair factor	Homo sapiens	80-83
11077043-5	2000	Since these platinum-resistant tumors also show higher mRNA levels of ERCC1 and XPA, platinum resistance appears to be associated with concurrent up-regulation of four genes (XPA, ERCC1, XPB, and CSB).	Platinum	85-93	XPA, DNA damage recognition and repair factor	Homo sapiens	175-178
11077043-5	2000	Since these platinum-resistant tumors also show higher mRNA levels of ERCC1 and XPA, platinum resistance appears to be associated with concurrent up-regulation of four genes (XPA, ERCC1, XPB, and CSB).	Platinum	85-93	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	180-185
11090055-0	2000	Cadmium and platinum suppression of erythropoietin production in cell culture: clinical implications.	Platinum	12-20	erythropoietin	Homo sapiens	36-50
11077043-5	2000	Since these platinum-resistant tumors also show higher mRNA levels of ERCC1 and XPA, platinum resistance appears to be associated with concurrent up-regulation of four genes (XPA, ERCC1, XPB, and CSB).	Platinum	85-93	ERCC excision repair 6, chromatin remodeling factor	Homo sapiens	196-199
11027435-9	2000	Intracellular platinum level in YES-2/AS-12 was significantly lower than that in YES-2 and YES-2/Neo following incubation with cisplatin, whereas ouabain pre-treatment resulted in no differences in intracellular platinum accumulations between the three cell lines.	Platinum	14-22	YES1 pseudogene 1	Homo sapiens	32-37
11099323-1	2000	PURPOSE: The p53 gene plays a critical role in cellular response to DNA damage and has been implicated in the response to platinum compounds in ovarian carcinoma patients.	Platinum	122-130	tumor protein p53	Homo sapiens	13-16
11099323-2	2000	Because taxanes could induce p53-independent apoptosis, we assessed the relevance of p53 gene status to response in ovarian carcinoma patients receiving paclitaxel and platinum-containing chemotherapy.	Platinum	168-176	tumor protein p53	Homo sapiens	85-88
11156248-10	2000	The pronounced growth inhibitory action of the platinums, cisplatin and carboplatinum, as single agents against A431 vulvar, A549 and LX-1 lung, and TSU-PR1 and PC-3 prostate tumors was increased several-fold when ZD1839 was added, with some regression of A431 and PC-3 tumors.	Platinum	47-56	proprotein convertase subtilisin/kexin type 1	Homo sapiens	161-165
11156248-10	2000	The pronounced growth inhibitory action of the platinums, cisplatin and carboplatinum, as single agents against A431 vulvar, A549 and LX-1 lung, and TSU-PR1 and PC-3 prostate tumors was increased several-fold when ZD1839 was added, with some regression of A431 and PC-3 tumors.	Platinum	47-56	proprotein convertase subtilisin/kexin type 1	Homo sapiens	265-269
10955812-0	2000	Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.	Platinum	180-188	tumor protein p53	Homo sapiens	44-47
12945428-1	2000	The performance of Pt/Al2O3 catalysts with CeO2-ZrO2 in difference ways was studied by NIR-FT-Raman, BET, H2 chemisorption, XRD.	Platinum	19-21	delta/notch like EGF repeat containing	Homo sapiens	101-104
11196780-1	2000	The reaction of [MCl2(NCMe)2] (M = Pd or Pt) with 2 molar equiv of MeC(CH2ER)3 (E = Se, R = Me; E = Te, R = Me or Ph) and 2 molar equiv of TlPF6 affords the bis ligand complexes [M(MeC(CH2ER)3)2][PF6]2.	Platinum	41-43	C-C motif chemokine ligand 28	Homo sapiens	67-70
10956227-5	2000	The trifunctional dinuclear platinum complexes showed a unique profile of cytotoxicity against human cancer cell lines, with low resistance factors in A2780, CH1, and 41M cell lines.	Platinum	28-36	SUN domain containing ossification factor	Homo sapiens	158-161
10922227-8	2000	Additionally, expression of cyclin D1 may make human head and neck cancer cells resistant to platinum-based chemotherapeutic approaches.	Platinum	93-101	cyclin D1	Homo sapiens	28-37
11003455-12	2000	Moreover, cetirizine reduced significantly BK-induced wheals by 70% for IDT (P&lt;0.01) and 65% for PT (P&lt;0.01).	Platinum	100-102	kininogen 1	Homo sapiens	43-45
10930966-8	2000	RESULTS: An increase in Epo levels occurred following every course of 5-FU or platinum based chemotherapy in patients with steady concentrations of creatinine and decreased levels of haemoglobin (Hb).	Platinum	78-86	erythropoietin	Homo sapiens	24-27
10747955-0	2000	Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes.	Platinum	128-136	high mobility group box 1 pseudogene 5	Homo sapiens	55-59
10807947-5	2000	A comparison of effects of drugs belonging to the same class but endowed with a different antitumor activity (i.e. cisplatin versus a novel multinuclear platinum complex and doxorubicin versus a disaccharide analogue) showed a correlation between drug efficacy, apoptotic response, and Bcl-2 phosphorylation.	Platinum	153-161	BCL2 apoptosis regulator	Homo sapiens	286-291
10813749-4	2000	Among other heavy metal cations, Au(3+), Pt(4+), Ni(2+), Pd(2+), but not Ga(3+) or Sn(2+), inhibited IL-1beta production in a concentration-dependent manner.	Platinum	41-43	interleukin 1 beta	Homo sapiens	101-109
10885669-8	2000	Thus, missense or frame-shift mutations that produce truncated tyrosinase lacking the melanosomal sorting signal(s) appear to be responsible for murine platinum coat color phenotypes and a proportion of human oculocutaneous albinism-1; mutations in AP-3 appear to be responsible for the mocha phenotype in mice and Hermansky-Pudlak-like syndrome in man.	Platinum	152-160	tyrosinase	Mus musculus	63-73
10767357-0	2000	Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer.	Platinum	102-110	zinc ribbon domain containing 2	Homo sapiens	65-68
10798649-5	2000	Activation of EGFR was analyzed by 1) indirect immunofluorescence microscopy, 2) immunoprecipitation using anti-EGFR and anti-phosphotyrosine (anti-PT), and 3) binding-site localization using EGF-fluorescein isothiocyanate (FITC).	Platinum	148-150	epidermal growth factor receptor	Rattus norvegicus	14-18
10767357-9	2000	It is suggested that high p27 expression levels in tumors may predict the good responses to platinum-based chemotherapy for NSCLC.	Platinum	92-100	zinc ribbon domain containing 2	Homo sapiens	26-29
10728763-10	2000	CONCLUSION: The HLA-DQB1*0301/4;DQA1*0301/ 2;DRB1*04 haplotype and its components may influence the production of aPS/PT in the antiphospholipid syndrome, which partly explains the correlation between the lupus anticoagulant and DQB1*03.	Platinum	118-120	major histocompatibility complex, class II, DQ beta 1	Homo sapiens	16-24
10753634-6	2000	In conclusion, BDP is a novel platinum derivative compound that appears more effective in increasing the ILS than cisplatin against the leukemia tumor mouse model.	Platinum	30-38	AT rich interactive domain 3B (BRIGHT-like)	Mus musculus	15-18
10778972-5	2000	hMLH1 and hMSH2 staining decreased significantly after platinum-based therapy.	Platinum	55-63	mutL homolog 1	Homo sapiens	0-5
10778972-5	2000	hMLH1 and hMSH2 staining decreased significantly after platinum-based therapy.	Platinum	55-63	mutS homolog 2	Homo sapiens	10-15
10728601-0	2000	Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer.	Platinum	69-77	ATP binding cassette subfamily C member 5	Homo sapiens	28-32
10728601-1	2000	To investigate the role of the multidrug resistance-associated protein (MRP1) homologue MRP5 in relation to platinum drug resistance, we examined the steady-state levels of the mRNAs for MRP5 in both lung cancer cell lines and peripheral mononuclear cells (PMN) after exposure to platinum drug and in normal lung and lung cancer tissue specimens.	Platinum	108-116	ATP binding cassette subfamily C member 1	Homo sapiens	31-76
10728601-1	2000	To investigate the role of the multidrug resistance-associated protein (MRP1) homologue MRP5 in relation to platinum drug resistance, we examined the steady-state levels of the mRNAs for MRP5 in both lung cancer cell lines and peripheral mononuclear cells (PMN) after exposure to platinum drug and in normal lung and lung cancer tissue specimens.	Platinum	108-116	ATP binding cassette subfamily C member 5	Homo sapiens	88-92
10728601-5	2000	The MRP5 expression levels in normal lung tissues and in tumors from patients exposed to platinum drugs during their lifetime were significantly higher than those in tissues from non-exposed patients.	Platinum	89-97	ATP binding cassette subfamily C member 5	Homo sapiens	4-8
10728601-7	2000	Our results suggest that increased expression levels of the MRP5 gene are associated with exposure to platinum drugs in lung cancer in vivo and/or the chronic stress response to xenobiotics.	Platinum	102-110	ATP binding cassette subfamily C member 5	Homo sapiens	60-64
10810335-8	2000	These results suggest that ERCC-1 may be a useful marker to monitor the repair of platinum-DNA damage in tumor cells, and further highlight that potential pharmacological approaches which specifically inhibit ERCC-1 expression may increase cellular sensitivity to cisplatin.	Platinum	82-90	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	27-33
10777605-1	2000	DNA polymerase beta (pol beta) is the only mammalian DNA polymerase identified to date that can catalyze extensive bypass of platinum-DNA adducts in vitro.	Platinum	125-133	DNA polymerase beta	Homo sapiens	0-19
10777605-1	2000	DNA polymerase beta (pol beta) is the only mammalian DNA polymerase identified to date that can catalyze extensive bypass of platinum-DNA adducts in vitro.	Platinum	125-133	DNA polymerase beta	Homo sapiens	21-29
10782524-12	2000	Moreover, cetirizine reduced significantly BK-induced wheals by 70% for IDT (P &lt; 0.01) and 65% for PT (P &lt; 0.01).	Platinum	102-104	kininogen 1	Homo sapiens	43-45
10762745-1	2000	The aim of this study was to evaluate the efficacy and toxicity of ifosfamide, 5-fluorouracil (5-FU) and leucovorin (IFL) as a second-line chemotherapy regimen in patients with recurrent undifferentiated nasopharyngeal carcinoma (NPC) previously treated with platinum/5-FU.	Platinum	259-267	interferon alpha 1	Homo sapiens	117-120
10728763-10	2000	CONCLUSION: The HLA-DQB1*0301/4;DQA1*0301/ 2;DRB1*04 haplotype and its components may influence the production of aPS/PT in the antiphospholipid syndrome, which partly explains the correlation between the lupus anticoagulant and DQB1*03.	Platinum	118-120	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	32-36
10728763-10	2000	CONCLUSION: The HLA-DQB1*0301/4;DQA1*0301/ 2;DRB1*04 haplotype and its components may influence the production of aPS/PT in the antiphospholipid syndrome, which partly explains the correlation between the lupus anticoagulant and DQB1*03.	Platinum	118-120	major histocompatibility complex, class II, DR beta 1	Homo sapiens	45-49
10728763-10	2000	CONCLUSION: The HLA-DQB1*0301/4;DQA1*0301/ 2;DRB1*04 haplotype and its components may influence the production of aPS/PT in the antiphospholipid syndrome, which partly explains the correlation between the lupus anticoagulant and DQB1*03.	Platinum	118-120	major histocompatibility complex, class II, DQ beta 1	Homo sapiens	20-24
10692490-0	2000	Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.	Platinum	39-47	tumor protein p53	Homo sapiens	10-13
10692490-10	2000	Our results suggest that the loss of functional p53 can increase cisplatin cytotoxicity in A2780, with loss of G(1)/S checkpoint control and decreased cisplatin-DNA adduct repair, but these effects can be circumvented by the use of JM335, which forms different DNA-platinum adducts.	Platinum	265-273	tumor protein p53	Homo sapiens	48-51
10638963-0	2000	Depletion of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells.	Platinum	91-99	protein kinase C alpha	Homo sapiens	31-34
11809106-6	2000	The non-responders to platinum or taxol based combination chemotherapy exhibited higher ratios of MDR1 and MRP expression than the responders (P &lt; 0.05).	Platinum	22-30	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
11809106-6	2000	The non-responders to platinum or taxol based combination chemotherapy exhibited higher ratios of MDR1 and MRP expression than the responders (P &lt; 0.05).	Platinum	22-30	ATP binding cassette subfamily C member 1	Homo sapiens	107-110
10638963-1	2000	Down-regulation of protein kinase C (PKC) by 12-Otetradecanoylphorbol-13-acetate (TPA) enhances the sensitivity of human ovarian carcinoma 2008 cells to various types of platinum compounds such as cisplatin (DDP), carboplatin and (-)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato)-platinum(II) monohydrate (DWA) by a factor of two- to threefold.	Platinum	170-178	protein kinase C alpha	Homo sapiens	37-40
10638963-13	2000	Although the mechanism of TPA induced sensitization is not yet fully understood, this study points to a central role for PKCalpha in modulating platinum drug sensitivity.	Platinum	144-152	protein kinase C alpha	Homo sapiens	121-129
10502292-6	1999	Single-stranded PTs inhibited both collagen synthesis and noncollagen protein synthesis induced by TGF-beta1, the mediator of the bleomycin fibrogenic effect.	Platinum	16-19	transforming growth factor, beta 1	Rattus norvegicus	99-108
11013397-4	2000	In an attempt to determine the origins of this heat capacity change, we have examined by isothermal titration calorimetry (ITC) the equilibrium binding of dT(pT)(34) to SSB over a broad pH range (pH 5.	Platinum	158-160	single-stranded DNA-binding protein	Escherichia coli	169-172
10597899-6	1999	The selective activity of the trans platinum complexes against the SKOV-3 cell line correlated with a deficiency in the repair of adducts within a fragment of the N-ras gene induced by trans compounds whereas adducts induced by the cis counterparts, and cisplatin, were repaired.	Platinum	36-44	NRAS proto-oncogene, GTPase	Homo sapiens	163-168
10637254-1	2000	PURPOSE: To determine whether p53 gene status predicts tumor responses to platinum- and fluorouracil-based induction chemotherapy in locoregionally advanced squamous cell carcinomas of the head and neck.	Platinum	74-82	tumor protein p53	Homo sapiens	30-33
10604725-4	1999	Each of the cell lines exhibited an ability to repair JM216 induced platinum/DNA lesions in the N-ras gene (gene-specific repair) at equitoxic concentrations of drug.	Platinum	68-76	NRAS proto-oncogene, GTPase	Homo sapiens	96-101
10502292-9	1999	Single-stranded PTs also blocked both the TGF-beta1-induced increase in collagen synthesis and noncollagen synthesis in these fibroblasts.	Platinum	16-19	transforming growth factor, beta 1	Rattus norvegicus	42-51
10477381-10	1999	RESULTS: The new key recommendations are: 1) The use of recombinant human erythropoietin in oncology is an alternative to treat chemotherapy-induced anemia when the chemotherapeutic regimen contains platinum; 2) Cancer-induced anemia reduces patients" quality of life.	Platinum	199-207	erythropoietin	Homo sapiens	74-88
10643655-5	1999	The relative fluorescence intensity of platinum-bound HSA decreases to about 55% for cis-DDP, 45% for trans-DDP and to 85% for DBP when compared to the complex-free protein, suggesting that the binding occurs in the proximity of the Trp214 residue.	Platinum	39-47	D-box binding PAR bZIP transcription factor	Homo sapiens	127-130
10506693-0	1999	Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma.	Platinum	44-52	SKI proto-oncogene	Homo sapiens	27-30
10506693-1	1999	BACKGROUND: SKI-2053R (SK Chemicals, Kyungki-Do, South Korea) is a new platinum derivative with antitumor activity against various cell lines, including cisplatin-resistant tumor cell lines.	Platinum	71-79	SKI proto-oncogene	Homo sapiens	12-15
10460158-0	1999	Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts.	Platinum	125-133	high mobility group box 1 pseudogene 5	Homo sapiens	30-59
10460158-6	1999	These data were consistent with the results of gel-shift experiments showing similar differences in the affinity of HMG1 for DNA modified with the different platinum adducts.	Platinum	157-165	high mobility group box 1 pseudogene 5	Homo sapiens	116-120
10432399-11	1999	In contrast, PTs showed a delayed increase in OPN staining, with a maximum after five to seven days, higher in the OSOM than in the cortex.	Platinum	13-16	secreted phosphoprotein 1	Rattus norvegicus	46-49
10521066-0	1999	Phase II trial of a novel platinum analog, SKI 2053R, in patients with previously untreated extensive-stage small-cell lung cancer.	Platinum	26-34	SKI proto-oncogene	Homo sapiens	43-46
10521066-1	1999	A phase II trial of a novel platinum analog, SKI 2053R, was performed in patients with previously untreated extensive-stage disease (ED) small-cell lung cancer (SCLC).	Platinum	28-36	SKI proto-oncogene	Homo sapiens	45-48
10626349-5	1999	The DNA distortions induced by this adduct exhibit unprecedented features such as the location of the platinum residue in the minor groove, the extrusion of the cytosines of the cross-linked d(GpC).d(GpC) site, the bending of the helix axis towards the minor groove and a large DNA unwinding.	Platinum	102-110	glycophorin C (Gerbich blood group)	Homo sapiens	200-203
10487615-3	1999	The relationship between GGT expression and clinical response to platinum-based chemotherapy was examined in 41 human germ cell tumours.	Platinum	65-73	gamma-glutamyltransferase light chain 5 pseudogene	Homo sapiens	25-28
10471039-0	1999	A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts.	Platinum	27-35	tumor protein p53	Homo sapiens	111-114
10471039-8	1999	The results showed that the transfer of functional p53 resulted in a marked (tenfold) reduction of cellular chemosensitivity to the multinuclear platinum complex but in a moderate sensitization to cisplatin.	Platinum	145-153	tumor protein p53	Homo sapiens	51-54
10432399-16	1999	PTs show a vesicular, perinuclear OPN staining pattern, whereas DTs show OPN staining at the apical cell side.	Platinum	0-3	secreted phosphoprotein 1	Rattus norvegicus	34-37
10408844-0	1999	Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer.	Platinum	101-109	erythropoietin	Homo sapiens	0-7
10391244-6	1999	Here we show that Pin1 binds to only one pT-P motif in tau and copurifies with PHFs, resulting in depletion of soluble Pin1 in the brains of Alzheimer"s disease patients.	Platinum	41-43	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	18-22
10326703-13	1999	When only patients given platinum-based treatment were considered, EST histology (P = 0.003) and AFP &gt;1000 kU/L (P = 0.003) were associated with relapse in univariate analysis; however, these factors were linked.	Platinum	25-33	alpha fetoprotein	Homo sapiens	97-100
10231332-0	1999	Allergy to complex salts of platinum in refinery workers: prospective evaluations of IgE and Phadiatop status.	Platinum	28-36	immunoglobulin heavy constant epsilon	Homo sapiens	85-88
18967526-1	1999	Modified silicagel (C18) was studied for separation and preconcentration of platinum group metals (Ru, Rh, Pd, Os, Ir and Pt) as ion associates of their chlorocomplexes with cation of onium salt N(1-carbaethoxypentadecyl)-trimethyl ammonium bromide.	Platinum	76-84	Bardet-Biedl syndrome 9	Homo sapiens	20-23
10483231-1	1999	A new method of application of platinum macromolecular complex poly{hexacis[chloroamine aquaplatinum (II)]}-mu-deoxyribonucleate (MCP) as a cell cycle synchronization inductor has been developed.	Platinum	31-39	CD46 molecule	Homo sapiens	130-133
11670950-5	1999	The most reactive complex, Pt(IV)(dach)Cl(4), showed an additional weak peak at 9.2 ppm due to H8 of the 5"-GMP bound to the Pt(IV) complex, indicating the existence of a Pt(IV) intermediate.	Platinum	27-29	5'-nucleotidase, cytosolic II	Homo sapiens	108-111
10370789-0	1999	Induction of gamma-glutamylcysteine synthetase gene expression by platinum drugs in peripheral mononuclear cells of lung cancer patients.	Platinum	66-74	glutamate-cysteine ligase catalytic subunit	Homo sapiens	13-46
10370789-7	1999	After platinum drug administration, the heavy subunit of gamma-GCS (gamma-GCSh) expression level increased 2.5-fold within 24 hours and the increase persisted for a month, whereas the light subunit of gamma-GCS (gamma-GCSl) expression level did not show an early response but had increased after a month.	Platinum	6-14	glutamate-cysteine ligase catalytic subunit	Homo sapiens	57-66
10370789-7	1999	After platinum drug administration, the heavy subunit of gamma-GCS (gamma-GCSh) expression level increased 2.5-fold within 24 hours and the increase persisted for a month, whereas the light subunit of gamma-GCS (gamma-GCSl) expression level did not show an early response but had increased after a month.	Platinum	6-14	glutamate-cysteine ligase catalytic subunit	Homo sapiens	68-77
10616580-11	1999	Platinum was detected in 61 tumour samples, the mean peak concentration being 13 SEM 2 micrograms/g (range 5-21).	Platinum	0-8	semaphorin 3G	Homo sapiens	81-86
18967526-1	1999	Modified silicagel (C18) was studied for separation and preconcentration of platinum group metals (Ru, Rh, Pd, Os, Ir and Pt) as ion associates of their chlorocomplexes with cation of onium salt N(1-carbaethoxypentadecyl)-trimethyl ammonium bromide.	Platinum	122-124	Bardet-Biedl syndrome 9	Homo sapiens	20-23
10499110-0	1999	Reactivity of an extremely sterically crowded monofunctional Pt complex, [Pt(1-MeC-N3)3(H2O)]2+ (1-MeC = 1-methylcytosine), toward model nucleobases and selectivity toward guanine in single- and double-stranded deoxyoligonucleotides.	Platinum	61-63	C-C motif chemokine ligand 28	Homo sapiens	79-82
10219677-4	1999	Among these biotransformation products, the identification of Pt(dach)(Met) was further confirmed by LC-ESI-MS, and the identification of Pt(dach)(Cys)2, Pt(dach)(GSH), Pt(dach)(GSH)2 and free dach was confirmed by atomic absorption and double isotope labeling.	Platinum	62-64	GS homeobox 2	Rattus norvegicus	178-183
10100719-0	1999	Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).	Platinum	94-102	tumor protein p53	Homo sapiens	14-17
10100719-6	1999	Differences between the two platinum agents were also evident in cell cycle studies: cisplatin arrested both wild-type and mutant p53 cells in G2-M, whereas DACH-acetato-Pt arrested wild-type p53 cells in G1 and mutant p53 cells in G2-M.	Platinum	28-36	tumor protein p53	Homo sapiens	130-133
10100719-6	1999	Differences between the two platinum agents were also evident in cell cycle studies: cisplatin arrested both wild-type and mutant p53 cells in G2-M, whereas DACH-acetato-Pt arrested wild-type p53 cells in G1 and mutant p53 cells in G2-M.	Platinum	28-36	tumor protein p53	Homo sapiens	192-195
10100719-6	1999	Differences between the two platinum agents were also evident in cell cycle studies: cisplatin arrested both wild-type and mutant p53 cells in G2-M, whereas DACH-acetato-Pt arrested wild-type p53 cells in G1 and mutant p53 cells in G2-M.	Platinum	28-36	tumor protein p53	Homo sapiens	192-195
10080591-0	1999	Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel.	Platinum	108-116	mucin 16, cell surface associated	Homo sapiens	27-33
10188880-0	1999	Increased platinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatin.	Platinum	10-18	stromal antigen 1	Homo sapiens	35-39
10499110-0	1999	Reactivity of an extremely sterically crowded monofunctional Pt complex, [Pt(1-MeC-N3)3(H2O)]2+ (1-MeC = 1-methylcytosine), toward model nucleobases and selectivity toward guanine in single- and double-stranded deoxyoligonucleotides.	Platinum	61-63	C-C motif chemokine ligand 28	Homo sapiens	99-102
9923557-0	1999	Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial.	Platinum	129-137	colony stimulating factor 3	Homo sapiens	14-51
10191716-1	1999	[meso-1,2-Bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) (meso-1-PtCl2), an estrogenic and cytotoxic platinum complex, shows activity against ER+ but not against ER- breast cancers in vivo (ER: estrogen receptor; ER+ and ER- indicate the presence or absence of the ER).	Platinum	69-77	transcription factor 15	Mus musculus	1-7
10191716-1	1999	[meso-1,2-Bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) (meso-1-PtCl2), an estrogenic and cytotoxic platinum complex, shows activity against ER+ but not against ER- breast cancers in vivo (ER: estrogen receptor; ER+ and ER- indicate the presence or absence of the ER).	Platinum	69-77	transcription factor 15	Mus musculus	83-95
10582148-8	1999	Erythropoietin is able to correct anemia in nearly 60%-80% of patients receiving platinum-based chemotherapy and in nearly 40% of patients treated with regimens without platinum compounds, leading to a reduction in blood transfusion requirement.	Platinum	81-89	erythropoietin	Homo sapiens	0-14
10582148-8	1999	Erythropoietin is able to correct anemia in nearly 60%-80% of patients receiving platinum-based chemotherapy and in nearly 40% of patients treated with regimens without platinum compounds, leading to a reduction in blood transfusion requirement.	Platinum	169-177	erythropoietin	Homo sapiens	0-14
9891541-0	1998	p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy.	Platinum	89-97	tumor protein p53	Homo sapiens	0-3
10778734-3	1999	We reviewed the records of 9 children (6 girls, 3 boys) with NF-1 associated OPT who were treated with the second generation platinum compound carboplatin.	Platinum	125-133	neurofibromin 1	Homo sapiens	61-65
10076573-6	1999	The intracellular platinum content of PC-14/HMG2 after exposure to 300 microM CDDP was 1.1 and 1.5 times that of PC-14 and PC-14/CMV, respectively.	Platinum	18-26	high mobility group box 2	Homo sapiens	44-48
9891461-2	1998	In this study, we examined lung-resistance protein (LRP) gene expression in vivo and in vitro in relation to platinum drug exposure.	Platinum	109-117	major vault protein	Homo sapiens	27-50
9891461-2	1998	In this study, we examined lung-resistance protein (LRP) gene expression in vivo and in vitro in relation to platinum drug exposure.	Platinum	109-117	major vault protein	Homo sapiens	52-55
9891461-3	1998	MATERIALS AND METHODS: The expression levels of the LRP gene were assessed by the reverse transcription polymerase chain reaction, in 80 autopsy samples (40 lung tumors and 40 corresponding normal lung tissues), two lung cancer cell lines and in peripheral mononuclear cells collected from 8 lung cancer patients before and after platinum drug administration.	Platinum	330-338	major vault protein	Homo sapiens	52-55
10367750-11	1999	The sensitization of cancer cells under the GRP-inducing stress conditions would explain, in part, the clinical potency of platinum drugs against solid tumors.	Platinum	123-131	gastrin releasing peptide	Homo sapiens	44-47
9841903-2	1999	A mutation of mouse tyrosinase, platinum (cp), leads to truncation of tyrosinase"s cytosolic tail, and results in misrouting to the cell periphery.	Platinum	32-40	tyrosinase	Mus musculus	20-30
9841903-2	1999	A mutation of mouse tyrosinase, platinum (cp), leads to truncation of tyrosinase"s cytosolic tail, and results in misrouting to the cell periphery.	Platinum	32-40	tyrosinase	Mus musculus	70-80
9813242-0	1998	The Kruppel-type zinc finger family gene, HKR1, is induced in lung cancer by exposure to platinum drugs.	Platinum	89-97	zinc finger protein 875	Homo sapiens	42-46
9813242-1	1998	To investigate the molecular mechanism associated with the signaling pathway of platinum drug administration, we focused on the C2H2-type zinc finger (ZNF) transcription factor gene family.	Platinum	80-88	zinc finger protein 763	Homo sapiens	151-154
9813242-5	1998	These results suggest that HKR1 may be associated with the regulation of a signaling pathway involved in the progression of lung cancer or the acquisition of resistance to platinum drugs.	Platinum	172-180	zinc finger protein 875	Homo sapiens	27-31
9891461-4	1998	RESULTS: The LRP gene expression levels of autopsy specimens exposed antemortem to platinum drugs were not significantly different to those of specimens without platinum drug exposure, for both lung tumors and normal lung tissues.	Platinum	83-91	major vault protein	Homo sapiens	13-16
9891541-0	1998	p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy.	Platinum	89-97	BCL2 apoptosis regulator	Homo sapiens	8-13
9688796-0	1998	Successful transcatheter embolotherapy with a new platinum microcoil: the Berenstein Liquid Coil.	Platinum	50-58	coilin	Homo sapiens	92-96
9861196-8	1998	Data exist in human ovarian cancer and in human gastric cancer that ERCC1 may be a useful marker for clinical drug resistance when platinum-based systemic chemotherapy is utilized.	Platinum	131-139	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	68-73
9865478-2	1998	With the injection of cisplatin into mice 3 h after the LPS treatment, platinum was detected in the CCR during the 7 days after the injection, while platinum was not detected in the CCR of cisplatin-injected mice without LPS pretreatment and of mice simultaneous treated with cisplatin and LPS.	Platinum	71-79	toll-like receptor 4	Mus musculus	56-59
9865478-4	1998	A dose of 5 mg/kg of aminoguanidine reduced the increase in the platinum level of the LPS-treated mouse, and platinum was no longer detected at doses of 20 mg/kg in the aminoguanidine-injected group.	Platinum	64-72	toll-like receptor 4	Mus musculus	86-89
9785333-7	1998	The causative mechanism of platinum-induced anaemia is reported to be, beside myelosuppression, a deficient production of erythropoietin (EPO) resulting from drug-induced renal tubular damage.	Platinum	27-35	erythropoietin	Homo sapiens	122-136
9785333-7	1998	The causative mechanism of platinum-induced anaemia is reported to be, beside myelosuppression, a deficient production of erythropoietin (EPO) resulting from drug-induced renal tubular damage.	Platinum	27-35	erythropoietin	Homo sapiens	138-141
9820175-0	1998	Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent.	Platinum	75-83	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
18967368-3	1998	Some considerations regarding the current signals obtained from flow injection experiments using both a 5- and a 750-mum radius platinum electrode were carried out in order to achieve the lowest limit of detection, a value of 0.03 mumol dm(-3) ferrocyanide being calculated by using the 5-mum radius microelectrode as amperometric detector.	Platinum	128-136	latexin	Homo sapiens	117-120
18967368-3	1998	Some considerations regarding the current signals obtained from flow injection experiments using both a 5- and a 750-mum radius platinum electrode were carried out in order to achieve the lowest limit of detection, a value of 0.03 mumol dm(-3) ferrocyanide being calculated by using the 5-mum radius microelectrode as amperometric detector.	Platinum	128-136	latexin	Homo sapiens	231-234
18967368-5	1998	A 12.5-mum platinum disc microelectrode maintained at +0.2 V vs. Ag/AgCl was used as amperometric detector.	Platinum	11-19	latexin	Homo sapiens	7-10
9792802-4	1998	Immunoblot analysis revealed that ET-1 induced a concentration-dependent protein tyrosine (PT) phosphorylation.	Platinum	91-93	endothelin-1	Sus scrofa	34-38
9738115-1	1998	Endovascular technique, primarily employing electrolytically detachable platinum coils--the Guglielmi Detachable Coil system--is a viable therapeutic option for the management of many intracranial aneurysms.	Platinum	72-80	coilin	Homo sapiens	113-117
9714063-11	1998	Our results suggest an overall association between wild type P53 and radiation and platinum drug sensitivity in these ovarian cancer cell lines.	Platinum	83-91	tumor protein p53	Homo sapiens	61-64
9708936-2	1998	BACKGROUND: The purpose of this study was to analyze whether the addition of granulocyte-colony stimulating factor (G-CSF) to platinum-based combination chemotherapy could increase platinum dose intensity and response rates and decrease hematologic toxicity in patients with advanced epithelial ovarian carcinoma.	Platinum	181-189	colony stimulating factor 3	Homo sapiens	77-114
9708936-2	1998	BACKGROUND: The purpose of this study was to analyze whether the addition of granulocyte-colony stimulating factor (G-CSF) to platinum-based combination chemotherapy could increase platinum dose intensity and response rates and decrease hematologic toxicity in patients with advanced epithelial ovarian carcinoma.	Platinum	181-189	colony stimulating factor 3	Homo sapiens	116-121
9708936-11	1998	CONCLUSIONS; The addition of G-CSF to this platinum-based chemotherapy regimen in patients with advanced ovarian carcinoma resulted in a modest increment in platinum dose intensity and appeared to reduce the incidence of Grade 3-4 neutropenia.	Platinum	43-51	colony stimulating factor 3	Homo sapiens	29-34
9708936-11	1998	CONCLUSIONS; The addition of G-CSF to this platinum-based chemotherapy regimen in patients with advanced ovarian carcinoma resulted in a modest increment in platinum dose intensity and appeared to reduce the incidence of Grade 3-4 neutropenia.	Platinum	157-165	colony stimulating factor 3	Homo sapiens	29-34
9688796-1	1998	PURPOSE: To determine the usefulness of a new platinum microcoil, the Berenstein Liquid Coil for vascular embolization.	Platinum	46-54	coilin	Homo sapiens	88-92
9649119-7	1998	The drug was found to significantly overcome platinum resistance in the 2780CP and the CH1 cisR cell lines and in the bcl-2 and the mutant p53 transfectants of A2780 cells.	Platinum	45-53	SUN domain containing ossification factor	Homo sapiens	87-90
9738983-8	1998	Platinum compounds induced cytokine production in human EC: cisplatin most prominently induced the release of IL-1 and IL-6, and TRK-710 had the greatest ability to induce the release of GM-CSF.	Platinum	0-8	interleukin 1 alpha	Homo sapiens	110-114
9738983-8	1998	Platinum compounds induced cytokine production in human EC: cisplatin most prominently induced the release of IL-1 and IL-6, and TRK-710 had the greatest ability to induce the release of GM-CSF.	Platinum	0-8	interleukin 6	Homo sapiens	119-123
9738983-8	1998	Platinum compounds induced cytokine production in human EC: cisplatin most prominently induced the release of IL-1 and IL-6, and TRK-710 had the greatest ability to induce the release of GM-CSF.	Platinum	0-8	colony stimulating factor 2	Homo sapiens	187-193
9738983-9	1998	Intracellular H2O2 production and IL-8 release were transiently induced immediately after treatment with platinum compounds, leading to IL-1 release when H2O2 production was eliminated.	Platinum	105-113	C-X-C motif chemokine ligand 8	Homo sapiens	34-38
9738983-9	1998	Intracellular H2O2 production and IL-8 release were transiently induced immediately after treatment with platinum compounds, leading to IL-1 release when H2O2 production was eliminated.	Platinum	105-113	interleukin 1 alpha	Homo sapiens	136-140
9873383-4	1998	cis-Dichloro-bis(2-aminohexadecanol)platinum(II) was the most active against P388, NSCLC-N6 and E39 (IC50: 11 micrograms/ml, 25 micrograms/ml, 31 micrograms/ml), while dichloro(1,3-heptadecanediamine)platinum(II) presented the highest activity against M96 (IC50: 13 micrograms/ml).	Platinum	36-44	metal response element binding transcription factor 2	Homo sapiens	252-255
9600857-9	1998	Under conditions where we can determine DeltaG degrees obs, DeltaS degrees obs, and DeltaHobs (25 degrees C, pH 8.1, 0.17 to 2 M NaBr), SSB binding to dT(pT)69 is enthalpically driven with a large unfavorable entropic contribution, both of which are dependent upon [NaBr].	Platinum	154-156	single-stranded DNA-binding protein	Escherichia coli	136-139
9671326-7	1998	Furthermore, epoetin alfa will reduce the degree of anemia and markedly reduce the need for transfusions, thereby preventing anemia in patients undergoing multiple cycles of platinum-based combination chemotherapy.	Platinum	174-182	erythropoietin	Homo sapiens	13-20
9813972-0	1998	The effect of subcutaneous recombinant human erythropoietin (r-HuEPO) on anemia in cancer patients receiving platinum-based chemotherapy.	Platinum	109-117	erythropoietin	Homo sapiens	45-59
9673402-3	1998	The mechanism of CDDP resistance was a significant decrease of intracellular platinum accumulation which was 40% of that in OST cells.	Platinum	77-85	dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit	Homo sapiens	124-127
9673402-4	1998	OST/R cells were exposed to CDDP for 6 hours, the platinum was released from the cytoplasm of OST/R cells without reaching a state of equilibrium.	Platinum	50-58	dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit	Homo sapiens	0-3
9673402-4	1998	OST/R cells were exposed to CDDP for 6 hours, the platinum was released from the cytoplasm of OST/R cells without reaching a state of equilibrium.	Platinum	50-58	dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit	Homo sapiens	94-97
9646496-2	1998	After purification of the sample extract with silica, in the multidimensional chromatographic method nitroarenes were separated on a RP18 precolumn from matrix constituents followed by on-line reduction to corresponding aminoarenes with a Pt catalyst on alumina and a further separation of 1-aminopyrene on a second RP18 column.	Platinum	239-241	pre-mRNA processing factor 3	Homo sapiens	316-320
9797696-10	1998	There was a statistically significant dose-response effect of platinum-based chemotherapy in patients with p53 negative tumours, which could not be seen in patients with p53 positive tumours (P = 0.01 versus P = 0.553).	Platinum	62-70	tumor protein p53	Homo sapiens	107-110
9583724-0	1998	Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer.	Platinum	76-84	folate receptor alpha	Homo sapiens	14-36
9628560-1	1998	SKI 2053R, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolan e] platinum(II), is a newly developed antitumor platinum complex derived from cisplatin.	Platinum	81-89	Ski proto-oncogene	Rattus norvegicus	0-3
9679554-1	1998	We examined the correlation between response to platinum-based chemotherapy and expression of glutathione S-transferase (GST), gamma-GGT (both by immunohistochemistry) and gamma-GCS (by in situ hybridization) in 51 patients with head and neck cancer, who received a total of 56 courses of chemotherapy.	Platinum	48-56	glutathione S-transferase kappa 1	Homo sapiens	94-119
9679554-1	1998	We examined the correlation between response to platinum-based chemotherapy and expression of glutathione S-transferase (GST), gamma-GGT (both by immunohistochemistry) and gamma-GCS (by in situ hybridization) in 51 patients with head and neck cancer, who received a total of 56 courses of chemotherapy.	Platinum	48-56	glutathione S-transferase kappa 1	Homo sapiens	121-124
9679554-8	1998	We conclude that GST expression correlates well with response to platinum based chemotherapy in head and neck cancer.	Platinum	65-73	glutathione S-transferase kappa 1	Homo sapiens	17-20
9569044-3	1998	Both subunits (heavy and light subunits) of gamma-GCS expression levels of normal lung and tumour tissues exposed to platinum drugs during life were significantly higher than those of non-exposed tissues, whereas only the MRP expression levels of tumours were elevated in association with ante-mortem platinum drug exposure.	Platinum	301-309	glutamate-cysteine ligase catalytic subunit	Homo sapiens	44-53
9636834-12	1998	Analysis of DNA platination revealed a slight decrease of DNA-bound platinum only in IGROV-1/Pt1 cells.	Platinum	68-76	zinc finger protein 77	Homo sapiens	93-96
9569044-7	1998	These results suggest that gamma-GCS expression is induced by platinum drugs in vivo and/or the physiological stress response to xenobiotics.	Platinum	62-70	glutamate-cysteine ligase catalytic subunit	Homo sapiens	27-36
9569044-0	1998	Expression of gamma-glutamylcysteine synthetase (gamma-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs.	Platinum	242-250	glutamate-cysteine ligase catalytic subunit	Homo sapiens	14-47
9569044-0	1998	Expression of gamma-glutamylcysteine synthetase (gamma-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs.	Platinum	242-250	glutamate-cysteine ligase catalytic subunit	Homo sapiens	49-58
9484843-9	1998	Inhibition of tyrosine phosphatases by orthovanadate pretreatment prolongs the time of JNK induction in response to both platinum compounds.	Platinum	121-129	mitogen-activated protein kinase 8	Homo sapiens	87-90
9569044-3	1998	Both subunits (heavy and light subunits) of gamma-GCS expression levels of normal lung and tumour tissues exposed to platinum drugs during life were significantly higher than those of non-exposed tissues, whereas only the MRP expression levels of tumours were elevated in association with ante-mortem platinum drug exposure.	Platinum	117-125	glutamate-cysteine ligase catalytic subunit	Homo sapiens	44-53
9752298-8	1998	RESULTS: The key recommendations are: 1) the use of recombinant human erythropoietin in oncology is validated for chemotherapy-induced anemia when the chemotherapeutic regimen contains platinum.	Platinum	185-193	erythropoietin	Homo sapiens	70-84
9491756-1	1998	A layer-by-layer structure of enzyme multilayers composed of glucose oxidase (GOx) or lactate oxidase (LOx) and ascorbate oxidase (AOx) was prepared on the surface of a platinum electrode.	Platinum	169-177	hydroxyacid oxidase 1	Homo sapiens	61-76
9491756-1	1998	A layer-by-layer structure of enzyme multilayers composed of glucose oxidase (GOx) or lactate oxidase (LOx) and ascorbate oxidase (AOx) was prepared on the surface of a platinum electrode.	Platinum	169-177	lysyl oxidase	Homo sapiens	86-101
9491756-1	1998	A layer-by-layer structure of enzyme multilayers composed of glucose oxidase (GOx) or lactate oxidase (LOx) and ascorbate oxidase (AOx) was prepared on the surface of a platinum electrode.	Platinum	169-177	lysyl oxidase	Homo sapiens	103-106
9491756-1	1998	A layer-by-layer structure of enzyme multilayers composed of glucose oxidase (GOx) or lactate oxidase (LOx) and ascorbate oxidase (AOx) was prepared on the surface of a platinum electrode.	Platinum	169-177	acyl-CoA oxidase 1	Homo sapiens	112-129
9491756-1	1998	A layer-by-layer structure of enzyme multilayers composed of glucose oxidase (GOx) or lactate oxidase (LOx) and ascorbate oxidase (AOx) was prepared on the surface of a platinum electrode.	Platinum	169-177	acyl-CoA oxidase 1	Homo sapiens	131-134
9609393-10	1998	Indeed, an inverse dose-response relationship for IFN-gamma expression was exhibited by all three platinum salts, suggestive of the elaboration by platinum salt activated LNC of an inhibitory factor or factors for IFN-gamma.	Platinum	98-106	interferon gamma	Mus musculus	50-59
9443623-5	1998	The amount of platinum accumulated from SKI 2053R into MKN-45 cells was greater for the treatment involving low concentrations and long-term exposures (12 and 24 h) than for that using high concentrations and short-term exposures (1 and 4 h) at the constant C x T values; however, the increased accumulation of CDDP was more prominent as the concentration was increased, even if the exposure time became shorter.	Platinum	311-315	SKI proto-oncogene	Homo sapiens	40-43
9492322-12	1998	Each enzymatic form was cross-linked to tRNA(Lys3) in the presence of a platinum derivative, giving different ribonucleoprotein complexes of molecular masses higher than 100 kDa, suggesting that primer tRNA may interact with both subunits in the heterodimeric enzyme.	Platinum	72-80	mitochondrially encoded tRNA glycine	Homo sapiens	40-49
9443623-8	1998	The peak levels of ultrafiltrable platinum observed for SKI 2053R at the 1-, 4-, 12-, and 24-h infusions were 3.10+/-0.49 (mean +/- SD), 1.24+/-0.06, 0.43+/-0.07, and 0.25+/-0.04 microg/ml, respectively.	Platinum	34-42	SKI proto-oncogene	Homo sapiens	56-59
9443623-5	1998	The amount of platinum accumulated from SKI 2053R into MKN-45 cells was greater for the treatment involving low concentrations and long-term exposures (12 and 24 h) than for that using high concentrations and short-term exposures (1 and 4 h) at the constant C x T values; however, the increased accumulation of CDDP was more prominent as the concentration was increased, even if the exposure time became shorter.	Platinum	14-22	SKI proto-oncogene	Homo sapiens	40-43
9443623-9	1998	The mean binding ratios of platinum from SKI 2053R to plasma protein at the end of 1-, 4-, 12-, and 24-h infusions were approximately 91%, 73%, 53%, and 51%, respectively.	Platinum	27-35	SKI proto-oncogene	Homo sapiens	41-44
9464331-10	1998	Accordingly, consolidation chemotherapy is necessary for patients with stage I a who are positive p53 and highly PA. Platinum-based chemotherapy for patients who had minimal residual tumor was effective, but 5 patients who had &gt; or = 2 cm tumor burden were not effective at all.	Platinum	117-125	tumor protein p53	Homo sapiens	98-101
9464331-11	1998	The response rate for platinum-based chemotherapy was 20% (1/5) among p53 positive, in contrast to 66.7% (4/6) among p53 negative patients.	Platinum	22-30	tumor protein p53	Homo sapiens	70-73
9423164-1	1997	The plasma disposition kinetics and tissue distribution of platinum was evaluated following intravenous bolus administration to CD1 immune-competent mice of cisplatin, cisplatin conjugated to anti-CEA monoclonal antibody A5B7 via a carboxymethyl dextran (CMdextran) carrier molecule, and cisplatin coupled to the CMdextran in the absence of antibody.	Platinum	59-67	CD1 antigen complex	Mus musculus	128-131
9435172-5	1998	Treatment with diethyldithiocarbamic acid (a drug protecting against cDDP nephrotoxicity), immediately after cDDP exposure, 1) partially lifted the cDDP-induced inhibition of the Na+/glucose cotransporter, 2) reduced platinum binding to BBM vesicles, but 3) did not modify the cDDP-induced decrease in protein-bound thiols.	Platinum	217-225	sodium/nucleoside cotransporter	Oryctolagus cuniculus	179-207
9475194-7	1998	We conclude that there is a significant total dose-response effect of platin-based chemotherapy in ovarian cancer patients without overexpression of c-erbB-2 but not in patients with c-erbB-2 overexpression.	Platinum	70-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	149-157
9383735-9	1997	Antioxidants, such as methionine, sodium thiosulfate, catalase, or platinum, prevented Met oxidation in rhuMAb HER2, presumably as free radicals or oxygen scavengers.	Platinum	67-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115
9298962-4	1997	Alteration of the nucleotides flanking the platinum lesion modulated HMG1domA recognition in this series by over 2 orders of magnitude and revealed an unprecedented preference for N2 = dA &gt; T &gt; dC.	Platinum	43-51	high mobility group box 1 pseudogene 5	Homo sapiens	69-73
18372523-0	1997	Relationship between heat shock protein 60 (HSP60) mRNA expression and resistance to platinum analogues in human ovarian and bladder carcinoma cell lines.	Platinum	85-93	heat shock protein family D (Hsp60) member 1	Homo sapiens	21-42
18372523-0	1997	Relationship between heat shock protein 60 (HSP60) mRNA expression and resistance to platinum analogues in human ovarian and bladder carcinoma cell lines.	Platinum	85-93	heat shock protein family D (Hsp60) member 1	Homo sapiens	44-49
18372523-6	1997	These data provide further evidence of a strong association between in vitro resistance to platinum compounds and increased HSP60 mRNA expression.	Platinum	91-99	heat shock protein family D (Hsp60) member 1	Homo sapiens	124-129
9379182-3	1997	The platinum compounds (compounds I and II) were used to modify DNA, which was then used in electrophoretic mobility shift assays with the high mobility group (HMG)-do-main protein, HMG1.	Platinum	4-12	high mobility group box 1 pseudogene 5	Homo sapiens	182-186
9298962-7	1997	The platinum-dependent recognition of the N1 = N2 = dA 15-bp probe saturates at 1 equiv of HMG1domA and is highly specific, as evidenced by the 1000-fold decrease in HMG1domA binding affinity for the corresponding unplatinated oligonucleotide.	Platinum	4-12	high mobility group box 1 pseudogene 5	Homo sapiens	91-95
9298962-7	1997	The platinum-dependent recognition of the N1 = N2 = dA 15-bp probe saturates at 1 equiv of HMG1domA and is highly specific, as evidenced by the 1000-fold decrease in HMG1domA binding affinity for the corresponding unplatinated oligonucleotide.	Platinum	4-12	high mobility group box 1 pseudogene 5	Homo sapiens	166-170
9360634-9	1997	Our data suggest that this alteration at codon 118 within the ERCC1 gene, may exist in platinum-sensitive and platinum-resistant ovarian cancer tissues.	Platinum	87-95	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	62-67
9380409-3	1997	Here we show that induction of PT is sufficient to activate CPP32-like proteases with DEVDase activity and the associated cleavage of the nuclear DEVDase substrate poly(ADP-ribose) polymerase (PARP).	Platinum	31-33	caspase 3	Homo sapiens	60-65
9380409-3	1997	Here we show that induction of PT is sufficient to activate CPP32-like proteases with DEVDase activity and the associated cleavage of the nuclear DEVDase substrate poly(ADP-ribose) polymerase (PARP).	Platinum	31-33	poly(ADP-ribose) polymerase 1	Homo sapiens	193-197
9413223-5	1997	Plasma concentrations of total and ultrafiltrable platinum for SKI 2034R declined in a biexponential fashion.	Platinum	50-58	SKI proto-oncogene	Canis lupus familiaris	63-66
9413223-6	1997	The mean area under the concentration-time curve (AUC0--&gt;infinity) determined for ultrafiltrable platinum derived from SKI 2034R, as an active component, was 2.76 +/- 0.13 micrograms.h/ml (mean +/- S.D.	Platinum	100-108	SKI proto-oncogene	Canis lupus familiaris	122-125
9360634-9	1997	Our data suggest that this alteration at codon 118 within the ERCC1 gene, may exist in platinum-sensitive and platinum-resistant ovarian cancer tissues.	Platinum	110-118	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	62-67
29389283-12	1997	Animals treated with c/s-platinum demonstrated significant elevation of DPOAE and ABR thresholds compared with control animals at 5 and 14 days.	Platinum	23-33	ABR activator of RhoGEF and GTPase	Homo sapiens	82-85
9765749-22	1997	The evidence in support of using EPO is stronger for patients receiving platinum-based chemotherapy regimens that for those receiving non-platinum-based regimens.	Platinum	72-80	erythropoietin	Homo sapiens	33-36
9765749-22	1997	The evidence in support of using EPO is stronger for patients receiving platinum-based chemotherapy regimens that for those receiving non-platinum-based regimens.	Platinum	138-146	erythropoietin	Homo sapiens	33-36
9487380-6	1997	A decreased EPO production is often relevant; anemia due to renal damage (platinum compounds, anfotericin B) with decreased EPO production.	Platinum	74-82	erythropoietin	Homo sapiens	12-15
9487381-21	1997	After standard dose chemotherapy, phase III randomized studies showed that erythropoietin is able to correct anemia in 60-80% of patients receiving platinum-based chemotherapy and in nearly 40% of patients receiving chemotherapy without platinum.	Platinum	148-156	erythropoietin	Homo sapiens	75-89
9487381-21	1997	After standard dose chemotherapy, phase III randomized studies showed that erythropoietin is able to correct anemia in 60-80% of patients receiving platinum-based chemotherapy and in nearly 40% of patients receiving chemotherapy without platinum.	Platinum	237-245	erythropoietin	Homo sapiens	75-89
9487381-29	1997	Erythropoietin is effective in 60-80% of anemic patients receiving platinum-containing chemotherapy and in approximately 40% of patients receiving chemotherapy without platinum.	Platinum	67-75	erythropoietin	Homo sapiens	0-14
9487381-29	1997	Erythropoietin is effective in 60-80% of anemic patients receiving platinum-containing chemotherapy and in approximately 40% of patients receiving chemotherapy without platinum.	Platinum	168-176	erythropoietin	Homo sapiens	0-14
10762913-1	1997	Nitinol Glidewire with Platinum Coil.	Platinum	23-31	coilin	Homo sapiens	32-36
11669744-19	1997	The Pt.Cu-X angle is interestingly less than 90 degrees, resulting in a relatively short interatomic distance between the terminal Pt and X atoms.	Platinum	4-6	cut like homeobox 1	Homo sapiens	7-11
9137537-6	1997	After exposure to CDDP for 4 h, the intracellular platinum content of OCUM-2M cells was significantly higher than that of OCUM-2M/DDP cells (51.9 +/- 1.8 vs 16.4 plus 1.0 ng/mg protein, mean +/- SD, respectively).	Platinum	50-58	translocase of inner mitochondrial membrane 8A	Homo sapiens	19-22
9012749-7	1997	Platinum/carbon replicas and thin sections of fracture-label specimens permitted high-resolution visualization of the distribution of dystrophin in plane views of the freeze-fractured plasma membrane and in relation to the sarcomeric banding patterns of the underlying myofibrils.	Platinum	0-8	dystrophin	Rattus norvegicus	134-144
9040103-4	1997	Urinary excretion of platinum (Pt) was increased when animals were dosed with the cisplatin-AL-1 complex, but not with the cisplatin-AL-2 complex.	Platinum	21-29	ephrin A5	Mus musculus	92-96
9040103-4	1997	Urinary excretion of platinum (Pt) was increased when animals were dosed with the cisplatin-AL-1 complex, but not with the cisplatin-AL-2 complex.	Platinum	31-33	ephrin A5	Mus musculus	92-96
9040103-7	1997	Complexation of cisplatin with alginates, especially AL-1, inhibited the accumulation of Pt in the kidneys and reduced blood urea nitrogen elevation by cisplatin.	Platinum	89-91	ephrin A5	Mus musculus	53-57
9252194-2	1997	The antibody GPt, derived after immunization of rabbits with highly platinated DNA and purified with affinity chromatography, detected the main platinum (Pt)-containing intrastrand and interstrand adducts.	Platinum	144-152	glutamic--pyruvic transaminase	Homo sapiens	13-16
8996528-12	1997	The more cytotoxic platinum analog, ormaplatin, also induced gadd153 and its induction was also based on cytotoxicity.	Platinum	19-27	DNA damage inducible transcript 3	Homo sapiens	61-68
9063478-1	1997	The gene transfectant with gamma-glutamylcysteine synthetase (gamma-GCS) gene, a rate limiting enzyme in GSH biosynthesis, exerted increased GSH content and ATP-dependent glutathione S-conjugate export pump (GS-X pump) decreased intracellular platinum and sensitivity against cisplatin.	Platinum	243-251	glutamate-cysteine ligase catalytic subunit	Homo sapiens	27-60
9063478-1	1997	The gene transfectant with gamma-glutamylcysteine synthetase (gamma-GCS) gene, a rate limiting enzyme in GSH biosynthesis, exerted increased GSH content and ATP-dependent glutathione S-conjugate export pump (GS-X pump) decreased intracellular platinum and sensitivity against cisplatin.	Platinum	243-251	glutamate-cysteine ligase catalytic subunit	Homo sapiens	62-71
9066588-10	1997	After 5 years 63% of the patients with negative versus 25% with positive EGFR were still alive indicating the impaired response of EGFR positive carcinomas to chemotherapy containing platinum compounds.	Platinum	183-191	epidermal growth factor receptor	Homo sapiens	73-77
9066588-10	1997	After 5 years 63% of the patients with negative versus 25% with positive EGFR were still alive indicating the impaired response of EGFR positive carcinomas to chemotherapy containing platinum compounds.	Platinum	183-191	epidermal growth factor receptor	Homo sapiens	131-135
8938138-7	1996	Potentiation of the anti-tumor activity of carboplatin by IL-1alpha was due to a significant (3- to 4-fold) increase in the accumulation of total Pt in IL-1-treated tumor xenograft, resulting in a 2-fold increase in DNA-Pt adduct formation in these tumors.	Platinum	146-148	interleukin 1 alpha	Homo sapiens	58-67
8978548-0	1996	Electrochemical Studies of the Interfacial Behavior of Insulin The interfacial behavior of insulin and chain A and chain B of insulin was investigated at the platinum electrode in a phosphate buffer, pH 7.0, using cyclic voltammetry.	Platinum	158-166	insulin	Homo sapiens	91-98
8978548-0	1996	Electrochemical Studies of the Interfacial Behavior of Insulin The interfacial behavior of insulin and chain A and chain B of insulin was investigated at the platinum electrode in a phosphate buffer, pH 7.0, using cyclic voltammetry.	Platinum	158-166	insulin	Homo sapiens	126-133
21781737-7	1996	Both SOD and catalase significantly lowered platinum content in the cerebral cortex following cisplatin administration in mice treated with LPS.	Platinum	44-52	catalase	Mus musculus	13-21
9042689-3	1996	Platelet activator substances and coagulation components thrombin and fibrinogen, were adsorbed onto respective series of platinum wire.	Platinum	122-135	coagulation factor II	Rattus norvegicus	57-65
8938138-7	1996	Potentiation of the anti-tumor activity of carboplatin by IL-1alpha was due to a significant (3- to 4-fold) increase in the accumulation of total Pt in IL-1-treated tumor xenograft, resulting in a 2-fold increase in DNA-Pt adduct formation in these tumors.	Platinum	146-148	interleukin 1 alpha	Homo sapiens	58-62
8971349-3	1996	When mice were treated with either allopurinol (20 mg/kg) or catalase (100 mg/kg) before cisplatin administration and low oxygen exposure, Pt was not detected in the cerebral cortex.	Platinum	139-141	catalase	Mus musculus	61-69
9042215-4	1996	Among the 21 patients with stage III-IV disease, a complete clinical response to front-line platinum-based chemotherapy was obtained by 46.2% of the 13 patients without anti-p53 antibodies and 25.0% of the 8 patients with anti-p53 antibodies.	Platinum	92-100	tumor protein p53	Homo sapiens	174-177
9042215-4	1996	Among the 21 patients with stage III-IV disease, a complete clinical response to front-line platinum-based chemotherapy was obtained by 46.2% of the 13 patients without anti-p53 antibodies and 25.0% of the 8 patients with anti-p53 antibodies.	Platinum	92-100	tumor protein p53	Homo sapiens	227-230
9816141-0	1996	Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer.	Platinum	80-88	glutathione S-transferase kappa 1	Homo sapiens	33-58
9816141-3	1996	We examined the correlation between expression of GSTs determined by immunohistochemistry and clinical response to platinum-based chemotherapy in 51 patients with head and neck cancer, who received a total of 56 courses of chemotherapy.	Platinum	115-123	glutathione S-transferase kappa 1	Homo sapiens	50-54
8932334-7	1996	Accumulation of platinum into PC-9 and PC-9/CDDP was increased by the treatment in a dose-dependent manner.	Platinum	16-24	proprotein convertase subtilisin/kexin type 9	Homo sapiens	30-34
8930899-8	1996	Platinum/carbon replicas of the fibroblast surface incubated either with lipoprotein lipase or antiheparan sulfate showed large aggregates of HSPGs regularly distributed along cytoplasmic fibers.	Platinum	0-8	lipoprotein lipase	Homo sapiens	73-91
8920766-5	1996	GGT activity was assayed in homogenates of surgical samples of ovarian tumors and compared with the clinical data of the patients in order to establish: a) the level of tumor GGT activity, b) its correlation with other clinical parameters of the neoplasms, c) the possibility of the induction in vivo of GGT after anticancer platinum-based therapy, since some of the patients were pretreated.	Platinum	325-333	inactive glutathione hydrolase 2	Homo sapiens	0-3
8920766-7	1996	The sensitive method used in this study allowed the quantitative evaluation of enzyme activity in all samples examined, showing that GGT activity values in ovarian carcinoma samples were extremely variable among the different subjects, both in untreated neoplasms (6.2 +/- 5.4 mU/mg protein) and in second-look laparotomy biopsies following platinum-based therapy (4.7 +/- 3.8 mU/mg protein).	Platinum	341-349	inactive glutathione hydrolase 2	Homo sapiens	133-136
11666688-5	1996	The crystal structures of Pt(bhq)(2) (1) and Pt(thq)(2) (3) present an important distortion of the square planar (SP-4) geometry toward a two-bladed helix.	Platinum	26-28	Sp4 transcription factor	Homo sapiens	114-118
9044710-1	1996	Divalent platinum compounds: cis-dichlorodiammineplatinum (II) (DDP) and its new macromolecular complexes poly (hexacis[chloroammineaquaplatinum(II)])-micro- deoxyribonucleats (MCP) have been used for the first time as the cell culture synchronization inductors.	Platinum	9-17	CD46 molecule	Homo sapiens	177-180
9275551-8	1996	CONCLUSIONS: The primary factor causing COC1/DDP resistance to DDP is the reduction of intracellular platinum accumulation and DNA ISC formation.	Platinum	101-109	translocase of inner mitochondrial membrane 8A	Homo sapiens	45-48
9275551-8	1996	CONCLUSIONS: The primary factor causing COC1/DDP resistance to DDP is the reduction of intracellular platinum accumulation and DNA ISC formation.	Platinum	101-109	translocase of inner mitochondrial membrane 8A	Homo sapiens	63-66
11666689-0	1996	Square Planar (SP-4) and Octahedral (OC-6) Complexes of Platinum(II) and -(IV) with Predetermined Chirality at the Metal Center.	Platinum	56-64	Sp4 transcription factor	Homo sapiens	15-19
22666910-4	1996	Such TEM-tomography proved that Pt-ion exchanged FAU zeolite crystals, after reduction and oxidation, are occupied internally and randomly of large platinum clusters mainly in the {111-twin planes.	Platinum	32-34	FAU ubiquitin like and ribosomal protein S30 fusion	Homo sapiens	49-52
8689632-3	1996	We have isolated sublines of the A2780 ovarian carcinoma cell line (C10 and C25) that are 8- and 12-fold resistant to oxaliplatin by repeatedly exposing the cells to increasing concentrations of the platinum agent.	Platinum	199-207	homeobox C10	Homo sapiens	68-71
8639546-2	1996	The oxidized form (2), PT, which is present in solutions of PTH2, was shown to be the actual inhibitory species which irreversibly inactivates the protease; recycling of PTH2 by dissolved oxygen results in complete inhibition of the protease at substoichiometric amounts of compound.	Platinum	23-25	parathyroid hormone 2	Homo sapiens	60-64
8639546-2	1996	The oxidized form (2), PT, which is present in solutions of PTH2, was shown to be the actual inhibitory species which irreversibly inactivates the protease; recycling of PTH2 by dissolved oxygen results in complete inhibition of the protease at substoichiometric amounts of compound.	Platinum	23-25	parathyroid hormone 2	Homo sapiens	170-174
8702230-5	1996	Plasma concentrations of total and ultrafiltrable platinum for SKI 2032R declined in a biexponential fashion.	Platinum	50-58	SKI proto-oncogene	Canis lupus familiaris	63-66
8702230-6	1996	The mean area under the concentration-time curve (AUC0 --&gt; infinity) determined for ultrafiltrable platinum derived from SKI 2032R, as an active component, was 2.36 +/- 0.23 micrograms.	Platinum	102-110	SKI proto-oncogene	Canis lupus familiaris	124-127
8911126-2	1996	In this phase I study, IL-1 alpha was administered by a continuous intravenous infusion at doses ranging 0.1-10 micrograms/m2 every 24 h for 4 days (96 h) 3 weeks before the first dose of carboplatin (400 mg/m2) in patients with potentially platinum-sensitive ovarian cancer.	Platinum	241-249	interleukin 1 alpha	Homo sapiens	23-33
8807890-3	1996	RESULTS: We have shown that the human mismatch-repair protein, hMSH2, also binds specifically to DNA containing cisplatin adducts and displays selectivity for the DNA adducts of therapeutically active platinum complexes.	Platinum	201-209	mutS homolog 2	Homo sapiens	63-68
8663001-1	1996	We recently reported that GS-X pump activity, as assessed by ATP-dependent transport of the glutathione-platinum complex and leukotriene C4, and intracellular glutathione (GSH) levels were remarkably enhanced in cis-diamminedichloroplatinum(II) (cisplatin)-resistant human leukemia HL-60 cells (Ishikawa, T., Wright, C. D., and Ishizuka, H. (1994) J. Biol.	Platinum	104-112	ATP binding cassette subfamily C member 1	Homo sapiens	26-30
8681412-1	1996	The adsorption behavior of serum albumin onto the surface of platinum, gold, and glassy carbon electrodes was studied in relation to the electrode potential, by using cyclic voltammetry and a quartz-crystal microbalance.	Platinum	61-69	albumin	Homo sapiens	27-40
15067484-3	1996	5% Pt on alumina has been prepared and characterized by physical methods (ESCA, XRD, TEM, DTA, TG).	Platinum	3-5	MFT2	Homo sapiens	85-88
22666910-4	1996	Such TEM-tomography proved that Pt-ion exchanged FAU zeolite crystals, after reduction and oxidation, are occupied internally and randomly of large platinum clusters mainly in the {111-twin planes.	Platinum	148-156	FAU ubiquitin like and ribosomal protein S30 fusion	Homo sapiens	49-52
8862006-4	1996	In a panel of 61 cancer cell lines which have not been subjected to laboratory drug selection, LRP was a superior predictor for in vitro resistance to MDR-related drugs when compared to Pgp and MRP, and LRP"s predictive value extended to MDR unrelated drugs, such as platinum compounds.	Platinum	267-275	major vault protein	Homo sapiens	95-98
8652559-3	1996	The ability of DNA modified by these platinum complexes to photo-cross-link to HMG1 was investigated.	Platinum	37-45	high mobility group box 1 pseudogene 5	Homo sapiens	79-83
21544361-2	1996	We observed that platinum-resistant tumors showed higher mRNA levels of p53, ERCC1, and XPA than platinum-sensitive tumors; mRNA expression patterns in responders differed substantially from nonresponders; and p53 expression showed a strong correlation with the expression of ERCC1, and of XPA in platinum-sensitive tumor tissues, but not with platinum-resistant tumors.	Platinum	97-105	tumor protein p53	Homo sapiens	210-213
8615617-8	1996	The mean area under the concentration-tine curve (AUC(0)--&gt; infinity) determined for ultrafiltrable platinum derived from SKI 2054R, as an active component was 6.61 +/- 2.34 micrograms .	Platinum	103-111	SKI proto-oncogene	Homo sapiens	125-128
8615617-13	1996	These results suggest that SKI 2054R is a new platinum complex which is worth being evaluated further.	Platinum	46-54	SKI proto-oncogene	Homo sapiens	27-30
21544361-0	1996	Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA.	Platinum	0-8	tumor protein p53	Homo sapiens	126-129
21544361-0	1996	Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA.	Platinum	0-8	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	131-136
21544361-0	1996	Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA.	Platinum	0-8	XPA, DNA damage recognition and repair factor	Homo sapiens	141-144
21544361-0	1996	Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA.	Platinum	23-31	tumor protein p53	Homo sapiens	126-129
21544361-0	1996	Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA.	Platinum	23-31	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	131-136
21544361-0	1996	Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA.	Platinum	23-31	XPA, DNA damage recognition and repair factor	Homo sapiens	141-144
21544361-2	1996	We observed that platinum-resistant tumors showed higher mRNA levels of p53, ERCC1, and XPA than platinum-sensitive tumors; mRNA expression patterns in responders differed substantially from nonresponders; and p53 expression showed a strong correlation with the expression of ERCC1, and of XPA in platinum-sensitive tumor tissues, but not with platinum-resistant tumors.	Platinum	17-25	tumor protein p53	Homo sapiens	72-75
21544361-2	1996	We observed that platinum-resistant tumors showed higher mRNA levels of p53, ERCC1, and XPA than platinum-sensitive tumors; mRNA expression patterns in responders differed substantially from nonresponders; and p53 expression showed a strong correlation with the expression of ERCC1, and of XPA in platinum-sensitive tumor tissues, but not with platinum-resistant tumors.	Platinum	17-25	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	77-82
21544361-2	1996	We observed that platinum-resistant tumors showed higher mRNA levels of p53, ERCC1, and XPA than platinum-sensitive tumors; mRNA expression patterns in responders differed substantially from nonresponders; and p53 expression showed a strong correlation with the expression of ERCC1, and of XPA in platinum-sensitive tumor tissues, but not with platinum-resistant tumors.	Platinum	17-25	XPA, DNA damage recognition and repair factor	Homo sapiens	88-91
21544361-2	1996	We observed that platinum-resistant tumors showed higher mRNA levels of p53, ERCC1, and XPA than platinum-sensitive tumors; mRNA expression patterns in responders differed substantially from nonresponders; and p53 expression showed a strong correlation with the expression of ERCC1, and of XPA in platinum-sensitive tumor tissues, but not with platinum-resistant tumors.	Platinum	17-25	tumor protein p53	Homo sapiens	210-213
21544361-2	1996	We observed that platinum-resistant tumors showed higher mRNA levels of p53, ERCC1, and XPA than platinum-sensitive tumors; mRNA expression patterns in responders differed substantially from nonresponders; and p53 expression showed a strong correlation with the expression of ERCC1, and of XPA in platinum-sensitive tumor tissues, but not with platinum-resistant tumors.	Platinum	17-25	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	276-281
21544361-2	1996	We observed that platinum-resistant tumors showed higher mRNA levels of p53, ERCC1, and XPA than platinum-sensitive tumors; mRNA expression patterns in responders differed substantially from nonresponders; and p53 expression showed a strong correlation with the expression of ERCC1, and of XPA in platinum-sensitive tumor tissues, but not with platinum-resistant tumors.	Platinum	17-25	XPA, DNA damage recognition and repair factor	Homo sapiens	290-293
21544361-2	1996	We observed that platinum-resistant tumors showed higher mRNA levels of p53, ERCC1, and XPA than platinum-sensitive tumors; mRNA expression patterns in responders differed substantially from nonresponders; and p53 expression showed a strong correlation with the expression of ERCC1, and of XPA in platinum-sensitive tumor tissues, but not with platinum-resistant tumors.	Platinum	97-105	tumor protein p53	Homo sapiens	210-213
21544361-2	1996	We observed that platinum-resistant tumors showed higher mRNA levels of p53, ERCC1, and XPA than platinum-sensitive tumors; mRNA expression patterns in responders differed substantially from nonresponders; and p53 expression showed a strong correlation with the expression of ERCC1, and of XPA in platinum-sensitive tumor tissues, but not with platinum-resistant tumors.	Platinum	97-105	tumor protein p53	Homo sapiens	210-213
8862006-6	1996	Furthermore, LRP expression at diagnosis has been shown to be a strong and independent prognostic factor for response to chemotherapy and outcome in acute myeloid leukemia and ovarian carcinoma (platinum-based treatment) patients.	Platinum	195-203	major vault protein	Homo sapiens	13-16
9815949-3	1995	Because both P-glycoprotein- and platinum-induced resistance appear to be clinically important and can be reversed in vitro with a short exposure of cyclosporin A (CSA) at 2000 and 5000 ng/ml, respectively, we undertook a trial of high-dose chemotherapy with carboplatin (1500mg/m2), mitoxantrone (75 mg/m2), and cyclophosphamide (120 mg/kg) over a 5-day period combined with escalating doses of CSA.	Platinum	33-41	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	164-167
9114434-0	1996	Induction of gamma-glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line.	Platinum	51-59	inactive glutathione hydrolase 2	Homo sapiens	13-42
9114434-12	1996	The data suggest that a) single, brief exposures to pharmacologically relevant concentrations of platinum complexes induce elevation in mRNA of gamma-GT, b) elevation in gamma-GT mRNA translates into elevated gamma-GT activity and increase in GSH salvage, and c) the degree of induction of gamma-GT mRNA differs between platinum complexes.	Platinum	97-105	inactive glutathione hydrolase 2	Homo sapiens	144-152
9114434-12	1996	The data suggest that a) single, brief exposures to pharmacologically relevant concentrations of platinum complexes induce elevation in mRNA of gamma-GT, b) elevation in gamma-GT mRNA translates into elevated gamma-GT activity and increase in GSH salvage, and c) the degree of induction of gamma-GT mRNA differs between platinum complexes.	Platinum	97-105	inactive glutathione hydrolase 2	Homo sapiens	170-178
9114434-12	1996	The data suggest that a) single, brief exposures to pharmacologically relevant concentrations of platinum complexes induce elevation in mRNA of gamma-GT, b) elevation in gamma-GT mRNA translates into elevated gamma-GT activity and increase in GSH salvage, and c) the degree of induction of gamma-GT mRNA differs between platinum complexes.	Platinum	97-105	inactive glutathione hydrolase 2	Homo sapiens	170-178
9114434-12	1996	The data suggest that a) single, brief exposures to pharmacologically relevant concentrations of platinum complexes induce elevation in mRNA of gamma-GT, b) elevation in gamma-GT mRNA translates into elevated gamma-GT activity and increase in GSH salvage, and c) the degree of induction of gamma-GT mRNA differs between platinum complexes.	Platinum	97-105	inactive glutathione hydrolase 2	Homo sapiens	170-178
9114434-12	1996	The data suggest that a) single, brief exposures to pharmacologically relevant concentrations of platinum complexes induce elevation in mRNA of gamma-GT, b) elevation in gamma-GT mRNA translates into elevated gamma-GT activity and increase in GSH salvage, and c) the degree of induction of gamma-GT mRNA differs between platinum complexes.	Platinum	320-328	inactive glutathione hydrolase 2	Homo sapiens	144-152
9114434-12	1996	The data suggest that a) single, brief exposures to pharmacologically relevant concentrations of platinum complexes induce elevation in mRNA of gamma-GT, b) elevation in gamma-GT mRNA translates into elevated gamma-GT activity and increase in GSH salvage, and c) the degree of induction of gamma-GT mRNA differs between platinum complexes.	Platinum	320-328	inactive glutathione hydrolase 2	Homo sapiens	170-178
9114434-12	1996	The data suggest that a) single, brief exposures to pharmacologically relevant concentrations of platinum complexes induce elevation in mRNA of gamma-GT, b) elevation in gamma-GT mRNA translates into elevated gamma-GT activity and increase in GSH salvage, and c) the degree of induction of gamma-GT mRNA differs between platinum complexes.	Platinum	320-328	inactive glutathione hydrolase 2	Homo sapiens	170-178
9114434-12	1996	The data suggest that a) single, brief exposures to pharmacologically relevant concentrations of platinum complexes induce elevation in mRNA of gamma-GT, b) elevation in gamma-GT mRNA translates into elevated gamma-GT activity and increase in GSH salvage, and c) the degree of induction of gamma-GT mRNA differs between platinum complexes.	Platinum	320-328	inactive glutathione hydrolase 2	Homo sapiens	170-178
8898974-2	1996	On the basis of this interaction with both endogenous and synthetic substances, glutathione and the key enzyme for its conjugation, glutathione S-transferase, appear to be critical determinants in tumor cell resistance to several antineoplastic drugs, e.g. platinum analogs.	Platinum	257-265	glutathione S-transferase kappa 1	Homo sapiens	132-157
8742842-20	1996	DNA REPAIR: In living cells, higher doses of trans-DDP as compared to cis-DDP are required to bind an equal number of Pt atoms per nucleotide [66].	Platinum	118-120	translocase of inner mitochondrial membrane 8A	Homo sapiens	51-54
8742842-20	1996	DNA REPAIR: In living cells, higher doses of trans-DDP as compared to cis-DDP are required to bind an equal number of Pt atoms per nucleotide [66].	Platinum	118-120	translocase of inner mitochondrial membrane 8A	Homo sapiens	74-77
9815949-3	1995	Because both P-glycoprotein- and platinum-induced resistance appear to be clinically important and can be reversed in vitro with a short exposure of cyclosporin A (CSA) at 2000 and 5000 ng/ml, respectively, we undertook a trial of high-dose chemotherapy with carboplatin (1500mg/m2), mitoxantrone (75 mg/m2), and cyclophosphamide (120 mg/kg) over a 5-day period combined with escalating doses of CSA.	Platinum	33-41	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	396-399
8652251-8	1995	Initially overexpressed in only a few tumours, the c-erbB-2 oncoprotein became overexpressed in 36% of platinum-resistant tumours; this modulation did not occur in platinum-sensitive tumours.	Platinum	103-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-59
7666081-6	1995	RESULTS: Preincubation of platinum-resistant A2780 human ovarian cancer cells with CSA 2 micrograms/mL significantly enhanced CBDCA cytotoxicity in clonogenic assays.	Platinum	26-34	IK cytokine	Homo sapiens	83-88
7591242-8	1995	Our results suggest that IFN alpha-2a-mediated sensitization of SCC-25 and SCC-4 cell lines to CDDP in vitro may be due to an increase in intracellular platinum accumulation.	Platinum	152-160	MAU2 sister chromatid cohesion factor	Homo sapiens	75-80
8654502-0	1995	Misrouting of tyrosinase with a truncated cytoplasmic tail as a result of the murine platinum (cp) mutation.	Platinum	85-93	tyrosinase	Mus musculus	14-24
8654502-1	1995	Mice homozygous for the platinum (cp) allele at the albino locus manifest severe oculocutaneous albinism despite the presence in vitro of tyrosinase activity at 25% wild-type levels.	Platinum	24-32	tyrosinase	Mus musculus	138-148
7666081-12	1995	Steady-state CSA levels of 2 micrograms/mL capable of reversing platinum resistance in vitro were observed.	Platinum	64-72	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	13-16
7563169-16	1995	CONCLUSIONS: Positive Lrp immunostaining in advanced ovarian carcinoma appears to be an indicator of poor response to standard chemotherapy (platinum or alkylating agents) and of adverse prognoses.	Platinum	141-149	ribosomal protein SA	Homo sapiens	22-25
8587776-1	1995	The pharmacokinetics and ototoxicity of the new platinum analogue TRK-710 (3, 9, 15 mg/kg x 3 days) were compared with those of cisplatin (1, 3, 5 mg/kg x 3).	Platinum	48-56	neurotrophic receptor tyrosine kinase 1	Homo sapiens	66-69
8686876-2	1995	Direct electron transfer is now reported for Mb in films of didodecyldimethylammonium bromide (DDAB) on platinum, tin-doped indium oxide, and gold electrodes.	Platinum	104-112	myoglobin	Homo sapiens	45-47
7789893-1	1995	Hexamethylmelamine (HMM) and oral etoposide (VP-16) have shown to be active against platinum-resistant epithelial ovarian cancer.	Platinum	84-92	host cell factor C1	Homo sapiens	45-50
7796401-0	1995	Initiatives with platinum- and quinazoline-based antitumor molecules--Fourteenth Bruce F. Cain Memorial Award Lecture.	Platinum	17-25	calcineurin binding protein 1	Homo sapiens	90-94
7738805-0	1995	In vitro cytotoxicities and in vivo distribution of transferrin-platinum(II) complex.	Platinum	64-72	transferrin	Homo sapiens	52-63
7702192-0	1995	Controlled deposition of glucose oxidase on platinum electrode based on an avidin/biotin system for the regulation of output current of glucose sensors.	Platinum	44-52	hydroxyacid oxidase 1	Homo sapiens	25-40
7628846-8	1995	All PT-positive CCs simultaneously expressed CB, suggesting a close association of PT and CB.	Platinum	4-6	cathepsin B	Homo sapiens	45-47
7628846-8	1995	All PT-positive CCs simultaneously expressed CB, suggesting a close association of PT and CB.	Platinum	4-6	cathepsin B	Homo sapiens	90-92
18966309-3	1995	The results show that most platinum metal ions, Co(II) and Cu(II) can form ternary mixed ligand complexes with MBTAE and salicylic acid.	Platinum	27-35	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	48-54
7603468-7	1995	Further studies showed that IL-1 alpha reduced the removal of platinum from DNA.	Platinum	62-70	interleukin 1 alpha	Homo sapiens	28-38
7733640-0	1995	In vitro antitumor activity of a new platinum complex, cis-malonato [(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum (II) (SKI 2053R), against human lung and stomach cancer cell lines.	Platinum	37-45	SKI proto-oncogene	Homo sapiens	140-143
7497577-6	1995	The mean area under the concentration-time curve (AUC0--&gt;infinity) determined for ultrafiltrable platinum derived from SKI 2053R, as an active component, was 7.72 +/- 2.74 micrograms h ml-1 (mean +/- SD), with an initial half-life of 0.37 +/- 0.20 h, a terminal half-life of 2.19 +/- 0.93 h, a total clearance of 16.83 +/- 4.76 ml min-1 kg-1, and a steady-state volume of distribution of 1.57 +/- 0.30 l/kg.	Platinum	100-108	SKI proto-oncogene	Homo sapiens	122-125
7497577-6	1995	The mean area under the concentration-time curve (AUC0--&gt;infinity) determined for ultrafiltrable platinum derived from SKI 2053R, as an active component, was 7.72 +/- 2.74 micrograms h ml-1 (mean +/- SD), with an initial half-life of 0.37 +/- 0.20 h, a terminal half-life of 2.19 +/- 0.93 h, a total clearance of 16.83 +/- 4.76 ml min-1 kg-1, and a steady-state volume of distribution of 1.57 +/- 0.30 l/kg.	Platinum	100-108	CD59 molecule (CD59 blood group)	Homo sapiens	334-344
8591689-3	1995	The inhibition of fumarase activity by the platinum compounds was followed kinetically by a spectrophotometric method.	Platinum	43-51	fumarate hydratase	Homo sapiens	18-26
7583709-6	1995	Possible mechanisms for this supra-additive relationship between IFN and cDDP have been investigated: increased intratumoral accumulation of platinum was seen at late time points (maximally at 36 hr) during the pharmacokinetic beta-phase of cDDP elimination from the plasma of the nude mice.	Platinum	141-149	interferon alpha 1	Homo sapiens	65-68
7583709-7	1995	Tumor:plasma platinum concentration ratios at 36-48 hr indicated significantly increased accumulation of platinum in tumors from IFN-treated mice compared to controls (p &lt; 0.05).	Platinum	13-21	interferon alpha 1	Homo sapiens	129-132
7583709-7	1995	Tumor:plasma platinum concentration ratios at 36-48 hr indicated significantly increased accumulation of platinum in tumors from IFN-treated mice compared to controls (p &lt; 0.05).	Platinum	105-113	interferon alpha 1	Homo sapiens	129-132
8591689-4	1995	These two platinum compounds generally inhibited fumarase less than cis-DDP at the concentrations and reaction media (phosphate buffer or NaCl-buffer) studied.	Platinum	10-18	fumarate hydratase	Homo sapiens	49-57
7954466-10	1994	Half times of removal of total platinum from DNA after JM216 exposure (25 microM for 2 h) were 20 h in CH1 and 11 h in CH1JM216R; at 24 h after JM216 exposure (25 microM for 2 h), no removal of DNA interstrand cross-links was observed in CH1, while in CH1/JM216R 20% of cross-links had been removed.	Platinum	31-39	SUN domain containing ossification factor	Homo sapiens	103-106
7954466-10	1994	Half times of removal of total platinum from DNA after JM216 exposure (25 microM for 2 h) were 20 h in CH1 and 11 h in CH1JM216R; at 24 h after JM216 exposure (25 microM for 2 h), no removal of DNA interstrand cross-links was observed in CH1, while in CH1/JM216R 20% of cross-links had been removed.	Platinum	31-39	SUN domain containing ossification factor	Homo sapiens	119-122
7954466-10	1994	Half times of removal of total platinum from DNA after JM216 exposure (25 microM for 2 h) were 20 h in CH1 and 11 h in CH1JM216R; at 24 h after JM216 exposure (25 microM for 2 h), no removal of DNA interstrand cross-links was observed in CH1, while in CH1/JM216R 20% of cross-links had been removed.	Platinum	31-39	SUN domain containing ossification factor	Homo sapiens	119-122
7835780-0	1994	Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.	Platinum	116-124	plasminogen activator, urokinase	Homo sapiens	11-14
7835780-0	1994	Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.	Platinum	116-124	serpin family E member 1	Homo sapiens	20-25
7947696-10	1994	The binding of SSB to dT(pT)n and dC(pC)n occurs with delta H0 &lt; 0 and delta C0P,obs = 0, since the bases in these ss-DNA molecules do not stack appreciably.	Platinum	25-29	single-stranded DNA-binding protein	Escherichia coli	15-18
7859338-0	1994	Electrochemically accelerated adsorption of serum albumin on the surface of platinum and gold electrodes.	Platinum	76-84	albumin	Homo sapiens	44-57
7859338-1	1994	Adsorption of serum albumin on the surface of platinum and gold electrodes was highly accelerated by the application of a constant potential to the electrodes.	Platinum	46-54	albumin	Homo sapiens	14-27
7957208-3	1994	The structural distortion upon platination appears to be restricted to the base pairs Pt-G6.C21 and T7.A20; Pt-G8.C19 forms a normal Watson-Crick base pair.	Platinum	86-88	TBL1X/Y related 1	Homo sapiens	92-95
7957208-3	1994	The structural distortion upon platination appears to be restricted to the base pairs Pt-G6.C21 and T7.A20; Pt-G8.C19 forms a normal Watson-Crick base pair.	Platinum	108-110	immunoglobulin kappa variable 1-27	Homo sapiens	103-106
7957208-8	1994	The platinum coordination distorts the DNA structure at the 5" side of the platinated-GTG-sequence and changes the minor groove face.	Platinum	4-12	gamma-glutamyltransferase 1	Homo sapiens	86-89
7923169-9	1994	Tumor and normal tissue platinum content were significantly increased by IL-1 alpha in animals treated with CBDCA (P &lt; 0.01) but not in those treated with cDDP.	Platinum	24-32	interleukin 1 alpha	Mus musculus	73-83
21607526-8	1994	Furthermore, combination of BN52205 and TNF-alpha resulted in a synergistic activity against the MDR(+) ovarian line, AD10, and the cis-platinum resistant line, C30.	Platinum	136-144	tumor necrosis factor	Homo sapiens	40-49
9975052-0	1994	Projectile and target autoionization electron emission in 700-eV Ne+-Na/M (M=Cr, Cu, Mo, and Pt) collisions.	Platinum	93-95	sodium voltage-gated channel alpha subunit 9	Homo sapiens	65-71
17833813-1	1994	The platinum-rhodium tip of a scanning tunneling microscope that operates inside of an atmospheric-pressure chemical reactor cell has been used to locally rehydrogenate carbonaceous fragments deposited on the (111) surface of platinum.	Platinum	4-12	TOR signaling pathway regulator	Homo sapiens	21-24
17833813-1	1994	The platinum-rhodium tip of a scanning tunneling microscope that operates inside of an atmospheric-pressure chemical reactor cell has been used to locally rehydrogenate carbonaceous fragments deposited on the (111) surface of platinum.	Platinum	226-234	TOR signaling pathway regulator	Homo sapiens	21-24
8064793-0	1994	Synthesis, structural characterization, and antitumor properties of a novel class of large-ring platinum(II) chelate complexes incorporating the cis-1,4-diaminocyclohexane ligand in a unique locked boat conformation.	Platinum	96-104	cytokine inducible SH2-containing protein	Mus musculus	145-150
8074675-0	1994	Cytochrome c oxidase in proteoliposomes visualised by platinum-carbon and by tungsten-tantalum shadowing: image analysis.	Platinum	54-62	cytochrome c, somatic	Homo sapiens	0-12
8064793-1	1994	The first two analogs 5a,b of a new class of neutral large-ring square-planar Pt(II) chelate complexes of the generic structure [Pt(cis-1,4-dach)X2] were synthesized via a refined technique, structurally characterized by NMR (1H, 13C, 195Pt), FAB mass spectrometry, and X-ray crystallography, and evaluated for antitumor activity in vitro and in vivo in sensitive and Pt-resistant murine leukemia cell systems.	Platinum	78-80	cytokine inducible SH2-containing protein	Mus musculus	132-137
8033054-9	1994	CONCLUSIONS: Intensive chemotherapy using cyclophosphamide, platinum compounds, epipodophyllotoxins, doxorubicin, and vincristine was effective in orbital involvement of retinoblastoma even with associated extra-CNS metastases.	Platinum	60-68	RB transcriptional corepressor 1	Homo sapiens	170-184
8060312-1	1994	Platinum electrodes (PLE) have been used recently to study the physiologic effects of the enzymatic conversion of L-arginine (L-arg) to nitric oxide (NO) by nitric oxide synthase (NOS).	Platinum	0-8	nitric oxide synthase 2	Homo sapiens	157-178
8040325-0	1994	Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.	Platinum	91-99	XPA, DNA damage recognition and repair factor	Homo sapiens	24-28
8040325-0	1994	Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.	Platinum	91-99	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	33-38
8040325-8	1994	These data suggest greater activity of the DNA excision repair genes ERCC1 and XPAC in ovarian cancer tissues of patients clinically resistant to platinum compounds.	Platinum	146-154	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	69-74
8040325-8	1994	These data suggest greater activity of the DNA excision repair genes ERCC1 and XPAC in ovarian cancer tissues of patients clinically resistant to platinum compounds.	Platinum	146-154	XPA, DNA damage recognition and repair factor	Homo sapiens	79-83
8040325-9	1994	These data also indicate highly variable splicing of ERCC1 mRNA in ovarian cancer tissues in vivo, whether or not such tissues are sensitive to platinum-based therapy.	Platinum	144-152	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	53-58
8057650-5	1994	The intratumoral concentration of platinum was significantly increased in St-40 treated with the sequence MMC to DDP, in comparison with the sequence DDP to MMC.	Platinum	34-42	translocase of inner mitochondrial membrane 8A	Homo sapiens	113-116
8040023-7	1994	In agreement with the morphological findings, the platinum concentration in the dorsal root ganglia was lower and sensory nerve conduction velocity in the tail nerve less markedly decreased in the animals treated with DDP plus GSH with respect to those treated with DDP alone.	Platinum	50-58	translocase of inner mitochondrial membrane 8A1	Rattus norvegicus	218-221
8052872-4	1994	The combination of thoracic radiotherapy plus platinum-based chemotherapy currently represents the cornerstone of such combination treatment for SCLC.	Platinum	46-54	SCLC1	Homo sapiens	145-149
7909492-5	1994	Immediately following a 1-h exposure to cisplatin (50 microM), RIF-1 cells contained 44.6 +/- 2.0 (SEM) pg platinum/micrograms DNA while RIF-8A cells contained 24.8 +/- 6.3 pg platinum/micrograms DNA.	Platinum	107-115	replication timing regulatory factor 1	Mus musculus	63-68
8151314-2	1994	PATIENTS AND METHODS: IL-1 alpha was administered by continuous intravenous infusion daily at doses of 0.1 to 10 micrograms/m2/24 hours over 4 days (96 hours) before the first cycle and/or following the second cycle of carboplatin in 21 patients with recurrent ovarian cancer who had platinum-responsive disease.	Platinum	284-292	interleukin 1 alpha	Homo sapiens	22-32
8027742-6	1994	The order of reactivity of the platinum compounds for the GCGC oligonucleotide was 1,1/t,t &gt; 1,0/t &gt; Pt(DIEN) &gt; cis-DDP.	Platinum	31-39	translocase of inner mitochondrial membrane 8A	Homo sapiens	125-128
8074278-0	1994	Application of polymer-protected ultrafine platinum particles to the immunological detection of human serum albumin.	Platinum	43-51	albumin	Homo sapiens	102-115
8297732-4	1994	Mean CSF-1 levels (n = 14) dropped significantly during six courses of platinum-based chemotherapy (P = 0.02).	Platinum	71-79	colony stimulating factor 1	Homo sapiens	5-10
7903206-15	1994	We are currently following the response of these patients to chemotherapy to determine if expression of GGT serves as a marker for identifying neoplasms with enhanced resistance to platinum-based therapy.	Platinum	181-189	inactive glutathione hydrolase 2	Homo sapiens	104-107
8137461-2	1994	Platinum tissue levels measured at 48 h after a single oral dose at 0.5 of the MTD were highest in the liver (6.0-19 micrograms/g) and second highest in the kidney (2.8-12 micrograms/g), and these levels were up to 5 times higher than those reported with equi-toxic doses of i.v.	Platinum	0-8	metallothionein 1E	Homo sapiens	79-82
8137461-6	1994	Liver platinum levels measured at 2 h, 2 days, 6 days and 10 days after a single oral dose at the MTD ranged widely (from 15 to 109 micrograms platinum/g), were related to the number of carbon atoms in the axial dicarboxylate and alicyclic amine groups (r = 0.9389) and showed a diversity of time-course profiles.	Platinum	6-14	metallothionein 1E	Homo sapiens	98-101
8137461-8	1994	Accumulation of platinum in the liver with repeated oral dosing weekly for 4 consecutive weeks at 0.5 of the MTD occurred with JM269 (3.3-fold increase, P &lt; 0.05) and JM225 (2.4-fold increase, P &lt; 0.05), and elevated plasma ALT activity (44 +/- 33 IU/l) was recorded with repeated oral doses of JM269.	Platinum	16-24	metallothionein 1E	Homo sapiens	109-112
8138561-6	1994	It is assumed that binding of the platinum moiety to macromolecular constituents of the culture or cells renders the drug inaccessible for binding to the estrogen receptor.	Platinum	34-42	estrogen receptor 1	Homo sapiens	154-171
8298520-7	1993	GM1 significantly increased peripheral axon regeneration (3427 +/- 64 myelinated axons for the 0.76-mm PT and 3623 +/- 270 for the 1.14-mm PT, mean +/- SEM) compared to the group receiving collagen alone (2516 +/- 156) and this effect did not depend on tube diameter.	Platinum	103-105	coenzyme Q10A	Mus musculus	0-3
8295700-4	1994	Plasma and CSF platinum levels were dose dependent.	Platinum	15-23	colony stimulating factor 2	Homo sapiens	11-14
8295700-6	1994	The mean peak total CSF concentration was 10.0% of the peak total plasma platinum and 20.2% of the peak free plasma platinum in patients with malignant glioma.	Platinum	73-81	colony stimulating factor 2	Homo sapiens	20-23
8295700-6	1994	The mean peak total CSF concentration was 10.0% of the peak total plasma platinum and 20.2% of the peak free plasma platinum in patients with malignant glioma.	Platinum	116-124	colony stimulating factor 2	Homo sapiens	20-23
8295700-7	1994	In patients with a solid metastatic brain tumor, the mean peak total CSF concentration was 1.9% of the peak total plasma platinum and 4.0% of the peak free plasma platinum after i.v.	Platinum	121-129	colony stimulating factor 2	Homo sapiens	69-72
8295700-7	1994	In patients with a solid metastatic brain tumor, the mean peak total CSF concentration was 1.9% of the peak total plasma platinum and 4.0% of the peak free plasma platinum after i.v.	Platinum	163-171	colony stimulating factor 2	Homo sapiens	69-72
8295700-9	1994	After intracarotid infusion, the mean peak total CSF concentration was 3.4% of the peak total plasma platinum and 7.0% for the peak free plasma platinum.	Platinum	101-109	colony stimulating factor 2	Homo sapiens	49-52
8295700-9	1994	After intracarotid infusion, the mean peak total CSF concentration was 3.4% of the peak total plasma platinum and 7.0% for the peak free plasma platinum.	Platinum	144-152	colony stimulating factor 2	Homo sapiens	49-52
8295700-10	1994	In patients with meningeal carcinomatosis, the mean peak CSF concentrations were 7.7% of the peak total plasma platinum and 13.7% of the peak free plasma platinum.	Platinum	111-119	colony stimulating factor 2	Homo sapiens	57-60
8295700-10	1994	In patients with meningeal carcinomatosis, the mean peak CSF concentrations were 7.7% of the peak total plasma platinum and 13.7% of the peak free plasma platinum.	Platinum	154-162	colony stimulating factor 2	Homo sapiens	57-60
8142057-8	1993	Approaches to circumvent resistance will probably involve not only the rational development of a new generation of platinum-based drugs (e.g., compounds designed to overcome reduced cisplatin accumulation or enhanced removal of cisplatin-induced DNA adducts) but also non-platinum drugs which are capable of modulating resistance (e.g., modulators of signal transduction pathways, ras and myc oncogene expression and glutathione biosynthesis).	Platinum	115-123	myelocytomatosis oncogene	Mus musculus	389-392
7693713-9	1993	Assuming that each CHIP28 monomer is a right cylindrical pore of length 5 nm and density 1.3 g/cm3, the monomer diameter would be 3.2 nm; a symmetrical arrangement of four cylinders would have a greatest diameter of 7.2 nm, which after correction for the thickness of platinum deposit, is similar to the measured IMP diameter of approximately 8.5 nm.	Platinum	268-276	aquaporin 1 (Colton blood group)	Homo sapiens	19-25
8222071-11	1993	These data show that in UV repair-deficient CHO cells, ERCC1 confers resistance to cisplatin and confers the ability to remove platinum from cellular DNA.	Platinum	127-135	DNA excision repair protein ERCC-1	Cricetulus griseus	55-60
8364203-12	1993	The active site His residue may be the target of oxidative inactivation, as evidenced by the partial protection afforded plasmin by the addition of Zn(II), histidine, or the platinum derivative, platinum(II) (2,2":6",2"-terpyridine) chloride.	Platinum	174-182	plasminogen	Homo sapiens	121-128
8363610-1	1993	Interleukin-1 alpha induced an increase in both the cellular accumulation of cis-diamminedichloroplatinum (II) (cisplatin) and DNA platination and significantly reduced the removal of platinum from DNA of human ovarian (NIH: OVCAR-3) carcinoma cells in culture.	Platinum	97-105	interleukin 1 alpha	Homo sapiens	0-19
8279755-12	1993	A platinum transferrin complex (MPTC-63) has been developed and shown to be cytostatic in tissue culture, animal, and human studies.	Platinum	2-10	transferrin	Homo sapiens	11-22
8135488-4	1993	CARL of ER allowed for calculating individual risk curves in stage III and IV, Grade 2 and 3, serous ovarian carcinoma after surgical debulking to &lt; or = 2 cm residual and platinum based chemotherapy.	Platinum	175-183	estrogen receptor 1	Homo sapiens	8-10
8357577-10	1993	Glucose oxidase (GOD) and glucose dehydrogenase (GDH) immobilized cylindrical platinum microelectrodes were fabricated, and their characteristics were evaluated, respectively, by using 1,4-benzoquinone (BQ) and ferricyanide as electron mediators.	Platinum	78-86	hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	Homo sapiens	26-47
21573377-2	1993	Five platinum derivatives were evaluated by using the ATP chemosensitivity assay and flow cytometry in a panel of 10 human gynecologic cancer cell lines: AE7, ECC1, HEC1A, HEC1B, AN3, BG1, CAOV3, SKOV3, SKUT1B and ME180.	Platinum	5-13	tripartite motif containing 44	Homo sapiens	179-182
21573377-2	1993	Five platinum derivatives were evaluated by using the ATP chemosensitivity assay and flow cytometry in a panel of 10 human gynecologic cancer cell lines: AE7, ECC1, HEC1A, HEC1B, AN3, BG1, CAOV3, SKOV3, SKUT1B and ME180.	Platinum	5-13	acyl-CoA synthetase bubblegum family member 1	Homo sapiens	184-187
8342024-3	1993	The Ixr1 protein, a member of the high mobility group-box protein family, bound specifically to DNA modified with cisplatin but not inactive platinum compounds.	Platinum	141-149	DNA-binding transcription repressor IXR1	Saccharomyces cerevisiae S288C	4-8
8342024-4	1993	A yeast strain with an inactivated IXR1 gene was half as sensitive to cisplatin and accumulated one-third as many platinum-DNA lesions after treatment with cisplatin as the parental strain.	Platinum	114-122	DNA-binding transcription repressor IXR1	Saccharomyces cerevisiae S288C	35-39
18965619-1	1993	Silicagel Separon SGX C18 (particle size 7 microm) was suitable for the preconcentration of 2-20 microg of Pt from 0.1M hydrochloric acid in the presence of cationic surfactants especially dimethyllaurylbenzylammonium bromide, with subsequent elution with 96% ethanol.	Platinum	107-109	Bardet-Biedl syndrome 9	Homo sapiens	22-25
8352556-6	1993	DMFs of 5 platinum drugs in NOS2CR cells, however, were more than those in NOS2 cells.	Platinum	10-18	nitric oxide synthase 2	Homo sapiens	28-32
8352556-7	1993	These results indicate that AMB sensitizes NOS2 and NOS2CR cells to platinum drugs, partially due to the increasing intracellular accumulation of these drugs.	Platinum	68-76	nitric oxide synthase 2	Homo sapiens	43-47
8352556-7	1993	These results indicate that AMB sensitizes NOS2 and NOS2CR cells to platinum drugs, partially due to the increasing intracellular accumulation of these drugs.	Platinum	68-76	nitric oxide synthase 2	Homo sapiens	52-56
8357577-10	1993	Glucose oxidase (GOD) and glucose dehydrogenase (GDH) immobilized cylindrical platinum microelectrodes were fabricated, and their characteristics were evaluated, respectively, by using 1,4-benzoquinone (BQ) and ferricyanide as electron mediators.	Platinum	78-86	hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	Homo sapiens	49-52
8435209-9	1993	The significantly elevated platinum levels in serum, kidney, jejunum and tumour tissue after WBH treatment may explain the thermal enhancement of DDP-mediated antitumour activity and side-effects but no correlation could be found for the differences in DDP-mediated normal tissue toxicities induced by the anaesthetics.	Platinum	27-35	translocase of inner mitochondrial membrane 8A1	Rattus norvegicus	146-149
8408183-1	1993	The platinum complex [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II),K, was tested for its antitumor activity on hormone-sensitive tumor models under peroral administration.	Platinum	4-12	transcription factor 15	Mus musculus	22-28
1445361-11	1992	Thus, our results indicate that HMG 2 binds with high affinity to DNA modified with therapeutically active platinum compounds.	Platinum	107-115	high mobility group box 2	Homo sapiens	32-37
1423261-8	1992	The rate of platinum accumulation at an equimolar concentration of cisplatin was 41M &gt; SKOV-3 &gt; CH1 &gt; PXN/94 &gt; HX/62.	Platinum	12-20	SUN domain containing ossification factor	Homo sapiens	102-105
1423261-8	1992	The rate of platinum accumulation at an equimolar concentration of cisplatin was 41M &gt; SKOV-3 &gt; CH1 &gt; PXN/94 &gt; HX/62.	Platinum	12-20	paxillin	Homo sapiens	111-114
1423261-12	1992	Interestingly, both the PXN/94 and the sensitive CH1 cell lines, which were established from patients pretreated with platinum drugs, showed reduced drug accumulation relative to the 41M cell line.	Platinum	118-126	paxillin	Homo sapiens	24-27
1423261-12	1992	Interestingly, both the PXN/94 and the sensitive CH1 cell lines, which were established from patients pretreated with platinum drugs, showed reduced drug accumulation relative to the 41M cell line.	Platinum	118-126	SUN domain containing ossification factor	Homo sapiens	49-52
1433335-7	1992	RESULTS: Patients who were clinically resistant to platinum-based therapy had a 2.6-fold higher expression level of ERCC1 in their tumor tissue than did patients who responded to that therapy (P = .015).	Platinum	51-59	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	116-121
1419639-4	1992	GST isoenzyme patterns were identical in benign tumours and malignant tumours before and after platinum/cyclophosphamide chemotherapy, while GST pi was the predominant transferase.	Platinum	95-103	glutathione S-transferase kappa 1	Homo sapiens	0-3
1419639-5	1992	Mean GST activity and GST pi amount were decreased (P &lt; 0.05) in malignant ovarian tumours after platinum/cyclophosphamide chemotherapy compared to untreated ovarian malignant tumours.	Platinum	100-108	glutathione S-transferase kappa 1	Homo sapiens	5-8
1419639-5	1992	Mean GST activity and GST pi amount were decreased (P &lt; 0.05) in malignant ovarian tumours after platinum/cyclophosphamide chemotherapy compared to untreated ovarian malignant tumours.	Platinum	100-108	glutathione S-transferase kappa 1	Homo sapiens	22-25
1433335-10	1992	CONCLUSION: We conclude that ERCC1 expression levels in human tumor tissue may have a role in clinical resistance to platinum compounds.	Platinum	117-125	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	29-34
1416035-4	1992	The response due to the platinum surface is prolonged by the presence of the Co(II)-tetren/PVC film.	Platinum	24-32	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	77-83
1953747-3	1991	When thioltransferase was not reduced, inhibition by preincubation with the platinum complexes required molar excesses of 1,300 and 675 to one for cis-platin and trans-platin, respectively or 400-500 microM for 50% inhibition.	Platinum	76-84	glutaredoxin-1	Sus scrofa	5-21
1305089-1	1992	The polarographic method using platinum electrode has been applied to study the effect of ceruloplasmin (CP) on the oxygen tension (pO2), oxygen saturation rate and rate of oxygen utilization in the muscular tissue of high-leukemic AKR mice, C57BL/6 mice with transplanted Lewis lung carcinoma (3LL) and rats after gamma-irradiation in a dose of 7 Gr.	Platinum	31-39	ceruloplasmin	Mus musculus	105-107
1385629-10	1992	Chronically increased ANP may prevent renal accumulation of platinum in the kidney.	Platinum	60-68	natriuretic peptide A	Rattus norvegicus	22-25
1606047-1	1992	We have prepared in radiolabeled form (platinum-191) a non-steroidal estrogen platinum-diamine complex (Pt-diamine complex) that is reported to have selective cytostatic activity in estrogen receptor positive mouse mammary tumors.	Platinum	39-47	estrogen receptor 1 (alpha)	Mus musculus	182-199
1606047-8	1992	However, attempts to observe the binding of the 191Pt-diamine complex with the estrogen receptor were complicated by a very high level of non-receptor binding, an irreversible binding to proteins in the receptor preparation, and a degradation of the platinum complex that, in part, releases the diamine.	Platinum	250-258	estrogen receptor 1	Rattus norvegicus	79-96
1566071-4	1992	Recombinant rat HMG1 binds specifically (dissociation constant 3.7 +/- 2.0 x 10(-7) molar) to DNA containing cisplatin d(GpG) or d(ApG) intrastrand cross-links, which unwind and bend DNA in a specific manner, but not to DNA modified by therapeutically inactive platinum analogs.	Platinum	261-269	high mobility group box 1	Rattus norvegicus	16-20
17014801-1	1992	The process of adsorption of bovine serum albumin onto a platinum electrode was monitored through the measurement of a nonlinear electrochemical property.	Platinum	57-65	albumin	Homo sapiens	36-49
28053427-1	1992	The spectrum of a platinum hollow-cathode lamp containing neon carrier gas was recorded photographically and photoelectrically with a 10.7 m normal-incidence vacuum spectrograph.	Platinum	18-26	lysosomal associated membrane protein 3	Homo sapiens	42-46
1953747-0	1991	Interactions of platinum complexes with thioltransferase(glutaredoxin), in vitro.	Platinum	16-24	glutaredoxin-1	Sus scrofa	40-56
1953747-0	1991	Interactions of platinum complexes with thioltransferase(glutaredoxin), in vitro.	Platinum	16-24	glutaredoxin-1	Sus scrofa	57-69
1449968-8	1992	The application of ex vivo MRS is illustrated by studies on the urinary excretion of platinum complexes.	Platinum	85-93	MROS	Homo sapiens	27-30
1449968-9	1992	1H-MRS has been used to demonstrate the presence of the cyclobutanedicarboxylate leaving group, both free and platinum bound, in the urine of patients treated with carboplatin.	Platinum	110-118	MROS	Homo sapiens	3-6
10002305-0	1992	Spin-polarized interface states at the Pd(111)/Fe(110), Pd(111)/Co(0001), and Pt(111)/Co(0001) interfaces.	Platinum	78-80	spindlin 1	Homo sapiens	0-4
1638521-8	1992	These data show that TNF enhanced the platinum + WBH-mediated antitumor effect without increasing normal tissue toxicity, suggesting that TNF may increase the therapeutic efficacy of CDDP or CBDCA combined with WBH.	Platinum	38-46	tumor necrosis factor	Rattus norvegicus	21-24
1638521-8	1992	These data show that TNF enhanced the platinum + WBH-mediated antitumor effect without increasing normal tissue toxicity, suggesting that TNF may increase the therapeutic efficacy of CDDP or CBDCA combined with WBH.	Platinum	38-46	tumor necrosis factor	Rattus norvegicus	138-141
1617660-6	1992	This is suggestive of a resistance mechanism involving increased DNA repair or tolerance to platinum-DNA adducts operating in the CH1cisR/CH1 pair of lines.	Platinum	92-100	SUN domain containing ossification factor	Homo sapiens	130-133
10045436-0	1992	Direct photon production at high pT in pi -Be and pBe collisions at 500 GeV/c.	Platinum	33-35	enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase	Homo sapiens	50-53
1617996-10	1992	New agents such as WR2721, IL-3, and IL-1 alpha are undergoing clinical evaluation to determine whether the toxicities of platinum compounds can be decreased and lead to further exploitation of the dose response relationship.	Platinum	122-130	interleukin 3	Homo sapiens	27-31
1617996-10	1992	New agents such as WR2721, IL-3, and IL-1 alpha are undergoing clinical evaluation to determine whether the toxicities of platinum compounds can be decreased and lead to further exploitation of the dose response relationship.	Platinum	122-130	interleukin 1 alpha	Homo sapiens	37-47
1441917-4	1992	All these changes were more marked in the group of rats which underwent the most intense DDP treatment and the tissue platinum concentrations were also higher in this group.	Platinum	118-126	translocase of inner mitochondrial membrane 8A1	Rattus norvegicus	89-92
1793720-1	1991	Two murine tumour models, the L1210 leukaemia and the ADJ/PC6 plasmacytoma, have featured prominently in the preclinical development of platinum drugs.	Platinum	136-144	proprotein convertase subtilisin/kexin type 5	Mus musculus	58-61
1930262-3	1991	We report here that the presence of SSB increases the number of platinum-DNA lesions and alters their distribution.	Platinum	64-72	single-stranded binding protein	Escherichia coli	36-39
1793720-2	1991	Mindful of the unequivocal need to discover new platinum-based drugs exhibiting activity in cisplatin/carboplatin refractory and relapsed cancers, and to devise clinically-predictive screening models, we have generated resistance in vivo in the ADJ/PC6 plasmacytoma to cisplatin (19- to 21-fold), to carboplatin (25-fold), iproplatin (greater than 14-fold) and tetraplatin (10-fold).	Platinum	48-56	proprotein convertase subtilisin/kexin type 5	Mus musculus	249-252
1902187-7	1991	In contrast, the extent of PT-catalyzed ADP-ribosylation of Gi alpha protein(s) decreases between Days 6.5 and 7.5--this decrease is global and not restricted to a particular germ layer of the Day 7.5 embryo--and then dramatically increases by Day 8.5 of gestation.	Platinum	27-29	guanine nucleotide binding protein (G protein), alpha inhibiting 2	Mus musculus	60-68
1877814-8	1991	And the mean concentrations of platinum in cancer tissues and lymph-nodes were higher than those of intra-arterial CDDP or EAP I injection therapy.	Platinum	31-39	ADAM metallopeptidase domain 7	Homo sapiens	123-128
1892748-0	1991	The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.	Platinum	85-93	glutathione S-transferase kappa 1	Homo sapiens	39-64
1902187-8	1991	In the Day 8.5 gestation embryo, the extent of PT-catalyzed ADP-ribosylation of Gi alpha proteins increases along the anterior-posterior axis, whereas the amount of immunoreactive alpha i subunit decreases along this axis.	Platinum	47-49	guanine nucleotide binding protein (G protein), alpha inhibiting 2	Mus musculus	80-88
1901253-6	1991	Following 18 h posttreatment incubation both lines showed some ability to remove each of the three main platinum-DNA lesions (Pt-GMP, Pt-AG and Pt-GG).	Platinum	126-128	5'-nucleotidase, cytosolic II	Homo sapiens	129-132
2027756-3	1991	The results indicate two waves of crosslinking [rate constants (0.2-0.3) min-1 and (0.015-0.025) min-1] that correlate with changes in ultra violet absorbance and ethidium bromide dependent fluorescence intensity, previously interpreted in terms of two consecutive, local conformational rearrangements of platinum-DNA (Schaller, W., Reisner, H., and Holler, E. (1987) Biochemistry 26, 943-950).	Platinum	305-313	CD59 molecule (CD59 blood group)	Homo sapiens	97-102
1830003-4	1991	Platinum wire electrodes are placed over the tip and at the bottom of the test tube.	Platinum	0-8	TOR signaling pathway regulator	Homo sapiens	45-48
1710482-0	1991	BOP/VIP--a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours.	Platinum	15-23	vasoactive intestinal peptide	Homo sapiens	4-7
2009531-6	1991	These findings suggest that c-myc levels may influence therapeutic success in some tumors and may regulate specific processes by which cells cope with DNA damage caused by DNA cross-linking agents such as the platinum analogues, but not ionizing radiation.	Platinum	209-217	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	30-33
2027756-3	1991	The results indicate two waves of crosslinking [rate constants (0.2-0.3) min-1 and (0.015-0.025) min-1] that correlate with changes in ultra violet absorbance and ethidium bromide dependent fluorescence intensity, previously interpreted in terms of two consecutive, local conformational rearrangements of platinum-DNA (Schaller, W., Reisner, H., and Holler, E. (1987) Biochemistry 26, 943-950).	Platinum	305-313	CD59 molecule (CD59 blood group)	Homo sapiens	73-78
1864496-0	1991	A self-assembled pigmented BLM on a platinum support: the light-induced electrical effects.	Platinum	36-44	BLM RecQ like helicase	Homo sapiens	27-30
2281204-3	1990	Plasma-free platinum concentrations ranged from 1.0 to 2.1 micrograms/ml at the end of infusions and declined rapidly with T1/2 of 0.6-1.5 hours.	Platinum	12-20	interleukin 1 receptor like 1	Homo sapiens	123-132
2042743-5	1991	The most prominent fragment ions containing platinum were [HB2.Pt.B3H]+ and [HB1.Pt.B2H]+, where B1, B2, and B3 were bases in the oligonucleotide tetramer, one of which was usually guanine.	Platinum	44-52	immunoglobulin kappa variable 7-3 (pseudogene)	Homo sapiens	97-111
2076570-4	1990	In 2 h exposure, however, the IC50 values of the platinum complexes were dramatically changed, i.e., a marked difference was observed between those of L" = RNH2 and L" = R2NH.	Platinum	49-57	NLR family, pyrin domain containing 4C	Mus musculus	156-160
1983886-4	1991	Six 5 x 15-mm platinum microcoils were deposited into the residual lumen of the aneurysm, resulting in complete thrombosis with obliteration of the aneurysm and preservation of the parent artery.	Platinum	14-22	SIX homeobox 5	Homo sapiens	0-5
2174300-10	1990	A trial of VIP as first salvage after a relapse from a complete response to platinum-based induction therapy is warranted.	Platinum	76-84	vasoactive intestinal peptide	Homo sapiens	11-14
2281204-5	1990	Parameters (Ke, Cl, T1/2 and Vd) of free platinum pharmacokinetics were 0.66 hr-1, 7.71l/hr, 1.35 hr and 15.71l in the younger group (age: 1.7-6.5 years old) and 1.44 hr-1, 11.41l/hr, 0.61 hr and 8.99l in the older group (age: 12.2-15.7 years old), respectively.	Platinum	41-49	interleukin 1 receptor like 1	Homo sapiens	20-31
1965411-7	1990	The response to cis-platin, a platin derivative and hexadecyl-phosphocholine was studied on the HIV LTR and H-ras1 regulated CAT activity in RFBHIV1-1 and RF202A-1 cells.	Platinum	20-26	HRas proto-oncogene, GTPase	Homo sapiens	108-114
2383621-0	1990	Influence of surface charge on adsorption of fibrinogen and/or albumin on a rotating disc electrode of platinum and carbon.	Platinum	103-111	fibrinogen beta chain	Homo sapiens	45-55
2354434-10	1990	Intracellular platinum levels were approximately 200 times higher after exposure of EMT6 cells to 25 microM of Pt(Nile blue)2 or Pt(neutral red)2 for 1 h at 37 degrees C than after exposure to the same concentration of cis-diamminedichloroplatinum(II).	Platinum	14-22	IL2 inducible T cell kinase	Mus musculus	84-87
2383621-1	1990	The adsorption of fibrinogen on to platinum and carbon and of albumin on to carbon was investigated for various changes of the surface by recording the variations of the double-layer capacitance of the electrochemical interface during adsorption, as a function of time.	Platinum	35-43	fibrinogen beta chain	Homo sapiens	18-28
2183874-9	1990	Total Pt had a larger Vdss (117 l m-2) and a lower total body clearance (14 ml min-1 m-2) than free Pt and carboplatin.	Platinum	6-8	CD59 molecule (CD59 blood group)	Homo sapiens	79-84
2139364-4	1990	In mice treated with 400 ng of PT and 1 mg of chicken egg albumin (EA), the percentage of these cells increased, 14 days after immunization, to an average value of 31.1 +/- 2.2%.	Platinum	31-33	ovalbumin (SERPINB14)	Gallus gallus	67-69
2116401-9	1990	Also contributing to the cisplatin resistance phenotype was a reduced intracellular level of platinum in the PC-9/CDDP.	Platinum	93-101	proprotein convertase subtilisin/kexin type 9	Homo sapiens	109-113
2323620-0	1990	Serum albumin: its relationship to marrow and renal toxicity from platinum-based combination chemotherapy.	Platinum	66-74	albumin	Homo sapiens	0-13
2302256-7	1990	Measurements of cell-associated platinum indicated that the degree of protection from the inactivating effects of cis-DDP by these aldehydes was related to the degree of reduced platinum accumulation.	Platinum	32-40	translocase of inner mitochondrial membrane 8A	Homo sapiens	118-121
2302256-7	1990	Measurements of cell-associated platinum indicated that the degree of protection from the inactivating effects of cis-DDP by these aldehydes was related to the degree of reduced platinum accumulation.	Platinum	178-186	translocase of inner mitochondrial membrane 8A	Homo sapiens	118-121
2337935-9	1990	Then, the structure-factor 2 score relationships among platinum complexes were analyzed by the Free-Wilson method.	Platinum	55-63	transcription termination factor 2	Homo sapiens	20-28
2169720-5	1990	Activity of glucose-6-phosphatase of rat renal microsomes was investigated after platinum-compound exposure.	Platinum	81-89	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	12-33
2188163-1	1990	The effect of three second generation platinum complexes on proliferation of tumor cells (HeLa, C6) and nontumor cells (LEP) was studied, and compared with that of cis-DDP.	Platinum	38-46	leptin	Homo sapiens	120-123
2318137-2	1990	The higher Pt concentrations in the blood of animals which were given the K-2-9 preparation provided selectivity of cytostatic accumulation in the tumour tissue, that was accompanied by more prolonged inhibition of the DNA synthesis.	Platinum	11-13	paired related homeobox 1	Mus musculus	74-79
33773464-10	2021	Treatment with PT prominently mitigated the oxidative stress (TBARS, NO, APOP), and inflammatory (MPO) markers and improved the endogenous antioxidant enzymes (catalase and SOD) activities in CCl4-intoxicated rats.	Platinum	15-17	myeloperoxidase	Rattus norvegicus	98-101
33232772-5	2021	A minimum of 2 cycles of platinum-based chemotherapy was compulsory before starting radiotherapy (RT).	Platinum	25-33	amyloid beta precursor protein	Homo sapiens	0-1
33970603-4	2021	Here, we demonstrate a 45% increase in spin Hall efficiency in the platinum/cobalt (Pt/Co) bilayer, of which 78% of the enhancement was preserved even after the strain was removed.	Platinum	67-75	spindlin 1	Homo sapiens	39-43
33970603-4	2021	Here, we demonstrate a 45% increase in spin Hall efficiency in the platinum/cobalt (Pt/Co) bilayer, of which 78% of the enhancement was preserved even after the strain was removed.	Platinum	84-86	spindlin 1	Homo sapiens	39-43
33970603-5	2021	Spin transparency and X-ray magnetic circular dichroism revealed that the enhancement was attributed to a bulk effect in the Pt layer.	Platinum	125-127	spindlin 1	Homo sapiens	0-4
33973803-0	2021	Association of NQO1Pro187Ser polymorphism with clinical outcomes and survival of lung cancer patients treated with platinum chemotherapy.	Platinum	115-123	NAD(P)H quinone dehydrogenase 1	Homo sapiens	15-19
33779077-3	2021	In this issue of EMBO Molecular Medicine, Hoppe et al present RAD51 expression as a biomarker of platinum resistance in high-grade serous ovarian cancer (HGSOC) patients (Hoppe et al, 2021).	Platinum	97-105	RAD51 recombinase	Homo sapiens	62-67
33941784-3	2021	BRCA1 methylation loss may be a major cross-resistance mechanism to platinum and PARPi.	Platinum	68-76	BRCA1 DNA repair associated	Homo sapiens	0-5
33822573-3	2021	Here, we experimentally demonstrate a SOT magnetization switching for a ferrimagnetic D022-Mn3Ge film with high bulk PMA and robust thermal stability factor under a critical current density of 6.6 x 1011 A m-2 through the spin Hall effect of an adjacent capping Pt and a buffer Cr layer.	Platinum	262-264	spindlin 1	Homo sapiens	222-226
33778494-4	2021	Accordingly, a TRDMT1 G155V mutation in an ovarian cancer super responder to platinum treatment.	Platinum	77-85	tRNA aspartic acid methyltransferase 1	Homo sapiens	15-21
33808149-6	2021	According to multivariable analysis, the significant benefit of platinum NACT was observed in early responders >=45 years, Ki-67 >= 65% and persisted lymph node involvement regardless of BRCA1/2 status.	Platinum	64-72	BRCA1 DNA repair associated	Homo sapiens	187-194
33764811-1	2022	Background: The molecular mechanisms underlying chemoresistance are still poorly understood in nasopharyngeal cancer; the protein expression of ERCC1 in DNA repair genes has been reported related to resistance platinum and predicting treatment outcomes in various malignant carcinomas, but the benefit for predicting outcomes with optimal cutoff value of ERCC1mRNA is controversial.	Platinum	210-218	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	144-149
33764811-1	2022	Background: The molecular mechanisms underlying chemoresistance are still poorly understood in nasopharyngeal cancer; the protein expression of ERCC1 in DNA repair genes has been reported related to resistance platinum and predicting treatment outcomes in various malignant carcinomas, but the benefit for predicting outcomes with optimal cutoff value of ERCC1mRNA is controversial.	Platinum	210-218	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	355-360
33778494-6	2021	In contrast, high expression of TRDMT1 in patients with ovarian cancer correlates with platinum resistance.	Platinum	87-95	tRNA aspartic acid methyltransferase 1	Homo sapiens	32-38
33778494-8	2021	These results suggest that TRDMT1 is a promising therapeutic target to sensitize ovarian tumors to platinum therapy.	Platinum	99-107	tRNA aspartic acid methyltransferase 1	Homo sapiens	27-33
33810010-0	2021	Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum.	Platinum	86-94	C-X3-C motif chemokine receptor 1	Homo sapiens	10-16
33801098-6	2021	This study elucidated that PT can be effective against melanoma through the inhibition of adrenocorticotropic hormone production in the brain of a mouse, which weakens the Nrf2-dependent antioxidant defenses of melanoma and also pancreatic cancers.	Platinum	27-29	pro-opiomelanocortin-alpha	Mus musculus	90-117
33813145-0	2021	A simple electrochemical immunosensor based on worm-like platinum for highly sensitive determination of alpha-fetoprotein.	Platinum	57-65	alpha fetoprotein	Homo sapiens	104-121
33804647-2	2021	Defective Homologous Recombination Repair (HRR) function, e.g., due to BRCA1/2 loss, is a determinant of response to platinum agents and PARP inhibitors in ovarian cancers.	Platinum	117-125	BRCA1 DNA repair associated	Homo sapiens	71-78
33804647-7	2021	Two DDR gene expression clusters correlating with treatment response were identified, with PARP10 identified as a novel marker of platinum response, which was confirmed in The Cancer Genome Atlas (TCGA) ovarian cancer cohort.	Platinum	130-138	poly(ADP-ribose) polymerase family member 10	Homo sapiens	91-97
33809542-0	2021	Prognostic Value of TNFR2 and STAT3 among High-Grade Serous Ovarian Cancer Survivors According to Platinum Sensitivity.	Platinum	98-106	TNF receptor superfamily member 1B	Homo sapiens	20-25
33809542-1	2021	This study"s goal was to determine the protein expression level of tumour necrosis factor receptor 2 (TNFR2) and signal transducer and activator of transcription 3 (STAT3) in high-grade serous ovarian cancer (HGSC) tissues in relation to the platinum-based chemotherapy response and the prognosis outcome.	Platinum	242-250	TNF receptor superfamily member 1B	Homo sapiens	67-100
33809542-1	2021	This study"s goal was to determine the protein expression level of tumour necrosis factor receptor 2 (TNFR2) and signal transducer and activator of transcription 3 (STAT3) in high-grade serous ovarian cancer (HGSC) tissues in relation to the platinum-based chemotherapy response and the prognosis outcome.	Platinum	242-250	TNF receptor superfamily member 1B	Homo sapiens	102-107
33809542-1	2021	This study"s goal was to determine the protein expression level of tumour necrosis factor receptor 2 (TNFR2) and signal transducer and activator of transcription 3 (STAT3) in high-grade serous ovarian cancer (HGSC) tissues in relation to the platinum-based chemotherapy response and the prognosis outcome.	Platinum	242-250	signal transducer and activator of transcription 3	Homo sapiens	113-163
33809542-1	2021	This study"s goal was to determine the protein expression level of tumour necrosis factor receptor 2 (TNFR2) and signal transducer and activator of transcription 3 (STAT3) in high-grade serous ovarian cancer (HGSC) tissues in relation to the platinum-based chemotherapy response and the prognosis outcome.	Platinum	242-250	signal transducer and activator of transcription 3	Homo sapiens	165-170
33809542-4	2021	The protein expression of TNFR2 and STAT3 were analysed using immunohistochemistry (IHC) staining and subsequently were correlated to the clinicopathological characteristics, platinum sensitivity as well as the duration of progression-free survival.	Platinum	175-183	TNF receptor superfamily member 1B	Homo sapiens	26-31
33799514-5	2021	Platinum-relapsed UC patients harboring FGFR2/3 mutations can be treated with erdafitinib, while enfortumab vedotin has emerged as a novel third-line treatment option for mUC.	Platinum	0-8	fibroblast growth factor receptor 2	Homo sapiens	40-47
33800294-0	2021	Polymorphisms in the Gene Encoding Caspase 8 May Predict the Response to First-Line Platinum-Based Chemotherapy in Locally Advanced or Advanced Non-Small-Cell Lung Cancer.	Platinum	84-92	caspase 8	Homo sapiens	35-44
33801098-6	2021	This study elucidated that PT can be effective against melanoma through the inhibition of adrenocorticotropic hormone production in the brain of a mouse, which weakens the Nrf2-dependent antioxidant defenses of melanoma and also pancreatic cancers.	Platinum	27-29	nuclear factor, erythroid derived 2, like 2	Mus musculus	172-176
33771891-6	2021	CD39 was further associated with primary chemorefractory and chemoresistant human HGSC and platinum-based chemotherapy of murine HGSC was significantly more effective in CD39-deficient mice.	Platinum	91-99	ectonucleoside triphosphate diphosphohydrolase 1	Mus musculus	170-174
32796711-0	2020	Cellular Responses to Platinum-Based Anticancer Drugs and UVC: Role of p53 and Implications for Cancer Therapy.	Platinum	22-30	tumor protein p53	Homo sapiens	71-74
33588906-3	2021	NSD1 mutations are correlated with improved clinical outcomes and increased sensitivity to platinum-based chemotherapy agents in human papillomavirus-negative (HPV-) tumors, despite weak T-cell infiltration.	Platinum	91-99	nuclear receptor binding SET domain protein 1	Homo sapiens	0-4
33812182-2	2021	To solve this problem, we conducted RNAi-based large-scale screening and determined that tyrosine kinase with immunoglobulin-like and EGF-like domains 1 (TIE-1) is a key molecule involved in the platinum resistance of ovarian cancer cells.	Platinum	195-203	tyrosine kinase with immunoglobulin like and EGF like domains 1	Homo sapiens	154-159
33161703-8	2020	Meanwhile, the upregulated acidity and H2O2 content in the tumor region generated by GOx catalytic oxidation of glucose dramatically facilitated the pH-responsive POD-like activity of the Pd@Pt nanozyme, which then catalyzed degradation of the H2O2 to generate abundant highly toxic  OH, thereby realizing nanozyme-mediated starving-enhanced chemodynamic cancer therapy.	Platinum	191-193	hydroxyacid oxidase 1	Homo sapiens	85-88
32860290-4	2020	In this study, we found that elevated expression of LAMP2A is found in NSCLC cell lines as well as patient"s tumors, and confers poor survival and platinum-resistance in NSCLC patients.	Platinum	147-155	lysosomal-associated membrane protein 2	Mus musculus	52-58
32494966-6	2020	Vasohibin-1 was associated with Ly (P = 0.003) and pT (P = 0.037), whereas vasohibin-2 was associated with Ly (P < 0.001), V (P < 0.001) and pStage (P < 0.001).	Platinum	51-53	vasohibin 1	Homo sapiens	0-11
32796638-1	2020	Herein, a novel electrochemical glucose biosensor based on glucose oxidase (GOx) immobilized on a surface containing platinum nanoparticles (PtNPs) electrodeposited on poly(Azure A) (PAA) previously electropolymerized on activated screen-printed carbon electrodes (GOx-PtNPs-PAA-aSPCEs) is reported.	Platinum	117-125	hydroxyacid oxidase 1	Homo sapiens	59-74
32796638-1	2020	Herein, a novel electrochemical glucose biosensor based on glucose oxidase (GOx) immobilized on a surface containing platinum nanoparticles (PtNPs) electrodeposited on poly(Azure A) (PAA) previously electropolymerized on activated screen-printed carbon electrodes (GOx-PtNPs-PAA-aSPCEs) is reported.	Platinum	117-125	hydroxyacid oxidase 1	Homo sapiens	76-79
26794883-4	2016	Predictors of the benefits of improved overall survival (OS) or probability of freedom from recurrence (FFR) from platinum-based adjuvant chemotherapy in patients with resected stage IB lung adenocarcinoma were investigated.	Platinum	114-122	VPS51 subunit of GARP complex	Homo sapiens	104-107
24882434-1	2014	BACKGROUND: Maintenance monotherapy with the PARP inhibitor olaparib significantly prolonged progression-free survival (PFS) versus placebo in patients with platinum-sensitive recurrent serous ovarian cancer.	Platinum	157-165	poly(ADP-ribose) polymerase 1	Homo sapiens	45-49
26338418-0	2015	A common polymorphism in the 5" UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy.	Platinum	96-104	ERCC excision repair 5, endonuclease	Homo sapiens	39-44
26338418-3	2015	Importantly, inhibition of DNA-PKcs restores sensitivity to platinum-based compounds by preventing uORF1-dependent ERCC5 expression.	Platinum	60-68	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	27-35
26338418-3	2015	Importantly, inhibition of DNA-PKcs restores sensitivity to platinum-based compounds by preventing uORF1-dependent ERCC5 expression.	Platinum	60-68	ERCC excision repair 5, endonuclease	Homo sapiens	115-120
25261661-0	2014	Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer.	Platinum	42-50	secreted phosphoprotein 1	Homo sapiens	0-11
25261661-1	2014	PURPOSE: To examine the expression of osteopontin (OPN) in patients with advanced non-small cell lung cancer (NSCLC), and to analyze the correlation of the expression level of OPN with response to platinum-based chemotherapy and the prognosis of NSCLC patients.	Platinum	197-205	secreted phosphoprotein 1	Homo sapiens	176-179
25261661-8	2014	Pearson"s correlation analysis results showed that OPN expression was significantly correlated with age (r=0.338, p=0.001) , distant metastasis (r=0.368, p&lt;0.001), curative effect of platinum-based regimen (r=0.403, p&lt;0.001), progression-free survival/PFS (r=-0.486, p&lt;0.001) and overall survival/OS (r=-0.552, p&lt;0.001).	Platinum	186-194	secreted phosphoprotein 1	Homo sapiens	51-54
25693518-6	2015	Further studies showed that the platinum level of DNA after CDDP exposure was significantly lower in MGMT-proficient cells than in MGMT-deficient cells.	Platinum	32-40	O-6-methylguanine-DNA methyltransferase	Homo sapiens	101-105
25693518-6	2015	Further studies showed that the platinum level of DNA after CDDP exposure was significantly lower in MGMT-proficient cells than in MGMT-deficient cells.	Platinum	32-40	O-6-methylguanine-DNA methyltransferase	Homo sapiens	131-135
23934192-2	2013	Although low ERCC1 expression correlates with platinum sensitivity, the clinical effectiveness of platinum therapy is limited, highlighting the need for alternative treatment strategies.	Platinum	46-54	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	13-18
23934192-6	2013	Importantly, we found that ERCC1 isoform 202, which has recently been shown to mediate platinum sensitivity, also modulated PARP1/2 sensitivity.	Platinum	87-95	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	27-32
23934192-6	2013	Importantly, we found that ERCC1 isoform 202, which has recently been shown to mediate platinum sensitivity, also modulated PARP1/2 sensitivity.	Platinum	87-95	poly(ADP-ribose) polymerase family member 12	Homo sapiens	124-131
25261661-9	2014	Furthermore, the OPN expression was an independent predictor of PFS and OS for patients with advanced NSCLC after receiving platinum-based first-line chemotherapy (p&lt;0.001).	Platinum	124-132	secreted phosphoprotein 1	Homo sapiens	17-20
25261661-10	2014	CONCLUSION: OPN expression is an independent predictor of response to platinum-based first-line chemotherapy and of the prognosis of patients with advanced NSCLC.	Platinum	70-78	secreted phosphoprotein 1	Homo sapiens	12-15
24882434-14	2014	INTERPRETATION: These results support the hypothesis that patients with platinum-sensitive recurrent serous ovarian cancer with a BRCA mutation have the greatest likelihood of benefiting from olaparib treatment.	Platinum	72-80	BRCA1 DNA repair associated	Homo sapiens	130-134
22863869-0	2013	Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy.	Platinum	101-109	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	4-9
22863869-1	2013	PURPOSE: Excision repair cross-complementation group 1 enzyme (ERCC1) plays a key role in the removal of platinum induced DNA adducts and cisplatin resistance.	Platinum	105-113	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	9-61
22863869-1	2013	PURPOSE: Excision repair cross-complementation group 1 enzyme (ERCC1) plays a key role in the removal of platinum induced DNA adducts and cisplatin resistance.	Platinum	105-113	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	63-68
22863869-3	2013	We evaluated the prognostic role of ERCC1 expression in bladder cancer receiving platinum-based neoadjuvant chemotherapy.	Platinum	81-89	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	36-41
22863869-10	2013	CONCLUSIONS: Our results showed that high ERCC1 expression was independently associated with shorter disease-free and overall survival in patients with bladder cancer who received neoadjuvant platinum-based chemotherapy.	Platinum	192-200	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	42-47
22863869-11	2013	ERCC1 may represent a potential predictive marker for platinum-based treatment in bladder cancer.	Platinum	54-62	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
34896676-4	2022	Initially, in the sensing system containing 4-AAP, TOPS, Tb-DPA and Pt/Pd NF, TOPS and 4-AAP is catalyzed by Pt/Pd NF to produce a purple compound (called as PC1), which endows a broad UV absorption that can fully cover the emission band of Tb-DPA.	Platinum	68-70	proprotein convertase subtilisin/kexin type 1	Homo sapiens	158-161
34781176-3	2022	In this work, N atom-doped graphene functionalized with hollow porous Pt-skin Ag-Pt alloy (HP-Ag/Pt/NGR) was designed as a dual signal amplifier.	Platinum	70-72	reticulon 4 receptor	Homo sapiens	100-103
34915428-0	2022	Platinum(IV) complexes as inhibitors of CD47-SIRPalpha axis for chemoimmunotherapy of cancer.	Platinum	0-8	CD47 molecule	Homo sapiens	40-44
34915428-0	2022	Platinum(IV) complexes as inhibitors of CD47-SIRPalpha axis for chemoimmunotherapy of cancer.	Platinum	0-8	signal regulatory protein alpha	Homo sapiens	45-54
34915428-4	2022	Two platinum-based immunomodulators MUP and DMUP were synthesized to enhance the phagocytic activity of macrophages by blocking the CD47-SIRPalpha axis.	Platinum	4-12	major urinary protein, pseudogene	Homo sapiens	36-39
34488091-3	2022	Herein, to monitor the cyanazine level, Pt and Pd doped CdO nanoparticle decorated SWCNTs composite (Pt-Pd-CdO/SWCNTs) has been synthesized as a conductive mediator and characterized by EDS, SEM and TEM techniques.	Platinum	101-103	cell adhesion associated, oncogene regulated	Homo sapiens	56-59
34488091-3	2022	Herein, to monitor the cyanazine level, Pt and Pd doped CdO nanoparticle decorated SWCNTs composite (Pt-Pd-CdO/SWCNTs) has been synthesized as a conductive mediator and characterized by EDS, SEM and TEM techniques.	Platinum	101-103	cell adhesion associated, oncogene regulated	Homo sapiens	107-110
34781176-3	2022	In this work, N atom-doped graphene functionalized with hollow porous Pt-skin Ag-Pt alloy (HP-Ag/Pt/NGR) was designed as a dual signal amplifier.	Platinum	81-83	reticulon 4 receptor	Homo sapiens	100-103
34881519-9	2022	CONCLUSIONS: First-line platinum-based chemotherapy showed durable benefit in patients with advanced or metastatic nonsquamous NSCLC harboring rare genetic mutation other than EGFR or ALK.	Platinum	24-32	epidermal growth factor receptor	Homo sapiens	176-180
34924242-9	2022	In the platinum-sensitive subgroup of BRCA1, patients with BRCA1 PV in the OCCR region showed shorter PFS than those in the non-OCCR group (P = 0.0197).	Platinum	7-15	BRCA1 DNA repair associated	Homo sapiens	38-43
34924242-9	2022	In the platinum-sensitive subgroup of BRCA1, patients with BRCA1 PV in the OCCR region showed shorter PFS than those in the non-OCCR group (P = 0.0197).	Platinum	7-15	BRCA1 DNA repair associated	Homo sapiens	59-64
34808283-3	2022	The deficiency of DNA repair by homologous recombination (HRD), which is caused by inactivation of BRCA1/2 genes or other genetic events, is associated with high tumor responsiveness to platinum compounds, bifunctional alkylating agents and topoisomerase II poisons.	Platinum	186-194	BRCA1 DNA repair associated	Homo sapiens	99-106
34420870-12	2022	sTIL amount is an independent predictor for improved survival, and might be an useful, routinely applicable tool to identify patients benefiting from perioperative platinum-based chemotherapy and checkpoint inhibitor therapy.	Platinum	164-172	STIL centriolar assembly protein	Homo sapiens	0-4
34881519-9	2022	CONCLUSIONS: First-line platinum-based chemotherapy showed durable benefit in patients with advanced or metastatic nonsquamous NSCLC harboring rare genetic mutation other than EGFR or ALK.	Platinum	24-32	ALK receptor tyrosine kinase	Homo sapiens	184-187
34904820-7	2022	By studying in detail the processes that affect the stability of the SAA phase, we have shown that out of several bimetallic combinations of coinage metals with prominent Pt-group metals only PtCu and PdCu are stable surface alloys under vacuum.	Platinum	171-173	serum amyloid A1 cluster	Homo sapiens	69-72
34788502-5	2022	Using this route, the alloying of Pt-Sn and formation of PtSn-SnO x interfaces can simultaneously be achieved, and the coverage of SnO x thin films on PtSn alloy nanoparticles can be facilely tuned by the strong interaction between Pt and SnO x .	Platinum	34-36	strawberry notch homolog 1	Homo sapiens	239-242
34788502-5	2022	Using this route, the alloying of Pt-Sn and formation of PtSn-SnO x interfaces can simultaneously be achieved, and the coverage of SnO x thin films on PtSn alloy nanoparticles can be facilely tuned by the strong interaction between Pt and SnO x .	Platinum	232-234	strawberry notch homolog 1	Homo sapiens	62-65
34788502-5	2022	Using this route, the alloying of Pt-Sn and formation of PtSn-SnO x interfaces can simultaneously be achieved, and the coverage of SnO x thin films on PtSn alloy nanoparticles can be facilely tuned by the strong interaction between Pt and SnO x .	Platinum	232-234	strawberry notch homolog 1	Homo sapiens	131-134
34788502-5	2022	Using this route, the alloying of Pt-Sn and formation of PtSn-SnO x interfaces can simultaneously be achieved, and the coverage of SnO x thin films on PtSn alloy nanoparticles can be facilely tuned by the strong interaction between Pt and SnO x .	Platinum	232-234	strawberry notch homolog 1	Homo sapiens	239-242
34727402-3	2022	To deepen the knowledge of the structural properties underlying the reactivity of platinum drugs with copper transporters, we studied the interaction of kiteplatin and two of its derivatives with the methionine-rich motif of copper importer Ctr1 and with the dithiol motif of the first domain of Menkes ATPase.	Platinum	82-90	dynein axonemal heavy chain 8	Homo sapiens	303-309
34388924-0	2022	Synergy of surface sodium and hydroxyl on NaTi2HO5 nanotubes accelerating the Pt-dominated ambient HCHO oxidation.	Platinum	78-80	N-acetyltransferase 1	Homo sapiens	42-46
34388924-7	2022	Dominated by Pt nanoparticles, the complete oxidation of HCHO can be performed on NaTi2HO5 nanotubes with enhanced early reaction speed.	Platinum	13-15	N-acetyltransferase 1	Homo sapiens	82-86
34968071-3	2022	Herein, the self-cascade nanozyme Pt/CeO2 with high efficiency toward simultaneous UA degradation and H2O2 elimination is demonstrated on the basis of both uricase- and CAT-like activities in Pt, Ir, Rh, and Pd platinum-group metals.	Platinum	34-36	urate oxidase	Rattus norvegicus	156-163
34968071-3	2022	Herein, the self-cascade nanozyme Pt/CeO2 with high efficiency toward simultaneous UA degradation and H2O2 elimination is demonstrated on the basis of both uricase- and CAT-like activities in Pt, Ir, Rh, and Pd platinum-group metals.	Platinum	34-36	catalase	Rattus norvegicus	169-172
34732853-5	2022	The basal level of RAD51 foci evaluated in geminin-positive/replicating cells strongly inversely correlated with olaparib response (p = 0.011); in particular, the lower the foci score, the greater the sensitivity to olaparib, while low RAD51 foci score seems to associate with platinum activity.	Platinum	277-285	RAD51 recombinase	Homo sapiens	19-24
34716858-5	2022	XIAP was found to contribute to developing platinum resistance and is an authentic target for miR-874-3p in SKOV3-DDP cells.	Platinum	43-51	X-linked inhibitor of apoptosis	Homo sapiens	0-4
34799380-1	2022	A 5-year follow-up of patients in the ongoing SOLO1 trial showed that patients with advanced BRCA-mutated ovarian cancer who had finished platinum-based chemotherapy had a significantly longer median progression-free survival when they received 2 years of olaparib as a maintenance therapy instead of placebo-56 months versus 13.8 months, respectively.	Platinum	138-146	BRCA1 DNA repair associated	Homo sapiens	93-97
34347217-0	2022	Association between ABCC2 polymorphism and hematological toxicity in patients with esophageal cancer receiving platinum plus 5-fluorouracil therapy.	Platinum	111-119	ATP binding cassette subfamily C member 2	Homo sapiens	20-25
34347217-1	2022	BACKGROUND: Platinum agents are taken up into cells by copper transporter (CTR) 1 (gene code: SLC31A1) and are excreted from cells by copper-transporting P-type adenosine triphosphatase (ATP7B) and multidrug resistance-associated protein (MRP) 2 (gene code: ABCC2).	Platinum	12-20	solute carrier family 31 member 1	Homo sapiens	55-81
34347217-1	2022	BACKGROUND: Platinum agents are taken up into cells by copper transporter (CTR) 1 (gene code: SLC31A1) and are excreted from cells by copper-transporting P-type adenosine triphosphatase (ATP7B) and multidrug resistance-associated protein (MRP) 2 (gene code: ABCC2).	Platinum	12-20	solute carrier family 31 member 1	Homo sapiens	94-101
34347217-1	2022	BACKGROUND: Platinum agents are taken up into cells by copper transporter (CTR) 1 (gene code: SLC31A1) and are excreted from cells by copper-transporting P-type adenosine triphosphatase (ATP7B) and multidrug resistance-associated protein (MRP) 2 (gene code: ABCC2).	Platinum	12-20	ATPase copper transporting beta	Homo sapiens	187-192
34347217-1	2022	BACKGROUND: Platinum agents are taken up into cells by copper transporter (CTR) 1 (gene code: SLC31A1) and are excreted from cells by copper-transporting P-type adenosine triphosphatase (ATP7B) and multidrug resistance-associated protein (MRP) 2 (gene code: ABCC2).	Platinum	12-20	ATP binding cassette subfamily C member 2	Homo sapiens	198-245
34347217-1	2022	BACKGROUND: Platinum agents are taken up into cells by copper transporter (CTR) 1 (gene code: SLC31A1) and are excreted from cells by copper-transporting P-type adenosine triphosphatase (ATP7B) and multidrug resistance-associated protein (MRP) 2 (gene code: ABCC2).	Platinum	12-20	ATP binding cassette subfamily C member 2	Homo sapiens	258-263
34347217-2	2022	In addition, glutathione S transferase (GST) P1 is involved in the metabolism of platinum agents.	Platinum	81-89	glutathione S-transferase pi 1	Homo sapiens	13-47
34347217-8	2022	CONCLUSIONS: We determined that ABCC2 -24C>T is significantly associated with grade 3-4 hematological toxicity after platinum plus 5-FU therapy.	Platinum	117-125	ATP binding cassette subfamily C member 2	Homo sapiens	32-37
34756749-2	2022	METHODS: TMEM205 expression was evaluated in platinum-sensitive (PS) versus platinum resistant (PR) ovarian cancer cell lines and patient serum/tissues.	Platinum	76-84	transmembrane protein 205	Homo sapiens	9-16
34756749-2	2022	METHODS: TMEM205 expression was evaluated in platinum-sensitive (PS) versus platinum resistant (PR) ovarian cancer cell lines and patient serum/tissues.	Platinum	76-84	transmembrane protein 37	Homo sapiens	96-98
34756749-10	2022	CONCLUSION: TMEM205 appears to be involved in the development of PR in ovarian cancer through the exosomal efflux of platinum agents.	Platinum	117-125	transmembrane protein 205	Homo sapiens	12-19
34756749-10	2022	CONCLUSION: TMEM205 appears to be involved in the development of PR in ovarian cancer through the exosomal efflux of platinum agents.	Platinum	117-125	transmembrane protein 37	Homo sapiens	65-67
34756749-11	2022	This study provides pre-clinical evidence that TMEM205 could serve as a possible biomarker for PR as well as a therapeutic target in combination with platinum agents.	Platinum	150-158	transmembrane protein 205	Homo sapiens	47-54
34689382-0	2022	Predictive value of EGFR mutation in NSCLC patients treated with platinum doublet postoperative chemotherapy.	Platinum	65-73	epidermal growth factor receptor	Homo sapiens	20-24
34689382-6	2022	This study demonstrated that EGFR mutation has either a poor prognostic or predictive impact on a poor response to postoperative chemotherapy with platinum doublet chemotherapy for stage II/III Ns-NSCLC patients.	Platinum	147-155	epidermal growth factor receptor	Homo sapiens	29-33
34756749-0	2022	Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.	Platinum	50-58	transmembrane protein 205	Homo sapiens	23-30
34756749-0	2022	Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.	Platinum	50-58	death associated protein	Homo sapiens	135-138
34756749-1	2022	INTRODUCTION: TMEM205 is a novel transmembrane protein associated with platinum resistance (PR) in epithelial ovarian carcinoma (OC), however, the specific mechanisms associated with this resistance remain to be elucidated.	Platinum	71-79	transmembrane protein 205	Homo sapiens	14-21
34756749-1	2022	INTRODUCTION: TMEM205 is a novel transmembrane protein associated with platinum resistance (PR) in epithelial ovarian carcinoma (OC), however, the specific mechanisms associated with this resistance remain to be elucidated.	Platinum	71-79	transmembrane protein 37	Homo sapiens	92-94
34756749-2	2022	METHODS: TMEM205 expression was evaluated in platinum-sensitive (PS) versus platinum resistant (PR) ovarian cancer cell lines and patient serum/tissues.	Platinum	45-53	transmembrane protein 205	Homo sapiens	9-16
34791815-10	2022	CONCLUSIONS: The combination therapies, which were the platinum regimen + Pemb and the platinum regimen + Niv + Ipi, rather than ICI monotherapy were effective first-line agents for treating squamous NSCLC with low PD-L1 levels.	Platinum	87-95	CD274 molecule	Homo sapiens	215-220
34911343-0	2022	Association of NAT-2 gene polymorphisms toward lung cancer susceptibility and prognosis in North Indian patients treated with platinum-based chemotherapy.	Platinum	126-134	N-acetyltransferase 2	Homo sapiens	15-20
34954996-14	2021	USP22 may be involved in the process of platinum-based chemotherapy resistance of colorectal cancer by regulating the expressions of P-gp and MRP1.	Platinum	40-48	ubiquitin specific peptidase 22	Homo sapiens	0-5
34963005-10	2022	This observation was due to a statistically significantly increased number of platinum-based chemotherapy lines in gBRCA1/2 mutation carriers vs noncarriers (PPM1D: mean (SD) = 2.04 (1.27) vs 1.04 (0.99), P < .001; TP53: mean (SD) =2.83 (1.33) vs 1.07 (1.01), P < .001).	Platinum	78-86	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	158-163
34963005-10	2022	This observation was due to a statistically significantly increased number of platinum-based chemotherapy lines in gBRCA1/2 mutation carriers vs noncarriers (PPM1D: mean (SD) = 2.04 (1.27) vs 1.04 (0.99), P < .001; TP53: mean (SD) =2.83 (1.33) vs 1.07 (1.01), P < .001).	Platinum	78-86	tumor protein p53	Homo sapiens	215-219
34954996-14	2021	USP22 may be involved in the process of platinum-based chemotherapy resistance of colorectal cancer by regulating the expressions of P-gp and MRP1.	Platinum	40-48	phosphoglycolate phosphatase	Homo sapiens	133-137
34954996-14	2021	USP22 may be involved in the process of platinum-based chemotherapy resistance of colorectal cancer by regulating the expressions of P-gp and MRP1.	Platinum	40-48	CD9 molecule	Homo sapiens	142-146
34890203-0	2021	Enhanced Electrocatalytic Oxidation of Small Organic Molecules on Platinum-Gold Nanowires: Influence of the Surface Structure and Pt-Pt/Pt-Au Pair Site Density.	Platinum	66-74	protein tyrosine phosphatase non-receptor type 2	Homo sapiens	130-135
34890203-0	2021	Enhanced Electrocatalytic Oxidation of Small Organic Molecules on Platinum-Gold Nanowires: Influence of the Surface Structure and Pt-Pt/Pt-Au Pair Site Density.	Platinum	136-138	protein tyrosine phosphatase non-receptor type 2	Homo sapiens	130-135
34948122-9	2021	Since the BIN1 gene rarely mutates in human cancers, our results suggest that simultaneous inhibition of PARP1 and ATM provokes a new BRCAness-independent synthetic lethal effect and ultimately re-establishes cisplatin sensitivity even in platinum-refractory cancer cells.	Platinum	239-247	poly(ADP-ribose) polymerase 1	Homo sapiens	105-110
34793589-0	2021	ZNF76 predicts prognosis and response to platinum chemotherapy in human ovarian cancer.	Platinum	41-49	zinc finger protein 76	Homo sapiens	0-5
34793589-7	2021	A strong relationship between ZNF76 expression and platinum resistance was determined in patients with OV.	Platinum	51-59	zinc finger protein 76	Homo sapiens	30-35
34793589-14	2021	In conclusion, ZNF76 may serve as a promising prognostic-related biomarker and predict the response to platinum in OV patients.	Platinum	103-111	zinc finger protein 76	Homo sapiens	15-20
34933901-3	2022	Coupling whole exome sequencing, bulk RNA and single-cell transcriptomics from paired pre- and on-treatment samples in treatment naive HER2-positive and HER2-negative gastric cancer patients, we define features associated with response to platinum-based CTX.	Platinum	239-247	erb-b2 receptor tyrosine kinase 2	Homo sapiens	135-139
34933901-3	2022	Coupling whole exome sequencing, bulk RNA and single-cell transcriptomics from paired pre- and on-treatment samples in treatment naive HER2-positive and HER2-negative gastric cancer patients, we define features associated with response to platinum-based CTX.	Platinum	239-247	erb-b2 receptor tyrosine kinase 2	Homo sapiens	153-157
34930918-3	2021	Accordingly, this study aims to investigate the mechanism of SOX6-induced autophagy and its potential significance in the platinum-based chemotherapy of cervical cancer.	Platinum	122-130	SRY-box transcription factor 6	Homo sapiens	61-65
34930918-9	2021	These findings uncovered the underlying mechanism and potential significance of SOX6-induced autophagy, and shed new light on the usage of MAP4K4 inhibitor or autophagy-specific inhibitor for sensitizing cervical cancer cells to the platinum-based chemotherapy.	Platinum	233-241	SRY-box transcription factor 6	Homo sapiens	80-84
34930918-9	2021	These findings uncovered the underlying mechanism and potential significance of SOX6-induced autophagy, and shed new light on the usage of MAP4K4 inhibitor or autophagy-specific inhibitor for sensitizing cervical cancer cells to the platinum-based chemotherapy.	Platinum	233-241	mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens	139-145
34921590-3	2022	Herein, the influence of surface properties and crystallite size on the propulsion mechanism of Pt/TiO2 chemical/light-driven hybrid microrobots is investigated.	Platinum	96-98	tiptop	Drosophila melanogaster	99-102
34866382-5	2021	We demonstrate the superior photocatalytic activity of these noble metal free materials through solar hydrogen generation at a hydrogen evolution rate of 22.01 mmol g-1 h-1, which is 1.5-fold that of Pt/CdS heterostructure photocatalyst particles.	Platinum	200-202	CDP-diacylglycerol synthase 1	Homo sapiens	203-206
34895243-6	2021	More importantly, anti-tumor experiments in vivo proved that MnP@Lip combined with platinum-based chemotherapeutics increased T cells infiltration in the tumor microenvironment, and inhibited tumor growth in the orthotopic therapeutic and postoperative tumor models.	Platinum	83-91	modifier of Niemann Pick type C1	Mus musculus	61-64
34895243-7	2021	CONCLUSIONS: This kind of therapeutic strategy that combined MnP@Lip nanoparticles with platinum-based chemotherapeutics may provide a novel insight for immunochemotherapy.	Platinum	88-96	modifier of Niemann Pick type C1	Mus musculus	61-64
34946777-1	2021	Mono-, and bimetallic Ni-, Ru-, and Pt-modified nanosized Beta zeolite catalysts were prepared by the post synthesis method and characterized by powder X-ray diffraction (XRD), nitrogen physisorption, HRTEM microscopy, temperature-programmed reduction (TPR-TGA), ATR FT-IR spectroscopy, and by solid-state MAS-NMR spectroscopy.	Platinum	36-38	T-box transcription factor 1	Homo sapiens	257-260
34921137-6	2021	Moreover, disturbing the redox homeostasis of cancer cells by genetic knockdown of RPRD1A sensitizes cancer cells to platinum-induced cell death.	Platinum	117-125	regulation of nuclear pre-mRNA domain containing 1A	Homo sapiens	83-89
34649182-4	2021	Among them, PT-65 exhibited most potent degradation potency against GSK3alpha (DC50 = 28.3 nM) and GSK3beta (DC50 = 34.2 nM) in SH-SY5Y cells.	Platinum	12-14	glycogen synthase kinase 3 alpha	Homo sapiens	68-77
34649182-4	2021	Among them, PT-65 exhibited most potent degradation potency against GSK3alpha (DC50 = 28.3 nM) and GSK3beta (DC50 = 34.2 nM) in SH-SY5Y cells.	Platinum	12-14	glycogen synthase kinase 3 alpha	Homo sapiens	99-107
34649182-5	2021	SPR assay confirmed that PT-65 binds to GSK3beta with high affinity (KD = 12.41 nM).	Platinum	25-27	glycogen synthase kinase 3 alpha	Homo sapiens	40-48
34265672-2	2021	Here we report the colorimetric detection of spike (S1) protein of SARS-CoV-2 based on excellent peroxidase-like activity of Au@Pt nanoparticles, with merits of rapidness, easy operation, and high sensitivity.	Platinum	128-130	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	45-50
34948122-9	2021	Since the BIN1 gene rarely mutates in human cancers, our results suggest that simultaneous inhibition of PARP1 and ATM provokes a new BRCAness-independent synthetic lethal effect and ultimately re-establishes cisplatin sensitivity even in platinum-refractory cancer cells.	Platinum	239-247	ATM serine/threonine kinase	Homo sapiens	115-118
34916851-2	2021	This study aims to compare the efficacy of platinum-based chemotherapy (etoposide combined with cisplatin/carboplatin, EP/EC) and transcatheter arterial chemoembolization (TACE) in patients with advanced PHNEC, and to evaluate the relevant prognostic factors.	Platinum	43-51	epiregulin	Homo sapiens	119-124
34883530-4	2022	Significantly, by means of SnO2 as a mediator or adaptor, not only different single-atom metal sites, such as Pt, Cu and Ni, etc., can be installed, but also the MOF supports can be changed (for example, UiO-66-NH2 , PCN-222, and DUT-67) to afford M1 /SnO2 /MOF architecture.	Platinum	110-112	lysine acetyltransferase 8	Homo sapiens	258-261
34346155-0	2021	Tailoring the Local Environment of Platinum in Single-Atom Pt1/CeO2 Catalysts for Robust Low-Temperature CO Oxidation.	Platinum	35-43	zinc finger protein 77	Homo sapiens	59-62
34944784-3	2021	The platinum-sensitive class is characterized by the expression of GATA6, miRNA-200a, and miRNA-200b, which might be developable as predictive biomarkers.	Platinum	4-12	GATA binding protein 6	Homo sapiens	67-72
34944784-7	2021	On top of this, HSP90 inhibition also enhanced the accumulation of DNA-bound platinum.	Platinum	77-85	heat shock protein 90 alpha family class A member 1	Homo sapiens	16-21
34519404-7	2021	Moreover, a similar energy gap between the NBN-PT dication (1.21 eV) and its isoelectronic structure peri -tetracene (1.11 eV) can be predicted by DFT calculations.	Platinum	47-49	nibrin	Homo sapiens	43-46
34876578-0	2021	Electric-field control of field-free spin-orbit torque switching via laterally modulated Rashba effect in Pt/Co/AlOx structures.	Platinum	106-108	spindlin 1	Homo sapiens	37-41
34346155-4	2021	Ultrafast shockwaves (> 1200 o C) in an inert atmosphere induce surface reconstruction of CeO 2 , generating Pt single atoms in an asymmetric Pt 1 O 4 configuration.	Platinum	109-111	zinc finger protein 77	Homo sapiens	142-146
34477047-2	2021	The promoting role of RecQ-Like Helicase 4 (RECQL4) in chemoresistance to platinum-based drugs has been identified, whereas the effect and specific mechanism of RECQL4 in regulating OXA resistance within COAD have not been explicated yet.	Platinum	74-82	RecQ like helicase 4	Homo sapiens	44-50
34908877-0	2021	Low Density Lipoprotein Receptor (LDLR) and 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase (HMGCR) Expression are Associated with Platinum-Resistance and Prognosis in Ovarian Carcinoma Patients.	Platinum	131-139	low density lipoprotein receptor	Homo sapiens	0-32
34908877-0	2021	Low Density Lipoprotein Receptor (LDLR) and 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase (HMGCR) Expression are Associated with Platinum-Resistance and Prognosis in Ovarian Carcinoma Patients.	Platinum	131-139	low density lipoprotein receptor	Homo sapiens	34-38
34908877-0	2021	Low Density Lipoprotein Receptor (LDLR) and 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase (HMGCR) Expression are Associated with Platinum-Resistance and Prognosis in Ovarian Carcinoma Patients.	Platinum	131-139	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	93-98
34908877-11	2021	Immunohistochemistry showed that LDLR expression was high and HMGCR was low in platinum-resistant patients.	Platinum	79-87	low density lipoprotein receptor	Homo sapiens	33-37
34908877-11	2021	Immunohistochemistry showed that LDLR expression was high and HMGCR was low in platinum-resistant patients.	Platinum	79-87	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	62-67
34783528-5	2021	Specifically, beta-Sb with single atom replacement has even superior that the reference catalysts IrO2(110) and Pt(111) with relatively low overpotential values for ORR and OER mechanisms.	Platinum	112-114	5'-aminolevulinate synthase 2	Homo sapiens	14-21
34605065-7	2021	In contrast, at a relatively low Pt loading (<6 wt%), the formation of single Pt sites in the form of PtC3 N is thermodynamically favorable, in which a synergy between the PtC3 N and the CoN4 sites could enhance the catalytic activity for the ORR, but showing insufficient stability.	Platinum	33-35	nuclear receptor coactivator 4	Homo sapiens	172-176
34605065-7	2021	In contrast, at a relatively low Pt loading (<6 wt%), the formation of single Pt sites in the form of PtC3 N is thermodynamically favorable, in which a synergy between the PtC3 N and the CoN4 sites could enhance the catalytic activity for the ORR, but showing insufficient stability.	Platinum	78-80	nuclear receptor coactivator 4	Homo sapiens	172-176
34753568-9	2021	A wide linear range (0.1-20 mum for gold nanoparticles, 0.1-10 mum for platinum nanoparticles) with high sensitivity (6.02 and 7.19 muA muM-1 cm-2 for gold and platinum, respectively) and a low limit of detection (75 and 62 nM for Au and Pt, respectively) were achieved.	Platinum	71-79	PWWP domain containing 3A, DNA repair factor	Homo sapiens	136-141
34967559-0	2021	Effect of XPD and TP53 Gene Polymorphisms on the Risk of Platinum-Based Chemotherapy Induced Toxicity in Bangladeshi Lung Cancer Patients.	Platinum	57-65	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	10-13
34967559-0	2021	Effect of XPD and TP53 Gene Polymorphisms on the Risk of Platinum-Based Chemotherapy Induced Toxicity in Bangladeshi Lung Cancer Patients.	Platinum	57-65	tumor protein p53	Homo sapiens	18-22
34967559-4	2021	Therefore, this study aimed to investigate XPD Lys751Gln and TP53 Arg72Pro polymorphisms on the risk of platinum-based chemotherapy-induced toxicity in lung cancer patients in the Bangladeshi population.	Platinum	104-112	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	43-46
34967559-4	2021	Therefore, this study aimed to investigate XPD Lys751Gln and TP53 Arg72Pro polymorphisms on the risk of platinum-based chemotherapy-induced toxicity in lung cancer patients in the Bangladeshi population.	Platinum	104-112	tumor protein p53	Homo sapiens	61-65
34908877-12	2021	Conclusion: The expression of LDLR and HMGCR proteins, involved in the regulation of cholesterol metabolism and the plasma LDL and cholesterol levels were significantly different in platinum-resistant and platinum-sensitive ovarian cancer patients.	Platinum	182-190	low density lipoprotein receptor	Homo sapiens	30-34
34908877-12	2021	Conclusion: The expression of LDLR and HMGCR proteins, involved in the regulation of cholesterol metabolism and the plasma LDL and cholesterol levels were significantly different in platinum-resistant and platinum-sensitive ovarian cancer patients.	Platinum	182-190	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	39-44
34477047-2	2021	The promoting role of RecQ-Like Helicase 4 (RECQL4) in chemoresistance to platinum-based drugs has been identified, whereas the effect and specific mechanism of RECQL4 in regulating OXA resistance within COAD have not been explicated yet.	Platinum	74-82	RecQ like helicase 4	Homo sapiens	22-42
34663950-3	2021	RESULTS: High SLFN11 associated with improved prognosis to the first-line treatment with DDAs platinum-plus-etoposide in SCLC patients, but was not strongly linked to paclitaxel-platinum response in ovarian cancer patients.	Platinum	94-102	schlafen family member 11	Homo sapiens	14-20
34794242-0	2021	The endocytic pathway of Pt nanoclusters and their induced apoptosis of A549 and A549/Cis cells through c-Myc/p53 and Bcl-2/caspase-3 signaling pathways.	Platinum	25-27	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	104-109
34794242-0	2021	The endocytic pathway of Pt nanoclusters and their induced apoptosis of A549 and A549/Cis cells through c-Myc/p53 and Bcl-2/caspase-3 signaling pathways.	Platinum	25-27	tumor protein p53	Homo sapiens	110-113
34794242-0	2021	The endocytic pathway of Pt nanoclusters and their induced apoptosis of A549 and A549/Cis cells through c-Myc/p53 and Bcl-2/caspase-3 signaling pathways.	Platinum	25-27	BCL2 apoptosis regulator	Homo sapiens	118-123
34794242-0	2021	The endocytic pathway of Pt nanoclusters and their induced apoptosis of A549 and A549/Cis cells through c-Myc/p53 and Bcl-2/caspase-3 signaling pathways.	Platinum	25-27	caspase 3	Homo sapiens	124-133
34955157-3	2021	Treatments with PARP inhibitors is a major advance in medical management with significant efficacy in maintenance after response to platinum-based chemotherapy.	Platinum	132-140	poly(ADP-ribose) polymerase 1	Homo sapiens	16-20
34266348-12	2021	The results revealed that CDC20 was a potential platinum-sensitivity indicator in advanced SOC.	Platinum	48-56	cell division cycle 20	Homo sapiens	26-31
34954894-0	2021	Identification of potent SENP1 inhibitors that inactivate SENP1/JAK2/STAT signaling pathway and overcome platinum drug resistance in ovarian cancer.	Platinum	105-113	SUMO specific peptidase 1	Homo sapiens	25-30
34620772-5	2021	RECENT FINDINGS: PD-1/PD-L1 immune checkpoint inhibitors (ICIs) have demonstrated activity in the postplatinum and platinum-ineligible settings.	Platinum	115-123	programmed cell death 1	Homo sapiens	17-21
34620772-5	2021	RECENT FINDINGS: PD-1/PD-L1 immune checkpoint inhibitors (ICIs) have demonstrated activity in the postplatinum and platinum-ineligible settings.	Platinum	115-123	CD274 molecule	Homo sapiens	22-27
34688610-3	2021	To investigate whether and how HNRNPUL1 affects CDDP resistance of ESCC, we evaluated the expression of HNRNPUL1 and found that it was associated with recurrence in ESCC patients receiving postoperative platinum-based chemotherapy and was an independent prognostic factor for disease-free survival (DFS).	Platinum	203-211	heterogeneous nuclear ribonucleoprotein U like 1	Homo sapiens	31-39
34583845-1	2021	Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.	Platinum	81-89	C-X-C motif chemokine receptor 2	Homo sapiens	34-39
34583845-1	2021	Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.	Platinum	81-89	BCL2 apoptosis regulator	Homo sapiens	40-45
34688610-3	2021	To investigate whether and how HNRNPUL1 affects CDDP resistance of ESCC, we evaluated the expression of HNRNPUL1 and found that it was associated with recurrence in ESCC patients receiving postoperative platinum-based chemotherapy and was an independent prognostic factor for disease-free survival (DFS).	Platinum	203-211	heterogeneous nuclear ribonucleoprotein U like 1	Homo sapiens	104-112
34672683-0	2021	Genetic polymorphisms in the mEH gene in relation to tobacco smoking: role in lung cancer susceptibility and survival in north Indian patients with lung cancer undergoing platinum-based chemotherapy.	Platinum	171-179	epoxide hydrolase 1, microsomal	Mus musculus	29-32
34292495-3	2021	METHODS: We retrospectively analyzed 19 patients with advanced EGFR-mutant NSCLC who had progressed to EGFR tyrosine kinase inhibitors (TKI) and platinum-based chemotherapy receiving docetaxel and nintedanib at 14 Spanish institutions from January 2013 to December 2019.	Platinum	145-153	epidermal growth factor receptor	Homo sapiens	63-67
34673143-4	2021	In a cohort of NSCLC patients, high TXNRD1 protein levels correlated with shorter disease-free survival and distal metastasis-free survival post-surgery, including a subset of individuals treated with platinum-based adjuvant chemotherapy.	Platinum	201-209	thioredoxin reductase 1	Homo sapiens	36-42
34780261-1	2021	BACKGROUND: Genetic polymorphism within the P1 isoenzyme of the Glutathione-S-Transferase (GST) family is found to modulate and alter the enzyme activity of GSTP1 protein and thus may result in a change of sensitivity to platinum-based chemotherapy.	Platinum	221-229	glutathione S-transferase kappa 1	Homo sapiens	64-89
34742578-11	2021	Near 100% rates of bi-allelic loss of BRCA in platinum-sensitive relapsed ovarian tumors suggest routine testing for BRCA zygosity is not required in this population and reflects BRCA loss being a driver of tumorigenesis.	Platinum	46-54	BRCA1 DNA repair associated	Homo sapiens	38-42
34780261-1	2021	BACKGROUND: Genetic polymorphism within the P1 isoenzyme of the Glutathione-S-Transferase (GST) family is found to modulate and alter the enzyme activity of GSTP1 protein and thus may result in a change of sensitivity to platinum-based chemotherapy.	Platinum	221-229	glutathione S-transferase kappa 1	Homo sapiens	91-94
34780261-1	2021	BACKGROUND: Genetic polymorphism within the P1 isoenzyme of the Glutathione-S-Transferase (GST) family is found to modulate and alter the enzyme activity of GSTP1 protein and thus may result in a change of sensitivity to platinum-based chemotherapy.	Platinum	221-229	glutathione S-transferase pi 1	Homo sapiens	157-162
34974867-1	2021	An electrochemical aptasensor for quantitatively detecting glypican-3 (GPC3) was constructed by combining hemin-reduced graphene oxide-platinum (H-rGO-Pt) nanoparticles (NPs) with reduced graphene oxide-gold (rGO-Au) nanoparticles (NPs).	Platinum	135-143	glypican 3	Homo sapiens	59-69
34974867-1	2021	An electrochemical aptasensor for quantitatively detecting glypican-3 (GPC3) was constructed by combining hemin-reduced graphene oxide-platinum (H-rGO-Pt) nanoparticles (NPs) with reduced graphene oxide-gold (rGO-Au) nanoparticles (NPs).	Platinum	135-143	glypican 3	Homo sapiens	71-75
34974867-0	2021	Highly Sensitive Electrochemical Aptasensor for Detection of Glypican-3 Using Hemin-Reduced Graphene Oxide-Platinum Nanoparticles Coupled with Conductive Reduced Graphene Oxide-Gold Nanoparticles.	Platinum	107-115	glypican 3	Homo sapiens	61-71
34818606-10	2021	Among patients with EGFR exon20ins, the most common prescribed first-line therapy was platinum-based chemotherapy (61.3%) followed by EGFR TKIs (21.5%); second-line treatments were varied, with no clear standard of care.	Platinum	86-94	epidermal growth factor receptor	Homo sapiens	20-24
34647981-13	2021	TP53 CHIP was associated with longer prior exposure to platinum (mean 14.0 months of 15 TP53 CHIP cases vs 11.1 months of 49 non-TP53 CHIP cases; P = .02).	Platinum	55-63	tumor protein p53	Homo sapiens	0-4
34647981-13	2021	TP53 CHIP was associated with longer prior exposure to platinum (mean 14.0 months of 15 TP53 CHIP cases vs 11.1 months of 49 non-TP53 CHIP cases; P = .02).	Platinum	55-63	tumor protein p53	Homo sapiens	88-92
34255356-3	2021	This study aimed to evaluate CTLA-4 expression in GC and its impact on survival, including patients treated with standard platinum-based chemotherapy (CMT), and association with PD-L1 expression.	Platinum	122-130	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	29-35
34554306-4	2021	Serum levels were determined by Human IL-17A Platinum ELISA kit.	Platinum	45-53	interleukin 17A	Homo sapiens	38-44
34825576-3	2022	Results: The results showed platinum-based chemotherapy plus pembrolizumab or nivolumab and ipilimumab was associated with the best survival rates for patients with <1% PD-L1 expression, while only platinum-based chemotherapy plus pembrolizumab produced better survival than chemotherapy in patients with 1-49% PD-L1 expression.	Platinum	28-36	CD274 molecule	Homo sapiens	169-174
34741432-5	2021	Moreover, the electrolyzer employing CoPt3 @Co2 P/Co@NCNT for anodic MOR and cathodic H2 production only requires a low voltage of 1.43 V at 10 mA cm-2 with impressive long-life cycling stability, which is obviously better than that of commercial Pt/C//RuO2 .	Platinum	247-249	complement C2	Homo sapiens	44-47
34917025-10	2021	Conclusion: In patients with well-controlled T2DM who were treated with insulin glargine, Lantus group showed lower MBG, GV, and lower PT (BG > 10.0 mmol/L, BG > 13.9 mmol/L) than Basalin group.	Platinum	135-137	insulin	Homo sapiens	72-79
34825576-3	2022	Results: The results showed platinum-based chemotherapy plus pembrolizumab or nivolumab and ipilimumab was associated with the best survival rates for patients with <1% PD-L1 expression, while only platinum-based chemotherapy plus pembrolizumab produced better survival than chemotherapy in patients with 1-49% PD-L1 expression.	Platinum	28-36	CD274 molecule	Homo sapiens	311-316
34825576-4	2022	As for patients with >=50% PD-L1 expression, platinum-based chemotherapy plus pembrolizumab/atezolizumab and pembrolizumab/cemiplimab monotherapy were associated with better survival than chemotherapy.	Platinum	45-53	CD274 molecule	Homo sapiens	27-32
34888242-0	2021	High Serpin Family A Member 10 Expression Confers Platinum Sensitivity and Is Associated With Survival Benefit in High-Grade Serous Ovarian Cancer: Based on Quantitative Proteomic Analysis.	Platinum	50-58	serpin family A member 10	Homo sapiens	5-30
34792359-1	2021	In this work, we study the water-gas shift (WGS) reaction catalyzed by alpha-MoC(100) supported typical platinum group metal (PGM) single atoms (Rh1, Pd1, and Pt1) and Au1 via density functional theory calculations.	Platinum	104-112	programmed cell death 1	Homo sapiens	150-153
34792359-1	2021	In this work, we study the water-gas shift (WGS) reaction catalyzed by alpha-MoC(100) supported typical platinum group metal (PGM) single atoms (Rh1, Pd1, and Pt1) and Au1 via density functional theory calculations.	Platinum	104-112	zinc finger protein 77	Homo sapiens	159-162
34900739-0	2021	Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.	Platinum	78-86	poly(ADP-ribose) polymerase 1	Homo sapiens	41-45
34964780-9	2021	CONCLUSION: Adding an anti-EGFR-mAb to the standard platinum-based chemotherapy regimens used for the first-line treatment of advanced NSCLC resulted in statistically notable improvements in OS, PFS, and ORR.	Platinum	52-60	epidermal growth factor receptor	Homo sapiens	27-31
34888242-8	2021	IHC results demonstrated that HGSOC patients with high SERPINA10 expression had longer PFI than the patients with low SERPINA10 expression (9 vs. 5 months, p = 0.038), and the SERPINA10 expression had an area under the receiver operating characteristic curve (AUC) value of 0.758 (95% CI = 0.612-0.905; p = 0.005) to discriminate the platinum-sensitive group from the platinum-resistant group.	Platinum	334-342	serpin family A member 10	Homo sapiens	55-64
34888242-8	2021	IHC results demonstrated that HGSOC patients with high SERPINA10 expression had longer PFI than the patients with low SERPINA10 expression (9 vs. 5 months, p = 0.038), and the SERPINA10 expression had an area under the receiver operating characteristic curve (AUC) value of 0.758 (95% CI = 0.612-0.905; p = 0.005) to discriminate the platinum-sensitive group from the platinum-resistant group.	Platinum	334-342	serpin family A member 10	Homo sapiens	118-127
34888242-8	2021	IHC results demonstrated that HGSOC patients with high SERPINA10 expression had longer PFI than the patients with low SERPINA10 expression (9 vs. 5 months, p = 0.038), and the SERPINA10 expression had an area under the receiver operating characteristic curve (AUC) value of 0.758 (95% CI = 0.612-0.905; p = 0.005) to discriminate the platinum-sensitive group from the platinum-resistant group.	Platinum	334-342	serpin family A member 10	Homo sapiens	176-185
34888242-8	2021	IHC results demonstrated that HGSOC patients with high SERPINA10 expression had longer PFI than the patients with low SERPINA10 expression (9 vs. 5 months, p = 0.038), and the SERPINA10 expression had an area under the receiver operating characteristic curve (AUC) value of 0.758 (95% CI = 0.612-0.905; p = 0.005) to discriminate the platinum-sensitive group from the platinum-resistant group.	Platinum	368-376	serpin family A member 10	Homo sapiens	176-185
34888242-9	2021	In conclusion, the results suggested that SERPINA10 could be a promising biomarker for predicting the response and survival in platinum-based chemotherapy of HGSOC.	Platinum	127-135	serpin family A member 10	Homo sapiens	42-51
34808009-1	2022	The utility of Schlafen 11 (SLFN11) expression as a predictive biomarker for platinum-based chemotherapy has been established for cancers from different histologies.	Platinum	77-85	schlafen family member 11	Homo sapiens	15-26
34808009-1	2022	The utility of Schlafen 11 (SLFN11) expression as a predictive biomarker for platinum-based chemotherapy has been established for cancers from different histologies.	Platinum	77-85	schlafen family member 11	Homo sapiens	28-34
34808009-5	2022	In the cohort of 50 BC cases treated with platinum-based chemotherapy, the SLFN11-positive group (N = 25) showed significantly better overall survival than the SLFN11-negative group (N = 25, P = 0.012).	Platinum	42-50	schlafen family member 11	Homo sapiens	75-81
34808009-5	2022	In the cohort of 50 BC cases treated with platinum-based chemotherapy, the SLFN11-positive group (N = 25) showed significantly better overall survival than the SLFN11-negative group (N = 25, P = 0.012).	Platinum	42-50	schlafen family member 11	Homo sapiens	160-166
34808009-11	2022	We conclude that SLFN11 is a predictive biomarker for BC patients who undergo platinum-based chemotherapy and that the combination of epigenetic modifiers could rescue refractory BC patients to platinum derivatives by reactivating SLFN11 expression.	Platinum	78-86	schlafen family member 11	Homo sapiens	17-23
34808009-11	2022	We conclude that SLFN11 is a predictive biomarker for BC patients who undergo platinum-based chemotherapy and that the combination of epigenetic modifiers could rescue refractory BC patients to platinum derivatives by reactivating SLFN11 expression.	Platinum	194-202	schlafen family member 11	Homo sapiens	17-23
34808009-11	2022	We conclude that SLFN11 is a predictive biomarker for BC patients who undergo platinum-based chemotherapy and that the combination of epigenetic modifiers could rescue refractory BC patients to platinum derivatives by reactivating SLFN11 expression.	Platinum	194-202	schlafen family member 11	Homo sapiens	231-237
34730347-2	2021	Here we synthesized a series of supported Pt1 SACs by depositing Pt atoms onto the pretuned anchoring sites on nitrogen-doped carbon using atomic layer deposition.	Platinum	65-67	zinc finger protein 77	Homo sapiens	42-45
34831435-11	2021	TCGA data analyses indicated that patients with low expression of Hh/EMT-related genes together with active autophagy flux tended to have a better prognosis and this correlates with a more effective response to platinum therapy.	Platinum	211-219	IL2 inducible T cell kinase	Homo sapiens	66-72
34831435-12	2021	In in vitro 3D spheroids, LPA upregulated BMI-1, downregulated autophagy and inhibited platinum toxicity while RV and Hh inhibitors restored autophagy and favored BAX-mediated cell death in response to platinum.	Platinum	202-210	BCL2 associated X, apoptosis regulator	Homo sapiens	163-166
34714618-0	2021	Highly Sensitive and Stable Determination of As(III) under Near-Neutral Conditions: Benefit from the Synergetic Catalysis of Pt Single Atoms and Active S Atoms over Pt1/MoS2.	Platinum	125-127	zinc finger protein 77	Homo sapiens	165-168
34789301-11	2021	CONCLUSION: This study revealed a specifically inhibitory effect of ghrelin on platinum-resistance via suppressing p-P38 and subsequently promoting p-CDK1 mediated cell cycle arrest in HO-8910 PM.	Platinum	79-87	mitogen-activated protein kinase 1	Homo sapiens	117-120
34676865-5	2021	The aim of this study was to investigate the ability of nanoparticles to deliver ROR2 siRNA into HGSOC cells, including platinum resistant models, and estimate the anti-metastatic effect via a 3D organotypic model for ovarian cancer.	Platinum	120-128	receptor tyrosine kinase like orphan receptor 2	Homo sapiens	81-85
34676865-13	2021	ROR2 targeting therapy shows potential in treating HGSOC including platinum resistant forms.	Platinum	67-75	receptor tyrosine kinase like orphan receptor 2	Homo sapiens	0-4
34789301-11	2021	CONCLUSION: This study revealed a specifically inhibitory effect of ghrelin on platinum-resistance via suppressing p-P38 and subsequently promoting p-CDK1 mediated cell cycle arrest in HO-8910 PM.	Platinum	79-87	cyclin dependent kinase 1	Homo sapiens	150-154
34714618-2	2021	Here, we developed a superior catalyst of Pt single atoms anchored on MoS2 (Pt1/MoS2) to catalyze the determination of As(III).	Platinum	42-44	zinc finger protein 77	Homo sapiens	76-79
34726214-1	2021	Thiol-functionalized UiO-66-anchored atomically dispersed metal ions, denoted as UiO-66(SM)2 (M = Pd, Pt, or Au), were prepared as photocatalysts for the selective oxidation of benzyl alcohol (BA) to benzaldehyde (BAD) under visible light irradiation.	Platinum	102-104	SM2	Homo sapiens	81-92
34824550-9	2021	Results: We found that ATPase Na+/K+ transporting subunit alpha 2 (ATP1A2), calsequestrin 2 (CASQ2) and ryanodine receptor 2 (RYR2) interacted with each other and could predict resistance to platinum-based therapy, correlating negatively with prognosis.	Platinum	191-199	ryanodine receptor 2	Homo sapiens	126-130
34824550-13	2021	GSEA predicted that ATP1A2, CASQ2 and RYR2 may act on the KRAS and mTORC1 pathways and participate in metabolic reprogramming and regulation of calcium homeostasis in platinum-resistant cells.	Platinum	167-175	ATPase Na+/K+ transporting subunit alpha 2	Homo sapiens	20-26
34824550-13	2021	GSEA predicted that ATP1A2, CASQ2 and RYR2 may act on the KRAS and mTORC1 pathways and participate in metabolic reprogramming and regulation of calcium homeostasis in platinum-resistant cells.	Platinum	167-175	calsequestrin 2	Homo sapiens	28-33
34824550-13	2021	GSEA predicted that ATP1A2, CASQ2 and RYR2 may act on the KRAS and mTORC1 pathways and participate in metabolic reprogramming and regulation of calcium homeostasis in platinum-resistant cells.	Platinum	167-175	ryanodine receptor 2	Homo sapiens	38-42
34824550-13	2021	GSEA predicted that ATP1A2, CASQ2 and RYR2 may act on the KRAS and mTORC1 pathways and participate in metabolic reprogramming and regulation of calcium homeostasis in platinum-resistant cells.	Platinum	167-175	KRAS proto-oncogene, GTPase	Homo sapiens	58-62
34824550-9	2021	Results: We found that ATPase Na+/K+ transporting subunit alpha 2 (ATP1A2), calsequestrin 2 (CASQ2) and ryanodine receptor 2 (RYR2) interacted with each other and could predict resistance to platinum-based therapy, correlating negatively with prognosis.	Platinum	191-199	ATPase Na+/K+ transporting subunit alpha 2	Homo sapiens	23-65
34824550-9	2021	Results: We found that ATPase Na+/K+ transporting subunit alpha 2 (ATP1A2), calsequestrin 2 (CASQ2) and ryanodine receptor 2 (RYR2) interacted with each other and could predict resistance to platinum-based therapy, correlating negatively with prognosis.	Platinum	191-199	ATPase Na+/K+ transporting subunit alpha 2	Homo sapiens	67-73
34824550-9	2021	Results: We found that ATPase Na+/K+ transporting subunit alpha 2 (ATP1A2), calsequestrin 2 (CASQ2) and ryanodine receptor 2 (RYR2) interacted with each other and could predict resistance to platinum-based therapy, correlating negatively with prognosis.	Platinum	191-199	calsequestrin 2	Homo sapiens	76-91
34824550-9	2021	Results: We found that ATPase Na+/K+ transporting subunit alpha 2 (ATP1A2), calsequestrin 2 (CASQ2) and ryanodine receptor 2 (RYR2) interacted with each other and could predict resistance to platinum-based therapy, correlating negatively with prognosis.	Platinum	191-199	calsequestrin 2	Homo sapiens	93-98
34824550-9	2021	Results: We found that ATPase Na+/K+ transporting subunit alpha 2 (ATP1A2), calsequestrin 2 (CASQ2) and ryanodine receptor 2 (RYR2) interacted with each other and could predict resistance to platinum-based therapy, correlating negatively with prognosis.	Platinum	191-199	ryanodine receptor 2	Homo sapiens	104-124
34293698-0	2021	Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways.	Platinum	0-8	autophagy related 3	Homo sapiens	173-177
34815697-7	2021	Results: Three differential genes, IFI27, JAG1, DNM3, may be closely related to platinum resistance of ovarian cancer, were screened by microarray datasets.	Platinum	80-88	dynamin 3	Homo sapiens	48-52
34815697-8	2021	According to the combined verification of bioinformatics, clinical case analyses and experiments, it was inferred that the increased expression of DNM3 was beneficial to patients with platinum resistance, but the high expression of IFI27 and JAG1 may lead to the risk of platinum resistance.	Platinum	184-192	dynamin 3	Homo sapiens	147-151
34815697-8	2021	According to the combined verification of bioinformatics, clinical case analyses and experiments, it was inferred that the increased expression of DNM3 was beneficial to patients with platinum resistance, but the high expression of IFI27 and JAG1 may lead to the risk of platinum resistance.	Platinum	271-279	interferon alpha inducible protein 27	Homo sapiens	232-237
34815697-8	2021	According to the combined verification of bioinformatics, clinical case analyses and experiments, it was inferred that the increased expression of DNM3 was beneficial to patients with platinum resistance, but the high expression of IFI27 and JAG1 may lead to the risk of platinum resistance.	Platinum	271-279	jagged canonical Notch ligand 1	Homo sapiens	242-246
34815697-9	2021	Conclusion: IFI27, JAG1 and DNM3 screened by relevant gene chips may serve as new biomarkers of platinum resistance in ovarian cancer.	Platinum	96-104	interferon alpha inducible protein 27	Homo sapiens	12-17
34815697-9	2021	Conclusion: IFI27, JAG1 and DNM3 screened by relevant gene chips may serve as new biomarkers of platinum resistance in ovarian cancer.	Platinum	96-104	jagged canonical Notch ligand 1	Homo sapiens	19-23
34815697-9	2021	Conclusion: IFI27, JAG1 and DNM3 screened by relevant gene chips may serve as new biomarkers of platinum resistance in ovarian cancer.	Platinum	96-104	dynamin 3	Homo sapiens	28-32
34293698-0	2021	Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways.	Platinum	0-8	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-32
34293698-0	2021	Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways.	Platinum	0-8	pyruvate kinase M1/2	Homo sapiens	149-152
34293698-0	2021	Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways.	Platinum	0-8	lactate dehydrogenase A	Homo sapiens	153-157
34824550-16	2021	These genes might act on KARS and mTORC1 pathways and participate in metabolic reprogramming and regulation of calcium homeostasis in platinum-resistant cells.	Platinum	134-142	lysyl-tRNA synthetase 1	Homo sapiens	25-29
34824550-16	2021	These genes might act on KARS and mTORC1 pathways and participate in metabolic reprogramming and regulation of calcium homeostasis in platinum-resistant cells.	Platinum	134-142	CREB regulated transcription coactivator 1	Mus musculus	34-40
34815697-7	2021	Results: Three differential genes, IFI27, JAG1, DNM3, may be closely related to platinum resistance of ovarian cancer, were screened by microarray datasets.	Platinum	80-88	interferon alpha inducible protein 27	Homo sapiens	35-40
34815697-7	2021	Results: Three differential genes, IFI27, JAG1, DNM3, may be closely related to platinum resistance of ovarian cancer, were screened by microarray datasets.	Platinum	80-88	jagged canonical Notch ligand 1	Homo sapiens	42-46
34956497-19	2021	CONCLUSION: With equivalent efficacy, EP regimen is safer than EL regimen in the treatment of SCLC, which suggests that etoposide plus platinum has better clinical application value for SCLC.	Platinum	135-143	epiregulin	Homo sapiens	38-40
34293698-0	2021	Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways.	Platinum	0-8	cyclin D1	Homo sapiens	162-167
34293698-0	2021	Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways.	Platinum	0-8	BCL2 apoptosis regulator	Homo sapiens	168-172
34730936-7	2021	The spontaneous formation under aerated conditions of a Pt(IV) derivative (CF3LPtCl3) is also reported, together with its molecular structure in the solid state.	Platinum	56-58	adhesion G protein-coupled receptor L3	Homo sapiens	75-84
34741718-7	2021	CONCLUSION: A high level of ERbeta and not ERalpha expression can predict the efficacy of front-line platinum plus taxane chemotherapy in stage III HGSOC patients.	Platinum	101-109	estrogen receptor 1	Homo sapiens	28-34
34771742-0	2021	Highly Expressed Progesterone Receptor B Isoform Increases Platinum Sensitivity and Survival of Ovarian High-Grade Serous Carcinoma.	Platinum	59-67	progesterone receptor	Homo sapiens	17-38
34661413-0	2021	Adsorption Motifs and Molecular Orientation at the Ionic Liquid/Noble Metal Interface: (C2C1Im)(NTf2) on Pt(111).	Platinum	105-107	nuclear transport factor 2	Homo sapiens	96-100
34388483-0	2021	Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.	Platinum	42-50	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	14-18
34388483-6	2021	Mechanism studies revealed that the bezafibrate-conjugated Pt(IV) complex CB, as a representative, could massively accumulate in A549 cells and genomic DNA, induce DNA damage, elevate intracellular ROS levels, perturb mitochondrial transmembrane potentials, activate the cellular metabolic sensor AMPK, and result in profound proliferation inhibition and apoptosis.	Platinum	59-61	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	297-301
34898581-0	2021	ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer Group.	Platinum	88-96	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
34898581-1	2021	We previously showed that ERCC1 19007 C>T polymorphism was associated with cancer-specific survival (CSS) after platinum-based chemotherapy in patients with advanced urothelial cancer (aUC).	Platinum	112-120	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	26-31
34730065-7	2021	MTHFR polymorphism might impact the development of pemetrexed and platinum-related toxicities but not as a clinical predictor of efficiency.	Platinum	66-74	methylenetetrahydrofolate reductase	Homo sapiens	0-5
34661413-2	2021	In this work, we investigated the adsorption behavior of the IL 1-ethyl-3-methyl-imidazolium bis(trifluoromethylsulfonyl)imide (C2C1Im)(NTf2) on Pt(111) by combining experimental and theoretical studies.	Platinum	145-147	nuclear transport factor 2	Homo sapiens	136-140
34661413-9	2021	In the monolayer (ML), (NTf2)- interacts strongly with the metal surface and adopts a specific orientation in which it interacts with the Pt surface via the SO2 groups.	Platinum	138-140	nuclear transport factor 2	Homo sapiens	24-28
34672608-3	2021	In the neutral solution, the electrocatalytic performance of the CNP@PNS-4 catalyst exhibits an onset potential of 0.98 V (vs reversible hydrogen electrode) and a half-wave potential of 0.91 V for ORR, which greatly surpasses commercial Pt/C (40%).	Platinum	237-239	2',3'-cyclic nucleotide 3' phosphodiesterase	Homo sapiens	65-68
34533854-6	2021	We subsequently observed that FGF13-mediated platinum resistance requires the microtubule-stabilizing effect of FGF13.	Platinum	45-53	fibroblast growth factor 13	Homo sapiens	112-117
34605272-12	2021	Finally, AR mediates the greater kidney size and PT volume density in male than in female mice.	Platinum	49-51	androgen receptor	Mus musculus	9-11
34520432-0	2021	PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.	Platinum	48-56	poly(ADP-ribose) polymerase 1	Homo sapiens	0-4
34520432-1	2021	OBJECTIVE: To determine the effect of poly-adenosine ribose phosphatase inhibitors (PARPi) on the response to subsequent platinum-based chemotherapy (PBC) in patients with recurrent, platinum-sensitive BRCA-mutated epithelial ovarian, peritoneal, or fallopian cancer (BRCAm EOC).	Platinum	121-129	BRCA1 DNA repair associated	Homo sapiens	202-206
34520432-1	2021	OBJECTIVE: To determine the effect of poly-adenosine ribose phosphatase inhibitors (PARPi) on the response to subsequent platinum-based chemotherapy (PBC) in patients with recurrent, platinum-sensitive BRCA-mutated epithelial ovarian, peritoneal, or fallopian cancer (BRCAm EOC).	Platinum	183-191	BRCA1 DNA repair associated	Homo sapiens	202-206
34294893-5	2021	Preclinical and emerging clinical trial data suggest that SLFN11 is a predictive biomarker of response to a wide range of therapeutics that cause DNA damage including platinum salts and topoisomerase I/II inhibitors, as well as PARP inhibitors, which has raised exciting possibilities for its clinical application.	Platinum	167-175	schlafen family member 11	Homo sapiens	58-64
34533854-5	2021	We then found that FGF13 simultaneously regulates the expression and distribution of hCTR1 and ATP7A in cancer cells, causes reduced platinum influx and promoted platinum sequestration and efflux upon cisplatin exposure.	Platinum	133-141	fibroblast growth factor 13	Homo sapiens	19-24
34533854-0	2021	FGF13 Enhances Resistance to Platinum Drugs by Regulating hCTR1 and ATP7A via a Microtubule-Stabilizing Effect.	Platinum	29-37	fibroblast growth factor 13	Homo sapiens	0-5
34533854-5	2021	We then found that FGF13 simultaneously regulates the expression and distribution of hCTR1 and ATP7A in cancer cells, causes reduced platinum influx and promoted platinum sequestration and efflux upon cisplatin exposure.	Platinum	162-170	fibroblast growth factor 13	Homo sapiens	19-24
34533854-6	2021	We subsequently observed that FGF13-mediated platinum resistance requires the microtubule-stabilizing effect of FGF13.	Platinum	45-53	fibroblast growth factor 13	Homo sapiens	30-35
34533854-7	2021	Only overexpression of FGF13 with the -SMIYRQQQ- tubulin binding domain could induce the platinum resistance effect.	Platinum	89-97	fibroblast growth factor 13	Homo sapiens	23-28
34533854-9	2021	Our research reveals the mechanism of FGF13 induced platinum drug resistance and suggests that FGF13 can be a sensibilization target and prognostic biomarker for chemotherapy.	Platinum	52-60	fibroblast growth factor 13	Homo sapiens	38-43
34533854-9	2021	Our research reveals the mechanism of FGF13 induced platinum drug resistance and suggests that FGF13 can be a sensibilization target and prognostic biomarker for chemotherapy.	Platinum	52-60	fibroblast growth factor 13	Homo sapiens	95-100
34619527-8	2021	ARID1A alterations may also mediate resistance to platinum chemotherapy and estrogen receptor degraders/modulators.	Platinum	50-58	AT-rich interaction domain 1A	Homo sapiens	0-6
34533854-0	2021	FGF13 Enhances Resistance to Platinum Drugs by Regulating hCTR1 and ATP7A via a Microtubule-Stabilizing Effect.	Platinum	29-37	solute carrier family 31 member 1	Homo sapiens	58-63
34533854-0	2021	FGF13 Enhances Resistance to Platinum Drugs by Regulating hCTR1 and ATP7A via a Microtubule-Stabilizing Effect.	Platinum	29-37	ATPase copper transporting alpha	Homo sapiens	68-73
34533854-2	2021	Previous studies have shown that fibroblast growth factor 13 (FGF13) is associated with resistance to platinum drugs in HeLa cells.	Platinum	102-110	fibroblast growth factor 13	Homo sapiens	33-60
34533854-2	2021	Previous studies have shown that fibroblast growth factor 13 (FGF13) is associated with resistance to platinum drugs in HeLa cells.	Platinum	102-110	fibroblast growth factor 13	Homo sapiens	62-67
34533854-4	2021	Here, we found that FGF13 was associated with poor platinum-based chemotherapy outcomes in a variety of cancers, such as lung, endometrial, and cervical cancers through bioinformatics analysis.	Platinum	51-59	fibroblast growth factor 13	Homo sapiens	20-25
34767024-2	2021	Objective: To compare the effectiveness of the immune checkpoint inhibitors atezolizumab (programmed cell death ligand 1 inhibitor) and nivolumab (programmed cell death 1 inhibitor) and the chemotherapy drug docetaxel in patients with advanced NSCLC resistant to platinum-based chemotherapy.	Platinum	263-271	programmed cell death 1	Homo sapiens	147-170
34127383-8	2021	Thirty-nine patients received platinum-based chemotherapy (PBC) and achieved a 43% objective response rate (ORR), median progression-free survival (mPFS) of 6.9 months, and median overall survival (mOS) of 31.0 months.	Platinum	30-38	Moloney sarcoma oncogene	Mus musculus	198-201
34272617-8	2021	Immunohistochemistry of MYOF in GC tissue samples revealed that high expression of MYOF was significantly associated with poor prognosis, T grade, N grade, and lymphatic invasion, and showed MYOF to be an independent prognostic indicator, especially in the GC patients treated with platinum-based chemotherapy.	Platinum	282-290	myoferlin	Homo sapiens	24-28
34272617-8	2021	Immunohistochemistry of MYOF in GC tissue samples revealed that high expression of MYOF was significantly associated with poor prognosis, T grade, N grade, and lymphatic invasion, and showed MYOF to be an independent prognostic indicator, especially in the GC patients treated with platinum-based chemotherapy.	Platinum	282-290	myoferlin	Homo sapiens	83-87
34265431-13	2021	CONCLUSION: With or without brain metastasis, pembrolizumab plus platinum-based histology-specific chemotherapy improved clinical outcomes versus chemotherapy alone across all PD-L1 subgroups, including patients with PD-L1 tumor proportion score <1%, and had a manageable safety profile in patients with advanced NSCLC.	Platinum	65-73	CD274 molecule	Homo sapiens	176-181
34778033-1	2021	Background: BRCA2 mutation has a more substantial impact on the homologous recombination and superior therapeutic response to platinum-based chemotherapy than BRCA1 mutation.	Platinum	126-134	BRCA2 DNA repair associated	Homo sapiens	12-17
34309133-0	2021	Rapid progression of metastatic pancreatic adenocarcinoma during platinum-based therapy in a patient harboring a pathogenic BRCA2 germline variant.	Platinum	65-73	BRCA2 DNA repair associated	Homo sapiens	124-129
34309133-5	2021	(3, 4) In contrast, platinum-based therapies would be predicted to be significantly less effective for PDACs in patients with pathogenic BRCA germline variants who have cancers which lack BRCA LOH.	Platinum	20-28	BRCA2 DNA repair associated	Homo sapiens	137-141
34309133-5	2021	(3, 4) In contrast, platinum-based therapies would be predicted to be significantly less effective for PDACs in patients with pathogenic BRCA germline variants who have cancers which lack BRCA LOH.	Platinum	20-28	BRCA2 DNA repair associated	Homo sapiens	188-192
34309133-9	2021	Here, we present a patient harboring a pathogenic BRCA germline variant whose PDAC grew rapidly during platinum-based therapy and lacked BRCA LOH and therefore was not likely BRCA-related.	Platinum	103-111	BRCA2 DNA repair associated	Homo sapiens	50-54
34309133-10	2021	Given the molecular fingerprint of BRCA-related PDAC in patients with pathogenic BRCA germline variants and the mechanism of action of platinum-based therapies and PARP inhibitors, this case underscores the importance of future studies aimed at determining whether the lack of BRCA LOH in PDACs in pathogenic BRCA germline variant carriers is a biomarker of less responsiveness to platinum-based chemotherapy and PARP inhibitors.	Platinum	381-389	BRCA2 DNA repair associated	Homo sapiens	35-39
34365218-4	2021	Utilizing improved PIP3-AKT and ERK1/2 activation Bioluminescence Resonance Energy Transfer (BRET) sensors, we report chemotherapy-induced ERK1/2 activation predominantly in cisplatin-paclitaxel resistant EOC cells and increased activation of both ERK1/2 and AKT in malignant ascites derived cancer cells from platinum-resistant patients but not from treatment-naive or platinum-sensitive relapse patients.	Platinum	310-318	mitogen-activated protein kinase 3	Homo sapiens	32-38
34365218-4	2021	Utilizing improved PIP3-AKT and ERK1/2 activation Bioluminescence Resonance Energy Transfer (BRET) sensors, we report chemotherapy-induced ERK1/2 activation predominantly in cisplatin-paclitaxel resistant EOC cells and increased activation of both ERK1/2 and AKT in malignant ascites derived cancer cells from platinum-resistant patients but not from treatment-naive or platinum-sensitive relapse patients.	Platinum	310-318	mitogen-activated protein kinase 3	Homo sapiens	248-254
34365218-4	2021	Utilizing improved PIP3-AKT and ERK1/2 activation Bioluminescence Resonance Energy Transfer (BRET) sensors, we report chemotherapy-induced ERK1/2 activation predominantly in cisplatin-paclitaxel resistant EOC cells and increased activation of both ERK1/2 and AKT in malignant ascites derived cancer cells from platinum-resistant patients but not from treatment-naive or platinum-sensitive relapse patients.	Platinum	310-318	AKT serine/threonine kinase 1	Homo sapiens	259-262
34717622-17	2021	The immunohistochemical staining results showed that p-FLNC, AKT1 and p-ERK1/2 were highly expressed in platinum-resistant clinical specimens but weakly expressed in platinum-sensitive specimens, and platinum-resistant osteosarcoma specimens demonstrated weak expression of p-JNK.	Platinum	104-112	filamin C	Homo sapiens	55-59
34717622-17	2021	The immunohistochemical staining results showed that p-FLNC, AKT1 and p-ERK1/2 were highly expressed in platinum-resistant clinical specimens but weakly expressed in platinum-sensitive specimens, and platinum-resistant osteosarcoma specimens demonstrated weak expression of p-JNK.	Platinum	104-112	AKT serine/threonine kinase 1	Homo sapiens	61-65
34717622-17	2021	The immunohistochemical staining results showed that p-FLNC, AKT1 and p-ERK1/2 were highly expressed in platinum-resistant clinical specimens but weakly expressed in platinum-sensitive specimens, and platinum-resistant osteosarcoma specimens demonstrated weak expression of p-JNK.	Platinum	104-112	mitogen-activated protein kinase 3	Homo sapiens	72-78
34431578-1	2021	BACKGROUND: The latest published CASPIAN trial demonstrated that adding durvalumab to etoposide and platinum (EP) improved survival dramatically for patients with extensive-stage small cell lung cancer (ES-SCLC).	Platinum	100-108	epiregulin	Homo sapiens	110-112
34365218-5	2021	Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2.	Platinum	29-37	mitogen-activated protein kinase 3	Homo sapiens	72-78
34365218-5	2021	Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2.	Platinum	29-37	ribosomal protein S6 kinase A1	Homo sapiens	192-201
34365218-5	2021	Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2.	Platinum	29-37	ATP binding cassette subfamily C member 1	Homo sapiens	275-280
34365218-5	2021	Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2.	Platinum	29-37	cyclin D1	Homo sapiens	310-319
34365218-5	2021	Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2.	Platinum	29-37	BCL2 apoptosis regulator	Homo sapiens	324-328
34365218-5	2021	Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2.	Platinum	93-101	mitogen-activated protein kinase 3	Homo sapiens	72-78
34365218-5	2021	Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2.	Platinum	93-101	ribosomal protein S6 kinase A1	Homo sapiens	192-201
34365218-5	2021	Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2.	Platinum	93-101	ATP binding cassette subfamily C member 1	Homo sapiens	275-280
34365218-5	2021	Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2.	Platinum	93-101	cyclin D1	Homo sapiens	310-319
34365218-5	2021	Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2.	Platinum	93-101	BCL2 apoptosis regulator	Homo sapiens	324-328
34771629-1	2021	BACKGROUND: Hypersensitivity reactions (HSR)s to platinum agents are increasing in frequency, due to their extensive use and repeated exposures in patients with increased life expectancy.	Platinum	49-57	HSR	Homo sapiens	40-43
34651161-5	2021	An experimental X-ray photoelectron spectroscopy study indicates that the chemical state of both molybdenum and carbon in Pt/beta-Mo2C are very different from those in the Pt-free carbide, which is also in agreement with the DFT results, which indicate that the Pt atoms generate a redistribution of charge density in their environment.	Platinum	262-264	pre T cell antigen receptor alpha	Homo sapiens	122-129
34651161-6	2021	Temperature programmed reaction analysis shows that at temperatures higher than 530 K, a two-fold increase in the production of H2, CH4 and C2H6 is observed for Pt/beta-Mo2C as compared to beta-Mo2C, suggesting a higher catalytic activity for the Pt-containing carbide than for the pristine catalyst.	Platinum	247-249	pre T cell antigen receptor alpha	Homo sapiens	161-168
34725559-9	2021	We found that patients with TGF-beta signaling mutations have shorter overall survival, disease-free survival, disease-specific survival, platinum overall survival, and platinum-free progression survival.	Platinum	138-146	transforming growth factor alpha	Homo sapiens	28-36
34569561-6	2021	Furthermore, with acid-sensitivity, demethylcantharidin (DMC), a protein phosphatase 2A (PP2A) inhibitor, was released to block the DNA repair pathway and thereby could sensitize platinum-based chemotherapy in intracellular acidic microenvironments.	Platinum	179-187	protein phosphatase 2 phosphatase activator	Homo sapiens	73-87
34569561-6	2021	Furthermore, with acid-sensitivity, demethylcantharidin (DMC), a protein phosphatase 2A (PP2A) inhibitor, was released to block the DNA repair pathway and thereby could sensitize platinum-based chemotherapy in intracellular acidic microenvironments.	Platinum	179-187	protein phosphatase 2 phosphatase activator	Homo sapiens	89-93
34697207-6	2021	The use of platinum-based chemotherapy, to which heterozygous BRCA2 carriers are known to respond, may have had a beneficial anticancer effect, but caution is advised given its extreme immediate toxicity at standard dosing.	Platinum	11-19	BRCA2 DNA repair associated	Homo sapiens	62-67
34725559-9	2021	We found that patients with TGF-beta signaling mutations have shorter overall survival, disease-free survival, disease-specific survival, platinum overall survival, and platinum-free progression survival.	Platinum	169-177	transforming growth factor alpha	Homo sapiens	28-36
34612043-6	2021	By changing the coordination atoms from highly electronegative N to low electronegative Co atoms, the prepared Pt single-atom alloy (SAA, Pt1-Co3) catalyst with ultralow Pt loading (0.06 wt %) gave a much high FDCA yield (99.6%).	Platinum	111-113	serum amyloid A1 cluster	Homo sapiens	133-136
34612043-8	2021	In Pt1-Co3 SAA, the central negatively charged Pt atom (-0.446e) facilitated the adsorption of the key intermediate; meanwhile, the nearby Co atoms around the Pt atom constituted the O2-preferred adsorption/activation sites.	Platinum	47-49	serum amyloid A1 cluster	Homo sapiens	11-14
34670865-9	2022	Collectively, our findings suggest that GAS6 levels could be used to predict response to carboplatin and AVB-500 could be used to treat platinum-resistant, homologous recombination-proficient high-grade serous ovarian cancer.	Platinum	136-144	growth arrest specific 6	Homo sapiens	40-44
34754149-5	2021	Superior survival outcomes have been reported in patients with PC and mutant BRCA gene treated with first-line platinum-based chemotherapy.	Platinum	111-119	BRCA1 DNA repair associated	Homo sapiens	77-81
34547887-4	2021	Magnetic bead-modified capture antibody and platinum nanoparticle-labeled detection antibody were used as the biorecognition element of the target carcinoembryonic antigen (CEA) (as a model analyte) and would form a sandwich-type immune complex with CEA.	Platinum	44-52	CEA cell adhesion molecule 3	Homo sapiens	147-171
34729116-10	2021	In addition, TTYH1 was related to a better clinical outcome in OC patients with platinums-based chemotherapy, but only indicated improved overall survival in OC patients who received taxol or platin + taxol chemotherapy.	Platinum	80-89	tweety family member 1	Homo sapiens	13-18
34729116-10	2021	In addition, TTYH1 was related to a better clinical outcome in OC patients with platinums-based chemotherapy, but only indicated improved overall survival in OC patients who received taxol or platin + taxol chemotherapy.	Platinum	192-198	tweety family member 1	Homo sapiens	13-18
34849052-4	2021	In addition, the increase of Co content led to an increase in the electrochemical active surface area (EASA) from 23.75 m2/gPt to 47.54 m2/gPt for pure Pt and Pt:Co (1:3), respectively, which corresponded the improvement of the utilization of Pt by a factor of 1.91.	Platinum	152-154	glutamic--pyruvic transaminase	Homo sapiens	123-126
34849052-4	2021	In addition, the increase of Co content led to an increase in the electrochemical active surface area (EASA) from 23.75 m2/gPt to 47.54 m2/gPt for pure Pt and Pt:Co (1:3), respectively, which corresponded the improvement of the utilization of Pt by a factor of 1.91.	Platinum	152-154	glutamic--pyruvic transaminase	Homo sapiens	139-142
34849052-4	2021	In addition, the increase of Co content led to an increase in the electrochemical active surface area (EASA) from 23.75 m2/gPt to 47.54 m2/gPt for pure Pt and Pt:Co (1:3), respectively, which corresponded the improvement of the utilization of Pt by a factor of 1.91.	Platinum	159-161	glutamic--pyruvic transaminase	Homo sapiens	123-126
34849052-4	2021	In addition, the increase of Co content led to an increase in the electrochemical active surface area (EASA) from 23.75 m2/gPt to 47.54 m2/gPt for pure Pt and Pt:Co (1:3), respectively, which corresponded the improvement of the utilization of Pt by a factor of 1.91.	Platinum	159-161	glutamic--pyruvic transaminase	Homo sapiens	139-142
34849052-4	2021	In addition, the increase of Co content led to an increase in the electrochemical active surface area (EASA) from 23.75 m2/gPt to 47.54 m2/gPt for pure Pt and Pt:Co (1:3), respectively, which corresponded the improvement of the utilization of Pt by a factor of 1.91.	Platinum	243-245	glutamic--pyruvic transaminase	Homo sapiens	123-126
34849052-4	2021	In addition, the increase of Co content led to an increase in the electrochemical active surface area (EASA) from 23.75 m2/gPt to 47.54 m2/gPt for pure Pt and Pt:Co (1:3), respectively, which corresponded the improvement of the utilization of Pt by a factor of 1.91.	Platinum	243-245	glutamic--pyruvic transaminase	Homo sapiens	139-142
34355483-3	2021	Herein, we successfully developed a series of Cs 2 Pt x Sn 1-x Cl 6 (0<=x<=1) with high stability, which show switchable photoluminescence and photocatalytic functions by varying the amount of Pt 4+ substitution.	Platinum	193-195	solute carrier family 38 member 3	Homo sapiens	56-60
34355483-5	2021	The Cs 2 Pt x Sn 1-x Cl 6 solid solution with small amount of Pt 4+ substitution exhibits photocatalytic hydrogen evolution activity.	Platinum	9-11	solute carrier family 38 member 3	Homo sapiens	14-18
34558910-3	2021	In the investigated devices, Pt is used as a source of the spin current and as a nonmagnetic spacer with variable thickness, which enables the magnitude of the interlayer ferromagnetic exchange coupling to be effectively tuned.	Platinum	29-31	spindlin 1	Homo sapiens	59-63
34729116-11	2021	The up-regulated expression of TTYH3 predicted worse survival in OC patients receiving platin, taxol, or platin + taxol chemotherapy regimen.	Platinum	87-93	tweety family member 3	Homo sapiens	31-36
34729116-11	2021	The up-regulated expression of TTYH3 predicted worse survival in OC patients receiving platin, taxol, or platin + taxol chemotherapy regimen.	Platinum	105-111	tweety family member 3	Homo sapiens	31-36
34729116-13	2021	Conclusions: TTYH3 was a potential predictor for poor clinical outcome in OC patients, particularly in patients with serous, late-stage, poorly differentiated, TP53-mutation or the patients treated with chemotherapy regimens (platin, taxol, or platin + taxol).	Platinum	226-232	tweety family member 3	Homo sapiens	13-18
34729116-13	2021	Conclusions: TTYH3 was a potential predictor for poor clinical outcome in OC patients, particularly in patients with serous, late-stage, poorly differentiated, TP53-mutation or the patients treated with chemotherapy regimens (platin, taxol, or platin + taxol).	Platinum	244-250	tweety family member 3	Homo sapiens	13-18
34680361-13	2021	Results indicate that dietary zinc, B12 and B6 intakes may be associated with platinum sensitivity dependent on MTHFR genotype.	Platinum	78-86	methylenetetrahydrofolate reductase	Homo sapiens	112-117
34627310-7	2021	Curiously, the combined mutations had a much smaller impact on PT binding affinity for monomeric gp120 (four to ninefold).	Platinum	63-65	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	97-102
34627310-12	2021	CONCLUSIONS: Together, the data suggest that the escape mutations significantly modified the energetic landscape of Env"s prefusogenic state, altering conformational dynamics to hinder PT-induced irreversible inactivation of Env.	Platinum	185-187	endogenous retrovirus group K member 20	Homo sapiens	116-119
34627310-12	2021	CONCLUSIONS: Together, the data suggest that the escape mutations significantly modified the energetic landscape of Env"s prefusogenic state, altering conformational dynamics to hinder PT-induced irreversible inactivation of Env.	Platinum	185-187	endogenous retrovirus group K member 20	Homo sapiens	225-228
34558569-3	2021	In this study, a hollow carbon catalyst, NOC-1000-1, was prepared by pyrolysis of a mixture of a N-enriched Zn/bispyrozolate-based metal-organic framework and urea to replace the labile Pt-based catalysts for ORR.	Platinum	186-188	nocturnin	Homo sapiens	41-44
34514790-2	2021	Among the many MOFs as candidates for fabrication of thin films, Hofmann-type MOFs {Fe(pz)(M(CN)4)} (pz = pyrazine; M = Ni (Nipz), M = Pt (Ptpz)) are attractive, because they undergo spin transitions with concomitant structural changes.	Platinum	135-137	protein tyrosine phosphatase receptor type Z1	Homo sapiens	139-143
34547887-4	2021	Magnetic bead-modified capture antibody and platinum nanoparticle-labeled detection antibody were used as the biorecognition element of the target carcinoembryonic antigen (CEA) (as a model analyte) and would form a sandwich-type immune complex with CEA.	Platinum	44-52	CEA cell adhesion molecule 3	Homo sapiens	173-176
34547887-4	2021	Magnetic bead-modified capture antibody and platinum nanoparticle-labeled detection antibody were used as the biorecognition element of the target carcinoembryonic antigen (CEA) (as a model analyte) and would form a sandwich-type immune complex with CEA.	Platinum	44-52	CEA cell adhesion molecule 3	Homo sapiens	250-253
34558910-0	2021	Study of Spin-Orbit Interactions and Interlayer Ferromagnetic Coupling in Co/Pt/Co Trilayers in a Wide Range of Heavy-Metal Thickness.	Platinum	77-79	spindlin 1	Homo sapiens	9-13
34593416-5	2021	However, not only PARP inhibitors, but also chemotherapeutic agents such as platinum agents, taxanes, and radium-223 are active in HRR gene mutation carriers, and platinum sensitivity may predict the efficacy of PARP inhibitors for mCRPC.	Platinum	163-171	poly(ADP-ribose) polymerase 1	Homo sapiens	18-22
34611298-8	2022	Knock-down or inhibition of USP28 by a specific inhibitor weakens the ability of SCC to cope with DNA damage during platin-based chemotherapy.	Platinum	116-122	ubiquitin specific peptidase 28	Homo sapiens	28-33
34675764-5	2021	Consistent with this observation, inhibition of Hif2alpha by PT-2385, not Hif1alpha by PX-478, prevented neurodegenerative symptoms, which were proved by Purkinje cell arrangement from the shrunken and irregular to the full and regular array.	Platinum	61-63	endothelial PAS domain protein 1	Mus musculus	48-57
34593416-5	2021	However, not only PARP inhibitors, but also chemotherapeutic agents such as platinum agents, taxanes, and radium-223 are active in HRR gene mutation carriers, and platinum sensitivity may predict the efficacy of PARP inhibitors for mCRPC.	Platinum	163-171	poly(ADP-ribose) polymerase 1	Homo sapiens	212-216
34637432-4	2021	In recent years, the addition of anti-programmed death ligand 1 (PD-L1) inhibitors to frontline platinum-based chemotherapy in extensive-stage SCLC has improved survival, and combination chemoimmunotherapy is now approved as the standard of care.	Platinum	96-104	CD274 molecule	Homo sapiens	65-70
34389637-0	2021	Amivantamab Is Active in Platinum-Resistant EGFR ex20-mutant NSCLC.	Platinum	25-33	epidermal growth factor receptor	Homo sapiens	44-48
34417675-9	2021	In the subset of BRCA1/2 carriers, the ORR was 32% among platinum-naive patients versus 9% among platinum-exposed patients.	Platinum	57-65	BRCA1 DNA repair associated	Homo sapiens	17-24
34128757-7	2021	Moreover, the administration of trabectedin/PLD was associated with a positive survival trend after two previous platinum lines and a significantly superior PFS after subsequent platinum-based therapy.	Platinum	113-121	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	44-47
34128757-7	2021	Moreover, the administration of trabectedin/PLD was associated with a positive survival trend after two previous platinum lines and a significantly superior PFS after subsequent platinum-based therapy.	Platinum	178-186	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	44-47
34128757-9	2021	Overall, real-word evidence has confirmed that trabectedin/PLD is an effective and safe non-platinum combination for advanced lines of chemotherapy in patients with platinum-sensitive recurrent ovarian cancer.	Platinum	92-100	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	59-62
34128757-9	2021	Overall, real-word evidence has confirmed that trabectedin/PLD is an effective and safe non-platinum combination for advanced lines of chemotherapy in patients with platinum-sensitive recurrent ovarian cancer.	Platinum	165-173	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	59-62
34253596-2	2021	Here we report that LB100, a small molecule inhibitor of PP2A, when combined with platinum-based chemotherapy, synergistically elicited an anti-tumor response both in vitro and in vivo with no apparent toxicity.	Platinum	82-90	protein phosphatase 2 phosphatase activator	Homo sapiens	57-61
34616492-1	2021	Background: In patients with newly diagnosed ovarian cancer, bevacizumab and poly(ADP-ribose) polymerase (PARP) inhibitors, alone or in combination, have shown benefit as maintenance treatment following platinum-based chemotherapy.	Platinum	203-211	poly(ADP-ribose) polymerase 1	Homo sapiens	77-104
34320692-1	2021	ERCC1 is a gene for repairing DNA damage whose function is related to carcinogenic-induced tumorigenesis and the effectiveness of platinum therapies.	Platinum	130-138	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
34510754-2	2021	Cancer/testis antigen 45 (CT45) is proved to enhance platinum-based chemosensitivity for individualized ovarian cancer therapy.	Platinum	53-61	cancer/testis antigen family 45 member A1	Homo sapiens	26-30
34616492-1	2021	Background: In patients with newly diagnosed ovarian cancer, bevacizumab and poly(ADP-ribose) polymerase (PARP) inhibitors, alone or in combination, have shown benefit as maintenance treatment following platinum-based chemotherapy.	Platinum	203-211	poly(ADP-ribose) polymerase 1	Homo sapiens	106-110
34350671-5	2021	The strong interaction of Pt and zeolite in Pt@beta is effective to promote the spillover of active hydrogen, giving an excellent activity and stability for hydrodeoxygenation reaction.	Platinum	26-28	pre T cell antigen receptor alpha	Homo sapiens	44-51
34638887-6	2021	In the case of the complex Pt2c, the adducts formed upon reaction with HEWL and RNase A were further characterized by solving the respective crystal structures: this allowed us to determine the exact location of the various Pt binding sites.	Platinum	224-226	ribonuclease A family member 1, pancreatic	Equus caballus	80-87
34622231-1	2021	CCNE1-amplified ovarian cancers (OVCAs) and endometrial cancers (EMCAs) are associated with platinum resistance and poor survival, representing a clinically unmet need.	Platinum	92-100	cyclin E1	Homo sapiens	0-5
34623852-0	2021	Observation of Pure-Spin-Current Diodelike Effect at the Au/Pt Interface.	Platinum	60-62	spindlin 1	Homo sapiens	20-24
34623852-4	2021	Here we demonstrate asymmetric transport of pure-spin currents across an interface of dissimilar nonmagnetic materials Au/Pt.	Platinum	122-124	spindlin 1	Homo sapiens	49-53
34623852-5	2021	We exploit Py/Au/Pt/Co structures where spin pumping can generate pure-spin current from either Py or Co independently.	Platinum	17-19	spindlin 1	Homo sapiens	40-44
34623852-5	2021	We exploit Py/Au/Pt/Co structures where spin pumping can generate pure-spin current from either Py or Co independently.	Platinum	17-19	spindlin 1	Homo sapiens	71-75
34659565-11	2021	More meaningfully, in a retrospective case study, we found that high ZEB2 expression predicts worse clinical efficacy of platinum chemotherapy.	Platinum	121-129	zinc finger E-box binding homeobox 2	Homo sapiens	69-73
34623852-7	2021	Experimental results are interpreted by extending conventional spin-pumping, spin-diffusion theory to include boundary conditions of reflected and transmitted spin current at the Au/Pt interface that are proportional to the established spin chemical potentials on either side of the interface.	Platinum	182-184	spindlin 1	Homo sapiens	63-67
34623852-7	2021	Experimental results are interpreted by extending conventional spin-pumping, spin-diffusion theory to include boundary conditions of reflected and transmitted spin current at the Au/Pt interface that are proportional to the established spin chemical potentials on either side of the interface.	Platinum	182-184	spindlin 1	Homo sapiens	77-81
34623852-7	2021	Experimental results are interpreted by extending conventional spin-pumping, spin-diffusion theory to include boundary conditions of reflected and transmitted spin current at the Au/Pt interface that are proportional to the established spin chemical potentials on either side of the interface.	Platinum	182-184	spindlin 1	Homo sapiens	159-163
34623852-7	2021	Experimental results are interpreted by extending conventional spin-pumping, spin-diffusion theory to include boundary conditions of reflected and transmitted spin current at the Au/Pt interface that are proportional to the established spin chemical potentials on either side of the interface.	Platinum	182-184	spindlin 1	Homo sapiens	236-240
34496563-0	2021	Extrinsic Surface Magnetic Anisotropy Contribution in Pt/Y3Fe5O12 Interface in Longitudinal Spin Seebeck Effect by Graphene Interlayer.	Platinum	54-56	spindlin 1	Homo sapiens	92-96
34681173-8	2021	Mild antagonism was observed in combination with platinum- or taxane-based chemotherapy, which was putatively related to treatment-induced activation of p38, JNK1/2, ERK1/2, MEK1/2, and AKT, functioning as potential pro-survival factors.	Platinum	49-57	mitogen-activated protein kinase 1	Homo sapiens	153-156
34549724-0	2021	SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer.	Platinum	61-69	schlafen family member 11	Homo sapiens	0-6
34549724-1	2021	Large independent analyses on cancer cell lines followed by functional studies have identified Schlafen 11 (SLFN11), a putative helicase, as the strongest predictor of sensitivity to DNA-damaging agents (DDAs), including platinum.	Platinum	221-229	schlafen family member 11	Homo sapiens	95-106
34549724-4	2021	By analyzing a cohort of high-grade serous ovarian carcinoma (HGSOC) specimens before platinum-based chemotherapy treatment, we show, for the first time to our knowledge, that SLFN11 density in both the neoplastic and microenvironmental components was independently associated with favorable outcome.	Platinum	86-94	schlafen family member 11	Homo sapiens	176-182
34549724-6	2021	We found that platinum treatments activated immune-related pathways in ovarian cancer cells in an SLFN11-dependent manner, representative of tumor-immune transactivation.	Platinum	14-22	schlafen family member 11	Homo sapiens	98-104
34681173-8	2021	Mild antagonism was observed in combination with platinum- or taxane-based chemotherapy, which was putatively related to treatment-induced activation of p38, JNK1/2, ERK1/2, MEK1/2, and AKT, functioning as potential pro-survival factors.	Platinum	49-57	mitogen-activated protein kinase 8	Homo sapiens	158-164
34681173-8	2021	Mild antagonism was observed in combination with platinum- or taxane-based chemotherapy, which was putatively related to treatment-induced activation of p38, JNK1/2, ERK1/2, MEK1/2, and AKT, functioning as potential pro-survival factors.	Platinum	49-57	mitogen-activated protein kinase 3	Homo sapiens	166-172
34681173-8	2021	Mild antagonism was observed in combination with platinum- or taxane-based chemotherapy, which was putatively related to treatment-induced activation of p38, JNK1/2, ERK1/2, MEK1/2, and AKT, functioning as potential pro-survival factors.	Platinum	49-57	mitogen-activated protein kinase kinase 1	Homo sapiens	174-180
34681173-8	2021	Mild antagonism was observed in combination with platinum- or taxane-based chemotherapy, which was putatively related to treatment-induced activation of p38, JNK1/2, ERK1/2, MEK1/2, and AKT, functioning as potential pro-survival factors.	Platinum	49-57	AKT serine/threonine kinase 1	Homo sapiens	186-189
34616674-1	2021	Purpose: Platinum-based chemotherapy remains the classic treatment option for patients with advanced non-small-cell lung cancer (NSCLC) who progress while receiving treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs).	Platinum	9-17	epidermal growth factor receptor	Homo sapiens	241-245
34572879-3	2021	We have previously identified that cell division cycle-associated protein 3 (CDCA3) is elevated in adenocarcinoma (LUAD) and correlates with sensitivity to platinum-based chemotherapy.	Platinum	156-164	cell division cycle associated 3	Homo sapiens	35-75
34603024-11	2021	Conclusion: Our research demonstrated the potential of using ANRIL rs1333049 (G > C) and miR-146A rs2910164 (C > G) as biomarkers to support the prediction of a better prognosis for lung cancer patients receiving platinum-based chemotherapy.	Platinum	213-221	CDKN2B antisense RNA 1	Homo sapiens	61-66
34603024-11	2021	Conclusion: Our research demonstrated the potential of using ANRIL rs1333049 (G > C) and miR-146A rs2910164 (C > G) as biomarkers to support the prediction of a better prognosis for lung cancer patients receiving platinum-based chemotherapy.	Platinum	213-221	microRNA 146a	Homo sapiens	89-97
34566424-0	2021	The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy.	Platinum	81-89	cellular communication network factor 4	Homo sapiens	15-20
34566424-1	2021	Purpose: To investigate the relationships between Wnt1 inducible signaling pathway protein 1 (WISP1) polymorphisms and the prognosis of platinum-based chemotherapy in lung cancer patients.	Platinum	136-144	cellular communication network factor 4	Homo sapiens	50-92
34566424-1	2021	Purpose: To investigate the relationships between Wnt1 inducible signaling pathway protein 1 (WISP1) polymorphisms and the prognosis of platinum-based chemotherapy in lung cancer patients.	Platinum	136-144	cellular communication network factor 4	Homo sapiens	94-99
34566424-4	2021	We used unconditional logistic regression analysis to assess the associations of 39 single nucleotide polymorphisms in WISP1 gene with platinum-based chemotherapy prognosis.	Platinum	135-143	cellular communication network factor 4	Homo sapiens	119-124
34566424-9	2021	Conclusion: WISP1 rs2929973, rs2977551 and rs2977549 may be contributed to a potential candidate biomarker for prediction of platinum-based chemotherapy prognosis in lung cancer patients.	Platinum	125-133	cellular communication network factor 4	Homo sapiens	12-17
34519755-4	2021	In this work, concave octahedral Pt-Pd alloy NCs with high-index {hhl} faces were synthesized using glycine as a coordination molecule and polyvinylpyrrolidone as the surfactant and reducing agent.	Platinum	33-35	hes family bHLH transcription factor 1	Homo sapiens	66-69
34288320-4	2021	The solution structure of QLDH MYT1L- L 1 Pt(dien) complex was determined by NMR.	Platinum	42-44	myelin transcription factor 1 like	Homo sapiens	31-36
34572879-3	2021	We have previously identified that cell division cycle-associated protein 3 (CDCA3) is elevated in adenocarcinoma (LUAD) and correlates with sensitivity to platinum-based chemotherapy.	Platinum	156-164	cell division cycle associated 3	Homo sapiens	77-82
34557089-0	2021	Platinum Accumulation and Cancer-Related Fatigue, Correlation With IL-8, TNF-alpha and Hemocytes.	Platinum	0-8	C-X-C motif chemokine ligand 8	Homo sapiens	67-71
34568657-0	2021	First-Principles Calculations for Adsorption of HF, COF2, and CS2 on Pt-Doped Single-Walled Carbon Nanotubes.	Platinum	69-71	chorionic somatomammotropin hormone 2	Homo sapiens	62-65
34568657-4	2021	It is found that all processes of HF, CS2, and COF2 adsorbed on Pt-SWCNT are exothermic.	Platinum	64-66	chorionic somatomammotropin hormone 2	Homo sapiens	38-41
34568657-6	2021	After comprehensive consideration of binding energy and charge transfer, the response of Pt- SWCNT to CS2 may be the best, and those to HF and COF2 are almost the same.	Platinum	89-91	chorionic somatomammotropin hormone 2	Homo sapiens	102-105
34568657-7	2021	In addition, after the adsorption of the three kinds of gases on Pt-SWCNT, the order of the conductivity of the Pt-SWCNT material is CS2 > COF2   HF via frontier molecular orbital theory analysis.	Platinum	65-67	chorionic somatomammotropin hormone 2	Homo sapiens	133-136
34568657-7	2021	In addition, after the adsorption of the three kinds of gases on Pt-SWCNT, the order of the conductivity of the Pt-SWCNT material is CS2 > COF2   HF via frontier molecular orbital theory analysis.	Platinum	112-114	chorionic somatomammotropin hormone 2	Homo sapiens	133-136
34568657-8	2021	The Pt-SWCNT material is probably more suitable as a gas sensor for the detection of CS2 in the application of gas-insulated equipment.	Platinum	4-6	chorionic somatomammotropin hormone 2	Homo sapiens	85-88
34558931-4	2021	The pure spin current nature is further corroborated by reversal of the polarity of spin-pumping signals when the spin detector is switched from platinum to tungsten which has an opposite sign of the spin Hall angle.	Platinum	145-153	spindlin 1	Homo sapiens	84-88
34558931-4	2021	The pure spin current nature is further corroborated by reversal of the polarity of spin-pumping signals when the spin detector is switched from platinum to tungsten which has an opposite sign of the spin Hall angle.	Platinum	145-153	spindlin 1	Homo sapiens	114-118
34558931-4	2021	The pure spin current nature is further corroborated by reversal of the polarity of spin-pumping signals when the spin detector is switched from platinum to tungsten which has an opposite sign of the spin Hall angle.	Platinum	145-153	spindlin 1	Homo sapiens	200-204
34557089-1	2021	Platinum-based chemotherapy drugs cause platinum accumulation and result in cancer-related fatigue (CRF), which is related to immune response through still ambiguous mechanisms.	Platinum	0-8	complement C1q like 1	Homo sapiens	76-98
34557089-1	2021	Platinum-based chemotherapy drugs cause platinum accumulation and result in cancer-related fatigue (CRF), which is related to immune response through still ambiguous mechanisms.	Platinum	40-48	complement C1q like 1	Homo sapiens	76-98
34557089-8	2021	Platinum accumulation may involve increasing IL-8, cause inflammation or aggravate anemia, which in combination lead to CRF.	Platinum	0-8	C-X-C motif chemokine ligand 8	Homo sapiens	45-49
34481526-6	2021	Autophagy inhibitor LY294002 or knockdown of ATG5 suppressed the inhibitory effects of PS-T.	Platinum	87-91	autophagy related 5	Homo sapiens	45-49
34612275-4	2021	They induce a directed and tunable charge relocation mechanism from deep Co to topmost Pt to optimize the adsorption energies of O2/O* and achieve excellent ORR kinetics performance with minimum Pt usage but maximum Pt atom utilization (i.e., Pt1 to Pt3) compared with benchmark Pt(111).	Platinum	216-218	zinc finger protein 77	Homo sapiens	243-246
34346470-5	2021	GDE with CFRH and CFAH supported platinum showed excellent ECSA retention of about 60-70% during accelerated degradation testing under half-cell conditions compared to only 13% for GDE with Pt/CVulcan reference material.	Platinum	33-41	amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase	Homo sapiens	0-3
34552616-5	2021	The genotypes for the same sample were concordant with the previously validated HUAXIA  Platinum kit.	Platinum	88-96	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	97-100
34481526-7	2021	In addition, as a key transcription factor controlling EMT initiation, Snail was found to be degraded by PS-T induced autophagy.	Platinum	105-109	snail family transcriptional repressor 1	Homo sapiens	71-76
34481526-8	2021	In addition, overexpression of Snail reversed the inhibitory effects of PS-T.	Platinum	72-76	snail family transcriptional repressor 1	Homo sapiens	31-36
34481526-10	2021	CONCLUSIONS: This study demonstrated that PS-T could inhibit EMT in breast cancer cells by inducing autophagy to degrade Snail protein, thus improving the prognosis of TNBC, offering potential treatment alternatives for TNBC patients.	Platinum	42-46	snail family transcriptional repressor 1	Homo sapiens	121-126
34252800-5	2021	Therefore, we design an early phago-/endosome-escaping micelle that can release platinum-based drugs into the cytoplasm of macrophages and cancer cells, thereby enhancing the ROS levels of the entire tumor tissue; inducing apoptosis of cancer cells, down-regulation of CD47 expression of cancer cells, polarization of M1 macrophages, and phagocytosis of cancer cells by M1 macrophages; and achieving the dual effect of chemotherapy and macrophage-mediated immunotherapy.	Platinum	80-88	CD47 molecule	Homo sapiens	269-273
34474677-0	2021	CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer.	Platinum	46-54	C-X-C motif chemokine ligand 2	Homo sapiens	0-5
34474677-2	2021	This study was designed to reveal the important role of CXCL2 in platinum resistance in epithelial ovarian cancer (EOC).	Platinum	65-73	C-X-C motif chemokine ligand 2	Homo sapiens	56-61
34474677-7	2021	As the results showed, CXCL2 was identified up-regulated in platinum-resistant EOC.	Platinum	60-68	C-X-C motif chemokine ligand 2	Homo sapiens	23-28
34474677-12	2021	This study identified a CXCL2-mediated mechanism in EOC platinum resistance.	Platinum	56-64	C-X-C motif chemokine ligand 2	Homo sapiens	24-29
34475400-2	2021	Herein, we synthesize atomically dispersed platinum on ruthenium oxide (Pt1/RuO2) using a simple impregnation-adsorption method.	Platinum	43-51	zinc finger protein 77	Homo sapiens	72-75
34475400-7	2021	Ab initio simulations and experiments reveal that the presence of Pt-O3f (3-fold coordinatively bonded O)-Rucus (coordinatively unsaturated Ru) bonds with the undercoordinated bridging O in Pt1/RuO2 favors the electrochemical dehydrogenation of methanol with lower energy barriers and onset potential than those encountered for Pt-C and Pt-Ru.	Platinum	66-68	zinc finger protein 77	Homo sapiens	190-193
34734033-2	2021	The purpose of the present study was to estimate the cost-effectiveness of atezolizumab versus platinum-based chemotherapy for first-line treatment in metastatic NSCLC with high PD-L1 expression, from the perspective of US and Chinese payers.	Platinum	95-103	CD274 molecule	Homo sapiens	178-183
34215621-4	2021	Known and novel interactions were identified, and one of these interactions, the resistance of KEAP1 mutant lung tumors to platinum therapy, was validated using a large patient response dataset.	Platinum	123-131	kelch like ECH associated protein 1	Homo sapiens	95-100
34117815-12	2021	Platinum treatment induced CD70 expression in ovarian cancer cells.	Platinum	0-8	CD70 antigen	Mus musculus	27-31
34293664-1	2021	BACKGROUND: The impact of maintenance therapy with PARP inhibitors (PARPi) on progression-free survival (PFS) in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer (PSROC) varies widely.	Platinum	146-154	collagen type XI alpha 2 chain	Homo sapiens	51-55
34363352-3	2021	In this study, hyaluronic acid (HA) which could specifically bind to CD44 on the surface of tumor cells, was used to modify amine-caged platinum nanoclusters (Pt NCs-NH2 ) to obtain targeting HA-Pt NCs-NH2 .	Platinum	136-144	CD44 molecule (Indian blood group)	Homo sapiens	69-73
34586745-0	2021	Glutathione peroxidase 4-dependent glutathione high-consumption drives acquired platinum chemoresistance in lung cancer-derived brain metastasis.	Platinum	80-88	glutathione peroxidase 4	Homo sapiens	0-24
34586745-12	2021	GPX4 inhibitor was found to augment the anticancer effect of platinum drugs in lung cancer BM, providing novel strategies for lung cancer patients with BM.	Platinum	61-69	glutathione peroxidase 4	Homo sapiens	0-4
34132072-8	2021	RESULTS: LINC01508 was downregulated in cisplatin-resistant OC cells and platinum-resistant OC tissue (p<0.01).	Platinum	73-81	long intergenic non-protein coding RNA 1508	Homo sapiens	9-18
34302857-2	2021	We aimed to clarify whether BRCA2 BRC domain-associated mutation correlates with sensibility of platinum-based chemotherapy and survival in high-grade serous ovarian cancer(HGSOC).	Platinum	96-104	BRCA2 DNA repair associated	Homo sapiens	28-33
34302857-6	2021	CONCLUSIONS: Somatic mutations in BRCA2 BRC domain confer a higher sensitivity to platinum-based therapy and are associated with a favourable survival in HGSOC.	Platinum	82-90	BRCA2 DNA repair associated	Homo sapiens	34-39
34132072-9	2021	LINC01508 downregulation was correlated with tumor size, residual tumor, and platinum resistance.	Platinum	77-85	long intergenic non-protein coding RNA 1508	Homo sapiens	0-9
34278473-3	2021	The present study aimed to investigate the possible function of the core of the TLS polymerase mitotic arrest deficient 2 like 2 (MAD2L2) in drug sensitivity, in order to provide a treatment rationale for platinum-based chemotherapy in colon cancer.	Platinum	205-213	FUS RNA binding protein	Homo sapiens	80-83
34590923-0	2021	Puerarin induces platinum-resistant epithelial ovarian cancer cell apoptosis by targeting SIRT1.	Platinum	17-25	sirtuin 1	Homo sapiens	90-95
34278473-3	2021	The present study aimed to investigate the possible function of the core of the TLS polymerase mitotic arrest deficient 2 like 2 (MAD2L2) in drug sensitivity, in order to provide a treatment rationale for platinum-based chemotherapy in colon cancer.	Platinum	205-213	mitotic arrest deficient 2 like 2	Homo sapiens	95-128
34278473-3	2021	The present study aimed to investigate the possible function of the core of the TLS polymerase mitotic arrest deficient 2 like 2 (MAD2L2) in drug sensitivity, in order to provide a treatment rationale for platinum-based chemotherapy in colon cancer.	Platinum	205-213	mitotic arrest deficient 2 like 2	Homo sapiens	130-136
34465291-8	2021	In mDJA patients with high VEGF-A expression, those who received platinum-based chemotherapy with bevacizumab as a first-line treatment had significantly longer progression-free survival and tended to have longer overall survival than those treated without bevacizumab (P = 0.025 and P = 0.056, respectively), whereas no differences were observed in mDJA patients with low VEGF-A expression.	Platinum	65-73	vascular endothelial growth factor A	Homo sapiens	27-33
34846397-0	2021	Scalable nanoporous carbon films allow line-of-sight 3D atomic layer deposition of Pt: towards a new generation catalyst layer for PEM fuel cells.	Platinum	83-85	mucin 1, cell surface associated	Homo sapiens	131-134
34341816-3	2021	The optimized 2.0% NiS/Zn3In2S6/g-C3N4 rivaled noble metal based Pt/g-C3N4 and showed an apparent quantum efficiency (AQE) of 24.3% at 420 nm, with a H2 yield of 4.135 mmol g-1 h-1, which was 30.4 and 9.51 times that of pure g-C3N4 and binary Zn3In2S6/g-C3N4 composites, respectively.	Platinum	65-67	solute carrier family 5 member 5	Homo sapiens	19-22
34318845-5	2021	Notably, the Ni species (Nin+) promoted the decomposition of water and produced hydrogen intermediates, which were then immediately adsorbed on the surface of Pt and recombined into molecular hydrogen.	Platinum	159-161	ninein	Homo sapiens	25-28
34453188-0	2021	Peroxidase-mimicking nanozyme with surface-dispersed Pt atoms for the colorimetric lateral flow immunoassay of C-reactive protein.	Platinum	53-55	C-reactive protein	Homo sapiens	111-129
34318860-4	2021	Therefore, GOx and Pt-NPs were coated with PLGA to obtain a functional nano-system (GOx-Pt-NS), which increased the cellular uptake of Pt-NPs.	Platinum	135-137	hydroxyacid oxidase 1	Homo sapiens	11-14
34318860-4	2021	Therefore, GOx and Pt-NPs were coated with PLGA to obtain a functional nano-system (GOx-Pt-NS), which increased the cellular uptake of Pt-NPs.	Platinum	135-137	hydroxyacid oxidase 1	Homo sapiens	84-87
34132814-18	2021	These findings suggest the variant allele C of T2285C polymorphism of PARP1 linked to an increase of NSCLC risk, and unfavorable efficacy and prognosis of NSCLC patients with platinum-based chemotherapy, which might be associated with enhancement of its mRNA expression and the diminishment of activity.	Platinum	175-183	poly(ADP-ribose) polymerase 1	Homo sapiens	70-75
34454564-1	2021	Tumors arising in BRCA1/2 germline mutation carriers usually demonstrate somatic loss of the remaining BRCA1/2 allele and increased sensitivity to platinum compounds, anthracyclines, mitomycin C and poly (ADP-ribose) polymerase inhibitors (PARPi).	Platinum	147-155	BRCA1 DNA repair associated	Homo sapiens	18-25
34454564-2	2021	Exposure to conventional platinum-based therapy or PARPi results in the restoration of BRCA1/2 function and development of resistance to systemic therapy, therefore, there is a need for other treatment options.	Platinum	25-33	BRCA1 DNA repair associated	Homo sapiens	87-94
34454589-0	2021	Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.	Platinum	101-109	FKBP prolyl isomerase 1A	Homo sapiens	41-46
34454589-0	2021	Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.	Platinum	101-109	paired box 9	Homo sapiens	47-51
34454589-7	2021	Re-establishment of FKBP1B expression in the resistant OVCAR3 phenotype in which this gene is hypermethylated and inhibited allowed it to achieve a degree of platinum sensitivity similar to the sensitive phenotype.	Platinum	158-166	FKBP prolyl isomerase 1B	Homo sapiens	20-26
34454589-7	2021	Re-establishment of FKBP1B expression in the resistant OVCAR3 phenotype in which this gene is hypermethylated and inhibited allowed it to achieve a degree of platinum sensitivity similar to the sensitive phenotype.	Platinum	158-166	carbonic anhydrase 3	Homo sapiens	55-61
34454589-10	2021	CONCLUSIONS: Epigenetic regulation of PAX9 and FKBP1B genes shows that methylation in non-promoter areas has the potential to control gene expression and thus biological consequences, such as the loss of platinum sensitivity.	Platinum	204-212	paired box 9	Homo sapiens	38-42
34454589-10	2021	CONCLUSIONS: Epigenetic regulation of PAX9 and FKBP1B genes shows that methylation in non-promoter areas has the potential to control gene expression and thus biological consequences, such as the loss of platinum sensitivity.	Platinum	204-212	FKBP prolyl isomerase 1B	Homo sapiens	47-53
34454589-11	2021	At the translational level, PAX9 behaves as a predictor of chemotherapy response to platinum in patients with ovarian cancer.	Platinum	84-92	paired box 9	Homo sapiens	28-32
34403254-3	2021	Herein, we report on triple-action platinum(IV) prodrugs, which, in addition to tumor targeting via maleimide-mediated albumin binding, release the immunomodulatory ligand 1-methyl-d-tryptophan (1-MDT).	Platinum	35-43	albumin	Mus musculus	119-126
34703544-0	2021	Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo.	Platinum	46-54	albumin	Homo sapiens	0-7
34703544-8	2021	KP2156 forms very stable albumin adducts in the bloodstream resulting in a superior pharmacological profile, such as distinctly prolonged terminal excretion half-life and enhanced effective platinum dose (measured by ICP-MS).	Platinum	190-198	albumin	Homo sapiens	25-32
34703544-11	2021	Summarizing, albumin-binding of platinum(iv) complexes potently enhances the efficacy of oxaliplatin therapy and should be further developed towards clinical phase I trials.	Platinum	32-40	albumin	Homo sapiens	13-20
34403254-6	2021	Moreover, we could demonstrate that the design of albumin-targeted multi-modal prodrugs using platinum(IV) is a promising strategy to enhance the cellular uptake of bioactive ligands with low cell permeability (1-MDT) and to improve their selective delivery into the malignant tissue.	Platinum	94-102	albumin	Mus musculus	50-57
34512203-11	2021	LAMB3 and LAMC2 expression was correlated with platinum resistance development.	Platinum	47-55	laminin subunit beta 3	Homo sapiens	0-5
34380320-3	2021	Here we demonstrate spin-orbit torque and quantify its efficiency in a bilayer system of topological kagome ferromagnet Fe3Sn2 and platinum.	Platinum	131-139	spindlin 1	Homo sapiens	20-24
34380320-5	2021	Both techniques give a consistent value of the effective spin Hall angle of the Fe3Sn2/Pt system.	Platinum	87-89	spindlin 1	Homo sapiens	57-61
34380311-4	2021	The platinum complex (Ph3P)2Pt(C2H4) also reacts with 1 to form an orange eta2 complex of tri-tert-butylphosphacyclobutadiene in 80% isolated yield.	Platinum	4-12	DNA polymerase iota	Homo sapiens	74-78
34380311-4	2021	The platinum complex (Ph3P)2Pt(C2H4) also reacts with 1 to form an orange eta2 complex of tri-tert-butylphosphacyclobutadiene in 80% isolated yield.	Platinum	4-12	tRNA-Ile (anticodon AAT) 9-1	Homo sapiens	90-93
34512203-11	2021	LAMB3 and LAMC2 expression was correlated with platinum resistance development.	Platinum	47-55	laminin subunit gamma 2	Homo sapiens	10-15
34420059-0	2022	Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab.	Platinum	139-147	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
34425813-0	2021	A novel germline BRCA2 mutation in a Chinese patient with prostate cancer sensitive to platinum chemotherapy: a case report.	Platinum	87-95	BRCA2 DNA repair associated	Homo sapiens	17-22
34420059-1	2022	BACKGROUND: We aimed to evaluate the prognostic value of natural killer (NK) cell activity for patients with HER2 + advanced gastric cancer (AGC) treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab.	Platinum	187-195	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-113
34414935-0	2021	Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis.	Platinum	125-133	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	27-72
34414935-5	2021	METHODS: We conducted a meta-analysis to reevaluate the association between polymorphisms of NER gene (ERCC1 rs2298881) and the clinical outcomes in gastric cancer patients receiving platinum-based chemotherapy.	Platinum	183-191	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	103-108
34414935-8	2021	Crude odds ratios (ORs) and hazard ratios (HRs) with 95% confidence interval (CI) were applied to evaluate the effect of ERCC1 rs2298881 on patients treated by platinum-based chemotherapy.	Platinum	160-168	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	121-126
34414935-12	2021	CONCLUSIONS: ERCC1 rs2298881 is suggested as a marker of clinical outcome in gastric cancer patients treated by platinum-based chemotherapy.	Platinum	112-120	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	13-18
34436399-0	2021	Effective Perturbations of the Amplitude, Gating, and Hysteresis of IK(DR) Caused by PT-2385, an HIF-2alpha Inhibitor.	Platinum	85-87	endothelial PAS domain protein 1	Homo sapiens	97-107
34342219-3	2021	Herein, we constructed a self-sufficient hybrid enzyme-based silk fibroin hydrogel system, consisting of Pt-decorated hollow Ag-Au trimetallic nanocages (HGN@Pt) and glucose oxidase (GOx), to supply O2 continuously and consume glucose concurrently and, thereby, synergistically enhance the anti-cancer efficacy of a combined starvation and photothermal therapy operating in a hypoxic tumor microenvironment.	Platinum	105-107	hydroxyacid oxidase 1	Homo sapiens	183-186
34436399-7	2021	The hysteretic strength of IK(DR) elicited by upright or inverted isosceles-triangular ramp voltage was decreased during exposure to PT-2385; meanwhile, the activation energy involved in the gating of IK(DR) elicitation was noticeably raised in its presence.	Platinum	133-135	IK cytokine	Rattus norvegicus	27-29
34436399-7	2021	The hysteretic strength of IK(DR) elicited by upright or inverted isosceles-triangular ramp voltage was decreased during exposure to PT-2385; meanwhile, the activation energy involved in the gating of IK(DR) elicitation was noticeably raised in its presence.	Platinum	133-135	IK cytokine	Rattus norvegicus	201-203
34436399-9	2021	Considering all of the experimental results together, the effects of PT-2385 on ionic currents demonstrated herein could be non-canonical and tend to be upstream of the inhibition of HIF-2alpha.	Platinum	69-71	endothelial PAS domain protein 1	Homo sapiens	183-193
34400618-0	2021	Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1.	Platinum	65-73	nuclear receptor subfamily 3 group C member 1	Homo sapiens	33-56
34396988-10	2021	Collectively, our results highlight mesothelial cells as a key driver of ovarian cancer chemoresistance and suggest that therapeutic targeting of osteopontin may be an effective strategy for enhancing platinum sensitivity in ovarian cancer.	Platinum	201-209	secreted phosphoprotein 1	Mus musculus	146-157
34400618-0	2021	Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1.	Platinum	65-73	microtubule associated serine/threonine kinase 1	Homo sapiens	89-94
34400618-1	2021	Agonists of glucocorticoid receptor (GR) are frequently given to cancer patients with platinum-containing chemotherapy to reduce inflammation, but how GR influences tumor growth in response to platinum-based chemotherapy such as cisplatin through inflammation-independent signaling remains largely unclear.	Platinum	86-94	nuclear receptor subfamily 3 group C member 1	Homo sapiens	12-35
34400618-1	2021	Agonists of glucocorticoid receptor (GR) are frequently given to cancer patients with platinum-containing chemotherapy to reduce inflammation, but how GR influences tumor growth in response to platinum-based chemotherapy such as cisplatin through inflammation-independent signaling remains largely unclear.	Platinum	86-94	nuclear receptor subfamily 3 group C member 1	Homo sapiens	37-39
34400618-1	2021	Agonists of glucocorticoid receptor (GR) are frequently given to cancer patients with platinum-containing chemotherapy to reduce inflammation, but how GR influences tumor growth in response to platinum-based chemotherapy such as cisplatin through inflammation-independent signaling remains largely unclear.	Platinum	193-201	nuclear receptor subfamily 3 group C member 1	Homo sapiens	151-153
34400618-2	2021	Combined genomics and transcription factor profiling reveal that MAST1, a critical platinum resistance factor that reprograms the MAPK pathway, is upregulated upon cisplatin exposure through activated transcription factor GR.	Platinum	83-91	microtubule associated serine/threonine kinase 1	Homo sapiens	65-70
34400618-2	2021	Combined genomics and transcription factor profiling reveal that MAST1, a critical platinum resistance factor that reprograms the MAPK pathway, is upregulated upon cisplatin exposure through activated transcription factor GR.	Platinum	83-91	nuclear receptor subfamily 3 group C member 1	Homo sapiens	222-224
34400618-4	2021	GR nuclear translocation and MAST1 upregulation coordinately occur in patient tumors collected after platinum treatment, and align with patient treatment resistance.	Platinum	101-109	nuclear receptor subfamily 3 group C member 1	Homo sapiens	0-2
34400618-4	2021	GR nuclear translocation and MAST1 upregulation coordinately occur in patient tumors collected after platinum treatment, and align with patient treatment resistance.	Platinum	101-109	microtubule associated serine/threonine kinase 1	Homo sapiens	29-34
34400618-6	2021	These findings not only provide insights into the underlying mechanism of GR in cisplatin resistance but also offer an effective alternative therapeutic strategy to improve the clinical outcome of patients receiving platinum-based chemotherapy with GR agonists.	Platinum	216-224	nuclear receptor subfamily 3 group C member 1	Homo sapiens	74-76
34400618-6	2021	These findings not only provide insights into the underlying mechanism of GR in cisplatin resistance but also offer an effective alternative therapeutic strategy to improve the clinical outcome of patients receiving platinum-based chemotherapy with GR agonists.	Platinum	216-224	nuclear receptor subfamily 3 group C member 1	Homo sapiens	249-251
34400619-0	2021	How the glucocorticoid receptor contributes to platinum-based therapy resistance in solid cancer.	Platinum	47-55	nuclear receptor subfamily 3 group C member 1	Homo sapiens	8-31
34492978-3	2021	A supported Pt catalyst on Fe-W-O amorphous nanosheets (denoted as Pt/a-Fe-W-O) was synthesized using a one-step solvothermal method.	Platinum	12-14	pre T cell antigen receptor alpha	Homo sapiens	67-71
34492978-6	2021	Consequently, the Pt/a-Fe-W-O catalyst with an optimal W/Fe molar ratio of 0.08:1 and a 1.51 wt% Pt loading exhibited a high specific reaction rate of 68.3 mumol gPt-1 s-1 and excellent stability during 24 h continuous test, outperforming most existing HCHO oxidation catalysts.	Platinum	97-99	pre T cell antigen receptor alpha	Homo sapiens	18-22
34344062-11	2021	Although the CPP group had a lower basal AMH level than the PT group"s basal AMH level; AMH response to GnRH stimulation was not different (p>0.05).	Platinum	60-62	anti-Mullerian hormone	Homo sapiens	77-80
34351305-1	2021	AIM: Overexpression of BCL2L1 (BCL-xL) was associated with platinum resistance in ovarian cancer (OvCa).	Platinum	59-67	BCL2 like 1	Homo sapiens	23-29
34351305-1	2021	AIM: Overexpression of BCL2L1 (BCL-xL) was associated with platinum resistance in ovarian cancer (OvCa).	Platinum	59-67	BCL2 like 1	Homo sapiens	31-37
34342437-1	2021	"Multi-action" Pt(IV) derivatives of cisplatin with combretastatin A4 (CA4) bioactive ligands that are conjugated to Pt(IV) by carbonate are unique because the ligand (IC50 < 10 nM) is dramatically 1000-folds more cytotoxic than cisplatin in vitro.	Platinum	117-119	carbonic anhydrase 4	Homo sapiens	71-74
34440757-2	2021	In the present study, miRNAs (let-7c, miR-26a, miR-30d, miR-98, miR-195, miR-202) reported to be involved in the polarization of macrophages were examined for associations with the outcomes of non-small cell lung cancer (NSCLC) patients (N = 125) treated with first-line platinum-based chemotherapy.	Platinum	271-279	microRNA 98	Homo sapiens	56-62
34180588-11	2021	CONCLUSIONS: The combination of first-generation EGFR-TKIs with platinum-based chemotherapy may be a first-line treatment for advanced lung adenocarcinoma patients harboring activated EGFR mutations and is well tolerated.	Platinum	64-72	epidermal growth factor receptor	Homo sapiens	184-188
34927877-3	2021	The ionization of elements and their recombination process during arc discharge allows the simultaneous incorporation of single metal atoms (Mn, Fe, Co, Ni, and Pt) into the crystalline carbon lattice during the formation of carbon nanohorns (CNHs) and N-doped arc graphene.	Platinum	161-163	activity regulated cytoskeleton associated protein	Homo sapiens	66-69
34386569-3	2021	Previous literature reported the use of platinum-based chemotherapy and c-Kit tyrosine kinase inhibitors for FATWO cases with c-Kit positive expression.	Platinum	40-48	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	126-131
34361752-2	2021	Soft Lewis acid ions, such as radioisotopes of platinum, rhodium and palladium, are particularly underdeveloped.	Platinum	47-55	POC1 centriolar protein A	Homo sapiens	0-4
34359703-0	2021	Functional Analysis of Non-Genetic Resistance to Platinum in Epithelial Ovarian Cancer Reveals a Role for the MBD3-NuRD Complex in Resistance Development.	Platinum	49-57	methyl-CpG binding domain protein 3	Homo sapiens	110-114
34367927-2	2021	Consequently, BRCA1/2-driven cancers are sensitive to platinum-based therapy and poly (ADP-ribose) polymerase inhibitors (PARPi).	Platinum	54-62	BRCA1 DNA repair associated	Homo sapiens	14-21
34367927-4	2021	This platinum/PARPi cross-resistance mechanism applies both for BRCA1 and BRCA2 genes and has been repeatedly validated in various laboratory models and multiple clinical studies.	Platinum	5-13	BRCA1 DNA repair associated	Homo sapiens	64-69
34367927-4	2021	This platinum/PARPi cross-resistance mechanism applies both for BRCA1 and BRCA2 genes and has been repeatedly validated in various laboratory models and multiple clinical studies.	Platinum	5-13	BRCA2 DNA repair associated	Homo sapiens	74-79
34367977-1	2021	Poly-(ADP)-ribose polymerase inhibitors (PARPi) and platinum-based drugs are promising therapies for triple negative breast cancers (TNBC) with BRCA1 or BRCA2 loss.	Platinum	52-60	BRCA1 DNA repair associated	Homo sapiens	144-149
34367977-1	2021	Poly-(ADP)-ribose polymerase inhibitors (PARPi) and platinum-based drugs are promising therapies for triple negative breast cancers (TNBC) with BRCA1 or BRCA2 loss.	Platinum	52-60	BRCA2 DNA repair associated	Homo sapiens	153-158
34355022-2	2021	Aberrant expression of ANXA3 promotes tumor cell proliferation, invasion, metastasis, angiogenesis, and therapy resistance to multiple chemotherapeutic drugs including platinum-based agents, fluoropyrimidines, cyclophosphamide, doxorubicin, and docetaxel.	Platinum	168-176	annexin A3	Homo sapiens	23-28
34391686-0	2022	EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.	Platinum	45-53	epidermal growth factor receptor	Homo sapiens	0-4
34391686-3	2022	Though platinum-based chemotherapy is the frontline standard of care for EGFR ex20ins NSCLC, its efficacy is not fully described.	Platinum	7-15	epidermal growth factor receptor	Homo sapiens	73-77
34419376-0	2022	Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma.	Platinum	53-61	KRAS proto-oncogene, GTPase	Homo sapiens	94-98
34373746-0	2021	Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers.	Platinum	27-35	X-ray repair cross complementing 1	Homo sapiens	91-96
34373746-6	2021	Results: LIG1 and LIG3 overexpression linked with aggressive phenotypes, platinum resistance and poor progression free survival (PFS).	Platinum	73-81	DNA ligase 1	Homo sapiens	9-13
34373746-6	2021	Results: LIG1 and LIG3 overexpression linked with aggressive phenotypes, platinum resistance and poor progression free survival (PFS).	Platinum	73-81	DNA ligase 3	Homo sapiens	18-22
34373746-9	2021	In ovarian cancer cell lines, LIG1 depletion increased platinum cytotoxicity.	Platinum	55-63	DNA ligase 1	Homo sapiens	30-34
34294681-3	2021	In our study, we found that the expression of Glycosyltransferase 8 domain containing 2 (GLT8D2) was significantly upregulated in ovarian cancer samples with CDDP (Cis-dichlorodiammine-platinum) resistance.	Platinum	185-193	glycosyltransferase 8 domain containing 2	Homo sapiens	46-87
34294681-3	2021	In our study, we found that the expression of Glycosyltransferase 8 domain containing 2 (GLT8D2) was significantly upregulated in ovarian cancer samples with CDDP (Cis-dichlorodiammine-platinum) resistance.	Platinum	185-193	glycosyltransferase 8 domain containing 2	Homo sapiens	89-95
34294681-7	2021	Importantly, pharmacological inhibition of FGFR and PI3K (phosphatidylinositol 3-kinase) signaling pathway significantly counteracted GLT8D2-induced chemoresistance and enhanced platinum"s therapeutic efficacy in ovarian cancer.	Platinum	178-186	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	58-87
34294681-7	2021	Importantly, pharmacological inhibition of FGFR and PI3K (phosphatidylinositol 3-kinase) signaling pathway significantly counteracted GLT8D2-induced chemoresistance and enhanced platinum"s therapeutic efficacy in ovarian cancer.	Platinum	178-186	glycosyltransferase 8 domain containing 2	Homo sapiens	134-140
34294681-8	2021	Therefore, our findings suggest that GLT8D2 is a potential therapeutic target for the treatment of ovarian cancer; targeting GLT8D2/FGFR/PI3K/AKT signaling axis may represent a promising strategy to enhance platinum response in patients with chemoresistant ovarian cancer.	Platinum	207-215	glycosyltransferase 8 domain containing 2	Homo sapiens	37-43
34294681-8	2021	Therefore, our findings suggest that GLT8D2 is a potential therapeutic target for the treatment of ovarian cancer; targeting GLT8D2/FGFR/PI3K/AKT signaling axis may represent a promising strategy to enhance platinum response in patients with chemoresistant ovarian cancer.	Platinum	207-215	glycosyltransferase 8 domain containing 2	Homo sapiens	125-131
34646363-2	2021	Background: The addition of PD-L1 inhibitors to platinum-based chemotherapy (CT) has newly received United States Food and Drug Administration (FDA) approval in extensive stage-small cell lung cancer (ES-SCLC).	Platinum	48-56	CD274 molecule	Homo sapiens	28-33
34298817-3	2021	Inhibition of PFKFB3 displays a cancer-specific synergy with platinum compounds in blocking cell viability and restores sensitivity in treatment-resistant models.	Platinum	61-69	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	14-20
34298817-4	2021	Notably, the synergies are associated with DNA-damage-induced chromatin association of PFKFB3 upon cancer transformation, which further increases upon platinum resistance.	Platinum	151-159	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	87-93
34298686-3	2021	Upregulation of Exo70 is observed in EOC tissues and is related to platinum resistance and progression-free survival of EOC patients.	Platinum	67-75	exocyst complex component 7	Homo sapiens	16-21
34316715-8	2021	Collectively, these results not only indicate that PARPi treatment pressure can reverse RAD51C methylation and restore RAD51C expression, but also provide a model for studying the clinical observation that PARPi and platinum sensitivity are sometimes dissociated.	Platinum	216-224	RAD51 paralog C	Homo sapiens	88-94
34244508-3	2021	The isolated single platinum atoms (Pt1) are steadily anchored in the square-planar sites on the surface of monodispersed Keggin-type phosphomolybdic acid (PMo) in the cavities of various MOFs, including MIL-101, HKUST-1, and ZIF-67.	Platinum	20-28	zinc finger protein 77	Homo sapiens	36-39
34244508-5	2021	Pt1-PMo@MIL-101 are seven times more active than the corresponding nanoparticles in the diboration of phenylacetylene, which can be attributed to the synergistic effect of the preconcentration of organic reaction substrates by porous MOFs skeleton and the decreased desorption energy of products on isolated Pt atom sites.	Platinum	308-310	zinc finger protein 77	Homo sapiens	0-3
34316715-8	2021	Collectively, these results not only indicate that PARPi treatment pressure can reverse RAD51C methylation and restore RAD51C expression, but also provide a model for studying the clinical observation that PARPi and platinum sensitivity are sometimes dissociated.	Platinum	216-224	RAD51 paralog C	Homo sapiens	119-125
34240438-3	2022	CASE SUMMARY: A 55-year-old man with stage IV lung adenocarcinoma and an EGFR L858R mutation received a 5-month course of platinum-based chemotherapy and icotinib.	Platinum	122-130	epidermal growth factor receptor	Homo sapiens	73-77
34307173-0	2021	Predictive Value of HE4 in Platinum-Based Chemotherapy for Ovarian Cancer: A Systematic Review.	Platinum	27-35	WAP four-disulfide core domain 2	Homo sapiens	20-23
34307173-1	2021	Objective: To evaluate the value of serum Human epididymis protein 4 (HE4) for predicting the resistance of ovarian cancer (OS) to platinum chemotherapy.	Platinum	131-139	WAP four-disulfide core domain 2	Homo sapiens	42-68
34307173-1	2021	Objective: To evaluate the value of serum Human epididymis protein 4 (HE4) for predicting the resistance of ovarian cancer (OS) to platinum chemotherapy.	Platinum	131-139	WAP four-disulfide core domain 2	Homo sapiens	70-73
34307173-7	2021	Our results showed that the sensitivity and specificity of preoperative serum HE4 in predicting the resistance of OC to platinum chemotherapy was 80% and 67%, respectively.	Platinum	120-128	WAP four-disulfide core domain 2	Homo sapiens	78-81
34307173-9	2021	Conclusion: HE4 may be an effective predictor of platinum-based chemotherapeutic resistance of OC.	Platinum	49-57	WAP four-disulfide core domain 2	Homo sapiens	12-15
34326746-3	2021	With developments in modern treatment and phase III clinical trial results, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) and ALK-TKI have proven thier superior effectivity in comparison with the standard platinum-based doublet and are commonly approved as first-line indications in previously untreated advanced non-small cell lung cancer (NSCLC) patients with EGFR or ALK mutations.	Platinum	233-241	epidermal growth factor receptor	Homo sapiens	76-108
34138542-6	2021	Moreover, Pt1/N-CNTs using only 0.41 wt % Pt achieved a much higher benzaldehyde yield than those of the state-of-the-art bulk Pt electrode (100 wt % Pt) and commercial Pt/C catalyst (20 wt % Pt).	Platinum	127-129	zinc finger protein 77	Homo sapiens	10-13
34234187-0	2021	A simple label-free electrochemical sensor for sensitive detection of alpha-fetoprotein based on specific aptamer immobilized platinum nanoparticles/carboxylated-graphene oxide.	Platinum	126-134	alpha fetoprotein	Homo sapiens	70-87
34234187-2	2021	Platinum nanoparticles on carboxylated-graphene oxide (PtNPs/GO-COOH) modified screen-printed graphene-carbon paste electrode (SPGE) was utilized as an immobilization platform, and the AFP aptamer was employed as a bio-recognition element.	Platinum	0-8	alpha fetoprotein	Homo sapiens	185-188
34234236-6	2021	Six (42.9%) of fourteen patients with ALK-positive lung cancer had stage IV disease, and five ALK-positive patients treated with platinum-based chemotherapy had poor outcome (all patients were dead and the mean survival time was 12 months), compared to 72 months for patients with ALK inhibitor therapy.	Platinum	129-137	ALK receptor tyrosine kinase	Homo sapiens	94-97
34298602-7	2021	Proteins are involved in metabolic reprogramming such as glycolysis, including putative hexokinase (HK), UDP-glucuronosyltransferase 1-6 (UD16), and 6-phosphogluconolactonase (6 PGL), and their presence correlates with the induction of platinum resistance.	Platinum	236-244	hexokinase 1	Homo sapiens	88-98
34298602-7	2021	Proteins are involved in metabolic reprogramming such as glycolysis, including putative hexokinase (HK), UDP-glucuronosyltransferase 1-6 (UD16), and 6-phosphogluconolactonase (6 PGL), and their presence correlates with the induction of platinum resistance.	Platinum	236-244	hexokinase 1	Homo sapiens	100-102
34298602-7	2021	Proteins are involved in metabolic reprogramming such as glycolysis, including putative hexokinase (HK), UDP-glucuronosyltransferase 1-6 (UD16), and 6-phosphogluconolactonase (6 PGL), and their presence correlates with the induction of platinum resistance.	Platinum	236-244	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	105-136
34298602-7	2021	Proteins are involved in metabolic reprogramming such as glycolysis, including putative hexokinase (HK), UDP-glucuronosyltransferase 1-6 (UD16), and 6-phosphogluconolactonase (6 PGL), and their presence correlates with the induction of platinum resistance.	Platinum	236-244	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	138-142
34298602-7	2021	Proteins are involved in metabolic reprogramming such as glycolysis, including putative hexokinase (HK), UDP-glucuronosyltransferase 1-6 (UD16), and 6-phosphogluconolactonase (6 PGL), and their presence correlates with the induction of platinum resistance.	Platinum	236-244	6-phosphogluconolactonase	Homo sapiens	149-174
34298602-7	2021	Proteins are involved in metabolic reprogramming such as glycolysis, including putative hexokinase (HK), UDP-glucuronosyltransferase 1-6 (UD16), and 6-phosphogluconolactonase (6 PGL), and their presence correlates with the induction of platinum resistance.	Platinum	236-244	6-phosphogluconolactonase	Homo sapiens	176-181
34567247-3	2021	Cyclin E1 (CCNE1) overexpression is a proposed marker of platinum resistance and is mutually exclusive with deficiency in homologous recombination.	Platinum	57-65	cyclin E1	Homo sapiens	0-9
34567247-3	2021	Cyclin E1 (CCNE1) overexpression is a proposed marker of platinum resistance and is mutually exclusive with deficiency in homologous recombination.	Platinum	57-65	cyclin E1	Homo sapiens	11-16
34298618-9	2021	Collectively, our findings implicate nuclear HKII-P-p53(Ser15) interaction in chemosensitivity and could provide an effective clinical strategy as a promising biomarker during platinum-based therapy.	Platinum	176-184	hexokinase 2	Homo sapiens	45-49
34298618-9	2021	Collectively, our findings implicate nuclear HKII-P-p53(Ser15) interaction in chemosensitivity and could provide an effective clinical strategy as a promising biomarker during platinum-based therapy.	Platinum	176-184	tumor protein p53	Homo sapiens	52-55
34277602-2	2021	Here, clinical data showed that the level of netrin-G1 (NTNG1) in cisplatin-resistant cancer was higher than that in cisplatin-sensitive cancer (2.2-fold, p = 0.005); patients with a high NTNG1 level in cancer tissues had shorter progression-free survival (11.0 vs. 25.0 months, p = 0.010) and platinum-free interval (5.0 vs. 20.0 months, p = 0.021) compared with patients with a low level.	Platinum	294-302	netrin G1	Homo sapiens	45-54
34277602-2	2021	Here, clinical data showed that the level of netrin-G1 (NTNG1) in cisplatin-resistant cancer was higher than that in cisplatin-sensitive cancer (2.2-fold, p = 0.005); patients with a high NTNG1 level in cancer tissues had shorter progression-free survival (11.0 vs. 25.0 months, p = 0.010) and platinum-free interval (5.0 vs. 20.0 months, p = 0.021) compared with patients with a low level.	Platinum	294-302	netrin G1	Homo sapiens	56-61
34117841-6	2021	The obtained Cr-CoP-NR/CC catalyst shows the potential to replace the costly Pt-based HER catalysts in the water electrolyzer.	Platinum	77-79	caspase recruitment domain family member 16	Homo sapiens	16-19
34268111-3	2021	The MALDI-TOF mass spectrometry assays revealed a strong association between hypermethylation of the MGRN1 upstream region and platinum resistance in HGSOC patients.	Platinum	127-135	mahogunin ring finger 1	Homo sapiens	101-106
34268111-6	2021	Similarly, EGR1 mRNA expression was lower in platinum-resistant HGSOC patients and was positively correlated with MGRN1 mRNA expression.	Platinum	45-53	early growth response 1	Homo sapiens	11-15
34430345-7	2021	Results: We have found reduced activity of TNF (normalized enrichment score: 2.03), IL-17 (normalized enrichment score: 1.93), MAPK (normalized enrichment score: 1.51), and relaxin signaling pathways (normalized enrichment score: 1.42) in the samples obtained after platinum-based therapy.	Platinum	266-274	tumor necrosis factor	Homo sapiens	43-46
34268111-6	2021	Similarly, EGR1 mRNA expression was lower in platinum-resistant HGSOC patients and was positively correlated with MGRN1 mRNA expression.	Platinum	45-53	mahogunin ring finger 1	Homo sapiens	114-119
34430345-7	2021	Results: We have found reduced activity of TNF (normalized enrichment score: 2.03), IL-17 (normalized enrichment score: 1.93), MAPK (normalized enrichment score: 1.51), and relaxin signaling pathways (normalized enrichment score: 1.42) in the samples obtained after platinum-based therapy.	Platinum	266-274	interleukin 17A	Homo sapiens	84-89
34268111-10	2021	The hypermethylation of the MGRN1 promoter region and low expression of MGRN1 were associated with platinum resistance and poor outcomes in HGSOC patients, probably by altering EGR1 expression.	Platinum	99-107	mahogunin ring finger 1	Homo sapiens	28-33
34268111-10	2021	The hypermethylation of the MGRN1 promoter region and low expression of MGRN1 were associated with platinum resistance and poor outcomes in HGSOC patients, probably by altering EGR1 expression.	Platinum	99-107	mahogunin ring finger 1	Homo sapiens	72-77
34268111-10	2021	The hypermethylation of the MGRN1 promoter region and low expression of MGRN1 were associated with platinum resistance and poor outcomes in HGSOC patients, probably by altering EGR1 expression.	Platinum	99-107	early growth response 1	Homo sapiens	177-181
34137582-6	2021	Coupling with cellular imaging due to their fluorescence property, anti-EpCAM@PDA-CDs@Pt(IV) offers a convenient and effective platform for imaging-guided chemo-photothermal synergistic therapy toward liver cancers in the near future.	Platinum	86-88	epithelial cell adhesion molecule	Homo sapiens	72-77
34262873-1	2021	Objectives: Pembrolizumab plus platinum-based chemotherapy and pembrolizumab monotherapy (PM) both become standard of care in patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) greater than 50%.	Platinum	31-39	CD274 molecule	Homo sapiens	190-215
34262873-1	2021	Objectives: Pembrolizumab plus platinum-based chemotherapy and pembrolizumab monotherapy (PM) both become standard of care in patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) greater than 50%.	Platinum	31-39	CD274 molecule	Homo sapiens	217-222
34172739-3	2021	Here, we use correlative super-resolution light and platinum replica electron microscopy to map Rab-GTPases (Rab27a and Rab3a) and their effectors (Granuphilin-a, Rabphilin3a, and Rim2) at the nanoscale in 2D.	Platinum	52-60	RAB27A, member RAS oncogene family	Homo sapiens	109-115
34190063-11	2021	The older group (>=50 years) had a stronger correlation of TPA with PT and KA, whereas the younger (<50 years) had stronger correlation with TK.	Platinum	68-70	plasminogen activator, tissue type	Homo sapiens	59-62
34239773-6	2021	Previously, it was shown that platinum-based chemotherapeutics inhibit STAT signaling.	Platinum	30-38	signal transducer and activator of transcription 3	Homo sapiens	71-75
34239773-8	2021	In vitro, subclinical doses of platinum-based drugs prevented the generation of COX-2+ M-MDSCs induced by tumor cells from melanoma patients.	Platinum	31-39	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	80-85
34172739-3	2021	Here, we use correlative super-resolution light and platinum replica electron microscopy to map Rab-GTPases (Rab27a and Rab3a) and their effectors (Granuphilin-a, Rabphilin3a, and Rim2) at the nanoscale in 2D.	Platinum	52-60	RAB3A, member RAS oncogene family	Homo sapiens	120-125
34172739-3	2021	Here, we use correlative super-resolution light and platinum replica electron microscopy to map Rab-GTPases (Rab27a and Rab3a) and their effectors (Granuphilin-a, Rabphilin3a, and Rim2) at the nanoscale in 2D.	Platinum	52-60	synaptotagmin like 4	Homo sapiens	148-161
34113940-7	2021	Both in vitro and in vivo experiments demonstrate that the Fe3+@Au1Ag24@PbP nanoplatform presented excellent PA/PT imaging-guided synergetic PTT/PDT/ferroptosis effects toward tumor cells and tumors.	Platinum	112-114	polycystin 1, transient receptor potential channel interacting	Homo sapiens	72-75
34162871-4	2021	Using cell models from systematic ECM screen to collagen-based 2D and 3D cultures, we demonstrate that both specific ECM substrates and stiffness increase resistance to platinum-mediated, apoptosis-inducing DNA damage via FAK and beta1 integrin-pMLC-YAP signaling.	Platinum	169-177	protein tyrosine kinase 2	Homo sapiens	222-225
34162871-4	2021	Using cell models from systematic ECM screen to collagen-based 2D and 3D cultures, we demonstrate that both specific ECM substrates and stiffness increase resistance to platinum-mediated, apoptosis-inducing DNA damage via FAK and beta1 integrin-pMLC-YAP signaling.	Platinum	169-177	integrin subunit beta 1	Homo sapiens	230-244
34162871-4	2021	Using cell models from systematic ECM screen to collagen-based 2D and 3D cultures, we demonstrate that both specific ECM substrates and stiffness increase resistance to platinum-mediated, apoptosis-inducing DNA damage via FAK and beta1 integrin-pMLC-YAP signaling.	Platinum	169-177	Yes1 associated transcriptional regulator	Homo sapiens	250-253
34148553-0	2021	ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis.	Platinum	51-59	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
34161330-11	2021	Our findings suggest that CHD4 mediates platinum sensitivity by modulating MDR1 expression in ovarian cancer.	Platinum	40-48	chromodomain helicase DNA binding protein 4	Homo sapiens	26-30
34161330-11	2021	Our findings suggest that CHD4 mediates platinum sensitivity by modulating MDR1 expression in ovarian cancer.	Platinum	40-48	ATP binding cassette subfamily B member 1	Homo sapiens	75-79
34161330-0	2021	CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.	Platinum	15-23	chromodomain helicase DNA binding protein 4	Homo sapiens	0-4
34161330-6	2021	CHD4 mRNA expression was significantly higher in platinum-resistant samples in a subsequent clinical sample analysis, suggesting that CHD4 overexpression conferred platinum resistance to ovarian cancer cells, resulting in poor patient survival.	Platinum	49-57	chromodomain helicase DNA binding protein 4	Homo sapiens	0-4
34161330-6	2021	CHD4 mRNA expression was significantly higher in platinum-resistant samples in a subsequent clinical sample analysis, suggesting that CHD4 overexpression conferred platinum resistance to ovarian cancer cells, resulting in poor patient survival.	Platinum	49-57	chromodomain helicase DNA binding protein 4	Homo sapiens	134-138
34161330-6	2021	CHD4 mRNA expression was significantly higher in platinum-resistant samples in a subsequent clinical sample analysis, suggesting that CHD4 overexpression conferred platinum resistance to ovarian cancer cells, resulting in poor patient survival.	Platinum	164-172	chromodomain helicase DNA binding protein 4	Homo sapiens	0-4
34161330-6	2021	CHD4 mRNA expression was significantly higher in platinum-resistant samples in a subsequent clinical sample analysis, suggesting that CHD4 overexpression conferred platinum resistance to ovarian cancer cells, resulting in poor patient survival.	Platinum	164-172	chromodomain helicase DNA binding protein 4	Homo sapiens	134-138
34161330-8	2021	However, CHD4 knockdown did not affect the expression of RAD51 or p21, the known targets of CHD4 in other cancer types that can modulate platinum sensitivity.	Platinum	137-145	chromodomain helicase DNA binding protein 4	Homo sapiens	92-96
34148553-1	2021	OBJECTIVE: To explore the relationship between ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in ovarian cancer by the method of meta-analysis.	Platinum	98-106	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
34140011-0	2021	Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.	Platinum	63-71	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	40-44
34148027-10	2021	However, the presence of BRCA1/2 alterations enhance the sensitivity to platinum-based chemotherapies.	Platinum	72-80	BRCA1 DNA repair associated	Homo sapiens	25-32
34220848-2	2021	In this study, high CD3+ T-cells and CD163+ tumor-associated macrophages (TAMs) densities identify a subgroup of immune infiltrated high-grade serous carcinomas (HGSCs) with better outcomes and superior response to platinum-based therapies.	Platinum	215-223	CD163 molecule	Homo sapiens	37-42
34140011-7	2021	RESULTS: For HGSOC without TIL (58%), EZH2 expression was almost 2-fold higher in platinum resistant tumors (P = 0.01).	Platinum	82-90	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	38-42
34140011-11	2021	Both mRNA and protein levels of EZH2 were lower in platinum resistant tumors although they were not associated with survival.	Platinum	51-59	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	32-36
34140011-12	2021	Co-expression analysis revealed EZH2 networks totaling 1049 mRNA and 448 proteins that were exclusive to platinum sensitive or resistant tumors.	Platinum	105-113	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	32-36
34140011-16	2021	The association between high EZH2 expression and platinum resistance in TIL- HGSOC warrants further study of the implications for therapeutic strategies.	Platinum	49-57	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	29-33
34203832-3	2021	Since the same domain in Tsg101 that houses the pocket was found to bind mono-ubiquitin (Ub) non-covalently, Ub binding was speculated to enhance P(T/S)AP interaction.	Platinum	146-149	tumor susceptibility 101	Homo sapiens	25-31
34117210-10	2021	In GC patients receiving platinum chemotherapy and a meta-analysis, a high level of GRP75 was positively associated with aggressive characteristics and poor prognosis including but not limited to gastrointestinal cancers, and was an independent predictor for overall survival.	Platinum	25-33	heat shock protein family A (Hsp70) member 9	Homo sapiens	84-89
34195229-4	2021	In addition, Notch3 signaling also contributes to tumor chemoresistance against several drugs, including doxorubicin, platinum, taxane, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) and gemcitabine, through complex mechanisms.	Platinum	118-126	notch receptor 3	Homo sapiens	13-19
34208258-0	2021	Modulation of Glutamate Transporter EAAT1 and Inward-Rectifier Potassium Channel Kir4.1 Expression in Cultured Spinal Cord Astrocytes by Platinum-Based Chemotherapeutics.	Platinum	137-145	solute carrier family 1 member 3	Rattus norvegicus	14-35
34208258-0	2021	Modulation of Glutamate Transporter EAAT1 and Inward-Rectifier Potassium Channel Kir4.1 Expression in Cultured Spinal Cord Astrocytes by Platinum-Based Chemotherapeutics.	Platinum	137-145	solute carrier family 1 member 3	Rattus norvegicus	36-41
34208223-3	2021	These ambidentate chelating ligands are intended to develop Co(III)/PGM (PGM = platinum group metal) heterobimetallic multitargeted complexes with anticancer potential.	Platinum	79-87	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	60-67
34208314-1	2021	Mono- and bimetallic Ni-, Ru- and Pt-modified hierarchical ZSM-5 materials were prepared by impregnation technique and characterized by X-ray diffraction (XRD), N2 physisorption, temperature-programmed reduction (TPR-TGA), ATR-FTIR and solid state NMR spectroscopy.	Platinum	34-36	translocated promoter region, nuclear basket protein	Homo sapiens	213-216
34208314-1	2021	Mono- and bimetallic Ni-, Ru- and Pt-modified hierarchical ZSM-5 materials were prepared by impregnation technique and characterized by X-ray diffraction (XRD), N2 physisorption, temperature-programmed reduction (TPR-TGA), ATR-FTIR and solid state NMR spectroscopy.	Platinum	34-36	ATR serine/threonine kinase	Homo sapiens	223-226
34178990-9	2021	Surprisingly, based on four sarcoma cell lines and eight PTCCs (three LPS and five other sarcoma), we demonstrated that MCM4 overexpression tumors were therapeutically sensitive to PARP inhibitor (PARPi) and platinum chemotherapy, independent of the histology subtypes.	Platinum	208-216	minichromosome maintenance complex component 4	Homo sapiens	120-124
34099668-3	2021	The highly reducible oxygen species provided by surface metal-oxide (M-O) interface could be activated by CO at low temperature (~50  C) with a high CO2 production rate of 487 mumolCO2 gPt-1 s-1 at 110  C. Experiment data combined with density functional calculation (DFT) results demonstrate that Pt cluster with surface Pt-O-Bi structure is the active site for CO oxidation via providing moderate CO adsorption and activating CO molecules with electron transformation between platinum atom and carbon monoxide.	Platinum	298-300	glutamic--pyruvic transaminase	Homo sapiens	185-190
34099668-3	2021	The highly reducible oxygen species provided by surface metal-oxide (M-O) interface could be activated by CO at low temperature (~50  C) with a high CO2 production rate of 487 mumolCO2 gPt-1 s-1 at 110  C. Experiment data combined with density functional calculation (DFT) results demonstrate that Pt cluster with surface Pt-O-Bi structure is the active site for CO oxidation via providing moderate CO adsorption and activating CO molecules with electron transformation between platinum atom and carbon monoxide.	Platinum	478-486	glutamic--pyruvic transaminase	Homo sapiens	185-190
34337539-13	2021	Moreover, since ATM plays an integral role in DNA damage response pathways, future studies will enhance our understanding of how outcomes of patients with altered ATM and PTEN expression can be improved further with poly-ADP ribose polymerase inhibitors (PARPi), combinations of PARPi and androgen receptor-targeted therapies, as well as platinum-based chemotherapies.	Platinum	338-346	ATM serine/threonine kinase	Homo sapiens	16-19
34115785-0	2021	Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy.	Platinum	90-98	epidermal growth factor	Homo sapiens	0-23
34115785-1	2021	In this study, we investigated serum epidermal growth factor (EGF) in an oncological population of head- and neck and pulmonary neoplasms and whether serum EGF could serve as a prognostic marker of survival and as a predictive marker for treatment response to platinum-based chemotherapy.	Platinum	260-268	epidermal growth factor	Homo sapiens	156-159
34178624-0	2021	Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report.	Platinum	57-65	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	146-150
34117210-11	2021	Collectively, our study indicated that GRP75 was involved in the cisplatin-resistance of GC and that GRP75 could be a potential therapeutic target for restoring the drug response in platinum-resistance cells and a useful additive prognostic tool in guiding clinical management of GC patients.	Platinum	182-190	heat shock protein family A (Hsp70) member 9	Homo sapiens	39-44
34117210-11	2021	Collectively, our study indicated that GRP75 was involved in the cisplatin-resistance of GC and that GRP75 could be a potential therapeutic target for restoring the drug response in platinum-resistance cells and a useful additive prognostic tool in guiding clinical management of GC patients.	Platinum	182-190	heat shock protein family A (Hsp70) member 9	Homo sapiens	101-106
34467344-4	2021	We combine microscopy (STEM) and spectroscopy (XAS and IR) studies with kinetic measurements, to convincingly show that the low activity on the fresh SAC is a result of limited accessibility of Pt single atoms (Pt1) due to high Pt-O coordination.	Platinum	194-196	zinc finger protein 77	Homo sapiens	211-214
34086719-2	2021	TOC and TN were determined using the high temperature (720 C) catalytic (Pt/Al2O3) oxidation method and the detection of TOC and TN was performed using an infrared or a chemiluminescence detector, respectively.	Platinum	73-75	C-type lectin domain family 3 member B	Homo sapiens	8-10
34141464-9	2021	The genes interacted with TYMS and BCL2L1 were linked to functional networks involving pathway of apoptosis, apoptosis-multiple species, colorectal cancer, platinum drug resistance and p53 signaling pathway.	Platinum	156-164	thymidylate synthetase	Homo sapiens	26-30
34082797-8	2021	Efficacy of PFK158 alone and with platinum drugs was determined in patient-derived primary ascites cultures expressing PLA2G3 by MTT assay and immunoblot analysis.	Platinum	34-42	phospholipase A2 group III	Homo sapiens	119-125
34082797-9	2021	RESULTS: Downregulation of PLA2G3 in OVCAR8 and 5 cells inhibited LD biogenesis, decreased growth and sensitized cells to platinum drug mediated cytotoxicity in vitro and in in vivo OVCAR5 xenograft.	Platinum	122-130	phospholipase A2, group III	Mus musculus	27-33
34059856-0	2021	Fighting against drug-resistant tumors by the inhibition of gamma-glutamyl transferase with supramolecular platinum prodrug nano-assemblies.	Platinum	107-115	gamma-glutamyltransferase 1	Homo sapiens	60-86
34141464-9	2021	The genes interacted with TYMS and BCL2L1 were linked to functional networks involving pathway of apoptosis, apoptosis-multiple species, colorectal cancer, platinum drug resistance and p53 signaling pathway.	Platinum	156-164	BCL2 like 1	Homo sapiens	35-41
34083285-0	2021	Calcitriol Combined With Platinum-based Chemotherapy Suppresses Growth and Expression of Vascular Endothelial Growth Factor of SKOV-3 Ovarian Cancer Cells.	Platinum	25-33	vascular endothelial growth factor A	Homo sapiens	89-123
34065298-4	2021	In this review, HUWE1 is postulated as a therapeutic response modulator, affecting the collision between platinum-DNA adducts and the replication fork, the primary cytotoxic action of platins.	Platinum	105-113	HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1	Homo sapiens	16-21
34141624-9	2021	Variant clonality and co-occuring TP53 variants affect the predictive value of HRR pathogenic variants for platinum agents in patients with EOC.	Platinum	107-115	tumor protein p53	Homo sapiens	34-38
34466740-5	2022	To this end, polyethylene glycol (PEG)-stabilized platinum (Pt) nanoparticles (Pt NPs) conjugated with a PD-L1 inhibitor (BMS-1) through a thermo-sensitive linkage were constructed.	Platinum	50-58	CD274 antigen	Mus musculus	105-110
34466740-5	2022	To this end, polyethylene glycol (PEG)-stabilized platinum (Pt) nanoparticles (Pt NPs) conjugated with a PD-L1 inhibitor (BMS-1) through a thermo-sensitive linkage were constructed.	Platinum	60-62	CD274 antigen	Mus musculus	105-110
34070597-0	2021	Polymorphisms in EGFR Gene Predict Clinical Outcome in Unresectable Non-Small Cell Lung Cancer Treated with Radiotherapy and Platinum-Based Chemoradiotherapy.	Platinum	125-133	epidermal growth factor receptor	Homo sapiens	17-21
34070597-5	2021	The association between functional EGFR SNPs and overall (OS), locoregional recurrence-free (LFRS), and metastasis-free (MFS) survival was examined in 436 patients with unresectable NSCLC receiving RT and platinum-based CHTRT.	Platinum	205-213	epidermal growth factor receptor	Homo sapiens	35-39
34086042-15	2021	Multiclonal BRCA2 reversion mutations associated with resistance to PARP inhibitors and platinum chemotherapy were detected in ctDNA from 2 patients.	Platinum	88-96	BRCA2 DNA repair associated	Homo sapiens	12-17
34091215-10	2021	However, PC arising in BRCA-2 carriers has a DNA repair defect, which is sensitive to platin based chemotherapy and mitomycin C.	Platinum	86-92	BRCA2 DNA repair associated	Homo sapiens	23-29
34295655-7	2021	Among the various treatment modalities administered, platinum-based combination or single-agent chemotherapy tended to elicit robust increases in the concentrations of HMGB1 and CRT.	Platinum	53-61	high mobility group box 1	Homo sapiens	168-173
34295655-7	2021	Among the various treatment modalities administered, platinum-based combination or single-agent chemotherapy tended to elicit robust increases in the concentrations of HMGB1 and CRT.	Platinum	53-61	calreticulin	Homo sapiens	178-181
34122547-4	2021	Decades later, we still rely on the same traditional regimen with etoposide and platinum (EP) as the mainstay of treatment with poor prognosis.	Platinum	80-88	epiregulin	Homo sapiens	90-92
34295175-3	2021	Despite these unfavourable prognostic implications, poly-ADP ribose polymerase inhibitors and platinum-based chemotherapy have been identified as potent targeted therapeutic agents towards BRCA1/2 deficient cancer cells.	Platinum	94-102	BRCA1 DNA repair associated	Homo sapiens	189-196
34068084-6	2021	In fact, ATM mutations may sensitize cancer cells to platinum-derived drugs, as BRCA1/2 mutations do, whereas their implications in objective responses to hormonal therapy or target-based agents are not well defined.	Platinum	53-61	ATM serine/threonine kinase	Homo sapiens	9-12
34104541-6	2021	The density of CD8+ cells was decreased and the density of FoxP3+ cells and CD20+ cells was increased in PT post-NAC.	Platinum	105-107	CD8a molecule	Homo sapiens	15-18
34104541-6	2021	The density of CD8+ cells was decreased and the density of FoxP3+ cells and CD20+ cells was increased in PT post-NAC.	Platinum	105-107	forkhead box P3	Homo sapiens	59-64
34104541-6	2021	The density of CD8+ cells was decreased and the density of FoxP3+ cells and CD20+ cells was increased in PT post-NAC.	Platinum	105-107	keratin 20	Homo sapiens	76-80
34094977-10	2021	Elevated ALOX5AP was markedly associated with poor overall survival and progression-free survival in multiple SOC patient cohorts as well as with adverse clinicopathological features, including lymphatic invasion, unsatisfactory cytoreductive surgery, rapid relapse after primary treatment, and platinum non-responsiveness.	Platinum	295-303	arachidonate 5-lipoxygenase activating protein	Homo sapiens	9-16
34068084-6	2021	In fact, ATM mutations may sensitize cancer cells to platinum-derived drugs, as BRCA1/2 mutations do, whereas their implications in objective responses to hormonal therapy or target-based agents are not well defined.	Platinum	53-61	BRCA1 DNA repair associated	Homo sapiens	80-87
34258530-0	2021	Prominent response to platinum-based chemotherapy in a patient with BRCA2 mutant-neuroendocrine prostate cancer and MDM2 amplification.	Platinum	22-30	BRCA2 DNA repair associated	Homo sapiens	68-73
34258154-4	2021	These parameters can be controlled by rational manipulation of the co-catalyst via three steps: i) Compositional design by partial substitution of Pt with Pd to form PtPd alloy, ii) location control by encapsulating the PtPd alloy into UiO-66-NH2 crystals, and iii) facet selection by exposing the encapsulated PtPd alloy (100) facets.	Platinum	147-149	protein tyrosine phosphatase receptor type D	Homo sapiens	166-170
34258530-0	2021	Prominent response to platinum-based chemotherapy in a patient with BRCA2 mutant-neuroendocrine prostate cancer and MDM2 amplification.	Platinum	22-30	MDM2 proto-oncogene	Homo sapiens	116-120
34084103-11	2021	Compared with the docetaxel plus platinum group, the gemcitabine plus platinum group had significantly higher RR (71.4% vs. 52.6%, P < 0.05); mPFS (9.7 vs. 7.8 months, P < 0.05), and mOS (20.6 vs. 16.8 months, P < 0.01).	Platinum	33-41	Moloney sarcoma oncogene	Mus musculus	183-186
34258531-0	2021	Editorial Comment to Prominent response to platinum-based chemotherapy in a patient with BRCA2 mutant-neuroendocrine prostate cancer and MDM2 amplification.	Platinum	43-51	BRCA2 DNA repair associated	Homo sapiens	89-94
34258531-0	2021	Editorial Comment to Prominent response to platinum-based chemotherapy in a patient with BRCA2 mutant-neuroendocrine prostate cancer and MDM2 amplification.	Platinum	43-51	MDM2 proto-oncogene	Homo sapiens	137-141
34268970-0	2021	The relation between tissue galectin-3 level and platinum resistance in neoadjuvant bladder cancer treatment.	Platinum	49-57	galectin 3	Homo sapiens	28-38
34268970-10	2021	CONCLUSION: The rate of down-staging after platinum-based neoadjuvant chemotherapy is significantly higher in patients with low galectin-3 staining in transurethral bladder biopsy tissue.	Platinum	43-51	galectin 3	Homo sapiens	128-138
34084103-11	2021	Compared with the docetaxel plus platinum group, the gemcitabine plus platinum group had significantly higher RR (71.4% vs. 52.6%, P < 0.05); mPFS (9.7 vs. 7.8 months, P < 0.05), and mOS (20.6 vs. 16.8 months, P < 0.01).	Platinum	70-78	Moloney sarcoma oncogene	Mus musculus	183-186
34927885-7	2021	Interestingly, the oxygen electrode activity (DeltaE) for (Fe,Co)-SA/CS and commercial Pt/C-RuO2 is calculated to be 0.73 V, exhibiting the bifunctional catalytic activity of (Fe,Co)-SA/CS.	Platinum	87-89	citrate synthase	Homo sapiens	186-188
34337294-7	2021	In particular, DNA repair dysfunction, including cases with BRCA mutations, is a causal element of sensitivity to platinum-based anti-cancer agents and poly-ADP ribose polymerase (PARP) inhibitors.	Platinum	114-122	BRCA1 DNA repair associated	Homo sapiens	60-64
34694672-8	2021	Au-, Pt nanoparticle-, and SnO2 -conjugated lectins inhibit biofilm significantly compared with control (p < 0.05), and rhlR gene expression is decreased in the presence of SiO2 -conjugated lectin.	Platinum	5-7	galectin 3	Gallus gallus	190-196
34589972-8	2021	We also recommended the combination of EGFR TKI with other agents (platinum-based chemotherapy or antiangiogenic agents); however, it can lead to toxicity.	Platinum	67-75	epidermal growth factor receptor	Homo sapiens	39-43
34164064-1	2021	Di(2-pyridyl)ketone dimethylplatinum(ii), (dpk)PtII(CH3)2, reacts with CD3OD at 25  C to undergo complete deuteration of Pt-CH3 fragments in ~5 h without loss of methane to form (dpk)PtII(CD3)2 in virtually quantitative yield.	Platinum	121-123	TAO kinase 3	Homo sapiens	43-46
34164064-3	2021	Kinetic analysis and isotope effects, together with support from density functional theory calculations indicate a metal-ligand cooperative mechanism wherein DPK enables Pt-CH3 deuteration by allowing non-rate-limiting protonation of PtII by CD3OD.	Platinum	170-172	TAO kinase 3	Homo sapiens	158-161
34400966-2	2021	A cetuximab-decorated drug delivery system can selectively deliver drugs into EGFR-highexpressing cancer cells to prevent the shortcomings of platinum-based chemotherapy.	Platinum	142-150	epidermal growth factor receptor	Homo sapiens	78-82
34163686-5	2021	Rational control experiments and first-principles calculations confirm that Pt1/Ni3Fe IMC can readily facilitate the hydrodeoxygenation reaction by a tandem mechanism, where the single Pt site accounts for C(double bond, length as m-dash)O group hydrogenation and the Ni3Fe interface promotes the C-OH bond cleavage.	Platinum	185-187	zinc finger protein 77	Homo sapiens	76-79
34515066-1	2021	BACKGROUND: Whether topotecan plus platinum-based chemotherapy (TP) can achieve better results than etoposide plus platinum-based chemotherapy (EP) for small-cell lung cancer (SCLC) treatment is still controversial in clinical applications.	Platinum	115-123	epiregulin	Homo sapiens	144-146
35429348-0	2022	L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma.	Platinum	35-43	L1 cell adhesion molecule	Homo sapiens	0-5
35429348-5	2022	The association between L1CAM and clinicopathologic features and L1CAM additive value in predicting platinum response were determined.	Platinum	100-108	L1 cell adhesion molecule	Homo sapiens	24-29
35429348-5	2022	The association between L1CAM and clinicopathologic features and L1CAM additive value in predicting platinum response were determined.	Platinum	100-108	L1 cell adhesion molecule	Homo sapiens	65-70
35500311-7	2022	Ultimately, the quenching labels of streptavidin modified Pt nanoparticles functionalized polydopamine composites (SA-Pt@PDA) were introduced via biotin and streptavidin recognition, realizing ECL emission quenching of S2O82-/O2 system for "on-off" detection of BCR-ABL fusion gene.	Platinum	58-60	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	262-269
35500311-7	2022	Ultimately, the quenching labels of streptavidin modified Pt nanoparticles functionalized polydopamine composites (SA-Pt@PDA) were introduced via biotin and streptavidin recognition, realizing ECL emission quenching of S2O82-/O2 system for "on-off" detection of BCR-ABL fusion gene.	Platinum	118-120	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	262-269
35429348-7	2022	Increased L1CAM expression at both genetic and protein level correlated with high-grade, non-endometrioid histology and poor response to platinum treatment.	Platinum	137-145	L1 cell adhesion molecule	Homo sapiens	10-15
35429348-8	2022	A predictive model adding L1CAM to prognostic clinical variables significantly improved platinum response prediction (C-index 78.1%, p=0.012).	Platinum	88-96	L1 cell adhesion molecule	Homo sapiens	26-31
35429348-10	2022	In vitro, inhibition of L1CAM significantly increased cell sensitivity to carboplatin, supporting a mechanistic link between L1CAM expression and response to platinum in EC cells.	Platinum	158-166	L1 cell adhesion molecule	Homo sapiens	125-130
35508254-2	2022	Herein, we have verified anticancer effectivity of synthesized novel water soluble mononuclear dipicolinic acid-1-allyl imidazole-based oxidovanadium (IV) complex (VOL(1-allylimz)2) with respect to anticancer effectivity of known standard platinum-based anticancer agent cisplatin.	Platinum	239-247	mediator complex subunit 25	Homo sapiens	107-113
35302657-0	2022	In high grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired-resistance derive from quiescent residual cancer cells that overexpress CRYAB, CEACAM6 and SOX2.	Platinum	33-41	CEA cell adhesion molecule 6	Homo sapiens	161-168
35580473-3	2022	Herein, a platinum (Pt) nanourchin-based multi-enzymatic platform (referred to PGMA) is established by surface conjugation of glucose oxidase (GOx) capped with manganese carbonyl (MnCO) and loading 3-amino-1,2,4-triazole (3-AT).	Platinum	10-18	hydroxyacid oxidase 1	Homo sapiens	126-141
35580473-3	2022	Herein, a platinum (Pt) nanourchin-based multi-enzymatic platform (referred to PGMA) is established by surface conjugation of glucose oxidase (GOx) capped with manganese carbonyl (MnCO) and loading 3-amino-1,2,4-triazole (3-AT).	Platinum	10-18	hydroxyacid oxidase 1	Homo sapiens	143-146
35580473-3	2022	Herein, a platinum (Pt) nanourchin-based multi-enzymatic platform (referred to PGMA) is established by surface conjugation of glucose oxidase (GOx) capped with manganese carbonyl (MnCO) and loading 3-amino-1,2,4-triazole (3-AT).	Platinum	20-22	hydroxyacid oxidase 1	Homo sapiens	126-141
35580473-3	2022	Herein, a platinum (Pt) nanourchin-based multi-enzymatic platform (referred to PGMA) is established by surface conjugation of glucose oxidase (GOx) capped with manganese carbonyl (MnCO) and loading 3-amino-1,2,4-triazole (3-AT).	Platinum	20-22	hydroxyacid oxidase 1	Homo sapiens	143-146
35580473-5	2022	The resultant GOx exposure initiates intratumoral glucose depletion, which is promoted by the O2 replenishment through Pt-catalyzed decomposition of H2O2.	Platinum	119-121	hydroxyacid oxidase 1	Homo sapiens	14-17
35302657-0	2022	In high grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired-resistance derive from quiescent residual cancer cells that overexpress CRYAB, CEACAM6 and SOX2.	Platinum	33-41	crystallin alpha B	Homo sapiens	154-159
35302657-0	2022	In high grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired-resistance derive from quiescent residual cancer cells that overexpress CRYAB, CEACAM6 and SOX2.	Platinum	33-41	SRY-box transcription factor 2	Homo sapiens	173-177
35194192-10	2022	Genetic or pharmacological targeting of GCLC sensitised PMDOs to a 1-h exposure to oxaliplatin, through increased platinum-DNA adduct formation.	Platinum	114-122	glutamate-cysteine ligase catalytic subunit	Homo sapiens	40-44
35617126-0	2022	Structures of Small Platinum Cluster Anions Ptn-: Experiment and Theory.	Platinum	20-28	pleiotrophin	Homo sapiens	44-47
35621996-4	2022	Both of the diplatinum halides exhibit three direct detachment channels with distinct anisotropies, analogous to the previously reported spectra for PtI2- and PtI-, suggesting a platinum-centered molecular core that dominates the photodetachment.	Platinum	178-186	serpin family B member 6	Homo sapiens	159-162
35219776-1	2022	BACKGROUND: Maintenance treatment with poly (ADP-ribose) polymerase (PARP) inhibitor is now the standard of care in patients with BRCA mutated platinum-sensitive recurrent ovarian cancer following response to chemotherapy.	Platinum	143-151	poly(ADP-ribose) polymerase 1	Homo sapiens	39-67
35219776-1	2022	BACKGROUND: Maintenance treatment with poly (ADP-ribose) polymerase (PARP) inhibitor is now the standard of care in patients with BRCA mutated platinum-sensitive recurrent ovarian cancer following response to chemotherapy.	Platinum	143-151	poly(ADP-ribose) polymerase 1	Homo sapiens	69-73
35404148-0	2022	BRCA1 expression associated with the prognostic value of platinum-based chemotherapy for stage II-IV non-small cell lung cancer: A meta-analysis.	Platinum	57-65	BRCA1 DNA repair associated	Homo sapiens	0-5
35612423-12	2022	Bioinformatic analyses revealed ADH1C to be mainly enriched in cell cycle, RNA transport, biosynthesis of amino acids, and platinum drug resistance pathways.	Platinum	123-131	alcohol dehydrogenase 1C (class I), gamma polypeptide	Homo sapiens	32-37
35404148-1	2022	PURPOSE: To explore the relationship between breast cancer susceptibility gene 1 (BRCA1) expression and the prognostic value of platinum-based chemotherapy for stage II-IV non-small cell lung cancer (NSCLC).	Platinum	128-136	BRCA1 DNA repair associated	Homo sapiens	82-87
35404148-2	2022	METHODS: PubMed, Web of Science, Embase, and Cochrane Library were searched from inception to August 2021, for retrieving literature related to BRCA1 expression and prognostic value of platinum-based chemotherapy in NSCLC patients.	Platinum	185-193	BRCA1 DNA repair associated	Homo sapiens	144-149
35404148-5	2022	Compared with the low BRCA1 expression, its high expression negatively affected the overall survival of NSCLC patients treated with platinum-based chemotherapy (hazard ratio (HR) = 1.53, 95% confidence interval (CI): 1.01-2.31, P < 0.05).	Platinum	132-140	BRCA1 DNA repair associated	Homo sapiens	22-27
35404148-9	2022	CONCLUSION: BRCA1 expression is correlated with the prognostic value of platinum-based chemotherapy for stage II-IV NSCLC patients.	Platinum	72-80	BRCA1 DNA repair associated	Homo sapiens	12-17
35404148-10	2022	In Caucasian population, compared with low BRCA1 expression, its high expression has a negative effect on the overall survival and event-free survival in stage II-IV NSCLC patients after platinum-based chemotherapy; however, this correlation was not found in China.	Platinum	187-195	BRCA1 DNA repair associated	Homo sapiens	43-48
35626154-5	2022	Therefore, we proposed an effective and stable therapeutic strategy based on the combination of oxaliplatin and LAT1 inhibitor, which is expected to solve the resistance of RCC to platinum-based drugs under hypoxia to a certain extent, providing a meaningful insight into the development of new therapeutic strategies and RCC treatment.	Platinum	180-188	solute carrier family 7 member 5	Homo sapiens	112-116
35219409-3	2022	At the high space velocity of 100,000 mL/(g hr), the temperature that correspond to 50% toluene conversion (T50) of Pt/Al2O3-H is 115 C lower than that of Pt/Al2O3-C, and the turnover frequency (TOF) value can reach 0.0756 sec-1.	Platinum	116-118	secretory blood group 1, pseudogene	Homo sapiens	223-228
35527787-0	2022	Differential and divergent activity of insulin-like growth factor binding protein 6 in platinum-sensitive versus platinum-resistant high-grade serous ovarian carcinoma cell lines.	Platinum	87-95	insulin like growth factor binding protein 6	Homo sapiens	39-83
35527787-7	2022	The comparative analysis of platinum-sensitive (PEA1) and platinum-resistant (PEA2) cell lines showed quantitative and qualitative differences in the activation of IGFBP6 signaling.	Platinum	28-36	insulin like growth factor binding protein 6	Homo sapiens	164-170
35527787-7	2022	The comparative analysis of platinum-sensitive (PEA1) and platinum-resistant (PEA2) cell lines showed quantitative and qualitative differences in the activation of IGFBP6 signaling.	Platinum	58-66	insulin like growth factor binding protein 6	Homo sapiens	164-170
35527787-11	2022	These data suggested that dysregulation of IGFBP6 signaling may serve a role in the progression of OC, and is likely associated with the development of platinum resistance.	Platinum	152-160	insulin like growth factor binding protein 6	Homo sapiens	43-49
35622184-3	2022	It has been hypothesized that caveolin-1 (Cav-1), a main component of the lipid raft, may regulate the response to platinum-based treatment in OCCC.	Platinum	115-123	caveolin 1	Homo sapiens	30-40
35622184-3	2022	It has been hypothesized that caveolin-1 (Cav-1), a main component of the lipid raft, may regulate the response to platinum-based treatment in OCCC.	Platinum	115-123	caveolin 1	Homo sapiens	42-47
35622184-8	2022	Of note, ACE2 positively regulated the expression of the platinum-clearing enzyme CYP3A4.	Platinum	57-65	angiotensin converting enzyme 2	Homo sapiens	9-13
35622184-8	2022	Of note, ACE2 positively regulated the expression of the platinum-clearing enzyme CYP3A4.	Platinum	57-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-88
35625946-7	2022	Among prognostic polymorphisms, we found a potential role of UGT2A1 both as a predictor of platinum-response (p = 0.01) and as prognostic of survival (p = 0.05).	Platinum	91-99	UDP glucuronosyltransferase family 2 member A1 complex locus	Homo sapiens	61-67
35629867-5	2022	The smaller particle size and higher zeta potential in the degassed HSC ink indicated the higher utilization of Pt, thus leading to optimized mass transfer in the catalyst layer (CL) during working conditions.	Platinum	112-114	fucosyltransferase 1 (H blood group)	Homo sapiens	68-71
35500202-2	2022	The SENP1/JAK2 (small ubiquitin-like modifier-specific protease 1/Janus activating kinase 2) axis activation has been proposed as a critical mechanism in platinum-resistant ovarian cancer, and as such, SENP1 inhibitors become a feasible alternative to reverse platinum resistance.	Platinum	260-268	SUMO specific peptidase 1	Homo sapiens	4-9
35500202-2	2022	The SENP1/JAK2 (small ubiquitin-like modifier-specific protease 1/Janus activating kinase 2) axis activation has been proposed as a critical mechanism in platinum-resistant ovarian cancer, and as such, SENP1 inhibitors become a feasible alternative to reverse platinum resistance.	Platinum	260-268	Janus kinase 2	Homo sapiens	10-14
35500202-2	2022	The SENP1/JAK2 (small ubiquitin-like modifier-specific protease 1/Janus activating kinase 2) axis activation has been proposed as a critical mechanism in platinum-resistant ovarian cancer, and as such, SENP1 inhibitors become a feasible alternative to reverse platinum resistance.	Platinum	260-268	SUMO specific peptidase 1	Homo sapiens	202-207
35616329-9	2022	Our study and recent findings of ACTL7A/ACTL9-deficient sperm together reveal that the sperm PT-specific ARP complex mediates the acrosome-nucleus connection.	Platinum	93-95	actin-like 7a	Mus musculus	33-39
35616329-9	2022	Our study and recent findings of ACTL7A/ACTL9-deficient sperm together reveal that the sperm PT-specific ARP complex mediates the acrosome-nucleus connection.	Platinum	93-95	actin-like 9	Mus musculus	40-45
35628603-8	2022	While analysis of the SIOVDB database did not reveal differences in Syndecan-3 expression between patients, sensitive, resistant or refractory to chemotherapy, KM Plotter analysis of 1435 ovarian cancer patients revealed that high syndecan-3 expression was associated with reduced survival in patients treated with taxol and platin.	Platinum	325-331	syndecan 3	Homo sapiens	231-241
35629708-0	2022	Electrocatalytic Properties of Mixed-Oxide-Containing Composite-Supported Platinum for Polymer Electrolyte Membrane (PEM) Fuel Cells.	Platinum	74-82	mucin 1, cell surface associated	Homo sapiens	117-120
35609013-2	2022	We introduce a novel electrocatalyst, Pt3 Ge, engineered with a desired crystallographic facet (202) accelerates hydrogen production by water electrolysis and records industrially desired operational stability compared to the commercial catalyst platinum.	Platinum	246-254	zinc finger protein 135	Homo sapiens	38-41
35629708-1	2022	TiO2-based mixed oxide-carbon composite supports have been suggested to provide enhanced stability for platinum (Pt) electrocatalysts in polymer electrolyte membrane (PEM) fuel cells.	Platinum	103-111	mucin 1, cell surface associated	Homo sapiens	167-170
35629708-1	2022	TiO2-based mixed oxide-carbon composite supports have been suggested to provide enhanced stability for platinum (Pt) electrocatalysts in polymer electrolyte membrane (PEM) fuel cells.	Platinum	113-115	mucin 1, cell surface associated	Homo sapiens	167-170
35583632-8	2022	SRPK1 expression is also closely related to the response of various tumours to platinum-based chemotherapeutic agents.	Platinum	79-87	SRSF protein kinase 1	Homo sapiens	0-5
35598358-5	2022	RESULTS: Platinum doublets and chemoimmunotherapy showed similar response rates (20-25%), disease control rates (80%) and median progression-free survival (mPFS,  7 months), which were longer compared to monochemotherapy (9%, 59%, 4.1 months), EGFR inhibitors (0%, 46%, 3.0) and PD-(L)1 inhibitors (0%, 30%, 2.1; p < 0.05).	Platinum	9-17	epidermal growth factor receptor	Homo sapiens	244-248
35598358-5	2022	RESULTS: Platinum doublets and chemoimmunotherapy showed similar response rates (20-25%), disease control rates (80%) and median progression-free survival (mPFS,  7 months), which were longer compared to monochemotherapy (9%, 59%, 4.1 months), EGFR inhibitors (0%, 46%, 3.0) and PD-(L)1 inhibitors (0%, 30%, 2.1; p < 0.05).	Platinum	9-17	CD274 molecule	Homo sapiens	279-286
35598358-7	2022	TP53 mutations and brain metastases were associated with shorter PFS under platinum doublets and EGFR inhibitors (HR 3.3-6.1, p < 0.01), and shorter OS for patients receiving both treatments (p < 0.05).	Platinum	75-83	tumor protein p53	Homo sapiens	0-4
35598358-11	2022	CONCLUSIONS: Platinum doublets and chemoimmunotherapy have the highest activity with ORR of 20-25% and mPFS of approximately 7 months, regardless of the cytotoxic partner, while PD-(L)1 inhibitors show limited efficacy.	Platinum	13-21	CD274 molecule	Homo sapiens	178-185
35471816-3	2022	2.38 A distance for Fe1 (Fe-N3) and Pt1 (Pt-N4) could be precisely controlled via a novel secondary-doping strategy.	Platinum	41-43	zinc finger protein 77	Homo sapiens	36-39
35597155-0	2022	Activin-A, Growth Differentiation Factor-11 and Transforming Growth Factor-beta as predictive biomarkers for platinum chemotherapy in advanced non-small cell lung cancer.	Platinum	109-117	growth differentiation factor 11	Homo sapiens	11-43
35597155-0	2022	Activin-A, Growth Differentiation Factor-11 and Transforming Growth Factor-beta as predictive biomarkers for platinum chemotherapy in advanced non-small cell lung cancer.	Platinum	109-117	tumor necrosis factor	Homo sapiens	48-79
35597155-3	2022	In vitro evidence implicates the transforming growth factor-beta (TGF-beta) superfamily ligands activin-A and growth differentiation factor 11 (GDF-11) in innate platinum resistance.	Platinum	162-170	tumor necrosis factor	Homo sapiens	33-64
35597155-3	2022	In vitro evidence implicates the transforming growth factor-beta (TGF-beta) superfamily ligands activin-A and growth differentiation factor 11 (GDF-11) in innate platinum resistance.	Platinum	162-170	transforming growth factor alpha	Homo sapiens	66-74
35597155-3	2022	In vitro evidence implicates the transforming growth factor-beta (TGF-beta) superfamily ligands activin-A and growth differentiation factor 11 (GDF-11) in innate platinum resistance.	Platinum	162-170	growth differentiation factor 11	Homo sapiens	110-142
35597155-3	2022	In vitro evidence implicates the transforming growth factor-beta (TGF-beta) superfamily ligands activin-A and growth differentiation factor 11 (GDF-11) in innate platinum resistance.	Platinum	162-170	growth differentiation factor 11	Homo sapiens	144-150
35538489-2	2022	In this study, by performing bioinformatic analysis with a public database and immunohistochemical staining of Wip1 in tumour tissue from SOC, we concluded that decreased expression of Wip1 was associated with a higher rate of tumour metastasis and platinum-based therapy resistance and increased ascites volume, which led to poorer prognosis in SOC patients.	Platinum	249-257	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	185-189
35558826-0	2022	Impact of sp2 carbon material species on Pt nanoparticle-based electrocatalysts produced by one-pot pyrolysis methods with ionic liquids.	Platinum	41-43	Sp2 transcription factor	Homo sapiens	10-13
35558826-2	2022	In this one-pot pyrolysis method, which does not require any reagents to reduce Pt metal precursors or stabilize Pt nanoparticles, Pt nanoparticles are readily immobilized onto the sp2 surface by a thin IL layer formed at the interface, which can work as a binder.	Platinum	131-133	Sp2 transcription factor	Homo sapiens	181-184
35442686-4	2022	Here, we show theoretically and experimentally that for Ta as heavy metal the interface only partially transmits the spin current while this effect is absent when Pt is used as heavy metal.	Platinum	163-165	spindlin 1	Homo sapiens	117-121
35547093-11	2022	Conclusion: HRD is an effective predictor of increased pCR rates in platinum-based NCT, especially in wild-type BRCA patients.	Platinum	68-76	BRCA1 DNA repair associated	Homo sapiens	112-116
35482577-5	2022	Finally, the G5MEKnC-encapsulated platinum nanoparticles (Ptn-G5MEK50C) were prepared by entrapping the platinum nanoparticles (1.40 nm) in the catalytic centers in the interior of G5MEK50C.	Platinum	34-42	pleiotrophin	Homo sapiens	58-61
35482577-5	2022	Finally, the G5MEKnC-encapsulated platinum nanoparticles (Ptn-G5MEK50C) were prepared by entrapping the platinum nanoparticles (1.40 nm) in the catalytic centers in the interior of G5MEK50C.	Platinum	104-112	pleiotrophin	Homo sapiens	58-61
35415731-1	2022	Palladium(II) and platinum(II) complexes featuring metalla-N-heterocyclic carbenes (7-12) were synthesised via metal-mediated coupling between equimolar cis-(MCl2(CNR)2) (R = 2,6-Me2C6H3 (Xyl), 2,4,6-Me3C6H3 (Mes)) and 2-aminopyridine or 2-aminopyrazine.	Platinum	18-26	cannabinoid receptor 2	Homo sapiens	158-168
35420408-1	2022	Based on luminol-capped Pt-tipped Au bimetallic nanorods (NRs) (L-Au-Pt NRs) as the anode emitter and SnS2 quantum dots (QDs) hybrid Eu metal organic frameworks (MOFs) (SnS2 QDs@Eu MOFs) as the cathode emitter, a dual-signal electrochemiluminescence (ECL) platform was designed for the ultrasensitive and highly selective detection of kanamycin (KAN).	Platinum	24-26	sodium voltage-gated channel alpha subunit 11	Homo sapiens	169-173
35405577-6	2022	The antitumor mechanisms of PT/DOX-MS were possibly due to that the introduction of PT-2385 could effectively inhibit the expression level of HIF-2alpha in hypoxic HCC cells, thereby down-regulating the expression levels of Cyclin D1, VEGF and TGF-alpha.	Platinum	28-30	endothelial PAS domain protein 1	Homo sapiens	142-152
35405577-6	2022	The antitumor mechanisms of PT/DOX-MS were possibly due to that the introduction of PT-2385 could effectively inhibit the expression level of HIF-2alpha in hypoxic HCC cells, thereby down-regulating the expression levels of Cyclin D1, VEGF and TGF-alpha.	Platinum	28-30	cyclin D1	Homo sapiens	224-233
35405577-6	2022	The antitumor mechanisms of PT/DOX-MS were possibly due to that the introduction of PT-2385 could effectively inhibit the expression level of HIF-2alpha in hypoxic HCC cells, thereby down-regulating the expression levels of Cyclin D1, VEGF and TGF-alpha.	Platinum	28-30	vascular endothelial growth factor A	Homo sapiens	235-239
35405577-6	2022	The antitumor mechanisms of PT/DOX-MS were possibly due to that the introduction of PT-2385 could effectively inhibit the expression level of HIF-2alpha in hypoxic HCC cells, thereby down-regulating the expression levels of Cyclin D1, VEGF and TGF-alpha.	Platinum	28-30	transforming growth factor alpha	Homo sapiens	244-253
35405577-7	2022	In addition, the combination of DOX and PT-2385 could jointly inhibit VEGF expression, which was another reason accounting for the combined anti-cancer effect of PT/DOX-MS.	Platinum	40-42	vascular endothelial growth factor A	Homo sapiens	70-74
35405577-7	2022	In addition, the combination of DOX and PT-2385 could jointly inhibit VEGF expression, which was another reason accounting for the combined anti-cancer effect of PT/DOX-MS.	Platinum	162-164	vascular endothelial growth factor A	Homo sapiens	70-74
35602944-4	2022	In particular, we intentionally modify the Fe/Pt interface by inserting an ordered L10-FePt alloy interlayer.	Platinum	46-48	immunoglobulin kappa variable 3-7 (non-functional)	Homo sapiens	83-86
35602944-5	2022	Subsequently, we establish that a Fe/L10-FePt (2 nm)/Pt configuration is significantly superior to a Fe/Pt bilayer structure, regarding THz emission amplitude.	Platinum	53-55	immunoglobulin kappa variable 3-7 (non-functional)	Homo sapiens	37-40
35602944-5	2022	Subsequently, we establish that a Fe/L10-FePt (2 nm)/Pt configuration is significantly superior to a Fe/Pt bilayer structure, regarding THz emission amplitude.	Platinum	53-55	glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase	Homo sapiens	49-51
35489694-0	2022	BAP1 loss by immunohistochemistry predicts improved survival to first line platinum/pemetrexed chemotherapy for pleural mesothelioma patients: A validation study.	Platinum	75-83	BRCA1 associated protein 1	Homo sapiens	0-4
35489694-9	2022	First-line platinum/pemetrexed treated patients with BAP1 loss had significantly longer median survival than those with retained BAP1 in both the Danish (20.1 vs 7.3 months, p < 0.001) and Australian cohorts (19.6 vs 11.1 months, p < 0.01).	Platinum	11-19	BRCA1 associated protein 1	Homo sapiens	53-57
35489694-11	2022	There was a higher OS in BSC patients with BAP1 loss, but significant only in the Australian cohort (16.8 vs 8.3 months, p < 0.01).results CONCLUSION: BAP1 is a predictive biomarker for survival following first-line combination platinum/pemetrexed chemotherapy and a potential prognostic marker in PM.	Platinum	228-236	BRCA1 associated protein 1	Homo sapiens	151-155
35501919-8	2022	We identified several genes that were commonly mutated in pre-NACT samples specific to platinum-resistant (CSPG4, SLC35G5, TUBA3D) or sensitive (CYP2D6, NUTM1, DNAH5) cases.	Platinum	87-95	chondroitin sulfate proteoglycan 4	Homo sapiens	107-112
35501919-8	2022	We identified several genes that were commonly mutated in pre-NACT samples specific to platinum-resistant (CSPG4, SLC35G5, TUBA3D) or sensitive (CYP2D6, NUTM1, DNAH5) cases.	Platinum	87-95	solute carrier family 35 member G5	Homo sapiens	114-121
35501919-8	2022	We identified several genes that were commonly mutated in pre-NACT samples specific to platinum-resistant (CSPG4, SLC35G5, TUBA3D) or sensitive (CYP2D6, NUTM1, DNAH5) cases.	Platinum	87-95	tubulin alpha 3d	Homo sapiens	123-129
35501919-8	2022	We identified several genes that were commonly mutated in pre-NACT samples specific to platinum-resistant (CSPG4, SLC35G5, TUBA3D) or sensitive (CYP2D6, NUTM1, DNAH5) cases.	Platinum	87-95	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	145-151
35501919-8	2022	We identified several genes that were commonly mutated in pre-NACT samples specific to platinum-resistant (CSPG4, SLC35G5, TUBA3D) or sensitive (CYP2D6, NUTM1, DNAH5) cases.	Platinum	87-95	NUT midline carcinoma family member 1	Homo sapiens	153-158
35501919-8	2022	We identified several genes that were commonly mutated in pre-NACT samples specific to platinum-resistant (CSPG4, SLC35G5, TUBA3D) or sensitive (CYP2D6, NUTM1, DNAH5) cases.	Platinum	87-95	dynein axonemal heavy chain 5	Homo sapiens	160-165
35501919-9	2022	Four mutated genes emerged exclusively in the platinum-resistant cases (ADGRV1, MUC17, MUC20, PAK2) following NACT.	Platinum	46-54	adhesion G protein-coupled receptor V1	Homo sapiens	72-78
35501919-9	2022	Four mutated genes emerged exclusively in the platinum-resistant cases (ADGRV1, MUC17, MUC20, PAK2) following NACT.	Platinum	46-54	mucin 17, cell surface associated	Homo sapiens	80-85
35501919-9	2022	Four mutated genes emerged exclusively in the platinum-resistant cases (ADGRV1, MUC17, MUC20, PAK2) following NACT.	Platinum	46-54	mucin 20, cell surface associated	Homo sapiens	87-92
35501919-9	2022	Four mutated genes emerged exclusively in the platinum-resistant cases (ADGRV1, MUC17, MUC20, PAK2) following NACT.	Platinum	46-54	p21 (RAC1) activated kinase 2	Homo sapiens	94-98
35405577-4	2022	Herein, a multifunctional polyvinyl alcohol (PVA)/hyaluronic acid (HA)-based microsphere (PT/DOX-MS) co-loaded with doxorubicin (DOX) and PT-2385, an effective HIF-2alpha inhibitor, was developed for enhanced TACE treatment efficacy.	Platinum	90-92	endothelial PAS domain protein 1	Homo sapiens	160-170
35501389-5	2022	RESULTS: Expression of X-linked inhibitor of apoptosis (XIAP) is increased in BRCA1-mutated cancers and high levels are associated with improved patient outcomes after platinum chemotherapy.	Platinum	168-176	X-linked inhibitor of apoptosis	Homo sapiens	23-54
35501389-5	2022	RESULTS: Expression of X-linked inhibitor of apoptosis (XIAP) is increased in BRCA1-mutated cancers and high levels are associated with improved patient outcomes after platinum chemotherapy.	Platinum	168-176	X-linked inhibitor of apoptosis	Homo sapiens	56-60
35501389-5	2022	RESULTS: Expression of X-linked inhibitor of apoptosis (XIAP) is increased in BRCA1-mutated cancers and high levels are associated with improved patient outcomes after platinum chemotherapy.	Platinum	168-176	BRCA1 DNA repair associated	Homo sapiens	78-83
35461409-1	2022	BACKGROUND: Platinum and taxane-based neoadjuvant chemotherapy with surgery (NAC + S) is a novel de-intensified treatment modality that is currently under investigation.	Platinum	12-20	synuclein alpha	Homo sapiens	77-80
35462552-15	2022	In a subgroup analysis, the predictive value of intratumoral and stromal CD4+ T cell density persisted in the platinum-containing chemotherapy group (A1+A2) but not in the non-platinum-containing group (B1+B2).	Platinum	110-118	CD4 molecule	Homo sapiens	73-76
35459212-5	2022	Specifically, levels of the mitophagy receptor BNIP3 are higher both in resistant cells and in ovarian cancer patient samples resistant to platinum-based treatments.	Platinum	139-147	BCL2 interacting protein 3	Homo sapiens	47-52
35547771-10	2022	In contrast, pharmaceutical inhibition and genetic ablation of SCD1/FADS2 retarded tumor growth, cancer stem cell (CSC) formation and reduced platinum resistance.	Platinum	142-150	stearoyl-Coenzyme A desaturase 1	Mus musculus	63-67
35547771-10	2022	In contrast, pharmaceutical inhibition and genetic ablation of SCD1/FADS2 retarded tumor growth, cancer stem cell (CSC) formation and reduced platinum resistance.	Platinum	142-150	fatty acid desaturase 2	Mus musculus	68-73
35481085-0	2022	Rapid electrochemical detection of MiRNA-21 facilitated by the excellent catalytic ability of Pt@CeO2 nanospheres.	Platinum	94-96	microRNA 21	Homo sapiens	35-43
35565194-8	2022	When treated with first-line platinum doublet (n = 195), KRASMUT was a negative factor for survival (p = 0.018), with median OS of 9 months vs. KRASWT at 11 months.	Platinum	29-37	KRAS proto-oncogene, GTPase	Homo sapiens	57-64
35565194-13	2022	kRAS mutations are associated with better response to treatment with immune checkpoint blockade and worse response to platinum doublet chemotherapy as well as shorter general OS in Stage IV NSCLC.	Platinum	118-126	KRAS proto-oncogene, GTPase	Homo sapiens	0-4
35354123-0	2022	Modeling surface spin polarization on ceria-supported Pt nanoparticles.	Platinum	54-56	spindlin 1	Homo sapiens	17-21
35354123-4	2022	We show that the inclusion of spin polarization can significantly reduce the major activation barrier in the proposed reaction pathway of CO oxidation on ceria-supported Pt nanoparticles.	Platinum	170-172	spindlin 1	Homo sapiens	30-34
35354123-5	2022	For metal-support interactions, surface spin polarization enhances the bonding between Pt nanoparticles and ceria surface oxygen, while CO adsorption on Pt nanoparticles weakens the interfacial interaction regardless of spin polarization.	Platinum	87-89	spindlin 1	Homo sapiens	40-44
35443055-7	2022	KRAS mutations were significantly associated with age at diagnosis >50 years (p=0.02) and platinum-sensitive disease (p=0.03).	Platinum	90-98	KRAS proto-oncogene, GTPase	Homo sapiens	0-4
35443055-12	2022	CONCLUSIONS: This study showed MAPK pathway alterations in LGSC, including KRAS mutations, are independently associated with platinum sensitivity and prolonged survival.	Platinum	125-133	KRAS proto-oncogene, GTPase	Homo sapiens	75-79
35388844-1	2022	The combination of a reducible transition metal oxide and a noble metal such as Pt often leads to active low-temperature catalysts for the preferential oxidation of CO in excess H2 gas (PROX reaction).	Platinum	80-82	pyruvate dehydrogenase complex component X	Homo sapiens	186-190
35440668-8	2022	Patients actively receiving platinum treatment had the lowest number of CTCs and a lower percentage of SLFN11-positive CTCs (p = 0.014).	Platinum	28-36	schlafen family member 11	Homo sapiens	103-109
35481085-2	2022	An electrochemical biosensor was successfully developed using Pt@CeO2 NSs as a capture probe for the ultra-sensitive and fast detection of miRNA-21, a new type of biomarker for disease diagnostics, especially for cancer.	Platinum	62-64	microRNA 21	Homo sapiens	139-147
35481085-7	2022	The ultra-sensitive and rapid detection of miRNA-21 was finally realized as expected benefiting from the excellent catalytic ability of Pt@CeO2 NSs toward H2O2 in a wide linear concentration range from 10 fM to 1 nM with the detection limit as low as 1.41 fM.	Platinum	136-138	microRNA 21	Homo sapiens	43-51
35091371-0	2022	Single-atom Pt-anchored Zn0.5Cd0.5S boosted photoelectrochemical immunoassay of prostate-specific antigen.	Platinum	12-14	kallikrein related peptidase 3	Homo sapiens	80-105
35091371-2	2022	Herein we synthesized single-atom platinum-anchored Zn0.5Cd0.5S nanostructures to construct an innovative photoelectrochemical (PEC) immunosensor for photocurrent determination of prostate-specific antigen (PSA).	Platinum	34-42	kallikrein related peptidase 3	Homo sapiens	180-205
35091371-2	2022	Herein we synthesized single-atom platinum-anchored Zn0.5Cd0.5S nanostructures to construct an innovative photoelectrochemical (PEC) immunosensor for photocurrent determination of prostate-specific antigen (PSA).	Platinum	34-42	kallikrein related peptidase 3	Homo sapiens	207-210
35425960-1	2022	PARP inhibitors (PARPi) are approved drugs for platinum-sensitive, high-grade serous ovarian cancer (HGSOC) and for breast, prostate, and pancreatic cancers (PaC) harboring genetic alterations impairing homologous recombination repair (HRR).	Platinum	47-55	collagen type XI alpha 2 chain	Homo sapiens	0-4
35091371-7	2022	Under optimized conditions, single-atom platinum-anchored Zn0.5Cd0.5S-based photoelectrochemical immunoassay gave good PEC signals toward PSA from 1.0 to 10000 pg/mL with a limit of detection of 0.22 pg/mL.	Platinum	40-48	kallikrein related peptidase 3	Homo sapiens	138-141
35425960-9	2022	The accuracy of the RAD51 test was similar to HRR gene mutations for predicting platinum response.	Platinum	80-88	RAD51 recombinase	Homo sapiens	20-25
35362315-3	2022	The SH-THE presents obvious dependence of epitaxial strain in Pt/Tm3Fe5O12 (TmIG) bilayers deposited on a series of (111)-oriented garnet substrates, indicating that the topological spin textures can be tuned by epitaxial strain in this system.	Platinum	62-64	spindlin 1	Homo sapiens	182-186
35421932-0	2022	Role of APOA1 in the resistance to platinum-based chemotherapy in squamous cervical cancer.	Platinum	35-43	apolipoprotein A1	Homo sapiens	8-13
35421932-1	2022	BACKGROUND: To investigate the mechanism by which apolipoprotein A1 (APOA1) enhances the resistance of cervical squamous carcinoma to platinum-based chemotherapy.	Platinum	134-142	apolipoprotein A1	Homo sapiens	50-67
35421932-1	2022	BACKGROUND: To investigate the mechanism by which apolipoprotein A1 (APOA1) enhances the resistance of cervical squamous carcinoma to platinum-based chemotherapy.	Platinum	134-142	apolipoprotein A1	Homo sapiens	69-74
35421932-4	2022	A screen for APOA1 downstream proteins affecting platinum-based chemoresistance using Tandem Mass Tag revealed 64 differentially expressed proteins in SiHa cells, which were subjected to Gene Ontology (annotation, Kyoto Encyclopedia of Genes and Genomes enrichment, subcellular localization, structural domain annotation and enrichment, clustering, and interaction network analyses.	Platinum	49-57	apolipoprotein A1	Homo sapiens	13-18
35421932-6	2022	CONCLUSIONS: Our analysis suggested that the mechanism may involve numerous regulatory pathways, including promoting tumor growth via the p38 MAPK signaling pathway through STAT1, promoting tumor progression via the PI3K signaling pathway through CD81 and C3, and promoting resistance to platinum-based chemotherapy resistance through TOP2A.	Platinum	288-296	signal transducer and activator of transcription 1	Homo sapiens	173-178
35421932-6	2022	CONCLUSIONS: Our analysis suggested that the mechanism may involve numerous regulatory pathways, including promoting tumor growth via the p38 MAPK signaling pathway through STAT1, promoting tumor progression via the PI3K signaling pathway through CD81 and C3, and promoting resistance to platinum-based chemotherapy resistance through TOP2A.	Platinum	288-296	CD81 molecule	Homo sapiens	247-251
35421932-6	2022	CONCLUSIONS: Our analysis suggested that the mechanism may involve numerous regulatory pathways, including promoting tumor growth via the p38 MAPK signaling pathway through STAT1, promoting tumor progression via the PI3K signaling pathway through CD81 and C3, and promoting resistance to platinum-based chemotherapy resistance through TOP2A.	Platinum	288-296	DNA topoisomerase II alpha	Homo sapiens	335-340
35421932-7	2022	The present study aimed to preliminarily explore the function and mechanism of APOA1 in platinum-based chemoresistance in cervical cancer, and the detailed mechanism needs to be further studied.	Platinum	88-96	apolipoprotein A1	Homo sapiens	79-84
35362315-6	2022	The results indicate that the epitaxial strain can effectively change the interfacial DMI in this system, suggesting that the strain-induced modification of the interfacial DMI is the driving force for the SH-THE and topological spin textures in the Pt/TmIG bilayers.	Platinum	250-252	spindlin 1	Homo sapiens	229-233
35315859-3	2022	The peroxidase activity enhances the intensity of the brownish coloring of the Fe3O4@Pt probes on the test strip, with a limit of detection of 10 pg mL-1 using the naked eye, which is remarkable for colorimetric lateral flow assays.	Platinum	85-87	L1 cell adhesion molecule	Mus musculus	149-153
35481288-4	2022	We observed that homozygosity for a loss-of-function SNP (rs2241880, leading to the substitution of a threonine residue in position 300 by an alanine) affecting autophagy related 16 like 1 (ATG16L1) is coupled to poor progression-free survival in platinum-treated HNSCC patients.	Platinum	247-255	autophagy related 16 like 1	Homo sapiens	161-188
35481288-4	2022	We observed that homozygosity for a loss-of-function SNP (rs2241880, leading to the substitution of a threonine residue in position 300 by an alanine) affecting autophagy related 16 like 1 (ATG16L1) is coupled to poor progression-free survival in platinum-treated HNSCC patients.	Platinum	247-255	autophagy related 16 like 1	Homo sapiens	190-197
35412302-5	2022	The introduction of iodine not only enhances the CT imaging signal with a much lower dose of Pt but also overcomes the resistance of tumor cells to Pt-containing nanomedicine by inhibiting the expression of Bcl-2.	Platinum	148-150	BCL2 apoptosis regulator	Homo sapiens	207-212
35396812-1	2022	BACKGROUND: Inhibitors of poly(ADP-ribose) polymerase (PARP) proteins potentiate antitumor activity of platinum chemotherapy.	Platinum	103-111	poly(ADP-ribose) polymerase 1	Homo sapiens	26-53
35396702-6	2022	Patients who took CYP3A inducers had a 4.4-fold increased incidence of hepatotoxicity, and furthermore, concomitant use of platinum-based antineoplastics revealed 4.2 times the hazard of time to hepatotoxicity compared to those receiving antimetabolites.	Platinum	123-131	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-23
35396812-1	2022	BACKGROUND: Inhibitors of poly(ADP-ribose) polymerase (PARP) proteins potentiate antitumor activity of platinum chemotherapy.	Platinum	103-111	poly(ADP-ribose) polymerase 1	Homo sapiens	55-59
35385581-6	2022	We find that templated insertions (TINS) consistent with TMEJ repair are highly specific to tumors with pathogenic bi-allelic mutations in BRCA2 and that high TINS genomic signature content in advanced ovarian cancers associate with overall survival following treatment with platinum agents.	Platinum	275-283	BRCA2 DNA repair associated	Homo sapiens	139-144
35456621-1	2022	Platinum(IV) prodrugs of the (Pt(PL)(AL)(COXi)(OH))2+ type scaffold (where PL is 1,10-phenanthroline or 5,6-dimethyl-1,10-phenanthroline, AL is 1S,2S-diaminocyclohexane, and COXi is a COX inhibitor, either indomethacin or aspirin) were synthesised and characterised, and their biological activity was explored.	Platinum	0-8	cytochrome c oxidase subunit 8A	Homo sapiens	184-187
35349346-2	2022	Further density functional theory calculation indicates that unique catalytic properties of Pt single-atom catalyst could be attributed intrinsically to the unique surface properties of Pt1-based active sites.	Platinum	92-94	zinc finger protein 77	Homo sapiens	186-189
35379563-4	2022	The AURA3 trial (NCT02151981) was a randomized controlled trial comparing osimertinib with platinum-based doublet chemotherapy (standard care) in patients with locally advanced or metastatic epidermal growth factor receptor mutant- and T790M-positive nonsmall cell lung cancer whose disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy.	Platinum	91-99	epidermal growth factor receptor	Homo sapiens	191-223
35051531-6	2022	Importantly, we found that disruption of PHF8-TOPBP1 axis suppresses breast tumorigenesis and creates a breast tumor-specific vulnerability to PARP inhibitor (PARPi) and platinum drug.	Platinum	170-178	PHD finger protein 8	Mus musculus	41-45
35051531-6	2022	Importantly, we found that disruption of PHF8-TOPBP1 axis suppresses breast tumorigenesis and creates a breast tumor-specific vulnerability to PARP inhibitor (PARPi) and platinum drug.	Platinum	170-178	topoisomerase (DNA) II binding protein 1	Mus musculus	46-52
35092538-6	2022	CONCLUSION: Our analyses suggest that 14% of ER+/Her2- patients may be HRD and therefore potentially eligible for treatments with HRD-directed therapies such as platinum agents and PARP inhibitors.	Platinum	161-169	epiregulin	Homo sapiens	45-47
35092538-6	2022	CONCLUSION: Our analyses suggest that 14% of ER+/Her2- patients may be HRD and therefore potentially eligible for treatments with HRD-directed therapies such as platinum agents and PARP inhibitors.	Platinum	161-169	erb-b2 receptor tyrosine kinase 2	Homo sapiens	49-53
35129371-5	2022	Results: For the PD-L1 high population, a PD-1 inhibitor plus platinum-doublet provided significant progression-free survival (PFS) benefit versus bevacizumab.	Platinum	62-70	CD274 molecule	Homo sapiens	17-22
35264742-0	2022	Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair.	Platinum	62-70	UPK1A antisense RNA 1	Homo sapiens	44-53
35153073-10	2022	DISCUSSIONS: Patients with platinum-sensitive BRCA1/2 mutated tumours who progressed during olaparib maintenance after second-line chemotherapy were less likely to respond to third-line chemotherapy compared to controls who did not receive olaparib, suggesting that resistance to olaparib may contribute to chemotherapy resistance.	Platinum	27-35	BRCA1 DNA repair associated	Homo sapiens	46-53
35497383-0	2022	Platinum Nanoparticle Size and Density Impacts Purine Electrochemistry with Fast-Scan Cyclic Voltammetry.	Platinum	0-8	Fas activated serine/threonine kinase	Homo sapiens	76-80
35497383-1	2022	We demonstrate the density and shape of platinum nanoparticles (PtNP) on carbon-fiber microelectrodes with fast-scan cyclic voltammetry (FSCV) directly impacts detection of adenosine.	Platinum	40-48	Fas activated serine/threonine kinase	Homo sapiens	107-111
35361267-9	2022	PNLDC1, SLC5A1, and SYNM were then identified as hub genes that were associated with both platinum response status and prognosis, which was further validated by the Fudan University Shanghai cancer center (FUSCC) cohort.	Platinum	90-98	PARN like ribonuclease domain containing exonuclease 1	Homo sapiens	0-6
35455437-0	2022	Association between Genetic Polymorphism of GSTP1 and Toxicities in Patients Receiving Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis.	Platinum	87-95	glutathione S-transferase pi 1	Homo sapiens	44-49
35455437-3	2022	Polymorphisms within the glutathione S-transferase pi 1 (GSTP1) gene may especially alter enzyme activity and, consequently, various toxicities in patients receiving platinum-based chemotherapy.	Platinum	166-174	glutathione S-transferase pi 1	Homo sapiens	25-55
35455437-3	2022	Polymorphisms within the glutathione S-transferase pi 1 (GSTP1) gene may especially alter enzyme activity and, consequently, various toxicities in patients receiving platinum-based chemotherapy.	Platinum	166-174	glutathione S-transferase pi 1	Homo sapiens	57-62
35455437-4	2022	Due to a lack of consistency in the degree of elevated complication risk, we performed a systematic literature review and meta-analysis to determine the level of platinum-associated toxicity in patients with the GSTP1 rs1695 polymorphism.	Platinum	162-170	glutathione S-transferase pi 1	Homo sapiens	212-217
35455437-10	2022	Our study found that the GSTP1 rs1695 polymorphism was significantly correlated with platinum-induced toxicities.	Platinum	85-93	glutathione S-transferase pi 1	Homo sapiens	25-30
35361267-9	2022	PNLDC1, SLC5A1, and SYNM were then identified as hub genes that were associated with both platinum response status and prognosis, which was further validated by the Fudan University Shanghai cancer center (FUSCC) cohort.	Platinum	90-98	solute carrier family 5 member 1	Homo sapiens	8-14
35361267-9	2022	PNLDC1, SLC5A1, and SYNM were then identified as hub genes that were associated with both platinum response status and prognosis, which was further validated by the Fudan University Shanghai cancer center (FUSCC) cohort.	Platinum	90-98	synemin	Homo sapiens	20-24
35285843-5	2022	In addition, these novel Pt complexes reversed cisplatin-induced resistance via inhibiting the expression of P-glycoprotein and decreasing the level of glutathione in A549cisR cells.	Platinum	25-27	ATP binding cassette subfamily B member 1	Homo sapiens	109-123
35392433-7	2022	We found that high expression of HELQ and XAB2 in the training cohort was associated with poor prognosis (for HELQ, P = 0.001, HR = 2.83, 95% CI: 1.46-5.49; for XAB2, P = 0.008, HR = 2.38, 95% CI: 1.23-4.63) and platinum resistance (for HELQ, P < 0.001; for XAB2, P = 0.006).	Platinum	212-220	helicase, POLQ like	Homo sapiens	33-37
35392433-7	2022	We found that high expression of HELQ and XAB2 in the training cohort was associated with poor prognosis (for HELQ, P = 0.001, HR = 2.83, 95% CI: 1.46-5.49; for XAB2, P = 0.008, HR = 2.38, 95% CI: 1.23-4.63) and platinum resistance (for HELQ, P < 0.001; for XAB2, P = 0.006).	Platinum	212-220	XPA binding protein 2	Homo sapiens	42-46
35392433-7	2022	We found that high expression of HELQ and XAB2 in the training cohort was associated with poor prognosis (for HELQ, P = 0.001, HR = 2.83, 95% CI: 1.46-5.49; for XAB2, P = 0.008, HR = 2.38, 95% CI: 1.23-4.63) and platinum resistance (for HELQ, P < 0.001; for XAB2, P = 0.006).	Platinum	212-220	XPA binding protein 2	Homo sapiens	161-165
35392433-7	2022	We found that high expression of HELQ and XAB2 in the training cohort was associated with poor prognosis (for HELQ, P = 0.001, HR = 2.83, 95% CI: 1.46-5.49; for XAB2, P = 0.008, HR = 2.38, 95% CI: 1.23-4.63) and platinum resistance (for HELQ, P < 0.001; for XAB2, P = 0.006).	Platinum	212-220	helicase, POLQ like	Homo sapiens	237-241
35392433-7	2022	We found that high expression of HELQ and XAB2 in the training cohort was associated with poor prognosis (for HELQ, P = 0.001, HR = 2.83, 95% CI: 1.46-5.49; for XAB2, P = 0.008, HR = 2.38, 95% CI: 1.23-4.63) and platinum resistance (for HELQ, P < 0.001; for XAB2, P = 0.006).	Platinum	212-220	XPA binding protein 2	Homo sapiens	258-262
35392433-9	2022	The expression levels of HELQ (RR 5.7, 95% CI 1.7-19.2) and XAB2 (RR 3.2, 95% CI 0.9-10.8) in ascites tumor cells were positively correlated to the risk of platinum resistance.	Platinum	156-164	helicase, POLQ like	Homo sapiens	25-29
35392433-9	2022	The expression levels of HELQ (RR 5.7, 95% CI 1.7-19.2) and XAB2 (RR 3.2, 95% CI 0.9-10.8) in ascites tumor cells were positively correlated to the risk of platinum resistance.	Platinum	156-164	XPA binding protein 2	Homo sapiens	60-64
35371325-7	2022	Results: Among BET members, mRNA expression BRD2 showed improve OS in all the ovarian malignancy patients, serous patients, stage III and IV, grade II and grade III, TP53 mutated ovarian cancer patients, as well as all patients treated with Platin based chemotherapy.	Platinum	241-247	bromodomain containing 2	Homo sapiens	44-48
35409089-10	2022	Inhibition of phospho-Chk2 phosphorylation of Brca1-S971 delays the end-resection; the delay of premature end-resection by combining Chk2 inhibition with ionizing radiation or carboplatin treatment restored ionizing radiation and platinum sensitivity in Wwox-deficient murine cells, as in human cells, supporting the use of murine in vitro and in vivo models in preclinical cancer treatment research.	Platinum	230-238	checkpoint kinase 2	Mus musculus	22-26
35409089-10	2022	Inhibition of phospho-Chk2 phosphorylation of Brca1-S971 delays the end-resection; the delay of premature end-resection by combining Chk2 inhibition with ionizing radiation or carboplatin treatment restored ionizing radiation and platinum sensitivity in Wwox-deficient murine cells, as in human cells, supporting the use of murine in vitro and in vivo models in preclinical cancer treatment research.	Platinum	230-238	breast cancer 1, early onset	Mus musculus	46-51
35409089-10	2022	Inhibition of phospho-Chk2 phosphorylation of Brca1-S971 delays the end-resection; the delay of premature end-resection by combining Chk2 inhibition with ionizing radiation or carboplatin treatment restored ionizing radiation and platinum sensitivity in Wwox-deficient murine cells, as in human cells, supporting the use of murine in vitro and in vivo models in preclinical cancer treatment research.	Platinum	230-238	checkpoint kinase 2	Mus musculus	133-137
35372032-0	2022	Platinum Chemotherapy Induces Lymphangiogenesis in Cancerous and Healthy Tissues That Can be Prevented With Adjuvant Anti-VEGFR3 Therapy.	Platinum	0-8	fms related receptor tyrosine kinase 4	Homo sapiens	122-128
35372032-8	2022	These platinum-induced phenomena could be blocked by VEGFR3 inhibition.	Platinum	6-14	FMS-like tyrosine kinase 4	Mus musculus	53-59
35230820-3	2022	Pt nanoparticles (Pt NPs) were grown in situ on the coordination sites for metal ions of beta-CD to prepare the beta-CD-Pt nanocomposite, which could not only enrich co-reactant 3-(dibutylamino) propylamine (TDBA) highly efficiently through its hydrophobic cavity but also immobilize TDBA via the Pt-N bond.	Platinum	297-299	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	89-96
35230820-3	2022	Pt nanoparticles (Pt NPs) were grown in situ on the coordination sites for metal ions of beta-CD to prepare the beta-CD-Pt nanocomposite, which could not only enrich co-reactant 3-(dibutylamino) propylamine (TDBA) highly efficiently through its hydrophobic cavity but also immobilize TDBA via the Pt-N bond.	Platinum	297-299	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	112-119
35371325-8	2022	As for BRD3, we found that BRD3 expression was related to better OS in endometrioid ovarian carcinoma and stage III+IV ovarian carcinoma patients, as well as all patients managed with Taxol and concurrent Taxol+Platin based chemotherapy.	Platinum	211-217	bromodomain containing 3	Homo sapiens	27-31
35371325-9	2022	In addition, BRDT was associated with better OS in all ovarian carcinoma patients, grade I and grade III, all clinical stage (I+II, III+IV) patients, as well as all patients cured with Taxol and concurrent Taxol+Platin chemotherapy.	Platinum	212-218	bromodomain testis associated	Homo sapiens	13-17
35406459-7	2022	Moreover, suppression of CSA dramatically sensitizes BC cells to platinum and taxane derivatives, which are commonly used for BC first-line therapy, even at very low doses not harmful to normal cells.	Platinum	65-73	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	25-28
35457829-2	2022	The local oxidation patterns are formed using platinum-coated tips with the aid of bias applied to the tip-substrate junction, and direct removal has been achieved using single crystal diamond tips, enabling the structure fabrication at the atomic and close-to-atomic scale.	Platinum	46-54	activation induced cytidine deaminase	Homo sapiens	76-79
35286059-2	2022	Herein, the full hydrolysis process of the AB molecule on single Pt atom coordinated by two carbon atoms and one nitrogen atom (Pt1-C2N1) on nitrogen doped graphene is investigated using the density functional theory (DFT) method.	Platinum	65-67	zinc finger protein 77	Homo sapiens	128-131
35326684-4	2022	For genes such as MGMT and BRCA1, promoter DNA methylation is associated with chemosensitivity to alkylating agents and platinum coordination complexes, respectively, and they have use as biomarkers directing patient treatment options.	Platinum	120-128	O-6-methylguanine-DNA methyltransferase	Homo sapiens	18-22
35326684-4	2022	For genes such as MGMT and BRCA1, promoter DNA methylation is associated with chemosensitivity to alkylating agents and platinum coordination complexes, respectively, and they have use as biomarkers directing patient treatment options.	Platinum	120-128	BRCA1 DNA repair associated	Homo sapiens	27-32
35277495-2	2022	Here we have conducted a photochemical reaction to stabilize ultralow Pt co-catalysts (0.26 wt%) onto the basal plane of hexagonal ZnIn2S4 nanosheets (PtSS-ZIS) to form a Pt-S3 protrusion tetrahedron coordination structure.	Platinum	171-173	zinc finger RANBP2-type containing 2	Homo sapiens	156-159
35277495-5	2022	The protruding single Pt atoms in PtSS-ZIS could inhibit the recombination of electron-hole pairs and cause a tip effect to optimize the adsorption/desorption behavior of H through effective proton mass transfer, which synergistically promote reaction thermodynamics and kinetics.	Platinum	22-24	zinc finger RANBP2-type containing 2	Homo sapiens	39-42
34982500-2	2022	In this contribution, a series of platinum(II) tethered chalcogenoviologens (PtL + -EV 2+ , E = S, Se, Te) is reported, which integrated the functions of photosensitizer, electron mediator and catalyst.	Platinum	34-42	pancreatic lipase	Homo sapiens	77-80
35226486-2	2022	The BET surface area of mPd@Pt NSs was found to be 210.4 m2 g-1, which is significantly higher than the currently reported unsupported Pt-based nanomaterials.	Platinum	135-137	mevalonate (diphospho) decarboxylase	Mus musculus	24-27
35326407-5	2022	In our study, we looked for a relationship between BIRC5 gene polymorphism and the effectiveness of platinum-based chemotherapy.	Platinum	100-108	baculoviral IAP repeat containing 5	Homo sapiens	51-56
35530157-0	2022	Genome-wide analysis identify novel germline genetic variations in ADCY1 influencing platinum-based chemotherapy response in non-small cell lung cancer.	Platinum	85-93	adenylate cyclase 1	Homo sapiens	67-72
35530157-6	2022	The results of fine-mapping showed that the G allele carriers of ADCY1 rs2280496 and C allele carriers of rs189178649 were more likely to be resistant to platinum-based chemotherapy.	Platinum	154-162	adenylate cyclase 1	Homo sapiens	65-70
35530157-7	2022	In conclusion, our study found that rs2280496 and rs189178649 in ADCY1 gene were associated the sensitivity of platinum-based chemotherapy in NSCLC patients.	Platinum	111-119	adenylate cyclase 1	Homo sapiens	65-70
35286638-3	2022	The Pt(IV)-lonidamine complex interacts with albumin relatively slowly but possesses high stability and lipophilicity (log P 1.62), which makes it possible the cellular uptake in a free (of proteins) form.	Platinum	4-6	albumin	Homo sapiens	45-52
35330134-2	2022	The multidrug resistance protein 1 (MRP1) is a membrane-bound ABC transporter involved in cross resistance to many structurally and functionally diverse classes of anticancer drugs including doxorubicin, taxane, and platinum.	Platinum	216-224	ATP binding cassette subfamily B member 1	Homo sapiens	4-34
35330134-2	2022	The multidrug resistance protein 1 (MRP1) is a membrane-bound ABC transporter involved in cross resistance to many structurally and functionally diverse classes of anticancer drugs including doxorubicin, taxane, and platinum.	Platinum	216-224	ATP binding cassette subfamily B member 1	Homo sapiens	36-40
35124372-3	2022	Poly(ADP-Ribose) polymerase 1 (PARP1) is an enzyme crucial for repairing DNA damage induced by platinum compounds, which undermines the effectiveness of platinum-based chemotherapy.	Platinum	95-103	poly(ADP-ribose) polymerase 1	Homo sapiens	0-29
35091288-6	2022	Further research indicated that IA-1 induced significant DNA damage and ROS generation, accompanied by high cellular platinum accumulation, resulting in a much higher apoptosis rate than cisplatin in A2780 cells.	Platinum	117-125	INSM transcriptional repressor 1	Homo sapiens	32-36
35224552-2	2022	Erdafitinib is approved for post-platinum mUC with activating somatic genomic alterations (GAs) in FGFR2/3.	Platinum	33-41	fibroblast growth factor receptor 2	Homo sapiens	99-106
35124372-3	2022	Poly(ADP-Ribose) polymerase 1 (PARP1) is an enzyme crucial for repairing DNA damage induced by platinum compounds, which undermines the effectiveness of platinum-based chemotherapy.	Platinum	95-103	poly(ADP-ribose) polymerase 1	Homo sapiens	31-36
35124372-3	2022	Poly(ADP-Ribose) polymerase 1 (PARP1) is an enzyme crucial for repairing DNA damage induced by platinum compounds, which undermines the effectiveness of platinum-based chemotherapy.	Platinum	153-161	poly(ADP-ribose) polymerase 1	Homo sapiens	0-29
35124372-3	2022	Poly(ADP-Ribose) polymerase 1 (PARP1) is an enzyme crucial for repairing DNA damage induced by platinum compounds, which undermines the effectiveness of platinum-based chemotherapy.	Platinum	153-161	poly(ADP-ribose) polymerase 1	Homo sapiens	31-36
35042068-1	2022	BACKGROUND: Prior durvalumab (anti-PD-L1 agent) studies in platinum-refractory metastatic urothelial carcinoma evaluated a dose of 10 mg/kg administered every two weeks.	Platinum	59-67	CD274 molecule	Homo sapiens	35-40
35124372-9	2022	Our finding that the TOPBP1/PARP1 pathway facilitates acquisition of oxaliplatin resistance uncovers a novel mechanism underlying platinum-based chemotherapy resistance in gastric cancer that may be utilized for developing effective therapeutic strategies.	Platinum	130-138	DNA topoisomerase II binding protein 1	Homo sapiens	21-27
35124372-9	2022	Our finding that the TOPBP1/PARP1 pathway facilitates acquisition of oxaliplatin resistance uncovers a novel mechanism underlying platinum-based chemotherapy resistance in gastric cancer that may be utilized for developing effective therapeutic strategies.	Platinum	130-138	poly(ADP-ribose) polymerase 1	Homo sapiens	28-33
35288463-12	2022	The costimulatory receptor CD226, which competes with CD96, was downregulated in tumors compared with blood and PT tissue.	Platinum	112-114	CD226 molecule	Homo sapiens	27-32
35232968-2	2022	Herein, we show that reaction sites consisting of single Pt atoms and neighboring oxygen vacancies (VO) can be prepared on CeO2 (Pt1/CeO2) with unique catalytic properties for the reversible dehydrogenation and rehydrogenation of large molecules such as cyclohexane and methylcyclohexane.	Platinum	57-59	zinc finger protein 77	Homo sapiens	129-137
35232968-4	2022	Combining of DRIFTS, AP-XPS, EXAFS, and DFT calculations, we show that the Pt1/CeO2 catalyst exhibits a super-synergistic effect between the catalytic Pt atom and its support, involving redox coupling between Pt and Ce ions, enabling adsorption, activation and reaction of large molecules with sufficient versatility to drive abstraction/addition of hydrogen without requiring multiple reaction sites.	Platinum	151-153	zinc finger protein 77	Homo sapiens	75-83
35232968-4	2022	Combining of DRIFTS, AP-XPS, EXAFS, and DFT calculations, we show that the Pt1/CeO2 catalyst exhibits a super-synergistic effect between the catalytic Pt atom and its support, involving redox coupling between Pt and Ce ions, enabling adsorption, activation and reaction of large molecules with sufficient versatility to drive abstraction/addition of hydrogen without requiring multiple reaction sites.	Platinum	209-211	zinc finger protein 77	Homo sapiens	75-83
35445643-2	2022	Thus, in the present study, we have comprehensively investigated the associations between SNPs of the Phase II detoxifying genes and its relationship towards platinum-induced toxicity of lung cancer patients.A total of 273 samples were enrolled in this study and polymorphisms of gene NQO1 (609C > T), SULT1A1 (Arg213 His), EPHX1 (Tyr113His, His139Arg), and NAT2 (481C > T, 803A > G, 590 G > A, 857 G > A) were evaluated in our study for their associated adverse events caused due to the administration of platinum-based chemotherapy to the lung cancer patients.For NQO1 609C > T polymorphism, the TT genotype showed reduced risk of constipation (OR =0.10, p=0.04) and anorexia (OR =0.15, p=0.03).	Platinum	158-166	NAD(P)H quinone dehydrogenase 1	Homo sapiens	285-289
34989480-4	2022	The immobilization of GOx-Ad is carried out by incubation of an aqueous enzyme solution on a coating of GNPs adsorbed on a platinum electrode.	Platinum	123-131	hydroxyacid oxidase 1	Homo sapiens	22-25
34989480-5	2022	The presence of immobilized GOx-Ad is evaluated in aqueous glucose solution by potentiostating the underlying platinum electrode at 0.7 V/SCE for the electro-oxidation of H2 O2 generated by the enzyme.	Platinum	110-118	hydroxyacid oxidase 1	Homo sapiens	28-31
35445643-2	2022	Thus, in the present study, we have comprehensively investigated the associations between SNPs of the Phase II detoxifying genes and its relationship towards platinum-induced toxicity of lung cancer patients.A total of 273 samples were enrolled in this study and polymorphisms of gene NQO1 (609C > T), SULT1A1 (Arg213 His), EPHX1 (Tyr113His, His139Arg), and NAT2 (481C > T, 803A > G, 590 G > A, 857 G > A) were evaluated in our study for their associated adverse events caused due to the administration of platinum-based chemotherapy to the lung cancer patients.For NQO1 609C > T polymorphism, the TT genotype showed reduced risk of constipation (OR =0.10, p=0.04) and anorexia (OR =0.15, p=0.03).	Platinum	158-166	sulfotransferase family 1A member 1	Homo sapiens	302-309
35445643-2	2022	Thus, in the present study, we have comprehensively investigated the associations between SNPs of the Phase II detoxifying genes and its relationship towards platinum-induced toxicity of lung cancer patients.A total of 273 samples were enrolled in this study and polymorphisms of gene NQO1 (609C > T), SULT1A1 (Arg213 His), EPHX1 (Tyr113His, His139Arg), and NAT2 (481C > T, 803A > G, 590 G > A, 857 G > A) were evaluated in our study for their associated adverse events caused due to the administration of platinum-based chemotherapy to the lung cancer patients.For NQO1 609C > T polymorphism, the TT genotype showed reduced risk of constipation (OR =0.10, p=0.04) and anorexia (OR =0.15, p=0.03).	Platinum	158-166	epoxide hydrolase 1	Homo sapiens	324-329
35445643-2	2022	Thus, in the present study, we have comprehensively investigated the associations between SNPs of the Phase II detoxifying genes and its relationship towards platinum-induced toxicity of lung cancer patients.A total of 273 samples were enrolled in this study and polymorphisms of gene NQO1 (609C > T), SULT1A1 (Arg213 His), EPHX1 (Tyr113His, His139Arg), and NAT2 (481C > T, 803A > G, 590 G > A, 857 G > A) were evaluated in our study for their associated adverse events caused due to the administration of platinum-based chemotherapy to the lung cancer patients.For NQO1 609C > T polymorphism, the TT genotype showed reduced risk of constipation (OR =0.10, p=0.04) and anorexia (OR =0.15, p=0.03).	Platinum	158-166	N-acetyltransferase 2	Homo sapiens	358-362
35445643-2	2022	Thus, in the present study, we have comprehensively investigated the associations between SNPs of the Phase II detoxifying genes and its relationship towards platinum-induced toxicity of lung cancer patients.A total of 273 samples were enrolled in this study and polymorphisms of gene NQO1 (609C > T), SULT1A1 (Arg213 His), EPHX1 (Tyr113His, His139Arg), and NAT2 (481C > T, 803A > G, 590 G > A, 857 G > A) were evaluated in our study for their associated adverse events caused due to the administration of platinum-based chemotherapy to the lung cancer patients.For NQO1 609C > T polymorphism, the TT genotype showed reduced risk of constipation (OR =0.10, p=0.04) and anorexia (OR =0.15, p=0.03).	Platinum	158-166	NAD(P)H quinone dehydrogenase 1	Homo sapiens	566-570
35281796-14	2022	After analysis combining the relevant clinical features, we found that the high expression of KDF1 is an independent prognostic factor of ovarian cancer and associated with platinum resistance and tumor metastasis in ovarian cancer.	Platinum	173-181	keratinocyte differentiation factor 1	Homo sapiens	94-98
35221331-8	2022	Overall, the findings of this study provided insights into the underlying mechanisms of NFS1 in oxaliplatin sensitivity and identified NFS1 inhibition as a promising strategy for improving the outcome of platinum-based chemotherapy in the treatment of CRC.	Platinum	204-212	NFS1 cysteine desulfurase	Homo sapiens	135-139
35251318-0	2022	A single-nucleotide-polymorphism in the 5"-flanking region of MSX1 gene as a predictive marker candidate for platinum-based therapy of esophageal carcinoma.	Platinum	109-117	msh homeobox 1	Homo sapiens	62-66
35184473-10	2022	(2) The expression of GLI1 was significantly related to the International Federation of Gynecology and Obstetrics (FIGO) stage, cancer antigen 125 (CA125) levels, lymph node metastasis, and Platinum resistance in EAOC patients (all P<0.05).	Platinum	190-198	GLI family zinc finger 1	Homo sapiens	22-26
35251318-7	2022	The methylation QTL database as well as online clinicogenomic databases suggested that the region including rs3815544 may regulate MSX1 expression through CpG methylation, and this down-regulation was statistically associated with poor prognosis after platinum-based therapies for EC.	Platinum	252-260	msh homeobox 1	Homo sapiens	131-135
35113100-0	2022	Platinum complexes as inhibitors of DNA repair protein Ku70 and topoisomerase IIalpha in cancer cells.	Platinum	0-8	X-ray repair complementing defective repair in Chinese hamster cells 6	Mus musculus	55-59
35197103-8	2022	These findings were confirmed in a retrospective MPM patient series, where SKP2 high levels were associated with a worse response to platinum-based therapy and inferior survival.	Platinum	133-141	S-phase kinase associated protein 2	Homo sapiens	75-79
35207810-0	2022	Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis.	Platinum	98-106	BRCA1 DNA repair associated	Homo sapiens	46-54
35228812-10	2022	ET-1 infusion induced similar alternations in WAS rats, but further significantly diminished the pressure to trigger PT and VMR, together with a more forceful and longer VMR.	Platinum	117-119	endothelin 1	Rattus norvegicus	0-4
35265524-4	2022	The patients with higher expression of ATP7A tended to have platinum drug resistance.	Platinum	60-68	ATPase copper transporting alpha	Homo sapiens	39-44
35132978-7	2022	Mechanistic analysis reveals that the negative charge distribution on the Pt-H and the -OH moieties in H-Pt-OH- is critical for the hydrogenation and carbonation of CO2.	Platinum	105-107	parathyroid hormone	Homo sapiens	74-78
34985925-2	2022	After more than two decades without clinical progress, the addition of programmed cell death protein 1 axis blockade to platinum-based chemotherapy has demonstrated sustained overall survival benefit and represents the current standard of care in the first-line setting.	Platinum	120-128	programmed cell death 1	Homo sapiens	71-102
35207810-2	2022	The purpose of this meta-analysis was to assess the values of BRCA1/2 and homologous recombination deficiency (HRD) in the prediction of the pathological complete response (pCR) rates of patients with TNBC treated with platinum-based neoadjuvant chemotherapy (NAC).	Platinum	219-227	BRCA1 DNA repair associated	Homo sapiens	62-69
35207810-6	2022	In 12 trials with BRCA status, 629 of 1266 (49.7%) patients with TNBC achieved pCR with platinum-based NAC, including 134 out of 222 (60.4%) BRCA1/2-mutated patients and 495 out of 1044 (47.4%) BRCA wildtype patients (OR, 1.62; 95% CI, 1.20-2.20).	Platinum	88-96	BRCA1 DNA repair associated	Homo sapiens	141-148
35207810-9	2022	CONCLUSIONS: BRCA1/2-mutated and HRD-positive patients with TNBC could benefit from platinum-based NAC.	Platinum	84-92	BRCA1 DNA repair associated	Homo sapiens	13-20
35204562-9	2022	Moreover, KIF20A and KIF23 overexpression was associated with worse prognosis in OC patients treated with platinum/taxol chemotherapy, while OCs overexpressing mitotic KIFs (11, 15, 18B, and C1) were resistant to MAPK pathway inhibitors.	Platinum	106-114	kinesin family member 20A	Homo sapiens	10-16
35170879-10	2022	CONCLUSIONS: In patients with TNBC, platinum-based neoadjuvant regimens ATPt and TCb increase pCR beyond that with AT alone, but TCb appears to be better tolerated than either AT or ATPt.	Platinum	36-44	pyruvate kinase M1/2	Homo sapiens	81-84
35170879-10	2022	CONCLUSIONS: In patients with TNBC, platinum-based neoadjuvant regimens ATPt and TCb increase pCR beyond that with AT alone, but TCb appears to be better tolerated than either AT or ATPt.	Platinum	36-44	pyruvate kinase M1/2	Homo sapiens	129-132
35170879-11	2022	Platinum-based regimens combined with targeted therapies (Bev, PARPi, and PD-1/PD-L1 inhibitor) also improve the pCR rate beyond that with AT alone, but this benefit is accompanied by greater toxicity.	Platinum	0-8	programmed cell death 1	Homo sapiens	74-78
35170879-11	2022	Platinum-based regimens combined with targeted therapies (Bev, PARPi, and PD-1/PD-L1 inhibitor) also improve the pCR rate beyond that with AT alone, but this benefit is accompanied by greater toxicity.	Platinum	0-8	CD274 molecule	Homo sapiens	79-84
35204562-9	2022	Moreover, KIF20A and KIF23 overexpression was associated with worse prognosis in OC patients treated with platinum/taxol chemotherapy, while OCs overexpressing mitotic KIFs (11, 15, 18B, and C1) were resistant to MAPK pathway inhibitors.	Platinum	106-114	kinesin family member 23	Homo sapiens	21-26
35159089-11	2022	Furthermore, inhibition of Drp1 using pharmacologic inhibitors (Mdivi-1) or RNA interference (siDNM1L) decreased mito-COX-2/p-Drp1Ser616 interaction-mediated mitochondrial fission, and increased apoptosis in HCC cells treated with platinum drugs.	Platinum	231-239	dynamin 1-like	Mus musculus	27-31
35159920-6	2022	Improved field emission properties were demonstrated for the Pt-assisted MWNTs with lower turn-on fields (for 0.01 mA cm-2 current density) of 2.0 V mum-1 and threshold field (for 10 mA cm-2 current density) of 3.5 V mum-1, as well as better stability under a long-term test of 80 h (started at 3.0 mA for the Pt-assisted emitter and 3.25 mA for the direct grown emitter).	Platinum	61-63	PWWP domain containing 3A, DNA repair factor	Homo sapiens	149-154
35159920-6	2022	Improved field emission properties were demonstrated for the Pt-assisted MWNTs with lower turn-on fields (for 0.01 mA cm-2 current density) of 2.0 V mum-1 and threshold field (for 10 mA cm-2 current density) of 3.5 V mum-1, as well as better stability under a long-term test of 80 h (started at 3.0 mA for the Pt-assisted emitter and 3.25 mA for the direct grown emitter).	Platinum	61-63	PWWP domain containing 3A, DNA repair factor	Homo sapiens	217-222
35159089-11	2022	Furthermore, inhibition of Drp1 using pharmacologic inhibitors (Mdivi-1) or RNA interference (siDNM1L) decreased mito-COX-2/p-Drp1Ser616 interaction-mediated mitochondrial fission, and increased apoptosis in HCC cells treated with platinum drugs.	Platinum	231-239	prostaglandin-endoperoxide synthase 2	Homo sapiens	118-123
34561996-1	2022	BACKGROUND: Platinum is reported to have adjuvant immune properties, whether oxaliplatin (OXA) could be utilized to synergize with anti-programmed cell death-1 (PD-1) antibody or anti-NKG2D (natural-killer group 2, member D) antibody is investigated.	Platinum	12-20	killer cell lectin-like receptor subfamily K, member 1	Mus musculus	184-189
35185593-9	2021	Serum assays showed that H2S levels were higher in the TM group than in the M group; compared with the levels in the TM group, the PT group levels were decreased and the NT group levels were increased.	Platinum	131-133	histocompatibility 2, S region (C4, Slp, Bf, C2)	Mus musculus	25-28
34561996-5	2022	RESULTS: The three platinum drugs (cisplatin, DDP; carboplatin, CBP; OXA) showed similar effects to inhibit A549 tumor growth in immune-deficient mice.	Platinum	19-27	CREB binding protein	Mus musculus	64-67
35124430-6	2022	FINDINGS: The PT-DsbA-L-KO mice showed amelioration of I/R, VAN-, and CLP-induced AKI progression via the downregulation of VDAC1.	Platinum	14-16	glutathione S-transferase kappa 1	Mus musculus	17-23
35029256-0	2022	Interactions between mitochondria-damaging platinum(IV) prodrugs and cytochrome c.	Platinum	43-51	cytochrome c, somatic	Homo sapiens	69-81
34998176-7	2022	Prevention of premature initiation of end-resection, by combining Chk2 inhibition with IR or carboplatin treatment, successfully sensitized IR and platinum-resistant Wwox-deficient cells by synthetic lethality, but did not alter response of Wwox-sufficient cells.	Platinum	147-155	checkpoint kinase 2	Homo sapiens	66-70
34998176-7	2022	Prevention of premature initiation of end-resection, by combining Chk2 inhibition with IR or carboplatin treatment, successfully sensitized IR and platinum-resistant Wwox-deficient cells by synthetic lethality, but did not alter response of Wwox-sufficient cells.	Platinum	147-155	WW domain containing oxidoreductase	Homo sapiens	166-170
35124430-6	2022	FINDINGS: The PT-DsbA-L-KO mice showed amelioration of I/R, VAN-, and CLP-induced AKI progression via the downregulation of VDAC1.	Platinum	14-16	voltage-dependent anion channel 1	Mus musculus	124-129
35045702-1	2022	Ground-state electron spin polarization (ESP) is generated in radical elaborated (bpy)Pt(CAT-NN) and (bpy)Pt(CAT-p-Me2PhMe2-NN) (bpy = 5,5"-di-tert-butyl-2,2"-bipyridine, CAT = 3-tert-butylcatecholate, p-Ph = para-phenylene, NN = nitronylnitroxide).	Platinum	86-88	spindlin 1	Homo sapiens	22-26
35093146-9	2022	Further Kyoto Encyclopaedia of Genes and Genomes (KEGG) analysis indicated the Differentially expressed genes (DEGs) in platinum-resistant and platinum-sensitive patients were mainly enriched in the phosphatidylinositol 3-kinase-Akt (PI3K-Akt) signaling pathway and focal adhesion pathway, which are associated with platinum resistance.	Platinum	120-128	AKT serine/threonine kinase 1	Homo sapiens	229-232
35093146-9	2022	Further Kyoto Encyclopaedia of Genes and Genomes (KEGG) analysis indicated the Differentially expressed genes (DEGs) in platinum-resistant and platinum-sensitive patients were mainly enriched in the phosphatidylinositol 3-kinase-Akt (PI3K-Akt) signaling pathway and focal adhesion pathway, which are associated with platinum resistance.	Platinum	120-128	AKT serine/threonine kinase 1	Homo sapiens	239-242
35093146-9	2022	Further Kyoto Encyclopaedia of Genes and Genomes (KEGG) analysis indicated the Differentially expressed genes (DEGs) in platinum-resistant and platinum-sensitive patients were mainly enriched in the phosphatidylinositol 3-kinase-Akt (PI3K-Akt) signaling pathway and focal adhesion pathway, which are associated with platinum resistance.	Platinum	143-151	AKT serine/threonine kinase 1	Homo sapiens	229-232
35093146-9	2022	Further Kyoto Encyclopaedia of Genes and Genomes (KEGG) analysis indicated the Differentially expressed genes (DEGs) in platinum-resistant and platinum-sensitive patients were mainly enriched in the phosphatidylinositol 3-kinase-Akt (PI3K-Akt) signaling pathway and focal adhesion pathway, which are associated with platinum resistance.	Platinum	143-151	AKT serine/threonine kinase 1	Homo sapiens	239-242
35081740-8	2022	The results suggest that MSH2 polymorphisms are involved in decreasing overall survival for patients undergoing platinum-based chemotherapy.	Platinum	112-120	mutS homolog 2	Homo sapiens	25-29
35158911-7	2022	In vitro treatment with platinum-derived drugs significantly enhanced gamma-H2AX and apoptotic markers expression in knock-out cells, indicating a synergic effect of SAMHD1 depletion and platinum-based treatment.	Platinum	24-32	SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1	Homo sapiens	166-172
35045702-1	2022	Ground-state electron spin polarization (ESP) is generated in radical elaborated (bpy)Pt(CAT-NN) and (bpy)Pt(CAT-p-Me2PhMe2-NN) (bpy = 5,5"-di-tert-butyl-2,2"-bipyridine, CAT = 3-tert-butylcatecholate, p-Ph = para-phenylene, NN = nitronylnitroxide).	Platinum	106-108	spindlin 1	Homo sapiens	22-26
35164068-0	2022	2-Hydroxyestradiol Overcomes Mesenchymal Stem Cells-Mediated Platinum Chemoresistance in Ovarian Cancer Cells in an ERK-Independent Fashion.	Platinum	61-69	mitogen-activated protein kinase 1	Homo sapiens	116-119
35086099-0	2022	Polymorphism in Thymidylate Synthase Gene Predicts Survival and Toxicity in North Indian Lung Cancer Patients Undergoing Platinum-Based Doublet Chemotherapy.	Platinum	121-129	thymidylate synthetase	Homo sapiens	16-36
35086099-2	2022	Thymidylate synthase (TS) is an important drug target for platinum-based doublet chemotherapy as it is the only de novo source of thymidylate production in the cell.	Platinum	58-66	thymidylate synthetase	Homo sapiens	0-20
35086099-2	2022	Thymidylate synthase (TS) is an important drug target for platinum-based doublet chemotherapy as it is the only de novo source of thymidylate production in the cell.	Platinum	58-66	thymidylate synthetase	Homo sapiens	22-24
35086099-11	2022	Furthermore, TS polymorphisms may influence the onset of platinum-related toxicity, such as hematological and gastrointestinal toxicity.	Platinum	57-65	thymidylate synthetase	Homo sapiens	13-15
35164068-4	2022	To discover compounds capable of restoring platinum sensitivity, we screened a number of candidates and monitored ability to induce PARP cleavage.	Platinum	43-51	collagen type XI alpha 2 chain	Homo sapiens	132-136
35164068-6	2022	Our results showed that 2-hydroxyestradiol (2HE2), a metabolite of estradiol, and dasatinib, an Abl/Src kinase inhibitor, were significantly effective in overcoming MSC-mediated platinum drug resistance.	Platinum	178-186	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	96-99
35062908-0	2022	Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma.	Platinum	53-61	fibrinogen beta chain	Homo sapiens	0-10
35062908-0	2022	Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma.	Platinum	53-61	albumin	Homo sapiens	11-18
35062908-1	2022	BACKGROUND: This study aims to evaluate the role of the fibrinogen/albumin ratio (FAR) in predicting platinum resistance and survival outcomes of patients with ovarian clear cell carcinoma (OCCC).	Platinum	101-109	fibrinogen beta chain	Homo sapiens	56-66
35062908-1	2022	BACKGROUND: This study aims to evaluate the role of the fibrinogen/albumin ratio (FAR) in predicting platinum resistance and survival outcomes of patients with ovarian clear cell carcinoma (OCCC).	Platinum	101-109	albumin	Homo sapiens	67-74
35042534-0	2022	A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients.	Platinum	36-44	small nucleolar RNA, C/D box 33	Homo sapiens	9-16
35106515-1	2022	A recent study by Limagne et al.1 in Cancer Cell demonstrates that addition of MEK inhibitor to standard-of-care platinum/pemetrexed promotes mitophagy-dependent CXCL10 expression via optineurin and TLR9.	Platinum	113-121	mitogen-activated protein kinase kinase 7	Homo sapiens	79-82
35106515-1	2022	A recent study by Limagne et al.1 in Cancer Cell demonstrates that addition of MEK inhibitor to standard-of-care platinum/pemetrexed promotes mitophagy-dependent CXCL10 expression via optineurin and TLR9.	Platinum	113-121	C-X-C motif chemokine ligand 10	Homo sapiens	162-168
35106515-1	2022	A recent study by Limagne et al.1 in Cancer Cell demonstrates that addition of MEK inhibitor to standard-of-care platinum/pemetrexed promotes mitophagy-dependent CXCL10 expression via optineurin and TLR9.	Platinum	113-121	optineurin	Homo sapiens	184-194
35106515-1	2022	A recent study by Limagne et al.1 in Cancer Cell demonstrates that addition of MEK inhibitor to standard-of-care platinum/pemetrexed promotes mitophagy-dependent CXCL10 expression via optineurin and TLR9.	Platinum	113-121	toll like receptor 9	Homo sapiens	199-203
35065580-1	2022	Methanol and formic acid electro-oxidation on Pt has been studied under well-defined flow conditions by a spectroscopic platform that combines differential electrochemical mass spectrometry (DEMS) and attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy.	Platinum	46-48	ATR serine/threonine kinase	Homo sapiens	257-260
35163014-0	2022	Role of Organic Cation Transporter 2 in Autophagy Induced by Platinum Derivatives.	Platinum	61-69	solute carrier family 22 member 2	Homo sapiens	8-36
35242226-3	2022	Gemcitabine + platinum (GP) is the standard first-line chemotherapy in metastatic patients.	Platinum	14-22	ring finger protein 130	Homo sapiens	24-26
34978181-0	2022	Plasmon-Enhanced Electrochemiluminescence of PTP-Decorated Eu MOF-Based Pt-Tipped Au Bimetallic Nanorods for the Lincomycin Assay.	Platinum	72-74	protein tyrosine phosphatase receptor type U	Homo sapiens	45-48
35209356-0	2022	Observation of the spin-Hall effect in Pt/GaAs by circular polarized photoconductivity.	Platinum	39-41	spindlin 1	Homo sapiens	19-23
35209356-1	2022	Electrically generated spin accumulation due to the spin Hall effect of Pt/GaAs is detected by circular polarized photoconductivity (CPPC), which shows electron spins with different polarizations accumulated around opposite sample boundaries.	Platinum	72-74	spindlin 1	Homo sapiens	23-27
35209356-1	2022	Electrically generated spin accumulation due to the spin Hall effect of Pt/GaAs is detected by circular polarized photoconductivity (CPPC), which shows electron spins with different polarizations accumulated around opposite sample boundaries.	Platinum	72-74	spindlin 1	Homo sapiens	52-56
35425256-1	2022	2,5-Dimethyltetrahydrofuran (DMTHF) is deoxygenated to n-hexane with >99% selectivity at mild conditions (90  C, 1 bar H2 pressure, fixed-bed reactor) in the presence of the bifunctional metal-acid catalyst Pt-CsPW comprising Pt and Cs2.5H0.5PW12O40 (CsPW), an acidic Cs salt of Keggin-type heteropoly acid H3PW12O40.	Platinum	226-228	chorionic somatomammotropin hormone 2	Homo sapiens	233-236
35046665-1	2022	Background: Recent clinical trials illustrated that gefitinib plus pemetrexed/platinum regimen improves survival in advanced lung adenocarcinoma patients with EGFR mutation, while data on its efficacy and safety in a real clinical setting are limited.	Platinum	78-86	epidermal growth factor receptor	Homo sapiens	159-163
35046665-9	2022	Conclusion: Gefitinib plus pemetrexed/platinum exhibits favorable efficacy with low occurrence of severe adverse events in advanced lung adenocarcinoma patients with EGFR mutation, suggesting it could be a potential option for these patients.	Platinum	38-46	epidermal growth factor receptor	Homo sapiens	166-170
35070248-4	2022	BRCA-mutated patients, already treated with platinum-derived drugs, who suffered DNA damage, cannot repair the breaks due to lurbinectedin interaction, whereas irinotecan provokes a dsDNA break that promotes synthetic lethality.	Platinum	44-52	BRCA1 DNA repair associated	Homo sapiens	0-4
35018214-2	2022	However, platinum-based chemopotentiation by PARP inhibitors (PARPi), particularly for non-small cell lung cancer (NSCLC), has only been confirmed in a few preclinical models and the molecular mechanisms that drive PARPi combinatorial synergy with chemotherapeutics remains poorly defined.	Platinum	9-17	poly(ADP-ribose) polymerase 1	Homo sapiens	45-49
35087742-1	2021	Background: PALB2, a gene in the homologous recombination repair (HRR) pathway of the DNA damage response (DDR), is associated with the efficacy of platinum-based chemotherapy, immunotherapy, and PARP inhibitor therapy in several tumors.	Platinum	148-156	partner and localizer of BRCA2	Homo sapiens	12-17
35087829-0	2021	CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.	Platinum	100-108	calmodulin regulated spectrin associated protein 1	Homo sapiens	0-7
35087829-8	2021	We found that for SCLC patients, CAMSAP1 mutation can activate anti-tumor immunity, mediate tumor cell apoptosis, inhibit epithelial-mesenchymal transition (EMT), improve prognosis, and improve platinum drug sensitivity, suggesting that CAMSAP1 mutation may be a potential biomarker indicating platinum drug sensitivity and patient prognosis in SCLC.	Platinum	194-202	calmodulin regulated spectrin associated protein 1	Homo sapiens	33-40
35087829-8	2021	We found that for SCLC patients, CAMSAP1 mutation can activate anti-tumor immunity, mediate tumor cell apoptosis, inhibit epithelial-mesenchymal transition (EMT), improve prognosis, and improve platinum drug sensitivity, suggesting that CAMSAP1 mutation may be a potential biomarker indicating platinum drug sensitivity and patient prognosis in SCLC.	Platinum	294-302	calmodulin regulated spectrin associated protein 1	Homo sapiens	33-40
35087829-8	2021	We found that for SCLC patients, CAMSAP1 mutation can activate anti-tumor immunity, mediate tumor cell apoptosis, inhibit epithelial-mesenchymal transition (EMT), improve prognosis, and improve platinum drug sensitivity, suggesting that CAMSAP1 mutation may be a potential biomarker indicating platinum drug sensitivity and patient prognosis in SCLC.	Platinum	294-302	calmodulin regulated spectrin associated protein 1	Homo sapiens	237-244
35053335-0	2022	TFEB Regulates ATP7B Expression to Promote Platinum Chemoresistance in Human Ovarian Cancer Cells.	Platinum	43-51	transcription factor EB	Homo sapiens	0-4
35053335-0	2022	TFEB Regulates ATP7B Expression to Promote Platinum Chemoresistance in Human Ovarian Cancer Cells.	Platinum	43-51	ATPase copper transporting beta	Homo sapiens	15-20
35053335-3	2022	In addition to liver, high ATP7B expression has been reported in tumors with elevated resistance to platinum (Pt)-based chemotherapy.	Platinum	100-108	ATPase copper transporting beta	Homo sapiens	27-32
35053335-5	2022	Although the mechanisms underlying Pt-tolerance are still ambiguous, accumulating evidence suggests that lysosomal sequestration of Pt drugs by ion transporters (including ATP7B) might significantly contribute to drug resistance development.	Platinum	132-134	ATPase copper transporting beta	Homo sapiens	172-177
35053335-8	2022	Using resistant ovarian cancer IGROV-CP20 cells, we found that TFEB directly binds to the predicted coordinated lysosomal expression and regulation (CLEAR) sites in the proximal promoter and first intron region of ATP7B upon Pt exposure.	Platinum	225-227	transcription factor EB	Homo sapiens	63-67
35053335-8	2022	Using resistant ovarian cancer IGROV-CP20 cells, we found that TFEB directly binds to the predicted coordinated lysosomal expression and regulation (CLEAR) sites in the proximal promoter and first intron region of ATP7B upon Pt exposure.	Platinum	225-227	ATPase copper transporting beta	Homo sapiens	214-219
35046958-10	2021	Interestingly, CD3+, CD8+ and FoxP3+ T cell densities decreased during chemotherapy in two small cohorts of patients treated with neoadjuvant or palliative platinum-based chemotherapy.	Platinum	156-164	CD8a molecule	Homo sapiens	21-24
35046958-10	2021	Interestingly, CD3+, CD8+ and FoxP3+ T cell densities decreased during chemotherapy in two small cohorts of patients treated with neoadjuvant or palliative platinum-based chemotherapy.	Platinum	156-164	forkhead box P3	Homo sapiens	30-35
35047406-14	2021	Interrogation of the TCGA dataset suggests shifts in platinum responses in patients consistent with genetic alterations in TIMP-2, -3 and MMP-2, -11 genes in tumors; and decreased overall survival (OS) and progression-free survival (PFS) in patients with altered MMP-14 genes.	Platinum	53-61	TIMP metallopeptidase inhibitor 2	Homo sapiens	123-133
35047406-14	2021	Interrogation of the TCGA dataset suggests shifts in platinum responses in patients consistent with genetic alterations in TIMP-2, -3 and MMP-2, -11 genes in tumors; and decreased overall survival (OS) and progression-free survival (PFS) in patients with altered MMP-14 genes.	Platinum	53-61	matrix metallopeptidase 2	Homo sapiens	138-148
35047406-14	2021	Interrogation of the TCGA dataset suggests shifts in platinum responses in patients consistent with genetic alterations in TIMP-2, -3 and MMP-2, -11 genes in tumors; and decreased overall survival (OS) and progression-free survival (PFS) in patients with altered MMP-14 genes.	Platinum	53-61	matrix metallopeptidase 14	Homo sapiens	263-269
34969744-6	2022	RESULTS: In advanced-stage group, OS, PFS, PFI, and platinum resistance were significantly correlated with PC-CA-125.	Platinum	52-60	mucin 16, cell surface associated	Homo sapiens	110-116
34969744-11	2022	Thus, CA-125 can be used to predict platinum resistance in ovarian cancer treatment.	Platinum	36-44	mucin 16, cell surface associated	Homo sapiens	6-12
35005470-0	2022	First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations.	Platinum	25-33	BRCA2 DNA repair associated	Homo sapiens	93-98
35005470-0	2022	First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations.	Platinum	25-33	phosphatase and tensin homolog	Homo sapiens	103-107
35005470-2	2022	Case presentation: We report the case of a Japanese patient with advanced castration-resistant prostate cancer who exhibited a prominent response to platinum therapy and had coexisting BRCA2 and PTEN mutations according to retrospective multigene panel analysis.	Platinum	149-157	BRCA2 DNA repair associated	Homo sapiens	185-190
35005470-2	2022	Case presentation: We report the case of a Japanese patient with advanced castration-resistant prostate cancer who exhibited a prominent response to platinum therapy and had coexisting BRCA2 and PTEN mutations according to retrospective multigene panel analysis.	Platinum	149-157	phosphatase and tensin homolog	Homo sapiens	195-199
35262460-0	2022	VEGF single nucleotide polymorphisms predict improved outcome in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.	Platinum	123-131	vascular endothelial growth factor A	Homo sapiens	0-4
35262460-1	2022	We aimed to investigate the prognostic role of genetic variants of VEGF in advanced NSCLC patients treated with platinum-based chemotherapy.	Platinum	112-120	vascular endothelial growth factor A	Homo sapiens	67-71
35221276-9	2022	The incidence of cardio-cerebrovascular adverse events in the combined gemcitabine + platinum (GP) and irinotecan + platinum (IP) regimen group was higher than that in the other combined chemotherapy regimen groups.	Platinum	85-93	ring finger protein 130	Homo sapiens	95-97
35356229-4	2022	This patient achieved clinical remission after platinum-based effective chemotherapy and programmed death 1 (PD-1) immunotherapy.	Platinum	47-55	programmed cell death 1	Homo sapiens	109-113